"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00632047","Early Detection of Breast Cancer and Cervical Cancer in Women in India",,"Unknown status","No Results Available","Breast Cancer|Cervical Cancer","Other: active surveillance|Other: educational intervention|Procedure: examination|Procedure: long-term screening","Effectiveness of well planned health education programs and low-cost screening methods (e.g., clinical breast exam and visual inspection of the cervix) in reducing the incidence of and mortality due to breast and cervical cancer","Tata Memorial Hospital|National Cancer Institute (NCI)","Female","35 Years to 64 Years   (Adult)","Phase 2","151538","Other|NIH","Interventional","Allocation: Randomized|Primary Purpose: Screening","CDR0000586791|TATA-1900215717A1","May 1998","December 2015",,"March 10, 2008",,"August 26, 2013","Tata Memorial Hospital, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT00632047"
2,"NCT04075058","Hypofractionated Radiation Therapy in Patients With Breast Cancer","HRBC","Completed","No Results Available","Breast Cancer","Radiation: Hypofractionated Radiation therapy","Local Recurrence|Acute skin toxicity|Cosmetic assessment|Quality of life|Disease free survival|Overall survival|Arm edema|Late effects- pain, shoulder stiffness|Late effects- Brachial plexopathy|Late effects- Lung, cardiac","Postgraduate Institute of Medical Education and Research","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1070","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HRBC","June 2015","December 2020","December 2020","August 30, 2019",,"June 23, 2021","Dr Budhi Singh Yadav, Chandigarh, N/A = Not Applicable, India",,"https://ClinicalTrials.gov/show/NCT04075058"
3,"NCT02460744","2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer",,"Completed","No Results Available","Breast Cancer","Radiation: Hypofractionation","acute skin and subcutaneous toxicity assessed using a RTOG grading system|Cosmetic score analysis using Harvard/NSABP/RTOG Breast Cosmesis Grading Scale","Postgraduate Institute of Medical Education and Research","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BHRT","June 2013","October 2014","October 2014","June 2, 2015",,"June 2, 2015","Dr Budhi Singh Yadav, Chandigarh, N/A = Not Applicable, India",,"https://ClinicalTrials.gov/show/NCT02460744"
4,"NCT03997110","Palliative Radiation for Advanced Cervical Cancer","RAPPAL","Recruiting","No Results Available","Cervical Cancer","Radiation: Short course palliative radiation.|Radiation: Long course palliative treatment.","Pain Relief (Numerical pain rating scale will be used)|Presence or absence of vaginal bleeding and/or discharge and relief in vaginal bleeding (as reported by the patient)|Change in use of analgesics (WHO ladder)|Compliance to therapy|Quality of Life using EORTC QLQC30 questionnaires|Quality of Life using EORTC QLQC-15 Pall questionnaires|Quality of Life using Cx-24 questionnaires|Acute gastrointestinal and genitourinary toxicities|Late gastrointestinal and genitourinary toxicities|Overall survival, defined as time from randomization until death due to any cause.|Patterns of terminal event (Due to local relapse or Distant Metastasis)","Tata Memorial Hospital|Tata Memorial Centre","Female","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH IRB 3157","June 19, 2020","August 1, 2024","February 1, 2025","June 25, 2019",,"May 2, 2022","Tata Memorial Hospital, Mumbai, Maharastra, India",,"https://ClinicalTrials.gov/show/NCT03997110"
5,"NCT00808379","Concurrent Chemo-Radiotherapy Versus Radiotherapy With Boost in Locally Advanced Unresectable Rectal Cancers",,"Unknown status","No Results Available","Rectal Cancer","Drug: Chemoradiation|Radiation: Additional Radiation boost to the primary tumor volume","Comparison of resectability rate of in the two groups at 6-8 weeks following radiotherapy.|Side effects and other adverse effects in the two groups during radiotherapy and up to 2 years post radiotherapy.|Comparison of pathological downstaging between the two groups who undergo surgery.","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","260","May 2006","February 2009","July 2009","December 15, 2008",,"December 15, 2008","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00808379"
6,"NCT02783235","Cervical Cancer Screening : Video Based Tutorials for ANMs/ASHAs/PHWs",,"Unknown status","No Results Available","Cervical Cancer","Other: cervical cancer screening","Improvement in the Post training knowledge about cancer|Satisfaction to the video based tutorials","Tata Memorial Hospital","Female","18 Years to 45 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TMH1605 Video Based Tutorials","January 29, 2018","September 2018","September 2018","May 26, 2016",,"August 6, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02783235"
7,"NCT04688086","A Prospective Study to Evaluate Clinical Performance of Thermalytix in Detecting Breast Cancers",,"Completed","No Results Available","Breast Cancer|Early Detection of Cancer","Diagnostic Test: Thermalytix","Sensitivity, specificity, positive predictive value and negative predictive value of Thermalytix|Sensitivity and specificity of Thermalytix for different patient characteristics","Niramai Health Analytix Private Limited|Max Healthcare Insititute Limited","Female","18 Years to 80 Years   (Adult, Older Adult)",,"459","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","NIR-THERMA-02","December 15, 2018","January 6, 2020","January 30, 2020","December 29, 2020",,"September 28, 2021","Max Healthcare Insititute Limited, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04688086"
8,"NCT01276730","Advanced Cervical Cancer Trial in India",,"Completed","No Results Available","Cervical Cancer","Drug: Interferon, Retinoic Acid and radiation|Drug: Cisplatin and radiation","Survival|Response rate|Overall toxicity|Determine immune response to Human Papillomavirus HPV","University of Louisville|James Graham Brown Cancer Center","Female","18 Years and older   (Adult, Older Adult)","Phase 2","209","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","464.05","October 2007","August 2015","August 2015","January 13, 2011",,"December 29, 2017","Chittaranjan National Cancer Institute, Kolkata, India",,"https://ClinicalTrials.gov/show/NCT01276730"
9,"NCT03110497","Single Application Brachytherapy in Cervical Cancer",,"Unknown status","No Results Available","Cervical Cancer","Radiation: Single application multi-fraction brachytherapy","Number of participants achieving specified dosimetric constraints|Number of participants with adverse events as assessed by CTCAE v 4.0|Local control rate|Percentage Inter-fraction dose variation","Tata Memorial Hospital","Female","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH-1759|REF/2017/03/013733","September 17, 2017","April 17, 2019","April 17, 2020","April 12, 2017",,"November 7, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03110497"
10,"NCT00447746","A Comparison Between D1 and D2 Lymphadenectomy in Gastric Cancer : A Prospective Randomized Controlled Trial",,"Unknown status","No Results Available","Gastric Cancer","Procedure: D1 or D2 lymphadenectomy for gastric cancer patients","5 year overall survival|: 5 year disease free survival|: 5 year local recurrence|: Postoperative morbidity and mortality rates","Tata Memorial Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH 262","March 2007",,"March 2014","March 15, 2007",,"March 15, 2007","Tata Memorial Hospital,Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00447746"
11,"NCT03788213","One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer","HYPORTAdjuvant","Recruiting","No Results Available","Breast Cancer Female","Radiation: 3 week RT|Radiation: 1 week RT","Locoregional Recurrence Rate (LRR)|Overall Survival (OS )|Invasive Disease Free Survival ( iDFS )|Adverse Event ( AE )|Quality of Life ( QoL )","Tata Medical Center|Christian Medical College, Vellore, India|Sanjay Gandhi Postgraduate Institute of Medical Sciences","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","2100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018/TMC/133/IRB/31","March 26, 2019","March 26, 2029","March 26, 2029","December 27, 2018",,"December 17, 2021","Sanjoy Chatterjee, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03788213"
12,"NCT04588909","Outcomes of Elective Colorectal Cancer Surgery During COVID 19 Pandemic: Implications for Cancer Care Policy",,"Active, not recruiting","No Results Available","Colo-rectal Cancer","Procedure: Colorectal resections","Early post operative mortality|Early Post operative complications|Incidence of SARS CoV2 infectivity among health care providers providing direct care to involved patients|Rate of hospital acquired SARS CoV 2 infection among operated patients.","Sheri Kashmir Institute of Medical Sciences","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","73/2020 (Supl 2)","March 23, 2020","September 22, 2020","October 22, 2020","October 19, 2020",,"October 19, 2020","Sher i Kashmir Institute of Medical Sciences, Srinagar, J&K, India",,"https://ClinicalTrials.gov/show/NCT04588909"
13,"NCT05258747","A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer",,"Recruiting","No Results Available","Ovarian Cancer|Breast Cancer","Drug: Olaparib tablets, 150 mg|Drug: Lynparza® (olaparib) tablets 150 mg","Maximum plasma concentration during the dosing interval at steady state (CmaxSS)|Area under the plasma concentration versus time curve for one dosing interval at steady state (AUC(0-t)ss)|Number of adverse events and serious adverse events","Sandoz","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","21-VIN-0166/SAN-0647","April 7, 2022","February 15, 2023","February 15, 2023","February 28, 2022",,"April 19, 2022","Sandoz Investigative Site, Vijayawada, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT05258747"
14,"NCT03909620","Utility of LDCT in Lung Cancer Screening in a TB Endemic Region",,"Completed","No Results Available","Lung Cancer","Diagnostic Test: Low-dose computed tomography of chest","Positivity rate with LDCT screening|Rate of detection of lung cancer|False positive rate|Proportion of patients requiring additional procedures (imaging/invasive procedures)|Proportion of patients developing complications due to additional procedures|Change in the 6-item Spielberger State-Trait Anxiety Inventory (STAI-6) questionnaire score|Cost in Indian Rupees to detect one case of lung cancer by LDCT screening|Proportion of patients who quit/re-initiated smoking after inclusion in study","Postgraduate Institute of Medical Education and Research","All","50 Years to 74 Years   (Adult, Older Adult)","Not Applicable","253","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","NK/5292/DM/760","May 1, 2019","March 31, 2020","December 31, 2021","April 10, 2019",,"March 29, 2022","Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03909620"
15,"NCT01769950","Choline-PET for Evaluating the Incidence of Nodal Metastases Among Newly Diagnosed Patients of Prostate Cancer","ChoPEN","Unknown status","No Results Available","Prostate Cancer","Other: Choline-PET","Detection of Choline-PET detected nodal metastases|Comparison of Choline-PET and CT for the detection of nodal metastatic disease|Comparison of Choline-PET and MRI for the detection of nodal metastatic disease","Bangalore Institute of Oncology","Male","Child, Adult, Older Adult","Not Applicable","120","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Choline-Prostate-1","January 2013","January 2014","February 2014","January 17, 2013",,"January 17, 2013","HealthCare Global- Bangalore Institute of Oncology, Bengaluru, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT01769950"
16,"NCT03519165","Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery","RIGoROCS","Completed","No Results Available","Ovarian Cancer","Device: EV1000(FloTrac System 4.0)","Postoperative length of Stay (LOS) in hospital in days|Cost of treatment|Post operative morbidity survey (POMS survey)|30 day morbidity and mortality","Tata Medical Center","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","145","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","EC/TMC/56/15","June 2016","June 2019","September 2019","May 8, 2018",,"January 31, 2020","Tata Medical Centre, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03519165"
17,"NCT00128362","Sentinel Node Biopsy and Axillary Sampling in Operable Breast Cancer",,"Terminated","No Results Available","Cancer of the Breast","Procedure: Radio-guided sentinel node biopsy|Procedure: Axillary sampling","Comparison of methodologies in predicting status of axillary lymph nodes|Number of lymph nodes identified by sentinel node biopsy and axillary sampling|Number of times the sentinel node is found within the sampled nodes|False negative rate by each method|Negative predictive value for each method","Tata Memorial Hospital|Indian Council of Medical Research","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","478","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TMH/115/2003|No.5/13/66/2003-NCD-III","September 2005","December 2011",,"August 9, 2005",,"June 24, 2014","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00128362"
18,"NCT01133067","Telephonic Contact and Subsequent Physical Follow up Treated Lung Cancer Patients","TELE001","Completed","Has Results","Lung Cancer",,"Concurrence Between the Telephonic Interview and the Physician Assessment|Cost Analysis","Tata Memorial Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PROJECT NO 754","July 2010","July 2016","July 2016","May 28, 2010","August 7, 2018","August 7, 2018","Tata Memorial Hospital, Mumbai, MS, India",,"https://ClinicalTrials.gov/show/NCT01133067"
19,"NCT03005743","Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial","COMBAT-Cx","Recruiting","No Results Available","Cervical Cancer","Radiation: Magnetic Resonance Image based Brachytherapy|Radiation: Conventional Radiograph based Brachytherapy","Local control|Late toxicities|Pelvic control rates|Distant failure rates|Progression free & cause specific survival|Overall survival|Quality of life questionnaire EORTC QLQ C30|Quality life questionnaire EORTC QLQ CX24","Tata Memorial Hospital","Female","Child, Adult, Older Adult","Not Applicable","1050","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH-1587","December 2016","December 2021","December 2023","December 29, 2016",,"January 23, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03005743"
20,"NCT00193726","Estrogen Priming to Increase the Efficacy of Adjuvant Chemotherapy in Operable Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: Tab Premarin (Ethinyl estradiol)|Drug: Placebo","Disease Free Survival|Overall Survival","Sudeep Gupta|Tata Memorial Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","273","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","122 of 2003","July 2005","March 30, 2012","March 30, 2012","September 19, 2005",,"September 20, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193726"
21,"NCT00193778","Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation",,"Completed","No Results Available","Cancer of the Breast","Procedure: Surgery for breast cancer|Other: No Loco-regional treatment","Overall survival|Progression free survival|Changes in VEGF, bFGF, Angiostatin and Endostatin","Tata Memorial Hospital","Female","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/153/2004","February 2005","July 30, 2020","July 30, 2020","September 19, 2005",,"October 8, 2020","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193778"
22,"NCT01935466","Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy ""PROBE""","PROBE-PIO","Completed","No Results Available","Bladder Cancer","Drug: Pioglitazone","Bladder cancer rate","Postgraduate Institute of Medical Education and Research","Male","50 Years and older   (Adult, Older Adult)",,"6107","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PROBEPIO","July 2013","October 2021","October 2021","September 5, 2013",,"January 25, 2022","Deptt of Endocrinology, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01935466"
23,"NCT00772824","Study of the Effect of Glutamine Supplementation on Chemotherapy Induced Toxicities in Breast Cancer Patients",,"Completed","No Results Available","Breast Cancer","Dietary Supplement: Glutamine|Dietary Supplement: IV Glutamine","Reduction in toxicity|Serum level of creatinine kinase and LDH","Banaras Hindu University","Female","18 Years to 85 Years   (Adult, Older Adult)","Phase 4","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","GLU_07","December 2007","December 2009","December 2009","October 15, 2008",,"July 17, 2018","Sir Sunder Lal Hospital, Varanasi, UP, India",,"https://ClinicalTrials.gov/show/NCT00772824"
24,"NCT04072718","Simultaneous Integrated Boost With Volumetric Arc Radiotherapy in Patients With Breast Cancer","SIBART-BC","Completed","No Results Available","Breast Cancer","Radiation: Radiotherapy","Acute radiation toxicities|cosmetic score analysis|local control|Late toxicity","Postgraduate Institute of Medical Education and Research","Female","18 Years to 60 Years   (Adult)","Phase 2","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INT/IEC/2017/127","August 10, 2017","March 31, 2020","March 31, 2020","August 28, 2019",,"July 14, 2020","Dr Budhi Singh Yadav, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04072718"
25,"NCT03936933","Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer",,"Recruiting","No Results Available","Breast Cancer","Drug: Goserelin acetate 3.6 mg Injection|Drug: ZOLADEX® 3.6mg Injection","To evaluate and compare the pharmacodynamics","Eurofarma Laboratorios S.A.","Female","18 Years to 59 Years   (Adult)","Phase 3","68","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EF 160","January 1, 2021","December 1, 2022","December 1, 2022","May 3, 2019",,"January 27, 2022","Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT03936933"
26,"NCT04249895","Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO )",,"Completed","No Results Available","All Cancer",,"Number of patients with complete data safe.","Tata Medical Center","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","EC/GOVT/24/IRB23","August 31, 2018","February 28, 2021","February 28, 2021","January 31, 2020",,"December 17, 2021","Sanjoy Chatterjee, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT04249895"
27,"NCT00123669","Primary Progesterone Therapy for Operable Breast Cancer",,"Completed","No Results Available","Breast Neoplasms","Drug: 500 mg of depot hydroxy-progesterone","To test the effect of primary progesterone in operable breast cancer on overall and disease free survival at 5 years","Tata Memorial Hospital|Ministry of Science and Technology, India","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","No. SP/SO/B29/2000","October 1997","May 29, 2020","May 29, 2020","July 25, 2005",,"July 22, 2020","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00123669"
28,"NCT02804477","Validation and Assessment of Patient Adherence to Opioids for Cancer Pain Using MMAS 8 Pain Clinic",,"Completed","No Results Available","Chronic Cancer Pain",,"validation and assessment of adherence to opioids for chronic cancer pain in pain clinic using Morisky medication adherence scale 8|relationship of adherence to opioids with demographic characteristics","Tata Memorial Centre","All","18 Years to 80 Years   (Adult, Older Adult)",,"330","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","TataMC 1680","June 2016","November 2016","January 2017","June 17, 2016",,"April 26, 2017","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02804477"
29,"NCT04351009","Sentinel Lymph Node Mapping and Analysis in Colon Cancer Using Indocyanine Green Dye",,"Recruiting","No Results Available","Colon Cancer","Procedure: sentinel lymph node mapping","Detection rate|Upstaging rate|Accuracy|Negative predictive value|Aberrant lymph node drainage","Asian Institute of Gastroenterology, India","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ICG001","June 8, 2020","June 30, 2022","June 30, 2022","April 17, 2020",,"January 18, 2022","Asian Institute of Gastroenterology, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT04351009"
30,"NCT02302105","Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer","POP-RT","Active, not recruiting","No Results Available","Prostate Cancer","Radiation: IGRT","Biochemical Disease Free Survival","Tata Memorial Centre","Male","Child, Adult, Older Adult","Not Applicable","224","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","POP-RT","November 25, 2011","October 23, 2025","October 23, 2025","November 26, 2014",,"November 23, 2021","Dr Vedang Murthy, Navi-Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02302105"
31,"NCT03669432","To Study the Impact of Radiation Treatment After Surgery in Patient With Locally Advanced Thyroid Cancer.","THYRO-RT","Active, not recruiting","No Results Available","Thyroid Cancer Stage IV|Radiation Toxicity","Radiation: Intensity Modulated Radiotherapy|Procedure: Surgery alone","locoregional recurrence|acute toxicity|late toxicity","Tata Memorial Hospital|Department of Atomic Energy","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1076","July 2013","July 2026","July 2026","September 13, 2018",,"May 2, 2022","Gouri Pantvaidya, Mumbai, Maharashtra, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03669432/Prot_SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT03669432/ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03669432"
32,"NCT05102240","Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer",,"Not yet recruiting","No Results Available","Cervix Cancer",,"Generation of software for automated target delineation for cervix cancer|Development and validation of Normal Tissue Complication Plots|Identify ""high risk patient population"" that may benefit from intensification of treatment in future","Tata Memorial Hospital|Bhabha Atomic Research Centre and Indian Institute of Technology, Mumbai.|Erasmus Medical Center","Female","18 Years to 90 Years   (Adult, Older Adult)",,"1800","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","TMC IRB 900787|CTRI/2021/08/035810","February 2022","September 2024","September 2024","November 1, 2021",,"February 14, 2022","Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05102240"
33,"NCT03005860","Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery",,"Unknown status","No Results Available","Female Breast Cancer","Drug: 2,6-Diisopropylphenol|Drug: Fluoromethyl hexafluoroisopropyl ether|Drug: Fentanyl Citrate|Drug: Atracurium Besylate","Change in baseline levels versus 24 hour postoperative levels (Tpre vs T24h ) of serum HIF-1a and VEGF-C in both groups.|Change in levels of serum biomarkers HIF-1a & VEGF-C in patients with breast cancer undergoing resection surgery at other time points - intraoperative, at 2hr postoperative. Ti, T2h in both groups.|Change in levels of serum biomarkers TGF-β, IL-17 IFN-g, TNF-a, IL-6 and MMP-2 at the four time points in both groups.|Measure expression of various lymphocyte subsets (CD3+ T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, γδT cells, NK cells and B cells peripheral blood lymphocytes at four time points","Tata Memorial Centre","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","PN 219","February 2017","January 2018","February 2018","December 29, 2016",,"January 16, 2017","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03005860"
34,"NCT03936218","Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer",,"Recruiting","No Results Available","Advanced Prostate Cancer","Drug: Inj. Goserelin (Test) Subcutaneously|Drug: Inj. Zoladex (Reference) Subcutaneously","To evaluate and compare the pharmacodynamics of test product against reference product and establish non inferiority.","Eurofarma Laboratorios S.A.","Male","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","94","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EF 161","January 1, 2021","December 1, 2022","December 1, 2022","May 3, 2019",,"January 27, 2022","Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT03936218"
35,"NCT01814345","Her 2 Testing in Indian Patients With Gastric Cancer",,"Terminated","No Results Available","Gastric Cancer",,"Incidence of Her2 testing in Gastric cancer","Tata Memorial Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1077|Her 2 in gastric cancer","June 2013","February 2017","February 2017","March 19, 2013",,"April 27, 2017","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01814345"
36,"NCT03168880","A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer","TNBC","Active, not recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Paclitaxel + Carboplatin|Drug: Paclitaxel only","DFS|OS","Tata Memorial Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","720","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRI/2012/07/002802","April 2010","November 30, 2022","November 30, 2024","May 30, 2017",,"April 27, 2022","Tata memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03168880"
37,"NCT02867865","Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers","POLCAGB","Recruiting","No Results Available","Gall Bladder Cancers","Drug: Gemcitabine|Drug: Cisplatin|Radiation: Chemoradiation|Procedure: PETCECT|Procedure: Laparoscopy","Overall Survival|Surgical resection rate|Progression free survival|Number of participants with treatment related serious adverse events|Deterioration free rate of quality of life (QOL) scores at baseline and three monthly","Tata Memorial Hospital","All","19 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","314","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1652","October 2016","August 2021","August 2022","August 16, 2016",,"November 14, 2018","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02867865"
38,"NCT02139605","""Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy",,"Recruiting","No Results Available","Gastric Cancer","Procedure: D3 Lymphadenectomy","primary endpoint:Overall Survival|Disease-free survival","Tata Memorial Centre","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","87","July 5, 2013","July 2025","July 2026","May 15, 2014",,"April 27, 2022","Dr Shailesh Vinayak Shrikhande, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02139605"
39,"NCT03797482","A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer","Hypoxia","Recruiting","No Results Available","Breast Cancer Female","Procedure: Intra-operative Tumor Tissue Biopsy","Gene expression changes|Immunohistochemistry for other markers","Tata Memorial Hospital","Female","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","Protocol 254","November 27, 2017","July 30, 2022","November 30, 2022","January 9, 2019",,"April 27, 2022","Tata Memorial Center, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03797482"
40,"NCT00193752","Para-Aortic Lymph Nodal Staging & Evaluation of Treatment Outcome by 18F FDG-PET in Advanced Cancer Cervix",,"Completed","No Results Available","Cancer of Cervix","Other: PET IMAGING","PET Scan for Para-Aortic Staging in Carcinoma Cervix|Clinical (FIGO), MRI, and PET - Abdomen and Pelvis Correlation|Volumetric Correlation of Local Disease by PET and MRI|Radiotherapy Response Evaluation and Post therapy Surveillance by serial PET Scans|overall survival","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TMH/205/2004/Cx_PET STUDY","September 2005","January 2015","January 2018","September 19, 2005",,"January 23, 2018","Tata Memorial Hospital, Mumbai, Maharastra, India",,"https://ClinicalTrials.gov/show/NCT00193752"
41,"NCT03669497","Hypo-Fractionated Radiotherapy in Breast Cancer","HYPORT-B","Recruiting","No Results Available","Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer","Radiation: Hypo fractionated whole breast radiotherapy","Toxicity (CTCAE v 4.03)|Response","Tata Medical Center","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/TMC/108/17","January 2, 2018","December 2, 2020","January 3, 2023","September 13, 2018",,"December 3, 2021","Sanjoy Chatterjee, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03669497"
42,"NCT02161900","Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer",,"Active, not recruiting","No Results Available","Non Metastatic Operable Breast Cancer","Other: Yogic and routine exercises","Disease-free survival|Quality of life, Improvements in overall survival","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","850","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH Project No. 735","November 12, 2010","March 31, 2023","April 30, 2025","June 12, 2014",,"May 2, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02161900"
43,"NCT03546023","Brief Pain Inventory to Assess Cancer Pain and Quality of Life",,"Completed","No Results Available","Chronic Cancer Pain","Other: Patient Interview","Functional activity measurement using the Brief Pain Inventory (BPI)","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)",,"900","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1921","June 5, 2018","June 4, 2019","June 4, 2019","June 6, 2018",,"September 11, 2019","Tata Memorial Centre, Mumbai, Maharashtra, India|Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03546023"
44,"NCT03638622","Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.","UH3-India","Completed","Has Results","Oral Cancer","Combination Product: Photodynamic Therapy","Number of Participants With no Residual Tumor Following Photodynamic Therapy (PDT)","Massachusetts General Hospital|Jawaharlal Nehru Medical College|National Cancer Institute (NCI)","All","21 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2015P001855|5UH3CA189901-04","March 10, 2017","October 12, 2020","October 12, 2020","August 20, 2018","February 21, 2021","February 21, 2021","J.N. Medical College, Aligarh Muslim University, Aligarh, UP, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/22/NCT03638622/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03638622"
45,"NCT01608451","Randomized Controlled Trial of Neo-adjuvant Progesterone and Vitamin D3 in Women With Large Operable Breast Cancer and Locally Advanced Breast Cancer",,"Terminated","No Results Available","Locally Advanced Breast Cancer and Large Operable Breast Cancer","Drug: Cholecalciferol|Drug: Inj. Progesterone","Disease-free survival|Improvements in overall survival, Tumor response","Tata Memorial Hospital","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vitamin D3/377/TMH|TMH project No. 377","September 2007","August 20, 2021","August 20, 2021","May 31, 2012",,"May 2, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01608451"
46,"NCT01118897","Tomotherapy in Locally Advanced Gallbladder and Pancreatic Cancers",,"Completed","No Results Available","Pancreatic Neoplasms Malignant|Malignant Neoplasm of Gall Bladder Non-resectable","Radiation: Tomotherapy","To assess the feasibility of concurrent chemo-radiation with dose escalated IMRT in locally advanced inoperable gallbladder and pancreatic cancers|Response to CTRT|R0 resection rate|Locoregional control|Overall survival","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 599","December 2008","January 2013","June 2013","May 7, 2010",,"August 7, 2015","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01118897"
47,"NCT00750503","Workplace Tobacco Cessation And Oral Cancer Screening Study",,"Completed","No Results Available","Tobacco Cessation|Oral Cancer","Behavioral: Behavioural and Pharmacotherapy for tobacco cessation","The prevalence of tobacco use and the the change in Knowledge, Attitude and Practices during post intervention. The reasons for initiation and continuation of tobacco consumption habit. The tobacco quit rates.|The prevalence of oral precancerous and cancerous lesions among this group and its correlation with the different forms and frequency of tobacco use.","Tata Memorial Hospital|Department of Atomic Energy","Male","18 Years to 60 Years   (Adult)","Phase 3","104","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","458","June 2007","June 2008","August 2008","September 10, 2008",,"September 10, 2008","Chemical Industry, Tal. Khed, District : Ratnagiri, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00750503"
48,"NCT01429766","A Prospective Study of Variation in Breath Holding Times at Various Phases of Respiration During the Course of Radiotherapy Including the Effect of Respiratory Training in Lung Cancer Patients",,"Unknown status","No Results Available","Small Cell Lung Cancer|Non Small Cell Lung Cancer","Other: Respiratory Training","Breath holding time in various phases of the respiratory cycle","Tata Memorial Hospital","All","Child, Adult, Older Adult","Phase 2","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","747","June 2010","May 2012","May 2012","September 7, 2011",,"September 7, 2011","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01429766"
49,"NCT04842994","Trial on Intraoperative Neuromonitoring (IONM) in Thyroid Cancer Surgery.","ACTION","Recruiting","No Results Available","Malignant Neoplasm of Thyroid Gland","Device: IONM tube","Primary objective assessment (Temporary RLN palsy)- FOL evaluation|Acoustic analysis|Aerodynamic voice measurement|Voice quality assessment","Tata Memorial Hospital","All","Child, Adult, Older Adult","Not Applicable","448","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","3223","August 16, 2019","August 2024","August 2024","April 13, 2021",,"May 5, 2022","Tata Memorial Hospital, Parel, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04842994"
50,"NCT02116920","HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening","PODBT","Unknown status","No Results Available","CIN|Cervix Cancer",,"Efficacy Outcome Measure","Tata Memorial Hospital|Ministry of Science and Technology, India","Female","30 Years to 65 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","BT/PR6121/SPD/11/1401/2012","May 2013","May 2016","May 2016","April 17, 2014",,"April 17, 2014","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02116920"
51,"NCT04085120","Ropivacaine/Dexamethasone and 10% Lignocaine Injection in GPN Block for Intractable Cancer Pain",,"Unknown status","No Results Available","Cancer, Oropharynx|Pain, Intractable|Cancer Pain","Procedure: 0.75 % Ropivacaine/ 4mg/mL dexamethasone injection|Procedure: 10% lignocaine injection","Pain reduction on the basis of the Numeric rating scale (NRS).|Brief Pain Inventory (BPI)- short form|WHO Quality of Life-BREF|Patient Global Impression of Change (PGIC)|Clinical Global Impression of Change (CGIC)|Analgesic requirement and rescue analgesic requirement","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","IEC-402/07.06.2019, RP-34/2019","August 23, 2019","January 31, 2020","February 28, 2020","September 11, 2019",,"September 11, 2019","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04085120"
52,"NCT04985253","Correlation of Predictive Accuracy of PREDICT Version 2.2 of Indian Women With Operable Breast Cancer","PREDICT","Active, not recruiting","No Results Available","Operable Breast Neoplasms","Other: prediction of overall survival using Web based PREDICTV2.0 portal","Five year overall survival|To compare the observed 5 year overall survival of operable breast cancer patients with the one predicted by PREDICT V2.0V 2.2 for subgroups like age at diagnosis, stage of disease, tumour grade and molecular class (ER/PR positive or TNBC)","Tata Memorial Centre","Female","18 Years to 99 Years   (Adult, Older Adult)",,"2780","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","3055","November 15, 2018","October 18, 2021","July 31, 2022","August 2, 2021",,"May 4, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04985253"
53,"NCT01785420","Pre Operative Trastuzumab in Operable Breast Cancer",,"Recruiting","No Results Available","Carcinoma Breast Stage I|HER2 Positive Breast Cancer","Drug: Trastuzumab|Drug: Placebo","Disease Free Survival|Overall survival|Circulating Tumour Cells in Peripheral Blood|4.1.3. Evaluation of the paraffin blocks for pTEN loss6-8 and p95ErbB2 truncated form of HER2","Dr Rajendra A. Badwe|Tata Memorial Hospital","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TMH Project-982","May 2013","April 2025","February 2027","February 7, 2013",,"April 27, 2022","Tata Memorial Centre, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT01785420"
54,"NCT01304199","Cancer Survivorship Issues: A Survey of Patients in India.AIIMS Study (CANSURVIVE)","CANSURVIVE","Unknown status","No Results Available","Cancer",,"To study the cancer survivorship experience(as binary responses)|To assess the mental status of cancer survivors|To identify the differences if any, in the cancer survivorship issues by age(Less than 50 or greater than 50 years)|To define follow up care for cancer survivors in India.","All India Institute of Medical Sciences, New Delhi","All","18 Years to 75 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IEC/NP-252/2010","January 2011","July 2013","December 2013","February 25, 2011",,"July 12, 2012","All India Institute of Medical Sciences Dr.B.R.A.Institute Rotary Cancer Hospital, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01304199"
55,"NCT00128817","Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers",,"Terminated","No Results Available","Larynx Neoplasms","Radiation: Concurrent Chemoradiation|Procedure: Laryngectomy + adjuvant radiotherapy/chemoradiotherapy","Overall survival at 3 and 5 years|Disease free survival at 3 and 5 years|Locoregional control rates at 3 and 5 years|Patterns of relapse|Salvage rates|Treatment-related adverse events|Completion of treatment|Quality of life","Tata Memorial Hospital|Ministry of Science and Technology, India","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/196/2004|DAECTC/Projno 4/2004-2005","May 2005","May 2015","May 2015","August 10, 2005",,"January 23, 2013","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00128817"
56,"NCT05250336","Tumor-Infiltrating Lymphocytes and Programmed Cell Death - Ligand 1 in Breast Cancer",,"Recruiting","No Results Available","Breast Cancer|Tumor Infiltrating Lymphocytes|Programmed Cell Death Ligand 1","Other: Observational Study","Correlation of TILs and PDL-1 in various molecular sub-types|PDL-1 expression in patients with Triple Negative Breast Cancer (TNBC)|TILs and Tumor response to treatment|PD-L1 expression and Tumor response to treatment","Sanjay Gandhi Postgraduate Institute of Medical Sciences","All","18 Years to 90 Years   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","2018-177-IMP-EXP-4","January 19, 2019","June 30, 2022","September 30, 2022","February 22, 2022",,"February 22, 2022","Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT05250336"
57,"NCT02745288","Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery - RCT",,"Completed","No Results Available","Mandibular Neoplasms","Procedure: inferior alveolar nerve block","IV fentanyl requirement during primary tumour removal|IV fentanyl requirement during neck dissection and primary tumour removal|Maximum change in heart rate from baseline during primary tumour removal|Maximum change in blood pressure from baseline during primary tumour removal|Need for rescue analgesics or vasoactive agents during primary tumour removal","Tata Memorial Centre","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","1648","June 2016","October 2016","October 2016","April 20, 2016",,"November 22, 2016","Tata Memorial Hospital, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT02745288"
58,"NCT00896155","Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients","CONSET","Unknown status","No Results Available","Pulmonary Fibrosis|Breast Cancer","Drug: Tamoxifen|Radiation: Radiotherapy","Development of Lung fibrosis|Locoregional failure and distant failure","Tata Memorial Hospital|Indian Council of Medical Research","Female","Child, Adult, Older Adult","Phase 3","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","349","December 2008","December 2011","December 2013","May 11, 2009",,"August 30, 2011","Tata Memorial Center, Parel, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT00896155"
59,"NCT01858571","Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies",,"Completed","No Results Available","Malignant Childhood Neoplasm","Drug: Low dose chemotherapy","Progression free survival|Overall Survival","All India Institute of Medical Sciences, New Delhi","All","5 Years to 18 Years   (Child, Adult)","Phase 3","108","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","IEC/NP-63/2013","October 2013","July 2016","January 2017","May 21, 2013",,"January 25, 2017","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01858571"
60,"NCT00655421","Oral Cancer Screening in Mumbai, India by Primary Health Care Workers",,"Unknown status","No Results Available","Oral Cancer|Precancerous Conditions","Other: Unaided Visual Inspection|Device: VelScope|Other: Toluidine Blue Assisted Oral Examination","To evaluate the feasibility and efficacy of performance of the three oral cancer screening tests viz. naked eye unaided examination , examination using VELScope and after application of Toluidine Blue by trained primary health workers.|To estimate the test characteristics of each of the three oral cancer screening techniques.","Tata Memorial Hospital|American Cancer Society, Inc.|Emory University","Male","18 Years and older   (Adult, Older Adult)","Phase 3","329","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Screening","391","April 2008","September 2009","September 2009","April 9, 2008",,"July 3, 2009","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00655421"
61,"NCT03022162","Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer",,"Completed","No Results Available","Breast Cancer Female|Neuropathic Pain",,"Prevalence of Paclitaxel induced CIPN-related pain|Prevalence of Paclitaxel induced CIPN|temporal characteristics and risk factors of CIPN-related pain|Use of Agents offered with an intend to prevent CIPN","Tata Memorial Centre","Female","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1758","December 1, 2017","May 31, 2018","May 31, 2018","January 16, 2017",,"October 14, 2020","Anuja Bidkar, Thane, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03022162"
62,"NCT04472845","HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).","HYPART","Recruiting","No Results Available","Breast Cancer|Hypofractionation|Radiotherapy Side Effect","Radiation: 1 week RT|Radiation: 2 week RT","Loco-regional recurrence, Change is being assessed|Disease-free survival, Change is being assessed|Overall survival, Change is being assessed|Acute radiation toxicity|Late adverse events, Change is being assessed|Quality of life(QoL), Change is being assessed","Postgraduate Institute of Medical Education and Research","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1018","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYPART","March 30, 2021","August 20, 2023","August 20, 2028","July 15, 2020",,"June 25, 2021","Budhi Singh Yadav, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04472845"
63,"NCT01797770","Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery","MBP","Unknown status","No Results Available","Rectal Cancer|Colon Cancer","Drug: polyethylene glycol|Other: No Preparation","anastomotic leak|surgical site infection|Intraoperative parameters assessment|bowel recovery|drain removal|Re-exploration|Hospital stay|Readmission","PVS Memorial Hospital","All","25 Years to 75 Years   (Adult, Older Adult)",,"90","Other","Observational","Time Perspective: Prospective","PVS2","January 2012","January 2014","February 2014","February 22, 2013",,"February 22, 2013","PVS Memorial Hospital, Kochi, Kerala, India",,"https://ClinicalTrials.gov/show/NCT01797770"
64,"NCT04094974","Heartrate Variability and Intraoperative Brain Conditions in Supratentorial Tumors",,"Completed","No Results Available","Supratentorial Brain Tumors","Device: ANSiscope","Brain relaxation|Hemodynamic Measurement-Heartrate|Hemodynamic Measurement-Bloodpressure","DyAnsys, Inc.","All","18 Years to 75 Years   (Adult, Older Adult)",,"58","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CS009","October 12, 2019","October 3, 2020","October 3, 2020","September 19, 2019",,"January 25, 2021","National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT04094974"
65,"NCT04365647","Intra-operative Variation in Size of Brain Tumors After Craniotomy",,"Completed","No Results Available","Brain Tumor, Primary",,"Tumor dimension change|Tumor distance from dural surface|Relationship of tumor size change with other characteristics","Sheri Kashmir Institute of Medical Sciences","All","15 Years to 75 Years   (Child, Adult, Older Adult)",,"51","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SKIMS, Soura","March 1, 2018","November 1, 2019","March 31, 2020","April 28, 2020",,"April 28, 2020","Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Jammu And Kashmir, India",,"https://ClinicalTrials.gov/show/NCT04365647"
66,"NCT01476670","Cerebral Blood Circulation in Patients With Posterior Fossa Brain Tumor",,"Unknown status","No Results Available","Brain Tumor","Other: Monitoring",,"All India Institute of Medical Sciences, New Delhi","All","18 Years to 60 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CA-CO2-TCD|Posterior fossa tumor - TCD","July 2012",,,"November 22, 2011",,"November 22, 2011","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01476670"
67,"NCT01758146","Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors",,"Unknown status","No Results Available","Breast Cancer","Drug: Tamoxifen|Drug: Letrozole","Disease free survival|recurrence-free survival .|overall survival (OS)","Postgraduate Institute of Medical Education and Research","Female","45 Years to 80 Years   (Adult, Older Adult)","Phase 3","412","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","BMI","January 2012","January 2020","June 2020","January 1, 2013",,"March 4, 2020","Department of Radiotherapy, Post Graduate Institute of Medical Education & Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01758146"
68,"NCT05144867","Stereotactic Radiosurgery vs Whole Brain Radiotherapy in Breast Cancer With Brain Oligometastasis","SRSvsWBRT","Recruiting","No Results Available","Breast Cancer|Brain Metastases, Adult|Stereotactic Radiosurgery|Whole Brain Radiotherapy","Radiation: Stereotactic Radiosurgery","Overall survival|Progression Free Survival (PFS)|Quality of Life - KPS|Quality of life - MINI MENTAL STATE","Postgraduate Institute of Medical Education and Research","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","98","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NK/7784/Study/249","August 31, 2021","August 31, 2025","August 31, 2026","December 3, 2021",,"December 3, 2021","Budhi Singh Yadav, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT05144867"
69,"NCT01145781","Trial to Evaluate Single- and Double- Freeze Cryotherapy in the Prevention of Cervical Neoplasia",,"Completed","No Results Available","Cervical Intraepithelial Neoplasia","Procedure: Cryotherapy","The primary end point is the cure rate at the end of one year|The secondary end points are the rates and the types of side effects and complications","Tata Memorial Hospital","Female","25 Years to 64 Years   (Adult)","Not Applicable","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","649","January 2010","January 2015","January 2015","June 17, 2010",,"May 1, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01145781"
70,"NCT00847717","Trial of IIb Preserving Neck Dissection",,"Completed","No Results Available","Oral Cancer","Procedure: Selective neck dissection|Procedure: Conventional Neck dissection","Spinal accessary nerve function|neck Node failure","Banaras Hindu University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SND_01","August 2007","August 2009","August 2009","February 19, 2009",,"July 17, 2018","Banaras Hindu University, Varanasi, UP, India",,"https://ClinicalTrials.gov/show/NCT00847717"
71,"NCT01391065","MR- PET Guided Biologically Optimised Interstitial Brachytherapy","MR-PET Brachy","Completed","No Results Available","Cervical Cancer","Radiation: MR PET Guided Brachytherapy","Local Response in spatial reference to High Risk GTV (as identified by functional imaging)|Incidence of Grade III rectal and bladder toxicity with biologically dose modulated brachytherapy","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH-IRB 843","February 23, 2011","February 2019","October 4, 2019","July 11, 2011",,"April 7, 2020","Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01391065"
72,"NCT01440621","Modafinil in Cancer Related Fatigue","ModCRF","Completed","No Results Available","Cancer Related Fatigue|Quality of Life","Drug: Modafinil|Drug: Pyridoxine","Reduction in Cancer Related Fatigue|Improvement in Quality of Life|Karnofsky Performance Status Scores|Effects of Modafinil on Systolic and Diastolic Blood Pressure|Changes in weight","Indira Gandhi Medical College, Shimla","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","217","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ModCRF","August 2010","February 2012","February 2012","September 26, 2011",,"March 23, 2012","Regional Cancer Centre, Shimla, Himachal Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01440621"
73,"NCT00193843","Oral Cancer Adjuvant Therapy (OCAT) Trial",,"Unknown status","No Results Available","Mouth Neoplasms","Procedure: Post-operative chemoradiotherapy / accelerated radiotherapy","Local-regional failure|Overall survival|Treatment related toxicity|Protocol compliance|Overall treatment time|Quality of life: assessment by EORTC-QLQ-C30 and EORTC-H&N-35","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/177/2004","June 2005",,"June 2017","September 19, 2005",,"December 26, 2005","Dr. Mandar. S. Deshpande, Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193843"
74,"NCT02150564","3D Ultra Sound for Resection of Brain Tumors","SonoRCT","Completed","No Results Available","Patients With Resectable Brain Tumors","Device: Sonowand|Procedure: Navigation","Percentage of patients where Gross total resection (GTR) achieved|Accuracy of US","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","72","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","TMC-ACTREC 101","March 2014","June 30, 2019","June 30, 2019","May 30, 2014",,"May 9, 2022","Advanced Centre for Treatment Research and Education in Cancer, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02150564"
75,"NCT05240378","Mortality of Cancer Surgery During SARS CoV2 Pandemic",,"Completed","No Results Available","SARS CoV 2 Infection|Cancer","Other: Surgery","30 day mortality|number of participants developing major or minor complications|number of health care worker with SARS CoV2 infection","Banaras Hindu University","All","18 Years to 99 Years   (Adult, Older Adult)",,"1576","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","Dean/2021/EC/3004","October 29, 2021","December 31, 2021","January 15, 2022","February 15, 2022",,"March 3, 2022","Banaras Hindu University, Varanasi, UP, India",,"https://ClinicalTrials.gov/show/NCT05240378"
76,"NCT01179074","Role of Radiotherapy Following Oesophageal Stenting in Cancer",,"Completed","No Results Available","Oesophageal Cancer","Procedure: oesophageal stenting with self expandable metal stent|Procedure: Oesophageal stent followed by external beam radiotherapy","Relief of dysphagia|Survival","All India Institute of Medical Sciences, New Delhi","All","Child, Adult, Older Adult","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SEMSRT-1","April 2007","March 2009","March 2009","August 11, 2010",,"August 11, 2010","Departments of Gastrointestinal surgery, Gastroenterology, Radiation Oncology, All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01179074"
77,"NCT03923998","Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers",,"Completed","No Results Available","Squamous Cell Carcinoma of Oral Cavity","Drug: Neoadjuvant chemotherapy|Radiation: Neoadjuvant radiotherapy|Procedure: Resection and reconstruction","Objective response rate|Disease free survival|Overall Survival|Quality of life assessment","Indrayani Hospital and Cancer Institute|Tata Capital Limited|Grant Medical Foundation Ruby hall Clinic","All","18 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OIT415","March 15, 2016","March 15, 2019","March 15, 2019","April 23, 2019",,"April 23, 2019","Indrayani hospital and cancer institute, Pune, Maharshtra, India",,"https://ClinicalTrials.gov/show/NCT03923998"
78,"NCT02247999","Improving Cervical Cancer Screening Among HIV-Infected Women in India",,"Completed","No Results Available","Cervical Cancer|HIV/AIDS|HPV|Cervical Intraepithelial Neoplasia|Biomarkers",,"Cervical Intraepithelial Neoplasia Grade II or more severe","National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)","Female","18 Years and older   (Adult, Older Adult)",,"1000","NIH","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","999913037|13-C-N037","November 28, 2012","October 8, 2020","October 8, 2020","September 25, 2014",,"October 9, 2020","National Institute of Epidemiology (NIE), Chennai, India",,"https://ClinicalTrials.gov/show/NCT02247999"
79,"NCT03137953","Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors",,"Unknown status","No Results Available","Buccal Mucosa Cancer|Gingival Cancer","Procedure: Clinical Evaluation|Diagnostic Test: Radiological Imaging","Proportion of patients undergoing skin preservation surgeries","HealthCare Global Enterprise Ltd.","All","Child, Adult, Older Adult","Not Applicable","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HCG/SX/002/2016","June 1, 2016","June 30, 2017","June 30, 2017","May 3, 2017",,"May 9, 2017","HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT03137953"
80,"NCT03727126","Robotic Versus Thoracolaparoscopic Esophagectomy for Esophageal Cancer",,"Recruiting","No Results Available","Esophageal Cancer","Procedure: Robotic esophagectomy|Procedure: Thoracolaparoscopic esophagectomy","Lymph node yield|Surgical margin status|Complications|ICU stay|Hospital stay|Mortality|Duration of surgery|Blood loss|Conversion rate","GEM Hospital & Research Center","All","Child, Adult, Older Adult","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEMBOT","November 1, 2018","December 31, 2020","January 1, 2021","November 1, 2018",,"October 14, 2020","GEM Hospital & Research Center, Chennai, Tamil Nadu, India|GEM Hospital & Research Center, Coimbatore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03727126"
81,"NCT03386695","Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra","HPV","Unknown status","No Results Available","Cervical Cancer","Other: Education by Pamphlets|Other: Health education programme","Agreement rate between health care personnel collected samples and self collected samples in these two groups.|Test characteristics of HPV self sample and health care worker collected sample by HPV HC 2.|Acceptability and barriers for self-collection of specimens for HPV DNA testing in an urban population.","Tata Memorial Hospital","Female","30 Years to 55 Years   (Adult)","Not Applicable","1600","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","TMHPO 1686","September 2018","January 2019","January 2020","December 29, 2017",,"August 6, 2018","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03386695"
82,"NCT02778308","Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma",,"Completed","No Results Available","Gallbladder Cancer","Drug: Gemcitabine + Cisplatin","Disease Free Survival|Overall Survival|Blood and lymphatic system Adverse events|Gastrointestinal system Adverse events","Govind Ballabh Pant Institute of Postgraduate Medical Education and Research","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FI/IEC/MAMC(32)/4/2012/239","January 2012","June 2018","December 2018","May 19, 2016",,"April 6, 2021","GIPMER, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02778308"
83,"NCT00409864","Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer",,"Completed","No Results Available","Gallbladder Cancer|Obstructive Jaundice","Procedure: Endoscopic biliary stenting, Percutaneous biliary stenting","Successful drainage: A decrease in bilirubin to less than 75% of the pretreatment value within 7 days|Early cholangitis: Occurring within 48 hours to 7 days of the procedure as evidenced by fever, leukocytosis and worsening LFTs.|Quality of life|Complications|Procedure-related and 30-day mortality|Stent patency time will be defined by time to stent occlusion","All India Institute of Medical Sciences, New Delhi","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","182","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIS/1/2003","October 2003","July 2005","December 2005","December 11, 2006",,"May 26, 2010","All India Institute of Medical Sciences,, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00409864"
84,"NCT04406844","Issues and Challenges in Cancer Patients on Active Treatment During the COVID-19 Pandemic",,"Recruiting","No Results Available","Oncology Patients",,"Oncology patients","Max Healthcare Insititute Limited","All","12 Years to 98 Years   (Child, Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","Onco_Covid-19","May 9, 2020","June 30, 2021","June 30, 2021","May 28, 2020",,"July 22, 2020","Max Superspeciality hospital, A Unit of Balaji Medical and Diagnostic Centre, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04406844"
85,"NCT03003273","Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study","DALFEN","Terminated","No Results Available","Neutropenia, Febrile|Pediatric Cancer","Other: stoppage of antibiotics|Other: amoxycillin/clavulanic acid|Other: levofloxacin","Treatment is considered to be successful if the following is attained without changing the regimen - Patient remains afebrile till recovery of ANC ≥500 •Measure of effect: Proportion of patients afebrile in each arm|Rate of re-admission","All India Institute of Medical Sciences, New Delhi","All","3 Years to 18 Years   (Child, Adult)","Phase 3","142","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IECPG-164","January 2017","December 2018","December 2018","December 28, 2016",,"February 1, 2019","Department of Medical Oncology, AIIMS, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT03003273"
86,"NCT03229603","A Pilot Study on HPV and Cervical Cancer Screening in Mumbai","HPV","Unknown status","No Results Available","HPV Infection","Other: Cluster of 3000 women","The feasibility of HPV testing as a single visit approach will be summarized using the appropriate descriptive statistics.|Overall agreement between clinician-collected versus self-collected samples will be compared using pairwise t tests|The focus group data will be analyzed using constant comparative data analysis to identify thematic components and sub-themes.|The HPV GeneXpert by health care provider and HPV HC2 samples by health care provider will be compared to study the agreement rates.|Documentation of six different genotypes/ genotype families of HPV from cervical tissue samples, which will inform the development of HPV vaccinations specific to the strains of HPV in India.|Probe for perceptions about self-collection of vaginal samples to describe acceptability of this process.|Fit a predictive model of HPV infection(s).","Tata Memorial Hospital|University of Arizona","Female","30 Years to 55 Years   (Adult)","Not Applicable","227","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","TMHPO1763","April 2018","April 2018","May 2018","July 25, 2017",,"December 22, 2017","Tata Memorial Hospital, Mumbai, Mharashtra, India",,"https://ClinicalTrials.gov/show/NCT03229603"
87,"NCT01633463","An Observational Study of Pain Assessment and Treatment Adequacy of Emergency Cancer Pain",,"Completed","No Results Available","OBSERVE PAIN MANAGEMENT PRACTICES IN EMERGENCY DEPARTMENT",,,"Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","emcap 2011","April 2011","June 2011","June 2011","July 4, 2012",,"July 4, 2012","Tata Memorial Hospital, Mumbai, Parel, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01633463"
88,"NCT01190982","Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: LEP-ETU","Assessment of Overall Response Rate (ORR) following treatment of LEP-ETU at 275 mg/m2 dose|LEP-ETU 275mg/m2 Induce Progression-Free Survival Assessment","INSYS Therapeutics Inc","Female","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LEP-ETU 202","March 2008","December 2011","December 2011","August 30, 2010",,"August 24, 2012","Indo-American Cancer Institute and Research Center, Banjara Hills, Hyderabad, India|P.D. Hinduja Antional Hospital & Medical Research Center, Mahim, Mumbia, India|Jaslok Hospital and Research Center, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT01190982"
89,"NCT02951325","Bladder Cancer Adjuvant Radiotherapy Trial","BART","Recruiting","No Results Available","Bladder Cancer|Urothelial Carcinoma Bladder","Other: Adjuvant RT","Improvement in loco-regional relapse free survival (LRFS)|Disease free survival (DFS)|Overall survival(OS)|RT toxicity (acute and late)|QOL|Patterns of failure","Tata Memorial Centre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BART","June 2016","April 13, 2023","April 13, 2023","November 1, 2016",,"October 7, 2021","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02951325"
90,"NCT05099809","Registry Trial to Evaluate the Safety and Efficacy of Hyperthermia in Locally Advanced Cancers","RESHMART","Recruiting","No Results Available","Locally Advanced Malignant Neoplasm","Other: Hyperthermia","Locoregional tumour control|Disease free survival|Overall survival|Acute treatment related morbidity|Late treatment related morbidity","Mahatma Gandhi Institute of Medical Sciences","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","MahatmaIGMS","December 1, 2021","December 31, 2022","June 30, 2023","October 29, 2021",,"May 5, 2022","Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India|Mahatma Gandhi Institute of Medical Sciences,, Sevagram, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05099809"
91,"NCT04546607","Evaluation of Clinical Efficacy and Safety of Nuvastatic in Cancer Asthenia",,"Completed","No Results Available","Asthenia|Cancer","Other: Nuvastatic TM (C5OSEW5050ESA) 1000 mg","To evaluate efficacy of CANSSUFIVE® Nuvastatic (C5OSEW5050ESA) in Improving Fatigue in Patients with Solid Stage I - IV Tumors.|To evaluate the safety and tolerability of CANSSUFIVE® Nuvastatic (C5OSEW5050ESA) in Patients with Solid Stage I - IV Tumors.|Quality of Life (QoL)|Fatigue Severity Scale|Brief Fatigue Inventory|Vitality subscale of the Medical Outcome Scale Short Form-36 (SF-36)|F2-isoprostane|The adverse events","Natureceuticals Sdn Bhd","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","110","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EBSB0045011CRA","September 2, 2017","October 28, 2019","October 31, 2019","September 14, 2020",,"September 16, 2020","Notrox Research Pvt Ltd, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT04546607"
92,"NCT00191789","Neoadjuvant Sequential Administration of Two Gemcitabine Combinations in Operable Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: gemcitabine|Drug: doxorubicin|Drug: cisplatin|Procedure: surgery","Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)|Summary of Deaths During Study|Progression Free Survival (PFS)|Overall Survival|Time to Treatment Failure|Number of Patients Eligible for Breast Conservation Surgery at Baseline and Number of Patients Undergoing Breast Conservation Surgery","Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 2","65","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7117|B9E-MC-S329","February 2003","April 2009","April 2009","September 19, 2005","July 22, 2010","July 27, 2010","For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Pune, Maharashtra, India|For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Vellore, Tamil Nadu, India|For additional information regarding investigative sites for this clinical trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT -5 hours, EST), or speak with your personal physician., Delhi, India",,"https://ClinicalTrials.gov/show/NCT00191789"
93,"NCT01145638","A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)",,"Completed","Has Results","Non-myeloid Malignancies|Chemotherapy Induced Anaemia","Drug: iron isomaltoside 1000|Drug: iron sulphate","Change in Hb Concentration|Change in Hemoglobin From Baseline to Week 24","Pharmacosmos A/S","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-Monofer-CIA-01|EudraCT no. 2009-016727-53","October 2010","April 2014","May 2014","June 16, 2010","December 3, 2015","December 3, 2015","Apollo Hospitals, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01145638"
94,"NCT02074137","Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer",,"Completed","No Results Available","Prostate Cancer Metastatic","Drug: CABAZITAXEL XRP6258|Drug: Prednisone|Drug: Prednisolone","Number of patients with Related Serious Adverse Events|Evaluation of use of cabazitaxel in terms of treatment duration, number of cycles, dose modifications|Radiological overall response (if radiological tumor assessment done) using Recist criteria|Number of patients with at least 50% decrease in PSA","Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 4","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CABAZL06499|U1111-1131-3161","July 2014","March 2016","March 2016","February 28, 2014",,"June 2, 2016","Investigational Site Number 356005, Kollkata, India|Investigational Site Number 356003, New Delhi, India|Investigational Site Number 356002, Trivandrum, India",,"https://ClinicalTrials.gov/show/NCT02074137"
95,"NCT00915369","A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer",,"Unknown status","No Results Available","Advanced Breast Cancer","Drug: Nanoxel (Paclitaxel Nanoparticle formulation )","The primary outcomes of the study would be the Pharmacokinetic data at all the four dose levels (220, 260, 310 and 375 mg/m2); Ability to identify a dose higher than 220 mg/m2 that demonstrate better efficacy and manageable toxicity|evaluation of the effect of Paclitaxel Nanoparticle formulation on QTc.","Fresenius Kabi Oncology Ltd.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DO/NDR/02/2008/01","March 2009","April 2010","April 2010","June 8, 2009",,"February 8, 2010","Nizam'S Institute of Medical Sciences, Hyderabaad, Andhra Pradesh, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|SEAROC Cancer Center, S K Soni Hospital, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT00915369"
96,"NCT01917695","Study on Early Stage Bulky Cervical Cancers",,"Unknown status","No Results Available","Carcinoma Cervix","Drug: Chemotherapy|Radiation: External Beam Radiotherapy|Radiation: Brachytherapy|Procedure: Radical Hysterectomy","Overall and Disease free Survival|Acute Adverse reactions and complications|SubAcute Adverse reactions and complications|Chronic Adverse reactions and complications","Rajkumar Kottayasamy Seenivasagam|Government Royapettah Hospital","Female","18 Years to 60 Years   (Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GRHCO-01","August 2013","August 2018","August 2018","August 7, 2013",,"August 13, 2015","Government Royapettah Hospital, Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01917695"
97,"NCT00193765","Elective vs Therapeutic Neck Dissection in Treatment of Early Node Negative Squamous Carcinoma of Oral Cavity",,"Unknown status","No Results Available","Oral Cancer","Procedure: Elective neck dissection in early oral cancer|Procedure: Therapeutic Neck Dissection","Overall Survival|Disease free survival|Role of ultrasound examination in routine initial workup of a node negative patient.|Role of ultrasonogrphy vs clinical examination in ideal follow up of patient.|Correlation between the tumour thickness assessment by surgeon on table , on frozen section and final histopathology.|Identify histological prognostic factors in primary that may help identify a sub-set of patients at an increased risk of cervical metastasis.","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","710","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/131/2003","January 2004","June 2019","June 2019","September 19, 2005",,"June 16, 2017","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193765"
98,"NCT02515006","Impact of Homeopathy for Persistent Insomnia in Patients With Cancer",,"Completed","No Results Available","Chronic Insomnia|Cancer","Other: Homeopathy Medicine","Changes in sleep efficiency on the Insomnia Severity Index|Change in Anxiety and Depression on Hospital Anxiety Depression Scale|Change in Quality of Life on Short Form-36 Scale","Adwin Life Care|Center For Homeopathy Research, India|Sonal Foundation, India","All","18 Years to 45 Years   (Adult)","Not Applicable","160","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Adwin/chr/1121","September 2014","April 2015","June 2015","August 4, 2015",,"August 4, 2015","Center for Homeopathy Research, Ahmedabad, Gujarat, India|Center for Homeopathy Research, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT02515006"
99,"NCT00193817","Three Field Radical Esophagectomy Versus Two Field Esophagectomy - a Prospective Trial",,"Unknown status","No Results Available","Cancer of Esophagus","Procedure: Two field vs Three field lymphadenectomy","Overall survival|Disease-free survival|Quality of Life","Tata Memorial Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH 111/IM-2004|DAECTC/Projno 5 / 2004-05","January 2005",,"December 2015","September 19, 2005",,"February 7, 2006","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193817"
100,"NCT05368116","Effectiveness of Video Assisted Self Management Program on Chemotherapy Related Side Effects .",,"Completed","No Results Available","Cancer Patients","Other: Video Assisted Self Management Program|Other: Standard of care","Knowledge regarding the management of chemotherapy related side effects.|self efficacy in relation to symptom management relevant to chemotherapy for patients with cancer.|Severity of Side effects including Nausea, Vomiting, Diarrhea, Constipation, Mucositis, Fever, Pain ,Dry Skin and alopecia related distress.","Institute of Liver and Biliary Sciences, India","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other","ILBS-VASMPCa-103","November 1, 2021","November 14, 2021","December 5, 2021","May 10, 2022",,"May 10, 2022","Institute of Liver and Biliary Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT05368116"
101,"NCT03511781","Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer","HYPORT","Completed","No Results Available","Carcinoma Breast Stage IV","Radiation: Hypofractionated Radiotherapy","Proportion of patients with CTCAE 4.03 defined Grade 3 or more toxicity","Tata Medical Center","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/TMC/31/14","September 2015","October 2020","March 2021","April 30, 2018",,"December 17, 2021","Tata Medical Center, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03511781"
102,"NCT05278052","Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","TARGET-02","Recruiting","No Results Available","Oligometastatic Disease|Metastatic Non Small Cell Lung Cancer","Radiation: Local consolidative radiation therapy|Drug: Standard maintenance therapy as decided by the treating medical oncologist","Overall survival (OS)|Progression free survival (PFS )|Local control rates of treated sites|New distant metastases|Health Related QOL using the EORTC-QLQ-C30 questionnaire|Health Related QOL using the EORTC- LC13 questionnaire|Response rates|Toxicity using CTC v5.0 (radiotherapy related acute and late toxicity)","Tata Memorial Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3445|CTRI/2020/04/024761","April 20, 2020","April 20, 2026","April 20, 2028","March 14, 2022",,"March 14, 2022","Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05278052"
103,"NCT03710018","Impact of Tumor Bed Localisation on Dosimetry Boost Irradiation in Patients Undergoing Breast Conserving Surgery",,"Unknown status","No Results Available","Breast Carcinoma",,"Volume of PTV|PTV coverage by 95% isodose line|Cosmesis","Tata Memorial Centre","All","18 Years to 90 Years   (Adult, Older Adult)",,"21","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1860","July 1, 2017","June 30, 2019","June 30, 2019","October 17, 2018",,"October 17, 2018","Tata Memorial Center, Mumbai, Maharashtra, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT03710018/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03710018"
104,"NCT00193739","Neoadjuvant Chemotherapy Followed by Surgery Versus Concurrent Chemoradiation in Carcinoma of the Cervix","NACTcervix","Unknown status","No Results Available","Cancer of Cervix","Drug: NACT|Procedure: Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|Drug: Inj.Cisplatin|Radiation: Concurrent chemo radiotherapy","Disease Free Survival|Over all survival|Rate of Distant Metastases","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","635","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","119 of 2003","September 4, 2003","July 31, 2020","July 31, 2020","September 19, 2005",,"September 20, 2019","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00193739"
105,"NCT05022576","Robotic-arm Assisted Ga-68 PSMA PET/CT Guided Transgluteal Prostate Biopsy",,"Completed","No Results Available","Prostate Cancer","Diagnostic Test: Robotic arm assisted PSMA PET/CT guided prostate biopsy","The diagnostic yield of the procedure|Safety of the procedure","Postgraduate Institute of Medical Education and Research","Male","Child, Adult, Older Adult","Not Applicable","78","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","INT/IEC/2019/001994","January 30, 2019","September 30, 2020","September 30, 2020","August 26, 2021",,"August 26, 2021","Department of Nuclear Medicine, PGIMER, Chandigarh, Chandīgarh, India",,"https://ClinicalTrials.gov/show/NCT05022576"
106,"NCT00391183","Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block.",,"Completed","No Results Available","Gallbladder Cancer","Procedure: Biliary stenting","Improvement in the physical functioning scale (containing five items) of EORTC QLQ-30 one month after after biliary stenting.|Improvements in other functional and social scales and single items of EORTC QLQ-30|Survival|Hospital stay|Cost of therapy|Complications|Performance status change","All India Institute of Medical Sciences, New Delhi","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","GE-CAGB/2005","January 2006","December 2012","December 2012","October 23, 2006",,"July 11, 2013","All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00391183"
107,"NCT03039465","A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients","TEP","Unknown status","No Results Available","Laryngeal Cancer|Hypopharynx Cancer","Device: Modified Trans-Esophageal Prosthesis","Change in Voice Quality|Change in Presence / Absence of Fluid Leak","HealthCare Global Enterprise Ltd.","All","Child, Adult, Older Adult","Not Applicable","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","HCG/SX/003/2016","April 18, 2016","December 31, 2017","December 31, 2017","February 1, 2017",,"February 1, 2017","HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT03039465"
108,"NCT05137561","Robotic-arm Assisted 68 Ga PSMA PET/CT Guided Prostate Biopsy Versus MR Directed TRUS Guided Prostate Biopsy","PROBIOP","Recruiting","No Results Available","Prostate Cancer|Prostate Neoplasm","Procedure: PSMA PET guided prostate biopsy|Procedure: MRI directed TRUS guided prostate biopsy","Diagnostic yield of mpMRI directed vs PET/CT directed prostate biopsy|Diagnostic performance of mpMRI directed vs PET/CT directed prostate biopsy|Incidence of procedure related complications","Postgraduate Institute of Medical Education and Research","Male","45 Years to 90 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NK/7840/MD/624","October 25, 2021","October 31, 2022","December 31, 2022","November 30, 2021",,"November 30, 2021","PGIMER, Chandigarh, Chandīgarh, India",,"https://ClinicalTrials.gov/show/NCT05137561"
109,"NCT05158907","Patient Reported Scale vs CTCAE Grading: A Prospective Comparator Study","PROSE","Recruiting","No Results Available","Gastrointestinal Cancer","Other: Patient reported Adverse event scale","Improvement in detection rate of adverse effects of patient reported adverse effect (AE) scale versus the standard CTCAE grading by a physician.|Patient Compliance to filling the patient reported AE scale.|Early intervention using patient reported AE scale and preventing severity of AE in the subsequent chemotherapy cycles.|Timely chemotherapy dose adjustments using patient reported adverse effect scale|Reduction in cost of cancer care using patient reported AE scale.","Tata Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","220","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","2021/TMC/239/IRB50","November 23, 2021","December 31, 2022","February 28, 2023","December 15, 2021",,"January 13, 2022","Tata Medical Center, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT05158907"
110,"NCT00193804","A Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix",,"Completed","No Results Available","Cancer of Cervix","Radiation: IMRT","To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with IMRT|To compare the disease free survivals|To compare the quality of life in both the groups|To compare the overall survivals","Tata Memorial Hospital|Varian Medical Systems","Female","18 Years to 65 Years   (Adult, Older Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TMH/158/2004/Cx_IMRT TRIAL","February 2005","June 20, 2017","June 30, 2019","September 19, 2005",,"September 16, 2019","Tata Memorial Hospital, Mumbai, Maharastra, India",,"https://ClinicalTrials.gov/show/NCT00193804"
111,"NCT02757222","Dose Escalation Versus Standard in Laryngopharyngeal Cancers","INTELHOPE","Recruiting","No Results Available","Malignant Neoplasm of Oropharynx Stage III|Malignant Neoplasm of Larynx Stage III|Malignant Neoplasm of Hypopharynx Stage III|Malignant Neoplasm of Oropharynx Stage IVa|Malignant Neoplasm of Oropharynx Stage IVb|Malignant Neoplasm of Larynx Stage IV|Malignant Neoplasm of Hypopharynx Stage IVa|Malignant Neoplasm of Hypopharynx Stage IVb","Radiation: Escalated Dose|Radiation: Standard Dose","Number of patients with Grade 3 through grade 5 adverse events that are related to dose escalation, graded according to NCI CTCAE version 4.0|Efficacy (improvement in complete response rates at 2 years) of dose escalation in intermediate and high risk Oropharyngeal cancer (OPC) patients and in node positive, locally advanced Laryngeal and Hypopharyngeal cancer patients.","Tata Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/TMC/38/14","January 2016","December 2022","December 2022","May 2, 2016",,"December 17, 2021","Tata Medical Centre, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT02757222"
112,"NCT04809324","Gross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers",,"Recruiting","No Results Available","Oral Cavity Cancer","Procedure: Gross examination of the resection specimen|Procedure: Frozen section","local recurrence free survival (LRFS) between two arms|Accuracy of gross examination|Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of GE and FS for the assessment of surgical margin","Dr.Pankaj Chaturvedi|Tata Memorial Centre","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","1206","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","protocol no 3541|CTRI/2021/03/032015","November 15, 2021","December 2026","June 2028","March 22, 2021",,"April 27, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India|ACTREC,Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, Raigad, India|Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT04809324"
113,"NCT05144100","Surgery Vs Chemoradiation for Oropharyngeal Cancer- A Phase II/III Integrated Design Randomized Control Trial","SCOPE","Not yet recruiting","No Results Available","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8|Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Procedure: Surgery with or without Neck Dissection|Radiation: Radiation|Drug: Cisplatin based chemotherpay","Event Free Survival.(EFS)|Overall Survival (OS)|Disease free survival (DFS)|Progression free survival (PFS)|Locoregional control (LRC)|Subjective Swallowing function|M.D. Anderson Dysphagia Inventory Head and neck cancer-specific quality of life and patietn reproted outcomes (QOL and PROs)|EORTC HN35 Head and neck cancer-specific quality of life and patietn reproted outcomes (QOL and PROs)","Tata Memorial Centre|All India Institute of Medical Sciences, New Delhi|Amrita Institute of Medical Sciences & Research Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","498","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3582","December 1, 2021","June 30, 2029","June 30, 2031","December 3, 2021",,"December 3, 2021","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05144100"
114,"NCT00193791","Concomitant Chemoradiation in Advanced Stage Carcinoma Cervix","CRACx","Completed","No Results Available","Cancer of Cervix","Other: CT + RT","To compare the disease free survivals.|To compare the overall survivals|To compare the distant metastasis rates|To compare the quality of life in both the groups|To compare the normal tissue toxicities (Acute & Late) of standard radiation therapy with concomitant chemo-radiation.","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","850","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/114/2003/CRACX TRIAL","July 7, 2003","May 2017","December 2017","September 19, 2005",,"September 17, 2019","Tata Memorial Hospital, Mumbai, Maharastra, India",,"https://ClinicalTrials.gov/show/NCT00193791"
115,"NCT05277844","Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC","TARGET-01","Recruiting","No Results Available","Oligometastatic Disease|Non-small Cell Lung Cancer|Driver Mutation","Radiation: Local Consolidative Radiation Therapy|Drug: TKI","Progression Free Survival (PFS)|Overall survival (OS)|Local control rates|Health Related Quality of Life using the EORTC-QLQ-C30 questionnaire|Health Related Quality of Life using the EORTC-LC13 questionnaire|Toxicities using CTC v5.0 (radiotherapy related)","Tata Memorial Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","106","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3338|CTRI/2019/11/021872","November 11, 2019","November 11, 2023","November 11, 2025","March 14, 2022",,"March 14, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05277844"
116,"NCT02891460","Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients",,"Completed","No Results Available","Urinary Bladder Neoplasms|Urologic Neoplasms|Neoplasms|Urinary Bladder Diseases|Urologic Diseases","Device: 40 mg MMC in 40 mL TC-3.|Device: 80 mg MMC in 40 mL TC-3.","Subject's degree of response at 2-4 weeks post-treatment|Adverse events (AE) including serious adverse events (SAE)|Anesthesia information|Blood and urine tests|The degree of pain during treatment|Gel clearance and urinary patency|Tumor recurrence rate during 12 months post- 2-4 week follow-up visit in complete response (CR) subjects.|Lesion Mass by time point (Screening and 2-4 weeks post-treatment)","UroGen Pharma Ltd.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","18","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TC-3 /2012 / P2","January 2013","February 2014","March 2015","September 7, 2016",,"September 8, 2016","Rajiv Gandhi Cancer Institute & Research Center, Delhi, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02891460"
117,"NCT02350855","Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients",,"Completed","No Results Available","Cachexia|Cancer","Dietary Supplement: Improved Atta|Other: Nutritional counseling|Behavioral: Physical activity counseling","Body weight|Mid upper arm circumference (MUAC)|Body fat percentage (BF%)|Nutritional status assessment (Indian Migrant study food frequency questionnaire (IMS-FFQ), two day 24 hour dietary recall and patient generated subjective global assessment)|Physical activity assessment (Indian Migrant Study Physical Activity questionnaire (IMS-PAQ)|Quality of life (QoL) assessment (EORTC-QLQ- C30 questionnaire)|Haemoglobin (Haemoglobin levels)|Serum albumin (Serum albumin levels)","University of Westminster|All India Institute of Medical Sciences, New Delhi","Female","18 Years and older   (Adult, Older Adult)","Phase 2","62","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","12_13_11","December 2013","July 2014","August 2014","January 30, 2015",,"January 30, 2015","All India Institute of Medical Sciences, New Delhi, India|University of Westminster, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02350855"
118,"NCT02561143","Effectiveness of Nutritional Counselling and ""Improved Atta"" Supplementation in Cachexic Adult Indian Cancer Patients",,"Completed","No Results Available","Cachexia|Cancer","Dietary Supplement: Improved Atta|Dietary Supplement: Wheat flour|Behavioral: Physical activity counseling|Other: Nutritional counseling","Change in body weight at 6 months|Change in mid upper arm circumference (MUAC) at 6 months|Change in body fat percentage (BF%) at 6 months|Indian Migrant study food frequency questionnaire (IMS-FFQ)|Two day 24 hour dietary recall|Patient generated subjective global assessment (PGSGA)|Indian Migrant Study Physical Activity Questionnaire (IMS-PAQ)|Change in quality of life by EORTC-QLQ- C30 (Quality of life Questionnaire) at 6 months|Change in haemoglobin levels at 6 months|Change in serum albumin levels|Change in C-reactive protein levels at 6 months","University of Westminster|All India Institute of Medical Sciences, New Delhi","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Supportive Care","IEC/NP-339/08.10.2014","April 2015","November 2015","May 2016","September 25, 2015",,"June 22, 2017","All India Institute of Medical Sciences, New Delhi, India|University of Westminster, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02561143"
119,"NCT00147862","Does Tranexamic Acid Administration Reduce Blood Loss During Head and Neck Surgery?",,"Completed","No Results Available","Head and Neck Neoplasms","Drug: Tranexamic Acid","Administration of tranexamic acid reduces perioperative blood loss and thus,|Requirement for replacement of blood in head and neck surgeries|To observe procoagulant effects leading to complications, if any.|Cost effectiveness of the drug in terms of savings on blood transfusion requirements.","Tata Memorial Hospital","All","Child, Adult, Older Adult","Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","TMH/185/IM-2004","May 2005",,"January 2007","September 7, 2005",,"February 7, 2007","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00147862"
120,"NCT01182831","Trial Comparing Two Techniques of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas",,"Unknown status","No Results Available","Pancreatic Cancer","Procedure: percutaneous fluoro guided celiac plexus neurolysis|Procedure: EUS guided neurolysis","immediate pain relief","Asian Institute of Gastroenterology, India","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIG-GIA-201001","January 2010","January 2011","January 2011","August 17, 2010",,"August 30, 2010","Asian Institute of Gastroenterology, Hyderabad, Andhra pradesh, India",,"https://ClinicalTrials.gov/show/NCT01182831"
121,"NCT01124409","Evaluation of 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Cancer.",,"Unknown status","No Results Available","HEAD AND NECK CANCER|CARCINOMA OROPHARYNX|CARCINOMA PYRIFORM SINUS|CARCINOMA LARYNX","Radiation: EPID Verification|Radiation: CBCT verification","compare the early tumour response between 3DCRT and IGRT in head and neck cancer.|To assess and compare early and late toxicities between 3DCRT and IGRT in head and neck cancer|To find out the different doses received by target and organs at risk during the various phases of adaptive RT.","All India Institute of Medical Sciences, New Delhi","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","41","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3DIGHNC","December 2009","August 2011","August 2011","May 17, 2010",,"June 23, 2011","All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01124409"
122,"NCT00408018","Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms",,"Terminated","No Results Available","Neoplasm","Drug: P276-00","Safety assessment by Laboratory investigations (Hematology,Biochemistry, urinalysis), ECG, Holter monitoring,Physical examination|Tumor measurements,Pharmacokinetics, MALDI- TOF to study plasma peptide pattern","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","28","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/02/05","March 2006","August 2008","October 2008","December 5, 2006",,"January 1, 2009","Nizam's Institute of Medicai Sciences, Hyderabaad, Andhra Pradesh, India|Global Hospital, Hyderabad, Andhra Pradesh, India|Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00408018"
123,"NCT02142907","Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast",,"Completed","No Results Available","Breast Cancer|Adverse Effect of Radiation Therapy",,"Radiation toxicities- acute and early-late|Cosmetic outcome and local control iii) Local control","Postgraduate Institute of Medical Education and Research","Female","20 Years to 75 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","BD","January 2013","January 2020","December 2020","May 20, 2014",,"June 23, 2021","Dr Budhi Singh Yadav, Chandigarh, N/A = Not Applicable, India",,"https://ClinicalTrials.gov/show/NCT02142907"
124,"NCT04489368","Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning","QARC","Active, not recruiting","No Results Available","Esophageal Neoplasm","Radiation: Neo-Adjuvant Radiotherapy|Drug: Neo-Adjuvant Chemotherapy|Procedure: Esophagectomy","Develop models to predict pCR based on pre-neoadjuvant imaging modalities|Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy","Dr Kundan Singh Chufal|Rajiv Gandhi Cancer Institute & Research Center, India","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Other","RGCIRC/IRB/80/2020","January 16, 2020","July 2022","July 2022","July 28, 2020",,"May 3, 2022","Illawarra Cancer Care Centre, Wollongong, Australia|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04489368"
125,"NCT02868151","Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers",,"Completed","No Results Available","Oral Mucositis","Drug: Ascorbic Acid|Drug: Zinc acetate","World Health Organization criteria of grading oral mucositis.for head and neck cancer patients","Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|Saveetha University|MNJ Institute of Oncology & Regional cancer Center","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ECR/227/INSP/AP/2014","August 2016","December 2017","October 2018","August 16, 2016",,"March 20, 2019","MNJ institute of oncology & regional cancer center, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT02868151"
126,"NCT02794337","TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer","TACE-SBRT","Recruiting","No Results Available","Carcinoma, Hepatocellular","Radiation: SBRT|Procedure: TACE|Drug: Sorafenib","In-field Progression Free Survival|Cause Specific Survival|Response assessment after treatment|Quality of Life Assessment of patients over a period of time|Toxicity Assessment","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","67","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMC IEC III 91","December 2014","January 2024","January 2024","June 9, 2016",,"April 27, 2022","Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India|Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02794337"
127,"NCT02818530","Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound",,"Terminated","No Results Available","Urological Cancer|Gastrointestinal Cancer|Malignant Female Reproductive System Neoplasm","Device: IOP by tonometer|Device: Anterior chamber depth measurement by ultrasound","Changes in intraocular pressure measured by tonometer|Changes in anterior chamber depth measured by ultrasound.|Time dependent changes in IOP during prolonged steep Trendelenberg position.|Time dependent changes in anterior chamber depth during prolonged trendelenberg position.","Tata Memorial Centre","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","PN 1690","June 21, 2017","May 7, 2018","May 7, 2018","June 29, 2016",,"May 14, 2018","Sohan Lal solanki, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02818530"
128,"NCT00776659","An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin",,"Terminated","Has Results","Breast Neoplasms","Other: Aromasin","Number of Participants With Locoregional/Distant Recurrence of Primary Breast Cancer|Number of Participants With Appearance of Second Primary or Contralateral Breast Cancer|Number of Participants Who Died|Number of Participants Who Discontinued Aromasin Therapy|Number of Participants With Gynecological, Cardiac, Thromboembolic, Musculoskeletal and Menopausal Adverse Events (AEs)|Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C), Total Cholesterol and Triglycerides at Month 6, 12, 18, 24, 30, 36 and 42|Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24, 30, 36 and 42","Pfizer","Female","18 Years to 75 Years   (Adult, Older Adult)",,"39","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A5991088","December 2008","September 2012","September 2012","October 21, 2008","November 19, 2013","November 19, 2013","Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT00776659"
129,"NCT00855985","Anastomotic Techniques in Pancreaticoduodenectomy","PG/PJ","Unknown status","No Results Available","Pancreatic Cancer|Pancreatic Fistula","Procedure: type of anastomosis after pancreaticoduodenectomy","pancreatic fistula rate|mortality|Hospital stay|need for postoperative intervention|major complication","Lakeshore Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","312","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","001","July 2004","October 2011","October 2011","March 5, 2009",,"September 27, 2011","Lakeshore Hospital & Research Center, Cochin, Kerala, India",,"https://ClinicalTrials.gov/show/NCT00855985"
130,"NCT05022342","Study of PIK3CA Mutations and Effectiveness and Tolerability Outcomes of Alpelisib in Real-world","SPEAR","Recruiting","No Results Available","Breast Cancer","Other: alpelisib plus fulvestrant","PART A: Percentage of patients with tumors harboring a PIK3CA mutation|PART B: Clinical Benefit Rate (CBR) as measured by RECIST 1.1|PART A: Age at early stage (initial) disease, and advanced/metastatic disease diagnosis|PART A: Clinical characteristics of the disease at early (initial) stage of diagnosis- TNM staging|PART A: Clinical characteristics of the disease at early (initial) stage of diagnosis - receptor expression|PART A: Clinical characteristics of advanced / metastatic disease stage - disease free interval (DFI)|PART A: Clinical characteristics of advanced / metastatic disease stage - number of metastasis|PART A: Clinical characteristics of advanced / metastatic disease stage - location of metastasis|PART A: Clinical characteristics of advanced / metastatic disease stage - receptor expression|PART A: Prior number of LoT for the advanced / metastatic disease|PART A: Prior treatment type|PART A: Prior treatment sequence by LoT|PART A: Time to next treatment|PART A: Reason (s) for discontinuation of prior therapy|PART A: PIK3CA mutation positive patients not prescribed alpelisib|PART B: Progression Free Survival (PFS) by RECIST 1.1|PART B: Overall Response Rate (ORR) by RECIST 1.1|PARTB: Duration of response (DoR) by RECIST 1.1|PART B: Tolerability of alpelisib plus fulvestrant measured by adverse events (AEs)|PART B: Number of patients with laboratory abnormalities","Novartis Pharmaceuticals|Novartis","All","18 Years to 100 Years   (Adult, Older Adult)",,"200","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CBYL719CIN02","October 27, 2021","September 30, 2025","September 30, 2025","August 26, 2021",,"January 12, 2022","Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Bhubaneshwar, Orissa, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Kolkata, India",,"https://ClinicalTrials.gov/show/NCT05022342"
131,"NCT03518853","Short Course Radiotherapy for Localized Prostate Cancer","SHORT","Completed","No Results Available","Adenocarcinoma of Prostate","Radiation: Short-course Hypofractionated Once-weekly Radiation Therapy","Incidence of Acute Gastrointestinal and Genitourinary toxicity as assessed by National Cancer Institute(NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0|Biochemical control (with measurement of Prostate Specific Antigen measured in ng/ml)|Incidence of Late Gastrointestinal Toxicity as assessed by NCI CTCAE v4.0|Incidence of Late Genitourinary Toxicity as assessed by NCI CTCAE v4.0|Assessing the Quality of Life by measuring patient reported outcomes using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 questionnaire|Assessing the Quality of Life by measuring patient reported outcomes using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) PR25 questionnaire","Tata Medical Center","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/TMC/0612|CTRI/2016/02/006671","December 2013","February 15, 2019","February 15, 2019","May 8, 2018",,"October 14, 2020","Tata Medical Centre, Kolkata, WestBengal, India",,"https://ClinicalTrials.gov/show/NCT03518853"
132,"NCT05236946","Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT",,"Recruiting","No Results Available","Asymptomatic Brain Metastases|Driver Mutation Positive Non-small Cell Lung Cancer","Radiation: Stereotactic radiosurgery/whole brain radiotherapy|Drug: Tyrosine kinase inhibitor","Intracranial progression free survival at 24 months|Overall Survival|Progression free survival|Neurocognition toxicity|Toxicity using CTC v5.1|Local Control","Tata Memorial Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","190","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTRI/2020/08/027279|IEC/3470","November 10, 2020","July 2024","July 2026","February 11, 2022",,"February 11, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05236946"
133,"NCT00193830","High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix",,"Completed","No Results Available","Cancer of Cervix|Cervical Cancer|Cancer of the Cervix|Cervix Cancer","Procedure: HIgh Dose Rate Vs Low DOse Rate Brachytherapy","To asses the feasibility of high dose rate brachytherapy|To compare the early and late reactions of high dose rate brachytherapy in contrast with low dose rate brachytherapy.|To compare the over-all survival and disease free survival in the two regimens.","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","750","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH/11062/1996/Cx_HDR STUDY","May 1996",,"January 2007","September 19, 2005",,"May 6, 2015","Tata Memorial Hospital, Mumbai, Maharastra, India",,"https://ClinicalTrials.gov/show/NCT00193830"
134,"NCT01209338","Acceptability and Feasibility of Human Papilloma Virus Vaccine",,"Unknown status","No Results Available","Cervical Cancer","Behavioral: Health education","To determine the Knowledge, Attitude and Practice about cervix cancer, Human Papilloma Virus (HPV).|. To identify the barriers and facilitators perceived by women for vaccinating their daughters against HPV infection and cervix cancer.","Tata Memorial Hospital","Female","18 Years and older   (Adult, Older Adult)","Not Applicable","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)","655","November 2009","December 2010","December 2010","September 27, 2010",,"September 28, 2010","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01209338"
135,"NCT04889599","A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours",,"Completed","No Results Available","Docetaxel|Solid Tumours|Bioequivalence","Drug: BH009 (Docetaxel injection)|Drug: Docetaxel injection","Cmax of docetaxel injection|AUC of docetaxel injection|To evaluate of safety and tolerability of BH009","Zhuhai Beihai Biotech Co., Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 3","46","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","20-VIN-0225","April 29, 2021","September 17, 2021","September 24, 2021","May 17, 2021",,"January 11, 2022","HCG City Cancer center, Andra, India|Nirmal Hospital Pvt. Ltd, Gujrat, India|HCG Manavata Cancer Centre, Mahara, India",,"https://ClinicalTrials.gov/show/NCT04889599"
136,"NCT01143922","Role of Intraoperative Ultrasound in Gastrointestinal (GI) Malignancies",,"Unknown status","No Results Available","Ultrasonography|Gastrointestinal Disease|Malignancy",,,"All India Institute of Medical Sciences, New Delhi","All","10 Years to 90 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","IOUS","August 2009",,,"June 15, 2010",,"June 15, 2010","AIIMS, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01143922"
137,"NCT04588402","Impact of HPV Vaccination on Prevention of Cervical HPV Infection in Sikkim, India","HPV-Vac-S","Recruiting","No Results Available","Cervical Cancer","Biological: The study being observational in nature, there is no intervention. The investigators will only collect cervical samples from married women within a specified age range at different intervals.","The reduction in the point prevalence of genotype-specific HPV infection in women within 7 years of initiation of HPV vaccination compared to that at baseline|The difference in the point prevalence of chlamydia trachomatis infection in women within 7 years of initiation of HPV vaccination compared to that at baseline","International Agency for Research on Cancer|Department of Health and Family welfare, Government of Sikkim|Sikkim Manipal Institute|Rajiv Gandhi Centre for Biotechnology","Female","18 Years to 22 Years   (Adult)",,"5500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SMIMS/IEC/C/2020-09","October 1, 2020","June 1, 2025","December 31, 2025","October 19, 2020",,"February 17, 2021","Sikkim Manipal Hospital, Gangtok, Sikkim, India",,"https://ClinicalTrials.gov/show/NCT04588402"
138,"NCT01307774","Survey of Predictors of Human Papillomavirus (HPV) Vaccination Among Parents of Rural Adolescent Girls in Mysore, India",,"Unknown status","No Results Available","Human Papillomavirus|Cervical Cancer",,"Parental Acceptability of HPV vaccine|Knowledge about HPV and Cervical Cancer","Purnima Madhivanan|Florida International University|Public Health Research Institute, India","All","18 Years to 55 Years   (Adult)",,"800","Other","Observational","Time Perspective: Cross-Sectional","IISP38250","June 2014","June 2015","December 2015","March 3, 2011",,"October 29, 2014","Public Health Research Institute of India, Mysore, Karnataka, India|Public Health Research Institute of India, Mysore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT01307774"
139,"NCT01762410","Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors",,"Suspended","No Results Available","Advanced Refractory Solid Tumors","Drug: P7170","Maximum tolerated dose|Number of subject with adverse events|Pharmacokinetic profile(Cmax,Tmax and AUC)|Activity of P7170 based on selected biomarkers|Objective response","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P7170/70/11","September 2012","November 2015","March 2016","January 7, 2013",,"September 29, 2014","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Medanta Duke Research Institute (MDRI), Gurgaon, Haryana, India|Central India Cancer Research Institute, Nagpur, Maharashtra, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01762410"
140,"NCT01913275","Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy",,"Unknown status","No Results Available","Periampullary Cancer|Pancreatic Cancer","Procedure: Endoscopic stenting|Procedure: cholecystojejunostomy","Technical success|Successful drainage|Procedure-related complication: was defined complications directly related to stent insertion/CJ|Intraoperative assessment|1. Procedure-related mortality|2. Duration of hospital stay|3. Postoperative complication:|a. Wound infection|b. Intra-abdominal abscess|c. Postoperative haemorrhage|d. Pancreaticojejunal leak|e. Bile leak","All India Institute of Medical Sciences, New Delhi","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","134","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIS/2/2001","March 2006","December 2013","February 2014","August 1, 2013",,"August 1, 2013","All India Institute of Medical sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT01913275"
141,"NCT01178736","Early Detection of Cancers in Low Resource Countries",,"Unknown status","No Results Available","Breast Neoplasms|Uterine Cervical Neoplasms|Ovarian Neoplasms|Endometrial Neoplasms","Procedure: Breast Cancer Screening and Diagnosis|Procedure: Cervical Cancer Screening and Diagnosis|Procedure: Ovarian Cancer Screening and Diagnosis|Procedure: Endometrial Cancer Screening and Diagnosis","The Effectiveness of an Innovative, Low-Cost Screening and Diagnostic Methodology|Effectiveness of CBE and Ultrasonography for Breast Cancer Detection","Woman's Cancer Foundation","Female","30 Years to 64 Years   (Adult)",,"36000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","WCF-2011-BRA-IND-CAM","March 2011","March 2014","March 2014","August 10, 2010",,"August 10, 2010","Hospital de Cancer de Barretos, Sao Paolo, Brazil|Sihanouk Hospital Center of Hope, Hope Worldwide Cambodia, Phnom Penh, Cambodia|Manipal Healthcare Group, Goa, India",,"https://ClinicalTrials.gov/show/NCT01178736"
142,"NCT05320328","RADIO FREQUENCY ABLATION IN UNRESECTABLE MALIGNANT BILIARY OBSTRUCTION","MBOP","Recruiting","No Results Available","Bile Duct Neoplasms|Gall Bladder Carcinoma","Device: Radio frequency ablation","Prospectively evaluate the safety and efficacy of combining intraductal Radio frequency ablation with biliary metal/ plastic stent placement for patients with malignant biliary obstruction.|Stent patency at 1 year","Asian Institute of Gastroenterology, India","All","18 Years to 75 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RFA","June 10, 2021","June 10, 2022","December 10, 2022","April 11, 2022",,"April 11, 2022","Asian Institute of Gastroenterology, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT05320328"
143,"NCT05038501","Prevalence of Comorbidities in Patients Undergoing Oncosurgeries at Tertiary Cancer Institute in North India.","oncosurgery","Completed","No Results Available","Comorbidities and Coexisting Conditions","Other: To study comorbidities in patients undergoing Oncosurgeries","To study Coronary Artery disease in patients undergoing Oncosurgeries|To study Diabetes Mellitus in patients undergoing Oncosurgeries.|To study Hypothyroidism in patients undergoing Oncosurgeries","Rajiv Gandhi Cancer Institute & Research Center, India","All","35 Years to 80 Years   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","RGCI \ MK 1967","July 1, 2021","August 31, 2021","August 31, 2021","September 9, 2021",,"October 4, 2021","Anita Kulkarni, Delhi, India",,"https://ClinicalTrials.gov/show/NCT05038501"
144,"NCT03067922","Postmastectomy Pain Syndrome in an Indian Cancer Hospital",,"Completed","No Results Available","Pain Syndrome|Mastectomy|Quality of Life","Other: Non interventional study","Incidence of Post mastectomy pain syndrome (PMPS)|pain severity|Impact on daily function|Impact on quality of life","Tata Memorial Centre","Female","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TataMC","March 6, 2017","March 6, 2018","September 6, 2018","March 1, 2017",,"September 11, 2019","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03067922"
145,"NCT03470948","Surgical Apgar Score After Whipple Procedure in Pancreatic Cancer Patients",,"Terminated","No Results Available","Postoperative Complications","Other: Observe postoperative complications","Incidence of major postoperative complications and/or death within 30 days of surgery","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"263","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TataMH","March 27, 2018","March 26, 2021","March 26, 2021","March 20, 2018",,"April 1, 2021","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03470948"
146,"NCT00667563","Vaccine Therapy in Preventing HPV in HIV-Positive Women in India",,"Completed","Has Results","Cervical Cancer|Nonneoplastic Condition|Precancerous Condition","Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Genetic: DNA analysis|Genetic: polymerase chain reaction|Other: cytology specimen collection procedure|Procedure: colposcopic biopsy","Safety, in Terms of Grade 3 or 4 Adverse Events Attributed to the Vaccine, According to NCI CTCAE v3.0|Number of Patients With Significant Decrease (at the 0.05 Significance Level) in CD4+ Cell Count|Number of Patients With Detectable HPV Antibodies to HPV 16 at Week 28|Number of Patients With a Significant Increase in HIV Viral Load|Number of Patients With Detectable Antibodies to HPV-6|Number of Patients With Detectable Antibodies to HPV-11|Number of Patients With Detectable Antibodies to HPV-18","AIDS Malignancy Consortium|National Cancer Institute (NCI)|The Emmes Company, LLC","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 1","150","Other|NIH|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AMC-054|U01CA121947|CDR0000593634","August 2009","November 2012","November 2012","April 28, 2008","April 11, 2014","February 29, 2016","YRG Care, Chennai, India",,"https://ClinicalTrials.gov/show/NCT00667563"
147,"NCT00715286","Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer (EOC): A Phase III Randomized Study",,"Unknown status","No Results Available","Ovarian Carcinoma","Other: timing of surgery","to compare the optimal debulking rate in primary surgery group and neoadjuvant chemotherapy group|post operative morbidity","All India Institute of Medical Sciences, New Delhi","Female","20 Years to 65 Years   (Adult, Older Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","I473","November 2001","April 2007","June 2009","July 15, 2008",,"July 15, 2008","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00715286"
148,"NCT03249766","Study of Prevalence of Ipsilateral Shoulder Pain in Patients After Thoracic Surgeries",,"Completed","No Results Available","Lung Cancer","Other: Observational","Prevalence of Ipsilateral shoulder pain","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"370","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1900","August 22, 2017","August 21, 2018","August 21, 2018","August 15, 2017",,"September 25, 2018","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03249766"
149,"NCT03962595","Patient Satisfaction Survey (PSS) In Breast Clinic","PSS","Unknown status","No Results Available","Breast Cancer",,"Linguistic validation of patient satisfaction survey (PSS) questionnaires in Hindi and Marathi.|Proportion of patients having mean overall satisfaction score <70|To compare the level of overall patient satisfaction between paid and service patients: percentage of patients having overall score below 75 of the maximum 125","Tata Memorial Centre","All","18 Years to 70 Years   (Adult, Older Adult)",,"340","Other","Observational","Observational Model: Other|Time Perspective: Prospective","1835","March 23, 2017","December 31, 2019","December 31, 2019","May 24, 2019",,"May 24, 2019","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03962595"
150,"NCT02803385","Comparison of Patient Controlled & Continuous Epidural Analgesia in Thoraco-abdominal Surgeries in Cancer Patients",,"Completed","No Results Available","Pain","Other: Continous Epidural Analgesia|Other: Patient Controlled Epidural Analgesia","To compare the pain scores during rest and movement with continuous epidural infusion (CEI) vs. patient controlled epidural analgesia (PCEA)|To compare patient satisfaction between the two groups using Verbal Rating scale|To assess the incidence of side effects in both groups including hypotension, motor weakness, pruritus, nausea, vomiting and any other","Tata Memorial Centre","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","1681","July 2016","December 2018","January 2019","June 17, 2016",,"October 6, 2021","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02803385"
151,"NCT02736604","Evaluation of Impact of Nitrous Oxide on PONV in Breast Surgeries",,"Completed","No Results Available","Breast Cancer","Drug: nitrous oxide anesthesia|Drug: air anesthesia|Device: laryngeal mask airway (LMA Supreme Size 3/4|Drug: sevoflurane","incidence and severity of post operative nausea and vomiting|measurement of pain score and analgesic requirements|Airway device cuff pressures","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","project number 1650","May 2016","November 2016","February 2017","April 13, 2016",,"April 26, 2017","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02736604"
152,"NCT01279135","Tomotherapy vs Conventional Radiation for Adjuvant Pelvic RT in Ca Cervix","PARCER","Completed","No Results Available","Cancer Cervix","Radiation: Conventional Radiation|Radiation: Tomotherapy based IGRT","Late bowel toxicity ≥ Grade II|To identify small bowel dose volume characteristics that predict for ≥ Grade II late toxicity|To evaluate acute toxicity difference in two study arms using CTCAE version 3.0|Preoperative functional imaging features that predict for local and distant recurrence will be identified|To compare quality of life between Tomotherapy vs conventional radiotherapy arm using EORTC QLQ C30|To compare quality of life between Tomotherapy vs conventional radiotherapy arm using EORTC QLQ CX24","Tata Memorial Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Project 803","January 1, 2011","December 30, 2019","January 31, 2020","January 19, 2011",,"June 11, 2020","Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01279135"
153,"NCT00407498","Open Label Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms",,"Completed","No Results Available","Neoplasm","Drug: P276-00","To determine the maximum tolerated dose and dose limiting toxicity of selective Cdk inhibitor P276-00 in patients with advanced refractory neoplasms.|To determine the toxic effects, pharmacokinetics and clinical response of this regimen.","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/01/04","May 2005","March 2008","September 2008","December 5, 2006",,"January 1, 2009","Juravinsky Cancer Centre, Hamilton, Ontario, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Nizam's Institute of Medicai Sciences, Hyderabaad, Andhrapradesh, India",,"https://ClinicalTrials.gov/show/NCT00407498"
154,"NCT04972630","R21 India Pal-Care Evaluation",,"Recruiting","No Results Available","Cancer Palliative Care","Behavioral: Pal-Care|Behavioral: Control-Usual Care","Average score for Quality of Life (QOL)|Palliative care outcomes","Medical University of South Carolina|National Cancer Institute (NCI)|Tata Medical Center, Kolkata, India","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","90","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","00089815|1R21CA252850-01|2019/GOVT/25/IRB8|2019-3793","November 1, 2021","July 2022","July 2022","July 22, 2021",,"November 4, 2021","Tata Medical Center, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT04972630"
155,"NCT01291095","Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma",,"Unknown status","No Results Available","HEAD AND NECK CANCER","Drug: CISPLATIN|Radiation: EXTERNAL BEAM RADIOTHERAPY","TO COMPARE THE LOCO-REGIONAL TUMOR CONTROL RATE BETWEEN AFRT & CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS.|TO COMPARE THE TOXICITY BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMAS|TO COMPARE POST-THERAPY QUALITY OF LIFE BETWEEN AFRT AND CRT IN LOCALLY ADVANCED HEAD AND NECK SQUAMOUS CELL CARCINOMA.","All India Institute of Medical Sciences, New Delhi","All","20 Years to 60 Years   (Adult)","Phase 2","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RCTOFAFRTVSCRTINHNSCCAIIMS","February 2011","July 2012","December 2012","February 8, 2011",,"March 4, 2011","Dr B.R.A.I.R.C.H, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, NEW DELHI, New Delhi, Other state, India",,"https://ClinicalTrials.gov/show/NCT01291095"
156,"NCT00889525","Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor",,"Completed","No Results Available","Cushing's Disease|Corticotroph Adenoma","Drug: Cabergoline","Response in term of mid night cortisol < 5.0 mcg/dl and/or Standard two day dexamethasone suppression test < 1.8 mcg/dl","Seth Gordhandas Sunderdas Medical College","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3",,"Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC/104/2005","November 2007",,,"April 29, 2009",,"April 29, 2009","Seth GSMC & KEM hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00889525"
157,"NCT01647503","Differentially Expressed Proteins in Sporadic Parathyroid Tumors",,"Unknown status","No Results Available","Primary Hyperparathyroidism|Hypercalcemia",,"Differentially expressed proteins in parathyroid adenomas tissue samples","Postgraduate Institute of Medical Education and Research","All","15 Years to 65 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","parathyroid tumorigenesis","July 2012","September 2015",,"July 23, 2012",,"April 16, 2014","PGIMER, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT01647503"
158,"NCT00497549","Trial Comparing Side-to-Side Stapled and Hand-sewn Esophagogastric Anastomosis in Neck",,"Completed","No Results Available","Esophageal Cancer","Procedure: side-to-side stapled|Procedure: hand sewn","Anastomotic leakage defined as a radiological defect at the anastomotic site or leakage of swallowed fluid out of the drain site or cervical wound.","All India Institute of Medical Sciences, New Delhi","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","174","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIS1/2004","July 2004","January 2010","December 2010","July 6, 2007",,"May 10, 2011","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00497549"
159,"NCT01464918","Safety and Efficacy of Using MASTER to Perform Endoscopic Submucosal Dissection in Human",,"Unknown status","No Results Available","Gastric Cancer|Colon Cancer","Device: Endoscopic submucosal dissection (ESD) using device, MASTER","Total time taken to complete the ESD procedure|Measure of ease of performing the ESD procedure|Safety","National University Hospital, Singapore|Prince of Wales Hospital, Shatin, Hong Kong|Apollo Gleneagles Hospitals, Kolkata","All","21 Years to 65 Years   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E11/058","November 2011","December 2012","December 2012","November 4, 2011",,"November 4, 2011","Prince of Wales Hospital, Shatin, Hong Kong, China|Apollo Gleneagles Hospitals, Kolkata, India|National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT01464918"
160,"NCT04480619","A Study of AIP-301 Ga-68 Positron Emission Tomography Study for Imaging of Patients With Solid Tumors: The SHIVA Study","Shiva","Not yet recruiting","No Results Available","PET Diagnosis of Breast and Other Neoplasms","Diagnostic Test: AIP-301","Specific Aims 1: Safety and tolerability assessment using AIP-301 Ga-68 PET/CT imaging in patients with breast neoplasms and other neoplasms: adverse events|Specific Aims 2: Safety and tolerability assessment using AIP-301 Ga-68 PET/CT imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal vital signs|Specific Aims 3: Safety and tolerability assessment using AIP-301 Ga-68 PET/CT imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal physical examination|Specific Aims 4: Safety and tolerability assessment using AIP-301 Ga-68 PET/CT imaging in patients with breast neoplasms and other neoplasms: incidence of abnormal clinical laboratory results|Specific Aim 1: Assess uptake in imaging of tumors to determine the ability of AIP-301 Ga-68 to localize breast tumors and other neoplasms as determined by PET imaging.|Specific Aims 2: Assess efficacy in imaging of breast tumors and other neoplasms to determine the ability of AIP-301 Ga-68 to localize cancers as determined by PET imaging.|Specific Aims 3: Assess efficacy in imaging of breast tumors and other neoplasms to determine the ability of AIP-301 Ga-68 to localize cancers as determined by PET imaging.","Advanced Imaging Projects, LLC|All India Institute of Medical Sciences, New Delhi|Post Graduate Institute of Medical Education and Research|University of Witwatersrand, South Africa|University of Lausanne Hospital|Positron Pharma|Università degli studi di Trieste|US Department of Veterans Affairs","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","210","Industry|Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","145314","August 30, 2020","August 30, 2021","August 30, 2021","July 21, 2020",,"July 21, 2020","Postgraduate Institute of Medical and Research, Chandigarh, India|All India Institute of Medical Sciences, New Delhi, India|University of Witwatersrand, Johannesburg, South Africa",,"https://ClinicalTrials.gov/show/NCT04480619"
161,"NCT02664103","Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer","METRO-ABC","Completed","No Results Available","Breast Cancer Metastatic","Drug: Fixed-dose combination of capecitabine and cyclophosphamide SAR439281","Proportion of patients with adverse events|Assessment of PK parameter: maximum concentration (Cmax)|Assessment of PK parameter: time to reach Cmax (Tmax)|Disease Control Rate (DCR)|Objective Response Rate (ORR)|Time to Progression (TTP)|Proportion of patients compliant with treatment","Sanofi","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","2","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAPCYR07568|U1111-1166-1149","January 23, 2016","November 6, 2017","November 6, 2017","January 26, 2016",,"February 1, 2018","Investigational Site Number 356009, Kollkata, India|Investigational Site Number 356002, Mumbai, India|Investigational Site Number 356007, New Delhi, India|Investigational Site Number 356008, Trivandrum, India|Investigational Site Number 356001, Vellore, India",,"https://ClinicalTrials.gov/show/NCT02664103"
162,"NCT00931008","Study to Evaluate SID 530 Compared to Taxotere",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: SID530, Taxotere","to test the bioequivalence of SID530 (test) to Taxotere|to evaluate the of safety and tolerability of SID530 as compared to the marketed Taxotere.","SK Chemicals Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)","SID530_2009","October 2009","January 2011","January 2011","July 2, 2009",,"January 24, 2013","Advanced Clinical Research Pharma, Miami, Florida, United States|Gabrail Cancer Center, Canton, Ohio, United States|City Cancer Hospital, Vijayawada AndhraPradesh, Ch. venkatka Krishnayya, India|Kamakshi Memorial Hospital, No-1, Radial Road, Pallikarani, Chennai, Tamilnadu, India",,"https://ClinicalTrials.gov/show/NCT00931008"
163,"NCT01151839","A Trial to Compare Preoperative Chemoradiation and Surgery Versus Surgery Alone in Squamous Cell Carcinoma of Oesophagus",,"Unknown status","No Results Available","Esophageal Neoplasms","Procedure: Esophagectomy|Procedure: Neoadjuvant chemoradiation followed by surgery","Resectability rate|postoperative morbidity|operative mortality|Early disease control|Treatment toxicity","All India Institute of Medical Sciences, New Delhi","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IESC/T-186/2010","June 2010","July 2012",,"June 29, 2010",,"July 12, 2010","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01151839"
164,"NCT05187091","The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas","SWOAR","Recruiting","No Results Available","Head and Neck Neoplasms|Swallowing Sparing IMRT","Radiation: Swallowing and submandibular sparing IMRT","Change in swallowing function post radiotherapy|Swallowing assessment|Aspiration assessment|Acute Toxicity|Late Toxicity assessment by RTOG|Late Toxicity assessment by LENT SOMA|Treatment outcome: Loco-regional tumor control|Treatment outcome: Overall survival|Quality of life assessment: EORTC QLQ C-30|Quality of life assessment: EORTC QLQ HN35","All India Institute of Medical Sciences, New Delhi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2021/05/043810","July 11, 2021","June 2023","June 2025","January 11, 2022",,"January 31, 2022","Nci, Aiims, Jhajjar, Haryana, India",,"https://ClinicalTrials.gov/show/NCT05187091"
165,"NCT03604939","Improving Access to Control of Diseases for Women","IMPACD","Completed","No Results Available","Cardio-vascular Disease|Stroke Cancer|Breast Cancer|Oral Cancer|Cervical Cancer","Diagnostic Test: Evaluation of social, cultural and behavioral factors|Diagnostic Test: Evaluation of the feasibility and acceptability of delivery of early detections services","Outcomes of the questionnaire survey 1/5|Outcomes of the questionnaire survey 2/5|Outcomes of the questionnaire survey 3/5|Outcomes of the questionnaire survey 4/5|Outcomes of the questionnaire survey 5/5|NCD Screening study 1/11|NCD Screening study 2/11|NCD Screening study 3/11|NCD Screening study 4/11|NCD Screening study 5/11|NCD Screening study 6/11|NCD Screening study 7/11|NCD Screening study 8/11|NCD Screening study 9/11|NCD Screening study 10/11|NCD Screening study 11/11|effect of different participant characteristics on the final diagnosis of hypertension and diabetes using multivariate analysis","International Agency for Research on Cancer|GBH Cancer Memorial Hospital Udaipur, India","Female","30 Years to 60 Years   (Adult)","Not Applicable","1200","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","DCA/SCR/2016/01","January 1, 2017","August 1, 2018","July 1, 2019","July 30, 2018",,"September 5, 2021","GBH Cancer Memorial Hospital, Udaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT03604939"
166,"NCT01351571","An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma",,"Completed","No Results Available","Renal Cell Cancer",,"Safety: Incidence of adverse events|Progression-free survival: time from first drug administration to documented disease progression or death of any cause|Overall response rate: complete response or partial response according to RECIST criteria|Overall survival","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"5","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML25251","August 2010","August 2011","August 2011","May 11, 2011",,"October 4, 2017","Aurangabad, India|Delhi, India",,"https://ClinicalTrials.gov/show/NCT01351571"
167,"NCT05251168","PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow Biopsy",,"Completed","No Results Available","Lymphoma|Bone Marrow Neoplasm","Procedure: PET Guided Bone Marrow Biopsy|Procedure: Trephine Bone Marrow Biopsy","Comparison results of PET guided bone marrow biopsy with trephine bone marrow biopsy","Postgraduate Institute of Medical Education and Research","All","18 Years to 80 Years   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Other|Time Perspective: Prospective","INT/IEC/2017/1416","January 1, 2017","December 31, 2018","March 31, 2019","February 22, 2022",,"February 23, 2022","Department of Nuclear Medicine, PGIMER, Chandigarh, Chandīgarh, India",,"https://ClinicalTrials.gov/show/NCT05251168"
168,"NCT03671044","A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients",,"Recruiting","No Results Available","Triple Negative Breast Cancer","Drug: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)|Drug: Nanosomal Docetaxel Lipid Suspension (100 mg/m2)|Drug: Taxotere® (100 mg/m2)","Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere)|Progression free survival (PFS)|To evaluate the overall survival (OS) of the patients|Incidence of adverse events as assessed by clinical examination, and/or laboratory parameters","Jina Pharmaceuticals Inc.|Intas Pharmaceuticals, Ltd.|Lambda Therapeutic Research Ltd.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","657","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0063-17","July 10, 2018","March 31, 2022","May 31, 2022","September 14, 2018",,"July 29, 2020","Columbus Regional Research Institute, LLC, Columbus, Georgia, United States|Cox Medical Center, Springfield, Missouri, United States|Gabrail Cancer Center, Canton, Ohio, United States|Kailash Cancer Hospital & Research Centre, Vadodara, Gujarat, India",,"https://ClinicalTrials.gov/show/NCT03671044"
169,"NCT05348239","Chlorophyllin Tablets for Urinary Bleeding Following Radiation Therapy for Cancers of Pelvic Organs","CLARITY","Recruiting","No Results Available","Hemorrhagic Cystitis","Drug: Sodium Copper Chlorophyllin","Assessment of Objective Response Rate (ORR) as per CTCAE v5.0.|Assessment of Bladder Cancer Index (BCI) scores.|Assessment of Treatment Failure (TF).|Evaluation of treatment failure-free survival.|Assessment of Quality of Life (QOL) using EORTC -QLQ C-30 questionnaire.","Tata Memorial Centre|Bhabha Atomic Research Centre (BARC), Mumbai","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","900878","March 26, 2022","March 31, 2024","March 31, 2024","April 27, 2022",,"April 27, 2022","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05348239"
170,"NCT02081131","Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT)","PLOT","Completed","No Results Available","Adenocarcinoma of Head of Pancreas|Cholangio Carcinoma|Duodenal Adenocarcinoma|Carcinoma of Ampulla of Vater","Procedure: Open surgery|Procedure: Laparoscopic surgery","Hospital Stay|Blood loss|Pathological radicality|Operating time|Complication rate","GEM Hospital & Research Center","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","64","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PLOT|CTRI/2013/09/004016","September 2013","September 2015","September 2015","March 7, 2014",,"September 15, 2015","Gem Hospital & Research Centre Private Limited, Coimbatore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02081131"
171,"NCT01387841","Effect of Yoga in Reducing Chemotherapy Induced Nausea and Vomiting",,"Completed","No Results Available","Breast Cancer|Malignant Female Reproductive System Neoplasm|Lymphomas|Chemotherapy-induced Nausea and Vomiting","Behavioral: yoga|Behavioral: Jacobsons PMRT group","Effect of yoga on chemotherapy induced nausea and vomiting|Quality of life after chemotherapy","Bharath Charitable Cancer Hospital and Institute|Bangalore Institute of Oncology|CENTRAL COUNCIL FOR RESEARCH IN YOGA AND NATUROPATHY","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","Y010810","May 2010","December 2012","January 2013","July 6, 2011",,"July 24, 2013","Health Care Global, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT01387841"
172,"NCT02985255","Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue",,"Unknown status","No Results Available","Tongue Neoplasms|Squamous Cell Carcinoma|Anterior Tongue Squamous Cell Carcinoma","Drug: Docetaxel|Drug: Cisplatin|Drug: 5FU|Radiation: Radiotherapy|Procedure: Glossectomy","Tongue Preservation Rate|Overall Survival|Progression Free Survival|Sensitivity and Specificity of PET-CT","HealthCare Global Enterprise Ltd.","All","1 Year to 99 Years   (Child, Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCG/SX/001/2016","April 2016","June 2017","June 2017","December 7, 2016",,"December 7, 2016","HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT02985255"
173,"NCT01947062","Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma",,"Unknown status","No Results Available","Lung Cancer|Squamous Cell Carcinoma of the Lung|Locally Advanced and Metastatic Squamous Cell Carcinoma of the Lung","Drug: Intravenous Cisplatin & etoposide|Drug: Intravenous Cisplatin & etoposide along with oral cyclophosphamide","Progression free survival|Response rate","Swami Rama Cancer Hospital and Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MetroCyclo1","October 2013","June 2014","October 2014","September 20, 2013",,"September 20, 2013","Swami Rama Cancer Hospital & Research Institute, Haldwani, Nainital, Uttarakhand, India",,"https://ClinicalTrials.gov/show/NCT01947062"
174,"NCT02679443","Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy","PEMVITASTART","Completed","No Results Available","Lung Adenocarcinoma|Neutropenia|Anemia|Thrombocytopenia|Nonsquamous Nonsmall Cell Neoplasm of Lung","Dietary Supplement: Folate and B12","Incidence of any grade hematological toxicity|Incidence of grade 3/4 hematological toxicity|Number of doses of G-CSF administered|Number of doses of ESAs administered|Number of PRBC transfusions administered|Relative Dose Intensity (RDI) delivered|Number of Inter-Cycle Delays (ICDs)","Postgraduate Institute of Medical Education and Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","161","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NK/2376/DM/913","July 2015","December 2016","December 2016","February 10, 2016",,"April 25, 2017","PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02679443"
175,"NCT03162198","Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Hepatocellular Carcinoma","Other: Cirrhosis with HCC|Other: Cirrhosis without HCC","Number of circulating tumor cells (CTCs) in cirrhotic patients with hepatocellular carcinoma (HCC)|Number of cell-free DNA (cfDNA) in cirrhotic patients with hepatocellular carcinoma (HCC)|Number of Circulating Tumor Cells in the peripheral blood of cirrhotic patients in both groups|To study the difference in amount of cfDNA in the peripheral blood of cirrhotic patients with and without HCC.|Number of Circulatory Tumor Cells with the tumor size of HepatoCellular Carcinoma.|Number of Circulatory Tumor Cells with the tumor number of HepatoCellular Carcinoma.|Number of Circulatory Tumor Cells withBarcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.|Number of cfDNA amount with the tumor size of HepatoCellular Carcinoma.|Number of cfDNA amount with the tumor number of HepatoCellular Carcinoma.|Number of cfDNA amount with the Barcelona Clinic of Liver Cancer (BCLC) stage of HepatoCellular Carcinoma.","Institute of Liver and Biliary Sciences, India","All","18 Years to 70 Years   (Adult, Older Adult)",,"53","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","ILBS-HCC-03","May 15, 2017","October 31, 2018","October 31, 2018","May 22, 2017",,"October 23, 2019","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT03162198"
176,"NCT00840190","A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies","Serenity","Completed","No Results Available","Solid Tumor|Hematologic Malignancy","Drug: P1446A-05","To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of P1446A-05 in subjects with advanced refractory malignancies|1 To evaluate safety and tolerability ,pharmacokinetics of P1446A-05 in study population 2. To evaluate efficacy of P1446A-05 3. To perform exploratory analysis of biomarkers associated with use of P1446A-05 in the study population","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","29","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P1446A-05/19/08","December 2008","March 2011","September 2011","February 10, 2009",,"November 21, 2012","Tata Memorial Centre, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|SEAROC Cancer Centre,, Jaipur, Rajasthan, India|Bhagwan Mahaveer Cancer Hospital, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT00840190"
177,"NCT00517959","SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors","SCRT","Unknown status","No Results Available","Low Grade Gliomas|Craniopharyngioma|Ependymomas|Meningiomas","Radiation: Stereotactic Conformal radiotherapy|Radiation: Conventional radiotherapy","Incidence of neuropsychological and neuroendocrine function in the two arms|Progression free and overall survival.","Tata Memorial Hospital|Terry Fox Foundation","All","3 Years to 25 Years   (Child, Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCRT Trial","May 2001","March 2013","June 2017","August 17, 2007",,"December 11, 2012","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00517959"
178,"NCT01659346","Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.",,"Withdrawn","No Results Available","Hepatocellular Carcinoma With Portal Vein Thrombosis","Procedure: Endoscopic Variceal Ligation|Drug: Carvedilol","First Variceal Bleeding|Death|Procedure related complications.|Reappearance of Esophageal varices in presence of Portal Vein Thrombosis","Institute of Liver and Biliary Sciences, India","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-HCC-01","February 2016","December 2017","December 2017","August 7, 2012",,"November 17, 2017","Institute of Liver and Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01659346"
179,"NCT01779336","Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors",,"Suspended","No Results Available","Advanced Refractory Solid Tumors","Drug: PL225B","Maximum tolerated dose|Number of subject with adverse events|Pharmacokinetic profile(Cmax,Tmax and AUC)|Activity of PL225B based on selected biomarkers|Objective response","Piramal Enterprises Limited","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","70","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PL225B/71/11","December 2012","November 2014","December 2014","January 30, 2013",,"September 29, 2014","USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Central India Cancer Research Institute, Nagpur, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01779336"
180,"NCT02754115","An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy",,"Recruiting","No Results Available","Colorectal Cancer|Ovarian Cancer|Peritoneal Disease","Other: Hyperthermic intraperitoneal chemotherapy","Changes in invasive blood pressure in perioperative period|Changes in body temperature in perioperative period|Changes in cardiac output in perioperative period|Changes in arterial blood gas in perioperative period|Length of stay in intensive care unit|Mortality","Tata Memorial Centre","All","18 Years to 70 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PN 1667","April 2016","December 2026","January 2027","April 28, 2016",,"April 27, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02754115"
181,"NCT02748707","Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study","ERLO-XIB","Active, not recruiting","No Results Available","Oral Squamous Cell Carcinoma|Carcinoma of Buccal Mucosa|Tongue Cancers|Head and Neck Cancers","Drug: Arm1|Drug: Arm 2|Drug: Arm 3|Other: Arm 4","Change in expression of selected biomarkers in tissue samples, assessed by immunohistochemistry (IHC) and PCR|Clinical and radiological Change in tumor size and appearance","Tata Memorial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","64","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","830","August 18, 2015","February 12, 2018","April 2023","April 22, 2016",,"April 28, 2022","Tata Memorial Center (TMC), Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02748707"
182,"NCT00963716","Hot and Cold Biopsy Forceps in the Diagnosis of Endobronchial Lesions",,"Completed","No Results Available","Endobronchial Growth|Lung Cancer","Device: Hot biopsy forceps|Device: Cold biopsy forceps","Quality of pathological specimen|Severity of bleeding","Postgraduate Institute of Medical Education and Research","All","18 Years and older   (Adult, Older Adult)","Not Applicable","168","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","Khan-1","November 2007","July 2009","July 2009","August 21, 2009",,"August 21, 2009","Department of Pulmonary Medicine, PGIMER, India, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT00963716"
183,"NCT00862355","Bioequivalence Study of SPARC147609 in Patients With Ovarian Cancer",,"Completed","No Results Available","Ovarian Carcinoma","Drug: SPARC147609|Drug: Reference147609","90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference product|Treatment emergent adverse events","Sun Pharma Advanced Research Company Limited","Female","18 Years and older   (Adult, Older Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other","DOX_2I_1476_09","March 2010","December 2010","January 2011","March 16, 2009",,"May 3, 2019","SPARC Site 1, Hyderabaad, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT00862355"
184,"NCT04022408","To Study the Role of Liquid Based Cytology (LBC) for Diagnosis and Characterization of Biliopancreatic Tumor s Compared With Standard Cytology and On-site Evaluation.",,"Unknown status","No Results Available","Pancreatobiliary-Type Carcinoma","Diagnostic Test: Liquid based cytology|Diagnostic Test: Conventional cytology","Sensitivity of LBC for diagnosis of Bilio-pancreatic tumors, compared to cytology, on-site evaluation, and cell-block preparation.|Comparison of liquid based cytology versus conventional cytology in the diagnosis of tumor with size < 2 cm or > 2 cm|Comparison of liquid based cytology versus conventional cytology in the diagnosis of tumor with respect to site of tumor (pancreas biliary tract or gall bladder).","Institute of Liver and Biliary Sciences, India","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","ILBS-Biliopancreatic Tumor-01","July 8, 2019","October 31, 2020","October 31, 2020","July 17, 2019",,"April 8, 2020","Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04022408"
185,"NCT00921375","Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia",,"Completed","No Results Available","Hyperuricemia","Drug: TULY","Percentage of reduction in plasma uric acid at 4 hrs after uric acid-lowering therapy|Plasma uric acid AUC 0-96 hr|Incidence of adverse events","Virchow Group","All","1 Year to 75 Years   (Child, Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","VB037/2007|VB037","February 2010","December 2011","January 2012","June 16, 2009",,"December 12, 2014","Dr. Raghunathrao, Hyd, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT00921375"
186,"NCT01271673","Cohort Study to Assess the Level of Compliance in Undertaking Breast Self Examination Among Women Attending Preventive Oncology Clinic",,"Unknown status","No Results Available","Breast Self Examination",,"Compliance to Breast Self Examination|Association of various socio-demographic factors and the level of compliance to Breast Self Examination","Tata Memorial Hospital","Female","20 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","827","November 2010","February 2011","April 2011","January 7, 2011",,"January 7, 2011","Department of Preventive Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01271673"
187,"NCT02419742","Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen",,"Completed","No Results Available","Breast Cancer","Drug: Carboplatin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Paclitaxel|Drug: Trastuzumab","Percentage of Participants Experiencing Clinically Significant Changes in Cardiac Function As Determined by Left Ventricular Ejection Fraction (LVEF) Measurements Using Echocardiography|Percentage of Participants With Adverse Events|Disease Free Survival (DFS)|Overall Survival (OS)","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 4","109","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28714","August 18, 2015","June 24, 2021","June 24, 2021","April 17, 2015",,"August 6, 2021","Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|MAX Balaji Hospital, Delhi, India|Dr. GVN Cancer Institute; Medical Oncology, Trichy, India",,"https://ClinicalTrials.gov/show/NCT02419742"
188,"NCT01260194","A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer",,"Terminated","Has Results","Gastric Cancer","Drug: trastuzumab [Herceptin]","Median Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants With Overall Tumor Response|Percentage of Participants With Clinical Benefit Response (CBR)|Duration of Response (DR)|Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters|Number of Participants With Clinically Significant Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Number of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Gastric Cancer","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25477","June 2011","January 2015","January 2015","December 15, 2010","March 14, 2016","November 2, 2016","New Delhi, Delhi, India|Bangalore, Karnataka, India|Bangalore, India|Nagpur, India|Noida, India|Vishakpatnam, India",,"https://ClinicalTrials.gov/show/NCT01260194"
189,"NCT01766323","Palliative Morphine With or Without Concurrent Modafinil",,"Unknown status","No Results Available","Cancer|Pain Palliation|Excessive Sleepiness","Drug: Modafinil|Drug: Placebo","Patient reported sleepiness scores|Mood changes","Dr. Rajendra Prasad Government Medical College","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care","ModMorphine","September 2012","June 2013","August 2013","January 11, 2013",,"January 11, 2013","Tanda Government Medical College and Hospital, Kangra, Himachal Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01766323"
190,"NCT05245630","Comparison of Robotic Arm-assisted PET/CT-guided Lung Biopsy With PET Fused CT- Fluoroscopy-guided Lung Biopsy",,"Completed","No Results Available","Lung Cancer|Lung Diseases|Adenocarcinoma of Lung","Procedure: Robotic arm assisted PET/CT guided biopsy|Procedure: PET fused CT-Fluoroscopy guided biopsy","To compare the accuracy ( in percentage) of trans-thoracic percutaneous PET fused CT-fluoroscopy guided lung biopsy and automated robotic arm assisted PET/CT guided lung biopsy|To compare the radiation exposure and complication in the both arms","Postgraduate Institute of Medical Education and Research","All","18 Years to 80 Years   (Adult, Older Adult)",,"59","Other","Observational","Observational Model: Other|Time Perspective: Prospective","NK/6832/MD/594","July 1, 2020","December 31, 2021","January 31, 2022","February 18, 2022",,"February 18, 2022","Department of Nuclear Medicine, PGIMER, Chandigarh, Chandīgarh, India",,"https://ClinicalTrials.gov/show/NCT05245630"
191,"NCT04512729","Detection Of Colonic Polyps In India: Diagnostic Colonoscopy","DoCPI","Recruiting","No Results Available","Colonic Polyp|Colonic Adenoma|Colonic Neoplasms","Diagnostic Test: Colonoscopy","Colonic Adenoma|Risk factors for Colonic adenoma","Asian Institute of Gastroenterology, India","All","18 Years and older   (Adult, Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DoCPI","August 4, 2020","November 30, 2020","December 30, 2020","August 13, 2020",,"October 30, 2020","D Nageshwar Reddy, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT04512729"
192,"NCT03471572","Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India","BRCA","Completed","No Results Available","Ovarian Cancer",,"BRCA1 or BRCA2 mutation positive status|Association between histopathological type and BRCA 1/BRCA 2 mutation positive status","AstraZeneca","Female","18 Years to 130 Years   (Adult, Older Adult)",,"240","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","D0818R00001","March 22, 2018","December 21, 2018","December 21, 2018","March 20, 2018",,"December 18, 2019","Research Site, Bangalore, Karnataka, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Delhi, New Delhi, India|Research Site, Hyderabad, Telangana, India|Research Site, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03471572"
193,"NCT04330040","Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer","SOLI","Active, not recruiting","No Results Available","Ovarian Cancer|Breast Cancer","Drug: Olaparib","To assess the safety of olaparib in Indian subjects","AstraZeneca","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","162","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D0816R00025","May 30, 2020","July 31, 2022","July 31, 2022","April 1, 2020",,"April 13, 2022","Research Site, Ahmedabad, India|Research Site, Ansari Nagar, India|Research Site, Bhubaneswar, India|Research Site, Chandigarh, India|Research Site, Faridabad, India|Research Site, Kamrup, India|Research Site, Kochi, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Vellore, India",,"https://ClinicalTrials.gov/show/NCT04330040"
194,"NCT04914195","Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer",,"Recruiting","No Results Available","Advanced Prostate Adenocarcinoma","Drug: Leuprolide Acetate 3.75 MG/ML","Testosterone response rate defined as Testosterone values sustained below castration level (0.5 ng/mL or 50 ng/dL) i.e. all Testosterone values at and after Day 28 until Day 57 must be < 0.5 ng/mL or < 50 ng/dL|Percentage of subjects who have reached castration level of Testosterone at the last visit (Day 57)|Percentage of breakthrough responses defined as a single total serum Testosterone value of >0.5 ng/mL or >50 ng/dL measured after achieving a castration Testosterone level|Time after first implantation until castration level of Testosterone is achieved|Percentage of subjects with Testosterone values sustained below 0.2 ng/mL or 20 ng/dL at and after Day 28 until Day 57|Change from baseline in Luteinizing hormone (LH) levels at Day 28 and 57|Change from baseline in Follicle Stimulating Hormone (FSH) levels at Day 28 and Day 57|Change from baseline in Prostate-specific antigen (PSA) at Day 57|Mean number of days of maintaining testosterone castration levels (mean number of castration days)|Mean maximum testosterone concentration during the dosing period after reaching the castration level","Bharat Serums and Vaccines Limited","Male","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","168","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","BSV_LEUPR_18_05","July 1, 2021","August 2022","December 2022","June 4, 2021",,"January 25, 2022","Government Med ical College & Superspeciality Hospital Nagpur, Nagpur, Maharashtra, India|MV hospital and Research Center, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT04914195"
195,"NCT05348876","A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)",,"Not yet recruiting","No Results Available","Non-metastatic Castration-resistant Prostate Cancer","Drug: Darolutamide (Nubeqa, BAY1841788)","Number of participants with adverse events (AEs) and serious adverse events (SAEs) and their severity|Number of participants with discontinuations of study treatment due to AEs|Number of participants with dose modifications of study treatment due to AEs|Number of participants with clinically significant abnormalities in laboratory parameters|Number of participants with clinically significant electrocardiograms abnormalities|Number of participants with clinically significant physical examination abnormalities|Number of participants with clinically significant changes in vital signs|Number of participants with changes in eastern cooperative oncology group (ECOG) performance status|Prostate-specific antigen (PSA) percent change from baseline to 16 weeks|PSA maximum percent decline from baseline at any time on study treatment|Time to initiation of first subsequent antineoplastic therapy|Time to initiation of first cytotoxic chemotherapy for prostate cancer","Bayer","Male","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","21707","May 9, 2022","June 30, 2023","June 30, 2023","April 27, 2022",,"May 5, 2022","MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, Andhra Pradesh, India|HCG-City Cancer Centre, Vijayawada, Andhra Pradesh, India|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Dr. RML Hospital & PGIMER, New Delhi, Delhi, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India|Surat Institute of Digestive Sciences, Surat, Gujarat, India|KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka, India|Fortis Hospital Bangalore, Bengaluru, Karnataka, India|Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, India|MVR Cancer Centre and Research Institute, Vellalasseri, Kerala, India|Sujan Surgical Cancer Hospital & Amravati Cancer Foundation, Amravati, Maharashtra, India|Tata Memorial Hospital, Mumbai,, Maharashtra, India|Jawaharlal Institute Of Postgraduate Medical Education and R, Gorimedu, Pondicherry, India|Victoria Hospital, Bangalore, Punjab, India|Dayanand Medical College & Hospital, Ludhiana, Punjab, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, Rajasthan, India|Erode Cancer Centre, Erode, Tamil Nadu, India|Post Graduate Institute of Medical Education and Research, Chandigarh, Uttar Pradesh, India|Mahamana Pandit Madan Mohan Malviya Cancer Centre, Varanasi, Uttar Pradesh, India|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT05348876"
196,"NCT02679755","Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Palbociclib|Drug: Letrozole","Number of Participants With Treatment-Emergent Adverse Events (All Causalities)|Number of Participants With Treatment-Emergent Adverse Events by Severity (All Causalities)|Number of Participants With Treatment-Emergent Adverse Events (Palbociclib-Related)|Number of Participants With Treatment-Emergent Adverse Events by Severity (Palbociclib-Related)|Number of Participants With Serious Adverse Events (All Causalities and Palbociclib-Related)|Percentage of Participants With Complete Response and Partial Response|The Objective Response Rate (ORR)|EQ-5D Health Utility Index Score|Change From Baseline in EQ-5D Health Utility Index Score|EQ-VAS Score|Change From Baseline in EQ-VAS Score","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 4","252","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","A5481037","March 9, 2016","July 25, 2019","July 25, 2019","February 10, 2016","October 5, 2020","August 17, 2021","Benjamin Carl Forster, North Sydney, New South Wales, Australia|Dr. Alexander Maxwell Menzies, North Sydney, New South Wales, Australia|HPS Pharmacies - North Sydney, North Sydney, New South Wales, Australia|Mater Hospital Sydney, North Sydney, New South Wales, Australia|Professor Frances Mary Boyle, North Sydney, New South Wales, Australia|Royal North Shore Hospital - Clinical Trials Pharmacy, St Leonards, New South Wales, Australia|Royal North Shore Hospital, Dept. of Medical Oncology, St Leonards, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, Corporate Office, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre-Pharmacy Department, Bedford Park, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre Pharmacy, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|Sunshine Hospital Pharmacy, St. Albans, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Pharmacy Department, Murdoch, Western Australia, Australia|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Dr. B.R.A Institute Rotary Cancer Hospital, All India Institue of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, M.P Shah Cancer Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|HealthCare Global Enterprises Ltd., Bangalore, Karnataka, India|Kasturba Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Meditrina Institute Of Medical Sciences, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/55/NCT02679755/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02679755"
197,"NCT03511378","Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Lupin's Pegfilgrastim|Drug: Neulasta®","Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84).|Comparison of Cumulative Incidence of Anti-peg Antibodies (Binding and Neutralizing) Between Treatment Groups at the End of Cycle 4 (Day 84).|Comparison of Incidence of Anti-pegfilgrastim Antibodies (Binding & Neutralizing) to Pegfilgrastim Between Treatment Groups on Day 10, Day 21, Day 42, Day 63 and Day 84|Secondary Immunogenicity Endpoint","Lupin Ltd.","Female","18 Years and older   (Adult, Older Adult)","Phase 4","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LRP/PegGCSF/2016/004","March 6, 2018","January 9, 2019","January 9, 2019","April 27, 2018","June 15, 2021","June 15, 2021","M S Patel Cancer Centre,, Gokal, Anand, India|City Cancer Center, Vijayawada, Andhra Pradesh, India|Research & Development Department, HCG Cancer Center, Ahmedabad, Gujarat, India|Apple Hospital, Sūrat, Gujarat, India|Nirmal Hospital, Sūrat, Gujarat, India|Shree Himalaya Cancer Hospital & Research Institute,, Vadodara, Gujarat, India|Kailash Cancer Hospital & Research Center, Vadodara, Gujarat, India|Adhar health Institute, Hisar, Haryana, India|Sri Venketeshwara Hospital, Dept of Medical oncology, Bengaluru, Karnataka, India|Curie Manavata Cancer Centre, Mumbai, Maharashtra, India|Government Medical College & Hospital, Nagpur, Maharashtra, India|Sterling Hospital, Nigdi, Maharashtra, India|Bhaktivedanta Hospital & Research Institute, Thāne, Maharashtra, India|Clinical Research Department, Bande, Nagpur, India|Acharya Tulsi Regional Cancer Treatment & Research Institute, Bīkaner, Rajahstan, India|Global Clinical Research Services Pvt Ltd., Hyderabad, Telangana, India|Apollo Gleneagles Hospitals, Kolkata, West Bengal, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03511378/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03511378"
198,"NCT03155997","Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer","monarchE","Active, not recruiting","Has Results","Breast Cancer","Drug: Abemaciclib|Drug: Standard Adjuvant Endocrine Therapy","Invasive Disease Free Survival (IDFS)|IDFS for Participants With Ki-67 Index ≥20%|Distant Relapse-Free Survival (DRFS)|Overall Survival (OS)|Pharmacokinetics (PK): Minimum Steady State Concentration (Cmin,ss) of Abemaciclib|Change From Baseline on the Functional Assessment of Cancer Therapy - Breast (FACT-B)|Change From Baseline on the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)|Change From Baseline on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F)|Change From Baseline on the EuroQol Five-Dimension Five-Level Questionnaire (EQ-5D-5L)","Eli Lilly and Company|NSABP Foundation Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","5637","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","16338|I3Y-MC-JPCF|2016-004362-26|NSABP B-58","July 12, 2017","March 16, 2020","June 24, 2029","May 16, 2017","April 9, 2021","January 24, 2022","University of Alabama Birmingham, Birmingham, Alabama, United States|Southern Cancer Center, P.C., Daphne, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of Arizona Cancer Center, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Arizona Oncology Associates, P.C., Tempe, Arizona, United States|Arizona Oncology Associates, P.C., Tucson, Arizona, United States|The University of Arizona Cancer Center, Tucson, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|St. Bernards Medical Center, Jonesboro, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Providence St. Joseph's Medical Center, Burbank, California, United States|City of Hope National Medical Center, Duarte, California, United States|California Cancer Associates Research and Excellence (cCARE), Fresno, California, United States|Loma Linda University School of Medicine, Loma Linda, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Pacific Cancer Care, Monterey, California, United States|St. Joseph Hospital, Orange, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Kaiser Permanente Medical Group, San Diego, California, United States|Univ of California San Francisco, San Francisco, California, United States|California Cancer Associates in Research and Excellence, San Marcos, California, United States|Sansum Clinic, Santa Barbara, California, United States|Dominican Hospital, Santa Cruz, California, United States|Kaiser Permanente, Vallejo, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|University of Southern Florida School of Medicine, Gainesville, Florida, United States|Millennium Oncology, Hollywood, Florida, United States|Mayo Clinic-Jacksonville, Jacksonville, Florida, United States|Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States|Ocala Oncology, P.A., Ocala, Florida, United States|Cancer Specialists of North Florida -St Augustine, Saint Augustine, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Tallahassee Memorial Cancer Center, Tallahassee, Florida, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Northeast Georgia Cancer Care, LLC, Athens, Georgia, United States|Northside Hospital Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|John H. Stroger Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Community Howard Oncology Center, Kokomo, Indiana, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Univ of Louisville School of Medicine, Louisville, Kentucky, United States|Lady of the Lake Physicians' Group, Baton Rouge, Louisiana, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Eastern Maine Medical Center, Brewer, Maine, United States|Central Maine Healthcare Corporation, Lewiston, Maine, United States|New England Cancer Specialists - Scarborough, Scarborough, Maine, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Meritus John Marsh Cancer Center, Hagerstown, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Minnesota Oncology/Hematology PA, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Jackson Oncology Associates PLLC, Jackson, Mississippi, United States|Research Medical Center, Kansas City, Missouri, United States|Cancer Alliance of Nebraska, Omaha, Nebraska, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|NCCA- National Cancer Care Alliance, Omaha, Nebraska, United States|Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Renown Medical Group, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Summit Medical Group PA, Florham Park, New Jersey, United States|Newark Beth Israel Medical Center, Newark, New Jersey, United States|The Valley Hospital - Luckow Pavilion, Paramus, New Jersey, United States|Community Medical Center, Toms River, New Jersey, United States|New York Oncology Hematology, P.C, Albany, New York, United States|Broome Oncology LLC, Johnson City, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|SUNY At Stony Brook, Stony Brook, New York, United States|White Plains Hospital, White Plains, New York, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Margaret R. Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Columbus Community Clinical Oncology Program, Columbus, Ohio, United States|Oncology Hematology Care Inc, Fairfield, Ohio, United States|Hematology Oncology Associates, PC, Medford, Oregon, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Providence Cancer Center Oncology Hematology Care, Portland, Oregon, United States|Northwest Cancer Specialists PC, Portland, Oregon, United States|Willamette Valley Cancer Institute & research Ctr., Springfield, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's Hospital & Health Network, Bethlehem, Pennsylvania, United States|PinnacleHealth Cancer Institute, Harrisburg, Pennsylvania, United States|Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|NSABP Foundation, Pittsburgh, Pennsylvania, United States|Univ of Pittsburgh Cancer Inst. (UPCI), Pittsburgh, Pennsylvania, United States|WellSpan Health/York Cancer Center Oncology Research, York, Pennsylvania, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Bon Secours Saint Francis Cancer Center, Greenville, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Sanford Research/USD, Sioux Falls, South Dakota, United States|UT/Erlanger Oncology & Hematology, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute SCRI, Chattanooga, Tennessee, United States|The West Clinic, Germantown, Tennessee, United States|Indian Path Community Hospital, Kingsport, Tennessee, United States|Brig Center For Cancer Care and Survivorship, Knoxville, Tennessee, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Texas Oncology - Amarillo, Amarillo, Texas, United States|Texas Oncology-Arlington South, Arlington, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|Texas Oncology - Carrollton, Carrollton, Texas, United States|Texas Oncology - Methodist Dallas Cancer Center, Dallas, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|Texas Oncology Denton, Denton, Texas, United States|Texas Oncology-El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology Fort Worth, Fort Worth, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|Texas Oncology - Tyler, Longview, Texas, United States|Texas Oncology - McAllen, McAllen, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology- Mesquite, Mesquite, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|University of Texas Health Science Center - San Antonio, San Antonio, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology-Sherman, Sherman, Texas, United States|Texas Oncology - The Woodlands, The Woodlands, Texas, United States|US Oncology, The Woodlands, Texas, United States|Texas Oncology Cancer Care and Research Center, Waco, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Hematology Oncology Associates of Fredericksburg Inc., Fredericksburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Shenandoah Oncology, P.C., Winchester, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States|Multicare Health System, Tacoma, Washington, United States|Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|Instituto de Investigaciones Clinicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Fundacion CENIT para la Investigacion en Neurociencias, Caba, Ciudad Autonoma Buenos Aires, Argentina|Centros de Investigaciones Cli-nicas. Clinica Viedma, Viedma, Rio Negro, Argentina|Instituto de Oncologia de Rosario, Rosario, Santa Fe, Argentina|Centro Medico San Roque, S.M. De Tucuman, Tucuman, Argentina|Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina|Instituto de Investigaciones Metabolicas, Buenos Aires, Argentina|Hospital Aleman, Capital Federal, Argentina|Clinica Adventista de Belgrano, Ciudad Autonoma Buenos Aires, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Sanatorio Parque, Salta, Argentina|Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan, San Juan, Argentina|Centro para la Atencion Integral del Paciente Oncologico, Tucuman, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Mater Private Hospital, North Sydney, New South Wales, Australia|St Vincent's Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Mater Adult Hospital Brisbane, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Epworth Research Institute, Richmond, Victoria, Australia|Eastern Health, Maroondah Hospital, Ringwood East, Victoria, Australia|St John of God Hospital - Subiaco, Subiaco, Western Australia, Australia|Breast Cancer Research Centre WA, Nedlands, Australia|Universitätsklinikum Graz, Graz, Steiermark, Austria|Universitätsklinik Innsbruck, Innsbruck, Tirol, Austria|Ordination Dr. Hubalek - Brustzentrum Schwaz, Schwaz, Tirol, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|AKH, Wien, Austria|KH Hietzing mit neurologischem Zentrum Rosenhügel, Wien, Austria|Jessa Ziekenhuis, Hasselt, Limburg, Belgium|AZ Nikolaas, Campus Moerland, Sint-Niklaas, Oost-Vlaanderen, Belgium|Vivalia St Joseph, Arlon, Belgium|AZ Klina, Brasschaat, Belgium|Algemeen Ziekenhuis St Jan Brugge, Brugge, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Hopital De Jolimont, Haine-St.- Paul, Belgium|VZW REgional Ziekenhuis Jan Yperman, Ieper, Belgium|AZ Groeninge, Kortrijk, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium|Clinique St Joseph, Liege, Belgium|Hôpital Civil Marie Curie, Lodelinsart, Belgium|Clinique St Elisabeth Namur, Namur, Belgium|Clinique Saint Pierre Ottignies, Ottignies, Belgium|CHU Dinant Godinne - UCL Namur, Yvoir, Belgium|Instituto do Cancer do Ceara, Fortaleza, Ceara, Brazil|Sírio-Libanês Brasilia-Centro de Oncologia-Asa Sul, Brasilia, District Federal, Brazil|Hospital Araujo Jorge da Assoc. Combate ao Cancer em Goias, Goiania, Goias, Brazil|Instituto de Cancer de Londrina, Londrina, Parana, Brazil|CIONC - Centro Integrado de Oncologia de Curitiba, Curitiba, Paraná, Brazil|Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Hospital São Lucas - PUCRS - ONCOLOGY, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto COI de Pesquisa Educação e Gestão, Rio de Janeiro, RJ, Brazil|Hospital Bruno Born de Lajeado, Lajeado, RS, Brazil|Fundação PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo, SP, Brazil|Hospital das Clinicas da FMRP, Ribeirao Preto, São Paulo, Brazil|Faculdade de Medicina do ABC, Santo André, São Paulo, Brazil|INCA - Instituto Nacional Do Cancer, Rio De Janeiro, Brazil|Clinica Onco Star, Sao Paulo, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, São Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária, São Paulo, Brazil|Ibcc-Instituto Brasileiro de Controle Do Câncer, São Paulo, Brazil|Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil|The Ottawa Hospital, Ottawa, Ontario, Canada|North York General Hospital, Toronto, Ontario, Canada|Humber River Regional Hospital, Toronto, Ontario, Canada|St Michaels Hospital, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital du Sacre-Coeur de Montreal, Montreal, Quebec, Canada|CHU de Quebec-Hopital de Saint-Sacrement, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke - CHUS, Sherbrooke, Quebec, Canada|The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China|Fujian Medical University Union Hospital, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The First Affiliated Hospital, Sun-Yat Sen University, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jiangsu Cancer Hospital, Nanjing, Jiangsu, China|Jiangsu Province Hospital, Nanjing, Nanjing, China|Shandong Cancer Hospital, JiNan, Shandong, China|Zhejiang Cancer Hospital, Hang Zhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Masarykuv onkologicky ustav, Brno, Czech Republic, Czechia|Nemocnice Horovice, Horovice, Czechia|Fakultni Nemocnice Ostrava, Ostrava, Czechia|Multiscan, s.r.o., Pardubice, Czechia|FN Plzen Lochotin, Plzen, Czechia|Thomayerova Nemocnice, Praha 4 - Krc, Czechia|Odense Universitetshospital, Odense C, Syd, Denmark|Aalborg Universitets hospital, Aalborg, Denmark|Aarhus Universitetshospital, Aarhus Sygehus, Aarhus C, Denmark|Sydvestjysk Sygehus Esbjerg, Esbjerg, Denmark|Herlev Hospital, Herlev, Denmark|Regionshospitalet Herning, Herning, Denmark|Rigshospitalet, København Ø, Denmark|Næstved Sygehus, Næstved, Denmark|Soenderborg Sygehus, Soenderborg, Denmark|Vejle Sygehus, Vejle, Denmark|Tampere University Hospital TAYS, Tampere, Pirkanmaa, Finland|Satakunta Central Hospital - Oncology, Pori, Satakunta, Finland|Helsinki Docrates Cancer Clinic, Helsinki, Finland|Keski-Suomen Keskussairaala, Jyväskylä, Finland|Kuopio University Hospital, Kuopio, Finland|Päijät-Häme Central hospital, Lahti, Finland|Oulu University Hospital - Oncology, Oulu, Finland|Turku University Central Hospital, Turku, Finland|Vaasa Central Hospital, Vaasa, Finland|Centre Jean Perrin, Clermont Ferrand BP 392, Cedex 1, France|Institut Sainte Catherine, Avignon Cedex 9, France|CHU de Besancon Hopital Jean Minjoz, Besancon Cedex, France|CHRU de Brest - Hôpital Morvan, Brest, France|CHU Henri Mondor, Creteil Cedex, France|Centre Georges Francois Leclerc, Dijon Cedex, France|Polyclinique De Blois, La Chaussee Saint Victor, France|Centre Hospitalier de Vendee Les Oudairies, La Roche Sur Yon, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Centre de Lutte Contre le Cancer Leon Berard, Lyon Cedex 08, France|Centre de Cancérologie du Grand Montpellier, Montpellier, France|Polyclinique de Gentilly, Nancy, France|Institut Curie, Paris CEDEX 05, France|Hôpital Privé des Côtes d'Armor- HPCA, Plérin, France|Centre Eugene Marquis, Rennes Cedex, France|Centre Henri Becquerel, Rouen Cedex, France|Institut de Cancérologie de l'Ouest Centre René Gauducheau, Saint Herblain Cedex, France|Universitätsklinikum Freiburg, Freiburg im Breisgau, Baden-Württemberg, Germany|Onkologische Schwerpunktpraxis, Freiburg im Breisgau, Baden-Württemberg, Germany|Praxis für Onkologie, Friedrichshafen, Baden-Württemberg, Germany|Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany|Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany|Hämatologisch-Onkologische Praxis Augsburg, Augsburg, Bavaria, Germany|Gesundheitszentrum St. Marien Amberg, Amberg, Bayern, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Klinikum der Universität München, München, Bayern, Germany|Rotkreuzklinikum München - Frauenklinik, München, Bayern, Germany|Klinikum Rechts der Isar der TU München, München, Bayern, Germany|Agaplesion Markus Krankenhaus, Frankfurt am Main, Hessen, Germany|Städtische Kliniken Offenbach am Main, Offenbach am Main, Hessen, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Langen, Hesse, Germany|Franziskus-Hospital Harderberg, Georgsmarienhütte, Niedersachsen, Germany|Gynäkologisch-onkologische Schwerpunktpraxis am Pelikanplatz, Hannover, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitätsklinikum Bonn, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Kliniken Essen-Mitte Ev. Huyssens-Stiftung, Essen, Nordrhein-Westfalen, Germany|HELIOS Klinikum Krefeld, Krefeld, Nordrhein-Westfalen, Germany|Evangelisches Krankenhaus Bethesda Mönchengladbach gGmbH, Mönchengladbach, Nordrhein-Westfalen, Germany|Universitätsklinikum Münster, Münster, Nordrhein-Westfalen, Germany|St. Elisabeth Gruppe - Marien Hospital Witten, Witten, Nordrhein-Westfalen, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Sachsen, Germany|Universitätsklinikum Schleswig-Holstein, Kiel, Schleswig-Holstein, Germany|SRH Wald-Klinikum Gera gGmbH, Gera, Thüringen, Germany|HELIOS Klinikum Emil von Behring, Berlin, Germany|Medizinisches Versorgungszentrum Onkologischer Schwerpunkt am Oskar-Helene-Heim, Berlin, Germany|Mammazentrum Hamburg Brustklinik am Krankenhaus Jerusalem, Hamburg, Germany|Kath. Marienkrankenhaus gGmbH, Hamburg, Germany|MVZ Onkologie Barmbek - Asklepios Klinik Barmbek, Hamburg, Germany|University General Hospital of Patras, Patras, Achaia, Greece|Metropolitan Hospital, Neo Faliro, Athens, Greece|General Hospital of Athens 'Alexandra', Athens, Attica, Greece|Ag. Savvas Hospital, Athens, Attica, Greece|Gen Onc Hosp Ag. Anargyroi, N. Kifissia, Attica, Greece|University General Hospital of Heraklion, Heraklion, Crete, Greece|Bioclinic of Thessaloniki, Thessaloniki, Macedonia, Greece|General Hospital of Thessaloniki Papageorgiou, N. Efkarpia, Thessaloniki, Greece|Errikos Dynan, Athens, Greece|Attikon' University Hospital, Haidari/Athens, Greece|University Hospital of Ioannina, Ioannina, Greece|Interbalkan Medical Center, Pylaia/Thessaloniki, Greece|Euromedica - General Clinic of Thessaloniki, Thessaloniki, Greece|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Bacs-Kiskun Megyei Korhaz, Kecskemet, Bacs-Kiskun, Hungary|Fovarosi Onkormanyzat Szent Margit Korhaza, Budapest, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Szent Imre Egyetemi Oktatokorhaz, Budapest, Hungary|Semmelweis Egyetem III. sz Belgyogyaszati Klinika, Budapest, Hungary|Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Budapest, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, Hungary|MNJ Institute of Oncology, Hyderabad, Andhra Pradesh, India|Dr. B. L. Kapur Memorial Hospital, New Delhi, Delhi, India|HCG Cancer Centre, Vadodara, Gujarat, India|Artemis Hospital, Gurgaon, Haryana, India|Manipal Hospital, Bangalore, Karmnataka, India|Regional Cancer Centre, Trivandrum, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nasik, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Deenanth Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamil Nadu, India|Apollo Gleneagles Hospitals, Kolkata, West Bengal, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|HCG Cancer Centre, Ahmedabad, India|Post Graduate Institute of Medical Education & Research, Chandigarh, India|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Assaf Harofeh Medical Center, Zerifin 70300, Israel|Ospedale Perrino, Brindisi, BR, Italy|Azienda Ospedaliero Universitaria di Ferrara, Cona, Ferrara, Italy|Istituto Scientifico Romagnolo - Studio e la Cura dei Tumori, Meldola, Forli, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Istituto Tumori Fondazione G. Pascale IRCCS, Napoli, Naples, Italy|Azienda Ospedaliera Santa Maria, Terni, TR, Italy|Ospedale Bellaria, Bologna, Italy|Azienda Ospedaliera Universitaria Ospedale San Martino di Genova, Genova, Italy|Ospedale Fatebenefratelli-Oftalmico, Milano, Italy|ASST Monza - Presidio Ospedaliero di Monza, Milano, Italy|Azienda Ospedaliera Universitaria Policlinico de Modena, Modena, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Istituto Oncologico Veneto, Padova, Italy|Azienda Ospedaliera Di Parma, Parma, Italy|I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy|Policlinico Ospedale S. Andrea, Roma, Italy|Azienda Ospedaliero-Universitaria S.Giovanni Battista, Torino, Italy|Presidio Ospedaliero Santa Chiara, Trento, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|JCHO Kurume General Hosp, Kurume, Fukuoka, Japan|Gunma Prefectural Cancer Center, Ohta, Gunma, Japan|Hiroshima University Hospital, Hiroshima-shi, Hiroshima-ken, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|The Hospital of Hyogo College of Medecine, Nishinomiya, Hyogo, Japan|University of tsukuba hospital, Tsukuba-shi, Ibaragi, Japan|Tokai University Hospital, Isehara, Kanagawa, Japan|St Marianna University School of Medicine Toyoko Hospital, Kawasaki, Kanagawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|KKR Tohoku Kosai Hospital, Aoba-ku, Sendai-shi, Miyagi, Japan|Kindai University Hospital, Osaka Sayama-shi, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Saitama Cancer Center, Kitaadachi-Gun, Saitama, Japan|Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|St. Lukes International Hospital, Chuo-Ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan|National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu Cancer Center, Fukuoka, Japan|Sagara Hospital, Kagoshima, Japan|Kumamoto University Hospital, Kumamoto, Japan|Kumamoto Shinto General hospital, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Chungbuk National University Hospital, Cheong Ju-City, Chung Cheong Buk-Do, Korea, Republic of|Soonchunhyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of|Dongnam Institute of Radiological and Medical Sciences, Busan, Gyeongsangnam Do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|Ewha University Mokdong Hospital, Seoul, Yangcheon-gu, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Centro de Estudios y Prevencion del Cancer A.C., Tuxtla Gutiérrez, Chiapas, Mexico|CIMAB S.A. de C.V., Torreon, Coahuila, Mexico|Grupo Medico Camino S.C., México City, Distrito Federal, Mexico|Health Pharma Professional Research, S.A. de C.V., Mexico City, Federal District, Mexico|COI Centro Oncológico Internacional S.A.P.I de C.V., Mexico, Federal District, Mexico|Hospital Civil De Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico|COI Centro Oncológico Internacional S.A.P.I de C.V., Tlajomulco de Zuniga, Jalisco, Mexico|CRI Centro Regiomontano de Investigacion S.C., Monterrey, Nuevo Leon, Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo Leon, Mexico|Joaquin Gabriel Reinoso Toledo (Consultorios de Medicina Especializada), Monterrey, Nuevo León, Mexico|Neurociencias Estudios Clinicos S.C., Culiacan, Sinaloa, Mexico|Consultorio Centro Hemato Oncologico Privado, San Bernardino, Toluca, Mexico|Medical Care and Research, S.A. de C.V., Merida, Yucatan, Mexico|Centro de Atención e Investigación Clínica en Oncología, Merida, Yucatan, Mexico|Unidad de Investigacion en Salud de Chihuahua S.C., Chihuahua, Mexico|Oaxaca Site Management Organization SC, Oaxaca, Mexico|Oncológica de Puebla, Puebla, Mexico|Oncológico Potosino, San Luis Potosí, Mexico|Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands|HagaZiekenhuis, Den Haag, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Universitair Medisch Centrum Maastricht, Maastricht, Netherlands|Palmerston North Hospital, Palmerston North, Wanganui, New Zealand|Auckland City Hospital, Auckland, New Zealand|Waikato Hospital, Hamilton, New Zealand|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpital Morski im. PCK Sp. z o.o., Gdynia, Poland|Przychodnia Lekarska ""Komed"", Konin, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska S.K.A., Lodz, Poland|Centrum Onkologii Ziemii Lubelskiej im. sw. Jana z Dukli, Lublin, Poland|Olsztynski Osrodek Onkologiczny, Olsztyn, Poland|Opolskie Centrum Onkologii, Opole, Poland|Wielkopolskie Centrum Onkologii im. M. Sklodowskiej-Curie, Poznan, Poland|MAGODENT Szpital Onkologiczny Elblaska, Warszawa, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut, Warszawa, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|Instituto Português de Oncologia Dr. Francisco Gentil, Coimbra, Portugal|Fundação Champalimaud, Lisboa, Portugal|Centro Hospitalar Lisboa Norte - Hospital de Santa Maria, Lisboa, Portugal|Hospital Geral de Santo Antonio, Porto, Portugal|IPOFG - Porto, Porto, Portugal|Puerto Rico Hematology/Oncology Group, Bayamon, Puerto Rico|University Of Puerto Rico, San Juan, Puerto Rico|Centrul de Oncologie Sf. Nectarie SRL, Craiova, Dolj, Romania|S.C. R.T.C. Radiology Therapeutic Center S.R.L., Otopeni, Ilfov, Romania|SC Oncopremium Team SRL, Baia Mare, Maramureș, Romania|Institutul Oncologic Dr Trestioreanu Bucuresti, Bucuresti, Sector 2, Romania|Spitalul Clinic Filantropia, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta, Constanta, Romania|Kazan Oncology Dispensary, Kazan, Tatarstan Republic, Russian Federation|Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation|SHI Kaluga Regional Hospital, Kaluga, Russian Federation|Kursk Regional Oncology Dispensary, Kursk, Russian Federation|Leningrad Regional Oncology Dispensary, Leningrad Region, Russian Federation|Principal Military Clinical Hospital n.a. N. N. Burdenko, Moscow, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Russian Oncological Research Center, Moscow, Russian Federation|Orenburg Regional Clinical Oncology Dispensary, Orenburg, Russian Federation|St. Petersburg City Clinical Oncological Dispensary, Saint-Petersburg, Russian Federation|Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|GOU VPO St-Petersburg SMA n/a Mechnikov Fed. Agen of Health, St. Petersburg, Russian Federation|FGU Research Institution of Oncology, St. Petersburg, Russian Federation|St-Petersburg scientifical practical cente spec medical care, St. Petersburg, Russian Federation|Volgograd regional clinical oncology dispensary, Volgograd, Russian Federation|Yaroslavl region regional clinical oncology hospital, Yaroslavl, Russian Federation|King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia|King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia|King Abdulaziz Medical City - National Guard Hospital, Riyadh, Saudi Arabia|King Fahad Medical City, Riyadh, Saudi Arabia|National Cancer Center, Singapore, Singapore|National University Hospital, Singapore, Singapore|Eastleigh Breast Care Center, Pretoria, Gauteng, South Africa|Cancercare Rondebosch Oncology, Cape Town, South Africa|Cancercare, George, South Africa|Sandton Oncology Centre, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Mary Potter Oncology Center, Pretoria, South Africa|Hospital Clinico Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Andalucía, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Arnau de Vilanova, Lleida, Cataluña, Spain|Hospital Clinico Universitario de Santiago, Santiago de Compostela, La Coruna, Spain|Hospital Fundación Alcorcón, Alcorcón, Madrid, Spain|Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain|Hospital Universitario de Canarias, La Laguna, Santa Cruz De Tenerife, Spain|Hospital del Mar, Barcelona, Spain|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Clinico Universitario San Cecilio, Granada, Spain|Complejo Hospitalario Ciudad De Jaen, Jaen, Spain|Hospital De La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Hospital Clinico De Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Nuestra Señora de Valme, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Quirón Salud Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Norrlands universitetssjukhus, Umeå, Vasterbotten, Sweden|Skånes universitetssjukhus Lund, Lund, Sweden|Länssjukhuset Sundsvall, Sundsvall, Sweden|Västmanlands sjukhus Västerås, Västerås, Sweden|Växjö Centrallasarettet, Växjö, Sweden|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital - Kaohsiung, Kaohsiung, Taiwan|Tri-Service General Hospital, Neihu Taipei, Taiwan|Taipei Medical University- Shuang Ho Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung City, Taiwan|MacKay Memorial Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Sun Yat-Sen Cancer Center, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Ankara Gulhane Training ve Research Hospital, Ankara, Kecioren, Turkey|Baskent Adana Educational Hospital, Adana, Turkey|Ankara University Medicine Hospital, Ankara, Turkey|Hacettepe University Faculty of Medicine, Ankara, Turkey|Dr.Abdurrahman Yurtaslan Ankara Oncology Training & Res Hosp, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Trakya University Faculty of Medicine, Edirne, Turkey|Istanbul University, Istanbul, Turkey|Acibadem Altunizade Hastanesi, Istanbul, Turkey|Istanbul Medeniyet University Medical Faculty, Istanbul, Turkey|Ege University Faculty of Medicine, Izmir, Turkey|Medical Park Izmir Hospital, Izmir, Turkey|Kocaeli University Medical Faculty Hospital, Izmit, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Dnipropetrovsk City Multifunctional Clinical Hospital #4 of Dnipropetrovsk Regional Council, Dnipro, Ukraine|Commu Instit ""Krivorizhskiy oncology dispensary"" Dnip reg Co, Kriviy Rig, Ukraine|Communal Enterprise ""Volyn Regional Medical Oncology Center"", Lutsk, Ukraine|Odesa Regional Clinical Hospital, Odesa, Ukraine|Poltava Regional Clinical Oncological Dispensary, Poltava, Ukraine|Central Municipal Clinical Hospital, Uzhhorod, Ukraine|Podilskyi Regional Center of Oncology, Vinnytsia, Ukraine|University Hospital of North Tees, Stockton-on-Tees, Cleveland, United Kingdom|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Broomfield Hospital, Chelmsford, Essex, United Kingdom|North Middlesex Hospital, London, Greater London, United Kingdom|Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom|Victoria Hospital, Blackpool, Lancashire, United Kingdom|Royal Preston Hospital, Preston, Lancashire, United Kingdom|Charing Cross Hospital, Chelsea, London, United Kingdom|Mount Vernon Hospital, Northwood, Middlesex, United Kingdom|Nottingham City Hospital, Nottingham, Nottinghamshire, United Kingdom|Western General Hospital, Edinburgh, Scotland, United Kingdom|Musgrove Park Hospital, Taunton, Somerset, United Kingdom|Royal Surrey County Hospital, Guildford, Surrey, United Kingdom|Guys/St. Thomas Hospital, London, Surrey, United Kingdom|Sarah Canon Research Institute UK, London, Surrey, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Airedale General Hospital, Keighley, WEST Yorkshire, United Kingdom|Pilgrim Hospital, Boston, United Kingdom|Churchill Hospital, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03155997/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT03155997/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03155997"
199,"NCT02301962","Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer",,"Unknown status","No Results Available","Cancer","Drug: Panitumumab","Number of subjects with adverse event.|Progression free survival.|Overall Response Rate.|Duration of response.","Dr. Reddy's Laboratories Limited|Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","58","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DRL-INDG02-PAN/2018","July 28, 2015","June 30, 2021","January 31, 2022","November 26, 2014",,"December 16, 2019","DRL Investigational Site, Vijayawada, Andhra Pradesh, India|DRL Investigational Site, Mumbai, Maharashtra, India|DRL Investigational Site, Nagpur, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Nashik, Maharashtra, India|DRL Investigational Site, Ludhiāna, Punjab, India|DRL Investigational Site, Jaipur, Rajasthan, India|DRL Investigational Site, Madurai, Tamilnadu, India|DRL Investigational Site, Hyderabad, Telangana, India|DRL Investigational Site, Kolkata, West Bengal, India|DRL Investigational Site, New Delhi, India|DRL Investigational Site, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02301962"
200,"NCT00455533","Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Ixabepilone|Drug: Paclitaxel|Drug: Cyclophosphamide|Drug: Doxorubicin","Percentage of Participants Achieving Pathologic Complete Response (pCR)|Percentage of Participants Achieving Pathologic Complete Response (pCR) in Biomarker-Defined Populations|Percentage of Participants Achieving Pathologic Complete Response (pCR) in 20- and 26-Gene Model Subgroups|Percentage of Participants Achieving Clinical Objective Response|Percentage of Participants Requiring Breast Conservation Surgery|Percentage of Participants Achieving Combined pCR and Minimal Residual Cancer Burden (RCB) 1|Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]), to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR|Randomized Participants With Non-missing pCR & Biomarker Expression (GENE [Probe Set]) to Explore Whether Gene Expression Patterns for GTSE1, Isoforms of β-tubulin, Kallikreins 5, 6, 10 Are Differentially Predictive of pCR/RCB1|Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-Specified Thresholds|Percentage of Participants With pCR/RCB1 and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds|Percentage of Participants With pCR and MDR1 Immunohistochemistry (IHC) Positivity Using Two Pre-specified Thresholds, Estrogen-Receptor (ER) Negative Participants|Prevalence of Biomarker Based on Optimal Threshold (Biomarker Positive Participants)|Overall Safety Summary: Deaths, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Drug-Related AEs, and Most Common Treatment-Related Non-Hematologic Adverse Events (TNAEs) Occuring in >=10% of Participants|Severity of Any Drug-Related AEs and Gastrointestinal AEs by System Organ Class|On-Study Hematology: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|On-Study Liver Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|On-Study Renal Function: Worst Common Terminology Criteria of Adverse Events (CTCAE Version 3) Grade Per Participant in Ixabepilone/Paclitaxel Phase|Number of Participants by Dose for AC|Number of Participants by Dose for Ixabepilone/Paclitaxel|Reason for First Dose Reduction of AC|Reason for First Dose Reduction of Ixabepilone/Paclitaxel|Number of Participants With Course Delay and Reason for Delay for AC|Number of Participants With Dose Delay and Reason for Dose Delay for Ixabepilone/Paclitaxel","Bristol-Myers Squibb","Female","18 Years and older   (Adult, Older Adult)","Phase 2","384","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA163-100|EUDRACT 2006-003047-24","October 2007","December 2009","December 2009","April 3, 2007","April 4, 2011","February 24, 2016","Comprehensive Cancer Center, Palm Springs, California, United States|Northwest Oncology & Hematology Associates, Coral Spring, Florida, United States|Florida Cancer Research Institute, Davie, Florida, United States|Medical Specialists Of Palm Beaches, Lake Worth, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Medical Center, Inc, Louisville, Kentucky, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Albert Einstein Cancer Center, Bronx, New York, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Providence Cancer Center, Spokane, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Wien, Austria|Local Institution, Bordeaux, France|Local Institution, Saint Herblain, France|Local Institution, Duesseldorf, Germany|Local Institution, Erlangen, Germany|Local Institution, Jena, Germany|Local Institution, New Delhi, Delhi, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Pune, Maharashtra, India|Local Institution, Bhopal, India|Local Institution, Hyderabad, India|Local Institution, Mumbai, India|Local Institution, Vellore, India|Local Institution, Bologna, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Callao, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Cebu City, Philippines|Local Institution, Davao City, Philippines|Local Institution, Quezon City, Philippines|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Lleida, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Coventry, Warwickshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00455533"
201,"NCT00122746","Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients",,"Unknown status","No Results Available","Cancer of the Cervix","Radiation: Radiotherapy alone|Radiation: Radiotherapy with cisplatin","3 year recurrence free survival|Incidence of Grade 3 acute toxicity|Pelvic control rates|Tumour response at 3 months.|Cancer specific survival rates.|Overall survival rates.|Acute and late toxicities after the treatment.","International Atomic Energy Agency","Female","18 Years and older   (Adult, Older Adult)","Phase 3","322","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33022","December 2004","June 2012",,"July 22, 2005",,"October 13, 2011","Dept. of Atomic Energy, Tata Memorial Centre, Mumbai, India|Johannesburg Hospital, Johannesburg, South Africa|Ocean Road Cancer Institute, Dar Es Salaam, Tanzania|Radiotherapy Centre, Kampala, Uganda|Radiotherapy Centre, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT00122746"
202,"NCT00099437","Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.","CONFIRM","Active, not recruiting","Has Results","Breast Cancer","Drug: Fulvestrant","Time to Progression (TTP)|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of Response (DoR)|Duration of Clinical Benefit (DoCB)|Overall Survival (OS)|Change From Randomisation in Trial Outcome Index (TOI) Over the Course of the Study|Overall Survival (OS) - Follow-up","AstraZeneca","Female","45 Years to 130 Years   (Adult, Older Adult)","Phase 3","736","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D6997C00002","February 13, 2005","February 27, 2009","December 30, 2022","December 14, 2004","June 15, 2010","February 23, 2022","Research Site, Casa Grande, Arizona, United States|Research Site, Fountain Valley, California, United States|Research Site, New Britain, Connecticut, United States|Research Site, Crystal River, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Urbana, Illinois, United States|Research Site, Rosedale, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Greenville, North Carolina, United States|Research Site, Pasadena, Texas, United States|Research Site, West Bend, Wisconsin, United States|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Liège, Belgium|Research Site, Turnhout, Belgium|Research Site, Barretos, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Antofagasta, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bogota, Colombia|Research Site, Cali, Colombia|Research Site, Brno, Czechia|Research Site, Ceske Budejovice, Czechia|Research Site, Pardubice, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Tabor, Czechia|Research Site, V Uvalu 84, Czechia|Research Site, Nyíregyháza, Hungary|Research Site, Szombathely, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Ansari Nagar, India|Research Site, Bhopal, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Manipal, India|Research Site, Marg Jaipur, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Vellore, India|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Carpi, Italy|Research Site, Genova, Italy|Research Site, Prato, Italy|Research Site, Reggio Emilia, Italy|Research Site, Varese, Italy|Research Site, Floriana, Malta|Research Site, Mexico City, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Białystok, Poland|Research Site, Poznań, Poland|Research Site, Łódź, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, St.-Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Trnava, Slovakia|Research Site, A Coruña, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Oviedo, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Cherkasy, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00099437"
203,"NCT01073865","Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: ZD9393 (Zoladex) 10.8 mg|Drug: ZD9393 (Zoladex) 3.6 mg","Number of Patients With Progression-free Survival (PFS) at 24 Weeks|Number of Responders at 24 Weeks|Oestradiol (E2) Serum Concentrations at 24 Weeks","AstraZeneca","Female","20 Years to 130 Years   (Adult, Older Adult)","Phase 3","222","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D8666C00001","February 26, 2010","September 19, 2012","November 20, 2017","February 23, 2010","January 10, 2014","December 12, 2018","Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Pune, India|Research Site, Thiruvananthapuram, India|Research Site, Amagasaki-shi, Japan|Research Site, Chiba, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hamamatsu, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kamogawa-shi, Japan|Research Site, Kitaadachi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Maharat Nakorn Ratchasima, Thailand|Research Site, Songkla, Thailand|Research Site, Ubonratchathani, Thailand",,"https://ClinicalTrials.gov/show/NCT01073865"
204,"NCT00856375","NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer","Drug: NKTR-102|Drug: irinotecan","Kaplan-Meier Estimate of PFS by Central Radiological Review: ITT Population|Kaplan-Meier Estimate of OS: ITT Population|ORR by Central Radiological Review: ITT Population|DoR by Central Radiological Review: ITT Population|Percentage of Participants (≥2%) With Treatment-Emergent Adverse Events NCI-CTCAE Grade 3 or Higher|PK Parameters of NKTR-102 or Irinotecan and Respective Metabolites","Nektar Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","83","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","08-PIR-03","December 2008","July 2014","December 2014","March 5, 2009","June 14, 2021","July 12, 2021","Investigator Site - Peoria, Peoria, Arizona, United States|Investigator Site - Burbank, Burbank, California, United States|Investigator Site - Los Angeles, Los Angeles, California, United States|Investigator Site - Vallejo, Vallejo, California, United States|Investigator Site - Centralia, Centralia, Illinois, United States|Investigator Site - Louisville, Louisville, Kentucky, United States|Investigator Site - Detroit, Detroit, Michigan, United States|Investigator Site - Buffalo, Buffalo, New York, United States|Investigator Site - Knoxville, Knoxville, Tennessee, United States|Investigator Site - Antwerp, Antwerp, Belgium|Investigator Site - Celle, Celle, Germany|Investigator Site - Karlsruhe, Karlsruhe, Germany|Investigator Site - Hyderabad, Hyderabad, Andra Pradesh, India|Investigator Site - Ahmedabad, Ahmedabad, Gujarat, India|Investigator Site - Bangalore, Bangalore, Karnatak, India|Investigator Site - Bangalore, Bangalore, Karnatak, India|Investigator Site - Kochi, Kochi, Kerata, India|Investigator Site - Mumbai, Mumbai, Maharashtra, India|Investigator Site - Kolkata, Kolkata, West Benagal, India|Investigator Site - Kolkata, Kolkata, West Bengal, India|Investigator Site - Elche, Elche, Spain|Investigator Site - Madrid, Madrid, Spain|Investigator Site - Aberdeen, Aberdeen, Scotland, United Kingdom|Investigator Site - Manchester, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00856375"
205,"NCT02103322","Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions",,"Completed","No Results Available","Chronic Myeloid Leukemia|Gastrointestinal Stromal Tumor","Drug: Imatinib Mesylate Tablets, 400 mg","Cmax|AUC0-tau|Tmax|Cmin|Cavg|Swing|Fluctuation Rate","Amneal Pharmaceuticals, LLC|Accutest Research Laboratories (I) Pvt. Ltd.","All","18 Years to 55 Years   (Adult)","Phase 2|Phase 3","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARL/CT/13/001","February 2014","March 2014","June 2014","April 3, 2014",,"June 27, 2014","Kailash Cancer Hospital & Research Centre, Vadodara, Gujurat, India|Srinivasam Cancer Care Hospitals India Pvt., Bangalore, Karnataka, India|Karnataka Caner Hospital, Bengaluru, Karnataka, India|Lokmaya Hospital, Pune, Maharashtra, India|Dr. G Viswanathan Speciality Hospitals, Tiruchirappalli, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02103322"
206,"NCT03681548","A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer.",,"Completed","No Results Available","Ovarian Cancer Recurrent","Drug: Doxorubicin Hydrochloride Liposome Injection","Assessment of bioequivalence using Cmax of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using AUC (0-t) of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using AUC (0-inf) of encapsulated and free doxorubicin in plasma|Assessment of bioequivalence using Cmax of total doxorubicin in plasma|Assessment of bioequivalence using AUC (0-t) of total doxorubicin in plasma|Assessment of bioequivalence using AUC (0-inf) total doxorubicin as secondary analyte|Assessment of safety","Ayana Pharma Ltd.,|Lambda Therapeutic Research Ltd.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LC-101-02|0384-18|CTRI/2018/07/014835","August 29, 2018","February 8, 2019","March 7, 2019","September 24, 2018",,"November 20, 2019","MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India|HCG City Cancer Centre, Vijayawada, Andhra Pradesh, India|Mahatma Gandhi Cancer Hospital & Research Institute, Visakhapatnam, Andhra Pradesh, India|Nirmal Hospital Pvt. Ltd., Surat, Gujarat, India|Unique Hospital - Multispeciality and Research Institute, Sūrat, Gujarat, India|Aman Hospital and Research Center, Vadodara, Gujarat, India|Kailash Cancer Hospital And Research Center, Vadodara, Gujarat, India|K R Hospital, Mysore, Karnataka, India|Apex Wellness Rishikesh Hospital, Nashik, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Noble Hospital Pvt Ltd., Pune, Maharashtra, India|Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneshwar, Odisha, India|Sri Ramachandra Medical Centre, Chennai, Tamil Nadu, India|Saveetha Medical College & Hospital, Chennai, Tamil Nadu, India|VGM Hospital, Coimbatore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03681548"
207,"NCT03243877","Performance of MammoAlert™, Point of Care System, for the Screening of Breast Cancer in Women 18 Years of Age or Older",,"Unknown status","No Results Available","Breast Cancer","Other: MammoAlert Screening Test","Screening performance (i.e., sensitivity and specificity)|Predictive values & likelihood ratios","POC Medical Systems, Inc.","Female","18 Years and older   (Adult, Older Adult)",,"2458","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","POC-BC-0217","June 17, 2017","November 26, 2017","August 31, 2018","August 9, 2017",,"April 11, 2018","KIMS USHALAKSHMI Centre for Breast Diseases KIMS Hospitals, Hyderabad, Andhra Pradesh, India|Indo American Cancer Hospital and Research Institute, Hyderabad, Andhra Pradesh, India|HCG MULTI Specialty Hospital HCG Cancer Center, Ahmadabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences and Research Centre, Kochi, Kerala, India|Tata Medical Center, Kolkata, WEST Bengal, India|Maulana Azad Medical College University of Delhi & Associated Lok Nayak Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT03243877"
208,"NCT04784715","Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)",,"Recruiting","No Results Available","Breast Cancer; HER2-positive; Metastatic","Drug: Trastuzumab deruxtecan|Drug: Placebo|Drug: Taxane|Drug: Pertuzumab|Drug: Trastuzumab","Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment|Progression Free Survival (PFS) by Investigator assessment|Overall Survival (OS)|Objective Response Rate (ORR) by BICR and Investigator assessment|Duration of Response (DoR) by BICR and Investigator Assessment|Time to second progression or death (PFS2) by Investigator assessment|Health related quality of life (HRQoL) using the EORTC QLQ-C30|Time to deterioration in EORTC-QLQ-C30 scores|Health related quality of life (HRQoL) using the EORTC QLQ-BR45|Serum concentration of trastuzumab deruxtecan and pertuzumab|Immunogenicity of trastuzumab deruxtecan, alone or with pertuzumab.|Safety and tolerability of trastuzumab deruxtecan, alone or with pertuzumab","AstraZeneca|Daiichi Sankyo, Inc.","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967UC00001","April 26, 2021","July 24, 2025","December 30, 2029","March 5, 2021",,"January 11, 2022","Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Springdale, Arkansas, United States|Research Site, Duarte, California, United States|Research Site, Glendale, California, United States|Research Site, Miami, Florida, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Louisville, Kentucky, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Morristown, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, New York, New York, United States|Research Site, Port Jefferson Station, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Denton, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shenandoah, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Cipolletti, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Auchenflower, Australia|Research Site, Macquarie University, Australia|Research Site, St Leonards, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont-Chevigny, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Barretos, Brazil|Research Site, Brasília, Brazil|Research Site, Florianópolis, Brazil|Research Site, Goiânia, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Iloilo City, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, ChongQing, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Hefei, China|Research Site, Kunming, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wu Han, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Yinchuan, China|Research Site, Aalborg, Denmark|Research Site, Copenhagen O, Denmark|Research Site, Odense C, Denmark|Research Site, Sønderborg, Denmark|Research Site, Vejle, Denmark|Research Site, Avignon, France|Research Site, Besancon, France|Research Site, Bordeaux, France|Research Site, Caen Cedex, France|Research Site, Le Mans, France|Research Site, Montpellier, France|Research Site, Montpellier, France|Research Site, Nice Cedex 2, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Rennes, France|Research Site, Saint Cloud, France|Research Site, Saint Herblain, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Frankfurt, Germany|Research Site, Frankfurt, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Koblenz Am Rhein, Germany|Research Site, Leipzig, Germany|Research Site, Mainz Am Rhein, Germany|Research Site, Mannheim, Germany|Research Site, Muenster, Germany|Research Site, München, Germany|Research Site, Neu-Isenburg, Germany|Research Site, Paderborn, Germany|Research Site, Rostock, Germany|Research Site, Troisdorf, Germany|Research Site, Tübingen, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szolnok, Hungary|Research Site, Veszprém, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Bengaluru, India|Research Site, Gurgaon, India|Research Site, Mysuru, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel-Aviv, Israel|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Candiolo, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Prato, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukushima-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Okayama, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheonan-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Acapulco, Mexico|Research Site, Alc. Cuauhtémoc, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Estado de México, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Guadalajara, Mexico|Research Site, Metepec, Mexico|Research Site, Mexico, Mexico|Research Site, MEX, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Constanta, Romania|Research Site, Floresti, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, Cape Town, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Parktown, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Rondebosch, South Africa|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, San Sebastian, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Växjö, Sweden|Research Site, Örebro, Sweden|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Karsiyaka, Turkey|Research Site, Malatya, Turkey|Research Site, Samsun, Turkey|Research Site, Buckhurst Hill, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Taunton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04784715"
209,"NCT00999921","Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer",,"Completed","Has Results","Benign Breast Disease|Fibrocystic Disease of Breast|Fibroadenoma|Mastalgia","Drug: Tamoxifen|Drug: Evening Primrose Oil","Number of Participants Analysed for Reduction in Lump Size ( 60% Reduction in Lump Size Considered to be a Satisfactory Response)|Number of Participants Analysed for Reduction in Mastalgia (Cardiff Breast Pain Score).|Number of Participants Analysed for Response of Cyclical Mastalgia (Good Response Was Defined as Disappearance of Mastalgia)","Medical College and Hospital Kolkata","Female","16 Years and older   (Child, Adult, Older Adult)","Phase 4","256","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MSVP-107/08","January 2008","August 2014","January 2015","October 22, 2009","April 29, 2015","May 18, 2015","Department of Surgery, Medical College, Kolkata, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT00999921"
210,"NCT02445586","Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Docetaxel|Drug: Pertuzumab|Drug: Trastuzumab","Overall Number of Participants by the Number of Serious Adverse Events Reported Per Participant|Overall Number of Participants With Serious Adverse Events by Severity (Initial and Most Extreme), According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03)|Number of Participants With Serious Adverse Events Related to Docetaxel|Number of Participants With Serious Adverse Events Related to Pertuzumab|Number of Participants With Serious Adverse Events Related to Trastuzumab|Overall Number of Participants With Serious Adverse Events by Action Taken With Study Drug|Overall Number of Participants With Serious Adverse Events by Event Outcome|Number of Participants With Hematological Abnormalities Reported as Serious Adverse Events|Number of Participants With Serum Chemistry Abnormalities Reported as Serious Adverse Events|Number of Participants With Coagulation Abnormalities Reported as Serious Adverse Events|Number of Participants Who Died Due to a Serious Adverse Event by Cause of Death|Overall Number of Participants by the Number of Non-Serious Adverse Events Reported Per Participant|Overall Number of Participants With Non-Serious Adverse Events by Severity, According to NCI-CTCAE v4.03|Number of Participants With Non-Serious Adverse Events Related to Docetaxel|Number of Participants With Non-Serious Adverse Events Related to Pertuzumab|Number of Participants With Non-Serious Adverse Events Related to Trastuzumab|Overall Number of Participants With Non-Serious Adverse Events by Chemotherapy Adjustment With Docetaxel and/or Trastuzumab|Overall Number of Participants With Non-Serious Adverse Events by Action Taken With Pertuzumab|Overall Number of Participants With Non-Serious Adverse Events by Event Outcome|Overall Number of Participants With Non-Serious Adverse Events by Treatment Emergence (TEAE Versus Non-TEAE)|Number of Participants With Hematological Abnormalities Reported as Non-Serious Adverse Events|Number of Participants With Serum Chemistry Abnormalities Reported as Non-Serious Adverse Events|Number of Participants With Coagulation Abnormalities Reported as Non-Serious Adverse Events|Number of Participants With Congestive Heart Failure|Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time|Number of Participants by Left Ventricular Ejection Fraction (LVEF) Findings Over Time|Number of Participants With Adverse Events Leading to Treatment Discontinuation|Overall Response Rate|Number of Participants by Best Overall Response|Number of Participants With Disease Progression or Death or Who Were Censored for Progression-Free Survival Analysis|Median Duration of Progression-Free Survival|Probability of Participants Remaining Event-Free in Progression-Free Survival From 2 to 32 Months|Number of Participants Who Died or Were Censored for Overall Survival Analysis|Median Duration of Overall Survival|Probability of Participants Remaining Alive in Overall Survival From 3 to 34 Months","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","52","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML29282","August 17, 2015","September 26, 2018","September 26, 2018","May 15, 2015","October 29, 2019","October 29, 2019","Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|Christian Medical College & Hospital; Medicine, Vellore, Tamil NADU, India|Indo-American Cancer Hospital & Research Center, Hyderabad, Telangana, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|M S Ramaiah Memorial Hospital, Bangalore, India|MAX Balaji Hospital, Delhi, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02445586/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/86/NCT02445586/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02445586"
211,"NCT03641560","A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy",,"Active, not recruiting","No Results Available","Metastatic Castration Resistant Prostate Cancer","Drug: Enzalutamide|Drug: Androgen deprivation therapy (ADT)","Safety assessed by incidence of adverse events (AEs)|Number of participants with laboratory test abnormalities and/or AEs|Number of participants with physical examination abnormalities and/or AEs|Number of participants with vital sign abnormalities and/or AEs|Efficacy assessed by prostate-specific antigen (PSA) response rate (≥ 50% reduction from baseline)","Astellas Pharma Inc","Male","18 Years and older   (Adult, Older Adult)","Phase 4","52","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9785-CL-0413","September 19, 2018","November 30, 2022","November 30, 2022","August 22, 2018",,"April 5, 2022","Site IN00002, Ahmedabad, India|Site IN00004, Hubli, India|Site IN00008, Kolkata, India|Site IN00003, Nashik, India|Site IN00007, Nashik, India|Site IN00010, New Delhi, India|Site IN00001, Pune, India|Site IN00011, Surat, India",,"https://ClinicalTrials.gov/show/NCT03641560"
212,"NCT02726009","A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: Degarelix","Frequency of adverse events|Severity of adverse events|Clinically significant changes in laboratory values (hematology and clinical biochemistry)|Clinically significant changes in vital signs|Cumulative probability of no Prostate Specific Antigen (PSA) failure|Cumulative probability of Progression Free Survival (PFS)|Change in International Prostate Symptom Score (IPSS)|Change in physician's satisfaction score","Ferring Pharmaceuticals","Male","18 Years to 79 Years   (Adult, Older Adult)","Phase 4","230","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","000201","May 2016","May 15, 2020","May 15, 2020","April 1, 2016",,"December 15, 2021","S. P Medical College and AG of Hospitals, Bikaner, Rajasthan, India|Krishna Institute of Medical Sciences, Secunderabad, Telangana, India|Bodyline Hospitals, Ahmedabad, India|HCG Multi Specialty Hospital, Ahmedabad, India|Shalby Hospital, Ahmedabad, India|HealthCare Global Enterprises Limited, Bangalore, India|KLE's Dr. Prabhakar Kore Hospital & MRC, Belgaum, India|Apollo Speciality Hospital, Chennai, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Muljibhai Patel Urological Hospital, Gujrat, India|CHL Hospital, Indore, India|SMS Medical College & Attached Hospital's, Jaipur, India|Tata Medical Center, Kolkata, India|King's George Medical University, Lucknow, India|Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Government Medical College and Super Specialty Hospital, Nagpur, India|Rml & Pgimer, New Delhi, India|Aman Hospital and Research Center, Vadodara, India",,"https://ClinicalTrials.gov/show/NCT02726009"
213,"NCT00387387","Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)",,"Completed","No Results Available","Neoplasms, Colorectal","Drug: Pazopanib|Drug: FOLFOX 6|Drug: CapeOx","Plasma AUC(0-24) of pazopanib on Day 1, 14 and 21 Plasma AUC(0-46) of 5-FU and AUC(0-8) of platinum on Day 1 Plasma AUC(0-24) of capecitabine, 5-FU, and platinum on Day 1|Pharmacokinetic endpoints (AUC, C24, Cmax, tmax, and half-life)collected predose and 1, 2, 3, 4, 5, 6, 8, and 24 hours on Day 1. Assessment of disease by imaging","GlaxoSmithKline","All","21 Years and older   (Adult, Older Adult)","Phase 1","50","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VEG105424","October 20, 2006","August 14, 2009","August 14, 2009","October 13, 2006",,"November 17, 2017","GSK Investigational Site, Hyderabad, Andhra Pradesh, India|GSK Investigational Site, Parel, India|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Oxford, Oxfordshire, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00387387"
214,"NCT03472053","A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non Small Cell Lung Cancer Stage IIIB","Drug: BIO-11006 plus standard of care|Drug: Standard of Care","Progression-free survival|Maintenance of body weight|Treatment emergent adverse effects","BioMarck Pharmaceuticals, Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIO-NSCLC-001","February 1, 2018","December 30, 2019","December 30, 2019","March 21, 2018",,"May 19, 2020","Vardhman Mahavir Medical College & Hospital, New Delhi, Delhi, India|Unique Hospital and Research Institute, Surat, Gujarat, India|Aadhar Health Institute, Hisar, Hariyana, India|HCG Manavata Cancer Center, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharastra, India|Navsanjeevani Hospital, Nashik, Maharastra, India|Chirayu Cancer Hospital, Bhopal, MP, India|Sparsh Hospitals and Critical Care, Bhubaneswar, Odisa, India|SMS Medical College & Hospital, Jaipur, Rajasthan, India|Nehru Hospital & Post Graduate Institute of Medical Education, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03472053"
215,"NCT03725475","A Study to Reveal the Patient Characteristics and Treatment Patterns of Stage III Non-small-cell Lung Cancer Patients","KINDLE","Completed","No Results Available","Non-small-cell Lung Cancer (NSCLC)",,"Overall survival (OS)|Progression-free survival (PFS)","AstraZeneca","All","Child, Adult, Older Adult",,"3111","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D133HR00004","November 26, 2018","September 30, 2019","September 30, 2019","October 31, 2018",,"October 5, 2020","Research Site, Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Santiago de Chile, Chile|Research Site, Cali, Colombia|Research Site, Cordoba, Colombia|Research Site, Medellin, Colombia|Research Site, Santo Domingo, Dominican Republic|Research Site, Anand, India|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Chennai, India|Research Site, Mohali, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Odissa, India|Research Site, Srinagar, India|Research Site, West Bengal, India|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Toluca, Mexico|Research Site, Lima, Peru|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, TaoYuan, Taiwan|Research Site, Bangkoknoi, Thailand|Research Site, Dusit, Thailand|Research Site, Pathumwan, Thailand|Research Site, Ratchathewi, Thailand|Research Site, Montevideo, Uruguay",,"https://ClinicalTrials.gov/show/NCT03725475"
216,"NCT02608359","A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer",,"Recruiting","No Results Available","Prostate Cancer","Drug: Abiraterone Acetate","The Number and Type of Adverse Events Reported by the Investigator or the Patient","Johnson & Johnson Private Limited","Male","18 Years and older   (Adult, Older Adult)",,"103","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR107096|212082PCR4021","May 31, 2016","May 31, 2022","May 31, 2022","November 18, 2015",,"April 28, 2022","Healthcare Global (HCG) Hospital, Bangalore, India|Tata Memorial Hospital, Bombay, India|Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India|Christian medical, Ludhiana, Punjab, India|P. D. Hinduja National Hospital and Research Center, Mumbai, India|Max Super specialty, New Delhi, India|Indraprastha Apollo Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02608359"
217,"NCT01201265","A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Bevacizumab|Drug: Carboplatin|Drug: Gemcitabine","Progression-free Survival (PFS)|Percentage of Participants Achieving an Overall Response|Percentage of Participants Achieving a Clinical Benefit Response (CBR)|Time to Progression (TTP)|Overall Survival (OS)|Number of Participants With an Adverse Event (AE)|Change From Baseline to Cycle 6 in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-30)|Change From Baseline in Systolic Blood Pressure (SBP)|Change From Baseline in Diastolic Blood Pressure (DBP)","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25420","February 2011","April 2015","April 2015","September 14, 2010","May 27, 2016","May 27, 2016","Ahmedabad, India|Bangalore, India|Bangalore, India|Delhi, India|Gandhinagar, India|Mumbai, India|Mumbai, India|Mumbai, India|New Delhi, India|New Delhi, India|Pune, India|Vellore, India",,"https://ClinicalTrials.gov/show/NCT01201265"
218,"NCT00300950","Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer",,"Completed","No Results Available","Pancreas Cancer","Biological: GI-4000|Drug: Gemcitabine","Recurrence free time and survival","GlobeImmune","All","18 Years and older   (Adult, Older Adult)","Phase 2","176","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GI-4000-02","January 2006","February 2015","February 2015","March 10, 2006",,"April 6, 2015","University of Alabama at Birmingham, Birmingham, Alabama, United States|Tower Cancer Research Foundation, Beverly Hills, California, United States|University of California San Diego, LaJolla, California, United States|UCLA Medical Center, Los Angeles, California, United States|Georgetown University Medical Center / Lombardi Cancer Center, Washington, District of Columbia, United States|Rush University Medical School, Chicago, Illinois, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Washington University, St. Louis, Missouri, United States|State University of NY at Stony Brook, Stony Brook, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Texas Oncology, PA, Dallas, Texas, United States|The Texas Cancer Center Dallas Southwest, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|South Texas Oncology & Hematology, San Antonio, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Froedtert Multi-Disciplinary Cancer Clinic, Milwaukee, Wisconsin, United States|PSG Hospitals, Peelamedu, Coimbatore, Tamil Nadu, India|Sri Ramchandra Medical College & Research Institute, Ponur, Chennai, Tamil Nadu, India|Indo American Cancer Hospital and Research Centre, Hyderabad, India|KMC Hospital, Mangalore, India|Govt Medical Colleg & Hospital, Nagpur, India|Lake Shore Hospital & Research Centre, Nettoor, Cochin, India|G B Pan Hospital & Maulana Azad Medical College, New Delhi, India|Nizam's Institute of Medical Sciences, Panjagutta, Hyderaba, India|Lifeline Multispecialty Hospital, Perungudi, Chennai, India|Regional Cancer Centre, Trivandrum, India",,"https://ClinicalTrials.gov/show/NCT00300950"
219,"NCT00384176","First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX","HORIZON III","Completed","Has Results","Colorectal Cancer","Drug: Cediranib|Drug: Bevacizumab|Drug: 5-fluorouracil ( in FOLFOX)|Drug: Leucovorin (in FOLFOX)|Drug: Oxaliplatin (in FOLFOX)","Progression Free Survival|Overall Survival|Objective Response Rate|Duration of Response|Percentage Change in Tumour Size|Time to Worsening of Health Related Quality of Life (QOL) Based on the FACT Colorectal Symptom Index (FCSI)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2|Phase 3","1814","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00013|Eudract Number 2005-003440-66","August 30, 2006","November 15, 2009","August 19, 2015","October 5, 2006","November 28, 2012","April 14, 2017","Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Casa Grande, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Palm Springs, California, United States|Research Site, San Diego, California, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Bay Pines, Florida, United States|Research Site, Fort Meyers, Florida, United States|Research Site, Port St Lucie, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, Galesburg, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Layfayette, Indiana, United States|Research Site, New Albany, Indiana, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Layfayette, Louisiana, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Ypsilanti, Michigan, United States|Research Site, St Louis, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Summit, New Jersey, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Northport, New York, United States|Research Site, Rochester, New York, United States|Research Site, Fayetteville, North Carolina, United States|Research Site, New Bern, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Coos Bay, Oregon, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, White River Junction, Vermont, United States|Research Site, Abingdon, Virginia, United States|Research Site, Alexandria, Virginia, United States|Research Site, Armidale, New South Wales, Australia|Research Site, Coffs Harbour, New South Wales, Australia|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Port Macquarie, New South Wales, Australia|Research Site, Randwick, New South Wales, Australia|Research Site, St. Leonards, New South Wales, Australia|Research Site, Tamworth, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Hobart, Tasmania, Australia|Research Site, Epping, Victoria, Australia|Research Site, Ashford, Australia|Research Site, Bedford Park, Australia|Research Site, Bendigo, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Coffs Harbour, Australia|Research Site, Darlinghurst, Australia|Research Site, East-Melbourne, Australia|Research Site, Epping, Australia|Research Site, Herston, Australia|Research Site, Hobart, Australia|Research Site, Hornsby, Australia|Research Site, Kogarah, Australia|Research Site, Lismore, Australia|Research Site, Malvern, Australia|Research Site, Nedlands, Australia|Research Site, Port Macquarie, Australia|Research Site, Randwick, Australia|Research Site, South Brisbane, Australia|Research Site, St. Leonards, Australia|Research Site, Tamworth, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Woodville South, Australia|Research Site, Kundratstrasse 3, Vienna, Austria|Research Site, Innsbruck, Austria|Research Site, Kundratstrasse 3, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Zams, Austria|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussels (woluwe-st-lambert), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Ghent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Surrey, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, St Catharines, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Chomutov, Czech Republic|Research Site, Kutna Hora, Czech Republic|Research Site, Nova Ves pod Plesi, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Tabor, Czech Republic|Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Helsinki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Vaasa, Finland|Research Site, Boulogne Cedex, France|Research Site, La Roche S YON, France|Research Site, Marseille Cedex 08, France|Research Site, Nantes,, France|Research Site, Nantes, France|Research Site, Paris Cedex 15, France|Research Site, Paris, France|Research Site, Saint Gregoire, France|Research Site, Dresden, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Halle, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Munchen, Germany|Research Site, München, Germany|Research Site, Neu-isenburg, Germany|Research Site, Tubingen, Germany|Research Site, Tübingen, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Pecs, Hungary|Research Site, Pécs, Hungary|Research Site, Szeged, Hungary|Research Site, Tatabanya, Hungary|Research Site, Tatabánya, Hungary|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Varanasi, Uttar Prad, India|Research Site, Kolkata, W Bengal, India|Research Site, Bangalore, India|Research Site, Bhopal, India|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Sheikhpura, India|Research Site, Holon, Israel|Research Site, Kfar-saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Tiberias, Israel|Research Site, Tzrifin, Israel|Research Site, Genova, GE, Italy|Research Site, Rozzano, MI, Italy|Research Site, Ancona, Italy|Research Site, Genova, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Riga, Latvia|Research Site, Floriana, Malta|Research Site, Valletta, Malta|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Molo, Philippines|Research Site, Quezon City, Philippines|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Gdynia, Poland|Research Site, Krakow, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Rybnik, Poland|Research Site, Warszawa, Poland|Research Site, Barnaul, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tumen, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Cape Town, South Africa|Research Site, Lyttelton Manor, South Africa|Research Site, Polokwane, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Cordoba, Andalucia, Spain|Research Site, Zaragoza, Aragon, Spain|Research Site, Oviedo, Asturias, Spain|Research Site, Barcelona, Cataluna, Spain|Research Site, Granollers, Cataluna, Spain|Research Site, Hospitalet de Llobregat(barcel, Cataluna, Spain|Research Site, Terrassa(barcelona), Cataluna, Spain|Research Site, Madrid, Comunidad de Madrid, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A Coruna, Galicia, Spain|Research Site, A Coruña, Spain|Research Site, Córdoba, Spain|Research Site, Granollers, Spain|Research Site, Hospitalet de Llobregat(Barcel, Spain|Research Site, Madrid, Spain|Research Site, Manresa, Spain|Research Site, Oviedo, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-yuan, Taiwan|Research Site, Nakhonratchasima, Naimuang, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Rachathewi, Thailand|Research Site, Songkla, Thailand|Research Site, Istanbul, Goztepe, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Cherkassy, Ukraine|Research Site, Chernigiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Donetsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kharkov, Ukraine|Research Site, Kherson, Ukraine|Research Site, Kiev, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lugansk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Simferopol, Ukraine|Research Site, Sumy, Ukraine|Research Site, Ternopil, Ukraine|Research Site, Ternopol, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Southampton, Hampshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Northwood, Middlesex, United Kingdom|Research Site, Sutton, Surrey, United Kingdom|Research Site, Bebington, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Bradford, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Ipswich, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Newcastle-upon-tyne, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Stockport, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Hanoi city, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT00384176"
220,"NCT00704730","Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer","EXAM","Completed","Has Results","Thyroid Cancer","Drug: XL184|Drug: Placebo","Progression-Free Survival (PFS)|Overall Survival (OS) With XL184 Compared With Placebo|Objective Response Rate (ORR)|Duration of Objective Response (OR): Independent Radiology Committee (IRC) Determined|Biochemical Response Calcitonin (CTN) %|Biochemical Response Carcinoembryonic Antigen (CEA) %","Exelixis","All","18 Years and older   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XL184-301","June 2008","October 2011","September 2020","June 25, 2008","September 9, 2014","April 20, 2021","University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham, Alabama, United States|TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Burbank, California, United States|UCLA, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Washington Cancer Institute, Washington, District of Columbia, United States|H. Lee Moffet Cancer Center and Research Institute, Tampa, Florida, United States|University of Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Iowa, Iowa City, Iowa, United States|Kansas University Medical Center, Kansas City, Kansas, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Capitol Comprehensive Cancer Care Clinic and Research Institute, Jefferson City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Ohio State University, James Cancer Hospital, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital & Health Network, Bethlehem, Pennsylvania, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Vermont Cancer Center at Fletcher Allen Health Care, Burlington, Vermont, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Klagenfurt, Austria|Multiple site locations, Wien, Austria|Cliniques Universitaires St. Luc, Brussels, Belgium|Universitair Ziekenhuis, Leuven, Belgium|Brasilia, Brazil|Lajeado, Brazil|Porto Alegre, Brazil|Multiple site locations, Sao Paulo, Brazil|Calgary, Alberta, Canada|Toronto, Ontario, Canada|CHUM - Hopital Saint-Luc, Montreal, Quebec, Canada|Sherbrooke, Quebec, Canada|Santiago, Chile|Odense, Denmark|Angers, France|Bordeaux, France|Lyon, France|Marseille, France|Reims, France|Villejuif, France|Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen, Essen, Germany|Gemeinschaftspraxis, Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Johannes-Gutenberg Universitaet Mainz, Mainz, Germany|Klinikum der Ludwig-Maximilians-Universitaet Muenchen, Muenchen, Germany|Ludwig-Maximilians-Universitaet Muenchen, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|Athens, Greece|Kidwai Institute of Oncology, Bangalore, India|Indo-American Cancer Institute and Research Center, Hyderabad, India|SEAROC Cancer Institute, S.K. Soni Hospital, Jaipur, India|Netaji Subhash Chandra Bose Cancer Hospital Research Institute, Kolkata, India|Central India Cancer Research Institute, Nagpur, India|Shatabdi Superspeciality Hospital, Nashik, India|All India Institute of Medical Sciences, New Dehli, India|Deenanath Mangeshkar Hospital & Research Center, Pune, India|Ruby Hall Clinic, Pune, India|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Tel Aviv, Israel|Florence, Italy|Milan, Italy|Naples, Italy|Pisa, Italy|Rome, Italy|Siena, Italy|Turin, Italy|Multiple site locations, Seoul, Korea, Republic of|Amsterdam, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Multiple site locations, Lima, Peru|Bydgoszcz, Poland|Gliwice, Poland|Pozan, Poland|Szczecin, Poland|Warszawa, Poland|Coimbra, Portugal|Oporto, Portugal|Porto, Portugal|Obninsk, Russian Federation|Ufa, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Riyadh, Saudi Arabia|Multiple site locations, Barcelona, Spain|Madrid, Spain|Murcia, Spain|Santiago de Compostela, Spain|Sevilla, Spain|Valencia, Spain|Gothenburg, Sweden|Lund, Sweden|Uppsala, Sweden|Berne, Switzerland|Geneve, Switzerland|Cardiff, United Kingdom|Glasgow, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle Upon Tyne, United Kingdom|Oxford, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00704730"
221,"NCT05104866","A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)",,"Recruiting","No Results Available","Breast Cancer","Drug: Dato-DXd|Drug: Capecitabine|Drug: Gemcitabine|Drug: Eribulin|Drug: Vinorelbine","Progression Free Survival|Overall Survival|Objective Response Rate (ORR)|Duration of Response (DoR)|Progression-Free Survival by Investigator assessment|Disease Control Rate (DCR)|Time to First Subsequent Therapy (TFST)|Time to Second Subsequent Therapy (TSST)|Time from randomization to second progression or death (PFS2)|Clinical Outcome Assessment- TTD in pain|Pharmacokinetics of Dato-DXd|Immunogenicity|Clinical Outcome Assessment- TTD in physical Functioning|Clinical Outcome Assessment- TTD in GHS","AstraZeneca|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D9268C00001","October 18, 2021","July 18, 2025","July 18, 2025","November 3, 2021",,"April 22, 2022","Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Francisco, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Kansas City, Missouri, United States|Research Site, Ridgewood, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Anderlecht, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Brasília, Brazil|Research Site, Jau, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Catarina, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, North York, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Ste-Foy, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Toronto, Canada|Research Site, Baoding, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Jinan, China|Research Site, Jinan, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Xiamen, China|Research Site, Xian, China|Research Site, Zhengzhou, China|Research Site, Bordeaux, France|Research Site, Lille cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Montpellier, France|Research Site, Plerin, France|Research Site, Reims, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif, France|Research Site, Aschaffenburg, Germany|Research Site, Bielefeld, Germany|Research Site, Düsseldorf, Germany|Research Site, Essen, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Ravensburg, Germany|Research Site, Rostock, Germany|Research Site, Wiesbaden, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Miskolc, Hungary|Research Site, Szekszárd, Hungary|Research Site, Szolnok, Hungary|Research Site, Coimbatore, India|Research Site, Gulbarga, India|Research Site, Gurgaon, India|Research Site, Howrah, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Ludhiana, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, Rishikesh, India|Research Site, Surat, India|Research Site, Ancona, Italy|Research Site, Bologna, Italy|Research Site, Candiolo, Italy|Research Site, Firenze, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Prato, Italy|Research Site, Roma, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Fukushima-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Estado de México, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Toluca, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Venlo, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Białystok, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Konin, Poland|Research Site, Koszalin, Poland|Research Site, Poznan, Poland|Research Site, Rzeszów, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Amanzimtoti, South Africa|Research Site, Cape Town, South Africa|Research Site, George, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Rondebosch, South Africa|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Bilbao (Vizcaya), Spain|Research Site, Huelva, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, La Coruña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Blackpool, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05104866"
222,"NCT01916317","Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer",,"Active, not recruiting","No Results Available","Operable Breast Cancer","Drug: 0.5% lignocaine 60mM","• To assess the in-vivo ability of local anesthetics agents like lignocaine to decrease the dissemination of cancer cells during surgery and improve the disease free interval|• To assess the in-vivo ability of local anesthetics agents like lignocaine on impacting long term survival","Tata Memorial Hospital|Shri Siddhivinayak Ganpati Cancer Hospital|Kolhapur Cancer Centre (KCC)|Max Super Speciality Hospital|Basavatarakam Indo- American Cancer Hospital (BIACH)|Malabar Cancer Centre (MCC)|North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)|All India Institute of Medical Sciences, New Delhi|Gujarat Cancer and Research Institute (GCRI)|Sterling Multi Speciality Hospital (SMSH)|Dr. B Barooha Cancer Institute (BBCI)","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH project 902","December 12, 2011","October 31, 2026","December 31, 2026","August 5, 2013",,"March 22, 2022","Dr. B Barooha Cancer Institute, Guwahati, Assam, India|All India Institute of Medical Science, New Delhi, Delhi, India|Gujarat Cancer & Research Institute (GCRI), Ahmedabad, Gujarat, India|Malabar Cancer Centre, Kannur, Kerela, India|Kolhapur Cancer Centre PVT LTD, Kolhapur, Maharashtra, India|Tata Memorial Centre Mumbai, Mumbai, Maharashtra, India|Sterling Multi Speciality Hospital, Pune, Maharashtra, India|Shree Siddhivinayak Ganapti Cancer Hospital Sangli, Sangli, Maharashtra, India|North Eastern Indira Gandhi Regional Institute of Health & Medical Sciences (NEIGRIHMS), Shillong, Meghalaya, India|Basavatarakam Indo- American Cancer Hospital, Hyderabad, Telangana, India|Max Super Speciality Hospital, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01916317"
223,"NCT00864175","Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: INCB007839|Drug: trastuzumab|Drug: Docetaxel","Overall response rate (complete + partial response) using RECIST (Response Evaluation Criteria in Solid Tumor) criteria|To determine the plasma pharmacokinetic (PK) profile of INCB007839 and trastuzumab when given in combination","Incyte Corporation","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","68","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INCB 7839-202","July 2007","June 2011","October 2011","March 18, 2009",,"January 18, 2018","Visakhapatnam, Andhra Pradesh, India|New Delhi, Ansari Nagar, India|Mangalore, Attavar, India|Bangalore, Karnataka, India|Hyderabaad, Punjagutta, India|Bangalore, Ram Nagar, India|Delhi, Rohini, India|Delhi, Vasundhara Enclave, India|Bhopal, India|Kolkata, India|Nashik, India|Pune, India",,"https://ClinicalTrials.gov/show/NCT00864175"
224,"NCT03573960","A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer",,"Active, not recruiting","No Results Available","Thyroid Neoplasms","Drug: Lenvatinib","Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)|Number of Dose Reductions|Time to First Dose Reduction|Objective Response Rate (ORR)|Progression-free Survival (PFS)|Percentage of Participants with Greater Than or Equal to (>=) Grade 2 Other TEAEs","Eisai Pharmaceuticals India Pvt. Ltd|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7080-M091-507","April 1, 2018","December 31, 2022","December 31, 2022","June 29, 2018",,"December 10, 2021","All India Institute of Medical Sciences, New Delhi, Delhi, India|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Shetty's Hospital, Bangalore, Karnataka, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Bhubaneshwar, Odisa, India|S. P. Medical College & A. G. Hospitals, Bīkaner, Rajasthan, India|Tata Memorial Hospital, Mumbai, India|BL Kapoor Hospital, New Delhi, New Delhi, India|Indrayani Hospital, Alandi, Pune, India|City Cancer Centre, Vijayawada, India",,"https://ClinicalTrials.gov/show/NCT03573960"
225,"NCT00299195","A Randomized Study of Sulindac in Oral Premalignant Lesions",,"Completed","Has Results","Leukoplakia, Oral|Benign Neoplasms","Drug: sulindac|Drug: Placebo","- To Evaluate the Efficacy of Sulindac in Subjects With Early or Advanced Oral Premalignant Lesion (OPL) by Both Clinical Response (Reduction in Size of All Lesions) and Histological Response (Change in Histological Grade).|To Evaluate the Effect of Sulindac in Modulating the Expression of the Intermediate Biomarkers Ki67, p53 Proteins and DNA Ploidy After 24 Weeks of Treatment of Study Drug, and Again After 8 Weeks Off Study Drug.|To Evaluate the Correlation Between Baseline COX-2 Expression or DNA Ploidy With Clinical Response or Biomarker Modulation|To Evaluate the Safety of Chronic Dosing of Sulindac in This Subject Population|To Explore the Relationship Between Genetic Polymorphisms of Genes Involved in Carcinogenesis and Clinical or Biomarker Response to Sulindac","Memorial Sloan Kettering Cancer Center|Amrita Institute of Sciences, AIMS, Cochin, India|Weill Medical College of Cornell University|Regional Cancer Center(RCC), Trivandrum, India|Narayana Hrudayalaya Hospitals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","63","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","04-099","February 23, 2006","January 6, 2020","January 6, 2020","March 6, 2006","November 19, 2020","November 19, 2020","Memorial Sloan Kettering Cancer Center, New York, New York, United States|Amrita Institute of Sciences (AIMS), Cochin, India|Regional Cancer Center (RCC), Trivandrum, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT00299195/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00299195"
226,"NCT03800134","A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer","AEGEAN","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Durvalumab|Other: Placebo|Drug: Carboplatin/Paclitaxel|Drug: Cisplatin/Gemcitabine|Drug: Pemetrexed/Cisplatin|Drug: Pemetrexed/Carboplatin","Pathological Complete Response (pCR) in modified intent-to-treat (mITT)|Event-Free Survival (EFS)|Disease-free survival (DFS) in modified resected population|Major Pathological Response (mPR)|Overall Survival (OS)|Event-free survival (EFS) in PD-L1-TC ≥1% positive patients|pCR in PD-L1-TC ≥1% positive patients|Disease-Free Survival (DFS) in PD-L1-TC ≥1% positive patients|Major Pathological Response (mPR) in PD-L1-TC ≥1% positive patients|Overall Survival (OS) in PD-L1-TC ≥1% positive patients|To assess disease-related symptoms and HRQoL (EORTC QLQ-C30) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery|To assess disease-related symptoms and HRQoL (EORTC QLQ-LC13) in patients treated with durva + chemo prior to surgery followed by durva post-surgery compared with placebo + chemo prior to surgery followed by placebo post-surgery|To assess the PK of durvalumab in blood (through concentration)|Presence of ADA for durvalumab","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","824","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","D9106C00001","December 6, 2018","April 30, 2024","April 30, 2024","January 11, 2019",,"May 9, 2022","Research Site, Phoenix, Arizona, United States|Research Site, Duarte, California, United States|Research Site, Long Beach, California, United States|Research Site, Orange, California, United States|Research Site, Rancho Mirage, California, United States|Research Site, San Diego, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Boca Raton, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Waterloo, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Hastings, Nebraska, United States|Research Site, Morristown, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Buffalo, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Port Jefferson Station, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Salisbury, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Bend, Oregon, United States|Research Site, Medford, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Fort Belvoir, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Kirkland, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Cordoba, Argentina|Research Site, Córdoba, Argentina|Research Site, Florencio Varela, Argentina|Research Site, La Plata, Argentina|Research Site, Pergamino, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Viedma, Argentina|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Rankweil, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Liège, Belgium|Research Site, Mons, Belgium|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Teresina, Brazil|Research Site, Vitoria, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Levis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saskatoon, Saskatchewan, Canada|Research Site, Quebec, Canada|Research Site, Santiago de Chile, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changzhou, China|Research Site, Chengdu, China|Research Site, Guang Zhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Kunming, China|Research Site, Linhai, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Ningbo, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xiamen, China|Research Site, Xian, China|Research Site, Xintai, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, San José, Costa Rica|Research Site, San José, Costa Rica|Research Site, Avignon Cedex, France|Research Site, Bordeaux, France|Research Site, Lyon Cedex 08, France|Research Site, Nice, France|Research Site, Rouen Cedex, France|Research Site, Toulon Cedex 9, France|Research Site, Tours, France|Research Site, Vantoux, France|Research Site, Bielefeld, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Göttingen, Germany|Research Site, Immenstadt, Germany|Research Site, Köln, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Gyöngyös - Mátraháza, Hungary|Research Site, Győr, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Törökbálint, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chandigarh, India|Research Site, Coimabatore, India|Research Site, Delhi, India|Research Site, Erode, India|Research Site, Gurgaon, India|Research Site, Gurgaon, India|Research Site, Hubli, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Maharashtra, India|Research Site, Manipal, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Mysuru, India|Research Site, Nagpur, India|Research Site, Namakkal, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Surat, India|Research Site, Thane, India|Research Site, Vishakhapatnam, India|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Habikino-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kitakyushu-shi, Japan|Research Site, Kurashiki shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Toyoake-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Chihuahua, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, México, Mexico|Research Site, Pachuca de Soto, Mexico|Research Site, Arnhem, Netherlands|Research Site, Breda, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Arequipa, Peru|Research Site, Bellavista, Peru|Research Site, Chiclayo, Peru|Research Site, Cusco, Peru|Research Site, La Libertad, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Baguio City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Białystok, Poland|Research Site, Kraków, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Poznań, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Hato Rey Central, Puerto Rico|Research Site, Brasov, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, P. Herzen Moscow Oncology Rese, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Syktyvkar, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Pamplona, Spain|Research Site, San Sebastian, Spain|Research Site, Santiago De Compostela (A Coruña), Spain|Research Site, Valencia, Spain|Research Site, Changhua, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Chiang Rai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Lampang, Thailand|Research Site, Dnipro, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03800134"
227,"NCT03839823","Study to Compare the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Combination Chemotherapy in Premenopausal or Perimenopausal Patients With Advanced or Metastatic Breast Cancer","RIGHT Choice","Active, not recruiting","No Results Available","Breast Cancer","Combination Product: Docetaxel / Capecitabine|Combination Product: Capecitabine / Vinorelbine|Combination Product: Paclitaxel / Gemcitabine|Drug: Ribociclib|Drug: Letrozole OR Anastrozole|Drug: Goserelin","Progression Free Survival|Time to treatment failure|Overall response rate (ORR)|Clinical benefit rate|Time to response|Overall survival|Frequency/severity of adverse events, lab abnormalities.|Change from baseline in the global health status/QOL scale score by using FACT-B questionnaire|3-month treatment failure rate","Novartis Pharmaceuticals|Novartis","Female","18 Years to 59 Years   (Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEE011A3201C","February 25, 2019","April 12, 2022","January 27, 2023","February 15, 2019",,"April 28, 2022","Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Giza, Egypt|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Pushkin Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Durban, Kwazulu Natal, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey|Novartis Investigative Site, Cankaya Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kecioren Ankara, Turkey|Novartis Investigative Site, Malatya, Turkey|Novartis Investigative Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03839823"
228,"NCT00565708","Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers","ASCOLT","Active, not recruiting","No Results Available","Colorectal Cancer","Other: placebo|Drug: Acetylsalicylic acid","Disease-free survival|Overall survival","National Cancer Centre, Singapore|University of Oxford|Australasian Gastro-Intestinal Trials Group|INDOX Cancer Research Network","All","18 Years and older   (Adult, Older Adult)","Phase 3","1587","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CDR0000577892|SINGAPORE-ICR-02|SINGAPORE-ASCOLT","December 2008","December 2025","June 2026","November 30, 2007",,"September 13, 2021","Bankstown-Lidcombe Hospital Bankstown Cancer Centre, Bankstown, New South Wales, Australia|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Clinical Research Centre, Camperdown, New South Wales, Australia|Coffs Harbour Health Campus North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Central Coast Cancer Centre Gosford Hospital, Gosford, New South Wales, Australia|Newcastle private Hospital, New Lambton Heights, New South Wales, Australia|Orange Health Service, Orange, New South Wales, Australia|Port Macquarie Base Hospital North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Northern Cancer Institute, St Leonards, St Leonards, New South Wales, Australia|St Vincent's Hospital, Sydney, New South Wales, Australia|Northwest Cancer Centre Tamworth Hospital, Tamworth, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|Townsville Hospital, Douglas, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Border Medical Oncology Research Unit, Albury, Victoria, Australia|Ballarat Regional Integrated Cancer Centre, Ballarat, Victoria, Australia|Barwon Health Andrew Love Cancer Centre, Geelong, Victoria, Australia|Austin Health Cancer Clinical Trials, Heidelberg, Victoria, Australia|Launceston General Hospital, Launceston, Victoria, Australia|Monash Health Medical Oncology, Melbourne, Victoria, Australia|Mildura Base Hospital, Mildura, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|St John of God Healthcare Southwest Oncology, Warrnambool, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|St John of God Hospital Subiaco, Subiaco, Western Australia, Australia|Beijing University Cancer Hospital, Beijing, Beijing, China|The First People's Hospital of Foshan City, Foshan, Guangdong, China|Sixth Affiliated Hospital, Guangzhou, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Sun Yat Sen University Cancer Center, Guangzhou, Guangdong, China|Zhongshan City People's Hospital, Zhongshan, Guangdong, China|Jinan Central Hospital, Jinan, Shandong, China|Yantai Yuhuangding Hospital, Yantai, Shandong, China|The Second Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|Queen Mary Hospital - Hong Kong, Hong Kong, China|Affiliated Hospital of Nantong University, Nantong, China|Kidwai Memorial Institute of Oncology, Bangalore, India|G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, India|Nizam's Institute of Medical Sciences, Hyderabad, India|Tata Memorial Hospital, Mumbai, India|All India Institute of Medical Sciences, New Delhi, India|Regional Cancer Center, Trivandrum, India|Christian Medical College and Hospital, Vellore, India|Dharmais Cancer Hospital, Jakarta, Indonesia|Cipto Mangunkusumo General Hospital, Jakarta, Indonesia|Rumah Sakit RSUP Dr. Sardjito, Yogyakarta, Indonesia|Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon-si, Korea, Republic of|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University of Malaysia Medical Center, Kuala Lumpur, Malaysia|University Kebangsaan Malaysia Medical Center, Kuala Lumpur, Malaysia|Christchurch Public Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|King Fahad Medical City, Riyadh, Saudi Arabia|National Cancer Centre - Singapore, Singapore, Singapore|Johns Hopkins Singapore International Medical Center, Singapore, Singapore|National Cancer Institute, Maharagama, Sri Lanka|Shuang Ho Hospital, Taipei, Taiwan|Koo Foundation Sun Yat Sen Cancer Centre, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Wan Fang Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00565708"
229,"NCT03822468","Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer","AMALEE","Active, not recruiting","No Results Available","Breast Cancer","Drug: Ribociclib|Drug: Letrozole or Anastrozole|Drug: Goserelin","Overall Response Rate (ORR)|Δ QTcF at Cycle 1 Day 15 (at 2h post-dose) (Key Secondary Endpoint)|Progression-free survival (PFS)|Clinical benefit rate (CBR)|Time to response (TTR)|Duration of response (DOR)|Pharmacokinetics (PK) of ribociclib: Cmax|Pharmacokinetics (PK) of ribociclib: Tmax|Pharmacokinetics (PK) of ribociclib: AUC0 - 24h","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 2","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEE011A2207|2018-004234-15","June 11, 2019","June 11, 2021","December 30, 2025","January 30, 2019",,"May 13, 2022","Southern Cancer Center PC, Mobile, Alabama, United States|Marin Cancer Care, Greenbrae, California, United States|Rocky Mountain Cancer Centers Rocky Mountain Cancer Ctr (50), Denver, Colorado, United States|Florida Retina Institute, Orlando, Florida, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|Weinberg Cancer Institute at Franklin Square Hospital, Baltimore, Maryland, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|New York Oncology Hematology SC, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Mount Sinai School of Medicine CFTY720D2306, New York, New York, United States|Northwest Cancer Ctr, Houston, Texas, United States|Texas Oncology, McAllen, Texas, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Novartis Investigative Site, San Juan, Argentina|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Valledupar, Cesar, Colombia|Novartis Investigative Site, Ibague, Tolima, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, San Jose, Costa Rica|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont Ferrand, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Langen, Hessen, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weiden, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Raipur, Chhattisgarh, India|Novartis Investigative Site, Nagpur, Maharashtra, India|Novartis Investigative Site, Bhubaneshwar, Orissa, India|Novartis Investigative Site, Delhii, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Kaunas, LTU, Lithuania|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Trujillo, La Libertad, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, San Miguel, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lisbon, Portugal|Novartis Investigative Site, Loures, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT03822468"
230,"NCT00294996","Trial of Myocet in Metastatic Breast Cancer",,"Unknown status","No Results Available","Breast Cancer","Drug: Myocet","Progression-Free Survival|Overall Survival|Safety","Sopherion Therapeutics","Female","18 Years and older   (Adult, Older Adult)","Phase 3","363","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STM01-102","January 2006",,,"February 22, 2006",,"March 31, 2009","Scripps Cancer Center Clinical Research, San Diego, California, United States|University of Colorado, Aurora, Colorado, United States|Northwest Hematology/Oncology Associates, Coral Springs, Florida, United States|Osceola Cancer Center, Kissimmee, Florida, United States|UM/Sylvester Cancer Center, Plantation, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Clintell, Inc, Skokie, Illinois, United States|Hutchinson Clinic P.A., Hutchinson, Kansas, United States|Western Maryland Health System, Cumberland, Maryland, United States|Brody School of Medicine @ ECU, Greenville, North Carolina, United States|Aultman Hospital Cancer Center, Canton, Ohio, United States|Hematology Oncology Consultants, Inc., Columbus, Ohio, United States|Vita Hematology Oncology, Bethlehem, Pennsylvania, United States|Hematology & Oncology Associates of NEPA, Dunmore, Pennsylvania, United States|PA Oncology Hematology Asso, Philadelphia, Pennsylvania, United States|M. Francisco Gonzalez, Columbia, South Carolina, United States|Sioux Valley Clinic, Sioux Falls, South Dakota, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Centro Oncologico de Excelencia, Buenos Aires, Argentina|Hospital Enrique Tornú, Buenos Aires, Argentina|Hospital Interzonal Gral de Agudos "" EVITA"", Buenos Aires, Argentina|Hospital Profesor A. Posadas, Buenos Aires, Argentina|Santorio Municipal Dr. J. Mendez, Buenos Aires, Argentina|Unidad Oncologica del Neuquen, Neuquen, Argentina|CAICI Instituto, Santa Fe, Argentina|Centro Oncologico Rosario, Santa Fe, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|Ceten, Villa Dominico, Argentina|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Centre/London Health Science Centre, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Center, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM Hospital Notre-Dame, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Hopital du St. Sacrement, Quebec, Canada|U.K Charité, Campus Mitte, Berlin, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|Gemeinschaftspraxis Gynäkologie & Geburtshilfe, Mannheim, Germany|Frauenklinik von Roten Kreuz, München, Germany|Klinikum Offenbach, Offenbach, Germany|Üniversitäts Klinikum Tübingen, Tübingen, Germany|Dr. Horst Schmidt Kliniken, Wiesbaden, Germany|Gujarat Cancer Research Institute, Asarwa, Gujarat, India|Kidwai Memorial Institute of Oncology, Bangalore, India|Manipal Hospital, Bangalore, India|Apollo Specialty Hospitals, Chennai, Chennai, India|Nizam's Institute of Medical Science, Hyderabaad, India|SMSMedicalCollegeHospital,, Jaipur, India|Lakeshore Hospital and Research Centre Ltd, Kerala, India|Himadri cancer welfare trusr, Kolkata, India|Orchid Nursing Home,, Kolkata, India|Ruby Hall Clinic, Maharashtra, India|Tata Memorial Hospital, Maharashtra, India|Kasturba Medical College,, Mangalore, India|Jaslok Hospital and Research Centre, Mumbai, India|Batra Hospital & Medical Research Center, New Delhi, India|Indraprastha Apollo Hospitals, New Delhi, India|Safdarjung Hospital & Vardhaman Mahaveer Medical College, New Delhi, India|Fortis Hospital, Noida, India|Azienda Ospedialera Pugliese-Ciaccio, Catanzaro, Italy|Clinica Oncologica Ospedale, Chieti, Italy|DIMI - Università di Genova, Genova, Italy|ARNAS CIVICO. Presidio Ospedaliero M. Ascoli, Palermo, Italy|Oncologia Medica, Pavia, Italy|Day Hospital Oncologico,, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|SP SK nr1 ACK AMG, Gdańsk, Poland|Centrum Onkologii - Instytut Marii Skłodowskiej-Curie Oddział Gliwice, Gliwice, Poland|Samodzielny Publiczny Szpital, Lublin, Poland|Zakład Opieki Zdrowotnej MSWiA, Olsztyn, Poland|Szpital Wojewódzki im. Św. Łukasza, Tarnow, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|SP ZOZ Szpital Wojewódzki, Zielona Gora, Poland|Regionalny Ośrodek Onkologiczny, Łódź, Poland|Regionalny Szpital Specjalistyczny, Świdnica, Poland|nstituto Português de Oncologia Francisco Gentil, Lisbon, Portugal|Non-state Health Care Insitution ""N.A. Semashko Central Clinical Hospital #2"" of the ""Russian Railways"" Joint Stock Company, Moscow, Russian Federation|State Institution ""N.N. Blokhin Russian Oncology Scientific Center"" of the Russian Academy of Medical Sciences, Moscow, Russian Federation|State Science Institution ""P.A. Hertzen Moscow Oncology Research Institute"" of the Federal Agency of Health Care and Social Development, Moscow, Russian Federation|State Health Care Institution ""Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|Municipal Health Care Institution of the City of Sochi ""Oncology Dispensary"", Sochi, Russian Federation|St. Petersburg State Health Care Institution ""City Clinical Oncology Dispensary"", St Petersberg, Russian Federation|State Science Institution ""Prof. N.N. Petrov Research Institute of Oncology"" of the Federal Agency of Health Care and Social Development, St Petersberg, Russian Federation|Research Institute of Pulmonology affiliated with State Educational Institution ""St. Petersburg State Medical University n.a. academician I.P. Pavlov"" of the Federal Agency of Health Care and Social Development, St. Petersberg, Russian Federation|State Health Care Institution ""Leningrad Regional Oncology Dispensary"", St. Petersburg, Russian Federation|State Health Care Institution of the Yaroslavl Region ""Yaroslavl Regional Oncology Dispensary"", Yaroslavl, Russian Federation|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Son Dureta, Palma de Mallorca, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital Mutua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Broomfield Hospital, Broomfield, United Kingdom|Christie Hospital NHS Trust, Cardiff, United Kingdom|Guy's Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00294996"
231,"NCT01989676","A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)",,"Completed","Has Results","Metastatic Breast Cancer","Biological: PF-05280014|Drug: Paclitaxel|Biological: Herceptin®","Objective Response Rate (ORR) Derived From Central Radiology Assessments: ITT Population|One-year Progression-Free Survival (PFS) Rate Derived From Central Radiology Assessments: ITT Population|Duration of Response (DOR) Per Central Radiology Assessments: ITT Population|Overall Survival: ITT Population|Serum Peak Concentration of PF-05280014 at Selected Cycles: Pharmacokinetics (PK) Population|Serum Peak Concentration of Trastuzumab-EU at Selected Cycles: PK Population|Serum Trough (Pre-dose) Concentration of PF-05280014 at Selected Cycles: PK Population|Serum Trough (Pre-dose) Concentration of Trastuzumab-EU at Selected Cycles: PK Population|Number of Participants With Positive Anti-Drug Antibodies (ADA) Sample: Safety Population|Number of Participants With Positive Neutralizing Antibodies (Nab) Prior to Treatment: Safety Population","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","707","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B3271002|REFLECTIONS B327-02|2013-001352-34","February 24, 2014","August 24, 2016","June 27, 2020","November 21, 2013","January 23, 2018","July 6, 2021","Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer Research Institute, Boca Raton, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|COIBA - Centro de Oncologia e Investigacion Buenos Aires, Berazategui, Buenos Aires, Argentina|Instituto De Oncologia De Rosario, Rosario, Santa FE, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Sanatorio de la Providencia, C.a.b.a, Argentina|CRIO - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Associacao de Combate ao Cancer em Goias - Hospital Araujo Jorge, Goiania, GO, Brazil|Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Parana, Brazil|Instituto do Cancer de Londrina - Hospital do Cancer de Londrina - HCL, Londrina, Parana, Brazil|Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado), Lajeado, RIO Grande DO SUL, Brazil|Associacao Hospital de Caridade Ijui, Ijui, RS, Brazil|Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RS, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral, Itajai, Santa Catarina, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, SAO Paulo, Brazil|Centro de Pesquisas Oncologicas de Santa Catarina - CEPON, Florianopolis, SC, Brazil|Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral, Itajai, SC, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Clinica Alemana de Temuco, Temuco, Region DE LA Araucania, Chile|Centro de Investigacion Clinica SIM, Temuco, Region DE LA Araucania, Chile|Administrative office, Temuco, Region DE LA Araucania, Chile|Fresenius Kabi Chile Therapia iv, Santiago, RM, Chile|Hospital Clinico Vina Del Mar, Vina del Mar, V Region, Chile|Instituto Oncologico, Clinica Renaca, Vina del Mar, V Region, Chile|Hospital Naval Almirante Nef, V Region, Chile|Instituto Oncologico Clinica Renaca, V Region, Chile|Onkologicka klinika VFN a 1. LF UK, Fakultni poliklinika, Praha 2, Czechia|General Hospital of Chania ""O Agios Georgios"", Chania, Crete, Greece|Interbalkan European Medical Center, Pylaia, Thessaloniki, Greece|General Hospital of Athens ""Hippokration"", Athens, Greece|Bacs-Kiskun Megyei Korhaz, Onkoradiologiai Kozpont, Kecskemet, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz, es Egyetemi Oktatokorhaz, Klinikai Onkologiai es Sugarterapias, Miskolc, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Department of Medicine New Block, Visakhapatnam, Andhra Pradesh, India|Manipal Hospital, Bengaluru, Karnataka, India|Manipal Centre for Clinical Research, Manipal, Karnataka, India|Tata Memorial Centre, Tata Memorial Hospital, Mumbai, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Navi Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Acharya Harihar Regional Cancer Center, Cuttack, Odisha, India|Acharya Tulsi Regional Cancer Treatment and Research Institute, Bikaner, Rajasthan, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil NADU, India|MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Telangana, India|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Japan Community Health care Organization Kurume General Hospital, Kurume-city, Fukuoka, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kumamoto University Hospital, Kumamoto-city, Kumamoto, Japan|Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|Chiba Cancer Center, Chiba, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Nakanoshima Osaka Breast Clinic, Osaka, Japan|Osaka Breast Clinic, Osaka, Japan|Shizuoka General Hospital, Shizuoka, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Pusan National University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Centre, Goyang-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|P.Stradins Clinical University Hospital, Riga, Latvia|Instituto Nacional de Cancerologia, Mexico City, Distrito Federal, Mexico|Consultorio dentro de la Torre Medica Dalinde (Oncologia Medica), Mexico, Distrito Federal, Mexico|Inter Hosp S.A. de C.V. ""Centro Medico Dalinde"", Mexico, Distrito Federal, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|Cancerologia de Queretaro S.C., Queretaro, Mexico|Hospital Militar Central, Lima, Peru|INNPARES, Lima, Peru|Resocentro, Lima, Peru|Clinica Anglo Americana, Lima, Peru|Instituto de Oncologia y Radioterapia de la Clinica Ricardo Palma, Lima, Peru|Radiologos S.R.L., Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Siglo XXI, Lima, Peru|Resocentro, Lima, Peru|Siglo XXI, Lima, Peru|Cebu Doctors' University Hospital, Cebu City, Cebu, Philippines|Cardinal Santos Medical Center, San Juan City, Mentro Manila, Philippines|Manila Doctors Hospital, Manila, Metro Manila, Philippines|Veterans Memorial Medical Center, Quezon City, Metro Manila, Philippines|University of Philippines Manila-Philippine General Hospital, Manila, NCR, Philippines|The Medical City, Pasig City, NCR, Philippines|St. Luke's Medical Center, Quezon City, NCR, Philippines|The Research Institute at Perpetual Succor Hospital, Cebu City, Region VII, Philippines|Manila Doctors Hospital, Manila, Philippines|COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|Szpitale Pomorskie Sp. z o.o. Oddzial Onkologii i Radioterapii, Gdynia, Poland|Centrum Terapii Wspolczesnej, Lodz, Poland|SPZOZ MSW z Warminsko-Mazurskim Centrum Onkologii w Olsztynie, Oddzial Kliniczny Chemioterapii, Olsztyn, Poland|MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Magodent Sp. z o.o. Oddzial Onkologii Klinicznej/Chemioterapii, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Hospital CUF Descobertas, Lisboa, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Cluj, Romania|S.C. Medisprof S.R.L, Cluj-Napoca, Cluj, Romania|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|SC Oncolab SRL, Oncologie, Craiova, Jud Dolj, Romania|Spitalul Universitar de Urgenta, Departamentul Oncologie Medicala, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Sibiu, Sibiu, Romania|Spitalul Judetean de Urgenta ""Sf.Ioan cel Nou"", Sectia Oncologie, Suceava, Romania|Spitalul Clinic Municipal de Urgenta Timisoara, Sectia Clinica Oncologie Medicala, Timisoara, Romania|Republic Clinical Hospital of Emergency Care, Grozny, Chechenkaya Republic, Russian Federation|State Healthcare Institution Kursk Regional Oncological Dispensary of the Healthcare Committee, Kislino Settlement, Kursk, Russian Federation|State Budgetary Healthcare Institution ""Leningrad Regional Oncological Dispensary"", Kuzmolovo, Vsevolozhskiy, Leningrad Region, Russian Federation|FSBSI Russian Cancer Research Center n.a. N.N.Blokhin, Moscow, NAP, Russian Federation|GBUZ of Perm region ""Perm regional oncology dispensary"", Perm, NAP, Russian Federation|Federal State Budgetary Institution ¿National Medical Research Oncology Centre named after N.N., Saint-Petersburg, Pos.pesochny, Russian Federation|State Healthcare Institution, Republican Clinical Oncology Dispensary of the Ministry of, Ufa, Republic OF Bashkortostan, Russian Federation|GBUZ Republican Clinical Hospital n.a. G.F. Kuvatova, Ufa, Republic OF Baskortostan, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Baskortostan Republic, Ufa, Republic OF Baskortostan, Russian Federation|State Budgetary Healthcare Institution ''Republic Oncological Dispensary'', Petrozavodsk, Republic OF Karelia, Russian Federation|State budget institution of healthcare of Mordovia Republic ""Republic Oncology Dispensary"", Saransk, Republic OF Mordovia, Russian Federation|Rostov Research Institute of Oncology, Rostov-on-Don, Rostov Region, Russian Federation|Private medical institution Euromedservice, Pushkin, Saint Petersburg, Russian Federation|Saint-Petersburg Clinical Research Center of Specialized Types of Medical Care (Oncology), Poselok Pesochny, Saint-petersburg, Russian Federation|LLC Medekspert, Kislovodsk, Stavropol Region, Russian Federation|Federal State Budgetary Healthcare Institution of ""Clinical Hospital #101 of Federal Medical and, Lermontov, Stavropol Region, Russian Federation|Centre of Specialized kinds of Medical Care of Pyatigorsk city, Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution of Stavropol Region Pyatigorsk Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation|LLC Novaya Clinica, Pyatigorsk, Stavropol Region, Russian Federation|Pyatigorsk City Hospital #2, Pyatigorsk, Stavropol Region, Russian Federation|Stavropol Regional Hospital for War Veterans, Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution Volgograd Regional Clinical Oncology Dispensary, Volzhskiy, Volgograd Region, Russian Federation|GBUZ Arkhangelsk Regional Clinical Oncological dispensary, Arkhangelsk, Russian Federation|State Budgetary Healthcare Institution ""Chelyabinsk Regional Clinical Oncological Dispensary"", Chelyabinsk, Russian Federation|""Regional Budgetary Healthcare Institution """"Ivanovo Regional Oncology Dispensary"""""", Ivanovo, Russian Federation|SBIH of Kaluga Region ""Kaluga Regional Clinical Oncology Dispensary"", Kaluga, Russian Federation|GBUZ ""Regional Oncology Dispensary #2"", Magnitogorsk, Russian Federation|Federal State Budgetary Institution ""Russian Oncological Scientific Center n.a. N.N. Blokhin"" of, Moscow, Russian Federation|LLC VitaMed, Moscow, Russian Federation|LLC VitaMed, Moscow, Russian Federation|State Budgetary Healthcare Institution ""Nizhniy Novgorod Regional Oncological Dispensary"", Nizhniy Novgorod, Russian Federation|""BIH of Omsk Region """"Clinical oncological dispensary"""""", Omsk, Russian Federation|Budgetary Institution of Healthcare of Orel region ""Orel oncological dispensary"", Orel, Russian Federation|SBEI HPE RyazSMU of MoH of the Russian Federation based on SBI of Ryazan Region ""Regional CLinical, Ryazan, Russian Federation|SBEI of HPE ""First Saint Petersburg State Medical University, Saint Petersburg, Russian Federation|SBI ""North-Western State Medical University n.a. I. I. Mechnikov"" of the MoH of the Russian, Saint-Petersburg, Russian Federation|Non-state healthcare agency Road Clinical Hospital PLC Russian Railways, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution ""Oncological Dispensary of Moscow District"", Saint-Petersburg, Russian Federation|Non-State Healthcare Institution ""Road Clinical Hospital at Saratov II Station"", Saratov, Russian Federation|State Budgetary Healthcare Institution of Stavropol region ""Stavropol regional clinical oncology, Stavropol, Russian Federation|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinic of Oncology-Clinical Center Nis, Nis, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|Onkologicky ustav sv. Alzbety, s.r.o., Bratislava, Slovakia|Narodny Onkologicky Ustav, Bratislava, Slovakia|GVI Oncology, Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, South Africa|wits Clinical Research, Joannesburg, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, Gauteng, South Africa|*Department of Medical Oncology, University of Pretoria & Steve Biko Academic Hospitals Complex, Pretoria, Gauteng, South Africa|Eastleigh Breast Care Centre, Pretoria, Gauteng, South Africa|Cape Town Oncology Trials, Kraaifontein, Western CAPE, South Africa|GVI Rondebosch Oncology Centre-Rondebosch Medical Centre, Rondebosch, Western CAPE, South Africa|National Cancer Institute, Ratchathewi, Bangkok, Thailand|Udonthani Cancer Hospital, Amphur Muang, Udonthani, Thailand|Faculty of Medicine, Chulongkorn University, Medical Oncology Unit, Bangkok, Thailand|Baskent University School of Medicine Adana Hospital, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Uludag Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali, Bursa, Turkey|Dicle University Medical Faculty, Diyarbakir, Turkey|Gaziantep University Medical Faculty, Gaziantep, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Municipal Institution ""Chernivtsi Regional Clinical Oncology Center"", Outpatient Department, Chernivtsi, Ukraine|Municipal Non-Profit Enterprise City Clinical Hospital No.4of Dnipro Regional Council, Department of, Dnipro, Ukraine|SI Institute of Medical Radiology n.a.S.P. Ilrygoriev of National Academy of Medical Science of, Kharkiv, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|Khmelnytskyi Regional Oncologic Dispensary, Khmelnytskyi, Ukraine|Municipal Enterprise 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council', Kryvyi Rih, Ukraine|Municipal Non-Profit Enterprise of Kyiv Regional Council ""Kyiv Regional Oncology Dispensary"", Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Mammology Center, Odesa, Ukraine|Zakarpattia Regional Clinical Oncological Center, Uzhgorod, Ukraine|Municipal Non-profit Enterprise Podilsk Regional Oncology Centre of Vinnytsia Regional Council, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01989676"
232,"NCT03564938","Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).",,"Recruiting","No Results Available","Metastatic Colorectal Cancer","Drug: Regorafenib (Stivarga, BAY73-4506)","Number of Adverse Events|Changes in Eastern Cooperative Oncology Group Performance Status (ECOG PS)|Percentage of participants with change in worst grades for hematological and biochemical toxicities according to CTCAE version 4.03, based on laboratory measurements|Change in Body weight (kg)|Change in Systolic / Diastolic BP (mmHg)|Change in heart rate (beats/min)|Disease control rate (DCR)|Overall response rate (ORR)|Progression free survival (PFS)|Overall survival (OS)","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19214","July 30, 2018","April 2, 2023","April 2, 2023","June 21, 2018",,"April 26, 2022","Apollo Research Foundation, Hyderabad, Andhra Pradesh, India|HCG-City Cancer Centre, Vijayawada, Andhra Pradesh, India|Sir Ganga Ram Hospital, New-Delhi, Delhi, India|The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India|Healthcare Center Global Hospital, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Healthcare Global Enterprises Ltd, Bengaluru, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Sushrut Hospital & Research Centre, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Fortis Hospital, West-Mumbai, Maharashtra, India|Sparsh Hospital & Critical Care, Bhubaneswar, Orissa, India|Shalby Hospital, Jaipur, Rajasthan, India|Apollo Speciality Hospitals, Madurai, Tamil N?du, India|IPGME & R / SSKM Hospital, Kolkata, West Bengal, India|Health Point Hospital, Kolkata, West Bengal, India|Indraprastha Apollo Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT03564938"
233,"NCT00718354","Overall Survival of Inoperable Gastric/GastroOesophageal Cancer Subjects on Treating With LMWH + Chemotherapy(CT) vs Standard CT","GASTRANOX","Completed","No Results Available","Gastric Cancer|Gastroesophageal Cancer","Drug: Enoxaparin|Drug: Standard Chemotherapy","Event Free Survival (EFS) - Composite endpoint of overall survival plus free of symptomatic VTE .|Incidence of SVTE Overall survival Major and minor haemorrhages during chemotherapy and / or up to 30 days after last dose is provided. Serious adverse events, All reported adverse events HIT","Thrombosis Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","740","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","TRI0702","July 2008","January 2010","August 2010","July 18, 2008",,"May 13, 2015","Mahatma Gandhi Cancer Hospital & Research Institute ,1/7 M.V.P. Colony, - ,, ., Vishakhapattanam, Andhra Pradesh, India|Mahavir Cancer Sansthan,Phulwari Sharif, Patna, Bihar, India|Gujarat Cancer Research Institute, Civil Hospital Campus,Asarwa, ,, Ahmedabad, Gujarat,, India|Department Of Radiotherapy,S.S.G. Hospital, -, Baroda,Vadodara, Gujarat,, India|Gokula Curie Cancer Centre,M.S.Ramaiah Memorial Hospital,MSR Nagar, MSRIT Post, Bangalore, Karnataka, India|Madhavan J.P., Trivandrum, Kerala,, India|MGM Medical College & MY Hospital,, Indore, M.P, India|Curie Manavta Cancer Centre, Opp.Hotel Sandeep Naka,Nashik, Mumbai, Maharashtra,, India|Ruby Hall Clinic,Cancer Building,40 sassoon Road, , ,, Pune, Maharashtra, India|Cancer Hospital & Research Institute, Cancer Hill, Gwalior, MP, India|Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, UP, India|B.P.Poddar Hospital & Medical Research Ltd,71/1, Humayun Kabir Sarani,, Block-G, New Alipore, Kolkata, west Bangol, India|Biswajit Sanyal, Calcutta, West Bengal, India|Chittaranjan National Cancer Institute,37, S.P.Mukhurjee Road, Kolkata, West Bengal, India|Dr. BRA IRCH,all India Institute of Medical Sciences,Ansari Nagar,, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00718354"
234,"NCT03109249","Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer",,"Completed","No Results Available","Recurrent or Metastatic Breast Cancer","Drug: SPARC1613|Drug: Reference1613","Maximum observed concentration (Cmax)","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLR_16_13","January 14, 2017","October 4, 2018","October 4, 2018","April 12, 2017",,"May 3, 2019","SPARC Site 40, Visakhapatnam, Andhra Pradesh, India|SPARC Site 20, Ahmedabad, Gujarat, India|SPARC site 39, Ahmedabad, Gujarat, India|SPARC site 38, Karamsad, Gujarat, India|SPARC Site 27, Surat, Gujarat, India|SPARC Site 35, Surat, Gujarat, India|SPARC Site 24, Vadodara, Gujarat, India|SPARC Site 13, Bangalore, Karnataka, India|SPARC site 41, Bangalore, Karnataka, India|SPARC Site 28, Bangalore, Karnataka, India|SPARC Site 22, Belgaum, Karnataka, India|SPARC Site 7, Mangalore, Karnataka, India|SPARC Site 25, Aurangabad, Maharashtra, India|SPARC Site 23, Aurangabad, Maharashtra, India|SPARC Site 2, Mumbai, Maharashtra, India|SPARC Site 12, Nagpur, Maharashtra, India|SPARC site 34, Nashik, Maharashtra, India|SPARC Site 37, Nashik, Maharashtra, India|SPARC Site 18, Pune, Maharashtra, India|SPARC Site 4, Pune, Maharashtra, India|SPARC Site 9, Aurangabad, Marashtra, India|SPARC Site 15, Khorda, Orissa, India|SPARC site 42, Chennai, Tamil Nadu, India|SPARC Site 32, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT03109249"
235,"NCT01077154","Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)",,"Terminated","Has Results","Breast Cancer","Drug: Placebo|Drug: Denosumab","Bone Metastasis-free Survival (BMFS)|Disease-free Survival (DFS)|Disease-free Survival (DFS) in the Postmenopausal Subset|Overall Survival|Distant Recurrence-free Survival","Amgen|Daiichi Sankyo, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","4509","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060359|2009-011299-32","June 2, 2010","August 31, 2017","March 26, 2018","February 26, 2010","October 3, 2018","September 28, 2021","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Alhambra, California, United States|Research Site, Anaheim, California, United States|Research Site, Beverly Hills, California, United States|Research Site, Campbell, California, United States|Research Site, Fresno, California, United States|Research Site, Fullerton, California, United States|Research Site, La Verne, California, United States|Research Site, Lancaster, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Torrance, California, United States|Research Site, Denver, Colorado, United States|Research Site, Grand Junction, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Melbourne, Florida, United States|Research Site, Athens, Georgia, United States|Research Site, Niles, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Cedar Rapids, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Columbia, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Danvers, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Edina, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis Park, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Denville, New Jersey, United States|Research Site, Hackensack, New Jersey, United States|Research Site, East Setauket, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Abilene, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Garland, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Plano, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Richlands, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, San Martin, Buenos Aires, Argentina|Research Site, Neuquen, NeuquÃ©n, Argentina|Research Site, Provincia De Santa Fe, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Camperdown, New South Wales, Australia|Research Site, Caringbah, New South Wales, Australia|Research Site, Kogarah, New South Wales, Australia|Research Site, Tweed Heads, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Bedford Park, South Australia, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Richmond, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Warrnambool, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Antwerpen, Belgium|Research Site, Bonheiden, Belgium|Research Site, Brugge, Belgium|Research Site, Brussel, Belgium|Research Site, Bruxelles, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont, Belgium|Research Site, LiÃ¨ge, Belgium|Research Site, Namur, Belgium|Research Site, Oostende, Belgium|Research Site, Ottignies, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Tournai, Belgium|Research Site, Wilrijk, Belgium|Research Site, Yvoir, Belgium|Research Site, Salvador, Bahia, Brazil|Research Site, Salvador, Bahia, Brazil|Research Site, Curitiba, ParanÃ¡, Brazil|Research Site, Londrina, ParanÃ¡, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, ItajaÃ-, Santa Catarina, Brazil|Research Site, Barretos, SÃ£o Paulo, Brazil|Research Site, Santo Andre, SÃ£o Paulo, Brazil|Research Site, Sao Paulo, SÃ£o Paulo, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Sydney, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, CautÃ-n, Chile|Research Site, Vina del Mar, ValparaÃ-so, Chile|Research Site, Santiago, Chile|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Herning, Denmark|Research Site, Vejle, Denmark|Research Site, Viborg, Denmark|Research Site, Ã…rhus C, Denmark|Research Site, Angers, France|Research Site, Bordeaux Cedex, France|Research Site, Dijon, France|Research Site, Grenoble, France|Research Site, HyÃ¨res, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Monaco, France|Research Site, Nantes Cedex 2, France|Research Site, Paris, France|Research Site, Pierre-Benite, France|Research Site, Saint Priest en Jarez Cedex, France|Research Site, Strasbourg cedex, France|Research Site, Villejuif cedex, France|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Bottrop, Germany|Research Site, Erlangen, Germany|Research Site, Frankfurt, Germany|Research Site, Kiel, Germany|Research Site, Koblenz, Germany|Research Site, Mannheim, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, MÃ¼nchen, Germany|Research Site, Recklinghausen, Germany|Research Site, Rostock, Germany|Research Site, Trier, Germany|Research Site, TÃ¼bingen, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Szolnok, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Limerick, Ireland|Research Site, Waterford, Ireland|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Sava, Israel|Research Site, Petah Tikva, Israel|Research Site, Poria Eylit, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Tel Aviv, Israel|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Brescia, Italy|Research Site, Meldola FC, Italy|Research Site, Milano, Italy|Research Site, Monza (MB), Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Treviglio (BG), Italy|Research Site, Varese, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Matsuyama-shi, Ehime, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kitakyushu-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Kure-shi, Hiroshima, Japan|Research Site, Akashi-shi, Hyogo, Japan|Research Site, Kagoshima-shi, Kagoshima, Japan|Research Site, Isehara-shi, Kanagawa, Japan|Research Site, Kumamoto-shi, Kumamoto, Japan|Research Site, Kyoto-shi, Kyoto, Japan|Research Site, Miyazaki-shi, Miyazaki, Japan|Research Site, Niigata-shi, Niigata, Japan|Research Site, Kurashiki-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Suita-shi, Osaka, Japan|Research Site, Hidaka-Shi, Saitama, Japan|Research Site, Kitaadachi-gun, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Shimotsuke-shi, Tochigi, Japan|Research Site, Utsunomiya-shi, Tochigi, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Subang Jaya, Selangor (incl. Putrajaya), Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Pachuca de Soto, Hidalgo, Mexico|Research Site, Monterrey, Nuevo LeÃ³n, Mexico|Research Site, Queretaro, QuerÃ©taro, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Colima, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Durango, Mexico|Research Site, Toluca, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Bergen op Zoom, Netherlands|Research Site, Breda, Netherlands|Research Site, Capelle aan den ijssel, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Dordrecht, Netherlands|Research Site, Hoofddorp, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Schiedam, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Tiel, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Venlo, Netherlands|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Metro Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Krakow, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Rzeszow, Poland|Research Site, Szczecin, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Craiova, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Bardejov, Slovakia|Research Site, Kosice, Slovakia|Research Site, Michalovce, Slovakia|Research Site, Poprad, Slovakia|Research Site, Presov, Slovakia|Research Site, Spisska Nova Ves, Slovakia|Research Site, Trebisov, Slovakia|Research Site, Ljublijana, Slovenia|Research Site, Maribor, Slovenia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Cape Town, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, CÃ¡diz, AndalucÃ-a, Spain|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Sevilla, AndalucÃ-a, Spain|Research Site, Zaragoza, AragÃ³n, Spain|Research Site, Santander, Cantabria, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Girona, CataluÃ±a, Spain|Research Site, Lleida, CataluÃ±a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Elche, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, A CoruÃ±a, Galicia, Spain|Research Site, AlcorcÃ³n, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Putzu City, Chiayi, Taiwan|Research Site, Keelung City, Keelung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Bornova-Izmir, Turkey|Research Site, Ä°zmir, Turkey|Research Site, Bebington, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Brighton, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Dorset, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle, United Kingdom|Research Site, Peterborough, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Portsmouth, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Truro, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/Prot_000.pdf|""Statistical Analysis Plan: SAP 3.0"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/SAP_001.pdf|""Statistical Analysis Plan: SAP 3.0 Addendum"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01077154/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01077154"
236,"NCT04511533","Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations",,"Active, not recruiting","No Results Available","Metastatic Non Small Cell Lung Cancer","Drug: Dacomitinib","Incidence of Adverse events (AEs)|Confirmed Objective Response Rate (ORR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1|Confirmed Duration of Response (DoR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","17","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A7471064","August 27, 2020","October 18, 2022","October 18, 2022","August 13, 2020",,"January 24, 2022","Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India|Hemato Oncology Clinic Ahmedabad Pvt. Ltd, Ahmedabad, Gujarat, India|Gujarat Hospital - Gastro and Vascular Centre, Surat, Gujarat, India|Artemis hospital, Gurugram, Haryana, India|National Cancer Institute, Nagpur, Maharashtra, India|Apex Wellness Hospital, Nashik, Maharashtra, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, Maharashtra, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India|Yashoda Hospital, Hyderabad, Telangana State, India|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, WEST Bengal, India|Tata Medical Center, Kolkata, WEST Bengal, India",,"https://ClinicalTrials.gov/show/NCT04511533"
237,"NCT00457691","Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: 5 fluorouracil|Drug: irinotecan|Drug: levo- leucovorin|Drug: sunitinib|Drug: placebo","Progression-free Survival (PFS)|Overall Survival (OS)|Number of Participants With Overall Confirmed Objective Response|Duration of Response (DR)|Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Assessment Inventory of Gastrointestinal Symptoms (MDASI-GI) Symptom Intensity Score|Change From Baseline in MDASI-GI Symptom Interference Score|Change From Baseline in European Quality of Life (EuroQol) EQ-5D Self-Report Questionnaire|Change From Baseline in EuroQol (EQ) Visual Analog Scale (VAS) (EQ-VAS)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","768","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A6181122","June 2007","March 2010","March 2010","April 6, 2007","June 3, 2011","March 30, 2015","Pfizer Investigational Site, La Plata, Buenos Aires, Argentina|Pfizer Investigational Site, Santa Fe, Argentina|Pfizer Investigational Site, Wollongong, New South Wales, Australia|Pfizer Investigational Site, East Bentleigh, Victoria, Australia|Pfizer Investigational Site, Frankston, Victoria, Australia|Pfizer Investigational Site, Fremantle, Western Australia, Australia|Pfizer Investigational Site, St. Poelten, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Santo André, SP, Brazil|Pfizer Investigational Site, Ruse, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Stara Zagora, Bulgaria|Pfizer Investigational Site, Varna, Bulgaria|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Pasto, Narino, Colombia|Pfizer Investigational Site, Nicosia, Cyprus|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Nova Ves Pod Plesi, Czech Republic|Pfizer Investigational Site, Pribram, Czech Republic|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bochum, Germany|Pfizer Investigational Site, Esslingen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Halle, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Moenchengladbach, Germany|Pfizer Investigational Site, Oldenburg, Germany|Pfizer Investigational Site, Regensburg, Germany|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Tuen Mun, New Territories, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Vellore, Tamil Nadu, India|Pfizer Investigational Site, Dublin 24, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Galway, Ireland|Pfizer Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Acapulco, Guerrero, Mexico|Pfizer Investigational Site, Ciudad Obregon, Sonora, Mexico|Pfizer Investigational Site, Forde, Norway|Pfizer Investigational Site, Tonsberg, Norway|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Santa Maria da Feira, Portugal|Pfizer Investigational Site, Évora, Portugal|Pfizer Investigational Site, Cluj-Napoca, Cluj, Romania|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, Saint Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Sremska Kamenica, Serbia|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Observatory, South Africa|Pfizer Investigational Site, Panorama, South Africa|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Port Elizabeth, South Africa|Pfizer Investigational Site, Sandton, South Africa|Pfizer Investigational Site, Elche, Alicante, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Mostoles, Madrid, Spain|Pfizer Investigational Site, Alicante, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Changhua, Taiwan|Pfizer Investigational Site, Chiayi County, Taiwan|Pfizer Investigational Site, Kaohsiang Hsien, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Kwei-Shan, Taoyuan, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Rachathevee, Bangkok, Thailand|Pfizer Investigational Site, Muang, Chiang Mai, Thailand|Pfizer Investigational Site, Muang, Khon Kaen, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Cherkasy, Ukraine|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Uzhgorod, Ukraine|Pfizer Investigational Site, Northwood, Middlesex, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00457691"
238,"NCT03830866","Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","CALLA","Active, not recruiting","No Results Available","Locally Advanced Cervical Cancer","Biological: Durvalumab|Drug: Cisplatin|Drug: Carboplatin|Radiation: external beam radiation therapy (EBRT) + brachytherapy","The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT in terms of Progression-Free Survival (PFS)|The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by the time from the date of randomization until death due to any cause in terms of Overall Survival (OS)|The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by proportion of patients with a complete response at the first tumor assessment after chemoradiotherapy in terms of Complete Response (CR) rate|The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by the number (%) of patients with at least one visit response of Complete Response (CR) or partial response (PR) in terms of Objective Response Rate (ORR)|The efficacy of durvalumab + SoC CCRT compared to placebo + SoC CCRT as assessed by time from detection of CR until the date of disease progression in terms of Duration of Response (DoR) in patients with a Complete Response (CR)|Disease-related symptoms and health related quality of life (HRQoL) in patients treated with durvalumab + SoC CCRT compared with placebo + SoC CCRT as assessed by the change from baseline in disease-related symptoms and HRQoL|To further assess the efficacy of durvalumab + SoC CCRT compared with placebo + SoC CCRT in terms of Proportion of patients alive and progression-free at 3 years (PFS 3 year).|The efficacy of durvalumab + SoC CCRT compared with placebo + SoC CCRT in terms of PFS in PD-L1 positive patients|The efficacy of durvalumab + SoC CCRT compared with placebo + SoC CCRT in terms of OS in PD-L1 positive patients","AstraZeneca","Female","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","770","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9100C00001","February 15, 2019","January 20, 2022","June 30, 2023","February 5, 2019",,"April 18, 2022","Research Site, Phoenix, Arizona, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Augusta, Georgia, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Bronx, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Barretos, Brazil|Research Site, Fortaleza, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Antofagasta, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Hefei, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Kaposvár, Hungary|Research Site, Szeged, Hungary|Research Site, Ahmedabad, India|Research Site, Coimbatore, India|Research Site, Gurgaon, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, Vishakhapatnam, India|Research Site, Fukuoka-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nakazu-gun, Japan|Research Site, Osaka-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toon-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alc. Cuauhtémoc, Mexico|Research Site, Deleg. Tlalpan, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mérida, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Veracruz, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cebu, Philippines|Research Site, Iloilo, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Gdańsk, Poland|Research Site, Gliwice, Poland|Research Site, Lublin, Poland|Research Site, Łódź, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Parktown, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03830866"
239,"NCT03583944","A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer",,"Completed","No Results Available","Breast Neoplasms","Drug: Eribulin Mesylate","Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants with TEAEs Related to Laboratory Parameters|Objective Tumor Response|Objective Response Rate (ORR)","Eisai Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7389-M065-401","March 28, 2018","June 28, 2019","June 28, 2019","July 12, 2018",,"November 27, 2019","Sir Ganga Ram Hospital, New Delhi, Delhi, India|HEMATO-ONCOLOGY CLINIC Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispecialty Hospitals India Pvt Ltd, Bangalore, Karnataka, India|KR Hospital Mysore Medical College, Mysore, Karnataka, India|Tata Memorial Hospital Department of Oncology, Mumbai, Maharashtra, India|HCG NCHRI Cancer Centre, Nagpur, Maharashtra, India|Lokmanya Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Bhubaneswar, Orissa, India|Deep Hospital, Ludhiana, Punjab, India|Sawai Man Singh Hospital, Jaipur, Rajasthan, India|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, Telangana, India|J.K.Cancer Institute, Kanpur, Uttar Pradesh, India|King George's Medical University,(Erstwhile Chhatrapati Shahuji Maharaj Medical University), Lucknow, Uttar Pradesh, India|Ajanta Research Centre, Ajanta Hospital & IVF Centre, Lucknow, Uttar Pradesh, India|Nilratan Sircar Medical College and Hospital, Kolkata, West Bengal, India|Netaji Subhash Chandra Bose Cancer Institute, Kolkata, West Bengal, India|IPGME&R S.S.K.M Hospital, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03583944"
240,"NCT04332549","To Assess the Bioavailability and Safety of Paclitaxel Injection Concentrate for Suspension in Subjects With Locally Recurrent or Metastatic Breast Cancer",,"Withdrawn","No Results Available","Metastatic Breast Cancer|Locally Recurrent Cancer","Drug: PICS (Reconstitution Method 1 or 2)","Maximum observed plasma concentration Plasma|area under the plasma concentration versus time curve, from time 0 to the last measurable concentration|area under the plasma concentration versus time curve from time 0 to infinity|Incidence of Treatment-Emergent Adverse Events","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SDO-006-20-01","April 27, 2020","January 28, 2021","January 28, 2021","April 2, 2020",,"June 1, 2020","SPARC Site 12, Visakhapatnam, Andhra Pradesh, India|SPARC Site 21, Ahmadabad, Gujarat, India|SPARC Site 22, Sūrat, Gujarat, India|SPARC Site 4, Bangalore, Karnataka, India|SPARC Site 10, Bangalore, Karnataka, India|SPARC Site 18, Bangalore, Karnataka, India|SPARC Site 13, Bangalore, Karnataka, India|SPARC Site 9, Aurangabad, Maharashtra, India|SPARC Site 8, Kolhāpur, Maharashtra, India|SPARC Site 2, Nagpur, Maharashtra, India|SPARC Site 1, Nagpur, Maharashtra, India|SPARC Site 17, Nagpur, Maharashtra, India|SPARC Site 3, Nashik, Maharashtra, India|SPARC Site 19, Nashik, Maharashtra, India|SPARC Site 15, Pune, Maharashtra, India|SPARC Site 16, Pune, Maharashtra, India|SPARC Site 5, Pune, Maharashtra, India|SPARC Site 11, Sāngli, Maharashtra, India|SPARC Site 20, Khorda, Orissa, India|SPARC Site 14, Madurai, Tamil Nadu, India|SPARC Site 7, Lucknow, Uttar Pradesh, India|SPARC Site 6, Gujrat, Vadodara, India",,"https://ClinicalTrials.gov/show/NCT04332549"
241,"NCT00626548","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer","ENTHUSE M0","Terminated","Has Results","Prostate Cancer","Drug: ZD4054|Drug: Palcebo","Overall Survival|Progression Free Survival|Health Related Quality of Life|Time to Prostate-specific Antigen (PSA) Progression|Time to Symptomatic Progression","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)","Phase 3","2577","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D4320C00015","January 2008","January 2011","May 2011","February 29, 2008","June 1, 2012","September 3, 2012","Research Site, Tucson, Arizona, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, San Francisco, California, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boca Raton, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Port St. Lucie, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Macon, Georgia, United States|Research Site, Kansas City, Kansas, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Mystle Beach, South Carolina, United States|Research Site, Raleigh, South Carolina, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Burlington, Vermont, United States|Research Site, Seattle, Washington, United States|Research Site, Wenatchee, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Hornsby, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Sydney, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Wels, Austria|Research Site, (Wilrijk) Antwerpen, Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, Parana, Brazil|Research Site, Londrina, PR, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Greenfeild Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Point-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, La Serena, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Vina del Mar, Chile|Research Site, Nanjing, Jiangsu, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Guangzhou City, China|Research Site, Hubei, China|Research Site, Jiangsu, China|Research Site, Shanghai, China|Research Site, Shanxi, China|Research Site, Tianjin, China|Research Site, Zejiang, China|Research Site, Bogota, Colombia|Research Site, Medellin, Colombia|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 4, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Frederiksberg, Denmark|Research Site, Herlev, Denmark|Research Site, Holstebro, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Oulu, Finland|Research Site, Seinajoki, Finland|Research Site, Tampere, Finland|Research Site, Caen cedex, France|Research Site, Creteil, France|Research Site, Lille, France|Research Site, Lyon cedex 03, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Orleans Cedex, France|Research Site, Paris, France|Research Site, Pierre Benite cedex, France|Research Site, Poitiers Cedex, France|Research Site, Reims cedex, France|Research Site, Reims, France|Research Site, Rennes cedex 9, France|Research Site, Rouen, France|Research Site, Suresnes, France|Research Site, Toulouse, France|Research Site, Vandoeuvre-les-Nancy cedex, France|Research Site, Villejuif, France|Research Site, Augsburg, Germany|Research Site, Bad Ems, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Borken, Germany|Research Site, Chemnitz, Germany|Research Site, Emmendingen, Germany|Research Site, Fuerth, Germany|Research Site, Gelsenkirchen-Buer, Germany|Research Site, Germering, Germany|Research Site, Goettingen, Germany|Research Site, Holzminden, Germany|Research Site, Kirchheim/Teck, Germany|Research Site, Leipzig, Germany|Research Site, Lubeck, Germany|Research Site, Mannheim, Germany|Research Site, Muehlacker, Germany|Research Site, Muehlheim an der Ruhr, Germany|Research Site, Muenchen-Planegg, Germany|Research Site, Muenchen, Germany|Research Site, Muenster, Germany|Research Site, Reutlingen, Germany|Research Site, Rostock, Germany|Research Site, Tuebingen, Germany|Research Site, Waltshut-Tiengen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Szekesfehervar, Hungary|Research Site, Ahmedabad, Gujarat, India|Research Site, Nadiad, Gujarat, India|Research Site, Kochi, Kerala, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, Tamil Nadu, India, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkota, West Bengal, India|Research Site, New Delhi, India|Research Site, Dublin 7, Ireland|Research Site, Dublin 8, Ireland|Research Site, Dublin, Ireland|Research Site, Be'er Sheva, Israel|Research Site, Be'er-Ya'akov, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jeruslaem, Israel|Research Site, Petah-Tikva, Israel|Research Site, Tel-HaShomer - Ramat Gan, Israel|Research Site, Ancona, Italy|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Catania, Italy|Research Site, Como, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Rome, Italy|Research Site, Terni, Italy|Research Site, Varese, Italy|Research Site, Hirosaki-City, Aomori, Japan|Research Site, Chiba-City, Chiba, Japan|Research Site, Narashino-city, Chiba, Japan|Research Site, Matsuyama-City, Ehime, Japan|Research Site, Fukuoka-City, Fukuoka, Japan|Research Site, Maebashi-City, Gunma, Japan|Research Site, Otake-City, Hiroshima, Japan|Research Site, Sapporo-City, Hokkaido, Japan|Research Site, Kobe-City, Hyogo, Japan|Research Site, Ibaraki-machi, Ibaraki, Japan|Research Site, Mito-City, Ibaraki, Japan|Research Site, Tsukuba-City, Ibaraki, Japan|Research Site, Kita-gun, Kagawa, Japan|Research Site, Sagamihara-City, Kanagawa, Japan|Research Site, Kamigyo-ku, Kyoto, Japan|Research Site, Kyoto-City, Kyoto, Japan|Research Site, Sendai-City, Miyagi, Japan|Research Site, Ueda-City, Nagano, Japan|Research Site, Kashihara, Nara, Japan|Research Site, Oita-City, Oita, Japan|Research Site, Kurashiki, Okayama, Japan|Research Site, Osaka-City, Osaka, Japan|Research Site, Osaka-Sayama-City, Osaka, Japan|Research Site, Suita-City, Osaka, Japan|Research Site, Wako-City, Saitama, Japan|Research Site, Hamamatsu-city, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Fuchu_city, Tokyo, Japan|Research Site, Itabashi-Ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Minato-Ku, Tokyo, Japan|Research Site, Mitaka-City, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Kyoto, Japan|Research Site, Nagasaki, Japan|Research Site, Bundang-Gu, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seo-gu, Pusan, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Seongbuk-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Liepaja, Latvia|Research Site, Riga, Latvia|Research Site, Distrito Federal, Ciudad de Mexico, Mexico|Research Site, Mexico DF, Distrito Federal, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hertogenbosch, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Tonsberg, Norway|Research Site, Trondheim, Norway|Research Site, Arequipa, Peru|Research Site, Bellavista, Peru|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, Gdynia, Poland|Research Site, Kielce, Poland|Research Site, Koscierzyna, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, Portugal|Research Site, Porto, Portugal|Research Site, Timisoara, Timis, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Omsk, Omsk region, Russian Federation|Research Site, Izhevsk, Russia, Russian Federation|Research Site, Tomsk, Tomsk Region, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Observatory, Cape Town, South Africa|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Parktown, Johannesburg, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Elche, Alicante, Spain|Research Site, Barakaldo, Bizkaia, Spain|Research Site, Bilbao, Vizcaya, Spain|Research Site, A Corunna, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Gothenburg, Sweden|Research Site, Helsingborg, Sweden|Research Site, Jonkoping, Sweden|Research Site, Orebro, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, CH-4031 Basel, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zuerich, Switzerland|Research Site, Taipei, Taiwan|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Reading, Berkshire, United Kingdom|Research Site, Cottingham, East Yorkshire, United Kingdom|Research Site, Stevenage, Hertfordshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Guildford, Surrey, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00626548"
242,"NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","ENTHUSE M1C","Completed","Has Results","Prostate Cancer","Drug: Docetaxel|Drug: ZD4054|Drug: Placebo","Overall Survival|Progression Free Survival|Incidence of Skeletal Related Events|Time to Prostate-specific Antigen (PSA) Progression|Time to Pain Progression|Pain Response|Health Related Quality of Life|PSA Response","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1494","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D4320C00033","January 2008","May 2011","July 2011","February 18, 2008","May 31, 2012","September 10, 2012","Research Site, Greenbrae, California, United States|Research Site, San Diego, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Gainsville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, PORTUGALt St. Lucie, Florida, United States|Research Site, Rockville, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, San Antonio, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bahia Blanca, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Santa Fe, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Wodonga, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Fortaleza, Ceara/ LA, Brazil|Research Site, Goiania, Goias/ LA, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas GERMANYais, Brazil|Research Site, Curitiba, Parana/ Brazil, Brazil|Research Site, Londrina, PR, Brazil|Research Site, PORTUGALto Alegre, Rio Grande do Sul/ LA, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, Ribeirao Preto, Sao Paulo/ LA, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Brno, CZECHOSLOVAKIA Republic, Czech Republic|Research Site, Jablonec nad Nisou, Czech Republic|Research Site, Kromeriz, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Prague 2, Czech Republic|Research Site, Prague 6, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Helsinki, Finland|Research Site, Joensuu, Finland|Research Site, Seinajoki, Finland|Research Site, La Roche sur Yon, FRANCEnce, France|Research Site, Marseille, FRANCEnce, France|Research Site, Paris, FRANCEnce, France|Research Site, Reims, FRANCEnce, France|Research Site, Villejuif, FRANCEnce, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Hannover, GERMANYmany, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Dresden, Germany|Research Site, Emmendingen, Germany|Research Site, Kirchheim-Teck, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Muenster, Germany|Research Site, Tuebingen, Germany|Research Site, Wuppertal, Germany|Research Site, Budapest, HUNGARYary, Hungary|Research Site, Gyor, HUNGARYary, Hungary|Research Site, Miskolc, HUNGARYary, Hungary|Research Site, Ny Regyh Za, HUNGARYary, Hungary|Research Site, Szeged, HUNGARYary, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Vellore, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkota, West Bengal, India|Research Site, Delhi, India|Research Site, New Delhi, India|Research Site, Genoa, Italy|Research Site, Lugo (RA), Italy|Research Site, Rome, Italy|Research Site, Cheongju, Chungbuk, Korea, Republic of|Research Site, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Nowon-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Nijmegen, Netherlands|Research Site, Cercado de Arequipa, Arequipa, Peru|Research Site, Cercado, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lublin, POLANDand, Poland|Research Site, Swidnica, POLANDand, Poland|Research Site, Warszaa, POLANDand, Poland|Research Site, Koscierzyna, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, PORTUGALtugal, Portugal|Research Site, PORTUGALto, PORTUGALtugal, Portugal|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Timisoara, Romania|Research Site, Barnaul, RUSSIAsia, Russian Federation|Research Site, Izhevsk, RUSSIAsia, Russian Federation|Research Site, Kursk, RUSSIAsia, Russian Federation|Research Site, Sochi, RUSSIAsia, Russian Federation|Research Site, Voronezh, RUSSIAsia, Russian Federation|Research Site, Belgrade, SERBIAbia, Serbia|Research Site, Beograd, SERBIAbia, Serbia|Research Site, Nis, SERBIAbia, Serbia|Research Site, Panorama, Cape Town, South Africa|Research Site, TyGERberg, Cape Town, South Africa|Research Site, Overport, Durban, South Africa|Research Site, Bloemfontein, South Africa|Research Site, PORt Elizabeth, South Africa|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Aarau, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, TAIWANwan, Taiwan|Research Site, TAIWANpei, TAIWANwan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Westgate Road, Newcastle Upon Tyne, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00617669"
243,"NCT00554229","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases","ENTHUSE M1","Completed","Has Results","Prostate Cancer","Drug: ZD4054|Drug: Placebo","Overall Survival|Progression Free Survival|Time to Use of Opiates|Incidence of Skeletal Related Events|Bone Metastases Formation|Health Related Quality of Life|Time to Prostate-specific Antigen (PSA) Progression|Time to Pain Progression|Time to Initiation of Chemotherapy|Pharmacokinetic Characteristics of ZD4054","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)","Phase 3","896","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4320C00014|2007-003227-20","November 2007","July 2010","August 2011","November 6, 2007","May 31, 2012","February 8, 2016","Research Site, Tucson, Arizona, United States|Research Site, Greenbrae, California, United States|Research Site, Los Angeles, California, United States|Research Site, Palm Springs, California, United States|Research Site, San Mateo, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Gainsville, Florida, United States|Research Site, Port St.Lucie, Florida, United States|Research Site, Des Moines, Iowa, United States|Research Site, Canton, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Wheeling, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Buenos Aires, Buenos Aires Province, Argentina|Research Site, Santa Fe, Santa Fe Province, Argentina|Research Site, Hornsby, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Redcliffe, Queensland, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Subiaco, Western Australia, Australia|Research Site, Graz, Austria|Research Site, Wels, Austria|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Fortaleza, Ceara, Brazil|Research Site, Goiania, Goias, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitiba, Parana, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Ribeirao Preto, Sao Paulo, Brazil|Research Site, Santo Andre, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kentville, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Granby, Quebec, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Point-Claire, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Haidian District, Beijing, China|Research Site, Xi Cheng District, Beijing, China|Research Site, Xicheng District, Beijing, China|Research Site, Wuhan, Hubei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Pudong New Area, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Xuhui District, Shanghai, China|Research Site, Xi'an, Shanxi, China|Research Site, Prague 4, Prague, Czech Republic|Research Site, Prague 6, Prague, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Aalborg, Denmark|Research Site, Aarhus, Denmark|Research Site, Herlev, Denmark|Research Site, Kobenhavn, Denmark|Research Site, Joensuu, Finland|Research Site, Kajaanintie, Finland|Research Site, Tampere, Finland|Research Site, Montpellier, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Suresnes, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Planegg, Muenchen, Germany|Research Site, Kirchheim, Teck, Germany|Research Site, Augsburg, Germany|Research Site, Bad Gegeberg, Germany|Research Site, Berlin, Germany|Research Site, Emmendingen, Germany|Research Site, Leipzig, Germany|Research Site, Luebeck, Germany|Research Site, Mannheim, Germany|Research Site, Muenchen, Germany|Research Site, Reutlingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Tuen Mun, Hong Kong|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Rohini, Delhi, India|Research Site, Trivandrum, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Chandigarh, Punjab, India|Research Site, Ludhiana, Punjab, India|Research Site, Bikaner, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Kolkota, West Bengal, India|Research Site, Gujarat, India|Research Site, New Delhi, India|Research Site, Milan, Italy|Research Site, Rome, Italy|Research Site, Asahi-City, Chiba, Japan|Research Site, Chiba-City, Chiba, Japan|Research Site, Narashino-city, Chiba, Japan|Research Site, Matsuyama-City, Ehime, Japan|Research Site, Fukuoka-City, Fukuoka, Japan|Research Site, Maebashi-City, Gunma, Japan|Research Site, Otake-City, Hiroshima, Japan|Research Site, Sapporo-City, Hokkaido, Japan|Research Site, Kobe-City, Hyogo, Japan|Research Site, Tsukuba-City, Ibaraki, Japan|Research Site, Kita-gun, Kagawa, Japan|Research Site, Sagamihara-City, Kanagawa, Japan|Research Site, Kyoto-City, Kyoto, Japan|Research Site, Sendai-City, Miyagi, Japan|Research Site, Oita-City, Oita, Japan|Research Site, Osaka-City, Osaka, Japan|Research Site, Osaka-Sayama-City, Osaka, Japan|Research Site, Suita-City, Osaka, Japan|Research Site, Wako-City, Saitama, Japan|Research Site, Hamamatsu-city, Shizuoka, Japan|Research Site, Sunto-gun, Shizuoka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Fuchu_city, Tokyo, Japan|Research Site, Itabashi-Ku, Tokyo, Japan|Research Site, Meguro-ku, Tokyo, Japan|Research Site, Mitaka-City, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Nagasaki, Japan|Research Site, Heungduk-gu Cheongju, Chungbuk, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seo-gu, Pusan, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Songpa-gu, Seoul, Korea, Republic of|Research Site, Metepec, Estado de Mexico, Mexico|Research Site, Distrito Federal Ciudad, Mexico|Research Site, Mexico City, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Bialystok, Poland|Research Site, Koscierzyna, Poland|Research Site, Krakow, Poland|Research Site, Rzeszow, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Coimbra, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Stary Oskol, Belgorodskaya region, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Izhevsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St. Petersgurg, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Novi Sad, Serbia|Research Site, Singapore, Singapore|Research Site, Tygerberg, Cape Town, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Pietermaritzburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Goteborg, Sweden|Research Site, Gothenburg, Sweden|Research Site, Stockholm, Sweden|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Locarno, Switzerland|Research Site, Sursee, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Reading, Berkshire, United Kingdom|Research Site, Cambridge, Cambridgeshire, United Kingdom|Research Site, Maidstone, Kent, United Kingdom|Research Site, Huddersfield, Yorkshire, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00554229"
244,"NCT00915018","Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer","NEFERTT","Completed","Has Results","Breast Cancer","Drug: Neratinib|Drug: Trastuzumab|Drug: Paclitaxel","Progression-Free Survival|Objective Response Rate|Duration of Response|Clinical Benefit Rate|Symptomatic or Progressive Central Nervous System (CNS) Lesions","Puma Biotechnology, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","479","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3144A2-3005 / B1891005","August 21, 2009","August 2013","June 28, 2018","June 5, 2009","November 6, 2017","August 22, 2018","Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Redwood Regional Medical Group, Santa Rosa, California, United States|Cancer Center of Central Connecticut, Plainville, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|North Broward Medical Center Cancer Center, Deerfield Beach, Florida, United States|Broward General Medical Center, Fort Lauderdale, Florida, United States|Mid Florida Cancer Centers, Orange City, Florida, United States|Florida Cancer Research Institute, Plantation, Florida, United States|Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|Phoebe Cancer Center, Albany, Georgia, United States|Dublin Hematology and Oncology Care, Dublin, Georgia, United States|Clintell, Skokie, Illinois, United States|Presence Hematology and Oncology, Skokie, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|CHRISTUS St. Frances Cabrini Hospital, Alexandria, Louisiana, United States|Hematology Oncology Services, Metairie, Louisiana, United States|Park Nicollet Institute, Saint Louis Park, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|The Valley Hospital, Luckow Pavilion Office of Oncology Clinical Trials, Paramus, New Jersey, United States|Gaston Hematology and Oncology Associates, Gastonia, North Carolina, United States|Summa Health System Hospitals, Akron, Ohio, United States|Warren Cancer Research Foundation, Tulsa, Oklahoma, United States|Samaritan Hematology and Oncology Consultants, Corvallis, Oregon, United States|Pawtucket Memorial Hospital, Pawtucket, Rhode Island, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|Tenessee Cancer Specialists, Knoxville, Tennessee, United States|Family Cancer Care, Memphis, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|El Paso Cancer Treatment Center, El Paso, Texas, United States|Texas Oncology-Allison Cancer Center, Midland, Texas, United States|Southlake Oncology, Southlake, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Charleston Area Medical Center, Health, Education, and Research Institute, Charleston, West Virginia, United States|The Queen Elizabeth Hospital, North Adelaide, South Australia, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Affinity Research Limited, Nassau, CB, Bahamas|N.N. Aleksandrov National Cancer Center of Belarus, Lesnoy, Minsk Region, Belarus|Institution Gomel Regional Clinical Oncology Dispensary, Gomel, Belarus|Institution of Healthcare Grodno Regional Clinical Hospital, Grodno, Belarus|Healthcare Institution Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Institut Jules Bordet, Brussels, Belgium|District Dispensary for Oncology Diseases Internal Unit- Plovdiv EOOD, Plovdiv, Bulgaria|District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD, Sofia, Bulgaria|Specialised Hospital of ActiveTreatment in Oncology, Clinic of Chemotherapy, Sofia, Bulgaria|Hopital Charles, LeMoyne Le Centre Intégré de Cancérologie de la Montérégie, Greenfield Park, Quebec, Canada|Centre Hospitalier Régional de Trois-Rivières, Trois-Rivieres, Quebec, Canada|Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Cancer Hospital, Tian Jin, China|Clinical Hospital Osijek, Department of Radiotherapy and Oncology, Osijek, Croatia|University Hospital For Tumors, Zagreb, Croatia|Rigshospitalet, Copenhagen, Onkologisk Klinik, Copenhagen, Denmark|Hôpital Henri-Mondor, Creteil, France|Centre Leon Berard Departement de Cancerologie Medicale, Lyon, France|Centre Val d'Aurelle, Montpellier, France|Hopital Hotel Dieu, Service d'Oncologie Medicale, Bat B2, 5ieme, Paris, France|Hopital La Pitie-Salpetriere, Paris, France|Groupe Hospitalier Paris Saint Joseph, Oncologie medicale, Paris, France|Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, Perigueux, France|Clinique Armoricaine de Radiologie, St. Brieuc, France|Centre de Radiothérapie, Clinique Sainte Anne, Service d'Oncologie Libérale, Strasbourg, France|CHU Strasbourg Departement Oncologie & Hematologie Hopital Civil, Strasbourg, France|CHU Bretonneau, Centre Henry Kaplan, Tours, France|Sozialstiftung Bamberg Klinik fuer Haematologie und internistische Onkologie, Bamberg, Germany|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, Wanchai, Hong Kong|Semmelweis Egyetem Radiologiai és Onkoterapias Klinika, Budapest, Hungary|Fovarosi Onkormanyzat Szent Imre Korhaz Klinikai Onkologiai Profil, Budapest, Hungary|Orszagos Onkologiai Intezet ""B"" Belgyogyaszati osztaly, Budapest, Hungary|Kaposi Mor Oktato Korhoz Onkologiai Centrum, Kaposvar, Hungary|Bacs-Kiskun Megyei Onkormanyzat Korhaza Onkoradiologiai Kozpont, Kecskemet, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|Szegedi Tudomanyegyetem Onkoterapias Klinika, Szeged, Hungary|Institute Rotary Cancer Hospital, AIIMS, New Delhi, Delhi, India|Jawaharlal Nehru Cancer Hospital, Bhopal, Madhya Pradesh, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Central India Cancer Research Institute, Nagpur, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashilk, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Searoc Cancer Center, Jaipur, Rajasthan, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India|B P Poddar and Medical Research Ltd., Kolkata, West Bengal, India|Kaplan Medical Center, Rehovot, Israel|Sourasky Medical Center, Tel Aviv, Israel|Assaf Harofeh Medical Center, Zerifin, Israel|Policlinico di Modena Oncologia ed Ematologia, Modena, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Policlinico Universitario Campus Bio-Medico, Roma, Italy|Ospedale San Pietro Fatebenefratelli, Roma, Italy|Ospedale San Giovanni Battista-Molinette, Torino, Italy|Hyogo Cancer Center, Hyogo, Akashi-shi, Japan|National Hospital Organization Beppu Medical Center, Oita, Beppu-shi, Japan|Tokyo Metropolitan Cancer and Infectious Disease Center, Komagome Hospital, Tokyo, Bunkyo-ku, Japan|Chiba Cancer Center, Chiba, Chiba-shi, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka-shi, Japan|National Hospital Organization Mito Medical Center, Ibaraki, Higashiibaraki-gun, Japan|Hiroshima University Hospital, Hiroshima, Hiroshima-shi, Japan|Hakuaikai Medical Corporation Sagara Hospital, Kagoshima, Kagoshima-city, Japan|National Cancer Center Hospital East, Chiba, Kashiwa-shi, Japan|Saitama Cancer Center, Saitama, Kitaadachi-gun, Japan|Kumamoto Municipal Hospital, Kumamoto, Kumamoto-city, Japan|Kurume Daiichi Social Insurance Hospital, Fukuoka, Kurume-Shi, Japan|National Hospital Organization Shikoku Cancer Center, Ehime, Matsuyama-city, Japan|Iwate Medical University Hospital, Iwate, Morioka-shi, Japan|Aichi Cancer Center, Aichi, Nagoya-shi, Japan|National Hospital Organization Nagoya Medical Center, Aichi, Nagoya, Japan|Niigata Cancer Center Hospital, Niigata, Niigata-shi, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka-shi, Japan|National Hospital Organization Osaka National Hospital, Osaka, Osaka-shi, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Sapporo-shi, Japan|Tohoku University Hospital, Miyagi, Sendai-city, Japan|Tenri Hospital, Nara, Tenri-shi, Japan|Kanagawa Cancer Center, Kanagawa, Yokohama-City, Japan|Hiroshima City Hospital, Hiroshima, Japan|National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Hiroshima, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Shinko Hospital, Hyogo, Japan|Kumamoto University Hospital, Kumamoto, Japan|Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan|Osaka University Hospital, Osaka, Japan|Jichi Medical University Hospital, Tochigi, Japan|Toranomon Hospital, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Tokyo, Japan|National Cancer Center, Center for Breast Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Yonsei University Health System Severance Hospital, Seoul, Seoul/Korea, Korea, Republic of|Piejuras Hospital, Liepajas Oncological Clinic, Liepaja, Latvia|Pauls Stradiņš Clinical University Hospital, Riga, Latvia|Riga Eastern University Hospital, Riga, Latvia|Hospital of Lithuanian University of Health sciences, Kaunas, Lithuania|Nacionalinis Vezio Institutas, Vilniaus Universiteto Onkologijos Institutas, Vilnius, Lithuania|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Sir Anthony Oncology Center, Floriana, Malta|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Wojewodzki Oddzial, Jelenia Gora, Dolnoslaskie, Poland|Magodent, Warszawa, Mazowieckie, Poland|Opolskie Centrum Onkologii, Opole, Opolskie, Poland|Zakład Opieki Zdrowotnej MSW z Warmińsko, Mazurskim Centrum Onkologii, Olsztyn, Warminsko-Mazurskie, Poland|Białostockie Centrum Onkologii, Bialystok, Poland|Hospital da Luz Servico de Oncologia Medica, Lisboa, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Cluj, Romania|SC Oncolab S.R.L., Craiova, Dolj, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical centre Nis Clinic of Oncology, Nis, Serbia|National University Hospital, National Cancer Institute, Singapore, Singapore|National Cancer Centre Singapore, Singapore, Singapore|GVI Oncology, Port Elizabeth, Eastern Cape, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|University of Witwatersrand Oncology, Donald Gordon Medical Centre, Johannesburg, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, Gauteng, South Africa|Eastleigh Breast Care Centre, Pretoria, Gauteng, South Africa|Westridge Medical Centre, Durban, KwaZulu Natal, South Africa|GVI Oncology, Kraaifontein, Western Cape, South Africa|Hospital Universitari Arnau de Vilanova, Lleida, Cataluna, Spain|Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, Galicia, Spain|Hospital Son Llàtzer, Palma, Illes Balears, Spain|Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain|Hospital Puerta De Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Infanta Cristina, Parla, Madrid, Spain|Hospital Madrid Norte Sanchinarro Centro Integral Oncológico Clara Campal Ensayos Clínicos, Sanchinarro, Madrid, Spain|Hospital Costa del Sol, Marbella, Malaga, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Centro Oncologico MD Anderson, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Tumor Center Hirslanden Medical Center, Aarau, Switzerland|Spital STS AG Onkologiezentrum Thun - Berner Oberland, Thun, Switzerland|Kantonsspital Winterthur Medizinische Onkologie, Winterthur, Switzerland|Chang Gung Medical Foundation, Linkou Branch, Taoyuan, Taiwan|Ege Universitesi Tip Fakultesi Tulay Aktas Onkoloji Hastanesi, Bornova, Izmir, Turkey|Komunalnyy Zaklad Cherkasskyy Oblasnyy Onkologichnyy Dyspanser, Cherkassy, Ukraine|Chernivtsi Regional Oncology Centre Outpatient Department Bukovynian State Medical University Department of Oncology and Radiology, Chernivtsi, Ukraine|City Multifield Clinical Hospital, Dnipropetrovsk, Ukraine|Donetsk Regional Antitumor Center Department of Pretumor Diseases and Tumor Treatment, Donetsk, Ukraine|S.P. Grigoreva Institute of Medical Radiology Department of Chemotherapy, Kharkiv, Ukraine|National Institute of Cancer Department of Conseravtive Methods of Treatment, Kyiv, Ukraine|Volyn Regional Oncological Center, Lutsk, Ukraine|State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Mariupil Oncological Center, Mariupil, Ukraine|Sumy Regional Clinical Oncology Centre, Sumy, Ukraine|Guy's and St Thomas NHS Foundation Trust Management Offices 4th Floor Bermondsey Wing Guy's Hospital, London, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00915018"
245,"NCT04538742","A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","DB-07","Recruiting","No Results Available","Metastatic Breast Cancer","Drug: Trastuzumab deruxtecan|Drug: Durvalumab|Drug: Paclitaxel|Drug: Pertuzumab|Drug: Tucatinib","Occurrence of adverse events (AEs)- Part 1|Occurrence of serious adverse events (SAEs)- Part 1|Occurrence of adverse events (AEs)- Part 2|Occurrence of serious adverse events (SAEs)- Part 2|Objective Response Rate (ORR)- Part 1 and Part 2|Progression Free Survival (PFS)- Part 1 and Part 2|Progression Free Survival 2 (PFS2)- Part 2|Duration of Response (DoR)- Part 2|Overall Survival (OS)- Part 2|Serum Concentration of Trastuzumab Deruxtecan (T-DXd)|Serum Concentration of Durvalumab|Serum Concentration of Pertuzumab|Plasma Concentration of Paclitaxel|Plasma Concentration of Tucatinib|Immunogenicity of trastuzumab deruxtecan|Immunogenicity of Durvalumab|Immunogenicity of Pertuzumab","AstraZeneca|Daiichi Sankyo Company, Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","450","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967JC00001","December 28, 2020","April 30, 2025","April 30, 2025","September 4, 2020",,"May 9, 2022","Research Site, West Hollywood, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Basking Ridge, New Jersey, United States|Research Site, Middletown, New Jersey, United States|Research Site, Montvale, New Jersey, United States|Research Site, Commack, New York, United States|Research Site, Harrison, New York, United States|Research Site, Long Island City, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Uniondale, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Providence, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Melbourne, Australia|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Toronto, Canada|Research Site, Dijon, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Bottrop, Germany|Research Site, Düsseldorf, Germany|Research Site, Erlangen, Germany|Research Site, Halle, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Recklinghausen, Germany|Research Site, Würzburg, Germany|Research Site, Gurgaon, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Rohini, India|Research Site, Bologna, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Rome, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Bydgoszcz, Poland|Research Site, Koszalin, Poland|Research Site, Lublin, Poland|Research Site, Rzeszów, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, Barcelona, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Hualien, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Buckhurst Hill, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04538742"
246,"NCT00898287","Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer","SAVIOR","Completed","No Results Available","Pancreatic Cancer","Drug: P276-00|Drug: Gemcitabine","To determine the maximum tolerated dose (MTD) of P276-00 administered along with Gemcitabine.|To evaluate pharmacokinetic parameters of P276-00.|To determine clinical benefit response to P276-00 in combination with Gemcitabine in patients with cancer of pancreas.|To determine objective tumor response rate to P276-00 in combination with Gemcitabine in patients with cancer of pancreas.|To characterize toxicities of P276-00 in combination with Gemcitabine.","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","23","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/28/08","May 2009","December 2010",,"May 12, 2009",,"January 20, 2012","Central India Cancer Research Institute, Nagpur, Ajayonco@hotmail.com, India|Global Hospital, Hyderabaad, Andhra Pradesh, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sri RamaChandra Medical Centre, Chennai, Tamil Nadu, India|Lifeline Mutispecilaity Hospital, Chennai, Tamil Nadu, India|Meenakshi Mission Hospital & Reasearch Centre, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00898287"
247,"NCT00849667","Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse",,"Completed","No Results Available","Ovarian Cancer","Drug: MORAb-003 (farletuzumab)|Drug: 0.9% Saline","Progression-free survival using by RECIST|Overall Survival, CA-125 PFS, GCIG PFS, Length of first versus second remission, Tumor Response,Serologic Response (CA-125), Quality of Life, Resource utilization and PK DDI substudy.","Morphotek","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MORAb003-004","April 2009","December 2012","April 2013","February 24, 2009",,"July 20, 2015","University Of Alabama At Birmingham, Birmingham, Alabama, United States|Oncology Specialties, PC, Huntsville, Alabama, United States|Arizona Hematology & Oncology Associates, Phoenix, Arizona, United States|St. Joseph's Hospital, Barrow Neurology Clinics, Phoenix, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Providence St. Joseph Medical Center, Burbank, California, United States|California Cancer Care, Inc., Greenbrae, California, United States|University of California San Diego, La Jolla, California, United States|University of California Los Angeles Medical Center, Los Angeles, California, United States|Gynecologic Oncology Associates, Newport Beach, California, United States|University of California Davis Cancer Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|University of Colorado, Aurora, Colorado, United States|Catholic Health Initiatives, Colorado Springs, Colorado, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Hematology Oncology P.C., Stamford, Connecticut, United States|Washington Hospital Center, Washington, District of Columbia, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|Gainsville Hematology Oncology Associates, Gainesville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Jupiter Medical center Physician's Group, Jupiter, Florida, United States|Hematology/Oncology Associates, Lake Worth, Florida, United States|Lakeland Regional Cancer Center, Lakeland, Florida, United States|Florida Hospital, Orlando, Florida, United States|Sarasota Memorial Healthcare System, Sarasota, Florida, United States|Gulfcoast Oncology, St. Petersburg, Florida, United States|Oncology-Hematology Associates of W. Broward P.A., Tamarac, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Medical College of Georgia, Augusta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kaiser Permanente - Moanalua Medical Center, Honolulu, Hawaii, United States|Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States|Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Loyola University Chicago, Maywood, Illinois, United States|Midwest Cancer Research Group, Skokie, Illinois, United States|Central DuPage Hospital, Winfield, Illinois, United States|St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States|St. Vincent Gynecologic Oncology, Indianapolis, Indiana, United States|Central Baptist Hospital, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Norton Healthcare, Louisville, Kentucky, United States|Hematology & Oncology Specialists, Metairie, Louisiana, United States|John Hopkins University, Balitmore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Weinberg Cancer Institute at Franklin Square, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Frederick Memorial Hospital, Frederick, Maryland, United States|Barbara Ann Kamanos Cancer Center, Detroit, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Sparrow Regional Cancer Center, Lansing, Michigan, United States|Park Nicollet Institute, St. Louis Park, Minnesota, United States|Saint Francis Memorial Health Center, Grand Island, Nebraska, United States|Good Samaritan Hospital Cancer Center, Kearney, Nebraska, United States|The Center for Cancer and Hematologic Disease, Camden, New Jersey, United States|Hematology-Oncolgy Associates of NNJ-PA, Denville, New Jersey, United States|John Theurer Cancer Center at Hackensack University MC, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Cooper Cancer Institute, Voorhees, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Arena Oncology Associates, Lake Success, New York, United States|Columbia University Medical Center, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology & Oncology, Winston-Salem, North Carolina, United States|Catholic Health Initiatives, Cincinnati, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Providence Oncology & Hematology Care, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|St. Luke's Hospital, Bethlehem, Pennsylvania, United States|Oncology Hematology Associates, DuBois, Pennsylvania, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Chattanooga's Program in Women's Oncology, Chattanooga, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA, Austin, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology, PA, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|International Beneficence Clinical Research, L.L.C., Harlingen, Texas, United States|University of Texas Health Science Center at Houston Medical School, Houston, Texas, United States|South Texas Oncology and Hematology, PA, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|US Oncology Research, Wichita Falls, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Northern Virginia Pelvic Surgery Associates, Annandale, Virginia, United States|Peninsula Cancer Institute - Riverside Gynecology Oncology, Newport News, Virginia, United States|Harrison Bremerton Hematology and Oncology, Bremerton, Washington, United States|Providence Everett Medical Center, Everett, Washington, United States|Cancer Care Northwest-South, Spokane, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Aurora Health Care, West Allis, Wisconsin, United States|Hospital Zonal Especializado en Oncología de Lanús, Buenos Aires, Argentina|Consultorios Medicos Privados SA, Buenos Aries, Argentina|Fundación Sanatorio Güemes, Caba, Argentina|Clinica Universitaria Reina Fabiola, Códoba, Argentina|Instituto Medico Platense, La Plata, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Hospital Bocalandro, Loma Hermosa, Argentina|Centro Oncologico Integral, Mar Del Plata, Argentina|CER Instituto Medico, Quilmes, Argentina|Centro Médico San Roque, San Miguel de Tucuman, Argentina|Centro Medico de Alta Complejidad Cemac, San Salvador de Jujuy, Argentina|ISIS Centro Especializado de LUCE SA, Santa Fe, Argentina|Tweed Hospital, Tweed Heads, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|The Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, South Brisbane, Queensland, Australia|North Adelaide Oncology Clinical Trials, North Adelaide, South Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Landeskrankenhaus Villach, Villach, Austria|Kaiser-Franz-Josef Spital, Wien, Austria|Krankenhaus Wien-Hietzing, Wien, Austria|Institut Jules Bordet, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|AZ Groeninge - Campus Maria's Voorzienigheid, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|CHU de Liège, Liège, Belgium|Sint-Augustinuskliniek, Wilrijk, Belgium|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil|Instituto de Pesquisas Clínicas para Estudos Multicêntricos, Caxias do Sul, Brazil|Santa Casa da Misericórdia de Curitiba, Curitiba, Brazil|Instituto do Câncer do Ceará - ICC, Fortaleza, Brazil|Hosp. Araujo Jorge, Goiania, Brazil|Associação Hospital de Caridade Ijuí, Ijuí, Brazil|Clinica de Neoplasias Litoral, Itajai, Brazil|Hospital Amaral Carvalho, Jaú, Brazil|Liga Norte-Riograndense Contra o Câncer, Natal, Brazil|Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Clínica de Oncologia de Porto Alegre S/S Ltda, Porto Alegre, Brazil|Instituto Ribeirãopretano de Combate ao Câncer, Ribeirão Preto, Brazil|INCA - Instituto Nacional do Câncer, Rio de Janeiro - RJ, Brazil|Clínica Oncologistas Associados, Rio de Janeiro, Brazil|Hospital Santa Izabel - Santa Casa de Misericordia da Bahia, Salvador, Brazil|Clínica AMO - Assistência Multidiciplinar em Oncologia, Salvador, Brazil|Centro de Estudos de Oncologia da FMABC, Santo André, Brazil|Saúde ABC Serviços Médicos Hospitalares Ltda, Santo André, Brazil|Instituto do Câncer Arnaldo Vieira de Carvalho, São Paulo, Brazil|Certo Oncologia, São Paulo, Brazil|Hospital Premier, São Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cancer Center For The Southern Interior, Kelowna, British Columbia, Canada|British Columbia Cancer Agency, Surrey, British Columbia, Canada|BCCA, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Instituto de Terapias Oncologicas, Santiago, Chile|Instituto Clínico Oncológico del Sur, Temuco, Chile|Instituto Oncologico Ltda., Viña del Mar, Chile|Centre Régional de lutte contre le cancer Paul Papin, Angers Cedex 9, France|Centre Hospitalier Louis Pasteur, Le Coudray, France|Institut Paoli Calmettes, Marseille, France|Hôpital Saint Louis, Paris Cedex 10, France|Institut Jean Godinot - Centre de lutte contre le cancer, Reims, France|Helios Klinikum Berlin-Buch, Berlin-Buch, Germany|Charité - Universitätsmedizin Berlin, Berlin, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Marien-Hospital Akademisches Lehrkrankenhaus, Düsseldorf, Germany|Frauenarztpraxis Dr. med. Gröll de Rivera, Ebersberg, Germany|Universitätsklinikum Essen, Essen, Germany|Krankenhaus Nordwest, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Kath. Marienkrankenhaus gGmbH, Hamburg, Germany|Universität Heidelberg, Heidelberg, Germany|St. Vincentius Kliniken Karlsruhe, Karlsruhe, Germany|Universitätsklinik Magdeburg, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Klinikum der Universität München - Innenstadt, München, Germany|Rotkreuzklinikum München, München, Germany|Klinikum Südstadt Rostock, Rostock, Germany|Klinikum Traunstein, Traunstein, Germany|University General Hospital of Heraklion, Heraklion, Crete, Greece|Alexandra Hospital, Athens, Greece|General Oncology Hospital Kifissias ""Oi Agioi Anargyroi"", Athens, Greece|University General Hospital of Patras, Patras, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Queen Mary Hospital, Pokfulam, Islands, Hong Kong|Tuen Mun Hospital, Tuen Mun, Hong Kong|Semmelweis Egyetem, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Petz Aladár Megyei Oktató Kórház, Gyor, Hungary|Bács-Kiskun Megyei Önkormányzat Kórháza, Kecskemét, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Rendelöintézet, Szolnok, Hungary|Veszprém Megyei Önkormányzat Csolnoky Ferenc Kórház-Rendelöintézet, Veszprém, Hungary|Apollo Hospitals International Limited, Gandhinagar, Gujarat, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, Madhya Pradesh, India|Jehangir, Clinical Development Centre, Pune, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Dr. Kamakshi Memorial Hospital, Chennai, Tamil Nadu, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|M.S Ramaiah Medical College and Teaching Hospital Ethical Review Board, Bangalore, India|Amrita Institute of Medical Sciences and Research Centre, Cochin, India|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabaad, India|SK Soni Hospital, Jaipur, India|Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, India|Lakeshore Hospital, Kochi, India|Tata Memorial Hospital, Mumbai, India|Shatabdi Superspeciality Hospital, Nashik, India|Curie Manavata Cancer Centre, Nasik, India|All India Institute of Medical Sciences, New Delhi, India|Regional Cancer Centre, Trivandrum, India|Rambam Medical Center, Haifa, Israel|Linn Medical Center, Clalit Health Services, Haifa, Israel|Wolfson Centre, Holon, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petach Tikva, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Assaf Harofe Medical Center, Zerifin, Israel|Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Azienda Ospedaliera Santi Antonio, Biagio e Cesare Arrigo, Alessandria, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy|Centro di Ricerca e Formazione ad Alta Tecnologia nelle Scienze Biomediche, Campobasso, Italy|Azienda Ospedaliera Cannizzaro, Catania, Italy|Humanitas Centro Catanese di Oncologia, Catania, Italy|Azienda Ospedaliera Sant'Anna, Como, Italy|Ospedale di Faenza, Faenza, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Presidio Ospedaliero Vito Fazzi, Lecce, Italy|Ospedale Mater Salutis ULSS 21 della regione Veneto, Legnago, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST, Meldola, Italy|Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Nazionale dei Tumori, Milano, Italy|Azienda Ospedaliera Niguarda Cà Granda, Milano, Italy|Istituto Nazionale per lo studio e la cura dei tumori ""Fondazione Giovanni Pascale"", Napoli, Italy|Ospedale Sacro Cuore Don Calabria, Negrar, Italy|Istituto Oncologico Veneto, Padova, Italy|Ospedale Santa Maria della Misericordia di Perugia, Perugia, Italy|Ospedale Santa Maria delle Croci, Ravenna, Italy|Arcispedale Santa Maria Nuova, Reggio Emilia, Italy|Azienda Policlinico Umberto I, Roma, Italy|Policlinico Universitario ""A. Gemelli"", Roma, Italy|Azienda Ospedaliero-Universitaria di Udine, Udine, Italy|Akashi, Japan|Amagasaki, Japan|Chiba, Japan|Fukuoka, Japan|Hidaka, Japan|Hiroshima, Japan|Kagoshima, Japan|Kashiwa, Japan|Kawasaki, Japan|Koto-Ku, Japan|Kumamoto, Japan|Kure, Japan|Kurume, Japan|Matsuyama, Japan|Minato-Ku, Japan|Morioka, Japan|Nagoya, Japan|Nakano-Ku, Japan|Niigata, Japan|Okayama, Japan|Osakasayama, Japan|Osaka, Japan|Sapporo, Japan|Sendai, Japan|Shinjuku-Ku, Japan|Sunto-Gun, Japan|Tsukuba, Japan|Tsu, Japan|Yamagata, Japan|Yonago, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, In Cheon, Korea, Republic of|Cheil General Hospital & Women's Healthcare Center, Seoul, Korea, Republic of|Seoul national univercity hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Union Medica Quirurgica de Colima, Colima, Mexico|Triva Investigaciones Medicas Sociedad Anónima de Capital Variable, Morelia, Mexico|Hospital Regional de Veracruz, Veracruz, Mexico|VU Medisch Centrum, Amsterdam, Netherlands|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Orbis Medisch Centrum, Sittard-Geleen, Netherlands|Perpetual Succour Hospital, Cebu City, Cebu, Philippines|Cebu Gynecologic Cancer Care Clinic, Cebu, Philippines|Manila Doctors Hospital, Manila, Philippines|San Juan de Dios Hospital, Pasay City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|Bialostockie Centrum Onkologii, Bialystok, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie oddzial w Gliwicach, Gliwice, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi, Lodz, Poland|Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland|Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Olsztynski Osrodek Onkologiczny ""Kopernik"" Sp. z o.o., Olsztyn, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Pozna, Poznan, Poland|SPZOZ Wojewodzki Szpital Specjalistyczny nr 3, Rybnik, Poland|Samodzielny Publiczny Szpital Kliniczny nr 2 PAM w Szczecinie, Szczecin, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Instituto Português de Oncologia Francisco Gentil, Centro Regional de Oncologia de Coimbra, EPE, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil (IPOLFG, EPE), Lisboa, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil (IPOPFG, EPE), Porto, Portugal|Hospital de São João, Porto, Portugal|Kursk Regional Oncology Centre, Kursk, Russian Federation|Russian Oncology Research Center named after N.N. Blokhin, Moscow, Russian Federation|Russian Oncology Research Center, Moscow, Russian Federation|Moscow Research Oncology Institute n.a. P.A.Gertsen, Moscow, Russian Federation|Medical Radiology Research Center of RAMS, Obninsk, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Republican Clinical Oncology Center of Bashkortostan Republic Ministry of Healthcare, Ufa, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|Hospital Universitario Reina Sofia, Córdoba, Andalucía, Spain|Hospital Virgen del Rocio, Sevilla, Andalucía, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Universitario Vall D'Hebron, Barcelona, Cataluna, Spain|Hospital Clinic i Provincial, Barcelona, Cataluña, Spain|Hospital de Mataró, Mataró, Cataluña, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Cataluña, Spain|Hospital Mutua de Terrassa, Terrassa, Cataluña, Spain|Hospital General Universitario de Elche, Elche, Comunidad Valenciana, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Comunidad Valenciana, Spain|Fundacion Hospital Alcorcon, Alcorcón, Madrid, Communidad de, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Madrid, Communidad de, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Communidad de, Spain|Hospital 12 de Octubre, Madrid, Madrid, Communidad de, Spain|Hospital Clinico San Carlos, Madrid, Spain|Universität Zürich, Zürich, Switzerland|National Cheng Kung University Hosptial, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital, Taoyuan, Taiwan|Municipal Institution of Cherkasy Regional Counsil ""Cherkasy Regional Oncology Dispensary"", Cherkasy, Ukraine|Chernivtsi Regional Clinical Oncology Dispansery, Chernivtsi, Ukraine|Kiev City Oncology Hospital, Kyiv, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Belfast City Hospital, Belfast, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Poole Hospital NHS Trust, Poole, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Clatterbridge Centre For Oncology, Wirral, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00849667"
248,"NCT02763566","A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer","MONARCH plus","Active, not recruiting","Has Results","Breast Cancer","Drug: Abemaciclib|Drug: Anastrozole|Drug: Letrozole|Drug: Placebo|Drug: Fulvestrant","Progression Free Survival (PFS) (Abemaciclib + NSAI & Placebo NSAI)|Progression Free Survival (PFS) (Abemaciclib + Fulvestrant and Placebo + Fulvestrant Arms)|Overall Survival (OS)|Percentage of Participants With Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]|Duration of Response (DoR)|Percentage of Participants Who Exhibit Stable Disease (SD) or CR or PR [Disease Control Rate (DCR)]|Percentage of Participants With Best Overall Response of CR, PR, or SD With Duration of SD for at Least 6 Months [Clinical Benefit Rate (CBR)]|Change From Randomization in Symptom Burden on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)|Pharmacokinetics (PK): Area Under the Concentration Curve of Abemaciclib, Its Metabolites (M2 & M20)","Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 3","463","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","15530|I3Y-CR-JPBQ","December 5, 2016","March 29, 2019","February 28, 2023","May 5, 2016","March 30, 2020","October 27, 2021","Hospital de Caridade Ijui, Ijui, Rio Grande Do Sul, Brazil|Instituto do Câncer - Hospital Mãe de Deus Center/AESC, Porto Alegre, Rio Grande Do Sul, Brazil|Fundação PIO XII, Barretos, Sao Paulo, Brazil|Hospital de Base Fac de Medicina de Sao Jose do Rio Preto, Sao Jose Rio Preto, Sao Paulo, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil|Clin. Pesq.e Centro Estudos Oncologia Ginecológica e Mamária, São Paulo, Brazil|Afflilated Hospital of Bengbu Medical College, Bengbu, Anhui, China|The 307th Hospital of Chinese People's Liberation Army, Beijing, Beijing, China|Fujian Provincial Cancer hospital, Fuzhou, Fujian, China|Fujian Province Hospital, Fuzhou, Fujian, China|Affiliated Cancer Hospital of Guangxi Medical University, Nan Ning, Guang XI, China|Guangdong Province People's Hospital, Guangzhou, Guangdong, China|Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Harbin Medical University Caner Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Wu Han Tongji Hospital, Wuhan City, Hubei, China|Wuhan Union (Xiehe) Hospital, Wuhan, Hubei, China|Hu Bei Cancer Hospital, Wuhan, Hubei, China|Hunan Province Tumor Hospital, Changsha, Hunan, China|Jilin Province Tumor Hospital, Chang Chun, Ji Lin, China|Nanjing Drum Tower Hosp Affiliated Hosp of Nanjing Univ Med, Nanjing, Jiangsu, China|Jiangsu Province Cancer Hospital, Nanjing, Jiangsu, China|Dalian Med. Univ. No 2 Affiliate Hospital, Dalian, Liao Ning, China|Liaoning Cander Hospital&Institute, Shenyang, Liaoning, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The First Affiliated Hospital with Nanjing Medical Universit, Nanjing, Nanjing, China|First Affiliated Hospital of Medical College, Xi'an Jiaotong, Xi'an, Shaanxi, China|Zhejiang Cancer Hospital, Hang Zhou, Zhejiang, China|Second Affiliate Hospital of Zhejiang Medical University, Hangzhou, Zhejiang, China|Beijing Tumor Hospital, Beijing, China|Shanghai Tumor Hospital, Shanghai, China|Shanghai First People's Hospital, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|Dr. B. L. Kapur Memorial Hospital, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute (GCRI), Ahmedabad, Gujarat, India|M S Ramaiah Medical College Hospital, Bangalore, Karnataka, India|Healthcare Global Enterprises Limited (HCG), Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Christian Medical College and Hospital, Vellore, Tamil Nadu, India|Medica Superspecialty Hospital, Kolkata, West Bengal, India|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Eastleigh Breast Care Center, Pretoria, Gauteng, South Africa|Sandton Oncology Centre, Johannesburg, South Africa","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02763566/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT02763566/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02763566"
249,"NCT00667251","Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer",,"Active, not recruiting","Has Results","Breast Cancer","Biological: trastuzumab|Drug: docetaxel|Drug: lapatinib ditosylate|Drug: paclitaxel","Progression-free Survival|Overall Survival|Time to CNS Metastases at the Time of First Progression|CNS Metastases at the Time of Progression (ITT)|CNS Metastases at the Time of Progression (HER2+)|Overall Objective Response Rate (Complete or Partial) ITT|Overall Objective Response Rate (Complete or Partial) HER2/Neu+|Clinical Benefit Response Rate (ITT)|Clinical Benefit Response Rate (HER2/Neu+))|Quality of Life as Measured by the EORTC QLQ-C30 Global Score From Baseline to 12 Weeks|Effects of Changes in Biomarkers on Clinical Outcomes|Economic Evaluation, Including Health Utilities, as Measured by the EQ-5D Questionnaire, and Healthcare Utilization","Novartis Pharmaceuticals|NCIC Clinical Trials Group|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","652","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","108919|CLAP016A2303|CAN-NCIC-MA31|2007-004568-27|CDR0000594764|EGF108919","October 7, 2008","August 1, 2012","December 31, 2022","April 28, 2008","June 18, 2014","March 10, 2022","Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Hot Springs, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Highland, California, United States|Novartis Investigative Site, Montebello, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Greenwich, Connecticut, United States|Novartis Investigative Site, Southington, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Trumbull, Connecticut, United States|Novartis Investigative Site, Waterbury, Connecticut, United States|Novartis Investigative Site, Kissimmee, Florida, United States|Novartis Investigative Site, Loxahatchee Groves, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Post Falls, Idaho, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Evansville, Indiana, United States|Novartis Investigative Site, Goshen, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Munster, Indiana, United States|Novartis Investigative Site, New Albany, Indiana, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Wheaton, Maryland, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Kearney, Nebraska, United States|Novartis Investigative Site, Kearney, Nebraska, United States|Novartis Investigative Site, Denville, New Jersey, United States|Novartis Investigative Site, Parsippany, New Jersey, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Chesapeake, Virginia, United States|Novartis Investigative Site, Salem, Virginia, United States|Novartis Investigative Site, Bellevue, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Sequim, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Wenatchee, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Cipolletti, Río Negro, Argentina|Novartis Investigative Site, Viedma, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Garran, Australian Capital Territory, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Kurralta Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Jette, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Victoria, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Sault Ste. Marie, Ontario, Canada|Novartis Investigative Site, St Catharines, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Thunder Bay, Ontario, Canada|Novartis Investigative Site, Charlottetown, Prince Edward Island, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Angers, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Marseille cedex 9, France|Novartis Investigative Site, Metz-Tessy, France|Novartis Investigative Site, Nantes cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Weiden, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Fulda, Hessen, Germany|Novartis Investigative Site, Lich, Hessen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Leer, Niedersachsen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Coesfeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koblenz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Poriya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Aviano (pn), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Sora (FR), Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecce, Puglia, Italy|Novartis Investigative Site, Sassari, Sardegna, Italy|Novartis Investigative Site, Prato (PO), Toscana, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Cuernavaca, Morelos, Mexico|Novartis Investigative Site, Ciudad Obregon, Sonora, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Plock, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Ivanovo, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Lipetsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Stavropol, Russian Federation|Novartis Investigative Site, Ufa,, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Alcorcon, Spain|Novartis Investigative Site, Alicante, Spain|Novartis Investigative Site, Badalona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Elche, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Jaen, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Lugo, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Majadahonda (Madrid), Spain|Novartis Investigative Site, Pozuelo De Alarcon (Madrid), Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Dnepropetrovsk, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Chelmsford, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Colchester, United Kingdom|Novartis Investigative Site, Cottingham, Hull, United Kingdom|Novartis Investigative Site, Derby, United Kingdom|Novartis Investigative Site, Edmonton, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Harrogate, United Kingdom|Novartis Investigative Site, Huddersfield, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Whitchurch, Cardiff, United Kingdom|Novartis Investigative Site, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00667251"
250,"NCT03256916","Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix","NELCER","Recruiting","No Results Available","Carcinoma Cervix,Stage III","Drug: Nelfinavir|Drug: Cisplatin|Radiation: Pelvic EBRT and Brachytherapy","Improvement in 3 year disease free survival|Change in locoregional control rates at 3 years|Overall survival at 5 years|Incidence of grade 3/4 adverse events|Changes in Akt levels in the tumor|Change in tumour hypoxia using multifunctional PET/ MRI.|Interindividual variability of Volume of distribution|Interindividual variability of Clearance of nelfinavir.|Interindividual variability of Clearence of Nelfinavir","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","348","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMH Project 1543","January 16, 2018","September 30, 2025","September 30, 2025","August 22, 2017",,"February 21, 2022","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03256916"
251,"NCT03433313","Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer",,"Unknown status","No Results Available","Breast Cancer","Drug: EG12014|Drug: Herceptin","Determination of pathologic complete response (pCR) at time of surgery|pCR at the time of surgery|Event-free survival (EFS) up to end of study (EOS)|Overall response (OR) prior to surgery|Overall survival (OS) up to End of Study (EOS)|Incidence of AEs|Evaluation of Immunogenicity of EG12014 and Herceptin|Measure serum trastuzumab concentration","EirGenix, Inc.","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EGC002|2017-003973-33","October 16, 2018","November 3, 2020","January 11, 2022","February 14, 2018",,"April 6, 2020","Detroit Clinical Research Center, Farmington Hills, Michigan, United States|Aultman Hospital, Cancer Center, Canton, Ohio, United States|Brest Regional Oncology Center, Brest, Belarus|Gomel Regional Clinical Oncology Center, Gomel, Belarus|N.N. Aleksandrov Republican Research Oncology and Medical Radiology Center, Lesnoy, Belarus|Minsk City Clinical Oncology Center, Minsk, Belarus|Mogilev Regional Oncology Center, Mogilev, Belarus|Vitebsk Regional Clinical Oncology Center, Vitebsk, Belarus|Medical Research Limited Society, Temuco, Chile|Oncocentro Apys, Viña Del Mar, Chile|Clinic Life Foundation, Medellín, Colombia|Rodrigo Botero SAS, Medellín, Colombia|LTD High-Tech Hospital MedCenter, Batumi, Georgia|JSC ""Evex Hospitals, Kutaisi, Georgia|LTD Acad. F. Todua Medical Center - LTD Research Institute of Clinical Medicine, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD Cancer Research Centre, Tbilisi, Georgia|LTD Health House, Tbilisi, Georgia|LTD Institute of Clinical Oncology, Tbilisi, Georgia|LTD S.Khechinashvili University Hospital, Tbilisi, Georgia|Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, Tbilisi, Georgia|Cytecare Cancer Hospitals, Bengaluru, India|King George's Medical University, Department of Endocrine surgery, Shatabdi Phase II, Lucknow, India|Tata Memorial Centre, Mumbai, India|HCG NCHRI Cancer Centre, Nagpur, India|Christian Medical College, Department of Medical Oncology, Vellore, India|Keimyung University - Dongsan Medical Center, Daegu, Korea, Republic of|Arkhangelsk Clinical Oncology Center, Arkhangel'sk, Russian Federation|Chelyabinsk Regional Clinical Oncology and Nuclear Medicine Center, Chelyabinsk, Russian Federation|Evimed, LLC, Chelyabinsk, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|Republican Clinical Oncology Center, Kazan, Russian Federation|Krasnoyarsk A.I. Kryzhanovsky Regional Oncology Center, Krasnoyarsk, Russian Federation|Kursk Regional Clinical Oncology Center, Kursk, Russian Federation|N.N. Blokhin National Medical Oncology Research Center, Moscow, Russian Federation|National Medical Research Center for Radiology, Moscow, Russian Federation|Vitamed"" LLC, Moscow, Russian Federation|A.F.Tsyb Medical Radiology Research Center, Obninsk, Russian Federation|Clinical Oncology Center, Omsk, Russian Federation|Pyatigorsk Interdistrict Oncology Center, Pyatigorsk, Russian Federation|Rostov Oncology Research Institute, Rostov-on-Don, Russian Federation|Regional Clinical Oncology Center, Ryazan', Russian Federation|AV Medical Group, Saint Petersburg, Russian Federation|City Clinical Oncology Center, Saint Petersburg, Russian Federation|Clinic ""Mart"", Saint Petersburg, Russian Federation|I.I. Mechnikov North-Western State Medical University, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Center (Outpatient Department), Saint Petersburg, Russian Federation|Leningrad Regional Oncology Center (Surgery Department), Saint Petersburg, Russian Federation|N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russian Federation|Oncology Center of Moskovskiy District, Saint Petersburg, Russian Federation|Private Medical Institution ""EVROMEDSERVIS"", Department of Oncology, Saint Petersburg, Russian Federation|St. Petersburg Clinical Research and Practical Center for Specialized Types of Medical Care (Oncology), Saint Petersburg, Russian Federation|Republican Oncology Center, Saransk, Russian Federation|Oncology Center #2, Sochi, Russian Federation|Tomsk National Research Medical Center, Tomsk, Russian Federation|Regional Clinical Oncology Center, Veliky Novgorod, Russian Federation|Volgograd Regional Clinical Oncology Center, Volgograd, Russian Federation|GVI Oncology, Cape Gate Oncology Centre, Cape Town, South Africa|The Oncology Centre, Durban, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Little Company of Mary Medical Center, Department of Oncology, Pretoria, South Africa|University of Pretoria, Department of Medical Oncology, Pretoria, South Africa|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Chernihiv Regional Oncology Center, Chernihiv, Ukraine|Chernivtsi Regional Clinical Oncology Center, Chernivtsi, Ukraine|Clinical Oncology Center, Dnipro, Ukraine|Dnipropetrovsk City Multispecialty Clinical Hospital #4, Department of Chemotherapy, Dnipro, Ukraine|Prikarpattia Clinical Oncology Center, Ivano-Frankivsk, Ukraine|Communal Non-profit enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|State Institution: S.P. Hryhoriev Institute of Medical Radiology under the Ukrainian Academy of Medical Sciences, Department of Clinical Oncology and Hematology, Kharkiv, Ukraine|Khmelnytskyi Regional Oncology Center, Khmelnytskyi, Ukraine|Kryvyi Rih Oncology Center, Department of Chemotherapy, Kryvyi Rih, Ukraine|Kyiv City clinical Hospital #2, Kyiv, Ukraine|Kyiv Regional Oncology Center, Department of Mastology, Kyiv, Ukraine|Medical Center ""Verum"", Kyiv, Ukraine|Medical Center of First Private Clinic, Kyiv, Ukraine|Volyn Regional Oncology Center, Department of Chemotherapy, Luts'k, Ukraine|Public Institution under Lviv Regional Council: Lviv Regional Treatment and Diagnostics Oncology Center, Department of Chemotherapy, Lviv, Ukraine|Mariupol Oncology Center, Mariupol, Ukraine|Odesa Regional Clinical Hospital, Center for Mastology, Department of Thoracic Surgery, Odesa, Ukraine|Odesa Regional Oncology Center, Odesa, Ukraine|Ternopil Regional Clinical Oncology Center, Department of Chemotherapy, Ternopil', Ukraine|Central City Clinical Hospital, Department of Oncology and Radiology, Uzhhorod, Ukraine|Zakarpattia Regional Clinical Oncology Center, Department of Chemotherapy, Uzhhorod, Ukraine|Podillia Regional Oncology Center, Vinnytsia, Ukraine|Zhytomyr Regional Oncology Center, Zhytomyr, Ukraine",,"https://ClinicalTrials.gov/show/NCT03433313"
252,"NCT04494425","Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer","DB-06","Recruiting","No Results Available","Advanced or Metastatic Breast Cancer","Drug: Trastuzumab deruxtecan|Drug: Capecitabine|Drug: Paclitaxel|Drug: Nab-Paclitaxel","Progression Free Survival (PFS) - in HR+, HER2-low populaton|Overall Survival (OS) - in HR+, HER2-low population|Progression Free Survival (PFS) - in intent to treat (ITT) population (HER2-Low and HER2 IHC >0<1+)|Overall Survival - in intent to treat (ITT) population (HER2-Low and HER2 IHC >0<1+)|Objective Response Rate (ORR) in HR+, HER-2 low populaton|Duration of response (DoR) - in HR+, HER-2 low populaton|Progression Free Survival by Investigator assessment - in the HR+, HER2-low population|Objective Response Rate (ORR) in the ITT population|Duration of response (DoR) - in the ITT population|PFS2 by Investigator assessment, time to first subsequent therapy (TFST) and time to second subsequent treatment or death (TSST) - in HR+, HER2-low and the ITT population|Safety and tolerability of drugs; number of adverse events (AEs)|Serum concentration of trastuzumab deruxtecan|Immunogenicity of trastuzumab deruxtecan|Health-related quality of life - EORTC-QLQ-C30|Time to deterioration in EORTC-QLQ-C30 scores|Health-related quality of life - EORTC QLQ-BR45","AstraZeneca|Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo","All","18 Years to 105 Years   (Adult, Older Adult)","Phase 3","850","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D9670C00001","July 24, 2020","June 30, 2023","October 30, 2025","July 31, 2020",,"April 21, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Springdale, Arkansas, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Marcos, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Camden, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Voorhees, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Rochester, New York, United States|Research Site, Westbury, New York, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Germantown, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Kingwood, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Issaquah, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Berazategui, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, Salta, Argentina|Research Site, San Miguel de Tucumán, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Adelaide, Australia|Research Site, Auchenflower, Australia|Research Site, Birtinya, Australia|Research Site, Concord, Australia|Research Site, Darlinghurst, Australia|Research Site, Fitzroy, Australia|Research Site, Frankston, Australia|Research Site, Hobart, Australia|Research Site, Melbourne, Australia|Research Site, Murdoch, Australia|Research Site, South Brisbane, Australia|Research Site, St Leonards, Australia|Research Site, Waratah, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Anderlecht, Belgium|Research Site, Bruges, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, Roeselare, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Wilrijk, Belgium|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Fortaleza, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, CA, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Baoding, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changzhou, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Foshan, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haerbin, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Lanzhou, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Nanchang, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Aalborg, Denmark|Research Site, Aarhus, Denmark|Research Site, Copenhagen Ø, Denmark|Research Site, Naestved, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Avignon Cedex 09, France|Research Site, Besançon, France|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Caen Cedex 05, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Pierre Benite, France|Research Site, Plerin SUR MER, France|Research Site, Rennes, France|Research Site, Saint Herblain Cedex, France|Research Site, Saint-cloud, France|Research Site, Tours, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Tübingen, Germany|Research Site, Velbert, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szolnok, Hungary|Research Site, Tatabánya, Hungary|Research Site, Veszprém, Hungary|Research Site, Amritsir, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Calicut, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Thiruvananthapuram, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar-Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel-Aviv, Israel|Research Site, Aviano, Italy|Research Site, Bergamo, Italy|Research Site, Candiolo, Italy|Research Site, Cona, Italy|Research Site, Genova, Italy|Research Site, Livorno, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Prato, Italy|Research Site, Rozzano, Italy|Research Site, Tricase, Lecce, Italy|Research Site, Udine, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Isehara, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya, Japan|Research Site, Naha-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shizuoka, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alc. Cuauhtémoc, Mexico|Research Site, Cdmx, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Guadalajra, Mexico|Research Site, León, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico, D.F., Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Breda, Netherlands|Research Site, Hengelo, Netherlands|Research Site, Leeuwarden, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Koszalin, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Rzeszów, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site, Porto, Portugal|Research Site, Arkhangelsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Ar Riyāḑ, Saudi Arabia|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Bukit Merah, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, El Palmar, Spain|Research Site, La Coruña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Sebastián, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Göteborg, Sweden|Research Site, Stockholm, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Växjö, Sweden|Research Site, Örebro, Sweden|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Truro, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04494425"
253,"NCT01783444","A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.","BOLERO-6","Completed","Has Results","Breast Cancer","Drug: Capecitabine|Drug: Exemestane|Drug: Everolimus","Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Everolimus Alone|Progression Free Survival (PFS) - Everolimus Plus Exemestane Versus Capecitabine Alone|Overall Survival (OS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Time to Eastern Cooperative Oncology Group (ECOG) Performance Deterioration|Time to 10% Definitive Deterioration in the Global Health Status / Quality of Life|Mean Change in Treatment Satisfaction Questionnaire for Medication (TSQM) Between Week 3 and 12","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 2","309","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001Y2201|2012-003757-28","February 26, 2013","July 2, 2018","July 30, 2018","February 5, 2013","February 26, 2021","February 26, 2021","University of California at Los Angeles Mattel Children's Hospital, Los Angeles, California, United States|Sharp Memorial Hospital SharpClinicalOncologyResearch, San Diego, California, United States|Florida Cancer Specialists Dept of Oncology (2), Fort Myers, Florida, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Lahey Clinic Dept of Lahey Clinic (2), Burlington, Massachusetts, United States|New England Hematology/ Oncology Associates, P.C. SC, Newton, Massachusetts, United States|Glacier View Research Institute - Cancer SC, Kalispell, Montana, United States|Trinitas Comprehensive Cancer Center SC, Elizabeth, New Jersey, United States|Hackensack University Medical Center Dept of Oncology, Hackensack, New Jersey, United States|Rutgers-New Jersey Medical School SC, Newark, New Jersey, United States|Oncology Hematology Care Inc Oncology Hematology Care 2, Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute Oklahoma Cancer Specialists, Tulsa, Oklahoma, United States|Chattanooga Oncology and Hematology Assoicates, PC Chattanooga Oncology, Chattanooga, Tennessee, United States|The Jones Clinic SC, Germantown, Tennessee, United States|University of Tennessee SC, Knoxville, Tennessee, United States|Sarah Cannon Research Institute SC (2), Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD, Fort Worth, Texas, United States|University of Virginia Health Systems SC-4, Charlottesville, Virginia, United States|Northwest Medical Specialties Dept of Onc, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Posadas, Misiones, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Malvern, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Næstved, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Budapest, HUN, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Kolkatta, West Bengal, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Limerick, Co Limerick, Ireland|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Hazmieh, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Eskilstuna, Sweden|Novartis Investigative Site, Joenkoeping, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Muang Lopburi, Lopburi, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, East Kilbride, United Kingdom|Novartis Investigative Site, Middlesborough, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT01783444/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT01783444/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01783444"
254,"NCT04961996","A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",,"Recruiting","No Results Available","Early Breast Cancer","Drug: Giredestrant|Drug: Endocrine Therapy of Physician's Choice|Drug: LHRH Agonist","Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast Cancers|Overall Survival|Invasive Disease-Free Survival (IDFS), Including Second Primary Non-Breast Cancers|Disease-Free Survival (DFS)|Distant Recurrence-Free Interval (DRFI)|Locoregional Recurrence-Free Interval (LRRFI)|Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)|Change from Baseline in the Mean Physical Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30|Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30|Change from Baseline in the Mean Role Functioning Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30|Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30|Change from Baseline in the Mean Global Health Status/Quality of Life (QoL) Scale Score at Specified Timepoints, Assessed Using the EORTC QLQ-C30|Change from Baseline in the EQ 5D-5L Index-Based Score at Specified Timepoints|Change from Baseline in the EQ 5D-5L Visual Analogue Scale (VAS) Score at Specified Timepoints|Incidence and Severity of Adverse Events, with Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE v5.0)|Plasma Concentrations of Giredestrant at Specified Timepoints","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","4100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GO42784|2021-000129-28","August 27, 2021","December 19, 2025","November 21, 2033","July 14, 2021",,"May 2, 2022","Southern Cancer Center, Daphne, Alabama, United States|CBCC Global Research Inc., at Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Cancer and Blood Specialty Clinic, Fountain Valley, California, United States|Sansum Clinic, Santa Barbara, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Torrance Memorial Physician Network/Cancer Care, Torrance, California, United States|Valley Breast Care and Women's Health Center, Van Nuys, California, United States|Rocky Mountain Cancer Centers (Longmont) - USOR, Longmont, Colorado, United States|Stamford Hospital; Clincal Trials Office - 1st Fl - Bennett Cancer Cente, Stamford, Connecticut, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Joliet Oncology Hematology Associates, Ltd., Joliet, Illinois, United States|Cancer Center of Kansas - Kingman, Kingman, Kansas, United States|Lahey Clinic Med Ctr, Lexington, Kentucky, United States|Maryland Oncology Hematology (Bethesda) - USOR, Bethesda, Maryland, United States|Massachusetts General Hospital; Lurie Center for Autism, Lexington, Massachusetts, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hunterdon Hematology Oncology, Flemington, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States|Northwest Cancer Specialists, P.C., Tigard, Oregon, United States|Texas Oncology, P.A. - El Paso; West, El Paso, Texas, United States|Texas Oncology (Flower Mound) - USOR, Flower Mound, Texas, United States|Texas Oncology-Fort Worth Cancer Center, Fort Worth, Texas, United States|Nebraska Cancer Specialists, Fort Worth, Texas, United States|Texas Oncology (McAllen) - USOR, McAllen, Texas, United States|Texas Oncology McKinney, McKinney, Texas, United States|USOR - Texas Oncology - San Antonio Northeast, San Antonio, Texas, United States|Texas Oncology (Tyler) - USOR, Tyler, Texas, United States|Texas Oncology (Waco) - USOR, Waco, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Border Medical Oncology Research Unit, Albury, New South Wales, Australia|Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia|Campbelltown Hospital; Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Kinghorn Cancer Centre; Pharmacy Department, Darlinghurst, New South Wales, Australia|Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research, North Sydney, New South Wales, Australia|Westmead Hospital; Pharmacy Distribution Centre, Northmead, New South Wales, Australia|North Coast Cancer Institute - Port Macquarie, Port Macquarie, New South Wales, Australia|Nepean Cancer Care Centre, Sydney, New South Wales, Australia|Wesley Medical Centre; Clinic For Haematology and Oncology, Auchenflower, Queensland, Australia|Cairns Hospital; Renal Services, Crains, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|St Andrews Medical Centre, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|ICON Cancer Care Hobart, Hobart, Tasmania, Australia|Victorian Breast and Oncology Care, East Melbourne, Victoria, Australia|Frankston Hospital; Oncology/Haematology, Frankston, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|South West Oncology, Warrnambool, Victoria, Australia|Ballarat Oncology & Haematology, Wendouree, Victoria, Australia|LKH-Universitätsklinikum Klinikum Graz, Graz, Austria|Medizinische Universitat Innsbruck; Department of Internal Medicine, Pneumology Centre, Innsbruck, Austria|LKH Rankweil, Interne E, Rankweil, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Universitätsklinikum St. Pölten; Klinische Abteilung für Innere Medizin 1, St. Pölten, Austria|Oö. Gesundheits- und Spitals-AG/LKH Steyr, Steyr, Austria|Klinikum Wels-Grieskirchen GmbH, Wels, Austria|Institute Jules Bordet; Med Onc & Translational Rsch, Belgium, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Grand Hopital de Charleroi asbl, Charleroi, Belgium|UZ Antwerpen, Edegem, Belgium|Chu Sart Tilman; Immunologie & Transplantation, Liege, Belgium|Centre Hospitalier Chrétien MontLégia, Liège, Belgium|Hospital Mae de Deus, Porto Alegre, RS, Brazil|Clinica de Pesquisas e Centro de Estudos Oncologia Ginecologica e Mamaria Ltda, São Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|The Moncton Hospital, Moncton, New Brunswick, Canada|Sault Area Hospital, Sault Ste. Marie, Ontario, Canada|Centre Integre Universitaire de Sante et de Services Sociaux du Saguenay Lac Saint Jean, Chicoutimi, Quebec, Canada|Hopital Charles Le Moyne, Greenfield Park, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|St-Jérome Medical Research, Inc., Saint-Jerome, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|CHU de Quebec-Universite Laval, Quebec, Canada|BIOCINETIC SpA, Peñalolen, Chile|Centro de Estudios Clínicos SAGA SpA, Providencia, Chile|Fundacion Arturo Lopez Perez; Quimioterapia, Providencia, Chile|Oncovida - Santiago, Providencia, Chile|Servicios Médicos URUMED SpA, Rancagua, Chile|Meditek Ltda, Santiago, Chile|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|ONCOCENTRO APYS; Oncología, Vina Del Mar, Chile|Centro de Investigaciones Clinicas Viña del Mar, Viña del Mar, Chile|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Consultorio Oncologico-Hospital Metropolitano Linc, Moravia, Costa Rica|Instituto de Investigación en Ciencias Médicas S.A., San Jose, Costa Rica|Centro de Cáncer y Hematología, San José, Costa Rica|Consultorio Oncologico-Hospital Metropolitano San, San José, Costa Rica|Oncotech S.A., San José, Costa Rica|University Hospital Centre Split, Split, Croatia|General Hospital Varazdin, Varazdin, Croatia|Nemocnice AGEL Novy Jicin a.s.; Oddeleni radioterapie a onkologie, Novy Jicin, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, Czechia|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Kuopion yliopistollinen sairaala, Kuopio, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|Turun Yliopistollinen Keskussairaala, Turku, Finland|High Technology Hospital MedCenter Ltd, Batumi, Georgia|EVEX Clinics, Saint Nikolozi Medical Centre, Kutaisi, Georgia|Research Institute of Clinical Medicine, Tbilisi, Georgia|Institute of Clinical Oncology LTD, Tbilisi, Georgia|Tbilisi Oncological Center, Ltd, Tbilisi, Georgia|LTD TIM, Tbilisi Institute of Medicine, Tbilisi, Georgia|S Khechinashvili University Clinic Ltd, Tbilisi, Georgia|Universitätsklinikum Aachen AÖR - Medizinische Fakultät der RWTH, Aachen, Germany|Hämatologisch/onkologische Gemeinschaftspraxis; Dres. Brudler/Heinrich/Bangerter, Augsburg, Germany|Ambulantes Tumorzentrum Spandau, Berlin, Germany|Lübecker Onkologische Schwerpunktpraxis, Bonn, Germany|Marienhospital Bottrop, Bottrop, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Carl-Thiem-Klinikum gGmbH, Cottbus, Germany|Kliniken Essen Mitte Evang. Huyssens Stiftung/Knappschaft GmbH, Essen, Germany|Centrum fur Hamatologie und Onkologie Bethanien, Frankfurt, Germany|Franziskus-Hospital Harderberg, Georgsmarienhutte, Germany|SRH Wald-Klinikum Gera; Brustzentrum Ostthüringen, Gera, Germany|Martin Luther Universitat Halle Wittenberg, Halle, Germany|Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Germany|Gynäkologisch Onkologische Praxis Hannover, Hannover, Germany|Vincentius-Diakonissen-Kliniken gAG, Karlsruhe, Germany|Facharztpraxis für Gynäkologie und Geburtshilfe PD Dr. med. Christian Kurbacher, Lübeck, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany|Universitäts-Frauenklinik, Marburg, Germany|Praxis fuer gynaekologische onkologie Prof. Dr. me, Mönchengladbach, Germany|Hämatologie und Onkologie Ravensburg / Wangen, Ravensburg, Germany|CaritasKlinikum Saarbruecken St Theresia, Saarbrücken, Germany|Leopoldina Krankenhaus Schweinfurt, Schweinfurt, Germany|Praxis fur Haematologie und Internistische Onkologie, Velbert, Germany|University of Athens Medical School - Regional General Hospital Alexandra, Athens, Greece|Sotiria Chest Hospital of Athens, Athens, Greece|General Oncology Hospital Kifissias ""Oi Agioi Anargyroi"", Athens, Greece|Aretaieio Hospital of Athens, Athina, Greece|Metropolitan General Hospital, Cholargos, Greece|Metropolitan Hospital First Oncology Clinic, Faliro, Greece|Metropolitan Hospital Fourth Oncology Clinic, Faliro, Greece|University General Hospital of Heraklion, Herakleion, Greece|University General Hospital of Ioannina, Ioannina, Greece|University General Hospital of Larissa, Larissa, Greece|IASO Obstetrics Gynecology Clinic, Marousi, Greece|Medical Center of Athens, Marousi, Greece|Olympion Clinic, Patras, Greece|University General Hospital of Patras, Patras, Greece|Bioclinic Thessaloniki, Thessaloniki, Greece|Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece|Euromedica PPDS, Thessaloniki, Greece|Papageorgiou General Hospital of Thessaloniki, Thessaloniki, Greece|Celan S.A., Ciudad de Guatemala, Guatemala|INTEGRA Cancer Institute, Ciudad de Guatemala, Guatemala|Oncomedica, Guatemala, Guatemala|Clínica Médica Especializada en Hematología, Guatemala, Guatemala|Queen Mary Hospital, Hong Kong, Hong Kong|Tolna Megyei Balassa János Kórház, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Szent Borbala Korhaz, Tatabánya, Hungary|Yashoda Hospital, Hyderabad, Andhra Pradesh, India|State Cancer Institute, Indira Gandhi Institute of Medical Sciences (IGIMS), Patna, Bihar, India|Gujarat Cancer & Research Inst., Ahmadabad CITY, Gujarat, India|Hemato Oncology Clinic Ahmedabad Pvt Ltd, Ahmadabad, Gujarat, India|Nirmal Hospital, Surat, Gujarat, India|Kiran Hospital Multi Super Speciality Hospital and Research Center, Surat, Gujarat, India|Himalaya Cancer Hospital & Research Institute, Vadodara, Gujarat, India|Kailash Cancer Hospital and Research Center, Vadodara, Gujarat, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|HCG NCHRI Cancer Center, Nagpur, Maharashtra, India|Shalinitai Meghe Medical College and Hospital, Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Chopda Medicare & Research Centre pvt. Ltd, Nashik, Maharashtra, India|Apex Wellness Hospital, Nashik, Maharashtra, India|Lokmanya Holistic Cancer Care and Research Center (LMRC), Pune, Maharashtra, India|Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneswar, Odisha, India|Erode Cancer Centre, Erode, Tamil NADU, India|Asirvatham Speciality Hospital, Madurai, Tamil NADU, India|Institute of Post Graduate Medical Education and Research (IPGMER) and SSKM Hospital, Kolkata, WEST Bengal, India|Fortis Hospital, Mohali, India|Bon Secours Hospital; Oncology, Cork, Ireland|Beaumont Hospital; Clinical Research and Education Centre, Smurfit Building, Dublin, Ireland|St Vincents University Hospital, Dublin, Ireland|Galway University Hospital, Galway, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Shamir Medical Center Assaf Harofeh, Beer Jacob, Israel|Soroka University Medical Centre, Beer Sheva, Israel|Sheba Medical Center - PPDS, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliera Universitaria Senese, Siena, Abruzzo, Italy|Azienda Ospedaliera di Rilievo Nazionale e di Alta Specialita San Giuseppe Moscati, Avellino, Campania, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Lazio, Italy|Ospedale San Raffaele S.r.l. - PPDS, Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda - Presidio Ospedaliero Ospedale Niguarda Ca' Granda, Milano, Lombardia, Italy|IRCCS Ospedale Sacro Cuore Don Calabria, Negrar, Veneto, Italy|St. Luke's International Hospital, Chuo, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hiroshima University Hospital, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Hokkaido, Japan|Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto University Hospital, Kumamoto, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|The Cancer Institute Hospital of Japanese Foundation For Cancer Research, Tokyo, Japan|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Soon Chun Hyang University Cheonan Hospital, Dongnam-gu, Cheonan-si, Korea, Republic of|National Cancer Centre, Gyeonggi-do, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center - PPDS, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Ajou University Hospital, Suwon City, Korea, Republic of|Ulsan University Hosiptal, Ulsan, Korea, Republic of|Riga East Clinical University Hospital Latvian Oncology Centre, Riga, Latvia|Pauls Stradins Clinical University Hospital, Rīga, Latvia|Centro de Investigación en Artritis y Osteoporosis - PPDS, Mexicali, BAJA California, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de Juárez, Oaxaca, Mexico|Neurociencias Estudios Clinicos S.C., Culiacán, Sinaloa, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Mexico|Cancerologia de Queretaro, Queretaro, Mexico|Oncológico Potosino, San Luis Potosí, Mexico|Metro Davao Medical and Research Center, Davao City, Philippines|University of Santo Tomas Hospital; Pharmacy, Manila, Philippines|Cardinal Santos Medical Center; Department of Internal Medicine, Section of Endocrinology, Manila, Philippines|East Avenue Medical Center; Breast Care Center, Quezon City, Philippines|St. Luke's Medical Center - Quezon City, Quezon City, Philippines|Regionalny Szpital Specjalistyczny im. W. Bieganskiego; Oddzial Neurologiczny, Grudziądz, Poland|Centrum Terapii Wspolczesnej J.M.Jasnorzewska Spolka Komandytowo-Akcyjna, Lodz, Poland|Centrum Medyczna Ostroleka - PRATIA - PPDS, Ostrołęka, Poland|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Poland|Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal|Champalimaud Cancer Center, Lisboa, Portugal|Hospital da Luz, Lisboa, Portugal|Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria; Servicos Farmaceuticos, Lisboa, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia / Espinho E.P.E, Vila Nova de Gaia, Portugal|Centro Hospitalar Trás Os Montes E Alto Douro EPE, Vila Real, Portugal|Spitalul Clinic de Obstetrica si Ginecologie Filantropia; Sectorul 1 BUCUREȘTI, București, Romania|Prof Dr I Chiricuta Institute of Oncology; Oncology Department, Cluj-napoca, Romania|Medisprof SRL, Cluj-Napoca, Romania|Affidea Romania SRL, Constanţa, Romania|Onco Clinic Consult SA, Craiova, Romania|Oncology Center Sf. Nectarie, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Timisoara Emergency County Clinical Hospital, Timişoara, Romania|Leningrad Regional Oncology Dispensary, Kuzmolovsky, Sankt Petersburg, Russian Federation|SPbGU Medical and diagnostic center of the clinic of high medical technology n a N I Pirogov, Saint Petersburg, Sankt Petersburg, Russian Federation|Private Healthcare Institution Clinical Hospital RZhD Medicine, St. Petersburg, Sankt Petersburg, Russian Federation|LLC AV Medical Grupp, St. Petersburg, Sankt Petersburg, Russian Federation|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Cancercare Rondebosch Oncology, Cape Town, South Africa|Sandton Oncology Medical Group (Pty) Ltd, City Of Johannesburg, South Africa|West Rand Oncology Centre; Flora Clinic, Floracliffe, South Africa|Excellentis Clinical Trial Consultants; Clinical Research, George, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Eastleigh Breast Care Centre, Pretoria, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitario Reina Sofia; Servicio de Farmacia, Córdoba, Cordoba, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|CHUS - H. Clinico U. de Santiago, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Fundación Alcorcón, Alcorcon, Madrid, Spain|Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda, Madrid, Spain|Clinica Universidad Navarra; Servicio de Farmacia, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra; Servicio de Farmacia, Pamplona, Navarra, Spain|Hospital Nuestra Senora de Valme, Seville, Sevilla, Spain|Hospital Universitario Virgen Macarena, Seville, Sevilla, Spain|Hospital Universitario Basurto, Bilbao, Vizcaya, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Clinica Tres Torres, Barcelona, Spain|Hospital Universitario Quiron Dexeus, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Clínico San Cecilio, Granada, Spain|Hospital Universitario Virgen de Las Nieves, Granada, Spain|Hospital Universitario de Jaen, Jaen, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Centro Oncologioco MD Anderson Internacional; Servicio de Farmacia, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain|Länssjukhuset Ryhov, Jönköping, Sweden|Skaraborgs sjukhus Skoevde, Dept of surgery, Skoevde, Sweden|Södersjukhuset, Stockholm, Sweden|Sundsvalls sjukhus, Sundsvall, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Universitätsspital Basel, Basel, Switzerland|Luzerner Kantonsspital LUKS; Studienzentrale Onkologie, Luzern, Switzerland|Hirslanden Klinik St. Anna Brustzentrum/Chirurgie, Luzern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kantonsspital Winterthur Medizin Pneumologie, Winterthur, Switzerland|Brust-Zentrum Zürich AG Seefeldstrasse 214 Zürich, Zürich, Switzerland|Koo Foundation Sun Yat-Sen Cancer Center, Beitou Dist., Taiwan|Mackay Memorial Hospital-Tamsui Branch, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taichung Veterans General Hospital, Xitun Dist., Taiwan|Siriraj Hospital, Mahidol University, Bangkok, Thailand|Medical Center of LLC Mriya Med-Service, Kryvyi Rih, Kherson Governorate, Ukraine|Municipal Non-profit Enterprise Odessa Regional Clinical Hospital of Odessa Regional Council, Odesa, Kherson Governorate, Ukraine|Communal Non-Profit Enterprise Chernihiv Medical Center of Modern Oncology of CRC, Chernihiv, KIEV Governorate, Ukraine|Regional Municipal Non-Commercial Enterprise Bukovynian Clinical Oncology Center, Chernivtsi, KIEV Governorate, Ukraine|Medical Center LLC ""Harmony of Beauty"", Kyiv, KIEV Governorate, Ukraine|Clinic Verum Expert LLC, Kyiv, KIEV Governorate, Ukraine|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, Kyiv, KIEV Governorate, Ukraine|Communal Nonprofit Enterprise Kyiv City Clinical Oncological Center, Kyiv, KIEV Governorate, Ukraine|Municipal Non-profit Enterprise Zhytomyr Regional Oncology Dispensary of Zhytomyr Regional Council, Zhytomyr, KIEV Governorate, Ukraine|Medical Clinical Research Center of Medical Center LLC Health Clinic, Vinnytsia, Podolia Governorate, Ukraine|The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council, Lutsk, Volhynian Governorate, Ukraine|Dnipropetrovsk State Medical Academy, Dnipropterovsk, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04961996"
255,"NCT00525408","A Study of Mycobacterium w Plus Docetaxel for Hormone Refractory Metastatic Prostate Cancer","HRPC","Terminated","No Results Available","Hormone Refractory Prostate Cancer","Biological: Mycobacterium w.|Drug: Docetaxel","Median Survival time|Time to Tumor Progression|hematological toxicity, PSA levels, Quality of Life","Cadila Pharnmaceuticals","Male","18 Years and older   (Adult, Older Adult)","Phase 2","134","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-60/1260","November 2007","January 2013","January 2013","September 5, 2007",,"March 12, 2012","V.M. Medical College & Safdarjang Hospital, New Delhi, Delhi, India|Rajiv Gandhi Cancer Institute & Research Center, Rohini, Delhi, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Kasturba Hospital,, Manipal, Karnataka, India|Regional Cancer Centre, Trivandrum, Kerala, India|Choithram Hospital & Research Centre, Indore, Madhya Pradesh, India|Seth G.S. Medical College & KEM Hospital, Parel, Mumbai, India|Lokmanya Tilak Municipal Medical College & General Hospital, Sion, Mumbai, India|Patel Hospital Pvt. Ltd., Jalandhar, Punjab, India|Christian Medical College, Ludhiana, Ludhiana, Punjab, India|S.P. Medical College & A. G. of Hospitals, Bikaner, Rajashthan, India|Christian Medical College, Vellore, Tamil Nadu, India|Chatrapati Sahuji Mahraj Medical University, Lucknow, Uttar Pradesh, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT00525408"
256,"NCT02658734","A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane",,"Completed","Has Results","HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","Drug: Trastuzumab emtansine","Severity of Adverse Events|Percentage of Participants With Adverse Events|Percentage of Participants With Serious Adverse Events (SAEs)|Severity of SAEs as Per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03|Percentage of Participants With Non-Serious Adverse Events of Special Interest|Laboratory Results Abnormalities|Percentage of Participants With Adverse Events Leading to Discontinuation of Study Medication|Percentage of Participants With Adverse Events Leading to Modification of Study Medication|Percentage of Participants With Adverse Events Leading to Interruption of Study Medication|Exposure to Study Drug|Percentage of Participants With Drug-Induced Liver Injury Meeting Hy's Law Criteria|Percentage of Participants With Congestive Heart Failure|Change in Left Ventricular Ejection Fraction (LVEF) as Measured by Echocardiogram|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Overall Survival (OS)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","70","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ML29662","November 1, 2016","December 14, 2019","December 14, 2019","January 20, 2016","February 9, 2021","April 2, 2021","Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Apollo Hospitals International Limited, Gandhinagar, Gujarat, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Christian Medical College & Hospital; Medicine, Vellore, Tamil NADU, India|Healthcare Global Enterprises Limited, Bangalore, India|Artemis Health Institute, Gurgaon, India|Fortis Memorial Research Institute; Department of Medical Oncology & Haematology, Gurgaon, India|Sir Gangaram Hospital; Medical Oncology, New Delhi, India|Max Super Speciality Hospital, New Delhi, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02658734/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/34/NCT02658734/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02658734"
257,"NCT01095003","Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: Vinflunine plus Capecitabine|Drug: Capecitabine","Progression Free Survival|Overall Survival|Overall Response Rate (ORR)|Disease Control Rate|Duration of Response","Pierre Fabre Medicament","Female","21 Years and older   (Adult, Older Adult)","Phase 3","770","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","L00070 IN 305 B0|2008-004171-21","May 2009","December 2011","October 2015","March 29, 2010","September 13, 2019","April 28, 2022","Buenos Aires, Argentina|Quilmes, Argentina|Rosario, Argentina|San Martin, Argentina|Tucuman, Argentina|Gomel, Belarus|Grodno, Belarus|Minsk, Belarus|Vitebsk, Belarus|Bruxelles, Belgium|Liège, Belgium|Curitiba, Brazil|Porto Alegre, Brazil|Santo Andre, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Brno, Czechia|Jihlava, Czechia|Tallinn, Estonia|Angers, France|Caen, France|Dijon, France|Le Mans, France|Lorient, France|Lyon, France|Montpellier, France|Nantes, France|Saint-Brieuc, France|Saint-Cloud, France|Saint-Herblain, France|Tours, France|Villejuif, France|Budapest, Hungary|Szekesfehervar, Hungary|Szolnok, Hungary|Aurangabad, India|Bangalore, India|Bhopal, India|Calcutta, India|Calicut, India|Jaipur, India|Mumbai, India|Patna, India|Pune, India|Trivandrum, India|Avellino, Italy|Cagliari, Italy|Cremona, Italy|Fabriano, Italy|Milano, Italy|Monza, Italy|Padova, Italy|Pisa, Italy|Rozzano, Italy|Verona, Italy|Chihuahua, Mexico|Leon, Mexico|Mexico City, Mexico|Saltillo, Mexico|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lodz, Poland|Lubin, Poland|Warsawa, Poland|Arkhangelsk, Russian Federation|Chelyabinsk, Russian Federation|Moscow, Russian Federation|Ryazan, Russian Federation|Saratov, Russian Federation|St-Petersburg, Russian Federation|Stavropol, Russian Federation|Tambov, Russian Federation|Ufa, Russian Federation|Vladimir, Russian Federation|Volgograd, Russian Federation|Nis, Serbia|Sremska Kamenica, Serbia|Durban, South Africa|Kimberley, South Africa|Pretoria, South Africa|Sandton, South Africa|Barcelona, Spain|Lleida, Spain|Madrid, Spain|Oviedo, Spain|Valencia, Spain|Genolier, Switzerland|Lausanne, Switzerland|Winterthur, Switzerland|Taipei, Taiwan|Taoyuan, Taiwan|Cherkasy, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Khmelnytskyï, Ukraine|Kyiv, Ukraine|Simferopol, Ukraine|Belfast, United Kingdom|Chelmsford, United Kingdom|Keighley, United Kingdom|London, United Kingdom|Nottingham, United Kingdom|Peterborough, United Kingdom|Portsmouth, United Kingdom|Sheffield, United Kingdom|Southend-on-Sea, United Kingdom|Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01095003"
258,"NCT00093002","Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer",,"Completed","No Results Available","Breast Cancer","Drug: Fulvestrant","Anti-proliferative effect after 4 weeks of treatment.|Safety, tolerability, tumor response and pharmacokinetics after 4 weeks of treatment.","AstraZeneca","Female","Child, Adult, Older Adult","Phase 2","179","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9238IL/0065|D6997C00003","June 2004",,"July 2007","September 29, 2004",,"June 12, 2008","Research Site, Little Rock, Arkansas, United States|Research Site, Boston, Massachusetts, United States|Research Site, Winchester, Massachusetts, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Laredo, Texas, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Barretos, Brazil|Research Site, Florianopolis, Brazil|Research Site, Goiamia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Berlin, Germany|Research Site, Hannover, Germany|Research Site, Magdeburg, Germany|Research Site, Munchen, Germany|Research Site, Rostock, Germany|Research Site, Bangalore, India|Research Site, Hyderabaad, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00093002"
259,"NCT00338286","A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy",,"Completed","Has Results","Breast Cancer|Neoplasm Metastasis","Other: Standard supportive care (packed RBC transfusion)|Drug: epoetin alfa + packed RBC transfusion","Progression Free Survival|Overall Survival|Time to Tumor Progression|Overall Response Rate (ORR)|Percentage of Participants With Suspected Thrombotic Vascular Events (TVEs)","Janssen Research & Development, LLC","Female","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2098","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR005143|EPOANE3010|2005-001817-17","March 2, 2006","July 7, 2014","January 31, 2017","June 20, 2006","March 24, 2016","March 19, 2018","Anaheim, California, United States|Gainesville, Florida, United States|Miami, Florida, United States|New Port Richey, Florida, United States|Rockledge, Florida, United States|Hazard, Kentucky, United States|Alexandria, Louisiana, United States|Marrero, Louisiana, United States|Jackson, Mississippi, United States|Lake Success, New York, United States|Staten Island, New York, United States|Philadelphia, Pennsylvania, United States|Corpus Christi, Texas, United States|Houston, Texas, United States|Buenos Aires, Argentina|Capital Federal, Argentina|Ciudad Autonoma De Buenos Airess, Argentina|Cordoba, Argentina|La Plata, Argentina|Mendoza, Argentina|Quilmes, Argentina|Rosario, Argentina|Santa Fe, Argentina|Barretos, Brazil|Curitiba, Brazil|Goiânia/Go, Brazil|Ijuí, Brazil|Jau, Brazil|Piracicaba, Brazil|Porto Alegre, Brazil|Ribeirão Preto/Sp, Brazil|Santo Andre, Brazil|Sao Paulo, Brazil|São José Do Rio Preto, Brazil|São Paulol, Brazil|Plovdiv, Bulgaria|Rousse, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Varna, Bulgaria|Arica, Chile|Santiago, Chile|Temuco, Chile|Valdivia, Chile|Valparaiso, Chile|Bogota, Colombia|Floridablanca-Santander, Colombia|Monteria, Colombia|Cuenca, Ecuador|Guayaquil, Ecuador|Portoviejo, Ecuador|Quito, Ecuador|Batumi, Georgia|Tbilisi, Georgia|Tblisi, Georgia|New Territories, Hong Kong|Ahmedabad, India|Andra Pradesh, India|Bangalore N/A, India|Bangalore, India|Bhopal, India|Cochin, India|Delhi, India|Hyderabad, India|Jaipur, India|Karnad, India|Kerala, India|Kolkata, India|Mangalore, India|Mumbai, India|Nashik, India|New Delhi, India|Pune, India|Tamil Nadu Na, India|Tamil Nadu, India|Thiruvananthapuram, India|Uttar Pradesh, India|Vellore, India|Bandung, Indonesia|Jakarta, Indonesia|Semarang, Indonesia|Yogyakarta, Indonesia|Bitola, Macedonia, The Former Yugoslav Republic of|Skopje, Macedonia, The Former Yugoslav Republic of|Georgetown, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Nilai, Malaysia|Tanjung Bunga, Malaysia|Chihuahua, Mexico|Guerrero, Mexico|Leon, Mexico|Merida, Mexico|Morelia, Mexico|Puebla, Mexico|San Luis Potosi, Mexico|Sinaloa, Mexico|Zapopan, Mexico|Cebu, Philippines|Davao City, Philippines|Iloilo City, Philippines|Manila, Philippines|Quezon City, Philippines|Białystok, Poland|Gdansk, Poland|Gliwice, Poland|Katowice N/A, Poland|Kraków, Poland|Lodz, Poland|Olsztyn, Poland|Poznan, Poland|Wroclaw, Poland|Brasov, Romania|Bucuresti, Romania|Cluj-Napoca, Romania|Iasi, Romania|Onesti, Romania|Sibiu, Romania|Suceava, Romania|Timisoara, Romania|Arkhangelsk, Russian Federation|Balashikha, Russian Federation|Belgorod, Russian Federation|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Engels Saratov Region, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Leningrad Region, Russian Federation|Lipetsk, Russian Federation|Magnitogorsk, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Orenburg, Russian Federation|Perm, Russian Federation|Pyatigorsk, Russian Federation|Ryazan, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St. Petersburg, Russian Federation|Tyumen, Russian Federation|Ufa, Russian Federation|Voronezh, Russian Federation|Bloemfontein, South Africa|Cape Town, South Africa|Durban, South Africa|Johannesburg, South Africa|Klerksdorp, South Africa|Port Elizabeth N/A, South Africa|Pretoria, South Africa|Changhua, Taiwan|Chiayi, Taiwan|Hualien, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei 112, Taiwan|Taipei, Taiwan|Tao-Yuan, Taiwan|Cherkassy, Ukraine|Chernihiv, Ukraine|Chernivtsi, Ukraine|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Francovsk, Ukraine|Kharkiv, Ukraine|Kiev, Ukraine|Lviv, Ukraine|Odessa, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Uzhgorod, Ukraine|Vinnitsa, Ukraine|Vinnytsia, Ukraine|Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT00338286"
260,"NCT04736199","Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","ARANOTE","Recruiting","No Results Available","Prostatic Neoplasms","Drug: Darolutamide (Nubeqa, BAY1841788)|Drug: Placebo|Other: Androgen deprivation therapy (ADT)","Radiological progression-free survival (rPFS)|Overall survival (OS)|Time to castration-resistant prostate cancer (CRPC)|Time to initiation of subsequent antineoplastic therapy|Time to PSA progression|PSA undetectable rates (<0.2 ng/mL)|Time to pain progression|Number of participants with adverse events as a measure of safety","Bayer|Orion Corporation, Orion Pharma","Male","18 Years and older   (Adult, Older Adult)","Phase 3","555","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","21140|2020-003093-48","February 23, 2021","March 27, 2024","September 26, 2025","February 3, 2021",,"April 22, 2022","Macquarie University Hospital, Macquarie University, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Cancer Research South Australia, South Terrace, South Australia, Australia|Peninsula Oncology Centre, Frankston, Victoria, Australia|Austin Health, Heidelberg, Australia|Assistência Multidisciplinar em Oncologia (AMO), Salvador, Bahia, Brazil|Hosp. Araujo Jorge da Associação de Combate ao Câncer, Goiânia, Goiás, Brazil|Hospital da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Cetus Oncologia Hospital Dia, Belo Horizonte, Minas Gerais, Brazil|Liga Paranaense de Combate ao Cancer-Hosp Erasto Gaertner, Curitiba, Parana, Brazil|Liga Norte Riograndense Contra o Câncer, Natal, Rio Grande Do Norte, Brazil|Unidade de Pesquisas Clinicas em Oncologia, Pelotas, Rio Grande Do Sul, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Mae de Deus, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Hospital de Base da Fundação F M S J Rio Preto, São José do Rio Preto, Sao Paulo, Brazil|Urobrasil, São Paulo, Sao Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo, Sao Paulo, Brazil|Inst. de Assistência Médica ao Sérvidor Público Estadual, São Paulo, Sao Paulo, Brazil|Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil|Exdeo Clinical Research Inc., Abbotsford, British Columbia, Canada|G. Kenneth Jansz Medicine Professional Corporation, Burlington, Ontario, Canada|Centre integre de Sante et de Services Sociaux de IOutaouais, Gatineau, Quebec, Canada|CIUSSS de l'Estrie- Centre Haute-Yamaska, Granby, Quebec, Canada|Centre de Recherche du CHUM, Montreal, Quebec, Canada|Centro Oncológico del Norte, Antofagasta, Araucanía, Chile|Centro de Investigación Clínica del Sur, Temuco, Araucanía, Chile|Sociedad Clinical Research Chile SpA, Valdivia, Los Lagos, Chile|Centro de Estudios Clínicos SAGA SpA, Providencia, Santiago, Chile|OncoCentro, Viña del Mar, Valparaíso, Chile|Fundación Arturo López Perez, Santiago, Chile|Oncovida, Santiago, Chile|Hospital Clínico de la Pontificia Univ. Católica de Chile, Santiago, Chile|UROMED, Santiago, Chile|Anhui Provincial Hospital, Hefei, Anhui, China|FuJian Medical University Union Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Guangzhou First People Hospital, Guangzhou, Guangdong, China|Cancer Hospital Chinese Academy of Medical Sciences,Shenzhen, Shenzhen, Guangdong, China|Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech., Wuhan, Hubei, China|Zhongnan hospital ,Wuhan University, Wuhan, Hubei, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School, Nanjing, Jiangsu, China|Nantong tumor hospital, Nantong, Jiangsu, China|The 2nd Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|1st Hospital of Jilin University, Changchun, Jilin, China|Liaoning Cancer Hospital and Institute, Shengyang, Liaoning, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Yantai Yuhuangding Hospital, Yantai, Shandong, China|SichuanAcademyofMedicalSciences&SichuanProvincialPeople'sHos, Chengdu, Sichuan, China|Sichuan University West China Hospital, Chengdu, Sichuan, China|Yunnan Cancer Hospital, Kunming, Yunnan, China|The 1st Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China|ZheJiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo First Hospital, Ningbo, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Peking University Third Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|Beijing Hospital, Beijing, China|Huashan Hospital, Fudan University, Shanghai, China|Xinhua Hos Affiliated to SH Jiaotong Uni School of Medicine, Shanghai, China|Shanghai Fifth People's Hospital,Fudan University, Shanghai, China|Docrates Klinikka, Helsinki, Finland|HUS, Meilahden sairaala, Helsinki, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Seinäjoen keskussairaala, Seinäjoki, Finland|Tampereen yliopistollinen sairaala, keskussairaala, Tampere, Finland|Mahatma Gandhi Cancer Hospital & Research Institute, Vishakapatnam, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|The Gujarat Cancer & Research Institute, Ahmedabad, Gujarat, India|HCG Cancer Centre - Ahmedabad, Ahmedabad, Gujarat, India|Cancer Care Clinic - Vadodara, Vadodara, Gujarat, India|KLES Dr. Prabhakar Kore Hospital & Medical Research Centre, Belagavi, Karnataka, India|Healthcare Global Enterprises Ltd, Bengaluru, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, India|Tata Memorial Hospital, Mumbai,, Maharashtra, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Sushrut Hospital & Research Centre, Mumbai, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Sparsh Hospital & Critical Care, Bhubaneswar, Orissa, India|Christian Medical Center & Hospital, Ludhiana, Punjab, India|SMS Medical College & Attached Hospitals, Jaipur, Rajasthan, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil N?du, India|Apollo Specialty Hospital- Teynampet, Chennai, Tamil Nadu, India|Tata Medical Center, Kolkata, India|Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India|Daugavpils Regional Hospital, Daugavpils, Latvia|RAKUS Hospital Gailezers, Riga, Latvia|URO Ltd., Riga, Latvia|P. Stradins Clinical University Hospital, Riga, Latvia|Vidzemes Hospital, Valmiera, Latvia|The Hospital of Lithuanian University of Health SciencesLUHS, Kaunas, Lithuania|PI Klaipedos University Hospital, Klaipeda, Lithuania|National Cancer Institute, Vilnius, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Canterbury Urology Research Trust, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Urology Waikato, Hamilton, New Zealand|Tauranga Urology Research Limited, Tauranga, New Zealand|Hospital Guillermo Almenara Irigoyen, La Victoria, Lima, Peru|Aliada, San Isidro, Lima, Peru|Hospital Militar Luis Arias Schreiber, Lima, Peru|Clínica El Golf, Lima, Peru|Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ltd ""EVIMED"", Chelyabinsk, Russian Federation|Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Republican Clinical Oncology Dispensary, Kazan, Russian Federation|Russian Oncological Scientific Center n.a. N.N. Blokhin RAMS, Moscow, Russian Federation|Research Centre of X-ray and Radiology, Moscow, Russian Federation|Volga District Med Center FMBA, Nizhny Novgorod, Russian Federation|Medical Center ""Avicenna"", Novosibirsk, Russian Federation|LLC Reafan, Novosibirsk, Russian Federation|Clinical Oncological Dispensary of Omsk Region, Omsk, Russian Federation|GBUZ RM ""Republican Oncology Dispensary"", Saransk, Russian Federation|St. Petersburg Clinical Hospital of RAS, St. Petersburg, Russian Federation|AV Medical Group, St. Petersburg, Russian Federation|Russian Scientific Radiology and Surgery Technologies Center, St. Petersburg, Russian Federation|Scientific Research Instutute of Oncology n.a. N.N. Petrov, St. Petersburg, Russian Federation|Multi-Field Clinical Medical Center ""Medical City"", Tyumen, Russian Federation|Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Vologda Regional Hospital, Vologda, Russian Federation|Sverdlovsk Regional Clinical Hospital #1, Yekaterinburg, Russian Federation|Cancercare Langenhoven, Port Elizabeth, Eastern Cape, South Africa|East Rand Medical Research Unit, Johannesburg, Gauteng, South Africa|University of Pretoria, Clinical Research Unit, Pretoria, Gauteng, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa|Cape Town Oncology Trials, Cape Town, South Africa|Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital Fundació Puigvert, Barcelona, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Universitario Puerta del Mar, Cádiz, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cherkasy Oncological Dispensary, Cherkasy, Ukraine|City Dnipropetrovsk Multi- field Clinical Hosp. 4 DSMA, Dnipro, Ukraine|Kyiv City Hospital #3, Kyiv, Ukraine|Kyiv Regional Oncological Dispensary, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT04736199"
261,"NCT04760288","A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).","AcceleRET-MTC","Not yet recruiting","No Results Available","Thyroid Cancer","Drug: Pralsetinib|Drug: Cabozantinib|Drug: Vandetanib","Progression-Free Survival (PFS)|Time-To-Treatment Failure (TTF)|Objective Response Rate (ORR)|Overall Survival (OS)|Percentage of Participants With Adverse Events (AEs)|Duration of Response (DOR)|Disease Control Rate (DCR)|Clinical Benefit Rate (CBR)|Time to deterioration of function|Quality of Life (QoL)|Acceptability and Palatability of Pralsetinib capsules","Hoffmann-La Roche","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","198","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CO42865|2020-005269-15","July 1, 2022","April 15, 2026","April 15, 2028","February 18, 2021",,"May 4, 2022","The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente, Torrance, California, United States|Instituto de Investigaciones Metabolicas (Idim), Ciudad Autonoma de Buenos Aires, Argentina|Centro Médico Privado CEMAIC, Córdoba, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Sanatorio Britanico de Rosario, Rosario, Argentina|Centro de Investigación Clínica - Clínica Viedma, Viedma, Argentina|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|The Alfred Hospital;Clinical Trial Pharmacy, Melbourne, Victoria, Australia|Medizinische Universität Graz; Klinische Abteilung für Allgemeine HNO, Graz, Austria|CETUS Hospital Dia Oncologia, Uberaba, MG, Brazil|Hospital de Clinicas de Porto Alegre (HCPA) - PPDS, Porto Alegre, PA, Brazil|Irmandade Da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, RS, Brazil|Fundação Pio XII Hospital de Câncer de Barretos, Barretos, SP, Brazil|Instituto Do Câncer Do Estado de São Paulo Octávio Frias de Oliveira, São Paulo, SP, Brazil|Multiprofile Hospital for Active Treatment Uni Hospital; Department of medicinal oncology, Panagyurishte, Bulgaria|Complex Oncology Center Plovdiv; Department of Medical Oncology and Oncology Diseases in Pneumology, Plovdiv, Bulgaria|University Multiprofile Hospital For Active Treatment ""Sveti Ivan Rilski"" EAD; clinical hematology, Sofia, Bulgaria|Tom Baker Cancer Centre; Dept of Pathology, Calgary, Alberta, Canada|Cross Cancer Institute; Clinical Trials, Edmonton, Alberta, Canada|McGill University Health Center; Glen-Cedars Cancer Centre, Oncology Pharmacy, Montreal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke; Pharmacie de Chimiotherapie, Sherbrooke, Quebec, Canada|Clinical Hospital Centre Osijek; Hematology, Osijek, Croatia|Clinical Hospital Sestre Milosrdnice, Zagreb, Croatia|Klinicki bolnicki centar Zagreb, Zagreb, Croatia|Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed, Odense C, Denmark|Hôtel Dieu -Angers; Pharmacie / Secteur Essais Cliniques, Angers, France|EDOG - Institut Bergonie - PPDS, Bordeaux, France|Centre Hospitalier Universitaire Lyon; Institut Hématologique et d'Oncologie Pédiatrique, Lyon, France|CHU Nantes, Nantes, France|Centre Antoine Lacassagne Centre Régional de Lutte Contre Le Cancer, Nice, France|Hopital Cochin, Paris, France|Institut Curie; Pharmacie, Paris, France|Hôpital Saint-Louis, Paris, France|ICANS, Strasbourg, France|Institut Universitaire de Cancer de Toulouse Oncopole; IUCT- Oncopole, Toulouse, France|Attikon University General Hospital, Ahens, Greece|University of Athens Medical School - Regional General Hospital Alexandra, Athens, Greece|Kianous Stavros, Thessaloniki, Greece|Semmelweis Egyetem, II. Belgyógyászati Klinika, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Szeged, Hungary|Panchshil Hospital, Ahmadabad CITY, Gujarat, India|Unity Hospital-Surat, Surat CITY, Gujarat, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|HCG NCHRI Cancer Center, Nagpur, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sparsh Hospitals & Critical Care (P) Ltd., Bhubaneswar, Odisha, India|Dayanand Medical College and Hospital, Ludhiana, Punjab, India|Hadassah Medical Center, Jerusalem, Israel|C.H. Regional Reina Sofia - PPDS, Cordoba, Calabria, Italy|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center - PPDS, Seoul, Korea, Republic of|VU Medisch Centrum, Amsterdam, Netherlands|Saint Louis University Hospital of Sacred Heart, Baguio City, Philippines|St. Luke's Medical Center - Quezon City, Quezon City, Philippines|Centrum Onkologii-Instytut Im. Marii Skłodowskiej Curie; I Klinika Radioterapii i Chemioterapii, Gliwice, Poland|Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie w Krakowie - Apteka/Pharmacy; Pharmacy, Warszawa, Poland|Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal|Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe, Porto, Portugal|Institutul National de Endocrinologie ""C. I. Parhon""; Sectorul 1 BUCUREȘTI, Bucuresti, Romania|Prof Dr I Chiricuta Institute of Oncology; Oncology Department, Cluj-napoca, Romania|Onco Clinic Consult SA, Craiova, Romania|CHUS - H. Clinico U. de Santiago, Santiago de Compostela, LA Coruña, Spain|Clinica Universidad Navarra; Servicio de Farmacia, Pamplona, Navarra, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|MD Anderson Cancer Center Madrid - España; Servicio de Farmacia, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario HM Sanchinarro - CIOCC; Farmacia - Ensayos Clínicos, Madrid, Spain|Hospital Regional Universitario de Malaga, Malaga, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Phramongkutklao Hospital, Bangkok, Thailand|Siriraj Hospital, Mahidol Uni ; Division of Rheumatology, Dept. of Medicine, Bangkok, Thailand|Chulalongkorn University Hospital; Hematology, Pathum Wan, Thailand|SI Institute for general and urgent surgery n.a. V.T.Zaitseva of NAMS of Ukraine, Kharkiv, Kharkiv Governorate, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS, Dnipro, KIEV Governorate, Ukraine|Ukr. Scientific Practical Center of Endocrine Surgery,Transplantation of Endocrine organs&Tissues, Kyiv, KIEV Governorate, Ukraine|Clinic Verum Expert LLC, Kyiv, KIEV Governorate, Ukraine|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, Kyiv, KIEV Governorate, Ukraine|St Bartholomew's Hospital, London, United Kingdom|Guys Hospital; Guys Cancer Center, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|The Royal Marsden NHS Foundation Trust - Royal Marsden Hospital (RMH) - Sutton, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04760288"
262,"NCT03176238","Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","EVEREXES","Completed","Has Results","Post Menopausal Breast Cancer","Drug: everolimus|Drug: exemestane","Summary of Number of Participants With Treatment Emergent Adverse Events (TEAE) - All Grades|Percentage of Participants Response Rates (Best Overall and Overall)|Percentage of Participants Clinical Benefit Rate|Progression Free Survival (PFS)|Percent of Participants Event-free Probability Estimates of Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status","Novartis Pharmaceuticals|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","235","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001JIC06","March 29, 2013","January 29, 2019","January 29, 2019","June 5, 2017","April 7, 2020","April 7, 2020","Novartis Investigative Site, Garran, Australian Capital Territory, Australia|Novartis Investigative Site, Caringbah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, St Albans, Victoria, Australia|Novartis Investigative Site, Karamsad, Gujarat, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Cuttack, Orissa, India|Novartis Investigative Site, Bandung, Indonesia|Novartis Investigative Site, Jakarta, Indonesia|Novartis Investigative Site, Jogyakarta, Indonesia|Novartis Investigative Site, Semarang, Indonesia|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Suwon, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Taegu, Korea, Republic of|Novartis Investigative Site, Kuala Lumpur, MYS, Malaysia|Novartis Investigative Site, Kota Kinabalu, Sabah, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Casablanca, Morocco|Novartis Investigative Site, Rabat, Morocco|Novartis Investigative Site, Cape Town, Western Cape, South Africa|Novartis Investigative Site, George, Western Cape, South Africa|Novartis Investigative Site, Western Cape, South Africa|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ariana, Tunisia|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Gaziantep, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kartal, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Ho Chi Minh, Vietnam","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03176238/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03176238/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03176238"
263,"NCT04711252","A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease.","SERENA-4","Recruiting","No Results Available","ER-Positive HER2-Negative Breast Cancer","Drug: AZD9833|Drug: Anastrozole|Drug: Anastrozole placebo|Drug: AZD9833 placebo|Drug: Palbociclib|Drug: Luteinizing hormone-releasing hormone (LHRH) agonist","Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST) version 1.1|Overall survival (OS)|Second progression-free survival (PFS2)|Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1|Duration of response (DoR) assessed by the Investigator as defined by RECIST version 1.1|Time to chemotherapy (TTC)|Time to first subsequent anti-cancer therapy (TFST)|Clinical benefit rate at 24 weeks (CBR24)|Time to second subsequent therapy (TSST)|Plasma concentration of AZD9833 at specified timepoints|Change from baseline in EORTC QLQ-C30 scale scores|Change from baseline in EORTC QLQ-BR45 scale scores","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D8532C00001|2020-002276-12","January 28, 2021","November 10, 2025","February 12, 2029","January 15, 2021",,"May 6, 2022","Research Site, Mobile, Alabama, United States|Research Site, Springdale, Arkansas, United States|Research Site, Harbor City, California, United States|Research Site, Lone Tree, Colorado, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Evergreen Park, Illinois, United States|Research Site, Urbana, Illinois, United States|Research Site, Edgewood, Kentucky, United States|Research Site, Lexington, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Syracuse, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Greenville, South Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Everett, Washington, United States|Research Site, Kennewick, Washington, United States|Research Site, Renton, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Feldkirch, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Anderlecht, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Sint-Niklaas, Belgium|Research Site, Panagyurishte, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Montreal, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Lanzhou, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 5, Czechia|Research Site, Besancon Cedex, France|Research Site, Bordeaux, France|Research Site, Brest Cedex, France|Research Site, Caen Cedex 05, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Montpellier, France|Research Site, Pierre Benite Cedex, France|Research Site, Plerin SUR MER, France|Research Site, Saint-cloud, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Bottrop, Germany|Research Site, Dessau-RoBlau, Germany|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Mönchengladbach, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Velbert, Germany|Research Site, Wuerzburg, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szekszárd, Hungary|Research Site, Tatabánya, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Ahmedabad, India|Research Site, Calicut, India|Research Site, Faridabad, India|Research Site, Gurgaon, India|Research Site, Karamsad, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Rohini, India|Research Site, Bergamo, Italy|Research Site, Genova, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Novara, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Prato, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukushima-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurashiki shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shimotsuke-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Johor Bahru, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Selangor, Malaysia|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Estado de México, Mexico|Research Site, La Paz, Mexico|Research Site, Metepec, Mexico|Research Site, Mexico, Mexico|Research Site, MEX, Mexico|Research Site, Monterrey, Mexico|Research Site, Puebla, Mexico|Research Site, Drammen, Norway|Research Site, Oslo, Norway|Research Site, Gdynia, Poland|Research Site, Konin, Poland|Research Site, Koszalin, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Rzeszów, Poland|Research Site, Skórzewo, Poland|Research Site, Łódź, Poland|Research Site, Braga, Portugal|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Kaluga, Russian Federation|Research Site, Kislino Village, Ryshkovsky Ru, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Košice, Slovakia|Research Site, Prešov, Slovakia|Research Site, Trencin, Slovakia|Research Site, Žilina, Slovakia|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Jaén, Spain|Research Site, Lleida, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Basel, Switzerland|Research Site, Bern, Switzerland|Research Site, Zürich, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, İstanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Colchester, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04711252"
264,"NCT05113251","Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer",,"Recruiting","No Results Available","Breast Neoplasms|Breast Cancer|HER2-positive Early Breast Cancer","Drug: Trastuzumab Deruxtecan|Drug: Paclitaxel|Drug: Trastuzumab|Drug: Pertuzumab|Drug: Doxorubicin|Drug: cyclophosphamide","rate of pathologic complete response (pCR)|Event-Free Survival|Invasive Disease-Free Survival (IDFS)|Overall Survival","AstraZeneca|Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","624","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967RC00001","October 25, 2021","February 5, 2024","June 26, 2026","November 9, 2021",,"April 8, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Beverly Hills, California, United States|Research Site, Glendale, California, United States|Research Site, Orange, California, United States|Research Site, Denver, Colorado, United States|Research Site, Grand Junction, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Scarborough, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Billings, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, East Brunswick, New Jersey, United States|Research Site, Summit, New Jersey, United States|Research Site, Commack, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Germantown, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Burlington, Vermont, United States|Research Site, Fairfax, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Wien, Austria|Research Site, Goiânia, Brazil|Research Site, Ijuí, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitoria, Brazil|Research Site, Panagyurishte, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Kunming, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Zhengzhou, China|Research Site, Aschaffenburg, Germany|Research Site, Augsburg, Germany|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Leipzig, Germany|Research Site, Muenster, Germany|Research Site, Mönchengladbach, Germany|Research Site, München, Germany|Research Site, Offenbach am Main, Germany|Research Site, Tübingen, Germany|Research Site, Gurgaon, India|Research Site, Ludhiana, India|Research Site, Manipal, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Raipur, India|Research Site, Rishikesh, India|Research Site, Thiruvananthapuram, India|Research Site, Vadodara, India|Research Site, Bologna, Italy|Research Site, Candiolo, Italy|Research Site, Livorno, Italy|Research Site, Napoli, Italy|Research Site, Negrar, Italy|Research Site, Padova, Italy|Research Site, Rome, Italy|Research Site, Chuo-ku, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Cebu City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo, Philippines|Research Site, Legazpi City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Biała Podlaska, Poland|Research Site, Bydgoszcz, Poland|Research Site, Koszalin, Poland|Research Site, Lublin, Poland|Research Site, Rzeszów, Poland|Research Site, Rzeszów, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT05113251"
265,"NCT01419197","A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","TH3RESA","Completed","Has Results","Breast Cancer","Drug: Trastuzumab emtansine|Drug: Treatment of physician's choice","Progression-free Survival|Overall Survival|Percentage of Participants With an Objective Response|Duration of the Objective Response|6-month and 1-year Survival|Time to Pain Symptom Progression|Change From Baseline in the EORTC QLQ-BM22 Pain Score on Day 1 of Each Cycle|Overall Survival (Final Analysis)|6-month and 1-year Survival (Final Analysis)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","602","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TDM4997g|BO25734|2011-000509-29","September 2011","February 2013","August 2015","August 18, 2011","May 5, 2014","October 12, 2016","Tucson, Arizona, United States|Hot Springs, Arkansas, United States|Hayward, California, United States|Highland, California, United States|Oakland, California, United States|Roseville, California, United States|Sacramento, California, United States|San Diego, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|South San Francisco, California, United States|Stockton, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|West Hollywood, California, United States|Denver, Colorado, United States|Trumbull, Connecticut, United States|Newark, Delaware, United States|Washington, District of Columbia, United States|Coral Springs, Florida, United States|Deerfield Beach, Florida, United States|Fort Myers, Florida, United States|Jacksonville, Florida, United States|Plantation, Florida, United States|Marietta, Georgia, United States|Post Falls, Idaho, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Maywood, Illinois, United States|Fort Wayne, Indiana, United States|Sioux City, Iowa, United States|Wichita, Kansas, United States|Scarborough, Maine, United States|Bethesda, Maryland, United States|Columbia, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|Omaha, Nebraska, United States|New Brunswick, New Jersey, United States|Bronx, New York, United States|Lake Success, New York, United States|Charlotte, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Nashville, Tennessee, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|San Antonio, Texas, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Kogarah, New South Wales, Australia|South Brisbane, Queensland, Australia|Frankston, Victoria, Australia|Perth, Western Australia, Australia|Leuven, Belgium|Wilrijk, Belgium|Salvador, BA, Brazil|Goiania, GO, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Itajai, SC, Brazil|Sao Paulo, SP, Brazil|Moncton, New Brunswick, Canada|Toronto, Ontario, Canada|Regina, Saskatchewan, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Angers, France|Bordeaux, France|Caen, France|Lyon, France|Montpellier cedex 5, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Reims CEDEX, France|Rouen, France|St-Priest-En-Jarez, France|Strasbourg, France|Toulouse, France|Toulouse, France|Tours, France|Villejuif, France|Bielefeld, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Kiel, Germany|Mainz, Germany|München, Germany|Ravensburg, Germany|Recklinghausen, Germany|Stuttgart, Germany|Trier, Germany|Troisdorf, Germany|Budapest, Hungary|Budapest, Hungary|Gyula, Hungary|Kecskemet, Hungary|Miskolc, Hungary|Szeged, Hungary|Szolnok, Hungary|Bangalore, India|Chennai, India|Kolkata, India|New Delhi, India|Pune, India|Pune, India|Beer Sheva, Israel|Hafia, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Potenza, Basilicata, Italy|Napoli, Campania, Italy|Genova, Liguria, Italy|Bergamo, Lombardia, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Biella, Piemonte, Italy|Cona (Ferrara), Veneto, Italy|Kyunggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Oslo, Norway|Bialystok, Poland|Bydgoszcz, Poland|Gdansk, Poland|Lublin, Poland|Poznan, Poland|Warszawa, Poland|Moscow, Russian Federation|Samara, Russian Federation|Stavropol, Russian Federation|Kosice, Slovakia|Poprad, Slovakia|La Coruna, La Coruña, Spain|Bilbao, Vizcaya, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Sevilla, Spain|Valencia, Spain|Umea, Sweden|Uppsala, Sweden|Örebro, Sweden|Bern, Switzerland|Zürich, Switzerland|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Brighton, United Kingdom|Guildford, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Nottingham, United Kingdom|Sheffield, United Kingdom|Stoke-on-Trent, United Kingdom|Westcliffe-on-sea, United Kingdom|Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01419197"
266,"NCT03125902","A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)","IMpassion131","Active, not recruiting","Has Results","Triple-Negative Breast Cancer","Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Drug: Atezolizumab Placebo|Drug: Paclitaxel","Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Subpopulation With Programmed Death-Ligand 1 (PD-L1)-Positive Tumour Status|Progression-Free Survival (PFS) Assessed Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the Intent-to-Treat (ITT) Population|Overall Survival (OS) in the PD-L1-Positive Subpopulation|Overall Survival (OS) in the ITT Population|Percentage of Participants Who Are Alive at 12 and 18 Months|Time to Deterioration (TTD) in Global Health Status/ Health Related Quality of Life (HRQoL) in the PRO Evaluable Population|Percentage of Participants Who Are Alive Without Progression Event at Month 12 Assessed Using RECIST v1.1|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Confirmed, Investigator-Assessed )|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the PD-L1-Positive Population (Unconfirmed, Investigator-Assessed)|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the Response-Evaluable Population (Confirmed, Investigator-Assessed )|Percentage of Participants With Objective Response Assessed Using RECIST v1.1 in the Response-Evaluable Population (Unconfirmed, Investigator-Assessed )|Duration of Objective Response (DOR) Assessed Using RECIST v1.1 in DOR-evaluable Population (Unconfirmed)|Percentage of Participants With Clinical Benefit Assessed Using RECIST v1.1 in Response-evaluable Population|Minimum Observed Serum Concentration (Cmin) of Atezolizumab in PK Evaluable Population|Maximum Observed Serum Concentration (Cmax) of Atezolizumab in PK-evaluable Population|Minimum Observed Plasma Concentration (Cmin) of Paclitaxel|Maximum Observed Plasma Concentration (Cmax) of Paclitaxel|Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)|Percentage of Participants With Anti-Drug Antibodies' (ADAs) Against Atezolizumab in ADA Evaluable Population|Overall Survival by PD-L1 Status, Intent to Treat Population|Progression Free Survival by PD-L1 Status, Intent to Treat Population|Duration of Confirmed Response (C-DoR) in (C-DoR)-Evaluable Population","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","651","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MO39196|2016-004024-29","August 25, 2017","November 15, 2019","June 30, 2022","April 24, 2017","January 7, 2021","May 16, 2022","Stanford Cancer Center, Stanford, California, United States|Florida Cancer Specialists; Department of Oncology, Fort Myers, Florida, United States|Florida Cancer Specialist, North Region, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States|HCA Midwest Health, Kansas City, Missouri, United States|The Valley Hospital, Paramus, New Jersey, United States|Magee-Woman's Hospital, Pittsburgh, Pennsylvania, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Centro de Pesquisas Clinicas em Oncologia - CPCO, Cachoeiro de Itapemirim, ES, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Kingston General Hospital, Kingston, Ontario, Canada|Grand River Hospital, Kitchener, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada|McGill University; Glen Site; Oncology, Montreal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke - Hopital Fleurimont, Sherbrooke, Quebec, Canada|Cancer Hospital Chinese Academy of Medical Sciences., Beijing, China|Beijing Union Hospital, Beijing, China|West China Hospital, Sichuan University; Department of Breast, Chengdu, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Shandong Cancer Hospital, Jinan, China|Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China|Jiangsu Cancer Hospital, Nanjing City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital), Shanghai, China|Liaoning cancer Hospital & Institute, Shenyang, China|Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province), Shijiazhuang, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|The Second Affiliated Hospital of Xi'an Jiao Tong University, Xi'an City, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Zhejiang Cancer Hospital, Zhejiang, China|Henan Cancer Hospital, Zhengzhou, China|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni nemocnice Ostrava; Klinika onkologicka FNO a LF OU, Ostrava-Poruba, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Clinique Sainte Catherine; Hopital De Semaine, Avignon, France|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital Morvan, Brest, France|CHD Les Oudairies, La Roche Sur Yon, France|Centre Oscar Lambret; Senologie, Lille, France|Centre Leon Berard; Departement Oncologie Medicale, Lyon, France|Centre D'Oncologie de Gentilly; Oncology, Nancy, France|Hopital Caremeau; Hematologie Oncologie, Nimes, France|Hopital Tenon, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Hopital Saint Louis, Service D Oncologie Medicale, Paris, France|Ch Pitie Salpetriere; Oncologie Medicale, Paris, France|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Centre Paul Strauss; Oncologie Medicale, Strasbourg, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, France|Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France|Ambulantes Tumorzentrum Spandau; Dres. Benno Mohr und Uwe Peters, Berlin, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|HOPA im Struensee-Haus, Dres. Erik Engel, Wiebke Hollburg, Hamburg, Germany|Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany|St. Elisabeth Krankenhaus Köln GmbH; Gynäkologie und Geburtshilfe, Koeln, Germany|Universitätsmedizin Mainz; Klinik u. Poliklinik f. Geburtshilfe u. Frauenheilkunde, Mainz, Germany|OnkoNet Marburg GmbH, Marburg, Germany|Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Münster, Germany|Klinikum Ernst von Bergmann; Frauenklinik, Potsdam, Germany|Dres. Helmut Forstbauer, Carsten Ziske und Kollegen; Onkologische Schwerpunktpraxis, Troisdorf, Germany|Universitätsklinik Tübingen; Frauenklinik, Tübingen, Germany|Anticancer Hospital Ag. Savas ; 2Nd Dept. of Oncology - Internal Medicine, Athens, Greece|ARETAIEION UNIVERSITY HOSPITAL; oncology unit, Athens, Greece|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|Apollo Speciality Hospital, Chennai, India|MAX Balaji Hospital, Delhi, India|Apollo Gleneagles Hospitals, Kolkata, India|Dr. B L Kapur Memorial Hospital; BLK Cancer Centre, New Delhi, India|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Rabin MC; Davidof Center - Oncology Institute, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Rambam Health Corporation; Oncology Institute, Rambam, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv Sourasky Medical Ctr; Oncology, Tel Aviv, Israel|Assaf Harofeh; Oncology, Zerifin, Israel|Fondazione Università G. D'Annunzio; Clinical Research Center (CRC); Centro Studi (CESI), Chieti, Abruzzo, Italy|Presidio Ospedaliero S. Giovanni Di Dio; U.O. Di Oncologia, Frattamaggiore, Campania, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena, Emilia-Romagna, Italy|Universita Campus Bio-Medico di Roma (UCBM), Roma, Lazio, Italy|IRCCS Istituto Regina Elena (IFO); Oncologia Medica B, Roma, Lazio, Italy|Azienda Policlinico Umberto I, Roma, Lazio, Italy|A.O. Universitaria S. Martino Di Genova, Genova, Liguria, Italy|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Lombardia, Italy|Asst Degli Spedali Civili Di Brescia, Brescia, Lombardia, Italy|Hospital San Raffaele, Milano, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy|IEO Istituto Europeo di Oncologia;Divisione Oncologia Medica, Milano, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Fondazione Del Piemonte Per L'oncologia IRCC Di Candiolo, Candiolo, Piemonte, Italy|Ospedale S. Vincenzo; Oncologia Medica, Taormina, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Sagara Hospital, Kagoshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Naha-nishi Clinic, Okinawa, Japan|Osaka International Cancer Institute, Osaka, Japan|Saitama Cancer Center, Saitama, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hématologie, Marrakech, Morocco|Institut National D'oncologie Sidi Mohammed Ben Abdellah; Anatomopathologie, Rabat, Morocco|Prof. Dr. I. Chiricuta Institute of Oncology, Cluj Napoca, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|Petrov Research Inst. of Oncology, Pesochny, Leningrad, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia|International Medical Center (IMC), Jeddah, Saudi Arabia|King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie A, Bratislava, Slovakia|POKO Poprad; Department of Oncology, Poprad, Slovakia|Wilgers Oncology Centre, Pretoria, South Africa|Private Oncology Centre, Pretoria, South Africa|Sandton Oncology Medical Group, Sandton, South Africa|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, A Coruña, LA Coruña, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Universitario de Fuenlabrada; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Adana Baskent University Medical Faculty; Oncology, Adana, Turkey|Ankara City Hospital, Ankara, Turkey|Uludag University Medical Faculty; Internal Medicine, Bursa, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Turkey|Izmir Ataturk Training and Research Hospital, Izmir, Turkey|Kocaeli University Faculty of Medicine; Medical oncology, Izmit, Turkey|Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology, Kadiköy, Turkey|Guys and St Thomas NHS Foundation Trust, Guys Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|K hospital, Hanoi, Vietnam|Hochiminh city oncology hospital, Hochiminh city, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03125902/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03125902/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03125902"
267,"NCT00929240","A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: bevacizumab [Avastin]|Drug: capecitabine [Xeloda]","Percentage of Participants With Disease Progression or Death (Maintenance Phase Data Cutoff October 4, 2013)|Progression Free Survival (Maintenance Phase Data Cutoff October 4, 2013)|Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Maintenance Phase Data Cutoff October 4, 2013)|Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Data Cutoff October 4, 2013)|Percentage of Participants Who Died (Maintenance Phase Data Cutoff October 4, 2013)|Overall Survival (Maintenance Phase Data Cutoff October 4, 2013)|Percentage of Participants Expected to Be Alive After 1 and 2 Years on Treatment (Maintenance Phase Data Cutoff October 4, 2013)|Percentage Of Participants With PD or Death Due to PD (Maintenance Phase Data Cutoff October 4, 2013)|Time To Progression (Maintenance Phase Data Cutoff October 4, 2013)|Quality of Life Assessed As Change From Baseline in Global Health Status Using The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - 30 (EORTC QLQ - C30) (Maintenance Phase Data Cutoff October 4, 2013)|Percentage of Participants With Best Overall Confirmed Objective Response of CR or PR Per RECIST 1.0 (Initial Treatment Phase)|Percentage of Participants With Clinical Benefit (CR, PR and SD) Per RECIST 1.0 (Initial Treatment Phase)","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 3","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO22223|2008-006872-31","July 2009","June 2014","June 2014","June 26, 2009","March 3, 2015","March 3, 2015","Fortaleza, CE, Brazil|Belo Horizonte, MG, Brazil|Rio de Janeiro, RJ, Brazil|Ijui, RS, Brazil|Porto Alegre, RS, Brazil|Jau, SP, Brazil|Santo Andre, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Beijing, China|Beijing, China|Beijing, China|Hangzhou, China|Hangzhou, China|Shanghai, China|Alexandria, Egypt|Cairo, Egypt|Amiens, France|Angers, France|Besancon, France|Bobigny, France|Dijon, France|Hyeres, France|Le Coudray, France|Lille, France|Paris, France|Paris, France|Perigueux, France|Rodez, France|St Priest En Jarez, France|Strasbourg, France|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Bangalore, India|Hyderabad, India|Mumbai, India|Mumbai, India|New Delhi, India|New Delhi, India|Napoli, Campania, Italy|Trieste, Friuli-Venezia Giulia, Italy|Genova, Liguria, Italy|Saronno, Lombardia, Italy|Brindisi, Puglia, Italy|Antella (FI), Toscana, Italy|Bydgoszcz, Poland|Wroclaw, Poland|Dammam, Saudi Arabia|Jeddah, Saudi Arabia|Jeddah, Saudi Arabia|Alcoy, Alicante, Spain|Sabadell, Barcelona, Barcelona, Spain|Alcazar de S. Juan, Ciudad Real, Spain|Barakaldo, Vizcaya, Spain|Jaen, Spain|Malaga, Spain|Toledo, Spain|Valencia, Spain|Ankara, Turkey|Ankara, Turkey|Antalya, Turkey|Istanbul, Turkey|Sıhhiye, ANKARA, Turkey",,"https://ClinicalTrials.gov/show/NCT00929240"
268,"NCT01764022","A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients",,"Completed","Has Results","Human Epithelial Receptor (HER)-2 Positive Breast Cancer","Drug: Trastuzumab|Drug: Paclitaxel","Overall Response Rate|Area Under the Curve After the First Test Drug Administration|Complete Response Rate|Partial Response Rate|Stabilization Rate|Progression Rate|Treatment Postponed Due to AE/SAE|Treatment Discontinuation Due to AE/SAE|Occurrence of Neutralizing Anti-trastuzumab Antibodies|Cmax After the First Test Drug Administration|Tmax After the First Test Drug Administration|T1/2 After the First Test Drug Administration|Cmax After the Sixth Test Drug Administration|Tmax After the Sixth Test Drug Administration","Biocad","Female","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCD-022-02","October 2012","March 2015","December 2017","January 9, 2013","October 24, 2016","November 29, 2018","Brest Region Clinical Oncology Dispensary, Brest, Belarus|Gomel Region Clinical Oncology Dispensary, Gomel, Belarus|Grodno Regional Hospital, Grodno, Belarus|Vitebsk State Medical University of Order of Peoples' Friendship, Vitebsk, Belarus|HCG Bangalore Institute of Oncology, Bangalore, India|M.S.Ramaiah Memorial Hospital, Bangalore, India|Narayana Hrudayalaya Hospitals, Bangalore, India|State Health Institution of Moscow ""Moscow City Oncology Hospital #62 of Moscow Board of Health"", Stepanovskoye, Moscow Region, Russian Federation|Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Non-governmental Healthcare Institution ""Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"", Chelyabinsk, Russian Federation|State-financed Health Institution ""Chelyabinsk Region Clinical Oncology Dispansary"", Chelyabinsk, Russian Federation|State-financed Health Institution ""Republican Clinical Oncology Hospital"", Izhevsk, Russian Federation|Institution of Russian Academy of Medical Sciences ""Russian Cancer Research Center named after N.N. Blokhin"", Moscow, Russian Federation|Federal State Institution ""Moscow Institute of Cancer Research named after P.A. Hertsen"" Ministry of Health of Russian Federation, Moscow, Russian Federation|Regional State Health Institution ""Orlov Oncology Dispansary"", Orel, Russian Federation|State Health Institution ""Region Oncology Dispansary"", Penza, Russian Federation|Perm Region Oncology Dispensary, Perm, Russian Federation|Federal Government Budgetary Institution ""Rostov Institute of Cancer Research"" of Ministry of Health of Russian Federation, Rostov-on-Don, Russian Federation|Saint Petersburg City Clinical Oncology Center, Saint Petersburg, Russian Federation|State-financed Health Institution ""Samara Region Clinical Oncology Dispansary"", Samara, Russian Federation|Oncology Dispensary 2, Sochi, Russian Federation|Military Medical Academy named after S.M. Kirov, St.Petersburg, Russian Federation|N.N.Petrov Oncology Research Center, St.Petersburg, Russian Federation|Russian scientific center of radiology and surgery technologies, St.Petersburg, Russian Federation|State-financed Health Institution ""Stavropol Region Clinical Oncology Dispansary"", Stavropol, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan, Ufa, Russian Federation|Volgograd District Oncology Dispensary №1, Volgograd, Russian Federation|Donetsk City Oncology Dispensary, Donetsk, Ukraine|Donetsk Regional Antitumor Center, Donetsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kryvyi Rih Oncology Dispensary, Kryvyi Rih, Ukraine|Lviv Regional State Cancer Diagnostics and Treatment Center, Lviv, Ukraine|City Hospital №2, Makiivka, Ukraine|Poltava Regional Clinical Oncology Dispensary, Poltava, Ukraine|Zakarpatskyi Regional Clinical Oncology Center, Uzhhorod, Ukraine|Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01764022"
269,"NCT01491737","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer","PERTAIN","Completed","Has Results","Breast Cancer","Drug: Pertuzumab|Drug: Trastuzumab|Drug: Aromatase Inhibitor|Drug: Induction Chemotherapy","Progression-Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Duration of Response (DOR)|Time to Response (TTR)|Change From Baseline in Health-Related Quality of Life as Determined by European Quality of Life 5-Dimension (EQ-5D) Visual Analog Scale (VAS) Scores|Overview of the Number of Participants With Adverse Events, Severity Determined According to NCI-CTCAE Version 4.03|Number of Participants Who Died Over the Course of the Study by Reported Cause of Death and Time of Death Relative to First or Last Dose of Study Treatment|Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 2","258","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO27775|2011-002132-10","February 17, 2012","March 17, 2016","November 14, 2019","December 14, 2011","June 7, 2017","October 28, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States|Ironwood Cancer TX & Rsch Ctrs, Chandler, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Comprehensive Blood & CA Ctr; Research, Bakersfield, California, United States|Rocky Mountain Cancer Center - Denver, Denver, Colorado, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Advanced Medical Specialties, Miami, Florida, United States|Georgia Cancer Specialists - Northside, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Crescent City Rsrch Cnsrtm, LLC, Marrero, Louisiana, United States|Weinberg CA Inst Franklin Sq, Baltimore, Maryland, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Washington University School of Medicine; Internal Medicine - Renal, Saint Louis, Missouri, United States|Hematology Oncology Associates; Carol G. Simon Ctr, Morristown, New Jersey, United States|Cooper Hospital; Hematology & Oncology, Voorhees, New Jersey, United States|NS-Long Island Jewish Hlth Sys, Lake Success, New York, United States|ProHEALTH Care Associates LLP, Lake Success, New York, United States|UPMC Cancer Centers, Pittsburgh, Pennsylvania, United States|Baylor College of Medicine; Lester & Sue Smith Breast Ctr, Houston, Texas, United States|Scott and White Hospital; Cancer Center, Temple, Texas, United States|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Clinique Tivoli; Sce Radiotherapie, Bordeaux, France|Hopital Morvan; Oncologie - Radiotherapie, Brest, France|Centre Jean Perrin; Oncologie, Clermont Ferrand, France|Clinique De La Sauvegarde; Chimiotherapie, Lyon, France|Centre Catherine de Sienne; Chimiotherapie, Nantes, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, France|CH De Senlis; Medecine 2, Senlis, France|Clinique Pasteur; Oncologie Medicale, Toulouse, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, France|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Bangalore Institute of Oncology, Bangalore, Karnataka, India|Jaslok Hospital & Research Centre; Medical Oncology, Mumbai, Maharashtra, India|Apollo Speciality Hospital, Chennai, India|Ruby Hall Clinic, Pune, India|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|Università degli Studi Federico II; Clinica di Oncologia Medica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Ospedale Regionale Di Parma; Divisione Di Oncologia Medica, Parma, Emilia-Romagna, Italy|A.O. Santa Maria Degli Angeli; U.O Di Oncologia Medica, Pordenone, Friuli-Venezia Giulia, Italy|Ospedale S.S. Trinità Nuovo; Divisione Oncologia, Sora, Lazio, Italy|Casa di Cura MultiMedica Ospedale di Castellanza; UO Senologia Medica, Castellanza, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|IRCCS Fondazione Maugeri; Oncologia Medica I, Pavia, Lombardia, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Ospedale Vito Fazzi; Div. Oncoematologia, Lecce, Puglia, Italy|Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica, Catania, Sicilia, Italy|A.O. Careggi; Radioterapia, Firenze, Toscana, Italy|Ospedale Misericordia E Dolce; Oncologia Medica, Prato, Toscana, Italy|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia, San Sebastian, Guipuzcoa, Spain|Hospital de Donostia; Servicio de Oncologia Medica, San Sebastian, Guipuzcoa, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Hospital de San Pedro de Alcantara, Caceres, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia, La Coruña, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia, Murcia, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Ege Uni Medical Faculty Hospital; Oncology Dept, Izmir, Turkey|Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Turkey|Brighton and Sussex Univ Hosp, Brighton, United Kingdom|University Hospital coventry; Oncology Department, Coventry, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Queen Elizabeth Hospital, London, United Kingdom|Queen Alexandra Hospital, Portsmouth, Portsmouth, United Kingdom|Scarborough General Hospital, Scarborough, United Kingdom|Weston Park Hospital; Cancer Clinical Trials Centre, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01491737"
270,"NCT04541706","Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India",,"Active, not recruiting","No Results Available","Advanced Non-Small Cell Lung Cancer","Drug: Lorlatinib","Incidence of Adverse events (AEs)|Percentage of Participants With Objective Responses based on Investigators' assessments|Percentage of Participants With Intracranial Objective Responses based on Investigators' assessments|Duration of response(DoR)|Intracranial duration of response (IC-DoR)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","111","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B7461030","August 27, 2020","July 11, 2022","July 11, 2022","September 9, 2020",,"June 21, 2021","Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|The Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India|Hemato Oncology Clinic Ahmedabad Pvt. Ltd, Ahmedabad, Gujarat, India|Artemis Hospital, Gurugram, Haryana, India|National Cancer Institute, Nagpur, Maharashtra, India|Apex Wellness Hospital, Nashik, Maharashtra, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, Maharashtra, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Bhaktivedanta Hospital and Research Institute, Thane, Maharashtra, India|Yashoda Hospital, Hyderabad, Telangana State, India|Tata Medical Center, Kolkata, WEST Bengal, India",,"https://ClinicalTrials.gov/show/NCT04541706"
271,"NCT00077857","A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: capecitabine (Xeloda®)|Drug: docetaxel (Taxotere®)","Time to Progression of Disease or Death|Percentage of Participants With Best Overall Response Being Complete Response (CR) or Partial Response (PR)|Time to Overall Response|Duration of Overall Response|Time to Treatment Failure|Overall Survival|Number of Participants With Adverse Events and Serious Adverse Events","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 2","470","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NO16853","July 2003","March 2010","March 2010","February 16, 2004","May 10, 2013","May 10, 2013","Birmingham, Alabama, United States|Hoover, Alabama, United States|Tucson, Arizona, United States|Berkeley, California, United States|Poway, California, United States|Boca Raton, Florida, United States|Fort Lauderdale, Florida, United States|Inverness, Florida, United States|Jacksonville, Florida, United States|Miami Shores, Florida, United States|Port Saint Lucie, Florida, United States|Tamarac, Florida, United States|Skokie, Illinois, United States|Urbana, Illinois, United States|Beech Grove, Indiana, United States|Des Moines, Iowa, United States|Overland Park, Kansas, United States|Houma, Louisiana, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Frederick, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Kalamazoo, Michigan, United States|Jefferson City, Missouri, United States|St Joseph, Missouri, United States|Paramus, New Jersey, United States|Summit, New Jersey, United States|Williamsville, New York, United States|Canton, Ohio, United States|Mayfield Heights, Ohio, United States|Allentown, Pennsylvania, United States|Kingston, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Collierville, Tennessee, United States|Knoxville, Tennessee, United States|Austin, Texas, United States|Houston, Texas, United States|Colchester, Vermont, United States|Abingdon, Virginia, United States|Walla Walla, Washington, United States|Mostar, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Tuzla, Bosnia and Herzegovina|Beijing, China|Beijing, China|Bengbu, China|Dalian, China|Dalian, China|Hangzhou, China|Shanghai, China|Tianjin, China|Pardubice, Czech Republic|Praha, Czech Republic|Praha, Czech Republic|Praha, Czech Republic|Tabor, Czech Republic|Ahmedabad, India|Bangalore, India|Bangalore, India|Cochin, India|Hyderabad, India|Hyderabad, India|Hyderabad, India|Jaipur, India|Kolkata, India|Ludhiana, India|Manipal, India|Mumbai, India|New Delhi, India|Trivandrum, India|Vellore, India|Poznan, Poland|Wroclaw, Poland|Chelyabinsk, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Omsk, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Yaroslavl, Russian Federation|Bloemfontein, South Africa|Durban, South Africa|Polokwane, South Africa|Bangkok, Thailand|Chiang Mai, Thailand|Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00077857"
272,"NCT00829166","A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer","EMILIA","Completed","Has Results","Breast Cancer","Drug: Trastuzumab emtansine|Drug: Lapatinib|Drug: Capecitabine","Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)|Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)|Percentage of Participants Who Died: Second Interim Analysis|Overall Survival: Second Interim Analysis (Co-primary Endpoint)|Percentage of Participants Who Died: Final Analysis|Overall Survival: Final Analysis|Percentage of Participants Who Were Alive at Year 1|Percentage of Participants Who Were Alive at Year 2|Percentage of Participants With PD or Death as Assessed by the Investigator|PFS as Assessed by the Investigator|Percentage of Participants With Objective Response (OR) as Assessed by an IRC|Duration of Objective Response (DOR) as Assessed by an IRC|Percentage of Participants With Clinical Benefit as Assessed by an IRC|Percentage of Participants With Treatment Failure|Time to Treatment Failure|Percentage of Participants With Symptom Progression|Time to Symptom Progression","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","991","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO21977|TDM4370g","February 2009","July 2012","September 2015","January 26, 2009","April 23, 2013","October 31, 2016","Chandler, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Anaheim, California, United States|Bakersfield, California, United States|Baldwin Park, California, United States|Bellflower, California, United States|Duarte, California, United States|Fontana, California, United States|Hayward, California, United States|Irvine, California, United States|La Jolla, California, United States|La Mesa, California, United States|Loma Linda, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Los Angeles, California, United States|Montebello, California, United States|Newport Beach, California, United States|Oakland, California, United States|Panorama City, California, United States|Riverside, California, United States|Roseville, California, United States|Sacramento, California, United States|San Diego, California, United States|San Diego, California, United States|San Francisco, California, United States|San Jose, California, United States|Santa Clara, California, United States|Santa Maria, California, United States|Santa Monica, California, United States|South San Francisco, California, United States|Thousand Oaks, California, United States|Vallejo, California, United States|Walnut Creek, California, United States|Woodland Hills, California, United States|Fort Collins, Colorado, United States|Norwalk, Connecticut, United States|Norwich, Connecticut, United States|Stamford, Connecticut, United States|Washington, District of Columbia, United States|Boca Raton, Florida, United States|Fernandina Beach, Florida, United States|Fort Myers, Florida, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Jacksonville, Florida, United States|Kissimmee, Florida, United States|Lakeland, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Miami, Florida, United States|Orange Park, Florida, United States|Pembroke Pines, Florida, United States|Athens, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Atlanta, Georgia, United States|Carrolton, Georgia, United States|Cartersville, Georgia, United States|Decatur, Georgia, United States|Douglasville, Georgia, United States|Macon, Georgia, United States|Marietta, Georgia, United States|Boise, Idaho, United States|Meridian, Idaho, United States|Nampa, Idaho, United States|Post Falls, Idaho, United States|Twin Falls, Idaho, United States|Chicago, Illinois, United States|Decatur, Illinois, United States|Effingham, Illinois, United States|Joliet, Illinois, United States|Morris, Illinois, United States|Peoria, Illinois, United States|Skokie, Illinois, United States|Zion, Illinois, United States|Bettendorf, Iowa, United States|Wichita, Kansas, United States|Paducah, Kentucky, United States|Covington, Louisiana, United States|Lafayette, Louisiana, United States|Marrero, Louisiana, United States|Metairie, Louisiana, United States|New Orleans, Louisiana, United States|Kittery, Maine, United States|Wells, Maine, United States|York, Maine, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Bethesda, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Peabody, Massachusetts, United States|Brownstown, Michigan, United States|Dearborn, Michigan, United States|Detroit, Michigan, United States|Detroit, Michigan, United States|Saint Joseph, Michigan, United States|West Bloomfield, Michigan, United States|Edina, Minnesota, United States|Maplewood, Minnesota, United States|Minneapolis, Minnesota, United States|Saint Louis Park, Minnesota, United States|Saint Paul, Minnesota, United States|St. Louis Park, Minnesota, United States|Joplin, Missouri, United States|Kansas City, Missouri, United States|Saint Louis, Missouri, United States|Saint Peters, Missouri, United States|St. Louis, Missouri, United States|St. Peters, Missouri, United States|Missoula, Montana, United States|Omaha, Nebraska, United States|Henderson, Nevada, United States|Cherry Hill, New Jersey, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Parsippany, New Jersey, United States|Voorhees, New Jersey, United States|Santa Fe, New Mexico, United States|Brockport, New York, United States|Canandaigua, New York, United States|Fresh Meadows, New York, United States|Geneva, New York, United States|Greece, New York, United States|Lake Success, New York, United States|Mount Kisco, New York, United States|Rochester, New York, United States|Stony Brook, New York, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Hickory, North Carolina, United States|Kinston, North Carolina, United States|Washington, North Carolina, United States|Cleveland, Ohio, United States|Cleveland, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Columbus, Ohio, United States|Middletown, Ohio, United States|Newark, Ohio, United States|Sandusky, Ohio, United States|Portland, Oregon, United States|Philadelphia, Pennsylvania, United States|Philadelphia, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|East Providence, Rhode Island, United States|Columbia, South Carolina, United States|North Charleston, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Austin, Texas, United States|Bryan, Texas, United States|Cypress, Texas, United States|Dallas, Texas, United States|El Paso, Texas, United States|Houston, Texas, United States|Shenandoah, Texas, United States|Temple, Texas, United States|Fairfax, Virginia, United States|Gig Harbor, Washington, United States|Lakewood, Washington, United States|Puyallup, Washington, United States|Tacoma, Washington, United States|Milwaukee, Wisconsin, United States|Wausau, Wisconsin, United States|Banja Luka, Bosnia and Herzegovina|Sarajewo, Bosnia and Herzegovina|Belo Horizonte, Brazil|Curitiba, Brazil|Goiania, Brazil|Itajai, Brazil|JAU, Brazil|Joao Pessoa, Brazil|Porto Alegre - Rs, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Santo Andre, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Kelowna, British Columbia, Canada|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Ottawa, Ontario, Canada|Sudbury, Ontario, Canada|Toronto, Ontario, Canada|Greenfield Park, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Bogota, Colombia|Bogota, Colombia|Monteria, Colombia|Herlev, Denmark|København, Denmark|Odense, Denmark|Helsinki, Finland|Tampere, Finland|Turku, Finland|Avignon, France|Bordeaux, France|Brest, France|Caen, France|Dijon, France|La Roche Sur Yon, France|Montpellier, France|Paris, France|Saint Brieuc, France|Saint Herblain, France|Vandoeuvre-les-nancy, France|Aschaffenburg, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bonn, Germany|Dortmund, Germany|Freiburg, Germany|Fuerstenwalde, Germany|Hamburg, Germany|Karlsruhe, Germany|Kiel, Germany|Offenbach, Germany|Stralsund, Germany|Hong Kong, Hong Kong|Bangalore, India|Gurgaon, India|Kolkata, India|New Delhi, India|Pune, India|Aviano, Italy|Bologna, Italy|Candiolo, Italy|Genova, Italy|Meldola, Italy|Milano, Italy|Milano, Italy|Napoli, Italy|Negrar, Italy|Pisa, Italy|Reggio Emilia, Italy|Roma, Italy|Rozzano, Italy|Sassari, Italy|Terni, Italy|Kyunggi-do, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Acapulco, Mexico|Oaxaca, Mexico|Toluca, Mexico|Newtown, New Zealand|Palmerston North, New Zealand|Diliman, Quezon City, Philippines|Quezon City, Luzon, Philippines|Bialystok, Poland|Gdansk, Poland|Krakow, Poland|Lublin, Poland|Opole, Poland|Poznan, Poland|Warszawa, Poland|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal|Kemerovo, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|Singapore, Singapore|Singapore, Singapore|Ljubljana, Slovenia|Barcelona, Spain|Córdoba, Spain|Lerida, Spain|Madrid, Spain|Madrid, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Gaelve, Sweden|Goteborg, Sweden|Luzern, Switzerland|St. Gallen, Switzerland|Kaohsung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bournemouth, United Kingdom|Cardiff, United Kingdom|Denbigh, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|New Castle Upon Tyne, United Kingdom|Northwood, United Kingdom|Poole, United Kingdom|Preston, United Kingdom|Romford, United Kingdom|Sutton, United Kingdom|Weston Super Mare, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00829166"
273,"NCT04942054","A Study in Patients With Advanced Breast Cancer",,"Not yet recruiting","No Results Available","HER2-negative Breast Cancer|Advanced Breast Cancer|Hormone Receptor-positive Breast Cancer","Drug: Part 1|Drug: Part 2|Drug: Part 3","Incidence of dose limiting toxicities at each dose levels (Part 1 only)|Incidence and severity of adverse events with each dose level|evaluation of Cmax (Part 1 and Part 2)|evaluation of tmax (Part 1 and Part 2)|evaluation of AUC (Part 1 and Part 2)|tumour response","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1","141","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCO-120-19-22","May 15, 2022","January 2024","January 2024","June 28, 2021",,"May 9, 2022","Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|The University of Chicago, Chicago, Illinois, United States|Michigan Center of Medical Research, Farmington Hills, Michigan, United States|Narayana Multispeciality Hospital, Ahmedabad, Gujarat, India|HealthCare Global Enterprises Ltd, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences (AIMS), Kochi, Kerala, India|Prince Aly Khan Hospital, Mumbai, Maharashtra, India|HCG Manavata cancer Centre, Nashik, Maharashtra, India|LMMF's Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Noble Hospital Pvt. Ltd.,, Pune, Maharashtra, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT04942054"
274,"NCT01134666","An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer",,"Terminated","No Results Available","Colorectal Neoplasms","Drug: Cetuximab","Safety and tolerability evaluated based on the incidence and severity of AEs.|Response rate","Merck KGaA, Darmstadt, Germany|Merck Ltd., India","All","Child, Adult, Older Adult",,"165","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR 062202-517","November 30, 2009","July 31, 2013","August 5, 2014","June 2, 2010",,"June 9, 2017","Indo- American Cancer Institute & Research Centre, Hyderabad, Andhra Pradesh, India|NVS Ramakrishna's Clinic, Hyderabad, Andhra Pradesh, India|Dr. Nikhil's Clinic, Secunderabad, Andhra Pradesh, India|Nikhil Gharyalpatil's Clinic, Secunderabad, Andhra Pradesh, India|Ravi Kumar's Clinic, Hyderabad, Andrapradesh, India|Ambaa Hospitals, Hyderabad, Andrapradesh, India|Swarna Sai Hospital, Hyderabad, Andrapradesh, India|Manipal Centre For Clinical Research, Mangalore, Bangalore, India|Medical College Calicut, Kerala, Calicut, India|Hemato Oncology Clinic, Ahmedabad, Gujarat, India|Kattimani Oncology Clinic, Hubli, Karnataka, India|SKIMS, Srinagar, Kashmir, India|S. K. I. M. S., Srinagar, Kashmir, India|Dr. T. P. Sahoo's Clinic, Bhopal, Madhya Pradesh, India|BND Onco Centre, Mumbai, Maharashtra, India|Joy Hospital, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Grace Nursing Home, Aizwal, Mizoram, India|Lilavati Hospital, Bandra, Mumbai, India|S.L.Raheja Hospital, Mahim, Mumbai, India|Apollo Cancer Institute, Delhi, New Delhi, India|Rajiv Gandhi Cancer Institute & Research, Delhi, New Delhi, India|Fortis Escorts Hospital, Amritsar, Punjab, India|Dr. Rajeev Bedi's Clinic, Chandigarh, Punjab, India|D.M.C Hospital, Ludhiana, Punjab, India|IVY Hospital, Mohali, Punjab, India|Cancer Clinic, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Bhagwan Mahaveer Cancer Hospital, Jaipur, Rajasthan, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, Rajasthan, India|Vyas Cancer Care, Jodhpur, Rajasthan, India|TC 14/ 764 Sreemangalam, Trivandrum, Tamilnadu, India|Shati Gopal Hospital, Ghaziabad, Uttar Pradesh, India|Annapurna Medical and Cancer Relief Society, Lucknow, Uttar Pradesh, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|Apollo Gleneagles Cancer Hospital, Kolkata, West Bengal, India|Nothern Railway Central Hospital, Delhi, India|Indraprastha Apollo Hospital, Delhi, India|Shanti Mukand Hospital, Delhi, India|Dharamshila Cancer Hospital & Research Centre, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01134666"
275,"NCT00191854","Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line",,"Completed","Has Results","Breast Cancer","Drug: gemcitabine|Drug: paclitaxel|Drug: carboplatin|Drug: cisplatin","Best Overall Response|Number of Participants With a Time to Treatment Failure (TTTF) Event|Progression Free Survival (PFS)|Duration of Response|Overall Survival","Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 2","147","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7451|B9E-AA-S355","March 2005","August 2008","November 2009","September 19, 2005","August 31, 2009","March 2, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santo André, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nan Jing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludhiana, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cuernavaca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villahermosa, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antalya, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT00191854"
276,"NCT04493853","Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency","CAPItello-281","Recruiting","No Results Available","Hormone-Sensitive Prostate Cancer","Drug: Capivasertib|Other: Placebo|Drug: Abiraterone Acetate","Radiographic Progression-free Survival (rPFS)|Overall survival (OS)|Time to Start of First Subsequent Therapy or Death (TFST)|Symptomatic Skeletal Event-Free Survival (SSE-FS)|Time to Pain Progression (TTPP)|Time to PSA progression|Time To Castration Resistance (TTCR)|Fatigue intensity, severity and interference domains assessed by the Brief Fatigue Inventory (BFI)|Overall Pain Severity and Pain Interference as assessed by BPI-SF questionnaire|Disease-Related Symptoms and HRQoL using the Functional Assessment of Cancer Therapy - Prostate Cancer (FACT-P) questionnaire|Progression-Free Survival after next-line treatment (PFS2)|Plasma concentration of capivasertib pre-dose|Plasma concentration of capivasertib 1h post-dose|Plasma concentration of capivasertib 4h post-dose","AstraZeneca","Male","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D361BC00001","July 13, 2020","November 11, 2024","November 11, 2025","July 30, 2020",,"May 16, 2022","Research Site, Anchorage, Alaska, United States|Research Site, Anchorage, Alaska, United States|Research Site, Tucson, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, San Diego, California, United States|Research Site, Denver, Colorado, United States|Research Site, Lakewood, Colorado, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pensacola, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Geneva, Illinois, United States|Research Site, Lisle, Illinois, United States|Research Site, Iowa City, Iowa, United States|Research Site, Fairway, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Troy, Michigan, United States|Research Site, Bozeman, Montana, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Englewood, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, Rochester, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Asheville, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Charleston, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Norfolk, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States|Research Site, Berazategui, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, La Plata, Argentina|Research Site, Mendoza, Argentina|Research Site, Rosario, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Birtinya, Australia|Research Site, Darlinghurst, Australia|Research Site, Kingswood, Australia|Research Site, Orange, Australia|Research Site, Richmond, Australia|Research Site, South Brisbane, Australia|Research Site, Wollongong, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Anderlecht, Belgium|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Kortrijk, Belgium|Research Site, Liège, Belgium|Research Site, Wilrijk, Belgium|Research Site, Barretos, Brazil|Research Site, Belem, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Joinville, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Abbotsford, British Columbia, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, CA, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Chicoutimi, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, He Fei, China|Research Site, Jinan, China|Research Site, Kunming, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shengyang, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Yantai, China|Research Site, Zhengzhou City, China|Research Site, Zhengzhou, China|Research Site, Brno, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kromeriz, Czechia|Research Site, Nachod, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Praha, Czechia|Research Site, Besançon Cedex, France|Research Site, Bordeaux, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Paris Cedex 14, France|Research Site, Pierre Benite, France|Research Site, Quimper Cedex, France|Research Site, Rennes Cedex 9, France|Research Site, Strasbourg, France|Research Site, Suresnes, France|Research Site, Villejuif Cedex, France|Research Site, Berlin, Germany|Research Site, Duisburg, Germany|Research Site, Emmendingen, Germany|Research Site, Hamburg, Germany|Research Site, Herne, Germany|Research Site, Mettmann, Germany|Research Site, Münster, Germany|Research Site, Nürnberg, Germany|Research Site, Nürtingen, Germany|Research Site, Wesel, Germany|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Lai Chi Kok, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szolnok, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chandigarh, India|Research Site, Faridabad, India|Research Site, Gurgaon, India|Research Site, Kanpur, India|Research Site, Kochi, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Manipal, India|Research Site, Meerut, India|Research Site, Mohali, India|Research Site, Mumbai, India|Research Site, Nagpur, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Rohini, India|Research Site, Thiruvananthapuram, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Zerifin, Israel|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kashihara-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Kawagoe-shi, Japan|Research Site, Kisarazu-shi, Japan|Research Site, Kita-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Miyazaki-city, Japan|Research Site, Morioka-shi, Japan|Research Site, Nagakute-shi, Japan|Research Site, Nagano-shi,, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Omihachiman-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Ota Shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Toon-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokosuka-shi, Japan|Research Site, Yufu-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Monterrey, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Puebla, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Hilversum, Netherlands|Research Site, Roosendaal, Netherlands|Research Site, Sittard-Geleen, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Baguio City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Bialystok, Poland|Research Site, Biała Podlaska, Poland|Research Site, Bielsko-Biała, Poland|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Koszalin, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Opole, Poland|Research Site, Poznań, Poland|Research Site, Rzeszow, Poland|Research Site, Słupsk, Poland|Research Site, Toruń, Poland|Research Site, Toruń, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novisibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Sala, Slovakia|Research Site, Trencin, Slovakia|Research Site, Amanzimtoti, South Africa|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Kraaifontein, South Africa|Research Site, Parow, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona (Barcelona), Spain|Research Site, Barcelona, Spain|Research Site, Las Palmas de Gran Canaria, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Lampang, Thailand|Research Site, Muang, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Eskisehir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Cambridge, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle Upon Tyne, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Whitchurch, United Kingdom|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04493853"
277,"NCT03017885","Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy",,"Recruiting","No Results Available","Non-small Cell Lung Cancer",,"Incidence of all Adverse Drug Reactions (ADRs) in nintedanib & docetaxel treated patients|Incidence of all Serious Adverse Events (SAEs) in nintedanib & docetaxel treated patients|Percentage of patients who require nintedanib dose reductions and discontinuations due to adverse events.","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","1199-0272","February 28, 2017","October 8, 2022","October 8, 2022","January 11, 2017",,"May 4, 2022","Zydus Hospitals and Healthcare Research Pvt. Ltd, Anand, India|Narayana Hrudyalaya, Bangalore, India|Manipal Hospitals, Bengaluru, India|HCG Hospital, Bengaluru, India|Sparsh Hospitals and Critical Care, Bhubaneshwar, India|Action Cancer Hospital, Delhi, Delhi, India|Apollo Health City Hospital, Hyderabad, India|Yashoda Hospitals, Hyderabad, India|Chittaranjan National Cancer Institute, Kolkata, India|Kasturba Medical College and Hospital, Mangalore, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India|SRM Institute of Medical Science, Vadapalani, India",,"https://ClinicalTrials.gov/show/NCT03017885"
278,"NCT01001377","ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cetuximab|Drug: Panitumumab","Overall Survival|Progression-free Survival|Objective Response|Duration of Response|Time to Response|Time to Treatment Failure|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score|Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Visual Analog Scale (VAS)|Change From Baseline in National Comprehensive Cancer Network Functional Assessment of Cancer Therapy Colorectal Symptom Index (NCCN FCSI ) Symptoms Score|Change From Baseline in NCCN FCSI Physical Well-being Scale Score|Change From Baseline in NCCN FCSI Functional Well-being Scale Score|Number of Participants With Adverse Events (AEs)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","1010","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20080763|ASPECCT|2009-010715-32","February 2, 2010","February 5, 2013","March 7, 2017","October 26, 2009","March 24, 2014","December 26, 2018","Research Site, Stockton, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Wichita, Kansas, United States|Research Site, Temple, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Liverpool, New South Wales, Australia|Research Site, St Leonards, New South Wales, Australia|Research Site, Wahroonga, New South Wales, Australia|Research Site, Wollongong, New South Wales, Australia|Research Site, Woodville South, South Australia, Australia|Research Site, Ballarat, Victoria, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Epping, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Heidelberg, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Edegem, Belgium|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Harbin, Heilongjiang, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, XI An, Shaanxi, China|Research Site, Shanghai, Shanghai, China|Research Site, Chengdu, Sichuan, China|Research Site, Chongqing, Sichuan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Horovice, Czechia|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Pribram, Czechia|Research Site, Znojmo, Czechia|Research Site, Besançon Cedex, France|Research Site, Montbéliard, France|Research Site, Saint Brieuc, France|Research Site, Saint Herblain, France|Research Site, Villejuif cedex, France|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Kochi, Kerala, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Beer Sheva, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovot, Israel|Research Site, Ancona, Italy|Research Site, Cesena, Italy|Research Site, Cremona, Italy|Research Site, Faenza RA, Italy|Research Site, Genova, Italy|Research Site, Lugo, Italy|Research Site, Meldola FC, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Torino, Italy|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Rotterdam, Netherlands|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Elblag, Poland|Research Site, Gdansk, Poland|Research Site, Jelenia Gora, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Bucharest, Romania|Research Site, Sibiu, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bardejov, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Nitra, Slovakia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kraaifontein, Western Cape, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Växjö, Sweden|Research Site, Putzu City, Chiayi, Taiwan|Research Site, Keelung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Belfast, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01001377"
279,"NCT04801186","Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer","REMPRO","Recruiting","No Results Available","Metastatic Castration-resistant Prostates Cancer",,"Describe the real-world treatment patterns in patients with mCRPC|Demographic and clinico-pathological profile|Survival outcomes associated with different treatment regimens used for mCRPC|Assess the real-world effectiveness|BRCA1/2 and HRRm status","AstraZeneca","Male","18 Years and older   (Adult, Older Adult)",,"1920","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D0817R00037","September 28, 2021","June 30, 2022","June 30, 2022","March 16, 2021",,"April 25, 2022","Research Site, Melbourne, Australia|Research Site, Bogota, Colombia|Research Site, Raml Station, Alexandria, Egypt|Research Site, Ramsis, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Faridabad, Haryana, India|Research Site, Bangalore, Karnataka, India|Research Site, Srinagar, Kashmir, India|Research Site, Mumbai, Maharashtra, India|Research Site, Bhubhaneshwar, Odisha, India|Research Site, Hyderabad, Telangana, India|Research Site, Kolkata, West Bengal, India|Research Site, Delhi, India|Research Site, Goyang-si, Gyeonggi, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi, Korea, Republic of|Research Site, Gangnam-gu, Seoul, Korea, Republic of|Research Site, Jongno-gu, Seoul, Korea, Republic of|Research Site, Seocho-gu, Seoul, Korea, Republic of|Research Site, Seodaemun-gu, Seoul, Korea, Republic of|Research Site, Kuwait, Kuwait|Research Site, Lima, Peru|Research Site, Doha, Qatar|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Istanbul, Turkey|Research Site, Abu Dhabi, United Arab Emirates|Research Site, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT04801186"
280,"NCT04873362","A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","Astefania","Recruiting","No Results Available","Breast Cancer","Drug: Atezolizumab|Drug: Trastuzumab Emtansine|Drug: Placebo|Drug: Trastuzumab","Invasive Disease-free Survival (IDFS)|IDFS Including Second Primary Non-breast Invasive Cancer|Disease-free Survival (DFS)|Overall Survival (OS)|Distant Recurrence-free Interval (DRFI)|Number of Participants with Clinically Meaningful Deterioration in Global Health Status/Quality of Life (GHS/QoL) Physical, Role, and Cognitive Function|Mean Absolute Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30|Mean Change From Baseline Scores in GHS/QoL, Physical, Role, and Cognitive Function, as Assessed Using the EORTC QLQ-C30|Percentage of Participants with Adverse Events (AEs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE v5.0)|Maximum Serum Concentrations (Cmax) for Atezolizumab|Cmax for Trastuzumab Emtansine|Cmax for Total Trastuzumab|Cmax for DM1|Minimum Serum Concentrations (Cmin) for Atezolizumab|Percentage of Participants with Anti-drug Antibodies (ADAs) to Atezolizumab|Percentage of Participants with ADAs to Trastuzumab Emtansine","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","1700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WO42633|2020-003681-40","May 4, 2021","December 18, 2025","October 26, 2034","May 5, 2021",,"May 10, 2022","Alabama Oncology, Alabaster, Alabama, United States|Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Burbank, California, United States|California Cancer Associate for Research & Excellence, Fresno, California, United States|Glendale Adventist Medical Ctr, Glendale, California, United States|UCLA Medical Center, Santa Monica, California, United States|Innovation Clinical Research Institute, Whittier, California, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|University Cancer & Blood Center, LLC; Research, Athens, Georgia, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Carrollton, Georgia, United States|Elmhurst Memorial Healthcare, Elmhurst, Illinois, United States|Edward Cancer Center Naperville, Naperville, Illinois, United States|Edward Cancer Center Plainfield, Plainfield, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Pontchartrain Cancer Center, Covington, Louisiana, United States|New England Cancer Specialists, Scarborough, Maine, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Henry Ford Health System; Dept of Transplantation Surgery, Detroit, Michigan, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|Central Care Cancer Center; NC, Bolivar, Missouri, United States|MD Anderson Cancer Center at Cooper, Camden, New Jersey, United States|The Valley Hospital, Paramus, New Jersey, United States|Cooper Cancer Institute, Voorhees, New Jersey, United States|Mount Sinai Medical Center, New York, New York, United States|Great Lakes Cancer Center, Williamsville, New York, United States|Messino Cancer Centers, Asheville, North Carolina, United States|Providence Health & Services - Oregon, Portland, Oregon, United States|Abramson Cancer Center; Univ of Pennsylvania; Clinical Research Unit, Philadelphia, Pennsylvania, United States|Lankenau Hospital, Wynnewood, Pennsylvania, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|SCRI Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|The West Clinic; West Cancer Center, Germantown, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Tennessee Oncology; Sarah Cannon Research Institute, Nashville, Tennessee, United States|Joe Arrington Cancer Research & Treatment Center, Lubbock, Texas, United States|Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg, Virginia, United States|Virginia Oncology Associates - New Port News, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Oncology Associates - Virginia Beach, Virginia Beach, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Kadlec Regional Medical Center, Kennewick, Washington, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Kinghorn Cancer Centre; St Vincents Hospital, Darlinghurst, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Princess Alexandra Hospital; Cancer Trials Unit, Woolloongabba, Queensland, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - Hämato-Onkologie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|AKH - Medizinische Universität Wien; Department of Oncology, Vienna, Austria|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|Clinique St. Elizabeth, Namur, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|KOC Plovdiv; First Medical Oncology Department, Plovdiv, Bulgaria|Medical Center ""Nadezhda Clinical"" EOOD; Medical Oncology Department, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria|Sichuan Cancer Hospital, Chengdu City, China|West China Hospital - Sichuan University, Chengdu City, China|Chongqing Cancer Hospital, Chongqing, China|The First Affilicated Hospital, Sun Yat-sen University, Guangzhou City, China|Guangdong Provincial People's Hospital; Breast, Guangzhou City, China|Sun Yat-sen Memorial Hospital, Guangzhou, China|Harbin Medical University Cancer Hospital, Harbin, China|Zhongshan Hospital Fudan University, Shanghai, China|Tianjin Medical University Cancer Institute & Hospital, Tianjing, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Zhejiang Cancer Hospital, Zhejiang, China|Henan Cancer Hospital, Zhengzhou, China|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni Nemocnice Hradec Kralove; Dept of Radiotherapy & Oncology, Hradec Kralove, Czechia|Nemocnice AGEL Novy Jicin a.s.; Oddeleni radioterapie a onkologie, Novy Jicin, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Fakultni Poliklinika Vseobecne Fakultni Niemocnice; Onkologicka Klinika, Praha 2, Czechia|Thomayerova nemocnice; Onkologicka klinika 1. LF UK A TN, Praha 4 - Krc, Czechia|Fakultni nemocnice v Motole; Onkologicka klinika 2. LF UK a FN Motol, Praha 5, Czechia|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Vejle Sygehus; Onkologisk Afdeling, Vejle, Denmark|Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Hopital Morvan, Brest, France|Centre Francois Baclesse; Comite Sein, Caen, France|Groupe Hospitalier Public Du Sud De L'Oise GHPSO; Oncologie, Creil Cedex 1, France|CLCC Leon Berard Lyon, Lyon, France|Centre Hospitalier Uni Ire Caremeau; Radiotherapie & Oncologie, Nimes, France|Groupe Hospitalier Diaconesses, Paris, France|Institut Curie; Oncologie Medicale, Paris, France|Pole Regional De Cancerologie, Poitiers, France|HOPITAL RENE HUGUENIN, Institut Curie; Service d'Oncologie Médicale., Saint-Cloud, France|Klinikum Augsburg; Frauenklinik, Augsburg, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie Dr. Reichert/Dr.Janssen, Aurich, Germany|Hochtaunus-Kliniken gGmbH; Krankenhaus Bad Homburg; Frauenklinik, Bad Homburg vdH, Germany|Hochwaldkrankenhaus; Abt.Gynäkologie Geburtshilfe u.Senologie, Bad Nauheim, Germany|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Vivantes Klinikum Am Urban; Zentrum für Brusterkrankungen, Berlin, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Frauenarztpraxis Dr. Apel, Dr. Kolpin, Erfurt, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany|AGAPLESION Markus-Krankenhaus, Frankfurt, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe, Frankfurt, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Germany|St. Barbara-Klinik Hamm-Heessen GmbH; Frauenklinik, Hamm, Germany|Diakovere Henriettenstift, Frauenklinik, Hannover, Germany|Städtisches Klinikum Karlsruhe gGmbH; Frauenklinik, Karlsruhe, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany|Universitätsklinikum Leipzig; Klinik und Poliklinik für Frauenheilkunde, Leipzig, Germany|Städtische Klinik Lüneburg; Frauenklinik, Lüneburg, Germany|Klinik & Poliklinik für Frauenheilkunde und Geburtshilfe, Campus Innenstadt, München, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, Germany|Klinikum Ernst von Bergmann; Frauenklinik, Potsdam, Germany|Leopoldina Krankenhaus der Stadt Schweinfurt GmbH, Schweinfurt, Germany|Johanniter-Krankenhaus Genthin-Stendal; Klinik Für Frauenheilkunde & Geburtshilfe, Stendal, Germany|Metropolitan General Hospital, Cholargos, Greece|University General Hospital of Heraklion, Crete, Greece|University Hospital of Larissa;Department of Medical Oncology, Larissa, Greece|Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Surgery, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital; Clinical Oncology, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Oncology, Hong Kong, Hong Kong|Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Oncology department, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont ; Department of Oncology, Debrecen, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, Delhi, India|Max Super Speciality Hospital; Medical Oncology, North WEST Delhi, Delhi, India|Hemato Oncology Clinic Ahmedabad Pvt Ltd, Ahmadabad, Gujarat, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|Christian Med Clg & Hspt, Vellore, India|AORN'S.G.Moscati; Oncologia, Avellino, Campania, Italy|U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Università degli Studi Federico II; Clinica di Oncologia Medica, Napoli, Campania, Italy|Policlinico S.Orsola-Malpighi; Istituto Oncologia R. Addarii, Bologna, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO), Aviano, Friuli-Venezia Giulia, Italy|ASU FC S. M. DELLA MISERICORDIA; Oncologia, Udine, Friuli-Venezia Giulia, Italy|Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|Ospedale San Raffaele; Medical Oncology, Milano, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1, Milano, Lombardia, Italy|Ospedale Civile - Livorno, Livorno, Toscana, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|University of Eastern Piedmont - Maggiore della Carità University Hospital, Novara, Umbria, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo LEON, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca de Juárez, Oaxaca, Mexico|Instituto Nacional De Cancerologia; Oncology; Tumores Mamarios, Distrito Federal, Mexico|Auckland City Hospital, Cancer and Blood Research, Auckland, New Zealand|Tauranga Hospital, Clinical Trials Unit; BOP Clinical School, Tauranga, New Zealand|Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej, Bialystok, Poland|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Narodowy Instytut Onkologii Odział w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, Poland|Wielkopolskie Centrum Onkologii; Oddzial Chemioterapii, Poznan, Poland|Centrum Onkologii Instytut im.M. Sklodowskiej-Curie; Klin. Nowot. Piersii i Chirurgii Rekonstruk, Warszawa, Poland|Hospital CUF Tejo; Oncologia Médica e Hematologia, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Filantropia Clinical Hospital; Medical oncology, Bucuresti, Romania|Prof.dr. Alexandru Trestioreanu, The Oncology Institute; Medical oncology I, Bucuresti, Romania|Amethyst Cluj; Medical Oncology, Cluj County, Romania|Cluj-Napoca Emergency Clinical County Hospital; Medical Oncology, Cluj-Napoca, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Radioterapie I - Oncologie, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center; Medical oncology, Craiova, Romania|Oncomed SRL, Timisoara, Romania|Republican Clinical Oncological Dispensary of the Ministry of Healthcare; Chemotherapy department, Kazan, Karelija, Russian Federation|FSBI""National Medical Research Center of Oncology named after N.N.Petrov"" MHRF, St Petersburg, Leningrad, Russian Federation|MEDSI Clinical Hospital on Pyatnitsky Highway; Department of antitumor drug therapy, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, Niznij Novgorod, Russian Federation|Medical Clinic ""AB Medical group"", Saint Petersburg, Sankt Petersburg, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, Russian Federation|Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky; Chemotherapy, Krasnoyarsk, Russian Federation|Oncology Dispensary#1; Out-Patient Oncology Dept, Moscow, Russian Federation|FSBI Russian Oncology Research Center n.a. Blokhin of MOH RF, Moscow, Russian Federation|LLC Medical and Sanitary Unit ""Clinician"", Novosibirsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|SBI of Healthcare Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|SBI of Healthcare Leningrad Regional Oncology Dispensary, St Petersburg, Russian Federation|Regional Oncology Dispensary, Tomsk, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|National Cancer Centre; Medical Oncology, Singapore, Singapore|Hospital General Universitario de Elche; Servicio de Oncologia, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, A Coruña, LA Coruña, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Quiron de Madrid; Servicio de Oncologia, Pozuelo de Alarcon, Madrid, Spain|Hospital Alvaro Cunqueiro; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Clinic Barcelona; Servicio de oncologia, Barcelona, Spain|Hospital Universitario Clínico San Cecilio; Servicio de oncologia, Granada, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Hospital Universitario Dr. Peset; Servicio de Oncologia, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|China Medical University Hospital; Surgery, Taichung, Taiwan|National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan, Taiwan|National Taiwan University Hospital ; Dept of Surgery & Hepatitis Research Center, Taipei 100, Taiwan|Taipei Veterans General Hospital; Department of Clinical Trial Pharmacy, Taipei, Taiwan|Mackay Memorial Hospital; Dept of Surgery, Taipei, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Srinagarind Hospital; Department of Surgery, Khon Kaen, Thailand|Songklanagarind Hospital; Department of Surgery, Songkla, Thailand|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Antalya Training and Research Hospital ; Oncology Department, Antalya, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, İ̇zmi̇r, Turkey|Dicle University Faculty of Medicine, Diyarbakir, Turkey|Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi, Edirne, Turkey|Istanbul Faculty of Medicine, Istanbul, Turkey|Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Medeniyet University Goztepe Training and Research Hospital., Kadiköy, Turkey|Inonu University Medical Faculty of Medicine; Medical Oncology Department, Malatya, Turkey|Acıbadem Altunizade Hastanesi; Oncology, Üsküdar, Turkey|Uzhgorod Central City Clinical Hospital, Uzhhorod, Katerynoslav Governorate, Ukraine|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, Ukraine|Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Disp, Sumy, Kholm Governorate, Ukraine|MI ""Clinical Oncological Dispensary"" of Dnipro Reg Council; chemotherapy department, Dnipro, KIEV Governorate, Ukraine|Innovacia Cancer Center, Liutizh, KIEV Governorate, Ukraine|CI Dnipropetrovsk CMCH #4 of Dnipropetrovsk RC SI Dnipropetrovsk MA of MOHU Ch of Oncology and MR, Dnipropetrovsk, Ukraine|Municipal Institution Kirovograd Regional Oncology Dispensary, Kirovograd, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Belfast City Hospital, Belfast, United Kingdom|Blackpool Victoria Hospital, Blackpool, United Kingdom|Bradford Royal Infirmary; Oncology Department, Bradford, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Velindre Cancer Centre; Clinical Trials Unit, Cardiff, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall, United Kingdom|Raigmore Hospital, Inverness, United Kingdom|Barts & London School of Med; Medical Oncology, London, United Kingdom|University College London Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Royal Preston Hospital, Preston, United Kingdom|Glan Clywd Hospital, Rhyl, United Kingdom|Royal Marsden Hospital - Surrey, Surrey, United Kingdom|Walsall Manor Hospital, Walsall, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04873362"
281,"NCT02278120","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer","MONALEESA-7","Active, not recruiting","Has Results","Advanced Metastatic Breast Cancer","Drug: LEE011|Drug: Tamoxifen|Drug: Letrozole|Drug: Anastrozole|Drug: Goserelin|Drug: LEE011 Placebo","Progression Free Survival (PFS) Per Investigator's Assessment|Overall Survival (OS)|Overall Response Rate (ORR) Per Local Assessment|Clinical Benefit Rate (CBR)|Safety and Tolerability of LEE011|Time to Response (TTR) Per Local Investigator's Assessment|Duration of Response (DOR) Per Investigator's Assessment - Patients With Confirmed Complete Response (CR) or Partial Response (PR)|Time to Definitive Deterioration of the ECOG PS From Baseline|Time to 10% Deterioration in the Global Health Status/QOL Scale Score of the EORTC QLQ-C30|Change From Baseline in the Global Health Status/QOL Scale Score of the EORTC QLQ-C30","Novartis Pharmaceuticals|Novartis","Female","18 Years to 59 Years   (Adult)","Phase 3","672","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLEE011E2301|2014-001931-36","November 20, 2014","August 21, 2017","June 30, 2022","October 29, 2014","February 26, 2019","February 18, 2022","Comprehensive Blood and Cancer Center SC-2, Bakersfield, California, United States|University of California at Los Angeles Dept of Onc, Los Angeles, California, United States|Comprehensive Cancer Center at Saint Joseph Hospital SC, Denver, Colorado, United States|Danbury Hospital SC, Danbury, Connecticut, United States|Florida Cancer Specialists Onc Dept, Fort Myers, Florida, United States|Florida Cancer Specialists SC-2, Fort Myers, Florida, United States|Memorial Cancer Institute SC, Hollywood, Florida, United States|University of Miami Univ Miami 2, Miami, Florida, United States|NorthWest Georgia Oncology Centers NW Georgia Oncology, Marietta, Georgia, United States|Moanalua Medical Center. Attn: Oncology Dept SC, Honolulu, Hawaii, United States|University of Chicago SC-3, Chicago, Illinois, United States|Norton Cancer Institute SC, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Dept of Onc., Baltimore, Maryland, United States|Massachusetts General Hospital Onc Dept, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center Onc Dept, Ann Arbor, Michigan, United States|Washington University School of Medicine SC, Saint Louis, Missouri, United States|Meridian Health Systems SC, Neptune, New Jersey, United States|University of New Mexico Hospital SC-2, Albuquerque, New Mexico, United States|Clinical Research Alliance, Lake Success, New York, United States|Duke University Medical Center Duke (SC), Durham, North Carolina, United States|Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Bon Secours Cancer Center SC, Greenville, South Carolina, United States|Erlanger Medical Center SC, Chattanooga, Tennessee, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders SC, Fort Worth, Texas, United States|Methodist Hospital / Methodist Cancer Center Dept of Oncology, Houston, Texas, United States|University of Texas MD Anderson Cancer Center SC-5, Houston, Texas, United States|Cancer Therapy and Research Center UT Health Science Center SC-4, San Antonio, Texas, United States|Brooke Army Medical Center SC, San Antonio, Texas, United States|Northern Utah Cancer Associates, Ogden, Utah, United States|Bon Secours Virginia Health System, Midlothian, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Kadlec Clinic Hematology and Oncology Kadlec Clinic Hematology & Onc, Kennewick, Washington, United States|Northwest Medical Specialties Dept of Onc, Tacoma, Washington, United States|University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 3, Madison, Wisconsin, United States|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Jujuy, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Ijuí, RS, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Strasbourg Cedex, Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Esslingen, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Offenbach, Germany|Novartis Investigative Site, Ravensburg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Kolkatta, West Bengal, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Lecce, LE, Italy|Novartis Investigative Site, Lucca, LU, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, El Chouf, LBN, Lebanon|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Johor Bahru, Johor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Metepec, Edo. De México, Mexico|Novartis Investigative Site, Leon, Guanajuato, Mexico|Novartis Investigative Site, Monterrey Nuevo Leon, Monterrey, Mexico|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Sant Joan Despi, Barcelona, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Alcorcon, Madrid, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Baracaldo, Vizcaya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, New Taipei City, TWN, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Diyarbakir, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Al Ain Abu Dhabi, United Arab Emirates","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02278120/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02278120/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02278120"
282,"NCT00022672","A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer",,"Completed","Has Results","Breast Cancer","Drug: trastuzumab (Herceptin®)|Drug: anastrazole (Arimidex®)","Progression Free Survival (PFS)|Percentage of Participants With Clinical Benefit|Duration of Response at 24 Months|Time to Response at 24 Months|Overall Survival at 24 Months|Percentage of Participants With Two-Year Survival|Percentage of Participants With Overall Tumor Response at 24 Months|Percentage of Participants With Best Tumor Response at 24 Months|Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status at Final Visit Compared to Baseline|Duration of Response at End of Study|Time to Response at End of Study|Percentage of Participants With Overall Tumor Response at End of Study|Percentage of Participants With Best Tumor Response at End of Study|Number of Participants With Adverse Events","Hoffmann-La Roche|Genentech, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO16216","January 2001","October 2009","October 2009","January 27, 2003","June 13, 2013","June 13, 2013","Phoenix, Arizona, United States|Little Rock, Arkansas, United States|Los Angeles, California, United States|Vallejo, California, United States|Gainsville, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Chicago, Illinois, United States|Chicago, Illinois, United States|Kansas City, Kansas, United States|Scarborough, Maine, United States|Detroit, Michigan, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Albuquerque, New Mexico, United States|Santa Fe, New Mexico, United States|Rochester, New York, United States|Cincinnati, Ohio, United States|Cleveland, Ohio, United States|Hershey, Pennsylvania, United States|Box Hill, Australia|Darlinghurst, Australia|Waratah, Australia|Porto Alegre, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Stara Zagora, Bulgaria|Calgary, Alberta, Canada|Edmonton, Alberta, Canada|Victoria, British Columbia, Canada|Winnipeg, Manitoba, Canada|Oshawa, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Beijing, China|Beijing, China|Shanghai, China|Shanghai, China|Wuhan, China|Avignon, France|Nice, France|Frankfurt, Germany|Kiel, Germany|München, Germany|Trier, Germany|Hong Kong, Hong Kong|Budapest, Hungary|Ahmedabad, India|Bangalore, India|Chennai, India|Cuttack, India|Ludhiana, India|Mumbai, India|New Delhi, India|New Delhi, India|New Delhi, India|Haifa, Israel|Haifa, Israel|Petach Tikva, Israel|Ramat-gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Genova, Italy|Vilnius, Lithuania|Guadalajara, Mexico|Mexico City, Mexico|Amsterdam, Netherlands|Rotterdam, Netherlands|Trondheim, Norway|Bialystok, Poland|Bydgoszcz, Poland|Gliwice, Poland|Krakow, Poland|Lodz, Poland|Szczecin, Poland|Warszawa, Poland|Warszawa, Poland|Barnaul, Russian Federation|Izhevsk, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|UFA, Russian Federation|Floracliffe, South Africa|Pretoria, South Africa|Barcelona, Spain|Córdoba, Spain|Girona, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Mataro, Spain|Reus, Spain|Valencia, Spain|Boras, Sweden|Gaelve, Sweden|Stockholm, Sweden|Örebro, Sweden|Taipei, Taiwan|Taoyuan, Taiwan|Ankara, Turkey|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Shhiye, Ankara, Turkey|Kiev, Ukraine|Kiev, Ukraine|Lvov, Ukraine|Odessa, Ukraine|Sumy, Ukraine|Zaporozhye, Ukraine|Cardiff, United Kingdom|Edinburgh, United Kingdom|Guildford, United Kingdom|Ipswich, United Kingdom|London, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Merseyside, United Kingdom|Newcastle Upon Tyne, United Kingdom|Southampton, United Kingdom|Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00022672"
283,"NCT01151215","Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer","MINT","Terminated","Has Results","Neoplasms|Breast Neoplasms|Breast Cancer","Drug: AZD8931|Drug: anastrozole|Drug: Placebo","Progression Free Survival as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1|Compare the Overall Survival in Patients Treated With AZD8931 in Combination With Anastrozole Versus Anastrozole Alone","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 2","482","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D0102C00004","June 2010","January 2013","January 2013","June 28, 2010","May 8, 2014","July 25, 2014","Research Site, Lake Success, New York, United States|Research Site, Belo Horizonte, Brazil|Research Site, Goiânia, Brazil|Research Site, Ijuí, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 4, Czech Republic|Research Site, Helsinki, Finland|Research Site, Tampere, Finland|Research Site, Turku, Finland|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Mumbai, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Vellore, India|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Durango, Mexico|Research Site, Juchitan, Mexico|Research Site, Merida, Mexico|Research Site, Monterrey, Mexico|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Piura, Peru|Research Site, Iloilo City, Philippines|Research Site, Lipa City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Elbląg, Poland|Research Site, Kraków, Poland|Research Site, Warszawa, Poland|Research Site, Kuzmolovsky, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Durban, South Africa|Research Site, Pretoria, South Africa|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Songkla, Thailand|Research Site, Dnipropetrovsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Coventry, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, Wythenshawe, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01151215"
284,"NCT04416633","Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced, NSCLC and Urothelial Cancer",,"Recruiting","No Results Available","Unresectable Non-small Cell Lung Cancer (NSCLC) and Urothelial Cancer","Drug: Durvalumab","To assess the safety of durvalumab among locally advanced unresectable non-small cell lung carcinoma and metastatic urothelial carcinoma","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D133HC00003","November 30, 2021","March 31, 2023","March 31, 2023","June 4, 2020",,"May 5, 2022","Research Site, Ansari Nagar, India|Research Site, Bhubaneswar, India|Research Site, Faridabad, India|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT04416633"
285,"NCT01133990","FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer",,"Completed","No Results Available","Colorectal Cancer","Drug: FOLIRI|Drug: FOLIRI plus E7820|Drug: FOLFIRI plus Bevacizumab","Safety Parameter: Adverse Events|Safety Parameter: Concomitant Meds|Safety Parameter: Lab tests|Safety Parameter: ECGs|Efficacy Parameter","Eisai Inc.|PharmaBio Development Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","5","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7820-701|2009-016015-37","April 2010","January 2011","January 2011","May 31, 2010",,"May 29, 2013","Rocky Mountain Cancer Center - Midtown, Denver, Colorado, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Hematology Oncology Associates SJ P.A., Mount Holly, New Jersey, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|North Coast Cancer Institute, Coffs Harbour, New South Wales, Australia|Sydney Haematology & Oncology Clinic, Hornsby, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, South Australia, Australia|Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Austin Hospital, Epping, Victoria, Australia|Newcastle Private Hospital, Merewether, Australia|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, Madhya Pradesh, India|Searoc Cancer Hosptial, Jaipur, Rajasthan, India|Gujarat Cancer & Research Institute, Ahmedabad, India|Kidwai Institute of Oncology, Bangalore, India|M. S. Ramaiah Memorial Hospital, Bangalore, India|Subodh Mitra Cancer Hospital and Research centre, Kolkata, India|Shatabdi Hospital, Nashik, India|Deenanath Mangeshkar Hospital and Research Center, Pune, India|Noble Hospital, Pune, India|Christian Medical College, Vellore, India|CCH #2 n.a. N. A. Semashko of LLC ""Russian Railways"", Moscow, Russian Federation|City Mariinskaya Hospital, St Petersburg, Russian Federation|Scientific Research Oncology Institute named after N.N. Petr, St Petersburg, Russian Federation|Yaroslav Regional Clinical Oncology Hospital, Yaroslav, Russian Federation|Mun. Multifield Clin.Hosp.#4,Dept. of Chemotherapy, DSMU, Dnipropetrovsk, Ukraine|Donetsk Regional Anticancer Centre, Donetsk, Ukraine|City Clinical Hospital #2, Kharkiv, Ukraine|The St.Inst. ""S.P.Grigoriev Med. Rad.Inst. of AMS of Ukr."", Kharkiv, Ukraine|Uzhgorod Centr.City Cl.Hosp.,City Onc.Center, UNMU,Fac.of PG, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01133990"
286,"NCT03562819","Study to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).","CONCORDANCE","Completed","No Results Available","NSCLC (Non-small Cell Lung Cancer)",,"Determine the level of concordance between EGFR mutation status|Assess the frequency of T790M mutation among study patients.","AstraZeneca","All","Child, Adult, Older Adult",,"268","Industry","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","D5161R00003","August 16, 2018","June 7, 2019","June 7, 2019","June 20, 2018",,"June 5, 2020","Reserch Site, Punjab, Chandigarh, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kerala, Kozhikode, India|Research Site, Mumbai, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Maharashtra, Mumbai, India|Research Site, Bhubaneswar, Odisha, India|Research Site, Hyderabad, Telanagana, India|Research Site, Kolkata, West Bangal, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03562819"
287,"NCT02437318","Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.","SOLAR-1","Active, not recruiting","Has Results","Breast Cancer","Drug: Fulvestrant|Drug: Alpelisib|Drug: Alpelisib placebo","Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort|Overall Survival (OS) for Patients With PI3KCA Mutant Status|Overall Response Rate (ORR)|Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status|Safety and Tolerability of Alpelisib in Combination With Fulvestrant|Time to 10% Deterioration in the Global Health Status/Quality of Life (QOL) Scale Score of the EORTC QLQ-C30|Plasma Concentration-time Profile of Alpelisib Given in Combinatio With Fulvestrant and Appropriate Pharmacokinetics (PK) Parameters|PFS Based on Radiology Assessments and Using RECIST 1.1 Criteria|Clinical Benefit Rate (CBR)|Change in the Global Health Status/(QOL) Scale Score of the EORTC QLQ-C30|Summary Statistics of Fulvestrant and Alpelisib Plasma Concentrations|PFS for Patients With PIK3CA Non-mutant Status|OS for Patients With PIK3CA Non-mutant Status","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","572","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CBYL719C2301|2015-000340-42","July 23, 2015","June 12, 2018","July 1, 2022","May 7, 2015","August 13, 2019","December 14, 2021","Ironwood Cancer and Research Centers Chandler 2, Chandler, Arizona, United States|Mayo Clinic - Arizona, Scottsdale, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Clinic SC, La Jolla, California, United States|Kaiser Permanente - California Southern, San Diego, California, United States|University of California San Francisco, San Francisco, California, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists-North SC, Saint Petersburg, Florida, United States|Rush University Medical Center Rush Uni Medical Center, Chicago, Illinois, United States|North Shore University Health System NorthShore University, Evanston, Illinois, United States|Edward Cancer Center SC, Naperville, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc. Dept.of Fort Wayne Med Onc/Hem, Fort Wayne, Indiana, United States|St. Francis Health Comprehensive Cancer Center SC, Topeka, Kansas, United States|Mercy Medical Center SC-2, Baltimore, Maryland, United States|Massachusetts General Hospital Updated Regulatory, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Detroit Clinical Research Center, Owosso, Michigan, United States|St. Luke's Cancer Institute SC, Kansas City, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Rutgers Cancer Institute of New Jersey SC-2, New Brunswick, New Jersey, United States|University Hospitals of Cleveland Seidman Cancer Center SC, Cleveland, Ohio, United States|Good Samaritan Regional Medical Center Good Samaritan Reg Med Ctr, Corvallis, Oregon, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|Prisma Health Upstate SC-2, Greenville, South Carolina, United States|Avera Cancer SC, Sioux Falls, South Dakota, United States|Tennessee Oncology SC-3, Nashville, Tennessee, United States|Texas Oncology PA Dallas Presbyterian Hospital SC-1, Dallas, Texas, United States|El Paso, Texas Oncology, El Paso, Texas, United States|Cancer Therapy and Research Center UT Health Science Center InstituteForDrugDevelopment(4), San Antonio, Texas, United States|US Oncology P A, Tyler, Texas, United States|Virginia Cancer Specialists SC, Fairfax, Virginia, United States|Wenatchee Valley Medical Center SC-2, Wenatchee, Washington, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Wahroonga, New South Wales, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Elizabeth Vale, South Australia, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Libramont, Belgium|Novartis Investigative Site, Ottignies, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Lajeado, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Vina del Mar, Chile|Novartis Investigative Site, Hradec Kralove, Czech Republic, Czechia|Novartis Investigative Site, Praha 4, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Prague 8, Czechia|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Angers cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, La Roche sur Yon cedex 9, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Recklinghausen, North Rhine-westphalia, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Homburg, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Velbert, Germany|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Szekszard, Hungary|Novartis Investigative Site, Vijayawada, Andhra Pradesh, India|Novartis Investigative Site, Nagpur - Maharashtra, Maharashtra, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Chieti, CH, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pontedera, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Rionero in Vulture, PZ, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Savona, SV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Kagoshima-city, Kagoshima, Japan|Novartis Investigative Site, Isehara, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kumamoto City, Kumamoto, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Kitaadachi-gun, Saitama, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Minato ku, Tokyo, Japan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Monterrey, N.L., Monterrey, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Venray, CE, Netherlands|Novartis Investigative Site, Terneuzen, Netherlands|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Floresti, Cluj, Romania|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Jerez, Cadiz, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Gavle, Sweden|Novartis Investigative Site, Oerebro, Sweden|Novartis Investigative Site, Vasteras, Sweden|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02437318/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/18/NCT02437318/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02437318"
288,"NCT03703297","Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy","ADRIATIC","Active, not recruiting","No Results Available","Small Cell Lung Cancer","Drug: Durvalumab|Drug: Tremelimumab|Other: Placebo","Progression-free survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Progression-free survival PFS|Progression-free survival at 18 months (PFS18)|Progression-free survival at 24 months (PFS24)|Time to death or distant metastasis (TTDM)|Proportion of patients alive at 24 months (OS24)|Proportion of patients alive at and 36 months (OS36)|Time from randomization to second progression (PFS2)|To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-C30 v3|To assess the PK of durvalumab and tremelimumab in blood (peak trough concentration)|Presence of anti-drug antibodies (ADA) for durvalumab and tremelimumab (confirmatory results: positive or negative)|PD-L1 expression in tumor and/or immune cells relative to response/efficacy outcomes (PFS, OS & ORR).|To assess symptoms and health-related QoL in patients treated withdurvalumab or durvalumab and tremelimumab combination therapy compared to placebo using the EORTC QLQ-LC13","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","730","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D933QC00001","September 27, 2018","May 10, 2024","May 10, 2024","October 11, 2018",,"March 7, 2022","Research Site, Tucson, Arizona, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Hines, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Lexington, Kentucky, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Summit, New Jersey, United States|Research Site, New Hyde Park, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Kennewick, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Charleston, West Virginia, United States|Research Site, Huntington, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudadela, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Aalst, Belgium|Research Site, Anderlecht, Belgium|Research Site, Bruxelles, Belgium|Research Site, Hasselt, Belgium|Research Site, Roeselare, Belgium|Research Site, Edmonton, Alberta, Canada|Research Site, Toronto, CA, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha, Czechia|Research Site, Berlin, Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Gerlingen, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Mainz, Germany|Research Site, Münster, Germany|Research Site, Oldenburg, Germany|Research Site, Regensburg, Germany|Research Site, Wuerzburg, Germany|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Chennai, India|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Terni, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan|Research Site, Kurume-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Tokushima-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Changwon-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Groningen, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Hengelo, Netherlands|Research Site, Gdańsk, Poland|Research Site, Olsztyn, Poland|Research Site, Poznań, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Kazan, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Las Palmas de Gran Canaria, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Hsinchu, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Keelung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Yunlin, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Konya, Turkey|Research Site, Samsun, Turkey|Research Site, Manchester, United Kingdom|Research Site, Truro, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03703297"
289,"NCT04607421","A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer",,"Recruiting","No Results Available","Neoplasms","Drug: Encorafenib|Drug: Cetuximab|Drug: Oxaliplatin|Drug: Irinotecan|Drug: Leucovorin|Drug: 5-FU|Drug: Capecitabine|Drug: Bevacizumab","Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs)|Phase 3: Progression free survival, by blinded independent review|Safety Lead-in: Incidence of adverse events|Safety Lead-in: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms|Safety Lead-in: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events|Safety Lead-in: Overall response rate by investigator|Safety Lead-in: Duration of response by Investigator|Safety Lead-in:Progression free survival by Investigator|Safety Lead-in: Time to response by Investigator|Safety Lead-in: Overall survival|Phase 3: Overall survival and Progression free survival by blinded independent review|Phase 3: Overall response rate by blinded independent review and by Investigator|Phase 3: Duration of response by blinded independent review and by Investigator|Phase 3: Time to response by blinded independent review and by Investigator|Phase 3: Progression free survival by Investigator|Phase 3: Progression free survival 2 by Investigator|Phase 3: Incidence of adverse events|Phase 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms|Phase 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|Phase 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire|Phase 3: Change from Baseline in the Patient Global Impression of Severity (PGIS)|Phase 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires|Phase 3: Confirm the MSI-status in tumor tissue|Phase 3: Determine the correlation between cfDNA genetic alterations and clinical outcome|Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746, irinotecan and SN-38|Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38|Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38|Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746 and oxaliplatin|Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746 and oxaliplatin|Safety Lead-in: Clearance of irinotecan, SN-38 and oxaliplatin|Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746 and oxaliplatin|Phase 3: Trough concentrations of encorafenib and its metabolite LHY746","Pfizer|Ono Pharmaceutical Co. Ltd|Merck KGaA, Darmstadt, Germany","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","765","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","C4221015|2020-001288-99","December 21, 2020","September 16, 2024","November 15, 2026","October 29, 2020",,"May 12, 2022","Mayo Clinic - Phoenix Oncology Pharmacy, Phoenix, Arizona, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|Mayo Clinic in Arizona - Scottsdale, Scottsdale, Arizona, United States|Tower Hematology Oncology Medical Group (THO), Beverly Hills, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC & USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center / Investigational Drug Services, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars- Sinai Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Keck Hospital of USC Pasadena, Pasadena, California, United States|Torrance Memorial Medical Center (TMMC), Torrance, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Georgetown University Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Aventura, Aventura, Florida, United States|Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center, Coral Gables, Florida, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Hospital of Miami, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|Orlando Health Cancer Institute, Orlando, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|BRCR Medical Center Inc., Plantation, Florida, United States|Lewis Cancer & Research Pavilion at St Joseph's/Candler Health System, Savannah, Georgia, United States|Lewis Cancer & Research Pavilion Pharmacy, Savannah, Georgia, United States|St. Joseph's/Candler Health System, Inc., Savannah, Georgia, United States|Summit Cancer Care, P.C., Savannah, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|St. Joseph's/Candler Health System, Inc., Savannah, Georgia, United States|Ochsner Clinic Foundation Research Pharmacy, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|University of Michigan Hospitals, Ann Arbor, Michigan, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Siteman Cancer Center - North County, Florissant, Missouri, United States|Barnes- Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center - South County, Saint Louis, Missouri, United States|Siteman Cancer Center - St Peters, Saint Peters, Missouri, United States|St Vincent Healthcare, Billings, Montana, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|Oncology Hematology West, PC dba Nebraska Cancer Specialists - IP Storage, Omaha, Nebraska, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Papillion, Nebraska, United States|Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|Memorial Sloan Kettering Cancer Center- Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center- Bergen, Montvale, New Jersey, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, Babylon, New York, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center Commack, Commack, New York, United States|Memorial Sloan Kettering Cancer Center - Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, New York, New York, United States|Memorial Sloan Kettering Cancer Center - Main Campus, New York, New York, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, Patchogue, New York, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York, United States|North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists, Riverhead, New York, United States|Memorial Sloan Kettering Cancer Center- Nassau, Uniondale, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Carolinas Medical Center Investigational Drug Services, Charlotte, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Atrium Health Mercy, Charlotte, North Carolina, United States|Atrium Health Pineville, Charlotte, North Carolina, United States|Levine Cancer Institute - Southpark, Charlotte, North Carolina, United States|Atrium Health University City, Charlotte, North Carolina, United States|Levine Cancer Institute University City, Charlotte, North Carolina, United States|Atrium Health Cabarrus, Concord, North Carolina, United States|Levine Cancer Institute - Concord, Concord, North Carolina, United States|Atrium Health Union, Monroe, North Carolina, United States|Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|The Ohio State University James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States|Stefanie Spielman Comprehensive Breast Cancer, Columbus, Ohio, United States|Martha Morehouse Medical Plaza, Columbus, Ohio, United States|University of Oklahoma Health Sciences Center, OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Onc and Heme Care Clinic - Westside, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|Providence St Vincent Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|UPMC Hillman Cancer Center Investigational Drug Service, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Health Clinic at Walgreens Clarksville, Clarksville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Cool Springs, Franklin, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Gallatin, Gallatin, Tennessee, United States|The West Clinic. PLLC. dba West Cancer Center, Germantown, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Hendersonville, Hendersonville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Hermitage, Hermitage, Tennessee, United States|Vanderbilt Health Clinic at Walgreens La Vergne, La Vergne, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Lebanon, Lebanon, Tennessee, United States|The West Clinic PLLC dba West Cancer Center, Memphis, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Murfreesboro, Murfreesboro, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Belle Meade, Nashville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Nippers Corner, Nashville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Donelson, Nashville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Hart Lane, Nashville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Bellevue, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|Vanderbilt Oncology IDS Pharmacy, Nashville, Tennessee, United States|Vanderbilt Health Clinic at Walgreens Smyrna, Smyrna, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|VCU Health System, Investigational Drug Service Pharmacy, Richmond, Virginia, United States|Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|Centro Medico San Roque, San Miguel De Tucumán, Tucumán, Argentina|Centro Medico San Roque, Tucuman, Tucumán, Argentina|Liverpool Hospital, Liverpool, New South Wales, Australia|Slade Pharmacy, Mount Kuring-Gai, New South Wales, Australia|GenesisCare - North Shore, St Leonards, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Monash Health, Clayton, Victoria, Australia|Peninsula Health, Frankston, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Université Libre de Bruxelles - Hôpital Erasme, Brussels, Bruxelles-capitale, Région DE, Belgium|Cliniques universitaires Saint-Luc, Brussels, Bruxelles-capitale, Région DE, Belgium|Grand Hôpital de Charleroi, Charleroi, Hainaut, Belgium|CHR Verviers East Belgium, Verviers, Liège, Belgium|AZ Groeninge Campus Kennedylaan, Kortrijk, West-vlaanderen, Belgium|ZNA Middelheim, Antwerpen, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman, Liège, Belgium|Clínica de Neoplasias Litoral, Itajaí, Santa Catarina, Brazil|Medical School Famerp-HB-FUNFARME_Do not use - Duplicate facility, Sao jose do Rio Preto, SÃO Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, SÃO Paulo, Brazil|MHAT Uni Hospital OOD, Panagyurishte, Pazardzhik, Bulgaria|MHAT ""Dr. Tota Venkova"" AD, Gabrovo, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, Bulgaria|MHAT Central Onco Hospital, Plovdiv, Bulgaria|Medical Center Nadezhda Clinical EOOD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment Sofiamed, Sofia, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|Kingston Health Sciences Centre-Kingston General Hospital Site, Kingston, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre Intégré de Santé et de Services Sociaux (CISSS) de Laval / Hôpital de la Cité-de-la-Sant, Laval, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Anhui Provincial Cancer Hospital, Hefei, Anhui, China|Beijing Cancer hospital, Beijing, Beijing, China|Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China|Henan provincial people's hospital, Zhengzhou, Henan, China|The Second Xiangya Hospital of Central South University, Changsha, Hunan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|Shengjing Hospital Of China Medical University, Shenyang, Liaoning, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Jiaotong University School of Medicine Ruijin Hospital, Shanghai, Shanghai, China|Shanghai General Hospital, Shanghai, Shanghai, China|Sichuan Province Cancer Hospital, Chengdu, Sichuan, China|The second Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Peking University First Hospital, Beijing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shengjing Hospital Of China Medical University, Shenyang, China|Shengjing Hospital Of China Medical University, Shenyang, China|Fakultní nemocnice Brno Bohunice, Brno, Brno-město, Czechia|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Hradec Králové, Czechia|Fakultni Thomayerova nemocnice, Prague, Praha 4, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Fakultni nemocnice Bulovka, Praha 8, Czechia|Rigshospitalet, Copenhagen, Denmark|Odense University Hospital, Odense C, Denmark|Docrates Syöpäsairaala, Helsinki, Nyland, Finland|Tampereen yliopistollinen sairaala, Tampere, Pirkanmaa, Finland|Helsinki University Central Hospital, Helsinki, Finland|Oulu University Hospital, Oulu, Finland|Turku University Hospital, Turku, Finland|Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie, Muenchen, Bayern, Germany|Institut für Klinisch Onkologische Forschung, Frankfurt, Hessen, Germany|Radiologie Berlin, Berlin - Charlottenburg, Germany|Onkologische Schwerpunktpraxis Kurfuerstendamm, Berlin, Germany|Waage Apotheke, Berlin, Germany|HELIOS Klinikum Berlin Buch GmbH, Berlin, Germany|Helios Klinikum Berlin-Buch, Berlin, Germany|Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Facharztzentrum Eppendorf, Hamburg, Germany|ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld, Hamburg, Germany|Radiologie im Israelitischen Krankenhaus, Hamburg, Germany|Klinikum Oldenburg AöR, Oldenburg, Germany|Klinikum Oldenburg AöR, Oldenburg, Germany|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Bhakti Vedanta Hospital and Research Institute, Thane, Maharashtra, India|R K Birla Cancer Center, SMS Hospital, Jaipur, Rajasthan, India|Sawai Man Singh Medical College Hospital (SMS Hospital), Jaipur, Rajasthan, India|Azienda Ospedaliera Universitaria di Cagliari - Presidio Policlinico Universitario ""D.Casula"", Monserrato (CA), Cagliari, Italy|IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, Italy|Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo IRCCS, Candiolo, Torino, Italy|Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Istituto Europeo di Oncologia IRCCS, Milano, Italy|IRCCS Istituto Oncologico Veneto (IOV), Padova, Italy|Chiba cancer center, Chiba-shi, Chiba, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|St. Marianna University Hospital, Kawasaki, Kanagawa, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Aichi Cancer Center Hospital, Nagoya, Nagoya, Aichi, Japan|Osaka Prefectural Hospital Organization Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka-city, Saitama, Japan|Saitama Prefectural Cancer Center, Ina-machi, Saitama, Japan|Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|National Hospital Organization - Osaka National Hospital - Institute For Clinical Research, Osaka, Japan|Keio University Hospital, Tokyo, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Kyungpook National University Hospital, Daegu, Taegu-kwangyǒkshi, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Chonnam National University Hwasun Hospital Pharmacy, Jeonnam, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Korea University Anam hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro de Investigacion Clinica de Oaxaca, Oaxaca, Mexico|Maastricht UMC+, Maastricht, Limburg, Netherlands|Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, Noord-holland, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Tauranga Hospital, Tauranga, BAY OF Plenty, New Zealand|Auckland City Hospital, Auckland, New Zealand|Sørlandet Sykehus Kristiansand, Kristiansand, Norway|Oslo universitetssykehus, Radiumhospitalet, Oslo, Norway|Oslo Universitetssykehus Ullevål, Oslo, Norway|Przychodnia Lekarska KOMED, Konin, Wielkopolskie, Poland|Szpital Specjalistyczny Podkarpacki Ósrodek Onkologiczny w Brzozowie, Brzozow, Poland|Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii, Bytom, Poland|Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii, Bytom, Poland|COPERNICUS PL sp. z. o. o. Wojewodzkie Centrum Onkologii w Gdansku Ambulatoryjna, Gdansk, Poland|COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii, Gdansk, Poland|Przychodnia Lekarska KOMED, Konin, Poland|Regional Specialised Hospital No. 4 in Bytom, Bytom, Śląskie, Poland|Sbi ""City Clinical Hospital №1, Nalchik, Kabardino-balkarian Republic, Russian Federation|State budget institution of healthcare of Mordovia Republic ""Republic Oncology Dispensary"", Saransk, Republic OF Mordovia, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Sankt-peterburg, Russian Federation|GBUZ, Chelyabinsk, Russian Federation|Kaluga Regional Clinical Oncology Center, Kaluga, Russian Federation|FSAEI HE I.M Sechenov First MSMU MoH Russia (Sechenovskiy University),, Moscow, Russian Federation|BHI of Omsk Region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|BHI of Omsk Region ""Clinical Oncology Dispensary"", Omsk, Russian Federation|State Budgetary Healthcare Institution ""Orenburg Regional Clinical Oncological Dispensary"", Orenburg, Russian Federation|LLC ""EuroCityClinic"", Saint Petersburg, Russian Federation|LLC ""Medicina Severnoy Stolitsy"", Saint-Petersburg, Russian Federation|LLC ""Severo-Zapadny Medical Center"", Saint-Petersburg, Russian Federation|Private Healthcare Institution ""Clinical Hospital ""RZD-Medicine"" of St. Petersburg, Saint-Petersburg, Russian Federation|FSBI ""Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov, St. Petersburg, Russian Federation|SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan, Ufa, Russian Federation|SHI YR Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|SHI YR Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|SHI YR Regional Clinical Oncology Hospital, Yaroslav, Russian Federation|Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica, Banska Bystrica, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|Cancercare Rondebosch Oncology, Rondebosch, Cape Town, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, South Africa|Cancercare Langenhoven Drive Oncology Centre, Port Elizabeth, Eastern CAPE, South Africa|Cape Town Oncology Trials, Cape Town, Western CAPE, South Africa|GVI Oncology, Cape Town, Western CAPE, South Africa|Complejo Hospitalario Universitario Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital General Universitario de Elche, Elche, Alicante, Spain|ICO L'Hospitalet (Hospital Duran i Reynals), Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario 12 de octubre, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Akademiska sjukhuset, Uppsala, Uppsala LÄN [se-03], Sweden|Norrlands universitetssjukhus, Umeå, Västerbottens LÄN [se-24], Sweden|Sahlgrenska Universitetssjukhuset, Göteborg, Västra Götalands LÄN [se14], Sweden|Västmanlands Sjukhus Västerås, Västerås, Sweden|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|Chi Mei Hospital, Liouying, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Medical University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Medical and diagnostic center of MediX-Ray International Group LLC Israeli Oncology Hospital ""LISOD"", Pliuty Village, KYIV Region, Obuhovskiy District, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council, Dnipro, Ukraine|PRECARPATHIAN NUCLEAR MEDICINE CENTER, Limited Liability Company, Ivano-Frankivsk, Ukraine|Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine|MNPE ""Prykarpatski Clinical Oncological Center"" of Ivano-Frankivsk Regional Council"", Ivano-Frankivsk, Ukraine|Municipal non-profit enterprise ""City clinical hospital #2 named after O.O.Shalimov"", Kharkiv, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|Communal enterprise ""Kryvyi Rih Oncology Dispensary"" of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|SI ""Insitute of Neurosurgery n.a.acad. A.P., Kyiv, Ukraine|SI ""Insitute of Neurosurgery n.a.acad. A.P., Kyiv, Ukraine|Municipal non-profit enterprise of Kyiv regional council ""Kyiv regional clinical hospital"", Kyiv, Ukraine|Municipal non-profit enterprise ""Zaporizhzhia Regional Antitumor Center"" Zaporizhzhia Regional, Zaporizhzhia, Ukraine|Freeman Hospital, Newcastle upon Tyne, HIGH Heaton, United Kingdom|Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom|Churchill Hospital - Oncology, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04607421"
290,"NCT01028495","A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer",,"Completed","No Results Available","Metastatic Pancreatic Cancer","Drug: RX-0201 plus Gemcitabine","Survival|Tumor Response|Toxicity and Safety Parameters|Karnofsky Performance Scale, Clinical Laboratory Assessment, and Molecular Markers","Rexahn Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RX-0201-P2-A-07","May 2009","July 2012","August 2012","December 9, 2009",,"September 12, 2019","Baptist Cancer Institute, Jacksonville, Florida, United States|Orchard Healthcare Research Inc., Skokie, Illinois, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, P.A., McAllen, Texas, United States|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, Kerala, India|Meenakshi Mission Hospital and Research Center, Madurai-625020, India|Central India Cancer Research Institute, Maharashtra, India|Shatabdi Superspeciality Hospital, Maharashtra, India|Rajiv Gandhi Cancer Institute and Research Center, Rohini New- Delhi, India|King George Hospital, Visakhapatanam, A.P, India",,"https://ClinicalTrials.gov/show/NCT01028495"
291,"NCT00920816","Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer",,"Completed","Has Results","Kidney Neoplasms","Drug: Axitinib (AG-013736)|Drug: Sorafenib","Progression Free Survival (PFS): First-Line Participants|Progression Free Survival (PFS): Second-Line Participants|Percentage of Participants With Objective Response (OR): First-Line Participants|Percentage of Participants With Objective Response (OR): Second-Line Participants|Duration of Response (DR): First-Line Participants|Duration of Response (DR): Second-Line Participants|Overall Survival (OS): First-Line Participants|Overall Survival (OS): Second-Line Participants","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","492","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","A4061051|2010-018585-23","August 25, 2009","July 27, 2012","April 29, 2021","June 15, 2009","February 4, 2014","May 6, 2022","Advanced Medical Specialties, Miami, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Indiana University Health Central Indiana Cancer Centers, Carmel, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Fishers, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Greenfield, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Indiana University Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Missouri Cancer Associates, Columbia, Missouri, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|US Oncology West Region, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, PA, Parsippany, New Jersey, United States|New York Oncology Hematology, PC, Albany, New York, United States|New York Oncology Hematology, PC, Albany, New York, United States|New York Oncology Hematology, PC, Latham, New York, United States|New York Oncology Hematology, PC, Rexford, New York, United States|New York Oncology Hematology, PC, Troy, New York, United States|Raleigh Hematology Oncology Associates, Cary, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Portland, Oregon, United States|Northwest Cancer Specialists, PC, Tualatin, Oregon, United States|Penn State Milton S. Hershey Medical Center, Penn State Cancer Institute, Hershey, Pennsylvania, United States|Medical University of South Carolina University Hospital, Charleston, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Texas Oncology- Amarillo, Amarillo, Texas, United States|Texas Oncology-Beaumont, Mamie McFaddin Ward Cancer Center, Beaumont, Texas, United States|Texas Oncology- Bedford, Bedford, Texas, United States|Texas Oncology- Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology- Fort Worth 12th Avenue, Fort Worth, Texas, United States|Texas Oncology- Southwest Fort Worth, Fort Worth, Texas, United States|Investigational Products Center (lPC), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Texas Oncology - Grapevine, Grapevine, Texas, United States|Cancer Care Centers of South Texas, Kerrville, Texas, United States|Texas Oncology- McAllen South Second Street, McAllen, Texas, United States|Texas Oncology- Midland Allison Cancer Center, Midland, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology-Weslaco, Weslaco, Texas, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Low Moor, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Roanoke, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Wytheville, Virginia, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Clinic of Oncology, Banja Luka, Bosnia and Herzegovina|Institute of Oncology, University Hospital Center Sarajevo, Sarajevo, Bosnia and Herzegovina|University Clinical Center Tuzla, Clinic for Oncology, Hematology and Radiotherapy, Tuzla, Bosnia and Herzegovina|Spetsializirana Bolnitsa za Aktivno Lechenie po Onkologiya, EAD, Klinika po Himioterapiya, Sofia, Bulgaria|SBALOZ D-r Marko Markov-Varna, Varna, Bulgaria|Instituto Clinico Oncologico del Sur, Temuco, Cautin, Chile|Instituto Clinico Oncologico del Sur, Temuco, IX Region, Chile|Instituto de Terapias Oncologicas Providencia, Providencia, Santiago, Chile|Private Office, Santiago, Chile|Cancer Institute and Hospital ,Chinese Academy of Medical Sciences, Beijing, Beijing, China|Chinese PLA General Hospital, Haidian District, Beijing, China|The Fuzhou General Hospital, PLA Nanjing Military Area Command, Fuzhou, Fujian, China|Nanfang Hospital, Guangzhou, Guang DONG, China|Urology Department, Sun Yet-Sen University Cancer Center, Guangzhou, Guangdong, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|The Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Urology Department, 1st Hospital of China Medical University, Shen Yang, LIAO NING, China|Xijing Hospital, The Fourth Military Medical University,Oncology Department, Xi'an, Shaanxi, China|Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Sir Run Run Shaw Hospital of College of Medicine of Zhejiang University, Center for Oncology, Hangzhou, Zhejiang, China|Department of Urology,Peking University First Hospital, Beijing, China|Beijing Cancer Hospital/Department of Renal Cancer and Melanoma, Beijing, China|South-Western Hospital, 3rd Military Medical University, Chongqing, China|Jiangsu Cancer Hospital, Nanjing, China|Fudan University, Cancer Hospital, Department of Urology, Shanghai, China|Tianjin Oncology Hospital,biology treatment department, Tianjin, China|Urology Department, The Second Hospital of Tianjin Medical University, Tianjin, China|BIBI General Hospital and Cancer Centre,, Hyderabad, Andhra Pradesh, India|Chinmaya Mission Hospital, Bangalore, Karnataka, India|Sri Venkateshwara Hospital, Bangalore, Karnataka, India|NU Hospitals, Bangalore, Karnataka, India|Cancer Care Clinic and Hospitals, Nagpur, Maharashtra, India|Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Shettys hospital, Bangalore, India|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, DF, Mexico|Hospital General de Mexico O.D., Mexico City, Distrito Federal, Mexico|Centro Hemato-Oncologico Privado, Toluca, Estado DE Mexico, Mexico|Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Rm. 3227 Doctors Clinic, Annex II Bldg., National Kidney & Transplant Institute, Quezon City, Diliman, Philippines|St. Lukes Medical Center, Quezon City, Metro Manila, Philippines|University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, Metro Manila, Philippines|Makati Medical Center, Makati City, Philippines|Room 805, Committee on Research Room, Manila Doctors Hospital, Manila, Philippines|Oncomed SRL, Timisoara, JUD. Timis, Romania|Institutul Oncologic ""Prof.Dr.I.Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Institutul Oncologic ''Prof.Dr. I. Chiricuta'' Cluj Napoca, Cluj-Napoca, Romania|Moscow State Healthcare Institution Oncology Clinical Dispensary #1, Moscow, Russian Federation|P.A. Herzen Moscow Oncology Research Institute,, Moscow, Russian Federation|GBU RO ""Ryazan Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|FGBOU VO ""Ryazan State Medical University named after academician I.P.Pavlov"", Ryazan, Russian Federation|FGBOU VO ""First Saint-Petersburg State Medical University n.a. I.P.Pavlov"", Saint-Petersburg, Russian Federation|Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic, Ufa, Russian Federation|GVI Oncology, Port Elizabeth, South Africa|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|KP Dnipropetrovska oblasna klinichna likarnia im. I.I. Mechnykova"" Dnipropetrovskoi oblasnoi rady,, Dnipro, Ukraine|Komunalne nekomertsiine pidpryiemstvo Kharkivskoi oblasnoi rady Oblasnyi medychnyi klinichnyi tsentr, Kharkiv, Ukraine|DU Instytut Urolohii NAMN Ukrainy, viddil onkourolohii, KNP Kyivskyi miskyi klinichnyi onkolohichnyi, Kyiv, Ukraine|Komunalne nekomertsiine pidpryiemstvo Lvivskoi oblasnoi rady Lvivskyi onkolohichnyi rehionalnyi, Lviv, Ukraine|SI ""Zaporizhzhya Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine"", Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00920816"
292,"NCT03032679","Pain and Impact of Chronic Pain on Function After Total Knee Replacements",,"Completed","No Results Available","Pain, Postoperative|Pain, Chronic|Osteogenic Sarcoma|Knee Arthropathy","Other: Non interventional study","pain severity in the immediate post-operative period following oncologic TKRs|the proportion of patients who continue to have pain at 4 and 6 months post surgery(CPSP)|• To identify the type of pain (neuropathic component) persisting at 4 and 6 months after TKR|Impact of the pain on daily function","Tata Memorial Centre","All","18 Years to 99 Years   (Adult, Older Adult)",,"139","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","1780","February 2, 2017","June 30, 2020","August 31, 2020","January 26, 2017",,"October 8, 2020","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03032679"
293,"NCT01254279","Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen",,"Completed","No Results Available","Prostate Cancer Metastatic","Drug: CABAZITAXEL","To provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen|To document safety of cabazitaxel in these patients","Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 3","984","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CABAZ_C_05331|2010-021128-92|U1111-1115-2476","December 2010","December 2014","December 2014","December 6, 2010",,"January 21, 2015","Investigational Site Number 036004, Box Hill, Australia|Investigational Site Number 036020, Campbelltown, Australia|Investigational Site Number 036001, Camperdown, Australia|Investigational Site Number 036002, Camperdown, Australia|Investigational Site Number 036011, Douglas, Australia|Investigational Site Number 036019, Nambour, Australia|Investigational Site Number 036023, North Adelaide, Australia|Investigational Site Number 036008, Parkville, Australia|Investigational Site Number 036005, Perth, Australia|Investigational Site Number 036003, Port Macquarie, Australia|Investigational Site Number 036025, Randwick, Australia|Investigational Site Number 036009, South Brisbane, Australia|Investigational Site Number 036022, South Brisbane, Australia|Investigational Site Number 036017, Southport, Australia|Investigational Site Number 036012, St Leonards, Australia|Investigational Site Number 036010, Sydney, Australia|Investigational Site Number 036013, Sydney, Australia|Investigational Site Number 036014, Sydney, Australia|Investigational Site Number 036016, Tweed Heads, Australia|Investigational Site Number 036024, Wendouree, Australia|Investigational Site Number 036007, Westmead, Australia|Investigational Site Number 036015, Wodonga, Australia|Investigational Site Number 040-004, Linz, Austria|Investigational Site Number 040-005, Salzburg, Austria|Investigational Site Number 040-003, Vienna, Austria|Investigational Site Number 040-002, Wien, Austria|Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056007, Bruxelles, Belgium|Investigational Site Number 056003, Haine St Paul, Belgium|Investigational Site Number 056005, Liège, Belgium|Investigational Site Number 056004, Ottignies, Belgium|Investigational Site Number 056001, Roeselare, Belgium|Investigational Site Number 056006, Tournai, Belgium|Investigational Site Number 070003, Banja Luka, Bosnia and Herzegovina|Investigational Site Number 070001, Sarajevo, Bosnia and Herzegovina|Investigational Site Number 070002, Zenica, Bosnia and Herzegovina|Investigational Site Number 100004, Plovdiv, Bulgaria|Investigational Site Number 100001, Sofia, Bulgaria|Investigational Site Number 100003, Sofia, Bulgaria|Investigational Site Number 100002, Sofia, Bulgaria|Investigational Site Number 124012, Kitchener, Canada|Investigational Site Number 124009, Laval, Canada|Investigational Site Number 124004, London, Canada|Investigational Site Number 124007, Moncton, Canada|Investigational Site Number 124001, Montreal, Canada|Investigational Site Number 124011, Montreal, Canada|Investigational Site Number 124010, Quebec, Canada|Investigational Site Number 124003, Toronto, Canada|Investigational Site Number 124002, Toronto, Canada|Investigational Site Number 124006, Winnipeg, Canada|Investigational Site Number 191-001, Zagreb, Croatia|Investigational Site Number 203001, Brno, Czech Republic|Investigational Site Number 208-001, Cph Ø, Denmark|Investigational Site Number 208-002, Herlev, Denmark|Investigational Site Number 208-003, Odense, Denmark|Investigational Site Number 246002, Helsinki, Finland|Investigational Site Number 246001, Seinäjoki, Finland|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Szolnok, Hungary|Investigational Site Number 348003, Szombathely, Hungary|Investigational Site Number 348004, Veszprém, Hungary|Investigational Site Number 356004, Chennai, India|Investigational Site Number 356006, Gurgaon, India|Investigational Site Number 356001, New Delhi, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356005, Trivandrum, India|Investigational Site Number 372004, Cork, Ireland|Investigational Site Number 372003, Dublin 24, Ireland|Investigational Site Number 372001, Dublin 7, Ireland|Investigational Site Number 372002, Dublin 7, Ireland|Investigational Site Number 380-001, Arezzo, Italy|Investigational Site Number 380-011, Aviano, Italy|Investigational Site Number 380-025, Bari, Italy|Investigational Site Number 380-007, Bergamo, Italy|Investigational Site Number 380-015, Bologna, Italy|Investigational Site Number 380-021, Fano, Italy|Investigational Site Number 380-012, Firenze, Italy|Investigational Site Number 380-003, Genova, Italy|Investigational Site Number 380-005, Genova, Italy|Investigational Site Number 380-014, Lecce, Italy|Investigational Site Number 380-023, Messina, Italy|Investigational Site Number 380-018, Milano, Italy|Investigational Site Number 380-022, Milano, Italy|Investigational Site Number 380-006, Napoli, Italy|Investigational Site Number 380-010, Napoli, Italy|Investigational Site Number 380-027, Napoli, Italy|Investigational Site Number 380-004, Orbassano, Italy|Investigational Site Number 380-017, Padova, Italy|Investigational Site Number 380-002, Parma, Italy|Investigational Site Number 380-009, Roma, Italy|Investigational Site Number 380-008, Roma, Italy|Investigational Site Number 380-024, Rozzano, Italy|Investigational Site Number 380-020, San Giovanni Rotondo, Italy|Investigational Site Number 380-013, Sassari, Italy|Investigational Site Number 380-016, Taormina, Italy|Investigational Site Number 398001, Almaty, Kazakhstan|Investigational Site Number 398003, Shymkent, Kazakhstan|Investigational Site Number 442001, Niederkorn, Luxembourg|Investigational Site Number 458002, Georgetown, Malaysia|Investigational Site Number 458001, Kuala Lumpur, Malaysia|Investigational Site Number 458003, Kuching, Malaysia|Investigational Site Number 484002, Durango, Mexico|Investigational Site Number 484006, Irapuato, Mexico|Investigational Site Number 484005, Toluca, Mexico|Investigational Site Number 484001, Zapopan, Mexico|Investigational Site Number 608001, Manila, Philippines|Investigational Site Number 616-001, Gdansk, Poland|Investigational Site Number 620002, Coimbra, Portugal|Investigational Site Number 620003, Lisboa, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620001, Porto, Portugal|Investigational Site Number 620005, Setúbal, Portugal|Investigational Site Number 642001, Bucharest, Romania|Investigational Site Number 642002, Cluj-Napoca, Romania|Investigational Site Number 642003, Timisoara, Romania|Investigational Site Number 688001, Belgrade, Serbia|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 702002, Singapore, Singapore|Investigational Site Number 702001, Singapore, Singapore|Investigational Site Number 703001, Bratislava, Slovakia|Investigational Site Number 703002, Kosice, Slovakia|Investigational Site Number 724018, Barcelona, Spain|Investigational Site Number 724019, Barcelona, Spain|Investigational Site Number 724023, Castellón de la Plana, Spain|Investigational Site Number 724020, Córdoba, Spain|Investigational Site Number 724025, Elche, Spain|Investigational Site Number 724017, Granada, Spain|Investigational Site Number 724006, Guadalajara, Spain|Investigational Site Number 724011, L'Hospitalet de Llobregat, Spain|Investigational Site Number 724002, La Coruña, Spain|Investigational Site Number 724010, León, Spain|Investigational Site Number 724003, Madrid, Spain|Investigational Site Number 724012, Madrid, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724008, Manresa, Spain|Investigational Site Number 724021, Málaga, Spain|Investigational Site Number 724009, Oviedo, Spain|Investigational Site Number 724022, Pamplona, Spain|Investigational Site Number 724005, San Cristóbal de La Laguna - Sta. Cruz de Tenerife, Spain|Investigational Site Number 724016, Santander, Spain|Investigational Site Number 724015, Santiago de Compostela, Spain|Investigational Site Number 724024, Sevilla, Spain|Investigational Site Number 724004, Terrassa, Spain|Investigational Site Number 724013, Valencia, Spain|Investigational Site Number 724014, Valencia, Spain|Investigational Site Number 724001, Zaragoza, Spain|Investigational Site Number 752-002, Umeå, Sweden|Investigational Site Number 752-001, Uppsala, Sweden|Investigational Site Number 005, Kaohsiung Hsien,, Taiwan|Investigational Site Number 004, Taichung, Taiwan|Investigational Site Number 002, Taipei, Taiwan|Investigational Site Number 003, Taipei, Taiwan|Investigational Site Number 001, Tao Yuan Hsien, Taiwan|Investigational Site Number 826011, Birmingham, United Kingdom|Investigational Site Number 826002, Bristol, United Kingdom|Investigational Site Number 826003, Glasgow, United Kingdom|Investigational Site Number 826013, Leeds, United Kingdom|Investigational Site Number 826009, London, United Kingdom|Investigational Site Number 826012, Manchester, United Kingdom|Investigational Site Number 826005, Nottingham, United Kingdom|Investigational Site Number 826008, Preston, United Kingdom|Investigational Site Number 826001, Sutton, United Kingdom|Investigational Site Number 826007, Torquay, United Kingdom|Investigational Site Number 826006, Whitechurch, United Kingdom|Investigational Site Number 826004, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01254279"
294,"NCT01238107","A Clinical Study With MT-102 in Subjects With Cancer Cachexia",,"Completed","No Results Available","Cancer Cachexia","Drug: MT-102","Demonstrate the effect of a 10mg / bd dose of MT-102 in comparison to placebo on the rate of weight change over a sixteen week period in patients with cachexia related to underlying stage III and stage IV colorectal or non-small cell lung cancer","PsiOxus Therapeutics Ltd|Veeda Oncology","All","25 Years to 80 Years   (Adult, Older Adult)","Phase 2","87","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MT-102-2001","April 2011","May 2013","May 2013","November 10, 2010",,"September 10, 2014","Charite Hospital Virchow-Klinikum Campus, Berlin, Germany|Kumaran Hospital Private Ltd, Kilpauk, Chennai, India|Dr Kamakshi Memorial Hospital, Pallikaranai, Chennai, India|Vedanta Institute of Medical Science, Ahmedabad, Gujarat, India|Shree Krishna Hopsital, Anand, Gujarat, India|Kailash Cancer Hospital & Research Centre, Goraj, Gujarat, India|TATA Memorial Hopsital, Mumbai, Maharashtra, India|Curie Manavta Cancer Centre, Nashik, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Noble Hopsital, Pune, India|Hospital Sultahan Bahiyah, Alor Setar, Kedha, Malaysia|Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia|Hospital Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia|Universiti Malaya Medical, Jalan Baharu, Kuala Lumpur, Malaysia|Tuanku Ja'afar Hospital, Seremban, Negeri Sembilan, Malaysia|International Islamic University Malaysia, Kuantan, Pahang, Malaysia|Penang General Hopsital, Pulau Pinang, Penang, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia",,"https://ClinicalTrials.gov/show/NCT01238107"
295,"NCT00511459","Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients",,"Completed","No Results Available","Locally Recurrent and Metastatic Breast Cancer","Drug: AMG 386 Placebo|Drug: AMG 386|Drug: Bevacizumab|Drug: Paclitaxel","Progression-free survival (PFS)|Objective Response (OR)|Duration of Response (DOR)|Time to response|Overall Survival|Time to progression (TTP)|Incidence of AEs and significant laboratory changes|AMG 386 Pharmakokinetic parameters|Incidence of the occurrence of anti-AMG 386 antibody formation","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 2","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20060341","July 2007","August 2010","May 2014","August 3, 2007",,"October 29, 2015","Research Site, Litchfield Park, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Campbell, California, United States|Research Site, Los Angeles, California, United States|Research Site, Murrieta, California, United States|Research Site, Santa Maria, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Orlando, Florida, United States|Research Site, Robbinsdale, Minnesota, United States|Research Site, Henderson, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Nashua, New Hampshire, United States|Research Site, Edison, New Jersey, United States|Research Site, Mountain Lakes, New Jersey, United States|Research Site, Asheville, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Columbia, South Carolina, United States|Research Site, Richardson, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Kurralta Park, South Australia, Australia|Research Site, Epping, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Innsbruck, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Wilrijk, Belgium|Research Site, Herlev, Denmark|Research Site, Helsinki, Finland|Research Site, La Roche Sur Yon Cedex 9, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Paris Cedex 20, France|Research Site, Paris Cedex 5, France|Research Site, Toulouse Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Gyula, Hungary|Research Site, Kaposvar, Hungary|Research Site, Szombathely, Hungary|Research Site, Veszprem, Hungary|Research Site, Bangalore, Karnataka, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Maastricht, Netherlands|Research Site, Gdansk, Poland|Research Site, Lubin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, JaÃ©n, AndalucÃ-a, Spain|Research Site, Sabadell, CataluÃ±a, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Madrid, Spain|Research Site, Guildford, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00511459"
296,"NCT04707196","A Study of Abemaciclib in Indian Women With Advanced Breast Cancer",,"Recruiting","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: Abemaciclib|Drug: Nonsteroidal Aromatase Inhibitor (NSAI)|Drug: Fulvestrant","Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (Serious or Non-Serious)|Percentage of Participants who Discontinue from Study Treatment Due to Adverse Events","Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 4","200","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17782|I3Y-IN-JPEC","February 22, 2021","March 3, 2023","March 3, 2023","January 13, 2021",,"May 11, 2022","MNJ Institute of Oncology, Hyderabad, Andhra Pradesh, India|Nirmal Hospital Pvt Ltd., Surat, Gujarat, India|Unique Hospital Multispecialty & Research Institute, Surat, Gujarat, India|Anand Multispeciality Hospital, Vadodara, Gujarat, India|Kailash Cancer Hospital & Research Centre (KCHRC), Waghodia, Gujarat, India|HCG Cancer Centre, Kalinga Rao Road, Bengaluru, Karnataka, India|Regional Cancer Centre, Trivandrum, Kerala, India|SRJ-CBCC Cancer Hospital, Indore, Madhya Pradesh, India|Kingsway Hospital, Nagpur, Maharashtra, India|Meditrina Institute of Medical Sciences, Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, India|Max Superspeciality Hospital, Chandigarh, India|Rajiv Gandhi Cancer Institute & Research Center, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04707196"
297,"NCT01337154","First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Stage IIIB Non-small Cell Lung Cancer With Pleural Effusion|Stage IV Non-small Cell Lung Cancer","Drug: Tamibarotene|Drug: Placebo","Progression-free survival|Objective response rate|Overall survival|Assessment of quality of life","CytRx","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TAMI-P2-NSCLC-01","April 2011","June 2013","June 2013","April 18, 2011",,"June 28, 2013","Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States|Kansas City Cancer Center, Kansas City, Kansas, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Department of Medical Oncology, Specialized Hospital for Active Treatment of Oncological Diseases, Sofia, Bulgaria|Medical Oncology Clinic, Multiprofile Hospital for Active Treatment, Varna, Bulgaria|Department of Medical Oncology, Complex Oncology Center, Veliko Tarnovo, Bulgaria|NIZAM's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|M S Patel Cancer Centre, Shree Krishna Hospital, Anand, Gujarat, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|Dr. Kamakshi Memorial Hospital, Chennai, Pallikaranai, India|G Kuppuswamy Naidu Memorial Hospital, Valvadi Narayanaswamy Cancer Centre, Coimbatore, Pappanaickenpalayam, India|Orchid Nursing Home, Kolkata, West Bengal, India|Instituto Nacional de Cancerologia, Mexico City, Mexico|State Medical Institution: Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk, Russian Federation|State Therapeutical and Prophylatic Institution: Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|State Medical Instituion Kursk Regional Oncology Center, Kursk, Russian Federation|Non-State Medical Institution: Central Clinical Hospital #2, Moscow, Russian Federation|St. Petersburg State Healthcare Institution: City Clinical Oncology Center, Saint-Pertersburg, Russian Federation|Public Institution: Dnipropetrovsk City Multispeciality Clinical Hospital #4, Dnipropetrovsk, Ukraine|Public Clinical Treatment and Prophylaxis Instituion: Donetsk Regional Antitumor Center, Donetsk, Ukraine|Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine|Public Healthcare Instituion: Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kyiv City Clinical Oncology Center, Kyiv, Ukraine|Zakarpattia Regional Clinical Oncology Center, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01337154"
298,"NCT00687817","Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer",,"Completed","No Results Available","Non-small Cell Lung Cancer","Drug: bavituximab plus paclitaxel and carboplatin","Overall response (complete response + partial response) to a combination of bavituximab plus carboplatin and paclitaxel in patients with previously untreated locally advanced or metastatic non-small-cell lung cancer|Time to tumor progression, duration of response, overall survival and safety","Peregrine Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","49","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPHM 0701","June 2008","July 2010","July 2010","June 2, 2008",,"March 24, 2011","Apollo Hospital, Bannerghatta Rd., Banglore, India|Kidwai Hospital, Munigowda Road, Banglore, India|M S Ramaiah Hospital, New BEL Rd, Banglore, India|Bangalore Institute of Oncology Speciality Centre, Sampangi Ram Nagar, Banglore, India|Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad, India|Yashoda Hospital, Somajiguda, Hyderabad, India|RCC Medical College, Trivandrum, Kerala, India|Orchid Nursing Home, Phoolanbhaghan, Kolkata, India|Ruby Hall Clinic, Pune, India",,"https://ClinicalTrials.gov/show/NCT00687817"
299,"NCT01828099","LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer",,"Active, not recruiting","Has Results","Non-Small Cell Lung Cancer","Drug: Ceritinib|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin","Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC)|Overall Survival (OS)|Overall Response Rate (ORR)|Duration of Response (DOR)|Disease Control Rate (DCR)|Time to Response (TTR)|Patient Reported Outcomes","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","376","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLDK378A2301|2013-000319-26","July 9, 2013","June 24, 2016","December 14, 2023","April 10, 2013","September 21, 2017","December 7, 2021","Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Auckland, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Itajai, SC, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chongqing, Chongqing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chongqing, China|Novartis Investigative Site, Guang Dong Province, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Toulon Cedex 9, Val De Marne, France|Novartis Investigative Site, Villejuif Cedex, Villejuif, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Limoges Cedex, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Heraklion Crete, Greece|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Bergamo, (bg), Italy|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Akashi, Hyogo, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Koto ku, Tokyo, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Reus, Tarragona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Kuei-Shan Chiang, Taoyuan/ Taiwan ROC, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taichung City, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Leeds, West Yorkshire, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01828099"
300,"NCT00374322","Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer",,"Completed","Has Results","Neoplasms, Breast","Drug: lapatinib|Other: placebo","Number of Participants (Par.) With Any Recurrence of the Initial Disease, Second Primary Cancer, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])|Number of Participants Who Died (Overall Survival)|Percentage of Participants With the Indicated Period of Recurrence-free Survival (Time to First Recurrence)|Percentage of Participants With the Indicated Period of Distant Recurrence-free Survival (Time to Distant Recurrence)|Time to Central Nervous System (CNS) Recurrence|Number of Participants With CNS Recurrence|Modified Disease-free Survival (MDFS)|Number of Participants With Any Recurrence of the Initial Disease, Contralateral Breast Cancer, or Death (Disease-free Survival [DFS])|Change From Baseline in Short Form-36 Version 2 (SF-36 v2) Scores for the Physical Component Summary (PCS)|Change From Baseline in SF-36 v2 Scores for the Mental Component Summary (MCS)|Change From Baseline in the SF-36 v2 Domain Scores for Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH)|Number of Participants With Hematology Values Outside the Reference Range for the Indicated Parameters|Number of Participants With Clinical Chemistry Values Outside the Reference Range for the Indicated Parameters|Number of Participants With Non-laboratory Toxicities of the Indicated Toxicity Grades|Number of Participants Experiencing Primary or Secondary Cardiac Events|Number of Participants With the Indicated Electrocardiogram (ECG) Findings","GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Phase 3","3166","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EGF105485","August 2006","September 2011","July 2013","September 11, 2006","August 18, 2014","August 18, 2014","GSK Investigational Site, Tuscaloosa, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Sedona, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Fayetteville, Arkansas, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Anaheim, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Gilroy, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, La Verne, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Fairfield, Connecticut, United States|GSK Investigational Site, Norwalk, Connecticut, United States|GSK Investigational Site, Torrington, Connecticut, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Plantation, Florida, United States|GSK Investigational Site, Port St. Lucie, Florida, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Joliet, Illinois, United States|GSK Investigational Site, Park Ridge, Illinois, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Ames, Iowa, United States|GSK Investigational Site, Sioux City, Iowa, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Marrero, Louisiana, United States|GSK Investigational Site, Scarborough, Maine, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Danvers, Massachusetts, United States|GSK Investigational Site, Newton, Massachusetts, United States|GSK Investigational Site, Kalamazoo, Michigan, United States|GSK Investigational Site, Duluth, Minnesota, United States|GSK Investigational Site, Edina, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Robbinsdale, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, St. Joseph, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Hooksett, New Hampshire, United States|GSK Investigational Site, Cherry Hill, New Jersey, United States|GSK Investigational Site, Morristown, New Jersey, United States|GSK Investigational Site, Paramus, New Jersey, United States|GSK Investigational Site, Sparta, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, East Setauket, New York, United States|GSK Investigational Site, Mount Kisco, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Charleston, North Carolina, United States|GSK Investigational Site, Gastonia, North Carolina, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Hickory, North Carolina, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Middletown, Ohio, United States|GSK Investigational Site, Drexel Hill, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Germantown, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bedford, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Duncanville, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Round Rock, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Chesapeake, Virginia, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Richland, Virginia, United States|GSK Investigational Site, Kirkland, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Yakima, Washington, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Neuquen, Neuquén, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, San Miguel de Tucumán, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Campbelltown, New South Wales, Australia|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Kogarah, New South Wales, Australia|GSK Investigational Site, Liverpool, New South Wales, Australia|GSK Investigational Site, North Sydney, New South Wales, Australia|GSK Investigational Site, Douglas, Queensland, Australia|GSK Investigational Site, Herston, Queensland, Australia|GSK Investigational Site, Redcliffe, Queensland, Australia|GSK Investigational Site, South Brisbane, Queensland, Australia|GSK Investigational Site, Bedford Park, South Australia, Australia|GSK Investigational Site, Elizabeth Vale, South Australia, Australia|GSK Investigational Site, Woodville, South Australia, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, East Melbourne, Victoria, Australia|GSK Investigational Site, Fitzroy, Victoria, Australia|GSK Investigational Site, Footscray, Victoria, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Parkville, Victoria, Australia|GSK Investigational Site, Ringwood East, Victoria, Australia|GSK Investigational Site, Wodonga, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Santo Andre, São Paulo, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, St. John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Barrie, Ontario, Canada|GSK Investigational Site, Brampton, Ontario, Canada|GSK Investigational Site, Kingston, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Ottawa, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Saskatoon, Saskatchewan, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Jinan, Shandong, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Osijek, Croatia|GSK Investigational Site, Pula, Croatia|GSK Investigational Site, Rijeka, Croatia|GSK Investigational Site, Split, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Prague 2, Czech Republic|GSK Investigational Site, Praha 8, Czech Republic|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Copenhagen, Denmark|GSK Investigational Site, Esbjerg, Denmark|GSK Investigational Site, Herlev, Denmark|GSK Investigational Site, Naestved, Denmark|GSK Investigational Site, Odense, Denmark|GSK Investigational Site, Roskilde, Denmark|GSK Investigational Site, Vejle, Denmark|GSK Investigational Site, Angers, France|GSK Investigational Site, Besançon, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Caen Cedex 05, France|GSK Investigational Site, Clermont Ferrand, France|GSK Investigational Site, Colmar Cedex, France|GSK Investigational Site, Dijon Cedex, France|GSK Investigational Site, Lille cedex, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Lyon Cedex 08, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille Cedex 09, France|GSK Investigational Site, Montbeliard, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Nantes cedex, France|GSK Investigational Site, Nice Cedex 2, France|GSK Investigational Site, Paris Cedex 15, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Rennes, France|GSK Investigational Site, Saint Grégoire, France|GSK Investigational Site, Saint-Cloud, France|GSK Investigational Site, Saint-Herblain, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Toulouse Cedex 3, France|GSK Investigational Site, Toulouse Cedex 9, France|GSK Investigational Site, Tourcoing, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Konstanz, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mannheim, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mayen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Mutlangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Rheinfelden, Baden-Wuerttemberg, Germany|GSK Investigational Site, Schwetzingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Singen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Stuttgart, Baden-Wuerttemberg, Germany|GSK Investigational Site, Tuebingen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Amberg, Bayern, Germany|GSK Investigational Site, Aschaffenburg, Bayern, Germany|GSK Investigational Site, Bayreuth, Bayern, Germany|GSK Investigational Site, Deggendorf, Bayern, Germany|GSK Investigational Site, Ebersberg, Bayern, Germany|GSK Investigational Site, Eggenfelden, Bayern, Germany|GSK Investigational Site, Erlangen, Bayern, Germany|GSK Investigational Site, Fuerth, Bayern, Germany|GSK Investigational Site, Kempten, Bayern, Germany|GSK Investigational Site, Krumbach, Bayern, Germany|GSK Investigational Site, Marktredwitz, Bayern, Germany|GSK Investigational Site, Memmingen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Rehling, Bayern, Germany|GSK Investigational Site, Rosenheim, Bayern, Germany|GSK Investigational Site, Roth, Bayern, Germany|GSK Investigational Site, Schwandorf, Bayern, Germany|GSK Investigational Site, Weiden, Bayern, Germany|GSK Investigational Site, Cottbus, Brandenburg, Germany|GSK Investigational Site, Fuerstenwalde, Brandenburg, Germany|GSK Investigational Site, Frankfurt am Main, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Kassel, Hessen, Germany|GSK Investigational Site, Kassel, Hessen, Germany|GSK Investigational Site, Wiesbaden, Hessen, Germany|GSK Investigational Site, Guestrow, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Goslar, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hildesheim, Niedersachsen, Germany|GSK Investigational Site, Salzgitter, Niedersachsen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duisburg, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Herne, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hilden, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muelheim, Nordrhein-Westfalen, Germany|GSK Investigational Site, Porta Westfalica, Nordrhein-Westfalen, Germany|GSK Investigational Site, Recklinghausen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Troisdorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Velbert, Nordrhein-Westfalen, Germany|GSK Investigational Site, Witten, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Homburg/Saar, Saarland, Germany|GSK Investigational Site, Neunkirchen, Saarland, Germany|GSK Investigational Site, Saarbruecken, Saarland, Germany|GSK Investigational Site, Blankenburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Stendal, Sachsen-Anhalt, Germany|GSK Investigational Site, Chemnitz, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Kauschwitz, Sachsen, Germany|GSK Investigational Site, Neustadt, Sachsen, Germany|GSK Investigational Site, Spremberg, Sachsen, Germany|GSK Investigational Site, Zittau, Sachsen, Germany|GSK Investigational Site, Zwickau, Sachsen, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Eisenach, Thueringen, Germany|GSK Investigational Site, Jena, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bremen, Germany|GSK Investigational Site, Bremen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Chania, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Wanchai, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Kistarcsa, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Chennai, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Kfar Saba, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Rehovot, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Avellino, Campania, Italy|GSK Investigational Site, Piacenza, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Sassari, Sardegna, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Negrar (Verona), Veneto, Italy|GSK Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, songpa-gu, Seoul, Korea, Republic of|GSK Investigational Site, Liepaja, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Klaipeda, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Mérida, Yucatán, Mexico|GSK Investigational Site, Chihuahua, Mexico|GSK Investigational Site, DF., Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, México D.F., Mexico|GSK Investigational Site, Auckland, New Zealand|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Hamilton, New Zealand|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Baguio City, Benguet, Philippines|GSK Investigational Site, Cebu, Philippines|GSK Investigational Site, Pasig City, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Torun, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Ryazan, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Banska Bystrica, Slovakia|GSK Investigational Site, Bardejov, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Nitra, Slovakia|GSK Investigational Site, Tygerberg, Western Province, South Africa|GSK Investigational Site, Athlone Park, Amanzimtoti, South Africa|GSK Investigational Site, Groenkloof, South Africa|GSK Investigational Site, Kraaifontein, South Africa|GSK Investigational Site, Overport, South Africa|GSK Investigational Site, Parktown, South Africa|GSK Investigational Site, Port Elizabeth, South Africa|GSK Investigational Site, Sandton, South Africa|GSK Investigational Site, Saxonwold, Johannesburg, South Africa|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cáceres, Spain|GSK Investigational Site, Girona, Spain|GSK Investigational Site, Jaén, Spain|GSK Investigational Site, Lerida, Spain|GSK Investigational Site, Llobregat, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Mataró, Spain|GSK Investigational Site, Orense, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Palma de Mallorca, Spain|GSK Investigational Site, Santa Cruz de Tenerife, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Zaragoza, Spain|GSK Investigational Site, Dnepropetrovsk, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lvov, Ukraine|GSK Investigational Site, Uzhgorod, Ukraine|GSK Investigational Site, Chelmsford, Essex, United Kingdom|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Bournemouth, United Kingdom|GSK Investigational Site, Edgbaston, Birmingham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Lindley, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Maidstone, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Shrewsbury, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00374322"
301,"NCT00680940","A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer","NSCLC","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Paclitaxel & Cisplatin|Biological: Mycobacterium w.","Overall survival time of patients, quality of life|Response rate, Hematological toxicity","Cadila Pharnmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","221","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-60/7260","June 2008","December 2010","December 2010","May 20, 2008",,"August 7, 2012","Gujarat Cancer & Research Institute, New Civil Hospital Campus, Asarwa, Ahmedabad, India|Regional Cancer Center, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India|MNJ Institute of Oncology, Regional Cancer Centre, Red Hills, Hyderabad, India|Malabar Institute of Medical Science (MIMS), Calicut, Kerala, India|B.P. Poddar Hospital and Medical Research Ltd., New Alipore, Kolkata, India|Choithram Hospital and Research Centre, Indore, Madhya Pradesh, India|Regional Cancer Centre, Indira Gandhi Institute of Medical Science, Sheikhpura, Patna, India|Patel Hospital Pvt. Ltd, Jalandhar, Punjab, India|Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, Rajasthan, India|V.N. Cancer Center, GKNM Hospital, Coimbatore, TamilNadu, India|Netaji Subash Chandra Bose Cancer Research Institute, Kolkata, West Bangal, India|Bankura Sammilani Medical College, Gobindnagar, West Bengal, India|Institute of Post Graduate Medical education & Research, Kolkata, West Bengal, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT00680940"
302,"NCT01412957","Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer",,"Completed","Has Results","Metastatic Colorectal Cancer","Other: Best Supportive Care (BSC)|Drug: Panitumumab","Overall Survival|Progression-free Survival|Overall Survival in Participants With Wild-type RAS|Progression Free Survival (PFS) in Participants With Wild-type RAS|Objective Response Rate|Objective Response Rate in Participants With Wild-type RAS|Number of Participants With Adverse Events (AEs)|Maximum Post-baseline Change From Baseline in Corrected QT (QTc) Interval","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20100007|2010-022951-49","November 2011","June 2014","November 2016","August 9, 2011","April 8, 2016","March 15, 2017","Research Site, Curitiba, Paraná, Brazil|Research Site, Natal, Rio Grande do Norte, Brazil|Research Site, Ijui, Rio Grande do Sul, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Greenfield Park, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Québec, Quebec, Canada|Research Site, Trois-Rivières, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Vina del Mar, Valparaíso, Chile|Research Site, Fuzhou, Fujian, China|Research Site, Fuzhou, Fujian, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Nanjing, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Xi An, Shaanxi, China|Research Site, Xi An, Shaanxi, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Shanghai, China|Research Site, Osijek, Croatia|Research Site, Pula, Croatia|Research Site, Rijeka, Croatia|Research Site, Split, Croatia|Research Site, Zagreb, Croatia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Visakhapatnam, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Nilai, Negri Sembilan, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Cuernavaca, Morelos, Mexico|Research Site, Oaxaca, Mexico|Research Site, Davao City, Davao, Philippines|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Lasi, Romania|Research Site, Ploiesti, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Belgrade, Serbia|Research Site, Nis, Serbia|Research Site, Sremska Kamenica, Serbia",,"https://ClinicalTrials.gov/show/NCT01412957"
303,"NCT01160601","Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer",,"Completed","No Results Available","Non-Squamous Non-Small Cell Lung Cancer","Drug: Paclitaxel / Carboplatin|Drug: bavituximab","Objective Response Rate","Peregrine Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPHM 1001","June 2010","June 2013","September 2013","July 12, 2010",,"April 19, 2017","Ironwood Cancer and Research Center, Chandler, Arizona, United States|Baptist Clinical Research, Jonesboro, Arkansas, United States|American Institute of Research, Whittier, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Community Hospital, Munster, Indiana, United States|Cedar Valley Medical Specialists, PC, Waterloo, Iowa, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Center for Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|The Christ Hospital Cancer Center Research, Cincinnati, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States|Hematology-Oncology of Knoxville/Mercy Medical Center, Knoxville, Tennessee, United States|Delta Hematology Oncology Associates, PC, Portsmouth, Virginia, United States|JSC A.Gvamichava National Oncology Center, Tbilisi, Georgia|Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia|BiBi General Hospital & Cancer Centre, Hyderabad, Andhra Pradesh, India|Mahavir Cancer Sansthan, Patna, Bihar, India|O.P. Jindal Institute of Cancer & Research, Hisar, Haryana, India|Bangalore Institute of Oncology Specialty Centre, Bangalore, Karnataka, India|Kodlikeri Memorial Hospital, Aurangabad, Maharashtra, India|Cancer Care Clinic, Nagpur, Maharashtra, India|Shatabdi Superspecialty Hospital, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|SMS Medical College Hospital, Jaipur, Rajasthan, India|State Institution of Healthcare ""Pyatigorsk Oncology Dispensary"", Pyatigorsk, Stavropol Territory, Russian Federation|State Institution of Healthcare of Yaroslavl Region ""Regional Clinical Oncology Hospital"", Yaroslavl, Yaroslavl Region, Russian Federation|State Medical Preventive Institution ""Chelyabinsk Regional Clinical Oncology"", Chelyabinsk, Russian Federation|State Institution of Healthcare "" Ivanovo Regional Oncology Dispensary "", Ivanovo, Russian Federation|Institution of Russian Academy of Medical Science ""Russian Oncology Scientific Centre named after N. N. Blokhina RAMN"", Moscow, Russian Federation|State Educational Institution of Higher Professional Education ""Saint-Petersburg State Medical University named after academician I.P. Pavlov of Federal Agency of Healthcare and Social Development"", Saint-Petersburg, Russian Federation|State Institution of Healthcare ""Tula Regional Oncology Dispensary"", Tula, Russian Federation|City multi-field clinical hospital # 4, Department of chemotherapy; Dnipropetrovsk State Medical Academy, Chair of Oncology and Medical Radiology;, Dnipropetrovsk, Ukraine|Municipal Clinical Medical and Prophylactic Institution ""Donetsk Regional Antineoplastic Center"", onco-chemotherapy department #1, Donetsk, Ukraine|State Institution ""Institute of Medical Radiology named after S.P. Grygoryev of AMS of Ukraine"", department of chemotherapy, Kharkiv, Ukraine|Kyiv City Oncology Hospital, Thoracal Department, Kyiv, Ukraine|Uzhgorod Central City Clinical Hospital, City Oncology Center, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01160601"
304,"NCT04655469","Personal Health Train for Radiation Oncology in India and The Netherlands","TRAIN","Active, not recruiting","No Results Available","Head and Neck Carcinoma",,"Overall survival|Recurrence|Distant metastases|Treatment-related adverse events","Maastricht Radiation Oncology","All","18 Years and older   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","629.002.212","April 10, 2020","April 10, 2022","February 1, 2024","December 7, 2020",,"December 7, 2020","Healthcare Global, Bengaluru, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Maastro, Maastricht, Limburg, Netherlands",,"https://ClinicalTrials.gov/show/NCT04655469"
305,"NCT01138163","Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer",,"Completed","No Results Available","Non-small-cell Lung Cancer","Drug: Docetaxel plus bavituximab or placebo","Objective Response Rate","Peregrine Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","121","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PPHM 0902","June 2010","October 2012","May 2013","June 7, 2010",,"April 19, 2017","Ironwood Cancer and Research Center, Chandler, Arizona, United States|South Bay Hematology Oncology, Campbell, California, United States|Medical Oncology Care Associates, Orange, California, United States|American Institute of Research, Whittier, California, United States|The Center for Hematology-Oncology/Boca Raton Community Hospital, Inc, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Georgia Cancer Specialists, PC, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cedar Valley Medical Specialists, PC, Waterloo, Iowa, United States|Jewish Hospital, Louisville, Kentucky, United States|Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States|Nebraska Hematology Oncology, PC, Lincoln, Nebraska, United States|Hanover Medical Specialists, PA, Wilmington, North Carolina, United States|The Christ Hospital Cancer Center Research, Cincinnati, Ohio, United States|Oncology/ Hematology Care, Inc, Cincinnati, Ohio, United States|Dayton Clinical Oncology Program, Dayton, Ohio, United States|Pennsylvania State Hershey Cancer Institute, Hershey, Pennsylvania, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Sarah Cannon Research Institute, LLC, Nashville, Tennessee, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|University of Utah Hospitals and Clinics, Huntsman Cancer Institute, Salt Lake City, Utah, United States|JSC A.Gvamichava National Oncology Center, Tbilisi, Georgia|Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia|BiBi General Hospital & Cancer Centre, Hyderabad, Andhra Pradesh, India|Nizam's Institute of Medical Sciences, Hyderabad, Andra Pradesh, India|Mahavir Cancer Sansthan, Patna, Bihar, India|O.P. Jindal Institute of Cancer & Research, Hisar, Haryana, India|Bangalore Institute of Oncology Specialty Centre, Bangalore, Karnataka, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Bharath Hospital and Institute of Oncology, Mysore, Karnataka, India|Kodlikeri Memorial Hospital, Aurangabad, Maharashtra, India|Cancer Care Clinic, Nagpur, Maharashtra, India|Shatabdi Superspecialty Hospital, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|SMS Medical College Hospital, Jaipur, Rajasthan, India|Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, India|Shanti Mukund Hospital Curie Cancer Center, Delhi, India|All India Institute of Medical Sciences, Delhi, India|State Medical Preventive Institution ""Chelyabinsk Regional Clinical Oncology"", Chelyabinsk, Russian Federation|State Institution of Healthcare "" Ivanovo Regional Oncology Dispensary "", Ivanovo, Russian Federation|Institution of Russian Academy of Medical Science ""Russian Oncology Scientific Centre named after N. N. Blokhina RAMN"", Moscow, Russian Federation|State Educational Institution of Higher Professional Education ""Saint-Petersburg State Medical University named after academician I.P. Pavlov of Federal Agency of Healthcare and Social Development"", Saint Petersburg, Russian Federation|State Institution of Healthcare ""Pyatigorsk Oncology Dispensary"", Stavropol', Russian Federation|State Institution of Healthcare ""Tula Regional Oncology Dispensary"", Tula, Russian Federation|State Institution of Healthcare of Yaroslavl Region ""Regional Clinical Oncology Hospital"", Yaroslavl, Russian Federation|City multi-field clinical hospital # 4, Department of chemotherapy; Dnipropetrovsk State Medical Academy, Chair of Oncology and Medical Radiology;, Dnipropetrovsk, Ukraine|Municipal Clinical Medical and Prophylactic Institution ""Donetsk Regional Antineoplastic Center"", onco-chemotherapy, Donetsk, Ukraine|State Institution ""Institute of Medical Radiology named after S.P. Grygoryev of AMS of Ukraine"", department of chemotherapy, Kharkiv, Ukraine|Kyiv City Oncology Hospital, Thoracal Department, Kyiv, Ukraine|Uzhgorod Central City Clinical Hospital, City Oncology Center, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01138163"
306,"NCT04035486","A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)","FLAURA2","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Osimertinib|Drug: Pemetrexed/Carboplatin|Drug: Pemetrexed/Cisplatin","Progression-free survival (PFS)|Overall Survival (OS)|Landmark Overall Survival (LOS)|Objective Response Rate (ORR)|Duration of Response (DoR)|Depth of Response|Disease Control Rate (DCR) by Investigator|Progression Free Survival 2 (PFS2)|Change from baseline and time to deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items (EORTC QLQ-C30)|Change from baseline and time to deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items (EORTC QLQ-LC13)|Concordance of epidermal growth factor receptor mutation status between the local epidermal growth factor receptor mutation test and the central cobas® epidermal growth factor receptor Mutation Test v2 results from tumor samples with evaluable results|Progression-free survival (PFS) by Investigator by plasma epidermal growth factor receptor mutation status.|Plasma concentration of osimertinib when given with or without chemotherapy|Plasma concentration of metabolite AZ5104 when osimertinib is given with or without chemotherapy","AstraZeneca","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","587","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5169C00001","July 2, 2019","April 3, 2023","June 3, 2026","July 29, 2019",,"April 18, 2022","Research Site, Bellflower, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, West Hollywood, California, United States|Research Site, Whittier, California, United States|Research Site, Orlando, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Henderson, Nevada, United States|Research Site, Albany, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Blacksburg, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Vancouver, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Cordoba, Argentina|Research Site, Santa Fe, Argentina|Research Site, Camperdown, Australia|Research Site, Chermside, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Melbourne, Australia|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Londrina, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Vitoria, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Olomouc, Czechia|Research Site, Ostrava - Vitkovice, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux Cedex, France|Research Site, Lyon, France|Research Site, Montpellier, France|Research Site, Villejuif Cedex, France|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Bunkyo-ku, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka, Japan|Research Site, Hidaka-shi, Japan|Research Site, Himeji-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan|Research Site, Osaka-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Las Pinas, Philippines|Research Site, Legazpi City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Syktyvkar, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Poprad, Slovakia|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Rondebosch, South Africa|Research Site, Changhua, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Cambridge, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04035486"
307,"NCT00480025","GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer",,"Terminated","Has Results","Lung Cancer, Non-Small Cell","Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Biological: Placebo Control","Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the Overall Population|Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the No-CT Population|Person Year Rate (PYAR) as Regards Disease-free Survival (DFS) in the CT Population|Person Year Rate (PYAR) as Regards Overall-survival (OS) in the Overall Population|Person Year Rate (PYAR) as Regards Overall-survival (OS) in the No-CT Population|Person Year Rate (PYAR) as Regards Overall-survival (OS) in the CT Population|Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the Overall Population|Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the No-CT Population|Person Year Rate (PYAR) as Regards Lung-cancer Specific Survival (LCSS) in the CT Population|Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the Overall Population|Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the No-CT Population|Kaplan-Meier Estimate (KME) of 2, 3, 4 and 5-year as Regards Disease-free Survival (DFS) in the CT Population|Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the Overall Population|Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the No-CT Population|Person Year Rate (PYAR) as Regards Disease-free Specific Survival (DFSS) in the CT Population|Number of Subjects Seropositive for Anti-Melanoma AntiGEn (MAGE)-A3 Antibodies (Anti-MAGE-A3 S+)|Number of Humoral Responders as Regards Anti-Melanoma AntiGEn (MAGE)-A3 Antibodies (Anti-MAGE-A3 HR)|Number of Subjects Seropositive for Anti-protein D (PD) Antibodies (Anti-PD S+)|Number of Humoral Responders as Regards Anti-protein D (PD) Antibodies (Anti-PD HR)|Health-related Quality of Life (HQL) Scores|Number of Patients With Abnormal Alanine Aminotransferase (ALT) Values by Maximum Grade|Number of Patients With Abnormal Alanine Aspartate Aminotransferase (AST) Values by Maximum Grade|Number of Patients With Abnormal Alkaline Phosphatase (ALKP) Values by Maximum Grade|Number of Patients With Abnormal Bilirubin (BIL) Values by Maximum Grade|Number of Patients With Abnormal Creatinine (CREA) Values by Maximum Grade|Number of Patients With Abnormal Haemoglobin (HGB) Values by Maximum Grade|Number of Patients With Abnormal Leukocytes (LEU) Values by Maximum Grade|Number of Patients With Abnormal Lymphocytes (LYM) Values by Maximum Grade|Number of Patients With Abnormal Neutrophils (NEU) Values by Maximum Grade|Number of Patients With Abnormal Platelets (PLA) Values by Maximum Grade|Number of Patients With Any Adverse Events (AEs) and With AEs by Maximum Grade Reported - Up to Data Lock Point (DLP)|Number of Patients With Serious Adverse Events (SAEs) - Up to Data Lock Point (DLP)","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","2278","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","109493|2007-001283-73","October 4, 2007","December 6, 2013","September 23, 2014","May 30, 2007","January 30, 2019","December 22, 2020","GSK Investigational Site, Birmingham, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Mobile, Alabama, United States|GSK Investigational Site, Phoenix, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Scottsdale, Arizona, United States|GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Fayetteville, Arkansas, United States|GSK Investigational Site, Fort Smith, Arkansas, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Burbank, California, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, La Jolla, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Montebello, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, Palo Alto, California, United States|GSK Investigational Site, Pleasant Hill, California, United States|GSK Investigational Site, Rancho Mirage, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Francisco, California, United States|GSK Investigational Site, Santa Rosa, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Vallejo, California, United States|GSK Investigational Site, West Hollywood, California, United States|GSK Investigational Site, Aurora, Colorado, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Danbury, Connecticut, United States|GSK Investigational Site, Torrington, Connecticut, United States|GSK Investigational Site, Waterbury, Connecticut, United States|GSK Investigational Site, Newark, Delaware, United States|GSK Investigational Site, Washington, District of Columbia, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Boynton Beach, Florida, United States|GSK Investigational Site, Deerfield Beach, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Alpharetta, Georgia, United States|GSK Investigational Site, Athens, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Macon, Georgia, United States|GSK Investigational Site, Marietta, Georgia, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Honolulu, Hawaii, United States|GSK Investigational Site, Coeur d'Alene, Idaho, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Decatur, Illinois, United States|GSK Investigational Site, Evanston, Illinois, United States|GSK Investigational Site, Harvey, Illinois, United States|GSK Investigational Site, Park Ridge, Illinois, United States|GSK Investigational Site, Peoria, Illinois, United States|GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Munster, Indiana, United States|GSK Investigational Site, New Albany, Indiana, United States|GSK Investigational Site, Waterloo, Iowa, United States|GSK Investigational Site, Ashland, Kentucky, United States|GSK Investigational Site, Hazard, Kentucky, United States|GSK Investigational Site, Lexington, Kentucky, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Alexandria, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Shreveport, Louisiana, United States|GSK Investigational Site, Annapolis, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Silver Spring, Maryland, United States|GSK Investigational Site, Towson, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Bay City, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Detroit, Michigan, United States|GSK Investigational Site, Flint, Michigan, United States|GSK Investigational Site, Grand Rapids, Michigan, United States|GSK Investigational Site, Lansing, Michigan, United States|GSK Investigational Site, Lapeer, Michigan, United States|GSK Investigational Site, Southfield, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Rochester, Minnesota, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Springfield, Missouri, United States|GSK Investigational Site, Billings, Montana, United States|GSK Investigational Site, Grand Island, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Lebanon, New Hampshire, United States|GSK Investigational Site, Long Branch, New Jersey, United States|GSK Investigational Site, Paramus, New Jersey, United States|GSK Investigational Site, Armonk, New York, United States|GSK Investigational Site, Buffalo, New York, United States|GSK Investigational Site, East Syracuse, New York, United States|GSK Investigational Site, Flushing, New York, United States|GSK Investigational Site, Mineola, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Greenville, North Carolina, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Bethlehem, Pennsylvania, United States|GSK Investigational Site, Danville, Pennsylvania, United States|GSK Investigational Site, Lancaster, Pennsylvania, United States|GSK Investigational Site, Langhorne, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Sayre, Pennsylvania, United States|GSK Investigational Site, Wilkes-Barre, Pennsylvania, United States|GSK Investigational Site, Willow Grove, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Sumter, South Carolina, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Cookeville, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Memphis, Tennessee, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Grapevine, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Round Rock, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Salt Lake City, Utah, United States|GSK Investigational Site, Fairfax, Virginia, United States|GSK Investigational Site, Roanoke, Virginia, United States|GSK Investigational Site, Everett, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, C.a.b.a., Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Cipolletti, Río Negro, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Tucuman, Argentina|GSK Investigational Site, Garran, Australian Capital Territory, Australia|GSK Investigational Site, Camperdown, New South Wales, Australia|GSK Investigational Site, Tweed Heads, New South Wales, Australia|GSK Investigational Site, Waratah, New South Wales, Australia|GSK Investigational Site, Westmead, New South Wales, Australia|GSK Investigational Site, Chermside, Queensland, Australia|GSK Investigational Site, South Brisbane, Queensland, Australia|GSK Investigational Site, Woolloongabba, Queensland, Australia|GSK Investigational Site, Adelaide, South Australia, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Box Hill, Victoria, Australia|GSK Investigational Site, Fitzroy, Victoria, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Richmond, Victoria, Australia|GSK Investigational Site, Nedlands, Western Australia, Australia|GSK Investigational Site, Perth, Western Australia, Australia|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Wels, Austria|GSK Investigational Site, Antwerpen, Belgium|GSK Investigational Site, Brussels, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Duffel, Belgium|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Genk, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Jette, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Namur, Belgium|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Barretos, São Paulo, Brazil|GSK Investigational Site, Santo André, São Paulo, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Surrey, British Columbia, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Newmarket, Ontario, Canada|GSK Investigational Site, Scarborough, Ontario, Canada|GSK Investigational Site, St Catherines, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Greenfield Park, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Québec, Canada|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Nanning, Guangxi, China|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Changchun, Jilin, China|GSK Investigational Site, Chengdu, Sichuan, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Changsha, China|GSK Investigational Site, Guangzhou, China|GSK Investigational Site, Harbin, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Wuhan, China|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Plzen, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Praha 8, Czechia|GSK Investigational Site, Usti nad Labem, Czechia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Angers cedex 9, France|GSK Investigational Site, Bayonne, France|GSK Investigational Site, Beauvais, France|GSK Investigational Site, Bethune Cedex, France|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Brest cedex, France|GSK Investigational Site, Bron, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Elbeuf, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Limoges Cedex, France|GSK Investigational Site, Lorient cedex, France|GSK Investigational Site, Lyon cedex 08, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Marseille cedex 20, France|GSK Investigational Site, Meaux, France|GSK Investigational Site, Metz, France|GSK Investigational Site, Montpellier, France|GSK Investigational Site, Mulhouse Cedex, France|GSK Investigational Site, Nantes, France|GSK Investigational Site, Nice, France|GSK Investigational Site, Nîmes, France|GSK Investigational Site, Paris cedex 20, France|GSK Investigational Site, Paris Cedex 5, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Perpignan, France|GSK Investigational Site, Périgueux cedex, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Rennes Cedex 09, France|GSK Investigational Site, Rouen, France|GSK Investigational Site, Saint Herblain, France|GSK Investigational Site, Saint-Priest en Jarez, France|GSK Investigational Site, Saint-Quentin, France|GSK Investigational Site, St Grégoire, France|GSK Investigational Site, Toulon cedex 09, France|GSK Investigational Site, Toulouse cedex 9, France|GSK Investigational Site, Vannes, France|GSK Investigational Site, Villefranche sur Saône, France|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Wangen, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Bayreuth, Bayern, Germany|GSK Investigational Site, Ebensfeld, Bayern, Germany|GSK Investigational Site, Gauting, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Rosenheim, Bayern, Germany|GSK Investigational Site, Wuerzburg, Bayern, Germany|GSK Investigational Site, Frankfurt/Oder, Brandenburg, Germany|GSK Investigational Site, Darmstadt, Hessen, Germany|GSK Investigational Site, Frankfurt/Main, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Frankfurt, Hessen, Germany|GSK Investigational Site, Fulda, Hessen, Germany|GSK Investigational Site, Immenhausen, Hessen, Germany|GSK Investigational Site, Offenbach, Hessen, Germany|GSK Investigational Site, Greifswald, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Rostock, Mecklenburg-Vorpommern, Germany|GSK Investigational Site, Braunschweig, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Oldenburg, Niedersachsen, Germany|GSK Investigational Site, Ostercappeln, Niedersachsen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bielefeld, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bochum, Nordrhein-Westfalen, Germany|GSK Investigational Site, Bonn, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Hemer, Nordrhein-Westfalen, Germany|GSK Investigational Site, Herne, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koeln, Nordrhein-Westfalen, Germany|GSK Investigational Site, Luedenscheid, Nordrhein-Westfalen, Germany|GSK Investigational Site, Moers, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Mulheim, Nordrhein-Westfalen, Germany|GSK Investigational Site, Neuss, Nordrhein-Westfalen, Germany|GSK Investigational Site, Oberhausen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Porta Westfalica, Nordrhein-Westfalen, Germany|GSK Investigational Site, Troisdorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Velbert, Nordrhein-Westfalen, Germany|GSK Investigational Site, Waldbrol, Nordrhein-Westfalen, Germany|GSK Investigational Site, Koblenz, Rheinland-Pfalz, Germany|GSK Investigational Site, Mainz, Rheinland-Pfalz, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Homburg, Saarland, Germany|GSK Investigational Site, Halle (Saale), Sachsen-Anhalt, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Weissenfels, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Zwickau, Sachsen, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, Germany|GSK Investigational Site, Kiel, Schleswig-Holstein, Germany|GSK Investigational Site, Luebeck, Schleswig-Holstein, Germany|GSK Investigational Site, Bad Berka, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Bremen, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Chania, Greece|GSK Investigational Site, Heraklion, Greece|GSK Investigational Site, Larissa, Greece|GSK Investigational Site, Marousi, Greece|GSK Investigational Site, Neo Faliro, Greece|GSK Investigational Site, Patra, Greece|GSK Investigational Site, Piraeus, Greece|GSK Investigational Site, Pylaia, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Kowloon, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Deszk, Hungary|GSK Investigational Site, Gyula, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Mátraháza, Hungary|GSK Investigational Site, Nyíregyháza, Hungary|GSK Investigational Site, Pozva, Hungary|GSK Investigational Site, Pécs, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Ahmedabad, India|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Beer-Sheva, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Kfar Saba, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Meldola (FC), Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Parma, Emilia-Romagna, Italy|GSK Investigational Site, Ravenna, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Udine, Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Lecco, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Monza, Lombardia, Italy|GSK Investigational Site, Rozzano (MI), Lombardia, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Orbassano (TO), Piemonte, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, Monserrato, Sardegna, Italy|GSK Investigational Site, Palermo, Sicilia, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Siena, Toscana, Italy|GSK Investigational Site, Perugia, Umbria, Italy|GSK Investigational Site, Legnago, Veneto, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Chiba, Japan|GSK Investigational Site, Ehime, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hiroshima, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Niigata, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Shizuoka, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Kyunggi-do, Korea, Republic of|GSK Investigational Site, Seongnam-si, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Harderwijk, Netherlands|GSK Investigational Site, Heerlen, Netherlands|GSK Investigational Site, Leeuwarden, Netherlands|GSK Investigational Site, Nieuwegein, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Trondheim, Norway|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Checiny, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Glucholazy, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lodz, Poland|GSK Investigational Site, Lublin, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Rzeszow, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Zakopane, Poland|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Kursk, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Stavropol, Russian Federation|GSK Investigational Site, Ufa,, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Leganes, Spain|GSK Investigational Site, Lerida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Málaga, Spain|GSK Investigational Site, Oviedo, Spain|GSK Investigational Site, Sabadell, Spain|GSK Investigational Site, San Sebastian de los Reyes, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Aarau, Switzerland|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Bruderholz, Switzerland|GSK Investigational Site, Thun, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Tainan, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taoyuan, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, Hat yai, Thailand|GSK Investigational Site, Dnipropetrovsk, Ukraine|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lviv, Ukraine|GSK Investigational Site, Odesa, Ukraine|GSK Investigational Site, Simferopol, Ukraine|GSK Investigational Site, Uzhgorod, Ukraine|GSK Investigational Site, Vinnytsia, Ukraine|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Wythenshawe, Greater Manchester, United Kingdom|GSK Investigational Site, Leicester, Leicestershire, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Aberdeen, United Kingdom|GSK Investigational Site, Bebington, United Kingdom|GSK Investigational Site, Belfast, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Inverness, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Maidstone, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00480025"
308,"NCT04172675","A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",,"Recruiting","No Results Available","Urinary Bladder Neoplasms","Drug: Erdafitinib|Drug: Investigator Choice (Gemcitabine)|Drug: Investigator Choice (Mitomycin C)","Recurrence-Free Survival (RFS)|Time to Disease Worsening|Time to Progression|Disease-Specific Survival|Overall Survival|Recurrence-Free Survival|Recurrence-Free Survival 2 (RFS2)|RFS by Central Histopathologic Review|Plasma Concentration of Erdafitinib|Number of Participants with Adverse events|Change from Baseline in Patient's Global Impression of Severity (of cancer) (PGIS)|Change from Baseline in Patient's Global Impression of Change (of cancer) (PGIC)|Change from Baseline in European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire (EORTC QLQ) -C30|Change from Baseline in EORTC QLQ- Non-Muscle-Invasive Bladder Cancer (NMIBC) 24|Change from Baseline in EuroQol European Quality of Life - 5 Dimensions-5 Levels (EQ-5D-5L)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108699|2019-002449-39|42756493BLC2003","February 28, 2020","October 26, 2022","August 11, 2027","November 21, 2019",,"April 27, 2022","Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States|USC Institute of Urology, Los Angeles, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|Foothills Urology - Golden Off, Golden, Colorado, United States|Urological Research Network, Hialeah, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Simmons Cancer Institute, Springfield, Illinois, United States|University of Kansas, Westwood, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|LCMC Health, Metairie, Louisiana, United States|Regional Urology, Shreveport, Louisiana, United States|MI Medicine, Ann Arbor, Michigan, United States|University of Missouri, Columbia, Missouri, United States|Albany Medical College, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|NYU Langone Health, New York, New York, United States|Strong Memorial Hospital University of Rochester, Rochester, New York, United States|Great Lakes Physician PC d/b/a Western New York Urology Associates, Sanborn, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Urology Group, Cincinnati, Ohio, United States|The Ohio State University- James Cancer Hospital, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States|Lancaster Urology, Lancaster, Pennsylvania, United States|University of Pittsburgh Medical Center - Cancer Centers, Pittsburgh, Pennsylvania, United States|Urology Associates, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Washington, Seattle, Washington, United States|William S. Middleton Memorial VA, Madison, Wisconsin, United States|Medical College of Wisconsin-Froedtert Hospital, Milwaukee, Wisconsin, United States|Hospital Sirio Libanes, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Buenos Aires, Argentina|CEMIC Saavedra, Ciudad Autonoma de Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autonoma de, Argentina|Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Cordoba, Argentina|Centro Urologico Profesor Bengio, Cordoba, Argentina|Hospital Privado de Cordoba, Cordoba, Argentina|Flinders Medical Centre, Bedford Park, Australia|St. Vincent's Hospital Sydney, Darlinghurst, Australia|Macquarie University, Macquarie University, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|Newcastle Private Hospital, New Lambton Heights, Australia|ICON Cancer Care, South Brisbane, Australia|Sydney Adventist Hospital, Wahroonga, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Cliniques Universitaires Saint Luc, Brussel, Belgium|AZ Maria Middelares, Gent, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart-Tilman, Liege, Belgium|Algemeen Ziekenhuis Delta, Roeselare, Belgium|Hospital Erasto Gaertner, Curitiba, Brazil|Oncocentro Ceará, Fortaleza, Brazil|Hospital Araújo Jorge da Associação de Combate ao Câncer em Goiás, Goiânia, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Instituto de Medicina Integral Professor Fernando Figueira, Recife, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP de Ribeirao Preto, Ribeirão Preto, Brazil|Centro de Tratamento de Tumores Botafogo - CTTB, Rio de Janeiro, Brazil|Instituto COI de Pesquisa, Educacao e Gestao, Rio de Janeiro, Brazil|Faculdade de Medicina Do Abc, Santo André, Brazil|Instituto do Cancer do Estado de Sao Paulo ICESP, Sao Paulo, Brazil|Hospital Do Servidor Publico Estadual, Sao Paulo, Brazil|Hospital Sirio Libanes, São Paulo, Brazil|Nanjing Drum Tower Hospital, Nanjing, China|Fudan University Shanghai Cancer Center, Shanghai, China|Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China|Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Krajská nemocnice Liberec, Liberec, Czechia|Urologicka klinika FNOL, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Hôpital Pellegrin CHU Bordeaux, Bordeaux, France|CHU Gabriel-Montpied, Clermont Ferrand, France|Hopital Huriez, Lille, France|Hôpital Edouard Herriot, Lyon Cedex 03, France|Institut Paoli Calmettes, Marseille Cedex 9, France|Hôpital Universitaire Pitié-Salpêtrière, Paris, France|Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France|Hopital Bichat Claude Bernard, Paris, France|CHU De Poitiers, Poitiers, France|Chu Rennes - Hopital Pontchaillou, Rennes Cedex, France|Hopital Charles Nicolle, Rouen, France|CHP Saint Gregoire, Saint Gregoire, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France|Centre Hospitalier Universitaire de Nancy - Hôpital Central, Vandœuvre-lès-Nancy Cedex, France|Gustave Roussy, Villejuif Cedex, France|GFO Kliniken Rhein Berg, Bergisch-Gladbach, Germany|Urologicum Duisburg, Duisburg, Germany|Praxis Dr. med. Stefan Carl, Emmendingen, Germany|Klinikum Herne - Urologie, Herne, Germany|Universitätsklinikum Schleswig Holstein Campus Lübeck, Lubeck, Germany|Klinikum rechts der Isar - III. Med. Klinik und Poliklinik, Muenchen, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Praxisklinik Urologie Rhein/Ruhr - Germany, Mülheim an der Ruhr, Germany|MVZ Urologie 24 gGmbH, Nuernberg, Germany|Studienpraxis Urologie Drs. Feyerabend, Nuertingen, Germany|CUROS - Uberörtliche urologische Gemeinschaftspraxis, Wesseling, Germany|Health Care Global Enterprises pvt Ltd, Bangalore, India|S.P.Medical College &amp; AG of Hospitals, Bikaner, India|Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India|Health Care Global Enterprises, Jaipur, India|Tata Medical Center, Kolkata, India|King George's Medical University, Lucknow, India|Meenakshi Mission Hospital and Research Center, Madhurai, India|Tata Memorial Hospital, Mumbai, India|Muljibhai Patel Urological Hospital, Nadiad, India|CIMET's Inamdar Multispeciality Hospital, Pune, India|Generale Regionale F. Miulli, Acquaviva delle Fonti, Italy|Ospedale Regionale Umberto Parini, Aosta, Italy|Fondazione Istituto G. Giglio, Cefalu, Italy|Ospedale Civile di Guastalla, Guastalla, Italy|Azienda Ospedaliera ''Vito Fazzi'', Lecce, Italy|UOC Oncologia Ospedale Provinciale di Macerata, Macerata, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IRCCS Ospedale San Raffaele, Milan, Italy|Humanitas Centro Catanese di Oncologia, Misterbianco/Catania, Italy|Fondazione G. Pascale - Istituto Nazionale Tumori IRCCS, Napoli, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy|Juntendo University Hospital, Bunkyo-Ku, Japan|Tokyo Medical and Dental University Hospital, Bunkyo-Ku, Japan|Asahi General Hospital, Chiba, Japan|Hakodate Goryokaku Hospital, Hakodate, Japan|Saitama Medical University International Medical Center, Hidaka, Japan|Hitachi General Hospital, Hitachi, Japan|St.Marianna University Hospital, Kanagawa, Japan|Nagoya University Hospital, Nagoya, Japan|JOHAS Osaka Rosai Hospital, Osaka, Japan|Gunma Prefectural Cancer Center, Ota, Japan|Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Japan|Toranomon Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|University of Tsukuba Hospital, Tsukuba-City, Japan|Yokohama City University Medical Center, Yokohama, Japan|Pusan National University Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|Korea University Medical Center (KUMC) - Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Pratia MCM Krakow, Krakow, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland|CRC Sp. z o.o., Poznan, Poland|Kliniczny Szpital Wojewodzki nr 1 w Rzeszowie, Rzeszow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 2 PUM, Szczecin, Poland|City Clinic Sp. z o.o., Warszawa, Poland|Medical Concierge Centrum Medyczne, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Dolnoslaskie Centrum Onkologii, Wroclaw, Poland|Fundacion Puigvert, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan County, Taiwan|Royal Surrey County Hospital NHS Trust, Guildford, United Kingdom|University College London Hospitals, London, United Kingdom|The Christie NHS Foundation Trust - Christie Hospital, Manchester, United Kingdom|South Tees Hospital NHS Foundation Trust-The James Cook University Hospital, Middlesborough, United Kingdom|Universirty of Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom|Lister Hospital, Stevenage, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04172675"
309,"NCT01239732","A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer",,"Completed","Has Results","Ovarian Cancer","Drug: Paclitaxel|Drug: Bevacizumab|Drug: Carboplatin","Percentage of Participants With at Least One Adverse Event (AE)|Progression-Free Survival (PFS)|Percentage of Participants Achieving Best Overall Response of Complete Response (CR) or Partial Response (PR) According to RECIST Version 1.0|Percentage of Participants Achieving an Overall Response by 50% Carcinoma Antigen 125 (CA-125) Response Criteria|Percentage of Participants Achieving an Overall Response by RECIST Version 1.0 and/or 50% CA-125 Response Criteria|Duration of Objective Response (DOR)|Overall Survival (OS)|Biological Progression-free Interval","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 3","1021","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO22923|2010-019525-34","December 2010","March 2015","March 2015","November 11, 2010","June 10, 2016","June 10, 2016","Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Rosario, Argentina|Tucuman, Argentina|Graz, Austria|Graz, Austria|Innsbruck, Austria|Ried-innkreis, Austria|Salzburg, Austria|Steyr, Austria|Villach, Austria|Wien, Austria|Wien, Austria|Salvador, BA, Brazil|Fortaleza, CE, Brazil|Goiania, GO, Brazil|Curitiba, PR, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Piracicaba, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sofia, Bulgaria|Varna, Bulgaria|Veliko Tarnovo, Bulgaria|Calgary, Alberta, Canada|Ottawa, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec, Canada|Aalborg, Denmark|Roskilde, Denmark|Vejle, Denmark|Cairo, Egypt|Tanta, Egypt|Tallinn, Estonia|Tallinn, Estonia|Tartu, Estonia|Amiens, France|Bordeaux, France|Brest, France|Caen, France|Clermont Ferrand, France|Grenoble, France|Lille, France|Lyon, France|Marseille, France|Mougins, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Paris, France|Reims CEDEX, France|Strasbourg, France|Toulouse, France|Villejuif, France|Athens, Greece|Athens, Greece|Athens, Greece|Heraklion, Crete, Greece|Larissa, Greece|Patras, Greece|Thessaloniki, Greece|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Budapest, Hungary|Debrecen, Hungary|Pecs, Hungary|Szeged, Hungary|Bangalore, India|Bangalore, India|Hyderabad, India|Jaipur, India|Kochi, India|New Delhi, India|Pune, India|Dublin, Ireland|Afula, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Rehovot, Israel|Tel Aviv, Israel|Napoli, Campania, Italy|Bologna, Emilia-Romagna, Italy|Meldola, Emilia-Romagna, Italy|Roma, Lazio, Italy|Roma, Lazio, Italy|Genova, Liguria, Italy|Brescia, Lombardia, Italy|Milano, Lombardia, Italy|Milano, Lombardia, Italy|Monza, Lombardia, Italy|Saronno, Lombardia, Italy|Novara, Piemonte, Italy|Torino, Piemonte, Italy|Torino, Piemonte, Italy|Palermo, Sicilia, Italy|Firenze, Toscana, Italy|Pisa, Toscana, Italy|Perugia, Umbria, Italy|Terni, Umbria, Italy|Shuwaikh, Kuwait|Daugavpils, Latvia|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Klaipeda, Lithuania|Vilnius, Lithuania|Bitola, Macedonia, The Former Yugoslav Republic of|Skopje, Macedonia, The Former Yugoslav Republic of|Distrito Federal, Mexico|Oaxaca, Mexico|Toluca, Mexico|Alkmaar, Netherlands|Amsterdam, Netherlands|Apeldoorn, Netherlands|Blaricum, Netherlands|Breda, Netherlands|Capelle a/d IJssel, Netherlands|Den Haag, Netherlands|Den Haag, Netherlands|Deventer, Netherlands|Dordrecht, Netherlands|Eindhoven, Netherlands|Leidschendam, Netherlands|Rotterdam, Netherlands|Sittard-Geleen, Netherlands|Utrecht, Netherlands|Bydgoszcz, Poland|Warszawa, Poland|Porto, Portugal|Bucuresti, Romania|Cluj Napoca, Romania|Iasi, Romania|Barnaul, Russian Federation|Moscow, Russian Federation|Obninsk, Kaluzhskaya Region, Russian Federation|Saint-Petersburg, Russian Federation|Stavropol, Russian Federation|UFA, Russian Federation|Dammam, Saudi Arabia|Belgrade, Serbia|Nis, Serbia|Bratislava, Slovakia|Kosice, Slovakia|Ljubljana, Slovenia|Maribor, Slovenia|Durban, South Africa|Johannesburg, South Africa|Sandton, South Africa|Elda, Alicante, Spain|Oviedo, Asturias, Spain|Llerena (Badajoz), Badajoz, Spain|Manresa, Barcelona, Spain|Cádiz, Cadiz, Spain|Jerez de La Frontera, Cadiz, Spain|San Sebastian de Los Reyes, Guipuzcoa, Spain|San Sebastian, Guipuzcoa, Spain|Palma De Mallorca, Islas Baleares, Spain|Palma de Mallorca, Islas Baleares, Spain|Santiago de Compostela, La Coruña, Spain|Las Palmas de Gran Canaria, Las Palmas, Spain|Leganes, Madrid, Spain|Reus, Tarragona, Spain|La Laguna, Tenerife, Spain|Santa Cruz de Tenerife, Tenerife, Spain|San Juan, Valencia, Spain|Barakaldo, Vizcaya, Spain|Bilbao, Vizcaya, Spain|Albacete, Spain|Alicante, Spain|Badajoz, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Burgos, Spain|Caceres, Spain|Castellon, Spain|Ciudad Real, Spain|Cordoba, Spain|Girona, Spain|Granada, Spain|Guadalajara, Spain|Jaen, Spain|La Coruña, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Malaga, Spain|Navarra, Spain|Salamanca, Spain|Segovia, Spain|Sevilla, Spain|Sevilla, Spain|Toledo, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valencia, Spain|Valladolid, Spain|Zaragoza, Spain|Eskilstuna, Sweden|Falun, Sweden|Karlstad, Sweden|Umeå, Sweden|Uppsala, Sweden|Örebro, Sweden|Aarau, Switzerland|Baden, Switzerland|Bellinzona, Switzerland|Bern, Switzerland|Genève 14, Switzerland|Zürich, Switzerland|Taipei City, Taiwan|Taipei City, Taiwan|Taoyuan Hsien, Taiwan|Ankara, Turkey|Ankara, Turkey|Diyarbakir, Turkey|Istanbul, Turkey|Montevideo, Uruguay",,"https://ClinicalTrials.gov/show/NCT01239732"
310,"NCT00678392","Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer",,"Completed","Has Results","Kidney Neoplasms","Drug: Axitinib (AG-013736)|Drug: Sorafenib","Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DR)|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Adverse Events (AEs) by Severity|Percentage of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Clinically Significant Laboratory Abnormalities: Hematology|Number of Participants With Clinically Significant Laboratory Abnormalities: Biochemistry|Number of Participants With Clinically Significant Laboratory Abnormalities: Urinalysis|Functional Assessment of Cancer Therapy Kidney Symptom Index-15 (FKSI-15) Score|Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS) Score|Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Health State Profile Utility Score|Euro Quality of Life Questionnaire- 5 Dimension (EQ-5D): Visual Analog Scale (VAS)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","723","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A4061032|AXIS TRIAL|2008-001451-21|AXIS","September 3, 2008","August 31, 2010","February 25, 2016","May 15, 2008","March 27, 2012","January 9, 2019","East Valley Hematology and Oncology Medical Group, Burbank, California, United States|Maurice Berkowtiz, MD, Burbank, California, United States|Agajanian Institute of Oncology and Hematology, Downey, California, United States|Los Angeles Hematology/Oncology Medical Group, Glendale, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|LAC-USC Medical Center, Los Angeles, California, United States|USC Norris Cancer Hospital and Clinics, Los Angeles, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Metropolitan Hematology/Oncology Medical Group, Los Angeles, California, United States|Ronald Regan UCLA Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|Agajanian Institute of Oncology and Hematology, Montebello, California, United States|Brian LeBerthon, MD, A Medical Corporation, West Covina, California, United States|Agajanian Institute of Oncology and Hematology, Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Denver: Division of Medical Oncology, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, LLP, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Rocky Mountain Cancer Centers, Parker, Colorado, United States|Rocky Mountain Cancer Centers, Thornton, Colorado, United States|Georgetown University Hospital, Lombardi Cancer Center, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Florida Cancer Specialists, Bonita Springs, Florida, United States|Florida Cancer Specialists, Bradenton, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|Florida Cancer Specialists, Cape Coral, Florida, United States|University of Miami Sylvester at Deerfield Beach, Deerfield Beach, Florida, United States|Florida Cancer Specialists, Englewood, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|University of Miami Hospital and Clinics, Miami, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|Florida Cancer Specialists, Naples, Florida, United States|M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Florida Cancer Specialists, Port Charlotte, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Florida Cancer Specialists, Venice, Florida, United States|Peachtree Hematology-Oncology Consultants, P.C., Atlanta, Georgia, United States|Chattanooga Oncology and Hematology Associates, PC, Ringgold, Georgia, United States|Mountain States Tumor Institute, Boise, Idaho, United States|Mountain States Tumor Institute, Fruitland, Idaho, United States|Mountain States Tumor Institute, Meridian, Idaho, United States|Mountain States Tumor Institute, Nampa, Idaho, United States|Mountain States Tumor Institute, Twin Falls, Idaho, United States|Loyola University Chicago Cardinal Bernardin Cancer Center, Maywood, Illinois, United States|Cental Indiana Cancer Centers, Carmel, Indiana, United States|Central Indiana Cancer Centers, Fishers, Indiana, United States|Cental Indiana Cancer Centers, Greenfield, Indiana, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|University of Minnesota Medical Center Fairview, Minneapolis, Minnesota, United States|Missouri Cancer Associates, Columbia, Missouri, United States|St. John's Mercy Medical Center, Saint Louis, Missouri, United States|St. John's Mercy, David C. Pratt Cancer Center, Saint Louis, Missouri, United States|St. John's Mercy Medical Center, Washington, Missouri, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center - The Hillcrest Building, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center - Sidney Kimmel Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syrcacuse, Inc., Oneida, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc., Oswego, New York, United States|Suny Upstate Medical University, Syracuse, New York, United States|Department of Medicine MSG @ SUNY HSC @ Syracuse, Inc, Syracuse, New York, United States|Raleigh Hematology Oncology Associates, DBA, Cary, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Investigational Chemotherapy Services, Durham, North Carolina, United States|Albermarie Hospitals, Elizabeth City, North Carolina, United States|Virginia Oncology Associates, Elizabeth City, North Carolina, United States|Raleigh Hematology Oncology Associates, P.C., Raleigh, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus, Ohio, United States|Ohio State University, Columbus, Ohio, United States|James Care in Kenny, Columbus, Ohio, United States|Monarch, Mayfield Heights, Ohio, United States|Lake University - Ireland Cancer Center (LUICC), Mentor, Ohio, United States|UHHS - Chagrin Highlands, Orange Village, Ohio, United States|UHHS - Westlake, Westlake, Ohio, United States|Oncology Associates of Oregon, P.C., Eugene, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Cancer Centers of the Carolinas, Easley, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Hematology and Oncology Associates of SC, LLC - Eastside Medical Center, Greenville, South Carolina, United States|Cancer Centers of the Carolinas, Seneca, Seneca, South Carolina, United States|Cancer Centers of the Carolinas, Spartanburg, South Carolina, United States|Chattanooga Oncology and Hematology Associates, PC, Chattanooga, Tennessee, United States|Chattanooga Oncology Hematology Associates P.C., Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Vanderbilt-Ingram Cancer Center-Cool Springs, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Chattanooga Oncology & Hematology Associates, Hixson, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|Texas Oncology - Austin Midtown, Austin, Texas, United States|Texas Oncology - Central Midtown, Austin, Texas, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - South Austin, Austin, Texas, United States|Texas Oncolgoy - Austin North, Austin, Texas, United States|Texas Oncology - Austin Northwest, Austin, Texas, United States|Texas Oncology, P.A., Bedford, Texas, United States|Texas Oncology - Cedar Park, Cedar Park, Texas, United States|Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Investigation Products Center (IPC), Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|US Oncology Research and Clinical Pharmacy, Fort Worth, Texas, United States|Genitourinary Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology - Seton Williamson, Round Rock, Texas, United States|Texas Oncology - Round Rock, Round Rock, Texas, United States|Texas Oncology, P.A., Tyler, Texas, United States|Deke Slayton Cancer Center, Webster, Texas, United States|Texas Oncology - Clear Lake, Webster, Texas, United States|Virginia Cancer Specialists, PC, Arlington, Virginia, United States|Virginia Oncology Associates, Chesapeake, Virginia, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Specialists, PC, Gainesville, Virginia, United States|Virginia Oncology Associates, Hampton, Virginia, United States|Virginia Cancer Specialists, PC, Leesburg, Virginia, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Virginia Oncology Associates, Virginia Beach, Virginia, United States|Virginia Cancer Specialists, PC, Woodbridge, Virginia, United States|Virginia Mason Medical Center, Section of Hematology/Oncology, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|The Canberra Hospital, Medical Oncology, Garran, Australian Capital Territory, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Heidelberg Repatriation Hospital, Austin Health, Heidelberg West, Victoria, Australia|Austin Hospital, Austin Health, Heidelberg, Victoria, Australia|Med. Abt. KH Barmherzige Brueder Wien, Krankenhaus der Barmherzigen Brueder Wien, Wien, Austria|Universitaets-Klinik fuer Innere Medizin I, Wien, Austria|Clinica Oncologistas Associados, Rio de Janeiro, RJ, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre (ISCMPA) - Hospital Santa Rita, Porto Alegre, RS, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, SP, Brazil|Fundacao Antonio Prudente, Sao Paulo, SP, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|British Columbia Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|RSM Durham Regional Cancer Centre Lakeridge Health Oshawa, Oshawa, Ontario, Canada|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Chaoyang District, China|The Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China|Beijing Cancer Hospital, Beijing, P.R., China|Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, China|Sun Yet-Sen University Cancer Center, Guangzhou, China|Urology Department, Renji Hospital,Shanghai Jiao Tong University School of Medicine, Shanghai, China|Tianjin Oncology Hospital,biology treatment department, Tianjin, China|Centre Leon Berard, Lyon, Cedex 08, France|Hopital Saint-André, Bordeaux Cedex, France|Hôpital Henri Mondor, CRETEIL Cedex, France|Institut Paoli-Calmettes, Marseille Cedex 09, France|Hopital Europeen Georges Pompidou, Paris Cedex 15, France|Centre Eugene Marquis, Rennes, France|Centre Rene Gauducheau - Service Oncologie Medicale, St Herblain Cedex, France|CHRU de Tours - Hopital Bretonneau, Tours Cedex 1, France|Centre Alexis Vautrin, Vandoeuvre les Nancy, France|Institut Gustave Roussy / Service d'Immunotherapie, Villejuif Cedex, France|RWTH Aachen, Urologische Klinik, Aachen, Germany|Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany|Innere Klinik und Poliklinik fuer Tumorforschung, Universitaetsklinikum Essen, Essen, Germany|Klinikum Region Hannover Krankenhaus Siloah, Hannover, Germany|Klinikum der Johannes-Gutenberg-Universitaet, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Ludwig-Maximilians-Universitaet Muenchen, Klinikum Grosshadern Urologische Klinik und Poliklinik, Muenchen, Germany|Klinikum Oldenburg gGmbH, Klinik fuer Innere Medizin II Onkologie / Haematologie, Oldenburg, Germany|Alexandra University Hospital / Oncology Dept., Athens, Attiki, Greece|""Theagenio""Cancer Hospital / 3rd. Dept. of Clinical Oncology, Thessaloniki, Macedonia, Greece|Fortis Memorial Research Institute, Gurgaon, Haryana, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Dept. of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India|Christian Medical College & Hospital, Ludhiana, Punjab, India|Bhagwan Mahaveer Cancer Hospital and Research Center, Jaipur, Rajasthan, India|Oncology Department, Dublin 24, Ireland|UOC Oncologia Medica, Ospedale San Donato, Arezzo, Italy|Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS, Aviano (PN), Italy|Dipartimento dei laboratori diagnositici e per le terapie cellulari, Aviano (PN), Italy|Azienda Ospedaliera Spedali Civili di Brescia, Unita' Operativa Oncologia Medica, Brescia, Italy|Struttura Complessa di Oncologia, Cremona, Italy|UOC Oncologia Medica B, IRCCS AO Universitaria San Martino, Genova, Italy|Fondazione IRCCS, Istituto Nazionale dei Tumori, SC Oncologia Medica 2, Milano, Italy|Divisione di Oncologia, AORN Antonio Cardarelli, Napoli, Italy|Istituto per lo Studio e la Cura dei Tumori Fondazione Pascale, Napoli, Italy|Unita' Operativa Oncologia Medica 2, Regione del Veneto, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Struttura Complessa di Oncologia Medica A, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini, Oncologia Medica, Padiglione Flajani, I piano, Roma, Italy|UO di Oncologia ed Ematologia, Istituto Clinico Humanitas, Rozzano (MI), Italy|Sapporo Medical University School of Medicine, Sapporo-shi, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|University of Tsukuba, Graduate School of Comprehensive Human Sciences, Department of Urology, Tsukuba, Ibaraki, Japan|Kinki University Hospital, Osakasayama, Osaka, Japan|Hamamatsu University School of Medicine, Hamamatsu-City, Shizuoka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|Tokyo Women's Medical University Medical Center East, Department of Urology, Arakawa-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan|Akita University Hospital, Akita, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|Kumamoto University Hospital, Kumamoto, Japan|Tokushima University, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Urologic Oncology Clinic, Center for Specific Organs Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Dong-A University Medical Center, Department of Medicine, Division of Hemato-Oncology, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Catholic University of Korea, Seoul St. Mary's Hospital, Department of Oncology, Seoul, Korea, Republic of|Centrum Medyczne HCP, Poznan, Wielkopolska, Poland|Wielkopolskie Centrum Onkologii im.Marii Sklodowskiej-Curie, Poznan, Wielkopolska, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Klinika Onkologii, Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego, Poznan, Poland|Pracownia Tomografii Komputerowej, Poznan, Poland|Klinika Onkologii, Wojskowy Instytut Medyczny, Warszawa, Poland|Klinika Urologii i Onkologii Urologicznej, Wroclaw, Poland|Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga Region, Russian Federation|Cancer Research Center named after N.N. Blokhin, Biotherapy Department, Moscow, Russian Federation|Cancer Research Center named after N.N.Blokhin, Chemotherapy Department, Moscow, Russian Federation|Russian Research Center of Roentgenology and Radiology, Moscow, Russian Federation|The Main Clinical Hospital of the Ministry of Internal Affairs of Russian Federation, Moscow, Russian Federation|Moscow Research Institute of Oncology P.A. Herzen, Moscow, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|National Cancer Centre Singapore, Singapore, Singapore|Onkologicky Ustav sv. Alzbety, Bratislava, Slovakia|Narodny Onkologicky ustav, Bratislava, Slovakia|Nemocnica s poliklinikou Zilina, Zilina, Slovakia|Institut Catala D'Oncologia L'Hospitalet, L'hospitalet de Llobregat, Barcelona, Spain|Clinica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Vall D¿Hebron, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario Virgen de La Victoria, Malaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Universitetssjukhuset, Onkologiska kliniken, Linkoping, Sweden|Norrlands Universitetssjukhus, Onkologkliniken, Umea, Sweden|Onkologkliniken, Vaxjo, Sweden|Chang Gung Medical Foundation-Kaohsiung Branch, Kaohsiung Hsien, Taiwan|Taichung Veterans General Hospital, Department of Surgery, Taichung, Taiwan|Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Taoyuan, Taiwan|Royal Marsden Hospital, London, England, United Kingdom|Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|Clatterbridge Centre for Oncology NHS Foundation Trust, Bebington, Wirral, United Kingdom|University of Birmingham, CRUK Institute for Cancer Studies, Birmingham, United Kingdom|Royal Bournemouth & Poole Hospitals, Bournemouth, United Kingdom|Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Department of Medical Oncology, St. Bartholomew's Hospital, London, United Kingdom|University Department of Medical Oncology/Oxford Cancer Centre, Oxford, United Kingdom|Royal Marsden Hospital NHS Foundation Trust, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00678392"
311,"NCT02546908","A Registry of Participants With Prostate Cancer in Asia",,"Completed","No Results Available","Prostatic Neoplasms","Other: No Intervention","Overall Survival (OS)|Prostate Cancer (PC)-related Mortality (PM)|Metastasis-free survival (MFS)|Progression-free Survival (PFS)|Time to Prostate-specific Antigen (PSA) Progression (TTPP)|European Quality of Life-5 Dimensions, 5 Levels (EQ-5D-5L) Score|Functional Assessment of Cancer Therapy for Prostate Cancer (FACT-P) Score","Janssen Research & Development, LLC","Male","21 Years and older   (Adult, Older Adult)",,"3644","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","CR107351|NOPRODPCR4001","September 9, 2015","September 1, 2020","September 1, 2020","September 11, 2015",,"September 22, 2020","Beijing, China|Guangzhou, China|Hangzhou, China|Shanghai, China|Shenyang, China|Sichuan, China|Su Zhou, China|Wuhan, China|Bangalore, India|Delhi, India|Mumbai, India|New Delhi, India|Chiba, Japan|Hirosaki, Japan|Ikoma, Japan|Kobe, Japan|Koshigaya, Japan|Matsuyama, Japan|Osaka-Sayama, Japan|Suita, Japan|Seoul, Korea, Republic of|Kuala Lumpur N/a, Malaysia|Kuala Lumpur, Malaysia|Kuching, Malaysia|Pulau Pinang, Malaysia|Singapore, Singapore|Kaohsiung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Songkla, Thailand",,"https://ClinicalTrials.gov/show/NCT02546908"
312,"NCT00707304","Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer","FORTIS-M","Completed","No Results Available","Non Small Cell Lung Cancer","Drug: Talactoferrin|Drug: Placebo","Overall survival|Progression free survival|Objective response and disease stablization rate|Safety and tolerability","Agennix","All","18 Years and older   (Adult, Older Adult)","Phase 3","742","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LF-0207","November 2008","March 2011","August 2012","June 30, 2008",,"August 21, 2012","Desert Oasis Cancer Center, Casa Grande, Arizona, United States|Arizona Oncology Associates, Tucson, Arizona, United States|University of Colorado Hospital, Aurora, Colorado, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Cancer Care & Hematology Specialists of Chicagoland, Niles, Illinois, United States|Central Indiana Cancer Centers, Greenfield, Indiana, United States|Kansas City Cancer Center, LLC, Overland Park, Kansas, United States|NCI, CCR, The Waren Grant Magnuson Clinical Center, Bethesda, Maryland, United States|Newland Medical Associates, Southfield, Michigan, United States|Minnesota Oncology and Hematology, PA, Minneapolis, Minnesota, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|NH Oncology-Hematology, PA, Hooksett, New Hampshire, United States|Montefiore Medical Center, Bronx, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Alamance Regional Medical Center, Burlington, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Rex Cancer Center, Raleigh, North Carolina, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Kaiser Group Health, Portland, Oregon, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology, Fort Worth, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care, Salem, Virginia, United States|Cancer Care Northwest, Spokane, Washington, United States|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Townsville Hospital, Townsville, Queensland, Australia|The Queen Elisabeth Hospital, Woodville South, South Australia, Australia|Epworth Healthcare, Richmond, Victoria, Australia|DDODIU-Plovdiv, EOOD, Aleksandur Stamboliyski, Plovdiv, Bulgaria|UMHAT 'Dr. Georgi Stranski', EAD, Pleven, Bulgaria|DDODIU-Plovdiv, EOOD, Plovdiv, Bulgaria|DDODIU - Sofia District EOOD, Sofia, Bulgaria|UMHAT 'Tsaritsa Yoanna - ISUL', EAD, Sofia, Bulgaria|Cross Cancer Institute, Edmonton, Alberta, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Hôtel-Dieu de Lévis, Lévis, Quebec, Canada|Gerald Bronfman Centre for Clinical Research in Oncology, Montreal, Quebec, Canada|Fakultni nemocnice Na Bulovce, Budinova, Praha, Czech Republic|Institut Onkologie a Rehabilitace Na Plesi, Nova Ves pod Plesi, Czech Republic|Vitkovicka nemocnice a.s., Ostrava, Czech Republic|Fakultni Nemocnice Ostrava, Ostrava, Czech Republic|Pardubicka krajska nemocnice, a.s., Pardubice, Czech Republic|Fakultni Nemocnice Kralovske Vinohrady, Praha, Czech Republic|Fakultni nemocnice v Motole, s.p., Praha, Czech Republic|Oblastni nemocnice Pribram, a.s., Pribram, Czech Republic|Nemocnice Tabor, a.s., Tabor, Czech Republic|Hopital Cardiologique, Chru Lille, Lille, Cedex, France|CHU Pontchaillou, Rennes, Cedex, France|CRLCC René Gauducheau, Saint-herblain, Cedex, France|CLCC Paul Strauss, Strasbourg, Cedex, France|Hopital Larrey, Toulouse, Cedex, France|Centre Catherine de Sienne, Eric Tabarly, Nantes, France|CHU Angers, Angers cedex, France|Hopital Morvan, Brest, France|Centre Francois Baclesse, Caen Cedex, France|Centre d'Oncology de Gentilly, Cedex, France|Centre Hospitalier du Mans, Le Mans Cedex, France|Centre Léon Berard, Lyon, France|Hopital Sainte Marguerite, Marseille Cedex 9, France|Hôpital Saint-Antoine, Paris, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, France|Hopital Maison Blanche, Reims, France|CHU de Nancy, Hopital de Brabois, Vandoeuvre les Nancy, France|Praxis fuer interdisziplinaere Onkologie, Freiburg, BW, Germany|Universitaetsklinikum Mannheim, Mannheim, BW, Germany|Universitaetsklinikum Erlangen - PS, Erlangen, BY, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, BY, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, BY, Germany|Gemeinschaftspraxis fuer Haematologie Onkologie, Wiesbaden, HE, Germany|Universitaetsklinikum Goettingen, Goettingen, NI, Germany|St. Johannes Hospital - PS, Dortmund, NW, Germany|Krankenhaus Grosshansdorf, Woehrendamm, SH, Germany|Staedt. Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle, ST, Germany|Zentralklinik Bad Berka, Bad Berka, TH, Germany|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Germany|General Hospital of Chania 'Ag. Georgios', Mournies, Crete, Greece|University Hospital of Larissa, Mezourlo, Larissa, Greece|University General Hospital of Patras, Rion, Patras, Greece|General Hospital of Athens ""Sotiria"", Athens, Greece|University Hospital of Heraklio, Crete, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Miskolc Megyei Jogu Varos Onkormanyzat Miskolci Egeszsegugyi, Csabai kapu, Miskolc, Hungary|Fejer Megyei Szent Gyorgy Korhaz, Seregelyesi, Szekesfehervar, Hungary|Semmelweis Egyetem, Budapest, Hungary|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Hungary|Szabolcs-Szatmar Bereg Megyei Josa Andras Oktato Korhaz, Nyiregyháza, Hungary|Torokbalinti Tudogyogyintezet, Torokbalint, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|King George Hospital, Vishakhapattanam, Andhhra Pradesh, India|Apollo Hospital, Hyderabad, Andhra Pradesh, India|Indo-American Cancer Institute and Research Center, Hyderabad, Andhra Pradesh, India|Kidwai Institute of Oncology, Bangalore, Karnataka, India|M. S. Ramaiah Memorial Hospital, Bangalore, Karnataka, India|A.J. Medical College Hosptial, Mangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|P.D. Hinduja Nat. Hospital & Med. Research Centre, Mumbai, Maharashtra, India|Kaushalya Medical Foundation Trust Hospital, Mumbai, Maharashtra, India|Cancer Care Clinic, Nagpur, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India|Searoc Cancer Hospital, Jaipur, Rajasthan, India|Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India|Dr. Kamakshi Memorial Hospital Pvt Ltd, Chennai, Tamilnadu, India|Christian Medical College Hospital, Vellore, Tamilnadu, India|Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Ancona, AN, Italy|Istituto per la Ricerca e la Cura del Cancro, Candiolo, Candiolo/TO, Italy|Ospedale Versilia, Lido di Camaiore, LU, Italy|Istituto Nazionale Tumori, Milano, MI, Italy|Azienda Ospedaliera San Gerardo, Monza, MI, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma,, RM, Italy|Ospedale Mater Salutis, Legnago, VR, Italy|CRO Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Azienda Ospedaliera Istituti Ospitalieri di Cremona, Cremona, Italy|Chonnam National University Hwasun Hospital, Hwasun up, Chonnam, Korea, Republic of|National Cancer Center, Ilsandong-gu, Goyang, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do,, Korea, Republic of|Samsung Medical Center, Gangnam-Gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|Korea University Anam Hospital, Seongbuk-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|The Catholic University of Korea St. Vincent's Hospital, Paldal-gu, Suwon Gyeonggi-do, Korea, Republic of|Dr. Anna Levcenko GP and Internist Practice, Daugavpils, Latvia|Piejuras Hospital, Liepaja, Latvia|Riga Eastern Clinical University Hospital, Riga, Latvia|P. Stradina Clinical University Hospital, Riga, Latvia|Nilai Cancer Institute (NCI Cancer Hospital), Negeri Sembilan, Darul Khusus, Malaysia|Lam Wah Ee Hospital, Pulau Pinang, Georgetown,, Malaysia|Hospital Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Pahang, Malaysia|Manila Doctors Hospital, Manila, Philippines|Lung Center of the Philippines, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Akademickie Centrum Kliniczne - Szpital AM w Gdansku, Gdansk, Poland|Nzoz Vesalius, Krakow, Poland|Miedziowe Centrum Zdrowia S.A., Lubin, Poland|NZOZ Olsztynski Osr. Onkologiczny ""Kopernik"" Sp.z o.o, Olsztyn, Poland|Specjalistyczny Szpital im. Prof. A. Sokolowskiego, Szczecin, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Str. Republicii nr. 34-36, Cluj-Napoca, Romania|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"", Baia Mare, Romania|Spitalul Judetean de Urgenta Braila, Braila, Romania|S.C. Ianuli Med Consult S.R.L., Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"" Suceava, Suceava, Romania|Oncology Dispensary #2 of Krasnodar Region, Dagomysskaya str., Sochi, Russian Federation|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|SHI Altay Regional Oncology Dispensary, Barnaul, Russian Federation|CCH #2 n.a. N. A. Semashko of LLC ""Russian Railways"", Moscow, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Perm Territorial Oncology Dispensary, Perm, Russian Federation|SEIHPE ""Saint Petersburg SMU RosZdrav n.a. I.I.Pavlov"", St. Petersburg, Russian Federation|National Cancer Centre, Hospital Drive, Singapore|Parkway Cancer Centre, Mount Elizabeth, Singapore|Medical Oncology Centre, Napier Road, Singapore|John Hopkins Singapore International Medical Centre, Singapore, Singapore|H Mutua de Terrassa, Barcelona, Spain|HU Virgen de las Nieves, Granada, Spain|Fundacion Jimenez Diaz, Madrid, Spain|HGU La Paz, Madrid, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung,, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou Branch, Toayuan, Taiwan|Gazi University Medical Faculty, Ankara, Turkey|Gaziantep University Medical Faculty, Gaziantep, Turkey|Istanbul Bilim University Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Bristol Haematology & Oncology Centre, Bristol, Brist, United Kingdom|Guy's & St Thomas' NHS Foundation Trust, London, Gt Lon, United Kingdom|Christie Hospital, Manchester, Gt Man, United Kingdom|Southampton General Hospital, Southampton, Hants, United Kingdom|Castle Hill Hospital, Cottingham Hull, Hull, United Kingdom|University Hospital of South Manchester NHS Foundation Trust Wythenshawe Hospital, Wythenshawe, Manchester, United Kingdom|Singleton Hospital, Swansea,, S Glam,, United Kingdom|University Hospital of North Staffordshire, Stoke on Trent, Staffs, United Kingdom|Wolverhampton New Cross Hospital, Wolverhampton, Staffs, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, Strath, United Kingdom|Ninewells Hospital, Dundee, Tays, United Kingdom|University Hospital of Coventry and Warwickshire, Coventry, Warwks, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00707304"
313,"NCT02477124","A See and Treat Paradigm for Cervical Pre-cancer",,"Terminated","No Results Available","Cervical Pre-cancer","Device: transvaginal digital colposcope (TVDC)|Other: Standard of care screening","Concordance of the TVDC to standard of care, as measured by weighted kappa statistic","Duke University","Female","25 Years and older   (Adult, Older Adult)","Not Applicable","514","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Pro00052865","September 2015","March 2020","March 2020","June 22, 2015",,"January 26, 2022","Duke University Medical Center, Durham, North Carolina, United States|AIIMS, New Delhi, India|La Liga Contra el Cancer, Lima, Peru|Kilimanjaro Christian Medical Centre, Moshi, Tanzania|University Teaching Hospital, Lusaka, Zambia",,"https://ClinicalTrials.gov/show/NCT02477124"
314,"NCT01041404","ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer",,"Completed","Has Results","Gastric Cancer","Drug: Trastuzumab|Drug: Fluorouracil|Drug: Cisplatin|Drug: Capecitabine","Overall Survival (OS) - Percentage of Participants With an Event|Overall Survival - Time to Event|Progression-Free Survival (PFS) - Percentage of Participants With an Event|Progression-Free Survival - Time to Event|Time to Progression (TTP) - Percentage of Participants With an Event|Time to Progression - Time to Event|Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response - Percentage of Participants With an Event|Duration of Response|Percentage of Participants With Clinical Benefit|European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores|EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores|Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)|Percentage of Participants With a Change in Analgesic Medication During the Study|Body Weight (Kilograms [kg]) at BL|Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight|Steady State Trastuzumab Area Under the Concentration (AUC)|Trastuzumab Minimum Serum Concentration (Cmin)|Trastuzumab Maximum Serum Concentration (Cmax)","Hoffmann-La Roche|Chugai Pharmaceutical","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BO18255","September 2005","June 2010","June 2010","December 31, 2009","November 5, 2014","November 5, 2014","Adelaide, Australia|Kurralta Park, Australia|Melbourne, Australia|Milton, Australia|Perth, Australia|Sydney, Australia|Leuven, Belgium|Barretos, Brazil|Rio de Janeiro, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Guangdong, China|Guangzhou, China|Jiangsu, China|Nanjing, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Shanghai, China|Suzhou, China|Wuhan, China|San Jose, Costa Rica|San José, Costa Rica|Herlev, Denmark|Odense, Denmark|Tampere, Finland|Brest, France|Caen, France|Colmar, France|Lille, France|Marseille, France|Reims, France|Rouen, France|Strasbourg, France|Heidelberg, Germany|Mainz, Germany|München, Germany|Trier, Germany|Witten, Germany|Guatemala City, Guatemala|Hyderabad, India|Kochi, India|Mumbai, India|New Delhi, India|Ancona, Italy|Firenze, Italy|Napoli, Italy|Parma, Italy|Roma, Italy|Udine, Italy|Aichi, Japan|Chiba, Japan|Ehime, Japan|Fukuoka, Japan|Hyogo, Japan|Nagano, Japan|Osaka, Japan|Osaka, Japan|Saitama, Japan|Saitama, Japan|Shizuoka, Japan|Tochigi, Japan|Tokyo, Japan|Tokyo, Japan|Tokyo, Japan|Yamagata, Japan|Buchun, Korea, Republic of|Bundang City, Korea, Republic of|Daegu, Korea, Republic of|Goyang-si, Korea, Republic of|Pusan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Guadalajara, Mexico|Merida, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Panama City, Panama|Callao, Peru|Lima, Peru|Lima, Peru|Braga, Portugal|Coimbra, Portugal|Faro, Portugal|Guimaraes, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Porto, Portugal|Chelyabinsk, Russian Federation|Ekaterinburg, Russian Federation|Ivanovo, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Ryazan, Russian Federation|Samara, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|UFA, Russian Federation|Yaroslavl, Russian Federation|Cape Town, South Africa|Cape Town, South Africa|Durban, South Africa|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Girona, Spain|Madrid, Spain|Valencia, Spain|Valencia, Spain|Changhua, Taiwan|Kaohsiung, Taiwan|Taipei, Taiwan|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Shhiye, Ankara, Turkey|Birmingham, United Kingdom|Denbigh, United Kingdom|Dundee, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Weston Super Mare, United Kingdom|Wirral, United Kingdom|Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01041404"
315,"NCT03521154","A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)","LAURA","Active, not recruiting","No Results Available","Non Small Cell Lung Cancer (Stage III)","Drug: Osimertinib 80mg/40mg|Drug: Placebo Osimertinib 80mg/40mg","Progression-free survival (PFS)|PFS in patients with EGFR Ex19del or L858R mutation|PFS in patients with EGFR mutations Ex19del or L858R detectable in plasma-derived ctDNA|Time to CNS PFS|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DoR)|Disease control rate (DCR)|Tumor shrinkage|Time to death or distant metastases (TTDM)|Time to treatment discontinuation|Second progression free survival on a subsequent treatment (PFS2)|Time to first subsequent therapy (TFST)|Time to second subsequent therapy (TSST)|Patients reported disease-related symptoms and HRQoL by EORTC QLQ-LC13 and EORTC QLQ-30 questionnaires|Incidence of Adverse Events (AEs)|Plasma concentrations of osimertinib and AZD5104","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","197","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5160C00048","July 19, 2018","January 31, 2023","June 29, 2026","May 11, 2018",,"May 16, 2022","Research Site, Duarte, California, United States|Research Site, Atlanta, Georgia, United States|Research Site, Florham Park, New Jersey, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Madison, Wisconsin, United States|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Barretos, Brazil|Research Site, Campinas, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Jinan, China|Research Site, Linhai, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyöngyös - Mátraháza, Hungary|Research Site, Pécs, Hungary|Research Site, Bangalore, India|Research Site, Gurgaon, India|Research Site, Hubli, India|Research Site, Karamsad, India|Research Site, Kolkata, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Hiroshima-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Nishinomiya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Selangor, Malaysia|Research Site, Mérida, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Kazan, Russian Federation|Research Site, Kostroma, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novisibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, San Sebastián, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Lampang, Thailand|Research Site, Mueang, Thailand|Research Site, Adana, Turkey|Research Site, Adapazari, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Hanoi City, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hcmc, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03521154"
316,"NCT00430781","Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer",,"Completed","Has Results","Neoplasms, Uterine Cervix|Metastatic Cervical Cancer","Drug: pazopanib (GW786034)|Drug: lapatinib (GW572016)","Progression-free Survival (PFS) in Interim Analysis|Progression-free Survival (PFS) in Final Analysis|Overall Survival|Clinical Benefit Response|Response|Time to Response|Duration of Response|Safety and Tolerability of Pazopanib, Lapatinib and the Combination of Pazopanib and Lapatinib","GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Phase 2","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VEG105281","November 2006","July 2008","July 2011","February 2, 2007","March 14, 2011","May 8, 2015","GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Stanford, California, United States|GSK Investigational Site, Augusta, Georgia, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Cleveland, Ohio, United States|GSK Investigational Site, Columbus, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Chattanooga, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Neuquen, Neuquén, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Tucuman, Tucumán., Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Brussel, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Roeselare, Belgium|GSK Investigational Site, Calgary, Alberta, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montréal, Quebec, Canada|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Bordeaux, France|GSK Investigational Site, Caen Cedex, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Marseille Cedex 09, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Villejuif, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Saarbruecken, Saarland, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Magdeburg, Sachsen-Anhalt, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Ahemdabad, India|GSK Investigational Site, Mangalore, India|GSK Investigational Site, New Delhi, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Cork, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Campobasso, Molise, Italy|GSK Investigational Site, Bari, Puglia, Italy|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, La Laguna (Santa Cruz de Tenerife), Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Marid, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT00430781"
317,"NCT03098030","Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer",,"Completed","Has Results","Small Cell Lung Cancer","Biological: Dinutuximab|Drug: Irinotecan|Drug: Topotecan","Overall Survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)|Clinical Benefit Rate (CBR)","United Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","483","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIV-SCLC-301","June 1, 2017","January 27, 2020","March 26, 2020","March 31, 2017","December 9, 2020","December 9, 2020","Alaska Clinical Research Center, Anchorage, Alaska, United States|Cancer Treatment Centers of America - Western Regional Medical Center, Goodyear, Arizona, United States|Innovative Clinical Research Institute, Tucson, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|VA Palo Alto Health Care System, Palo Alto, California, United States|Olive View - UCLA, Sylmar, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Eastern Connecticut Hematology and Oncology Assoc, Norwich, Connecticut, United States|Alpha Oncology Research LLC, DeBary, Florida, United States|21st Century Oncology, Jacksonville, Florida, United States|Comprehensive Hematology Oncology, Saint Petersburg, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Floyd Cancer Center, New Albany, Indiana, United States|Physicians' Clinic of Iowa Hematology and Oncology, Cedar Rapids, Iowa, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|21st Century Oncology, Louisville, Kentucky, United States|Cox Health Medical, Springfield, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|The University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States|UH Cleveland Medical Center, Cleveland, Ohio, United States|Cancer Treatment Centers of America at Southwestern RMC, Tulsa, Oklahoma, United States|Kaiser Permanente Northwest Center for Health Research CRSS, Portland, Oregon, United States|Fox Chase Cancer Center Office of Clinical Research, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America at Eastern Regional Medical Center, Philadelphia, Pennsylvania, United States|Charleston Oncology, Charleston, South Carolina, United States|Spartanburg Medical Center/Gibbs Cancer Center and Research Institute, Spartanburg, South Carolina, United States|Prairie Lakes Health Care, Watertown, South Dakota, United States|Center for Biomedical Research, Knoxville, Tennessee, United States|Texas Health Physicians Group, Arlington, Texas, United States|Plano Cancer Institute, Plano, Texas, United States|The University of Texas Health Science Center at Tyler, Office of Clinical Studies, Tyler, Texas, United States|Vista Oncology (Shelton office), Shelton, Washington, United States|United Hospital Center, Bridgeport, West Virginia, United States|Camden Clark Medical Center / Regional Cancer Center, Parkersburg, West Virginia, United States|University of Wisoncsin - Carbone Cancer Ctr, Madison, Wisconsin, United States|Mid North Coast Cancer Institute Coff Habour Health Campus, Coffs Harbour, New South Wales, Australia|Mater Misericordiae Limited and Mater Medical Research Institute Limited, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Medical Oncology Department, Specialized Hospital for Active Treatment of Oncology Sveti Mina EOOD - Blagoevgrad, Blagoevgrad, Bulgaria|Department of Medical Oncology, Complex Oncology Center - Burgas EOOD, Burgas, Burgas, Bulgaria|Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dobrich AD, Dobrich, Dobrich, Bulgaria|Medical Oncology Department, Multiprofile Hospital for Active Treatment - Dr. Tota Venkova AD, Gabrovo, Gabrovo, Bulgaria|Medical Oncology Department, Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagiurishte, Panagyurishte, Bulgaria|Clinic of Oncology, UMHAT Dr. Georgi Stranski - Pleven, Pleven, Bulgaria|Clinic of Oncology, UMHAT Pulmed, Plovdiv, Bulgaria|First Department of Medical Oncology, Gastroenterology and Pulmology, Complex Oncology Center - Plovdiv EOOD, Plovdiv, Bulgaria|First Department for Medical Oncology, Multiprofile Hospital for Active Treatement Serdika EOOD, Sofia, Sofia, Bulgaria|Medical Oncology Clinic, Multiprofile Hospital for Active Treatment (MHAT) for Female's Health - Nadezhda OOD, Sofia, Sofia, Bulgaria|Medical Oncology Department, University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Sofia, Sofia, Bulgaria|Clinic for Chemotherapy, Specialized Hospital for Active Treatment in Oncology EAD, Sofia, Sofia, Bulgaria|Clinic of Oncology, UMHAT SofiaMed, Sofia, Bulgaria|Clinic of Oncology, MHAT Sveta Marina, Varna, Bulgaria|Cross Cancer Institute - Clinical Trials Unit, Edmonton, Alberta, Canada|Horizon Health Network - The Moncton Hosoital, Moncton, New Brunswick, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Windsor Regional Hospital Cancer Program, Windsor, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|L'Institut Universitaire de Cardiologie et de pneumologie de Quebec, Québec, Quebec, Canada|Hopital Nord, Marseille, Alpes-Côte d'Azur, France|Institut Regional du Cancer de Montpellier, Montpellier, Occitanie, France|Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, Pays De La Loire, France|Clinique Victor Hugo, Le Mans, Pays De La Loire, France|URCOT : Unité de Recherche Commune en Oncologie Thoracique Service de pneumologie de l'hôpital de la Croix-Rousse, Bron, Rhône-Alpes, France|URCOT : Unité de Recherche Commune en Oncologie Thoracique Service de pneumologie de l'hôpital de la Croix-Rousse, Lyon, Rhône-Alpes, France|Service de Pneumologie aiguë et Cancérologie Thoracique Centre hospitalier Lyon-Sud, Pierre Bénite, Rhône-Alpes, France|CHU Brest, Brest, France|Centre François Baclesse, Caen, France|CHI Créteil, Créteil, France|Institut Paoli-Calmettes, Service Dòncologie Médicale, Marseille, France|Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint-Herblain, France|Centre Paul Strauss, Strasbourg, France|Nouvel Hôpital Civil de Strasbourg, Strasbourg, France|LTD High Technology Hospital Medcenter, Batumi, Georgia|LTD ''Accad. F. Todua Medical Center-Research Institute of Clinical Medicine'', Tbilisi, Georgia|High Technology Medical Center, University Clinic, Tbilisi, Georgia|Institute of Clinical Oncology, Tbilisi, Georgia|Multiprofile Clinic Consillium Medulla, Tbilisi, Georgia|Princess Margaret Hospital, Kowloon, Hong Kong|Queen Elizabeth Hospital, Kowloon, Hong Kong|Queen Mary Hospital, Pokfulam, Hong Kong|Hetenyi Geza Hospital, Szolnok, Jasz-Nagykun-Szolnok, Hungary|Koranyi National Institute of Pulmonology - Horváth, Budapest, Hungary|Koranyi National Institute of TBC and Pulmonology, Budapest, Hungary|Korányi National Institute, Budapest, Hungary|Semmelweis Egyetem AOK Pulmonologiai Klinika, Budapest, Hungary|Veszprém Megyei Tüdőgyógyintézet, Farkasgyepű, Hungary|Matrai Gyogyintezet, Matrahaza, Hungary|Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály, Miskolc, Hungary|Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza, Tatabanya, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Hungary|Sri Venkateshwara Hospitals, Bangalore, Karnataka, India|KLES Dr Prabhakar Kore Hospital & MRC, Nehru Nagar, Karnataka, India|Jaslok Hospital & Research Center, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Birla Cancer Centre, SMS Hospital, Jaipur, Rajasthan, India|Healthcare Global (HCG) Towers, Bangalore, India|Bhagawan Mahaveer Cancer Hospital, Jaipur, India|Dipartimento di Oncologia, ARNAS Garibaldi, Catania, Italy|Istituto Nazionale dei Tumori, Milan, Italy|Istituto Europeo di Oncologia (IEO), Milano, Milan, Italy|Ospedale Santa Maria della Misericordia, Perugia, Perugia, Italy|Radiation Oncology, Campus Bio-Medico University, Rome, Italy|Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy|A.O.U. San Luigi Gonzaga, Orbassano (Torino), Torino, Italy|Kosin University Gospel Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Chungcheongbuk-do, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Kyungpook University Chilgok Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Centre, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|CHA Bundang Medical Center, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsangnam-do, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeonnam, Korea, Republic of|Gachon Universtiy Gil Medical Center, Namdong, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Boramae Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Wonju Severance Christian Hospital, Wonju-Si, Gangwon-do, Korea, Republic of|Hospital of Lithuanian University of Health Sciences (LSMU) Kauno Klinikos, Kaunas, Lithuania|National Cancer Institute, Vilnius, Lithuania|Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Department of Medicine, Faculty of Medicine, Kuala Lumpur, Malaysia|Hospital Umum Sarawak, Kuching, Malaysia|National Cancer Institute, Putrajaya, Malaysia|Cebu Doctors University Hospital, Cebu City, Philippines|Davao Doctors Hospital, Davao City, Philippines|Manila Doctors Hospital, Manila, Philippines|St. Luke's Medical Center - Quezon City, Quezon City, Philippines|St. Luke's Medical Centre, Quezon City, Philippines|Szpital Specjalistyczny w Prabutach Sp. z o.o, Prabuty, Pomeranian Voivodeship, Poland|Samodzielny Publiczny Zespół Gruźlicy i Chorób Płuc w Olsztynie, Olsztyn, Warminsko-Mazurskie, Poland|Samodzielny Specjalistyczny ZespółZakładów Opieki Zdrowotnej im. dr. Teodora Dunina, Mrozy, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Szpital Chorób Płuc im Św. Józefa w Pilchowicach, Pilchowice, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Poznań, Poland|Centrum Onkologii-Instytut im. Sklodowskiej-Curie, Warszawa, Poland|Wojskowy Instytut Medyczny, Warszawa, Poland|Centrum Terapii Wspolczesnej J.M. Jasnorzewska sp. komandytowo-akcyjna, Łódź, Łódź Voivodeship, Poland|Oncopremium Team LTD, Baia-Mare, Romania|Institute of Oncology Prof. Dr. I.Chiricuta Cluj-Napoca, Cluj-Napoca, Romania|Medisprof LTD, Cluj-Napoca, Romania|SC Oncolab LTD, Craiova, Romania|SC Oncology Center Sf. Nectarie LTD, Craiova, Romania|Emergency County Hospital Satu-Mare, Medical Oncology Clinic, Satu-Mare, Romania|Emergency Hospital ,Sf. Ioan cel Nou', Suceava, Romania|Oncocenter Oncology Clinic LTD, Timisoara, Romania|State Budgetary Healthcare Institution of Arkhangelsk Region Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|State Budgetary Healthcare Institution of Sverdlovsk Region, Sverdlovsk Regional Oncology Dispensary, Ekaterinburg, Russian Federation|Region Budgetary Healthcare Institution, Kursk Regional Clinical Oncology Dispensary of Healthcare Committee of Kursk Region, Kursk, Russian Federation|Federal State Budgetary Institution, Natiоnal Medical Research Center of Oncology n.a. N.N. Blokhin of Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation|State Budgetary Healthcare Institution of Moscow, Moscow City Oncology Hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|State Budgetary Healthcare Institution of Arkhangelsk region ""Arkhangelsk Clinical Oncology Dispensary"", Moscow, Russian Federation|State Budgetary Healthcare Institution of Novosibirsk Region, Сity Clinical Hospital #1, Novosibirsk, Russian Federation|State Budgetary Healthcare Institution of Novosibirsk Region, Novosibirsk Regional Oncology Dispensary, Novosibirsk, Russian Federation|Budgetary Healthcare Institution of Omsk Region, Clinical Oncology Dispensary, Omsk, Russian Federation|State Budgetary Healthcare Institution, Orenburg Regional Clinical Oncology Dispensary, Orenburg, Russian Federation|Center of Palliative Care-Devita LLC, Saint Petersburg, Russian Federation|State Budgetary Healthcare Institution, Leningrad Regional Clinical Hospital, Saint-Petersburg, Russian Federation|BioEq, LLC, Saint-Petersburg, Russian Federation|Federal State Budgetary Institution, Scientific Research Institute of Oncology n.a. Petrov, Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution, Saint-Petersburg Clinical Scientific Practical Center of Specialized Kinds of Medical Care (Oncological), Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|State Budgetary Healthcare Institution, Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|State Budgetary Healthcare Institution of Yaroslavl Region, Regional Oncology Hospital, Yaroslavl, Russian Federation|St. Jacob´s Hospital Bardejov - Department of Clinical Oncology, Bardejov, Slovakia|Faculty Hospital Zilina, Žilina, Slovakia|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|CHU A Coruña, Coruña, Galicia, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Quirón Dexeus, Barcelona, Spain|Hospital Universitari Vall d´Hebron, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Instituto Catalán de Oncología (ICO) - Josep Trueta, Girona, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Hospital General Universitário Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Norte Sanchinarro, Madrid, Spain|H. M. Puerta del Sur (H. Móstoles), Madrid, Spain|Hospital Regional de Málaga (H. Carlos Haya), Málaga, Spain|Complexo Hospitalario Universitario de Ourense (CHUO), Ourense, Spain|Hospital Virgen de los Lirios Alcoy, Planta, Spain|Corporació Sanitària Parc Taulí, Sabadell, Spain|Hospital Universitario Virgen de Valme, Sevilla, Spain|Hospital Universitario y Politécnico de La Fe, Valencia, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain|Hospital Lozano Blesa, Zaragoza, Spain|E-Da Hospital, Kaohsiung City, Taiwan|E-Da Hospital, Kaohsiung City, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan|Chung Shan Medical University Hospital, Taichung City, Taiwan|Chi Mei Hospital, Liouying, Tainan City, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan City, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|National Cancer Institute of Thailand, Bangkok, Thailand|Siriraj Hopsital, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Naresuan University Hospital, Phitsanulok, Thailand|Songklanagarind Hospital, Songkhla, Thailand|Municipal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council,"" Municipal Institution ""Multifield Dnipropetrovsk City Hospital #4"" of Dnipropetrovsk Regional Council, Department of Chemotherapy, Dnipro, Dnipropetrovsk, Ukraine|Municipal Nonprofit Institution ""Cental Municipal Clinical Hospital"" of Uzhgorod City Council, Municipal Oncology Centre, Uzhgorod, Zakarpattia, Ukraine|Regional Communal Nonprofit Enterprise, Municipal Institution Chernivtsi Regional Clinical Oncology Dispensary, Surgery Department, State Higher Educational Establishment of Ukraine, Bukovinian State Medical University, Department of Onc and Radiology, Chernivtsi, Ukraine|Communal Non-profit Enterprise ""Kyiv City Clinical Oncology Center"" of Executive body of Kyiv City Council, Kyiv City Clinical Oncology Center by Main Department of Health Protection Kyiv, Hospital of Day Stay for Oncology Patients, Kiev, Ukraine|Municipal Nonprofit Institution ""Odessa Regional Oncology Dispensary"" of Odessa Regional Council, Municipal Institution Odesa Regional Oncology Dispensary, Hospital of Day Stay (Unit of Dispensary-Polyclinic Department), Odessa, Ukraine|Municipal Nonprofit Institution ""Podilsky Regional Oncology Center"" of Vinnytsa City Council, Podilsky Regional Oncology Сenter, Department of Chemotherapy, Vinnitsya, Ukraine|Princess Alexandra Hospital, Harlow, Essex, United Kingdom|Royal Marsden Hospital, Chelsea, London, United Kingdom|St James' Institute of Oncology, Leeds, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03098030/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT03098030/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03098030"
318,"NCT04269200","Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer","DUO-E","Recruiting","No Results Available","Endometrial Neoplasms","Drug: olaparib|Biological: durvalumab|Drug: durvalumab placebo|Drug: olaparib placebo|Drug: Carboplatin|Drug: Paclitaxel","Progression Free Survival (PFS) for Arm B vs Arm A|Progression Free Survival (PFS) for Arm C vs Arm A|Second Progression (PFS2)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of response (DoR)|Time to first subsequent therapy (TFST)|Time to second subsequent therapy (TSST)|Time to discontinuation or death (TDT)|The pharmacokinetics (PK) of durvalumab will be determined after steady state doses|Safety and tolerability of drugs by assessment of AEs/SAEs|The immunogenicity of durvalumab as determined by concentration of Anti-drug antibodies (ADA) to durvalumab","AstraZeneca|The Gynecologic Oncology Group (GOG) Foundation Inc|The European Network for Gynaecological Oncological Trial groups (ENGOT)","Female","18 Years to 150 Years   (Adult, Older Adult)","Phase 3","699","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9311C00001|2019-004112-60|GOG-3041|ENGOT-EN10","May 21, 2020","September 26, 2023","March 5, 2025","February 13, 2020",,"May 13, 2022","Research Site, Tucson, Arizona, United States|Research Site, Concord, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Newark, Delaware, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Arlington Heights, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hinsdale, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Ames, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Scarborough, Maine, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Paul, Minnesota, United States|Research Site, Jackson, Mississippi, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Camden, New Jersey, United States|Research Site, Paramus, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, Johnson City, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Eugene, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Tigard, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Providence, Rhode Island, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Germantown, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Madison, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Bedford Park, Australia|Research Site, Campbelltown, Australia|Research Site, Clayton, Australia|Research Site, Kogarah, Australia|Research Site, Malvern, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, Port Macquarie, Australia|Research Site, Sydney, Australia|Research Site, Bruges, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Libramont-Chevigny, Belgium|Research Site, Liège, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Pelotas, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Chicoutimi, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Dalian, China|Research Site, Guangdong, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Kunming, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Taiyuan, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Zhanjiang, China|Research Site, Zhengzhou, China|Research Site, Zhengzhou, China|Research Site, Zhengzhou, China|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogota, Colombia|Research Site, Bogota, Colombia|Research Site, Bogota, Colombia|Research Site, Cali, Colombia|Research Site, Cali, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Monteria, Colombia|Research Site, Pereira, Colombia|Research Site, Rionegro, Colombia|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Dresden, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Karlsruhe, Germany|Research Site, Konstanz, Germany|Research Site, Leipzig, Germany|Research Site, Athens, Greece|Research Site, Chaidari, Greece|Research Site, Marousi, Greece|Research Site, Thessaloniki, Greece|Research Site, HKG, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Tun Mun, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Győr, Hungary|Research Site, Szolnok, Hungary|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Hisar, India|Research Site, Ludhiana, India|Research Site, Mumbai, India|Research Site, Mysuru, India|Research Site, Nagpur, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Be'er Ya'akov, Israel|Research Site, Hadera, Israel|Research Site, Jerusalem, Israel|Research Site, Nahariya, Israel|Research Site, Tel Aviv, Israel|Research Site, Chuo-ku, Japan|Research Site, Kashiwa-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nakagami-gun, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Toon-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Kaunas, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Aguascalientes, Mexico|Research Site, Ciudad de Mexico, Mexico|Research Site, Durango, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Oaxaca, Mexico|Research Site, Queretaro, Mexico|Research Site, San Luis Potosi, Mexico|Research Site, Veracruz, Mexico|Research Site, Gdansk, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Olsztyn, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Anzorey, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moskva, Russian Federation|Research Site, Saransk, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, El Palmar, Spain|Research Site, Girona, Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Mallorca, Spain|Research Site, Sevilla, Spain|Research Site, Vigo, Spain",,"https://ClinicalTrials.gov/show/NCT04269200"
319,"NCT00606502","Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment",,"Completed","Has Results","Non-small Cell Lung Cancer","Drug: Pralatrexate|Drug: Erlotinib|Dietary Supplement: Vitamin B12|Dietary Supplement: Folic Acid","Overall Survival (OS) of Patients Receiving Pralatrexate vs. Erlotinib|Response Rate (RR) to Treatment of Patients Receiving Pralatrexate vs. Erlotinib|Progression-free Survival (PFS) of Patients Receiving Pralatrexate vs. Erlotinib|Adverse Events of Patients Receiving Pralatrexate vs. Erlotinib","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","201","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PDX-012|2007-004673-26","January 2008","June 24, 2010","June 24, 2010","February 4, 2008","January 20, 2011","March 5, 2021","Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Donald Berdeaux, Great Falls, Montana, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Hematology and Oncology Associates South Jersey, Mount Holly, New Jersey, United States|New York Oncology Hematology-Oncology Associates, P.C., Latham, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|New Bern Cancer Care, New Bern, North Carolina, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Baptist Regional Cancer Center, Knoxville, Tennessee, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Providence Everett Medical Center, Everett, Washington, United States|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Cuidad De Buenos Aires, Argentina|Policlinica Privada - Instituto de Medicina Nuclear, Bahia Blanca, Provincia De Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Argentina|Centro Oncologico Rosario, Rosario, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|CAIPO (Centero Para la Atencion Integral del Paciente Oncologico), Tucuman, Argentina|Associação Hospital de Caridade de Ijuí, Ijui, RS, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil|Clinionco - Clínica de Oncologia de Porto Alegre, Porto Alegre, RS, Brazil|Fundação Pio XII - Hospital do Câncer de Barretos, Barretos, SP, Brazil|Biocancer S.A., Belo Horizonte, Brazil|Instituto do Cancer - Arnaldo Vieira de Carvalho, Sao Paulo, Brazil|Masarykuv onkologicky ustav, Brno, Czechia|Palacký University Medical School and Teaching Hospital, Olomouc, Czechia|Vitkovicka nemocnice, a. s., Ostrava, Czechia|Fakultni nemocnice na Bulovce, Praha 8, Czechia|Fakultni nemocnice v Motole, Praha, Czechia|Nemocnice Na Homolce, Praha, Czechia|National Koranyi TBC and Pulmonology Institute, Budapest, Pest, Hungary|Jósa András Teaching Hospital, Nyiregyhaza, Szabolcs-Szatmár-Bereg, Hungary|Vas County Markusovszky Hospital, Szombathely, Vas, Hungary|Zala County Hospital, Zalaegerszeg, Zala, Hungary|Matrai Allami Gyogyintezet, Matrahaza, Hungary|Komarom-Esztergom Megyei Onkorm. Szent Borbala Korhaza, Tatabánya, Hungary|MNJ Radium Hospital and Radium Institute of Oncology and Regional Cancer Centre, Hyderabaad, Andhra Pradesh, India|Indo American Cancer Institute and Research Center, Hyderabad, Andhra Pradesh, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Regional Cancer Center, Trivandrum, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre Pvt Ltd, Pune, Mahara, India|B.P. Poddar Cancer Institute, Kolkata, West Bengal, India|Dharmashila Cancer Hospital & Research Centre, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00606502"
320,"NCT01168973","A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy",,"Completed","Has Results","Non-Small Cell Lung Cancer","Biological: Ramucirumab|Drug: Placebo (for Ramucirumab)|Drug: Docetaxel","Overall Survival|Progression-Free Survival (PFS) Time|Percentage of Participants Achieving an Objective Response (Objective Response Rate)|Percentage of Participants Achieving Disease Control (Disease Control Rate)|Maximum Improvement on Lung Cancer Symptom Scale (LCSS)|Change From Baseline to 30-Day Follow-Up Visit on European Quality of Life Questionnaire-5 Dimension (EQ-5D) Health State Scores|Maximum and Minimum Serum Concentrations (Cmax and Cmin) of Ramucirumab|Number of Participants With Anti-Ramucirumab Antibodies","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1253","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13852|I4T-MC-JVBA|2010-021297-11|CP12-1027|CTRI/2011/08/001942","December 2010","December 2013","August 2016","July 23, 2010","December 29, 2014","September 25, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sedona, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alhambra, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fullerton, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Long Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Northridge, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redondo Beach, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Barbara, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Monica, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lawrenceville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Savannah, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomington, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cedar Rapids, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Overland Park, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashland, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mount Sterling, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baton Rouge, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Metairie, Louisiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chevy Chase, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Danvers, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Framingham, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newton, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Joplin, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Henderson, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reno, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lebanon, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portsmouth, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Latham, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abington, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sioux Falls, South Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abilene, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amarillo, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beaumont, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., El Paso, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lewisville, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., McAllen, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mesquite, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Midland, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Webster, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christiansburg, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfax, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lacey, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wenatchee, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Córdoba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Rioja, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grimmenstein, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wels, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belo Horizonte, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goiania, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moncton, New Brunswick, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toulouse, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bad Soden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bielefeld, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gerlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Villingen-Schwenningen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kifissia, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gyula, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Matrahaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pécs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szekesfehervar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cuttack, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jerusalem, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Petah Tikva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Safed, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Novara, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palermo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arnhem, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grafton, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oslo, Norway|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tromsø, Norway|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdynia, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glucholazy, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Opole, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Otwock, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Girona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Palmas De Gran Canaria, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataró, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pozuelo De Alarcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskilstuna, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linkoping, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Solna, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Basel, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fribourg, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Luzern, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zurich, Switzerland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neihu Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cottingham, East Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Preston, Lancashire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wythenshawe, Manchester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scunthorpe, North Lincolnshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coventry, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01168973"
321,"NCT01996241","Evaluation of an Intervention for Adolescent Girls in Karnataka","Samata","Completed","Has Results","Secondary School Entry and Completion|Child Marriage","Behavioral: Multi-level, structural and norms-based intervention","Number of Participants Completing Secondary School [Sit 10th Standard Exam]|Number of Participants Married [by Trial End Line]|Number of Participants Entering Into 8th Standard [Start Secondary School]|Number of Participants Passing 10th Standard [Pass 10th Standard Exam]|Number of Participants Having Sexual Debut [by Trial End Line]|Number of Participants Married and Co-habiting With Husband [by Trial End Line]","Karnataka Health Promotion Trust|University of Manitoba|London School of Hygiene and Tropical Medicine","Female","13 Years to 15 Years   (Child)","Not Applicable","2457","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","111/2013","January 2014","December 31, 2017","December 31, 2017","November 27, 2013","September 25, 2019","October 15, 2019","Bagalkot and Bijapur Districts, Bagalkot, Karnataka, India","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01996241/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT01996241/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01996241"
322,"NCT04742192","Non-interventional, Prospective Study to Determine Prevalence of EGFR Mutations in Non-small Cell Lung Cancer","EARLY-EGFR","Recruiting","No Results Available","Non-small Cell Lung Cancer",,"Overall proportion of patients with EGFRm|Proportion of EGFRm in Pathologic Stage|Proportion of patients with the EGFRm types|Proportion of patients who were prescribed modalities","AstraZeneca","All","18 Years and older   (Adult, Older Adult)",,"550","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","D5161R00028","March 4, 2021","November 30, 2022","November 30, 2022","February 8, 2021",,"May 11, 2022","Research Site, Buenos Aires, Argentina|Research Site, Rosario - Santa Fe, Argentina|Research Site, Santiago de Chile, Chile|Research Site, Santiago de Chile, Chile|Research Site, Bogotá, Colombia|Research Site, Montería -Cordoba, Colombia|Research Site, San Jose, Costa Rica|Research Site, Santo Domingo, Dominican Republic|Research Site, Alexandria, Egypt|Research Site, Cairo, Egypt|Research Site, Tanta, Egypt|Research Site, Kashmir, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Kuwait City, Kuwait|Research Site, Cdmx, Mexico|Research Site, Guadalajara, Mexico|Research Site, Monterrey, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Cebu City, Philippines|Research Site, Iliolo City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Singapore, Singapore|Research Site, Bangkok, Thailand|Research Site, Muang, Thailand|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04742192"
323,"NCT00538863","Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain",,"Completed","Has Results","Cancer|Pain","Drug: Fentanyl sublingual spray","Percentage of Patients That Experienced 1 or More Adverse Events","INSYS Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","319","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","INS-06-007","December 2007","October 2010","October 2010","October 3, 2007","October 11, 2013","October 11, 2013","Huntsville, Alabama, United States|Winfield, Alabama, United States|Glendale, Arizona, United States|Scottsdale, Arizona, United States|Laguna Hills, California, United States|Loma Linda, California, United States|Los Gatos, California, United States|San Mateo, California, United States|Bradenton, Florida, United States|Lake Worth, Florida, United States|Miami, Florida, United States|Winter Park, Florida, United States|Newnan, Georgia, United States|Chicago, Illinois, United States|Skokie, Illinois, United States|Zion, Illinois, United States|Elkhart, Indiana, United States|Bethesda, Maryland, United States|Southfield, Michigan, United States|Edina, Minnesota, United States|Jefferson City, Missouri, United States|Great Falls, Montana, United States|Kalispell, Montana, United States|Missoula, Montana, United States|Voorhees, New Jersey, United States|Flat Rock, North Carolina, United States|Winston-Salem, North Carolina, United States|Canton, Ohio, United States|Dayton, Ohio, United States|Eugene, Oregon, United States|Altoona, Pennsylvania, United States|Danville, Pennsylvania, United States|Lemoyne, Pennsylvania, United States|Kingsport, Tennessee, United States|Bellaire, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Port Sam Houston, Texas, United States|Tacoma, Washington, United States|Appleton, Wisconsin, United States|Oakville, Ontario, Canada|Montreal, Quebec, Canada|Saskatoon, Saskatchewan, Canada|Quebec, Canada|Ahmedabad, India|Bangalore, India|Bhopal, India|Hyderabad, India|Jaipur, India|Mumbai, India|Nasik, India|Pune, India",,"https://ClinicalTrials.gov/show/NCT00538863"
324,"NCT00300781","Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer",,"Completed","Has Results","Breast Neoplasms|Neoplasms","Drug: neratinib","16-week Progression Free Survival|Objective Response Rate|Clinical Benefit Rate|Duration of Response","Puma Biotechnology, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 2","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3144A1-201 / B1891012","August 4, 2006","April 2008","January 30, 2018","March 9, 2006","September 13, 2017","August 14, 2018","University of Colorado Hospital, Aurora, Colorado, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Louisiana State University, Shreveport, Louisiana, United States|The Cancer Center at GBMC, Baltimore, Maryland, United States|Oncology Care Associates, Bethesda, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|Faulkner Hospital, Boston, Massachusetts, United States|Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Institut Jules Bordet Unite du Chimiotherapie, Brussels, Belgium|University Hospital Gasthuisberg, Leuven, Belgium|St-Augustinus Ziekenhuis Oncology Department, Wilrijk, Belgium|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, China|No. 81 Hospital of Chinese People's Liberation Army, Nanjing, Jiangsu, China|Cancer Hospital Peking Union Medical College, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, China|Institut Gustave ROUSSY Service de Pathologie Mammaire, Villejuif Cedex, France|Jehangir Clinical Development Centre, Pune, Maharashtra, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|Nizam's Institute of Medical Sciences, Hyderabad, Panjagutta, India|Tata Memorial Centre, Mumbai, Parel, India|Hospital Regional Lic. Adolfo Lopez Mateos Oncología Médica, Mexico City, Mexico|Arke Estudios Clínicos S.A. de C.V., Mexico City, Mexico|Hospital de Especialidades MIG, Mexico City, Mexico|N.N. Blokhin Russian Cancer Research Center of RAMS, Moscow, Russian Federation|Medical Radiological Research Center of RAMS, Department of Radiation and Surgical Methods, Obninsk, Russian Federation|City Oncology Dispensary, Saint Petersburg, Russian Federation|City Hospital N 31 Oncology Haematology Dept. For Adults, Saint Petersburg, Russian Federation|Breast Tumor Department, N.N. Petrov Research Institute of Oncology, Saint-Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00300781"
325,"NCT00527735","Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)",,"Completed","Has Results","Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung","Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin","Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC)|Progression-free Survival (PFS) in Participants With NSCLC Per Modified World Health Organization (mWHO) Criteria|Overall Survival in Participants With NSCLC|Best Overall Response Rate (BORR) Per mWHO Criteria in Participants With NSCLC and SCLC|Immune-related Best Overall Response Rate (irBORR) Per irRC in Participants With NSCLC and Small-cell Lung Cancer (SCLC)|Immune-related Disease Control Rate (irDCR) Per irRC and Disease Control Rate (DCR) Per mWHO Criteria in Participants With NSCLC and SCLC|Immune-related Duration of Response (irDoR) Per irRC and DoR Per mWHO Criteria in Participants With NSCLC and SCLC|Number of Participants With NSCLC Who Have Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, and Drug-related AEs by Worst Common Terminology Criteria (CTC) Grade|Percentage of Participants With NSCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade|irPFS in Participants With SCLC Per irRC|Number of Participants With NSCLC Who Have Abnormalities in On-Study Liver Function Test Results By Worst CTC Grade|Number of Participants With NSCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings|Percentage of Participants With NSCLC Who Have Abnormalities in Pancreatic Enzyme Clinical Laboratory Test Results by Worst CTC Grade|Number of Participants With NSCLC Who Have Positive Human Antihuman Antibody (HAHA) Status Postbaseline|Number of Participants With SCLC With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs by Worst CTC Grade|Number of Participants With SCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade|Number of Participants With SCLC Who Have Abnormalities in Liver Function Test Results by Worst CTC Grade|Percentage of Participants With SCLC Who Have Abnormalities in Pancreatic Enzyme and Other Clinical Laboratory Test Results by Worst CTC Grade|Progression-free Survival (PFS) in Participants With SCLC Per mWHO Criteria|Number of Participants With SCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings|Number of Participants With SCLC Who Have Positive HAHA Status Postbaseline|Overall Survival in Participants With SCLC","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 2","334","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CA184-041","February 2008","October 2009","December 2011","September 11, 2007","July 16, 2012","July 18, 2018","Birmingham Hematology & Oncology Assoc. Llc, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Arizona, United States|Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Compassionate Cancer Care Medical Group, Corona, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|The Angeles Clinic & Research Institute, Inc, Los Angeles, California, United States|Oncology Care Medical Associates, Montebello, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|M D Anderson Cancer Center- Orlando, Orlando, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Local Institution, Park Ridge, Illinois, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|The John R. Marsh Cancer Center, Hagerstown, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Cancer Center, Minneapolis, Minnesota, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Local Institution, New York, New York, United States|Cmc-Northeast/ Northeast Oncology Associates, Concord, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Hematology Oncology Consultants, Inc, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Santee Hematology/Oncology, Sumter, South Carolina, United States|Southwest Cancer Treatment And Research Center, Lubbock, Texas, United States|Local Institution, Belfort, France|Local Institution, Caen, France|Local Institution, Marseille Cedex 9, France|Local Institution, Rennes Cedex 9, France|Local Institution, Bochum, Germany|Local Institution, Coswig, Germany|Local Institution, Ebensfeld, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (Saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Koeln, Germany|Local Institution, Leipzig, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Navrangpura, Ahmedabad, Gujarat, India|Local Institution, Manipal, Karnataka, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Vellore, India|Local Institution, Genova, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Ivanovo, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Sochi, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Kharkov, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Ternopol, Ukraine|Local Institution, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT00527735"
326,"NCT02299505","Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Non-Small Cell Lung Cancer","Drug: ceritinib","Plasma concentration of ceritinib|Safety profile|Objective response rate (ORR)|Duration of response (DOR)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 1","306","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLDK378A2112|2014-004001-32","April 9, 2015","June 16, 2016","March 6, 2020","November 24, 2014",,"February 9, 2022","Highlands Oncology Group, Fayetteville, Arkansas, United States|Loma Linda University, Loma Linda, California, United States|Goshen Center for Cancer Care IU Health - SC, Indianapolis, Indiana, United States|Maryland Oncology Hematology, P.A. SC-2, Rockville, Maryland, United States|Essex Oncology of North Jersey PA SC, Belleville, New Jersey, United States|Greenville Health System SC, Greenville, South Carolina, United States|Utah Cancer Specialists Dept.of Utah Cancer Spec. (3), Salt Lake City, Utah, United States|Novartis Investigative Site, Grafton, Auckland, Australia|Novartis Investigative Site, Auckland, Australia|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Natal, RN, Brazil|Novartis Investigative Site, Passo Fundo, RS, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Itajai, SC, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Nieuwegein, Netherlands|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Tarnobrzeg, Poland|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Hat Yai, Songkla, Thailand|Novartis Investigative Site, Bangkok, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Talas / Kayseri, Turkey|Novartis Investigative Site, Wirral, Merseyside, United Kingdom|Novartis Investigative Site, Newcastle Upon Tyne, Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02299505"
327,"NCT04351555","A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","NeoADAURA","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Osimertinib|Drug: Cisplatin|Drug: Carboplatin|Drug: Placebo|Drug: Pemetrexed","Major Pathological Response (MPR)|Pathological complete response (pCR)|Event-free survival (EFS)|Overall Survival (OS)|Disease free survival (DFS)|Downstaging|Difference between treatment arms in change from baseline in EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items)|Concordance of EGFRm status between tumour tissue DNA and patient-matched plasma-derived ctDNA|Corcordance of EGFR mutation status between the local and central cobas EGFR mutation test results from baseline tumour samples|PK plasma concentrations of osimertinib|Difference between treatment arms in change from baseline in EORTC QLQ-LC13 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items)","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D516AC00001","December 16, 2020","March 26, 2024","March 29, 2029","April 17, 2020",,"March 31, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Monica, California, United States|Research Site, Santa Rosa, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Detroit, Michigan, United States|Research Site, Columbia, Missouri, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Commack, New York, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Cleveland, Ohio, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Linz, Austria|Research Site, Vienna, Austria|Research Site, Wien, Austria|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Bento Goncalves, Brazil|Research Site, Florianópolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Ibirapuera, Brazil|Research Site, Jau, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Panagyurishte, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Antofagasta, Chile|Research Site, La Serena, Chile|Research Site, Las Condes, Chile|Research Site, Providencia, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Talca, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Linhai, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Shandong, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenzhen, China|Research Site, Suzhou, China|Research Site, Urumqi, China|Research Site, Wanzhou, China|Research Site, Wenzhou, China|Research Site, Xiamen, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, Berlin, Germany|Research Site, Bielefeld, Germany|Research Site, Essen, Germany|Research Site, Esslingen a.N., Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Georgsmarienhuette, Germany|Research Site, Gerlingen, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Homburg, Germany|Research Site, Köln, Germany|Research Site, Oldenburg, Germany|Research Site, Regensburg, Germany|Research Site, Rheinland-Pfalz, Germany|Research Site, Würzburg, Germany|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Chennai, India|Research Site, Coimabatore, India|Research Site, Kolkata, India|Research Site, Manipal, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Namakkal, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Bari, Italy|Research Site, Monza, Italy|Research Site, Orbassano, Italy|Research Site, Padova, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Varese, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daejeon, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, D.F, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico City, Mexico|Research Site, La Libertad, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Białystok, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Kazan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Perm, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Bellinzona, Switzerland|Research Site, Bern, Switzerland|Research Site, Geneva, Switzerland|Research Site, Zürich, Switzerland|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Pathumthani, Thailand|Research Site, Pathumwan, Thailand|Research Site, Phisanulok, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04351555"
328,"NCT00448305","EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients",,"Completed","No Results Available","Breast Neoplasms","Drug: EndoTAG-1 + paclitaxel|Drug: EndoTAG-1|Drug: Paclitaxel","4-month progression free survival (PFS) rate|median progression free survival (PFS) time|tumor response|4-month survival rate|median overall survival time|pain assessment|clinical benefit assessment via quality of life (QoL)Scale|adverse events|laboratory values|dose variations","MediGene","Female","18 Years and older   (Adult, Older Adult)","Phase 2","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT 4002|EudraCT-Nr. 2006-002221-23","January 2007","February 2010","March 2011","March 16, 2007",,"January 5, 2012","Institut Jules Bordet - Centre des Tumeurs de l'Université Libre de Bruxelles, Brussels, Belgium|CHU Brugmann, Brussels, Belgium|UZ Antwerpen, Edegem, Belgium|CHU Liège, Liège, Belgium|Centre Oscar Lambret, Lille, France|Cente Antoine Lacassagne, Nice, France|Institut Curie, Paris, France|Hôpital de Jour Centre Henri Kaplan, Tours, France|Institut Gustave Roussy, Villejuif, France|Vedanta Institute of Medical Science, Ahmedabad, India|Bangalore Institute of Oncology, Bangalore, India|Searoc Cancer Center, Jaipur, India|Lakeshore Hospital, Kochin, India|Deenanath Mangeshkar Hospital, Pune, India|Kaushalya Medical Foundation, Thane, India|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Gliwice, Poland|Instytut im. M. Sklodowskiej-Curie, Lublin, Poland|NZOZ Grupowa Specjalistyczna, Olsztyn, Poland|Klinika Onkologii Adadmii Medycznej, Poznan, Poland|Institute of Oncology ""Prof. Dr. Al. Trestioreanu"", Bucharest, Romania|Institute of Oncology ""Prof. Dr. I. Chiricuta"", Cluj Napoca, Romania|Center of Medical Oncology, Iasi, Romania|Emergency County Hospital Sibiu, Sibiu, Romania|Oncology Clinic ""Oncomed"", Timisoara, Romania|Dnepropetrovsk State Medical Acedamy, Dnepropetrovsk, Ukraine|Institute of Medical Radiology of Acedamy of Medical Sciences, Kharkov, Ukraine|Department of Abdominal Surgery, Kiev, Ukraine|Institut of Oncology, Kiev, Ukraine|Surgical Department, Kiev, Ukraine|Rivne Regional Oncological Dispensary, Rovno, Ukraine|Sumy Reginal Oncology Center, Sumy, Ukraine|Regional Clinical Oncological Dispensary, Uzhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT00448305"
329,"NCT03296163","A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","STELLA","Completed","Has Results","Non-small Cell Lung Cancer","Drug: MB02 (Bevacizumab Biosimilar Drug)|Drug: EU-approved Avastin®|Drug: Carboplatin|Drug: Paclitaxel","Objective Response Rate (ORR) at Week 18|Progression-free Survival (PFS)|Overall Survival (OS)|Incidence of Treatment-emergent Adverse Events (TEAEs)|Immunogenicity Assessments (Anti-drug Antibodies [ADA] and Neutralizing Antibodies [NAb])","mAbxience S.A","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","627","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","MB02-C-02-17","February 6, 2018","July 3, 2019","February 27, 2020","September 28, 2017","March 26, 2021","April 26, 2021","MedRadius, Maceió, AL, Brazil|Instituto do Câncer do Ceará - ICC, Fortaleza, CE, Brazil|Centro Brasileiro de Radioterapia Oncologia e Mastologia, Goiânia, GO, Brazil|Hospital Erasto Gaertner - Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Instituto Nacional de Cancer- INCA, Rio de Janeiro, RJ, Brazil|Centro de Pesquisa e Educação da Serra Gaúcha (CEPESG), Caxias do Sul, RS, Brazil|IPCEM Universidade de Caxias Do Sul, Caxias do Sul, RS, Brazil|Hospital de Caridade de Ijuí, Ijuí, RS, Brazil|Instituto do Câncer - Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Hospital São Lucas da PUCRS, Pôrto Alegre, RS, Brazil|Hospital de Câncer de Barretos, Barretos, SP, Brazil|Hospital de Base de São José do Rio Preto, São José do Rio Prêto, SP, Brazil|Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, São Paulo, SP, Brazil|Instituto de Ensino e Pesquisa São Lucas, São Paulo, SP, Brazil|Hospital Santa Marcelina, Sao Paulo, Brazil|Central Hospital Plovdiv, Plovdiv, Bulgaria|Acıbadem City Clinic Cancer Center UMHAT, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Oncology Diseases Sofia District EOOD, Sofia, Bulgaria|Fundación Arturo López Pérez - Instituto Oncológico FALP, Santiago, Chile|Health & Care Spa, Santiago, Chile|Instituto Clinico Oncologico del Sur ICOS, Temuco, Chile|Oncocentro APYS, Viña del Mar, Chile|Cancer Center of Adjara Autonomous Republic, Batumi, Georgia|Acad. F . Todua medical center-research institute of clinical medicine, Tbilisi, Georgia|Consilium Medulla, Tbilisi, Georgia|Institute of Clinical Oncology, Tbilisi, Georgia|LTD Aversi Clinic, Tbilisi, Georgia|LTD Cancer Research Centre, Tbilisi, Georgia|Tbilisi State Medical Universitys First university Clinic, Tbilisi, Georgia|General Hospital of Athens ""Ippokratio"", Athens, Greece|Sotiria General Hospital for Chest Diseases, Athens, Greece|University General Hospital of Larissa, Lárisa, Greece|Agioi Anargyroi General Oncological Hospital of Kifissia, Néa Kifisiá, Greece|General Hospital of Thessaloniki ""George Papanikolaou"", Thessaloníki, Greece|National Koranyi Institute of TB and Pulmonology, Budapest, Hungary|Országos Korányi Pulmonológiai Intézet (OKPI), Budapest, Hungary|Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza, Deszk, Hungary|Veszprém Megyei Tüdőgyógyinzézet, Farkasgyepű, Hungary|Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Miskolc, Hungary|Zydus Hospital, Ahmedabad, India|Action Cancer Hospital, Delhi, India|Aadhar Health Institute, Hisar, India|NIMS - Nizam's Institute of Medical Sciences, Hyderabad, India|Ganadhipati Purushottam Shekhawati Hospital Research Centre, Jaipur, India|PVS Hospital Pvt Ltd, Kerola, India|Apollo Gleneagles Hospital, Kolkata, India|Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India|Shatabdi Super Speciality Hospital, Nashik, India|Deenanath Mangeshkar Hospital & Research Center, Pune, India|Nirmal Hospital Pvt. Ltd., Surat, India|Kiran Super Multispeciality Hospital, Sūrat, India|Shree Himalaya Cancer Hospital Research Institute, Vadodara, India|Queen's NRI Hospital Gurudwara Lane, Visakhapatnam, India|Notre Dame de Secours, Jbaïl, Lebanon|Hospital Pulau Pinang, George Town, Pulau Pinang, Malaysia|Institut Perubatan dan Pergigian Termaju Universiti Sains Malaysia, Kepala Batas, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Pusat Perubatan Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Umum Sarawak, Kuching, Malaysia|National Cancer Institute, Putrajaya, Malaysia|Instituto Nacional de Cancerologia, Mexico City, Mexico|Hospital Universitario Dr. Jose Eleuterio González, Monterrey, Mexico|Sultan Qaboos University Hospital, Muscat, Oman|Baguio General Hospital & Medical Center, Baguio, Philippines|Cebu Doctors University Hospital - CDUH, Cebu, Philippines|Perpetual Succour Hospital - PSH, Cebu, Philippines|De La Salle University Medical Center - DLSUMC, Dasmariñas, Philippines|Davao Doctors Hospital - DDH, Davao, Philippines|Makati Medical Center, Makati City, Philippines|Philippine General Hospital - PGH, Manila, Philippines|The Medical City, Pasig, Philippines|St. Luke's Medical Center - Global City, Taguig, Philippines|SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary, Arkhangel'sk, Russian Federation|Regional state budgetary Healthcare Institution ""Belgorod oncology dispensary"", Belgorod, Russian Federation|State Budget Healthcare Institution Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Kaluga Regional Clinical Oncology center, Kaluga, Russian Federation|Republic Clinical Oncology Dispensary, Kazan', Russian Federation|Kursk Republican Clinical Oncology Dispensary, Kursk, Russian Federation|""VitaMed"" LLC, Moscow, Russian Federation|Moscow City Oncology Hospital No 62, Moscow, Russian Federation|N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|University Headache Clinic LLC, Moscow, Russian Federation|Federal budget Healthcare Institution ""Volga District Medical Centre"" under Federal Medical and Biological Agency, Novgorod, Russian Federation|GBUZ of SK Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation|Ryazan Regional Clinical Oncology Dispensary, Ryazan', Russian Federation|City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|GUZ ""Leningrad Regional Clinical Hospital"", Saint Petersburg, Russian Federation|State Budgetary healthcare Institution ""Samara regional clinical oncology dispensary"", Samara, Russian Federation|CHC Bezanijska Kosa, Belgrade, Serbia|Institute of Oncology and Radiology of Serbia (IORS), Belgrade, Serbia|Clinical Center Kragujevac, Kragujevac, Serbia|Clinical center Nis (Clinic for pulmonary diseases), Niš, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain|Bangkok International Hospital And Wattanosod Hospital, Bangkok, Thailand|Chiang Mai University (CMU) - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital, Chiang Mai, Thailand|Chiang Rai Prachanukroh Hospital, Chiang Rai, Thailand|Songklanagarind Hospital, Hat Yai, Thailand|Buddhachinaraj Hospital, Phitsanulok, Thailand|Istanbul Medeniyet University Medical Faculty, İstanbul, Turkey|Suat Seren Chest Diseases Hospital, İzmir, Turkey|Municipal Institution Cherkasy Regional Oncology Dispensary of Cherkasy Regional Council, Cherkasy, Ukraine|Public Higher Education Insititution of Ukraine ""Bukovinian State Medical University"", Chernivtsi, Ukraine|Multifield Clinical Hospital No.4, Dnepropetrovsk, Ukraine|Clinical Oncology Dispensary, Dnipro, Ukraine|State Institution ""Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine"", Kharkiv, Ukraine|State Institution ""V.T. Zaycev Institute of general and urgent surgery of National academy medical sciences of Ukraine"", Kharkiv, Ukraine|Medical and Diagnostic Centre Private Enterprise of Private Manufacturing Company ""ACINUS"", Kropyvnytskyi, Ukraine|Municipal Institution ""Kryviy Rih Oncology Dispensary"" of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|National Cancer Institute, Kyiv, Ukraine|National Institute of Cancer, Kyiv, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Center, L'viv, Ukraine|Healthcare facility ""Volyn regional Oncological Dispensary"", Luts'k, Ukraine|Odessa Regional Clinical Oncology Dispensary, Odessa, Ukraine|Uzhgorod National University, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsya, Ukraine|Communal Institution ""Zaporizhzhya Regional Clinical Oncological Dispensary"" of Zaporizhzhya regional council, Zaporizhzhya, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03296163/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT03296163/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03296163"
330,"NCT03447769","Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A","Canopy-A","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Canakinumab|Drug: Placebo","Disease free survival (DFS) by local investigator|Overall Survival (OS)|Disease free survival (DFS) by local investigator in PD-L1 subgroups|Disease free survival (DFS) by local investigator in CD8 subgroups|Overall Survival (OS) by local investigator in PD-L1 subgroups|Overall Survival (OS) by local investigator in CD8 subgroups|Lung Cancer Specific Survival (LCSS)|Area Under the Plasma Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast) of canakinumab|Maximum Observed Plasma Concentration (Cmax) of canakinumab|Trough Concentration (Cmin) of canakinumab|Anti-drug Antibody (ADA) prevalence at baseline|Anti-drug Antibody (ADA) incidence|Time to definitive 10 point deterioration symptom scores of pain,cough and dyspnea per EORTC QLQ-LC13 questionnaire|Time to definitive 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire|Time to first 10 point deterioration for symptom scores of pain, cough and dyspnea per EORTC QLQ-LC13 questionnaire|Time to first 10 point deterioration of global health status/QoL, shortness of breath and pain per EORTC QLQ-C30 questionnaire|Utility scores of the EQ-5D-5L","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","1382","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CACZ885T2301|2017-004011-39","March 16, 2018","August 31, 2023","September 15, 2025","February 27, 2018",,"May 2, 2022","Highlands Oncology Group, Fayetteville, Arkansas, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, United States|University of California at Los Angeles, Los Angeles, California, United States|VA Palo Alto Health Care System CRLX030A2301, Palo Alto, California, United States|Sansum Clinic, Santa Barbara, California, United States|Rocky Mountain Cancer Centers Denver-Mdtn(Bone&MarrowTransp), Denver, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Advanced Medical Specialties Drug Ship - 2, Miami, Florida, United States|Florida Cancer Affiliates of Ocala, Ocala, Florida, United States|Florida Cancer Specialists North, Saint Petersburg, Florida, United States|Florida Cancer Specialists Panhandle, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Rush University Medical Center CLDT600AUS06, Chicago, Illinois, United States|Cancer Center of Kansas Dept.ofCancerCtr.ofKansas, Wichita, Kansas, United States|VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska, United States|Louis Stokes Cleveland Department of Veterans Affairs MC, Cleveland, Ohio, United States|Oncology Associates of Oregon, PC, Eugene, Oregon, United States|Chattanooga Oncology and Hematology Associates PC Chattanooga Oncology, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|VA North Texas Health Care System, Dallas, Texas, United States|Texas Oncology MamieMcFaddenWardCtr, Dallas, Texas, United States|Virginia Cancer Specialists Fairfax Northern Virginia, Fairfax, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia Inc, Salem, Virginia, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Mar del Plata, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Klagenfurt, Austria|Novartis Investigative Site, Krems, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Teresina, Piaui, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Hefei, Anhui, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chongqing, Chongqing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shenzhen, Guangdong, China|Novartis Investigative Site, Zhanjing, Guangong, China|Novartis Investigative Site, Zunyi, Guizhou, China|Novartis Investigative Site, Zhengzhou, Henan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Shenyang, Liaoning, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, XI An, Shanxi, China|Novartis Investigative Site, Shenyang, Shengyang, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Changsha, China|Novartis Investigative Site, Chengdu, China|Novartis Investigative Site, Fujian, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Ostrava Vitkovice, Czechia|Novartis Investigative Site, Prague 2, Czechia|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Le Mans, Cedex 09, France|Novartis Investigative Site, Montpellier cedex 5, Herault, France|Novartis Investigative Site, Amiens, France|Novartis Investigative Site, Angers Cedex 9, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, La Rochelle, France|Novartis Investigative Site, La Seyne sur mer, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Suresnes, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Batumi, Georgia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Tbilisi, Georgia|Novartis Investigative Site, Heidelberg, Baden-Württemberg, Germany|Novartis Investigative Site, Gauting, Bayern, Germany|Novartis Investigative Site, Bochum, Nordrhein Westfalen, Germany|Novartis Investigative Site, Velbert, North Rhine-westphalia, Germany|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Chemnitz, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erfurt, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Georgsmarienhuette, Germany|Novartis Investigative Site, Gera, Germany|Novartis Investigative Site, Gerlingen, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Halle (Saale), Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Nuernberg, Germany|Novartis Investigative Site, Solingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, Attica, Greece|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Torokbalint, Pest, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Dublin 9, D9, Ireland|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Ravenna, RA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Perugia, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Hirosaki, Aomori, Japan|Novartis Investigative Site, Matsuyama, Ehime, Japan|Novartis Investigative Site, Iizuka-city, Fukuoka, Japan|Novartis Investigative Site, Asahikawa-city, Hokkaido, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, Japan|Novartis Investigative Site, Himeji, Hyogo, Japan|Novartis Investigative Site, Kanazawa-city, Ishikawa, Japan|Novartis Investigative Site, Shiwa-gun, Iwate, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Natori, Miyagi, Japan|Novartis Investigative Site, Hirakata-city, Osaka, Japan|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Sakai, Osaka, Japan|Novartis Investigative Site, Hidaka-city, Saitama, Japan|Novartis Investigative Site, Sunto Gun, Shizuoka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Minato ku, Tokyo, Japan|Novartis Investigative Site, Wakayama-city, Wakayama, Japan|Novartis Investigative Site, Ube-city, Yamaguchi, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Cheongju si, Chungcheongbuk Do, Korea, Republic of|Novartis Investigative Site, Jeollanam-do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Tripoli, Lebanon|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Drammen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Tromsø, Norway|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, Surquillo, Lima, Peru|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Krakow, Ma3opolska, Poland|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Floresti, Cluj, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Kaliningrad, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Obninsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Pushkin Saint Petersburg, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Santander, Cantabria, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Fribourg, Switzerland|Novartis Investigative Site, Geneve 14, Switzerland|Novartis Investigative Site, Taichung, Taiwan ROC, Taiwan|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Hualien, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chaingmai, Thailand|Novartis Investigative Site, Ankara, Yenimahalle, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey|Novartis Investigative Site, Cambridge, Cambrigdeshire, United Kingdom|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Cheltenham, Gloucestershire, United Kingdom|Novartis Investigative Site, Wirral, Merseyside, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, United Kingdom|Novartis Investigative Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03447769"
331,"NCT00940251","Evaluation of Safety and Efficacy of Mersina, an Ayurvedic Formulation: A Double Blind, Placebo Controlled Study in Type 2 Diabetic Patients With Secondary Failure to Oral Drugs",,"Completed","No Results Available","Antihyperglycemic Effect in Type 2 Diabetic Patients With Secondary Failure to Oral Hypoglycemic Agents","Drug: Mersina","antidiabetic activity|Improvement in metabolic, insulin level, HbA1c,kidney and lipid profile","Jyoti Clinical and Pathological Laboratory","All","30 Years to 60 Years   (Adult)","Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MER1","September 2008","October 2008","November 2008","July 15, 2009",,"July 15, 2009","Jyoti Clinical and Pathological Laboratory, Shirpur, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00940251"
332,"NCT00625664","Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer","CILAB","Completed","No Results Available","Urinary Bladder Neoplasms","Drug: larotaxel (XRP9881)|Drug: gemcitabine|Drug: cisplatin","Overall survival defined as the time interval from the date of randomization to the date of death due to any cause|Radiological tumor assessments (CT/MRI)|Adverse Events, laboratory assessments, vital signs, Physical Examinations, and ECOG Performance Status","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","337","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC6668|EUDRACT: 2007-001943-23","February 2008","February 2011","February 2011","February 28, 2008",,"May 5, 2016","Sanofi-Aventis Investigational Site Number 840068, Anchorage, Alaska, United States|Sanofi-Aventis Investigational Site Number 840035, Berkeley, California, United States|Sanofi-Aventis Investigational Site Number 840012, Burbank, California, United States|Sanofi-Aventis Investigational Site Number 840029, La Jolla, California, United States|Sanofi-Aventis Investigational Site Number 840046, Los Angeles, California, United States|Sanofi-Aventis Investigational Site Number 840003, Sacramento, California, United States|Sanofi-Aventis Investigational Site Number 840005, San Bernardino, California, United States|Sanofi-Aventis Investigational Site Number 840033, San Diego, California, United States|Sanofi-Aventis Investigational Site Number 840031, Denver, Colorado, United States|Sanofi-Aventis Investigational Site Number 840032, Stamford, Connecticut, United States|Sanofi-Aventis Investigational Site Number 840034, Washington, District of Columbia, United States|Sanofi-Aventis Investigational Site Number 840021, Washington, District of Columbia, United States|Sanofi-Aventis Investigational Site Number 840001, Boca Raton, Florida, United States|Sanofi-Aventis Investigational Site Number 840048, Boynton Beach, Florida, United States|Sanofi-Aventis Investigational Site Number 840049, Jacksonville, Florida, United States|Sanofi-Aventis Investigational Site Number 840061, Lakeland, Florida, United States|Sanofi-Aventis Investigational Site Number 840060, Athens, Georgia, United States|Sanofi-Aventis Investigational Site Number 840030, Boise, Idaho, United States|Sanofi-Aventis Investigational Site Number 840024, Maywood, Illinois, United States|Sanofi-Aventis Investigational Site Number 840062, Peoria, Illinois, United States|Sanofi-Aventis Investigational Site Number 840039, Goshen, Indiana, United States|Sanofi-Aventis Investigational Site Number 840054, Kansas City, Kansas, United States|Sanofi-Aventis Investigational Site Number 840057, Paducah, Kentucky, United States|Sanofi-Aventis Investigational Site Number 840004, Metarie, Louisiana, United States|Sanofi-Aventis Investigational Site Number 840045, Baltimore, Maryland, United States|Sanofi-Aventis Investigational Site Number 840006, Detroit, Michigan, United States|Sanofi-Aventis Investigational Site Number 840026, Lansing, Michigan, United States|Sanofi-Aventis Investigational Site Number 840047, St. Joseph, Michigan, United States|Sanofi-Aventis Investigational Site Number 840009, Hackensack, New Jersey, United States|Sanofi-Aventis Investigational Site Number 840044, Lake Success, New York, United States|Sanofi-Aventis Investigational Site Number 840013, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840050, New York, New York, United States|Sanofi-Aventis Investigational Site Number 840056, Rochester, New York, United States|Sanofi-Aventis Investigational Site Number 840015, Syracuse, New York, United States|Sanofi-Aventis Investigational Site Number 840041, Chapel Hill, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840007, Charlotte, North Carolina, United States|Sanofi-Aventis Investigational Site Number 840019, Sylvania, Ohio, United States|Sanofi-Aventis Investigational Site Number 840020, Bethlehem, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840065, Dunmore, Pennsylvania, United States|Sanofi-Aventis Investigational Site Number 840058, Woonsocket, Rhode Island, United States|Sanofi-Aventis Investigational Site Number 840052, Charleston, South Carolina, United States|Sanofi-Aventis Investigational Site Number 840002, Knoxville, Tennessee, United States|Sanofi-Aventis Investigational Site Number 840008, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840018, Houston, Texas, United States|Sanofi-Aventis Investigational Site Number 840017, Lubbock, Texas, United States|Sanofi-Aventis Investigational Site Number 840016, San Antonio, Texas, United States|Sanofi-Aventis Investigational Site Number 840064, Temple, Texas, United States|Sanofi-Aventis Investigational Site Number 840010, Woodlands, Texas, United States|Sanofi-Aventis Investigational Site Number 840036, Seattle, Washington, United States|Sanofi-Aventis Investigational Site Number 840011, Madison, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 840025, Marshfield, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 840038, Milwaukee, Wisconsin, United States|Sanofi-Aventis Investigational Site Number 032002, Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032003, Ciudad De Buenos Aires, Argentina|Sanofi-Aventis Investigational Site Number 032004, Mendoza, Argentina|Sanofi-Aventis Investigational Site Number 032005, Rosario, Argentina|Sanofi-Aventis Investigational Site Number 032001, Santa Fe, Argentina|Sanofi-Aventis Investigational Site Number 036002, Adelaide, Australia|Sanofi-Aventis Investigational Site Number 036003, Bedford Park, Australia|Sanofi-Aventis Investigational Site Number 036004, St Leonards, Australia|Sanofi-Aventis Investigational Site Number 056005, Aalst, Belgium|Sanofi-Aventis Investigational Site Number 056001, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056002, Bruxelles, Belgium|Sanofi-Aventis Investigational Site Number 056004, Ottignies, Belgium|Sanofi-Aventis Investigational Site Number 056003, Wilrijk, Belgium|Sanofi-Aventis Investigational Site Number 056006, Yvoir, Belgium|Sanofi-Aventis Investigational Site Number 076006, Barretos, Brazil|Sanofi-Aventis Investigational Site Number 076004, Florianopolis, Brazil|Sanofi-Aventis Investigational Site Number 076001, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076003, Porto Alegre, Brazil|Sanofi-Aventis Investigational Site Number 076002, Rio De Janeiro, Brazil|Sanofi-Aventis Investigational Site Number 076007, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 076005, Sao Paulo, Brazil|Sanofi-Aventis Investigational Site Number 124007, Edmonton, Canada|Sanofi-Aventis Investigational Site Number 124001, London, Canada|Sanofi-Aventis Investigational Site Number 124006, Montreal, Canada|Sanofi-Aventis Investigational Site Number 124003, Quebec, Canada|Sanofi-Aventis Investigational Site Number 124002, Weston, Canada|Sanofi-Aventis Investigational Site Number 152001, Santiago, Chile|Sanofi-Aventis Investigational Site Number 250006, Avignon, France|Sanofi-Aventis Investigational Site Number 250003, Bordeaux Cedex, France|Sanofi-Aventis Investigational Site Number 250005, Hyeres, France|Sanofi-Aventis Investigational Site Number 250011, Le Mans, France|Sanofi-Aventis Investigational Site Number 250004, Lyon, France|Sanofi-Aventis Investigational Site Number 250012, Perpignan, France|Sanofi-Aventis Investigational Site Number 250007, Poitiers Cedex, France|Sanofi-Aventis Investigational Site Number 250008, Saint Herblain, France|Sanofi-Aventis Investigational Site Number 250009, Strasbourg, France|Sanofi-Aventis Investigational Site Number 250001, Suresnes, France|Sanofi-Aventis Investigational Site Number 356003, Bangalore, India|Sanofi-Aventis Investigational Site Number 356007, Kolkata, India|Sanofi-Aventis Investigational Site Number 356004, New Delhi, India|Sanofi-Aventis Investigational Site Number 356001, New Delhi, India|Sanofi-Aventis Investigational Site Number 356002, Vellore, India|Sanofi-Aventis Investigational Site Number 356005, Vishakhapatnam, India|Sanofi-Aventis Investigational Site Number 376005, Haifa, Israel|Sanofi-Aventis Investigational Site Number 376004, Kfar Saba, Israel|Sanofi-Aventis Investigational Site Number 376003, Petah-Tikva, Israel|Sanofi-Aventis Investigational Site Number 376002, Tel Aviv, Israel|Sanofi-Aventis Investigational Site Number 376007, Tel Hashomer, Israel|Sanofi-Aventis Investigational Site Number 376001, Tzrifin, Israel|Sanofi-Aventis Investigational Site Number 380004, Bari, Italy|Sanofi-Aventis Investigational Site Number 380003, Lecce, Italy|Sanofi-Aventis Investigational Site Number 380005, Meldola, Italy|Sanofi-Aventis Investigational Site Number 380006, Pavia, Italy|Sanofi-Aventis Investigational Site Number 380002, Perugia, Italy|Sanofi-Aventis Investigational Site Number 380001, Roma, Italy|Sanofi-Aventis Investigational Site Number 380008, Viterbo, Italy|Sanofi-Aventis Investigational Site Number 484003, Aguascalientes, Mexico|Sanofi-Aventis Investigational Site Number 484007, Chihuahua, Mexico|Sanofi-Aventis Investigational Site Number 484005, Chihuahua, Mexico|Sanofi-Aventis Investigational Site Number 484004, Monterrey, Mexico|Sanofi-Aventis Investigational Site Number 528005, Amsterdam, Netherlands|Sanofi-Aventis Investigational Site Number 528002, Arnhem, Netherlands|Sanofi-Aventis Investigational Site Number 528006, Hoofddorp, Netherlands|Sanofi-Aventis Investigational Site Number 528003, Maastricht, Netherlands|Sanofi-Aventis Investigational Site Number 528004, Nijmegen, Netherlands|Sanofi-Aventis Investigational Site Number 528001, Sittard-Geleen, Netherlands|Sanofi-Aventis Investigational Site Number 528007, Zwolle, Netherlands|Sanofi-Aventis Investigational Site Number 616002, Poznan, Poland|Sanofi-Aventis Investigational Site Number 616004, Rybnik, Poland|Sanofi-Aventis Investigational Site Number 616001, Warszawa, Poland|Sanofi-Aventis Investigational Site Number 616005, Wroclaw, Poland|Sanofi-Aventis Investigational Site Number 643009, Chelyabinsk, Russian Federation|Sanofi-Aventis Investigational Site Number 643010, Kursk, Russian Federation|Sanofi-Aventis Investigational Site Number 643006, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643008, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643004, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643005, Moscow, Russian Federation|Sanofi-Aventis Investigational Site Number 643001, Obninsk, Russian Federation|Sanofi-Aventis Investigational Site Number 643003, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643007, Saint-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643002, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 643011, St-Petersburg, Russian Federation|Sanofi-Aventis Investigational Site Number 710008, Bloemfontein, South Africa|Sanofi-Aventis Investigational Site Number 710003, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710001, Cape Town, South Africa|Sanofi-Aventis Investigational Site Number 710007, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710009, Durban, South Africa|Sanofi-Aventis Investigational Site Number 710006, Port Elizabeth, South Africa|Sanofi-Aventis Investigational Site Number 710005, Pretoria, South Africa|Sanofi-Aventis Investigational Site Number 724006, Badalona, Spain|Sanofi-Aventis Investigational Site Number 724001, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724004, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724008, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724002, Barcelona, Spain|Sanofi-Aventis Investigational Site Number 724003, Madrid, Spain|Sanofi-Aventis Investigational Site Number 724010, Oviedo, Spain|Sanofi-Aventis Investigational Site Number 724013, Palma De Mallorca, Spain|Sanofi-Aventis Investigational Site Number 724007, Palma De Mallorca, Spain|Sanofi-Aventis Investigational Site Number 724009, Pamplona, Spain|Sanofi-Aventis Investigational Site Number 724011, Santiago De Compostela, Spain|Sanofi-Aventis Investigational Site Number 724012, Zaragoza, Spain|Sanofi-Aventis Investigational Site Number 752001, Umeå, Sweden|Sanofi-Aventis Investigational Site Number 752002, Uppsala, Sweden|Sanofi-Aventis Investigational Site Number 792002, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792003, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792004, Ankara, Turkey|Sanofi-Aventis Investigational Site Number 792006, Istanbul, Turkey|Sanofi-Aventis Investigational Site Number 792001, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00625664"
333,"NCT03775486","Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)","ORION","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer NSCLC","Drug: Durvalumab|Drug: Placebo for Olaparib|Drug: Olaparib|Drug: Nab-paclitaxel+carboplatin|Drug: Gemcitabine+carboplatin|Drug: Pemetrexed+carboplatin|Drug: Gemcitabine+cisplatin|Drug: Pemetrexed+cisplatin","Progression-free survival|Overall survival|Objective response rate|Duration of response|PFS in homologous recombination repair related gene mutation (HRRm) population|Concentration of Durvalumab|Change from baseline and time to deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13|Change from baseline and time to deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30|Presence of anti-drug antibodies (ADA) for Durvalumab|'Number of Participants with Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events (CTCAE)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 2","401","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D9102C00001|2018-003460-30","December 21, 2018","January 11, 2021","June 2, 2022","December 14, 2018",,"April 26, 2022","Research Site, Bonita Springs, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Kansas City, Missouri, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Aalst, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Deszk, Hungary|Research Site, Farkasgyepü, Hungary|Research Site, Törökbálint, Hungary|Research Site, Ahmedabad, India|Research Site, Ahmedabad, India|Research Site, Jamnagar, India|Research Site, Kochi, India|Research Site, Mysuru, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, Pune, India|Research Site, Thiruvananthapuram, India|Research Site, Chuo-ku, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kurume-shi,, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Ube-shi, Japan|Research Site, Dongjakgu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seodaemun-gu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suweonsi Paldalgu, Korea, Republic of|Research Site, Chihuahua, Mexico|Research Site, Culiacan, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Blaricum, Netherlands|Research Site, Harderwijk, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Białystok, Poland|Research Site, Poznan, Poland|Research Site, Prabuty, Poland|Research Site, Łódź, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nal'chik, Russian Federation|Research Site, P. Herzen Moscow Oncology Rese, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dnipro, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kirovohrad, Ukraine|Research Site, Odesa, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Dundee, United Kingdom|Research Site, Hull, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03775486"
334,"NCT04211337","A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","LIBRETTO-531","Recruiting","No Results Available","Medullary Thyroid Cancer","Drug: Selpercatinib|Drug: Cabozantinib|Drug: Vandetanib","Progression Free Survival (PFS) by BICR|Treatment Failure-Free Survival (TFFS) by Blinded Independent Committee Review (BICR)|Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) by BICR|Duration of Response (DoR) by BICR|Overall Survival (OS)|PFS2 by Investigator|Comparative Tolerability: Percentage of Time with High Side Effect Bother Based on the Functional Assessment of Cancer Therapy-Side Effects (FACT-GP5)|The Concordance of the Local Lab and the Central Lab RET Results: Percentage of Participants with RET-Positive Specimens as Called by the Central Lab, which is also RET-Positive as Called by a Local Lab (Positive Percent Agreement)","Loxo Oncology, Inc.|Eli Lilly and Company","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17478|J2G-MC-JZJB|2019-001978-28","February 11, 2020","May 20, 2024","November 13, 2026","December 26, 2019",,"April 19, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic Hospital, Phoenix, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|UCLA Medical Center, Los Angeles, California, United States|University of California, Davis - Health Systems, Sacramento, California, United States|UCSF Medical Center at Mission Bay, San Francisco, California, United States|Los Angeles Biomedical Research Institute at Harbor - UCLA Medical, Torrance, California, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|University of Chi Med Center, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University Medical School, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Ohio State University Medical Center, Columbus, Ohio, United States|University of Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin-Madison Hospital and Health Clinic, Madison, Wisconsin, United States|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Centre Hospitalier Universitaire Sart Tilman, Liege, Belgium|Oncocentro BH, Belo Horizonte, Minas Gerais, Brazil|Hospital de Cancer de Londrina, Londrina, Paraná, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto de Educação, Pesquisa e Gestão em Saúde, Rio de Janeiro, RJ, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Clinica Onco Star, Sao Paulo, SP, Brazil|Hospital PUC-CAMPINAS, Campinas, São Paulo, Brazil|Hospital das Clinicas da FMRP, Ribeirão Preto, São Paulo, Brazil|INCA Hospital do Câncer III, Rio de Janeiro, Brazil|Oncoclinicas Rio de Janeiro S.A., Rio de Janeiro, Brazil|Soc. Beneficente de Senhoras Hospital Sirio Libanes-Oncology, Sao Paolo, Brazil|Icesp - Instituto Do Câncer Do Estado de São Paulo, Sao Paulo, Brazil|Centro Paulista de Oncologia, São Paulo, Brazil|London Health Science Centre - Victoria Hospital, London, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Anhui Provincial Hospital, Hefei, Anhui, China|Beijing Tongren Hospital affiliated to Capital Medical Unive, Beijing, Beijing, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Province Cancer Hospital, Lanzhou, Gansu, China|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jilin Cancer Hospital, Chang Chun, Ji Lin, China|Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China|Jinan Central Hospital, Jinan, Shandong, China|Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Cheng Du, Sichuan, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Chongqing Cancer Hospital, Chongqing, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni Nemocnice v Motole, Praha 5, Czechia|Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille, Bouches-du-Rhône, France|Centre Georges François Leclerc, Dijon, Côte-d'Or, France|Centre Hospitalier Universitaire d'Angers, Angers, Maine-et-Loire, France|Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne, Clermont-Ferrand, Puy-de-Dôme, France|Centre Leon Berard, Lyon, Rhône-Alpes, France|Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux, France|Centre François Baclesse, Caen Cedex 5, France|Hôpital C. HURIEZ, Lille, France|Hopital Pitie Salpetriere -Unité Thyroïde-Tumeurs Endocrines, PARIS- cedex 13, France|Institut de cancérologie Strasbourg Europe, Strasbourg, France|Institut Claudius Regaud, Toulouse cedex 9, France|Gustave Roussy, Villejuif Cedex, France|Klinikum der Universität München Großhadern, München, Bayern, Germany|Universitätsklinikum Würzburg A. ö. R., Würzburg, Bayern, Germany|Medizinische Hochschule Hanover, Hannover, Niedersachsen, Germany|Universitätsmedizin Johannes Gutenberg Universität Mainz, Mainz, Rheinland-Pfalz, Germany|Charité Campus Mitte, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Studiengesellschaft Hämato-Onkologie Hamburg - Prof Laack & Partner, Hamburg, Germany|Otto-von-Guericke-Universität, Magdeburg, Germany|Alexandra General Hospital of Athens, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Irakleío, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|Regional Cancer Centre, Trivandrum, Kerala, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic and Grant Medical Foundation, Pune, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, India|Postgraduate Institute of Medical Education & Research, Chandigarh, India|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Sheba Medical Center, Ramat Gan, Israel|Istituto Nazionale dei Tumori, Milano, Lombardie, Italy|Ospedale San Luca, IRCCS Istituto Auxologico, Milano, Milan, Italy|Polic.Umberto I -Univ. La Sapienza, Roma, Rome, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, SI, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Ospedale Garibaldi-Nesima, Catania, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedlaliero-Univeristaria Pisana, Stabilimento Ospedaliero di Cisanello, Pisa, Italy|I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy|Azienda Ospedaliero-Universitaria S.Giovanni Battista, Torino, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Osaka University Hospital, Suita, Osaka, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam Do, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Nederlands Kanker Instituut - Antoni van Leeuwenhoek, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Maastricht UMC+, Maastricht, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Gliwice, Poland|Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Kielce, Poland|National medical research center of radiology Obninsk, Obninsk, Kaluga Region, Russian Federation|Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (policlinic, hospital), Saint-Petersburg, Northwestern Federal District, Russian Federation|LLC Evimed, Chelyabinsk, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|National Medical Research Center of Endocrinology of Ministry of Health Dept, Moscow, Russian Federation|Saint-Petersburg City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Barcelona, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Clinica Universitaria De Navarra, Pamplona, Navarra, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Gartnavel General Hospital, Glasgow, Glasgow City, United Kingdom|University College Hospital - London, London, Greater London, United Kingdom|Royal Marsden NHS Trust, London, Greater London, United Kingdom|Velindre Cancer Centre, Cardiff, South Glamorgan, United Kingdom|Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04211337"
335,"NCT01230710","A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Erlotinib","Percentage of Participants With Progression-free Survival at Week 52|Progression-free Survival (PFS)|Overall Survival|Percentage of Participants With a Complete Response (CR) or a Partial Response (PR)|Percentage of Participants With Disease Control","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","51","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML25478","March 2011","September 2013","September 2013","October 29, 2010","March 30, 2015","March 30, 2015","Bangalore, India|Chennai, India|Delhi, India|Hyderabad, India|Jaipur, India|Kolkata, India|Nasik, India",,"https://ClinicalTrials.gov/show/NCT01230710"
336,"NCT03191786","A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","IPSOS","Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Drug: Vinorelbine|Drug: Gemcitabine","Overall Survival|Percentage of Participants Who Are Alive at Specified Timepoints|Percentage of Participants With Objective Response, as Determined by the Investigator Using Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 (v1.1)|Progression-Free Survival (PFS), as Determined by the Investigator Using RECIST v1.1|Duration of Response, as Determined by the Investigator Using RECIST v1.1|Percentage of Participants With Adverse Events (AEs)|Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC-QLQ-C30) Score|Change From Baseline in EORTC QLQ Supplementary Lung Cancer Module 13 (EORTC QLQ-LC13) Score|Time to Deterioration in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC QLQ-C30 Score|Time to Deterioration in Patient-Reported Lung Cancer Symptoms As Assessed by EORTC QLQ-LC13 Score|Overall Survival in Participants With PD-L1 Positive Status|Progression-Free Survival (PFS), as Determined by the Investigator Using RECIST v1.1 in Participants With PD-L1 Positive Status","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","453","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO29872|2015-004105-16","September 11, 2017","May 31, 2022","July 31, 2022","June 19, 2017",,"February 16, 2022","Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Centro de Investigacion; Clinica - Clinica Viedma S.A., Viedma, Argentina|UZ Brussel, Brussel, Belgium|Grand Hôpital de Charleroi Notre Dame, Charleroi, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Umhat Dr Georgi Stranski; Clinic of Chemotherapy, Pleven, Bulgaria|Complex Oncology Center (COC)-Plovidiv, Plovdiv, Bulgaria|BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Regional health authority A vitalite health network, Moncton, New Brunswick, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|Princess Margaret Cancer Center, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|Hu Nan Provincial Cancer Hospital, Changsha, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China|Anhui Provincial Hospital, Hefei, China|Shanghai Chest Hospital, Shanghai, China|Tianjin Cancer Hospital, Tianjin, China|Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center, Wuhan, China|Fundacion Cardioinfantil, Bogota, Colombia|Fundación Centro de Investigación Clínica CIC, Medellin, Colombia|Oncomedica S.A., Monteria, Colombia|Oncólogos de Occidente, Pereira, Colombia|Fakultni nemocnice Olomouc; Pneumologicka klinika, Olomouc, Czechia|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Evang. Lungenklinik Berlin Klinik für Pneumologie, Berlin, Germany|LungenClinic Großhansdorf GmbH, Großhansdorf, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle, Germany|Fachklinik für Lungenerkrankungen, Immenhausen, Germany|Klinikum der Philipps-Universität Marburg, Marburg, Germany|Asklepios Klinik München-Gauting, München-Gauting, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg, Germany|Universitätsklinikum Tübingen; Innere Medizin VIII, Medizinische Onkologie und Pneumologie, Tübingen, Germany|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|HealthCare Global Cancer Centre; Medical Oncology, Ahmedabad, Gujarat, India|Kailash Cancer Hospital and Research Center, Vadodara, Gujarat, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Indo-American Cancer Hospital & Research Center, Hyderabad, Telangana, India|Tata Medical Center; Department of Medical Oncology, Kolkata, WEST Bengal, India|P.D. Hinduja Nat. Hospital & Med. Research Centre, Mahim (West), India|Max Super Speciality Hospital, New Delhi, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, India|Mater Misericordiae University Hospital - Institute for Cancer Research, Dublin, Ireland|University Hospital Limerick - Clinical Trials Department, Limerick, Ireland|Ospedale Provinciale Santa Maria Delle Croci; Oncologia Medica, Ravenna, Emilia-Romagna, Italy|Azienda Ospedaliera San Camillo Forlanini; U.O.C. Pneumologia Ad Indirizzo Oncologico 1, Roma, Lazio, Italy|Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy|Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department, Almaty, Kazakhstan|Almaty Cancer Hospital; Chemotherapy department, Almaty, Kazakhstan|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Oncologico Potosino, San Luis Potosí, SAN LUIS Potosi, Mexico|Centro Estatal de Cancerologia de Chihuahua; ONCOLOGY, Chihuahua, Mexico|Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock, Poland|Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad; Klinika Nowot.Pluca i Klatki Piers, Warszawa, Poland|CHUC - Unidade de Pneumologia Oncológica; Hospital de Dia de Oncologia Edificio Sao Jeronimo, Coimbra, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca; Oncologie Medicala, Cluj Napoca, Romania|Centrul de Radioterapie AMETHYST, Floresti, Romania|Oncocenter Timisoara, Timişoara, Romania|Specializovana nemocnica sv. Svorada Zobor, n.o., Nitra, Slovakia|Fakultna nemocnica Trnava, Trnava, Slovakia|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital de Cruces; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Institut Catala d Oncologia Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario de la Princesa; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital Arnau de Vilanova (Valencia) Servicio de Oncologia, Valencia, Spain|Ospedale Regionale di Bellinzona Medizin Onkologie, Bellinzona, Swaziland|Spital STS AG - Spital Thun Medizin Onkologie; MEDIZINISCHE KLINIK, Thun, Switzerland|Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland|Clatterbridge Cancer Centre, Bebington, United Kingdom|Birmingham Heartlands Hospital; Department of Haematology, Birmingham, United Kingdom|Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall, United Kingdom|New Victoria Hospital, Glasgow, United Kingdom|UCLH - Clinical Trials Pharmacy B&D Centre, London, United Kingdom|Christie Hospital Nhs Trust; Medical Oncology, Manchester, United Kingdom|YORK DISTRICT HOSPITAL; Haematology/Oncology Department, York, United Kingdom|Bach Mai Hospital, Hanoi, Vietnam|Cho Ray Hospital, Hochiminh city, Vietnam",,"https://ClinicalTrials.gov/show/NCT03191786"
337,"NCT03875235","Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)","TOPAZ-1","Active, not recruiting","No Results Available","Biliary Tract Neoplasms","Drug: Durvalumab|Drug: Placebo","Overall survival|PFS according to RECIST 1.1 using investigator assessment|ORR according to RECIST 1.1 using investigator assessment|DoR according to RECIST 1.1 using investigator assessment|EORTC QLQ-C30 and EORTC QLQ-BIL21|PFS, ORR, DoR, and DCR according to RECIST 1.1 using Investigator assessments and OS by PD-L1 expression|Serum concentration of durvalumab (peak and trough concentration)|Tiered results of ADAs for durvalumab","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D933AC00001","April 16, 2019","August 11, 2021","March 31, 2025","March 14, 2019",,"April 20, 2022","Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Westwood, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Burlington, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Burgas, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Puerto Montt, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Baoding, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Chongqing, China|Research Site, Foshan, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shandong, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Xian, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Clichy, France|Research Site, Dijon Cedex, France|Research Site, Montpellier CEDEX 5, France|Research Site, Nice, France|Research Site, PARIS Cedex 12, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Faenza, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Chuo-ku, Japan|Research Site, Kashiwa, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Mitaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Gdańsk, Poland|Research Site, Kościerzyna, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Barnaul, Russian Federation|Research Site, Kostroma, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Sisaket, Thailand|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Mersin, Turkey|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Romford, United Kingdom|Research Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03875235"
338,"NCT00445458","A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer",,"Completed","Has Results","Advanced Breast Cancer|Advanced Malignant Solid Tumors|Breast Neoplasms","Drug: HKI-272|Drug: Paclitaxel","Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel|Maximum Tolerated Dose|Objective Response Rate|Maximum Plasma Concentration of Neratinib|Area Under the Concentration-time Curve 0-24","Puma Biotechnology, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","110","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3144A1-203 / B1891014","September 11, 2007","May 2011","February 7, 2018","March 9, 2007","May 9, 2018","July 26, 2018","Scripps, Clinic General, La Jolla, California, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Boston University Medical Center, Boston, Massachusetts, United States|Mid-Michigan Physicians-HOS Division, Lansing, Michigan, United States|Oncology Care Associates, Saint Joseph, Michigan, United States|Columbia University Medical Center, New York, New York, United States|CTRC at The University of Texas Health Science Center, San Antonio, Texas, United States|Institut Jules Bordet Unite du Chimiotherapie, Brussels, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|AZ Groeninge Campus Maria's Voorzienigheid (MV), Kortrijk, Belgium|Oncologisch Centrum GZA - Location St Augustinus, Wilrijk, Belgium|Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada|The Hospital Affiliated Academy Military Medical Science, Chinese People's Liberation Army, Beijing, Beijing, China|Chinese People's Liberation Army General Hospital, Beijing, Beijing, China|Tianjin Cancer Hospital, TianJin, Tianjin, China|Tianjin Union Medicine Center Department of Oncology, Tianjin, Tianjin, China|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|UNIMED Medical Institute, Hong Kong, Hong Kong|Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong|Department of Surgery Queen Mary Hospital, Hong Kong, Hong Kong|Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, Maharashtra, India|M.M.F. Joshi Hospital & Ratna Memorial Hospital, Pune, Maharashtra, India|Tata Memorial Hospital, Mumbai, Parel, India|Birla Cancer Centre, S.M.S. Medical College & Hospital, Jaipur, Rajasthan, India|Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Division of Oncology, Department of Internal Medicine, Seoul, Korea, Republic of|Wojewodzki Szpital Specjalistyczny im. Ludwika Rydygiera, Oddzial Onkologii, Krakow, Poland|Oddzial Chemioterapii Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland|City Multifield Clinical Hospital #4 Department of chemotherapy, Dnipropetrovs'k State Medical Academy, Chair of Oncology and Medical Radiology, Dnipropetrovsk, Ukraine|State Oncological Regional Treatment and Diagnostic Center Department of chemotherapy, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT00445458"
339,"NCT00415194","A Study for Patients With Head and Neck Cancer",,"Completed","Has Results","Head and Neck Neoplasms","Drug: pemetrexed|Drug: cisplatin|Drug: placebo","Overall Survival (OS)|Progression-free Survival (PFS)|Percent of Participants With a Tumor Response (Response Rate)|Duration of Response (DoR)|Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score|Correlation Between Biomarkers and Treatment Effect","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","8431|H3E-MC-JMHR","December 2006","March 2010","March 2010","December 22, 2006","April 6, 2011","June 28, 2011","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beech Grove, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stony Brook, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., North Smithfield, Rhode Island, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S.M. De Tucuman, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fé, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belo Horizonte, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanning, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aarhus, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tours, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Essen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leipzig, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Luebeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nyiregyhaza, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bhopal, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patna, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Confreria, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hwasun-Gun, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pusan, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durango, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Michoacan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma Sur, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nijmegen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olsztyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Targu Mures, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barnaul, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murmansk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloemfontein, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durban, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parktown, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murcia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hualien, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liouying/Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00415194"
340,"NCT00363415","Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer",,"Completed","Has Results","Small Cell Lung Cancer","Drug: pemetrexed|Drug: etoposide|Drug: carboplatin","Overall Survival|Overall Survival (Subgroups)|Progression Free Survival|Change From Baseline to Each Cycle in Functional Assessment of Cancer Therapy - Lung (FACT-L)|Overall Survival (Subgroups: LDH<=Upper Limit of Normal and History of Brain Metastases=Yes)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","908","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9691|H3E-MC-JMHO","August 2006","June 2008","June 2008","August 15, 2006","October 6, 2009","October 28, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Huntsville, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anchorage, Alaska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burbank, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mission Hills, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orange, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poway, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Springfield, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scarborough, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lincoln, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sparta, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Concord, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zanesville, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dunmore, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., East Stroudsburg, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ephrata, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Media, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wilkes-Barre, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Knoxville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everett, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bahia Blanca, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mar Del Plata, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Camperdown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coffs Harbour, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Macquarie, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brisbane, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermisdie, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Redcliffe, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., South Brisbane, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Townsville, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woodville, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hobart, Tasmania, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Geelong, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wodonga, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Florianópolis, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fortaleza, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jau, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brest, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caen, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Clichy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Borstel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gauting, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hemer, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nürnberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regensburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rostock, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stralsund, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marousi Attikis, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pylaia/Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deszk, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pecs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szekesfehervar, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szombathely, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torokbalint, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zalaegerszeg, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludhiana, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monteforte Irpino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ravenna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Sisto, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arnhem, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Bosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heerlen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auckland, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Christchurch, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wellington, New Zealand|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gdansk, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krakow-Nowa Huta, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Otwock, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szczecin-Zdunowo, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zabrze-Biskupice, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Maria Da Feira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vila Nova De Gaia, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelyabinsk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Engels, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kazan, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murmansk, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stavropol, Russian Federation|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cape Town, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durban, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Parktown, South Africa|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barakaldo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Besevler/Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Samsun, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Truro, Cornwall, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelmsford, Essex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wolverhampton, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00363415"
341,"NCT01185314","To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","PIONEER","Completed","No Results Available","Non Small Cell Lung Cancer","Procedure: Testing for mutation status","EGFR mutation status of Asian patients with advanced NSCLC","AstraZeneca","All","20 Years and older   (Adult, Older Adult)","Not Applicable","1270","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","D7913L00086","September 2010","July 2011","July 2011","August 19, 2010",,"August 8, 2011","Research Site, Beijing, Beijing, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Changchun, Jilin, China|Research Site, Shenyang, Liaoning, China|Research Site, Jinan, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Hong Kong, Hong Kong|Research Site, Rohini, Delhi, India|Research Site, Vadodara, Gujarat, India|Research Site, Kochi, Kerala, India|Research Site, Mumbai, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, Cebu City, Philippines|Research Site, Manila City, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Taguig City, Philippines|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Songkla, Thailand|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT01185314"
342,"NCT01101334","Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer",,"Completed","Has Results","Advanced Non-small Cell Lung Cancer (NSCLC)","Drug: CS-7017|Drug: erlotinib","Summary of Analysis of Progression-Free Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy|Analysis of Overall Survival Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy|Overall Response Rate Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy|Summary of Treatment-Emergent Adverse Events (TEAEs) Occurring in ≥10% of Participants Following Administration of CS-7017 and Erlotinib in Participants With Advanced Non-Small Cell Lung Cancer Who Failed First Line Therapy","Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS7017-A-U204","March 2010","April 2013","April 2013","April 9, 2010","June 16, 2020","June 16, 2020","DHHA, Denver, Colorado, United States|Gabrail Cancer Center, Canton, Ohio, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Zentrum fur Pneumologie und Thoraxchirurgie, Gauting, Germany|King George Hospital, Visakhapatnam, Andhra Pradesh, India|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Kodlikeri Memorial Hospital, Aurangabad, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Noble Hospital, Pune, Maharastra, India|Apollo Speciality Hospital, Chennai, Tamil Nadu, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, India|Orchid Nursing Home, Kolkata, West Bengal, India|St. Vincent's Hospital, Gyeonggi-Do, Korea, Republic of|Hwasun Hospital, Jeonnam, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01101334"
343,"NCT00550173","A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: pemetrexed|Drug: erlotinib","Progression-Free Survival (PFS)|Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]|Overall Survival (OS)|Number of Participants With Adverse Events|Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)|Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)|Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status|Probability of OS at 12 Months","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","247","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10725|H3E-MC-S103","November 2007","January 2012","January 2012","October 29, 2007","February 13, 2013","February 13, 2013","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanning, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sha Tin, Hong Kong|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ahmedabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bhopal, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mohali, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vishakhapatnam, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jin-Ju-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poole, Dorset, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chelmsford, Essex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00550173"
344,"NCT00347919","Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer",,"Completed","Has Results","Neoplasms, Breast","Drug: pazopanib (GW786034) 400 mg|Drug: lapatinib (GW572016) 1500 mg|Drug: lapatinib (GW572016) 1000 mg|Drug: pazopanib (GW786034) 800 mg","Percentage of Participants With Progressive Disease at Week 12 in Cohort 1|Overall Survival for Cohort 1|Response at Week 12 for Cohort 1 and Cohort 2|Duration of Response in Cohort 1|Time to Response (Complete or Partial Response) in Cohort 1 and Cohort 2|Percentage of Participants With Progressive Disease at Week 12","GlaxoSmithKline","Female","21 Years and older   (Adult, Older Adult)","Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VEG20007","July 2006","August 2008","March 2015","July 4, 2006","February 21, 2011","February 25, 2016","GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Alhambra, California, United States|GSK Investigational Site, Bakersfield, California, United States|GSK Investigational Site, Fullerton, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Northridge, California, United States|GSK Investigational Site, Oxnard, California, United States|GSK Investigational Site, Redondo Beach, California, United States|GSK Investigational Site, Santa Barbara, California, United States|GSK Investigational Site, Santa Maria, California, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Henderson, Nevada, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Lubbock, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, Weston, Ontario, Canada|GSK Investigational Site, Besançon, France|GSK Investigational Site, Hyeres, France|GSK Investigational Site, Lille Cedex, France|GSK Investigational Site, Lyon cedex 03, France|GSK Investigational Site, Marseille Cedex BP 156, France|GSK Investigational Site, Paris Cedex 5, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Delhi, India|GSK Investigational Site, Jaipur, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Petach Tikva, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Rehovot, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Incheon, Korea, Republic of|GSK Investigational Site, seodaemun-gu, Seoul, Korea, Republic of|GSK Investigational Site, songpa-gu, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Petaling Jaya, Malaysia|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Islamabad, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Multan, Pakistan|GSK Investigational Site, Callao, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Elblag, Poland|GSK Investigational Site, Kielce, Poland|GSK Investigational Site, Kraków, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chelmsford, Essex, United Kingdom|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Sutton, Surrey, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Ipswich, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00347919"
345,"NCT00537381","An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer",,"Completed","Has Results","Prostatic Neoplasms","Drug: Docetaxel|Drug: Prednisone|Biological: Intetumumab|Drug: Placebo","Progression-Free Survival (PFS)|Number of Participants With Best Overall Response (OR)|Number of Participants With Prostate Specific Antigen (PSA) Response|Overall Survival|Percent Change From Baseline in 'C-telopeptide of Type I Collagen (CTx)' Marker Concentration|Percent Change From Baseline in 'N-telopeptide of Type I Collagen (NTx)' Marker Concentration|Percent Change From Baseline in 'Vascular Endothelial Growth Factor (VEGF)' Marker Concentration","Centocor, Inc.","Male","18 Years and older   (Adult, Older Adult)","Phase 2","131","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR013249|C1034T08|2006-005766-39","May 2007","November 2009","November 2009","October 1, 2007","May 20, 2013","June 20, 2013","Birmingham, Alabama, United States|Los Angeles, California, United States|San Bernardino, California, United States|Wichita, Kansas, United States|Shreveport, Louisiana, United States|Charleston, South Carolina, United States|N Charleston, South Carolina, United States|Graz, Austria|Wels N/A, Austria|Wien, Austria|Antwerpen, Belgium|Brasschaat, Belgium|Brussel, Belgium|Doornik, Belgium|Haine-Saint-Paul, La Louviere, Belgium|Leuven, Belgium|Liÿge, Belgium|Ottignies, Belgium|Roeselare, Belgium|Wilrijk, Belgium|Aschaffenburg, Germany|Berlin, Germany|Freiburg, Germany|Kirchheim, Germany|Köln, Germany|Marburg, Germany|München, Germany|Tübingen, Germany|Ahmedabad, India|Bangalore, India|Chennai, India|Mumbai, India|New Delhi, India|Pune, India|Apeldoorn, Netherlands|Den Haag, Netherlands|Leiden, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gdansk, Poland|Inowroclaw, Poland|Koscierzyna, Poland|Lodz, Poland|Lublin, Poland|Ekaterinburg, Russian Federation|Moscow N/A, Russian Federation|Moscow Region, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|St-Petersburg Leningrad, Russian Federation|Voronezh, Russian Federation|Yaroslavl, Russian Federation|Johannesburg Gauteng, South Africa|Pretoria Gauteng, South Africa|Pretoria, South Africa|Cambridge, United Kingdom|Leicester, United Kingdom|Lincoln, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00537381"
346,"NCT00949910","An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Erlotinib","Percentage of Participants With Objective Response According to Response Evaluation Criteria in Solid Tumors (RECIST)|Percentage of Participants With Disease Control According to RECIST|Percentage of Participants by Best Overall Response According to RECIST|Percentage of Participants With Death or Disease Progression According to RECIST|Progression-Free Survival (PFS) According to RECIST|Percentage of Participants Who Died|Overall Survival (OS)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 4","6586","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO18109|2004-000564-28|INC-9042","November 2004","April 2009","April 2009","July 31, 2009","October 4, 2016","October 5, 2016","Tirana, Albania|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Buenos Aires, Argentina|Córdoba, Argentina|La Plata, Argentina|Salta, Argentina|Santa Fe, Argentina|Adelaide, Australia|Camperdown, Australia|Chermside, Australia|Frankston, Australia|Fremantle, Australia|Geelong, Australia|Kurralta Park, Australia|Malvern, Australia|Melbourne, Australia|Melbourne, Australia|Perth, Australia|St. Leonards, Australia|Sydney, Australia|Sydney, Australia|Tugun, Australia|Waratah, Australia|Wodonga, Australia|Wollongong, Australia|Bludesch, Austria|Grimmenstein, Austria|Innsbruck, Austria|Klagenfurt, Austria|Kufstein, Austria|Leoben, Austria|Linz, Austria|Linz, Austria|Natters, Austria|Oberpullendorf, Austria|Salzburg, Austria|Wels, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Wien, Austria|Zams, Austria|Aalst, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Antwerpen, Belgium|Arlon, Belgium|Baudour, Belgium|Blankenberge, Belgium|Borgerhout, Belgium|Boussu, Belgium|Brasschaat, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Bruxelles, Belgium|Charleroi, Belgium|Edegem, Belgium|Genk, Belgium|Gent, Belgium|Gilly, Belgium|Godinne, Belgium|Gosselies, Belgium|Haine-saint-paul, Belgium|Hasselt, Belgium|Kortrijk, Belgium|Libramont, Belgium|Liege, Belgium|Mons, Belgium|Namur, Belgium|Oostende, Belgium|Ottignies, Belgium|Oudenaarde, Belgium|Roeselare, Belgium|Sint-niklaas, Belgium|Tielt, Belgium|Tournai, Belgium|Turnhout, Belgium|Wilrijk, Belgium|Banja Luka, Bosnia and Herzegovina|Sarajevo, Bosnia and Herzegovina|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Belo Horizonte, Brazil|Brasilia, Brazil|Brasilia, Brazil|Campinas, Brazil|Campinas, Brazil|Caxias do Sul, Brazil|Curitiba, Brazil|Curitiba, Brazil|Curitiba, Brazil|Fortaleza, Brazil|Fortaleza, Brazil|Fortaleza, Brazil|Ijui, Brazil|Jaú, Brazil|Joao Pessoa, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirao Preto, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Rio de Janeiro, Brazil|Salvador, Brazil|Salvador, Brazil|Salvador, Brazil|Santos, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|Sorocaba, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Santiago, Chile|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Chengdu, China|Guangzhou, China|Guangzhou, China|Hangzhou, China|Harbin, China|Nanjing, China|Shanghai, China|Shanghai, China|Shanghai, China|Tianjin, China|Wuhan, China|Bogota, Colombia|Cali, Colombia|Zagreb, Croatia|Brno, Czech Republic|Hradec Kralove, Czech Republic|Olomouc, Czech Republic|Plzen, Czech Republic|Praha, Czech Republic|Guayaquil, Ecuador|Quito, Ecuador|Cairo, Egypt|Giza, Egypt|Giza, Egypt|Tallin, Estonia|Tartu, Estonia|Haemeenlinna, Finland|Helsinki, Finland|Helsinki, Finland|Joensuu, Finland|Kuopio, Finland|Oulu, Finland|Pori, Finland|Tampere, Finland|Turku, Finland|Vaasa, Finland|Amberg, Germany|Augsburg, Germany|Aurich, Germany|Bad Berka, Germany|Berlin, Germany|Berlin, Germany|Berlin, Germany|Bonn, Germany|Celle, Germany|Dortmund, Germany|Dresden, Germany|Essen, Germany|Flensburg, Germany|Frankfurt Am Main, Germany|Frankfurt, Germany|Freiburg, Germany|Gauting, Germany|Gerlingen, Germany|Giessen, Germany|Grosshansdorf, Germany|Halle (saale), Germany|Hamburg, Germany|Hamburg, Germany|Heidelberg, Germany|Herne, Germany|Homburg/Saar, Germany|Kassel, Germany|Koblenz, Germany|Köln, Germany|Köln, Germany|Leipzig, Germany|Leverkusen, Germany|Lostau, Germany|Löwenstein, Germany|Lübeck, Germany|Mainz, Germany|Mannheim, Germany|Minden, Germany|Muenchen, Germany|Mönchengladbach, Germany|München, Germany|München, Germany|Neuruppin, Germany|Nürnberg, Germany|Oldenburg, Germany|Osnabrück, Germany|Rostock, Germany|Saarbruecken, Germany|Trier, Germany|Ulm, Germany|Wangen, Germany|Wiesbaden, Germany|Wuerselen, Germany|Wuppertal, Germany|Athens, Greece|Athens, Greece|Athens, Greece|Haidari, Greece|Heraklion, Greece|Neo Faliro, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Thessaloniki, Greece|Guatemala City, Guatemala|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Budapest, Hungary|Budapest, Hungary|Budapest, Hungary|Deszk, Hungary|Kecskemet, Hungary|Mátraháza, Hungary|Nyíregyháza, Hungary|Pecs, Hungary|Torokbalint, Hungary|Bangalore, India|New Delhi, India|New Delhi, India|Pune, India|Vellore, India|Jakarta, Indonesia|Cork, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Dublin, Ireland|Galway, Ireland|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Haifa, Israel|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Nahariya, Israel|Petach Tikva, Israel|Ramat-gan, Israel|Rehovot, Israel|Safed, Israel|Tel Aviv, Israel|Zerifin, Israel|Ancona, Italy|Avellino, Italy|Aviano, Italy|Bari, Italy|Benevento, Italy|Bergamo, Italy|Bollate, Italy|Bologna, Italy|Bologna, Italy|Brescia, Italy|Candiolo, Italy|Catania, Italy|Catanzaro, Italy|Cosenza, Italy|Cuneo, Italy|Fabriano, Italy|Feltre - Bl, Italy|Firenze, Italy|Genova, Italy|La Spezia, Italy|Lido di Camaiore, Italy|Livorno, Italy|Meldola, Italy|Messina, Italy|Milano, Italy|Milano, Italy|Milano, Italy|Mirano, Italy|Modena, Italy|Napoli, Italy|Napoli, Italy|Nuoro, Italy|Orbassano, Italy|Palermo, Italy|Palermo, Italy|Parma, Italy|Pavia, Italy|Perugia, Italy|Pescara, Italy|Pisa, Italy|Rionero in Vulture, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Roma, Italy|Salerno, Italy|Salerno, Italy|San Giovanni Rotondo, Italy|Sassari, Italy|Siena, Italy|Sondrio, Italy|Taormina, Italy|Torino, Italy|Trento, Italy|Udine, Italy|Bundang City, Korea, Republic of|Busan, Korea, Republic of|Cheonan, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gwangju, Korea, Republic of|Iksan, Korea, Republic of|Incheon, Korea, Republic of|Kyunggi-do, Korea, Republic of|Pusan, Korea, Republic of|Pusan, Korea, Republic of|Pusan, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Suwon, Korea, Republic of|Riga, Latvia|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Acapulco, Mexico|Chihuahua, Mexico|Chihuahua, Mexico|Guadalajara, Mexico|Guadalajara, Mexico|Juarez, Mexico|Leon, Mexico|Leon, Mexico|Matamoros, Mexico|Merida, Mexico|Merida, Mexico|Mexicali, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Monterrey, Mexico|Obregon, Mexico|Obregon, Mexico|Puebla, Mexico|San Luis Potosi, Mexico|Tampico, Mexico|Tijuana, Mexico|Toluca, Mexico|Torreon, Mexico|Zapopan, Mexico|'s Hertogenbosch, Netherlands|Alkmaar, Netherlands|Amersfoort, Netherlands|Amstelveen, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Arnhem, Netherlands|Assen, Netherlands|Beverwijk, Netherlands|Boxmeer, Netherlands|Breda, Netherlands|Capelle Ad Yssel, Netherlands|Den Haag, Netherlands|Drachten, Netherlands|Eindhoven, Netherlands|Enschede, Netherlands|Groningen, Netherlands|Groningen, Netherlands|Haarlem, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Hengelo, Netherlands|Hoofddorp, Netherlands|Leiden, Netherlands|Leiderdorp, Netherlands|Maastricht, Netherlands|Nieuwegein, Netherlands|Nijmegen, Netherlands|Roermond, Netherlands|Rotterdam, Netherlands|Sliedrecht, Netherlands|Veldhoven, Netherlands|Venlo, Netherlands|Vlaardingen, Netherlands|Vlissingen, Netherlands|Zaandam, Netherlands|Zwolle, Netherlands|Christchurch, New Zealand|Hamilton, New Zealand|Palmerston North, New Zealand|Wellington, New Zealand|Panama City, Panama|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Gdansk, Poland|Lublin, Poland|Olsztyn, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wroclaw, Poland|Zabrze, Poland|Lisboa, Portugal|Porto, Portugal|Setubal, Portugal|São Martinho do Bispo, Portugal|Vila Nova de Gaia, Portugal|Alba Iulia, Romania|Baia Mare, Romania|Bucharest, Romania|Bucharest, Romania|Bucharest, Romania|Cluj Napoca, Romania|Oradea, Romania|Sibiu, Romania|Suceava, Romania|Timisoara, Romania|Barnaul, Russian Federation|Kazan, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Obninsk, Russian Federation|Samara, Russian Federation|Smolensk, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Stavropol, Russian Federation|Tumen, Russian Federation|Ufa, Russian Federation|Volgograd, Russian Federation|Riyadh, Saudi Arabia|Belgrade, Serbia|Novi Sad, Serbia|Banska Bystrica, Slovakia|Bratislava, Slovakia|Kosice, Slovakia|Nitra, Slovakia|Poprad, Slovakia|Ljubljana, Slovenia|Falun, Sweden|Goeteborg, Sweden|Göteborg, Sweden|Linkoeping, Sweden|Lund, Sweden|Malmoe, Sweden|Stockholm, Sweden|Uppsala, Sweden|Aarau, Switzerland|Aarau, Switzerland|Baden, Switzerland|Chur, Switzerland|Locarno, Switzerland|Luzern, Switzerland|Zürich, Switzerland|Changhua, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Bangkok, Thailand|Bangkok, Thailand|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Istanbul, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Izmir, Turkey|Shhiye, Ankara, Turkey|Montevideo, Uruguay|Caracas, Venezuela|Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00949910"
347,"NCT00409188","Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","START","Completed","Has Results","Non-small Cell Lung Cancer","Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Placebo","Overall Survival|Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)|Time To Progression (TTP)|One-, Two- and Three-year Survival Rate|Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions","EMD Serono|Merck KGaA, Darmstadt, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 3","1513","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EMR 63325-001","January 2007","April 2012","April 2015","December 8, 2006","November 20, 2015","November 20, 2015","Saint Edward Mercy Medical Center, Fort Smith, Arkansas, United States|Pacific Cancer Medical Center, Anaheim, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Norris Cancer Hospital, Los Angeles, California, United States|Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States|Clinical Trials and Research Associates, Inc., Montebello, California, United States|Desert Hematology Oncology Medical Group, Inc, Rancho Mirage, California, United States|Stockton Hematology Oncology Medical Group, Inc., Stockton, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Pasco Hernando Oncology Associates P.A, Brooksville, Florida, United States|University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States|Florida Hospital Memorial System, Ormond Beach, Florida, United States|Southern Illinois Hematology/Oncology, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States|Kentucky Cancer Center, Hazard, Kentucky, United States|Leonard J. Chabert Medical Center, Houma, Louisiana, United States|Hematology and Oncology Specialists, LLC, Metarie, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|University of Maryland, Marlene and Steward Greenbaum Cancer Center, Baltimore, Maryland, United States|Lahey Clinic, Burlington, Massachusetts, United States|Oncology Care Associates, Saint Joseph, Michigan, United States|University of Minnesota Physicians, Masonic Cancer Center, Minneapolis, Minnesota, United States|Saint Louis University Cance Center, Saint Louis, Missouri, United States|Deaconess Billings Clinic, Billings, Montana, United States|Big Sky Oncology, Sletten Cancer Institute, Great Falls, Montana, United States|Nebraska Cancer Care, LLC, Hastings, Nebraska, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|St. Vincents Comprehensive Cancer Center, New York, New York, United States|Hematology Oncology Associates of Rockland, Nyack, New York, United States|Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Carolinas Hematology-Oncology, Charlotte, North Carolina, United States|Hanover Medical Specialts PA, Wilmington, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Southwestern Regional Medical Center, Tulsa, Oklahoma, United States|Southwestern Regional Medical Center, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Univ. of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|Center for Oncology Research, Dallas, Texas, United States|John Peter Smith Center for Cancer Care, Fort Worth, Texas, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Cancer Therapy & Research Center, Institute for Drug Development, San Antonio, Texas, United States|Fairfax-Northern Virginia Hematology Oncology, PC, Fairfax, Virginia, United States|Wheeling Hospital, Wheeling, West Virginia, United States|Hospital Italiano Regional del Sur, Bahia Blanca, Buenos Aires, Argentina|Paliar, Capital, Buenos Aires, Buenos Aires, Argentina|Corporacion Medica General San Martin, San Martin, Buenos Aires, Argentina|Centro Oncologico de Roario, Rosario, Santa Fe, Argentina|Centro de Educacion Medica e Investigaciones Clinicas ""Norberto Quirno"" (CEMIC), Ciudad Autonoma de Buenos Aires, Argentina|Instituto Especializado Alexander Fleming, Ciudad Autonoma de Buenos Aires, Argentina|Sociedad Intaliana de Beneficencia en Buenos Aires, Hospital Italiano, Ciudad Autonoma de Buenos Aires, Argentina|Clinica Universitaria Reina Fabiola, Cordoba, Argentina|Research Site, Tandil, Argentina|Research Site, Nedlands, Western Australia, Australia|Research Site, Bankstown, NSW, Australia|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Kingswood, Australia|Research Site, Saint Leonards, Australia|Research Site, Woolloongabba, Australia|Research Site, Graz, Styria, Austria|Research Site, Linz, Upper Austria, Austria|Research Site, Inssbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wein, Venna, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Brasschaat, Belgium|Research Site, Brussels, Belgium|Research Site, Haine-Saint Paul, Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Mechelen, Belgium|Nugieo de Oncologia da Bahia, Salvador, Bahia, Brazil|Hospital das Clinicas da Faculdade de Medinina de Univeridade, São Paulo, De ao Paulo, Brazil|Hospital LifeCenter, Belo Horizonte, Minas Gerais, Brazil|Hospital Nossa Senhora da Conceicao, Centro de Pesquisas Medicas e Ensaios Clinicos, Porto Alegre, Rio Grande Do Sol, Brazil|Associacao Hospital de Caridade Ijui, Ijuí, Rio Grande Do Sul, Brazil|Hospital de Clinicas de Porto Alegre, Dept. de Endocrinologia, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Sao Lucas-Pucrs, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Algre, Rio Grande Do Sul, Brazil|Centro de Oncologia de Campinas - OCC, Campinas, Sao Paulo, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Sao Paulo, Brazil|Instituto de Oncologia de Sorocaba, Sorocaba, Sao Paulo, Brazil|Research Site, Ondina-Salvdor, Brazil|Instituto Nacional do Cancer - INCA, Rio de Janeriro, Brazil|Instituto do Cancer Arnaldo Vieira de Caralho-Onco-pneumonia, Sao Paulo, Brazil|Santa Casa de Misericordia De Sao Paulo, Sao Paulo, Brazil|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institue, Edmonton, Alberta, Canada|Frazer Valley Cancer Center, Surrey, British Columbia, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Vancouver Island Cancer Center, Victoria, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Capital District Health Authority, Halifax, Nova Scotia, Canada|Cape Breton Districk Health Authority Cancer Care, Sydney, Nova Scotia, Canada|Juravinski Cancer Center, Hamilton, Ontario, Canada|Niagara Health System, Saint Catharines, Ontario, Canada|Thunder Bay Regional Health Science Center Northwestern Ontario Regional Center, Thunder Bay, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Windsor Regional Cancer Center, Windsor, Ontario, Canada|Hopital Notre Dame, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Hopital Laval, Sainte-Foy, Quebec, Canada|Research Site, Beijing, China|Research Site, Guangzhou, China|Research Site, Shanghai, China|Research Site, Hradec Králové, Czech Republic|Research Site, Ostrava-Poruba, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha, Czech Republic|Research Site, Usti nad Labem, Czech Republic|Research Site, Herlev, Denmark|Research Site, Odense C, Denmark|Research Site, Besancon, Franche-Comte, France|Research Site, Pierre-Benite Cedex, Rhone-Alpes, France|Research Site, Beuvry, France|Research Site, Brest, France|Research Site, Caen, France|Research Site, Chauny, France|Research Site, Marseille Cedex, France|Research Site, Marseille, France|Research Site, Nancy, France|Research Site, Nantes-Saint Herblain, France|Research Site, Paris Cedex 15, France|Research Site, Perpignan, France|Research Site, Poitiers Cedex, France|Research Site, Strasbourg Cedex, France|Research Site, Essen, Nordrhein-Westfalen, Germany|Research Site, Hemer, Nordrhein-Westfalen, Germany|Research Site, Mainz, Rheinland-Pfalz, Germany|Research Site, Homburg, Saar, Germany|Research Site, Berlin, Germany|Research Site, Coswig, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Gauting, Germany|Research Site, Großhansdorf, Germany|Research Site, Hamburg, Germany|Reseach Site, Heidelberg, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Koln, Germany|Research Site, Leipzig, Germany|Research Site, Magdeburg, Germany|Research Site, Mainz, Germany|Research Site, Minden, Germany|Research Site, Muchen, Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Rostock, Germany|Research Site, Maroussi, Athens, Greece|Research Site, Athens, Attica, Greece|Research Site, Thessaloniki, Nea Efkarpia, Greece|Research Site, Athens, Greece|Research Site, Chidari, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Shatin, New Territories, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Budapest, Hungary|Research Site, Mátraháza, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Tatabayana, Hungary|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Vellore, India|Research Site, Dublin, Ireland|Research Site, Tel Hashomer, Tel Avir, Israel|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach Tikva, Israel|Research Site, Tel Aviv, Israel|Research Site, Zerifin, Israel|Research Site, Candiolo, Torino, Italy|Research Site, Avelino, Italy|Research Site, Bologna, Italy|Research Site, Carpi, Italy|Research Site, Chieti, Italy|Research Site, Forli, Italy|Research Site, Genova, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Orbassano-Torino, Italy|Research Site, Palermo, Italy|Research Site, Parma, Italy|Research Site, Rome, Italy|Research Site, Rozzano-Milano, Italy|Research Site, Sassari, Italy|Research Site, Trento, Italy|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Gyeonggi-Do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Consultorio del, Morelia, Michoacan, Mexico|Centro Oncologico de Chihuahua, Chihuahua, Mexico|Instituto Nacional de Cancerologia (INCAN), Mexico City, Mexico|Research Site, Amsterdam, Noord-Holland, Netherlands|Research Site, Amsterdam, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Hoofdrop, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Warszawa, Mazowieckie, Poland|Research Site, Bialystok, Poland|Research Site, Bydgoszcz, Poland|Research Site, Bytom, Poland|Research Site, Gdynia, Poland|Research Site, Kraków, Poland|Genova, Lodz, Poland|Research Site, Olsztyn, Poland|Research Site, Otwock, Poland|Research Site, Poznan, Poland|Research Site, Torun, Poland|Research Site, Warsaw, Poland|Genova, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Zabrze, Poland|Genova, Coimbra, Portugal|Genova, Lisboa, Portugal|Genova, Porto, Portugal|Genova, Santa Maria de Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Iasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Reseaerch Site, Kazan, Tatarstan, Russian Federation|Research Site, Yaroslavl, Yaroslavlr, Russian Federation|Research Site, Barnaul, Russian Federation|Genova, Chelaybinsk, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Nitra, Slovakia|Research Site, Mataro, Barcelona, Spain|Research Site, Barakaldo, Bilbao, Spain|Research Site, Donostia-San Sebastian, Guipuzcoa, Spain|Research Site, A Coruna, Spain|Research Site, Alicante, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, Girona, Spain|Research Site, Jaen, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Gävle, Sweden|Research Site, Göteborg, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Umea, Sweden|Research Site, Uppsala, Sweden|Research Site, Basel, Switzerland|Research Site, Geneve, Switzerland|Research Site, Genève, Switzerland|Research Site, Winterthur, Switzerland|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Cornwall, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Guildford, United Kingdom|Research Site, Inverness, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, Torquay, United Kingdom|Research Site, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00409188"
348,"NCT00686959","Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer","PROCLAIM","Completed","Has Results","Non Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Etoposide|Drug: Vinorelbine|Drug: Paclitaxel|Drug: Carboplatin|Radiation: Thoracic Radiation Therapy (TRT)","Overall Survival|Progression-free Survival (PFS)|Objective Response Rate (Complete Response [CR] + Partial Response [PR])|Survival Rates at 1, 2, and 3 Years|First Site of Disease Failure in Terms of Relapse|Percentage of Participants With a Post Baseline Swallowing Diary Score >=4","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","598","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11514|H3E-MC-JMIG","September 2008","October 2014","November 2014","May 30, 2008","November 26, 2015","June 28, 2016","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, Alabama, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Scottsdale, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fountain Valley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Haven, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hollywood, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., West Palm Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thomasville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Quincy, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Albany, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Westwood, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Louisville, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairhaven, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ann Arbor, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fargo, North Dakota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleston, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Longview, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Marcos, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, Vermont, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morgantown, West Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Launceston, Tasmania, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Antwerp, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gilly, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haine-St.- Paul, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Namur, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turnhout, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barretos, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Curitiba, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newmarket, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jinan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sichuan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wu Han, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayonne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pierre Benite, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hemer, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Immenhausen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oldenburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rheine, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabaad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dublin, Ireland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., S-Hertogenbosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Maria Da Feira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vila Franca De Xira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elche, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet De Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Majadahonda, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Terrassa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fatih, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Melikgazi, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umuttepe, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edgbaston, Birmingham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Greater London, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edinburgh, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00686959"
349,"NCT01125566","LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment",,"Completed","Has Results","Breast Neoplasms","Drug: BIBW 2992|Drug: trastuzumab|Drug: vinorelbine","Progression-free Survival (PFS)|Overall Survival (OS)|Best RECIST Assessment|Objective Response (OR)","Boehringer Ingelheim","Female","18 Years and older   (Adult, Older Adult)","Phase 3","508","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.75|2009-015476-98","June 22, 2010","June 8, 2013","July 6, 2018","May 18, 2010","August 21, 2014","July 18, 2019","Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Robert A. Moss MD, FACP, Inc, Fountain Valley, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|University of California, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc, Redondo Beach, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc, Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|North Shore Cancer Research Associates, Skokie, Illinois, United States|Cedar Valley Cancer Center, Waterloo, Iowa, United States|Pro Health Care Associated, Lake Success, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Utah Cancer Specialists Cancer Center, Salt Lake City, Utah, United States|Instituto Medico de Asistencia e Investigaciones S. A., Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Argentina|Sanatorio de la Provodencia, Ciudad Autonoma de Bs As, Argentina|Sanatorio Parque, Rosario, Argentina|Port Macquarie Base Hospital (PMBH), Port Macquarie, New South Wales, Australia|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Peninsula Haematology & Oncology, Frankston, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Mount Medical Centre, Perth, Western Australia, Australia|Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria|Kaiser Franz Josef Spital Vienna, Wien, Austria|Grodno Regional Clinical Hospital, Grodno, Belarus|N. N. Alexandrov National Cancer Center of Belarus, Minsk Region, Belarus|Public Health Inst. Minsk City Clinical Oncology Dispensary, Minsk, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Brussels - HOSP Jules Bordet, Bruxelles, Belgium|Edegem - UNIV UZ Antwerpen, Edegem, Belgium|Liège - HOSP St-Joseph, Liège, Belgium|Centro de Pesquisas Clínicas em Oncología, Cachoeiro de Itapemirim, Brazil|Hospital Santa Cruz, Curitiba, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, Brazil|Associação Hospitalar Moinhos de Vento, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Novos Tratamentos CliniOnco, Porto Alegre, Brazil|Instituto Nacional do Câncer - INCA, Rio de Janeiro, Brazil|Faculdade de Medicina do ABC, Santo André, Brazil|Centro de Referência da Saude da Mulher-Hosp Perola Byington, Sao Paulo, Brazil|BC Cancer Agency - Vancouver, Vancouver, British Columbia, Canada|Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|Instituto Clínico Oncológico del Sur - ICOS, Temuco, Chile|Cancer Hospital of Chinese Academy of Medical Science, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|307 Hospital of PLA, Beijing, China|Chinese PLA General Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|West China Hospital, Chengdu, China|Fujian Provincial Tumor Hospital, Fuzhou, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Guangdong Provincial People's Hospital, Guangzhou, China|NanFang Hosptial, Guangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Haerbin, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Qilu Hospital, Shangdong University, Jinan, China|the 81th Hospital of PLA, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Wuhan Union Hospital, Wuhan, China|Hospital Ceske Budejovice, Ceske Budejovice, Czechia|University Hospital Olomouc, Olomouc, Czechia|General Faculty Hospital, Prague, Prague 2, Czechia|MEDICON a.s., Praha 4, Praha 4, Czechia|El Manial Specialized Hospital, Cairo, Egypt|Oncology Centre- Mansoura University, Mansoura, Egypt|HOP Amiens-Picardie Sud, Amiens Cedex 1, France|CTR P Papin, Onco, Angers, Angers Cedex 9, France|HOP Jean Minjoz, Besançon Cedex, France|CLI Bordeaux Nord Aquitaine, Bordeaux, France|CTR J Perrin, Onco, Clermont-Ferrand, Clermont-Ferrand Cedex, France|HOP Victor Hugo, Le Mans, France|CTR Catherine de Sienne, Nantes, France|HOP Saint-Louis, Paris, France|INS Jean Godinot, Onco, Reims, Reims, France|CTR Eugène Marquis, Rennes Cedex, France|CTR René Huguenin, St Cloud, France|CTR Paul Strauss, Strasbourg Cedex, France|Universitätsklinikum Aachen, AöR, Aachen, Germany|Medizinisches Zentrum Bonn, Bonn, Germany|OnkoDok GbR, Bottrop, Germany|DONAUISAR Klinikum Deggendorf-Dingolfing-Landau gKU, Deggendorf, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Kliniken Essen - Mitte gGmbH, Essen, Germany|Gynäk.-onkol. Gem.praxis, Dr. Uleer, Hildesheim, Hildesheim, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|St. Elisabeth-Krankenhaus, Köln, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Klinikum der Universität München - Campus Innenstadt, München, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Onkologische Praxis Oldenburg, Oldenburg, Germany|Universitätsfrauenklinik am Klinikum Südstadt, Rostock, Germany|Facharzt für Innere Medizin, Wuppertal, Germany|Gujarat Cancer and Research Institute, Ahmedabad, India|Sujan Surgical Cancer Hospital, Amravati, India|KIDWAI memoraial Institute of oncology, Bangalore, India|Sri Venkateshwara Hospital, Bengaluru, India|Dr. Rai Memorial Cancer Centre, Chennai, India|Bibi General Hospital and Cancer Centre, Hyderabad, India|Orchid Nursing Home, Kolkata, India|Natinal Cancer Institute, Maharagama, India|Central India Cancer Research Institute, Nagpur, India|Curie Manavata Cancer centre, Nashik, India|Jehangir Hospital Oncology Department, Pune, India|K.E.M Hospital, Pune, India|King George Hospital, Visakhapatnam, India|Beaumont Hospital, Dubliin 9, Ireland|St Vincent's University Hospital, Dublin 4, Ireland|Mater Misericordiae University Hospital, Dublin 7, Ireland|St James's Hospital, Dublin 8, Ireland|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem 91031, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Azienda Ospedaliera Universitaria Arcispedale Sant'Anna, Ferrara, Italy|Istituto Europeo di Oncologia, Milan, Italy|P.O. Monserrato, Monserrato (CA), Italy|Tokai University Hospital, Kanagawa, Isehara, Japan|Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Osaka, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, Japan|National Cancer Center, Goyang, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|P. Stradins Clinical Univ. Hospital, Oncology Clinic, Riga, Latvia|Riga East Univ. Hospital, Oncology Centre, Riga, Latvia|Hammoud Hospital University Medical Centre (HHUMC), Lebanon, Lebanon|Hospital of Lithuanian Univ.of HealthSciences Kauno Klinikos, Kaunas, Lithuania|National Cancer Institute, Vilnius, Vilnius, Lithuania|Hospital de Jesus, Colonia Centro, Mexico|Albert SchweitzerZiekenhuis, Dordrecht, Netherlands|Máxima Medisch Centrum, locatie Eindhoven, Eindhoven, Netherlands|Zuyderland Medisch Centrum, Geleen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|METC Academisch Ziekenhuis Maastricht/Universiteit van Maastricht, Maastricht, Netherlands|Isala Zwolle, Zwolle, Netherlands|Hospital Nacional Adolfo Guevara Velasco, Cusco, Peru|Clinica San Judas Tadeo, Lima, Peru|Instituto Oncologico Miraflores S.A., Miraflores, Peru|Clinica Peruano Americana de Trujillo, Trujillo, Peru|Bialystock's Oncology Center, Bialystok, Poland|Wojewodzki Specialist Hospital No. 4, Bytom, Bytom, Poland|University Clinical Center, Gdansk, Gdansk, Poland|Provincial Specialist M. Kopernik Hospital, Lodz, Poland|Ziemia Lubelska Oncological Center, Lublin, Lublin, Poland|Oncology Centre of Olsztyn ""KOPERNIK"" Sp. z.o.o., Olsztyn, Poland|Wielkopolskie Oncology Centre n.a. Maria Sklodowska-Courie, Poznan, Poland|Military Medical Institute, Warsaw, Poland|Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, Portugal|CHUC, EPE - CHC-Maternidade Bissaya Barreto, Coimbra, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|St.Auton.Heal.Inst.""Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"", Kazan, Russian Federation|N.A. Semashko Central Clinical Hospital, Moscow, Moscow, Russian Federation|GUZ ""Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|Regional Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Johns Hopkins Singapore International Medical Center, Singapore, Singapore|St. Jacobs Hosp.Outpat.Pneumology&Phthisiology Dept,Bardejov, Bardejov, Slovakia|National Institute of Oncology, Bratislava, Bratislava, Slovakia|POKO Policlinic Dept. of Clinical Oncology, Poprad, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|WCR CMJAH Clinical Trial Site, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|GVI oncology Medi Clinic, Kraaifontein, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Wilgers oncology, Pretoria, South Africa|Rondebosch Oncology Centre, Rondebosch, Cape Town, South Africa|Hospital del Mar, Barcelona, Spain|Hospital Universitari Dexeus, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Complejo Hospitalario Universitario Insular - Materno Infantil, Las Palmas de Gran Canaria, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Shatabdi Superspeciality Hospital, Maharashtra, Sri Lanka|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan County, Taiwan|Hacettepe Universitesi Tip Fakultesi, Ic Hastaliklari ABD, Ankara, Turkey|Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali, Izmir, Turkey|Ninewells Hospital & Medical School, Dundee, United Kingdom|Guy's Hospital, London, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom|Queen Elizabeth Hospital, Woolwich, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01125566"
350,"NCT00806286","Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer",,"Completed","Has Results","Metastatic Non-small Cell Lung Cancer","Drug: CS7017 tablets|Drug: Paclitaxel|Drug: Carboplatin|Drug: Placebo Tablets","Percentage of Participants With Progression-Free Survival at 18 Weeks Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer|Percentage of Participants With Progression-Free Survival Based on Radiologic and Clinical Assessments and Death After Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer|Summary of Kaplan-Meier Analysis of Overall Survival Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer|Number of Participants With Best Overall Tumor Response and Objective Response Rate Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer|Number of Participants With Treatment-Emergent Adverse Events Related to CS-7017/Placebo Following Administration of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-naïve Participants With Metastatic Non-small Cell Lung Cancer","Daiichi Sankyo, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CS7017-A-U202","December 2008","January 2012","August 2012","December 10, 2008","May 13, 2020","May 13, 2020","University Colorado Cancer Center, Aurora, Colorado, United States|Georgetown Univ. Medical Center, Washington, District of Columbia, United States|Southern Illinois Hematology/Oncology, Centralia, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|Michiana Hematology-Oncology, South Bend, Indiana, United States|Harbor View Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Penn State Milton Hershey Cancer Center, Hershey, Pennsylvania, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Pentagon Research, Aundh, Maharashtra, India|Shatabdi Super Specialty Hospital, Nashik, Mumbai Naka, India|Hemato-Oncology Clinic, Vedanta, Gujarat, Navrangpura, Ahmedabad, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, India|Orchid Nursing Home, Kolkata, West Bengal, India|Apollo Specialty Hospital, Chennai, India|Ruby Hall Clinic, Pune, India|Noble Hospital, Pune, India|Oddzial Chemioterapii ZOZ MSWiA, Olsztyn, Poland|Oddzial Onkologii Klinicznej z Pododdzialem Dziennej Chemioterapii, Poznan, Poland|Specjalistyczny Szpital im. Prof. Alfresa Sokolowskiego, Szczecin, Poland|Oncomed SRL, Timisoara, Judet Timis, Romania|Spitalul Municipal Ploiesti, Ploiesti, Prahova, Romania|Institutul Oncologic Prof. Dr. Alexandru Trestioreanu, Bucuresti, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|Centrul de Oncologie Medicala, Iasi, Romania",,"https://ClinicalTrials.gov/show/NCT00806286"
351,"NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Placebo|Other: Best Supportive Care","Investigator-assessed Objective Progression-free Survival (PFS)|Independently-assessed Objective Progression-free Survival (PFS)|Overall Survival (OS)|Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score|Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)|Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)|Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase|Percentage of Participants With Serious Adverse Events During Maintenance Phase|Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off|Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","939","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12560|H3E-EW-S124|CTRI/2009/091/000113","November 2008","June 2010","November 2017","November 11, 2008","July 18, 2011","December 14, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Adelaide, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wendouree, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aalst, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genk, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gilly, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sint Niklaas, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Espoo, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Turku, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dijon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans Cedex 1, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre-Les-Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gerlingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Großhansdorf, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neo Faliro, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bhopal, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madurai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Patna, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avellino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aviano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lido Di Camaiore, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reggio Emilia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Udine, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ede, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heerlen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vila Franca De Xira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manresa, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bornova, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sihhiye, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zeytinburnu, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guildford, Surrey, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Birmingham, West Midlands, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00789373"
352,"NCT00682981","A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)",,"Completed","No Results Available","Extensive-stage Small Cell Lung Cancer","Drug: Obatoclax|Drug: Carboplatin/etoposide","Determine the recommended Phase II dose of obatoclax administered as a 3-hour or 24-hour infusion for 3 consecutive days in Phase I, and response rate in Phase II.","Gemin X|Cephalon|Teva Branded Pharmaceutical Products R&D, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","218","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GEM017","May 2008","November 2011","November 2011","May 23, 2008",,"July 21, 2016","Clearview Cancer Institute, Huntsville, Alabama, United States|Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Mayo Clinic-Arizona, Scottsdale, Arizona, United States|Arizona Clinical Research Center, Tucson, Arizona, United States|City of Hope and Beckman Research Institute, Duarte, California, United States|University of California-San Diego Moores Cancer Center, LaJolla, California, United States|Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|University of Miami-Sylvester Cancer Center, Miami, Florida, United States|Florida Cancer Institute, New Port Richey, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Northwest Georgia Oncology Centers, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Iowa Blood and Cancer Center, PLC, Cedar Rapids, Iowa, United States|Cancer Center of Kansas, Wichita, Kansas, United States|James Brown Cancer Center, Louisville, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Kalamazoo Hematology and Oncology, Kalamazoo, Michigan, United States|Mid Ohio Oncology/Hematology, Inc., Columbus, Ohio, United States|Cancer Care Associates-Oklahoma City, Oklahoma City, Oklahoma, United States|Cancer Care Associates-Tulsa, Tulsa, Oklahoma, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Greater Philadelphia Cancer and Hematology Specialists, Philadelphia, Pennsylvania, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|McLeod Cancer & Blood Center, Johnson City, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Baylor, Dallas, Texas, United States|UT Southwestern Medical Center at Dallas, Dallas, Texas, United States|Tyler Cancer Center, Tyler, Texas, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Wheeling Hospital, Wheeling, West Virginia, United States|MHAT ""Dr. Tota Venkova"", Gabrovo, Bulgaria|District Dispensary for Cancer Diseases, Plovdiv, Plovdiv, Bulgaria|District Dispensary for Oncology Diseases, Sofia City, Sofia, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|McGill University, Montreal, Quebec, Canada|Regional Hospital Kladno, Kladno, Czech Republic|Hospital Kutna Hora, Kutna Hora, Czech Republic|University Hospital Olomouc, Olomouc, Czech Republic|Faculty Hospital Ostrava, Ostrava-Poruba, Czech Republic|University Hospital Na Bulovce, Prague, Czech Republic|National Institute of Tuberculosis & Pulmonology, Budapest, Hungary|Semmelweis University Medical School, Budapest, Budapest, Hungary|University Of Debrecen Medical and Health Science Centre, Debrecen, Hungary|Csongrad County Council's Hospital for Chest Diseases, Deszk, Hungary|Bacs-Kiskun County Hospital, Kecskemet, Hungary|State Hospital Matrahaza, Matrahaza, Hungary|Clinfan Ltd. SMO Tolna County Hospital, Szekszard, Hungary|Pest County Hospital, Torokbalint, Hungary|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Kailash Cancer Hospital and Research Centre, Goraj, Gujarat, India|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, Madhya Pradesh, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|Dr. Kamakshi Memorial Hospital, Chennai, Tamal Nadu, India|Galaxy Cancer Institute, Pushpanjali Crosslay Hospital, Ghaziabad, Uttar Pradesh, India|Orchid Nursing Home, Kolkata, West Bengal, India|Wojewodzki Szpital Specjalistyczny im. K. Dluskiego, Bialystok, Poland|SPZ Gruzlicy i Chorob Pluc, Olsztyn, Poland|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Poland|Specjalistyczny Szpital im Prof Alfreda Sokolowskiego, Szczecin-Zdunowo, Poland|Wojewodzki Szpital Chorob Pluc, Wodzislaw Slaski, Poland|Prof. Dr. Ion Chiricuta Oncology Institute Cluj Napoca, Cluj, Romania|Oncology Medical Centre SCM, Iasi, Romania|Emergency Clinical County Hospital Oradea, Oradea, Romania|Center for Pulmonary Diseases, Clinic for Internal Medicine, Kragujevac, Serbia|Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia|Northern Ireland Cancer Centre Queens University Belfast, Belfast, Northern Ireland, United Kingdom|Royal Bournemouth Hospital, Dorset, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Royal Surrey County Hospital, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00682981"
353,"NCT04975308","A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer","EMBER-3","Recruiting","No Results Available","Breast Neoplasms|Neoplasm Metastasis","Drug: Imlunestrant|Drug: Exemestane|Drug: Fulvestrant|Drug: Abemaciclib","Progression Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR): Percentage of Participants Who Achieve a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR)|Duration of Response (DoR)|Clinical Benefit Rate (CBR): Percentage of Participants Who Achieve a Best Overall Response of CR, PR or Stable Disease for Greater than or Equal to (≥) 24 Weeks|PFS by Estrogen Receptor 1 Gene (ESR1) Mutation Status in Plasma|Patient Reported Outcomes (PRO): Time to Worsening of ""Worst Pain""|Pharmacokinetics (PK): Steady State Plasma Concentrations of Imlunestrant|PK: Steady State Plasma Concentrations of Imlunestrant and Abemaciclib","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18175|J2J-OX-JZLC|2021-000079-35","October 4, 2021","June 13, 2023","September 13, 2026","July 23, 2021",,"April 19, 2022","Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|University of California, Davis - Health Systems, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Banner MD Anderson Cancer Center at North Colorado Medical Center, Greeley, Colorado, United States|Rocky Mountain Cancer Center, Lone Tree, Colorado, United States|Banner MD Anderson Cancer Center at McKee Medical Center, Loveland, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Univ of Florida School of Medicine, Gainesville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chi Med Center, Chicago, Illinois, United States|Minnesota Oncology/Hematology PA, Coon Rapids, Minnesota, United States|Broome Oncology, Binghamton, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Aultman Hospital, Canton, Ohio, United States|Zangmeister Cancer Center, Columbus, Ohio, United States|Willamette Valley Cancer Institute & Research Ctr., Eugene, Oregon, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Texas Oncology - Austin Central, Austin, Texas, United States|Texas Oncology - Carrollton, Carrollton, Texas, United States|Texas Oncology - Methodist Charlton Cancer Center, Dallas, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Texas Oncology - Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology - Denison, Denison, Texas, United States|Texas Oncology Denton, Denton, Texas, United States|Texas Oncology Fort Worth, Fort Worth, Texas, United States|Texas Oncology - Willowbrook, Houston, Texas, United States|Texas Oncology - McKinney, McKinney, Texas, United States|Texas Oncology - Paris, Paris, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology - San Antonio Medical Center, San Antonio, Texas, United States|Texas Oncology - The Woodlands, The Woodlands, Texas, United States|US Oncology, The Woodlands, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Blue Ridge Cancer Care, Salem, Virginia, United States|Fundación CENIT para la Investigación en Neurociencias, Caba, BA, Argentina|Instituto de Investigaciones Clínicas Mar del Plata, Mar del Plata, Buenos Aires, Argentina|CIPREC, Caba, Ciudad Autónoma De Buenos Aire, Argentina|Clinica Viedma, Viedma, Río Negro, Argentina|Instituto Argentino de Diagnóstico y Tratamiento (IADT), Buenos Aires, Argentina|Cent Priva Especiali Médicas Ambulatorias Inve Clin CEMAIC, Cordoba, Argentina|Instituto San Marcos, San Juan, Argentina|Sanatorio Norte, Santiago del Estero, Argentina|St Vincent's Hospital, Darlinghurst, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Cancer Research SA, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Universitätsklinikum Graz, Graz, Steiermark, Austria|Private Practice - Dr. Hubalek, Schwaz, Tirol, Austria|Medizinische Universität Wien, Vienna, Wien, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Imelda General Hospital, Bonheiden, Antwerpen, Belgium|UZ Brussel, Brussels, Bruxelles-Capitale, Région De, Belgium|UZ Gent, Gent, Oost-Vlaanderen, Belgium|AZ Nikolaas, Sint-Niklaas, Oost-Vlaanderen, Belgium|AZ Groeninge Campus Kennedylaan, Kortrijk, West-Vlaanderen, Belgium|Institut Jules Bordet, Brussels-Capital, Belgium|Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven, Belgium|Hospital de Cancer de Londrina, Londrina, Paraná, Brazil|Faculdade de Medicina do ABC, Santo Andre, SP, Brazil|Icesp - Instituto Do Câncer Do Estado de São Paulo, São Paulo, Brazil|Clínica de Pesquisa e Centro de Estudos em Ginecologia Oncológica e Mamária LTDA, São Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil|Afflilated Hospital of Bengbu Medical College, Bengbu, Anhui, China|Beijing Hospital, Beijing, Beijing, China|The Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China|Beijing Cancer hospital, Beijing, Beijing, China|Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science &Technology, Luoyang, Henan, China|People's Hospital of Henan Province, Zhengzhou, Henan, China|Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Hubei Cancer Hospital, Wuhan, Hubei, China|The First People's Hospital of Changde City, Changde, Hunan, China|Hunan Provincial People's Hospital, ChangSha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|The Third Hospital of Nanchang, Nanchang, Jiangxi, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jiangsu Province Hospital, Nanjing, Nanjing, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Jinan Central Hospital, Jinan, Shandong, China|Yantai Yuhuangding Hospital, Yantai, Shandong, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China|Xinjiang Medical University Cancer Hospital - Urumqi, Urumqi, Xinjiang, China|The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China|Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Hwa Mei Hospital University of Chinese Academy of Sciences, Ningbo, Zhejiang, China|Sichuan Cancer Hospital, Chengdu, China|Jining Medical University - Affiliated Hospital, Jining, China|Wu Han Tongji Hospital, Wuhan, China|Thomayerova nemocnice, Praha, Praha 4 - Krč, Czechia|Nemocnice Na Bulovce, Prague, Praha 8, Czechia|Nemocnice Horovice, Horovice, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Oblastní nemocnice Příbram, a.s., Pribram, Czechia|Institut de cancérologie Strasbourg Europe (ICANS), Strasbourg, Alsace, France|Centre de Cancérologie du Grand Montpellier, Montpellier, Languedoc-Roussillon, France|Centre Hospitalier de la Côte Basque, Bayonne, Pyrénées-Atlantiques, France|Polyclinique De Blois, La Chaussee Saint Victor, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France|Institut Curie, Paris, France|Institut Curie, Saint-Cloud, Île-de-France, France|Klinikum Ludwigsburg, Ludwigsburg, Baden-Württemberg, Germany|Universitätsklinikum Erlangen, Erlangen, Bayern, Germany|Rotkreuzklinikum München - Frauenklinik (Gemeinnützige GmbH), München, Bayern, Germany|Klinikum der Universität München Großhadern, München, Bayern, Germany|Agaplesion Markus Krankenhaus, Frankfurt, Hessen, Germany|Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Niedersachsen, Germany|Kliniken Essen-Mitte, Evangelische Huyssens-Stiftung, Essen, Nordrhein-Westfalen, Germany|Evangelisches Krankenhaus Bethesda Mönchengladbach, Mönchengladbach, Nordrhein-Westfalen, Germany|Universitaetsklinikum Schleswig-Holstein Campus Kiel, Kiel, Schleswig-Holstein, Germany|Ostholstein Onkologie, Oldenburg in Holstein, Schleswig-Holstein, Germany|Agios Savvas Regional Cancer Hospital, Athens, Attikí, Greece|Alexandra General Hospital of Athens, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Irakleío, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, Thessaloníki, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|General Hospital of Thessaloniki Papageorgiou, Thessaloniki, Greece|Maulana Azad Medical College, New Delhi, Delhi, India|HCG-Bangalore, Bengaluru, Karnataka, India|Regional Cancer Centre - Thiruvananthapuram, Thiruvananthapuram, Kerala, India|HCG Cancer Centre, Mumbai, Maharashtra, India|Government Medical College And Hospital - Nagpur, Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Yashoda Hospitals, Hyderabad, Telangana, India|University of Naples Federico II, Naples, Campania, Italy|Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy|Cro-Irccs, Aviano, Friuli-Venezia Giulia, Italy|Fondazione Policlinico Universitario Agostino Gemelli, Roma, Lazio, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Lombardia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Toscana, Italy|Ospedale San Martino, Genova, Italy|Istituto Europeo di Oncologia IRCCS, Milano, Italy|Azienda Ospedaliero Universitaria, Modena, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Chiba cancer center, Chiba-shi, Chiba, Japan|Kurume General Hospital, Kurume, Fukuoka, Japan|Gunma Prefectural Cancer Center, Ota, Gunma, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|University of tsukuba hospital, Tsukuba-shi, Ibaragi, Japan|St. Marianna University Hospital, Kawasaki, Kanagawa, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hiroshima City Hospital, Hiroshima, Japan|Sagara Hospital, Kagoshima, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Osaka International Cancer Institute, Osaka, Japan|Shizuoka Prefectural General Hospital, Shizuoka, Japan|Soon Chun Hyang University Cheonan Hospital, Cheonan-si, Chungcheongnam-do [Chungnam], Korea, Republic of|Gachon University Gil Hospital, Namdong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Korea, Republic of|Ajou University Hospital, Suwon-si, Kyǒnggi-do, Korea, Republic of|Yeungnam Univeristy Medical Center, Gyeongsan-si, Kyǒngsangbuk-do, Korea, Republic of|Dong-A University Hospital, Busan, Pusan-Kwangyǒkshi, Korea, Republic of|Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Gangnam Severance Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Centro de Investigación Clínica de Alta Especialidad, Torreón, Coahuila, Mexico|Grupo Medico Camino Sc, Mexico City, Distrito Federal, Mexico|Christus Muguerza Clinica Vidriera (Christus Muguerza Sistemas Hospitalarios S.A. de C.V.), Monterrey Nuevo León, C.P., Monterrey, Mexico|COI Centro Oncológico Intl. S.A.P.I. de C.V._ S.F., Paso De Las Lomas, MX, Mexico|Private Practice - Dr. Joaquin Reinoso, Monterrey, Nuevo León, Mexico|Centro Medico Zambrano Helion, San Pedro Garza Garcia, Nuevo León, Mexico|Unidad de Investigación en Salud, Chihuahua, Mexico|Oaxaca Site Management Organization, Oaxaca, Mexico|Unidad Médica Onco-hematológica, Puebla, Mexico|Medische Centrum Leeuwarden, Leeuwarden, Fryslân, Netherlands|Maastricht UMC+, Maastricht, Limburg, Netherlands|Haga Ziekenhuis locatie Leyweg, Den Haag, Zuid-Holland, Netherlands|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF, Moscow, Moskva, Russian Federation|N.N.Petrov Research Institute of Oncology, St. Petersburg, Peterburg, Russian Federation|Volgograd Regional Clinical Cancer Clinic No.1, Volgograd, Volgogradskaya Oblast', Russian Federation|SHI Kaluga Regional Hospital, Kaluga, Russian Federation|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalunya [Cataluña], Spain|Hospital Universitari Arnau de Vilanova, Lleida, Cataluña, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, Spain|Hospital Universitario de Canarias, San Cristobal de La laguna, Santa Cruz De Tenerife, Spain|Hospital Universitario San Cecilio, Granada, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Quirón Salud Valencia, Valencia, Spain|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng-Kung Uni. Hosp., Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Acibadem Altunizade Hospital, Üsküdar / Stanbul, İstanbul, Turkey|Ege University Medicine of Faculty, Bornova, İzmir, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, Turkey|University of Health Sciences,Gulhane School of Medicine, Ankara, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Hacettepe Universitesi, Ankara, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, Turkey|Akdeniz University Medical Faculty, Antalya, Turkey|Dicle Üniversitesi, Diyarbakir, Turkey|Trakya University, Edirne, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Acıbadem Maslak Hastanesi, İstanbul, Turkey|TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|İnönü Üniversitesi Turgut Özal Tıp Merkezi, Malatya, Turkey|Mersin University, Mersin, Turkey|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department, Kryvyi Rih, Dnipropetrovska Oblast, Ukraine|CNPE ""Regional Center of Oncology"", Kharkiv, Kharkivska Oblast, Ukraine|Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council, Odesa, Odeska Oblast, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncology Center Of Vinnytsia Regional Council"", Vinnytsia, Vinnytska Oblast, Ukraine|Municipal Enterprise ""Volyn Regional Medical Oncology Centre"" of the Volyn Regional Council, Lutsk, Volynska Oblast, Ukraine|Uzhgorod Central City Clinical Hospital, Uzhhorod, Zakarpatska Oblast, Ukraine",,"https://ClinicalTrials.gov/show/NCT04975308"
354,"NCT03853655","Adjuvant Radiotherapy in Early Stage Oral Cancers","AREST","Recruiting","No Results Available","Cancer of Mouth|Cancer of the Tongue|Cancer of the Head and Neck|Buccal Mucosa Cancer|Floor of Mouth Carcinoma","Radiation: Post-operative adjuvant radiotherapy","loco-regional recurrence free survival|Disease free survival|Overall survival","Tata Memorial Hospital|NATIONAL CANCER GRID","All","18 Years and older   (Adult, Older Adult)","Not Applicable","392","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1713","August 2, 2018","August 1, 2023","September 30, 2026","February 25, 2019",,"May 4, 2022","Dr. B Barooah Cancer Institute, Guwahati, Assam, India|HCG Hospital, Ahmedabad, Gujarat, India|Kailash Cancer Hospital and Research Centre, Goraj, Gujarat, India|Sree Sankara Cancer Hospital, Bangalore, Karnataka, India|Mazumdar Shaw Medical Centre, Bangalore, Karnataka, India|Malabar Cancer Centre, Kannur, Kerala, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03853655"
355,"NCT02136927","Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer",,"Terminated","No Results Available","Breast Cancer","Drug: SPARC1210|Drug: Reference1210","Maximum observed concentration (Cmax)","Sun Pharma Advanced Research Company Limited","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLR_12_10","August 2014","April 2016","April 2016","May 13, 2014",,"May 3, 2019","SPARC Site 12, Hyderabad, Andhra Pradesh, India|SPARC Site 9, Hyderabad, Andhra Pradesh, India|SPARC Site 6, New Delhi, Delhi, India|SPARC Site 2, Goraj, Gujarat, India|SPARC Site 8, Cochin, Kerala, India|SPARC Site 11, Mumbai, Maharashtra, India|SPARC Site 5, Nagpur, Maharashtra, India|SPARC Site 4, Nashik, Maharashtra, India|SPARC Site 1, Pune, Maharashtra, India|SPARC Site 3, Pune, Maharashtra, India|SPARC Site 10, Chennai, Tamil Nadu, India|SPARC Site 7, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02136927"
356,"NCT01566240","Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer","INTERLACE","Recruiting","No Results Available","Cervical Cancer","Drug: Paclitaxel|Drug: Carboplatin|Radiation: Radiotherapy|Drug: Cisplatin","Overall Survival|Progression free survival|Adverse events (AE) as assessed by the Common Terminology Criteria for Adverse Events v4.03|Quality of Life (UK and Ireland only) as assessed by EORTC QLQ-C30, QLQ-CX24 and EQ-5D|Patterns of first relapse (local and/or systemic)","University College, London|Cancer Research UK","Female","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCL 11/0034|2011-001300-35|C37815/A12832","September 2012","August 2022","May 2026","March 29, 2012",,"April 29, 2021","Chittaranjan National Cancer Institute (CNCI), Kolkata, India|Saroj Gupta Cancer Centre and Research Institute, Kolkata, India|Istituto Europeo di Oncologia, Milan, Lombardy, Italy|Instituto Nacional de Cancerologia (INCAN), Mexico City, Mexico|North Devon District Hospital, Barnstaple, Devon, United Kingdom|University College London Hospital, London, Greater London, United Kingdom|Weston Park Hospital, Sheffield, South Yorkshire, United Kingdom|Belfast City Hospital, Belfast, United Kingdom|Pilgrim Hospital, Boston, United Kingdom|Royal Sussex County Hospital, Brighton, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|Cheltenham General Hospital, Cheltenham, United Kingdom|Royal Derby Hospital, Derby, United Kingdom|Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|Beatson WOSCC, Glasgow, United Kingdom|Gloucester Royal Hospital, Gloucester, United Kingdom|Grantham and District Hospital, Grantham, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Lincoln County Hospital, Lincoln, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|St Bart's Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|James Cook University Hospital, Middlesbrough, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Norfolk and Norwich University Hospital, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Royal Stoke University Hospital, Stoke-On-Trent, United Kingdom|Torbay Hospital, Torquay, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|The Clatterbridge Cancer Centre, Wirral, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01566240"
357,"NCT03853551","Osimertinib Study in Indian Patients",,"Completed","Has Results","Non Small Cell Lung Cancer (NSCLC)","Drug: Osimertinib","Safety of Osimertinib","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","60","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5161C00005","April 18, 2019","April 15, 2020","April 15, 2020","February 25, 2019","June 3, 2021","June 3, 2021","Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, New Dehli, India|Research Site, New Delhi, India","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03853551/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/51/NCT03853551/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03853551"
358,"NCT00102804","Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Pemetrexed|Drug: Placebo|Other: Best Supportive Care","Progression-Free Survival (PFS) Time|Overall Survival (OS) Time|Time to Objective Progressive Disease (TPD)|Time to Worsening of Symptoms (TWS)|Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)|Number of Participants With Adverse Events (AEs)|Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","663","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","5122|H3E-MC-JMEN","March 2005","August 2007","December 2013","February 2, 2005","December 29, 2014","December 29, 2014","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portsmouth, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marshfield, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bankstown, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coffs Harbour, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kogarah, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Macquarie, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nambour, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Townsville, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashford, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankston, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sofia, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Varna, Bulgaria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dalian, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ji Nan, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nan Jing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zagreb, Croatia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ostrava-Poruba, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czech Republic|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hannover, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Magdeburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ulm, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mosdos, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Szombathely, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Banglagore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jaipur, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., P.O Ernakulam, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bari, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Messina, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rozzano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ede, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zutphen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zwolle, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcoi, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alcorcon, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Granada, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mataró, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Murcia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Palma De Mallorca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Cruz De Tenerife, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT00102804"
359,"NCT01160211","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",,"Active, not recruiting","Has Results","Neoplasms, Breast","Drug: lapatinib|Drug: trastuzumab|Drug: Aromatase inhibitor","PFS of Lapatinib+Trastuzumab+AI Combination vs. Trastuzumab+AI Combination|Median Kaplan Meier Estimates for PFS of Lapatinib+Trastuzumab+AI Combination vs. Trastuzumab+AI Combination|PFS of Trastuzumab/AI vs. Lapatinib/AI and Trastuzumab/Lapatinib/AI vs. Lapatinib/AI|Overall Survival (OS) Events of Lapatinib+Trastuzumab+AI vs. Trastuzumab+AI and Lapatinib+AI vs. Trastuzumab+AI|Overall Response Rate (ORR; Complete or Partial Response) in Lapatinib+Trastuzumab+AI vs. Trastuzumab+AI and Lapatinib+AI vs. Trastuzumab+AI|Clinical Benefit Rate (CBR; Complete Response, Partial Response, or Stable Disease for at Least 6 Months) in Lapatinib+Trastuzumab+AI vs. Trastuzumab+AI and Lapatinib+AI vs. Trastuzumab+AI|Duration of Response in Lapatinib+Trastuzumab+AI vs. Trastuzumab+AI and Lapatinib+AI vs. Trastuzumab+AI|Changes in the Quality of Life (QoL) Status Relative to Baseline FACT-B Overall and Subscale Scores at Last On-treatment Assessment|Time to Response in Lapatinib+Trastuzumab+AI vs. Trastuzumab+AI and Lapatinib+AI vs. Trastuzumab+AI","Novartis Pharmaceuticals|GlaxoSmithKline|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","369","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","114299|2010-019577-16|CLAP016A2307","May 5, 2011","March 11, 2016","May 2, 2023","July 12, 2010","July 15, 2019","August 31, 2021","Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Pleasant Hill, California, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Goshen, Indiana, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Cary, North Carolina, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Aut6noma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Viedma, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Argentina|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Adelaide, Australia|Novartis Investigative Site, Douglas, Australia|Novartis Investigative Site, Ringwood East, Australia|Novartis Investigative Site, Tweed Heads, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Fortaleza, Ceará, Brazil|Novartis Investigative Site, Goiania, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Fuzhou, Fujian, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Harbin, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Osijek, Croatia|Novartis Investigative Site, Pula, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Besancon, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Paris Cedex 20, France|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Aachen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bottrop, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Chania, Greece|Novartis Investigative Site, Heraklion, Greece|Novartis Investigative Site, Perioxi Dragana, Alexandroupolis, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Gyula, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Zalaegerszeg, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Chennai, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Surat, India|Novartis Investigative Site, Dublin 7, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Parma, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Rozzano (MI), Lombardia, Italy|Novartis Investigative Site, San Giovanni Rotondo, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Kagoshima, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Shizuoka, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Lorenskog, Norway|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, San Borja, Lima, Peru|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Arequipa, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Trujillo, Peru|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Konin, Poland|Novartis Investigative Site, Lubin, Poland|Novartis Investigative Site, Otwock, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wieliszew, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Coimbra, Portugal|Novartis Investigative Site, Evora, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisbon, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Timisoara, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tver, Russian Federation|Novartis Investigative Site, Belgrade, Serbia|Novartis Investigative Site, Kragujevac, Serbia|Novartis Investigative Site, Sremska Kamenica, Serbia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Port Elizabeth, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, La Coruna, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Kaohsiung Hsien, Taiwan|Novartis Investigative Site, Taipei City, Taiwan|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Lyutizh, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Vinnitsia, Ukraine|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Birmingham, West Midlands, United Kingdom|Novartis Investigative Site, Huddersfield, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01160211"
360,"NCT00744497","Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer","READY","Completed","Has Results","Prostatic Neoplasms","Drug: Placebo|Drug: Dasatinib|Drug: Docetaxel|Drug: Prednisone","Overall Survival: Time From Randomization to Date of Death|Percentage of Participants With an Objective Tumor Response by Modified Response Evaluation Criteria in Solid Tumors (RECIST)|Time to First Skeletal-related Event (SRE)|Percentage of Participants With A Reduction in Urinary N-telopeptide (uNTx) Level From Baseline|Progression-free Survival (PFS)|Time to Prostate Specific Antigen (PSA) Progression|Percentage of Participants With a Reduction in Pain Intensity From Baseline","Bristol-Myers Squibb","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1930","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CA180-227|2008-000701-11","October 2008","August 2012","July 2015","September 1, 2008","February 6, 2014","October 17, 2016","University Of South Alabama / Mitchell Cancer Institute, Mobile, Alabama, United States|Southern Cancer Center, Mobile, Alabama, United States|Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Compassionate Cancer Care Medical Group Inc, Riverside, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Va San Diego Healthcare System, San Diego, California, United States|Edward Alexson, Md, Inc., Santa Ana, California, United States|Connecticut Oncology Group, Middletown, Connecticut, United States|Va Connecticut Healthcare System, West Haven, Connecticut, United States|Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Fort Wayne Medical Oncology And Hematology Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|North Mississippi Hematology And Oncology Associates, Ltd, Tupelo, Mississippi, United States|New York Oncology Hematology, Pc, Albany, New York, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Samuel S. Stratton Vamc, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology Oncology Associates, Pllc, Winston-salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Mid Ohio Oncology/Hematology, Inc,Dba, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Regional Hemetology Oncology, Pc, Langhorne, Pennsylvania, United States|Upmc Cancer Pavilion, Pittsburgh, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Cancer Centers Of The Carolinas, Greenville, South Carolina, United States|Boston Baskin Cancer Foundation, Memphis, Tennessee, United States|Cancer Specialists Of South Texas, Pa, Corpus Christi, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Providence Regional Cancer System, Lacey, Washington, United States|University Of Washington, Seattle, Washington, United States|Dean Hematology And Oncology Clinic, Madison, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, La Plata, Buenos Aires, Argentina|Local Institution, Ramos Mejia, Buenos Aires, Argentina|Local Institution, Cipolletti, Rio Negro, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordaba, Argentina|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Lismore, New South Wales, Australia|Local Institution, Port Macquarie, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Milton, Queensland, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Ringwood, Victoria, Australia|Local Institution, Fremantle, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Santo Andre, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Abbottsford, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Owen Sound, Ontario, Canada|Local Institution, Sudbury, Ontario, Canada|Local Institution, Thunder Bay, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Sherbrooke, Quebec, Canada|Local Institution, Regina, Saskatchewan, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Praha 8, Czech Republic|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon, France|Local Institution, Besancon Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Paris, France|Local Institution, St Genis Laval, France|Local Institution, Strasbourg, France|Local Institution, Aachen, Germany|Local Institution, Berlin, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Kirchheim, Germany|Local Institution, Markkleeberg, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Zalaegerszeg, Hungary|Local Institution, Trivandrum, Kerala, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Ahmedabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Kolkatta, India|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Arezzo, Italy|Local Institution, Genova, Italy|Local Institution, Lecce, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Perugia, Italy|Local Institution, Roma, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Tijuana, Baja California, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Huixquilucan, Estado De Mexico, Mexico|Local Institution, Toluca, Estado De Mexico, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Mexico, Queretaro, Mexico|Local Institution, Stavanger, Norway|Local Institution, Callao, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Bialystok, Poland|Local Institution, Lodz, Poland|Local Institution, Warszawa, Poland|Local Institution, Baia Mare, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Bloemfontein, Free State, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Gauteng, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Gijon, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Kungalv, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Cardiff, Glamorgan, United Kingdom|Local Institution, London, Middlesex, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Leeds, West Yorkshire, United Kingdom|Local Institution, Essex, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00744497"
361,"NCT00830180","Open Label Extension In Cancer Patients",,"Completed","Has Results","Neoplasms|Bone Metastases","Biological: Anti-NGF AB","Change From Parent Study (A4091003 [NCT00545129]) Baseline in Brief Pain Inventory-Short Form (BPI-sf) Average Pain Score for at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From A4091029 Baseline in BPI-sf Average Pain Score at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Parent Study (A4091003 [NCT00545129]) Baseline in BPI-sf Worst Pain Score at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Study A4091029 Baseline in BPI-sf Worst Pain Score at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Parent Study (A4091003 [NCT00545129]) Baseline in BPI-sf Least Pain Score at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Study A4091029 Baseline in BPI-sf Least Pain Score at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Parent Study (A4091003 [NCT00545129]) Baseline in BPI-sf Score for Right Now Pain at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Study A4091029 Baseline in BPI-sf Score for Right Now Pain at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Parent Study (A4091003 [NCT00545129]) Baseline in BPI-sf Score for Pain Interference With Function (Composite Score) Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Study A4091029 Baseline in BPI-sf Score for Pain Interference With Function (Composite Score) at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Parent Study (A4091003 [NCT00545129]) Baseline in BPI-sf Item Scores for Pain Interference at Weeks 4, 8, 16, 24, 40, 48, 56 and 64|Change From Study A4091029 Baseline in BPI-sf Item Scores for Pain Interference at Weeks 4, 8, 16, 24, 40, 48, 56 and 64","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","A4091029|2008-005182-66|CANCER PAIN OL EXTENSION","October 29, 2009","February 14, 2013","February 14, 2013","January 27, 2009","February 2, 2021","April 5, 2021","UCSD Center for Pain Medicine, La Jolla, California, United States|UCSD Medical Center - Thornton Hospital, La Jolla, California, United States|UCSD Periman Ambulatory Care Center, La Jolla, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|WK River Cities Clinical Research Center, Shreveport, Louisiana, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Nuhr Zentrum, Senftenberg, Austria|Clinic of Oncology, Banja Luka, Bosnia and Herzegovina|General Hospital Varazdin, Varazdin, Croatia|Fejer Megyei Szt. Gyorgy Korhaz - Rendelointezet/Aneszteziologiai es Intenziv Betegellato Osztaly, Szekesfehervar, Hungary|Central India Cancer Research Institute Central India Cancer Research Institute, Nagpur, Maharashtra, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, India|Severance Hospital, Yonsei University College of Medicine, Seodaemun-gu, Seoul, Korea, Republic of|Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul, Korea, Republic of|Latvian Oncology Centre, Riga, Latvia|Niepubliczny Zaklad Opieki Zdrowotnej, Bydgoszcz, Poland|Hospicjum im Ks Eugeniusza Dutkiewicza SAC w Gdansku, Gdansk, Poland|**Poradnia Medycyny Paliatywnej, Hospicjum Palium, Poznan, Poland|Wielkopolskie Centrum Onkologii im. Marii Sklodowskiej-Curie, Poznan, Poland|NZOZ Zespol Opieki Domowej Polskiego Towarzystwa Opieki Paliatywnej, Wloclawek, Poland|Fakultna Nemocina s Poliklinikou FD Roosevelta Banska Bystrica, Banska Bystrica, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia",,"https://ClinicalTrials.gov/show/NCT00830180"
362,"NCT01204749","TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer",,"Completed","No Results Available","Fallopian Tube Cancer|Ovarian Cancer|Primary Peritoneal Cancer","Drug: AMG 386|Drug: AMG 386 Placebo|Drug: Paclitaxel","Progression-Free Survival|Overall survival|Objective Response Rate|Duration of response|CA-125 response rate per Gynecologic Cancer Intergroup (GCIG) and change in CA-125|Incidence of adverse events and significant laboratory abnormalities|Pharmacokinetics of AMG 386 (Cmax and Cmin)|Incidence of the occurrence of anti-AMG 386 antibody formation|Patient reported Health Related Quality of Life (HRQOL) and ovarian cancer related symptoms using Functional Assessment of Cancer Therapy - Ovary questionnaire (FACT-O)|Overall health status using EuroQOL(EQ-5D)","Amgen","Female","18 Years and older   (Adult, Older Adult)","Phase 3","919","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090508","November 2010","March 2013","December 2016","September 17, 2010",,"December 15, 2016","Research Site, Phoenix, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, San Diego, California, United States|Research Site, Stanford, California, United States|Research Site, Englewood, Colorado, United States|Research Site, Danbury, Connecticut, United States|Research Site, New Haven, Connecticut, United States|Research Site, Hollywood, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Boise, Idaho, United States|Research Site, Peoria, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Brightwaters, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston Salem, North Carolina, United States|Research Site, Abington, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Tacoma, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, New Lambton Heights, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Bendigo, Victoria, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Footscray, Victoria, Australia|Research Site, Malvern, Victoria, Australia|Research Site, Parkville, Victoria, Australia|Research Site, Edegem, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, Porto Alegre, Rio Grande do Sul, Brazil|Research Site, ItajaÃ-, Santa Catarina, Brazil|Research Site, Ribeirao Preto, SÃ£o Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, SÃ£o Paulo, Brazil|Research Site, Gabrovo, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Temuco, CautÃ-n, Chile|Research Site, Valparaiso, ValparaÃ-so, Chile|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Brno, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Amiens, France|Research Site, Angers, France|Research Site, Avignon Cedex 2, France|Research Site, Bayonne, France|Research Site, Besancon Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Bordeaux Cedex, France|Research Site, Brest Cedex 2, France|Research Site, Dijon, France|Research Site, Le Mans, France|Research Site, Lille Cedex, France|Research Site, Lyon, France|Research Site, Marseille cedex 05, France|Research Site, Marseille Cedex 09, France|Research Site, Marseille, France|Research Site, Montpellier Cedex 5, France|Research Site, Nancy, France|Research Site, Nantes Cedex 2, France|Research Site, Nice cedex 2, France|Research Site, OrlÃ©ans cedex 2, France|Research Site, Paris cedex 15, France|Research Site, PÃ©rigueux cedex, France|Research Site, Reims Cedex, France|Research Site, Saint GrÃ©goire cedex, France|Research Site, Saint Herblain, France|Research Site, Strasbourg, France|Research Site, Villejuif cedex, France|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Kefar Sava, Israel|Research Site, Tel Hashomer, Israel|Research Site, Tel-Aviv, Israel|Research Site, Benevento, Italy|Research Site, Catania, Italy|Research Site, Cosenza (CS), Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Potenza, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Nagoya-city, Aichi, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Kure-city, Hiroshima, Japan|Research Site, Sapporo-city, Hokkaido, Japan|Research Site, Tsukuba-city, Ibaraki, Japan|Research Site, Morioka-city, Iwate, Japan|Research Site, Niigata-city, Niigata, Japan|Research Site, Osakasayama-city, Osaka, Japan|Research Site, Hidaka-Shi, Saitama, Japan|Research Site, Suntou-gun, Shizuoka, Japan|Research Site, Chuo-ku, Tokyo, Japan|Research Site, Yonago-city, Tottori, Japan|Research Site, Kurume-city, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Johor Bahru, Johor, Malaysia|Research Site, Kota Bahru, Kelantan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, San Luis Potosi, San Luis PotosÃ-, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Gdansk, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Coimbra, Portugal|Research Site, Guimaraes, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Bucharest, Romania|Research Site, Bucharest, Romania|Research Site, Cluj Napoca, Romania|Research Site, Suceava, Romania|Research Site, Targu Mures, Romania|Research Site, Ivanovo, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Ljubljana, Slovenia|Research Site, Groenkloof, Gauteng, South Africa|Research Site, Johannesburg, Gauteng, South Africa|Research Site, Kraaifontein, Western Cape, South Africa|Research Site, Observatory, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, CÃ³rdoba, AndalucÃ-a, Spain|Research Site, Huelva, AndalucÃ-a, Spain|Research Site, MÃ¡laga, AndalucÃ-a, Spain|Research Site, Sevilla, AndalucÃ-a, Spain|Research Site, Palma de Mallorca, Baleares, Spain|Research Site, Salamanca, Castilla LeÃ³n, Spain|Research Site, Badalona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Elche, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Santiago de Compostela, Galicia, Spain|Research Site, Vigo, Galicia, Spain|Research Site, San SebastiÃ¡n, PaÃ-s Vasco, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, UmeÃ¥, Sweden|Research Site, Uppsala, Sweden|Research Site, Baden, Switzerland|Research Site, Bellinzona, Switzerland|Research Site, Chur, Switzerland|Research Site, Geneva 14, Switzerland|Research Site, Zurich, Switzerland|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Poole, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01204749"
363,"NCT00235898","Clinical Trial in Patients With Metastatic Colorectal Cancer",,"Completed","No Results Available","Colon Cancer|Rectal Cancer","Drug: CoFactor|Drug: 5-FU|Drug: Leucovorin",,"Mast Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","03-CoFactor","May 2005","March 2008",,"October 12, 2005",,"August 25, 2008","Global Hospital, Hyderabad, Andhra Pradesh, India|Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|Kasturba Medical College, Mangalore, Attavar, India|Department of Medical Oncology, Deenanath Mangeshkar Hospital and Research Centre, Pune, Erandawane, India|Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Department of Oncology, Christian Medical College, Vellore, Tamil Nadu, India|Manipal Hospital, Bangalore, India|SMS Medical College Hospital, Jaipur, India|Department of Medical Oncology, Dayanad Medical College and Hospital, Ludhiana, India|Department of Medical Oncology, Jaslok Hospital and Research Centre, Mumbai, India|Colorectal Cancer Clinic, Centrum Cancer Clinic Onkologii-Instytut im M. Skladowskiej-Curie, Roentgena, Warszawa, Poland|Department and Clinic for Oncology and Radiotherapy, Gdansk, Poland|Department for Oncology and Radiotherapy, Szpital Morski im. PCK, Gdynia Redlowo, Poland|Oncological Chemotherapy Clinic, Regionalny Osrodek Onkologiczny, Lodz, Poland|Oncological Chemotherapy Department Centrum Onkologii Ziemi, Lublin, Poland|Clinical Oncology Department, Wojewodski Szpital Zespolony, Torun, Poland|Gastroenterology and Hepatology Department, Fundeni Clinical Institute, Bucharest, Romania|Professor of Dr. Alexandru Trestioreanu, Institute of Oncology II, Bucharest, Romania|Department of Medical Oncology and Radiotherapy II, Cluj-Napoca, Romania|Medical Oncology Department, County Hospital Sibiu, Sibiu, Romania|Clinical Center of Serbia, Belgrade, Serbia|Institute of Oncology and Radiology Serbia, Belgrade, Serbia|CHC Bezanijska, Belgrade, Serbia|CHC Kragujevac, Kragujevac, Serbia|Clinic Centre Nis, Nis, Serbia|Clinic for Internal Medicine, Institute for Oncology Sremska, Sremska Kamenica, Serbia|General Hospital Djordje Joanovic, Zrenjanin, Serbia|Haematology/Lung/GI Cancer Services, Harlow, Essex, United Kingdom|Oncology Research, North Middlesex University Hospital, Middlesex, London, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00235898"
364,"NCT02365597","An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer",,"Recruiting","No Results Available","Urothelial Cancer","Drug: Erdafitinib|Drug: Midazolam|Drug: Metformin","Percentage of Participants with Best Overall Response|Progression-free survival|Duration of Response|Overall survival|Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Biomarker Assessment|Plasma Concentration of Erdafitinib|Plasma Clearance of Erdafitinib|Volume of Distribution of Erdafitinib|Plasma Concentration of Midazolam and its Metabolite (1-OH-midazolam)|Plasma Concentration of Metformin","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","236","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR105065|42756493BLC2001|2014-002408-26","April 22, 2015","June 30, 2022","June 30, 2022","February 19, 2015",,"April 27, 2022","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Arizona Oncology Associates, PC - NAHOA, Sedona, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|Marin Cancer Care Inc., Greenbrae, California, United States|Cedars Sinai Medical Center - Pediatric Infectious Disease, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|University of California Irvine, Orange, California, United States|University of California - Davis Medical Center, Sacramento, California, United States|Stanford University Medical Center, Stanford, California, United States|Rocky Mountain Cancer Center, Aurora, Colorado, United States|Georgetown Univ. Medical Center - Lombardi Cancer Center, Washington, District of Columbia, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|The University of Iowa - Division of Hematology, Oncology and Blood & Marrow Transplantation, Iowa City, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Univ of Michigan Medical Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute - Wayne State University, Detroit, Michigan, United States|Minnesota Oncology, Minneapolis, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Weill Medical College of Cornell University, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Hematology Oncology Associates, PC, Medford, Oregon, United States|Northwest Cancer Specialists PC, Tualatin, Oregon, United States|Penn State Milton S. Hershey Medical Ctr., Hershey, Pennsylvania, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|SCRI - Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology-Dallas Presbyterian Hospital, Dallas, Texas, United States|Texas Oncology - Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Texas Oncology-Denton South, Denton, Texas, United States|Texas Oncology-Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Virginia Oncology Associates, Hampton, Virginia, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|LKH-Univ. Klinikum Graz, Graz, Austria|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Krankenhaus der Barmherzigen Brüder, Vienna, Austria|Medical University Vienna, Vienna, Austria|O.L.V. Ziekenhuis, Aalst, Belgium|Cliniques Universitaires Saint Luc, Brussel, Belgium|Clinique Notre Dame, Charleroi, Belgium|U.Z. Gent, Gent, Belgium|GZA Ziekenhuizen- Campus St Augustinus, Wilrijk, Belgium|ICO, Site Paul Papin, ANGERS Cedex, France|Institut Bergonié, Bordeaux, France|Centre Francois Baclesse, Caen Cédex 05, France|Centre Georges-François Leclerc, Dijon, France|Centre Leon Bérard, Lyon, France|APHM Hopital Timone, Marseille, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Institut de Cancérologie du Gard, Nîmes, France|Hospital Saint-Louis, Paris Cedex 10, France|Hopital Europeen Georges-Pompidou, Paris Cedex 15, France|I.C.O. René Gauducheau, Saint Herblain Cedex, France|Hopital Foch, Suresnes, France|Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse cedex 09, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France|Gustave Roussy, Villejuif Cedex, France|Vivantes Klinikum Am Urban, Abt. fur Kardiologie, Berlin, Germany|Waldkrankenhaus St. Marien -Urologische Universitätsklinik-, Erlangen, Germany|Kliniken Essen-Mitte; Evangelische Huyssens-Stiftung, Essen, Germany|Goethe Universität Frankfurt, Frankfurt, Germany|Universitatsklinikum Freiburg, Freiburg, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Georg-August-Universitaet Goettingen - Innere Medizin - Haematologie, Onkologie, Göttingen, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover;Klinik f. Urologie u. Urologische Onkologie, Hannover, Germany|University Hospital Heidelberg, Heidelberg, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Germany|University hospital Muenster, Dpt. of Urology, Muenster, Germany|Caritas Krankenhaus St. Josef - Innere Medizin II, Regensburg, Germany|Klinikum St. Elisabeth, Straubing, Germany|Kliniken Nordoberpfalz, Klinik für Urologie, Weiden/Opf, Germany|Health Care Global Enterprises pvt Ltd, Bangalore, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai, India|Netaji Subhas chandra Bose Cancer Research Institute, Kolkata, India|Bhaktivedanta Hospital & Research Institute, Mira Road (East), India|Kokilaben Dhirubhai Ambani Hosp. & Med. Research Inst, Mumbai, India|Muljibhai Patel Urological Hospital, Nadiad, India|Soroka Medical Center, Beer Sheba, Israel|Asaf Harofe Medical Center, Beer Yaakov, Israel|Rambam Medical Center, Haifa, Israel|Meir Medical Center, Kfar-Saba, Israel|Rabin Medical Center - Bellins, Petah Tikva, Israel|Sourasky Medical Center, Tel Aviv Sourasky Med Ctr, Tel-Aviv, Israel|Unità Operativa di Oncologia Medica, Arezzo, Italy|Oncologia-IRCCS IRST, Meldola, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Oncologia Medica A - Ist Naz Tumori G Pascale, Napoli, Italy|Ospedale Maggiore della Carità, Novara, Italy|Oncologia Medica Azienda Sanitaria Ospedaliera San Luigi Gonzaga, Orbassano, Italy|Istituto Oncologico Veneto - IRCCS, Padova, Italy|Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma, Parma, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Azienda Ospedaliera San Camillo - Roma, Roma, Italy|UOC di Oncologia Medica Università Cattolica del Sacro Cuore Policlinico Universitario A. Gemelli, Roma, Italy|University Hospital Umberto I, Rome, Italy|Istituto Clinico Humanitas UO di Emodinamica e Cradiologia Interventistica, Rozzano, Italy|Oncologia Medica-Città Della Salute E Della Scienza Di Torino, Torino, Italy|Azienda Ospedaliero - Universitaria Ospedali Riuniti, Torrette Di Ancona, Italy|Chungnam National University Hospital - Dept. of Internal Medicine, Daejeon, Korea, Republic of|National Cancer Center, Goyangsi, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center (AMC), Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Arensia Exploratory Medicine, Chisinau, Moldova, Republic of|Spitalul Clinic de Urologie Prof. Dr. Theodor Burghele, Bucharest, Romania|Spitalul Clinic Sf. Maria, Bucharest, Romania|Institutul Clinic Fundeni, Bucuresti, Romania|Arensia Exploratory Medicine - Romania, Bucuresti, Romania|Institutul Oncologic ''Prof Dr. Ion Chiricuta'' Cluj-Napoca, Cluj-Napoca, Romania|ONCOLAB, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Spitalul Clinic Municipal De Urgenta Timisoara; Sectia Oncologie, Timisoara, Romania|Altai Regional Oncology Dispensary, Barnaul, Russian Federation|Cancer Research Center, Moscow N/a, Russian Federation|Scientific Research Institute of Urology, Moscow, Russian Federation|Hertzen Oncology Research Institute, Moscow, Russian Federation|Clinical Oncology Dispensary, Omsk, Russian Federation|Pyatigorsk Regional Oncology Dispensary, Pyatigorsk, Russian Federation|Leningradski Regional Oncological Dispensary, Saint-Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Sankt-Peterburg, Russian Federation|Bashkiria State Medical University, Ufa, Russian Federation|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hosp. Univ. de La Princesa, Madrid, Spain|Hospital U. Gregorio Marañón, Madrid, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hosp. Virgen de La Victoria, Málaga, Spain|Clinica Universitaria de Navarra, Pamplona, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Hosp. Clinico Univ. de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hosp. Clinico Univ. de Valencia, Valencia, Spain|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital- Linkou, Taoyuan, Taiwan|Hacettepe University Medical Faculty, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd, Istanbul, Turkey|Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Royal Blackburn Hospital, Blackburn, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Queens Hospital, Essex, United Kingdom|Charing Cross Hospital, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Marsden Hospital, Sutton, United Kingdom|Clatterbridge Centre for Oncology, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02365597"
365,"NCT00312377","ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer","ZODIAC","Completed","Has Results","Non-small Cell Lung Cancer|Lung Cancer","Drug: Docetaxel|Drug: Vandetanib","Progression-Free Survival (PFS) in the Overall Population|Progression-Free Survival (PFS) in the Female Population|Overall Survival (OS) in the Overall Population|Overall Survival (OS) in the Female Population|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Time to Deterioration of Disease-related Symptoms (TDS) by Functional Assessment of Cancer Therapy - Lung (FACT-L) Lung Cancer Subscale (LCS).|Time to Deterioration of Disease-related Symptoms (TDS) by FACT-L Pulmonary Symptom Index (PSI)","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","1690","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00032|6474IL/0032|2005-004749-32","May 2006","August 2008","March 2014","April 10, 2006","May 24, 2011","September 30, 2016","Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Ocala, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Joliet, Illinois, United States|Research Site, Park Ridge, Illinois, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, St. Louis, Missouri, United States|Research Site, Henderson, Nevada, United States|Research Site, Albany, New York, United States|Research Site, Armonk, New York, United States|Research Site, New York, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Vancouver, Washington, United States|Research Site, Bahía Blanca, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Mendoza, Argentina|Research Site, Rosario, Argentina|Research Site, Graz, Austria|Research Site, Grimmenstein, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wels, Austria|Research Site, Wien, Austria|Research Site, Brussels (Jette), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Edegem, Belgium|Research Site, Genk, Belgium|Research Site, Liege, Belgium|Research Site, Fortaleza, Brazil|Research Site, Goiânia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Wuhan, China|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Odense, Denmark|Research Site, Roskilde, Denmark|Research Site, Vejle, Denmark|Research Site, Bordeaux Cedex, France|Research Site, Boulogne Billancourt, France|Research Site, Caen Cedex, France|Research Site, Dijon, France|Research Site, Nancy, France|Research Site, Paris, France|Research Site, Pierre Benite Cedex, France|Research Site, Saint Herblain, France|Research Site, Bad Berka, Germany|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Großhansdorf, Germany|Research Site, Halle, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Oldenburg, Germany|Research Site, Ulm, Germany|Research Site, Wiesbaden, Germany|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Ahmedabad, India|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Jakarta Timur, Indonesia|Research Site, Yogyakarta, Indonesia|Research Site, Ancona, Italy|Research Site, Avellino, Italy|Research Site, Bologna, Italy|Research Site, Genova, Italy|Research Site, Mantova, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Reggio Emilia, Italy|Research Site, Akashi-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuoka, Japan|Research Site, Isehara-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Okazaki-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Toyonaka, Japan|Research Site, Ube-shi, Japan|Research Site, Utsunomiya-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Seoul, Korea, Republic of|Research Site, Kubang Kerian, Malaysia|Research Site, Nilai, Malaysia|Research Site, Penang, Malaysia|Research Site, Durango, Mexico|Research Site, Morelia, Mexico|Research Site, Toluca, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Den Bosch, Netherlands|Research Site, Groningen, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Coimbra, Portugal|Research Site, Funchal, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Singapore, Singapore|Research Site, A Coruña, Spain|Research Site, Alicante, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Zaragoza, Spain|Research Site, Chiang Mai, Thailand|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Hanoi city, Vietnam|Research Site, Ho Chi Minh city, Vietnam",,"https://ClinicalTrials.gov/show/NCT00312377"
366,"NCT01360554","ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer","ARCHER 1009","Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Dacomitinib (PF-00299804)|Drug: Active Comparator (erlotinib)|Drug: Placebo erlotinib|Drug: Placebo PF00299804","Progression-Free Survival (PFS) Per Independent Radiologic Review.|Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants.|PFS Based on Investigator Review.|PFS Based on Investigator Review in KRAS-WT Participants.|Overall Survival (OS).|OS in KRAS-WT Participants.|Best Overall Response (BOR) Per Independent Radiologic Review.|BOR Per Investigator Review.|Duration of Response (DR) Based on Independent Radiologic Review.|DR Based on Investigator Review.|Trough Concentrations (Ctrough) of Dacomitinib.|Trough Concentrations (Ctrough) of PF-05199265.|Time to Deterioration (TTD) in Pain, Dyspnea, Fatigue or Cough Patient Reported Disease Symptoms.|Mean and Difference in Mean in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Mean and Difference in Mean in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30.|Mean and Difference in Mean in Lung Cancer Symptom Scores as Assessed by the EORTC QLQ- LC13.|Mean and Difference in Mean of the EuroQoL-5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) Score","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","878","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A7471009|2010-022656-22","June 16, 2011","September 30, 2013","September 14, 2015","May 25, 2011","May 24, 2017","May 24, 2017","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Northwest Alabama Cancer Center, Florence, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|University of South Alabama Medical Center, Mobile, Alabama, United States|Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Ironwood physicians P C dba Ironwood Cancer & Research Centers, Chandler, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Gilbert, Arizona, United States|Desert Oncology Associates dba Ironwood Cancer and Research Centers, Mesa, Arizona, United States|Ironwood Physicians P.C. dba Ironwood Cancer and Research Centers, Mesa, Arizona, United States|Highlands Oncology Group PA, Fayetteville, Arkansas, United States|Highlands Oncology Group, PA, Rogers, Arkansas, United States|Central Hematology Oncology Medical Group Inc., Alhambra, California, United States|UCLA Hematology Oncology-Alhambra, Alhambra, California, United States|City of Hope, Duarte, California, United States|St. Jude Heritage Healthcare, Fullerton, California, United States|Drug Management Only, Los Angeles, California, United States|Drug Managerrent Only:, Los Angeles, California, United States|UCLA West Medical Pharmacy, Los Angeles, California, United States|Administrative Address: UCLA Hematology Oncology-Clinical Research Unit (CRU), Los Angeles, California, United States|Drug Shipment Address: Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States|Regulatory Management Only:, Los Angeles, California, United States|Regulatory Management:, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|TORI Central Administration, Los Angeles, California, United States|Westwood Bowyer Clinic, Peter Morton Medical Building, Los Angeles, California, United States|UCLA/Pasadena Healthcare Hematology-Oncology, Pasadena, California, United States|Central Hematology Oncology Medical Group, Inc., Pasadena, California, United States|Cancer Care Associates Medical Group Inc., Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Hematology Oncology-Parkside, Santa Monica, California, United States|UCLA Hematology Oncology-Santa Monica, Santa Monica, California, United States|UCLA Santa Monica Medical Center & Orthopedic Hospital, Santa Monica, California, United States|City of Hope South Pasadena Cancer Center, South Pasadena, California, United States|UCLA/Santa Clarita Valley Cancer Center, Valencia, California, United States|UCLA Cancer Center, Westlake Village, California, United States|Norwalk Hospital, Norwalk, Connecticut, United States|Florida Hospital, Orlando, Florida, United States|Cancer Institute of Florida, Orlando, Florida, United States|Hematology and Oncology Consultants, P.A., Orlando, Florida, United States|Investigational Drug Services, Florida Hospital, Orlando, Florida, United States|Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Austell, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Carrollton, Georgia, United States|Northwest Georgia Oncology Centers, PC, Cartersville, Georgia, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Atlanta Cancer Care, Decatur, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|The Cancer Center at DeKalb Medical, Decatur, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Douglasville, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Duluth, Georgia, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Oncology Specialists of North Georgia, LLC, Gainesville, Georgia, United States|The Longstreet Clinic Cancer Center, Gainesville, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Lawrenceville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Suburban Hematology-Oncology Associates, P.C., Snellville, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Ingalls Memorial Hospital - In-Patient Pharmacy, Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Monroe Medical Associates, Munster, Indiana, United States|Cedar Valley Medical Specialists, P.C., Waterloo, Iowa, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|University Medical Center, Inc., Louisville, Kentucky, United States|University Medical Center, Inc, Louisville, Kentucky, United States|Baptist Hospital East, Louisville, Kentucky, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Karmanos Cancer Institute at Farmington Hills, Farmington Hills, Michigan, United States|North Mississippi Hematology and Oncology Associates, Ltd., Starkville, Mississippi, United States|North Mississippi Hematology and Oncology Associates, Ltd.,, Tupelo, Mississippi, United States|Siteman Cancer Center-West County, Creve Coeur, Missouri, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine-IDS Pharmacy, Saint Louis, Missouri, United States|Siteman Cancer Center-St. Peters, Saint Peters, Missouri, United States|Dartmouth-Hitchcock Medical Center /Mary Hitchcock Memorial Hospital, Lebanon, New Hampshire, United States|Oncology and Hematology Specialists, P.A., Denville, New Jersey, United States|Stony Brook University-Cancer Center, Stony Brook, New York, United States|Carolina Oncology Specialists PA, Hickory, North Carolina, United States|Carolina Oncology Specialists PA, Lenoir, North Carolina, United States|Mercy clinic oklahoma communities, Inc. - Mercy clinic oncology/Hematology - Norman, Norman, Oklahoma, United States|Mercy Physicians of Oklahoma-Communities, Inc. - Mercy Clinic Oncology/Hematology - McAuley, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City - Oncology Infusion, Oklahoma City, Oklahoma, United States|Good Samaritan Hospital Samaritan Ambulatory Infusion Services, Corvallis, Oregon, United States|Samaritan Hematology & Oncology Consultants, Corvallis, Oregon, United States|Samaritan Pharmacy Services, Corvallis, Oregon, United States|Samaritan North Lincoln Hospital, Lincoln City, Oregon, United States|Samaritan Pacific Communities Hospital, Newport, Oregon, United States|Guthrie Clinic, Limited, Sayre, Pennsylvania, United States|Robert Packer Hospital, Sayre, Pennsylvania, United States|Texas Oncology-Longview Cancer Center, Longview, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Texas Oncology - Waco, Waco, Texas, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Kadlec Medical Center, Richland, Washington, United States|Outpatient Imaging Center, Richland, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Sozialmedizinisches Zentrum Baumgartner Hoehe - Otto Wagner Spital und Pflegezentrum, Vienna, Austria|Institut Jules Bordet, Brussels, Belgium|Laboratoire de la Porte de Hall, Brussels, Belgium|Grand Hopital de Charleroi Oncologie-Hematologie, Charleroi, Belgium|CHU Ambroise Parre- Service Biologie Clinique, Mons, Belgium|Heilig Hart Ziekenhuis Roeselare-Menen, Roeselare, Belgium|Tumour Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center, Wuhan, Hubei, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Shanghai Pulmonary Hospital, Shanghai, China|Aalborg Sygehus Syd, Aalborg, Denmark|Helsingin yliopistollinen sairaala, Meilahden kolmiosairaala, keuhkosairauksien poliklinikka, Helsinki, Finland|Satakunnan keskussairaala/Keuhkosairauksien osasto A4, Pori, Finland|Centre Georges Francois Leclerc, Dijon, France|Hopital Albert Michallon, Grenoble cedex 09, France|Hôpital Paris Saint Joseph, Paris, France|CHU de Poitiers, Poitiers Cedex, France|Institut de Cancerologie de lOuest - Rene Gauducheau, Saint Herblain cedex, France|Universitaetsklinikum Aachen, Aachen, Germany|Asklepios Fachkliniken Muenchen-Gauting, Gauting, Germany|Lungenfachklinik Immenhausen, Immenhausen, Germany|Universitaetsmedizin der Johannes Gutenberg-Universitaet, Mainz, Germany|Krankenhaus Bethanien, Medizinische Klinik III, Moers, Germany|University Hospital of Larissa, Larissa, Thessaly, Greece|Sotiria General Hospital of Athens, Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|Semmelweis Egyetem Pulmonologiai Klinika, Budapest, Hungary|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Debrecen, Hungary|Veszprem Megyei Onkormanyzat Tudogyogyintezete, Farkasgyepu, Hungary|Pandy Kalman Megyei Korhaz, Aktiv Tudogyogyaszat, Gyula, Hungary|Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft., Nyiregyhaza, Hungary|Zala Megyei Korhaz, Pulmonologiai Osztaly, Zalaegerszeg-Pozva, Hungary|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Manipal Hospital, Bangalore, Karnataka, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharastra, India|St Vincent's University Hospital, Dublin, Leinster, Ireland|Beaumont Hospital, Dublin, Leinster, Ireland|St. James Hospital, Dublin, Ireland|Oncology Department, Waterford, Ireland|Aichi cancer center central hospital /Thoracic Oncology, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama-city, Ehime, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kanazawa University Hospital, Kanazawa city, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, Japan|Okayama University Hospital, Okayama-city, Okayama, Japan|National Hospital Organization Kinki-chuo Chest Medical Center, Sakai-Shi, Osaka-fu, Japan|Osaka City General Hospital Department of Clinical Oncology, Osaka-city, Osaka, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube-shi, Yamaguchi, Japan|National Hp. Org. Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center/Department of Thoracic Oncology, Fukuoka, Japan|Kyushu University Hospital Respiratory Medicine, Fukuoka, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Clinical Trial Center, Seoul, Korea, Republic of|Asan Medical Center, Department of Oncology, Seoul, Korea, Republic of|Oaxaca Site Management Organization, Oaxaca, Mexico|Mazowieckie Centrum Leczenia Chorob Pluc i Gruzlicy, Otwock, Mazowieckie, Poland|Zoz All-Medi, Otwock, Mazowieckie, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warsaw, Mazowieckie, Poland|Nukleomed, Warsaw, Mazowieckie, Poland|City Hospital #2 Krasnodar Multi-Field Diagnostic and Treatment Association, Krasnodar, Krasnodarskij Kraj, Russian Federation|Oncology Center # 2, Sochi, Krasnodarskij Kraj, Russian Federation|Federal State Healthcare Clinical Hospital #101 of the Federal Biomedical Agency, Pyatigorsk, Stavropolskij Kraj, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation|Clinic of Hospital Surgery, Saint-Petersburg, Russian Federation|Military Medical Academy n.a. S.M.Kirov, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|St.-Petersburg State Medical University I.P.Pavlov of Roszdrav, Saint-Petersburg, Russian Federation|Research Institute of Pulmonology, Saint-Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|Univerzitna Nemocnica Bratislava, Klinika pneumologie a ftizeologie I- Oddelenie klinickej onkologie, Bratislava, Slovakia|Specializovana nemocnica sv. Svorada Zobor, n.o., Nitra, Slovakia|Fakultna nemocnica s poliklinikou, Nove Zamky, Slovakia|WCR: Wits Clinical Research, Parktown,Johannesburg, Gauteng, South Africa|GVI Oncology Clinical Research Unit, Kraaifontein, Western Cape, South Africa|Department of Oncotherapy, Bloemfontein, South Africa|GVI Oncology, Port Elizabeth, South Africa|Hospital General Universitario de Elche - Edificio UIAE, Elche, Alicante, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Provincial de Castellon - Servicio de Oncologia, Castellón, Castellon, Spain|HOSPITAL DE LA SANTA CREU I SANT PAU - Pharmacy, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - AGDAC, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Anatomia Patológica, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Diagnostic per la Imatge i Med. Nuclear, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau - Hospital de Día, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Provincial de Castellon (Farmacia), Castellon, Spain|Hospital Universitario 12 de Octubre-Radiology, Madrid, Spain|Hospital Universitario 12 de Octubre01, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Virgen del Rocio. Hospital General Planta Baja. Servicio de Oncologia., Sevilla, Spain|KPE/Onkologikliniken, Karlstad, Sweden|Karolinska Universitetssjukhuset, Stockholm, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland|Hopitaux Universitaires de Geneve, Geneve 14, Switzerland|Ospedale Regionale di Locarno La Carita, Locarno, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Kent Oncology Centre, Maidstone, Kent, United Kingdom|New Cross Hospital - Royal Wolverhampton Hospital NHS Trust, Wolverhampton, West Midlands, United Kingdom|North Middlesex NHS Trust, Edmonton, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Cancer Clinical Trials Unit, London, United Kingdom|Christie Hospital NHS Trust, Department of Medical Oncology, Manchester, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom|Lung and Melanoma Research Team, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01360554"
367,"NCT01424566","A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer",,"Completed","Has Results","Pain|Advanced Cancer","Drug: Nabiximols|Drug: Placebo (GA-0034)","Change From Randomization Baseline In Mean NRS Average Pain At End Of Treatment|Percent Improvement From Eligibility Baseline In Mean NRS Average Pain Score At End Of Treatment|Change From Randomization Baseline In Mean NRS Worst Pain At End Of Treatment|Change From Randomization Baseline In Mean Sleep Disruption NRS At End Of Treatment|Subject Global Impression Of Change At Last Visit (Up To Day 36 Of The Double-blind Period)|Physician Global Impression Of Change At Last Visit (Up To Day 36 Of The Double-blind Period)|Patient Satisfaction Questionnaire At Last Visit (Up To Day 36 Of The Double-blind Period)|Change From Randomization Baseline In Daily Total Opioid Use (Morphine Equivalent) At End Of Treatment|Change From Randomization Baseline In Daily Maintenance Opioid Dose (Morphine Equivalent) At End Of Treatment|Change From Randomization Baseline In Daily Break-through Opioid Dose (Morphine Equivalent) At End Of Treatment|Change From Randomization Baseline In NRS Constipation At Last Visit (Up To Day 36 Of The Double-blind Period)","Jazz Pharmaceuticals|Otsuka Pharmaceutical Development & Commercialization, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","406","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GWCA1103|2010-022905-17","June 29, 2012","July 10, 2015","December 28, 2015","August 29, 2011","April 23, 2018","April 23, 2018","East Melbourne, Australia|Parkville, Australia|Shumen, Bulgaria|Varna, Bulgaria|Vratsa, Bulgaria|Lunen, Germany|Stadtroda, Germany|Wetzlar, Germany|Budapest, Hungary|Deszk, Hungary|Komárom, Hungary|Nyíregyháza, Hungary|Szikszó, Hungary|Bangalore, India|Jaipur, India|Pune, India|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Ramat Gan, Israel|Zerifin, Israel|Garbagnate Milanese, Italy|Piacenza, Italy|Torino, Italy|Klaipeda, Lithuania|Siauliai, Lithuania|Vilnius, Lithuania|Bydgoszcz, Poland|Czeladź, Poland|Gdansk, Poland|Gliwice, Poland|Klodzko, Poland|Opole, Poland|Ostrowiec Swietokrzyski, Poland|Poznan, Poland|Warszawa, Poland|Warszawa, Poland|Wloclawek, Poland|Alba Iulia, Romania|Baia Mare, Romania|Braila, Romania|Bucuresti, Romania|Focșani, Romania|Oradea, Romania|Satu Mare, Romania|Sibiu, Romania|Suceava, Romania|Cadiz, Spain|Granada, Spain|Madrid, Spain|Salamanca, Spain|Sevilla, Spain|Changhua City, Taiwan|Taichung, Taiwan|Tainan City, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Bury Saint Edmunds, United Kingdom|Edinburgh, United Kingdom|Glasgow, United Kingdom|Manchester, United Kingdom|Norwich, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01424566"
368,"NCT00089999","Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer",,"Completed","Has Results","Neoplasms, Breast","Drug: Lapatinib","Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee (IRC)|Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Investigator|Percentage of Participants With Clinical Benefit (CR or PR or Stable Disease [SD] for at Least 24 Weeks), as Assessed by the IRC and Investigator|Time to Response, as Assessed by the IRC and Investigator|Duration of Response (DoR), as Assessed by the IRC and Investigator|Progression-free Survival, as Assessed by the IRC and Investigator|Time to Treatment Failure, as Assessed by IRC and Investigator|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)","GlaxoSmithKline","Female","18 Years and older   (Adult, Older Adult)","Phase 2","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EGF20009","June 2004","March 2008","March 2008","August 23, 2004","August 29, 2014","February 28, 2017","GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Delhi, India|GSK Investigational Site, Hyderabad, Andhra Pradesh, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Bandar Tun Razak, Cheras, Malaysia|GSK Investigational Site, Kubang Kerian, Malaysia|GSK Investigational Site, Tanjong Bungah, Malaysia|GSK Investigational Site, Tanjong Bungah, Malaysia|GSK Investigational Site, Ixtaltepec / Espinal, Oaxaca, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Mexico, Mexico|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Rawalpindi, Pakistan|GSK Investigational Site, Callao, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Bydogoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT00089999"
369,"NCT01457846","Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer","SHINE","Terminated","Has Results","Gastro-oesophageal Junction Cancer|Gastric Cancer","Drug: AZD4547|Drug: paclitaxel","Median Progression Free Survival|Overall Survival : Number of Patients Who Had Died at DCO (Data Cut Off)|Objective Response Rate|Percentage Change From Baseline at Week 8 in Target Lesion Size|Percentage of Patients Without Progressive Disease at 8 Weeks","AstraZeneca","All","25 Years to 130 Years   (Adult, Older Adult)","Phase 2","960","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D2610C00004","November 2011","August 2013","February 2015","October 24, 2011","March 7, 2017","March 7, 2017","Research Site, Brussels (Anderlecht), Belgium|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Leuven, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Fredericton, New Brunswick, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Brno, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Saint Cloud, France|Research Site, Villejuif, France|Research Site, Hamburg, Germany|Research Site, Mainz, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Hyderabad, India|Research Site, Nagpur, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Ancona, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Anyang-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Jeonju-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Brasov, Romania|Research Site, Cluj Napoca, Romania|Research Site, A Coruña, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Keelung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Kharkiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Aberdeen, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01457846"
370,"NCT01763645","A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer",,"Completed","Has Results","Non-small Cell Lung Cancer","Drug: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin","Overall Response Rate|Area Under the Curve After the First Test Drug Administration|Complete Response Rate|Partial Response Rate|Stabilization Rate|Progression Rate|Occurrence of Anti-bevacizumab Antibodies","Biocad","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","138","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BCD-021-02","October 2012","November 2014","November 2014","January 9, 2013","October 24, 2016","March 30, 2018","Brest Regional Clinical Dispensary, Brest, Belarus|Gomel Regional Clinical Oncology Dispensary, Gomel, Belarus|Grodno Regional Clinical Hospital, Grodno, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|HCG Bangalore Institute of Oncology, Bangalore, India|M.S.Ramaiah Memorial Hospital, Bangalore, India|Narayana Hrudayalaya Hospitals, Bangalore, India|Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Non-governmental Healthcare Institution ""Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"", Chelyabinsk, Russian Federation|State-financed Health Institution ""Chelyabinsk Region Clinical Oncology Dispansary"", Chelyabinsk, Russian Federation|State Healthcare Facility ""Kursk Regional Oncology Dispensary"", Kursk, Russian Federation|State Health Institution of Moscow ""Moscow City Oncology Hospital #62 of Moscow Board of Health"", Moscow Region, Russian Federation|Institution of Russian Academy of Medical Sciences ""Russian Cancer Research Center named after N.N. Blokhin"", Moscow, Russian Federation|Federal State Institution ""Moscow Institute of Cancer Research named after P.A. Hertsen"" Ministry of Health of Russian Federation, Moscow, Russian Federation|Murmansk Regional Oncology Dispensary, Murmansk, Russian Federation|Nizhny Novgorod Region State Budgetary Healthcare Facility ""Clinical Diagnostics Center"", Nizhny Novgorod, Russian Federation|State Healthcare Facility ""Nizhny Novgorod Regional Oncology Dispensary"", Nizhny Novgorod, Russian Federation|City Clinical Hospital №1, Novosibirsk, Russian Federation|Regional State Health Institution ""Orlov Oncology Dispansary"", Orel, Russian Federation|State Health Institution ""Region Oncology Dispansary"", Penza, Russian Federation|Perm Region Oncology Dispensary, Perm, Russian Federation|Federal Government Budgetary Institution ""Rostov Institute of Cancer Research"" of Ministry of Health of Russian Federation, Rostov-on-Don, Russian Federation|Saint Petersburg City Clinical Oncology Center, Saint Petersburg, Russian Federation|State-financed Health Institution ""Samara Region Clinical Oncology Dispansary"", Samara, Russian Federation|Oncology Dispensary 2, Sochi, Russian Federation|St. Petersburg State Medical University n.a. I. P. Pavlov, St. Petersburg, Russian Federation|St. Petersburg Research and Practice Center for Secondary Care in Oncology, St. Petersburg, Russian Federation|N.N.Petrov Oncology Research Center, St.Petersburg, Russian Federation|Military Medical Academy named after S.M. Kirov, St.Petersburg, Russian Federation|Russian scientific center of radiology and surgery technologies, St.Petersburg, Russian Federation|State-financed Health Institution ""Stavropol Region Clinical Oncology Dispansary"", Stavropol, Russian Federation|Volgograd District Oncology Dispensary №1, Volgograd, Russian Federation|Volgograd Regional Oncology Dispensary №3, Volgograd, Russian Federation|State Health Institution ""Voronezh Region Clinical Oncology Dispansary"", Voronezh, Russian Federation|Donetsk City Oncology Dispensary, Donetsk, Ukraine|Donetsk Regional Antitumor Center, Donetsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Kryvyi Rih Oncology Dispensary, Kryvyi Rih, Ukraine|Lviv State Regional Cancer Diagnostic and Treatment Center, Lviv, Ukraine|City Hospital № 2, Makiivka, Ukraine|Poltava Regional Clinical Oncology Dispensary, Poltava, Ukraine|Zakarpatskyi Clinical Oncology Dispensary, Uzhhorod, Ukraine|Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsia, Ukraine|Zaporizhia Regional Clinical Oncology Dispensary, Zaporizhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01763645"
371,"NCT00630110","Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Cancer","Drug: docetaxel|Drug: NPI-2358 + docetaxel","Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358|Compare response rate, duration of response, 6-month survival, progression free survival and safety.|Pharmacokinetics","Nereus Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","172","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NPI-2358-101","February 2008","June 2011","June 2011","March 6, 2008",,"August 16, 2011","Mayo Clinic, Scottsdale, Arizona, United States|San Diego Pacific Oncology & Hematology Associates, Encinitas, California, United States|University San Diego Moores Cancer Center, San Diego, California, United States|Kaiser Permanente, San Diego, California, United States|Premiere Oncology, Santa Monica, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University Texas Health Science Center at San Antonio (CTRC), San Antonio, Texas, United States|Policlinica Privada Instituto de Medicina Nuclear, Bahia Blanca, Argentina|Hospital Britanico, Capital Federal, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Universitaria Privada Reina Fabiola, Cordoba, Argentina|Caici Centro de Asistencia e Investigacion Clinica Integral, Rosario, Argentina|Hospital del Centrenario, Rosario, Argentina|Mater Adult Hospital, South Brisbane, Queensland, Australia|Bendigo Health Care Group, Bendigo, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Fundacap Pip XII Hospital do Cancer de Barretos, Barretos, Brazil|Hospital Erasto Gaertner Liga do Combate as Cancer, Curitiba, Brazil|Associacao Hospital de Caridade Ijui, Ijui, Brazil|Hospital Sao Lucas, Porte Alegre, Brazil|Hospital de clinicas de Porto Alegre, Porto Alegre, Brazil|Clinionco-Clinica de Oncologia de Porto Alegre, Porto Alegre, Brazil|Hosp.das Clinicas da Univ.de Sao Paulo, Sao Paulo, Brazil|Instituto do Cancer Aenaldo Vieira de Carvahlo, Sao Paulo, Brazil|Instituto Nacional del Cancer Oncology, Santiago, Chile|Hospital Carlos Van Buren, Valparaiso, Chile|Chittaranjan National Cancer Institute, Kolkata, W. Bengal, India|Kidwai Memorial Institute of Oncology, Bangalore, India|Apollo Speciality Hospital, Chennai, India|Apollo Hospital, Hyderabad, India|SEAROC Cancer Centre S.K. Soni Hospital, Jaipur, India|Subodh Mitra Cancer Hospital & Research Centre, Kolkata, India|Tata Memorial Hospital, Mumbai, India|Ruby Hall Clinic, Pune, India|Andhra Medical College, Vishakhapatnam, India",,"https://ClinicalTrials.gov/show/NCT00630110"
372,"NCT04821622","Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC",,"Recruiting","No Results Available","Prostate Cancer","Drug: talazoparib plus enzalutamide|Drug: Placebo plus enzalutamide","radiological Progression-Free Survival|Overall Survival|Objective response in measurable soft tissue disease|Duration of response in measurable soft tissue disease|Prostate Specific Antigen (PSA) response|Time to PSA progression|Time to initiation of antineoplastic therapy|Time to first symptomatic skeletal event|Opiate use for prostate cancer pain|Incidence of adverse events|Pharmacokinetic assessment of talazoparib|Pharmacokinetic assessment of enzalutamide and its metabolite|Relationship between ctDNA burden and outcome|Patient-reported outcomes in pain symptoms - change from baseline|Patient-reported outcomes in pain symptoms - time to deterioration|Patient-reported outcomes in cancer specific general health status - change from baseline|Patient-reported outcomes in cancer specific global health status/QoL - change from baseline|Patient-reported outcomes in cancer specific global health status/QoL - time to definitive deterioration|Patient-reported outcomes in cancer specific symptoms - time to definitive deterioration|Patient-reported outcome: cancer specific functioning, and symptoms - change from baseline","Pfizer|Astellas Pharma Inc","Male","18 Years and older   (Adult, Older Adult)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C3441052|TALAPRO-3|2021-000248-23","May 12, 2021","December 11, 2024","April 10, 2027","March 29, 2021",,"May 16, 2022","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Institute of Urology, PLLC, Tucson, Arizona, United States|Arkansas Urology, Little Rock, Arkansas, United States|Arkansas Urology Research Clinic, Sherwood, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Adventist Health Glendale, Glendale, California, United States|VA Long Beach Healthcare System, Long Beach, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States|AdventHealth Medical Group Hematology and Oncology, Orlando, Florida, United States|Investigational Drug Services, Advent Health Orlando, Orlando, Florida, United States|Investigational Drug Services, Orlando, Florida, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Austell, Georgia, United States|Wellstar Cobb Hospital, Austell, Georgia, United States|Northwest Georgia Oncology Centers, a Service of Tanner Medical Center Villa Rica, Carrollton, Georgia, United States|West Georgia Infusion Center, a Service of Tanner Medical Center Villa Rica, Carrollton, Georgia, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Cartersville, Georgia, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Douglasville, Georgia, United States|Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital, Marietta, Georgia, United States|Comprehensive Urologic Care, SC, Lake Barrington, Illinois, United States|Mid-Illinois Hematology & Oncology Associates, Ltd, Normal, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|Revive Research Institute, Inc., Farmington Hills, Michigan, United States|Revive Research Institute Inc., Sterling Heights, Michigan, United States|David C. Pratt Cancer Center, Saint Louis, Missouri, United States|New Jersey Cancer Care, P.A., Belleville, New Jersey, United States|Premier Medical Group of the Hudson Valley PC, Poughkeepsie, New York, United States|Clinical Research Solutions, Middleburg Heights, Ohio, United States|Providence Cancer Institute Clackamas Clinic, Clackamas, Oregon, United States|Providence Cancer Institute Newberg Clinic, Newberg, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Cancer Institute Franz Clinic, Portland, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence Oncology and Hematology Care Clinic - Westside, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Keystone Urology Specialists, Lancaster, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Parkway Surgery Center, Myrtle Beach, South Carolina, United States|Bristol Regional Medical Center, Bristol, Tennessee, United States|Ballad Health Cancer Care - Kingsport, Kingsport, Tennessee, United States|Holston Valley Hospital and Medical Center, Kingsport, Tennessee, United States|Indian Path Community Hospital, Kingsport, Tennessee, United States|Urology Clinics of North Texas, Dallas, Texas, United States|Kelsey Research Foundation, Houston, Texas, United States|Oncology Consultants, P.A., Houston, Texas, United States|oncology Consultants, P.A., Houston, Texas, United States|Kelsey-Seybold Clinic, Houston, Texas, United States|Houston Metro Urology, Houston, Texas, United States|Oncology Consultants P.A., Houston, Texas, United States|Urology San Antonio, San Antonio, Texas, United States|Texas Oncology-Deke Slayton Cancer Center, Webster, Texas, United States|Huntsman Cancer Institute - University of Utah, Salt Lake City, Utah, United States|COIBA, Berazategui, Buenos Aires, Argentina|Centro de Investigacion Pergamino SA - Clinica Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro de Investigaciones Clínicas - Clínica Viedma, Viedma, RÍO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Oncologico Korben, Caba, Argentina|Instituto Médico Especializado Alexander Fleming, Caba, Argentina|Centro Medico Privado CEMAIC, Córdoba, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Southern Medical Day Care Centre, Wollongong, New South Wales, Australia|Gallipoli Medical Research Foundation, Greenslopes Private Hospital, Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Epworth Freemasons-Epworth HealthCare, East Melbourne, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Western Health, Sunshine Hospital, St Albans, Victoria, Australia|Onze Lieve Vrouw Ziekenhuis Aalst, Aalst, Belgium|Institut Jules Bordet, Anderlecht, Belgium|Cliniques universitaires Saint-Luc, Brussels, Belgium|AZ (Algemeen Ziekenhuis) Maria Middelares, Gent, Belgium|AZ (Algemeen Ziekenhuis) Sint-Lucas, Gent, Belgium|AZ (Algemeen Ziekenhuis) Groeninge, Kortrijk, Belgium|CHU de Liege, Liege, Belgium|ZNA Jan Palfijn, Merksem, Belgium|Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Panagyurishte, Bulgaria|Complex Oncology Center - Plovdiv EOOD, Plovdiv, Bulgaria|Independent medical-diagnostic laboratory ""Medisken"" EOOD, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Georgi EAD, Plovdiv, Bulgaria|Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda EAD, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv. Ivan Rilski"" EAD, Sofia, Bulgaria|Acibadem City Clinic University Multiprofile Hospital for Active Treatment EOOD, Sofia, Bulgaria|Complex Oncology Center - Stara Zagora Ltd., Stara Zagora, Bulgaria|MRI SMDLOD ""Mediscan"" Ltd, Stara Zagora, Bulgaria|UMHAT ""Prof. Dr. Stoyan Kirkovich"", Stara Zagora, Bulgaria|Prostate Cancer Centre, Calgary, Alberta, Canada|Centre of Applied Urology Research, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada|London Health Sciences Centre, London, Ontario, Canada|The Ottawa Hospital Cancer Center, Ottawa, Ontario, Canada|University Health Network-Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CIUSSS- saguenay-Lac-Saint-Jean, Chicoutimi, Quebec, Canada|Urology South Shore Research, Greenfield Park, Quebec, Canada|CHUM - Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Center, Montreal, Quebec, Canada|The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China|Peking University First Hospital, Beijing, Beijing, China|Lanzhou University Second Hospital, Lanzhou, Gansu, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Henan Cancer Hospital, Zhengzhou, Henan, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei, China|Tongji Hospital, Tongji Medical College,Huazhong University of Science and Technology, Wuhan, Hubei, China|Hubei Cancer Hospital, Wuhan, Hubei, China|Hunan Cancer Hospital, Changsha, Hunan, China|The Third Xiangya Hospital of Central South University, Changsha, Hunan, China|Zhongda Hospital Southeast University, Nanjing, Jiangsu, China|Nantong Tumor Hospital, Nantong, Jiangsu, China|The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China|The First hospital of Jilin University, Changchun, Jilin, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China|Fudan University Cancer Hospital, Shanghai, Shanghai, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China|Ningbo First Hospital, Ningbo, Zhejiang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China|The First Affiliated Hospital Chongqing Medical University, Chongqing, China|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Fakultni nemocnice Motol, Praha 5, Czechia|Fakultni nemocnice Bulovka, Praha 8- Liben, Czechia|Helsinki University Hospital, Helsinki, Finland|Docrates Cancer Center, Helsinki, Finland|Kuopio University Hospital, Kuopio, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland|CHU Morvan de Brest, Brest, Bretagne, France|Hopital Henri Mondor, Creteil, ILE DE France, France|Clinique Belharra, Bayonne, France|CHU Morvan de Brest, Brest, France|Clinique Victor Hugo, Le Mans, France|Hopital Prive le Bois, Lille, France|Hopital Bichat - Claude Bernard, Paris cedex 18, France|Hopital Bichat - Claude Bernard, Paris, France|Hopital Lyon Sud, Pierre-Benite, France|Institut Jean Godinot, Reims Cedex, France|CHP Saint-Grégoire, Saint Gregoire, France|Hopitaux Universitaires de Strasbourg - ICANS (Institut de Cancerologie Strasbourg Europe), Strasbourg, France|Gustave Roussy, Villejuif Cedex, France|Urologische Gemeinschaftspraxis Wesel, Wesel, Nordrhein-westfalen, Germany|Urologicum Duisburg, Duisburg, Germany|Universitaetsklinikum Frankfurt, Frankfurt, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Uro-/Onkologisches Zentrum, Leipzig, Germany|Studienpraxis Urologie, Nuertingen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Péterfy Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Intézet, Budapest, Hungary|Országos Onkológiai Intézet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, Hungary|Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Miskolc, Hungary|Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet, Sopron, Hungary|Indraprastha Apollo Hospital, New Delhi, Delhi, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, Delhi, India|Gujarat Gastro and Vascular Hospital, Surat, Gujarat, India|Artemis hospital, Gurugram, Haryana, India|Medanta- The Medicity hospital, Gurugram, Haryana, India|Bhakti Vedanta Hospital and Research Institute, Mumbai, Thane, Maharashtra, India|Sahyadri Clinical Research & Development Centre, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Valentis Cancer Hospital, Meerut, Uttar Pradesh, India|Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, WEST Bengal, India|Azienda Ospedaliero-Universitaria Policlinico S. Orsola Malpighi, Bologna, BO, Italy|ASST Cremona, Cremona, CR, Italy|Istituto Romagnolo per lo Studio dei Tum.ori ""Dino Amadori"" (IRST), Meldola, FC, Italy|Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy|Istituto Nazionale Tumori IRCCS Fondazione G. Pascale - Napoli, Napoli, Naples, Italy|Ospedale Santa Chiara, Trento, TN, Italy|AOU San Luigi Gonzaga, Orbassano, TO, Italy|Ospedale San Donato, Arezzo, Italy|IRCCS Istituto Tumori ""Giovanni Paolo II"" di Bari, Bari, Italy|ASST degli Spedali Civili de Brescia, Brescia, Italy|Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Hirosaki University School of Medicine & Hospital, Hirosaki, Aomori, Japan|Chiba cancer center, Chiba-shi, Chiba, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Kure Medical Center and Chugoku Cancer Center, Kure, Hiroshima, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Yokosukakyosai, Yokosuka, Kanagawa, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Hamamatsu University School of Medicine University Hospital, Hamamatsu, Shizuoka, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Kagoshima University Hospital, Kagoshima, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Tokushima University Hospital, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Korea, Republic of|José Luis González Trujillo (Consultorio Privado), León, Guanajuato, Mexico|Axis Heilsa S. de R.L. de C.V., Monterrey, Nuevo LEÓN, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEÓN, Mexico|Centro de Investigacion Clinica de Oaxaca, Oaxaca, Mexico|Meander Medisch Centrum, Amersfoort, Utrecht, Netherlands|Hagziekenhuis, Den Haag, Zuid-holland, Netherlands|Moscow Research Oncology Institute n.a P.A. Gertsen (MROI n.a P.A. Gertsen), Obninsk, Kaluga Region, Russian Federation|MRRC n.a. A.F. Tsyb - branch of FSBI ""NMRC of Radiology"" Minzdrav Russia, Obninsk, Kaluga Region, Russian Federation|State budget institution of healthcare of Mordovia Republic ""Republic Oncology Dispensary"", Saransk, Republic OF Mordovia, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|Limited Liability Company ""4D Ultrasound Clinic"" (LLC ""4D Ultrasound Clinic""), Pyatigorsk, Stavropol Region, Russian Federation|State Budgetary Healthcare Institution of Arkhangelsk Region, Arkhangelsk, Russian Federation|Evimed Llc, Chelyabinsk, Russian Federation|SBIH ""Chelyabinsk Regional Clinical Centre of Oncology and Nuclear Medicine"", Chelyabinsk, Russian Federation|Regional Budgetary Healthcare Institution ""Ivanovskiy Regional Oncology Dispensary"" (RBHI ""IvROD""), Ivanovo, Russian Federation|Federal State Budgetary Institution ""Russian Research Center of Roentgenology and Radiology"" of, Moscow, Russian Federation|Branch of the Limited Liability Company ""Hadassah Medical Ltd."", Moscow, Russian Federation|Federal State Budgetary Institution ""Central Clinical Hospital with ambulance"", Moscow, Russian Federation|Moscow Research Oncology Institute n.a P.A. Gertsen (MROI n.a P.A. Gertsen), Moscow, Russian Federation|BHI of Omsk region ""Clinical Oncological Dispensary"", Omsk, Russian Federation|LLC ""Medicina Severnoy Stolitsy"", Saint-Petersburg, Russian Federation|LLC ""Severo-Zapadny Medical Center"", Saint-Petersburg, Russian Federation|Private Institution Educational Organization of Higher Education ""Medical University ""REAVIZ"", Samara, Russian Federation|SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan, Ufa, Russian Federation|Budgetary Healthcare Institution of Vologda region ""Vologda Regional Clinical Hospital"", Vologda, Russian Federation|Budgetary Healthcare Institution of Vologda region ""Vologda Regional Clinical Hospital"", Vologda, Russian Federation|State Budgetary Institution of Healthcare of Yaroslavl Region ""Regional Clinical Oncology Hospital"", Yaroslavl, Russian Federation|Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica, Banska Bystrica, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia|Vychodoslovensky onkologicky ustav, a.s., Kosice, Slovakia|UROEXAM, spol. s r.o., Nitra, Slovakia|POKO Poprad s.r.o., Poprad, Slovakia|MILAB s.r.o., Presov, Slovakia|Privatna urologicka ambulancia, s.r.o., Trencin, Slovakia|Sandton Oncology Medical Group (Pty) Ltd, Johannesburg, Gauteng, South Africa|Clinical Research Unit, University of Pretoria, Pretoria, Gauteng, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona [barcelona], Spain|Althaia, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, Spain|Hospital Universitario Lucus Augusti, Lugo, Galicia, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|FundaciÃ³n Instituto Valenciano de OncologÃ-a, Valencia, Valenciana, Comunitat, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|MD Anderson Cancer Center, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Virgen de la Macarena, Sevilla, Spain|Hospital Politecnic Universitari La Fe, Valencia, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan City, Taiwan|Adana City Training and Research Hospital, Adana, Turkey|Ankara University Faculty of Medicine, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey|Inonu University, Faculty of Medicine, Malatya, Turkey|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council; Chemotherapy Department, Kryviy Rih, Dnipropetrovska Oblast, Ukraine|Medical & diagnostic center of LISOD-Israeli Oncological Hosp ""MedX-ray International Group"", Pliuty Village, KYIV Region, Ukraine|Asklepion Medical Center, Khodosivka, Kyivska Oblast, Ukraine|National Cancer Institute, Kyiv, Kyivska Oblast, Ukraine|Municipal Ent ""Dnipropetrovsk Regional Clinical Hosp (I.I.Mechnikov Dnipropetrovsk Regional council), Dnipro, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital #4"" of Dnipro City Council, Dnipro, Ukraine|Communal non-profit enterprise ""Regional clinical hospital of Ivano-Frankivsk Regional Council"", Ivano-Frankivsk, Ukraine|Municipal Non-Commercial Enterprise of Kharkiv Regional Council Regional Medical Clinical Center of, Kharkiv, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"", Kharkiv, Ukraine|Comm Noncommerc Entp Lviv Reg Council ""Lviv Oncological Regional Therapeutical and Diagnostic Cntr, Lviv, Ukraine|Maidstone and Tunbridge Wells NHS Trust, Maidstone, Kent, United Kingdom|Lancashire Teaching Hospitals NHS Foundation Trust, Preston, Lancashire, United Kingdom|NHS Lothian, Edinburgh, Midlothian, United Kingdom|Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom|NHS Greater Glasgow and Clyde, Glasgow, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04821622"
373,"NCT00793546","Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer",,"Terminated","Has Results","Advanced Breast Cancer","Drug: Bosutinib|Drug: exemestane|Drug: Exemestane","Progression Free Survival (PFS) Based on Independent Radiologist|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs)|Progression Free Survival (PFS) Based on Investigator|Percentage of Participants With Objective Response|Overall Survival (OS)|Duration of Response (DR)|Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B)|Euro Quality of Life (EQ-5D)- Health State Profile Utility Score|Euro Quality of Life (EQ-5D)- Visual Analog Scale (VAS)|Maximum Observed Plasma Concentration (Cmax)|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)]","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","42","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3160A6-2206|B1871009","February 2009","June 2010","June 2010","November 19, 2008","November 4, 2012","November 4, 2012","Pfizer Investigational Site, Lake Worth, Florida, United States|Pfizer Investigational Site, Joliet, Illinois, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, New Brunswick, New Jersey, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Bethlehem, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, South Brisbane, Queensland, Australia|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Olsztyn, Poland|Pfizer Investigational Site, Lynnwood, Gauteng, South Africa|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site",,"https://ClinicalTrials.gov/show/NCT00793546"
374,"NCT02603432","A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)",,"Active, not recruiting","Has Results","Urothelial Cancer","Biological: Avelumab|Other: Best Supportive Care|Biological: Following the planned interim analysis for this study: Avelumab","Overall Survival (OS)|Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)|Progression-Free Survival (PFS) as Assessed by Investigator|Percentage of Participants With Objective Response (OR) as Assessed by Blinded Independent Central Review (BICR)|Percentage of Participants With Objective Response as Assessed by Investigator|Time to Tumor Response (TTR) as Assessed by Blinded Independent Central Review (BICR)|Time to Tumor Response (TTR) as Assessed by Investigator|Duration of Response (DOR) as Assessed by Blinded Independent Central Review (BICR)|Duration of Response (DOR) as Assessed by Investigator|Percentage of Participants With Disease Control (DC) as Assessed by Blinded Independent Central Review (BICR)|Percentage of Participants With Disease Control (DC) as Assessed by Investigator|Number of Participants With Treatment-Emergent Adverse Events (AEs) Graded Based on, National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03|Number of Participants With Laboratory Abnormalities Greater Than or Equal to (>=) Grade 3 (G3), Based on National Cancer Institute Common Terminology Criteria (NCI-CTCAE), Version 4.03|Change From Baseline in Vital Signs - Blood Pressure at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit|Change From Baseline in Vital Signs - Pulse Rate at Day 1 of Cycle 2, 3, 4, 5, 6, 7 and End of Treatment (EOT) Visit|Maximum Plasma Concentration (Cmax) of Avelumab|Predose Plasma Concentration (Ctrough) of Avelumab|Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status|Number of ADA Ever Positive Participants For Each Serum of ADA Titers for Avelumab|Number of Participants With Neutralizing Antibodies (nAb) Against Avelumab by Never Positive and Ever Positive Status|Number of Participants With Programmed Death Receptor-1 Ligand 1 (PD-L1) Biomarker Expression in Tumor Tissue as Assessed by Immunohistochemistry (IHC)|Number of Participants With Cluster of Differentiation 8 (CD8) T Lymphocytes (Cytotoxic T Lymphocytes)|Change From Baseline in National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (NCCN-FACT) Bladder Symptom Index- 18 (FBlSI-18) Score at Day 1 of Cycle 6|Time to Deterioration (TTD) Based on National Comprehensive Cancer Network- Functional Assessment of Cancer Therapy (NCCN-FACT) Bladder Symptom Index- 18 (FBlSI-18) Disease Related Symptoms-Physical Subscale (DRS-P) Scores|Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Overall Health Utility Score at Cycle 6|Change From Baseline in European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) - Visual Analog Scale (VAS) Score at Cycle 6","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","700","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B9991001|2015-003262-86|JAVELIN BLADDER 100","April 25, 2016","October 21, 2019","June 3, 2022","November 11, 2015","December 17, 2020","January 20, 2022","Anschutz Cancer Center Pavilion Pharmacy, Aurora, Colorado, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|University of Colorado Denver, CTO (CTRC), Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States|University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora, Colorado, United States|Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States|Smilow Cancer Hospital at Yale-New Haven, New Haven, Connecticut, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Cleveland Clinic Taussing Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Inova Schar Cancer Institute Infusion Pharmacy, Fairfax, Virginia, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino S.A., Pergamino, Buenos Aires, Argentina|Fundación CENIT para la Investigación en Neurociencias, Caba, Argentina|GP Diagnostico SRL, La Rioja, Argentina|Hospital Regional Dr. Enrique Vera Barros, La Rioja, Argentina|Instituto del Diagnostico, La Rioja, Argentina|Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Concord Hospital, Concord, New South Wales, Australia|Dubbo Base Hospital, Dubbo, New South Wales, Australia|Ramsay Pharmacy, Kogarah, New South Wales, Australia|St George Private Hospital, Kogarah, New South Wales, Australia|Epic Pharmacy, Lismore, New South Wales, Australia|North Coast Radiology St Vincents, Lismore, New South Wales, Australia|Northern Rivers Pathology Service, Lismore, New South Wales, Australia|St Vincent's Pathology Lismore, Lismore, New South Wales, Australia|Macquarie University Hospital Pharmacy, Macquarie University, New South Wales, Australia|Macquarie University, Macquarie University, New South Wales, Australia|The Murwillumbah Hospital, Murwillubah, New South Wales, Australia|The Tweed Hospital Pharmacy Department, Tweed Heads, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Icon Cancer Care Wesley, Auchenflower, Queensland, Australia|River City Pharmacy, Auchenflower, Queensland, Australia|Oncology Pharmacy, Birtinya, Queensland, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Icon Cancer Care Chermside, Chermside, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Slade Health, Geebung, Queensland, Australia|Icon Cancer Care South Brisbane, South Brisbane, Queensland, Australia|Icon Cancer Care, South Brisbane, Queensland, Australia|Icon Cancer Care Southport, Southport, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|SA Pharmacy, Level 3 Pharmacy, Bedford Park, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Ashford Cancer Centre Research, Kurralta park, South Australia, Australia|Cancer Care SA Pty Ltd, Kurralta Park, South Australia, Australia|Icon Cancer Care SA trading as Icon Pharmacy Adelaide, Kurralta Park, South Australia, Australia|The Queen Elizabeth Hospital, Woodville South, South Australia, Australia|BHS Diagnostic Services, Ballarat, Victoria, Australia|Lake Imaging, Ballarat, Victoria, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Eastern Health Clinical School, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Monash Cancer Centre, East Bentleigh, Victoria, Australia|Moorabbin Radiology, East Bentleigh, Victoria, Australia|Ballarat Day Procedure Centre, Wendouree, Victoria, Australia|Ballarat Oncology & Haematology Services, Wendouree, Victoria, Australia|Nova Pharmacy, Wendouree, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Slade Health, Mount Waverley, Australia|Macquarie Heart, New South Wales, Australia|AZ Klina - Apotheek, Brasschaat, Belgium|AZ Klina, Brasschaat, Belgium|Hôpital Erasme, Brussels, Belgium|Hôpital Erasme, Bruxelles, Belgium|UZ Gent, Gent, Belgium|UZ Gent, Ghent, Belgium|AZ Groeninge, Kortrijk, Belgium|CHU de Liège, Liège, Belgium|GZA Sint-Augustinus, Wilrijk, Belgium|Hospital da Bahia, Salvador, BA, Brazil|CENOB Centro de Oncologia da Bahia S/S Ltda. / Oncovida, Salvador, BA, Brazil|Hospital Mãe de Deus/Aesc, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto Nacional de Câncer - INCA, Rio de Janeiro, RJ, Brazil|Associação Hospital de Caridade Ijuí / Hospital de Caridade de Ijuí, Ijuí, RS, Brazil|Associação Educadora São Carlos - AESC / Hospital Mãe de Deus, Porto Alegre, RS, Brazil|Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Ambulatório Quimioterapia, Porto Alegre, RS, Brazil|Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Centro de Abastecimento Farmaceu, Porto Alegre, RS, Brazil|Associação Educadora São Carlos - AESC / Hospital Mãe de Deus - Farmácia Oncológica, Porto Alegre, RS, Brazil|Associação Educadora São Carlos - AESC / Hospital Mãe de Deus, Porto Alegre, RS, Brazil|Uniao Brasileira de Educacao e Assistencia / Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Fundação FPio XII Barretos, Barretos, SP, Brazil|Fundação Pio XII Barretos, Barretos, SP, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Fundacao Faculdade de Medicina / Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP, Sao Paulo, SP, Brazil|Centro Integrado de Pesquisa Clinica - CIP, São José do Rio Preto, SP, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio Libanês, São Paulo, SP, Brazil|Hospital Israelita Albert Einstein - SP, São Paulo, SP, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio Libanês/ Instituo Sirio Libanes de Ensino e Pesqu, São Paulo, Brazil|William Osler Health System, Brampton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montréal, Quebec, Canada|Fakultni nemocnice u sv. Anny v Brne, Brno, Ceska Republika, Czechia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice u sv.Anny v Brne, Brno, Czechia|Nemocnice Horovice, NH Hospital a.s., Horovice, Czechia|Nemocnice Horovice, Horovice, Czechia|Aalborg Universitetshospital Syd, Aalborg, Denmark|Aalborg Universitetshospital, Aalborg, Denmark|Sygehusapoteket Aalborg, Aalborg, Denmark|Aarhus Universitetshospital, Aarhus C, Denmark|Aarhus Universitetshospital, Aarhus N, Denmark|CT-Klinikken A/S, Aarhus N, Denmark|Rigshospitalet, Onkologisk Klinik, afsnit 5073, Copenhagen OE, Denmark|Herlev Hospital, Herlev, Denmark|Herlev og Gentofte Hospital, Herlev, Denmark|Klinik for Klinisk Fysiologi,Nuklearmedicin og PET, København Ø, Denmark|Rigshospitalet, København Ø, Denmark|Odense Universitetshospital, Odense C, Denmark|Odense Universitetshospital, Odense, Denmark|Groupe hospitalier Pitie Saleptriere, Paris, Cedex 13, France|Institut de cancérologie de l'Ouest - Site Paul Papin, Angers Cedex 02, France|Institut de cancérologie de l'Ouest - Site Paul Papin, Angers, France|Centre d'Oncologie et de Radiothérapie du Pays-Basque, Bayonne, France|Clinique CAPIO Belharra, Bayonne, France|Hôpital Jean Minjoz, BESANCON cedex, France|CHU Besançon, Besançon, France|Hôpital Henri Mondor, CRÉTEIL Cedex, France|Hôpital Privé Toulon-Hyères - Clinique Sainte Marguerite, Hyères, France|Clinique Victor Hugo, Le Mans, France|Centre Oscar Lambret, Lille cedex, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon cedex 8, France|Centre Léon Berard, LYON cedex 8, France|Hopital La Conception, Marseille cedex 5, France|Institut Paoli Calmettes, Marseille Cedex 9, France|Institut Paoli Calmettes, Marseille, France|Hopital de La Timone, Marseille, France|Hopital de La Timone, Marseille, France|CHU Nimes - Institut de Cancerologie du Gard, Nimes Cedex 9, France|CHU Nimes, Nimes Cedex 9, France|CHU Nimes - Hopital Caremeau, Nimes, France|Groupe Hospitalier Pitié Salpêtrière, PARIS cedex 13, France|Groupe Hospitalier Pitié Salpêtrière, Paris, France|Centre Eugene Marquis, Rennes Cedex, France|Centre Henri Becquerel, Rouen Cedex 1, France|CHU de Rouen - Hôpital Charles Nicolle, Rouen, France|CHU de Rouen, Rouen, France|Institut de Cancérologie de l'Ouest - Centre René Gauducheau, Saint Herblain Cedex, France|Centre de Radiothérapie - Clinique Sainte Anne, Strasbourg, France|Clinique Sainte Anne, Strasbourg, France|Hopital Foch, Suresnes, France|Institut Gustave Roussy, Villejuif cedex, France|Institut Gustave Roussy, Villejuif, France|Medical Center of Athens, Marousi, Athens, Greece|Metropolitan General Hospital, Athens, PC, Greece|Sotiria General Chest Disease Hospital, Athens, Greece|Alexandra General Hospital, Oncology Department, Athens, Greece|University General Hospital of Patras, Division of Oncology, Patra, Greece|EUROMEDICA General Clinic of Thessaloniki, Thessaloniki, Greece|Department of Clinical Oncology, Hong Kong, Hong Kong|Kaposvári Egyetem Egészségügyi Centrum, Kaposvár, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Dr Ram Manohar Lohia (RML) Hospital & PGI MER, New Delhi, Delhi, India|CIMS Cancer, Care Institute of Medical Sciences, CIMS Hospital, Ahmedabad, Gujarat, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Apollo Hospitals, Hyderabad, Telangana, India|Medica Superspecialty hospital, Kolkata, WEST Bengal, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Hadassah University Hospital, Kiryat Hadassah, Jerusalem, Israel|The Chaim Sheba Medical Center, Tel-Hashomer, Ramat - GAN, Israel|Assaf Harofe MC, Beer Yaakov, Israel|Rambam Health Care Campus, Haifa, Israel|The Chaim Sheba Medical Center, Ramat - Gan, Israel|Farmacia Ospedaliera, Candiolo, (torino), Italy|AOU Ospedali Riuniti di Ancona, Torrette, Ancona, Italy|U.O. Anatomia Patologica, Forli, Forli-cesena, Italy|U.O. Radiologia, Forli, Forli-cesena, Italy|U.O.S. Medicina Nucleare, Forli, Forli-cesena, Italy|Farmacia Oncologica, Meldola, Forli-cesena, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Forli-cesena, Italy|U.O.C. Farmacia, Genova, Genoa, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy|Farmacia Studi Clinici, Rozzano, Milan, Italy|Istituto Clinico Humanitas, Rozzano, Milan, Italy|AUSL della Romagna - RAVENNA, Presidio Ospedaliero di Faenza, Faenza, Ravenna, Italy|Presidio Ospedaliero di Lugo, Lugo, Ravenna, Italy|Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo, Candiolo, Torino, Italy|Farmacia Ospedaliera, Arezzo, Italy|Presidio Ospedaliero San Donato, Arezzo, Italy|Centro di Riferimento Oncologico - IRCCS, Aviano (PN), Italy|S.O.C. di Farmacia, Aviano (PN), Italy|Azienda Ospedaliero-Universitaria Policlinico S.Orsola Malpighi, Bologna, Italy|U.O. Farmacia Clinica - IDS, Bologna, Italy|Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy|SC Farmacia, Milan, Italy|Instituto Europeo di Oncologia, Milan, Italy|Servizio di Farmacia, Milan, Italy|Azienda Ospedaliera di Rilievo Nazionale ""A. Cardarelli"", Naples, Italy|UOSC Farmacia, Naples, Italy|Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale, Napoli, Italy|S.C. Farmacia Ospedaliera, Napoli, Italy|A.O.U. Pisana Ospedale S. Chiara, Pisa, Italy|Presidio Ospedaliero di Ravenna, Ravenna, Italy|Servizio Farmacia Ospedaliera - Farmacia Oncologica, Ravenna, Italy|Azienda Ospedaliera San Camillo Forlanini_Oncologia Medica, Rome, Italy|U.O.C. Farmacia, Rome, Italy|Azienda Ospedaliera S. Maria di Terni, Terni, Italy|S.C. Farmacia Interna, Terni, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|Hirosaki University School of Medicine & Hospital, Hirosaki, Aomori, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Gunma Prefectural Cancer Center, Ota, Gunma, Japan|National Hospital Organization hokkaido Cancer Center, Sapporo,, Hokkaido, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Kobe City Medical Center General Hospital, Kobe-city, Hyogo, Japan|Tsukuba Medical Center Hospital, Tsukuba, Ibaraki, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, Japan|National Hospital Organization Sagamihara National Hospital, Sagamihara, Kanagawa, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan|Hamamatsu University School of Medicine, University Hospital, Hamamatsu, Shizuoka, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, Japan|Keio University Hospital, Shinjuku-Ku, Tokyo, Japan|Yamaguchi University Hospital, Ube, Yamaguchi, Japan|Chiba Cancer Center, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan|Kagoshima University Hospital, Kagoshima, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Niigata University Medical & Dental Hospital, Niigata, Japan|Osaka City University Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|National Cancer Center - Clinical Trial Pharmacy, Goyang-si, Gyeonggi-do, Korea, Republic of|National Cancer Center Urology center for Prostate Cancer, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Clinical Pharmacy, Seongnam-si, Gyeonggido, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggido, Korea, Republic of|Chungnam National University Hospital, Clinical Pharmacy, Daejeon, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center - Clinical Trial Pharmacy, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center Clinical Trial Pharmacy, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Ciudad DE Mexico, Mexico|Phylasis Clinicas Research S. de R.L. de C.V., Cuautitlan Izcalli, Estado DE Mexico, Mexico|Centro de Investigación Clínica de Leon S.C., Leon, Guanajuato, Mexico|Hospital Médica Campestre (Administradora Hospitalaria S.A de C.V.), León, Guanajuato, Mexico|Rijnstate Arnhem, Arnhem, Netherlands|Ziekenhuis Rijnstate, Arnhem, Netherlands|St Apotheek der Haarlemse Ziekenhuizen, Haarlem, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|Radboudumc, Nijmegen, Netherlands|Auckland City Hospital Pharmacy, Grafton, Auckland, New Zealand|Auckland City Hospital, Grafton, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Akershus University Hospital, Lorenskog, Norway|Sykehusapoteket HF 23 Lørenskog, Lorenskog, Norway|Sykehusapoteket HF 23 Lørenskog, Nordbyhagen, Norway|Sykehusapoteket Lorenskog, Nordbyhagen, Norway|Bildediagnostisk avdeling, Nordbyhagen, Norway|Stavanger University Hospital, Stavanger, Norway|Centralny Szpital Kliniczny MSWiA, Warszawa, Masovian, Poland|Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Lublin, Poland|Lecznice CITOMED Sp. z o.o., Torun, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny, Torun, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu, Torun, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera, Szpital Specjalistyczny dla Dzieci I Doroslych, Torun, Poland|Instituto Português de Oncologia de Coimbra Francisco Gentil, EPE, Coimbra, Portugal|Hospital Da Luz Coimbra, SA, Coimbra, Portugal|Centro Hospitalar de Lisboa Central, E.P.E. - Hospital de Santo António dos Capuchos, Lisboa, Portugal|Hospital CUF Descobertas, SA, Lisboa, Portugal|Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A., Porto, Portugal|Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Dr. Campos Costa - Consultório de Tomografia Computorizada, S.A.- Matosinhos, Senhora da Hora, Portugal|Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE, Vila Real, Portugal|State Budgetary Healthcare Insti. Republican Clinical Oncology Dispensary of the MoH of Bashk. Rep., Ufa, Bashkortostan Republic, Russian Federation|Federal State Budgetary Institution ""National medical research radiology center"" MoH RF, Obninsk, Kaluzhskaya Region, Russian Federation|Private Medical Institution ""Evromedservice"", Pushkin, Saint Petersburg, Russian Federation|Principal Military Clinical Hospital n.a. N.N. Burdenko, Moscow, Russian Federation|Moscow Research Oncology Institute named after P. A. Gertsen, Moscow, Russian Federation|BHI of Omsk region ""Clinical oncological dispensary"", Omsk, Russian Federation|FGBIH ""Clinical Hospital #122 n.a. L.G. Sokolov of Federal Medico-biological agency"", St. Petersburg, Russian Federation|Non-State Healthcare Institution ""Railway Clinical Hospital JSC RZhD"", St. Petersburg, Russian Federation|FSBEI HE ""First St. Petersburg State Medical University n. a. academician l.P Pavlov"" MoH RF, St. Petersburg, Russian Federation|FSBEI HE ""First St. Petersburg State Medical University n.a. academician I.P Pavlov"" MoH RF, St. Petersburg, Russian Federation|FSBEI HE ""First St. Petersburg State Medical University n.a. academician I.P Pavlov"", St. Petersburg, Russian Federation|""Ramsay Diagnostics Rus"", LLC, St. Petersburg, Russian Federation|FSBI ""Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov, St. Petersburg, Russian Federation|Hospital Orkli, LLC, St. Petersburg, Russian Federation|Mart, Llc, St. Petersburg, Russian Federation|SHI YR ""Regional Clinical Oncology Hospital"", Yaroslavl, Russian Federation|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Clinical Centre Nis, Clinic of Oncology, Nis, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia|C.H. Univ. Santiago de Compostela, Santiago de Compostela, A Coruña, Spain|Hospital Comarcal General de Elda de Virgen de la Salud, Elda, Alicante, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Institut Catalá d'Oncología - Hospital Duran i Reynals, l´Hospitalet de LLobregat, Barcelona, Spain|Institut Catalá d'Oncología, L´Hospitalet de Llobregat, Barcelona, Spain|Althaia. Xarxa Assistencial Universitaria de Manresa, Manresa, Barcelona, Spain|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital General Universitario de Elche, Elche, Comunidad Valenciana, Spain|Hospital Clinico Universitario de Valencia, Valencia, Comunidad Valenciana, Spain|C. H. Universitario de Vigo- Hospital Álvaro Cunqueiro, Vigo, Galicia, Spain|C.H. Universitario de Vigo- Hospital Meixoeiro, Vigo, Galicia, Spain|Hospital Universitario Infanta Sofia, San Sebastian de los Reyes, Madrid, Spain|Hospital Universitario Infanta Sofia, San Sebastián de los Reyes, Madrid, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Vithas Internacional Medimar, Alicante, Spain|Hospital Universitario Infanta Cristina, Badajoz, Spain|Hospital del Mar, Barcelona, Spain|Hospital Quiron of Barcelona, Barcelona, Spain|Hospital Quirón de Barcelona, Barcelona, Spain|Hospital de La Santa Creu i Sant pau_Oncology department, Barcelona, Spain|Hospital de La Santa Creu i Sant Pau, Barcelona, Spain|CETIR Grup Medic, Barcelona, Spain|Cetir, Centre Mèdic, S.L, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Institut Catala d'Oncologia, Gerona, Spain|Institut Diagnostic de la lmatge, Gerona, Spain|Hospital Universitario Lucus Augusti, Lugo, Spain|Fundacion Maria Rafols para la investigacion del Diagnostico de la imagen, Madrid, Spain|Gabinete Radiologico Doctor Pita, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Ruber International, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario HM Sanchinarro - CIOCC, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|APL, Stockholm, Sweden|Karolinska University Hospital, Stockholm, Sweden|Clinical Trial Pharmacy, China Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Department of Pharmacy, National Cheng Kung University Hospital, Tainan, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Investigational Drug services, National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan|Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|Chemotherapy pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan|Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom|St Bartholomew 's Hospital, Barts Health NHS Trust, London, United Kingdom|St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom|Guy's & St. Thomas' NHS Foundation Trust, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital, London, United Kingdom|Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02603432/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT02603432/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02603432"
375,"NCT03682068","Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","NILE","Recruiting","No Results Available","Unresectable Locally Advanced Urothelial Cancer|Metastatic Urothelial Cancer","Drug: Durvalumab|Drug: Tremelimumab|Drug: Cisplatin + Gemcitabine|Drug: Carboplatin + Gemcitabine","Overall Survival (OS)|Overall Survival at 24 months (OS24)|Progression Free Survival (PFS)|Alive and Progression Free Survival at 12 months (APF12)|Objective Response Rate (ORR)|Duration of Response (DoR)|Disease Control Rate (DCR)|Time from randomization to second (PFS2)|To assess disease-related symptoms, physical functioning, and other Health-related quality of life","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1292","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D933SC00001","September 27, 2018","June 30, 2023","October 30, 2025","September 24, 2018",,"April 15, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Bakersfield, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fullerton, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Salinas, California, United States|Research Site, Santa Barbara, California, United States|Research Site, Santa Maria, California, United States|Research Site, Truckee, California, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Orlando, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Kansas City, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Bozeman, Montana, United States|Research Site, Livingston, New Jersey, United States|Research Site, Neptune, New Jersey, United States|Research Site, Bronx, New York, United States|Research Site, New Hyde Park, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Germantown, Tennessee, United States|Research Site, Fort Worth, Texas, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Rosario, Argentina|Research Site, Box Hill, Australia|Research Site, Elizabeth Vale, Australia|Research Site, Kogarah, Australia|Research Site, Macquarie University, Australia|Research Site, Murdoch, Australia|Research Site, Orange, Australia|Research Site, South Brisbane, Australia|Research Site, St Albans, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Burgas, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Dalian, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Jinan, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Zhengzhou, China|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyula, Hungary|Research Site, Győr, Hungary|Research Site, Kecskemét, Hungary|Research Site, Szolnok, Hungary|Research Site, Ahmedabad, India|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Calicut, India|Research Site, Gurgaon, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Mangalore, India|Research Site, Mysuru, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vadodara, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Arezzo, Italy|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Pavia, Italy|Research Site, Roma, Italy|Research Site, San Giovanni Rotondo, Italy|Research Site, Terni, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kita-gun, Japan|Research Site, Koshigaya-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Miyazaki-city, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Toyama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Legazpi City, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bialystok, Poland|Research Site, Gdańsk, Poland|Research Site, Grudziądz, Poland|Research Site, Koszalin, Poland|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Radom, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Łódź, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, St.-Petersburg,, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tyumen, Russian Federation|Research Site, Vologda, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Lugo, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Santander, Spain|Research Site, Sevilla, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Lampang, Thailand|Research Site, Mueang, Thailand|Research Site, Songkla, Thailand|Research Site, Adana, Turkey|Research Site, Adapazari, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03682068"
376,"NCT04469127","A Study of AIP-303 in HER2 Positive Breast Cancer and/or Metastatic Breast Cancer Patients","Heroine01","Not yet recruiting","No Results Available","HER2 Positive Breast Cancer","Drug: AIP-303","Specific Aim 1|Specific Aim 2|Specific Aim 3|Specific Aim 4|Specific Aim 5|Specific Aim 6","Advanced Imaging Projects, LLC|All India Institute of Medical Sciences, New Delhi|University of Lausanne|University of Witwatersrand, South Africa|Postgraduate Institute of Medical and Research|PositronPharma|Università degli studi di Trieste|US Department of Veterans Affairs","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","150","Industry|Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","145358","August 30, 2020","August 30, 2021","August 30, 2021","July 13, 2020",,"July 22, 2020","Department of Veterans Affairs, Iowa City, Iowa, United States|PositronPharma, Santiago, Chile|All India Institute of Medical Sciences, New Delhi, Dehli, India|Postgraduate Institute of Medical and Research, Chandigarh, India|Università degli Studi di Trieste, Cremona, Italy|University of Witwatersrand, Johannesburg, South Africa|University of Lausanne, Lausanne, Switzerland",,"https://ClinicalTrials.gov/show/NCT04469127"
377,"NCT03337724","A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","IPATunity130","Active, not recruiting","No Results Available","Breast Cancer","Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo","Progression-Free Survival (PFS)|Objective Response Rate (ORR)|Duration of Response (DOR)|Clinical Benefit Rate (CBR)|Overall Survival (OS)|Global Health Status (GHS)/Health-Related Quality of Life (HRQoL) Score|Time to Deterioration in Pain|Incidence and Severity of Adverse Events (AEs)|Changes in Vital Signs|Changes in Targeted Laboratory Results|Plasma Concentration of Ipatasertib and Its Metabolite (G-037720)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","580","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CO40016|2017-001548-36","January 6, 2018","December 22, 2022","December 22, 2022","November 9, 2017",,"May 9, 2022","UCSD Moores Cancer Center, La Jolla, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|USC Norris Cancer Center; USC Oncology Hematology Newport Beach, Newport Beach, California, United States|Kaiser Permanente - Oakland, Oakland, California, United States|Kaiser Permanente - Roseville, Roseville, California, United States|Kaiser Permanente Sacramento Medical Center, Sacramento, California, United States|UC Davis; Comprehensive Cancer Center, Sacramento, California, United States|Kaiser Permanente - San Francisco (2238 Geary), San Francisco, California, United States|UCSF Comprehensive Cancer Ctr, San Francisco, California, United States|K. Permanente - San Jose, San Jose, California, United States|Kaiser Permanente - San Leandro, San Leandro, California, United States|K. Permanente - Santa Clara, Santa Clara, California, United States|Kaiser Permanente - South San Francisco, South San Francisco, California, United States|Kaiser Permanente - Vallejo, Vallejo, California, United States|K. Permanente - Walnut Creek, Walnut Creek, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Memorial Hospital West, Pembroke Pines, Florida, United States|University of Maryland, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan Kettering, New York, New York, United States|West Clinic, Germantown, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy, Dallas, Texas, United States|Oncology Consultants PA, Houston, Texas, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Hosp Provincial D. Centenarios; Oncology Dept, Rosario, Argentina|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Westmead Hospital; Medical Oncology, Wentworthville, New South Wales, Australia|Mater Hospital; Cancer Services, South Brisbane, Queensland, Australia|Cabrini Medical Centre; Oncology, Malvern, Victoria, Australia|Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit, Bull Creek, Western Australia, Australia|Cliniques Universitaires St-Luc, Bruxelles, Belgium|GHdC Site Notre Dame, Charleroi, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Hospital Araujo Jorge; Departamento de Ginecologia E Mama, Goiania, GO, Brazil|Hospital do Câncer de Londrina, Londrina, PR, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Hospital Perola Byington, Sao Paulo, SP, Brazil|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Sociedad de Investigaciones Medicas Ltda (SIM), Temuco, Chile|Clinica CIMCA, San José, Costa Rica|ICIMED Instituto de Investigación en Ciencias Médicas, San José, Costa Rica|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|Centre Georges Francois Leclerc; Oncologie 3, Dijon, France|ICM; Medecine B3, Montpellier cedex 5, France|Centre Catherine De Sienne, Nantes, France|APHP - Hospital Saint Louis, Paris, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, France|Onkologische Schwerpunktpraxis Kurfürstendamm, Berlin, Germany|Praxis für Interdisziplinäre Onkologie und Hämatologie GbR, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf; Frauenklinik, Hamburg, Germany|Universitätsklinikum des Saarlandes; Klinik f. Frauenheilkunden und Geburtshilfe, Homburg/Saar, Germany|Praxis Dr.med. Katja Ziegler-Löhr, Köln, Germany|Dres. Andreas Köhler und Roswitha Fuchs, Langen, Germany|Mühlenkreiskliniken; Johannes Wesling Klinikum Minden; Klinik für Frauenheilkunde und Geburtshilfe, Minden, Germany|Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie, Recklinghausen, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, Germany|Universitätsklinikum Würzburg; Frauenklinik, Würzburg, Germany|Anticancer Hospital Ag Savas; 1St Dept of Internal Medicine, Athens, Greece|Agioi Anargyroi; 3Rd Dept. of Medical Oncology, Athens, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz Es Egyetemi Oktato Korhaz; Onkologiai Osztaly, Miskolc, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Hetenyi Geza County Hospital; Onkologiai Kozpont, Szolnok, Hungary|Zala County Hospital ICU, Zalaegerszeg, Hungary|Indraprastha Apollo Hospitals, New Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Istituto Nazionale Tumori Irccs Fondazione g. PASCALE;U.O.C. Oncologia Medica Senologica, Napoli, Campania, Italy|Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica, Bologna, Emilia-Romagna, Italy|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, Italy|Ospedale Santa Maria Annunziata; Oncologia, Bagno a Ripoli, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center;Breast Oncology, Fukuoka, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Hyogo College of Medicine Hospital, Hyogo, Japan|St. Marianna University Hospital, Kanagawa, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Tokai University Hospital, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|National Hospital Organization Osaka National Hospital, Osaka, Japan|Kinki University Hospital, Faculty of Medicine; Surgery, Osaka, Japan|Saitama Cancer Center, Breast Oncology, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|St. Luke's International Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Showa University Hospital; Breast Surgery, Tokyo, Japan|National Cancer Center, Goyang-si, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Centro Medico Dalinde, Cdmx, Mexico CITY (federal District), Mexico|Centro Médico Zambrano Hellion, Monterrey, Nuevo LEON, Mexico|Merida   Investigacion Clinica, Mérida, Yucatan, Mexico|Consultorio de Medicina Especializada; Dentro de Condominio San Francisco, Mexico City, Mexico|Clinical Hospital; Oncology Department, Bitola, North Macedonia|PHI University Clinic of Radiotherapy and Oncology; Breast malignancy, Skopje, North Macedonia|PHI University Clinic of Radiotherapy and Oncology; Malignant diseases of thorax, Skopje, North Macedonia|Centro Medico Monte Carmelo, Arequipa, Peru|Hospital Daniel Alcides Carrion, Callao, Peru|Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel, Lima, Peru|Hospital Nacional Cayetano Heredia; Ocología; Servicio de Hematología Oncología Médica, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Instituto Regional de Enfermedades Neoplasicas - IREN Norte, Trujillo, Peru|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; III Klin. Radioter. i Chemioter., Gliwice, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chorób Piersi z Podod. Onko Klinicznej, Łódź, Poland|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, Russian Federation|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Blokhin Cancer Research Center; Combined Treatment, Moskva, Moskovskaja Oblast, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|SBIH Kaluga Region Clinical Oncology Dispensary, Kaluga, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|Federal State Institution, Moscow Research Oncology Institute n.a. P.A. Hertzen; Oncourology, Moscow, Russian Federation|FSI Rostov research oncological institute of MoH and SD of RF; PAD, Rostov-on-Don, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National University Hospital; National University Cancer Institute, Singapore (NCIS), Singapore, Singapore|National Cancer Centre; Medical Oncology, Singapore, Singapore|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital del Mar; Servicio de Oncologia, Barcelona, Spain|Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Spain|Hospital Clinic Barcelona; Servicio de oncologia, Barcelona, Spain|Hospital de Donostia; Servicio de Oncologia, Guipuzcoa, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Hospital Clinico Universitario; Oncologia, Valencia, Spain|Chi Mei Medical Center Liou Ying Campus, Liuying Township, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center; Hemato-Oncology, Taipei City, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Ankara City Hospital, Ankara, Turkey|Dicle Uni Medical Faculty; Internal Medicine, Diyarbakir, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Prof. Dr. Cemil Tascioglu City Hospital; Med Onc, Istanbul, Turkey|Katip Celebi University Ataturk Training and Research Hospital; Oncology, Izmir, Turkey|Sakarya University Medical School; Medical Oncology, Sakarya, Turkey|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, Ukraine|National Cancer Institute MOH of Ukraine, Kiev, Ukraine|Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine|Velindre Cancer Centre, Cardiff, United Kingdom|University Hospital coventry; Oncology Department, Coventry, United Kingdom|The Beatson West of Scotland Cancer Centre; Cancer Clinical Trials Unit, Glasgow, United Kingdom|Royal Marsden Hospital - London, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Stoke University Hospital, Stoke-on-Trent, United Kingdom|Royal Marsden Hospital; Dept of Medical Oncology, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03337724"
378,"NCT02941926","Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC","COMPLEEMENT-1","Active, not recruiting","Has Results","Breast Cancer","Drug: Ribociclib|Drug: Letrozole|Drug: Goserelin|Drug: Leuprolide","Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase|Time-to-Progression (TTP) Based on Investigator's Assessment (Core Phase)|Overall Response Rate (ORR) Based on Investigator's Assessment (Core Phase)|Clinical Benefit Rate (CBR) Based on Investigator's Assessment (Core Phase)|Change From Baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) Score (Core Phase)|Number of Participants With AEs and SAEs in the Extension Phase|Percentage of Participants With Clinical Benefit (Extension Phase)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","3246","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLEE011A2404|2016-003467-19","November 30, 2016","November 8, 2019","September 5, 2022","October 21, 2016","May 9, 2022","May 9, 2022","Alaska Cancer Research and Education Center, Anchorage, Alaska, United States|Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Arizona Oncology Associates Arizona Oncology Assoc. (2), Tucson, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|Pacific Shores Medical Group SC, Long Beach, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of California Irvine UC Irvine (11), Orange, California, United States|Ventura County Hematology and Oncology, Oxnard, California, United States|PCR Oncology, Pismo Beach, California, United States|California Pacific Medical Center Onc Dept, San Francisco, California, United States|Centura Health Research Center Centura Health Research Center, Denver, Colorado, United States|Poudre Valley Hospital Poudre Valley Health System, Fort Collins, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Florida Cancer Research Institute Dept of Oncology, Davie, Florida, United States|Foundation for Sickle Cell Disease Research, Hollywood, Florida, United States|Watson Clinic Center for Research 1730 Location, Lakeland, Florida, United States|Mid Florida Hematology and Oncology Center, Orange City, Florida, United States|Summit Cancer Care Summit Cancer Care (SC), Savannah, Georgia, United States|John D Archbold Memorial Hospital John D. Archbold Mem Hosp (4), Thomasville, Georgia, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Stroger Cook County Hospital Division of Hematology & Onc, Chicago, Illinois, United States|Joliet Oncology-Hematology Associates Presence Cancer Center, Joliet, Illinois, United States|Mid Illinois Hematology Oncology Mid Illinois Hema/Onc (3), Normal, Illinois, United States|Alpha Med Physician Group, LLC, Tinley Park, Illinois, United States|Indiana University Health Goshen Center for Cancer SC, Goshen, Indiana, United States|Northwest Oncology, Munster, Indiana, United States|June E. Nylan Cancer Center, Sioux City, Iowa, United States|University of Kansas Cancer Center University of Kansas Med Ctr 9, Kansas City, Kansas, United States|Sarah Cannon at Overland Park Regional Medical Center, Overland Park, Kansas, United States|John Ochsner Heart and Vascular Institute Clinical Trials, New Orleans, Louisiana, United States|Mercy Oncology / Hematology Center SC, Portand, Maine, United States|Greater Baltimore Medical Center Cancer Center Greater Baltimore Medical Ctr, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A. Columbia, Rockville, Maryland, United States|Kaiser Permanente, Rockville, Maryland, United States|Medical Faculty Assc Inc Medical Faculty Assc., Inc. (2, Washington DC, Maryland, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Nebraska Hematology-Oncology, P.C., Lincoln, Nebraska, United States|Nebraska Cancer Specialists Oncology Hematology West, Omaha, Nebraska, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada Henderson (4), Las Vegas, Nevada, United States|Trinitas Comprehensive Cancer Center, Elizabeth, New Jersey, United States|Englewood Hospital and Medical Center, Englewood, New Jersey, United States|The Valley Hospital / Luckow Pavillion, Paramus, New Jersey, United States|Somerset Hematology Oncology Associates Somerset Hematolgy Onc -MI, Somerset, New Jersey, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Clinical Research Alliance, Lake Success, New York, United States|Oncology Speciialists of Charlotte, Charlotte, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|The Christ Hospital Cancer Center Research Program Linder Research Center, Cincinnati, Ohio, United States|University Hospitals of Cleveland Seidman Cancer Center Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic Cleveland Clinic (5), Cleveland, Ohio, United States|Dayton Physicians, Kettering, Ohio, United States|Oklahoma Cancer Specialists and Research Institute SC-2, Tulsa, Oklahoma, United States|Oregon Health and Science University SC-5, Portland, Oregon, United States|McLeod Center for Cancer Treatment and Research, Florence, South Carolina, United States|Carolina Blood and Cancer Care of South Carolina, Rock Hill, South Carolina, United States|Northwest Cancer Ctr Millennium Oncology - FL, Houston, Texas, United States|Cancer Therapy and Research Center UT Health Science Center, San Antonio, Texas, United States|Hope Cancer Center of East Texas, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|PeaceHealth St Joseph Medical Center, Bellingham, Washington, United States|Providence Regional Medical Centre of Everett, Everett, Washington, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Valley Medical Center Research Valley Medical Center, Renton, Washington, United States|Virginia Mason Medical Center-Oncology SC, Seattle, Washington, United States|Northwest Medical Specialties Dept.ofNW Med. Specialties, Tacoma, Washington, United States|Columbia St Mary s Hospital of Milwaukee St. Mary's Hospital Ozaukee, Milwaukee, Wisconsin, United States|Cheyenne Regional Medical Center Cheyenne Regional Med Ctr (3), Cheyenne, Wyoming, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel De Tucuman, Tucuman, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Sint Niklaas, Vlaams Brabant, Belgium|Novartis Investigative Site, Antwerp, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Luxembourg, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Gabrovo, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Surrey, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Winnipeg, Manitoba, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Cambridge, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Kingston, Ontario, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, North York, Ontario, Canada|Novartis Investigative Site, Oshawa, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Sault Ste Marie, Ontario, Canada|Novartis Investigative Site, Sudbury, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Laval, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Liberec, Czech Republic, Czechia|Novartis Investigative Site, Prague 8, Czech Republic, Czechia|Novartis Investigative Site, Zlin, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Olomouc, CZE, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ceske Budejovice, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Prague 5, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 4, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Dijon Cedex, Cote D Or, France|Novartis Investigative Site, Limoges cedex, Haute Vienne, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Tours Cedex 9, Indre Et Loire, France|Novartis Investigative Site, Reims Cedex, Marne, France|Novartis Investigative Site, Albi, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Avignon Cedex, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Bordeaux Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Colmar Cedex, France|Novartis Investigative Site, Corbeil Essonnes, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Le Mans Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon Cedex 08, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Mont de Marsan cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nantes Cedex, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 13, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Plerin Sur Mer, France|Novartis Investigative Site, Périgueux Cédex, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen Cedex 1, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulon La Seyne Sur Mer, France|Novartis Investigative Site, Troyes, France|Novartis Investigative Site, Vandoeuvre-les-Nancy cedex, France|Novartis Investigative Site, Ioannina, GR, Greece|Novartis Investigative Site, Thessaloniki, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Tamil Nadu, Chennai, India|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Admedabad, Gujarat, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Alessandria, AL, Italy|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, L'Aquila, AQ, Italy|Novartis Investigative Site, Arezzo, AR, Italy|Novartis Investigative Site, Asti, AT, Italy|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Treviglio, BG, Italy|Novartis Investigative Site, Benevento, BN, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, Monserrato, CA, Italy|Novartis Investigative Site, Cuneo, CN, Italy|Novartis Investigative Site, Cremona, CR, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Cona, FE, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Grosseto, GR, Italy|Novartis Investigative Site, Lecco, LC, Italy|Novartis Investigative Site, Livorno, LI, Italy|Novartis Investigative Site, Lucca, LU, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Macerata, MC, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Taormina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Nuoro, NU, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Prato, PO, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Fano, PU, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Reggio Emilia, RE, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Siena, SI, Italy|Novartis Investigative Site, Sassari, SS, Italy|Novartis Investigative Site, Savona, SV, Italy|Novartis Investigative Site, Trento, TN, Italy|Novartis Investigative Site, Candiolo, TO, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Terni, TR, Italy|Novartis Investigative Site, Udine, UD, Italy|Novartis Investigative Site, Saronno, VA, Italy|Novartis Investigative Site, Mirano, VE, Italy|Novartis Investigative Site, Negrar, VR, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Viterbo, VT, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Novara, Italy|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Tanjong Bungah, Penang, Malaysia|Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Putrajaya, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Ciudad de Mexico, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Venray, CE, Netherlands|Novartis Investigative Site, Apeldoorn, DZ, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Beverwijk, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Ede, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Goes, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hilversum, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Roermond, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-Geleen, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Zutphen, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Gralum, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Panama City, Panama|Novartis Investigative Site, Taguig City, Metro Manila, Philippines|Novartis Investigative Site, Las Pinas, Philippines|Novartis Investigative Site, San Juan City, Philippines|Novartis Investigative Site, Zory, Slaskie, Poland|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Bytom, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lublin, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Braga, Portugal|Novartis Investigative Site, Guimaraes, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, Kazan, Tatarstan Republic, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kaluga, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow Rerion Balashiha, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Rostov-na-Donu, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Makkah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Banska Bystrica, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Maribor, Slovenia|Novartis Investigative Site, Elche, Alicante, Spain|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Cordoba, Andalucia, Spain|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Huelva, Andalucia, Spain|Novartis Investigative Site, Jaen, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Jerez, Cadiz, Spain|Novartis Investigative Site, Toledo, Castilla La Mancha, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Lerida, Cataluna, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Girona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Barcelona, Cataluña, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Caceres, Extremadura, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Santiago de Compostela, Galicia, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Las Palmas De Gran Canarias, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Bilbao, Pais Vasco, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Vigo, Pontevedra, Spain|Novartis Investigative Site, La Laguna, Santa Cruz De Tenerife, Spain|Novartis Investigative Site, Reus, Tarragona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Granollers, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Gothenburg, Sweden|Novartis Investigative Site, Orebro, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Vaxjo, Sweden|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Peterborough, Cambridgeshire, United Kingdom|Novartis Investigative Site, Truro, Cornwall, United Kingdom|Novartis Investigative Site, Portsmouth, Hants, United Kingdom|Novartis Investigative Site, Maidstone, Kent, United Kingdom|Novartis Investigative Site, York, North Yorkshire, United Kingdom|Novartis Investigative Site, Aberdeen, Scotland, United Kingdom|Novartis Investigative Site, Ipswich, Suffolk, United Kingdom|Novartis Investigative Site, Guildford, Surrey, United Kingdom|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Bristol, United Kingdom|Novartis Investigative Site, Cardiff, United Kingdom|Novartis Investigative Site, East Sussex, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Preston, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Stoke-on-Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02941926/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/26/NCT02941926/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02941926"
379,"NCT03763604","Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer",,"Available","No Results Available","Metastatic Breast Cancer","Drug: Abemaciclib",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"17088|I3Y-MC-Y001",,,,"December 4, 2018",,"May 5, 2022","Liverpool Hospital, Liverpool, New South Wales, Australia|Liverpool Hospital, Liverpool, New South Wales, Australia|Mater Private Hospital, North Sydney, New South Wales, Australia|North West Cancer Centre, North Tamworth, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Wollongong Hospital, Wollongong, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide Oncology and Haematology, Calvary Central Districts Hospital, Elizabeth Vale, South Australia, Australia|Icon Cancer Centre - Hobart, Hobart, Tasmania, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital Outpatients, Box Hill, Victoria, Australia|Epworth Eastern Hospital, Box Hill, Victoria, Australia|Melbourne Cancer Care, Brighton, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Dr. Zimet Private Room, Richmond, Victoria, Australia|Slade Pharmacy Epworth Hospital, Richmond, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Icon Cancer Care - The Wesley Medical Centre, Auchenflower, Australia|Northern Beaches Hospital, Freches Forest, Australia|Northern Beaches Hospital, Freches Forest, Australia|Northern Beaches Hospital, Freches Forest, Australia|South Coast District Hospital, Victor Harbor, Australia|Tom Baker Cancer Center, Calgary, Alberta, Canada|Tom Baker Cancer Center, Calgary, Alberta, Canada|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Vancouver, Vancouver, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island, Victoria, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island, Victoria, British Columbia, Canada|British Columbia Cancer Agency - Vancouver Island, Victoria, British Columbia, Canada|Grand River Regional Cancer Centre, Kitchener, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Algoma District Cancer Program, Sault Ste. Marie, Ontario, Canada|Unity Health Toronto, St. Michael's Hospital, Toronto, Ontario, Canada|CHUL du CHU de Québec, Québec City, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Cairo Oncology Center (Cairo Cure), Mohandeseen, Cairo, Egypt|Apollo Cancer Institute, Apollo Speciality Hospital, Teynampet, Chennai, India|Indraprastha Apollo Hospital, New Delhi, India|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Torre, Roma, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Ospedale Di Circolo E Fondazione Macchi, Varese, Italy|National Cancer Center, Ilsandong-gu, Goyang-si Gyeonggi-do, Korea, Republic of|National Cancer Center, Ilsandong-gu, Goyang-si Gyeonggi-do, Korea, Republic of|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Inha University Hospital, Incheon, Incheon-gwangyeoksi [Incheon], Korea, Republic of|St. Mary's Hospital, Gyeonggi-do, Korea, Korea, Republic of|St. Mary's Hospital, Gyeonggi-do, Korea, Korea, Republic of|Gachon University Gil Hospital, Namdong-gu, Incheon, Korea, Korea, Republic of|Gachon University Gil Hospital, Namdong-gu, Incheon, Korea, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Korea, Republic of|National Cancer Center, Goyang-si, Kyǒnggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of|Ewha University Mokdong Hospital, Seoul, Yangcheon-gu, Korea, Republic of|Chungbuk National University Hospital, Chungcheongbuk-do, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Pantai Hospital Sungai Petani, Sungai Petani, Kedah, Malaysia|Gleneagles Penang, Georgetown, Penang, Malaysia|Penang Adventist Hospital, Georgetown, Penang, Malaysia|Penang Adventist Hospital, Georgetown, Penang, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, Malaysia|Beacon Hospital, Off Jalan Templer, Petaling JAYA, Malaysia|Beacon Hospital, Off Jalan Templer, Petaling JAYA, Malaysia|Pantai Hospital Penang, Bayan BARU, Pulau Pinang, Malaysia|Loh Guan Lye Specialists' Centre, Georgetown, Pulau Pinang, Malaysia|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|Subang Jaya Medical Centre, Petaling Jaya, Selangor, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Pantai Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Institut Kanser Negara, Putrajaya, Malaysia|Elizabeth Au Oncology, Singapore, Singapore|Vincent Pallotti Hospital, Pinelands, Cape Town, South Africa|Flora Clinic, Floracliff, Gauteng, South Africa|Olivedale Clinic, Johannesburg, Gauteng, South Africa|Netcare Linksfield Hospital, Johannesburg, Gauteng, South Africa|Donald Gordon Medical Center, Johannesburg, Gauteng, South Africa|Donald Gordon Medical Center, Johannesburg, Gauteng, South Africa|Wits Donald Gordon Clinical Trial Center, Johannesburg, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Sandton Oncology, Morningside, Gauteng, South Africa|DGMC Oncology, Parktown, Gauteng, South Africa|Amanzimtoti Oncology Centre, Durban, KwaZulu-Natal, South Africa|Hopelands Cancer Centre Hilton, Hilton, KZN, South Africa|Hopelands Cancer Centre Hilton, Hilton, KZN, South Africa|Abraham Oncology, Richards Bay, KZN, South Africa|GVI Oncology, George, Western Cape, South Africa|Dr Pirjol and Szpak Inc. Oncology Pratice, Amanzimtoti, South Africa|Cancercare Rondebosch Oncology, Cape Town, South Africa|Hospital Virgen de los Lirios, Alcoy, Alicante, Spain|Hospital Universitario Puerta del Mar, Cádiz, Andalucía, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Andalucía, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari Vall d'Hebron, Barcelona, Barcelona [Barcelona], Spain|Hospital Universitari General de Catalunya, Sant Cugat del Vallès, Barcelona [Barcelona], Spain|Hospital Universitari de Girona Dr. Josep Trueta, Girona, Barcelona, Spain|Hospital Duran I Reynals, Hospitalet De Llobregat, Barcelona, Spain|Hospital Duran I Reynals, Hospitalet De Llobregat, Barcelona, Spain|Hospital Duran I Reynals, Hospitalet De Llobregat, Barcelona, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain|Institut Catala d'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Corporacion Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Germans Trias i Pujol, Badalona, Catalunya [Cataluña], Spain|Hospital Germans Trias i Pujol, Badalona, Catalunya [Cataluña], Spain|Hospital Universitario de Canarias, Tenerife, La Laguna, Spain|Hospital Universitario de Canarias, Tenerife, La Laguna, Spain|Hospital Universitario de Canarias, Tenerife, La Laguna, Spain|Hospital Universitario Ramón y Cajal, Madrid, Madrid, Comunidad De, Spain|Hospital la Zarzuela, Aravaca, Madrid, Spain|Hospital De Mostoles, Mostoles, Madrid, Spain|Hospital De Mostoles, Mostoles, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Palma De Mallorca(Baleares), Spain|H. San Francisco de Borja (H. GANDIA), Gandia, Valencia, Spain|Hospital Lluis Alcanyis, Xativa, Valencia, Spain|Hospital De Basurto, Bilbao, Vizcaya, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Quironsalud Barcelona- END, Barcelona, Spain|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, Spain|Hospital Quirón Salud Barcelona-Instituto Oncológico Baselga, Barcelona, Spain|Hospital Universitari Dexeusa, Barcelona, Spain|Instituto Oncologico Dr Rosell (IOR), Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Arquitecto Marcide (Área Sanitaria de Ferrol), Coruña, Spain|Hospital Universitario San Cecilio, Granada, Spain|Hospital Universitario San Cecilio, Granada, Spain|Cl. Universitaria Navarra, Madrid, Spain|Centro Oncológico MD Anderson, Madrid, Spain|Hospital Ruber Internacional, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Hospital Infanta Cristina, Madrid, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Clinico Universitario Valencia, Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova Valencia, Valencia, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital de Sagunto, Valencia, Spain|IDCQ HOSPITALES Y SANIDAD, S.L.U. (Hospital Quirón Zaragoza), Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|Hospital Universitario Zaragoza, Zaragoza, Spain|Hospital Universitario Zaragoza, Zaragoza, Spain|Universitätsspital Basel, Basel, Basel Stadt, Switzerland|Hôpital de la Tour, La Tour Hôpital Privé SA, Meyrin, Geneva, Switzerland|Tumorzentrum ZeTuP Rapperswil-Jona, Rapperswil, Saint Gallen, Switzerland|Tumor- und Brustzentrum ZeTuP Sankt Gallen, St. Gallen, Saint Gallen, Switzerland|Cantonal Hospital St.Gallen, st.Gallen, Sankt Gallen, Switzerland|Oncologia Varini Calderoni Christinat, Lugano, Ticino, Switzerland|Hôpitaux Universitaires de Genève, Geneva, Switzerland|HUG-Hôpitaux Universitaires de Genève, Genève, Switzerland|Luzerner Kantonsspital, Luzern, Switzerland|OnkoZentrum Zürich AG, Zürich, Switzerland|OnkoZentrum Zürich AG, Zürich, Switzerland|Chiayi Chang Gung Memorial Hospital, Putzu City, Chiayi County, Taiwan|Chiayi Chang Gung Memorial Hospital, Putzu City, Chiayi County, Taiwan|Chiayi Chang Gung Memorial Hospital, Putzu City, Chiayi County, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Niaosong Dist, Kaohsiung City, Taiwan|Tri-Service General Hospital, Taipei City, Taipei, Taiwan|National Taiwan University Hospital Yunlin Branch, Zhongzheng District, Taipei, Taiwan|National Taiwan University Hospital Yunlin Branch, Zhongzheng District, Taipei, Taiwan|MacKay Memorial Hospital, New Taipei City, Tamsui District, Taiwan|Taichung Tzu Chi Hospital, Taichung, Tanzi District, Taiwan|Saint Paul's Hospital, Taoyuan, Taoyuan District, Taiwan|Kaohsiung Municipal Siaogang Hospital, Kaohsiung City, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Koo Foundation Sun Yan-Sen Cancer Center, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan|Far Eastern Memorial Hospital, Taipei, Taiwan|National Taiwan University Hospital Yunlin Branch, Yunlin County, Douliu City, Taiwan|Maharaj Nakorn Chiang Mai Hospital, Muang Chiangmai, Chiangmai, Thailand|Rajavithi Hospital, Bangkok, Ratchathewi District, Thailand|Songklanagarind Hospital, Hat Yai, Songkhla, Thailand|King Chulalongkorn Memoiral Hospsital, Bangkok, Thailand|Ramathibodi Hopsital, Bangkok, Thailand|Addenbrookes Hospital, Cambridge, Cambridgeshire, United Kingdom|Loom Dene, Radlett, Hertfordshire, United Kingdom|Northern Centre for Cancer Treatment, Newcastle Upon Tyne, Tyne And Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03763604"
380,"NCT00399035","Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","HORIZON II","Completed","Has Results","Metastatic Colorectal Cancer","Drug: Cediranib|Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|Drug: XELOX (Capecitabine and Oxaliplatin)|Drug: Cediranib Placebo","Progression-free Survival|Overall Survival|Overall Response Rate|Best Percentage Change in Tumour Size|Duration of Response|Rate of Resection of Liver Metastases|Time to Wound Healing Complications","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","1254","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8480C00051|EUDRACT No 2006-001194-14|HORIZON II","November 2006","March 2010","August 2016","November 14, 2006","October 30, 2012","December 28, 2016","Research Site, Buenos Aires City, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Resistencia, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, Ashford, Australia|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Hornsby, Australia|Research Site, Liverpool, Australia|Research Site, Waratah, Australia|Research Site, Wodonga, Australia|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Jaú, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, ChongQing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Brno, Czech Republic|Research Site, Ceske Budejovice, Czech Republic|Research Site, Cheb, Czech Republic|Research Site, Jicin, Czech Republic|Research Site, Jihlava, Czech Republic|Research Site, Olomouc, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 6, Czech Republic|Research Site, Pribram - Zdabor, Czech Republic|Research Site, Sumperk, Czech Republic|Research Site, Zlin, Czech Republic|Research Site, Znojmo, Czech Republic|Research Site, Essen, Germany|Research Site, Freiburg, Germany|Research Site, Goslar, Germany|Research Site, Hamburg, Germany|Research Site, Hildesheim, Germany|Research Site, Mannheim, Germany|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Györ, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szombathely, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, India|Research Site, Trivandrum, India|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Gliwice, Poland|Research Site, Kraków, Poland|Research Site, Olsztyn, Poland|Research Site, Toruń, Poland|Research Site, Wrocław, Poland|Research Site, Bellinzona, Switzerland|Research Site, Lausanne, Switzerland|Research Site, Locarno, Switzerland|Research Site, Zürich, Switzerland|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Aberdeen, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00399035"
381,"NCT00725387","Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy",,"Completed","No Results Available","Neoplasms",,"Percent of patients with evidence of new lesions on combined F-18/F-18 FDG PET/CT.","Stanford University","All","18 Years and older   (Adult, Older Adult)",,"214","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","VAR0024|98043|SU-07232008-1266","August 2007","December 2018","June 2019","July 30, 2008",,"September 18, 2019","Stanford University School of Medicine, Stanford, California, United States|Aalborg Hospital, Aalborg, Denmark|Apollo Hospital, Chennai, India|Coimbra University Hospital, Coimbra, Portugal|Pretoria Academic Hospital, Pretoria, South Africa",,"https://ClinicalTrials.gov/show/NCT00725387"
382,"NCT01183780","A Study in Second Line Metastatic Colorectal Cancer",,"Completed","Has Results","Colorectal Cancer","Biological: Ramucirumab|Biological: Placebo|Drug: Irinotecan|Drug: Folinic Acid|Drug: 5-Fluorouracil","Overall Survival (OS)|Progression-free Survival (PFS) Time|Percentage of Participants Achieving an Objective Response (Objective Response Rate)|Change From Baseline in European Organisation for Research and Treatment of Cancer [EORTC] QLQ-C30 Global Health Status|Change From Baseline in EuroQol- 5D (EQ-5D)|Percentage of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies|Observed Maximum Concentration (Cmax) and Observed Minimum Concentration (Cmin) of Ramucirumab","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1072","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13856|I4T-MC-JVBB|CP12-0920|2010-021037-32|CTRI/2011/07/001900","December 2, 2010","July 17, 2014","June 20, 2016","August 18, 2010","July 15, 2015","September 25, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sedona, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fayetteville, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Little Rock, Arkansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Duarte, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Escondido, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fresno, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Greenbrae, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Jolla, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rancho Cucamonga, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denver, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waterbury, Connecticut, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boynton Beach, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Lauderdale, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Myers, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ocala, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Port Saint Lucie, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Petersburg, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Titusville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augusta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marietta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thomasville, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Harvey, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peoria, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warrenville, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goshen, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muncie, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cherry Hill, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hackensack, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Morristown, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bronx, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hudson, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Jamaica, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Raleigh, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bend, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kingston, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Willow Grove, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Abilene, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beaumont, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Denton, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Flower Mound, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fort Worth, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garland, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., McAllen, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odessa, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Round Rock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sherman, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sugar Land, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Temple, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tyler, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Waco, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Webster, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita Falls, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ogden, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fairfax, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newport News, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winchester, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kennewick, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Spokane Valley, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milwaukee, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caba, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rosario, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucumain, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Viedma, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Randwick, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St. Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wodonga, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bedford Park, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Elizabeth Vale, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Krems, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bonheiden, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charleroi, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edegem, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haine-St.- Paul, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ijui, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Itajai, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sao Jose Do Rio Preto, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pardubice, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Copenhagen, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Chaussee Saint Victor, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Augsburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Balingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bamberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Halle, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lübeck, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mönchengladbach, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Weiden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chania, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ioannina, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kecskemet, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kolkata, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beer Sheva, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haifa, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Macerata, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Padova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reggio Emilia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiba, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ehime, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gifu, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hokkaido, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyogo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kochi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Osaka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saitama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shizuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tochigi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anyang, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Incheon, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suwon-City, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Breda, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Deventer, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Groningen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sittard - Geleen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayamon, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucharest, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cluj-Napoca, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ljubljana, Slovenia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sevilla, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kuei Shan Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01183780"
383,"NCT04232384","Comparison of ""Roll-over' Technique With Standard Abdominal Paracentesis in Suspected Peritoneal Carcinomatosis","ROLLON","Terminated","No Results Available","Ascites|Peritoneal Carcinomatosis|Peritoneum Neoplasm|Tuberculous Peritonitis","Procedure: Standard Paracentesis|Procedure: Roll Over Paracentesis","Yield of malignant cells|Cellularity of the smear of the smear","Postgraduate Institute of Medical Education and Research","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","71","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Diagnostic","NK/6111/DM/055","June 15, 2020","July 1, 2021","July 1, 2021","January 18, 2020",,"March 17, 2022","Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04232384"
384,"NCT00076024","AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer",,"Completed","Has Results","Breast Neoplasms","Drug: Placebo|Drug: Docetaxel|Drug: AG-013736 (axitinib)","Time to Tumor Progression (TTP)|Percentage of Participants With Objective Response (OR) for Phase 2 (Double-blind)|Percentage of Participants With Objective Response (OR) for Phase 2 (Open-label)|Duration of Response (DR) for Phase 2 (Double-blind)|Duration of Response (DR) for Phase 2 (Open-label)","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A4061010","February 2004","January 2007","November 2008","January 14, 2004","March 16, 2012","June 26, 2012","Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Berkeley, California, United States|Pfizer Investigational Site, Montebello, California, United States|Pfizer Investigational Site, Monterey Park, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Gabriel, California, United States|Pfizer Investigational Site, Whittier, California, United States|Pfizer Investigational Site, Jacksonville Beach, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Melbourne, Florida, United States|Pfizer Investigational Site, Orange Park, Florida, United States|Pfizer Investigational Site, Palatka, Florida, United States|Pfizer Investigational Site, St. Augustine, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Zion, Illinois, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Stony Brook, New York, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Corvallis, Oregon, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Novy Jicin, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Rozzano (Mi), Italy|Pfizer Investigational Site, Taormina, ME, Italy|Pfizer Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Girona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malaga, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Southampton, Hampshire, United Kingdom|Pfizer Investigational Site, Rickmansworth, Middlesex, United Kingdom|Pfizer Investigational Site, Nottingham, Nottinghamshire, United Kingdom|Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00076024"
385,"NCT00099294","Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer",,"Completed","No Results Available","Pancreatic Cancer","Drug: Glufosfamide","Overall Survival|Objective tumor response rate|Duration of objective tumor response rate|Progression-free survival|6 month and 12 month survival|Serum CA 19-9|Pain Intensity|Performance Status","Threshold Pharmaceuticals|PPD","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-CR-302","September 2004","January 2007","January 2007","December 10, 2004",,"April 30, 2009","Augusta Oncology Associates, Los Angeles, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Mile High Oncology, Denver, Colorado, United States|Northwestern Connecticut Oncology - Hematology Associates, Torrington, Connecticut, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Hematology/Oncology of the North Shore, Skokie, Illinois, United States|Fort Wayne Medical Oncology/Hem, Fort Wayne, Indiana, United States|Norton Healthcare Center, Louisville, Kentucky, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Hattiesburg Clinic Oncology, Hattiesburg, Mississippi, United States|Columbia Comprehensive Cancer Care Clinic, Columbia, Missouri, United States|Bond Clinic, Rolla, Missouri, United States|Deaconess Billings Clinic, Billings, Montana, United States|Office of Clinical Trials, Paramus, New Jersey, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Hanover Medical Specialists, Wilmington, North Carolina, United States|Vita Hematology Oncology PC, Bethlehem, Pennsylvania, United States|The Family Cancer Center , PLLC, Collierville, Tennessee, United States|Center for Oncology Research and Treatment, Dallas, Texas, United States|JPS Center for Cancer Care, Fort Worth, Texas, United States|Northern Utah Associates, Ogden, Utah, United States|Cancer Outreach Association, Abingdon, Virginia, United States|Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States|Hospital Interzonal General de Agudos, Buenos Aires, Argentina|Hospital Posadas, Buenos Aires, Argentina|Policlinica Privada Instituto de Medicina Nuclear, Buenos Aires, Argentina|Hospital Udaondo, Buenos Aires, Argentina|Hospital Alvarez, Buenos Aires, Argentina|Hospital Churruca - Visca, Buenos Aires, Argentina|Instituto Medico Alexander Fleming, Buenos Aires, Argentina|Instituto CAICI, Santa Fe, Argentina|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Brazil|Hospital Vera Cruz - Clinica de Oncologia, Belo Horizonte, Brazil|Hospital Luxemburgo, Belo Horizonte, Brazil|Hospital de Clínicas da UFPR, Curitiba, Brazil|Associacao de Combate ao Cancer em Goias, Hospital Araujo Jorge, Setor de Oncologia Clinica, Goiania, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Instituto Nacional do Cancer - INCA, Rio de Janeiro, Brazil|Clinica de Oncologia Medica S/C Ltda, Sao Paulo, Brazil|Hospital do Cancer - AC Camargo, Sao Paulo, Brazil|Grupo Paulista Oncologia Integrada, São Paulo, Brazil|Department of Chemotherapy Dr. Georgi Stranski General Hospital of Pleven University, Pleven, Bulgaria|First Internal Department Plovdiv Regional Oncology Center with In-patient Department, Plovdiv, Bulgaria|Department of Chemotherapy Sofia Regional Oncology Center, Sofia, Bulgaria|Chemotherapy Clinic Queen Joanna General Hospital, Sofia, Bulgaria|Haematology and Oncology Clinic Military Medical Academy, Sofia, Bulgaria|Chemotherapy Clinic Specialized Oncology Hospital, Sofia, Bulgaria|Department of Chemotherapy Veliko Tarnovo Regional Oncology Center, Tarnovo, Bulgaria|Department of Medicinal Oncotherapy and Palliative Care Dr. Marko Markov Regional Oncology Center, Varna, Bulgaria|Fakultni nemocnice Brno Oddeleni Klinicke Onkologie, Brno, Czech Republic|Masarykuv onkologicky Ustav, Brno, Czech Republic|Krajska nemocnice Pardubice,oddeleni Radiacni Onkologie, Kyjevska, Czech Republic|Onkologicka Klinika, Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Onkologicke Oddeleni, Batova krajska nemocnice Zlin, Zlin, Czech Republic|National Institute of Oncology, Budapest, Hungary|Szent Imre Korhaz Onkologia, Budapest, Hungary|Szent László Kórház, Onkológia, Budapest, Hungary|Vaszary Kolos Korhaz, Esztergom, Hungary|Petz Aladar County Hospital, Department of Oncology, Gyor, Hungary|Baranya megyei Korhaz Onkologial osztaly, Rakoczi, Hungary|Bangalore Institute of Oncology, Bangalore, India|Curie Centre of Oncology, Bangalore, India|Radhakrishan Birla Cancer Centre, Jaipur, India|Jaslok Hospital and Research Centre, Mumbai, India|Sir Ganga Ram Hospital, New Delhi, India|Hospital Universitario ""Dr. Angel Leano"", Zapopan, Jalisco, Mexico|Hospital y Clinica OCA S.A. De C.V., Monterrey, NL, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Departamento de Radioterapia., San Luis Potosi, SLP, Mexico|Hospital regional ISSSTE ""Merida"", Merida, Yucatan, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Hospital Clinica del Parque, Chihuahua, Mexico|Centro Medico ISSEMYM, Metepec, Mexico|Hospital general ""5 de Diciembre"" ISSSTE, Mexicali, Mexico|Hospital Regional de Especialidades No. 30 IMSS, Mexicali, Mexico|Hospital de Oncologia Centro Medico, Mexico, DF, Mexico|Instituto Nacional de Ciencias Medicas u Nutricion ""Salvador Zubiran"", Mexico, DF, Mexico|Fundeni Clinical Institute, Bucharest, Romania|Trestioreanu Institute of Oncology, Bucharest, Romania|""I. Chiricuta"" Institute of Oncology, Cluj-Napoca, Romania|Craiova Emergency Clinical County Hospital, Craiova, Romania|Timisoara City Hospital, Timisoara, Romania|Institute of Medical Radiology, Russian Academy of Medical Science, Obninsk, Kaluzhskaya Region, Russian Federation|Cheliabinsk Regional Oncology Center, Cheliabinsk, Russian Federation|Irkutsk Regional Oncology Center, Irkutsk, Russian Federation|Clinical Oncology Center, Kazan, Russian Federation|Krasnodar City Oncology Center, Krasnodar, Russian Federation|Blokhin Cancer Research Center, Dept of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation|Central Clinical Hospital of the presidentof the Russian Federation, Moscow, Russian Federation|Hertzen Research Institute of Oncology, Moscow, Russian Federation|Central Clinical Hospital of the Ministru of Transport n.a. Semashko, Moscow, Russian Federation|Orenburg, Regional Oncology Center, Orenburg, Russian Federation|Samara Oncology Center, Samara, Russian Federation|St. Petersburg, Central Research Institute of Radiology, St. Petersburg, Russian Federation|Medical Academy of Postgraduate Education, St. Petersburg, Russian Federation|St. Petersburg Oncology Center, St. Petersburg, Russian Federation|Mechnikov State Medical Academy, St.Petersburg, Russian Federation|Voronezh Regional Clinical Oncology Center, Voronezh, Russian Federation|Yaroslavl Regional Oncology Center, Yaroslavl, Russian Federation|Dnepropetrovsk City Clinical Hospital, Dnepropetrovsk, Ukraine|Donetsk Regional Antitumor Center, Donetsk, Ukraine|State Communal Healthcare Institution: Kharkov Regional Clinical Oncological Center, Kharkov, Ukraine|Institute of Oncology under the Academy of Medical Sciences of Ukraine, Kiev, Ukraine|Kiev Municipal Clinical Hospital #10, Kiev Center for Biliary, Biliary tracts and Pancreas Surgery, Kiev, Ukraine|Krivoy Rog City Oncology Center, Krivoy Rog, Ukraine|Lugansk Regional Clinical Oncological Center, Lugansk, Ukraine|Nikolaev Regional Oncology Centre, Nikolaev, Ukraine|Odessa Regional Clinical Hospital, Odessa, Ukraine|Vinnitsa Regional Clinical Oncology Center, Vinnitsa, Ukraine|Zaporozhye Medical Academy of Postgraduate Education, Zaporozhye, Ukraine|Zhitomir Regional Clinical Hospital n.a. O.F. Gerbachevsky, Zhitomir, Ukraine",,"https://ClinicalTrials.gov/show/NCT00099294"
386,"NCT01516307","Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects",,"Completed","No Results Available","Metastatic Breast Cancer","Biological: OPT-822/OPT-821(30 μg/100 μg)|Biological: Phosphate Buffer Saline (PBS)|Drug: Cyclophosphamide","Progression Free Survival (PFS)|Overall Survival (OS)","OBI Pharma, Inc","Female","21 Years and older   (Adult, Older Adult)","Phase 2","349","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","OPT-822-001","December 2011","August 2016","August 2019","January 24, 2012",,"September 16, 2020","The University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center, Fullerton, California, United States|University of California, San Diego (UCSD), La Jolla, California, United States|University of California, Irvine (UCI), Orange, California, United States|University of California, San Francisco (UCSF), San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|University of California, Los Angeles (UCLA), Santa Monica, California, United States|Memorial Regional Hospital, Hollywood, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Weill Cornell Medical College, New York, New York, United States|Hope Women's Cancer Center, Asheville, North Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|UNIMED Medical Institute, Hong-Kong, China|HCG, Bangalore Institute of Oncology, Bengaluru, India|Curie Manavata Cancer Centre, Mumbai, India|Pusan National University Hospital, Busan-si, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Inha University Hospital, Chungcheongbuk-Do, Korea, Republic of|National Cancer Center, Chungcheongbuk-Do, Korea, Republic of|Kyungpook National University Medical Center, Daegu, Korea, Republic of|Yeungnam University Medical Center, Daegu, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital ,, Seoul, Korea, Republic of|Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan|Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan|Chang Gung Memorial Hospital-KS, Kaohsiung, Taiwan|Chang Gung Memorial Hospital -Linkou, Linkou, Taiwan|Mackay Memorial Hospital, New Taipei City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan City, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|Koo Foundation Sun Yat-Sen Cancer Center, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei City, Taiwan|Chang Gung Memorial Hospital-Taipei, Taipei, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Shuang-Ho Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01516307"
387,"NCT00384735","An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized Trial","TOSS","Completed","No Results Available","Sarcoma",,"Overall Survival|Disease free survival","Terry Fox Foundation|Tata Memorial Hospital","All","1 Year to 65 Years   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TOSS","January 1, 2006","June 30, 2010","December 31, 2015","October 6, 2006",,"October 8, 2020","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00384735"
388,"NCT03556358","Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer",,"Completed","Has Results","Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer","Biological: TX05 (trastuzumab)|Biological: Herceptin®|Drug: Paclitaxel|Drug: Epirubicin|Drug: Cyclophosphamide","Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)|Objective Response Rate (ORR)","Tanvex BioPharma USA, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","809","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TX05-03","June 28, 2018","November 27, 2020","February 4, 2021","June 14, 2018","January 14, 2022","January 14, 2022","Tanvex Investigational Site 1008, Lesnoy, Minsk Region, Belarus|Tanvex Investigational Site 1007, Babruysk, Mogilev Region, Belarus|Tanvex Investigational Site 1003, Gomel, Belarus|Tanvex Investigational Site 1006, Grodno, Belarus|Tanvex Investigational Site 1002, Minsk, Belarus|Tanvex Investigational Site 1005, Mogilev, Belarus|Tanvex Investigational Site 1001, Vitebsk, Belarus|Tanvex Investigational Site 4001, Temuco, Chile|Tanvex Investigational Site 4002, Viña Del Mar, Chile|Tanvex Investigational Site 5006, Batumi, Georgia|Tanvex Investigational Site 5002, Batumi, Georgia|Tanvex Investigational Site 5003, Tbilisi, Georgia|Tanvex Investigational Site 5001, Tbilisi, Georgia|Tanvex Investigational Site 5005, Tbilisi, Georgia|Tanvex Investigational Site 5012, Tbilisi, Georgia|Tanvex Investigational Site 5013, Tbilisi, Georgia|Tanvex Investigational Site 5004, Tbilisi, Georgia|Tanvex Investigational Site 5010, Tbilisi, Georgia|Tanvex Investigational Site 5011, Tbilisi, Georgia|Tanvex Investigational Site 5008, Tbilisi, Georgia|Tanvex Investigational Site 5009, Tbilisi, Georgia|Tanvex Investigational Site 5007, Tbilisi, Georgia|Tanvex Investigational Site 6003, Budapest, Hungary|Tanvex Investigational Site 6007, Budapest, Hungary|Tanvex Investigational Site 6005, Debrecen, Hungary|Tanvex Investigational Site 6006, Győr, Hungary|Tanvex Investigational Site 6004, Miskolc, Hungary|Tanvex Investigational Site 6001, Pécs, Hungary|Tanvex Investigational Site 7007, Nashik, Maharashtra, India|Tanvex Investigational Site 7015, Pune, Maharashtra, India|Tanvex Investigational Site 7003, Pune, Maharashtra, India|Tanvex Investigational Site 7004, Pune, Maharashtra, India|Tanvex Investigational Site 7002, Bīkaner, Rajasthan, India|Tanvex Investigational Site 7010, Madurai, Tamil Nadu, India|Tanvex Invesitgational Site 7033, Ahmedabad, India|Tanvex Investigational Site 7019, Bangalore, India|Tanvex Investigational Site 7037, Bangalore, India|Tanvex Investigational Site 7022, Belgaum, India|Tanvex Investigational Site 7034, Chandigarh, India|Tanvex Investigational Site 7013, Coimbatore, India|Tanvex Investigational Site 7024, Gurgaon, India|Tanvex Investigational Site 7045, Hyderabad, India|Tanvex Investigational Site 7036, Hyderabad, India|Tanvex Investigational Site 7009, Jaipur, India|Tanvex Investigational Site 7039, Kolkata, India|Tanvex Investigational Site 7040, Kolkata, India|Tanvex Investigational Site 7006, Kolkata, India|Tanvex Investigational Site 7005, Lucknow, India|Tanvex Investigational Site 7012, Manipala, India|Tanvex Investigational Site 7041, Model Town, India|Tanvex Investigational Site 7031, Naka, India|Tanvex Investigational Site 7001, Nashik, India|Tanvex Investigational Site 7042, Trichy, India|Tanvex Investigational Site 7018, Vadodara, India|Tanvex Investigational Site 7017, Vijayawada, India|Tanvex Investigational Site 2102, Monterrey, Nuevo León, Mexico|Tanvex Investigational Site 2117, Aguascalientes, Mexico|Tanvex Investigational Site 2109, Aguascalientes, Mexico|Tanvex Investigational Site 2116, Cancun, Mexico|Tanvex Investigational Site 2111, Ciudad de mexico, Mexico|Tanvex Investigational Site 2104, Cuauhtemoc, Mexico|Tanvex Investigational Site 2114, Cuauhtémoc, Mexico|Tanvex Investigational Site 2101, Cuautitlán Izcalli, Mexico|Tanvex Investigational Site 2113, Mexico, Mexico|Tanvex Investigational Site 2103, Monterrey, Mexico|Tanvex Investigational Site 2106, Oaxaca, Mexico|Tanvex Investigational Site 2112, San Luis Potosí, Mexico|Tanvex Investigational Site 2110, Tequisquiapan, Mexico|Tanvex Investigational Site 2108, Zapopan, Mexico|Tanvex Investigational Site 1104, Chiclayo, Lambayeque, Peru|Tanvex Investigational Site 1112, Lima Cercado, Lima, Peru|Tanvex Investigational Site 1108, San Borja, Lima, Peru|Tanvex Investigational Site 1113, San Borja, Lima, Peru|Tanvex Investigational Site 1101, Arequipa, Peru|Tanvex Investigational Site 1107, Arequipa, Peru|Tanvex Investigational Site 1110, Lima, Peru|Tanvex Investigational Site 1105, San Isidro, Peru|Tanvex Investigational Site 1102, San Isidro, Peru|Tanvex Investigational Site 1109, Surquillo, Peru|Tanvex Investigational Site 1103, Trujillo, Peru|Tanvex Investigational Site 1210, Santo Tomas, Batangas, Philippines|Tanvex Investigational Site 1203, Cebu City, Cebu, Philippines|Tanvex Investigational Site 1204, Cebu City, Cebu, Philippines|Tanvex Investigational Site 1211, Cebu City, Cebu, Philippines|Tanvex Investigational Site 1208, Quezon City, Manila, Philippines|Tanvex Investigational Site 1207, Manila, Metro Manila, Philippines|Tanvex Investigational Site 1206, Bacolod City, Negros Occidental, Philippines|Tanvex Investigational Site 1212, Davao City, Philippines|Tanvex Investigational Site 1214, Makati City, Philippines|Tanvex Investigational Site 1201, Manila, Philippines|Tanvex Investigational Site 1209, Quezon City, Philippines|Tanvex Investigational Site 1213, Quezon City, Philippines|Tanvex Investigational Site 1529, Krasnodar, Krasnodar Region, Russian Federation|Tanvex Investigational Site 1513, Sochi, Krasnodar Region, Russian Federation|Tanvex Investigational Site 1509, Omsk, Omsk Region, Russian Federation|Tanvex Investigational Site 1522, Ufa, Republic Of Bashkortostan, Russian Federation|Tanvex Investigational Site 1510, Pushkin, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1511, Novosibirsk, Siberia, Russian Federation|Tanvex Investigational Site 1519, Pyatigorsk, Stavropol Region, Russian Federation|Tanvex Investigational Site 1518, Tomsk, Tomsk Region, Russian Federation|Tanvex Investigational Site 1535, Arkhangel'sk, Russian Federation|Tanvex Investigational Site 1531, Belgorod, Russian Federation|Tanvex Investigational Site 1538, Chelyabinsk, Russian Federation|Tanvex Investigational Site 1520, Ivanovo, Russian Federation|Tanvex Investigational Site 1515, Izhevsk, Russian Federation|Tanvex Investigational Site 1502, Kaluga, Russian Federation|Tanvex Investigational Site 1540, Kazan, Russian Federation|Tanvex Investigational Site 1512, Krasnoyarsk, Russian Federation|Tanvex Investigational Site 1505, Kursk, Russian Federation|Tanvex Investigational Site 1530, Moscow, Russian Federation|Tanvex Investigational Site 1536, Moscow, Russian Federation|Tanvex Investigational Site 1514, Moscow, Russian Federation|Tanvex Investigational Site 1507, Moscow, Russian Federation|Tanvex Investigational Site 1503, Omsk, Russian Federation|Tanvex Investigational Site 1537, Orenburg, Russian Federation|Tanvex Investigational Site 1521, Rostov-Na-Donu, Russian Federation|Tanvex Investigational Site 1516, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1517, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1523, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1525, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1506, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1526, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1501, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1524, Saint-Petersburg, Russian Federation|Tanvex Investigational Site 1508, Saransk, Russian Federation|Tanvex Investigational Site 1533, Tomsk, Russian Federation|Tanvex Investigational Site 1534, Yaroslavl, Russian Federation|Tanvex Investigational Site 1808, Chernihiv, Ukraine|Tanvex Investigational Site 1821, Chernivtsi, Ukraine|Tanvex Investigational Site 1803, Dnepropetrovsk, Ukraine|Tanvex Investigational Site 1824, Dnipro, Ukraine|Tanvex Investigational Site 1820, Kherson, Ukraine|Tanvex Investigational Site 1812, Khmelnytskyi, Ukraine|Tanvex Investigational Site 1815, Kiev, Ukraine|Tanvex Investigational Site 1811, Kiev, Ukraine|Tanvex Investigational Site 1802, Kiev, Ukraine|Tanvex Investigational Site 1814, Kirovogrado, Ukraine|Tanvex Investigational Site 1819, Kropyvnytskyi, Ukraine|Tanvex Investigational Site 1804, Kryvyi Rih, Ukraine|Tanvex Investigational Site 1809, Kyiv, Ukraine|Tanvex Investigational Site 1810, Odesa, Ukraine|Tanvex Investigational Site 1806, Sumy, Ukraine|Tanvex Investigational Site 1822, Ternopil', Ukraine|Tanvex Investigational Site 1818, Vinnitsya, Ukraine|Tanvex Investigational Site 1813, Zaporizhzhia, Ukraine|Tanvex Investigational Site 1823, Úzhgorod, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03556358/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/58/NCT03556358/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03556358"
389,"NCT02472964","Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.","HERiTAge","Completed","Has Results","Breast Cancer","Biological: Trastuzumab|Biological: MYL- 1401O|Drug: Paclitaxel|Drug: Docetaxel","Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population","Mylan Inc.|Mylan GmbH|Viatris Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MYL-Her 3001|2011-001965-42","July 2012","March 2016","August 2018","June 16, 2015","October 30, 2018","February 14, 2022","Mylan Investigational Site, Barretos, Brazil|Mylan Investigational Site, Brasilia, Brazil|Mylan Investigational Site, Goiania, Brazil|Mylan Investigational Site, Ijui, Brazil|Mylan Investigational Site, Jau, Brazil|Mylan Investigational Site, Joinville, Brazil|Mylan Investigational Site, Morumbi, Brazil|Mylan Investigational Site, Porto Alegre, Brazil|Mylan Investigational Site, Salvador,, Brazil|Mylan Investigational Site, Santo Andre, Brazil|Mylan Investigational Site, Sao Paulo, Brazil|Mylan Investigational Site, Sorocaba, Brazil|Mylan Investigational Site, Santiago, Chile|Mylan Investigational Site, Temuco, Chile|Mylan Investigational Site, Batumi, Georgia|Mylan Investigational Site, Tblisi, Georgia|Mylan Investigational Site, Budapest, Hungary|Mylan Investigational Site, Debrecen, Hungary|Mylan Investigational Site, Gyod, Hungary|Mylan Investigational Site, Gyula, Hungary|Mylan Investigational Site, Miskolc, Hungary|Mylan Investigational Site, Nyiregyhaza, Hungary|Mylan Investigational Site, Szekszard, Hungary|Mylan Investigational Site, Szolnok, Hungary|Mylan Investigational Site, Ahmedabad, India|Mylan Investigational Site, Bangalore, India|Mylan Investigational Site, Chennai, India|Mylan Investigational Site, Gurgaon, India|Mylan Investigational Site, Hyderabad, India|Mylan Investigational Site, Jaipur, India|Mylan Investigational Site, Karamsad, India|Mylan Investigational Site, Madurai, India|Mylan Investigational Site, Mumbai, India|Mylan Investigational Site, Nashik, India|Mylan Investigational Site, Pune, India|Mylan Investigational Site, Surat, India|Mylan Investigational Site, Vijaywada, India|Mylan Investigational Site, Daugavpils, Latvia|Mylan Investigational Site, Leipaja, Latvia|Mylan Investigational Site, Riga, Latvia|Mylan Investigational Site, Arequipa, Peru|Mylan Investigational Site, Lima, Peru|Mylan Investigational Site, Surquillo, Peru|Mylan Investigational Site, Brasov, Romania|Mylan Investigational Site, Bucharest, Romania|Mylan Investigational Site, Bucuresti, Romania|Mylan Investigational Site, Cluj- Napoca, Romania|Mylan Investigational Site, Constanta, Romania|Mylan Investigational Site, Craiva, Romania|Mylan Investigational Site, Filimon Sirbu, Romania|Mylan Investigational Site, Iasi, Romania|Mylan Investigational Site, Oradea, Romania|Mylan Investigational Site, Timisoara, Romania|Mylan Investigational Site, Arkhangelsk, Russian Federation|Mylan Investigational Site, Ivanovo, Russian Federation|Mylan Investigational Site, Kazan, Russian Federation|Mylan Investigational Site, Kursk, Russian Federation|Mylan Investigational Site, Moscow, Russian Federation|Mylan Investigational Site, Rostov-On-Don, Russian Federation|Mylan Investigational Site, Ryazan, Russian Federation|Mylan Investigational Site, Samara, Russian Federation|Mylan Investigational Site, St. Petersburg, Russian Federation|Mylan Investigational Site, Belgrade, Serbia|Mylan Investigational Site, Kamenica, Serbia|Mylan Investigational Site, Sremska, Serbia|Mylan Investigational Site, Bardejov, Slovakia|Mylan Investigational Site, Kosice, Slovakia|Mylan Investigational Site, Nove Zamky, Slovakia|Mylan Investigational Site, Trnava, Slovakia|Mylan Investigator Site, Bloemfontein, South Africa|Mylan Investigator Site, Durban, South Africa|Mylan Investigational Site, George, South Africa|Mylan Investigational Site, Johannesburg, South Africa|Mylan Investigator Site, Kraaifontein, South Africa|Mylan Investigational Site, Port Elizabeth, South Africa|Mylan Investigational Site, Pretoria, South Africa|Mylan Investigational Site, Vereeniging, South Africa|Mylan Investigator Site, Bangkok, Thailand|Mylan Investigator Site, Chiang mai, Thailand|Mylan Investigator Site, Phitsanulok, Thailand|Mylan Investigator Site, Rajthavee, Thailand|Mylan Investigator Site, Songkla, Thailand|Mylan Investigator Site, Ankara, Turkey|Mylan Investigator Site, Istanbul, Turkey|Mylan Investigator Site, Izmir, Turkey|Mylan Investigator Site, Kocaeli, Turkey|Mylan Investigator Site, Cherkassy, Ukraine|Mylan Investigator Site, Chernivtsi, Ukraine|Mylan Investigator Site, Dnipropetrovsk, Ukraine|Mylan Investigator Site, Lutsk, Ukraine|Mylan Investigator Site, Lviv, Ukraine|Mylan Investigator Site, Sumy, Ukraine|Mylan Investigator Site, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT02472964"
390,"NCT00507429","Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer","FACT","Terminated","Has Results","Anaplastic Thyroid Cancer","Drug: CA4P|Drug: paclitaxel|Drug: carboplatin","Overall Survival|To Determine Progression Free Survival|To Determine Percentage of 1 Year Survival","Mateon Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OXC4T4-302","August 2007","October 2011","November 2011","July 26, 2007","June 9, 2014","June 9, 2014","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, School of Medicine, New Haven, Connecticut, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Care Center at John Hopkins, Baltimore, Maryland, United States|University of Minnesota Otolaryngology Department, Minneapolis, Minnesota, United States|Ireland Cancer Center/Division od Hematology, Cleveland, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Belarus National Medical University, Minsk, Belarus|Regional Oncology Dispensary with Inpatient Sector, Plodiv, Bulgaria|Specialized Hospital for Active Treatment of Oncology, Sofia, Bulgaria|Universtiy Multiprofile Hospital, ISUI, Clinic of Oncotherapy, Sofia, Bulgaria|University Hospital, Cairo, Cairo, Egypt|Mediciti Hospital, Hyderabaad, Andhra Pradesh, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Apollo Cancer Institute, New Delhi, Delhi, India|Kidwai Memorial Hospital, Bangalore, Karnataka, India|Shirdi Sai Baba Cancer Hospital, Manipal, Karnataka, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Christian Medial College, Vellore, Tamil Nadu, India|Telaviv Sourasky Medical Center, Head and Neck Service Division of Oncology, Tel-Aviv, Israel|Lo Studio E la Cura, Milano, Italy|INT Napoli Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto (IOV) - IRCCS, Padova, Italy|Azienda Ospedaliero - Universitaria Pisana, Pisa, Italy|Zaklad Medyczny Nuklearnej i Endykrynologii, Gliwice, Poland|Klinika Nowotworow Glowy i Szyji, Warszawa, Poland|Institutul Oncologic, Cluj-Napoca, Romania|SC Meditech SRL, Craiova, Romania|Centr of Medical Oncology, Iasi, Romania|Clinical County Hospital Sibiu, Sibiu, Romania|Emergency Clinical County Hospital ""Sf. loan cel Nou"", Suceava, Romania|City Clinical Oncology Dispensary, Saint Petersburg, Russian Federation|Ukrainian Academy of Medical Science, Lomonosova 33/43, Kiev, Ukraine|Regional Clinical Oncology Dispensary, Lvov, Ukraine|Beatson Oncology Centre, Gartnavel General Hospital, Glasgow, Scotland, United Kingdom|Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom|Southampton Hospital Oncology Centre, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00507429"
391,"NCT00858364","Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy",,"Terminated","Has Results","Non-Small Cell Lung Cancer|Anemia|Cancer|Lung Cancer","Drug: Darbepoetin alfa|Drug: Placebo","Overall Survival (OS)|Progression-free Survival (PFS)|Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 5 to End of the Efficacy Treatment Period|Number of Participants With Adverse Events of Special Interest|Percentage of Participants With an Objective Tumor Response|Number of Participants Who Developed Neutralizing Antibodies to Darbepoetin Alfa|Percentage of Participants With a Red Blood Cell Transfusion or Hemoglobin ≤ 8.0 g/dL From Week 1 to End of the Efficacy Treatment Period|Change From Baseline in Hemoglobin to End of Efficacy Treatment Period","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","2549","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20070782|2007-005792-34","July 17, 2009","June 7, 2017","June 7, 2017","March 9, 2009","July 6, 2018","July 6, 2018","Research Site, Anniston, Alabama, United States|Research Site, Birmingham, Alabama, United States|Research Site, Anchorage, Alaska, United States|Research Site, Tucson, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Hot Springs, Arkansas, United States|Research Site, Jonesboro, Arkansas, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Anaheim, California, United States|Research Site, Arcadia, California, United States|Research Site, Berkeley, California, United States|Research Site, Burbank, California, United States|Research Site, Downey, California, United States|Research Site, Fountain Valley, California, United States|Research Site, Fresno, California, United States|Research Site, Fresno, California, United States|Research Site, La Verne, California, United States|Research Site, Lancaster, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Merced, California, United States|Research Site, Mission Hills, California, United States|Research Site, Montebello, California, United States|Research Site, Oxnard, California, United States|Research Site, Palm Springs, California, United States|Research Site, Pismo Beach, California, United States|Research Site, Pomona, California, United States|Research Site, Redlands, California, United States|Research Site, Saint Helena, California, United States|Research Site, Salinas, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Simi Valley, California, United States|Research Site, Soquel, California, United States|Research Site, Torrance, California, United States|Research Site, Vallejo, California, United States|Research Site, West Covina, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Englewood, Colorado, United States|Research Site, Bridgeport, Connecticut, United States|Research Site, Southington, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Washington, District of Columbia, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Fort Lauderdale, Florida, United States|Research Site, Holiday, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Kissimmee, Florida, United States|Research Site, Lake Worth, Florida, United States|Research Site, Lakeland, Florida, United States|Research Site, Lecanto, Florida, United States|Research Site, Miami, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, New Port Richey, Florida, United States|Research Site, Orange City, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Rockledge, Florida, United States|Research Site, Tamarac, Florida, United States|Research Site, The Villages, Florida, United States|Research Site, Titusville, Florida, United States|Research Site, Weston, Florida, United States|Research Site, Albany, Georgia, United States|Research Site, Augusta, Georgia, United States|Research Site, Stockbridge, Georgia, United States|Research Site, Thomasville, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Galesburg, Illinois, United States|Research Site, Gurnee, Illinois, United States|Research Site, Mount Vernon, Illinois, United States|Research Site, Skokie, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Michigan City, Indiana, United States|Research Site, Muncie, Indiana, United States|Research Site, Council Bluffs, Iowa, United States|Research Site, Dubuque, Iowa, United States|Research Site, Iowa City, Iowa, United States|Research Site, Sioux City, Iowa, United States|Research Site, Waterloo, Iowa, United States|Research Site, Hutchinson, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Ashland, Kentucky, United States|Research Site, Hazard, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Morehead, Kentucky, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Alexandria, Louisiana, United States|Research Site, Lafayette, Louisiana, United States|Research Site, Marrero, Louisiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Ruston, Louisiana, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Lewiston, Maine, United States|Research Site, Rockport, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Bethesda, Maryland, United States|Research Site, Chevy Chase, Maryland, United States|Research Site, Cumberland, Maryland, United States|Research Site, Frederick, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Westminster, Maryland, United States|Research Site, Attleboro, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Cambridge, Massachusetts, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Clarkston, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Kalamazoo, Michigan, United States|Research Site, Southfield, Michigan, United States|Research Site, Southgate, Michigan, United States|Research Site, Willmar, Minnesota, United States|Research Site, Biloxi, Mississippi, United States|Research Site, Hattiesburg, Mississippi, United States|Research Site, Jackson, Mississippi, United States|Research Site, Tupelo, Mississippi, United States|Research Site, Columbia, Missouri, United States|Research Site, Jefferson City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Springfield, Missouri, United States|Research Site, Great Falls, Montana, United States|Research Site, Kalispell, Montana, United States|Research Site, Grand Island, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Henderson, Nevada, United States|Research Site, North Las Vegas, Nevada, United States|Research Site, Manchester, New Hampshire, United States|Research Site, Sparta, New Jersey, United States|Research Site, Teaneck, New Jersey, United States|Research Site, Vineland, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Santa Fe, New Mexico, United States|Research Site, Albany, New York, United States|Research Site, Brooklyn, New York, United States|Research Site, Buffalo, New York, United States|Research Site, Glens Falls, New York, United States|Research Site, Goshen, New York, United States|Research Site, Lake Success, New York, United States|Research Site, Latham, New York, United States|Research Site, Nyack, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Staten Island, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Valhalla, New York, United States|Research Site, Asheboro, North Carolina, United States|Research Site, Asheville, North Carolina, United States|Research Site, Burlington, North Carolina, United States|Research Site, Concord, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Goldsboro, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, Hickory, North Carolina, United States|Research Site, High Point, North Carolina, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Kinston, North Carolina, United States|Research Site, Pinehurst, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Washington, North Carolina, United States|Research Site, Bismarck, North Dakota, United States|Research Site, Akron, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Massillon, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Port Clinton, Ohio, United States|Research Site, Sylvania, Ohio, United States|Research Site, Wooster, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Tulsa, Oklahoma, United States|Research Site, Bethlehem, Pennsylvania, United States|Research Site, Gettysburg, Pennsylvania, United States|Research Site, Langhorne, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Upland, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wynnewood, Pennsylvania, United States|Research Site, Pawtucket, Rhode Island, United States|Research Site, Providence, Rhode Island, United States|Research Site, Woonsocket, Rhode Island, United States|Research Site, Aiken, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Charleston, South Carolina, United States|Research Site, Columbia, South Carolina, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Sumter, South Carolina, United States|Research Site, Aberdeen, South Dakota, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Watertown, South Dakota, United States|Research Site, Johnson City, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Abilene, Texas, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Beaumont, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Bryan, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Garland, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Longview, Texas, United States|Research Site, McAllen, Texas, United States|Research Site, Mesquite, Texas, United States|Research Site, Midland, Texas, United States|Research Site, Paris, Texas, United States|Research Site, Richardson, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Sherman, Texas, United States|Research Site, Southlake, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Temple, Texas, United States|Research Site, The Woodlands, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Waco, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Wichita Falls, Texas, United States|Research Site, Ogden, Utah, United States|Research Site, White River Junction, Vermont, United States|Research Site, Christiansburg, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Lynchburg, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Bremerton, Washington, United States|Research Site, Burien, Washington, United States|Research Site, Edmonds, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Tacoma, Washington, United States|Research Site, Vancouver, Washington, United States|Research Site, Yakima, Washington, United States|Research Site, Green Bay, Wisconsin, United States|Research Site, Janesville, Wisconsin, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Quilmes, Buenos Aires, Argentina|Research Site, Cordoba, Córdoba, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Research Site, Ciudad Autónoma de Buenos Aires, Distrito Federal, Argentina|Research Site, San Salvador de Jujuy, Jujuy, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, San Miguel de Tucuman, Tucuman, Argentina|Research Site, Buenos Aires, Argentina|Research Site, La Rioja, Argentina|Research Site, Santa Fe, Argentina|Research Site, Steyr, Austria|Research Site, Wien, Austria|Research Site, Ieper, Belgium|Research Site, Libramont, Belgium|Research Site, Liège, Belgium|Research Site, Namur, Belgium|Research Site, Ottignies, Belgium|Research Site, Salvador, Bahia, Brazil|Research Site, Salvador, Bahia, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Fortaleza, Ceará, Brazil|Research Site, Brasilia, Distrito Federal, Brazil|Research Site, Cachoeiro de Itapemirim, Espírito Santo, Brazil|Research Site, Campo Grande, Mato Grosso Do Sul, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Belo Horizonte, Minas Gerais, Brazil|Research Site, Curitba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Curitiba, Paraná, Brazil|Research Site, Londrina, Paraná, Brazil|Research Site, Belem, Pará, Brazil|Research Site, Ijui, Rio Grande Do Sul, Brazil|Research Site, Passo Fundo, Rio Grande Do Sul, Brazil|Research Site, Pelotas, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Porto Alegre, Rio Grande Do Sul, Brazil|Research Site, Itajaí, Santa Catarina, Brazil|Research Site, Ribeirao Preto, São Paulo, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Santo Andre, São Paulo, Brazil|Research Site, Sao Jose dos Campos, São Paulo, Brazil|Research Site, Sao Paulo, São Paulo, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Rousse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Moncton, New Brunswick, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Saint-Jerome, Quebec, Canada|Research Site, Temuco, Cautín, Chile|Research Site, Renaca, Valparaíso, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Beijing, Beijing, China|Research Site, Chongqing, Chongqing, China|Research Site, Fuzhou, Fujian, China|Research Site, Fuzhou, Fujian, China|Research Site, Lanzhou, Gansu, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Zhongshan, Guangdong, China|Research Site, Haikou, Hainan, China|Research Site, Haikou, Hainan, China|Research Site, Shijiazhuang, Hebei, China|Research Site, Harbin, Heilongjiang, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Suzhou, Jiangsu, China|Research Site, Nanchang, Jiangxi, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, XI An, Shaanxi, China|Research Site, Jinan, Shandong, China|Research Site, Chengdu, Sichuan, China|Research Site, Chengdu, Sichuan, China|Research Site, Urumqi, Xinjiang, China|Research Site, Kunming, Yunnan, China|Research Site, Kunming, Yunnan, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Chongqing, China|Research Site, Chongqing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Rijeka, Croatia|Research Site, Zagreb, Croatia|Research Site, Benesov U Prahy, Czechia|Research Site, Horovice, Czechia|Research Site, Kutna Hora, Czechia|Research Site, Kyjov, Czechia|Research Site, Nova Ves pod Plesi, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 8, Czechia|Research Site, Pribram, Czechia|Research Site, Bad Berka, Germany|Research Site, Bad Saarow, Germany|Research Site, Bamberg, Germany|Research Site, Grosshansdorf, Germany|Research Site, Halle (Saale), Germany|Research Site, Hemer, Germany|Research Site, Köln-Merheim, Germany|Research Site, Köln, Germany|Research Site, Moers, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, München, Germany|Research Site, Münster, Germany|Research Site, Ulm, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Chania, Greece|Research Site, Larissa, Greece|Research Site, Nea Kifissia, Athens, Greece|Research Site, Piraeus, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, New Delhi, Delhi, India|Research Site, Panaji, Goa, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Belgaum, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Ahmednagar, Maharashtra, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Miraj, Maharashtra, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Thane, Maharashtra, India|Research Site, Jaipur, Rajasthan, India|Research Site, Jaipur, Rajasthan, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Kolkata, West Bengal, India|Research Site, Kolkata, West Bengal, India|Research Site, Bangalore, India|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Jerusalem, Israel|Research Site, Kefar Saba, Israel|Research Site, Poria Eylit, Israel|Research Site, Rehovot, Israel|Research Site, Tel Aviv, Israel|Research Site, Catania, Italy|Research Site, Faenza RA, Italy|Research Site, Grosseto, Italy|Research Site, Lecce, Italy|Research Site, Legnago VR, Italy|Research Site, Lugo RA, Italy|Research Site, Meldola FC, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Ravenna, Italy|Research Site, Reggio Calabria, Italy|Research Site, San Giovanni Rotondo FG, Italy|Research Site, Nagoya-shi, Aichi, Japan|Research Site, Fukui-Shi, Fukui, Japan|Research Site, Chikushino-shi, Fukuoka, Japan|Research Site, Kurume-shi, Fukuoka, Japan|Research Site, Amagasaki-shi, Hyogo, Japan|Research Site, Kobe-shi, Hyogo, Japan|Research Site, Kobe, Hyogo, Japan|Research Site, Nishinomiya-shi, Hyogo, Japan|Research Site, Kanazawa, Ishikawa, Japan|Research Site, Sagamihara-shi, Kanagawa, Japan|Research Site, Okayama-shi, Okayama, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Osaka-shi, Osaka, Japan|Research Site, Bunkyo-ku, Tokyo, Japan|Research Site, Shinjuku-ku, Tokyo, Japan|Research Site, Yonago-shi, Tottori, Japan|Research Site, Kyoto, Japan|Research Site, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Gyeonggi-do, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Esch-Sur-Alzette, Luxembourg|Research Site, Luxembourg, Luxembourg|Research Site, Kota Bharu, Kelantan, Malaysia|Research Site, Kuantan, Pahang, Malaysia|Research Site, Georgetown, Pinang, Malaysia|Research Site, Kota Kinabalu, Sabah, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Research Site, Saltillo, Coahuila, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Mexico, Distrito Federal, Mexico|Research Site, Leon, Guanajuato, Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Monterrey, Nuevo León, Mexico|Research Site, Queretaro, Querétaro, Mexico|Research Site, San Luis Potosi, San Luis Potosí, Mexico|Research Site, Merida, Yucatán, Mexico|Research Site, Chihuahua, Mexico|Research Site, Colima, Mexico|Research Site, Oaxaca, Mexico|Research Site, Puebla, Mexico|Research Site, Breda, Netherlands|Research Site, Eindhoven, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Davao City, Davao, Philippines|Research Site, Baguio City, Philippines|Research Site, Cebu City, Philippines|Research Site, Makati City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Metro Manila, Philippines|Research Site, Pasig City, MetroManila, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Glucholazy, Poland|Research Site, Konin, Poland|Research Site, Krakow, Poland|Research Site, Krakow, Poland|Research Site, Lomza, Poland|Research Site, Olsztyn, Poland|Research Site, Olsztyn, Poland|Research Site, Rzeszow, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, San Juan, Puerto Rico|Research Site, San Juan, Puerto Rico|Research Site, Cluj Napoca, Romania|Research Site, Craiova, Romania|Research Site, Lasi, Romania|Research Site, Sibiu, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Belgorod, Russian Federation|Research Site, Ivanovo, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Lipetsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Orenburg, Russian Federation|Research Site, Penza, Russian Federation|Research Site, Pyatigorsk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, Stavropol, Russian Federation|Research Site, Tula, Russian Federation|Research Site, Tver, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Ulyanovsk, Russian Federation|Research Site, Voronezh, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Belgrade, Serbia|Research Site, Gornji Matejevac, Serbia|Research Site, Kragujevac, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Golnik, Slovenia|Research Site, Pohorje, Slovenia|Research Site, Umhlanga, KwaZulu-Natal, South Africa|Research Site, Bloemfontein, South Africa|Research Site, Johannesburg, South Africa|Research Site, Overport, South Africa|Research Site, Polokwane, South Africa|Research Site, Granada, Andalucía, Spain|Research Site, Las Palmas de Gran Canaria, Canarias, Spain|Research Site, Barcelona, Cataluña, Spain|Research Site, Alicante, Comunidad Valenciana, Spain|Research Site, Benidorm, Comunidad Valenciana, Spain|Research Site, Valencia, Comunidad Valenciana, Spain|Research Site, Pontevedra, Galicia, Spain|Research Site, Aarau, Switzerland|Research Site, Aarau, Switzerland|Research Site, Chur, Switzerland|Research Site, Sursee, Switzerland|Research Site, Zurich, Switzerland|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Chernihiv, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kirovograd, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lutsk, Ukraine|Research Site, Lviv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Bebington, United Kingdom|Research Site, Dorechester, United Kingdom|Research Site, Dorset, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Manchester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT00858364/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT00858364/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT00858364"
392,"NCT00356525","Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor",,"Terminated","Has Results","Lung Neoplasms","Drug: pemetrexed|Drug: gemcitabine|Drug: carboplatin|Drug: Pemetrexed","Objective Tumor Response|Overall Survival|Time to Progressive Disease|Duration of Response|Time to Treatment Failure","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9934|H3E-US-S082","September 2006","June 2008","April 2009","July 26, 2006","July 29, 2009","August 17, 2010","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miami, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evanston, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chapel Hill, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Caxias Do Sul, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santo Andre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India",,"https://ClinicalTrials.gov/show/NCT00356525"
393,"NCT01932125","An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",,"Recruiting","No Results Available","Ovarian Neoplasms|Peritoneal Neoplasms|Fallopian Tube Neoplasms","Drug: Bevacizumab","Safety: Incidence of adverse events|Progression-free survival|Overall survival|Overall response rate (complete response + partial response)|Clinical benefit rate (complete response + partial response + stable disease)","Hoffmann-La Roche","Female","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ML28446","December 5, 2018","August 31, 2023","August 31, 2023","August 30, 2013",,"May 3, 2022","City Cancer Centre, Vijayawada, Andhra Pradesh, India|Sir Gangaram Hospital, NEW Delhi Delhi, Delhi, India|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Shalby Hospital Limited, Ahmedabad, Gujarat, India|Manipal Hospital; Department of Oncology, Bangalore, Karnataka, India|HCG NMR Cancer Centre, Hubli, Karnataka, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, Kerala, India|Marthwada Regional Cancer Center & Research Institute, Aurangabad, Maharashtra, India|Mumbai Oncocare Center; Medical Oncology, Mumbai, Maharashtra, India|HCG NCHRI Cancer Center, Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Sahyadri Speciality Hospital, Pune City, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd; Cancer Research Room, Pune, Maharashtra, India|Peerless Hospitex Hospital and Research Center Ltd., Kolkata, WEST Bengal, India|Apollo Hospitals International Ltd, Ahmedabad, India|HealthCare Global Enterprises Limited; Medical Oncology, Bangalore, India|Fortis Malar Hospital, Chennai, India|Apollo Speciality Hospital, Chennai, India|Sri Ramchandra Medical Centre, Chennai, India|Bharat Cancer Hospital & Research Institute-Nirali Memorial Radiation Centre, Gujarat, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India|Apollo Gleneagles Hospitals, Kolkata, India|Batra Hospital & Medical Research Centre, New Delhi, India|Grant Medical Foundation, Ruby Hall Clinic, Pune, India|Nirmal Hospital Pvt. Ltd.; Department of Oncology, Surat, India",,"https://ClinicalTrials.gov/show/NCT01932125"
394,"NCT00573131","Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer",,"Terminated","Has Results","Esophageal Cancer|Adenocarcinoma of the Esophagus|Squamous Cell Carcinoma","Drug: OncoGel (Paclitaxel gel)|Drug: cisplatin|Drug: 5-FU|Radiation: radiation therapy|Procedure: esophageal resection","Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","PR016-CLN-pro003","January 2008","November 2010","November 2010","December 13, 2007","May 16, 2014","May 11, 2022","University of California San Diego, San Diego, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Baylor University Medical Center, Dallas, Texas, United States|Digestive Health Specialists of Tyler, Texas, Tyler, Texas, United States|University Hospital Brno, Brno, Czechia|Hospital Jablonec nad Nisou, Jablonec nad Nisou, Czechia|University Hospital Olomouc, Olomouc, Czechia|University Hospital Motol, Praha, Czechia|Massaryk's Hospital in Usti nad Labem, Usti nad Labem, Czechia|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Bombay Hospital & Medical Research Centre, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital, Erandwane, Pune, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India|Samodzielny Publiczny Szpital Kliniczny, Lublin, Poland|Samodzielnego Publicznego Szpitala Klinicznego, Szczecin, Poland",,"https://ClinicalTrials.gov/show/NCT00573131"
395,"NCT00193934","Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer",,"Completed","No Results Available","Cancer of the Uterine Cervix",,"Assess the prognostic significance, with respect to overall survival, of the factors, FIGO stage. Overall survival is defined as the date of registration to date of death from any cause.","Trans Tasman Radiation Oncology Group|Peter MacCallum Cancer Centre, Australia","Female","18 Years and older   (Adult, Older Adult)",,"109","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","TROG 04.02","January 2006","May 2014","May 15, 2014","September 19, 2005",,"July 12, 2017","Washington University School of Medicine, Saint Louis, Missouri, United States|Liverpool Hospital, Liverpool, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Wentworthville, New South Wales, Australia|Royal Brisbane Hospital, Herston, Queensland, Australia|North Queensland Oncology Service, Townsville, Queensland, Australia|Premion - Tugun, Tugun, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Tata Memorial Hospital, Mumbai, India|Meenakshi Mission Hospital, Tamil Nadu, India|Auckland Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Dunedin Hospital, Dunedin, New Zealand|National University Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00193934"
396,"NCT01104584","Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)","GEMMA 2","Completed","Has Results","Breast Cancer","Drug: Gadobutrol (Gadavist, Gadovist, BAY86-4875)","Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per Reader|Breast Level Specificity of CMRM for Non-malignant Breasts by Reader|Breast Level Specificity of CMRM Based on Malignant Breasts|Percentage Difference of Participants Whose Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM|Percentage Difference of Participants Whose Additional Index Cancers Were Detected Using CMRM vs UMRM, CMRM vs XRM, and CMRM vs CMRM+XRM|Difference of Confidence in Diagnosis for Breast Region Diagnosis Using CMRM vs UMRM, CMRM+XRM vs UMRM+XRM and CMRM+XRM vs XRM by Reader, Participant Level","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","460","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","91782|2009-009598-90","May 2010","September 2011","January 2012","April 15, 2010","November 11, 2014","November 11, 2014","Tucson, Arizona, United States|Oakland, California, United States|Englewood, Colorado, United States|Chicago, Illinois, United States|New York, New York, United States|Columbus, Ohio, United States|Providence, Rhode Island, United States|San Antonio, Texas, United States|Tacoma, Washington, United States|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Erlangen, Bayern, Germany|München, Bayern, Germany|Frankfurt, Hessen, Germany|Greifswald, Mecklenburg-Vorpommern, Germany|Göttingen, Niedersachsen, Germany|Göttingen, Niedersachsen, Germany|Bochum, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Münster, Nordrhein-Westfalen, Germany|Gera, Thüringen, Germany|Berlin, Germany|Mumbai, Maharashtra, India|Delhi, India|Mumbai, India|Eindhoven, EJ, Netherlands|Maastricht, Netherlands|Nijmegen, Netherlands|Bydgoszcz, Poland|Gliwice, Poland|Krakow, Poland|Szczecin, Poland|Warszawa, Poland|Sabadell, Barcelona, Spain|Alzira, Valencia, Spain|Barcelona, Spain|Cordoba, Spain|Girona, Spain|Taichung, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taipei, Taiwan|Taizung, Taiwan",,"https://ClinicalTrials.gov/show/NCT01104584"
397,"NCT04482309","A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","DPT02","Recruiting","No Results Available","Bladder Cancer, Biliary Tract Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Rare Tumors","Drug: Trastuzumab deruxtecan","Objective Response Rate (ORR)|Duration of response (DoR)|Disease control rate (DCR)|Progression free survival (PFS)|Proportion of patients alive and progression-free at 6 months and 12 months|Overall survival (OS)|Proportion of patients alive at 6 and 12 months|Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Pharmacokinetics (PK) assessed by serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181|The immunogenicity of T-DXd assessed by the presence of ADAs for T-DXd","AstraZeneca|Daiichi Sankyo Co., Ltd.","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967VC00001","August 18, 2020","May 31, 2023","May 31, 2023","July 22, 2020",,"May 11, 2022","Research Site, Burbank, California, United States|Research Site, Duarte, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Muncie, Indiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Middletown, New Jersey, United States|Research Site, Commack, New York, United States|Research Site, Harrison, New York, United States|Research Site, New York, New York, United States|Research Site, Rochester, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Auchenflower, Australia|Research Site, Camperdown, Australia|Research Site, Heidelberg, Australia|Research Site, Kogarah, Australia|Research Site, Nedlands, Australia|Research Site, Randwick, Australia|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Yvoir, Belgium|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Curitiba, Brazil|Research Site, Fortaleza, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitória, Brazil|Research Site, Edmonton, Alberta, Canada|Research Site, Kelowna, British Columbia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Canada|Research Site, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Gurgaon, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, Rohini, India|Research Site, Milan, Italy|Research Site, Milan, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Rome, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Amsterdam, Netherlands|Research Site, Delft, Netherlands|Research Site, Den Haag, Netherlands|Research Site, Groningen, Netherlands|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Gliwice, Poland|Research Site, Kraków, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Kaluga, Russian Federation|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhnii Novgorod, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Córdoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Valencia, Spain|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Muang, Thailand|Research Site, Ongkharak, Thailand|Research Site, Sisaket, Thailand|Research Site, Glasgow, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Northwood Middlesex, United Kingdom|Research Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04482309"
398,"NCT00410761","An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer",,"Active, not recruiting","Has Results","Thyroid Cancer","Drug: ZD6474 (Vandetanib)","Progression-Free Survival(PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Overall Survival (OS)|Biochemical Response Calcitonin (CTN)|Biochemical Response Carcinoembryonic Antigen (CEA)|Time to Worsening of Pain (TWP)","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","437","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00058|2005-005077-29|LPS14811","November 30, 2006","July 31, 2009","December 31, 2022","December 13, 2006","March 26, 2012","November 1, 2021","Investigational Site Number 3, Little Rock, Arkansas, United States|Investigational Site Number 8, San Francisco, California, United States|Investigational Site Number 9, Aurora, Colorado, United States|Investigational Site Number 11, New Haven, Connecticut, United States|Investigational Site Number 15, Jacksonville, Florida, United States|Investigational Site Number 18, Chicago, Illinois, United States|Investigational Site Number 17, Lexington, Kentucky, United States|Investigational Site Number 2, Boston, Massachusetts, United States|Investigational Site Number 7, Detroit, Michigan, United States|Investigational Site Number 14, Rochester, Minnesota, United States|Investigational Site Number 10, Saint Louis, Missouri, United States|Investigational Site Number 6, Cincinnati, Ohio, United States|Investigational Site Number 22, Portland, Oregon, United States|Investigational Site Number 19, Charleston, South Carolina, United States|Investigational Site Number 13, Houston, Texas, United States|Investigational Site Number 21, Burlington, Vermont, United States|Investigational Site Number 1001, St Leonards, Australia|Investigational Site Number 1901, Wien, Austria|Investigational Site Number 1101, Bruxelles, Belgium|Investigational Site Number 1102, Leuven, Belgium|Investigational Site Number 2301, Porto Alegre, Brazil|Investigational Site Number 2302, Ribeirão Preto, Brazil|Investigational Site Number 1203, Calgary, Canada|Investigational Site Number 1202, London, Canada|Investigational Site Number 1201, Moncton, Canada|Investigational Site Number 1204, Sherbrooke, Canada|Investigational Site Number 1205, Toronto, Canada|Investigational Site Number 3601, Praha 5, Czechia|Investigational Site Number 2701, Odense C, Denmark|Investigational Site Number 2802, BORDEAUX Cedex, France|Investigational Site Number 2803, LYON Cedex 8, France|Investigational Site Number 2801, Villejuif, France|Investigational Site Number 2002, Essen, Germany|Investigational Site Number 2001, Halle, Germany|Investigational Site Number 2005, Würzburg, Germany|Investigational Site Number 1601, Pécs, Hungary|Investigational Site Number 1401, Mumbai, India|Investigational Site Number 1402, Vellore, India|Investigational Site Number 2506, Catania, Italy|Investigational Site Number 2502, Milano, Italy|Investigational Site Number 2503, Napoli, Italy|Investigational Site Number 2501, Pisa, Italy|Investigational Site Number 2505, Roma, Italy|Investigational Site Number 2504, Siena, Italy|Investigational Site Number 1501, Seoul, Korea, Republic of|Investigational Site Number 2403, Cd. Madero, Mexico|Investigational Site Number 2402, Mexico City, Mexico|Investigational Site Number 2404, México, Mexico|Investigational Site Number 2902, Groningen, Netherlands|Investigational Site Number 2901, Utrecht, Netherlands|Investigational Site Number 1701, Gliwice, Poland|Investigational Site Number 1702, Poznan, Poland|Investigational Site Number 1703, Warszawa, Poland|Investigational Site Number 2602, Coimbra, Portugal|Investigational Site Number 2601, Lisboa, Portugal|Investigational Site Number 1801, Bucarest, Romania|Investigational Site Number 3301, Obninsk, Russian Federation|Investigational Site Number 3402, Belgrade, Serbia|Investigational Site Number 3401, Belgrad, Serbia|Investigational Site Number 3003, Madrid, Spain|Investigational Site Number 3001, Madrid, Spain|Investigational Site Number 3002, Pamplona, Spain|Investigational Site Number 3102, Stockholm, Sweden|Investigational Site Number 3101, Uppsala, Sweden|Investigational Site Number 2101, Basel, Switzerland|Investigational Site Number 2102, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT00410761"
399,"NCT00674973","A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer",,"Completed","Has Results","Pancreatic Cancer","Drug: Erlotinib|Drug: Placebo","Progression-Free Survival|Percentage of Participants With Best Overall Response Rate|Percentage of Participants With Disease Control Rate (DCR)|Overall Survival|Number of Participants With Adverse Events (AEs)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2","207","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BO21129|2007-003738-40","June 2008","December 2010","March 2015","May 8, 2008","April 26, 2016","June 17, 2016","Kogarah, New South Wales, Australia|St. Leonards, New South Wales, Australia|Sydney, New South Wales, Australia|Box Hill, Victoria, Australia|Salvador, Bahia, BA, Brazil|Belo Horizonte, MG, Brazil|Curitiba, PR, Brazil|Ijui, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Jau, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Gabrovo, Bulgaria|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Vratsa, Bulgaria|Vratza, Bulgaria|Zagreb, Croatia|Bochum, Germany|Dresden, Germany|Esslingen, Germany|Greifswald, Germany|Hamburg, Germany|Köln, Germany|Saarbruecken, Germany|Ulm, Germany|Hong Kong, Hong Kong|Hong Kong, Hong Kong|Bangalore, India|Chennai, India|Jaipur, India|Kochi, India|Kolkata, India|Ludhiana, India|Mumbai, India|New Delhi, India|Pune, India|Vellore, India|Bologna, Emilia-Romagna, Italy|Udine, Friuli-Venezia Giulia, Italy|Riga, Latvia|Kaunas, Lithuania|Vilnius, Lithuania|Vilnius, Lithuania|Kuala Lumpur, Malaysia|Penang, Malaysia|Monterrey, Mexico|Arequipa, Peru|Chiclayo, Peru|San Isidro, Peru|Bucharest, Romania|Cluj Napoca, Romania|Craiova (Dolj county), Romania|Irkutsk, Russian Federation|Kazan, Russian Federation|Krasnodar, Russian Federation|Moscow, Russian Federation|St Petersburg, Russian Federation|St Petersburg, Russian Federation|Singapore, Singapore|Ljubljana, Slovenia|Kiev, Ukraine|London, United Kingdom|London, United Kingdom|London, United Kingdom|London, United Kingdom|Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00674973"
400,"NCT03567798","Thrombocytopenia Induced by Chemotherapy","papayaleaf","Completed","No Results Available","Thrombocytopenia","Dietary Supplement: UPLAT|Other: Placebo","Increase in the platelet counts from baseline levels to the end of therapy.","Socrates School Of Health","All","18 Years to 55 Years   (Adult)","Not Applicable","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","SPL/UP/2017/01","July 18, 2017","November 20, 2017","November 20, 2017","June 26, 2018",,"June 27, 2018","North East Cancer Centre Hospital and research Institute, Guwahati, Assam, India",,"https://ClinicalTrials.gov/show/NCT03567798"
401,"NCT00825955","Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment","BRISK PS","Completed","No Results Available","Liver Cancer","Drug: Brivanib|Other: Placebo|Procedure: Best Supportive Care","To compare overall survival of subjects with advanced HCC who have progressed on/after or are intolerant to Sorafenib and receive Brivanib plus best supportive care (BSC) to those receiving placebo plus BSC|To compare time to progression (TTP) (Investigator assessed using modified Response Evaluation Criteria In Solid Tumors (RECIST) for HCC criteria)|To compare the Independent Radiological Review Committee (IRRC) assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST for HCC criteria|To assess duration of response, duration of disease control and time to response|To assess safety profile of brivanib. Safety will be assessed by the number of adverse events (AEs), serious adverse events (SAEs), periodic data monitoring committee (DMC) review","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","587","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CA182-034|EUDRACT #: 2008-005084-34","February 17, 2009","November 15, 2011","August 25, 2017","January 21, 2009",,"October 9, 2019","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Richard Finn, M.D., Los Angeles, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|UF Health Clinical Research Center, Gainesville, Florida, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|3912 Taubman Center, Ann Arbor, Michigan, United States|Henry Ford Health System Irb, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Mount Sinai School Of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|University Of Texas, Houston, Texas, United States|The University Of Texas Health Science Center, San Antonio, Texas, United States|Mcguire Dvamc, Richmond, Virginia, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, Bruxelles, Belgium|Local Institution, Salvador - Ba, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Bordeaux, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble Cedex 09, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 04, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Vandoeuvre Cedex, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg, Germany|Local Institution, Halle, Germany|Local Institution, Hannover, Germany|Local Institution, Mainz, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kifisia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Kochi, Kerala, India|Local Institution, Chennai, India|Local Institution, Kolkata, India|Local Institution, New Delhi, India|Local Institution, Ancona, Italy|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Ogaki-shi, Gifu, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kochi-shi, Kochi, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Toyama City, Toyama, Japan|Local Institution, Shimonoseki-shi, Yamaguchi, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Oviedo, Spain|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan Hsien, Taiwan",,"https://ClinicalTrials.gov/show/NCT00825955"
402,"NCT00364351","Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy",,"Completed","Has Results","Non Small Cell Lung Cancer","Drug: Vandetanib|Drug: Erlotinib","Progression-Free Survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Pain|Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Dyspnoea|Time to Deterioration of Disease-related Symptoms (TDS) by EORTC Quality of Life Questionnaire - Cough","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","1574","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00057|EUDRACT No. 2006-000259-16","August 2006","September 2008","November 2016","August 15, 2006","May 24, 2011","January 25, 2018","Research Site, Berkeley, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Boynton Beach, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Wichita, Kansas, United States|Research Site, Lexington, Kentucky, United States|Research Site, Louisville, Kentucky, United States|Research Site, Metairie, Louisiana, United States|Research Site, Baltimore, Maryland, United States|Research Site, Columbia, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Latham, New York, United States|Research Site, Hickory, North Carolina, United States|Research Site, Canton, Ohio, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Greenville, South Carolina, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Amarillo, Texas, United States|Research Site, Garland, Texas, United States|Research Site, Webster, Texas, United States|Research Site, Fairfax, Virginia, United States|Research Site, Norfolk, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Burien, Washington, United States|Research Site, Yakima, Washington, United States|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Gonnet, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Fe, Argentina|Research Site, Ashford, Australia|Research Site, Bedford Park, Australia|Research Site, Chermside, Australia|Research Site, Geelong, Australia|Research Site, Hornsby, Australia|Research Site, Kogarah, Australia|Research Site, Malvern, Australia|Research Site, Prahran, Australia|Research Site, Wodonga, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Caxias do Sul, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiânia, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santo André, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Oshawa, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sault Ste. Marie, Ontario, Canada|Research Site, Thunder Bay, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, York, Ontario, Canada|Research Site, Charlottetown, Prince Edward Island, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Dalian, China|Research Site, Hangzhou, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Wuhan, China|Research Site, Herlev, Denmark|Research Site, København Ø, Denmark|Research Site, Næstved, Denmark|Research Site, Caen, France|Research Site, Clermont Ferrand, France|Research Site, Marseille, France|Research Site, Paris Cedex 12, France|Research Site, RENNES Cedex 9, France|Research Site, Vesoul Cedex, France|Research Site, Großhansdorf, Germany|Research Site, Göttingen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Karlsruhe, Germany|Research Site, Löwenstein, Germany|Research Site, Mainz, Germany|Research Site, Mönchengladbach, Germany|Research Site, Ulm, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Bangalore, India|Research Site, Karnataka, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Bandung, Indonesia|Research Site, Jakarta, Indonesia|Research Site, Solo, Indonesia|Research Site, Ancona, Italy|Research Site, Avellino, Italy|Research Site, Catania, Italy|Research Site, Genova, Italy|Research Site, Mantova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Seoul, Korea, Republic of|Research Site, Juchitan, Mexico|Research Site, Monterrey, Mexico|Research Site, Morelia, Mexico|Research Site, Puebla, Mexico|Research Site, Saltillo, Mexico|Research Site, Zacatecas, Mexico|Research Site, Harderwijk, Netherlands|Research Site, Nieuwegein, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bergen, Norway|Research Site, Haugesund, Norway|Research Site, Kristiansand, Norway|Research Site, Oslo, Norway|Research Site, Stavanger, Norway|Research Site, Tromsø, Norway|Research Site, Trondheim, Norway|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Elche(Alicante), Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Mataró(Barcelona), Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Lampang, Thailand|Research Site, Songkla, Thailand|Research Site, Birmingham, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00364351"
403,"NCT00669565","Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer",,"Completed","No Results Available","Carcinoma Breast Stage IV","Drug: Bavituximab","The primary objective of this study is to determine the overall response rate (CR+PR)","Peregrine Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 2","46","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPHM 0702","July 2008","July 2010","August 2010","April 30, 2008",,"March 24, 2011","Rajalakshmi Multispecialty Hospital, Bangalore, India|Bangalore Institute of Oncology, Banglore, India|Apollo Specialty Hospitals, Chennai, India|Nizam's Institute of Medical Sciences, Hyderabaad, India|Regional Cancer Center, Kerala, India|Medical College Hospital, Kolkata, India|Bharath Hospital and Institite of Oncology, Mysore, India|Curie Manavata Cancer Center, Nashik, India|Ruby Hall Clinic, Pune, India",,"https://ClinicalTrials.gov/show/NCT00669565"
404,"NCT02576431","A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","NAVIGATE","Recruiting","No Results Available","Solid Tumors Harboring NTRK Fusion","Drug: BAY2757556 (Larotrectinib, Vitrakvi)","Best overall response rate by IRC|Best overall response rate by investigator|Duration of response (DOR) by IRC|Duration of response (DOR) by investigator|Clinical benefit rate (CBR)|Progression-free survival (PFS) after Larotrectinib|Overall survival time|Progression-free survival (PFS) after past cancer therapy|Number of subjects with adverse events|Number of subjects with serious adverse events|Number of subjects with treatment-related adverse events|Severity of adverse events|Severity of serious adverse events|Severity of treatment-related adverse events|Duration of adverse events|Duration of serious adverse events|Duration of treatment-related adverse events|Number of subjects with safety-relevant changes in clinical parameters or vital signs after drug administration|Severity of safety-relevant changes in clinical parameters or vital signs after drug administration|Proportion of patients with any tumor regression (i.e., measured as shrinkage of target lesions) as a best response|Concordance coefficient","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 2","204","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20289|LOXO-TRK-15002|2015-003582-28","September 30, 2015","August 15, 2023","August 29, 2025","October 15, 2015",,"May 6, 2022","Stanford Cancer Center, Palo Alto, California, United States|UCLA-Santa Monica Medical Center, Santa Monica, California, United States|Memorial Hospital West, Pembroke, Florida, United States|University of Chicago, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth Hitchock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of North Carolina Hospitals, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|University of Washington, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|Centro Medico Austral, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Hospital Británico, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Centro Estudios Médicos e Invest. Clínicas ""Dr. N. Quirno"", Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Hospital Alemán, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Fundación Cenit para la Investigación en Neurociencias, Caba, Ciudad Auton. De Buenos Aires, Argentina|Instituto de Oncología de Rosario, Rosario, Santa Fe, Argentina|Centro Médico San Roque, San Miguel de Tucumán, Tucuman, Argentina|Macquarie University Hospital, Macquarie University, New South Wales, Australia|Royal Darwin Hospital, Tiwi, Northern Territory, Australia|St John of God Healthcare, Subiaco, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Institut Jules Bordet/Jules Bordet Instituut, Anderlecht, Belgium|Hosp. Araujo Jorge da Associação de Combate ao Câncer, Goiânia, Goiás, Brazil|Cenantron Centro Avançado de Tratamento Oncológico, Ltda., Belo Horizonte, Minas Gerais, Brazil|Associação Hospital de Caridade de Ijuí, Ijuí, Rio Grande Do Sul, Brazil|Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Hospital de Base da Fundação F M S J Rio Preto, São José do Rio Preto, Sao Paulo, Brazil|Instituto do Câncer do Estado de São Paulo, São Paulo, Sao Paulo, Brazil|Clín. de Pesq. e Centro de Estudos em Onco Gineco Mamária, São Paulo, Sao Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, Sao Paulo, Brazil|IBCC - Instituto Brasileiro de Controle do Cancer, São Paulo, Sao Paulo, Brazil|Instituto Nacional do Câncer - INCA - HC II, Rio de Janeiro, Brazil|INCA - Hospital do Cancer III, Rio de Janeiro, Brazil|Oncoclínicas Rio de Janeiro S.A, Rio de Janeiro, Brazil|Hospital Sirio Libanes, Sao Paulo, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Juravinski Cancer Centre-McMaster Medical Unit, Hamilton, Ontario, Canada|London Regional Cancer Program, London Health Sciences Ctr, London, Ontario, Canada|Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|Sichuan University West China Hospital, Chengdu, Sichuan, China|Beijing Cancer Hospital, Beijing, China|Zhongshan Hospital, Fudan University, Shanghai, China|Instituto Nacional de Cancerología, Bogotá, Cundinamarca, Colombia|Oncomédica S.A., Montería, Córdoba, Colombia|Fundación Oftalmológica de Santander Carlos Ardila Lule, Floridablanca, Santander, Colombia|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Fakultni Nemocnice Olomouc, Olomouc, Czechia|Fakultni Thomayerova Nemocnice, Praha 4, Czechia|Finsen Centre, Copenhagen, Denmark|Hopital Jean Minjoz, Besancon, France|Institut Bergonié - Unicancer Nouvelle Aquitaine, Bordeaux Cedex, France|Hôpital Saint André - Bordeaux, Bordeaux, France|Centre Léon Bérard, Lyon Cedex, France|Centre Antoine Lacassagne, Nice Cedex 2, France|Hôpital Saint Louis, Paris, France|Hopital Saint Antoine - Paris, Paris, France|Hôpital de la Pitié-Salpétrière, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Hôpital de la Milétrie, POITIERS cedex, France|Hôpital Guillaume et René Laennec - Nantes, Saint Herblain, France|Institut de Cancérologie de l'Ouest - Saint Herblain, Saint Herblain, France|ICANS - Institut de Cancérologie de Strasbourg Europe, Strasbourg, France|Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany|Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany|Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany|Charité Comprehensive Cancer Center (CCCC), Berlin, Germany|AGIOS SAVVAS Anticancer Hospital of Athens, Athens, Greece|LAIKO General Hospital of Athens, Athens, Greece|General Hospital of Athens ""ALEXANDRA"", Athens, Greece|General Oncology Hospital of Kifissia AGIOI ANARGYROI, Kifissia / Athens, Greece|University General Hospital of Patra, Patra, Greece|MH Egeszsegugyi Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Bacs-Kiskun Megyei Korhaz, Kecskemet, Hungary|All India Institute of Medical Sciences, New Delhi, Delhi, India|Tata Memorial Hospital, Mumbai,, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Insti, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Jawaharlal Institute Of Postgraduate Medical Education and R, Gorimedu, Pondicherry, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|St Vincents University Hospital, Dublin, Ireland|A.O.R.N. San Giuseppe Moscati, Avellino, Campania, Italy|A.O.U. di Bologna Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy|A.S.U. Friuli Centrale - A. Regionale Coordinamento Salute, Udine, Friuli-Venezia Giulia, Italy|IRCCS Istituti Fisioterapici Ospitalieri - IFO, Roma, Lazio, Italy|Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Lazio, Italy|IRCCS Ospedale Policlinico San Martino, Genova, Liguria, Italy|Istituto Clinico Humanitas - Humanitas Mirasole S.p.A., Milano, Lombardia, Italy|IRCCS Istituto Europeo di Oncologia s.r.l. (IEO), Milano, Lombardia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Lombardia, Italy|Istituto Oncologico Veneto IRCCS (IOV), Padova, Veneto, Italy|Nagoya University Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Oslo universitetssykehus HF Radiumhospitalet, Oslo, Norway|Wojskowy Instytut Medyczny, Warszawa, Poland|Fundacao Champalimaud, Lisboa, Portugal|CHULN - Hospital Santa Maria, Lisboa, Portugal|CHUP - Hospital Santo Antonio, Porto, Portugal|IPO Porto, Porto, Portugal|Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Ltd ""EVIMED"", Chelyabinsk, Russian Federation|Republican Clinical Oncology Dispensary, Kazan, Russian Federation|Moscow Clinical Scientific Centre n.a.Loginov, Moscow, Russian Federation|Russian Oncological Scientific Center n.a. N.N. Blokhin RAMS, Moscow, Russian Federation|1st Moscow State Medical University n.a. I.M.Sechenov, Moscow, Russian Federation|Moscow Scient. Res. Institute of Oncology n.a P.A. Hertzen, Moscow, Russian Federation|City Oncological Hospital #62, Moscow, Russian Federation|Clinical Diagnostical Center, Nizhny Novgorod, Russian Federation|St. Petersburg Clinical Onc. Cent. of Spec. Types of Care, St. Petersburg, Russian Federation|National Cancer Center Singapore, Singapore, Singapore|Onkologicky Ustav Svatej Alzbety, s.r.o., Bratislava, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia|Institut Català d'Oncologia Hospitalet, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario ""Marqués de Valdecilla"", Santander, Cantabria, Spain|Hospital del Mar, Barcelona, Spain|Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona, Spain|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Fundacion Jimenez Diaz (Clinica de la Concepcion), Madrid, Spain|Centro Integral Oncológico Clara Campal, Madrid, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset i Solna, Stockholm, Sweden|Chang Gung Memorial Hospital Kaohsiung, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Ankara Sehir Hastanesi, Ankara, Turkey|Trakya Univ. Tip Fak., Edirne, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa-Cerrahpasa Tip Fakultesi, Istanbul, Turkey|TC Saglik Bakanligi Goztepe ProfDr Suleyman Yalcin Sehir Has, Istanbul, Turkey|Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey|National Cancer Institute, Kiev, Ukraine|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Institute Of Cancer-Barts and The London School of Medicine, London, United Kingdom|University College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02576431"
405,"NCT00424255","Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery",,"Completed","Has Results","Neoplasms, Head and Neck","Drug: Lapatinib|Radiation: Chemoradiation|Other: Placebo","Disease Free Survival (DFS)|Overall Survival (OS)|Disease Specific Survival (DSS)|Time to Locoregional Recurrence (TTLR)|Time to Distant Relapse (TTDR)|Number of Participants With a Second Primary Tumor|Extent of Exposure|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With the Indicated Chemistry Toxicities by Maximum Toxicity Grade (G3 and G4) at the Worst-case On-therapy Visit|Number of Participants With the Indicated Hematological Toxicities by Maximum Toxicity Grade (G3 and G4) at the Worst-case On-therapy Visit|Number of Participants With On-therapy and Follow-up Late Radiation Morbidity Events|Change From Baseline in Blood Pressure at the Indicated Time Points|Change From Baseline in Heart Rate at the Indicated Time Points|Change From Baseline in Body Temperature at the Indicated Time Points|Change From Baseline in Body Weight at the Indicated Time Points|Number of Participants With Abnormal 12-lead Electrocardiogram (ECG) Findings at the Indicated Time Points|Number of Participants With the Indicated Eastern Cooperative Oncology Group (ECOG) Performance Status Value|Change From Baseline in Quality of Life Status as Assessed by the Functional Assessement of Cancer Therapy-Head and Neck (FACT-H&N) Questionnaire|Change From Baseline in Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale|Number of Participants With the Indicated Biomarker Expression Status|Number of Participants With the Indicated Worst-case On-therapy Left Ventricular Ejection Fraction (LVEF) Change From Baseline","GlaxoSmithKline","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","688","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EGF102988","December 2006","March 2013","November 2013","January 19, 2007","February 11, 2014","July 18, 2014","GSK Investigational Site, Springfield, Illinois, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Lubbock, Texas, United States|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Santa Fe, Argentina|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Rankweil, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Halifax, Nova Scotia, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Wuhan, Hubei, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Fuzhou, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Ostrava - Poruba, Czech Republic|GSK Investigational Site, Praha 8, Czech Republic|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Angers Cedex 09, France|GSK Investigational Site, Annecy, France|GSK Investigational Site, Caen, France|GSK Investigational Site, Colmar, France|GSK Investigational Site, Ferolles-Attilly, France|GSK Investigational Site, La Roche sur Yon, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Paris, France|GSK Investigational Site, Reims, France|GSK Investigational Site, Saint Cloud, France|GSK Investigational Site, Strasbourg, France|GSK Investigational Site, Toulouse, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Karlsruhe, Baden-Wuerttemberg, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Halle, Sachsen-Anhalt, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Haidari, Athens, Greece|GSK Investigational Site, Neo Faliro, Greece|GSK Investigational Site, Peiraius, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Kowloon, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Kochi, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Rathgar, Dublin, Ireland|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Venezia, Veneto, Italy|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Ufa,, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Kosice, Slovakia|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Gerona, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Huesca, Spain|GSK Investigational Site, Lerida, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Orense, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Santiago de Compostela, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Zaragoza, Spain|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Brighton, Sussex East, United Kingdom|GSK Investigational Site, Guildford, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00424255"
406,"NCT04884360","D9319C00001- 1L OC Mono Global RCT","MONO-OLA1","Recruiting","No Results Available","Ovarian Cancer","Drug: Olaparib|Other: Matching placebo","Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard 1st line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard 1st line platinum-based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt HRD positive tumour and a CR/PR following standard first line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of OS in participants with Stage III/IV ovarian cancer with a BRCAwt tumour and a CR/PR following standard first-line platinum-based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum-based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TFST in participants with a BRCAwt tumour and a CR or PR following standard first line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of PFS2 in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of TSST in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt HRD positive tumour and a CR/PR following standard first-line platinum based chemotherapy treatment.|To demonstrate superiority of olaparib as maintenance treatment relative to placebo by assessment of time to TDT in participants with a BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment.|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt HRD positive tumour and a CR/PR following 1st line platinum based chemotherapy|Superiority of olaparib as maintenance treatment relative to placebo by assessment of time to earliest progression by RECIST 1.1/CA 125/death in participants with a BRCAwt tumour and a CR/PR following first-line platinum based chemotherapy.|Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with a BRCAwt HRD positive tumour and a CR or PR following standard first-line platinum based chemotherapy treatment|Assess Health-related quality of life in participants treated with olaparib compared with placebo in participants with BRCAwt tumour and a CR or PR following standard first-line platinum based chemotherapy treatment","AstraZeneca","Female","18 Years and older   (Adult, Older Adult)","Phase 3","420","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D9319C00001","May 31, 2021","July 2, 2024","July 2, 2025","May 13, 2021",,"April 14, 2022","Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guiyang, China|Research Site, Haikou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hefei, China|Research Site, Hefei, China|Research Site, Jiaxing, China|Research Site, Jining, China|Research Site, Lanzhou, China|Research Site, Linyi, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Qingdao, China|Research Site, Rui'an, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shengyang, China|Research Site, ShenZhen, China|Research Site, Shijiazhuang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wenzhou, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wulumuqi, China|Research Site, Wuxi, China|Research Site, Xiamen, China|Research Site, Xianyang, China|Research Site, Xuzhou, China|Research Site, Xuzhou, China|Research Site, Yanji, China|Research Site, Zibo, China|Research Site, Zunyi, China|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bogotá, Colombia|Research Site, Bogotá, Colombia|Research Site, Ibague, Colombia|Research Site, Medellin, Colombia|Research Site, Medellín, Colombia|Research Site, Gurgaon, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Namakkal, India|Research Site, Nashik, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Arequipa, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Bialystok, Poland|Research Site, Gdynia, Poland|Research Site, Gliwice, Poland|Research Site, Grzepnica, Poland|Research Site, Poznań, Poland|Research Site, Szczecin, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Samsun, Turkey|Research Site, Chernihiv, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kryvyi Rih, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Ha noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04884360"
407,"NCT02953340","SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide",,"Completed","Has Results","Neutropenia|Breast Cancer","Drug: SPI-2012|Drug: Pegfilgrastim|Drug: Docetaxel|Drug: Cyclophosphamide","Duration of Severe Neutropenia (DSN) in Cycle 1|Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1|Depth of ANC Nadir in Cycle 1|Number of Participants With Febrile Neutropenia (FN) in Cycle 1|Duration of Severe Neutropenia (DSN) in Cycles 2, 3 and 4|Number of Participants With Neutropenic Complications in Cycle 1|Number of Participants With Febrile Neutropenia in Cycles 2, 3 and 4|Relative Dose Intensity (RDI) of TC Chemotherapy|Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs), and Death|Number of Participants With Clinically Significant Laboratory Abnormalities","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","237","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SPI-GCF-302|2016-003469-24","May 10, 2017","June 8, 2018","May 6, 2019","November 2, 2016","March 2, 2022","March 2, 2022","ACRC/ Arizona Clinical Research Center Inc., Tucson, Arizona, United States|Yuma Regional Cancer Center, Yuma, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|NEA Baptist Clinic   Fowler Family Center for Cancer Care, Jonesboro, Arkansas, United States|Pacific Cancer Medical Center, Inc., Anaheim, California, United States|Compassionate Care Research Group, Inc., Fountain Valley, California, United States|California Cancer Associates for Research and Excellence Inc., Fresno, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Desert Regional Medical Center, Palm Springs, California, United States|Emad Ibrahim, MD, INC., Redlands, California, United States|Innovative Clinical Research Institute/ The Oncology Institute of Hope and Innovation, Whittier, California, United States|Denver Health & Hospital Authority, Denver, Colorado, United States|Pasco Pinellas Cancer Center, Holiday, Florida, United States|Lakes Research, LLC, Miami Lakes, Florida, United States|Mid-Florida Hematology and Oncology Centers, Orange City, Florida, United States|Millennium Oncology, Pembroke Pines, Florida, United States|BRCR Medical Center Inc, Plantation, Florida, United States|Pinellas Hematology and Oncology, Saint Petersburg, Florida, United States|Bond & Steele Clinic, PA., Winter Haven, Florida, United States|John B. Amos Cancer Center, Columbus, Georgia, United States|Cancer Center of Middle Georgia, Dublin, Georgia, United States|Dwight D. Eisenhower Army Medical Center, Fort Gordon, Georgia, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Oncology Specialists, SC, Park Ridge, Illinois, United States|FPN Oncology and Hematology Specialists, Indianapolis, Indiana, United States|Commonwealth Hematology-Oncology, PSC, Danville, Kentucky, United States|Pontchartrain Cancer Center, Covington, Louisiana, United States|Quest Research Institute, Royal Oak, Michigan, United States|Coborn Cancer Center, Saint Cloud, Minnesota, United States|Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi, United States|Freeman Health Systems, Joplin, Missouri, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|CHI Health St Francis, St Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Waverly Hematology Oncology, Cary, North Carolina, United States|Gaston Hematology & Oncology Associates, PC, Gastonia, North Carolina, United States|Aultman Hospital, Canton, Ohio, United States|The Christ Hospital Cancer Center, Cincinnati, Ohio, United States|St. Elizabeth Youngstown Hospital JACBCC/Oncology/ Mercy Health Youngstown LLC, Youngstown, Ohio, United States|Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States|The West Clinic, PC, d/b/a West Cancer Center, Germantown, Tennessee, United States|CHI St Joseph Health Cancer Center, Bryan, Texas, United States|Envision Cancer Center, LLC, Laredo, Texas, United States|Texas Oncology, PA- McAllen South 2nd Street, McAllen, Texas, United States|HOPE Cancer Center of East Texas, Tyler, Texas, United States|Delta Hematology/Oncology Associates, Portsmouth, Virginia, United States|Providence Regional Center Partnership, Everett, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|West Virginia University, Morgantown, West Virginia, United States|CISSS de la Montérégie-Centre, Longueuil, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Magyar Honvedseg Egeszsegugyi Kozpont, Onkologiai Osztaly, Budapest, Hungary|Szent Imre Egyetemi Oktatokorhaz, Klinikai Onkologiai Osztaly, Budapest, Hungary|Orszagos Onkologiai Intezet, """"B"""" Belgyogyaszati Onkologiai Osztaly, Budapest, Hungary|Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Okato Korhaz, Klinikai Onkologiai es Sugarterapias Centrum, Miskolc, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak, Egyetemi Oktato Korhaz, Onkoradiologiai Osztaly, Nyíregyháza, Hungary|Tolna Megyei Balassa Janos Korhaz, Klinikai Onkologiai Osztaly, Szekszard, Hungary|KEM Hospital Research Centre, Pune, Maharashtra, India|Christian Medical College, Vellore, Tamil Nadu, India|Samsung Medical Center, Irwon-ro, Gangnam-gu Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Ilsan-ro, Gangwon-do, Korea, Republic of|National Cancer Center, IIsan-ro, Gyeonggi-do, Korea, Republic of|Cha Bundang Medical Center, Yatap-ro, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Daehwa-ro, Jongno-gu Seoul, Korea, Republic of|Inha University Hospital, Inhang-ro, Jung-guIncheon, Korea, Republic of|Korea University Anam Hospital, Inchon-ro, Seongbuk-guSeoul, Korea, Republic of|Severance Hospital, Yonsei-ro, Seoul, Korea, Republic of|BIALOSTOCKIE CENTRUM ONKOLOGII im. Marii Sklodowskiej-Curie Oddzial Onkologii Klinicznej im. Ewy Pileckiej z Pododdzialem Chemioterapii dziennej, Bialystok, Poland|Regionalny Szpital Specjalistyczny im. dr Wladyslawa Bieganskiego Oddział Onkologii Klinicznej, Grudziadz, Poland|Instytut Centrum Zdrowia Matki Polki Klinika Chirurgii Onkologicznej i Chorob Piersi z Pododdzialem Onkologii Klinicznej, Lodz, Poland|Pracownia Leku Cytotoksycznego Szpitala Klinicznego Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Szpital Rejonowy im. Dr. Jozefa Rostka w Raciborzu Dzienny Oddzial Chemioterapii, Racibórz, Poland|MrukMed. Lekarz Beata Madej Mruk i Partner. Spolka Partnerska Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Zachodniopomorskie Centrum Onkologii Osrodek Innowacyjnosci, Rozwoju i Badan Klinicznych, Szczecin, Poland","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02953340/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT02953340/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02953340"
408,"NCT01172548","Safety and Efficacy Evaluation of Two Year Imatinib Treatment in Adjuvant Gastrointestinal Stromal Tumor (GIST)","INV555","Completed","No Results Available","Gastrointestinal Stromal Tumors","Drug: imatinib mesylate","Recurrence Free Survival Rate|Compare Recurrence Free Survival Rate to historical controls|Compare Overall Survival to historical controls|Compare Time To Recurrence to historical controls|Adverse Events|Treatment Compliance - tracking if the patient is coming to visits as per visit schedule in protocol","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","132","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","CSTI571BIC08","August 2008","March 2014","March 2014","July 29, 2010",,"May 31, 2017","Novartis Investigative Site, Alger, Algeria|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Ahmedabad, Gujrat, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Kazan, Tatarstan Republic, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Tainan 704, Taiwan ROC, Taiwan|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Ko, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Tunis, Tunisia|Novartis Investigative Site, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01172548"
409,"NCT02992574","Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer","PMRT-NNBC","Recruiting","No Results Available","Breastcancer","Radiation: Post Mastectomy Radiation therapy","Disease free survival|Chest wall recurrence|Regional recurrence|Metastasis-free survival|Overall survival|Acute Morbidity of radiotherapy|Late Morbidity of radiotherapy|Quality of life","Tata Memorial Centre","Female","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","1022","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1602|CTRI/2016/12/007532","May 27, 2016","December 2028","December 2028","December 14, 2016",,"June 13, 2018","Max Super Speciality Hospital(A unit of Devki Devi Foundation), New Delhi, Delhi, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Kolhapur Cancer Centre Pvt Ltd, Kolhapur, Maharashtra, India|Tata Memorial Centre, Mumbai, Maharashtra, India|Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India|Post Graduate Institute of Medical Education & Research, Chandigarh, India|Max Super Speciality Hospital, Shalimar Bagh, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02992574"
410,"NCT04513522","A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India","CheckMate 7C9","Recruiting","No Results Available","Kidney Neoplasms","Biological: Nivolumab|Biological: Ipilimumab","Incidence of high-grade immune-mediated adverse events (IMAEs) assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 3 to 4 and Grade 5|Time to onset of all high grade immune-mediated adverse events (IMAEs) assessed using Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Grade 3 to Grade 5|Time to resolution of all high grade IMAEs assessed using CTCAE v4.0 Grade 3 to Grade 5|Percentage of participants who received immune modulating medication in all high grade IMAEs assessed using CTCAE v4.0 Grade 3 to Grade 5|Objective Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1|Time to Response (TTR) using RECIST 1.1|Duration of Response (DOR) using RECIST 1.1","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-7C9","December 17, 2020","December 29, 2023","December 30, 2023","August 14, 2020",,"April 28, 2022","Local Institution - 0011, Trivandrum, Kerala, India|Local Institution - 0006, Bangalore, India|Local Institution - 0017, Delhi, India|Local Institution - 0002, Karnataka, India|Local Institution - 0019, Kolkata, India|Local Institution, Mumbai, India|Local Institution - 0016, Mumbai, India|Local Institution - 0013, Mumbai, India|Local Institution - 0007, New Delhi, India|Local Institution - 0012, Pune, India",,"https://ClinicalTrials.gov/show/NCT04513522"
411,"NCT05048797","A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations",,"Recruiting","No Results Available","Locally Advanced or Metastatic Non-Small Cell Lung Cancer","Drug: Trastuzumab Deruxtecan|Drug: Cisplatin|Drug: Carboplatin|Drug: Pembrolizumab|Drug: Pemetrexed","Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)|Overall Survival (OS)|Progression Free Survival (PFS) by investigator assessment|Objective Response Rate (ORR)|Duration of Response (DoR)|Time to second progression or death (PFS2)|Landmark analysis of PFS (PFS12)|Landmark analysis of OS (OS24)|Central Nervous System (CNS) - Progression Free Survival (PFS)|Safety and tolerability of T-DXd versus Standard of Care treatment|Pharmacokinetics (PK) of T-DXd, total anti-HER2 antibody and DXd in serum|Immunogenicity of T-DXd|Patient-reported pulmonary symptoms associated with Non-Small Cell Lung Cancer|Patient-reported tolerability of T-DXd described using symptomatic AEs|Patient-reported tolerability of T-DXd described using overall side-effect bother|Patient-reported tolerability of T-DXd described using physical function","AstraZeneca|Daiichi Sankyo, Inc.","All","18 Years to 123 Years   (Adult, Older Adult)","Phase 3","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D967SC00001","October 28, 2021","January 17, 2025","March 1, 2027","September 17, 2021",,"April 26, 2022","Research Site, Anchorage, Alaska, United States|Research Site, Duarte, California, United States|Research Site, Los Angeles, California, United States|Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Francisco, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Boston, Massachusetts, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, New York, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Kennewick, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Leuven, Belgium|Research Site, Barretos, Brazil|Research Site, Blumenau, Brazil|Research Site, Brasília, Brazil|Research Site, Natal, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Uberlândia, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Kunming, China|Research Site, Kunming, China|Research Site, Linhai, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, ShenZhen, China|Research Site, Wenzhou, China|Research Site, Wu Han, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Research Site, Yangzhou, China|Research Site, Zhengzhou City, China|Research Site, Vejle, Denmark|Research Site, Bordeaux, France|Research Site, Dijon, France|Research Site, Le Mans Cedex, France|Research Site, Lyon, France|Research Site, Marseille cedex, France|Research Site, Nantes, France|Research Site, Rennes Cedex 9, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif Cedex, France|Research Site, Berlin-Zehlendorf, Germany|Research Site, Dresden, Germany|Research Site, Erfurt, Germany|Research Site, Heidelberg, Germany|Research Site, Immenhausen, Germany|Research Site, Köln, Germany|Research Site, Mainz, Germany|Research Site, Mannheim, Germany|Research Site, München, Germany|Research Site, Oldenburg, Germany|Research Site, Ravensburg, Germany|Research Site, Würzburg, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, Rohini, India|Research Site, Milan, Italy|Research Site, Monza, Italy|Research Site, Orbassano, Italy|Research Site, Parma, Italy|Research Site, Roma, Italy|Research Site, Verona, Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yonago-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cdmx, Mexico|Research Site, Culiacán, Mexico|Research Site, Guadalajara Jalisco, Mexico|Research Site, Merida, Mexico|Research Site, Mexico City, Mexico|Research Site, Oaxaca, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Gdańsk, Poland|Research Site, Olsztyn, Poland|Research Site, Przemysl, Poland|Research Site, Warszawa, Poland|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Kadıkoy/Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT05048797"
412,"NCT00373113","A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine",,"Terminated","Has Results","Breast Neoplasms","Drug: Capecitabine|Drug: Sunitinib malate","Progression-Free Survival (PFS)|Time to Tumor Progression (TTP)|Number of Participants With Overall Response (OR)|Duration of Response (DR)|Time to Tumor Response (TTR)|Overall Survival (OS)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|EORTC QLQ Breast Cancer Module (BR23)","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 3","482","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A6181107","November 2006","October 2009","June 2011","September 7, 2006","November 18, 2010","June 25, 2012","Pfizer Investigational Site, Bahia Blanca, Prov. de Buenos Aires, Argentina|Pfizer Investigational Site, Viedma, Rio Negro, Argentina|Pfizer Investigational Site, Rosario, Santa Fé, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Cordoba, Argentina|Pfizer Investigational Site, Tucuman, Argentina|Pfizer Investigational Site, Darlinghurst, New South Wales, Australia|Pfizer Investigational Site, Herston, Queensland, Australia|Pfizer Investigational Site, Adelaide, South Australia, Australia|Pfizer Investigational Site, Heidelberg, Victoria, Australia|Pfizer Investigational Site, Parkville, Victoria, Australia|Pfizer Investigational Site, Perth, Western Australia, Australia|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Stara Zagora, Bulgaria|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Temuco, IX Región, Chile|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Bogotá, Cundinamarca, Colombia|Pfizer Investigational Site, Bayonne, France|Pfizer Investigational Site, Besancon, France|Pfizer Investigational Site, Clermont Ferrand, France|Pfizer Investigational Site, Lille, France|Pfizer Investigational Site, Neuilly Sur Seine, France|Pfizer Investigational Site, Nice, France|Pfizer Investigational Site, Rennes Cedex, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Jena, Germany|Pfizer Investigational Site, Kiel, Germany|Pfizer Investigational Site, Leer, Germany|Pfizer Investigational Site, Luebeck, Germany|Pfizer Investigational Site, Magdeburg, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Meiningen, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Offenburg, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Tuen Mun, Hong Kong|Pfizer Investigational Site, Wan Chai,, Hong Kong|Pfizer Investigational Site, Navrangpura / Ahmedabad, Gujarat, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Jaipur, Rajasthan, India|Pfizer Investigational Site, Lucknow, Uttar Pradesh, India|Pfizer Investigational Site, Firenze, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Reggio Emilia, Italy|Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Matsuyama-shi, Ehime, Japan|Pfizer Investigational Site, Kitakyushu-City, Fukuoka, Japan|Pfizer Investigational Site, Suita, Osaka, Japan|Pfizer Investigational Site, Kita-adachi-gun, Saitama, Japan|Pfizer Investigational Site, Bunkyo-ku, Tokyo, Japan|Pfizer Investigational Site, Chuo-Ku, Tokyo, Japan|Pfizer Investigational Site, Fukuoka, Japan|Pfizer Investigational Site, Osaka, Japan|Pfizer Investigational Site, Goyang-si, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Daegu, Korea, Republic of|Pfizer Investigational Site, Incheon, Korea, Republic of|Pfizer Investigational Site, Pusan, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Toluca, Estado de Mexico, Mexico|Pfizer Investigational Site, Acapulco, Guerrero, Mexico|Pfizer Investigational Site, Morelia, Michoacan, Mexico|Pfizer Investigational Site, Ciudad Obregon, Sonora, Mexico|Pfizer Investigational Site, Chihuahua, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, San Juan City, Philippines|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Sandton, South Africa|Pfizer Investigational Site, Mataro, Barcelona, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Alcorcon, Madrid, Spain|Pfizer Investigational Site, Bilbao, Vizcaya, Spain|Pfizer Investigational Site, Cordoba, Spain|Pfizer Investigational Site, Gerona, Spain|Pfizer Investigational Site, Jaen, Spain|Pfizer Investigational Site, La Coruña, Spain|Pfizer Investigational Site, Las Palmas de Gran Canaria, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malaga, Spain|Pfizer Investigational Site, Salamanca, Spain|Pfizer Investigational Site, Changhua, Taiwan|Pfizer Investigational Site, Kaohsiung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyuan, Taiwan|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Cardiff, South Wales, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Nottingham, United Kingdom|Pfizer Investigational Site, Somerset, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00373113"
413,"NCT03519971","Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer",,"Active, not recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Durvalumab|Other: Placebo|Drug: Cisplatin/ Etoposide|Drug: Carboplatin/ Paclitaxel|Drug: Pemetrexed/ Cisplatin|Drug: Pemetrexed/ Carboplatin|Radiation: Radiation","Progression-free survival (PFS)|Overall Survival (OS)|Objective Response Rate (ORR)|Overall Survival at 24 months|Rate of complete response|Duration of response (DoR)|Disease Control Rate (DCR)|Time from randomization to second progression PFS2|Time to death or distant metastasis (TTDM)|Presence of ADA for durvalumab in combination with CRT|To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using EORTC QLQ-C30 v3|To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using QLQ-LC13|To assess the PK of durvalumab in blood (peak trough concentration) when in combination with CRT","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","328","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","D933KC00001","March 29, 2018","June 30, 2022","November 13, 2023","May 9, 2018",,"February 17, 2022","Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Brno, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyula, Hungary|Research Site, Győr, Hungary|Research Site, Törökbálint, Hungary|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Gurgaon, India|Research Site, Karamsad, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, Vadodara, India|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kyoto, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sendai-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Chungcheongbuk-do, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Mérida, Mexico|Research Site, México, Mexico|Research Site, Orizaba, Mexico|Research Site, La Libertad, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Cebu City, Philippines|Research Site, Denver, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Elbląg, Poland|Research Site, Gdańsk, Poland|Research Site, Olsztyn, Poland|Research Site, Warszawa, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Mueang, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Diyarbakir, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03519971"
414,"NCT03631199","Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","CANOPY-1","Active, not recruiting","No Results Available","Non-small Cell Lung Cancer","Drug: canakinumab|Drug: canakinumab matching placebo|Drug: pembrolizumab|Drug: carboplatin|Drug: cisplatin|Drug: paclitaxel|Drug: nab-paclitaxel|Drug: pemetrexed","Safety run-in part: Incidence of dose limiting toxicities (DLTs)|Double-blind, randomized, placebo-controlled part: Progression free survival (PFS) per investigator assessment using RECIST v1.1|Double-blind, randomized, placebo-controlled part: Overall survival (OS) per investigator assessment using RECIST v1.1|Safety run-in part: Overall response rate (ORR) per investigator assessment using RECIST v1.1|Double-blind, randomized, placebo-controlled part : Overall response rate (ORR) per investigator assessment using RECIST v1.1|Safety run-in part: Disease control rate (DCR) per investigator assessment using RECIST v1.1|Double-blind, randomized, placebo-controlled part : Disease control rate (DCR) per investigator assessment using RECIST v1.1|Safety run-in part: Duration of response (DOR) per investigator assessment using RECIST v1.1|Double-blind, randomized, placebo-controlled part : Duration of response (DOR) per investigator assessment using RECIST v1.1|Double-blind, randomized, placebo-controlled part only: Time to response (TTR) per investigator assessment using RECIST v1.1|Safety run-in part: Antidrug antibodies (ADA) of canakinumab|Double-blind, randomized, placebo-controlled part : Antidrug antibodies (ADA) of canakinumab|Safety run-in part: Antidrug antibodies (ADA) of pembrolizumab|Double-blind, randomized, placebo-controlled part : Antidrug antibodies (ADA) of pembrolizumab|Safety run-in part: Serum canakinumab concentration|Double-blind, randomized, placebo-controlled part : Serum canakinumab concentration|Safety run-in part: Serum pembrolizumab concentration|Double-blind, randomized, placebo-controlled part : Serum pembrolizumab concentration|Safety run-in part: Plasma pemetrexed concentration|Double-blind, randomized, placebo-controlled part : : Plasma pemetrexed concentration|Safety run-in part: Plasma cisplatin concentration|Double-blind, randomized, placebo-controlled part: Plasma cisplatin concentration|Safety run-in part: Plasma carboplatin concentration|Double-blind, randomized, placebo-controlled part: Plasma carboplatin concentration|Safety run-in part: Plasma paclitaxel concentration|Double-blind, randomized, placebo-controlled part: Plasma paclitaxel concentration|Double-blind, randomized, placebo-controlled part: Plasma nab-paclitaxel concentration|Double-blind, randomized, placebo-controlled part only :Time to definitive 10 point deterioration symptom scores of pain, cough and dyspnea per QLQ-LC13 questionnaire|Double-blind, randomized, placebo-controlled part only: Time to definitive deterioration in global health status/QoL, shortness of breath and pain per QLQ-C30 questionnaire|Double-blind, randomized, placebo-controlled part only: change from baseline in score as per the EQ-5D-5L questionnaire","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","673","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CACZ885U2301|2018-001547-32","December 21, 2018","August 9, 2021","September 22, 2022","August 15, 2018",,"May 3, 2022","Pacific Shores Medical Group, Long Beach, California, United States|USC Kenneth Norris Comprehensive Cancer Center, Los Angeles, California, United States|Advent Health Cancer Institute, Orlando, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Linz, Oberoesterreich, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Temuco, Region De La Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Valledupar, Cesar, Colombia|Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Prague 2, Czech Republic, Czechia|Novartis Investigative Site, Brno - Bohunice, Czechia|Novartis Investigative Site, Ostrava Vitkovice, Czechia|Novartis Investigative Site, Herning, Denmark|Novartis Investigative Site, Oulu, Finland|Novartis Investigative Site, Marseille cedex 20, Bouches Du Rhone, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Saint Herblain, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Georgsmarienhuette, Germany|Novartis Investigative Site, Gerlingen, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Halle (Saale), Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Athens, GR, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Veszprem, Hungary|Novartis Investigative Site, Reykjavik, Iceland|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Gurgaon, Haryana, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Avellino, AV, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Modena, MO, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Perugia, PG, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Sapporo city, Hokkaido, Japan|Novartis Investigative Site, Himeji, Hyogo, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Sakai, Osaka, Japan|Novartis Investigative Site, Sunto Gun, Shizuoka, Japan|Novartis Investigative Site, Chuo ku, Tokyo, Japan|Novartis Investigative Site, Ube-city, Yamaguchi, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Kuantan, Pahang, Malaysia|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Drammen, Norway|Novartis Investigative Site, Taguig City, Metro Manila, Philippines|Novartis Investigative Site, Makati City, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, San Juan City, Philippines|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Tomaszw Mazowiecki, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Craiova, Dolj, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Pushkin Saint Petersburg, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Partizanske, Slovakia|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Las Palmas De Gran Canarias, Las Palmas De Gran Canaria, Spain|Novartis Investigative Site, San Sebastian, Pais Vasco, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, High Heaton, Newcastle Upon Tyne, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03631199"
415,"NCT01903018","A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00",,"Completed","No Results Available","Radiation Induced Mucositis in Head and Neck Cancer","Drug: P276-00|Radiation: Radiation Therapy|Drug: Cisplatin","Number of severe Radiation Induced Mucositis (WHO grade >=3)|Time to onset of severe RIM (WHO Grade ≥ 3)|Duration of severe RIM (WHO Grade>=3)|Progression-Free Survival (PFS)|Overall Survival (OS)","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","73","Industry","Interventional","Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","P276-00/64/11","July 2012","March 2014","September 2014","July 19, 2013",,"September 4, 2014","Bharat Cancer Hospital & Research Institute, Surat, Gujarat, India|Sri Venkateshwara Hospitals, Bangalore, Karnataka, India|Mazumdar Shaw Cancer Center, Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Curie Manavta Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Meenakshi Mission Hosp. & Res. Centre, Madurai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01903018"
416,"NCT00482014","A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer",,"Completed","Has Results","Non-Small-Cell Lung Cancer","Drug: pemetrexed|Drug: cisplatin|Drug: carboplatin|Radiation: radiation therapy","Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin|Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin|Phase 2 - Survival Probability at 2 Years|Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)|Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)|Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events|Phase 2 - Time to Progression|Phase 2 - Median Survival|Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9031|H3E-US-S047","May 2007","October 2011","October 2011","June 4, 2007","November 27, 2012","November 27, 2012","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Burlington, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Corpus Christi, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Temple, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India",,"https://ClinicalTrials.gov/show/NCT00482014"
417,"NCT01856478","LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy",,"Active, not recruiting","No Results Available","Head and Neck Neoplasms","Drug: methotrexate|Drug: afatinib","progression free survival (PFS), defined as the time from the date of randomization to the date of progression evaluated according to RECIST 1.1 or to the date of death, whichever occurs first|Overall survival (OS), defined as the time from the date of randomization to the date of death (regardless of the cause of death)|Objective response defined as complete response (CR) or partial response (PR) determined by RECIST 1.1 according to the best response to study medication|Health related quality of life (HRQOL) will be assessed based on patient-reported questionaires","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","340","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.161|1200-0161","May 23, 2013","August 22, 2018","October 31, 2022","May 17, 2013",,"May 4, 2022","Beijing Chao-Yang Hospital, Beijing, China|Cancer Hospital of Chinese Academy of Medical Science, Beijing, China|Navy General Hospital, Beijing, China|Peking Union Medical College Hospital, Beijing, China|Affiliated toumor hospital of bengbu medical college, Bengbu, China|First Hospital of Jilin University, Changchun, China|The Second People's Hospital of Sichuan, Chengdu, China|West China Hospital, Chengdu, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Haerbin, China|Zhejiang Cancer Hospital, Hangzhou, China|the 81th Hospital of PLA, Nanjing, China|Renji Hospital Shanghai Jiaotong Univesrity School of Medicine, Shanghai, China|Shanghai Changzheng Hospital, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Ninth People's Hospital, Shanghai, China|Wuhan Union Hospital, Wuhan, China|Tongji Hospital, Tongji University, Wuhan, China|Alexandria University Hospital, Alexandria, Egypt|National Cancer Institute, Cairo University, Cairo, Egypt|Mansoura University Faculty of Medicine, Dakahlia, Egypt|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hongkong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Sujan Surgical Cancer Hospital, Amravati, India|Pristine Hospital, Bengaluru, India|Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner, India|Rajiv Gandhi Government General Hospital, Chennai, India|M N J Institute of Oncology and Regional Cancer Centre, Hyderabad, India|Geetanjali Medical College and Hospital, Jaipur, India|J K Cancer Institute, Kanpur, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|King George Medical University, Lucknow, India|Government Medical College & Hospital, Nagpur, India|Shatabdi Hospital, Nashik, Nasik, India|Ruby Hall Clinic, Pune, India|Noble Hospital Pvt Ltd, Pune, India|National Cancer Center, Goyang, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Perpetual Succour Hospital (Cebu), Cebu City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Keelung Chang Gung Memorial Lover's Lake Branch, Keelung City, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Maharaj Nakom Chiangmai Hospital, Chiang Mai, Thailand|Srinagarind Hospital, Muang, Thailand|Naresuan University Hospital, Phitsanulok, Thailand|Songklanagarind Hospital, Songkla, Thailand",,"https://ClinicalTrials.gov/show/NCT01856478"
418,"NCT00490139","ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","ALTTO","Completed","Has Results","Neoplasms, Breast","Drug: Lapatinib|Biological: Trastuzumab","Disease-free Survival (DFS)|Overall Survival (OS)|Time to Recurrence|Time to Distant Recurrence|Time to Central Nervous System Recurrence|DFS Ignoring Non-breast Second Primary Malignancies","Novartis Pharmaceuticals|North Central Cancer Treatment Group|National Cancer Institute (NCI)|Breast International Group|Canadian Cancer Trials Group|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","8382","Industry|Other|NIH","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF106708|CLAP016B2301|2006-000562-36","May 16, 2007","December 6, 2013","July 1, 2021","June 22, 2007","August 18, 2014","July 23, 2021","Novartis Investigative Site, Mobile, Alabama, United States|Novartis Investigative Site, Anchorage, Alaska, United States|Novartis Investigative Site, Fairbanks, Alaska, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Burlingame, California, United States|Novartis Investigative Site, Castro Valley, California, United States|Novartis Investigative Site, Duarte, California, United States|Novartis Investigative Site, Fairfield, California, United States|Novartis Investigative Site, Fremont, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Glendale, California, United States|Novartis Investigative Site, Greenbrae, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, La Jolla, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Martinez, California, United States|Novartis Investigative Site, Marysville, California, United States|Novartis Investigative Site, Monterey, California, United States|Novartis Investigative Site, Mountain View, California, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Oakland, California, United States|Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Palm Springs, California, United States|Novartis Investigative Site, Palo Alto, California, United States|Novartis Investigative Site, Pismo Beach, California, United States|Novartis Investigative Site, Pleasanton, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, San Leandro, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Edwards, Colorado, United States|Novartis Investigative Site, Englewood, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Glenwood Springs, Colorado, United States|Novartis Investigative Site, Grand Junction, Colorado, United States|Novartis Investigative Site, Greeley, Colorado, United States|Novartis Investigative Site, Lone Tree, Colorado, United States|Novartis Investigative Site, Longmont, Colorado, United States|Novartis Investigative Site, Loveland, Colorado, United States|Novartis Investigative Site, Montrose, Colorado, United States|Novartis Investigative Site, Pueblo, Colorado, United States|Novartis Investigative Site, Thornton, Colorado, United States|Novartis Investigative Site, Wheat Ridge, Colorado, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, New Haven, Connecticut, United States|Novartis Investigative Site, Stamford, Connecticut, United States|Novartis Investigative Site, Torrington, Connecticut, United States|Novartis Investigative Site, Dover, Delaware, United States|Novartis Investigative Site, Milford, Delaware, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Fort Myers, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jupiter, Florida, United States|Novartis Investigative Site, Lakeland, Florida, United States|Novartis Investigative Site, Miami Beach, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Orange Park, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Titusville, Florida, United States|Novartis Investigative Site, Weston, Florida, United States|Novartis Investigative Site, Athens, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Augusta, Georgia, United States|Novartis Investigative Site, Austell, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Fort Gordon, Georgia, United States|Novartis Investigative Site, Gainesville, Georgia, United States|Novartis Investigative Site, Lawrenceville, Georgia, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Riverdale, Georgia, United States|Novartis Investigative Site, Rome, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Valdosta, Georgia, United States|Novartis Investigative Site, 'Aiea, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Honolulu, Hawaii, United States|Novartis Investigative Site, Lihue, Hawaii, United States|Novartis Investigative Site, Wailuku, Hawaii, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Boise, Idaho, United States|Novartis Investigative Site, Alton, Illinois, United States|Novartis Investigative Site, Aurora, Illinois, United States|Novartis Investigative Site, Berwyn, Illinois, United States|Novartis Investigative Site, Bloomington, Illinois, United States|Novartis Investigative Site, Canton, Illinois, United States|Novartis Investigative Site, Carthage, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Eureka, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Galesburg, Illinois, United States|Novartis Investigative Site, Harvey, Illinois, United States|Novartis Investigative Site, Havana, Illinois, United States|Novartis Investigative Site, Highland Park, Illinois, United States|Novartis Investigative Site, Hopedale, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Joliet, Illinois, United States|Novartis Investigative Site, Kankakee, Illinois, United States|Novartis Investigative Site, Kewanee, Illinois, United States|Novartis Investigative Site, La Grange, Illinois, United States|Novartis Investigative Site, Libertyville, Illinois, United States|Novartis Investigative Site, Macomb, Illinois, United States|Novartis Investigative Site, Maywood, Illinois, United States|Novartis Investigative Site, Moline, Illinois, United States|Novartis Investigative Site, Monmouth, Illinois, United States|Novartis Investigative Site, Mount Vernon, Illinois, United States|Novartis Investigative Site, Naperville, Illinois, United States|Novartis Investigative Site, Niles, Illinois, United States|Novartis Investigative Site, Normal, Illinois, United States|Novartis Investigative Site, Oak Lawn, Illinois, United States|Novartis Investigative Site, Ottawa, Illinois, United States|Novartis Investigative Site, Park Ridge, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Pekin, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peoria, Illinois, United States|Novartis Investigative Site, Peru, Illinois, United States|Novartis Investigative Site, Princeton, Illinois, United States|Novartis Investigative Site, Rockford, Illinois, United States|Novartis Investigative Site, Skokie, Illinois, United States|Novartis Investigative Site, Spring Valley, Illinois, United States|Novartis Investigative Site, Springfield, Illinois, United States|Novartis Investigative Site, Urbana, Illinois, United States|Novartis Investigative Site, Warrenville, Illinois, United States|Novartis Investigative Site, Winfield, Illinois, United States|Novartis Investigative Site, Beech Grove, Indiana, United States|Novartis Investigative Site, Elkhart, Indiana, United States|Novartis Investigative Site, Fort Wayne, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Kokomo, Indiana, United States|Novartis Investigative Site, La Porte, Indiana, United States|Novartis Investigative Site, Michigan City, Indiana, United States|Novartis Investigative Site, Mishawaka, Indiana, United States|Novartis Investigative Site, Muncie, Indiana, United States|Novartis Investigative Site, Richmond, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, South Bend, Indiana, United States|Novartis Investigative Site, Ames, Iowa, United States|Novartis Investigative Site, Bettendorf, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Cedar Rapids, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Mason City, Iowa, United States|Novartis Investigative Site, Ottumwa, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Waterloo, Iowa, United States|Novartis Investigative Site, Anthony, Kansas, United States|Novartis Investigative Site, Chanute, Kansas, United States|Novartis Investigative Site, Dodge City, Kansas, United States|Novartis Investigative Site, El Dorado, Kansas, United States|Novartis Investigative Site, Fort Scott, Kansas, United States|Novartis Investigative Site, Independence, Kansas, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Kingman, Kansas, United States|Novartis Investigative Site, Lawrence, Kansas, United States|Novartis Investigative Site, Liberal, Kansas, United States|Novartis Investigative Site, Newton, Kansas, United States|Novartis Investigative Site, Olathe, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Overland Park, Kansas, United States|Novartis Investigative Site, Parsons, Kansas, United States|Novartis Investigative Site, Prairie Village, Kansas, United States|Novartis Investigative Site, Pratt, Kansas, United States|Novartis Investigative Site, Salina, Kansas, United States|Novartis Investigative Site, Shawnee Mission, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Topeka, Kansas, United States|Novartis Investigative Site, Wellington, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Wichita, Kansas, United States|Novartis Investigative Site, Winfield, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Houma, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, New Orleans, Louisiana, United States|Novartis Investigative Site, Portland, Maine, United States|Novartis Investigative Site, Scarborough, Maine, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Bethesda, Maryland, United States|Novartis Investigative Site, Easton, Maryland, United States|Novartis Investigative Site, Frederick, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Silver Spring, Maryland, United States|Novartis Investigative Site, Towson, Maryland, United States|Novartis Investigative Site, Westminster, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Burlington, Massachusetts, United States|Novartis Investigative Site, Gloucester, Massachusetts, United States|Novartis Investigative Site, Hyannis, Massachusetts, United States|Novartis Investigative Site, Lowell, Massachusetts, United States|Novartis Investigative Site, Peabody, Massachusetts, United States|Novartis Investigative Site, Adrian, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Battle Creek, Michigan, United States|Novartis Investigative Site, Big Rapids, Michigan, United States|Novartis Investigative Site, Byron Center, Michigan, United States|Novartis Investigative Site, Dearborn, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Escanaba, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Flint, Michigan, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Iron Mountain, Michigan, United States|Novartis Investigative Site, Jackson, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Lansing, Michigan, United States|Novartis Investigative Site, Livonia, Michigan, United States|Novartis Investigative Site, Monroe, Michigan, United States|Novartis Investigative Site, Muskegon, Michigan, United States|Novartis Investigative Site, Pontiac, Michigan, United States|Novartis Investigative Site, Port Huron, Michigan, United States|Novartis Investigative Site, Saginaw, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Saint Joseph, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Traverse City, Michigan, United States|Novartis Investigative Site, Warren, Michigan, United States|Novartis Investigative Site, Albert Lea, Minnesota, United States|Novartis Investigative Site, Alexandria, Minnesota, United States|Novartis Investigative Site, Bemidji, Minnesota, United States|Novartis Investigative Site, Burnsville, Minnesota, United States|Novartis Investigative Site, Coon Rapids, Minnesota, United States|Novartis Investigative Site, Duluth, Minnesota, United States|Novartis Investigative Site, Edina, Minnesota, United States|Novartis Investigative Site, Fergus Falls, Minnesota, United States|Novartis Investigative Site, Fridley, Minnesota, United States|Novartis Investigative Site, Hutchinson, Minnesota, United States|Novartis Investigative Site, Litchfield, Minnesota, United States|Novartis Investigative Site, Mankato, Minnesota, United States|Novartis Investigative Site, Maplewood, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Robbinsdale, Minnesota, United States|Novartis Investigative Site, Saint Cloud, Minnesota, United States|Novartis Investigative Site, Saint Louis Park, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Saint Paul, Minnesota, United States|Novartis Investigative Site, Shakopee, Minnesota, United States|Novartis Investigative Site, Waconia, Minnesota, United States|Novartis Investigative Site, Willmar, Minnesota, United States|Novartis Investigative Site, Woodbury, Minnesota, United States|Novartis Investigative Site, Jackson, Mississippi, United States|Novartis Investigative Site, Keesler Air Force Base, Mississippi, United States|Novartis Investigative Site, Pascagoula, Mississippi, United States|Novartis Investigative Site, Bolivar, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Cape Girardeau, Missouri, United States|Novartis Investigative Site, Independence, Missouri, United States|Novartis Investigative Site, Joplin, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Liberty, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Joseph, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Bozeman, Montana, United States|Novartis Investigative Site, Butte, Montana, United States|Novartis Investigative Site, Great Falls, Montana, United States|Novartis Investigative Site, Havre, Montana, United States|Novartis Investigative Site, Helena, Montana, United States|Novartis Investigative Site, Kalispell, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Missoula, Montana, United States|Novartis Investigative Site, Grand Island, Nebraska, United States|Novartis Investigative Site, Lincoln, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Omaha, Nebraska, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Concord, New Hampshire, United States|Novartis Investigative Site, Exeter, New Hampshire, United States|Novartis Investigative Site, Hooksett, New Hampshire, United States|Novartis Investigative Site, Keene, New Hampshire, United States|Novartis Investigative Site, Laconia, New Hampshire, United States|Novartis Investigative Site, Lebanon, New Hampshire, United States|Novartis Investigative Site, Manchester, New Hampshire, United States|Novartis Investigative Site, Portsmouth, New Hampshire, United States|Novartis Investigative Site, Hackensack, New Jersey, United States|Novartis Investigative Site, Hamilton, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Marlton, New Jersey, United States|Novartis Investigative Site, Morristown, New Jersey, United States|Novartis Investigative Site, Mount Holly, New Jersey, United States|Novartis Investigative Site, Neptune, New Jersey, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Pomona, New Jersey, United States|Novartis Investigative Site, Princeton, New Jersey, United States|Novartis Investigative Site, Ridgewood, New Jersey, United States|Novartis Investigative Site, Somerville, New Jersey, United States|Novartis Investigative Site, Sparta, New Jersey, United States|Novartis Investigative Site, Summit, New Jersey, United States|Novartis Investigative Site, Vineland, New Jersey, United States|Novartis Investigative Site, Voorhees, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Las Cruces, New Mexico, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Bronx, New York, United States|Novartis Investigative Site, Buffalo, New York, United States|Novartis Investigative Site, Clifton Springs, New York, United States|Novartis Investigative Site, Cooperstown, New York, United States|Novartis Investigative Site, East Syracuse, New York, United States|Novartis Investigative Site, Elmhurst, New York, United States|Novartis Investigative Site, Jamaica, New York, United States|Novartis Investigative Site, Lake Success, New York, United States|Novartis Investigative Site, Manhasset, New York, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, New Hyde Park, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Stony Brook, New York, United States|Novartis Investigative Site, Syracuse, New York, United States|Novartis Investigative Site, Utica, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Fayetteville, North Carolina, United States|Novartis Investigative Site, Gastonia, North Carolina, United States|Novartis Investigative Site, Goldsboro, North Carolina, United States|Novartis Investigative Site, Hendersonville, North Carolina, United States|Novartis Investigative Site, Kinston, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Rutherfordton, North Carolina, United States|Novartis Investigative Site, Statesville, North Carolina, United States|Novartis Investigative Site, Washington, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Bismarck, North Dakota, United States|Novartis Investigative Site, Fargo, North Dakota, United States|Novartis Investigative Site, Grand Forks, North Dakota, United States|Novartis Investigative Site, Minot, North Dakota, United States|Novartis Investigative Site, Beachwood, Ohio, United States|Novartis Investigative Site, Bellefontaine, Ohio, United States|Novartis Investigative Site, Bowling Green, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Chillicothe, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Clyde, Ohio, United States|Novartis Investigative Site, Columbia, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Delaware, Ohio, United States|Novartis Investigative Site, Elyria, Ohio, United States|Novartis Investigative Site, Findlay, Ohio, United States|Novartis Investigative Site, Franklin, Ohio, United States|Novartis Investigative Site, Greenville, Ohio, United States|Novartis Investigative Site, Independence, Ohio, United States|Novartis Investigative Site, Kettering, Ohio, United States|Novartis Investigative Site, Lambertville, Ohio, United States|Novartis Investigative Site, Lima, Ohio, United States|Novartis Investigative Site, Marietta, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Maumee, Ohio, United States|Novartis Investigative Site, Mayfield Heights, Ohio, United States|Novartis Investigative Site, Newark, Ohio, United States|Novartis Investigative Site, Oregon, Ohio, United States|Novartis Investigative Site, Sandusky, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Springfield, Ohio, United States|Novartis Investigative Site, Sylvania, Ohio, United States|Novartis Investigative Site, Tiffin, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Troy, Ohio, United States|Novartis Investigative Site, Wauseon, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Wilmington, Ohio, United States|Novartis Investigative Site, Wooster, Ohio, United States|Novartis Investigative Site, Wright-Patterson Air Force Base, Ohio, United States|Novartis Investigative Site, Xenia, Ohio, United States|Novartis Investigative Site, Zanesville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Coos Bay, Oregon, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Gresham, Oregon, United States|Novartis Investigative Site, Hillsboro, Oregon, United States|Novartis Investigative Site, Klamath Falls, Oregon, United States|Novartis Investigative Site, Milwaukie, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Tualatin, Oregon, United States|Novartis Investigative Site, Abington, Pennsylvania, United States|Novartis Investigative Site, Bethlehem, Pennsylvania, United States|Novartis Investigative Site, Bryn Mawr, Pennsylvania, United States|Novartis Investigative Site, Butler, Pennsylvania, United States|Novartis Investigative Site, Danville, Pennsylvania, United States|Novartis Investigative Site, Ephrata, Pennsylvania, United States|Novartis Investigative Site, Hazleton, Pennsylvania, United States|Novartis Investigative Site, Hershey, Pennsylvania, United States|Novartis Investigative Site, Kingston, Pennsylvania, United States|Novartis Investigative Site, Lancaster, Pennsylvania, United States|Novartis Investigative Site, Langhorne, Pennsylvania, United States|Novartis Investigative Site, Lewistown, Pennsylvania, United States|Novartis Investigative Site, Media, Pennsylvania, United States|Novartis Investigative Site, Nashville, Pennsylvania, United States|Novartis Investigative Site, Paoli, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Phoenixville, Pennsylvania, United States|Novartis Investigative Site, Pottstown, Pennsylvania, United States|Novartis Investigative Site, Sayre, Pennsylvania, United States|Novartis Investigative Site, Scranton, Pennsylvania, United States|Novartis Investigative Site, Sellersville, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, State College, Pennsylvania, United States|Novartis Investigative Site, West Reading, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wilkes-Barre, Pennsylvania, United States|Novartis Investigative Site, Wynnewood, Pennsylvania, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Providence, Rhode Island, United States|Novartis Investigative Site, Warwick, Rhode Island, United States|Novartis Investigative Site, Anderson, South Carolina, United States|Novartis Investigative Site, Charleston, South Carolina, United States|Novartis Investigative Site, Columbia, South Carolina, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Spartanburg, South Carolina, United States|Novartis Investigative Site, Aberdeen, South Dakota, United States|Novartis Investigative Site, Rapid City, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Sioux Falls, South Dakota, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Franklin, Tennessee, United States|Novartis Investigative Site, Germantown, Tennessee, United States|Novartis Investigative Site, Jackson, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Abilene, Texas, United States|Novartis Investigative Site, Amarillo, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Beaumont, Texas, United States|Novartis Investigative Site, Bedford, Texas, United States|Novartis Investigative Site, Cedar Park, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Sam Houston, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lackland Air Force Base, Texas, United States|Novartis Investigative Site, Longview, Texas, United States|Novartis Investigative Site, McAllen, Texas, United States|Novartis Investigative Site, Mesquite, Texas, United States|Novartis Investigative Site, Midland, Texas, United States|Novartis Investigative Site, Paris, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Marcos, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Sugar Land, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Wichita Falls, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Berlin, Vermont, United States|Novartis Investigative Site, Burlington, Vermont, United States|Novartis Investigative Site, Saint Johnsbury, Vermont, United States|Novartis Investigative Site, Charlottesville, Virginia, United States|Novartis Investigative Site, Danville, Virginia, United States|Novartis Investigative Site, Fredericksburg, Virginia, United States|Novartis Investigative Site, Hampton, Virginia, United States|Novartis Investigative Site, Norfolk, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Auburn, Washington, United States|Novartis Investigative Site, Bellingham, Washington, United States|Novartis Investigative Site, Bremerton, Washington, United States|Novartis Investigative Site, Burien, Washington, United States|Novartis Investigative Site, Centralia, Washington, United States|Novartis Investigative Site, Federal Way, Washington, United States|Novartis Investigative Site, Kennewick, Washington, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Mount Vernon, Washington, United States|Novartis Investigative Site, Olympia, Washington, United States|Novartis Investigative Site, Port Angeles, Washington, United States|Novartis Investigative Site, Poulsbo, Washington, United States|Novartis Investigative Site, Puyallup, Washington, United States|Novartis Investigative Site, Renton, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Wenatchee, Washington, United States|Novartis Investigative Site, Charleston, West Virginia, United States|Novartis Investigative Site, Huntington, West Virginia, United States|Novartis Investigative Site, Wheeling, West Virginia, United States|Novartis Investigative Site, Chippewa Falls, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Eau Claire, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, La Crosse, Wisconsin, United States|Novartis Investigative Site, Madison, Wisconsin, United States|Novartis Investigative Site, Manitowoc, Wisconsin, United States|Novartis Investigative Site, Marinette, Wisconsin, United States|Novartis Investigative Site, Marshfield, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Minocqua, Wisconsin, United States|Novartis Investigative Site, Oconto Falls, Wisconsin, United States|Novartis Investigative Site, Oshkosh, Wisconsin, United States|Novartis Investigative Site, Rhinelander, Wisconsin, United States|Novartis Investigative Site, Rice Lake, Wisconsin, United States|Novartis Investigative Site, Stevens Point, Wisconsin, United States|Novartis Investigative Site, Sturgeon Bay, Wisconsin, United States|Novartis Investigative Site, Weston, Wisconsin, United States|Novartis Investigative Site, Wisconsin Rapids, Wisconsin, United States|Novartis Investigative Site, Casper, Wyoming, United States|Novartis Investigative Site, Sheridan, Wyoming, United States|Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Camperdown, New South Wales, Australia|Novartis Investigative Site, Coffs Harbour, New South Wales, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Port Macquarie, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Taree, New South Wales, Australia|Novartis Investigative Site, Tweed Heads, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Waratah, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Nambour, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Woodville, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, East Bentleigh, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Footscray, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, Wendouree, Victoria, Australia|Novartis Investigative Site, Bunbury, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Subiaco, Western Australia, Australia|Novartis Investigative Site, Campbelltown, Australia|Novartis Investigative Site, Lismore, Australia|Novartis Investigative Site, Murdoch, Australia|Novartis Investigative Site, Guessing, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Rankweil, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Steyr, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Villach, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Wolfsberg, Austria|Novartis Investigative Site, Aalst, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Bonheiden, Belgium|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Charleroi, Belgium|Novartis Investigative Site, Edegem, Belgium|Novartis Investigative Site, Genk, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine Saint Paul, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Huy, Belgium|Novartis Investigative Site, Kortrijk, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Mons, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Sint-Niklaas, Belgium|Novartis Investigative Site, Tournai, Belgium|Novartis Investigative Site, Turnhout, Belgium|Novartis Investigative Site, Verviers, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Porte Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Shumen, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Kelowna, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Sault Ste. Marie, Ontario, Canada|Novartis Investigative Site, St Catharines, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Charlottetown, Prince Edward Island, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Regina, Saskatchewan, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Temuco, Región De La Araucania, Chile|Novartis Investigative Site, Valdivia, Región De Los Lagos, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Valparaiso, Valparaíso, Chile|Novartis Investigative Site, Vina del Mar, Valparaíso, Chile|Novartis Investigative Site, Arica, Chile|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Varazdin, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Ceske Budejovice, Czechia|Novartis Investigative Site, Chomutov, Czechia|Novartis Investigative Site, Jihlava, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Pardubice, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Praha 2, Czechia|Novartis Investigative Site, Praha 4, Czechia|Novartis Investigative Site, Praha 5, Czechia|Novartis Investigative Site, Praha 8, Czechia|Novartis Investigative Site, Usti nad Labem, Czechia|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Arhus C, Denmark|Novartis Investigative Site, Esbjerg, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Hilleroed, Denmark|Novartis Investigative Site, Koebenhavn Oe, Denmark|Novartis Investigative Site, Naestved, Denmark|Novartis Investigative Site, Odense, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Viborg, Denmark|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, ANGERS Cedex 2, France|Novartis Investigative Site, Annecy, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bethune, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brive La Gaillarde, France|Novartis Investigative Site, Bron, France|Novartis Investigative Site, Caen Cedex 05, France|Novartis Investigative Site, Caen, France|Novartis Investigative Site, Clermont Ferrand, France|Novartis Investigative Site, Coudekerque Branche, France|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Draguignan, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Grenoble Cedex, France|Novartis Investigative Site, Hyeres, France|Novartis Investigative Site, La Seyne Sur Mer, France|Novartis Investigative Site, Le Chesnay, France|Novartis Investigative Site, Le Havre, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille Cedex 09, France|Novartis Investigative Site, Marseille cedex 5, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz cedex 01, France|Novartis Investigative Site, Mont de Marsan, France|Novartis Investigative Site, Montauban, France|Novartis Investigative Site, Montbeliard, France|Novartis Investigative Site, Mulhouse, France|Novartis Investigative Site, Nancy, France|Novartis Investigative Site, Nice Cedex 2, France|Novartis Investigative Site, Nimes cedex 9, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Paris Cedex 14, France|Novartis Investigative Site, Paris Cedex 5, France|Novartis Investigative Site, Perigueux, France|Novartis Investigative Site, Perin Sur Mer, France|Novartis Investigative Site, Perpignan, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rouen cedex 1, France|Novartis Investigative Site, Rouen, France|Novartis Investigative Site, Saint Gregoire, France|Novartis Investigative Site, Saint Jean, France|Novartis Investigative Site, Saint-Cloud, France|Novartis Investigative Site, Saint-Herblain, France|Novartis Investigative Site, Saint-Martin Boulogne, France|Novartis Investigative Site, Saint-Priest en Jarez Cedex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours cedex, France|Novartis Investigative Site, Valenciennes, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Aalen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Baden-Baden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Boeblingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Emmendingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Esslingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Goeppingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Heidelberg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Konstanz, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Loerrach, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ludwigsburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mutlangen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ostfildern, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Reutlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Rheinfelden, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwaebisch Hall, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Schwetzingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Sigmaringen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuebingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Tuttlingen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ansbach, Bayern, Germany|Novartis Investigative Site, Aschaffenburg, Bayern, Germany|Novartis Investigative Site, Augsburg, Bayern, Germany|Novartis Investigative Site, Bad Reichenhall, Bayern, Germany|Novartis Investigative Site, Bayreuth, Bayern, Germany|Novartis Investigative Site, Coburg, Bayern, Germany|Novartis Investigative Site, Dachau, Bayern, Germany|Novartis Investigative Site, Deggendorf, Bayern, Germany|Novartis Investigative Site, Donauwoerth, Bayern, Germany|Novartis Investigative Site, Ebersberg, Bayern, Germany|Novartis Investigative Site, Eggenfelden, Bayern, Germany|Novartis Investigative Site, Erlangen, Bayern, Germany|Novartis Investigative Site, Forchheim, Bayern, Germany|Novartis Investigative Site, Freising, Bayern, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Garmisch-Partenkirchen, Bayern, Germany|Novartis Investigative Site, Kempten, Bayern, Germany|Novartis Investigative Site, Kronach, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Landshut, Bayern, Germany|Novartis Investigative Site, Marktredwitz, Bayern, Germany|Novartis Investigative Site, Memmingen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muhr, Bayern, Germany|Novartis Investigative Site, Munchen, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Rosenheim, Bayern, Germany|Novartis Investigative Site, Roth, Bayern, Germany|Novartis Investigative Site, Schwandorf, Bayern, Germany|Novartis Investigative Site, Traunstein, Bayern, Germany|Novartis Investigative Site, Waldmuenchen, Bayern, Germany|Novartis Investigative Site, Weiden, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Koenigs Wusterhausen, Brandenburg, Germany|Novartis Investigative Site, Luckenwalde, Brandenburg, Germany|Novartis Investigative Site, Ludwigsfelde, Brandenburg, Germany|Novartis Investigative Site, Bremerhaven, Bremen, Germany|Novartis Investigative Site, Bad Soden, Hessen, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Fulda, Hessen, Germany|Novartis Investigative Site, Hanau, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Limburg, Hessen, Germany|Novartis Investigative Site, Marburg, Hessen, Germany|Novartis Investigative Site, Offenbach, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Wiesbaden, Hessen, Germany|Novartis Investigative Site, Greifswald, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Guestrow, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Schwerin, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Aurich, Niedersachsen, Germany|Novartis Investigative Site, Braunschweig, Niedersachsen, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Cuxhaven, Niedersachsen, Germany|Novartis Investigative Site, Georgsmarienhuette, Niedersachsen, Germany|Novartis Investigative Site, Goettingen, Niedersachsen, Germany|Novartis Investigative Site, Goslar, Niedersachsen, Germany|Novartis Investigative Site, Hameln, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Leer, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Oldenburg, Niedersachsen, Germany|Novartis Investigative Site, Osnabrueck, Niedersachsen, Germany|Novartis Investigative Site, Rotenburg (Wuemme), Niedersachsen, Germany|Novartis Investigative Site, Stade, Niedersachsen, Germany|Novartis Investigative Site, Stadthagen, Niedersachsen, Germany|Novartis Investigative Site, Vechta, Niedersachsen, Germany|Novartis Investigative Site, Westerstede, Niedersachsen, Germany|Novartis Investigative Site, Bergisch Gladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bielefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bochum, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Bonn, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duesseldorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Duisburg, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Eschweiler, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Gummersbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Hamm-Heessen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Herne, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Krefeld, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Leverkusen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Minden, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muelheim, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Olpe, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Porta Westfalica, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Solingen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Troisdorf, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wesel, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuerselen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Wuppertal, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Ludwigshafen, Rheinland-Pfalz, Germany|Novartis Investigative Site, Mainz, Rheinland-Pfalz, Germany|Novartis Investigative Site, Trier, Rheinland-Pfalz, Germany|Novartis Investigative Site, Homburg/Saar, Saarland, Germany|Novartis Investigative Site, Landstuhl, Saarland, Germany|Novartis Investigative Site, Neunkirchen, Saarland, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Aschersleben, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Magdeburg, Sachsen-Anhalt, Germany|Novartis Investigative Site, Stendal, Sachsen-Anhalt, Germany|Novartis Investigative Site, Weissenfels, Sachsen-Anhalt, Germany|Novartis Investigative Site, Chemnitz, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Hoyerswerda, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Leipzig, Sachsen, Germany|Novartis Investigative Site, Radebeul, Sachsen, Germany|Novartis Investigative Site, Rodewisch, Sachsen, Germany|Novartis Investigative Site, Schkeuditz, Sachsen, Germany|Novartis Investigative Site, Torgau, Sachsen, Germany|Novartis Investigative Site, Zittau, Sachsen, Germany|Novartis Investigative Site, Zwickau, Sachsen, Germany|Novartis Investigative Site, Bad Oldesloe, Schleswig-Holstein, Germany|Novartis Investigative Site, Flensburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Geesthacht, Schleswig-Holstein, Germany|Novartis Investigative Site, Heide, Schleswig-Holstein, Germany|Novartis Investigative Site, Itzehoe, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Luebeck, Schleswig-Holstein, Germany|Novartis Investigative Site, Neumuenster, Schleswig-Holstein, Germany|Novartis Investigative Site, Rendsburg, Schleswig-Holstein, Germany|Novartis Investigative Site, Erfurt, Thueringen, Germany|Novartis Investigative Site, Gera, Thueringen, Germany|Novartis Investigative Site, Jena, Thueringen, Germany|Novartis Investigative Site, Meiningen, Thueringen, Germany|Novartis Investigative Site, Muehlhausen, Thueringen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Brandenburg, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Bremen, Germany|Novartis Investigative Site, Friedrichshafen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Heraklion,Crete, Greece|Novartis Investigative Site, Patra, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Gurgaon, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Kolkatta (w.b.), India|Novartis Investigative Site, Mangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Trivandrum, India|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Sligo, Ireland|Novartis Investigative Site, Tallaght, Dublin, Ireland|Novartis Investigative Site, Wilton, Cork, Ireland|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Holon, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Netanya, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Avellino, Campania, Italy|Novartis Investigative Site, Carpi (MO), Emilia-Romagna, Italy|Novartis Investigative Site, Lugo (Ravenna), Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Ravenna, Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Viterbo, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Alzano Lombardo (BG), Lombardia, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Cremona, Lombardia, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Mantova, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Rozzano (MI), Lombardia, Italy|Novartis Investigative Site, San Fermo Della Battaglia (Co), Lombardia, Italy|Novartis Investigative Site, Saronno (VA), Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Varese, Lombardia, Italy|Novartis Investigative Site, Fano (Pesaro Urbino), Marche, Italy|Novartis Investigative Site, Fermo (AP), Marche, Italy|Novartis Investigative Site, Asti, Piemonte, Italy|Novartis Investigative Site, Biella, Piemonte, Italy|Novartis Investigative Site, Candiolo (TO), Piemonte, Italy|Novartis Investigative Site, Brindisi, Puglia, Italy|Novartis Investigative Site, Lecce, Puglia, Italy|Novartis Investigative Site, Monserrato (CA), Sardegna, Italy|Novartis Investigative Site, Sassari, Sardegna, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Ragusa, Sicilia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Lido Di Camaiore (LU), Toscana, Italy|Novartis Investigative Site, Livorno, Toscana, Italy|Novartis Investigative Site, Montepulciano (Siena, Toscana, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Poggibonsi (Siena), Toscana, Italy|Novartis Investigative Site, Prato, Toscana, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Chieti, Italy|Novartis Investigative Site, Cosenza, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Chiba, Japan|Novartis Investigative Site, Ehime, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Ibaraki, Japan|Novartis Investigative Site, Kanagawa, Japan|Novartis Investigative Site, Kyoto, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Incheon, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Novartis Investigative Site, Kubang Kerian, Malaysia|Novartis Investigative Site, Sarawak, Malaysia|Novartis Investigative Site, Toluca, Estado De México, Mexico|Novartis Investigative Site, Merida, Yucatán, Mexico|Novartis Investigative Site, Chihuahua, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Mexico D.F., Mexico|Novartis Investigative Site, Mexico DF, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Arnhem, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Delft, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Eindhoven, Netherlands|Novartis Investigative Site, Gouda, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Leidschendam, Netherlands|Novartis Investigative Site, Purmerend, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Utrecht, Netherlands|Novartis Investigative Site, Hamilton, New Zealand|Novartis Investigative Site, Palmerston North, New Zealand|Novartis Investigative Site, Wellington, New Zealand|Novartis Investigative Site, Forde, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Tromso, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Lahore, Pakistan|Novartis Investigative Site, Rawalpindi, Pakistan|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Cebu, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Sampaloc Manila, Philippines|Novartis Investigative Site, San Juan, Philippines|Novartis Investigative Site, Bydgoszcz, Poland|Novartis Investigative Site, Elblag, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Gliwice, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Orenburg, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Voronezh, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Poprad, Slovakia|Novartis Investigative Site, Rimavska Sobota, Slovakia|Novartis Investigative Site, Zilina, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Groenkloof, Pretoria, 0001, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Observatory, South Africa|Novartis Investigative Site, Panorama, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Saxonwold, Johannesburg, South Africa|Novartis Investigative Site, Alcoy/Alicante, Spain|Novartis Investigative Site, Barakaldo (Vizcaya), Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Burgos, Spain|Novartis Investigative Site, Cadiz, Spain|Novartis Investigative Site, Castellon, Spain|Novartis Investigative Site, Cordoba, Spain|Novartis Investigative Site, Coria, Spain|Novartis Investigative Site, Elda, Spain|Novartis Investigative Site, Granada, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Huesca, Spain|Novartis Investigative Site, La Laguna (Santa Cruz De Tenerife), Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Lugo, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Malaga, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Mostoles (Madrid), Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Murcia, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Palma de Mallorca, Spain|Novartis Investigative Site, Pamplona, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, San Sebastian, Spain|Novartis Investigative Site, Santander, Spain|Novartis Investigative Site, Santiago, Spain|Novartis Investigative Site, Segovia, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Tarrasa, Barcelona, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Zamora, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Aarau, Switzerland|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Chur, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Locarno, Switzerland|Novartis Investigative Site, St Gallen, Switzerland|Novartis Investigative Site, Thun, Switzerland|Novartis Investigative Site, Zuerich, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Kaohsiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiangmai, Thailand|Novartis Investigative Site, Hatyai, Songkhla, Thailand|Novartis Investigative Site, Khon Kaen, Thailand|Novartis Investigative Site, Phitsanulok, Thailand|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Ivano-Frankivsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Uzhorod, Ukraine|Novartis Investigative Site, Chelmsford, Essex, United Kingdom|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Prittlewell Chase, Essex, United Kingdom|Novartis Investigative Site, Nottingham, Gloucestershire, United Kingdom|Novartis Investigative Site, Canterbury, Kent, United Kingdom|Novartis Investigative Site, Manchester, Lancashire, United Kingdom|Novartis Investigative Site, Preston, Lancashire, United Kingdom|Novartis Investigative Site, Northwood, Middlesex, United Kingdom|Novartis Investigative Site, Edinburgh, Midlothian, United Kingdom|Novartis Investigative Site, Headington, Oxford, Oxfordshire, United Kingdom|Novartis Investigative Site, Ashford, United Kingdom|Novartis Investigative Site, Blackpool, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom|Novartis Investigative Site, Cheltenham, United Kingdom|Novartis Investigative Site, Cottingham, United Kingdom|Novartis Investigative Site, Dorchester, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Grimsby, United Kingdom|Novartis Investigative Site, Guildford, United Kingdom|Novartis Investigative Site, Gwynedd, United Kingdom|Novartis Investigative Site, Ipswich, United Kingdom|Novartis Investigative Site, Lancaster, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Lindley, Huddersfield, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Maidstone, United Kingdom|Novartis Investigative Site, Margate, United Kingdom|Novartis Investigative Site, Newcastle upon Tyne, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Plymouth, United Kingdom|Novartis Investigative Site, Poole, Dorset, United Kingdom|Novartis Investigative Site, Portsmouth, United Kingdom|Novartis Investigative Site, Romford, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Shrewsbury, United Kingdom|Novartis Investigative Site, Southport, United Kingdom|Novartis Investigative Site, St Helens, United Kingdom|Novartis Investigative Site, Stoke on Trent, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom|Novartis Investigative Site, Whitchurch, Cardiff, United Kingdom|Novartis Investigative Site, Worthing, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00490139"
419,"NCT00676507","Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy","STOP","Completed","No Results Available","Lung Neoplasm|Carcinoma Non-small Cell Lung Cancer Stage IIIA|Carcinoma Non-small Cell Lung Cancer Stage IIIB|Carcinoma Non-small Cell Lung Cancer Stage IV","Biological: Lucanix™|Other: Placebo Comparator","Compare the overall survival of subjects with stage III or IV non-small cell lung cancer treated with belagenpumatucel-L (Lucanix™) vs placebo.|Evaluate the progression free survival (PFS) of subjects treated with Lucanix™ compared to treatment within the Best Support Care control group.|Evaluate the quality of life (QOL) as determined by the Lung Cancer Symptom Scale (LCSS) compared to treatment within the Best Supportive Care control group.|Evaluate the time-to-progression of subjects treated with Lucanix™ compared to treatment within the Best Supportive Care control group.|Evaluate the best overall tumor response in subjects treated with Lucanix™ compared to treatment in the Best Supportive Care control group.|Evaluate the response duration in subjects treated with Lucanix™ compared to the Best Supportive Care control group.|Evaluate the rate of CNS metastases development in subjects treated with Lucanix™ as compared to the Best Supportive Care control group.|Adverse events of subjects treated with Lucanix™ will be compared to subjects in the Best Supportive Care control group.","NovaRx Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","532","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","NR001-03|BB-IND 8868","July 2008","January 2013","January 2013","May 13, 2008",,"May 8, 2015","Southern Cancer Center, Mobile, Alabama, United States|Alaska Regional Hospital, Anchorage, Alaska, United States|Mayo Clinic Cancer Center, Scottsdale, Arizona, United States|Clopton Clinic Hematology/Oncology, Jonesboro, Arkansas, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|University of California, San Diego, La Jolla, California, United States|UCLA Pasadena Oncology, Pasadena, California, United States|Cancer Care Associates, Redondo, California, United States|Innovative Research Center of California, San Diego, California, United States|Sansum Clinic, Santa Barbara, California, United States|Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|UCLA Cancer Center, Santa Monica, California, United States|UCLA Cancer Center-Valencia, Valencia, California, United States|UCLA Cancer Center, Westlake Village, California, United States|University of Colorado Health Science Center, Aurora, Colorado, United States|Pasco Hernando Oncology Associates, P.A., Brooksville, Florida, United States|Medical Specialist of Palm Beaches, Lake Worth, Florida, United States|Ocala Oncology, Ocala, Florida, United States|Space Coast Medical Center, Titusville, Florida, United States|Atlanta Cancer Care, Roswell, Georgia, United States|Kootenai Cancer Center, Coeur d'Alene, Idaho, United States|St. Francis Medical Group Oncology and Hematology Specialists, Indianapolis, Indiana, United States|Iowa Blood and Cancer Center, Cedar Rapids, Iowa, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Hematology Oncology Life Center, Alexandria, Louisiana, United States|National Cancer Institute Center for Cancer Research, Medical Oncology Branch, Bethesda, Maryland, United States|Henry Ford Health System, Detroit, Michigan, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|University of Tennessee Cancer Institute, Southaven, Mississippi, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Eastchester Center for Cancer Care, Bronx, New York, United States|Richmond University Medical Center, Staten Island, New York, United States|Allergy Partners of West North Carolina, Asheville, North Carolina, United States|Cancer Care of WNC, Asheville, North Carolina, United States|Gabrail Cancer Center Research LLC, Canton, Ohio, United States|Optim Oncology, Midwest City, Oklahoma, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|University of Tennessee Cancer Institute, Bartlett, Tennessee, United States|University of Tennessee Cancer Institute, Germantown, Tennessee, United States|University of Tennessee Cancer Institute, Memphis, Tennessee, United States|Texas Cancer Center Abilene, Texas Oncology P.A., Abilene, Texas, United States|Mary Crowley Cancer Research Centers, Dallas, Texas, United States|Allison Cancer Center, Texas Oncology, P.A., Midland, Texas, United States|Tyler Cancer Center, Texas Oncology, Tyler, Texas, United States|Seattle Cancer Care Alliance/Fred Hutchinson Cancer Res Ctr/Univ. of Washington Med Ctr, Seattle, Washington, United States|Davis Memorial Cancer Care Center, Elkins, West Virginia, United States|Marshfield Clinic Weston Center, Weston, Wisconsin, United States|University of Alberta Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Orszagos Koranyi TBC es Pulmonologiai Intezet, Budapest, Hungary|Semmelweis Egyetem Pulmonológiai Klinika, Budapest, Hungary|Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary|Csongrád Megyei Önkormányzat Mellkasi Betegségek Szakkórháza, Deszk, Hungary|Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András Oktató Kórháza, Nyíregyháza, Hungary|Fejér Megyei Szent György Kórház, Székesfehérvár, Hungary|Pest Megyei Tüdőgyógyintézet, Törökbálint, Hungary|Gujarat Cancer Hospital and Research Institute, Ahmedabad, India|SEAROC Cancer Center, S.K., Jaipur, India|Tata Memorial Hospital, Mumbai, India|Noble Hospital, Pune, India|Ziekenhuis Groep Twente - locatie Twenteborg Ziekenhuis, Almelo, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Universitair Medisch Centrum Maastricht, Maastricht, Netherlands|Akademickie Centrum Kliniczne Szpital Akademii Medycznej w Gdansku, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Lublin, Poland|Wielkopolskie Centrum Pulmunologii i Torakochirurgii, Poznan, Poland|Centrum Onkologii - Instytut im.Marii Sklodowskiej-Curie, Warsaw, Poland|Dolnoslaskie Centrum Chorob Pluc, Wroclaw, Poland|Klinicko-bolnicki centar Bezanijska kosa, Belgrade, Serbia|Klinicki Centar Nis, Nis, Serbia|Institute for pulmonary disease Sremska Kamenica, Sremska Kamenica, Serbia|Clatterbridge Centre for Oncology, Bebington, Wirral, United Kingdom|Ninewells Hospital and Medical School, Dundee, United Kingdom|The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Guy's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00676507"
420,"NCT00353496","Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours","CLARINET","Completed","Has Results","Endocrine Tumors","Drug: lanreotide (Autogel formulation)|Drug: Placebo","Progression-Free Survival (PFS)|Percentage of Patients Alive & Without Disease Progression|Pharmacokinetic Profile of Lanreotide|Change in the Global Health Status Quality of Life Assessment|Percentage of Patients With a Greater Than or Equal to 50% Decrease in Plasma Chromogranin A (CgA) Levels|Percentage of Patients Still Alive Based on Available Overall Survival Data","Ipsen","All","18 Years and older   (Adult, Older Adult)","Phase 3","264","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2-55-52030-726|2005-004904-35","June 2006","April 2013","April 2013","July 18, 2006","February 18, 2015","March 6, 2015","Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States|University of Iowa, Iowa City, Iowa, United States|The John Hopkins Hospital, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|MD Anderson Cancer Center, Houston, Texas, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|University Hospital, Vienna, Austria|UZ Antwerpen, Antwerpen, Belgium|UCL Saint Luc, Bruxelles, Belgium|UZ Gent, Gent, Belgium|Fakultni nemocnice Na, Bulovce, Prague, Czech Republic|Fekultni nemocnice Olomouc, Olomouc, Czech Republic|General faculty, Praha, Czech Republic|Sygehus Hospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Hôpital A. Paré, Boulogne Billancourt, France|Hôpital Beaujon, Clichy, France|CAC Oscar Lambret, Lille, France|Hôpital Edouard Herriot, Lyon, France|CHU la Timone, Marseille, France|Hôpital R. Debré, Reims, France|CHI Frejus St Raphael, St Raphael, France|Hôpital Rangueil, Toulouse, France|Unité de gastro enterologie IGR, Villejuif, France|Charite Hospital, Berlin, Germany|University Hospital, Erlangen, Germany|University Hospital, Lubeck, Germany|Gutenberg University Hospital, Mainz, Germany|University Hospital, Munchen, Germany|Lukas Hospital, Neuss, Germany|Global Hospital, Hyderabad, India|Tata Memorial Hospital, Mumbai, India|Centro di Refierimiento Oncologica, Aviano, Italy|Azienda Malpighi, Bologna, Italy|INSCT, Milano, Italy|University of Naples, Naples, Italy|Hospital S. Chiara, Pisa, Italy|Azienda San Giovanni Battista, Torino, Italy|UMC Gronigen, Gronigen, Netherlands|Erasmu MC, Rotterdam, Netherlands|UMC Utrecht, Utrecht, Netherlands|Centrum Onkologii-Instytut im. Marii Sklodowskiej - Curie, oddzial w Gliwicach, Zaklad Medycyny Nuklearnej i Endokrynologii Onkologicznej ul., Gliwice, Poland|Katedra i Klinika Endokrynologii Przemiany Materii i Chorob Wewnetrznych Uniwersytetu Medycznego w Poznaniu, Poznan, Poland|Samodzielny Publiczny Centralny Szpital Kliniczny, Katedra i Klinika Chorob Wewnetrznych I Endokrynologii ul. Banacha 1 a, Warszawa, Poland|Szpital Bielanski im. Ks. Jerzego Popieluszki, Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Klinika Endokrynologii Centrum Medycznego Ksztalcenia Podyplomowego, Warszawa, Poland|Zaklad Diagnosttyki Radiologicznej, Centralny Szpital Klincny, Ministrerstwa Spraw Wewnetrznych i Administratracji w Warzawie, Warszawa, Poland|Silesian Medical University, Zabrze, Poland|Narodny onkologicky ustav, Bratislava, Slovakia, Slovakia|Vychodoslovensky onkologicky ustav, Rastislavova, Slovakia, Slovakia|Hospital Vall d'Hebron, Barcelona, Spain|Institut Catala Oncologia, Barcelona, Spain|Hospital G. Maranon, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Nuestra Senora de la Candelaria, Tenerife, Spain|Sahlgrenska Hospital, Goteborg, Sweden|Karolinska University Hospital, Stockholm, Sweden|University Hospital, Uppsala, Sweden|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Royal Victoria Hospital, Belfast, United Kingdom|University Hospital Wales, Cardiff, United Kingdom|Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|St James Hospital, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|Royal Free Hospital, London, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|QMC, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00353496"
421,"NCT01345669","LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy",,"Terminated","Has Results","Head and Neck Neoplasms","Drug: Placebo|Drug: Afatinib","Disease Free Survival (DFS)|Disease Free Survival (DFS) Rate at 2 Years|Percentage of Patient Deaths (Overall Survival (OS))|Patients With Improved Health Related Quality of Life (HRQOL)|Time to Deterioration in Health Related Quality of Life (HRQOL)|Health Related Quality of Life (HRQOL) Scores Over Time","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","617","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1200.131|2011-000392-14","October 17, 2011","September 12, 2016","September 12, 2016","May 2, 2011","October 23, 2017","December 7, 2017","1200.131.00171 Boehringer Ingelheim Investigational Site, Little Rock, Arkansas, United States|1200.131.00181 Boehringer Ingelheim Investigational Site, Orange, California, United States|1200.131.00177 Boehringer Ingelheim Investigational Site, Aurora, Colorado, United States|1200.131.00185 Boehringer Ingelheim Investigational Site, New Haven, Connecticut, United States|1200.131.00173 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States|1200.131.00176 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States|1200.131.00182 Boehringer Ingelheim Investigational Site, Omaha, Nebraska, United States|1200.131.00175 Boehringer Ingelheim Investigational Site, Lebanon, New Hampshire, United States|1200.131.00179 Boehringer Ingelheim Investigational Site, Stony Brook, New York, United States|1200.131.00188 Boehringer Ingelheim Investigational Site, The Bronx, New York, United States|1200.131.10200 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|1200.131.00172 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|1200.131.00184 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States|1200.131.00198 Boehringer Ingelheim Investigational Site, Spokane Valley, Washington, United States|1200.131.00183 Boehringer Ingelheim Investigational Site, Wenatchee, Washington, United States|1200.131.05451 Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Bs As, Argentina|1200.131.05457 Boehringer Ingelheim Investigational Site, Cordoba, Argentina|1200.131.05458 Boehringer Ingelheim Investigational Site, San Miguel de Tucuman, Argentina|1200.131.05452 Boehringer Ingelheim Investigational Site, Santa Fe, Argentina|1200.131.05453 Boehringer Ingelheim Investigational Site, Villa Dominico, Argentina|1200.131.06151 Boehringer Ingelheim Investigational Site, Wooloongabba, Queensland, Australia|1200.131.04353 Boehringer Ingelheim Investigational Site, Leoben, Austria|1200.131.04357 Boehringer Ingelheim Investigational Site, Linz, Austria|1200.131.04355 Boehringer Ingelheim Investigational Site, Salzburg, Austria|1200.131.04351 Boehringer Ingelheim Investigational Site, Wien, Austria|1200.131.04359 Boehringer Ingelheim Investigational Site, Wien, Austria|1200.131.03259 Boehringer Ingelheim Investigational Site, Brussel, Belgium|1200.131.03256 Boehringer Ingelheim Investigational Site, Charleroi, Belgium|1200.131.03255 Boehringer Ingelheim Investigational Site, Hasselt, Belgium|1200.131.03253 Boehringer Ingelheim Investigational Site, Kortrijk, Belgium|1200.131.03252 Boehringer Ingelheim Investigational Site, Liège, Belgium|1200.131.03254 Boehringer Ingelheim Investigational Site, Liège, Belgium|1200.131.03258 Boehringer Ingelheim Investigational Site, Namur, Belgium|1200.131.05554 Boehringer Ingelheim Investigational Site, Barretos, Brazil|1200.131.05555 Boehringer Ingelheim Investigational Site, Jau, Brazil|1200.131.05557 Boehringer Ingelheim Investigational Site, Passo Fundo, Brazil|1200.131.05553 Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|1200.131.05551 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|1200.131.05556 Boehringer Ingelheim Investigational Site, Sao Paulo, Brazil|1200.131.00152 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada|1200.131.00157 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|1200.131.00151 Boehringer Ingelheim Investigational Site, Windsor, Ontario, Canada|1200.131.00153 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.131.00154 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.131.00155 Boehringer Ingelheim Investigational Site, Montreal, Quebec, Canada|1200.131.05652 Boehringer Ingelheim Investigational Site, Vina De Mar, Chile|1200.131.05651 Boehringer Ingelheim Investigational Site, Vina del Mar, Chile|1200.131.04254 Boehringer Ingelheim Investigational Site, Brno, Czechia|1200.131.04253 Boehringer Ingelheim Investigational Site, Praha 5, Czechia|1200.131.04251 Boehringer Ingelheim Investigational Site, Praha 8, Czechia|1200.131.04551 Boehringer Ingelheim Investigational Site, København Ø, Denmark|1200.131.2052 Boehringer Ingelheim Investigational Site, Alexandria, Egypt|1200.131.35851 Boehringer Ingelheim Investigational Site, Turku, Finland|1200.131.03353 Boehringer Ingelheim Investigational Site, Le Havre, France|1200.131.03362 Boehringer Ingelheim Investigational Site, Marseille Cedex 5, France|1200.131.03359 Boehringer Ingelheim Investigational Site, Nice cedex 2, France|1200.131.03365 Boehringer Ingelheim Investigational Site, Orléans Cedex 2, France|1200.131.03355 Boehringer Ingelheim Investigational Site, Pierre-Bénite, France|1200.131.03367 Boehringer Ingelheim Investigational Site, Rouen, France|1200.131.03370 Boehringer Ingelheim Investigational Site, Saint Cloud, France|1200.131.03354 Boehringer Ingelheim Investigational Site, Saint Herblain Cedex, France|1200.131.03369 Boehringer Ingelheim Investigational Site, Saint Priest en Jarez, France|1200.131.03366 Boehringer Ingelheim Investigational Site, Salouel, France|1200.131.03356 Boehringer Ingelheim Investigational Site, Tours, France|1200.131.03357 Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|1200.131.04954 Boehringer Ingelheim Investigational Site, Essen, Germany|1200.131.04961 Boehringer Ingelheim Investigational Site, Freiburg, Germany|1200.131.04953 Boehringer Ingelheim Investigational Site, Hannover, Germany|1200.131.04956 Boehringer Ingelheim Investigational Site, Jena, Germany|1200.131.04959 Boehringer Ingelheim Investigational Site, Kaiserslautern, Germany|1200.131.04951 Boehringer Ingelheim Investigational Site, Leipzig, Germany|1200.131.04957 Boehringer Ingelheim Investigational Site, Rostock, Germany|1200.131.04964 Boehringer Ingelheim Investigational Site, Trier, Germany|1200.131.04963 Boehringer Ingelheim Investigational Site, Ulm, Germany|1200.131.04962 Boehringer Ingelheim Investigational Site, Villingen-Schwenningen, Germany|1200.131.03054 Boehringer Ingelheim Investigational Site, Chaidari, Greece|1200.131.03052 Boehringer Ingelheim Investigational Site, Thessaloniki, Greece|1200.131.03651 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1200.131.03652 Boehringer Ingelheim Investigational Site, Budapest, Hungary|1200.131.03656 Boehringer Ingelheim Investigational Site, Budpest, Hungary|1200.131.03654 Boehringer Ingelheim Investigational Site, Debrecen, Hungary|1200.131.03655 Boehringer Ingelheim Investigational Site, Kecskemet, Hungary|1200.131.09178 Boehringer Ingelheim Investigational Site, Ahmadabad, India|1200.131.09165 Boehringer Ingelheim Investigational Site, Bangalore, India|1200.131.09152 Boehringer Ingelheim Investigational Site, Bikaner, India|1200.131.09163 Boehringer Ingelheim Investigational Site, Chennai, India|1200.131.09173 Boehringer Ingelheim Investigational Site, Chennai, India|1200.131.09179 Boehringer Ingelheim Investigational Site, Delhi, India|1200.131.09170 Boehringer Ingelheim Investigational Site, Gurgaon, India|1200.131.09180 Boehringer Ingelheim Investigational Site, Hyderabad, India|1200.131.09172 Boehringer Ingelheim Investigational Site, Jaipur, India|1200.131.09176 Boehringer Ingelheim Investigational Site, Karamsad,Anand, Gujarat, India|1200.131.09162 Boehringer Ingelheim Investigational Site, Madurai, Tamil Nadu, India|1200.131.09175 Boehringer Ingelheim Investigational Site, Mazagaon, Mumbai, India|1200.131.09151 Boehringer Ingelheim Investigational Site, New Delhi, India|1200.131.09164 Boehringer Ingelheim Investigational Site, Pune, India|1200.131.09159 Boehringer Ingelheim Investigational Site, Vishakapatnam, India|1200.131.97251 Boehringer Ingelheim Investigational Site, Haifa, Israel|1200.131.97253 Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|1200.131.03957 Boehringer Ingelheim Investigational Site, Confreria (CN), Italy|1200.131.03951 Boehringer Ingelheim Investigational Site, Milano, Italy|1200.131.03955 Boehringer Ingelheim Investigational Site, Milano, Italy|1200.131.03960 Boehringer Ingelheim Investigational Site, Milano, Italy|1200.131.08156 Boehringer Ingelheim Investigational Site, Aichi, Nagoya, Japan|1200.131.08153 Boehringer Ingelheim Investigational Site, Chiba, Kashiwa, Japan|1200.131.08151 Boehringer Ingelheim Investigational Site, Hokkaido, Sapporo, Japan|1200.131.08161 Boehringer Ingelheim Investigational Site, Hyogo, Akashi, Japan|1200.131.08157 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan|1200.131.08159 Boehringer Ingelheim Investigational Site, Kanagawa, Isehara, Japan|1200.131.08164 Boehringer Ingelheim Investigational Site, Miyagi, Natori, Japan|1200.131.08160 Boehringer Ingelheim Investigational Site, Osaka, Osaka, Japan|1200.131.08155 Boehringer Ingelheim Investigational Site, Shizuoka, Sunto-gun, Japan|1200.131.08152 Boehringer Ingelheim Investigational Site, Tochigi, Shimotsuke, Japan|1200.131.08163 Boehringer Ingelheim Investigational Site, Tokyo, Koto-ku, Japan|1200.131.08154 Boehringer Ingelheim Investigational Site, Tokyo, Meguro-ku, Japan|1200.131.05252 Boehringer Ingelheim Investigational Site, Mexico, Mexico|1200.131.03152 Boehringer Ingelheim Investigational Site, Amsterdam, Netherlands|1200.131.03153 Boehringer Ingelheim Investigational Site, Leiden, Netherlands|1200.131.03151 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands|1200.131.35155 Boehringer Ingelheim Investigational Site, Almada, Portugal|1200.131.35154 Boehringer Ingelheim Investigational Site, Coimbra, Portugal|1200.131.35153 Boehringer Ingelheim Investigational Site, Lisboa, Portugal|1200.131.35151 Boehringer Ingelheim Investigational Site, Porto, Portugal|1200.131.35152 Boehringer Ingelheim Investigational Site, Évora, Portugal|1200.131.00759 Boehringer Ingelheim Investigational Site, Moscow, Russian Federation|1200.131.00753 Boehringer Ingelheim Investigational Site, Omsk, Russian Federation|1200.131.00760 Boehringer Ingelheim Investigational Site, Pyatigorsk, Russian Federation|1200.131.00761 Boehringer Ingelheim Investigational Site, Pyatigorsk, Russian Federation|1200.131.00763 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|1200.131.00755 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|1200.131.00762 Boehringer Ingelheim Investigational Site, Ufa, Russian Federation|1200.131.03451 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.131.03454 Boehringer Ingelheim Investigational Site, Barcelona, Spain|1200.131.03463 Boehringer Ingelheim Investigational Site, Girona, Spain|1200.131.03452 Boehringer Ingelheim Investigational Site, Hospitalet de Llobregat, Spain|1200.131.03459 Boehringer Ingelheim Investigational Site, Lugo, Spain|1200.131.03457 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.131.03464 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.131.03465 Boehringer Ingelheim Investigational Site, Madrid, Spain|1200.131.03456 Boehringer Ingelheim Investigational Site, Málaga, Spain|1200.131.03462 Boehringer Ingelheim Investigational Site, Málaga, Spain|1200.131.03455 Boehringer Ingelheim Investigational Site, Pamplona, Spain|1200.131.03460 Boehringer Ingelheim Investigational Site, Pozuelo De Alarcón, Madrid, Spain|1200.131.03466 Boehringer Ingelheim Investigational Site, Sevilla, Spain|1200.131.03458 Boehringer Ingelheim Investigational Site, Zaragoza, Spain|1200.131.03461 Boehringer Ingelheim Investigational Site, Ávila, Spain|1200.131.04652 Boehringer Ingelheim Investigational Site, Göteborg, Sweden|1200.131.04651 Boehringer Ingelheim Investigational Site, Stockholm, Sweden|1200.131.04151 Boehringer Ingelheim Investigational Site, Basel, Switzerland|1200.131.04152 Boehringer Ingelheim Investigational Site, Bern, Switzerland|1200.131.03854 Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|1200.131.03851 Boehringer Ingelheim Investigational Site, Kiev, Ukraine|1200.131.04456 Boehringer Ingelheim Investigational Site, Denbighshire, United Kingdom|1200.131.04455 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom|1200.131.04459 Boehringer Ingelheim Investigational Site, Exeter, United Kingdom|1200.131.04460 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom|1200.131.04453 Boehringer Ingelheim Investigational Site, Leicester, United Kingdom|1200.131.04451 Boehringer Ingelheim Investigational Site, London, United Kingdom|1200.131.04452 Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|1200.131.04454 Boehringer Ingelheim Investigational Site, Sheffield, United Kingdom|1200.131.04458 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom|1200.131.04457 Boehringer Ingelheim Investigational Site, Whitchurch, Cardiff, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01345669"
422,"NCT00465491","Study of Picoplatin Efficacy After Relapse","SPEAR","Unknown status","No Results Available","Small Cell Lung Cancer","Drug: picoplatin|Other: best supportive care","overall survival|objective response rate|disease control rate|duration of response|progression-free survival","Poniard Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","399","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0601","April 2007","May 2009",,"April 25, 2007",,"April 14, 2009","Consultorios Privados, Buenos Aires, Argentina|Clinica Constituyentes, Buenos Aires, Argentina|CETEN Centro de Estudio y Tratamiento de Enfermedades Neoplasicas, Buenos Aires, Argentina|IADT (Insttituto Argentino de Diagnostico y Tratamiento S.A.), Buenos Aires, Argentina|Centro Oncologico, Buenos Aires, Argentina|Instituto Alexander Fleming, Buenos Aires, Argentina|PALIAR, Buenos Aires, Argentina|IONC, Cordoba, Argentina|Centro Oncologico de Rosario, Santa Fe, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|Centro Medico San Roque, Tucuman, Argentina|Gomel Regional Oncological Dispensary, Gomel, Belarus|Institution of Healthcare ""Grodno Regional Clinical Hospital, Grodno, Belarus|Minsk City Clinical Oncology Dispensary, Minsk, Belarus|Research Institute of Oncology and Medical Radiology named by N.N. Aleksandrov, Minsk, Belarus|Vitebsk Regional Oncology Dispensary, Vitebsk, Belarus|Clinic for Lung Diseases, Clinical Center, Banja Luka, Banja Luka, Bosnia and Herzegovina|Clinic of Pulmonary Diseases Podhrastovi, Sarajevo, Bosnia and Herzegovina|Multiprofile Hospital for Active Treatment, Dr. Tota Venkova, Gabrovo, Bulgaria|University Multifunctional Hospital for Active Treatment ""Dr. Georgi Stranski"", Pleven, Bulgaria|District Dispensary for Cancer Diseases with Inpatient Hospital Plovdiv, Plovdiv, Bulgaria|Regional Oncodispensary with Inpatient Sector, Rousse, Bulgaria|Inter-district Dispensary for Cancer Diseases w/Inpatient Hospital, Shumen, Bulgaria|Regional Oncodispensary with Inpatient Sector-Sofia District, Sofia, Bulgaria|Inter-district Dispensary for Cancer Disease w/Inpatient Hospital ""Dr. Marko Markov"", Varna, Varna, Bulgaria|Multiprofile Hospital for Active Treatment ""St. Marina"", Varna, Bulgaria|Instituto Nacional de Cancer, Santiago, Chile|Clinical Hospital, Dubrovnik, Croatia|Clinical Hospital, Osijek, Croatia|Clinical Hospital Split, Split, Croatia|Clinic for Pulmonary Diseses ""Jordanovac"", Zagreb, Croatia|St. George County Hospital, Fejer County, Hungary|University of Szeged, Szeged, Hungary|General Rehablitation and Medicinal Bath Hospital, Szombathely, Hungary|Gujrat Cancer Research Institute, Asarwa, Ahmadabad, India|Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|Lakeshore Hospital and Research Center, Kochin, Kerala, India|Shatabdi Superspeciality Hospital, Nasik, Maharashtra, India|Curie Centre of Oncology, Bangalore, India|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India|Apollo Speciality Hospital, Chennai, India|MNJ Institute of Oncology, Hyderabaad, India|Indo American Institute of Oncology, Hyderabaad, India|Yashoda Group of Hospitals, Hyderabad, India|SEAROC Cancer Center, Jaipur, India|Institute of Post Graduate Medical Education and Research, Kolkata, India|Orchid Nursing Home, Kolkata, India|King George Medical University, Lucknow, India|KMC (Karturba Medical College) Hospital, Manipal, India|Jaslok Hospital and Research Centre, Mumbai, India|Tata Memorial Centre, Mumbai, India|Sir Ganga Ram Hospital, New Delhi, India|Rajiv Gandhi Cancer Institute, Delhi, New Delhi, India|Mahaveer Cancer Sansthan, Patna, India|Jahangir Hospital and Research Centre, Pune, India|Smt. Vasantben R. Desai Cancer Research Center, Rajkot, India|Regional Cancer Centre, Trivandrum, India|King George Hospital, Vishakhapatnam, India|Daugavas Hospital, Daugavpils, Latvia|Paul Stradins Clincial University Hospital, Riga, Latvia|Special Hospital for Pulmonary Diseases, Niksic, Montenegro|Dolnoslaskie Centre of Lung Diseases, Wroclaw, Dolnoslaskie, Poland|Silesian Medical University in Katowice, Zabrze, Dolny Slask, Poland|Kujawsko-Pomorski Centre of Pulmonology, Bydgoszcz, Poland|NMP, Memorial Voyvodship Hospital, Czestochowa, Poland|Dr. Bieganski Memorial Regional Specialsitic Hospital, Grudziadz, Poland|Regional Hospital, Department of Pulmonary Diseases and Chemotherapy, Krakow, Poland|Independent Public Group for Tuberculosis and Lung Disease in Olsztyn, Olsztyn, Poland|Conservative Outpatient Oncology Department, Voyevodship Hospital in Plock, Plock, Poland|Department of Clinical Oncology, Wielkopolskie Centre of Lung Diseases and Tuberculosis, Poznan, Poland|Department of Pulmonology, Voyvodship Specialsitic Hospital in Radom, Radom, Poland|SP ZOZ Voyevodship Specialistic Hospital #3, Rybnik, Poland|Department of Chemotherapy, Prof. A. Sokolowski Memorial Specialistic Hospital in Szczecin, Szczecin, Poland|Department of Clinical Oncology, SP ZOZ, Yoyvodship Specialistic Hospital, Torun, Poland|Prof. Dr. Ion Chiricuta, Institute of Oncology Cluj-Napoca, Cluj-Napoca, Cluj, Romania|Baia Mare ""Constantin Opris"" County Emergency Hospital, Baia Mare, Maramures County, Romania|IANULI Medconsult SRL, Bucharest, Romania|Bucharest Institute of Oncology, Bucharest, Romania|Prof. Dr. Ion Chircuta, Oncology Institute, Cluj-Napoca, Romania|Clinical Emergency County Hospital Constanta, Constanta, Romania|Medical Oncology Center Iasi, Iasi, Romania|Schuller Municipal Hospital Ploiesti-Medical Oncology Department, Ploiesti, Romania|Clinical County Hospital, Sibiu, Romania|Sf. loan cel Nou, Emergency County Hospital, Suceava, Romania|OncoMed, Timisoara, Romania|Buryatia Republican Oncology Center, Ulan-Ude, Buryatia, Russian Federation|Regional Oncology Center, Birobidzhan, Jewish Republic, Russian Federation|Republican Oncology Center of the Ministry of Healthcare of Karelia Republic, Petrozavodsk, Karelia Republic, Russian Federation|Komi Republican Oncology Center, Syktyvkar, Komi Republic, Russian Federation|Clinical Oncology Center, Kazan, Tatarstan Republic, Russian Federation|Kazan Oncology Center, Kazan, Tatarstan Republic, Russian Federation|Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk, Russian Federation|Altai Regional Oncology Center, Barnaul, Russian Federation|Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|City Hospital #1, Cherepovets, Russian Federation|Chita Regional Oncology Center, Chita, Russian Federation|Sverdlovsk Regional Oncology Center, Ekaterinburg, Russian Federation|Regional Oncology Center, Engels, Russian Federation|Regional Oncology Center, Irkutsk, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|Republican Clinical Oncology Center of the Republic of Udmurtia, Izhevsk, Russian Federation|Kaluga Regional Oncology Center, Kaluga, Russian Federation|Regional Clinical Oncology Center, Khabarovsk, Russian Federation|Regional Clinical Oncology Center, Kirov, Russian Federation|City Oncology Center, Komsomolsk-na-Amure, Russian Federation|Krasnodar Clinical Oncology, Krasnodar, Russian Federation|Regional Clinical Hospital #1, Krasnodar, Russian Federation|Kurst Regional Oncology Center, Kurst, Russian Federation|Lipetsk Regional Oncology Center, Lipetsk, Russian Federation|Magnitogorsk Clinical Oncology Hospital, Magnitogorsk, Russian Federation|Blokhin Russian Oncology Research Center, Moscow, Russian Federation|Central Clinical Hospital and Outpatient Unit of the Medical Center under the Russian Presidential Administration, Moscow, Russian Federation|Semashko Central Clinical Hospital #2 under Russian Railways, Moscow, Russian Federation|Novorossiysk Oncology Center, Novorossiysk, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Medical Radiology Research Center under RAMS, Obnninsk, Russian Federation|Orel Oncology Center, Orel, Russian Federation|Orenburg Regional Clinical Oncology Center, Orenburg, Russian Federation|Regional Oncology Center, Penza, Russian Federation|Pyatigorsk Affiliate of Stavropol Regional Clinical Oncology Center, Pyatigorsk, Russian Federation|Ogarev Mordovian State University, Saransk, Russian Federation|State Higher Education Institution Saratov State Medical University under the Federal Agency for Healthcare and Social Development, Saratov, Russian Federation|Oncology Center, Sochi, Russian Federation|St. Petersburg City Multifield Hospital #2, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical University, St. Petersburg, Russian Federation|Pavlov St. Petersburg State Medical University, Pulmonology Research Institute, St. Petersburg, Russian Federation|City Clinical Oncology Center, Thoracic Oncology Department #6, St. Petersburg, Russian Federation|Tambov Regional Oncology Center, Tambov, Russian Federation|Tomsk Regional Oncology Center, Tomsk, Russian Federation|Tula Regional Oncology Center, Tula, Russian Federation|Ufa, Republican Oncology Center, Ufa, Russian Federation|Primorsky Regional Oncology Center, Vladivostok, Russian Federation|Volgograd Regional Clinical Oncology Center#1, Volograd, Russian Federation|Voronezh Regional Clinical Oncology Center, Voronezh, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Republican of Clinical Hospital, Mariy-El Republican, Yoshkar-Ola, Russian Federation|Clinic for Pulmonary Diseases and TBC, Knez Selo, Serbia|Institute for Pulmonary Diseases of Vijvodina, Vijvodina, Serbia|Volyn Regional Oncology Center, Lutsk, Ukraine|Public Treatment and Prevention Institution Mariupol City Interdistrict Oncology Center, Mariupol, Ukraine|Sumy Regional Oncology Center, Sumy, Ukraine|Ternopol Regional Clinical Oncology Center, Ternopol, Ukraine|Zaporozhye Regional Clinical Oncology Center, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT00465491"
423,"NCT00263588","Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer",,"Completed","Has Results","Neoplasms, Breast","Drug: lapatinib","The Number of Participants With Central Nervous System (CNS) Best Overall Response|The Percentage of Participants With Central Nervous System (CNS) Objective Response Rate - Response Rate (CR + PR)|Percentage of Participants With Improvement in Neurological Signs and Symptoms (NSS) Measured Using the Neurological Examination Worksheet|Percentage of Subjects With a CNS Objective Response or Improvement in Baseline Neurological Signs and Symptoms (NSS)|Duration of Central Nervous System (CNS) Objective Response|Percentage of Patients With CNS Disease Control (Complete Response, Partial Response or Stable Disease) at 6 Months of Lapatinib Therapy|Time to Progression (TTP) at Any Site|Overall Survival (OS)|Summary of Site of First Progression|Primary Cause of Death","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","242","Industry","Interventional","Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF105084|CLAP016A2202|2005-003944-68","December 2, 2005","September 25, 2007","March 15, 2018","December 9, 2005","December 12, 2019","December 12, 2019","Novartis Investigative Site, San Francisco, California, United States|Novartis Investigative Site, Vallejo, California, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Washington, District of Columbia, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Sioux City, Iowa, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Santa Fe, New Mexico, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Yakima, Washington, United States|Novartis Investigative Site, North Sydney, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, South Brisbane, Queensland, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Ringwood East, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Adelaide, Australia|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Dijon Cedex, France|Novartis Investigative Site, Paris Cedex 05, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse cedex, France|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Neo Faliro, Greece|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Reggio Emilia, Emilia-Romagna, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Perugia, Umbria, Italy|Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Saitama, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Tokyo, Japan|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Geneve, Switzerland|Novartis Investigative Site, Locarno, Switzerland|Novartis Investigative Site, Tainan County, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Manchester, Lancashire, United Kingdom|Novartis Investigative Site, Brighton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00263588"
424,"NCT00680901","LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib",,"Active, not recruiting","Has Results","Neoplasms, Gastrointestinal Tract","Drug: Lapatinib|Drug: Placebo|Drug: Capecitabine|Drug: Oxaliplatin","Overall Survival|Overall Survival in All Randomized Participants|Progression Free Survival (PFS)|Number of Participants With a Response of Confirmed Complete Response (CR) or Confirmed Partial Response (PR)|Number of Participants With Clinical Benefit (CB)|Time to Response (TTR)|Duration of Response (DOR)|Number of Participants With Any Non-serious Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) or Any Serious Adverse Event (SAE)|Number of Participants With Adverse Events of the Indicated Severity, Per the National Cancer Institute (NCI) Common Terminology Criteria in Adverse Events (CTCAE)|Mean Change in Scores on the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QOL) Questionnaire Core 30 (QLQ-C30) From Baseline to Week 36|Mean Change in Scores on the EORTC Quality of Life (QOL) Questionnaire of Stomach 22 (QLQ-STO22) From Baseline to Week 36|Mean Change in Scores on the Questionnaire EuroQoL-5 Dimensions (EQ-5D) From Baseline to Week 36|Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Clinical Chemistry Parameters|Number of Participants With a Worst-case on Therapy Grade 3 or Grade 4 for the Indicated Hematology Parameters","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","545","Industry","Interventional","Allocation: Randomized|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EGF110656|2007-005725-29|CLAP016C2301","June 4, 2008","September 24, 2012","December 31, 2022","May 20, 2008","October 29, 2013","March 10, 2022","Novartis Investigative Site, Alhambra, California, United States|Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, La Verne, California, United States|Novartis Investigative Site, Northridge, California, United States|Novartis Investigative Site, Oxnard, California, United States|Novartis Investigative Site, Redondo Beach, California, United States|Novartis Investigative Site, Santa Maria, California, United States|Novartis Investigative Site, Santa Monica, California, United States|Novartis Investigative Site, Terre Haute, Indiana, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, Ciudad Aut6noma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Quilmes, Buenos Aires, Argentina|Novartis Investigative Site, Neuquen, Neuquén, Argentina|Novartis Investigative Site, Cipolletti, Río Negro, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Florianopolis, Santa Catarina, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Jau, São Paulo, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Temuco, Región De La Araucania, Chile|Novartis Investigative Site, Santiago, Región Metro De Santiago, Chile|Novartis Investigative Site, Vina del Mar, Valparaíso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Hefei, Anhui, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Ha Er Bin, Heilongjiang, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Changchun, Jilin, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Fuzhou, China|Novartis Investigative Site, Hangzhou, China|Novartis Investigative Site, Qingdao, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Tallinn, Estonia|Novartis Investigative Site, Tartu, Estonia|Novartis Investigative Site, Pokfulam, Hong Kong|Novartis Investigative Site, Tuen Mun, Hong Kong|Novartis Investigative Site, Gyor, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Miskolc, Hungary|Novartis Investigative Site, Pecs, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szolnok, Hungary|Novartis Investigative Site, Calcutta, India|Novartis Investigative Site, Coimbatore, India|Novartis Investigative Site, Kochi, India|Novartis Investigative Site, Kochi, India|Novartis Investigative Site, Kolkata, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Parel, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Trivandrum, India|Novartis Investigative Site, Beer-Sheva, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petah-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Zrifin, Israel|Novartis Investigative Site, L'Aquila, Abruzzo, Italy|Novartis Investigative Site, Rionero In Vulture (PZ), Basilicata, Italy|Novartis Investigative Site, Cesena, Emilia-Romagna, Italy|Novartis Investigative Site, Meldola (FC), Emilia-Romagna, Italy|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Parma, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Rimini, Emilia-Romagna, Italy|Novartis Investigative Site, Udine, Friuli-Venezia-Giulia, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Bergamo, Lombardia, Italy|Novartis Investigative Site, Treviglio (BG), Lombardia, Italy|Novartis Investigative Site, Pesasro, Marche, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, Firenze, Toscana, Italy|Novartis Investigative Site, Macerata, Italy|Novartis Investigative Site, Busan, Korea, Republic of|Novartis Investigative Site, Daegu, Korea, Republic of|Novartis Investigative Site, Hwasun, Korea, Republic of|Novartis Investigative Site, Seodaemun-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Suwon, Kyonggi-do, Korea, Republic of|Novartis Investigative Site, Suwon, Korea, Republic of|Novartis Investigative Site, Acapulco, Guerrero, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Leeuwarden, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Callao, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Olsztyn, Poland|Novartis Investigative Site, Plock, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rybnik, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Torun, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Sochi, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Stavropol, Russian Federation|Novartis Investigative Site, Ufa,, Russian Federation|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan County, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Hatyai, Songkhla, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Gaziantep, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnepropetrovsk, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Donetsk, Ukraine|Novartis Investigative Site, Ivano-Frankivsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kryvyi Rih, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lutsk,, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Plyuty, Ukraine|Novartis Investigative Site, Simferopil, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Sumy, Ukraine|Novartis Investigative Site, Ternopil, Ukraine|Novartis Investigative Site, Uzhgorod, Ukraine|Novartis Investigative Site, Vinnitsia, Ukraine|Novartis Investigative Site, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT00680901"
425,"NCT04919226","Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","COMPOSE","Recruiting","No Results Available","Neuroendocrine Tumors","Drug: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT|Drug: CAPTEM (Capecitabine and Temozolomide)|Other: Amino-Acid Solution|Drug: Everolimus|Drug: FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)","Progression-Free Survival|Overall Survival","ITM Solucin GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DP-1111-02CT","December 21, 2021","September 2024","September 2026","June 9, 2021",,"April 28, 2022","Washington University Alvin J. Siteman Cancer Center, Saint Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Haut-Leveque Hospital, Department of Hepatogastroenterology and Digestive Tract Oncology, Pessac, Bordeaux, France|Nantes University Hospital Center - Hotel Dieu Hospital, Nantes, Cedex, France|Edouard Herriot Hospital, Medical Oncology Unit, Lyon, France|IUCT Oncopole - Institut Universitaire du Cancer de Toulouse, Toulouse, France|All India Institute Of Medical Sciences, Nuclear Medicine, New Delhi, Delhi, India|HCG Cancer Centre, Medical Oncology, Bangalore, Karnataka, India|VU Medical Center (VUMC), Department of Medical Oncology, Amsterdam, Netherlands|University Hospital Vall d'Hebron, Department of Medical Oncology, Barcelona, Spain|ICO Hospitalet, Catalan Institute of Oncology, Barcelona, Spain|University Hospital 12 de Octubre, Department of Gastroenterology, Madrid, Spain|Central University Hospital de Asturias (HUCA), IUOPA - Universitary Institute of Oncology, Oviedo, Spain|University Hospital Complex of Santiago (CHUS), Santiago De Compostela, Spain|University and Polytechnic Hospital La Fe, Endocrinology, Valencia, Spain|Uppsala University Hospital, Department of Oncology, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04919226"
426,"NCT00694382","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy","SAVE-ONCO","Completed","No Results Available","Venous Thromboembolism|Cancer","Drug: Semuloparin sodium|Drug: Placebo (for semuloparin)","Percentage of Participants Who Experienced Venous Thromboembolism Event [VTE] or VTE-related Death|Time-to-first Occurrence of VTE or VTE-related Death (Cumulative Incidence Function)|Percentage of Participants who required the initiation of curative anticoagulant or thrombolytic treatment after VTE assessment|Percentage of Participants Who Experienced Clinically Relevant Bleedings|Overall survival [OS]","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","3212","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC6521|2007-007943-29","June 2008","November 2010","November 2010","June 10, 2008",,"January 23, 2013","Investigational Site Number 840006, Birmingham, Alabama, United States|Investigational Site Number 840007, Casa Grande, Arizona, United States|Investigational Site Number 840060, Tucson, Arizona, United States|Investigational Site Number 840050, Fountain Valley, California, United States|Investigational Site Number 840072, Fullerton, California, United States|Investigational Site Number 840037, Indian Wells, California, United States|Investigational Site Number 840069, La Verne, California, United States|Investigational Site Number 840009, Long Beach, California, United States|Investigational Site Number 840001, Oceanside, California, United States|Investigational Site Number 840011, Rancho Mirage, California, United States|Investigational Site Number 840029, West Covina, California, United States|Investigational Site Number 840005, Norwich, Connecticut, United States|Investigational Site Number 840064, Torrington, Connecticut, United States|Investigational Site Number 840038, Woodbridge, Connecticut, United States|Investigational Site Number 840052, Washington, District of Columbia, United States|Investigational Site Number 840025, Washington, District of Columbia, United States|Investigational Site Number 840074, Clearwater, Florida, United States|Investigational Site Number 840019, Jacksonville, Florida, United States|Investigational Site Number 840051, Rockledge, Florida, United States|Investigational Site Number 840073, Sarasota, Florida, United States|Investigational Site Number 840070, Roswell, Georgia, United States|Investigational Site Number 840016, Park Ridge, Illinois, United States|Investigational Site Number 840028, Quincy, Illinois, United States|Investigational Site Number 840008, Skokie, Illinois, United States|Investigational Site Number 840033, Goshen, Indiana, United States|Investigational Site Number 840010, Indianapolis, Indiana, United States|Investigational Site Number 840014, Louisville, Kentucky, United States|Investigational Site Number 840048, Mount Sterling, Kentucky, United States|Investigational Site Number 840047, Metairie, Louisiana, United States|Investigational Site Number 840032, Ruston, Louisiana, United States|Investigational Site Number 840042, Bethesda, Maryland, United States|Investigational Site Number 840066, Easton, Maryland, United States|Investigational Site Number 840059, Tupelo, Mississippi, United States|Investigational Site Number 840024, Rochester, New York, United States|Investigational Site Number 840031, Syracuse, New York, United States|Investigational Site Number 840020, Durham, North Carolina, United States|Investigational Site Number 840021, Durham, North Carolina, United States|Investigational Site Number 840026, High Point, North Carolina, United States|Investigational Site Number 840046, Bismarck, North Dakota, United States|Investigational Site Number 840003, Middletown, Ohio, United States|Investigational Site Number 840022, Sylvania, Ohio, United States|Investigational Site Number 840075, East Providence, Rhode Island, United States|Investigational Site Number 840067, Beaumont, Texas, United States|Investigational Site Number 840004, El Paso, Texas, United States|Investigational Site Number 840034, Houston, Texas, United States|Investigational Site Number 840035, Sugar Land, Texas, United States|Investigational Site Number 840063, Kennewick, Washington, United States|Investigational Site Number 840018, Tacoma, Washington, United States|Investigational Site Number 032006, Buenos Aires, Argentina|Investigational Site Number 032003, Capital Federal, Argentina|Investigational Site Number 032004, Rosario, Argentina|Investigational Site Number 032005, San Miguel De Tucuman, Argentina|Investigational Site Number 032007, Tucuman, Argentina|Investigational Site Number 036004, Adelaide, Australia|Investigational Site Number 036002, Bedford Park, Australia|Investigational Site Number 036001, Box Hill, Australia|Investigational Site Number 036009, Lismore, Australia|Investigational Site Number 036007, Perth, Australia|Investigational Site Number 036006, Ringwood East, Australia|Investigational Site Number 036008, Westmead, Australia|Investigational Site Number 036003, Woodville, Australia|Investigational Site Number 036005, Woolloongabba, Australia|Investigational Site Number 040002, Graz, Austria|Investigational Site Number 040003, Wien, Austria|Investigational Site Number 040004, Wien, Austria|Investigational Site Number 112002, Gomel, Belarus|Investigational Site Number 112003, Minsk, Belarus|Investigational Site Number 112001, Minsk, Belarus|Investigational Site Number 112004, Vitebsk, Belarus|Investigational Site Number 056008, Bonheiden, Belgium|Investigational Site Number 056011, Brussels, Belgium|Investigational Site Number 056005, Gent, Belgium|Investigational Site Number 056010, Haine-Saint-Paul, Belgium|Investigational Site Number 056006, Kortrijk, Belgium|Investigational Site Number 056009, Liège, Belgium|Investigational Site Number 056004, Merksem, Belgium|Investigational Site Number 056003, Oostende, Belgium|Investigational Site Number 056012, Ottignies, Belgium|Investigational Site Number 056002, Sint Niklaas, Belgium|Investigational Site Number 076002, Belo Horizonte, Brazil|Investigational Site Number 076022, Curitiba, Brazil|Investigational Site Number 076015, Curitiba, Brazil|Investigational Site Number 076012, Florianopolis, Brazil|Investigational Site Number 076001, Fortaleza, Brazil|Investigational Site Number 076009, Goiania, Brazil|Investigational Site Number 076007, Goiania, Brazil|Investigational Site Number 076016, Goiania, Brazil|Investigational Site Number 076024, Ijui, Brazil|Investigational Site Number 076003, Joinville, Brazil|Investigational Site Number 076010, Londrina, Brazil|Investigational Site Number 076026, Passo Fundo, Brazil|Investigational Site Number 076027, Passo Fundo, Brazil|Investigational Site Number 076023, Porto Alegre, Brazil|Investigational Site Number 076020, Porto Alegre, Brazil|Investigational Site Number 076014, Salvador, Brazil|Investigational Site Number 076018, Salvador, Brazil|Investigational Site Number 076011, Santo Andre, Brazil|Investigational Site Number 076006, Sao Jose Dos Campos, Brazil|Investigational Site Number 076008, Sao Paulo, Brazil|Investigational Site Number 076017, Sao Paulo, Brazil|Investigational Site Number 076004, Taguatinga, Brazil|Investigational Site Number 100001, Rousse, Bulgaria|Investigational Site Number 100003, Varna, Bulgaria|Investigational Site Number 124008, Greenfield Park, Canada|Investigational Site Number 124007, Kelowna, Canada|Investigational Site Number 124010, Moncton, Canada|Investigational Site Number 124003, Montreal, Canada|Investigational Site Number 124002, Ottawa, Canada|Investigational Site Number 124009, Owen Sound, Canada|Investigational Site Number 124006, Rimouski, Canada|Investigational Site Number 124013, Saint John, Canada|Investigational Site Number 124001, Sherbrooke, Canada|Investigational Site Number 124012, Victoria, Canada|Investigational Site Number 124011, Weston, Canada|Investigational Site Number 152002, Temuco, Chile|Investigational Site Number 156014, Beijing, China|Investigational Site Number 156008, Beijing, China|Investigational Site Number 156022, Beijing, China|Investigational Site Number 156031, Changchun, China|Investigational Site Number 156021, Chengdu, China|Investigational Site Number 156019, Chongqing, China|Investigational Site Number 156003, Dalian, China|Investigational Site Number 156025, Guangzhou, China|Investigational Site Number 156026, Hangzhou, China|Investigational Site Number 156030, Nanning, China|Investigational Site Number 156029, Qingdao, China|Investigational Site Number 156024, Shanghai, China|Investigational Site Number 156028, Shanghai, China|Investigational Site Number 156020, Shanghai, China|Investigational Site Number 156011, Shanghai, China|Investigational Site Number 156013, Shantou, China|Investigational Site Number 156012, Suzhou, China|Investigational Site Number 156004, Xi'An, China|Investigational Site Number 156009, Xi'An, China|Investigational Site Number 156027, Yinchuan, China|Investigational Site Number 170010, Bogota, Colombia|Investigational Site Number 170005, Manizales, Colombia|Investigational Site Number 170002, Medellin, Colombia|Investigational Site Number 170006, Medellin, Colombia|Investigational Site Number 170007, Medellín, Colombia|Investigational Site Number 170008, Monteria, Colombia|Investigational Site Number 170004, Pereira, Colombia|Investigational Site Number 191006, Pula, Croatia|Investigational Site Number 191005, Rijeka, Croatia|Investigational Site Number 191007, Varazdin, Croatia|Investigational Site Number 191003, Zadar, Croatia|Investigational Site Number 191008, Zagreb, Croatia|Investigational Site Number 191001, Zagreb, Croatia|Investigational Site Number 191004, Zagreb, Croatia|Investigational Site Number 203004, Hradec Kralove, Czech Republic|Investigational Site Number 203008, Kolin, Czech Republic|Investigational Site Number 203007, Nova Ves Pod Plesi, Czech Republic|Investigational Site Number 203003, Praha 5, Czech Republic|Investigational Site Number 208001, Herlev, Denmark|Investigational Site Number 233001, Tallinn, Estonia|Investigational Site Number 246001, Turku, Finland|Investigational Site Number 250002, Antibes, France|Investigational Site Number 250010, Colmar, France|Investigational Site Number 250020, Gap, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250025, Lille Cedex, France|Investigational Site Number 250012, Lille Cedex, France|Investigational Site Number 250003, Lyon, France|Investigational Site Number 250001, Marseille, France|Investigational Site Number 250024, Montpellier Cedex, France|Investigational Site Number 250006, Paris Cedex 10, France|Investigational Site Number 250027, Paris Cedex 10, France|Investigational Site Number 250004, Paris Cedex 14, France|Investigational Site Number 250021, Reims, France|Investigational Site Number 250019, Rouen, France|Investigational Site Number 250017, Saint Gregoire, France|Investigational Site Number 250014, Vandoeuvre Les Nancy, France|Investigational Site Number 276012, Augsburg, Germany|Investigational Site Number 276025, Berlin, Germany|Investigational Site Number 276016, Berlin, Germany|Investigational Site Number 276002, Berlin, Germany|Investigational Site Number 276029, Berlin, Germany|Investigational Site Number 276004, Bochum, Germany|Investigational Site Number 276014, Dresden, Germany|Investigational Site Number 276009, Dresden, Germany|Investigational Site Number 276030, Essen, Germany|Investigational Site Number 276005, Frankfurt Am Main, Germany|Investigational Site Number 276032, Gauting, Germany|Investigational Site Number 276038, Halle/Saale, Germany|Investigational Site Number 276034, Halle, Germany|Investigational Site Number 276037, Hamburg, Germany|Investigational Site Number 276007, Hannover, Germany|Investigational Site Number 276006, Köln, Germany|Investigational Site Number 276020, Leer, Germany|Investigational Site Number 276010, Leipzig, Germany|Investigational Site Number 276017, Magdeburg, Germany|Investigational Site Number 276011, Mannheim, Germany|Investigational Site Number 276003, Minden, Germany|Investigational Site Number 276021, München, Germany|Investigational Site Number 276019, München, Germany|Investigational Site Number 276015, München, Germany|Investigational Site Number 276013, Neumünster, Germany|Investigational Site Number 276022, Oldenburg, Germany|Investigational Site Number 276035, Paderborn, Germany|Investigational Site Number 276031, Passau, Germany|Investigational Site Number 276023, Rosenheim, Germany|Investigational Site Number 276008, Singen, Germany|Investigational Site Number 276024, Westerstede, Germany|Investigational Site Number 300004, Athens, Greece|Investigational Site Number 300003, Heraklion, Greece|Investigational Site Number 300002, Thessaloniki, Greece|Investigational Site Number 344001, Hong Kong, Hong Kong|Investigational Site Number 348005, Budapest, Hungary|Investigational Site Number 348006, Budapest, Hungary|Investigational Site Number 348009, Budapest, Hungary|Investigational Site Number 348004, Budapest, Hungary|Investigational Site Number 348010, Farkasgyepu, Hungary|Investigational Site Number 348001, Gyula, Hungary|Investigational Site Number 348012, Mátraháza, Hungary|Investigational Site Number 348003, Sopron, Hungary|Investigational Site Number 348008, Szikszó, Hungary|Investigational Site Number 348011, Szolnok, Hungary|Investigational Site Number 348007, Zalaegerszeg, Hungary|Investigational Site Number 356006, Bangalore, India|Investigational Site Number 356008, Bangalore, India|Investigational Site Number 356009, Bhopal, India|Investigational Site Number 356018, Chennai, India|Investigational Site Number 356020, Chennai, India|Investigational Site Number 356019, Coimbatore, India|Investigational Site Number 356015, Hyderabad, India|Investigational Site Number 356025, Hyderabad, India|Investigational Site Number 356011, Jaipur, India|Investigational Site Number 356014, Kochi, India|Investigational Site Number 356003, Kolkata, India|Investigational Site Number 356013, Kolkata, India|Investigational Site Number 356017, Kolkata, India|Investigational Site Number 356005, Madurai, India|Investigational Site Number 356016, Miraj, India|Investigational Site Number 356001, Mumbai, India|Investigational Site Number 356023, Nagpur, India|Investigational Site Number 356002, New Delhi, India|Investigational Site Number 356004, Pune, India|Investigational Site Number 356024, Pune, India|Investigational Site Number 356012, Vishakhapatnam, India|Investigational Site Number 360002, Bandung, Indonesia|Investigational Site Number 360001, Denpasar, Indonesia|Investigational Site Number 360004, Medan, Indonesia|Investigational Site Number 372004, Dublin 7, Ireland|Investigational Site Number 372003, Dublin, Ireland|Investigational Site Number 372002, Dublin, Ireland|Investigational Site Number 376003, Jerusalem, Israel|Investigational Site Number 376004, Kfar Saba, Israel|Investigational Site Number 376001, Nahariya, Israel|Investigational Site Number 376006, Petah-Tikva, Israel|Investigational Site Number 376007, Tzrifin, Israel|Investigational Site Number 380005, Castellanza, Italy|Investigational Site Number 380014, Cattolica, Italy|Investigational Site Number 380007, Cesena, Italy|Investigational Site Number 380015, Cremona, Italy|Investigational Site Number 380009, Faenza, Italy|Investigational Site Number 380012, Lecce, Italy|Investigational Site Number 380006, Lugo, Italy|Investigational Site Number 380001, Meldola, Italy|Investigational Site Number 380011, Parma, Italy|Investigational Site Number 380020, Perugia, Italy|Investigational Site Number 380013, Ravenna, Italy|Investigational Site Number 380016, Rimini, Italy|Investigational Site Number 380004, Sondrio, Italy|Investigational Site Number 380010, Sora, Italy|Investigational Site Number 380008, Taormina, Italy|Investigational Site Number 380019, Terni, Italy|Investigational Site Number 380003, Treviglio, Italy|Investigational Site Number 380017, Udine, Italy|Investigational Site Number 410008, Daegu, Korea, Republic of|Investigational Site Number 410007, Seoul, Korea, Republic of|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 410006, Seoul, Korea, Republic of|Investigational Site Number 410005, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410009, Seoul, Korea, Republic of|Investigational Site Number 410004, Suwon, Korea, Republic of|Investigational Site Number 428002, Liepaja, Latvia|Investigational Site Number 428003, Riga, Latvia|Investigational Site Number 428001, Riga, Latvia|Investigational Site Number 440001, Kaunas, Lithuania|Investigational Site Number 440002, Vilnius, Lithuania|Investigational Site Number 458001, Kota Kinabalu, Malaysia|Investigational Site Number 458003, Kuala Lumpur, Malaysia|Investigational Site Number 458004, Penang, Malaysia|Investigational Site Number 458005, Penang, Malaysia|Investigational Site Number 484002, Acapulco, Mexico|Investigational Site Number 484006, Aguascalientes, Mexico|Investigational Site Number 484007, Durango, Mexico|Investigational Site Number 484008, Mérida, Mexico|Investigational Site Number 484012, Puebla, Mexico|Investigational Site Number 484003, Toluca, Mexico|Investigational Site Number 484010, Xalapa, Mexico|Investigational Site Number 528006, Den Haag, Netherlands|Investigational Site Number 528004, Groningen, Netherlands|Investigational Site Number 528005, Helmond, Netherlands|Investigational Site Number 528001, Hoofddorp, Netherlands|Investigational Site Number 528003, Rotterdam, Netherlands|Investigational Site Number 578001, Oslo, Norway|Investigational Site Number 604012, Arequipa, Peru|Investigational Site Number 604004, Callao, Peru|Investigational Site Number 604011, Callao, Peru|Investigational Site Number 604001, Cercado, Peru|Investigational Site Number 604002, Chiclayo, Peru|Investigational Site Number 604008, Lima, Peru|Investigational Site Number 604007, Lima, Peru|Investigational Site Number 604009, Lima, Peru|Investigational Site Number 604005, Lima, Peru|Investigational Site Number 604006, Lima, Peru|Investigational Site Number 604010, Lima, Peru|Investigational Site Number 604003, Lima, Peru|Investigational Site Number 616009, Bialystok, Poland|Investigational Site Number 616008, Bielsko-Biala, Poland|Investigational Site Number 616006, Gliwice, Poland|Investigational Site Number 616004, Krakow, Poland|Investigational Site Number 616003, Lubin, Poland|Investigational Site Number 616019, Olsztyn, Poland|Investigational Site Number 616021, Otwock, Poland|Investigational Site Number 616010, Poznan, Poland|Investigational Site Number 616001, Prabuty, Poland|Investigational Site Number 616014, Rybnik, Poland|Investigational Site Number 616005, Rzeszow, Poland|Investigational Site Number 616013, Torun, Poland|Investigational Site Number 616018, Warszawa, Poland|Investigational Site Number 616002, Warszawa, Poland|Investigational Site Number 616015, Wroclaw, Poland|Investigational Site Number 620003, Aveiro, Portugal|Investigational Site Number 620009, Guimarães, Portugal|Investigational Site Number 620004, Lisboa, Portugal|Investigational Site Number 620008, Matosinhos, Portugal|Investigational Site Number 620007, Porto, Portugal|Investigational Site Number 620002, Setúbal, Portugal|Investigational Site Number 642004, Brasov, Romania|Investigational Site Number 642002, Bucuresti, Romania|Investigational Site Number 642001, Cluj Napoca, Romania|Investigational Site Number 642006, Cluj-Napoca, Romania|Investigational Site Number 642010, Iasi, Romania|Investigational Site Number 642003, Suceava, Romania|Investigational Site Number 642008, Timisoara, Romania|Investigational Site Number 643024, Berdsk, Russian Federation|Investigational Site Number 643006, Chelyabinsk, Russian Federation|Investigational Site Number 643001, Kazan, Russian Federation|Investigational Site Number 643004, Krasnoyarsk, Russian Federation|Investigational Site Number 643010, Obninsk, Russian Federation|Investigational Site Number 643005, Omsk, Russian Federation|Investigational Site Number 643022, Pyatigorsk, Russian Federation|Investigational Site Number 643023, Rostov-On-Don, Russian Federation|Investigational Site Number 643020, Saratov, Russian Federation|Investigational Site Number 643019, Smolensk, Russian Federation|Investigational Site Number 643021, Sochi, Russian Federation|Investigational Site Number 643014, St-Petersburg, Russian Federation|Investigational Site Number 643015, St-Petersburg, Russian Federation|Investigational Site Number 643011, St-Petersburg, Russian Federation|Investigational Site Number 643009, St.Petersburg, Russian Federation|Investigational Site Number 643008, Tomsk, Russian Federation|Investigational Site Number 643016, Tula, Russian Federation|Investigational Site Number 643018, Tyumen, Russian Federation|Investigational Site Number 643012, Ufa, Russian Federation|Investigational Site Number 643007, Vladivostok, Russian Federation|Investigational Site Number 643017, Voronezh, Russian Federation|Investigational Site Number 643003, Yaroslavl, Russian Federation|Investigational Site Number 688002, Belgrade, Serbia|Investigational Site Number 688004, Belgrade, Serbia|Investigational Site Number 688007, Kragujevac, Serbia|Investigational Site Number 688005, Nis, Serbia|Investigational Site Number 703003, Trnava, Slovakia|Investigational Site Number 705003, Golnik, Slovenia|Investigational Site Number 705002, Maribor, Slovenia|Investigational Site Number 710003, Durban, South Africa|Investigational Site Number 710002, Durban, South Africa|Investigational Site Number 724008, Barakaldo, Spain|Investigational Site Number 724010, Barakaldo, Spain|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724006, Islas Baleares, Spain|Investigational Site Number 724011, Lérida, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724007, Madrid, Spain|Investigational Site Number 724013, Madrid, Spain|Investigational Site Number 724012, Madrid, Spain|Investigational Site Number 724005, Orense, Spain|Investigational Site Number 724003, Puerto De Sagunto, Spain|Investigational Site Number 724002, Valencia, Spain|Investigational Site Number 752003, Göteborg, Sweden|Investigational Site Number 752005, Mora, Sweden|Investigational Site Number 752002, Uppsala, Sweden|Investigational Site Number 752001, Växjö, Sweden|Investigational Site Number 756006, Aarau, Switzerland|Investigational Site Number 756004, Winterthur, Switzerland|Investigational Site Number 158004, Changhua, Taiwan|Investigational Site Number 804008, Cherkasy, Ukraine|Investigational Site Number 804009, Chernivtsi, Ukraine|Investigational Site Number 804002, Dnipropetrovsk, Ukraine|Investigational Site Number 804006, Donetsk, Ukraine|Investigational Site Number 804005, Krivoy Rog, Ukraine|Investigational Site Number 804001, Lutsk, Ukraine|Investigational Site Number 804010, Lviv, Ukraine|Investigational Site Number 804011, Sumy, Ukraine|Investigational Site Number 804004, Ternopil, Ukraine|Investigational Site Number 826016, Bangor, United Kingdom|Investigational Site Number 826010, Brighton, United Kingdom|Investigational Site Number 826015, Coventry, United Kingdom|Investigational Site Number 826013, Dundee, United Kingdom|Investigational Site Number 826007, Hull, United Kingdom|Investigational Site Number 826002, Lincoln, United Kingdom|Investigational Site Number 826017, Lincoln, United Kingdom|Investigational Site Number 826005, Manchester, United Kingdom|Investigational Site Number 826004, Norwich, United Kingdom|Investigational Site Number 826009, Peterborough, United Kingdom|Investigational Site Number 826011, Portsmouth, United Kingdom|Investigational Site Number 826001, Shrewsbury, United Kingdom|Investigational Site Number 826014, Wirral, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00694382"
427,"NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","Neo ALTTO","Completed","Has Results","Neoplasms, Breast","Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel","Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery|Number of Participants With Overall Response at Week 6|Overall Response at the Time of Surgery|Number of Participants With Negative Lymph Nodes at the Time of Surgery|Number of Participants With Actual Indicated Surgery|Mean Change From Baseline in Tumor Size at Week 6 and at Surgery|Number of Participants Starting Paclitaxel Before Completing 6 Weeks of Treatment With Either Lapatinib or Trastuzumab|Event-free Survival (EFS) - Median Clinical Follow-up|Event-free Survival (EFS) - Events and Censoring|Overall Survival (OS) - Median Survival Follow-up|Overall Survival (OS) - Deaths and Censoring|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Median Clinical Follow-up (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and Event-free Survival (EFS) - Number of Participants With EFS Events (EFS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Median Clinical Follow-up (OS Landmark Population)|Assess Associations Between Locoregional Pathological Complete Response (pCR) and and Overall Survival (OS) - Number of Participants Who Died (OS Landmark Population)|To Assess Safety Via a Comparison of the Three Treatment Arms - to Measure On-treatment Primary Cardiac Endpoints|Metabolic Response Rate Determined by Positron Emission Tomography/Computed Tomography (PET/CT)|Percentage of Participants With the Indicated Biomarker Expression - PIK3CA.|Percentage of Participants With the Indicated Biomarker Expression - PTEN.|Ratio (95% CI) of Geometric Means in p95HER2 Expression in HR Positive Patients With pCR vs no pCR|Percentage of Participants With Circulating Tumor Cells (CTC) in the Bloodstream","Novartis Pharmaceuticals|Breast International Group|SOLTI Breast Cancer Research Group|Novartis","Female","18 Years and older   (Adult, Older Adult)","Phase 3","455","Industry|Other","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","EGF106903|2006-000564-81|CLAP016B2302","January 5, 2008","May 27, 2010","December 23, 2019","November 4, 2007","October 13, 2011","September 21, 2021","Novartis Investigative Site, Berazategui, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Quilmes, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Tucuman, Argentina|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Namur, Belgium|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Santo Andre, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Novy Jicin, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Levallois-Perret, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Freiburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Fuerth, Bayern, Germany|Novartis Investigative Site, Nuernberg, Bayern, Germany|Novartis Investigative Site, Fuerstenwalde, Brandenburg, Germany|Novartis Investigative Site, Frankfurt am Main, Hessen, Germany|Novartis Investigative Site, Rostock, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Stralsund, Mecklenburg-Vorpommern, Germany|Novartis Investigative Site, Celle, Niedersachsen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Dortmund, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Witten, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Halle, Sachsen-Anhalt, Germany|Novartis Investigative Site, Kiel, Schleswig-Holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Wanchai, Hong Kong|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Hyderabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Nagpur, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Lecco, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Monza, Lombardia, Italy|Novartis Investigative Site, Sondrio, Lombardia, Italy|Novartis Investigative Site, Trento, Trentino-Alto Adige, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Songpa-gu, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Karachi, Pakistan|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucuresti, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Ryazan, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Pretoria, Gauteng, South Africa|Novartis Investigative Site, Athlone Park, Amanzimtoti, South Africa|Novartis Investigative Site, Capital Park, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Girona, Spain|Novartis Investigative Site, Lerida, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Mataro, Spain|Novartis Investigative Site, Santiago de Compostela, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Torrevieja (Alicante), Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Chernivtsi, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Kiev, Ukraine|Novartis Investigative Site, Krivoy Rog, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Odessa, Ukraine|Novartis Investigative Site, Simferopol, Ukraine|Novartis Investigative Site, Epping, Essex, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00553358"
428,"NCT04251533","Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss","EPIK-B3","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Drug: alpelisib|Drug: placebo|Drug: nab-paclitaxel","Progression-free Survival (PFS) Per Investigator Assessment in Study part A|Progression-free Survival (PFS) Per Investigator Assessment in Study part B2|Overall Response Rate (ORR) based on local radiology assessments in subjects with measurable disease at baseline in study Part B1|Overall Survival (OS) in Study Part A|Overall Survival (OS) in Study Part B2|Overall response rate (ORR) with confirmed response in Study Part A|Overall response rate (ORR) with confirmed response in Study Part B2|Clinical benefit rate (CBR) with confirmed response in Study Part A|Clinical benefit rate (CBR) with confirmed response in Study Part B1|Clinical benefit rate (CBR) with confirmed response in Study Part B2|Time to response (TTR) in Study Part A|Time to response (TTR) in Study Part B1|Time to response (TTR) in Study Part B2|Duration of Response (DOR) with confirmed response in Study Part A|Duration of Response (DOR) with confirmed response in Study Part B1|Duration of Response (DOR) with confirmed response in Study Part B2|Overall Survival (OS) in Study Part B1|Progression-free Survival (PFS) Per Investigator Assessment in Study part B1|Plasma concentrations of alpelisib - Part A|Plasma concentrations of alpelisib - Part B1|Plasma concentrations of alpelisib -Part B2|Plasma concentrations of paclitaxel - Part A|Plasma concentrations of paclitaxel - Part B1|Change from baseline in the global health status/Quality of life (QoL) scale score of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30-item Core Module (EORTC QLQ-C30) in study Part A|Change from baseline in the global health status/QoL scale score of the EORTC QLQ-C30 in study Part B2|Time to 10% definitive deterioration in the global health status/QOL scale score of the EORTC QLQ-C30 in study Part A|Time to 10% definitive deterioration in the global health status/QOL scale score of the EORTC QLQ-C30 in study Part B2|PFS based on local radiology assessments using RECIST 1.1 criteria for subjects by PIK3CA mutation status measured in baseline ctDNA in study Part A|PFS based on local radiology assessments using RECIST 1.1 criteria for subjects by PIK3CA mutation status measured in baseline ctDNA in study Part B2|Time to definitive deterioration of the Eastern Cooperative Oncology Group (ECOG) performance status (PS) from baseline in Study Part A|Time to definitive deterioration of the ECOG performance status from baseline in Study Part B2","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","566","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBYL719H12301|2019-002637-11","June 8, 2020","June 19, 2023","January 9, 2026","February 5, 2020",,"May 3, 2022","Comprehensive Blood and Cancer Center Dept. of CBCC (2), Bakersfield, California, United States|Cancer and Blood Specialty Clinic, Los Alamitos, California, United States|USC Norris Cancer Center, Los Angeles, California, United States|University of California at Los Angeles Santa Monica Location, Los Angeles, California, United States|Cancer Care Associates Medical Group Center, Redondo Beach, California, United States|Florida Cancer Specialists Dept of Oncology (2), Fort Myers, Florida, United States|Florida Cancer Specialists FL Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists Onc Dept, Fort Myers, Florida, United States|Florida Cancer Affiliates of Ocala, Ocala, Florida, United States|University of Illinois Cancer Center at Chicago, Chicago, Illinois, United States|Fort Wayne Medical Oncology/Hematology, Inc. Jefferson Blvd, Fort Wayne, Indiana, United States|University of Kansas Hospital and Medical Center DeptofUofKansas CancerCenter-2, Kansas City, Kansas, United States|Hematology and Oncology Clinic SC, Baton Rouge, Louisiana, United States|Sinai Hospital of Baltimore Dept of Sinai Hospital - 2, Baltimore, Maryland, United States|Mayo Clinic Rochester Mayo - Roch., Rochester, Minnesota, United States|Park Nicollet Institute Dept Onc, Saint Louis Park, Minnesota, United States|Research Medical Center HCA Midwest Division, Kansas City, Missouri, United States|Comprehensive Cancer Centers of Nevada CCC of Nevada (1), Las Vegas, Nevada, United States|New York Oncology Hematology, P.C., Albany, New York, United States|Cleveland Clinic Foundation Taussig Cancer Center, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute Cancer Pavilion, 5th floor, Pittsburgh, Pennsylvania, United States|Chattanooga Oncology and Hematology Associates PC Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Tennessee Oncology Tennessee Oncology (3), Nashville, Tennessee, United States|Texas Oncology, P.A. Austin, Bedford, Texas, United States|Texas Oncology PA Dallas Presbyterian Hospital SC, Dallas, Texas, United States|Texas Oncology Texas Oncology - Denton, Dallas, Texas, United States|US Oncology US Oncology Associates, Dallas, Texas, United States|El Paso, Texas Oncology, El Paso, Texas, United States|Texas Oncology Houston Memorial City SC, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio, San Antonio, Texas, United States|US Oncology P A, Tyler, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Northwest Medical Specialties Northwest Medical - Puyallup, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Murdoch, Western Australia, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Innsbruck, Tyrol, Austria|Novartis Investigative Site, Leoben, Austria|Novartis Investigative Site, Salzburg, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Vienna, Austria|Novartis Investigative Site, Caxias do Sul, RS, Brazil|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, Hefei, Anhui, China|Novartis Investigative Site, Chongqing, Chongqing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guiyang, Guizhou, China|Novartis Investigative Site, Shijiazhuang, Hebei, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanchang, Jiangxi, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Shengyang, Liaoning, China|Novartis Investigative Site, Jinan, Shandong, China|Novartis Investigative Site, Xian, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Dalian, China|Novartis Investigative Site, Qingdao, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shenyang, China|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Ibague, Tolima, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Split, HRV, Croatia|Novartis Investigative Site, Zagreb, Croatia|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Angers Cedex 02, France|Novartis Investigative Site, Besancon Cedex, France|Novartis Investigative Site, Clermont Ferrand, France|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Le Mans, France|Novartis Investigative Site, Metz, France|Novartis Investigative Site, Nimes Cedex 9, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Villejuif Cedex, France|Novartis Investigative Site, Ravensburg, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bavaria, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Velbert, North Rhine-westphalia, Germany|Novartis Investigative Site, Luebeck, Schleswig-holstein, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Mannheim, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Wuerzburg, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Tatabanya, Hungary|Novartis Investigative Site, Faridabad, Haryana, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Be'er Sheva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Brindisi, BR, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Rionero in Vulture, PZ, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, El Chouf, LBN, Lebanon|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Petaling Jaya, Selangor, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Tuxtla Gutierrez, Chiapas, Mexico|Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Stavanger, Norway|Novartis Investigative Site, Tromsoe, Norway|Novartis Investigative Site, Trujillo, La Libertad, Peru|Novartis Investigative Site, Lima, Peru|Novartis Investigative Site, Gdynia, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Rzeszow, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Cluj Napoca, Romania|Novartis Investigative Site, Cluj-Napoca, Romania|Novartis Investigative Site, Constanta, Romania|Novartis Investigative Site, Craiova, Romania|Novartis Investigative Site, Ploiesti, Romania|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Pushkin Saint Petersburg, Russian Federation|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Kosice, Slovakia|Novartis Investigative Site, Ljubljana, Slovenia|Novartis Investigative Site, Port Elizabeth, Western Cape, South Africa|Novartis Investigative Site, Johannesburg, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Almeria, Andalucia, Spain|Novartis Investigative Site, Sabadell, Barcelona, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Badajoz, Extremadura, Spain|Novartis Investigative Site, Palma De Mallorca, Islas Baleares, Spain|Novartis Investigative Site, Ferrol, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Santa Cruz de Tenerife, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Aarau, Switzerland|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Lausanne, Switzerland|Novartis Investigative Site, Zurich, Switzerland|Novartis Investigative Site, Kaoshiung, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Nottingham, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04251533"
429,"NCT00387127","Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer",,"Completed","Has Results","Neoplasms, Head and Neck","Drug: Lapatinib oral tablets|Drug: radiotherapy|Drug: cisplatin chemotherapy","Number of Participants (Par.) With Complete Response (CR), as Assessed by Independent Radiological Review|Number of Participants With CR, as Assessed by the Investigator|Progression-Free Survival (PFS), as Assessed by the Investigator|Overall Survival (OS)|Number of Participants Who Died Due to Progressive Disease|Disease-specific Survival|Number of Participants With Loco-regional Recurrence of Initial Disease|Loco-regional Control|Number of Participants With Distant Recurrence of Initial Disease|Distant Relapse|Number of Participants With Overall Response (OR), as Assessed by the Investigator|Number of Participants Positive and Negative for the Expression of Biomarkers in Tumor Tissue: Human Epidermal Growth Factor Receptor (HER)-1, HER2, HER3, HER4, P16, and Transforming Growth Factor (TGF-alpha)|Plasma Proteome Analysis|Analysis of Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA) From Tumor Samples|Number of Participants Negative and Positive for Human Papilloma Virus (HPV) Infection, as Determined From Tumor Samples|Number of Participants Positive and Negative for Biomarker HER1/ErbB1 Categorized in the Indicated Independent Review Panel-assessed Tumor Responses by Expression of Biomarkers From Tumor Tissue: Sensitivity Analysis - 0 Versus (1, 2, 3)|Number of Participants Positive and Negative for Biomarker HER1/ErbB1 Categorized in the Indicated Independent Review Panel-assessed Tumor Responses by Expression of Biomarkers From Tumor Tissues: Sensitivity Analysis - 0, 1, 2 Versus 3","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","67","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EGF105884","November 2006","June 2009","January 2014","October 12, 2006","January 5, 2015","June 25, 2015","GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Hamilton, Ontario, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Lens, France|GSK Investigational Site, Lille, France|GSK Investigational Site, Lyon, France|GSK Investigational Site, Paris cedex 15, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Ahemdabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Thiruvananthapuram, India|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Cambridge, Cambridgeshire, United Kingdom|GSK Investigational Site, Northwood, Middlesex, United Kingdom|GSK Investigational Site, Coventry, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00387127"
430,"NCT02364999","A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC",,"Completed","Has Results","Non-Small Cell Lung Cancer","Drug: Bevacizumab-Pfizer|Drug: Bevacizumab-EU|Drug: Paclitaxel|Drug: Carboplatin","Objective Response Rate (ORR) by Week 19|Number of Participants With Treatment-Emergent Adverse Events|Number of Participants With Laboratory Abnormalities (Without Regard to Baseline Abnormality)|Duration of Response (DOR)|Progression Free Survival Rate at 55 Weeks|Survival Rate at 55 Weeks|Serum Concentration of Bevacizumab up to 1 Year|Number of Participants With Anti-Drug Antibody (ADA)|Number of Participants With Neutralizing Antibody (NAb)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","719","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B7391003|2014-003878-16","April 2015","May 2017","December 2017","February 18, 2015","June 27, 2018","February 7, 2019","Southern Cancer Center, PC, Daphne, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Southern Cancer Center, PC, Mobile, Alabama, United States|Beaver Medical Group, L.P., Highland, California, United States|Cancer Center of Central Connecticut, New Britain, Connecticut, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Phoebe Putney Memorial Hospital, Albany, Georgia, United States|Swedish Covenant Hospital, Chicago, Illinois, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Holy Cross Hospital Resource Center, Silver Spring, Maryland, United States|Maryland Oncology & Hematology, PA, Silver Spring, Maryland, United States|Holy Cross Hospital, Hospital Pharmacy, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology & Hematology, PA, Wheaton, Maryland, United States|St. Joseph's Regional Medical Center, Paterson, New Jersey, United States|Millennium Oncology, Houston, Texas, United States|Millennium Oncology, Kingwood, Texas, United States|Millennium Oncology, Shenandoah, Texas, United States|Millennium Oncology, The Woodlands, Texas, United States|Epic Pharmacy, Lismore, New South Wales, Australia|The Tweed Hospital, Tweed Heads, New South Wales, Australia|Cardiac Services, John Flynn Private Hospital -, Tugun, Queensland, Australia|South Coast Radiology, John Flynn Private Hospital, Tugun, Queensland, Australia|Austin Health - Olivia Newton - John Cancer & Wellness Centre, Heidelberg, Victoria, Australia|Western Health, Sunshine Hospital, St Albans, Victoria, Australia|Hospital Santa Izabel / Santa Casa de Misericordia da Bahia, Salvador, Bahia, Brazil|Oncoclinic (Clinica de Oncologia e Atendimento de Urgencia Ltda), Fortaleza, Ceara, Brazil|COT - Centro Oncologico do Triangulo Ltda, Uberlandia, Minas Gerais, Brazil|Liga Paranaense de Combate ao Cancer - Hospital Erasto Gaertner, Curitiba, Parana, Brazil|Hospital Bruno Born (Sociedade Beneficencia e Caridade de Lajeado), Lajeado, RIO Grande DO SUL, Brazil|Oncosinos (Lessa Ferreira Servicos Oncologicos Ltda), Novo Hamburgo, RIO Grande DO SUL, Brazil|Hospital da Cidade de Passo Fundo - HCPF, Passo Fundo, RIO Grande DO SUL, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre - ISCMPA, Porto Alegre, RIO Grande DO SUL, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre - Hospital Santa Rita, Porto Alegre, RIO Grande DO SUL, Brazil|Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia, Porto Alegre, RIO Grande DO SUL, Brazil|Instituto Joinvillense de Hematologia e Oncologia SS Ltda - Clinica de Hematologia e Oncologia, Joinville, Santa Catarina, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto -, Sao Jose do Rio Preto, SAO Paulo, Brazil|Instituto de Oncologia de Sorocaba - ONCO Clinicas Especializadas SC Ltda, Sorocaba, SAO Paulo, Brazil|Instituto COI de Pesquisa, Educacao e Gestao - COI Clinicas Barra Da Tijuca, Rio de Janeiro, Brazil|lnstituto do Cancer do Estado de Sao Paulo - Octavio Frias de -, Sao Paulo, Brazil|Instituto de Assistencia Medica ao Servidor Publico Estadual - IAMSPE/HSPE-FMO, Sao Paulo, Brazil|Complex Oncological Center Shumen EOOD, Shumen, Bulgaria|Instituto Clinico Oncologico del Sur (ICOS), Temuco, Region DE LA Araucania, Chile|Bradford Hill Centro de Investigaciones Clinicas, Santiago, Region Metropolitana, Chile|Centro Internacional de Estudios Clinicos (CIEC), Santiago, Region Metropolitana, Chile|Fresenius Kabi Chile, Therapia i.v., Santiago, Region Metropolitana, Chile|Instituto Clínico Oncológico del Sur (ICOS), Temuco, Región DE LA Araucanía, Chile|Centro de Investigaciones Clinicas Vina del Mar Ltda., Vina del Mar, V Region, Chile|University Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|Nemocnice na Plesi s.r.o, Nova Ves pod Plesi, Czechia|Nemocnice Novy Jicin a.s, Novy Jicin, Czechia|Lekarna Agel Novy Jicin, Novy Jicin, Czechia|Nemocnice Pelhrimov p.o, Radioterapeuticke oddeleni, Pelhrimov, Czechia|Lekarna Oblastni nemocnice Pribram, Pribram, Czechia|Centre Hospitalier General De Mont De Marsan, Mont De Marsan Cedex, France|Centre Hospitalier Montbeliard, Montbeliard, France|L'hopital prive du Confluent S.A.S., Nantes Cedex, France|Hopital d'instruction des armees Sainte Anne, Toulon Cedex 9, France|Klinikum Bayreuth GmbH, Bayreuth, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Viereck-Apotheke, Berlin, Germany|Vivantes GmbH Apotheke des Humboldt-Klinikums, Berlin, Germany|Vivantes Klinikum Spandau, Berlin, Germany|Staedtisches Klinikum Braunschweig gGmbH Apotheke, Braunschweig, Germany|Staedtisches Klinikum Braunschweig gGmbH Institut fuer Roentgendiagnostik und Nuklearmedizin, Braunschweig, Germany|Staedtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Fachkrankenhaus Coswig GmbH, Coswig, Germany|Apotheke Johannstadt Sven Ullrich e.K., Dresden, Germany|Klinikum Esslingen GmbH, Esslingen a.N., Germany|Radiologie Nuklearmedizin Adickesallee, Frankfurt am Main, Germany|St. Elisabethen - Krankenhaus, Frankfurt am Main, Germany|Sued-Apotheke, Frankfurt am Main, Germany|Asklepios Fachkliniken Muenchen Gauting, Gauting, Germany|Johannes-Apotheke, Groebenzell, Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH - Apotheke, Halle (Saale), Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH - Institut fuer Radiologie, Halle (Saale), Germany|Krankenhaus Martha-Maria Halle-Doelau gGmbH, Halle (Saale), Germany|Zytoservice Deutschland GmbH, Hamburg, Germany|Katholisches Marienkrankenhaus gGmbH, Hamburg, Germany|Institut fuer Diagnostische und Interventionelle Radiologie, Hannover, Germany|Medizinische Hochschule Hannover Zentralapotheke, Hannover, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum des Saarlandes - Klinik fuer Diagnostische und Interventionelle Radiologie, Homburg/Saar, Germany|Universitaetsklinikum des Saarlandes - Klinik fuer Innere Medizin V - Pneumologie, Allergologie,, Homburg/Saar, Germany|Universitaetsklinikum des Saarlandes, Apotheke, Homburg/Saar, Germany|Vincentius-Diakonissen-Kliniken gAG Karlsruhe, Karlsruhe, Germany|Vincentius-Diakonissen-Kliniken gAG Klinik fuer Diagnostische und Interventionelle Radiologie, Karlsruhe, Germany|Vincentius-Diakonissen-Kliniken gAG Zentralapotheke, Karlsruhe, Germany|Institut Fuer Versorgungsforschung In Der Onkologie, Koblenz, Germany|Radiologisches Institut Koblenz, Koblenz, Germany|Sonnenschein Apotheke, Koblenz, Germany|Hirsch-Apotheke, Leer, Germany|Onkologie UnterEms, Leer, Germany|Zentrum fuer Radiologie und Nuklearmedizin am Johannisplatz (ZRN Leipzig), Leipzig, Germany|Arkana Apotheke OHG, Leipzig, Germany|POIS Leipzig GbR, Pneumologisch/onkologisch/internistisches Studienzentrum, Leipzig, Germany|Onkologie Moers GbR, Moers, Germany|Friedrich-Ebert-Krankenhaus Neumuenster, Neumuenster, Germany|University Hospital of Heraklion, Heraklion, Crete, Greece|Univ. of Athens Hosp. of Chest Diseases of Athens ''Sotiria'', Athens, Greece|General Oncology Hospital of Kifissia ""Ag. Anargiroi"", Athens, Greece|University General Hospital Of Patras, Patras, Greece|Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece|European Inter-Balkan Medical Centre, Thessaloniki, Greece|Thermi Clinic S.A, Thessaloniki, Greece|Gen.Hospital ""G. Papanikolaou"", Thessaloniki, Greece|Semmelweis Egyetem Klinikai Pulmonologiai Klinikai Gyogyszertar, Budapest, Hungary|Semmelweis Egyetem, Pulmonologiai Klinika, Budapest, Hungary|Csongrad Megyei Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary|Veszprem Megyei Tudogyogyintezet, Farkasgyepu, Hungary|Petz Aladar Megyei Oktato Korhaz, Pulmonologiai Osztaly, Gyor, Hungary|Matrai Gyogyintezet Pulmonologiai Osztaly, Matrahaza, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz - Rendelointezet, Megyei Onkologiai Kozpont, Szolnok, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Zala Megyei Korhaz, Zalaegerszeg, Hungary|Mahatma Gandhi Cancer Hospital And Research Institute, Visakhapatnam, Andhra Pradesh, India|HealthCare Global Enterprises Limited, Bangalore, Karnataka, India|Shatabdi Super Speciality Hospital, Nashik, Maharashtra, India|Sahyadri Clinical Research and Development Center (A Unit of Sahayadri hospitals Limited), Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Institute of Respiratory Diseases, SMS Medical College & Hospital, Jaipur, Rajasthan, India|UOC Oncologia, Treviglio, BG, Italy|Oncologia Medica, Fondazione Poliambulanza Instituto Ospedaliero, Brescia, BS, Italy|UO Oncologia Medica, Catania, CT, Italy|Unita di Oncologia Toracica, Meldola, FC, Italy|UOC di Oncologia Medica, Lido di Camaiore, LU, Italy|UOSD Pneumologia Oncologica - Padiglione Flaiani, Roma, RM, Italy|S.C. Oncologia Medica-Presidio Ospedaliero Sondrio, Sondrio, SO, Italy|UOC Oncologia Medica, Legnago, VR, Italy|National Hospital Organization Hirosaki National Hospital, Hirosaki, Aomori, Japan|National Hospital Organization Asahikawa Medical Center, Asahikawa, Hokkaido, Japan|National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan|National Hospital Organization Mito Medical Center, Higashi-ibaraki-gun, Ibaraki, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|National Hospital Organization Mie Chuo Medical Center, Tsu, MIE, Japan|National Hospital Organization Sendai Medical Center, Sendai, Miyagi, Japan|National Hospital Organization Tokyo National Hospital, Kiyose, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Saiseikai Fukuoka General Hospital, Fukuoka, Japan|National Hospital Organization Kochi National Hospital, Kochi, Japan|National Hospital Organization Oita Medical Center, Oita, Japan|Japanese Red Cross Okayama Hospital, Okayama, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of|VHS Medical Center, Seoul, Gangdong-gu, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Nilai Medical Centre, Nilai, Negeri Sembilan, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Penang, Malaysia|Penang Adventist Hospital, Penang, Malaysia|Klinisch Chemisch en Hematologisch Laboratorium (KCHL), Arnhem, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Ziekenhuis De Gelderse Vallei, Ede, Netherlands|Elkerliek Ziekenhuis, Helmond, Netherlands|Cebu Doctors' University Hospital, Cebu City, Cebu, Philippines|Davao Doctors Hospital, Davao City, Davao DEL SUR, Philippines|Wojewodzki Szpital Zespolony w Elblagu, Elblag, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Kopernika w Lodzi,, Lodz, Poland|Samodzielny Publiczny Zespol Gruzlicy i Chorob Pluc w Olsztynie, Olsztyn, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im.Eugenii i Janusza Zeylandow, Poznan, Poland|MRUKMED. Lekarz Beata Madej Mruk i Partner. Sp. p. Oddzial nr 1 w Rzeszowie, Rzeszow, Poland|Samodzielny Publiczny Wojewodzki Szpital Zespolony w Szczecinie Szpital Wojewodzki w, Szczecin-Zdunowo, Poland|Wojewodzki Szpital Zespolony im. L. Rydygiera w Toruniu Szpital Obserwacyjno-Zakazny, Torun, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Wojskowy Instytut Medyczny, Klinika Onkologii, Warszawa, Poland|Wojewodzki Szpital Chorob Pluc im. dr Alojzego Pawelca, Wodzislaw-Slaski, Poland|SPAD Imaging International S.R.L, Craiova, Dolj, Romania|SC Cardio-Center SRL, Craiova, Dolj, Romania|SC Oncolab SRL, Oncologie, Craiova, Jud Dolj, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Cardiologie, Targu-Mures, Mures, Romania|Spitalul Clinic Judetean Mures, radiologie si imagistica medicala, Targu-Mures, Mures, Romania|Spitalul Clinic Judetean Mures, sectia Clinica de Oncologie Medicala, Targu-Mures, Mures, Romania|S.C. Oncocenter Oncologie Clinica SRL, Timisoara, Timis, Romania|Medisprof, Cluj Napoca, Romania|Spitalul Clinic Municipal, Cluj-Napoca, Romania|SC Hiperdia SA, Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta ""Sf Apostol Andrei"" Constanta Clinica Oncologie Medicala, Constanta, Romania|Centrul Medical Pozimed, SC Pozitron Medical Investigation SRL, Constanta, Romania|S.C. Centrul de Oncologie Sf. Nectarie S.R.L., Oncologie Medicala, Craiova, Romania|SC Radiotherapy Center Cluj SRL, Jud Cluj, Romania|Hiperdia Timisoara, Cardiologie, Timisoara, Romania|Hiperdia Timisoara, Radiologie si imagistica medicala, Timisoara, Romania|Dr's Grineva Private Clinic, Sochi, Krasnodar Region, Russian Federation|SHI Oncology Dispensary #2 of Health Department of Krasnodar Region, Sochi, Krasnodar Region, Russian Federation|""SAHI of Moscow """"Moscow City Oncology Hospital #62 of Health Department of Moscow"""""", P/o Stepanovskoe, Moscow Region, Russian Federation|""RBHI """"Kursk Regional Clinical Oncology Dispensary"""" of Healthcare Committee of Kursk Region"", Kislino Steading Of Kursk Region, Ryshkovskiy Village Council, Russian Federation|SBHI of Stavropol Region ""Essentuki Central City Hospital"", Essentuki, Stavropol Region, Russian Federation|Federal State Budgetary Institution of Healthcare ""Clinical Hospital #, Lermontov, Stavropol Region, Russian Federation|SBHI of Stavropol Region ""Pyatigorsk Oncology Dispensary"", Pyatigorsk, Stavropol Region, Russian Federation|Stavropol Krai State Budget Healthcare Institute ""Stavropol Regional Oncology Clinic"", Stavropol, Stavropol Region, Russian Federation|S.G. Primushko Republican Clinical Oncology Dispensary, Izhevsk, Udmurt Republic, Russian Federation|SBHI of Vladimir Region ""Regional Clinical Oncology Dispensary"", Vladimir, Vladimir Region, Russian Federation|State Budget Healthcare Institution of Arkhangelsk Region, Arkhangelsk, Russian Federation|Evimed Llc, Chelyabinsk, Russian Federation|Chelyabinsk Regional Hospital, Chelyabinsk, Russian Federation|SBHI ""Chelyabinsk Regional Clinical Hospital"", Chelyabinsk, Russian Federation|""SBHI """"Chelyabinsk Regional Clinical Oncology Dispensary"""""", Chelyabinsk, Russian Federation|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|MRT-Expert, LLC, Chelyabinsk, Russian Federation|Road Clinical Hospital on the station Chelyabinsk of OJSC ""RZD"", Chelyabinsk, Russian Federation|SBHI ""Regional clinical hospital #2"" of MoH of Krasnodar Region, Krasnodar, Russian Federation|FSBI ""N.N.Blokhin Russian Cancer Research Center"" RAMS, Moscow, Russian Federation|P.A.Hertsen Moscow Oncology Research Institute - Branch of the National Medical Radiological, Moscow, Russian Federation|Privolzhskiy District Medical Center of Federal Biomedical Agency, Nizhniy Novgorod, Russian Federation|SBHI NR Clinical Diagnostic Center, Nizhniy Novgorod, Russian Federation|SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary, Nizhniy Novgorod, Russian Federation|SBHI of NNR Nizhniy Novgorod Regional Oncology Dispensary, Nizhniy Novgorod, Russian Federation|""Budgetary Healthcare Institution of Omsk Region """"Clinical Oncology Dispensary"""""", Omsk, Russian Federation|SBEI HPE RyazSMU of MoH of Russia based on SBI of Ryazan Region, Ryazan, Russian Federation|SPb SBHI ""City Clinical Oncology Dispensary"", Saint Petersburg, Russian Federation|FSBI 'Scientific-Research Oncology Institute n.a. N.N.Petrov' of MoH of RF, Saint-Petersburg, Russian Federation|Saratov scientific research institute of traumatology and orthopedics, Saratov, Russian Federation|NHI Road clinical hospital at the st. Saratov II of OJSC Russian Railways, Saratov, Russian Federation|Clinical hospital n.a. S.R. Mirotvortseva of SSMU, Saratov, Russian Federation|Limited Liability Company ""Common health"", Sochi, Russian Federation|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Amanzimtoti Oncology Centre, Amanzimtoti, Kwa-zulu Natal, South Africa|Drs Schnetler, Corbett and Partners Inc, Cape Town, Western CAPE, South Africa|Dr Lior Sareli Inc, Cape Town, Western CAPE, South Africa|Cape Town Oncology Trials (Pty) Ltd, Kraaifontein, Western CAPE, South Africa|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Hospital Son Llatzer, Palma de Mallorca, Islas Baleares, Spain|Hospital Universitario Fundacion Alcorcon, Alcorcon, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Servicio de Oncologia, Madrid, Spain|Consorcio Hospital Universitario General De Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Chulalongkorn University, Patumwan, Bangkok, Thailand|Chiangrai Prachanukroh Hospital, Muang, Chiang RAI, Thailand|Chula Clinical Research Center, Bangkok, Thailand|Clinical Research Center, Phramongkutklao Hospital, Bangkok, Thailand|Medical Oncology Unit, Department of Medicine, Phramongkutklao Hospital, Bangkok, Thailand|Division of Medical Oncology, Department of Medicine, Faculty of Medicine Siriraj Hospital,, Bangkok, Thailand|Prachachuen Imaging Center Co., Ltd., Bangkok, Thailand|Oncology Unit, Department of Medicine, Faculty of Medicine, Naresuan University, Phitsanulok, Thailand|Baskent Universitesi Tip Fakultesi Adana Hastanesi, Adana, Turkey|Cukurova Universitesi Tip Fakultesi Balcali Hastanesi, Adana, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Diskapi Yildirim Beyazit Egitim ve Arastirma Hastanesi, Ankara, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Yildirim Beyazit Universitesi Tip Fakultesi Ataturk Egitim ve Arastirma Hastanesi, Ankara, Turkey|Yedikule Gogus Hastaliklari ve Gogus Cerrahisi, Istanbul, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Turkey|Iyitem Goruntuleme ve Tani Merkezi, Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari, Istanbul, Turkey|Prof Dr Nuri Tenekeci Tani Merkezi, Istanbul, Turkey|Euromed Goruntuleme ve Tani Merkezi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi lc Hastaliklari Anabilim Dali, Izmir, Turkey|LLC ""Medical clinic ""INNOVACIA"", chemotherapy department, Lyutizh, KYIV Region, Ukraine|""Municipal Institution """"Chernivtsi Regional Clinical Oncology Dispensary"""",, Chernivtsi, Ukraine|MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC', Dep.-nt of Chemotherapy;, Dnipropetrovsk, Ukraine|Communal Non-Profit Enterprise ""Regional Center of Oncology"",, Kharkiv, Ukraine|MI 'Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council', Kryvyi Rih, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Poltava Reg. Clinical Oncology Dispensary of PRC, thoracic department, SHEI of Ukr., Poltava, Ukraine|""RMI """"Sumy Reg. Clin. Oncology Dispensary"""". oncothoracic dep.-nt. Surny State Univ.,, Sumy, Ukraine|""Central City Clinical Hospital, City Oncology Center, SHEI """"Uzhhorod National University"""", Uzhhorod, Ukraine|Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsia, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02364999/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02364999/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02364999"
431,"NCT01271725","LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures",,"Completed","Has Results","Breast Neoplasms","Drug: Vinorelbine 25 mg/m2 weekly|Drug: Afatinib 40mg once daily (OD)|Drug: Paclitaxel 80 mg/m2 weekly","Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1|Best Overall Response According to RECIST v1.1 (With Confirmation)|Best Overall Response According to RECIST v1.1 (Regardless of Confirmation)|Progression Free Survival (PFS)|Duration of Objective Response According to RECIST v1.1|Percentage of Patients With Highest Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 Grade of 3 or Higher|Change From Baseline to End of Treatment in Systolic Blood Pressure (SBP)|Change From Baseline to End of Treatment in Diastolic Blood Pressure (DBP)|Number of Patient With Possibly Clinically Significant (PCS) Laboratory Values","Boehringer Ingelheim","Female","18 Years and older   (Adult, Older Adult)","Phase 2","74","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.98|2010-021945-29","May 24, 2011","March 13, 2017","March 13, 2017","January 7, 2011","June 17, 2019","June 17, 2019","Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Sujan Surgical Cancer Hospital, Amravati, India|Tata Memorial Hospital, Maharashtra, India|Curie Manavata Cancer Centre, Maharashtra, India|Central India Cancer Research Institute, Nagpur, India|Ruby Hall Clinic, Pune, India|Regional Cancer Center, Thiruvananthapuram, India|University Clinical Center, Gdansk, Gdansk, Poland|St.Auton.Heal.Inst.""Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"", Kazan, Russian Federation|Clinical Oncology Dispensary No. 1, Dept. Chemotherapy, Krasnodar, Russian Federation|N.A. Semashko Central Clinical Hospital, Moscow, Moscow, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncol. Dispensary"", Pyatigorsk, Russian Federation|SBIH ""Samara Regional Clinical Oncol. Dispensary"", Samara, Samara, Russian Federation|GUZ ""Oncological Dispesary #2"", Sochi, Russian Federation|Stavropol Regional Clin. Oncology Dispensary Dept. Oncology, Stavropol, Russian Federation|Yaroslavl Regional Clinical Oncology Hosp. Dept.Chemotherapy, Yaroslavl, Russian Federation|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|North Devon District Hospital, Barnstaple, United Kingdom|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Charing Cross Hospital, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01271725/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01271725/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01271725"
432,"NCT01304524","A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3","HPV-003","Completed","No Results Available","Cervical Intraepithelial Neoplasia","Biological: VGX 3100|Biological: Placebo|Device: CELLECTRA™-5P","Number of Participants with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Measure of Efficacy.|Number of Participants with Virologically-proven Clearance of HPV 16 or 18 in Combination with Histopathological Regression of Cervical Lesions to CIN 1 or Less as a Secondary Measure of Efficacy","Inovio Pharmaceuticals","Female","18 Years to 55 Years   (Adult)","Phase 2","167","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","HPV-003","April 2011","May 2014","April 2015","February 25, 2011",,"September 7, 2018","Phoenix, Arizona, United States|Tucson, Arizona, United States|Colton, California, United States|La Mesa, California, United States|Los Angeles, California, United States|Lakewood, Colorado, United States|Boynton Beach, Florida, United States|Fort Lauderdale, Florida, United States|Sarasota, Florida, United States|Baltimore, Maryland, United States|Saginaw, Michigan, United States|Missoula, Montana, United States|Bronx, New York, United States|Port Jefferson, New York, United States|Raleigh, North Carolina, United States|Winston-Salem, North Carolina, United States|Columbus, Ohio, United States|Oklahoma City, Oklahoma, United States|Eugene, Oregon, United States|Philadelphia, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Murray, Utah, United States|Pleasant Grove, Utah, United States|Sandy, Utah, United States|Richmond, Virginia, United States|Renton, Washington, United States|Spokane, Washington, United States|Victoria, Australia|Montreal, Quebec, Canada|Vancouver, Canada|Tallinn, Estonia|Tartu, Estonia|Batumi, Georgia|Tbilisi, Georgia|Bangalore, Karnataka, India|Jaipur, Rajasthan, India|Kolkata, India|New Delhi, India|Pune, India|Seoul, Korea, Republic of|San Juan, Puerto Rico|Bloemfontein, South Africa|Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01304524"
433,"NCT00497809","Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia",,"Completed","No Results Available","Breast Cancer|Neutropenia","Drug: AVI-014 versus Filgrastim","The primary efficacy endpoint is duration of grade 4 neutropenia (DSN), defined as ANC <0.5 x 109/L during chemotherapy cycle 1.|• Incidence of grade 4 neutropenia • Duration of neutropenia (defined as the number of days with ANC <0.5 x 109/L and <0.1 x 109/L)","AviGenics","Female","18 Years and older   (Adult, Older Adult)","Phase 2","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AVI-014-P02","August 2007","July 2008","July 2009","July 9, 2007",,"May 3, 2011","Pacific Cancer Medical Center, Anaheim, California, United States|California Cancer Center, Greenbrae, California, United States|Ghassan Al-Jazayrly, MD, Inc., Los Angeles, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Brian LeBerthon, MD, A Medical Corporation, West Covina, California, United States|Infosphere Clinical Research, West Hills, California, United States|Physicians Research Alliance LLC., Debary, Florida, United States|Southern Illinois Hematology/Oncology, Centralia, Illinois, United States|Gabrail Cancer Center, Canton, Ohio, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|University of Oklahoma Health Sciences Ctr, Oklaoma City, Oklahoma, United States|Cancer Care Institute of Carolina, Aiken, South Carolina, United States|Cancer Specialists of South Texas, Corpus Christi, Texas, United States|Cancer Outreach Associates PC, Abingdon, Virginia, United States|Jawaharlal Nehru Cancer Hospital and Research Centre, Idgah Hills, Bhopal, India|Apollo Specialty Hospital, Padma Complex, 320 Mount Road, Chennai, India|Amrita Institute of Medical Sciences, Amrita Lane Elamakkara, Cochin, India|Dharamshila Hospital and research Centre, Vasundhara Enclave, Delhi, India|Apollo Hospitals Educational and Research Foundation, Jubilee hills, Hyderabad, India|Kidwai Memorial Institute of Oncology, Dr. M.H. Marigowda Road, Bangalore, Karnataka, India|Mohan Dai Oswal Cancer Treatment & Research Foundation, G.T. Road, Sherpur Bye Pass, Ludhiana, India|Dayanand Medical College and Hospital, Tagore Nagar, Civil Lines, Ludhiana, India|Meenakshi Mission Hospital and Research Centre, Lake Area, Melur Road, Madurai,, India|Kasturba Medical College Hospital, Attavar, Mangalore, India|Tata Memorial Hospital,, Dr. E Borges Road, Parel, Mumbai, India|Indraprastha Apollo Hospital, Delhi Mathura road, Sarita vihar, New Delhi, India|Dharamshila Cancer Center, Dharamshila Marg, Vasundhara Enclave, New Delhi, India|Regional Cancer Centre, IGIMS, Sheikhpura, Patna, India|Ruby Hall Clinic, 40 Sasoon Road, Pune, India|King George Hospital, Vizag, Vishakhapattanam, India|IRCH, AIIMS, Ansari Nagar,, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00497809"
434,"NCT01516736","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim","PROTECT2","Completed","Has Results","Chemotherapy-induced Neutropenia|Breast Cancer","Drug: LA-EP2006|Drug: Neulasta®","Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy|Incidence of Febrile Neutropenia (FN)|Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles|Depth of ANC Nadir in Cycle 1|Number of Patients With ANC Nadir Per Day in Cycle 1|Time to ANC Recovery in Days in Cycle 1|Frequency of Infections by Cycle and Across All Cycles|Mortality Due to Infection","Sandoz|Sandoz GmbH","Female","18 Years and older   (Adult, Older Adult)","Phase 3","308","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","LA-EP06-302","March 2012","August 2013","December 2013","January 25, 2012","June 28, 2017","August 30, 2017","Sandoz Investigational Site, Hot Springs, Arkansas, United States|Sandoz Investigational Site, Jonesboro, Arkansas, United States|Sandoz Investigational Site, Corona, California, United States|Sandoz Investigational Site, Wichita, Kansas, United States|Sandoz Investigational Site, Mount Sterling, Kentucky, United States|Sandoz Investigational Site, Detroit, Michigan, United States|Sandoz Investigational Site, Bismarck, North Dakota, United States|Sandoz Investigational Site, Eugene, Oregon, United States|Sandoz Investigational Site, Germantown, Tennessee, United States|Sandoz Investigational Site, Newport News, Virginia, United States|Sandoz Investigational Site, Tucuman, Argentina|Sandoz Investigational Site, Temuco, Chile|Sandoz Investigational Site, Chennai, India|Sandoz Investigational Site, Delhi, India|Sandoz Investigational Site, Gujarat, India|Sandoz Investigational Site, Hyderabad, India|Sandoz Investigational Site, Karamsad, India|Sandoz Investigational Site, Lucknow, India|Sandoz Investigational Site, Maharashtra, India|Sandoz Investigational Site, Mangalore, India|Sandoz Investigational Site, Mumbai, India|Sandoz Investigational Site, Pradesh, India|Sandoz Investigational Site, Surat, India|Sandoz Investigational Site, Vadodara, India|Sandoz Investigational Site, Vellore, India|Sandoz Investigational Site, Visakhapatnam, India|Sandoz Investigational Site, Kelantan, Malaysia|Sandoz Investigational Site, Nilai, Malaysia|Sandoz Investigational Site, Penang, Malaysia|Sandoz Investigational Site, Penang, Malaysia|Sandoz Investigational Site, San Juan, Puerto Rico|Sandoz Investigational Site, San Juan, Puerto Rico|Sandoz Investigational Site, Arkhangelsk, Russian Federation|Sandoz Investigational Site, Bashkortostan, Russian Federation|Sandoz Investigational Site, Bryansk, Russian Federation|Sandoz Investigational Site, Kazan, Russian Federation|Sandoz Investigational Site, Krasnoyarsk, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Omsk, Russian Federation|Sandoz Investigational Site, Orel, Russian Federation|Sandoz Investigational Site, Orenburg, Russian Federation|Sandoz Investigational Site, Rostov-na-Donu, Russian Federation|Sandoz Investigational Site, St Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, Tomsk, Russian Federation|Sandoz Investigational Site, Vladimir, Russian Federation|Sandoz Investigational Site, Barcelona, Spain|Sandoz Investigational Site, Madrid, Spain|Sandoz Investigational Site, Santiago de Compostela, Spain|Sandoz Investigational Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT01516736"
435,"NCT01496313","To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer",,"Active, not recruiting","Has Results","Thyroid Cancer","Drug: 300mg vandetanib|Drug: 150mg vandetanib","Overall Response Rate (ORR) for Vandetanib 150 and 300mg With Responses Determined by the Investigator|Best Objective Response|Duration of Objective Response (RECIST 1.1) by Treatment Arm|Time to Objective Response (RECIST 1.1) by Treatment Arm|Percentage Change From Baseline in Target Lesion Size (RECIST 1.1) by Treatment Arm|Plasma Concentration of Vandetanib in the Bloodstream (Cmax) for Patients by Treatment Arm.","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 4","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","D4200C00097|2011-004701-24|LPS14809","August 28, 2012","April 2014","December 31, 2022","December 21, 2011","November 27, 2015","November 1, 2021","Research Site, Houston, Texas, United States|Research Site, Olomouc, Czechia|Research Site, Praha 5, Czechia|Research Site, Bangalore Karnataka, India|Research Site, Vellore, India|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Catania, Italy|Research Site, Milano, Italy|Research Site, Palermo, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Groningen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Gliwice, Poland|Research Site, Warszawa, Poland|Research Site, Zgierz, Poland|Research Site, Saint Petersburg, Russian Federation|Research Site, Cardiff, United Kingdom|Research Site, Greater London, United Kingdom|Research Site, London, United Kingdom|Research Site, Tyne & Wear, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01496313"
436,"NCT00268905","A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors",,"Completed","Has Results","Cancer","Drug: E7389 + carboplatin AUC 5|Drug: E7389 + carboplatin AUC 6|Drug: E7389+carboplatin AUC 6","Maximum Tolerated Dose (MTD) of Eribulin Mesylate of E7389 in Combination With Carboplatin in Subjects With Advanced Solid Tumors.|Safety of Eribulin Mesylate in Combination With Carboplatin as Measured by the Number of Subjects With Treatment Emergent Adverse Events.|Percent of Subjects With Best Overall Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria.","Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","64","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7389-A001-104","October 2006","November 2011",,"December 23, 2005","January 25, 2013","February 12, 2013","New Brunswick, New Jersey, United States|Bronx, New York, United States|Lake Success, New York, United States|New York, New York, United States|Graz, Austria|Salzburg, Austria|Vienna, Austria|Vijayawada, Andhra Pradesh, India|New Delhi, Delhi, India|Pune, Maharashtra, India|Melur, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00268905"
437,"NCT04606771","A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC","CoC","Recruiting","No Results Available","Non-Small Cell Lung Cancer","Drug: Osimertinib + Savolitinib|Drug: Savolitinib + Placebo","Objective Response Rate (ORR)|Progression-free Survival (PFS)|Duration of Response (DoR)|Tumour Size Assessment (TSA)|Overall Survival (OS)|Progression Free Survival|Duration of Response|Tumour Size Assessment|Total clearance in EGFR mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in EGFR mutation allele frequencies).|Plasma concentrations of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|Time dependency of the PK of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|AUCss of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|Cssmax of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|Tssmax of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|CLss/F of savolitinib, osimertinib and their metabolites, (M2 and M3 for savolitinib; AZ5104 for osimertinib)|Number and percentage of subjects with adverse events (AEs) in different categories: All AEs|Number and percentage of subjects with adverse events (AEs) in different categories: Serious AEs|Number and percentage of subjects with adverse events (AEs) in different categories: Causally related AEs|Number and percentage of subjects with adverse events (AEs) in different categories: Discontinuations due to AEs|Number and percentage of subjects with adverse events (AEs) in different categories: Deaths|Number of subjects with at least one treatment emergent change in laboratory parameters in Albumin|Number of subjects with at least one treatment emergent change in laboratory parameters in Alkaline phosphatase|Number of subjects with at least one treatment emergent change in laboratory parameters in ALT|Number of subjects with at least one treatment emergent change in laboratory parameters in Amylase|Number of subjects with at least one treatment emergent change in laboratory parameters in AST|Number of subjects with at least one treatment emergent change in laboratory parameters in Total bilirubin|Number of subjects with at least one treatment emergent change in laboratory parameters in Total Calcium|Number of subjects with at least one treatment emergent change in laboratory parameters in Creatinine|Number of subjects with at least one treatment emergent change in laboratory parameters in Glucose|Number of subjects with at least one treatment emergent change in laboratory parameters in Magnesium|Number of subjects with at least one treatment emergent change in laboratory parameters in Sodium|Number of subjects with at least one treatment emergent change in laboratory parameters in Potassium|Number of subjects with at least one treatment emergent change in laboratory parameters in Total Protein|Number of subjects with at least one treatment emergent change in laboratory parameters in BUN or urea|Number of subjects with at least one treatment emergent change in laboratory parameters in Lactate dehydrogenase|Number of subjects with at least one treatment emergent change in laboratory parameters in Haematocrit|Number of subjects with at least one treatment emergent change in laboratory parameters in Haemoglobin|Number of subjects with at least one treatment emergent change in laboratory parameters in Leucocyte cell count|Number of subjects with at least one treatment emergent change in laboratory parameters in Platelet count|Number of subjects with at least one treatment emergent change in laboratory parameters in Red blood cell count|Number of subjects with at least one treatment emergent change in laboratory parameters in Reticulocytes|Number of subjects with at least one treatment emergent change in laboratory parameters in Neutrophil count|Number of subjects with at least one treatment emergent change in laboratory parameters in Lymphocyte count|Number of subjects with at least one treatment emergent change in laboratory parameters in Eosinophil count","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","D5084C00009|2020-000813-33","September 28, 2020","February 27, 2023","February 29, 2024","October 28, 2020",,"April 27, 2022","Research Site, Duarte, California, United States|Research Site, La Jolla, California, United States|Research Site, Sacramento, California, United States|Research Site, Rochester, Minnesota, United States|Research Site, Brooklyn, New York, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Capital Federal, Argentina|Research Site, Ciudad Autónoma de Bs. As., Argentina|Research Site, La Plata, Argentina|Research Site, Belo Horizonte, Brazil|Research Site, Fortaleza, Brazil|Research Site, Fortaleza, Brazil|Research Site, Ibirapuera, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitoria, Brazil|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Bangalore, India|Research Site, Mumbai, India|Research Site, Rohini, India|Research Site, Daegu, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Jeonnam, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Taichung City, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Muang, Thailand|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam",,"https://ClinicalTrials.gov/show/NCT04606771"
438,"NCT04658862","A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","SunRISe-2","Recruiting","No Results Available","Urinary Bladder Neoplasms","Biological: Cetrelimab|Drug: TAR-200|Drug: Cisplatin|Drug: Gemcitabine|Radiation: Conventional radiation therapy|Radiation: Hypo-fractioned radiation therapy","Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) event|Metastasis-free survival (MFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Number of Participants with Adverse Events (AEs) According to Common Terminology Criteria for Adverse Events (CTCAE)|Number of Participants with AEs by Severity according to Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE)|Number of Participants with Clinical Laboratory Abnormalities","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","550","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108917|2020-002620-36|17000139BLC3001","December 7, 2020","December 30, 2026","December 31, 2028","December 9, 2020",,"April 22, 2022","Bladder Cancer Genitourinary Oncology, Phoenix, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of California Irvine Medical Center, Orange, California, United States|Providence Saint John's Health Center, Santa Monica, California, United States|The Urology Center of Colorado, Denver, Colorado, United States|Foothills Urology - Golden Off, Golden, Colorado, United States|UF Health Jacksonville, Jacksonville, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|The University Of Chicago Medicine, Chicago, Illinois, United States|DuPage Medical Group, Lisle, Illinois, United States|Johns Hopkins Medical Institutions, Baltimore, Maryland, United States|Chesapeake Urology Associates, Towson, Maryland, United States|University Hospitals Seidman Cancer Center, Ann Arbor, Michigan, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|Adult Pediatric Urology & Urogynecology, P.C, Omaha, Nebraska, United States|New Jersey Urology LLC, Voorhees, New Jersey, United States|Cardiology Clinic at Montefiore Hutchinson Complex, Bronx, New York, United States|Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|NYU Langone Health, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center, Herbert Irving Pavilion, New York, New York, United States|Associated Medical Professionals, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Vidant Urology - Greenville, Greenville, North Carolina, United States|Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem, North Carolina, United States|Ohio State University, Columbus, Ohio, United States|Oklahoma City VAMC, Oklahoma City, Oklahoma, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oregon Urology Institute, Springfield, Oregon, United States|MidLantic Urology, Bala-Cynwyd, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Allegheny, Pittsburgh, Pennsylvania, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Urology Associates, PC, Nashville, Tennessee, United States|Rio Grande Urology, El Paso, Texas, United States|University of Texas Medical Branch, League City, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Spokane Urology, Spokane, Washington, United States|Fundacion Intecnus, Bariloche, Argentina|Hospital Sirio Libanes, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Argentina|Centro Urologico Profesor Bengio, Córdoba, Argentina|Sanatorio Allende Cerro, Córdoba, Argentina|Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina|Centro de Investigacion Pergamino SA, Pergamino, Argentina|Instituto de Oncologia de Rosario, Rosario, Argentina|CEDIC Centro de Investigaciones Clinicas, Viedma, Argentina|Flinders Medical Centre, Bedford Park, Australia|Royal North Shore Hospital, St Leonards, Australia|Krankenhaus der barmherzigen Schwestern, Linz, Austria|KH.D Barmherzige Bruder Salzburg, Salzburg, Austria|Universitätsklinikum Salzburg - Landeskrankenhaus, Salzburg, Austria|Krankenhaus der Barmherzigen Brüder, Vienna, Austria|Medizinische Universität Wien, Wien, Austria|Wilhelminenspital der Stadt Wien, Wien, Austria|Hopital Erasme, Anderlecht, Belgium|ZNA Middelheim, Antwerpen, Belgium|AZ Sint-Lucas, Assebroek, Belgium|Algemeen Ziekenhuis Klina, Brasschaat, Belgium|AZ Sint-Jan Brugge-Oostende AV, Brugge, Belgium|Az Groeninge, Kortrijk, Belgium|Fundacao Pio Xii - Hospital De Cancer De Barretos, Barretos, Brazil|Fundação Hospitalar São Francisco de Assis, Belo Horizonte, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Centro de Pesquisas Oncológicas - CEPON, Florianópolis, Brazil|Centro Regional Integrado de Oncologia - Crio, Fortaleza, Brazil|Hospital de Caridade de Ijui, Ijuí, Brazil|Clinica de Oncologia Reichow, Jardim Blumenau, Brazil|Hospital Amaral Carvalho, Jaú, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Brazil|Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil|Hospital São Lucas - PUCRS, Porto Alegre, Brazil|Hospital Sao Rafael, Salvador, Brazil|CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia, Santo André, Brazil|ICESP - Instituto do Câncer do Estado de São Paulo, Sao Paolo, Brazil|Hospital Sirio Libanes, Sao Paulo, Brazil|Fundação Faculdade de Medicina de São José Do Rio Preto, São José Do Rio Preto, Brazil|Instituto de Assistência Médica ao Servidor Público Estadual - HSPE-FMO, São Paulo, Brazil|Centro Oncológico do Triângulo, Uberlândia, Brazil|Exdeo Clinical Research Inc, Abbotsford, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|The Male/Female Health and Research Centre, Barrie, Ontario, Canada|William Osler Health System, Brampton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|CHU de Québec -L'Hôtel-Dieu de Québec, Québec, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Chinese Academy of Medical Sciences(CAMS) & Peking Union Medical College(PUMC), Beijing, China|Peking University First Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Beijing Hospital, Beijing, China|The First Hospital of Jilin University, Changchun, China|Hunan Cancer hospital, Changsha Shi, China|The Third Xiangya Hospital of Central Sourth University, Changsha, China|General Hospital of Western Theater Command PLA, Chengdu Shi, China|West China Hospital of Sichuan University, Chengdu, China|Chongqing University Cancer Hospital, Chongqing, China|First Affiliated Hospital of Dalian Medical University, Dalian, China|Guangzhou First Municipal People's Hospital, Guang Zhou Shi, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Zhejiang Provincial People's Hospital, Hangzhou, China|The First Affiliated Hospital of NanChang University, Nanchang, China|Nanjing Drum Tower Hospital, Nanjing, China|Qingdao Municipal Hospital, Qingdao, China|Renji Hospital, Shanghai, China|Shengjing Hospital of China Medical University, Shenyang, China|Liaoning Cancer Hospital & Institute, Shenyang, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou Shi, China|Wuhan Union Hospital, Wuhan, China|Wuhan Tongji Hospital, Tongji Medical College, Wuhan, China|Yantai Yuhuangding Hospital, Yantai, China|Henan Cancer Hospital, Zhengzhou, China|Kromerizska nemocnice a.s., Kromeriz, Czechia|Slezska nemocnice v Opave, Opava, Czechia|Fakultni nemocnice Plze, Plzen-Bory, Czechia|Urocentrum Praha, Praha 2, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Thomayerova nemocnice, Praha 4, Czechia|Fakultni nemocnice v Motole, Praha 5, Czechia|Androgeos S.R.O., Praha 6, Czechia|Nemocnice Na Bulovce, Praha 8, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Krajska Nemocnice Tomase Bati, Zlin, Czechia|Hôpital Côte de Nacre, Caen cedex 9, France|Clinique Sainte Marguerite, Hyeres, France|Polyclinique de Limoges - Francois Chenieux, Limoges, France|Hôpital Edouard Herriot, Lyon Cedex 03, France|Institut Paoli-Calmettes, Marseille, France|Institut Regional du Cancer de Montpellier, Montpellier, France|CHU Nîmes, Nimes, France|Hopital Europeen Georges-Pompidou, Paris, France|Hôpital Bichat - Claude Bernard, Paris, France|CHU De Poitiers, Poitiers, France|Centre Hospitalier Prive, Saint-Grégoire, France|Hopital Foch, Suresnes, France|Institut Universitaire du Cancer Toulouse Oncopole, Toulouse Cedex 9, France|Marien-Krankenhaus GmbH Bergisch Gladbach, Bergisch Gladbach, Germany|Urologicum Duisburg, Duisburg, Germany|Universitätsklinikum Düsseldorf, Düesseldorf, Germany|Waldkrankenhaus St. Marien -Urologische Universitätsklinik, Erlangen, Germany|Agaplesion Frankfurter Diakonie Kliniken GmbH, Markus Krankenhaus, Frankfurt Am Main, Germany|Universitatsklinikum Frankfurt, Frankfurt am Main, Germany|Klinikum Herne - Urologie, Herne, Germany|Matthias Schulze - Germany, Markkleeberg, Germany|Universitätsklinikum Münster, Münster, Germany|Klinikum Nürnberg Nord - Hautklinik, Nürnberg, Germany|Kliniken Nordoberpfalz AG/Klinikum Weiden, Weiden, Germany|Alexandra General Hospital of Athens, Athens, Greece|Attikon University General Hospital of Attica, Athens, Greece|Metropolitan General A.E., Holargos, Greece|University Hospital Of Larissa, Larissa, Greece|Hygeia Diagnostic & Therapeutic Center Of Athens, Marousi, Greece|Athens Medical Center, Maroussi, Greece|Metropolitan Hospital, Neo Faliro, Greece|Bioclinic - Thessaloniki, Thessaloniki, Greece|Euromedica General Clinic, Thessaloniki, Greece|Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece|'Papageorgiou' General Hospital of Thessaloniki, Thessaloniki, Greece|Anassa General Clinic, Volos, Greece|Orszagos Onkologiai Intezet, Budapest N/a, Hungary|Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary|Bajcsy-Zsilinszky Kórház és Rendelőintézet, Budapest, Hungary|Jahn Ferenc Del-pesti Korhaz es Rendelointezet, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyõr, Hungary|Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Nyíregyháza, Hungary|Pecsi Tudomanyegyetem Klinikai Kozpont, Pécs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet, Szolnok, Hungary|Sujan Surgical Cancer Hospital &amp; Amravati Cancer Foundation, Amravati, India|Acharya Tulsi Regional Cancer Treatment Research Institute, Bikaner, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Birla Cancer Centre, Jaipur, India|Shatabdi Super Speciality Hospital, Nashik, India|BLK Super Specialty Hospital, New Delhi, India|Aakash Healthcare Super Speciality Hospital, New Delhi, India|Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India|Indira Gandhi Institute of Medical Sciences, Patna, India|Jehangir Clinical Development Center Pvt Ltd, Pune, India|Hillel Yaffe Medical Center, Hadera, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah University Hospita - Ein Kerem, Jerusalem, Israel|Ziv Medical Center, Safed, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari, Bari, Italy|Fondazione del Piemonte per I'Oncologia IRCC Candiolo, Candiolo, Italy|SPDC Villa Scassi, Genova, Italy|Ospedale San Martino, Genova, Italy|Ospedale S. Maria della Scaletta, Imola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale San Raffaele, Milan, Italy|Istituto Oncologico Veneto - IRCCS, Padova, Italy|Istituto Oncologico Veneto - IRCCS, Padova, Italy|Azienda Sanitaria Locale Salerno - Po Andrea Tortora Di Pagani, Pagani, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|ASL Napoli 2 Nord-SM delle Grazie Hospital, Pozzuoli, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Sant Andrea, Roma, Italy|Istituto Nazionale Tumori Regina Elena, Rome, Italy|Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Ospedale San Bortolo, Vicenza, Italy|Aso Co.,Ltd Iizuka Hospital, Iizuka, Japan|St.Marianna University Hospital, Kanagawa, Japan|Nara Medical University Hospital, Kashihara, Japan|Saitama Medical University Hospital, Kawagoe-Shi, Japan|Kimitsu Chuo Hospital, Kisarazu, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|JOHAS Osaka Rosai Hospital, Osaka, Japan|Sagamihara Kyodo Hospital, Sagamihara-Shi, Japan|Tokuyama Central Hospital, Shunan, Japan|Toranomon Hospital, Tokyo, Japan|Fujita Health University Hospital, Toyoake, Japan|Yamaguchi University Hospital, Ube, Japan|Yokohama City University Medical Center, Yokohama, Japan|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Namdong, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan-si, Korea, Republic of|CRYPTEX Investigacion clinica S.A De C.V, Ciudad de México, Mexico|Oncologia Integral Satelite, Ciudad de México, Mexico|Consultorio Privado Dr Jose Arturo Rodriguez Rivera, Guadalajara, Mexico|Centro De Estudio Y Prevencion Del Cancer, Juchitan De Zaragoza, Mexico|Dr. Marco Antonio Badillo Santoyo, Leon, Mexico|i Can Oncology Center, Monterrey, Mexico|Centro de Investigacion Clinica Chapultepec, Morelia, Mexico|Oncológico Potosino, San Luis Potosi, Mexico|Investigación Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapopan, Mexico|The Julius Center - Utrecht Science Park - Stratenum, Utrecht, Netherlands|Szpital Uniwersytecki nr 2 im. dr. Jana Biziela w Bydgoszczy, Bydgoszcz, Poland|Uniwersytet Medyczny w Lublinie - Katedra i Klinika Urologii i Onkologii Urologicznej, Lublin, Poland|Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego, Lublin, Poland|Samodzielny Publiczny Szpital Wojewodzki im. Papieza Jana Pawla II, Siedlce, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Poland|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka,, Słupsk, Poland|Centralny Szpital Kliniczny MSWiA w Warszawie, Warszawa, Poland|NZOZ Szpital Mazovia, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroclaw, Poland|Hospital Garcia de Orta, Almada, Portugal|Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal|Centro Hospitalar de Lisboa Central, Lisboa, Portugal|H. Santa Maria - Centro Hospitalar de Lisboa Norte, Lisboa, Portugal|Fundação Champalimaud, Lisbon, Portugal|Hospital de Sao Joao, Porto, Portugal|Centro Hospitalar de Trás os Montes e Alto-Douro, Vila Real, Portugal|Altlay Regional Oncology Dispensary, Barnaul, Russian Federation|Chelyabinsk Regional Clinical Center Of Oncology And Nuclear Medicine, Chelyabinsk, Russian Federation|Ivanovo Regional Oncology Dispensary, Ivanovo, Russian Federation|Krasnoyarsk Regional Oncology Dispensary, Krasnoyarsk, Russian Federation|N. N. Blokhin Russian Academy of Medical Sciences, Moscow, Russian Federation|Hertzen Oncology Research Institute, Moscow, Russian Federation|Moscow City Oncology Hospital № 62, Moscow, Russian Federation|A. Tsyb Medical Radiological Research Center, Obninsk, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|Hospital for War Veterans, Rostov, Russian Federation|Ryazan State Medical University named after I.P.Pavlov, Ryazan, Russian Federation|City Multiple-Discipline Hospital # 2, Saint Petersburg, Russian Federation|FSBHI RSCRST n.a. Ac. Granov A.M. of MoH, Saint Petersburg, Russian Federation|N.N. Petrov Research Institute Of Oncology, Saint Petersburg, Russian Federation|N.N. Petrov Research Institute Of Oncology, Saint Petersburg, Russian Federation|Leningrad Regional Oncology Dispensary, Saint-Petersburg, Russian Federation|Severo-Zapadnyy Gosudarstvennyy Meditsinskiy Universitet Im. I. I. Mechnikova, Sankt-Peterburg, Russian Federation|Ogarev Mordovian State University, Saransk, Russian Federation|State Medical Institution Oncological Center #2 of Healthcare Department at Krasnodar Regio, Sochi, Russian Federation|Multifunctional clinical medical center 'Medical city', Tyumen, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa|Life Wilgers Hospital, Pretoria, South Africa|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. Univ. Germans Trias I Pujol, Badalona, Spain|Fundacion Puigvert, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Puerta Del Mar, Cadiz, Spain|Hosp. Univ. Virgen de Las Nieves, Granada, Spain|Hosp. de Jerez de La Frontera, Jerez de la Frontera, Spain|Clinica Univ. de Navarra, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. de La Paz, Madrid, Spain|Hosp. Univ. Hm Monteprincipe, Madrid, Spain|Hosp. Virgen de La Victoria, Málaga, Spain|Hosp. Univ. Son Espases, Palma de Mallorca, Spain|Corporacio Sanitari Parc Tauli, Sabadell, Spain|Hosp. Univ. Infanta Sofia, San Sebastián De Los Reyes, Spain|Hosp. Univ. Marques de Valdecilla, Santander, Spain|Instituto Valenciano de Oncologia, Valencia, Spain|Hosp. Clinico Univ. de Valencia, Valencia, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taoyuan, Taiwan|Adana Baskent Yuregir Hospital, Adana, Turkey|Yildirim Beyazit University Medical Faculty Ankara Atatürk Research and Training Hospital, Ankara, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Dokuz Eylul Universitesi Tip Fakultesi, Balcova, Turkey|Bezmialem University Medical Faculty, Fatih, Turkey|Medical Park Gaziantep Hastanesi, Gaziantep, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey|Office Of Ahmet Cag Cal, MD, Izmir, Turkey|Izmir Medical Park Hospital, Izmir, Turkey|Inonu University Medical Faculty, Malatya, Turkey|Erciyes Univ MKD Hospital, Melikgazi, Turkey|T.C. Saglik Bakanligi Ankara Numune Egitim ve Arastirma Hastanesi, Seyhan, Turkey|Chernihivskyi oblasnyi onkolohichnyi dyspanser, Chernihiv, Ukraine|Chernivtsi Regional Clinical Hospital, Chernivtsi, Ukraine|SE Dnipropetrovsk Medical Academy, Dnipro, Ukraine|MIH V.I. Shapoval Regional Clinical Centre of Urology and Nephrology, Kharkiv, Ukraine|Kharkiv Regional Clinical Hospital, Kharkiv, Ukraine|Khersonsky Regional Oncology Center, Kherson, Ukraine|Main Military Clinical Hospital of MDU, Kiev, Ukraine|Asklepion LLC, Kiev, Ukraine|Krivorizhskiy Oncology Dispensary, Kriviy Rih, Ukraine|Oleksandrivska Clinical Hospital of Kyiv City, Infectional Department #2, Kyiv, Ukraine|Kyiv City Clinical Hospital #3, Kyiv, Ukraine|State Institution Academy Of Medical Sciences Of Ukraine, Kyiv, Ukraine|P.L. Shupyk National Medical Academy of Post-Graduate Education, Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Ukraine|Odeska miska klinichna likarnya No10, Odessa, Ukraine|Sumy Regional Clinical Oncology Centre, Sumy, Ukraine",,"https://ClinicalTrials.gov/show/NCT04658862"
439,"NCT00440310","Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases",,"Completed","Has Results","Liver Metastases|Colorectal Neoplasms|Neoplasm Metastasis|Neoplasm Recurrence, Local","Drug: Talaporfin sodium|Procedure: Percutaneous placement of device in liver metastases|Device: Interstitial light emitting diodes|Drug: FOLFOX4 regimen|Drug: FOLFIRI regimen","Overall Survival","Light Sciences Oncology","All","18 Years and older   (Adult, Older Adult)","Phase 3","483","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSO-OL006","February 2007","May 2011","October 2011","February 27, 2007","August 25, 2015","August 25, 2015","Landeskrankenhaus Feldkirch, Feldkirch, Austria|Krankenhaus Hietzing mit Neurologischen Zentrum Rosenhugel, Wien, Austria|Clinical Hospital Mostar, Internal Clinic, Department of Gastroenterology, Mostar, Bosnia and Herzegovina|Clinical Centre of the University of Sarajevo, Institute of Oncology, Sarajevo, Bosnia and Herzegovina|General Hospital Karlovac, Karlovac, Croatia|Clinical Centre Zagreb, Clinical Oncology, Zagreb, Croatia|General Hospital ""Sveti Duh"", Zagreb, Croatia|University Hospital Dubrava, Zagreb, Croatia|Ostalb-Klinikum Aalen Darmzentrum Medizinische Klinik I, Aalen, Germany|Helios Kliniken - Innere Medizin und Kardiologie, Borna, Germany|Katholisches Krankenhaus St. Johann Nepomuk, Erfurt, Germany|Johann Wolfgang Goethe Universitat, Frankfurt, Germany|Kliniken Ludwigsburg Bietigheim, Ludwigsburg, Germany|Bangalore Institute of Oncology, Bangalore, Karnataka, India|Mahavir Cancer Sansthan, Phulwarisharif, Patna, India|CIIGMA Institute of Medical Sciences, Aurangabad, India|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India|SEAROC Cancer Center, S. K. Soni hospital, Jaipur, India|Shatabdi Super Specialty Hospital, Mumbai, India|Cancer Clinic, Shreevardhan complex, Nagpur, India|Ruby Hall Clinic, Pune, India|Azienda Ospedaliero-Universitaria Riunti, Ancona, Italy|Azienda Ospedaliera Careggi U.O. Oncologia Medica, Firenze, Italy|Azienda Ospedaliera Universitaria Padovana, Padova, Italy|Policlinico Tor Vergata - Oncologia Medica, Rome, Italy|Riga Eastern Hospital, Latvian Oncology Center, Riga, Latvia|Centrum Onkologii - Instytut im. Marii Skłodowskiej -Curie Oddział w Krakowie, Kraków, Poland|Szpital Uniwersytecki CMUJ, Klinika Chirurgii Ogólnej i Gastroenterologicznej, Kraków, Poland|Klinika Chirurgii Onkologicznej, Lublin, Poland|Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Klinika Chirurgii Ogólnej i Onkologicznej, Szczecin, Poland|Centrum Onkologii - Instytut im. Marii Skłodowskiej -Curie, Klinika Nowotworów Jelita Grubego, Warszawa, Poland|Szpital Wojewódzki im. M. Kopernika, Klinika Chemioterapii Onkologicznej, Łódź, Poland|Fundeni Clinical Institute, Bucharest, Romania|Oncology Institute ""Ion Chircuta"", Cluj-Napoca, Romania|St. Spiridon University Emergency Hospital, Iasi, Romania|State Institution ""Altay"" Territorial Oncological Dispensary, Barmaul, Russian Federation|State Healthcare Institution ""Sverdlovsk' Regional Oncological Dispensary"", Ekaterinburg, Russian Federation|Main Military Clinical Hospital named after Burdenko attached to Ministry of Defense of Russian Federation, Moscow, Russian Federation|Municipal Cliical Hospital # 33 named after Ostroumov, Moscow, Russian Federation|Russian Oncological Scientific Center named after Blokhin, Moscow, Russian Federation|Privolzhsky District Medical Center, Nizhny Novgorod, Russian Federation|Central Research Institute of Roentgenology and Radiology, St. Petersburg, Russian Federation|Scientific Research Institution of Oncology, St. Petersburg, Russian Federation|State Educational Institution of High Professional Education ""Military-Medical Academy named after S.M. Kirov attached to Ministry of Defense of Russia"", St. Petersburg, Russian Federation|Tambov Regional Oncological Dispensary, Tambov, Russian Federation|State Healthcare Institution of Yaroslavl region, ""Regional clinical oncological hospital"", Yaroslavl, Russian Federation|Institute of Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Institute of Oncology, Sremska Kamenica, Serbia|Karolinska University Hospital, Stockholm, Sweden|Municipal Institution ""Cherkassy"" Regional Oncological Dispensary of Cherkassy, Cherkassy, Ukraine|Municipal Multiple-Discipline Clinical Hospital #4, Dnepropetrovsk, Ukraine|Donetsk Cancer Centre, Donetsk, Ukraine|Kharkov Regional Clinical Oncology Dispansery, Kharkov, Ukraine|The Central Hospital of the Ministry of Defense, Kyiv, Ukraine|Zaporozhye Medical Academy for postgraduate education, Zaporozhye, Ukraine",,"https://ClinicalTrials.gov/show/NCT00440310"
440,"NCT00094029","A Treatment Protocol for Patients With Gastrointestinal Stromal Tumor (GIST) Who May Derive Benefit From Treatment With SU011248",,"Approved for marketing","No Results Available","Gastrointestinal Neoplasm","Drug: Sutent",,"Pfizer","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"A6181036","September 2004","October 2011","October 2011","October 11, 2004",,"March 9, 2012","Pfizer Investigational Site, Duarte, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Santa Monica, California, United States|Pfizer Investigational Site, Washington, District of Columbia, United States|Pfizer Investigational Site, Gainesville, Florida, United States|Pfizer Investigational Site, Gainsville, Florida, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Niles, Illinois, United States|Pfizer Investigational Site, Park Ridge, Illinois, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, New Bedford, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Rochester, Minnesota, United States|Pfizer Investigational Site, Creve Coeur, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Burnos Aires, Argentina|Pfizer Investigational Site, Camperdown, New South Wales, Australia|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, Auchenflower, Queensland, Australia|Pfizer Investigational Site, Bedford Park, South Australia, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Ashford SA, Australia|Pfizer Investigational Site, Auchenflower QLD, Australia|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Aarhus C, Denmark|Pfizer Investigational Site, Herlev, Denmark|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Bordeaux Cedex, France|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Duesseldorf, Germany|Pfizer Investigational Site, Koeln, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Happy Valley, Hong Kong|Pfizer Investigational Site, Hong Kong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, New Delhi, Delhi, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Vellore, Tamil Nadu, India|Pfizer Investigational Site, Tel Hashomer, Israel|Pfizer Investigational Site, Tel-Aviv, Israel|Pfizer Investigational Site, Aviano (PN), Italy|Pfizer Investigational Site, Aviano, PN, Italy|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Candiolo (TO), Italy|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Groningen, Gr, Netherlands|Pfizer Investigational Site, Leiden, Netherlands|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, L'Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Lausanne, Switzerland|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Ratchatawi, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Inciralti / IZMIR, Turkey|Pfizer Investigational Site, Istanbul, Turkey|Pfizer Investigational Site, Leeds, England, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Newcastle upon Tyne, United Kingdom|Pfizer Investigational Site, Newcastle-Upon-Tyne, United Kingdom|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela",,"https://ClinicalTrials.gov/show/NCT00094029"
441,"NCT00917384","Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma",,"Completed","Has Results","Gastric Cancer|Adenocarcinoma","Biological: ramucirumab|Drug: Placebo|Other: Best Supportive Care (BSC)","Overall Survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants Who Are Progression-Free at Week 12 (PFS Rate)|Percentage of Participants With Objective Response (Objective Response Rate [ORR])|Duration of Response (DOR)|Change From Baseline in Quality of Life (QoL) as Measured by the European Organisation for Research and Treatment of Cancer Questionnaire (EORTC-QLQ-C30)|Number of Participants With Adverse Events|Maximum Concentration (Cmax) of IMC-1121B|Number of Participants Who Developed Antibodies Against IMC-1121B","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","355","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13893|2008-005964-15|CP12-0715|I4T-IE-JVBD","August 2009","July 2012","December 2015","June 10, 2009","October 16, 2014","September 25, 2019","ImClone Investigational Site, Bakersfield, California, United States|ImClone Investigational Site, La Jolla, California, United States|ImClone Investigational Site, Redlands, California, United States|ImClone Investigational Site, Chicago, Illinois, United States|ImClone Investigational Site, New Orleans, Louisiana, United States|ImClone Investigational Site, Boston, Massachusetts, United States|ImClone Investigational Site, Omaha, Nebraska, United States|ImClone Investigational Site, New York, New York, United States|ImClone Investigational Site, West Reading, Pennsylvania, United States|ImClone Investigational Site, Providence, Rhode Island, United States|ImClone Investigational Site, Charleston, South Carolina, United States|ImClone Investigational Site, Knoxville, Tennessee, United States|ImClone Investigational Site, Memphis, Tennessee, United States|ImClone Investigational Site, Houston, Texas, United States|ImClone Investigational Site, Buenos Aires, Argentina|ImClone Investigational Site, Capital Federal, Argentina|ImClone Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|ImClone Investigational Site, Ciudada Autonoma, Argentina|ImClone Investigational Site, Cordoba, Argentina|ImClone Investigational Site, Rosario, Argentina|ImClone Investigational Site, Wodonga, New South Wales, Australia|ImClone Investigational Site, Hobart, Tasmania, Australia|ImClone Investigational Site, East Melbourne, Victoria, Australia|ImClone Investigational Site, Perth, Western Australia, Australia|ImClone Investigational Site, Bedford Park, Australia|ImClone Investigational Site, St. Leonards, Australia|ImClone Investigational Site, Woodville, Australia|ImClone Investigational Site, Sarajevo, Bosnia and Herzegovina|ImClone Investigational Site, Barretos, Brazil|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Belo Horizonte, Brazil|ImClone Investigational Site, Brasilia, Brazil|ImClone Investigational Site, Curitiba, Brazil|ImClone Investigational Site, Curitiba, Brazil|ImClone Investigational Site, Florianopolis, Brazil|ImClone Investigational Site, Ijui, Brazil|ImClone Investigational Site, Lajeados, Brazil|ImClone Investigational Site, Londrina, Brazil|ImClone Investigational Site, Passo Fundo, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Porto Alegre, Brazil|ImClone Investigational Site, Sao Paulo, Brazil|ImClone Investigational Site, Edmonton, Alberta, Canada|ImClone Investigational Site, Montreal, Quebec, Canada|ImClone Investigational Site, Sherbrooke, Quebec, Canada|ImClone Investigational Site, Concepcion, Chile|ImClone Investigational Site, La Serena, Chile|ImClone Investigational Site, Santiago, Chile|ImClone Investigational Site, Monteria, Colombia|ImClone Investigational Site, Osijek, Croatia|ImClone Investigational Site, Pula, Croatia|ImClone Investigational Site, Slavonski Brod, Croatia|ImClone Investigational Site, Zagreb, Croatia|ImClone Investigational Site, Brno, Czechia|ImClone Investigational Site, Hradec Kralove, Czechia|ImClone Investigational Site, Liberec, Czechia|ImClone Investigational Site, Nova Ves pod Plesi, Czechia|ImClone Investigational Site, Olomouc, Czechia|ImClone Investigational Site, Pardubice, Czechia|ImClone Investigational Site, Prague, Czechia|ImClone Investigational Site, Praha 10, Czechia|ImClone Investigational Site, Praha 2, Czechia|ImClone Investigational Site, Pribram, Czechia|ImClone Investigational Site, Alexandria, Egypt|ImClone Investigational Site, Cairo, Egypt|ImClone Investigational Site, Guatemala, Guatemala|ImClone Investigational Site, Guatemala, Guatemala|ImClone Investigational Site, Hyderabad, Andh Prad, India|ImClone Investigational Site, Hyderabad, Andh Prad, India|ImClone Investigational Site, New Delhi, Delhi, India|ImClone Investigational Site, Bangalore, Karna, India|ImClone Investigational Site, Bangalore, Karna, India|ImClone Investigational Site, Cochin, Kerala, India|ImClone Investigational Site, Thiruvananthapuram, Kerala, India|ImClone Investigational Site, Trivandrum, Kerala, India|ImClone Investigational Site, Chennai, Kilpauk, India|ImClone Investigational Site, Bhopal, Madh Prad, India|ImClone Investigational Site, Indore, Madh Prad, India|ImClone Investigational Site, Mumbai, Mahara, India|ImClone Investigational Site, Nashik, Mahara, India|ImClone Investigational Site, Pune, Mahara, India|ImClone Investigational Site, Chennai, Tamilnadu, India|ImClone Investigational Site, Chennai, Tamilnadu, India|ImClone Investigational Site, Kolkata, W Bengal, India|ImClone Investigational Site, Kolkata, W Bengal, India|ImClone Investigational Site, Bangalore, India|ImClone Investigational Site, Chennai, India|ImClone Investigational Site, Hyderabad, India|ImClone Investigational Site, Hyderabad, India|ImClone Investigational Site, Kolkata, India|ImClone Investigational Site, Mumbai, India|ImClone Investigational Site, Mumbai, India|ImClone Investigational Site, Pune, India|ImClone Investigational Site, West Bengal, India|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Jakarta, Indonesia|ImClone Investigational Site, Sumatera Utara, Indonesia|ImClone Investigational Site, West Java, Indonesia|ImClone Investigational Site, Aviano, Italy|ImClone Investigational Site, Bologna, Italy|ImClone Investigational Site, Brescia, Italy|ImClone Investigational Site, Cremona, Italy|ImClone Investigational Site, Lido di Camaiore, Italy|ImClone Investigational Site, Lucca, Italy|ImClone Investigational Site, Meldola, Italy|ImClone Investigational Site, Mirano, Italy|ImClone Investigational Site, Noale, Italy|ImClone Investigational Site, Potenza, Italy|ImClone Investigational Site, Rimini, Italy|ImClone Investigational Site, Udine, Italy|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Seoul, Korea, Republic of|ImClone Investigational Site, Beirut, Lebanon|ImClone Investigational Site, Floriana, Malta|ImClone Investigational Site, Floriana, Malta|ImClone Investigational Site, Aguascelientes, Mexico|ImClone Investigational Site, Christchurch, New Zealand|ImClone Investigational Site, Cebu City, Philippines|ImClone Investigational Site, Pasig City, Philippines|ImClone Investigational Site, Gdansk, Poland|ImClone Investigational Site, Krakow, Poland|ImClone Investigational Site, Olsztyn, Poland|ImClone Investigational Site, Baia Mare, Romania|ImClone Investigational Site, Cluj Napoca, Romania|ImClone Investigational Site, Cluj Napoca, Romania|ImClone Investigational Site, Suceava, Romania|ImClone Investigational Site, Chelyabinsk, Russian Federation|ImClone Investigational Site, Kursk, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Moscow, Russian Federation|ImClone Investigational Site, Pyatigorsk, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, St. Petersburg, Russian Federation|ImClone Investigational Site, Cape Town, South Africa|ImClone Investigational Site, Alcorcon, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Barcelona, Spain|ImClone Investigational Site, Elche, Spain|ImClone Investigational Site, Madrid, Spain|ImClone Investigational Site, Santander, Spain|ImClone Investigational Site, Sevilla, Spain|ImClone Investigational Site, Kaohsiung, Taiwan|ImClone Investigational Site, Taichung County, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Taipei, Taiwan|ImClone Investigational Site, Bangkok, Thailand|ImClone Investigational Site, Chiang Mai, Thailand|ImClone Investigational Site, Rajathevee District, Thailand|ImClone Investigational Site, Adana, Turkey|ImClone Investigational Site, Gaziantep, Turkey|ImClone Investigational Site, Istanbul, Turkey|ImClone Investigational Site, Izmir, Turkey|ImClone Investigational Site, Bebington, Wirral, United Kingdom|ImClone Investigational Site, London, United Kingdom|ImClone Investigational Site, Sutton, United Kingdom|ImClone Investigational Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00917384"
442,"NCT00925600","Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss",,"Completed","Has Results","Cancer|Cataract|Low Bone Mineral Density|Osteopenia|Osteoporosis|Prostate Cancer","Biological: Denosumab|Biological: Placebo","Percentage of Participants With Lens Opacification Event Development or Progression by Month 12","Amgen","Male","30 Years to 120 Years   (Adult, Older Adult)","Phase 3","769","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","20080560|2009-012076-26","November 30, 2009","May 12, 2016","May 12, 2016","June 22, 2009","May 30, 2017","May 30, 2017","Research Site, Anaheim, California, United States|Research Site, Laguna Hills, California, United States|Research Site, Murrieta, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Diego, California, United States|Research Site, San Luis Obispo, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Englewood, Colorado, United States|Research Site, Middlebury, Connecticut, United States|Research Site, New Britain, Connecticut, United States|Research Site, Trinity, Florida, United States|Research Site, Coeur d'Alene, Idaho, United States|Research Site, Greenwood, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Kansas City, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Annapolis, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Greenbelt, Maryland, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Sartell, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Missoula, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Omaha, Nebraska, United States|Research Site, Berlin, New Jersey, United States|Research Site, Bricktown, New Jersey, United States|Research Site, Englewood, New Jersey, United States|Research Site, Lawrenceville, New Jersey, United States|Research Site, Mount Laurel, New Jersey, United States|Research Site, Albany, New York, United States|Research Site, Garden City, New York, United States|Research Site, Kingston, New York, United States|Research Site, New York, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Gastonia, North Carolina, United States|Research Site, Greenville, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Bala-Cynwyd, Pennsylvania, United States|Research Site, Lancaster, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Myrtle Beach, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Richmond, Virginia, United States|Research Site, Salem, Virginia, United States|Research Site, Wahroonga, New South Wales, Australia|Research Site, Herston, Queensland, Australia|Research Site, Bentleigh East, Victoria, Australia|Research Site, Ringwood East, Victoria, Australia|Research Site, Pleven, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Kelowna, British Columbia, Canada|Research Site, Vancouver, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Barrie, Ontario, Canada|Research Site, Brampton, Ontario, Canada|Research Site, Brantford, Ontario, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Guelph, Ontario, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, North Bay, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Oakville, Ontario, Canada|Research Site, Scarborough, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Laval, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Benesov, Czechia|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jindrichuv Hradec, Czechia|Research Site, Kromeriz, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Praha 6, Czechia|Research Site, Usti nad Labem, Czechia|Research Site, Zlin, Czechia|Research Site, Lyon Cédex 3, France|Research Site, Paris Cedex 5, France|Research Site, Alexandroupoli, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Larissa, Greece|Research Site, Patra, Greece|Research Site, Thessaloniki, Greece|Research Site, Thessaloniki, Greece|Research Site, Baja, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Miskolc, Hungary|Research Site, Nyiregyhaza, Hungary|Research Site, Szeged, Hungary|Research Site, Ahmedabad, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Aurangabad, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Ludhiana, Punjab, India|Research Site, Madurai, Tamil Nadu, India|Research Site, Kolkata, West Bengal, India|Research Site, Jelgava, Latvia|Research Site, Riga, Latvia|Research Site, Riga, Latvia|Research Site, Distrito Federal, Mexico|Research Site, Distrito Federal, Mexico|Research Site, Christchurch, New Zealand|Research Site, Takapuna, North Shore City, New Zealand|Research Site, Tauranga, New Zealand|Research Site, Whangarei, New Zealand|Research Site, Gdansk, Poland|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Gdynia, Poland|Research Site, Katowice, Poland|Research Site, Myslowice, Poland|Research Site, Opole, Poland|Research Site, Poznan, Poland|Research Site, Rzeszow, Poland|Research Site, Siedlce, Poland|Research Site, Slupsk, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Ivanovo, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Rostov-na-Donu, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kosice, Slovakia|Research Site, Martin, Slovakia|Research Site, Nitra, Slovakia|Research Site, Trencin, Slovakia|Research Site, Celje, Slovenia|Research Site, Ljubljana, Slovenia|Research Site, Slovenj Gradec, Slovenia|Research Site, Paarl, Western Cape, South Africa|Research Site, George, South Africa|Research Site, Kempton Park, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Tygerberg, South Africa|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00925600"
443,"NCT01154140","A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung","PROFILE 1014","Completed","Has Results","Non Squamous Lung Cancer","Drug: treatment","Progression-Free Survival (PFS) Based on IRR|Overall Survival (OS)|Overall Survival Probability at Month 12 and 18|Objective Response Rate (ORR): Percentage of Participants With Objective Response as Assessed by IRR|Duration of Response (DR) Based on IRR|Time to Tumor Response (TTR) Based on IRR|Percentage of Participants With Disease Control at Week 12 Based on IRR|Time to Progression (TTP) Based on IRR|Time to Intracranial Progression (IC-TTP) Based on IRR|Time to Extracranial Progression (EC-TTP) Based on IRR|Percentage of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Percentage of Participants With Adverse Events (AEs) According to Maximum Severity|Plasma Predose Concentration (Ctrough) of Crizotinib and Its Metabolite PF-06260182|Percentage of Participants For Each Anaplastic Lymphoma Kinase (ALK) Gene Fusion Variants|Objective Response Rate (ORR) of Anaplastic Lymphoma Kinase (ALK) Variant Groups Based on IRR|Time to Deterioration (TTD) in Chest Pain, Dyspnea or Cough|Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Change From Baseline in Lung Cancer Symptom Scores as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13)|Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)- Visual Analog Scale (VAS)|Percentage of Participants With Hospital Admissions-Healthcare Resource Utilization (HCRU)|Percentage of Participants With Laboratory Test Abnormalities By Maximum Severity: National Cancer Institute Common Terminology Criteria for Adverse Event (Version 4.0) Grade 1 to 4 Hematological Test Abnormalities|Percentage of Participants With Laboratory Test Abnormalities By Maximum Severity: National Cancer Institute Common Terminology Criteria for Adverse Event (Version 4.0) Grade 1 to 4 Chemistry Test Abnormalities","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","343","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A8081014|2010-021336-33|XALCORI","January 13, 2011","November 30, 2013","November 30, 2016","June 30, 2010","January 5, 2015","November 6, 2017","Tower Cancer Research Foundation, Beverly Hills, California, United States|Tower Hematology Oncology Medical Group, Beverly Hills, California, United States|CCTAP, Fontana, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Loma Linda University Cancer Center (LLUCC)-Schuman Pavilion, Loma Linda, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|CCTAP, Los Angeles, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|CCTAP, San Diego, California, United States|Georgetown University Hospital, Washington, D.C., District of Columbia, United States|Research Pharmacy, Georgetown University Medical Center, Washington, D.C., District of Columbia, United States|Lynn Cancer Institute Center for Hematology Oncology, Boca Raton, Florida, United States|Florida Hospital, Orlando, Florida, United States|Cancer Institute of Florida, Orlando, Florida, United States|Investigational Drug Services, Orlando, Florida, United States|Georgia Cancer Specialists, Athens, Georgia, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|Georgia Cancer Specialists, Decatur, Georgia, United States|Georgia Cancer Specialists, Macon, Georgia, United States|Georgia Cancer Specialists, Marietta, Georgia, United States|Georgia Cancer Specialists, Sandy Springs, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Al Fisher, Pharm D., Harvey, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Monroe Medical Associates, Harvey, Illinois, United States|Monroe Medical Associates, Tinley Park, Illinois, United States|Indiana University Hospital, Indianapolis, Indiana, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Lois and Eskenazi Hospital, Indianapolis, Indiana, United States|Monroe Medical Association, Munster, Indiana, United States|The Community Hospital, Munster, Indiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Maine Center for Cancer Medicine, Biddeford, Maine, United States|Maine Center for Cancer Medicine, Brunswick, Maine, United States|Maine Center for Cancer Medicine, Sanford, Maine, United States|Maine Center for Cancer Medicine, Scarborough, Maine, United States|Kresge Eye Institute, Bingham Farms, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Kresge Eye Institute, Detroit, Michigan, United States|Karmanos Cancer Institute at Farmington Hills, Farmington Hills, Michigan, United States|Siteman Cancer Center - West County, Creve Coeur, Missouri, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University Center for Advanced Medicine Infusion Center Pharmacy, Saint Louis, Missouri, United States|Siteman Cancer Center, Saint Peters, Missouri, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hematology-Oncology Associates of Northern New Jersey, Morristown, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|UNM Eye Clinic, Albuquerque, New Mexico, United States|Memorial Medical Center, Las Cruces, New Mexico, United States|NSLIJ Health System/Monter Cancer Center, Lake Success, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Long Island Jewish Medical Center, New Hyde Park, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|OHSU Knight Cancer Institute, Beaverton, Oregon, United States|OHSU Knight Cancer Institute, Gresham, Oregon, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|OHSU Knight Cancer Institute, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|OHSU Knight Cancer Institute, Tualatin, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Vincent Armenio, East Providence, Rhode Island, United States|Pharma Resource, East Providence, Rhode Island, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|Vanderbilt Oncology Pharmacy, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|UT Southwestern Medical Center - Simmons Cancer Center Pharmacy, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|UT Southwestern University Hospital - William P. Clements, Jr., Dallas, Texas, United States|UT Southwestern University Hospital - Zale Lipshy, Dallas, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Macarthur Cancer Therapy Centre, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|The Prince Charles Hospital, Chermside, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|The Royal Brisbane & Womens Hospital, Herston, Queensland, Australia|Parkhaven Medical Center, Hyde Park, Queensland, Australia|Department of Medical Oncology, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, Department of Haematology and Medical Oncology, East Melbourne, Victoria, Australia|Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia|Klinikum Wels-Grieskirchen, Wels, Austria|UZ Antwerpen-Pneumologie, Edegem, Antwerp, Belgium|Grand Hopital de Charleroi -Site Notre Dame, Charleroi, Hainaut, Belgium|Cliniques Universitaires St Luc, Brussels, Belgium|Universitair Ziekenhuis Brussel / Medische Oncologie, Brussel, Belgium|Institut Jules Bordet, Centre des Tumeurs de l'ULB, Bruxelles, Belgium|Universitair Ziekenhuis Gent (U.Z. Gent), Gent, Belgium|Centre Hospitalier Universitaire de Liege, Liege, Belgium|Department of Pulmonary Diseases AZ Delta, Roeselare, Belgium|Instituto Nacional de Cancer - INCA, Rio de Janeiro, RJ, Brazil|Associacao Hospital de Caridade de Ijui, Ijui, RS, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|Fundacao Pio XII Hospital de Cancer de Barretos, Barretos, São Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|R.S. McLaughlin Durham Regional Cancer Centre, Oshawa, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University Health Centre (MUHC), Glen Site, Cedars Cancer Centre, Montreal, Quebec, Canada|Institut universitaire de cardiologie et de pneumologie de Quebec (IUCPQ), Ste-Foy, Quebec, Canada|Instituto Clinico Oncologico del Sur, Temuco, Cautin, Chile|Instituto Nacional del Cancer, Santiago, RM, Chile|Hospital Clinico Universidad de Chile, Seccion de Oncologia, Independencia, Santiago, Rm, Chile|307 Hospital of PLA, Beijing, Beijing, China|Oncology Center, Guangdong General Hospital, Guangzhou, Guangdong, China|Union Hospital, Tongji Medical College of Huazhong University of Science & Technology/Cancer Center, Wuhan, Hubei, China|No.81 Hospital of the PLA, Nanjing, Jiangsu, China|Oncology Department, West China Hospital of Sichuan University, Chengdu, Sichuan, China|Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China|Shanghai Chest Hospital/Department of Pulmonary Medicine, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Shanghai Pulmonary Hospital/Dept. of Oncology, Shanghai, China|Helsingin yliopistollinen keskussairaala, Meilahden kolmiosairaala,Keuhkosairauksien poliklinikka, Helsinki, Finland|Satakunnan keskussairaala/Keuhkosairauksien osasto A4, Pori, Finland|Tampereen yliopistollinen sairaala, Tampere, Finland|Hopital Avicenne, Bobigny Cedex, France|CHU de Caen, Caen Cedex, France|CHU Grenoble, Grenoble Cedex, France|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon Cedex 08, France|APHM - Hopital Nord / Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques, Marseille Cedex 20, France|Hopital Arnaud de Villeneuve / CHU de Montpellier, Montpellier, France|Hopital Tenon, Service de Pneumologie, Paris cedex 20, France|Nouvel Hopital Civil - HSU - Pôle de Pathologie Thoracique - Service de Pneumologie, Strasbourg, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Charite - Universitaetsmedizin Berlin, Campus Mitte, Berlin, Germany|Thoraxklinik am Universitaetsklinikum Heidelberg, Heidelberg, Germany|St.Vincentius-Kliniken Karlsruhe, Karlsruhe, Germany|UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|HSK Dr.- Horst-Schmidt-Kliniken GmbH,, Wiesbaden, Germany|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong|The Gujarat Cancer & Research Institute (M.P Shah Cancer Hospital),, Ahmedabad,, Gujarat, India|Tata Memorial Centre, Tata Memorial Hospital,, Mumbai, Maharashtra, India|Aseptic Compounding Unit, Dublin, Ireland|Department of Medical Oncology, Dublin, Ireland|Struttura Operativa Complessa Oncologia Medica A Centro di Riferimento Oncologico, Aviano, Pordenone, Italy|Farmacia, Aviano (PN), Italy|Istituto dei tumori Giovanni Paolo II, Bari, Italy|Unità Operativa di Oncologia Medica Azienda USL Città di Bologna, Bologna, Italy|Azienda Ospedaliero-Universitaria ""Mater Domini"", Catanzaro, Italy|Unità Operativa di Farmacia - Campus Salvatore venuta, Catanzaro, Italy|Ospedale Civile Azienda USL Toscana Nord Ovest, Livorno, Italy|Unità Operativa Farmacia Ospedaliera PO di Livorno, Livorno, Italy|Fondazione IRCCS Istituto Nazionale Tumori, Struttura Complessa di Medicina Oncologica 1, Milano, Italy|Farmacia Istituto Europeo di Oncologia IRCCS, U.O. Farmacia, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Ospedale Niguarda Ca'Granda, Divisione Oncologia Medica Falck, Milano, Italy|A.O.R.N. Ospedale Dei Colli - Monaldi, Napoli, Italy|Farmacia, Napoli, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|S.C. Farmacia Ospedaliera , Azienda Ospedaliero Universitaria San Luigi Gonzaga, Orbassano (TO), Italy|Oncologia Medica, Azienda Ospedaliero- Universitaria di Parma, Parma, Italy|Farmacia Ospedaliera, Perugia, Italy|SC Oncologia Medica, Ospedale Santa Maria della Misericordia, Perugia, Italy|IRCCS -Arcispedale S. Maria Nuova Tecnologie Avanzate e Modelli Assistenziali in Oncologia, Reggio Emilia, Italy|Istituto Regina Elena, Struttura Complessa Oncologia Medica A, Roma, Italy|Azienda Ospedaliera San Camillo Forlanini-Padiglione Flaiani, Roma, Italy|Farmacia Interna, Roma, Italy|Unita Operativa, Oncologia Medica, Istituto di Medicina Interna e Geriatria, Roma, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Hyogo Cancer Center, Akashi, Hyogo, Japan|Kanagawa Cardiovascular and Respiratory Center, Yokohama, Kanagawa, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Okayama University Hospital, Okayama-city, Okayama, Japan|Kinki University Hospital, Osakasayama-shi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|National Hospital Organization Yamaguchi-Ube Medical Center, Ube-shi, Yamaguchi, Japan|National Hospital organization Kyushu Cancer Center, Fukuoka, Japan|Kyushu University Hospital Respiratory Medicine, Fukuoka, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Sungkyunkwan Univ. School of Medicine, Seoul, Korea, Republic of|Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg|Instituto Nacional de Cancerologia, Mexico, D.f., Mexico|Jeroen Bosch Ziekenhuis, 's Hertogenbosch, NB, Netherlands|VUMC, Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht / afdeling longziekten en tuberculose, Maastricht, Netherlands|Oslo universitetssykehus HF - Radiumhospitalet, Oslo, Norway|Clinica Anglo Americana/Centro de Investigacion Oncologia CAA, San Isidro, Lima, Peru|Centro Hospitalar e Universitario de Coimbra - Hospital Geral, Coimbra, Portugal|Instituto Português de Oncologia de Lisboa, Prof. Francisco Gentil E.P.E., Lisboa, Portugal|Centro Hospitalar de Lisboa Norte - Hospital Pulido Valente, Lisboa, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Portugal|Russian Oncological Research Center N.N. Blokhin, Moscow, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|First Saint-Petersburg State Medical University n.a. I.P. Pavlov, Saint-Petersburg, Russian Federation|First Saint-Petersburg State Medical University n.a. I.P., Saint-Petersburg, Russian Federation|Russian Scientific Center of Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|National University Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Parkway Cancer Centre, Singapore, Singapore|OncoCare Cancer Centre, Singapore, Singapore|University of Witwatersrand Oncology, Johannesburg, Gauteng, South Africa|Rondebosch Oncology Centre, Rondebosch Medical Centre, Cape Town, South Africa|Hospital General Universitario de Elche, Elche, Alicante, Spain|Hospital Universitario Virgen Macarena, Sevilla, Andalucia, Spain|Hospital Clinico Universitario Lozano Blesa, Zaragoza, Aragon, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Catalunya, Spain|Hospital Universitari Vall D'Hebron, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario Virgen de La Victoria, Malaga, Spain|Universitaetsspital Basel, Basel, Switzerland|Luzerner Kantonsspital (LUKS), Luzern, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Chang Gung Medical Foundation, Kaohsiung Branch, Kaohsiung City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Comprehensive Cancer Center, Taichung, Taiwan|Chang Gung Medical Foundation, LinKou Branch, Taoyuan, Taiwan|City Multiple-Discipline Clinical Hospital #4,, Dnipropetrovsk, Ukraine|City Multiple-Discipline Clinical Hospital #4, Dnipropetrovsk, Ukraine|Department of Oncology and Medical Radiology, SI ""DMA of MOH, Ukraine, Dnipropetrovsk, Ukraine|Kyiv City Clinical Oncologic Center/Department of Chemotherapy, Kyiv, Ukraine|Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine|Addenbrooke's Hospital, Oncology Centre, Cambridge, Cambridgeshire, United Kingdom|Lister Hospital, Stevenage, Hertfordshire, United Kingdom|Queen Elizabeth II Hospital, Welwyn Garden City, Hertfordshire, United Kingdom|Spire Manchester Hospital, Manchester, Lancashire, United Kingdom|Mount Vernon Hospital, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom|NHS Greater Glasgow and Clyde Health Board, Beatson West of Scotland Cancer Centre,, Glasgow, Scotland, United Kingdom|Ross Hall Hospital, Glasgow, Scotland, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, United Kingdom|The Christie Hospital NHS Foundation Trust, Department of Medical Oncology, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01154140"
444,"NCT00890305","Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone",,"Completed","No Results Available","Metastatic Colorectal Cancer","Drug: CT-011|Drug: FOLFOX","The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone.|Composite of safety, tolerability, pharmacokinetics and immunogenicity of CT-011.|Anti tumor activity of the antibody.|Objective response rate by RECIST.|Progression-free survival rates.|Response duration.|Overall survival.|Tumor and immunological markers.","Medivation, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","171","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-2008-01|2009-014593-18","May 2009","May 2012","March 2013","April 29, 2009",,"July 8, 2015","The Cancer Center of Huntsville, PC, Huntsville, Alabama, United States|University of South Florida, Tampa, Florida, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Signal Point Clinical Research Center, Middletown, Ohio, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|MHAT ""Dr. Tota Venkova"", Gabrovo, Bulgaria|InterDistrict Dispensary in Oncology Diseases with Stationary-Ruse, EOOD, Ruse, Bulgaria|InterDistrict Dispensary in Oncology Diseases with Stationary, Shumen, Bulgaria|Multiprofile Hospital for Active Treatment ""Tsaritza Joanna"", Sofia, Bulgaria|Specialized Hospital for Active Treatment for Oncology, Sofia, Bulgaria|InterDistrict Dispensary of Oncology Diseases with Stationary, Varna, Bulgaria|Multiprofile Hospital for Active Treatment ""Sv. Marina"", EAD,, Varna, Bulgaria|Regional Cancer Centre, Indira Gandhi Institute of Medical Sciences, Sheikhpura, Patna, Bihar, India|Cancer Clinic, Nagpur, Maharashtra, India|Curie Manavata Cancer Centre, Opp., Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|G. Kuppuswamy Naidu Memorial Hospital, Pappanaickenpalayam, Coimbatore, Tamilnadu, India|Hospital Almanzor Aguinaga Asenjo - Chiclayo, Chiclayo, Peru|Clinica Ricardo Palma, Lima, Peru|Hospital Regional nivel III Cayetano Heredia Essalud Piura, Piura, Peru|Ponce School of Medicine/CAIMED Center, Ponce, Puerto Rico|Fundacion de Investigacion de Diego, Santurce, Puerto Rico|""Prof. Dr. Ion Chiricuţă"" Institute of Oncology, Cluj-Napoca, Romania|Clinical Emergency Hospital - Oncology Department, Constanta, Romania|Oncolab SRL, No. 1, Craiova, Romania|Center of Medical Oncology, Iasi, Romania|Clinical Hospital Pelican Oradea, Oradea, Romania|No. 1 City Hospital, Ploiesti, Romania|""Sf. Ioan cel Nou"" Clinical Emergency County Hospital, Suceava, Romania|Clinic of Oncology - Radiotherapy, Tg. Mures, Romania",,"https://ClinicalTrials.gov/show/NCT00890305"
445,"NCT01955824","A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy",,"Completed","No Results Available","Lung Cancer|Tuberculosis|Sarcoidosis|Interstitial Lung Disease","Drug: 1% lignocaine|Drug: 2% lignocaine","Cough suppression (by Operator and Patient)|Pain control","Postgraduate Institute of Medical Education and Research","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Bron/Lig/Tr-1","May 2014","November 2014","November 2014","October 8, 2013",,"December 30, 2014","Bronchoscopy suite, PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01955824"
446,"NCT00471146","Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.",,"Completed","Has Results","Carcinoma, Pancreatic Ductal","Drug: AG-013736|Drug: Gemcitabine|Drug: placebo","Overall Survival (OS)|Progression Free Survival (PFS)|Percentage of Participants With Objective Response (OR)|Duration of Response (DR)|Change From Baseline in European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ- C30) Score|Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Pancreatic 26 (EORTC QLQ- PAN26) Score|Change From Baseline Brief Pain Inventory-short Form (BPI-sf) Score|Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) Health State Profile|Change From Baseline in Euro QoL Questionnaire- 5 Dimension (EQ-5D) VAS Score|Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","A4061028","July 2007","January 2009","November 2010","May 9, 2007","July 16, 2012","July 16, 2012","Pfizer Investigational Site, Antioch, California, United States|Pfizer Investigational Site, Corona, California, United States|Pfizer Investigational Site, Glendora, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, La Jolla, California, United States|Pfizer Investigational Site, LaVerne, California, United States|Pfizer Investigational Site, Pamona, California, United States|Pfizer Investigational Site, Pasadena, California, United States|Pfizer Investigational Site, Pleasent Hill, California, United States|Pfizer Investigational Site, Pomona, California, United States|Pfizer Investigational Site, Rancho Cucamonga, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, Redlands, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Leandro, California, United States|Pfizer Investigational Site, West Covina, California, United States|Pfizer Investigational Site, Hollywood, Florida, United States|Pfizer Investigational Site, Pembroke Pines, Florida, United States|Pfizer Investigational Site, Stuart, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Augusta, Georgia, United States|Pfizer Investigational Site, Coeur D'Alene, Idaho, United States|Pfizer Investigational Site, Alton, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Beech Grove, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Jeffersonville, Indiana, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Shelbyville, Kentucky, United States|Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, Baton Rouge, Louisiana, United States|Pfizer Investigational Site, Annapolis, Maryland, United States|Pfizer Investigational Site, Burlington, Massachusetts, United States|Pfizer Investigational Site, Peabody, Massachusetts, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Columbus, Mississippi, United States|Pfizer Investigational Site, Corinth, Mississippi, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, Billings, Montana, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Mineola, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Canton, Ohio, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Sylvania, Ohio, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Round Rock, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Lynchburg, Virginia, United States|Pfizer Investigational Site, Everett, Washington, United States|Pfizer Investigational Site, Federal Way, Washington, United States|Pfizer Investigational Site, Kennewick, Washington, United States|Pfizer Investigational Site, Lakewood, Washington, United States|Pfizer Investigational Site, Puyallup, Washington, United States|Pfizer Investigational Site, Tacoma, Washington, United States|Pfizer Investigational Site, Bahia Blanca, Buenos Aires, Argentina|Pfizer Investigational Site, La Plata, Buenos Aires, Argentina|Pfizer Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|Pfizer Investigational Site, Santa Fe, Argentina|Pfizer Investigational Site, St. Leonards, New South Wales, Australia|Pfizer Investigational Site, Wollongong, New South Wales, Australia|Pfizer Investigational Site, Clayton, Victoria, Australia|Pfizer Investigational Site, East Bentleigh, Victoria, Australia|Pfizer Investigational Site, Salzburg, Austria|Pfizer Investigational Site, Wels, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Brussel, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Moncton, New Brunswick, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, Kingston, Ontario, Canada|Pfizer Investigational Site, Oshawa, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Clichy cedex, France|Pfizer Investigational Site, La Chaussee Saint Victor, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Montpellier Cedex 02, France|Pfizer Investigational Site, PARIS Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Pessac Cedex, France|Pfizer Investigational Site, Rouen, France|Pfizer Investigational Site, St Herblain Cedex, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Greifswald, Germany|Pfizer Investigational Site, Magdeburg, Germany|Pfizer Investigational Site, Mannheim, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Oldenburg, Germany|Pfizer Investigational Site, Ulm, Germany|Pfizer Investigational Site, Shatin, NT, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Kaposvar, Hungary|Pfizer Investigational Site, Szentes, Hungary|Pfizer Investigational Site, Zalaegerszeg, Hungary|Pfizer Investigational Site, Ahmedabad, Gujarat, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Cochin, Kerala, India|Pfizer Investigational Site, Andhra, Pradesh, India|Pfizer Investigational Site, Chennai, Tamil Nadu, India|Pfizer Investigational Site, Dublin 24, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Catania, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Verona, Italy|Pfizer Investigational Site, Nagoya, Aichi, Japan|Pfizer Investigational Site, Chiba-shi, Chiba-ken, Japan|Pfizer Investigational Site, Chiba city, Chiba, Japan|Pfizer Investigational Site, Kashiwa-shi, Chiba, Japan|Pfizer Investigational Site, Fukuoka-shi, Fukuoka-ken, Japan|Pfizer Investigational Site, Yokohama-shi, Kanagawa, Japan|Pfizer Investigational Site, Osaka-shi, Osaka-fu, Japan|Pfizer Investigational Site, Suntougun, Shizuoka, Japan|Pfizer Investigational Site, Chuo-ku, Tokyo, Japan|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Amsterdam, Noord Holland, Netherlands|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Omsk, Russian Federation|Pfizer Investigational Site, Sochi, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Observatory, South Africa|Pfizer Investigational Site, Parktown, South Africa|Pfizer Investigational Site, Port Elizabeth, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Sandton, South Africa|Pfizer Investigational Site, Palma de Mallorca, Islas Baleares, Spain|Pfizer Investigational Site, Mostoles, Madrid, Spain|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Las Palmas de Gran Canaria, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Malaga, Spain|Pfizer Investigational Site, Santa Cruz de Tenerife, Spain|Pfizer Investigational Site, Toledo, Spain|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Winterthur, Switzerland|Pfizer Investigational Site, Kuei-Shan Jsoamg, Taoyuan County, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Whitchurch, Cardiff, United Kingdom|Pfizer Investigational Site, Maidstone, Kent, United Kingdom|Pfizer Investigational Site, Leicester, Leicestershire, United Kingdom|Pfizer Investigational Site, Withington, Manchester, United Kingdom|Pfizer Investigational Site, Northwood, Middlesex, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Southhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00471146"
447,"NCT00034268","A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: LY900003",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6428|H7X-MC-JVAA","March 2002",,,"April 25, 2002",,"July 19, 2006","Hot Springs, Arkansas, United States|Springdale, Arkansas, United States|Los Angeles, California, United States|Santa Rosa, California, United States|Denver, Colorado, United States|Fort Collins, Colorado, United States|Wilmington, Delaware, United States|Tucker, Georgia, United States|Indianapolis, Indiana, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Robbinsdale, Minnesota, United States|Latham, New York, United States|New York, New York, United States|Arlington, Texas, United States|Dallas, Texas, United States|Abingdon, Virginia, United States|Marshfield, Wisconsin, United States|Ciudad De Buenos Aires, Argentina|Mendoza, Argentina|Brasschaat, Belgium|Edegem, Belgium|Liege, Belgium|Merksem, Belgium|Oostende, Belgium|Las Condes, Santiago, Chile|Brest, France|Nice Cedex 1, France|Paris Cedex 20, France|Pessac Cedex, France|Rouen Cedex, France|Saint Herblain Cedex, France|Tours Cedex, France|Vandoeuvre Les Nancy Cedex, France|Frankfurt, Hessen, Germany|Augsburg, Germany|Berlin, Germany|Freiburg, Germany|Grobhansdorf, Germany|Hamburg, Germany|Heidelberg, Germany|Hofheim, Germany|Koin, Germany|Leipzig, Germany|Munchen, Germany|Neustadt/Suedharz, Germany|Trier, Germany|Ulm, Germany|Budapest, Hungary|Bangalore, Karnataka, India|Mumbai, Maharashtra, India|Pune, Maharashtra, India|Ludhiana, Punjab, India|New Dehli, India|Rozzano, Milano, Italy|Perugia, Italy|Pisa, Italy|Ravenna, Italy|Roma, Italy|Amsterdam, Netherlands|Arnhem, Netherlands|Den Bosch, Netherlands|Groningen, Netherlands|Nieuwegien, Netherlands|Zwolle, Netherlands|Oslo, Norway|Otwock, Mazowieckie, Poland|Krakow-Nowa Huta, Poland|Warszawa, Poland|Wroclaw, Poland|Bayamon, Puerto Rico|Ponce, Puerto Rico|Cluj Napoca, Cluj, Romania|Moscow, Russian Federation|Overport, Durban, South Africa|Arcadia, Gauteng, South Africa|Durban, South Africa|Parklands, South Africa|Tygerberg, South Africa|Oviedo, Asturias, Spain|Badalona, Barcelona, Spain|Sabadell, Barcelona, Spain|Valencia, Valenica, Spain|Barakaldo, Vizcaya, Spain|Alicante, Spain|Barcelona, Spain|Madrid, Spain|Palma De Mallorca, Spain|Zaragoza, Spain|Linkoping, Sweden|Lund, Sweden|Stockhlom, Sweden|Zurich, Switzerland|Tao-Yuan, Kuei-Shan, Taiwan|Taichung, Taiwan, Province of China, Taiwan|Taipei, Taiwan|Hull, East Yorkshire, United Kingdom|London, Greater London, United Kingdom|Southampton, Hampshire, United Kingdom|Nottingham, Nottinghamshire, United Kingdom|Glasgow, Scotland, United Kingdom|Cardiff, South Glamorgan, United Kingdom|Newcastle-Upon-Tyne, Tyneside, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00034268"
448,"NCT04139317","Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%",,"Active, not recruiting","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: Capmatinib|Biological: Pembrolizumab","Progression-free survival (PFS) based on local investigator assessment as per RECIST 1.1|Objective response rate (ORR) based on local investigator assessment as per RECIST 1.1|Disease control rate (DCR) based on local investigator assessment as per RECIST 1.1|Time-to-response (TTR) based on local investigator assessment as per RECIST 1.1|Duration of response (DOR) based on local investigator assessment as per RECIST 1.1|Overall survival (OS)|Antidrug antibodies (ADA) of pembrolizumab|AUC of capmatinib derived from plasma capmatinib concentration|Ctrough of pembrolizumab derived from serum pembrolizumab concentration|Cmax of capmatinib derived from plasma capmatinib concentration|Tmax of capmatinib derived from plasma capmatinib concentration|Incidence of adverse events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC280I12201","January 22, 2020","January 14, 2022","February 16, 2023","October 25, 2019",,"April 26, 2022","Novartis Investigative Site, Wollongong, New South Wales, Australia|Novartis Investigative Site, North Adelaide, South Australia, Australia|Novartis Investigative Site, Shepparton, Victoria, Australia|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Yvoir, Belgium|Novartis Investigative Site, Quebec, Canada|Novartis Investigative Site, Ostrava Vitkovice, Czechia|Novartis Investigative Site, Lille, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Shatin, New Territories, Hong Kong|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Yokohama-city, Kanagawa, Japan|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Zwolle, Netherlands|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Changhua, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04139317"
449,"NCT00530764","A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy.","SPRAY","Completed","Has Results","Palliative Care|Pain|Cancer","Drug: Sativex Low Dose|Drug: Sativex Medium Dose|Drug: Sativex High Dose","Number of Patients With at Least 30% Improvement in Numerical Rating Scale (NRS) Average Pain Score From Baseline|Change in Cumulative Average Pain Response Curves|Change in Mean Daily NRS Pain Score (Average Pain).|Change in Mean Daily NRS Pain Score (Worst Pain).|Change in Sleep Disruption NRS|Change in Brief Pain Inventory - Short Form (BPI-SF)|Change in Patient Assessment of Constipation Quality of Life (PAC-QoL)|Change in Patient Global Impression of Change - PGIC|Change in Montgomery Asberg Depression Rating Scale (MADRS)","Jazz Pharmaceuticals|Quintiles, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","GWCA0701","November 2007","January 2010","January 2010","September 17, 2007","June 17, 2011","June 20, 2013","Cancer Care Center of Tuscaloosa, Tuscaloosa, Alabama, United States|Desert Oasis Cancer Center, Casa Grande, Arizona, United States|Pacific Coast Hematology/Oncology Medical Group, Inc., Fountain Valley, California, United States|Office of Dr. Ronald Yanagihara, Gilroy, California, United States|University of California San Diego, La Jolla, California, United States|Loma Linda University, Loma Linda, California, United States|Florida Institute of Medical Research, Jacksonville, Florida, United States|Clinical Pharmacology Services, Tampa, Florida, United States|Center of Hope for Cancer and Blood Disorders, Riverdale, Georgia, United States|Louisiana Research Associates, New Orleans, Louisiana, United States|The Center for Clinical Research - Washington County Hospital, Hagerstown, Maryland, United States|Capital Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|A & A Pain Institute of St. Louis, St. Louis, Missouri, United States|Office of Donald H. Berdeaux MD, Great Falls, Montana, United States|Summit Medical Group, Berkeley Heights, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|Metropolitan Hospital Center, New York, New York, United States|Four Seasons Hospice & Pallative Care, Flat Rock, North Carolina, United States|Center for Clinical Research, Winston-Salem, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Lone Star Oncology, Austin, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Jules Bordet Institute, Bruxelles, Belgium|CHU Charleroi (Hôpital civil de Charleroi), Charleroi, Belgium|UZ Leuven - Algologisch Centrum Anesthesiologie, Pellenberg, Belgium|Vancouver Health Research Center, Victoria, British Columbia, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Instituto Radio-oncológico Santiago (INRAD), Santiago, Chile|Clínica Ciudad del Mar, Viña del Mar, Chile|Ambulance pro lécbu bolesti, ARO, Benešov, Czech Republic|Ambulance pro lécbu bolesti, Ceské Budejovice, Czech Republic|Nemocnice Ceské Budejovice, Ceské Budejovice, Czech Republic|FN Hradec Králové - Klinika onkologie a radioterapie, Hradec Králové, Czech Republic|Nemocnice Jihlava, Jihlava, Czech Republic|FN a LF UP Olomouc - Ambulance pro lécbu bolesti, Olomouc, Czech Republic|AR klinika FN Plzen -Ambulance pro lécbu bolesti, Plzen, Czech Republic|Fakultní nemocnice Na Bulovce, Praha 8 - Liben, Czech Republic|ARO, Krajská zdravotni, K.Z. a.s, Nemocnice, Teplice, Czech Republic|Docrates Clinic, Helsinki, Finland|Centre hospitalier Lyon Sud, Pierre-Benite, France|Praticien hospitalier, Tarbes, France|RWTH Aachen Universität, Aachen, Germany|Schmerz- und Palliativzentrum Göppingen, Göppingen, Germany|St.-Marien-Hospital Lunen, Lunen, Germany|Schmeiz - u Pallielivzendium Wiesbaden, Wiesbaden, Germany|Yashoda Hospital, Andhra Pradesh, India|Bangalore Institute of Oncology, Bangalore,, India|CBCC- Apollo Hospital, Gandhinagar, India|Apollo Hospital, Hyderabaad, India|Indo-American Cancer Institute and Research Center, Hyderabaad, India|Bhagwaan Mahaveer Cancer Hospital and Research Centre, Jaipur, India|CHL - Apollo Hospitals, Madhya Pradesh, India|Jawaharlal Nehru Cancer Hospital, Madhya Pradesh, India|Meenakshi Mission Hospital & Research Centre, Madurai, India|All India Institute of Medical Sciences, New Delhi, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, India|Deenanath Mangeshkar Hospital and Research Center, Pune, India|Seroc Cancer Center, Rajasthan, India|Regina Elana Cancer Institute, Rom, Italy|Dir. S.C.D.U. Psicologia Clinica ed Oncologica, Turin, Italy|Hospital Aranda de la Parra, Leon, Mexico|Htal Ángeles de Pedregal, Mexico DF, Mexico|Beskidzkie Centrum Onkologii im. Jana Pawla, Bielsko-Biala, Poland|Poradnia Leczenia Bolu, Edyty Jakubow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Gdansk, Poland|NZOZ Hospicjum Milosierdzia Bozego, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Niepubliczny Zaklad Opieki Zdrowotnej, Tychy, Poland|Centrum Onkologii - Instytut im. M. Sklodowskiej - Curie, Warszawa, Poland|Spitalul Judetean de Urgenta ""Constantin Opris"", Baia Mare, Maramures, Romania|Spitalul Judetean de Urgenta Braila, Braila, Jud. Braila, Romania|Hospice ""Casa Sperantei"", Brasov, Romania|Spitalul Universitar de Urgenta Elias, Bucuresti, Romania|S.C. IanuliMed S.R.L. Oncologie Medicala, Bucuresti, Romania|Policnica Orizont-Oncologie Medicala, Craiova, Romania|District Hospital Dr. Alexandru Simionescu, Hunedoara, Romania|Centrul de Oncologie Medicala, Iasi, Romania|Spitalul Municipal Onesti, Onesti, Jud. Bacau, Romania|Spitalul Municipal Ploiesti, Ploiesti, Romania|Spitalul Clinic Judetean Sibiu Oncologie, Sibiu, Romania|Spitalul Judetean de Urgenta ""Sf. Ioan cel Nou"", Suceava, Romania|Dr. Pirjol & Szpak Inc., Amanzimtoti, South Africa|Medi Clinic, Bloemfontein, South Africa|Pain Clinic, Cape Town, South Africa|Pretoria Urology Research Unit, Hatfield, Pretoria, South Africa|Trialtech Research - Embassy Drive Medical Centre, Hatfield, Pretoria, South Africa|Oncology/Haematology Dept Research Unit, Kimberley, South Africa|Eastleigh Breast Cancer Center, Lynnwood, South Africa|Hospital Virgen del Mar, Almeria, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial, Barcelona, Spain|HU Puerta del Mar, Oncologia, Cadiz, Spain|Hospital Universitario de Bellvitge, Feixa, Llarga, sn, Spain|Hospital Univ. Virgen de las Nieves, Granada, Spain|Hospital de la Rioja, Logrono, Spain|Hospital Los Montalvos, Salamanca, Spain|Basingstoke & North Hampshire NHS Foundation Trust, Basingstoke, United Kingdom|West Suffolk Hospital, Bury St Edmunds, United Kingdom|Fairfield General Hospital, Bury, Lancashire, United Kingdom|Edinburgh Cancer Research Centre (CRUK), Edinburgh, United Kingdom|James Paget Hospital, Gorleston on Sea, Norfolk, United Kingdom|International Observatory on End of Life Care, Lancaster, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|The Royal Marsden NHS Foundation Trust, London, United Kingdom|Marie Curie Hospice Holme Tower, Penarth, United Kingdom|The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom|Weston Area Health Trust, Weston super Mare, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00530764"
450,"NCT03444766","Study of Nivolumab for Advanced Cancers in India",,"Completed","Has Results","Non-Small Cell Lung Cancer (NSCLC)|Non-Small-Cell Lung Carcinoma|Nonsmall Cell Lung Cancer|Kidney Cancer|Kidney Neoplasms|Renal Cancer|Renal Neoplasms","Drug: Nivolumab","Number of Participants With Treatment-related Adverse Events|Number of Participants With Treatment-related Select Adverse Events|Number of Participants With Treatment-related Serious Adverse Events|Number of Participants With Adverse Events Leading to Discontinuation","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA209-887","March 6, 2018","July 17, 2019","July 17, 2019","February 23, 2018","December 4, 2020","December 4, 2020","Local Institution, Bangalore, India|Local Institution, Bangalore, India|Local Institution, Bengaluru, India|Local Institution, Hyderabad, India|Local Institution, Jaipur, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Vellore, India","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03444766/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/66/NCT03444766/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03444766"
451,"NCT00038103","Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen",,"Completed","Has Results","Breast Neoplasms","Drug: Exemestane|Drug: Celecoxib + Exemestane","Number of Subjects With Clinical Benefit|Number of Subjects With Objective Response|Duration of Clinical Benefit|Duration of Objective Response (in Subjects With CR or PR)|Duration of Long-Term SD|Time to Tumor Progression|Time to Treatment Failure|Survival","Pfizer","Female","18 Years and older   (Adult, Older Adult)","Phase 2","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NQ8-01-02-013|A3191139","January 2002","March 2008","March 2008","May 30, 2002","February 25, 2010","February 25, 2010","Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Namur, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sydney, Nova Scotia, Canada|Pfizer Investigational Site, Bogota, Bogota . DC, Colombia|Pfizer Investigational Site, Cali, Colombia|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Mexico, Distrito Federal, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Manila, Philippines",,"https://ClinicalTrials.gov/show/NCT00038103"
452,"NCT01360853","Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer","ONTRAC","Completed","No Results Available","Metastatic Pancreatic Adenocarcinoma","Drug: ON 01910.Na|Drug: Gemcitabine","Survival|Progression-free survival|Tumor size|Safety/tolerability|QOL questionnaire|Biomarkers|Population Pharmacokinetics|Full Pharmacokinetics","Onconova Therapeutics, Inc.|Academic GI Cancer Consortium (AGICC)","All","18 Years and older   (Adult, Older Adult)","Phase 3","160","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","04-22|11PAN01","May 2011","June 2015","December 2015","May 26, 2011",,"August 4, 2016","UCSD Moores Cancer Center, La Jolla, California, United States|Desert Comprehensive Cancer Center, Palm Springs, California, United States|Pacific Cancer Care, Salinas, California, United States|Premiere Oncology, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Kaiser Permanente Colorado, Denver, Colorado, United States|Poudre Valley Cancer Center of the Rockies, Fort Collins, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|University of Hawaii Cancer Center, Honolulu, Hawaii, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|UMASS Medical School, Worcester, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|New York University Langone Medical Center, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cone Health Cancer Center, Greensboro, North Carolina, United States|Hendersonville Hematology and Oncology at Pardee, Hendersonville, North Carolina, United States|Rex Cancer Center UNC Healthcare, Raleigh, North Carolina, United States|St. Alexis Medical Center-Mid Dakota Clinic PC, Bismarck, North Dakota, United States|University of Cincinnati Cancer Center, Cincinnati, Ohio, United States|Kaiser Permanente NW, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States|McLeod Regional Medical Center, Florence, South Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Semmelweis University Department of Diagnostic Radiology and Oncotherapy, Budapest, Hungary|Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary|Hetenyi Geza Hospital 5004, Szolnok, Hungary, Szolnok, Hungary|Basavatarakam Indo-American Cancer Hospital, Hyderabad, Andhra Pradesh, India|Regional Cancer Center, Thiruvananthapuram, Kerala, India|Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India|Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Lifeline Multispeciality Hospitals, Chennai, Tamil Nadu, India|State Budget Medical Institution of the Arkhangelsk Region, Arkhangelsk, Russian Federation|Chelyabinsk Regional Clinical Oncology Center, Chelyabinsk, Russian Federation|State Budget Medical Institution Clinical Oncology Center 1, Krasnodar, Russian Federation|Budget Medical Institution of the Omsk Region: Clinical Oncology Center, Omsk, Russian Federation|State Budget Medical Institution: Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|State Medical Institution: Tula Regional Oncology Center, Tula, Russian Federation|Zakarpattia Regional Clinical Oncology Center Department of Chemotherapy, Uzhhorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01360853"
453,"NCT03997123","Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC","CAPItello-290","Recruiting","No Results Available","Triple Negative Breast Neoplasms","Drug: Capivasertib|Drug: Paclitaxel|Drug: Placebo","Overall Survival (OS)|Progression-Free Survival (PFS)|Investigator assessment of PFS2|Response Rate (ORR)|Safety and tolerability of drugs by assessment of AEs/SAEs|Minimum plasma concentration(Cmin), plasma concentration1-2 hours post-dose (C1-2h) and 4 hours post-dose (C4h) during months 1 and 2|EORTC QLQ BR23(European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire breast cancer specific module)|The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 items)|Duration of Response (DoR)|Clinical Benefit Rate (CBR)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","924","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D3614C00001","June 25, 2019","May 19, 2023","May 19, 2023","June 25, 2019",,"May 12, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Redlands, California, United States|Research Site, West Hollywood, California, United States|Research Site, Whittier, California, United States|Research Site, Whittier, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Plantation, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Brooklyn, New York, United States|Research Site, Greenvale, New York, United States|Research Site, New York, New York, United States|Research Site, Nyack, New York, United States|Research Site, Rochester, New York, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Harrisburg, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Spring, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Charlottesville, Virginia, United States|Research Site, Fairfax, Virginia, United States|Research Site, Midlothian, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad Autonomade Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Goiania, Brazil|Research Site, Londrina, Brazil|Research Site, Natal, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Victoria, British Columbia, Canada|Research Site, Kitchener, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Halifax, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Foshan, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Jinan, China|Research Site, Kunming, China|Research Site, Lanzhou, China|Research Site, Linyi, China|Research Site, Nanchang, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenyang, China|Research Site, Shijiazhuang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Urumqi, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Wuxi, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Zhengzhou, China|Research Site, Zhengzhou, China|Research Site, Bogota, Colombia|Research Site, Cali, Colombia|Research Site, Floridablanca, Colombia|Research Site, Ibague, Colombia|Research Site, Medellin, Colombia|Research Site, Monteria, Colombia|Research Site, Valledupar, Colombia|Research Site, Chomutov, Czechia|Research Site, Horovice, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Jihlava, Czechia|Research Site, Liberec, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 4, Czechia|Research Site, Brest Cedex, France|Research Site, Lille Cedex, France|Research Site, Lyon Cedex 08, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Saint Herblain, France|Research Site, Toulouse Cedex 9, France|Research Site, Villejuif, France|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Patras, Greece|Research Site, Thessaloniki, Greece|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Győr, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Szekszárd, Hungary|Research Site, Veszprém, Hungary|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Gurgaon, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Maharashtra, India|Research Site, Mumbai, India|Research Site, Mysuru, India|Research Site, Nagpur, India|Research Site, Nagpur, India|Research Site, Nasik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hidaka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Isehara, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kawasaki-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Ota-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Sunto-gun, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan-si, Korea, Republic of|Research Site, Cheonan-si, Korea, Republic of|Research Site, Cheongju-si, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Selangor, Malaysia|Research Site, Aguascalientes, Mexico|Research Site, Culiacan, Mexico|Research Site, Estado de México, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Arequipa, Peru|Research Site, Callao, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bacolod, Philippines|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Baguio City, Philippines|Research Site, Cagayan De Oro City, Philippines|Research Site, Cebu City, Philippines|Research Site, Davao City, Philippines|Research Site, Iloilo City, Philippines|Research Site, Iloilo, Philippines|Research Site, Las Pinas, Philippines|Research Site, Legazpi City, Philippines|Research Site, Manila, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Grudziądz, Poland|Research Site, Konin, Poland|Research Site, Kościerzyna, Poland|Research Site, Olsztyn, Poland|Research Site, Ostrołęka, Poland|Research Site, Poznan, Poland|Research Site, Racibórz, Poland|Research Site, Radom, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wroclaw, Poland|Research Site, Guimarães, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Arkhangelsk, Russian Federation|Research Site, Barnaul, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Chelyabinsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Rostov-on-Don, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Tomsk, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Jeddah, Saudi Arabia|Research Site, Makkah, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Bratislava, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Košice, Slovakia|Research Site, Prešov, Slovakia|Research Site, Zilina, Slovakia|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Pretoria, South Africa|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Hospitalet deLlobregat, Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Göteborg, Sweden|Research Site, Linköping, Sweden|Research Site, Lund, Sweden|Research Site, Stockholm, Sweden|Research Site, Stockholm, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Changhua, Taiwan|Research Site, Hsinchu, Taiwan|Research Site, Hualien City, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Hat Yai, Thailand|Research Site, Mueang, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Mersin, Turkey|Research Site, Colchester, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Huddersfield, United Kingdom|Research Site, Hull, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Maidstone, United Kingdom|Research Site, Sheffield, United Kingdom|Research Site, Stoke-on-Trent, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, York, United Kingdom|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03997123"
454,"NCT00545129","A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone",,"Completed","Has Results","Neoplasm Metastasis|Palliative Care","Drug: Tanezumab 10 mg IV|Drug: IV Placebo for tanezumab","Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Week 6|Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Weeks 1, 2, 4, 8, 12 and 16|Change From Baseline in Daily Worst Pain Intensity Numeric Rating Scale (NRS) Score at Week 1, 2, 4, 6, 8, 12 and 16: Baseline Observation Carried Forward (BOCF)|Change From Baseline in Daily Worst Pain Intensity Numeric Rating Scale (NRS) Score at Week 1, 2, 4, 6, 8, 12 and 16: Last Observation Carried Forward (LOCF)|Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Average Pain Scores at Week 1, 2, 4, 6, 8, 12 and 16: BOCF|Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Average Pain Scores at Week 1, 2, 4, 6, 8, 12 and 16: LOCF|Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Worst Pain Scores at Week 1, 2, 4, 6, 8, 12 and 16: BOCF|Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Worst Pain Scores Weeks 1, 2, 4, 6, 8, 12 and 16: LOCF|Percentage of Participants Achieving Greater Than or Equal to (>=) 30 Percent (%), >=50%, >=70% and >=90% Reduction in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score: BOCF|Percentage of Participants Achieving Greater Than or Equal to (>=) 30 Percent (%), >=50%, >=70% and >=90% Reduction in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score: LOCF|Average Daily Opioid Consumption|Number of Doses of Rescue Medication Required Per Week|Change From Baseline in Opioid-Related Symptom Distress Scale (OR-SDS) at Weeks 2, 4, 6, 12, and 16|Change From Baseline in Brief Pain Inventory (BPI) Pain Interference With Function Composite Score and Individual Pain Interference Item Scores of General Activity, Walking Ability and Normal Work at Weeks 1, 2, 4, 6, 8, 12, and 16: BOCF|Change From Baseline in Brief Pain Inventory (BPI) Pain Interference With Function Composite Score and Individual Pain Interference Item Scores at Weeks 1, 2, 4, 6, 8, 12, and 16: LOCF|Patient's Global Evaluation of Study Medication|Change From Baseline in Patient's Global Assessment of Disease (Cancer Pain) Activity at Weeks 1, 2, 4, 6, 8, 12, and 16: BOCF|Change From Baseline in Patient's Global Assessment of Disease (Cancer Pain) Activity at Weeks 1, 2, 4, 6, 8, 12, and 16: LOCF|Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment Of Disease (Cancer Pain) Activity: BOCF|Percentage of Participants Achieving Improvement Of >=2 Points in Patient's Global Assessment Of Disease (Cancer Pain) Activity: LOCF|Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Number of Participants With Physical Examination Abnormalities|Number of Participants With Abnormal Neurological Examination|Vital Sign Examination: Body Temperature|Vital Sign Examination: Blood Pressure (BP)|Vital Sign Examination: Respiratory Rate|Vital Sign Examination: Heart Rate|Body Weight of Participants|Number of Participants With Abnormal Laboratory Examination|Number of Participants With Anti-drug Antibodies|Electrocardiogram Examination|Electrocardiogram Examination: Heart Rate","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","59","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A4091003|2008-005181-31|CANCER PAIN POC","April 29, 2009","December 24, 2011","February 7, 2012","October 17, 2007","June 18, 2021","June 18, 2021","UCSD Center for Pain Medicine, La Jolla, California, United States|UCSD Medical Center - Thornton Hospital, La Jolla, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Indiana Pain and Spine Clinic, South Bend, Indiana, United States|WK River Cities Clinical Research Center, Shreveport, Louisiana, United States|Willis Knighton Pierremont Health Center, Shreveport, Louisiana, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Medical University of South Carolina, Department of Urology, Charleston, South Carolina, United States|MUSC Department of Radiology, Charleston, South Carolina, United States|MUSC Investigational Pharmacy, Charleston, South Carolina, United States|MUSC Urology Ambulatory Care, Charleston, South Carolina, United States|Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, United States|Landeskrankenhaus Graz - Universitaetsklinik fuer Orthopaedie und Orthopaedische Chirurgie, Graz, Austria|Krankenhaus der Elisabethinen Linz, Institut fuer Anaesthesiologie und Intensivmedizin, Linz, Austria|Nuhr Zentrum, Senftenberg, Austria|Clinic of Oncology, Banja Luka, Bosnia and Herzegovina|Institute of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|General Hospital Varazdin, Varazdin, Croatia|Institut Gustave Roussy, Villejuif, France|Fovarosi Onkormanyzat Peterfy Sandor Utcai Korhaz - Fajdalom Ambulancia, Budapest, Hungary|Fovarosi Onkormanyzat Jahn Ferenc Del-pesti Korhaz - Fajdalom Ambulancia, Budapest, Hungary|Fejer Megyei Szt. Gyorgy Korhaz - Rendelointezet/Aneszteziologiai es Intenziv Betegellato Osztaly, Szekesfehervar, Hungary|Shri Siddhivinayak Ganpati Cancer Hospital, Miraj, Maharashtra, India|Central India Cancer Research Institute, Nagpur, Maharashtra, India|Shatabdi Superspeciality Hospital, Nashik, Maharashtra, India|Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, India|Rajiv Gandhi Cancer Institute and Research Centre,, New Delhi, India|Severance Hospital, Yonsei University College of Medicine, Yonsei Cancer Center, Seoul, Korea, Republic of|Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine, Seoul, Korea, Republic of|10th Department, Latvian Oncological Centre / Riga Eastern Clinical University Hospital, Riga, Latvia|Centro de Cancer del Centro Medico ABC, Mexico, Distrito Federal, Mexico|Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima L13, Peru|Oncocare, Lima, Peru|Niepubliczny Zaklad Opieki Zdrowotnej, Bydgoszcz, Poland|Hospicjum im. Ks. Eugeniusza Dutkiewicza SAC w Gdansku, Gdansk, Poland|Poradnia Medycyny Paliatywnej, Hospicjum Palium, Poznan, Poland|NZOZ Zespol Opieki Domowej, Wloclawek, Poland|Fakultna Nemocnica s Poliklinikou F.D.Roosevelta, Banska Bystrica, Slovakia|Narodny onkologicky ustav, Bratislava, Slovakia",,"https://ClinicalTrials.gov/show/NCT00545129"
455,"NCT02162667","Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer",,"Completed","Has Results","HER2-positive Carcinoma of Breast","Drug: Trastuzumab","The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)|The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status|The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS|Overall Response Rate (ORR) From Local Review|Disease-free Survival|Progression-Free Survival|Overall Survival|The Number of Patients Who Had Progressive Disease or Recurrence|Maximum Serum Concentration After Administration (Cmax) in Each Cycle|Trough Serum Concentration (Ctrough) in Each Cycle","Celltrion|Nippon Kayaku Co., Ltd.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","562","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CT-P6 3.2|2013-004525-84","June 2014","May 26, 2016","October 2018","June 13, 2014","October 29, 2019","October 29, 2019","Buenos Aires, Argentina|Córdoba, Argentina|Quilmes, Argentina|Rosario, Argentina|San Salvador De Jujuy, Argentina|Santa Rosa, Argentina|Brest, Belarus|Minsk, Belarus|Minsk, Belarus|Sarajevo, Bosnia and Herzegovina|Barretos, Brazil|Brasilia, Brazil|Caxias Do Sul, Brazil|Curitiba, Brazil|Goiânia, Brazil|Ijuí, Brazil|Jaú, Brazil|Joaçaba, Brazil|Lajeado, Brazil|Natal, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Porto Alegre, Brazil|Recife, Brazil|Ribeirão Preto, Brazil|Sorocaba, Brazil|São Paulo, Brazil|São Paulo, Brazil|São Paulo, Brazil|São Paulo, Brazil|Santiago, Chile|Temuco, Chile|Guayaquil, Ecuador|Guayaquil, Ecuador|Machala, Ecuador|Quito, Ecuador|Nancy, France|Tbilisi, Georgia|Tbilisi, Georgia|Tbilisi, Georgia|Tbilisi, Georgia|Tbilisi, Georgia|Larissa, Greece|Budapest, Hungary|Debrecen, Hungary|Bangalore, India|Chennai, India|Chennai, India|Delhi, India|Jaipur, India|Kolkata, India|Mumbai, India|Nashik, India|Nashik, India|New Delhi, India|Pune, India|Bari, Italy|Pavia, Italy|Piacenza, Italy|Rimini, Italy|Tokyo, Japan|Daugavpils, Latvia|Riga, Latvia|Acapulco, Mexico|Monterrey, Mexico|Arequipa, Peru|Arequipa, Peru|Lima, Peru|Trujillo, Peru|Cebu, Philippines|Makati, Philippines|Manila, Philippines|Pasig, Philippines|Quezon City, Philippines|San Juan City, Philippines|Taguig, Philippines|Gdansk, Poland|Lodz, Poland|Warsaw, Poland|Lisbon, Portugal|Brasov, Romania|Bucharest, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Cluj-Napoca, Romania|Suceava, Romania|Arkhangelsk, Russian Federation|Kazan, Russian Federation|Krasnoyarsk, Russian Federation|Kursk, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Nizhny Novgorod, Russian Federation|Novosibirsk, Russian Federation|Obninsk, Russian Federation|Omsk, Russian Federation|Samara, Russian Federation|Saransk, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|Kragujevac, Serbia|Cape Town, South Africa|George, South Africa|Johannesburg, South Africa|Johannesburg, South Africa|Port Elizabeth, South Africa|Pretoria, South Africa|Sevilla, Spain|Zaragoza, Spain|Kaohsiung, Taiwan|Taichung City, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Adana, Turkey|Ankara, Turkey|Ankara, Turkey|Gaziantep, Turkey|Cherkasy, Ukraine|Donetsk, Ukraine|Kharkiv, Ukraine|Kherson, Ukraine|Khmel'nyts'kyy, Ukraine|Poltava, Ukraine|Sumy, Ukraine|Uzhhorod, Ukraine|Vinnytsya, Ukraine|Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT02162667"
456,"NCT02928406","A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract",,"Active, not recruiting","No Results Available","Urinary Tract Cancer","Drug: Atezolizumab","Percentage of Participants With Adverse Events|Overall Survival (OS)|Progression Free Survival (PFS) as per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|PFS as per Modified Response Evaluation Criteria in Solid Tumors (Modified RECIST)|Percentage of Participants With Best Overall Response as Assessed by RECIST v1.1|Percentage of Participants With Best Overall Response as Assessed by Modified RECIST|Percentage of Participants With Disease Control as Assessed by RECIST v1.1|Percentage of Participants With Disease Control as Assessed by Modified RECIST|Duration of Response as Assessed by RECIST v1.1|Duration of Response as Assessed by Modified RECIST|Change From Baseline in Health-Related Quality of Life (HRQoL), as Assessed Using European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score|Change from Baseline in European Quality of Life (EuroQoL) Group 5-Dimension 5-Level (EQ-5D-5L) Self Report Questionnaire Health Utility Score","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","1004","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO29983|2016-002625-11","November 30, 2016","June 30, 2022","June 30, 2022","October 10, 2016",,"May 10, 2022","Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Hospital Aleman, Caba, Argentina|Hospital Britanico de Buenos Aires, Ciudad Autonoma Buenos Aires, Argentina|Canberra Hospital; Medical Oncology, Canberra, Australian Capital Territory, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Prince of Wales Hospital; Oncology, Randwick, New South Wales, Australia|Northern Cancer Institute, St Leonards, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital; Hematology/Oncology, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Hospital Olivia Newton John Cancer Centre, Heidelberg, Victoria, Australia|Medizinische Universität Innsbruck; Universitätsklinik für Urologie, Innsbruck, Austria|Ordensklinikum Linz Elisabethinen; Abteilung für Urologie und Andrologie, Linz, Austria|Landeskrankenhaus Salzburg; Universitätsklinik für Urologie und Andrologie der PMU, Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie, Wien, Austria|Medizinische Universität Wien; Universitätsklinik für Urologie, Wien, Austria|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|UZ Leuven Gasthuisberg, Leuven, Belgium|CHU Sart-Tilman, Liège, Belgium|Pronutrir - suporte nutricional e quimioterapia ltda., Fortaleza, CE, Brazil|Centro Integrado de Oncologia de Curitiba, Curitiba, PR, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital de Cancer de Barretos, Barretos, SP, Brazil|Hospital Sírio-Libanês, Sao Paulo, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Complex Oncology Center (COC)-Plovidiv, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD, Sofia, Bulgaria|SHATOD - Sofia, Sofia, Bulgaria|Tom Baker Cancer Centre-Calgary, Calgary, Alberta, Canada|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|The Ottawa Hospital Cancer Center; General Campus, Ottawa, Ontario, Canada|Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, Nanjing City, China|Clinica del Country, Bogota, Colombia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Fakultni nemocnice u sv. Anny v Brne, Brno, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Fakultni Thomayerova Nemocnice; Onkologicke Oddeleni, Praha, Czechia|Aalborg Universitetshospital, Klinik Kirurgi-Kræft, Onkologisk afd., Aalborg, Denmark|Aarhus Universitetshospital; Kræftafdelingen, Aarhus N, Denmark|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Rigshospitalet; Onkologisk Klinik, København Ø, Denmark|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|Universitätsklinikum ""Carl Gustav Carus""; Klinik und Poliklinik für Urologie, Dresden, Germany|Universitätsklinikum Erlangen; Medizinische Klinik 5; Hämatologie und Internistische Onkologie, Erlangen, Germany|Universitätsmedizin Göttingen Georg-August-Universität; Klinik für Urologie, Göttingen, Germany|Krankenhaus Martha-Maria Halle-Dölau, Klinik für Urologie, Halle (Saale), Germany|Medizinische Hochschule Hannover; Klinik für Urologie und Onkologische Urologie, Hannover, Germany|Onkologische Schwerpunktpraxis, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Urologie, Lübeck, Germany|Kliniken Maria Hilf GmbH, Krankenhaus St. Franziskus, Mönchengladbach, Germany|Klinikum rechts der Isar der TU München; Urologische Klinik und Poliklinik, München, Germany|Universitätsklinikum Münster, Klinik für Urologie und Kinderurologie, Münster, Germany|Universitätsklinikum Tübingen; Klinik für Urologie, Tübingen, Germany|Universitätsklinikum Ulm; Klinik für Urologie, Ulm, Germany|Alexandras General Hospital of Athens; Oncology Department, Athens, Greece|IASO General Hospital of Athens, Athens, Greece|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Metropolitan Hospital; 2Nd Oncology Clinic, Piraeus, Greece|Thermi Clinic; Oncology Clinic, Thermi Thessalonikis, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Papageorgiou General Hospital; Medical Oncology, Thessaloniki, Greece|Honvédelmi Minisztérium Állami Egészségügyi Központ; Onkológiai Osztály; Oncology department, Budapest, Hungary|Semmelwies University of Medicine; Urology Dept., Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Szegedi Tudomanyegyetem, AOK, Szent-Gyorgyi Albert Klinikai Kozpont, Onkoterapias Klinika, Szeged, Hungary|Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház; Onkológiai Osztály, Szolnok, Hungary|HealthCare Global Cancer Centre; Medical Oncology, Ahmedabad, Gujarat, India|TATA Medical Centre; Medical Oncology, Kolkata, WEST Bengal, India|Artemis Health Institute, Gurgaon, India|Max Super Speciality Hospital, New Delhi, India|Cork University Hospital, Cork, Ireland|Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital; Oncology Day Unit, Dublin, Ireland|Policlinico Ospedaliero Ss Annunziata; U.O. Di Clinica Oncologica, Chieti, Abruzzo, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Campania, Italy|ISTITUTO NAZIONALE TUMORI IRCCS FONDAZIONE G. PASCALE; Dipartimento Uro-Ginecologico, Napoli, Campania, Italy|AZ.Osp S. Orsola - Malpighi-Reparto di Oncologia Medica, Bologna, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, Italy|Policlinico Universitario Campus Biomedico Di Roma; U.O.Oncologia Medica, Roma, Lazio, Italy|Azienda Ospedaliera San Camillo Forlanini; Oncologia Medica, Roma, Lazio, Italy|Policlinico Universitario ""Agostino Gemelli""; U.O.C. Oncologia Medica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|ASST DI CREMONA; Dip. Medicina - S.C. Oncologia, Cremona, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Istituto Europeo Di Oncologia, Milano, Lombardia, Italy|A.O. UNIVERSITARIA S. LUIGI GONZAGA; Oncologia Medica, Orbassano, Piemonte, Italy|Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica, Bari, Puglia, Italy|IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia, San Giovanni Rotondo, Puglia, Italy|A.O.U. Cagliari-P.O. Monserrato;U.O. Oncologia, Cagliari, Sardegna, Italy|Ospedale Cannizzaro, Oncologia, Catania, Sicilia, Italy|Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia, Arezzo, Toscana, Italy|Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2, Pisa, Toscana, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima, Padova, Veneto, Italy|Azienda Ospedaliera di Verona-Policlinico G.B. Rossi; Oncologia Medica, Verona, Veneto, Italy|Hotel Dieu de France; Oncology, Beirut, Lebanon|Hospital of Lithuanian University of Health Sciences Kaunas Clinics - Endocrinology clinic, Kaunas, Lithuania|National Cancer Institute, Vilnius, Lithuania|NKI/AvL, Amsterdam, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Maastricht University Medical Centre; Medical Oncology, Maastricht, Netherlands|St. Antonius locatie Leidsche Rijn, Utrecht, Netherlands|Centrum Onkologii Ziemi LUBELSKIEJ im. Sw Jana z Dukli, I oddz. Chemioterapii, Lublin, Poland|Szpital Kliniczny Przemienienia Pańskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznan, Poland|Szpital Grochowski im. dr med. Rafała Masztaka Sp. z o.o., Warszawa, Poland|NZOZ Onko-Dent G. L. Slomian, Spolka Jawna, Żory, Poland|Hospital de Braga; Servico de Oncologia Medica X, Braga, Portugal|HUC; Servico de Urologia e Transplantacao Renal, Coimbra, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Oncopremium Team Srl, Baia Mare, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Spital de zi-Parter, Cluj-Napoca, Romania|Centrul de Oncologie Sfantul Nectarie, Craiova, Romania|Centrul de Radioterapie AMETHYST, Floresti, Romania|Oncomed SRL; Oncologie, Timisoara, Romania|Blokhin Cancer Research Center; Urological Dept, Moscow, Russian Federation|P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation|King Faisal Specialist Hospital & Research Centre; Oncology, Riyadh, Saudi Arabia|Narodny onkologicky ustav, Bratislava, Slovakia|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Complejo Hospitalario de Althaia; Servicio de Oncologia, Manresa, Barcelona, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, Spain|Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain|Complejo Hospitalario Universitario de Santiago (CHUS) ; Servicio de Oncologia, Santiago de Compostela, LA Coruña, Spain|Hospital Universitario de Canarias;servicio de Oncologia, La Laguna, Tenerife, Spain|Hospital de Basurto; Servicio de Oncologia, Bilbao, Vizcaya, Spain|Hospital del Mar Barcelona, Barcelona, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Oncología, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, Spain|Hospital Duran i Reynals; Oncologia, Barcelona, Spain|Hospital San Pedro De Alcantara; Servicio de Oncologia, Caceres, Spain|Hospital Universitari de Girona Dr. Josep Trueta; Servicio de Oncologia, Girona, Spain|Hospital General Universitario de Guadalajara; Servicio de Oncologia, Guadalajara, Spain|Hospital Lucus Augusti; Servicio de Oncologia, Lugo, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Clinico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, Spain|Hospital de Navarra; Servicio de Oncologia, Navarra, Spain|Complejo Hospitalario de Orense; Servicio de Oncologia, Orense, Spain|Hospital Universitario Virgen del Rocio; Servicio de Oncologia, Sevilla, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Hospital La Fe, Valencia, Spain|Ospedale Regionale di Bellinzona Medizin Onkologie, Bellinzona, Swaziland|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Inselspital Bern; Universitätsklinik für medizinische Onkologie, Bern, Switzerland|Kantonsspital Graubünden Medizin Onkologie; Onkologie und Hämatologie, Chur, Switzerland|Hôpitaux Universit. de Genève Médecine Oncologie; Oncologie, Geneve, Switzerland|Luzerner Kantonsspital; Medizinische Onkologie, Luzern, Switzerland|Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland|National Cheng Kung Uni Hospital; Dept of Hematology and Oncology, Tainan, Taiwan|Chang Gung Medical Foundation-Linkou, Urinary Oncology, Taoyuan, Taiwan|Velindre Cancer Centre, Cardiff, United Kingdom|Raigmore Hospital; Dept of Radiotherapy & Oncology, Inverness, United Kingdom|Leicester Royal Infirmary NHS Trust, Leicester, United Kingdom|Barts and the London NHS Trust., London, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02928406"
457,"NCT02795988","A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer",,"Active, not recruiting","No Results Available","Gastrointestinal Neoplasms|Adenocarcinoma","Biological: IMU-131|Drug: Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.","Safety and tolerability of IMU-131 (Phase 1b)|Recommended Phase 2 dose of IMU-131 (Phase 1b)|Clinical efficacy of IMU-131 (Phase 2)|Progression Free Survival (Phase 2)|Time to progression (Phase 2)|Disease Control Rate (Phase 2)|Objective Response Rate (Phase 2)|Duration of Objective Response (Phase 2)|Change in Tumor Size (Phase 2)|Humoral and cellular immunogenicity of IMU-131(Phase 2)|Incidence of TEAE's (Phase 2)","Imugene Limited","All","20 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","IMU.ACS.001","August 30, 2017","January 2022","February 2022","June 10, 2016",,"January 20, 2022","ARENSIA Exploratory Medicine LLC, Tbilisi, Georgia|City Cancer Center, Vijayawada, Andhra Pradesh, India|North East Cancer Hospital and Research Institute, Guwahati, Assam, India|Shetty's Hospital, Bengaluru, Karnataka, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Victoria Hospital, Bangalore, India|MNJ Institute of Oncology and Regional Cancer Centre, Hyderabad, India|Tata Medical Centre, Kolkata, India|HCG NCHRI Cancer Centre, Nagpur, India|Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, Patna, India|ARENSIA Exploratory Medicine IMSP Institutul Oncologic, Chisinau, Moldova, Republic of|Oncology Institute of Vojvodina, Sremska Kamenica, Južnobanatski Okrug, Serbia|Institute for Oncology and Radiology of Serbia - PPDS, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|National Cheng-Kung University Hospital, Tainan, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Division of Medical Oncology, Department of Medicine, Prince of Songkla University, Songklanagarind Hospital, Hat Yai, Songkhla Province, Thailand|National Cancer Institute of Thailand, Bangkok, Thailand|Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand|ARENSIA Exploratory Medicine LLC, Kapitanivka, Ukraine",,"https://ClinicalTrials.gov/show/NCT02795988"
458,"NCT02069704","Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients",,"Completed","Has Results","Metastatic Colorectal Cancer (mCRC)","Drug: Bevacizumab biosimilar (BEVZ92)|Drug: Avastin® (bevacizumab, reference product)","Area Under the Concentration-versus-time Curve (AUC) at Cycle 1 (AUC0-336h) of BEVZ92 and Avastin®|AUC at Steady State (AUCss) of BEVZ92 and Avastin®|Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Reported With BEVZ92 and Avastin®|Anti-Drug Antibody (ADA) of BEVZ92 and Avastin®|Objective Response Rate (ORR) of BEVZ92 and Avastin®|Cmax,sd of BEVZ92 and Avastin®|Progression-free Survival (PFS) of BEVZ92 and Avastin®|Cmax,ss of BEVZ92 and Avastin®|Ctrough,sd of BEVZ92 and Avastin®|Ctrough,ss of BEVZ92 and Avastin®|Elimination Half-life (t1/2) of BEVZ92 and Avastin®|Elimination Rate Constant (Kel) of BEVZ92 and Avastin®|Volume of Distribution (Vd) of BEVZ92 and Avastin®","mAbxience S.A|Laboratorio Elea Phoenix S.A.|Libbs Farmacêutica LTDA","All","18 Years and older   (Adult, Older Adult)","Phase 1","142","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BEVZ92-A-01-13","October 29, 2014","October 2015","June 2017","February 24, 2014","July 23, 2019","July 23, 2019","Hospital de Gastroenterologia ""Dr. Carlos Bonorino Udaondo"", Buenos Aires, Argentina|Instituto Oncológico de Rosario, Rosario, Argentina|Fundaçáo Pio XII - Hospital do Cancer de Barretos, Barretos, Brazil|Hospital Caridade, Ijui, Brazil|Hospital Sao Lucas da Pucrs, Porto Alegre, Brazil|Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, São Paulo, Brazil|Hosp. A.C Camargo, São Paulo, Brazil|Instituto do Cancer del estado de S. Paulo (ICEPS ), São Paulo, Brazil|M S Patel Cancer Centre- Shree Krishna Hospital, Karamsad, Gujarat, India|Sri Ramachandra Hospital, Chennai, India|Tata Hospital, Mumbai, India|Central India Canter Research Institute, Nagpur, India|Curie Manavta Cancer Center, Nashik, India|Regional Cancer Center & Medical College, Thiruvananthapuram, India|Centro Oncológico Clara Campal, Madrid, Spain|Dnipropetrovsk City Multiple-discipline Clinical Hospital №4, Dnipropetrovsk, Ukraine|Kharkiv Regional Clinical Oncology Center, Kharkiv, Ukraine|Danylo Halytskiy Lviv National Medical University, Lviv, Ukraine",,"https://ClinicalTrials.gov/show/NCT02069704"
459,"NCT00863746","A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).","MISSION","Completed","Has Results","Carcinoma|Non-Small-Cell Lung","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","Overall Survival|Progression-free Survival|Disease Control|Objective Tumor Response|Time to Progression|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire for Palliative Care (EORTC QLQ-C15-PAL) - Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Coughing Subscale|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13) - Dyspnea|Mean Change From Baseline in EuroQol-5D (EQ-5D) - Index Score|Mean Change From Baseline in EuroQol-5D (EQ-5D) - VAS Score","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","703","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","13266|2008-006914-62","April 2009","March 2012","April 2013","March 18, 2009","July 30, 2013","January 19, 2015","Fayetteville, Arkansas, United States|Stanford, California, United States|Philadelphia, Pennsylvania, United States|Ramos Mejía, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina|Rosario, Santa Fe, Argentina|Rosario, Santa Fe, Argentina|Córdoba, Argentina|Córdoba, Argentina|Santa Fé, Argentina|Graz, Austria|Linz, Austria|Wien, Austria|Antwerpen, Belgium|Bruxelles - Brussel, Belgium|Charleroi, Belgium|Genk, Belgium|Brasilia, Distrito Federal, Brazil|Belo Horizonte, Minas Gerais, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Santo André, Sao Paulo, Brazil|São José dos Campos, Sao Paulo, Brazil|São Paulo, Sao Paulo, Brazil|Sao Paulo, Brazil|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Varna, Bulgaria|Montreal, Quebec, Canada|Santiago, Chile|Santiago, Chile|Guangzhou, Guangdong, China|Nanjing, Jiangsu, China|Chengdu, Sichuan, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Beijing, China|Guangzhou, China|Shanghai, China|Shanghai, China|Caen, France|Dijon, France|La Roche Sur Yon Cedex, France|La Tronche, France|Lille, France|Lyon Cedex, France|Saint Herblain, France|Tours, France|Heidelberg, Baden-Württemberg, Germany|Karlsruhe, Baden-Württemberg, Germany|Mannheim, Baden-Württemberg, Germany|Ulm, Baden-Württemberg, Germany|Gauting, Bayern, Germany|München, Bayern, Germany|Kassel, Hessen, Germany|Köln, Nordrhein-Westfalen, Germany|Großhansdorf, Schleswig-Holstein, Germany|Bad Berka, Thüringen, Germany|Hamburg, Germany|Athens, Greece|Heraklion, Greece|Thessaloniki, Greece|Shatin, N.T, Hong Kong|Hongkong, Hong Kong|Kowloon, Hong Kong|Budapest, Hungary|Budapest, Hungary|Edeleny, Hungary|Farkasgyepu, Hungary|Torokbalint, Hungary|Zalaegerszeg, Hungary|Mumbai, Maharashtra, India|Pune, Maharashtra, India|Kerala, India|Bandung, Indonesia|Jakarta, Indonesia|Holon, Israel|Jerusalem, Israel|Jerusalem, Israel|Kfar Saba, Israel|Petach Tikva, Israel|Zrifin, Israel|Rozzano, Milano, Italy|Monza, Monza-Brianza, Italy|Orbassano, Torino, Italy|Avellino, Italy|Genova, Italy|Livorno, Italy|Parma, Italy|Perugia, Italy|Roma, Italy|Nagoya, Aichi, Japan|Kashiwa, Chiba, Japan|Akashi, Hyogo, Japan|Osakasayama, Osaka, Japan|Sakai, Osaka, Japan|Itabashi-ku, Tokyo, Japan|Koto-ku, Tokyo, Japan|Fukuoka, Japan|Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Amsterdam, Netherlands|Harderwijk, Netherlands|Heerlen, Netherlands|Helmond, Netherlands|Nieuwegein, Netherlands|Zwolle, Netherlands|Lahore, Punjab, Pakistan|Karachi, Sindh, Pakistan|Callao, Peru|Lima, Peru|Lima, Peru|Lima, Peru|Lima, Peru|San Borja, Peru|Cebu City, Philippines|Manila, Philippines|Metro Manila, Philippines|Quezon City, Philippines|Kielce, Poland|Krakow, Poland|Olsztyn, Poland|Rzeszow, Poland|Szczecin, Poland|Warszawa, Poland|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Singapore, Singapore|Port Elizabeth, Eastern Cape, South Africa|Johannesburg, Gauteng, South Africa|Prietoria, Gauteng, South Africa|Durban, Kwazulu-Natal, South Africa|Cape Town, Western Cape, South Africa|Cruces/Barakaldo, Bilbao, Spain|Orense, Ourense, Spain|Barcelona, Spain|Barcelona, Spain|Lleida, Spain|Lugo, Spain|Madrid, Spain|Málaga, Spain|Sevilla, Spain|Zamora, Spain|Falun, Sweden|Göteborg, Sweden|Linköping, Sweden|Lund, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Bangkok, Thailand|Chiang Mai, Thailand|Songkhla, Thailand|Ankara, Turkey|Instanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kocaeli, Turkey|Bristol, Avon, United Kingdom|Cambridge, Cambridgeshire, United Kingdom|Greater Manchester, Manchester, United Kingdom|Sutton, Surrey, United Kingdom|Leeds, West Yorkshire, United Kingdom|Aberdeen, United Kingdom|London, United Kingdom|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00863746"
460,"NCT00813605","QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma",,"Completed","No Results Available","Metastatic Colorectal Cancer","Other: FOLFIRI|Biological: AMG 655|Other: Placebo|Biological: AMG 479","Progression Free Survival|Overall Survival, Objective Response, Duration of Response, Time to Response|Incidence of adverse events|Significant laboratory abnormalities|Incidence of antibody formation","NantCell, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","155","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20060579|QUILT-2.018","March 2009","January 2011","June 2012","December 23, 2008",,"October 27, 2016","Research Site, Beverly Hills, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Maria, California, United States|Research Site, Denver, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Miami, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Port Saint Lucie, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Joliet, Illinois, United States|Research Site, Fishers, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Paducah, Kentucky, United States|Research Site, Worcester, Massachusetts, United States|Research Site, Lebanon, New Hampshire, United States|Research Site, Hudson, New York, United States|Research Site, New York, New York, United States|Research Site, High Point, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Amarillo, Texas, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Temple, Texas, United States|Research Site, Tyler, Texas, United States|Research Site, Roanoke, Virginia, United States|Research Site, Bordeaux Cedex, France|Research Site, Boulogne Billancourt, France|Research Site, Lille, France|Research Site, Lyon Cedex 08, France|Research Site, New Territories, Hong Kong|Research Site, Budapest, Hungary|Research Site, Gyor, Hungary|Research Site, Pecs, Hungary|Research Site, Szeged, Hungary|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Mumbai, Maharashtra, India|Research Site, Nagpur, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Kolkata, West Bengal, India|Research Site, Bangalore, India|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Gdansk, Poland|Research Site, Gliwice, Poland|Research Site, Opole, Poland|Research Site, Arkhangelsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, St Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, Barcelona, CataluÃ±a, Spain|Research Site, L'Hospitalet de Llobregat, CataluÃ±a, Spain|Research Site, Pamplona, Navarra, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00813605"
461,"NCT03766295","Masitinib Plus Gemcitabine in Pancreatic Cancer",,"Completed","No Results Available","Locally Advanced or Metastatic Pancreatic Cancer","Drug: Masitinib|Drug: Gemcitabine|Drug: Placebo","Overall Survival (median)|Survival rates|Progression Free Survival","AB Science","All","18 Years and older   (Adult, Older Adult)","Phase 3","377","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AB12005","July 2014","December 2020","December 2020","December 6, 2018",,"December 8, 2020","Hospital AZ Sint-Jan, Brugge, Belgium|Polyclinique de Limoges site CHENIEUX, Limoges, France|Centre Hospitalier de Longjumeau, Longjumeau, France|General University Hospital of Patras, Patras, Greece|Sanjeevani CBCC USA Cancer Hospital, Raipur, India|Omsk Clinical oncology dispensary Omsk, Omsk, Russian Federation|National Oncology Institute, Bratislava, Slovakia|Institut Salah Azaiez de Cancerologie, Bab Saadoun, Tunisia|Center of Surgical Innovations, Kiev, Ukraine",,"https://ClinicalTrials.gov/show/NCT03766295"
462,"NCT02260544","Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection",,"Completed","No Results Available","Ovarian Epithelial Cancer Recurrent","Drug: Doxorubicin Hydrochloride Liposome Injection","Pharmacokinetic ( PK ) parameter : the maximum plasma doxorubicin concentration ( Cmax ) [ Time frame : 2 cycles ]|PK parameter : the areas under the plasma concentration versus time curve calculated from 0 to the last measurable observation ( AUC 0-t)|PK parameter : the areas under the plasma concentration versus time curve extrapolated from 0 to infinity ( AUC 0-inf)|Incidence of treatment-emergent adverse events ( TEAEs)","Dr. Reddy's Laboratories Limited","Female","18 Years to 60 Years   (Adult)","Phase 1","49","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","591-13","July 2014","April 2015","August 2015","October 9, 2014",,"September 23, 2016","City Cancer Center, Vijaywada, Andhra Pradesh, India|Nirmal Hospital Pvt Ltd, Surat, Gujarat, India|Srinivasam Cancer Care Hospitals India Private Limited, Bangalore, Karnataka, India|Erode Cancer Center, Erode, Karnataka, India|Cancer Clinic and Nursing Home & Jasleen Hospital, Nagpur, Maharahtra, India|Curie Manavta Cancer Centre, Nashik, Maharashtra, India|Acharya HariHar Regional Cancer Centre, Cuttack, Orissa, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India|Dr. G. Viswanathan Speciality Hospitals, Trichy, Tamil Nadu, India|Bibi General Hospital, Hyderabad, Telangana, India|MNJ Institute of Oncology & Regional Cancer Centre, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT02260544"
463,"NCT00553410","Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer","SOLE","Completed","Has Results","Breast Cancer","Drug: Letrozole","Disease-free Survival (DFS)|Overall Survival|Distant Recurrence-free Interval (DRFI)|Breast Cancer-free Interval","International Breast Cancer Study Group|Breast International Group","Female","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","4884","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IBCSG 35-07 / BIG 1-07|2007-001370-88|CDR0000574249","August 2007","April 2018","May 15, 2019","November 4, 2007","January 29, 2019","March 11, 2020","Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Faulkner Hospital, Boston, Massachusetts, United States|Armidale Hospital, Armidale, New South Wales, Australia|Bankstown - Lidcombe Hospital, Bankstown, New South Wales, Australia|Southern Highlands Cancer Center, Bowral, New South Wales, Australia|Concord Repatriation General Hospital, Concord, New South Wales, Australia|Breast Center, Gateshead, New South Wales, Australia|Port Mcquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Private Hospital, Randwick, New South Wales, Australia|Tamworth Base Hospital, Tamworth, New South Wales, Australia|Tweed Heads Hospital, Tweed Heads, New South Wales, Australia|Calvary Mater Newcastle, Waratah, New South Wales, Australia|North West Regional Hospital, Burnie, Tasmania, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Maroondah Hospital, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Landeskrankenhaus Feldkirch, Feldkirch, Austria|Medizinische Universitaet Graz, Graz, Austria|Innsbruck Universitaetsklinik, Innsbruck, Austria|Krankenhaus BHS Linz, Linz, Austria|Allgemeines Krankenhaus Linz, Linz, Austria|St. Johanns-Spital, Salzburg, Austria|Medical University of Vienna, Vienna, Austria|Allgemeines Krankenhaus - Universitatskliniken, Vienna, Austria|Krankenhaus Lainz, Vienna, Austria|Hanusch-Krankenhaus, Vienna, Austria|LKH Villach, Villach, Austria|Klinikum Kreuzschwestern Wels GmbH, Wels, Austria|Ziekenhuis Netwerk Antwerpen Middelheim, Antwerpen, Belgium|Cliniques du Sud Luxembourg, Arlon, Belgium|Imelda vzw, Ziekenhuis, Bonheiden, Belgium|AZ Klina, Brasschaat, Belgium|Institut Jules Bordet, Brussels, Belgium|Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Centre Hospitalier Universitaire Brugmann, Brussels, Belgium|Algemeen Ziekenhuis Sint-Maarten - Campus Rooiberg, Duffel, Belgium|Universitair Ziekenhuis Gent, Ghent, Belgium|Hopital de Jolimont, Haine Saint Paul, Belgium|Virga Jesse Hospital, Hasselt, Belgium|Centre Hospitalier Hutois, Huy, Belgium|AZ Groeninge - Oncologisch Centrum, Kortrijk, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Centre Hospitalier de l'Ardenne, Libramont, Belgium|Centre Hospitalier Regional de la Citadelle, Liege, Belgium|Clinique Saint-Joseph, Liege, Belgium|CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium|Jan Palfijn Hospital, Merksem, Belgium|AZ Damiaan, Oostende, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|Clinique Saint Vincent, Rocourt, Belgium|AZ Nikolaas - Sint-Niklaas, Sint-Niklaas, Belgium|Sint-Elisabethziekenhuis, Turnhout, Belgium|Centre Hospitalier Peltzer-La Tourelle, Verviers, Belgium|Hospital Santiago Oriente Dr. Luis Tisne Brousse, Penalolen, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Hospital Clinico San Borja Arriaran, Santiago, Chile|Instituto Nacional Del Cancer, Santiago, Chile|IRAM - Chile, Santiago, Chile|Hospital Clinico Regional de Valdivia at University Austral de Chile, Valdivia, Chile|Hospital Carlos Van Buren, Valparaiso, Chile|Aarhus Universitetshospital - Aarhus Sygehus, Aarhus C, Denmark|Copenhagen County Herlev University Hospital, Copenhagen, Denmark|Centralsygehus Esbjerg, Esbjerg, Denmark|Herning Central Hospital, Herning, Denmark|Hillerod Hospital, Hillerod, Denmark|Naestved Hospital, Naestved, Denmark|Odense University Hospital, Odense, Denmark|Bornholms Hospital, Ronne, Denmark|Roskilde Amtssygehuset, Roskilde, Denmark|Sonderborg Sygehus, Sonderborg, Denmark|Vejle Sygehus, Vejle, Denmark|Viborg Sygehus, Viborg, Denmark|Institut Bergonie, Bordeaux, France|Aalen Breast Center, Aalen, Germany|Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany|Allgemeinen Krankenhaus Celle Kinderklinik, Celle, Germany|Klinikum Deggendorf, Deggendorf, Germany|Praxis Dr. Wilke - Onkologie am Klinikum Fuerth, Fuerth, Germany|Vinzenzkrankenhaus Hannover gGmbH, Hannover, Germany|Henriettenstiftung Krankenhaus, Hannover, Germany|Gynaekologisch-onkologische Praxis Hannover, Hannover, Germany|Frauenheilkunde u. Geburtshilfe, Ilsede, Germany|Asklepios Klinik Lich, Lich, Germany|Gemeinschaftspraxis Gynaekologie & Geburtshilfe, Mannheim, Germany|Klinikum Meiningen GmbH, Meiningen, Germany|Klinikum Memmingen, Memmingen, Germany|Klinikum Offenback GmbH, Offenbach, Germany|Deaconess Hospital, Schwabisch Hall, Germany|Johanniter Kankenhaus Stendal, Stendal, Germany|SRH Zentralklinikum Suhl GmbH, Suhl, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|National Institute of Oncology - Budapest, Budapest, Hungary|Szeged University, Szeged, Hungary|Tata Memorial Hospital, Mumbai, India|Centro di Riferimento Oncologico - Aviano, Aviano, Italy|Ospedale degli Infermi - ASL 12, Biella, Italy|Azienda Sanitaria di Bolzano, Bolzano, Italy|Spedali Civili di Brescia, Brescia, Italy|A. Perrino Hospital, Brindisi, Italy|Azienda Istituti Ospitalieri, Cremona, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|European Institute of Oncology, Milan, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Misericordia e Dolce Hospital, Prato, Italy|Ospedale Civile Rimini, Rimini, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Osaka Rosai Hospital, Sakai, Osaka, Japan|Sagara Hospital, Kagoshima, Japan|Kumamoto University Faculty of Medical and Pharmaceutical Sciences, Kumamoto, Japan|Kyoto University Hospital, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Yao Municipal Hospital, Osaka, Japan|Tokyo Metropolitan - Komagome Hospital, Tokyo, Japan|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Russian Academy of Medical Sciences Cancer Research Center, Moscow, Russian Federation|Tygerberg Hospital, Kapstadt, South Africa|Sandton Oncology Medical Research, Sandton, South Africa|Vall d'Hebron University Hospital, Barcelona, Spain|M. D. Anderson International Espana SA, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Son Llatzer, Palma De Mallorca, Spain|Hospital Sant Joan de Reus, Reus, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital de Torrevieja, Torrevieja, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Lasarettet i Boras, Boras, Sweden|Malarsjukhuset Hospital, Eskilstuna, Sweden|Sahlgrenska University Hospital, Gothenburg, Sweden|Lidkoping Hospital, Lidkoping, Sweden|Skaraborgs Hospital, Skovde, Sweden|Karolinska University Hospital - Huddinge, Stockholm, Sweden|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden, Baden, Switzerland|Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Oncocare Sonnenhof-Klinik Engeriedspital, Bern, Switzerland|AndreasKlinik Cham Zug, Cham, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Brustzentrum Thurgau at Kantonsspital Frauenfeld, Frauenfeld, Switzerland|Kantonsspital Freiburg, Freiburg, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Lago Maggiore Oncology Foundation, Locarno, Switzerland|Ospedale ""la Carita"", Locarno, Locarno, Switzerland|Ospedale Civico, Lugano, Switzerland|Ospedale Beata Vergine, Mendrisio, Switzerland|Kantonsspital Olten, Olten, Switzerland|Hopital Regional de Sion-Herens-Conthey, Sion, Switzerland|Tumor Zentrum ZeTup St. Gallen und Chur, St. Gallen, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Regionalspital, Thun, Switzerland|Kantonsspital Winterthur, Winterthur, Switzerland|Breast Center, Zurich, Switzerland|City Hospital Triemli, Zurich, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|Borders General Hospital, Melrose, England, United Kingdom|Dumfries & Galloway Royal Infirmary, Dumfries, Scotland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT00553410/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/10/NCT00553410/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT00553410"
464,"NCT00412776","Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer",,"Terminated","No Results Available","Carcinoma, Squamous Cell of Head and Neck|Carcinoma, Squamous Cell|Neoplasms, Squamous Cell|Head and Neck Neoplasms|Mouth Neoplasms|Head and Neck Cancer","Drug: Proxinium","Survival|Tumour response, safety and quality of life","Viventia Bio","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","165","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VB4-845-01-IIIA","December 2005","April 2008","April 2008","December 18, 2006",,"December 23, 2015","Hospital Italiano Regional del Sur, Bahia Blanca, Argentina|Hospital Municipal de Agudos Leonidas Lucero, Bahia Blanca, Argentina|Centro de Estudio y Tratamiento de las Enfermedades Neoplasicas (CETEN), Buenos Aires, Argentina|Hospital de Clinicas ""Jose de San Martin"", Buenos Aires, Argentina|Hospital Nacional Alejandro Posadas, Buenos Aires, Argentina|Hospital Universitario Austral, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Argentina|Hospital Italiano Garibaldi, Rosario, Argentina|Hospital de Câncer de Barretos - Fundação Pio XII, Barretos, Brazil|Cettro - Centro de Tratamento Oncológico Ltda., Brasilia, Brazil|Centro Regional Integrado de Oncologia - CRIO, Fortaleza, Brazil|Hospital Araújo Jorge, Goiania - GO, Brazil|Hospital Amaral Carvalho, Jau, Brazil|Pro-Onco Centro De Tratamento Oncológico S/C Ltda, Londrina, Brazil|Biocor - Hospital de Doenças Cardiovasculares Ltda, Nova Lima, Brazil|CECAN - Centro do Câncer Francisco Cunha Filho, Piracicaba, Brazil|Hospital São Lucas da PUCRS, Porto Alegre - RS, Brazil|Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre - RS, Brazil|Instituto Ribeirãopretano de Combate ao Câncer, Riberao Preto-SP, Brazil|INCA - Instituto Nacional do Câncer, Rio de Janeiro, Brazil|SOS Vida - Soluções em Saúde, Salvador - BA, Brazil|Santo André Diagnósticos e Tratamentos Ltda, Santo Andre-SP, Brazil|Grupo de Pesquisas Médicas, São Paulo - SP, Brazil|Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo - SP, Brazil|Hospital Do Câncer A. C. Camargo, São Paulo, Brazil|Clinical Hospital ""Sestre milosrdnice"", Zagreb, Croatia|Clinical Hospital Centre Zagreb, Clinic for ENT, Department for Head and Neck Surgery, Zagreb, Croatia|Universtity Hospital for Tumors, Department for Head and Neck Surgery, Zagreb, Croatia|Centre Georges-Francois Leclerc, Dijon, France|Clinique Guillaume Le Conquerant, Le Havre, France|Centre Régional de Lutte contre le Cancer Val d'Aurelle, Montpellier, France|Charité -Universitätsmedizin Berlin, Berlin, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universität Heidelberg, Heidelberg, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitätsklinikum Schleswig Holstein, Lübeck, Germany|Johannes Gutenberg-Universität, Mainz, Germany|Klinikum der Philipps-Universität Marburg, Marburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Fovarosi Onkormanyzat Uzsoki utcai Korhaza, Fej-nyaksebeszet, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|Debreceni Egyetem OEC, Onkologiai Tanszek, Debrecen, Hungary|Petz Aladar Megyei Korhaz, Ful-orr-gege, Fej, Nyak Sebeszet, Gyor, Hungary|Department of Medical Oncology, Bangalore Institute of Oncology, Bangalore, India|Kidwai Memorial Institute of Oncology, Bangalore, India|Global Hospitals, Hyderabaad, India|MNJ Institute of Oncology, Hyderabaad, India|Nizam's Institute of Medical Sciences, Hyderabaad, India|Birla Cancer Institute SMS Medical College Hospital, Jaipur, India|SK Soni Hospital, Jaipur, India|Soumya Hospita, Karkhana, India|Amrita Institute of Medical Sciences and Research Centre, Kochin, India|Netaji Subash Chandra Bose Cancer Research Institute, Kolkata, India|Orchid Nursing Home, Kolkata, India|Department of Medical Oncology Dayanand Medical College & Hospital, Ludhiana, India|Asian Institute of Oncology, S L Raheja Hospital, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Department of Medical Oncology AIIMS, Institute Rotary Cancer Hospital, New Delhi, India|Department of Medical Oncology Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India|Regional Cancer Centre, Trivandrum, India|Soroka University Medical Center, Beer Sheva, Israel|The Lady Davis Carmel Medical Center, Haifa, Israel|Haddasa Ein Carem Hospital, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Kaplan Medical Center, Rehovot, Israel|Tel Aviv University Medical School, Tel Aviv, Israel|Sheba - Medical Center, Tel-Hashomer, Israel|Azienda Ospedaliera San Gerardo, Monza, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera Pisana, Pisa, Italy|Hospital Clínica del Parque, Chihuahua, Chih., Mexico|Centro Anticanceroso de la Cruz Roja Mexicana de Mérida, Merida, Mexico|OCA Hospital, Monterrey N.L., Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosi, SLP, Mexico|Hospital ""Dr. Angel Leaño"", Zapopan, Jalisco, Mexico|Swietokrzyskie Centrum Onkologii, Kielce, Poland|Wojewodzki Szpital Specjalistyczny im. L.Rydygiera, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. Mikolaja Kopernika, Regionalny Osrodek Onkologiczny, Lodz, Poland|Zaklad Opieki Zdrowotnej MSWiA z Warminsko-Mazurskim Centrum Onkologii, Olsztyn, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej, Opolskie Centrum Onkologii, Opole, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Centrum Onkologii Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|""Prof. Dr. I. Chiricuta"" Institute of Oncology Medical Oncology and Radiotherapy II Department, Cluj-Napoca, Romania|Oradea Clinical County Hospital Department of Medical Oncology, Oradea, Romania|Regional Oncology Dispensary, Astrakhan, Russian Federation|Sverdlovsk Regional Oncology Dispensary, Ekaterinburg, Russian Federation|State Medical Institution Kursk Regional Oncology Dispensary Out-patient department, Kursk, Russian Federation|Central Clinical Hospital #2 after MA Semashko OAO ""RRW"", Moscow, Russian Federation|Moscow Scientific-Research Oncology Institute after P.A. Gertsen, Moscow, Russian Federation|SI Russian Oncology Scientific Center after NN Blokhin RAMS, Moscow, Russian Federation|PHI OAO RRW Railway Clinical Hospital at station Gorkiy, Nizhniy Novgorod, Russian Federation|Stavropol Regional Oncology Center, Pyatigorsk branch Out-patient department, Pyatigorsk, Russian Federation|PHI Dorozhnaya Clinical Hospital at Saratov II Station of Pryvolzhskaya railway OAO Russian Railways, Saratov, Russian Federation|SIH Leningrad Regional Oncology Dispansery, St. Petersburg, Russian Federation|SPBSIH City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Tambov Regional Oncological Dispensary Surgery Department, Tambov, Russian Federation|Republican Clinical Oncological Dispenser Radiological Therapy, Ufa, Russian Federation|State Medical Institution Regional Clinical Oncology Dispensary, Ulyanovsk, Russian Federation|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy (MMA) Clinic for Maxillofacial Surgery, Belgrade, Serbia|Teaching Hospital with Policlinic of F. D. Roosevelt Department of Otorhinolaryngology and Surgery, Banská Bystrica, Slovakia|Oncology Institute of St. Elisabeth Clinic of Stomatology and Maxillofacial Surgery, Bratislava, Slovakia|Teaching Hospital with Policlinic Bratislava 1st Clinic of Otorhinolaryngology, Bratislava, Slovakia|Vychodoslovensky oncologicky ustav a.s., Kosice, Slovakia|Teaching Hospital with Policlinic Nové Zámky Clinic of Otorhinolaryngology, Nove Zamky, Slovakia|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Provincial de Pontevedra, Pontevedra, Spain|Hospital Universitario de Salamanca, Salamanca, Castilla y León, Spain|Chernovtsy Regional Oncology Center, Chernivtsy, Ukraine|Kharkov Regional Clinical Oncology Dispensary, Kharkov, Ukraine|Institute of Oncology of AMS of Ukraine, Kiev, Ukraine|Institute of Otolaryngology, Kiev, Ukraine|Volyn Regional Oncology Dispensary, Lutsk, Ukraine|Uzhgorod National University, Uzhorod, Ukraine|Zaporozhye Regional Clinical Oncology Dispensary, Zaporozhye, Ukraine|University Hospital Aintree, Liverpool, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00412776"
465,"NCT03761225","Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer",,"Completed","No Results Available","Metastatic Castrate Resistant Prostate Cancer","Drug: Masitinib|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo","Progression Free Survival|Overall Survival","AB Science","Male","18 Years and older   (Adult, Older Adult)","Phase 3","714","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AB12003","September 2014","December 15, 2020","December 15, 2020","December 3, 2018",,"June 11, 2021","Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Canada|Polyclinique d'oncologie de Gentilly, Nancy, France|Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India|Centro di Riferimento Oncologico, Aviano, Italy|Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Universiti Malaya Medical Centre, Kuala Lumpur, Malaysia|Clinical Oncology Dispensary, Omsk, Russian Federation|Clinic Andros LLC, St. Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03761225"
466,"NCT00002476","Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer",,"Completed","No Results Available","Head and Neck Cancer","Biological: bleomycin sulfate|Drug: fluorouracil|Drug: leucovorin calcium|Drug: methotrexate|Drug: vincristine sulfate|Radiation: low-LET cobalt-60 gamma ray therapy|Radiation: low-LET photon therapy|Radiation: radiation therapy",,"Cancer Research UK|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Other","Interventional","Primary Purpose: Treatment","CRC-PHASE-III-91001|CDR0000076951|UKHAN-1","January 1990",,"January 2010","June 9, 2004",,"August 2, 2013","Raj Tilak, Indore, India|Royal Sussex County Hospital, Brighton, England, United Kingdom|Middlesex Hospital- Meyerstein Institute, London, England, United Kingdom|Derriford Hospital, Plymouth, England, United Kingdom|Southend General Hospital, Westcliff-On-Sea, England, United Kingdom|Royal Victoria Hospital, Belfast, Northern Ireland, United Kingdom|Belfast City Hospital Trust, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00002476"
467,"NCT00293540","Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer",,"Completed","Has Results","Breast Cancer","Procedure: oophorectomy|Drug: Tamoxifen","Overall Survival","International Breast Cancer Research Foundation|Breast Cancer Research Foundation","Female","18 Years and older   (Adult, Older Adult)","Phase 3","249","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OSU-0476","February 2006","February 2014","March 2015","February 17, 2006","June 28, 2016","July 27, 2016","Ohio State University, Columbus, Ohio, United States|Dhaka Medical College Hospital, Dhaka, Bangladesh|4th Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Beijing Hospital, Beijing, China|Cancer Institute, Beijing, China|Choa Yang Capital Institute, Beijing, China|National Railroad, Beijing, China|Peoples Hospital, Beijing, China|Qilu Hospital, Ji Nan, China|Fudan University, Shanghai, China|Nizam's Institute, Hyderabaad, India|Dr. Ciptomanounkusumo General Hospital, Jakarta, Indonesia|UN. Mayala, Kuala Lumpur, Malaysia|National Institute of Oncology, Rabat, Morocco|University College Hospital, Ibadan, Nigeria|East Avenue Medical Center, Manila, Philippines|Jose Reyes, Manila, Philippines|Philippines General Hospital, Manila, Philippines|Rizal, Manila, Philippines|Vicente Sotto Hospital, Manila, Philippines|Hospital K, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT00293540"
468,"NCT03056755","Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","BYLieve","Active, not recruiting","No Results Available","Breast Cancer","Drug: Alpelisib|Drug: Fulvestrant|Drug: Letrozole|Drug: Goserelin|Drug: Leuprolide","Percentage of participants who are alive without disease progression at 6 months|Progression free survival (PFS) for each cohort|Progression free survival (PFS) on next line treatment PFS2) for each cohort|Overall response rate (ORR) for each cohort|Clinical benefit rate (CBR) for each cohort|Duration of response (DOR)|Overall suvivial (OS) for each cohort|Percentage of participants with clinical benefit as assessed by the Investigator during the extension phase","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","383","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CBYL719X2402|2016-004586-67","August 14, 2017","June 14, 2021","July 17, 2023","February 17, 2017",,"May 16, 2022","Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Mayo Clinic (Arizona), Phoenix, Arizona, United States|Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C, Anaheim, California, United States|Beverly Hills Cancer Center, Beverly Hills, California, United States|University of Calif Irvine Medical Center, Orange, California, United States|Kaiser Permanente Southern California, San Diego, California, United States|University of California, San Francisco, San Francisco, California, United States|Yale University Yale Cancer Center, New Haven, Connecticut, United States|Advent Health Cancer Institute, Orlando, Florida, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Louisville Hospital/James Brown Cancer Ctr. SC, Louisville, Kentucky, United States|Mercy Medical Center, Baltimore, Maryland, United States|Greater Baltimore Medical Center Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|Josephine Ford Cancer Institute, Detroit, Michigan, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Memorial Sloane Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland Seidman Cancer Center, Cleveland, Ohio, United States|Texas Oncology Charles A. Sammons Cancer Ctr, Dallas, Texas, United States|Cancer Care Centers of South Texas HOAST CCC of So. TX- San Antonio(2), San Antonio, Texas, United States|UT Health San Antonio, San Antonio, Texas, United States|Virginia Oncology Associates SC, Norfolk, Virginia, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Sante Fe, Argentina|Novartis Investigative Site, La Rioja, Argentina|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Temuco, Araucania, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Vejle, Denmark|Novartis Investigative Site, Nice Cedex 2, Alpes Maritimes, France|Novartis Investigative Site, Saint-Cloud, Hauts De Seine, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Montpellier Cedex 5, France|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Toulouse Cedex 9, France|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Osaka-city, Osaka, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Jalisco, Mexico|Novartis Investigative Site, Maastricht, AZ, Netherlands|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Castellon, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Sutton, Surrey, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03056755"
469,"NCT00417079","XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer","TROPIC","Completed","Has Results","Neoplasms|Prostatic Neoplasms","Drug: cabazitaxel (XRP6258) (RPR116258)|Drug: mitoxantrone|Drug: prednisone","Overall Survival|Time to Progression Free Survival (PFS)|Overall Tumor Response|Time to Tumor Progression|Time to Prostatic Specific Antigen (PSA) Progression|PSA (Prostate-Specific Antigen) Response|Time to Pain Progression|Pain Response","Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 3","755","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC6193","January 2007","September 2009","September 2009","December 29, 2006","December 23, 2010","March 10, 2011","sanofi-aventis US, Bridgewater, New Jersey, United States|sanofi-aventis Argentina, Buenos Aires, Argentina|sanofi-aventis Belgium, Diegem, Belgium|sanofi-aventis Brazil, Sao Paulo, Brazil|sanofi-aventis Canada, Laval, Quebec, Canada|sanofi-aventis Chile, Santiago, Chile|sanofi-aventis Czech Republic, Praha, Czech Republic|sanofi-aventis Denmark, Horsholm, Denmark|sanofi-aventis Finland, Helsinki, Finland|sanofi-aventis France, Paris, France|sanofi-aventis Germany, Berlin, Germany|Sanofi-Aventis Hungaria, Budapest, Hungary|sanofi-aventis India, Mumbai, India|sanofi-aventis Italy, Milano, Italy|sanofi-aventis South Korea, Seoul, Korea, Republic of|sanofi-aventis Mexico, Mexico, Mexico|sanofi-aventis Netherlands, Gouda, Netherlands|sanofi-aventis Russia, Moscow, Russian Federation|sanofi-aventis Singapore, Singapore, Singapore|sanofi-aventis Slovakia, Bratislava, Slovakia|sanofi-aventis South Africa, Midrand, South Africa|sanofi-aventis Spain, Barcelona, Spain|sanofi-aventis Sweden, Bromma, Sweden|sanofi-aventis Taiwan, Taipei, Taiwan|sanofi-aventis Turkey, Istanbul, Turkey|sanofi-aventis UK, Guildford, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00417079"
470,"NCT05152147","A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","HERIZON-GEA-01","Recruiting","No Results Available","Gastric Neoplasms|Gastroesophageal Adenocarcinoma|Esophageal Adenocarcinoma","Drug: Zanidatamab|Drug: Tislelizumab|Drug: Trastuzumab|Drug: Capecitabine|Drug: Oxaliplatin|Drug: Cisplatin|Drug: 5-Fluorouracil|Diagnostic Test: In situ hybridization (ISH)-based companion diagnostic assay|Diagnostic Test: Immunohistochemistry (IHC)-based companion diagnostic assay","Progression-free survival (PFS) by blinded independent central review (BICR)|Overall survival|Confirmed objective response rate (ORR) by BICR|Duration of response (DOR) by BICR|PFS per Investigator assessment|ORR per Investigator assessment|DOR per Investigator assessment|Incidence of adverse events|Incidence of clinical laboratory abnormalities|Health-related quality of life (HRQoL) as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (core cancer questionnaire) C30 (QLQ-C30)|HRQoL as assessed by the EORTC Quality of Life Questionnaire (oesophago-gastric module) OG25 (QLQ-OG25)|HRQoL as assessed by the EuroQol 5-dimensions 5-levels (EQ-5D-5L) questionnaire|Serum concentration of zanidatamab, tislelizumab, and trastuzumab|Incidence of anti-drug antibodies (ADAs)","Zymeworks Inc.|BeiGene, Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","714","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ZWI-ZW25-301|2021-000296-36","December 2, 2021","June 2024","July 2025","December 9, 2021",,"May 16, 2022","Instituto de Investigaciones Metabólicas - IDIM, Ciudad Autónoma de Buenos Aires, Argentina|Fundación Centro de Medicina Nuclear y Molecular E, Córdoba, Argentina|Centro Médico Privado CEMAIC, Córdoba, Argentina|Research Site, Parque Patricios, Argentina|Centro de Investigación Pergamino S.A., Pergamino, Argentina|Centro de Investigaciones Médicas Tucumán, San Miguel De Tucumán, Argentina|Research Site, Viedma, Argentina|Border Medical Oncology Research Unit, Albury, Australia|Research Site, Bedford Park, Australia|Austin Health, Heidelberg, Australia|Liverpool Hospital, Liverpool, Australia|Fional Stanley Hospital, Murdoch, Australia|Imelda VZW, Bonheiden, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|Research Site, Brussels, Belgium|UZ Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Research Site, Liège, Belgium|Research Site 1, Barretos, Brazil|Research Site 2, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Brasília, Brazil|Research Site, Fortaleza, Brazil|Research Site, Ijuí, Brazil|Research Site 1, Porto Alegre, Brazil|Research Site 2, Porto Alegre, Brazil|Research Site 3, Porto Alegre, Brazil|Research Site 4, Porto Alegre, Brazil|Research Site, Rio De Janeiro, Brazil|Research Site, Santo André, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Montreal, Canada|Research Site, Toronto, Canada|Corporacion de Beneficencia Osorno, Osorno, Chile|Centro de Estudios Clínicos SAGA SpA, Providencia, Chile|Research Site, Providencia, Chile|Meditek Ltda, Recoleta, Chile|Sociedad Oncovida S.A, Santiago, Chile|Icegclinic, Santiago, Chile|BIOCINETIC SpA, Santiago, Chile|Sociedad de Investigaciones Medicas Limitada, Temuco, Chile|Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China|Beijing Tiantan Hospital, Capital Medical University, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University Third Hospital, Beijing, China|Beijing Luhe Hospital, Capital Medical University, Beijing, China|Research Site 1, Beijing, China|Research Site 2, Beijing, China|Research Site 3, Beijing, China|The First Affiliated Hospital of Bengbu Medical College, Bengbu, China|Research Site, Changchun, China|Hunan Cancer Hospital, Changsha, China|Changzhi People Hospital, Changzhi, China|Research Site, Changzhou, China|Sichuan Cancer Hospital & Institute, Chengdu, China|Foshan First People's Hospital, Foshan, China|The First Affiliated Hospital of Fujian Medical University, Fuzhou, China|Fujian Cancer Hospital, Fuzhou, China|The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China|Research Site, Guangzhou, China|Hainan General Hospital, Haikou, China|Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Research Site 1, Hangzhou, China|Research Site 2, Hangzhou, China|Research Site, Harbin, China|Anhui Provincial Cancer Hospital, Hefei, China|The Second Affiliated Hospital of Anhui Medical University, Hefei, China|Research Site, Hohhot, China|Shandong Cancer Hospital, Jinan, China|Jinan Cancer Hospital, Jinan, China|Research Site, Jining, China|Research Site, Kunming, China|The First Hospital of Lanzhou University, Lanzhou, China|Gansu Provincial Cancer Hospital, Lanzhou, China|The First Affiliated Hospital of Nanchang University, Nanchang, China|Research Site, Nanjing, China|The Affiliated Hospital of Qingdao University, Qingdao, China|Fudan University Affiliated Zhongshan Hospital, Shanghai, China|Research Site 1, Shanghai, China|Research Site 2, Shanghai, China|Research Site 3, Shanghai, China|Research Site 4, Shanghai, China|Research Site 5, Shanghai, China|Research Site, Shangrao, China|Research Site 1, Shenyang, China|Research Site 2, Shenyang, China|Peking University Shenzhen Hospital, Shenzhen, China|Research Site, Shenzhen, China|Research Site, Shijiazhuang, China|Tianjin Medical University General Hospital, Tianjin, China|Tianjin Medical University Cancer Institute & Hospital, Tianjin, China|The Tonghua Central Hospital, Tonghua, China|Weihai Municipal Hospital, Weihai, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|Union Hospital Tongji Medical College HuaZhong University of Science and Technology, Wuhan, China|Hubei Cancer Hospital, Wuhan, China|Research Site, Wuxi, China|First Affiliated Hospital of Xi 'an Jiaotong University, Xi'an, China|Research Site, Xi'an, China|Research Site, Xiamen, China|Northern Jiangsu People's Hospital, Yangzhou, China|Research Site, Yangzhou, China|Research Site 1, Zhengzhou, China|Research Site 2, Zhengzhou, China|Research Site 3, Zhengzhou, China|Cancer Hospital affiliated to Xinjiang Medical University, Ürümqi, China|Research Site, Hradec Králové, Czechia|Research Site 1, Tallinn, Estonia|Research Site 2, Tallinn, Estonia|Institut Sainte Catherine, Avignon, France|Hopital Jean Minjoz, Besançon, France|EDOG - Institut Bergonie - PPDS, Bordeaux, France|Research Site, Dijon, France|Research Site, Grenoble, France|Research Site, Lyon, France|Research Site, Nantes, France|CHRU de Poitiers La Miletrie, Poitiers, France|EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes, France|CHRU de Brest - Hopital Morvan, Saint-Priest-en-Jarez, France|Hôpital de Rangueil, Toulouse, France|Hôpital Saint Antoine, Villejuif, France|Research Site 1, Tbilisi, Georgia|Research Site 2, Tbilisi, Georgia|Research Site 3, Tbilisi, Georgia|Research Site 4, Tbilisi, Georgia|Research Site, Frankfurt am Main, Germany|Research Site, Hannover, Germany|Research Site, Leipzig, Germany|Research Site, Trier, Germany|Research Site, Ulm, Germany|Aretaieio Hospital of Athens, Athens, Greece|Attikon University General Hospital, Athens, Greece|Research Site, Piraeus, Greece|Bioclinic Thessaloniki Oncology Department, Thessaloniki, Greece|Agios Loucas Clinic SA, Thessaloniki, Greece|Interbalkan Medical Center of Thessaloniki Oncology Department, Thessaloniki, Greece|Research Site 1, Guatemala City, Guatemala|Research Site 2, Guatemala City, Guatemala|Research Site 3, Guatemala City, Guatemala|Research Site, Salcaja, Guatemala|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, Bangalore, India|Research Site, Bhubaneswar, India|Research Site, Gurgaon, India|Research Site, Hyderabad, India|Research Site, Jaipur, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Patna, India|Research Site, Pune, India|Research Site, Vijayawada, India|Research Site 1, Dublin, Ireland|Research Site 2, Dublin, Ireland|Research Site, Bologna, Italy|Research Site, Candiolo, Italy|Research Site, Genova, Italy|Research Site, Meldola, Italy|Research Site 1, Milano, Italy|Research Site 2, Milano, Italy|Research Site 3, Milano, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Centro Ricerche Cliniche Di Verona, Verona, Italy|Research Site, Vicenza, Italy|Hallym University Sacred Heart Hospital, Anyang-si, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnam-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Gangnam Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Research Site, George Town, Malaysia|Research Site 1, Kuala Lumpur, Malaysia|Research Site 2, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Putrajaya, Malaysia|Research Site 1, Mexico City, Mexico|Research Site 2, Mexico City, Mexico|Research Site 3, Mexico City, Mexico|Research Site, Monterrey, Mexico|Research Site, Oaxaca, Mexico|Research Site, Eindhoven, Netherlands|Research Site, Groningen, Netherlands|Research Site, Leiden, Netherlands|Research Site, Tilburg, Netherlands|Research Site, Arequipa, Peru|Research site, Bellavista, Peru|Research Site, Chiclayo, Peru|Research Site, Jesús María, Peru|Research Site 1, Lima, Peru|Research Site 2, Lima, Peru|Research Site 3, Lima, Peru|Research Site 4, Lima, Peru|Research Site 5, Lima, Peru|Research Site, Santiago de Surco, Peru|Research Site 1, Trujillo, Peru|Research Site 2, Trujillo, Peru|Centrum Medyczne Poznan - PRATIA - PPDS, Skórzewo, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Łódź, Poland|Research Site, Almada, Portugal|Research Site, Coimbra, Portugal|Research Site, Guimarães, Portugal|Centro Hospitalar Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, Portugal|Research Site, Loures, Portugal|Research Site 1, Porto, Portugal|Research Site 2, Porto, Portugal|Research Site 3, Porto, Portugal|Research Site 4, Porto, Portugal|Fundeni Clinical Institute, București, Romania|Cardiomed SRL, Cluj-Napoca, Romania|Prof Dr I Chiricuta Institute of Oncology - PPDS, Cluj-Napoca, Romania|Medisprof SRL, Cluj-Napoca, Romania|Onco Clinic Consult SA, Craiova, Romania|Oncology Center Sfantul Nectarie, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Research Site 1, Belgrade, Serbia|Research Site 2, Belgrade, Serbia|Research Site 3, Belgrade, Serbia|Research Site 4, Belgrade, Serbia|Research site, Niš, Serbia|Research Site, Sremska Kamenica, Serbia|Research site 1, Singapore, Singapore|Research site 2, Singapore, Singapore|Research site, Cape Town, South Africa|Research site, Mogale City, South Africa|Research site 1, Pretoria, South Africa|Research site 2, Pretoria, South Africa|Corporacio Sanitaria Parc Tauli, Sabadell, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Spain|Hospital Universitario Vall d'Hebron - PPDS, Barcelona, Spain|Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz - PPDS, Madrid, Spain|Hospital Regional Universitario de Malaga - Hospital General, Málaga, Spain|Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitario Miguel Servet, Zaragoza, Spain|China Medical University Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Research site, Bangkok Noi, Thailand|Research Site 1, Bangkok, Thailand|Research Site 2, Bangkok, Thailand|Research site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research site, Lak Si, Thailand|Research site 1, Phitsanulok, Thailand|Research site 2, Phitsanulok, Thailand|Research site, Antalya, Turkey|Research site, Balçova, Turkey|Research site, Bursa, Turkey|Research site, Denizli, Turkey|Research site, Edirne, Turkey|Research site, Fatih, Turkey|Research site, Sur, Turkey|Research site, Tarabya, Turkey|Research site, Trabzon, Turkey|Research site, Yenimahalle, Turkey|Research site, Çankaya, Turkey|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council - PPDS, Dnipropetrovsk, Ukraine|Communal Non-profit Enterprise Regional Center of Oncology, Kharkiv, Ukraine|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|Medical Center of Limited Liability Company ""Medical center ""VERUM EXPERT"", Kyiv, Ukraine|Treatment and Diagnostic Center of LLC Specialized Clinic Prognosis Optima, Kyiv, Ukraine|SI ""National Institute of Surgery and Transplantology n.a. O.O. Shalimov "" of NAMS of Ukraine, Kyiv, Ukraine|Communal Nonprofit Enterprise Kyiv City Clinical Oncological Center, Kyiv, Ukraine|The Municipal Enterprise Volyn Regional Medical Oncology Centre of the Volyn Regional Council, Lutsk, Ukraine|Municipal Non-profit Enterprise ""Odessa Regional Oncology Dispensary"" of Odesa RC, Odesa, Ukraine|Research site, Bristol, United Kingdom|Research site, Edgbaston, United Kingdom|Research site, Edinburgh, United Kingdom|Research site, Leeds, United Kingdom|Research site 1, London, United Kingdom|Research site 2, London, United Kingdom|Research site 3, London, United Kingdom|Research site, Northwood, United Kingdom|Edith Cavell Hospital, Peterborough, United Kingdom|Research site, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05152147"
471,"NCT00665197","Palliative Radiotherapy and Brachytherapy for Oesophageal Cancer Dysphagia",,"Completed","No Results Available","Esophageal Cancer","Radiation: Protracted Course Radiotherapy|Radiation: Short Course Radiotherapy","Dysphagia relief|Quality of life|Treatment Toxicity","International Atomic Energy Agency","All","18 Years to 81 Years   (Adult, Older Adult)","Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E3.30.27","February 2007","February 2011","February 2011","April 23, 2008",,"October 13, 2011","Credit Valley Hospital Statistical Centre, Credit Valley, Ontario, Canada|Chinese Academy of Medical Sciences, Beijing, Beijing, China|University of Zagreb Clinical Hospital, Zagreb, Croatia|Tata Memorial Hospital, Mumbai, Parel, India|Institute of Nuclear Medicine and Oncology, Lahore, Punjab, Pakistan|University of the Witwatersrand Department of Radiat. Oncology, Johannesburg, Parktown, South Africa|Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok, Siriraj, Thailand",,"https://ClinicalTrials.gov/show/NCT00665197"
472,"NCT04177108","A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.",,"Active, not recruiting","No Results Available","Triple-Negative Breast Cancer","Drug: Atezolizumab|Drug: Ipatasertib|Drug: Paclitaxel|Drug: Placebo for Atezolizumab|Drug: Placebo for Ipatasertib","Investigator-assessed Progression Free Survival (PFS)|Overall Survival (OS)|Percentage of Participants with Adverse Events (AEs)","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","242","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CO41101|2019-000810-12","November 25, 2019","June 30, 2022","June 30, 2022","November 26, 2019",,"May 6, 2022","USA Mitchell Cancer Institute, Mobile, Alabama, United States|Highlands Oncology Group, Springdale, Arkansas, United States|UCLA, Los Angeles, California, United States|Kaiser Permanente-SCPMG; Oncology Research, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Kaiser Permanente - Franklin, Denver, Colorado, United States|Stamford Hospital; BCC, MOHR, Stamford, Connecticut, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Memorial Healthcare System - Memorial Regional Hospital, Hollywood, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Nancy N. and J.C. Lewis Cancer & Research Pavillion -St. Josephs / Candler Health System-CCD PRIME, Savannah, Georgia, United States|Rush University, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Ochsner Health System, New Orleans, Louisiana, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Medstar Franklin Square Medical Center, Baltimore, Maryland, United States|St. Joseph Mercy Hospital; Cancer Care Center., Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|CHI Health Saint Francis; Oncology, Grand Island, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Hackensack Univ Med Ctr, Hackensack, New Jersey, United States|Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Kaiser Permanente - Portland, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Oncology, P .A, Charleston, South Carolina, United States|Greenville Health System; Cancer Center, Greenville, South Carolina, United States|The West Clinic; West Cancer Center, Germantown, Tennessee, United States|Vanderbilt Univ Medical Ctr, Nashville, Tennessee, United States|Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina|Inst. Angel Roffo; Haematology, Buenos Aires, Argentina|Hospital Britanico, Ciudad Autonoma Bs As, Argentina|Instituto Medico Rio Cuarto, Cordoba, Argentina|Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina|Fundacion Scherbovsky, Mendoza, Argentina|Macquarie University Hospital, Macquarie Park, New South Wales, Australia|Mid North Coast Cancer Institute, Port Macquarie, New South Wales, Australia|Royal North Shore Hospital; Department of Medical Oncology, St Leonards, New South Wales, Australia|Calvary Mater Newcastle; Medical Oncology, Waratah, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Monash Health Monash Medical Centre, Clayton, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Sunshine Hospital; Oncology Research, St Albans, Victoria, Australia|St John of God Hospital; Bendat Cancer Centre, Subiaco, Western Australia, Australia|Tiroler Landeskrankenanstalten Ges.M.B.H.; Abt. Für Gynäkologie, Innsbruck, Austria|Ordensklinikum Linz Barmherzige Schwestern; Interne 1 - Hämato-Onkologie, Linz, Austria|Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU, Salzburg, Austria|Medizinische Universität Wien; Univ.Klinik für Innere Medizin I, Wien, Austria|AZ Maria Middelares, Gent, Belgium|Jessa Zkh (Campus Virga Jesse), Hasselt, Belgium|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, Sao Paulo, SP, Brazil|Núcleo de Pesquisa São Camilo; ONCOLOGIA CLINICA / QUIMIOTERAPIA, Sao Paulo, SP, Brazil|MHAT Nadezhda, Sofia, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Fraser Valley Centre British Columbia Cancer Agency, Surrey, British Columbia, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|Royal Victoria Hospital, Barrie, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|McGill University; Glen Site; Oncology, Montreal, Quebec, Canada|Jewish General Hospital; Research Unit, Montréal, Quebec, Canada|Hopital du Saint Sacrement, Quebec City, Quebec, Canada|Clinica del Country, Bogota, Colombia|Oncólogos de Occidente, Pereira, Colombia|Clinica CIMCA, San José, Costa Rica|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, Denmark|Docrates Cance Center, Helsinki, Finland|KYS Sadesairaala; Syopatautien poliklinikka, Kuopio, Finland|VAASAN KESKUSSAIRAALA; Onkologian poliklinikka, Vaasa, Finland|Centre Eugene Marquis; Service d'oncologie, Rennes, France|Agioi Anargyroi Cancer Hospital; 2Nd Oncology Dept., Kifisia, Greece|Euromedical General Clinic of Thessaloniki; Oncology Department, Thessaloniki, Greece|Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital; Clinical Onc, Hong Kong, Hong Kong|Prince of Wales Hospital; Department of Clinical Onocology, Shatin, Hong Kong|Sahyadri Super Specialty Hospital Hadapsar, Pune, Maharashtra, India|Shaare Zedek Medical Center, Jerusalem, Israel|Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|ASU FC S. M. DELLA MISERICORDIA; Oncologia, Udine, Friuli-Venezia Giulia, Italy|ASST DEGLI SPEDALI CIVILI DI BRESCIA; Oncologia Medica, Brescia, Lombardia, Italy|ASST DI LECCO; Oncologia Medica, Lecco, Lombardia, Italy|IRCCS Istituto Clinico Humanitas; Oncologia, Rozzano, Lombardia, Italy|Ospedale Civile; Unita Operativa Di Oncologia Medica, Livorno, Toscana, Italy|IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|Fukushima Medical University Hospital, Fukushima, Japan|Gunma Prefectural Cancer Center, Gunma, Japan|Hiroshima University Hospital, Hiroshima, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kumamoto Shinto General Hospital, Kumamoto, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Kyungpook National University Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Investigacion Oncofarmaceutica, La Paz, BAJA California SUR, Mexico|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Christus Muguerza Clinica Vidriera, Monterrey, Nuevo LEON, Mexico|Auckland City Hospital, Cancer and Blood Research, Auckland, New Zealand|Tauranga Hospital, Clinical Trials Unit; BOP Clinical School, Tauranga, New Zealand|Wellington Regional Hospital; Clinical Trials Unit, Wellington, New Zealand|Centro Medico Monte Carmelo, Arequipa, Peru|Instituto Regional de Enfermedades Neoplasicas, Arequipa, Peru|Unidad de Investigación Oncologica; Hospital Nacional Daniel Alcides Carrion, Lima, Peru|Clínica San Gabriel; Unidad de Investigación Oncológica de la Clínica San Gabriel, Lima, Peru|Hospital Arzobispo Loayza, Lima, Peru|Oncosalud Sac; Oncología, Lima, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Clinica Ricardo Palma, San Isidro, Peru|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; Centr.Diagn.i Lecz.Chor.Piersi, Gliwice, Poland|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Kraków, Poland|Wielkopolskie Centrum Onkologii, Poznan, Poland|Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Nowotworow Piersi i Chirurgii Rekonstr, Warszawa, Poland|Instyt. Centrum Zdrowia Matki Polki; Klinika Chirurgii Onk. Chorób Piersi z Podod. Onko Klinicznej, Łódź, Poland|Hospital da Luz; Departamento de Oncologia Medica, Lisboa, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|Hospital Beatriz Angelo; Departamento de Oncologia, Loures, Portugal|Centro Hospitalar do Porto - Hospital de Santo António; Oncologia, Porto, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Oncology Center Sf. Nectarie, Craiova, Romania|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Arhangelsk, Russian Federation|University сlinic of headaches, Moscow, Moskovskaja Oblast, Russian Federation|SBIH ""Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM"", Moskva, Moskovskaja Oblast, Russian Federation|Fed State Budgetary Inst ""N.N. Blokhin Med Center of Oncology"" MHRF, Moskva, Moskovskaja Oblast, Russian Federation|FSAI Treatment and rehabilitation Centre Ministry of Health; Clinical research and chemotherapy., Moskva, Moskovskaja Oblast, Russian Federation|Clinical Oncology Dispensary of Ministry of Health of Tatarstan, Kazan, Russian Federation|P.A. Gertsen Cancer Research Inst. ; Chemotherapy Dept, Moscow, Russian Federation|Limited Liability Company ""RC Medical"", Novosibirsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|National Cancer Centre; Medical Oncology, Singapore, Singapore|National Hospital; Oncotherapy Dept, Bloemfontein, South Africa|Cancercare, George, South Africa|Wits Clinical Research, Johannesberg, South Africa|Cancercare, Port Elizabeth, South Africa|Wilgers Oncology Centre, Pretoria, South Africa|Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, A Coruña, LA Coruña, Spain|Hospital Universitario Puerta de Hierro; Servicio de Oncologia, Majadahonda, Madrid, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Centro Integral Oncologico Clara Campal; Servicio de Oncología, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Clínico Universitario de Valencia; Servicio de Oncología, Valencia, Spain|Universitätsspital Basel, Basel, Switzerland|Universitätsspital Zürich Gynäkologische Klinik; Klinik für Gynäkologie, Zürich, Switzerland|China Medical University Hospital; Surgery, Taichung, Taiwan|VETERANS GENERAL HOSPITAL; Department of General Surgery, Taipei, Taiwan|National Taiwan Uni Hospital; General Surgery, Taipei, Taiwan|Chang Gung Memorial Hosipital at Linkou, Taoyuan City, Taiwan|Chulalongkorn Hospital; Medical Oncology, Bangkok, Thailand|Rajavithi Hospital; Division of Medical Oncology, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital; Department of Surgery/Head Neck and Breast Unit; Clinical Trial, Chiang Mai, Thailand|Khonkaen Hospital, Khonkaen, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Memorial Ankara Hastanesi, Ankara, Turkey|Medipol University MF; Oncology Department, Istanbul, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara, Turkey|SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU; Purulent Surgery department, Kharkiv, Kharkiv Governorate, Ukraine|Regional Oncology Center; Department of Mammology, Chernigiv, Ukraine|Chemotherapy SI Dnipropetrovsk MA of MOHU, Dnipropetrovsk, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|MI Kyiv Regional Council Kyiv Regional Oncological Dispensary; Department of Mammology, Kyiv, Ukraine|Municipal Institution Odesa Regional Clinical Hospital, Odesa, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|BEATSON WEST OF SCOTLAND CANCER CENTRE; Clinical Research Unit - Level 1, Glasgow, United Kingdom|The Royal Marsden Hospital, Fulham, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04177108"
473,"NCT04154644","Performance, Safety, and Efficacy of a New Cryotherapy Device for Cervical Dysplasia [Part II]","CryoPop","Completed","No Results Available","Cervical Dysplasia","Device: CryoPop","Efficacy of CryoPop: negative Pap smear and negative biopsy (if performed) on each study participant.|Safety of CryoPop: Incidences of adverse events documented throughout the study.","Jhpiego|Jawaharlal Nehru Medical College","Female","30 Years to 49 Years   (Adult)","Not Applicable","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","1UH3CA189923-01","April 9, 2019","October 31, 2021","November 30, 2021","November 6, 2019",,"January 14, 2022","JN Medical College, Belgaum, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT04154644"
474,"NCT00866970","Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia",,"Completed","No Results Available","NSCLC|Fatigue|Cachexia","Biological: ALD518|Biological: Infusion of 0.9% Saline without ALD518","Change in Safety parameters.|Time to symptomatic progressions at Weeks 12 and 24","CSL Behring","All","18 Years and older   (Adult, Older Adult)","Phase 2","124","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALD518-CLIN-004","September 2008","August 2009","December 2009","March 23, 2009",,"July 9, 2020","Rivercity Hospital Research Centre, Auchenflower, Queensland, Australia|Australian Clinical Research Organisation, Kippa Ring, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Palliative Care Launceston General Hospital, Launceston, Tasmania, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Atlantic Health Sciences Corporation, Saint John, New Brunswick, Canada|McGill University, Department of Oncology, Montreal, Quebec, Canada|A. Gvamichava National Cancer Centre, Tbilisi, Georgia|Union Cancer Prevention Centre, Tbilisi, Georgia|Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia|Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India|Dr. Kamakshi Memorial Hospital, Pallikaranai, Chennai, India|GKNM Hospital, Pappanaickenpalayam, Coimbatore, India|Curie Manavata Cancer Centre, Nasik, Maharashtra, India|Kidwai Memorial Institute of Oncology, Bangalore, India|Kailash Cancer Hospital and Research Centre, Gujarat, India|IndoAmerican Cancer Institute & Research Center, Hyderabad, India|SEAROC Cancer Centre, Jaipur, India|Orchid Nursing Home, Kolkata, India|Tata Memorial Hospital, Mumbai, India|Shatabdi Hospital, Mumbai, India|Mahavir Cancer Sansthan, Patna, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, India|P3 Research LTD, Tauranga, New Zealand|Oddzial Chorob Pluc i Leczenia Raka Pluc, Bydgoszcz, Poland|Oddzial Chemioterapii Szpital Morski, Gdynia, Poland|II Oddzia Chorob Pluc z Pododdzialem Chemioterapii, Krakow, Poland|Oddzial II Chemioterapii Specjalistyczny Szpital, Szczecin, Poland|Professor Dr. Al Trestioreanu Institute, Bucharest, Romania|Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy, Cluj-Napoca, Romania|Oradea Clinical County Hospital Medical Oncology Department, Oradea, Romania|County Hospital Sibiu Medical Oncology Department, Sibiu, Romania|Territorial Clinical Oncology Dispensary, Krasnodar, Krasnodar Territory, Russian Federation|Republic Oncology Dispensary, Ufa, Republic Of Bashkortostan, Russian Federation|Stavropol Territorial Clinical, Pyatigorsk, Stavropol Territory, Russian Federation|City Clinical Hospital No. 1, Novosibirsk, Russian Federation|Saint-Petersburg State Medical University, I.P. Pavlov, Saint-Petersburg, Russian Federation|St. Petersburg City Oncology Dispensary, Saint-Petersburg, Russian Federation|Yaroslavl Regional clinical Oncology Hospital, Yaroslavl, Russian Federation|Institute of Lung Diseases and TB, Belgrade, Serbia|Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia|Clinical Centre Kragujevac, Kragujevac, Serbia|Institute for Pulmonary diseases of Vojvodina, Sremska, Serbia",,"https://ClinicalTrials.gov/show/NCT00866970"
475,"NCT00066703","Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","TEXT","Active, not recruiting","Has Results","Breast Cancer","Drug: exemestane|Drug: tamoxifen|Drug: triptorelin","Disease-free Survival|Breast Cancer-free Interval|Distant Recurrence-free Interval|Overall Survival","International Breast Cancer Study Group|National Cancer Institute (NCI)|Breast International Group","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2672","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCSG 25-02 / BIG 3-02|IBCSG 25-02|BIG 3-02|NABCI IBCSG 25-02|EU-20347|2004-000168-28|CDR0000316458","November 3, 2003","March 11, 2011","December 2025","August 7, 2003","April 5, 2016","March 11, 2021","Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center, Burbank, California, United States|Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|Providence Holy Cross Cancer Center, Mission Hills, California, United States|Desert Regional Medical Center Comprehensive Cancer Center, Palm Springs, California, United States|Sutter Cancer Center at Roseville Medical Center, Roseville, California, United States|Sutter Cancer Center, Sacramento, California, United States|Mercy General Hospital, Sacramento, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Ruby L. Golleher Cancer Program at Presbyterian Intercommunity Hospital, Whittier, California, United States|University of Colorado Cancer Center at UC Health Sciences Center, Aurora, Colorado, United States|Shaw Regional Cancer Center, Edwards, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Front Range Cancer Specialists, Fort Collins, Colorado, United States|Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, United States|Sibley Memorial Hospital, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|Mayo Clinic - Jacksonville, Jacksonville, Florida, United States|Northeast Georgia Medical Center, Gainesville, Georgia, United States|Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise, Idaho, United States|Kootenai Cancer Center - Coeur d'Alene, Coeur d'Alene, Idaho, United States|Resurrection Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|CCOP - Carle Cancer Center, Urbana, Illinois, United States|Elkhart Clinic, LLC, Elkhart, Indiana, United States|Elkhart General Hospital, Elkhart, Indiana, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Howard Community Hospital, Kokomo, Indiana, United States|Center for Cancer Therapy at LaPorte Hospital and Health Services, La Porte, Indiana, United States|Saint Joseph Regional Medical Center, Mishawaka, Indiana, United States|CCOP - Northern Indiana CR Consortium, South Bend, Indiana, United States|Memorial Hospital of South Bend, South Bend, Indiana, United States|Michiana Hematology-Oncology, PC - South Bend, South Bend, Indiana, United States|South Bend Clinic, South Bend, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Cancer Center of Kansas, PA - Chanute, Chanute, Kansas, United States|Cancer Center of Kansas, PA - Dodge City, Dodge City, Kansas, United States|Cancer Center of Kansas, PA - El Dorado, El Dorado, Kansas, United States|Cancer Center of Kansas-Independence, Independence, Kansas, United States|Cancer Center of Kansas, PA - Kingman, Kingman, Kansas, United States|Lawrence Memorial Hospital, Lawrence, Kansas, United States|Cancer Center of Kansas, PA - Newton, Newton, Kansas, United States|Menorah Medical Center, Overland Park, Kansas, United States|Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States|Cancer Center of Kansas, PA - Pratt, Pratt, Kansas, United States|Cancer Center of Kansas, PA - Salina, Salina, Kansas, United States|Shawnee Mission Medical Center, Shawnee Mission, Kansas, United States|Cotton-O'Neil Cancer Center, Topeka, Kansas, United States|Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States|Associates in Womens Health, PA - North Review, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Medical Arts Tower, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Wichita, Wichita, Kansas, United States|CCOP - Wichita, Wichita, Kansas, United States|Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita, Kansas, United States|Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States|Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States|Mercy Medical Center, Baltimore, Maryland, United States|Suburban Hospital, Bethesda, Maryland, United States|Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States|Tufts Medical Center Cancer Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Bethke Cancer Center at Emerson Hospital, Concord, Massachusetts, United States|Addison Gilbert Hospital, Gloucester, Massachusetts, United States|Lowell General Hospital, Lowell, Massachusetts, United States|NSMC Cancer Center - Peabody, Peabody, Massachusetts, United States|MidMichigan Medical Center - Midland, Midland, Michigan, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Lakeland Regional Cancer Care Center - St. Joseph, Saint Joseph, Michigan, United States|Lakeside Cancer Specialists, PLLC, Saint Joseph, Michigan, United States|Fairview Ridges Hospital, Burnsville, Minnesota, United States|Mercy and Unity Cancer Center at Mercy Hospital, Coon Rapids, Minnesota, United States|Fairview Southdale Hospital, Edina, Minnesota, United States|Mercy and Unity Cancer Center at Unity Hospital, Fridley, Minnesota, United States|HealthEast Cancer Care at St. John's Hospital, Maplewood, Minnesota, United States|Virginia Piper Cancer Institute at Abbott - Northwestern Hospital, Minneapolis, Minnesota, United States|Hennepin County Medical Center - Minneapolis, Minneapolis, Minnesota, United States|Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center, Robbinsdale, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States|Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States|Regions Hospital Cancer Care Center, Saint Paul, Minnesota, United States|United Hospital, Saint Paul, Minnesota, United States|Ridgeview Medical Center, Waconia, Minnesota, United States|Truman Medical Center - Hospital Hill, Kansas City, Missouri, United States|Saint Luke's Cancer Institute at Saint Luke's Hospital, Kansas City, Missouri, United States|St. Joseph Medical Center, Kansas City, Missouri, United States|North Kansas City Hospital, Kansas City, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Research Medical Center, Kansas City, Missouri, United States|Heartland Regional Medical Center, Saint Joseph, Missouri, United States|Saint Louis University Cancer Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, Saint Louis, Missouri, United States|Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center, Grand Island, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States|Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton, Marlton, New Jersey, United States|Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare, Vineland, New Jersey, United States|Fox Chase Virtua Health Cancer Program at Virtua West Jersey, Voorhees, New Jersey, United States|Our Lady of Mercy Medical Center Comprehensive Cancer Center, Bronx, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Cancer Institute at New York University Medical Center, New York, New York, United States|Randolph Hospital, Asheboro, North Carolina, United States|Mission Hospitals - Memorial Campus, Asheville, North Carolina, United States|Hope A Women's Cancer Center, Asheville, North Carolina, United States|Moses Cone Regional Cancer Center at Wesley Long Community Hospital, Greensboro, North Carolina, United States|Pardee Memorial Hospital, Hendersonville, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Annie Penn Cancer Center, Reidsville, North Carolina, United States|Aultman Cancer Center at Aultman Hospital, Canton, Ohio, United States|MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States|Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania, United States|Geisinger Hazleton Cancer Center, Hazleton, Pennsylvania, United States|Geisinger Medical Group - Scenery Park, State College, Pennsylvania, United States|Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center, Wilkes-Barre, Pennsylvania, United States|CCOP - Greenville, Greenville, South Carolina, United States|Medical X-Ray Center, PC, Sioux Falls, South Dakota, United States|Sanford Cancer Center at Sanford USD Medical Center, Sioux Falls, South Dakota, United States|Erlanger Cancer Center at Erlanger Hospital - Baroness, Chattanooga, Tennessee, United States|West Tennessee Cancer Center at Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Doctor's Hospital of Laredo, Laredo, Texas, United States|Mountainview Medical, Berlin, Vermont, United States|Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States|Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States|Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown, West Virginia, United States|Langlade Memorial Hospital, Antigo, Wisconsin, United States|Aurora Memorial Hospital of Burlington, Burlington, Wisconsin, United States|Oncology Alliance - Franklin, Franklin, Wisconsin, United States|Oncology Alliance, SC - Milwaukee - East, Glendale, Wisconsin, United States|Oncology Alliance - Kenosha South, Kenosha, Wisconsin, United States|Aurora Advanced Healthcare East Mequon Clinic, Mequon, Wisconsin, United States|Columbia-Saint Mary's Hospital-Ozaukee, Mequon, Wisconsin, United States|Columbia Saint Mary's Water Tower Medical Commons Milwaukee, Mequon, Wisconsin, United States|Oncology Alliance, SC - Milwaukee - South, Milwaukee, Wisconsin, United States|Aurora Health Center - Racine, Racine, Wisconsin, United States|Aurora Health Center - Waukesha, Waukesha, Wisconsin, United States|University of Wisconcin Cancer Center at Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Oncology Alliance, SC - Milwaukee - West, Wauwatosa, Wisconsin, United States|Cancer Therapy Centre at Campbelltown Hospital, Campbelltown, New South Wales, Australia|Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia|Lismore Base Hospital, Lismore, New South Wales, Australia|Cancer Therapy Centre at Liverpool Hospital, Liverpool, New South Wales, Australia|Tamworth Base Hospital, Tamworth, New South Wales, Australia|Manning Base Hospital, Taree, New South Wales, Australia|Tweed Heads Hospital, Tweed Heads, New South Wales, Australia|Newcastle Mater Misericordiae Hospital, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Breast Unit Mercy Private, East Melbourne, Victoria, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|St. Vincent's Hospital - Melbourne, Fitzroy, Victoria, Australia|Austin Hospital, Heidelberg, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Maroondah Hospital, Ringwood East, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Institut Jules Bordet, Brussels, Belgium|Centre Hospitalier Hutois, Huy, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|CHU Liege - Domaine Universitaire du Sart Tilman, Liege, Belgium|Centre Hospitalier Peltzer-La Tourelle, Verviers, Belgium|Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Tom Baker Cancer Centre - Calgary, Calgary, Alberta, Canada|Cross Cancer Institute at University of Alberta, Edmonton, Alberta, Canada|Doctor Leon Richard Oncology Centre, Moncton, New Brunswick, Canada|Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada|Trillium Health Centre - Mississauga Site, Toronto, Ontario, Canada|Windsor Regional Cancer Centre at Windsor Regional Hospital, Windsor, Ontario, Canada|Hopital Charles Lemoyne, Greenfield Park, Quebec, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, Canada|Cairo Oncology Center, Cairo, Egypt|National Cancer Institute of Egypt, Cairo, Egypt|Brustzentrum Klinikum Mittelbaden, Baden-Baden, Germany|Klinikum Deggendorf, Deggendorf, Germany|Frauenklinik des Universitaetsklinikum Erlangen, Erlangen, Germany|Universitaetsfrauenklinik Frankfurt, Frankfurt, Germany|Universitaets-Frauenklinik Goettingen, Göttingen, Germany|St. Vincentius - Kliniken, Karlsruhe, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Universitatsklinik Mainz, Mainz, Germany|Universitaetsfrauenklinik Mannheim, Mannheim, Germany|Klinikum Schwaebisch Gmuend Stauferklinik, Mutlangen, Germany|Klinikum Nuernberg - Klinikum Nord, Nuremberg, Germany|Caritas - Krankenhaus Saint Josef, Regensburg, Germany|Klinikum Obergoeltzsch Rodewisch, Rodewisch, Germany|Klinikum Rosenheim, Rosenheim, Germany|Klinikum Landkreis Tuttlingen, Tuttlingen, Germany|National Institute of Oncology, Budapest, Hungary|Tata Memorial Hospital, Mumbai, India|Centro di Riferimento Oncologico - Aviano, Aviano, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Azienda Sanitaria di Bolzano, Bolzano, Italy|Spedali Civili di Brescia, Brescia, Italy|Ospedale Civile Ramazzini, Carpi, Italy|European Institute of Oncology, Milan, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Misericordia e Dolce Hospital, Prato, Italy|Ospedale Civile Rimini, Rimini, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Policlinico Universitario Udine, Udine, Italy|Ospedale di Circolo e Fondazione Macchi, Varese, Italy|Waikato Hospital, Hamilton, New Zealand|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Institute of Oncology - Ljubljana, Ljubljana, Slovenia|Sandton Oncology Centre, Johannesburg, South Africa|Sahlgrenska University Hospital, Gothenburg, Sweden|University Hospital of Linkoping, Linkoping, Sweden|Skaraborgs Hospital, Skovde, Sweden|Universitaetsspital-Basel, Basel, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, Switzerland|Inselspital Bern, Bern, Switzerland|Oncocare Sonnenhof-Klinik Engeriedspital, Bern, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Onkologie-Praxis ZeTup Chur, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Ospedale ""la Carita"", Locarno, Locarno, Switzerland|Ospedale Civico, Lugano, Switzerland|Ospedale Beata Vergine, Mendrisio, Switzerland|Kantonsspital - St. Gallen, St. Gallen, Switzerland|Regionalspital, Thun, Switzerland|UniversitaetsSpital Zuerich, Zurich, Switzerland|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Peterborough Hospitals Trust, Peterborough, England, United Kingdom|South Tyneside District Hospital, South Shields, England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00066703"
476,"NCT04940052","Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer",,"Recruiting","No Results Available","Differentiated Thyroid Cancer","Drug: Dabrafenib|Drug: Trametinib|Drug: Trametinib placebo|Drug: Dabrafenib placebo","Progression Free Survival|Overall Response Rate|Overall Survival|Duration of response|Number of participants with trametinib associated serous retinopathy ocular events","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CDRB436J12301","November 15, 2021","February 19, 2024","October 30, 2026","June 25, 2021",,"April 22, 2022","Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Tainan, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Adana, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Edirne, Turkey",,"https://ClinicalTrials.gov/show/NCT04940052"
477,"NCT01599754","Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients","ATLAS","Terminated","Has Results","Clear Cell Renal Carcinoma","Drug: Axitinib|Drug: Placebo","Disease Free Survival (DFS) as Assessed by Blinded Independent Review Committee (IRC)|Overall Survival (OS)|Number of Participants With Treatment-Emergent Adverse Events (AE) and Serious Adverse Events (SAEs)|Number of Participants With Treatment-Emergent Treatment Related Adverse Events and Serious Adverse Events (SAEs)|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity|Number of Participants With Laboratory Abnormalities By Maximum CTCAE Grade: Hematology|Number of Participants With Laboratory Abnormalities By Maximum CTCAE Grade: Chemistry|Number of Participants With Laboratory Abnormalities: Thyroid Function|Number of Participants With Laboratory Abnormalities: Urinalysis","SFJ Pharma Ltd. II|Pfizer|SFJ Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","724","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AP311736","April 2012","October 10, 2017","May 2018","May 16, 2012","August 28, 2019","September 20, 2019","La Jolla, California, United States|Los Angeles, California, United States|Palo Alto, California, United States|Pleasant Hill, California, United States|Denver, Colorado, United States|Washington, District of Columbia, United States|Ocala, Florida, United States|Atlanta, Georgia, United States|Annapolis, Maryland, United States|Baltimore, Maryland, United States|Saint Paul, Minnesota, United States|Omaha, Nebraska, United States|Hackensack, New Jersey, United States|Albany, New York, United States|New York, New York, United States|Portland, Oregon, United States|Charleston, South Carolina, United States|Chattanooga, Tennessee, United States|Austin, Texas, United States|Bedford, Texas, United States|Dallas, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Norfolk, Virginia, United States|Seattle, Washington, United States|Beijing, China|Changchun, China|Chongqing, China|Dalian, China|Guangzhou, China|Hangzhou, China|Jinan, China|Nanchang, China|Shanghai, China|Suzhou, China|Tianjin, China|Wuhan, China|Besançon, France|Bordeaux Cedex, France|Hyères, France|Le Mans Cedex 02, France|Lyon, France|Marseille cedex 5, France|Paris Cedex 15, France|Rennes Cedex, France|Saint Herblain, France|Suresnes Cedex, France|Vandoeuvre les Nancy Cedex, France|Hong Kong, Hong Kong|Ahmeadbad, India|Aurangabad, India|Bangalore, India|Chennai, India|Hyderabad, India|Karamsad, India|Kochi, India|Kolkota, India|Lucknow, India|Ludhiana, India|Mangalore, India|Manipal, India|Mumbai, India|Nashik, India|New Delhi, India|Pune, India|Surat, India|Vishakhapatnam, India|Aichi, Japan|Akita, Japan|Aomori, Japan|Chiba, Japan|Fukuoka, Japan|Gifu, Japan|Hokkaido, Japan|Hyogo, Japan|Kagawa, Japan|Kanagawa, Japan|Kumamoto, Japan|Kyoto, Japan|Nagasaki, Japan|Nigata, Japan|Osaka, Japan|Shizuoka, Japan|Tokushima, Japan|Tokyo, Japan|Yamagata, Japan|Yamaguchi,, Japan|Busan, Korea, Republic of|Daegu, Korea, Republic of|Daejeon, Korea, Republic of|Gyeonggi, Korea, Republic of|Jeonnam, Korea, Republic of|Seoul, Korea, Republic of|Barcelona, Spain|Leganes, Spain|Llobregat, Spain|Madrid, Spain|Oviedo, Spain|San Sebastian, Spain|Sevilla, Spain|Valencia, Spain|Zaragoza, Spain|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01599754/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/54/NCT01599754/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01599754"
478,"NCT01234311","A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer",,"Completed","No Results Available","Prostate Cancer","Drug: tasquinimod|Drug: Placebo","A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men with Metastatic Castrate Resistant Prostate Cancer","Active Biotech AB","Male","18 Years and older   (Adult, Older Adult)","Phase 3","1245","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","10TASQ10","March 2011","February 2015","August 2015","November 4, 2010",,"October 21, 2015","Tucson, Arizona, United States|Oxnard, California, United States|Santa Monica, California, United States|Santa Rosa, California, United States|Wellington, Florida, United States|Atlanta, Georgia, United States|Meridian, Idaho, United States|Melrose Park, Illinois, United States|Park Ridge, Illinois, United States|Jeffersonville, Indiana, United States|Baltimore, Maryland, United States|Rockville, Maryland, United States|Boston, Massachusetts, United States|Jefferson City, Missouri, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Lawrenceville, New Jersey, United States|Buffalo, New York, United States|Poughkeepsie, New York, United States|Concord, North Carolina, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Springfield, Oregon, United States|Bala Cynwyd, Pennsylvania, United States|Lancaster, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Myrtle Beach, South Carolina, United States|Nashville, Tennessee, United States|Dallas, Texas, United States|Salt Lake, Utah, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Salem, Virginia, United States|Burien, Washington, United States|Ciudad Autonoma de Buenos Aires, Argentina|Santa Rosa, Argentina|Venado Tuerto, Argentina|Camperdown, New South Wales, Australia|Coffs Harbour, New South Wales, Australia|Darlinghurst, New South Wales, Australia|Tweed Heads, New South Wales, Australia|Richmond, Victoria, Australia|Subiaco, Western Australia, Australia|Bruxelles, Belgium|Gent, Belgium|Kortrijk, Belgium|Liege, Belgium|Botucatu, Sao Paulo, Brazil|Cachoeiro de Itapemirim - ES, Brazil|Curitiba, Parana, Brazil|Florianopolis, Brazil|Juiz de Fora, Minas Gerais, Brazil|Mogi das Cruzes, Sao Paulo, Brazil|Natal, Rio Grande do Norte, Brazil|Passo Fundo, Brazil|Porto Alegre, RS, Brazil|Rio de Janeiro, Brazil|Salvador/BA, Brazil|Sao Paulo, Brazil|Volta Redonda - RJ, Brazil|Pleven, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Kelowna, British Columbia, Canada|Victoria, British Columbia, Canada|Brantford, Ontario, Canada|North York, Ontario, Canada|Oakville, Ontario, Canada|Santiago, Chile|Temuco, Chile|Vina del Mar, Chile|Beijing, China|Chengdu, China|Shanghai, China|Shantou, China|Wuhan, China|Bogota, Colombia|Cali, Colombia|Novy Jicin, Czech Republic|Olomouc, Czech Republic|Praha 2, Czech Republic|Praha 5, Czech Republic|Usti nad Labem, Czech Republic|Tartu, Estonia|Angers, France|Cannes, France|Marseille, France|Montpellier, France|Paris, France|Pierre Benite, France|Rennes, France|Suresnes, France|Dresden, Germany|Hamburg, Germany|Koln, Germany|Mannheim, Germany|Marburg, Germany|Munchen, Germany|Munster, Germany|Nurtingen, Germany|Tubingen, Germany|Weiden, Germany|Athens, Greece|Patras, Greece|Thessaloniki, Greece|Pune, India|Beer-Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat-Gan, Israel|Tel-Aviv, Israel|Zerifin, Israel|Cremona, Italy|Lecco, Italy|Meldola, Italy|Milano, Italy|Padova, Italy|Ravenna, Italy|Roma, Italy|Torino, Italy|Gwangju, Korea, Republic of|Seoul, Korea, Republic of|Liepaja, Latvia|Riga, Latvia|Beirut, Lebanon|Bsalim, Lebanon|Kaunas, Lithuania|Vilnius, Lithuania|Chihuahua, Chih., Mexico|Culiacan, Sinaloa, Mexico|Leon, GTO, Mexico|Puebla, Mexico|Zapopan, Jalisco, Mexico|Amsterdam, Netherlands|Groningen, Netherlands|Leiden, Netherlands|Nijmegen, Netherlands|Tilburg, Netherlands|Christchurch, New Zealand|Nelson, New Zealand|Palmerston North, New Zealand|Tauranga, New Zealand|Panama, Panama|Arequipa, Peru|Bialystok, Poland|Lodz, Poland|Myslowice, Poland|Poznan, Poland|Warszawa, Poland|Wroclaw, Poland|Baia Mare, Romania|Bucharest, Romania|Cluj-Napoca, Romania|Craiova, Romania|Ploiesti, Romania|Suceava, Romania|Timisoara, Romania|Ekaterinburg, Russian Federation|Moscow, Russian Federation|Novosibirsk, Russian Federation|Omsk, Russian Federation|St. Petersburg, Russian Federation|Vladimir, Russian Federation|Bratislava, Slovakia|Trencin, Slovakia|Sevilla, Andalucia, Spain|Zaragoza, Aragon, Spain|Oviedo, Asturias, Spain|Santander, Cantabria, Spain|Sabadell, Cataluna, Spain|Alcorcon, Madrid, Communidad de, Spain|Pamplona, Navarra, Spain|Barcelona, Spain|San Sebastian de los Reyes, Spain|Valencia, Spain|Göteborg, Sweden|Karlstad, Sweden|Stockholm, Sweden|Kaohsiung, Taiwan|Taichung, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan|Istanbul, Turkey|Chernivtsi, Ukraine|Dnipropetrovsk, Ukraine|Donetsk, Ukraine|Ivano-Frankivsk, Ukraine|Kharkiv, Ukraine|Kyiv, Ukraine|Lutsk, Ukraine|Lviv, Ukraine|Odesa, Ukraine|Uzhgorod, Ukraine|Zaporizhzhya, Ukraine|Birmingham, United Kingdom|Chichester, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Northwood, United Kingdom|Nottingham, United Kingdom|Oxford, United Kingdom|Scunthorpe, United Kingdom|Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01234311"
479,"NCT05319392","Transcriptomic Signatures in Gastric Adenocarcinoma","GAC","Recruiting","No Results Available","Gastric Adenocarcinoma","Diagnostic Test: Observational study","Transcriptome profiling of Gastric adenocarcinoma|Differential gene expression analysis in Gastric adenocarcinoma|Influence of tumor microenvironment on gene expression profile of gastric adenocarcinoma|Correlation of tumor microenvironment related genes with patient's clinical features|Patient risk stratification based on correlation between gene expression and overall survival","Sanjay Gandhi Postgraduate Institute of Medical Sciences","All","18 Years to 80 Years   (Adult, Older Adult)",,"48","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2021-240-PhD-EXP-42","August 6, 2021","April 6, 2025","October 6, 2025","April 8, 2022",,"April 15, 2022","Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT05319392"
480,"NCT02551159","Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer","KESTREL","Completed","Has Results","Squamous Cell Carcinoma of the Head and Neck","Biological: MEDI4736|Biological: Tremelimumab|Biological: MEDI4736+Tremelimumab|Biological: Cetuximab|Drug: 5-fluorouracil (5FU)|Drug: Cisplatin|Drug: Carboplatin","Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab Versus Standard of Care (SOC)|Overall Survival (OS) Median Duration in the PD-L1 TC/IC High Subgroup|Overall Survival (OS) Status in the PD-L1 TC/IC High Subgroup - Durvalumab + Tremelimumab Versus Standard of Care (SOC)|Percentage of Patients Alive at 12, 18 and 24 Months in the PD-L1 TC/IC High Subgroup|Progression Free Survival (PFS) in the PD-L1 TC/IC High Subgroup|Objective Response Rate (ORR) in the PD-L1 TC/IC High Subgroup|Duration of Response (DoR) in the PD-L1 TC/IC High Subgroup|Overall Survival (OS) Status in the All-comers (Full Analysis Set)|Overall Survival (OS) Median Duration in the All-comers (Full Analysis Set)|Percentage of Patients Alive at 12, 18 and 24 Months in the All-comers (Full Analysis Set)|Progression Free Survival (PFS) in the All-comers (Full Analysis Set)|Objective Response Rate (ORR) in the All-comers (Full Analysis Set)|Duration of Response (DoR) in the All-comers (Full Analysis Set)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","823","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D419LC00001","October 15, 2015","July 6, 2020","May 21, 2021","September 16, 2015","October 13, 2021","October 13, 2021","Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Morristown, New Jersey, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Nashville, Tennessee, United States|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Brussels, Belgium|Research Site, Brussels, Belgium|Research Site, Bruxelles, Belgium|Research Site, Leuven, Belgium|Research Site, Namur, Belgium|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianópolis, Brazil|Research Site, Ijui, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Recife, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Santo André, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Moncton, New Brunswick, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Dijon, France|Research Site, Lyon Cedex 08, France|Research Site, Nice, France|Research Site, Paris, France|Research Site, Poitiers Cedex, France|Research Site, Toulouse Cedex, France|Research Site, Vandoeuvre les Nancy, France|Research Site, Villejuif, France|Research Site, Berlin, Germany|Research Site, Erlangen, Germany|Research Site, Essen, Germany|Research Site, Frankfurt am Main, Germany|Research Site, Freiburg, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Mainz, Germany|Research Site, Tübingen, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Thessaloniki, Greece|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Gurgaon, India|Research Site, Karamsad, India|Research Site, Madurai, India|Research Site, Pune, India|Research Site, Cona, Italy|Research Site, Firenze, Italy|Research Site, Messina, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Palermo, Italy|Research Site, Salerno, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Akashi-shi, Japan|Research Site, Chiba-shi, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hirakata-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Kitaadachi-gun, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo, Japan|Research Site, Sunto-gun, Japan|Research Site, Takatsuki-shi, Japan|Research Site, Toyoake-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seo-Gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Cebu City, Philippines|Research Site, Las Pinas, Philippines|Research Site, Quezon City, Philippines|Research Site, Białystok, Poland|Research Site, Bielsko-Biała, Poland|Research Site, Gdańsk, Poland|Research Site, Gdynia, Poland|Research Site, Lublin, Poland|Research Site, Poznan, Poland|Research Site, Poznan, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Łódź, Poland|Research Site, Suceava, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sochi, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Bratislava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Badajoz, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Jaén, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella, Spain|Research Site, Málaga, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Pathumthani, Thailand|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kapitanivka Village, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kirovohrad, Ukraine|Research Site, Kryvyi Rih, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Bebington, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Ha Noi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02551159/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/59/NCT02551159/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02551159"
481,"NCT00191100","Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix",,"Completed","Has Results","Cancer of Cervix","Drug: Gemcitabine|Drug: Cisplatin|Radiation: Brachytherapy|Radiation: Pelvic radiation","Number of Participants With Progressive Disease or Death Due to Any Cause at 3 Years|Number of Participants With Progressive Disease or Death Due to Disease Under Study at Various Time Points|Local Failure Rate|Tumor Response|Number of Participants Who Died From Any Cause at Various Time Points|Number of Participants With Progressive Disease or Death Due to Any Cause at Various Time Points","Eli Lilly and Company","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","515","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4015|B9E-MC-JHQS","May 2002","April 2008","April 2008","September 19, 2005","May 25, 2009","August 11, 2009","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sarajevo, Bosnia and Herzegovina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Karachi, Pakistan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lima, Peru|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00191100"
482,"NCT03543020","Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain",,"Terminated","No Results Available","Alopecia; X-Rays","Radiation: radiation therapy to brain","To record the degree of alopecia at the conclusion of radiotherapy compared to pre- radiotherapy status with use of scalp sparing radiotherapy technique.|radiation dose range levels that causes alopecia|in vivo dosimetry values for scalp doses in modern radiotherapy treatment","Fortis Memorial Research Institute","All","Child, Adult, Older Adult",,"25","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2017-008IP-20","July 17, 2017","December 31, 2018","January 30, 2019","June 1, 2018",,"March 4, 2019","Department of Radiation Oncology, Fortis Memorial Research Institute, Gurgaon, Haryana, India",,"https://ClinicalTrials.gov/show/NCT03543020"
483,"NCT00864331","Optimization of Treatment of Advanced Nonsmall Cell Lung Cancer Using Radiotherapy and Chemotherapy",,"Completed","No Results Available","Non Small Cell Lung Cancer","Radiation: radiation|Other: Chemotherapy and radiotherapy|Drug: Chemotherapy|Other: Palliative radiotherapy and chemotherapy","Survival|To assess the differences in toxicity of two treatment options in both stage III (A and B) NSCLC (Study A) and Stage IIIB (wet) and stage IV NSCLC (Study B)|To assess the differences in Health Related Quality of Life (HRQoL) of two treatment options in both Study A and Study B","International Atomic Energy Agency","All","18 Years and older   (Adult, Older Adult)","Phase 3","251","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","E33029","February 2008","November 2012","November 2012","March 18, 2009",,"August 7, 2013","Instituto de Radiomedicine, Santiago, Chile|Affiliated Hospital of Ning Xia Medical College, Department of Radiation Oncology, Yinchuan, China|University of Zagreb Faculty of Medicine, Zagreb, Croatia|Misr Oncology Center (MOC), Cairo, Egypt|Tata Memorial Centre (TMC) Department of Atomic Energy (DAE), Mumbai, India|General Hospital Kuala Lumpur, Institute of Radiotherapy and Oncology, Kuala Lumpur, Malaysia|Sir Paul Boffa Hospital, Floriana, Malta|Ministère de la Santé, Institut National d'Oncologie Sidi Mohamed Ben Abdellah, Rabat, Morocco|Nuclear Medicine Oncology and Radiotherapy Institute, Islamabad, Pakistan|Instituto Oncológico National, Panama City, Panama|Instituto Nacional de Enfermadades Neoplasicas Depto. De Radioterapia, Lima, Peru|University of Witwatersrand Johannesburg Hospital Dept of Radiation Oncology, Johannesburg, South Africa|Institut de la Sante Publique, Institut National de Cancer Salah Azaiz, Tunis, Tunisia",,"https://ClinicalTrials.gov/show/NCT00864331"
484,"NCT00034125","Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.",,"Completed","No Results Available","Breast Neoplasms","Drug: LY353381|Drug: tamoxifen",,"Eli Lilly and Company","Female","18 Years and older   (Adult, Older Adult)","Phase 3",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","3883|H4Z-MC-JWXD",,,,"April 24, 2002",,"July 19, 2006","Miami, Florida, United States|Shreveport, Louisiana, United States|Boston, Massachusetts, United States|Nashville, Tennessee, United States|Capital Federal, Buenos Aires, Argentina|Ciudad De Buenos Aires, Argentina|Las Condes, Santiago, Chile|Providencia, Santiago, Chile|Ahmedabab, Gujarat, India|Mexico City, Benito Juarez, Mexico|Colima, Mexico",,"https://ClinicalTrials.gov/show/NCT00034125"
485,"NCT00122772","CRP on Radiobiological and Clinical Studies on Viral-Induced Cancer's Response to Radiotherapy",,"Completed","No Results Available","Cervix Cancer","Radiation: Radiotherapy|Radiation: Radiotherapy/Cisplatin","Clinical Outcome|Treatment Toxicity|Molecular markers that will predict tumor control/resistance|Whether E6 and E7 viral proteins predict cellular radiosensitivity in oxic and hypoxic conditions in vitro and tumor control/resistance in vivo|Effectiveness of a questionnaire template on a computer in face-to-face interviews in a multicentre multinational study.","International Atomic Energy Agency","Female","18 Years and older   (Adult, Older Adult)","Phase 3","601","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33026","November 2005","June 2010","June 2010","July 22, 2005",,"October 14, 2011","University of Vienna; Department of Radiotherapy and Radiobiology, Vienna, Austria|rmandade de Santa Casa de Misericordia de Porto Alegre; Hospital Santa Rita, Porto Alegre, Brazil|Peel Regional Cancer Centre, Mississauga, Ontario, Canada|Department of Atomic Energy (DAE); Tata Memorial Centre (TMC); Tata, Mumbai, India|National Cancer Center, Seoul, Korea, Republic of|Radiotherapy and Oncology University Clinic, Skopje, Macedonia, The Former Yugoslav Republic of|Institut National d'Oncologie, Rabat, Morocco|Bahawalpur Institute of Nuclear Medicine and Oncology (BINO), Bahawalpur, Pakistan|Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru|Department of Radiation Oncology, Groote Schuur Hospital, Cape Town, South Africa|Christie Hospital; NHS Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00122772"
486,"NCT00417209","Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen","PAPRIKA","Completed","No Results Available","Pancreatic Neoplasms","Drug: Larotaxel (XRP9881)|Drug: 5-Fluorouracil|Drug: Capecitabine","overall survival (OS) defined as the time interval from the date of randomization to the date of death due to any cause|Progression free survival (PFS); Overall Response Rate (proportion of patients with confirmed RECIST-defined complete response (CR) or partial response (PR); clinical benefit based on the measurement of tumor related symptoms;","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","408","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC6596|EUDRACT: 2006-003086-14","December 2006","July 2009","November 2009","December 29, 2006",,"June 3, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Quebec, Canada|Sanofi-Aventis Administrative Office, Santiago de Chile, Chile|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Lysaker, Norway|Sanofi-Aventis Administrative Office, Lima, Peru|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Madrid, Spain|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00417209"
487,"NCT03390686","A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients",,"Recruiting","No Results Available","Lung Cancer|Non-small Cell Lung Cancer","Drug: Bevacizumab|Drug: HD204|Drug: Carboplatin|Drug: Paclitaxel","Best Objective Response Rate by 24 weeks|Progression Free Survival|Overall Survival (OS)|Duration of Response|Incidence of Treatment-related Adverse Events using CTCAE v4.03|Trough Level [Ctrough] (Pharmacokinetics)|Maximum Plasma Concentration [Cmax] (Pharmacokinetics)|Anti-Drug Antibodies (Immunogenecity)|Neutralizing Antibodies (Immunogenecity)","Prestige Biopharma Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SAMSON-II","November 15, 2019","May 2022","December 2022","January 4, 2018",,"September 8, 2021","Alexandrov Cancer Center, Minsk, Belarus|MHAT ""Dr. Tota Venkova"", AD, Gabrovo, Bulgaria|CHC Osijek, Osijek, Osijecko-baranjska, Croatia|LTD ""High Technology Hospital Medcenter"", Batumi, Georgia|Institute of Clinical Oncology, Tbilisi, Georgia|Interbalkan Hospital, Thessaloníki, Asklipiou 10, Greece|Tudogyogyintezet Torokbalint, Törökbálint, Hungary|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Riga East University Hospital Latvian Oncology centre, Riga, Latvia|HRPZ II, Kota Bharu, Kelantan, Malaysia|Asian Hospital and Medical Center, Muntinlupa, Philippines|Magodend Szpital Elblaska, Warszawa, Poland|MEDSI, Moscow, Otradnoye, Russian Federation|IPD of Vojvodina, Sremska Kamenica, Serbia|Nemocnica na okraji mesta, n.o., Partizánske, Slovakia|Maharaj Nakorn Chiang Mai, Chiang Mai, Muang, Thailand|Acibadem Adana Hospital, Adana, Turkey|Oncology Dispensary, Odessa, Ukraine",,"https://ClinicalTrials.gov/show/NCT03390686"
488,"NCT00418886","Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients","ZEAL","Active, not recruiting","Has Results","Non Small Cell Lung Cancer|Lung Cancer","Drug: Vandetanib|Drug: Pemetrexed","Progression-Free Survival (PFS) in the Overall Population|Progression-Free Survival (PFS) in the Female Population|Overall Survival (OS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Duration of Response (DoR)|Time to Deterioration of Disease-related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score|Time to Deterioration of Disease-related Symptoms (TDS) by Average Symptom Burden Index (ASBI) Score|Longitudinal Analysis of Lung Cancer Symptom Scale (LCSS) Total Score|Longitudinal Analysis of Average Symptom Burden Index (ASBI) Score","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","698","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00036|EUDRACT No. 2006-003695-35|LPS15296","January 2007","September 2008","December 31, 2022","January 5, 2007","March 26, 2012","November 1, 2021","Research Site, Casa Grande, Arizona, United States|Research Site, Chandler, Arizona, United States|Research Site, Farmington, Connecticut, United States|Research Site, Stamford, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Orlando, Florida, United States|Research Site, Gainesville, Georgia, United States|Research Site, Skokie, Illinois, United States|Research Site, Sioux City, Iowa, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Portland, Maine, United States|Research Site, Baltimore, Maryland, United States|Research Site, Rockville, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Rochester, New York, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cincinnati, Ohio, United States|Research Site, Middletown, Ohio, United States|Research Site, Hilton Head Island, South Carolina, United States|Research Site, Austin, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Avellaneda, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, La Plata, Argentina|Research Site, Ramos Mejía, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Chermside, Australia|Research Site, Fitzroy, Australia|Research Site, Footscray, Australia|Research Site, Heidelberg, Australia|Research Site, Randwick, Australia|Research Site, St. Leonards, Australia|Research Site, Wodonga, Australia|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Leuven, Belgium|Research Site, Liège, Belgium|Research Site, Bogota, Colombia|Research Site, Medellín, Colombia|Research Site, Pereira, Colombia|Research Site, Valledupar, Colombia|Research Site, Avignon Cedex 09, France|Research Site, Lyon Cedex 04, France|Research Site, Paris Cedex 15, France|Research Site, Pontoise Cedex, France|Research Site, Strasbourg Cedex, France|Research Site, Hannover, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, N. Faliro, Greece|Research Site, Patras, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Ahmedabad, India|Research Site, Vellore, India|Research Site, Beer-Sheeva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petach-Tikva, Israel|Research Site, Safed, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Zerifin, Israel|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Roma, Italy|Research Site, S.Andrea Delle Fratte, Italy|Research Site, Aguascalientes, Mexico|Research Site, Mexico, Mexico|Research Site, Puebla, Mexico|Research Site, Cebu City, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Lisboa, Portugal|Research Site, Santa Maria da Feira, Portugal|Research Site, Setúbal, Portugal|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Port Elizabeth, South Africa|Research Site, Pretoria, South Africa|Research Site, A Coruña, Spain|Research Site, Lugo, Spain|Research Site, Majadahonda, Spain|Research Site, Mataró(Barcelona), Spain|Research Site, Málaga, Spain|Research Site, Orense, Spain|Research Site, Santiago De Compostela(A Coru, Spain|Research Site, Vigo(Pontevedra), Spain|Research Site, Lund, Sweden|Research Site, Sundsvall, Sweden|Research Site, Umeå, Sweden|Research Site, Uppsala, Sweden|Research Site, Västerås, Sweden|Research Site, Taipei, Taiwan|Research Site, Birmingham, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Wolverhampton, United Kingdom|Research Site, Caracas, Venezuela|Research Site, Valencia, Venezuela",,"https://ClinicalTrials.gov/show/NCT00418886"
489,"NCT04109391","Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03",,"Completed","No Results Available","HER2-positive Breast Cancer|Early-stage Breast Cancer|Breast Cancer|Breast Neoplasms|Stage II Breast Cancer|Stage IIIA Breast Cancer","Biological: TX05 (trastuzumab)|Biological: Herceptin (trastuzumab)","Rate of Adverse Events|Immunogenicity Assessments|Disease-Free Survival|Overall Survival","Tanvex BioPharma USA, Inc.","Female","18 Years and older   (Adult, Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","TX05-03E","August 23, 2019","December 25, 2021","March 8, 2022","September 30, 2019",,"April 26, 2022","Tanvex Investigational Site 1003E, Gomel, Belarus|Tanvex Investigational Site 1006E, Grodno, Belarus|Tanvex Investigational Site 1008E, Lesnoy, Belarus|Tanvex Investigational Site 1002E, Minsk, Belarus|Tanvex Investigational Site 1005E, Mogilev, Belarus|Tanvex Investigational Site 1001E, Vitebsk, Belarus|Tanvex Investigational Site 4001E, Temuco, Chile|Tanvex Investigational Site 4002E, Vina del Mar, Chile|Tanvex Investigational Site 5006E, Batumi, Georgia|Tanvex Investigational Site 5002E, Batumi, Georgia|Tanvex Investigational Site 5001E, Tbilisi, Georgia|Tanvex Investigational Site 5005E, Tbilisi, Georgia|Tanvex Investigational Site 5010E, Tbilisi, Georgia|Tanvex Investigational Site 5008E, Tbilisi, Georgia|Tanvex Investigational Site 6003E, Budapest, Hungary|Tanvex Investigational Site 7031E, Nashik, Maharashtra, India|Tanvex Investigational Site 7033E, Ahmedabad, India|Tanvex Investigational Site 7019E, Bangalore, India|Tanvex Investigational Site 7022E, Belgaum, India|Tanvex Investigational Site 7045E, Hyderabad, India|Tanvex Investigational Site 7036E, Hyderabad, India|Tanvex Investigational Site 7006E, Kolkata, India|Tanvex Investigational Site 7001E, Nashik, India|Tanvex Investigational Site 7015E, Pune, India|Tanvex Investigational Site 7017E, Vijayawada, India|Tanvex Investigational Site 2109E, Aguascalientes, Mexico|Tanvex Investigational Site 2103E, Monterrey, Mexico|Tanvex Investigational Site 2106E, Oaxaca, Mexico|Tanvex Investigational Site 2110E, Tequisquiapan, Mexico|Tanvex Investigational Site 2108E, Zapopan, Mexico|Tanvex Investigational Site 1101E, Arequipa, Peru|Tanvex Investigational Site 1107E, Arequipa, Peru|Tanvex Investigational Site 1104E, Chiclayo, Peru|Tanvex Investigational Site 1112E, Lima Cercado, Peru|Tanvex Investigational Site 1105E, Lima, Peru|Tanvex Investigational Site 1108E, San Borja, Peru|Tanvex Investigational Site 1102E, San Isidro, Peru|Tanvex Investigational Site 1109E, Surquillo, Peru|Tanvex Investigational Site 1103E, Trujillo, Peru|Tanvex Investigational Site 1211E, Cebu city, Philippines|Tanvex Investigational Site 1212E, Davao City, Philippines|Tanvex Investigational Site 1214E, Makati City, Philippines|Tanvex Investigational Site 1209E, Quezon City, Philippines|Tanvex Investigational Site 1213E, Quezon City, Philippines|Tanvex Invesitgational Site 1210E, Santo Tomas, Philippines|Tanvex Investigational Site 1513E, Sochi, Krasnodar Region, Russian Federation|Tanvex Investigational Site 1535E, Arkhangelsk, Russian Federation|Tanvex Investigational Site 1531E, Belgorod, Russian Federation|Tanvex Investigational Site 1502E, Kaluga, Russian Federation|Tanvex Investigational Site 1505E, Kislino, Russian Federation|Tanvex Investigational Site 1529E, Krasnodar, Russian Federation|Tanvex Investigational Site 1512E, Krasnoyarsk, Russian Federation|Tanvex Investigational Site 1530E, Moscow, Russian Federation|Tanvex Investigational Site 1507E, Moscow, Russian Federation|Tanvex Investigational Site 1511E, Novosibirsk, Russian Federation|Tanvex Investigational Site 1503E, Omsk, Russian Federation|Tanvex Investigational Site 1509E, Omsk, Russian Federation|Tanvex Investigational Site 1537E, Orenburg, Russian Federation|Tanvex Investigational Site 1526E, Pesochnyy, Russian Federation|Tanvex Investigational Site 1510E, Pushkin, Russian Federation|Tanvex Investigational Site 1521E, Rostov-Na-Donu, Russian Federation|Tanvex Investigational Site 1516E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1524E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1525E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1506E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1501E, Saint Petersburg, Russian Federation|Tanvex Investigational Site 1523E, Sankt-peterburg, Russian Federation|Tanvex Investigational Site 1508E, Saransk, Russian Federation|Tanvex Investigational Site 1534E, Yaroslavl, Russian Federation|Tanvex Investigational Site 1820E, Antonivka, Ukraine|Tanvex Investigational Site 1803E, Chernihiv, Ukraine|Tanvex Investigational Site 1808E, Chernihiv, Ukraine|Tanvex Investigational Site 1821E, Chernivtsi, Ukraine|Tanvex Investigational Site 1824E, Dnipro, Ukraine|Tanvex Investigational Site 1811E, Kiev, Ukraine|Tanvex Investigational Site 1802E, Kiev, Ukraine|Tanvex Investigational Site 1819E, Kropyvnytskyi, Ukraine|Tanvex Investigational Site 1814E, Kropyvnytskyi, Ukraine|Tanvex Investigational Site 1804E, Kryvyi Rih, Ukraine|Tanvex Investigational Site 1815E, Kyiv, Ukraine|Tanvex Investigational Site 1809E, Kyiv, Ukraine|Tanvex Investigational Site 1810E, Odesa, Ukraine|Tanvex Investigational Site 1806E, Sumy, Ukraine|Tanvex Investigational Site 1822E, Ternopil, Ukraine|Tanvex Investigational Site 1818E, Vinnytsia, Ukraine|Tanvex Investigational Site 1813E, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT04109391"
490,"NCT00574275","Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","VANILLA","Terminated","Has Results","Pancreatic Neoplasm","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Gemcitabine","Overall Survival (OS)|Progression Free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors [RECIST] Criteria|Objective Response Rate (ORR) Assessed by the Investigators According to RECIST Criteria|Clinical Benefit|Safety-Number of Participants With Adverse Events (AE)|Number of Participants With Anti-drug Antibodies","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","546","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC10547|EudraCT 2007-003476-19","December 2007","October 2009","November 2010","December 17, 2007","September 25, 2012","June 7, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Santafe de Bogota, Colombia|Sanofi-Aventis Administrative Office, Nikosia, Cyprus|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Mexico, Mexico|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Puerto Rico, Puerto Rico|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Brastislava, Slovakia|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT00574275"
491,"NCT00923702","Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India",,"Unknown status","No Results Available","Cervical Cancer|Cervical Precancerous Lesions","Biological: Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)","Geometric mean titers of serum neutralizing antibodies to vaccine included HPV types (16/18/6/11) at 7, 12, 24, 36, 48 months.|Frequency of incident and persistent HPV 16/18/6/11 infection.|Frequency of infection by other non-targeted high-risk HPV types.|Frequency of HPV 16/18-associated precancerous lesions and cancer.|Frequency of cervical neoplasia associated with non-included HPV types.","Dr R. Sankaranarayanan|All India Institute of Medical Sciences, New Delhi|Cancer Foundation of India|Christian Fellowship Community Health Centre|Deutsches Krebsforschungszentrum (DKFZ)|Gujarat Cancer & Research Institute|Jehangir Clinical Development Centre|MNJ Institute of Oncology & Regional cancer Center|Rajiv Gandhi Centre for Biotechnology|Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital|Tata Memorial Centre|International Agency for Research on Cancer","Female","10 Years to 18 Years   (Child, Adult)","Phase 4","20000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","BMGF48979|ISRCTN98283094|REFCTRI-2009 000137","September 2009","July 2019","July 2021","June 18, 2009",,"September 1, 2016","MNJ Institute of Oncology & Regional Cancer Center, Hyderabad, Andhra Pradesh, India|Cancer Foundation of India, Kolkata, Bengal, India|Gujarat Cancer & Research Institute (GCRI), Ahmedabad, Gujarat, India|Tata Memorial Centre Rural Cancer Project, Nargis Dutt Memorial Cancer Hospital, Barshi, Maharashtra, India|Tata Memorial Center, Tata Memorial Hospital & Cancer Research Inst, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre (JCDC) Pvt. Ltd., Pune, Maharashtra, India|Christian Fellowship Community Health Centre, Ambilikkai, Tamil Nadu, India|All India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00923702"
492,"NCT00694915","Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder","STCC","Completed","No Results Available","Bladder Cancer","Biological: Mycobacterium w|Biological: BCG (Bacillus Calmette-Guerin)","Recording of any clinical adverse reactions at anytime during the study for assessment of safety|Recurrence Rate-Evaluated after 3 months by doing sonography, cystoscopy, and cytology|Quality of Life- The measure of an individual's sense of well-being and ability to carry out various activities|Time to Tumor progression -will be evaluated every 3 months for 15 months during the study period","Cadila Pharnmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-60/9150","August 28, 2008","March 31, 2014","October 7, 2015","June 11, 2008",,"August 17, 2021","Urocare Hospital, Rajkot, Gujarat, India|Muljibhai Patel Urological Hospital, Nadiad, Gujrat, India|Indira Gandhi Medical College, Shimla, Himachal Pradesh, India|N.R.R. Hospital, Bangalore, Karnataka, India|Kasturba Medical college and Hospital, Manipal, Karnataka, India|Lourdes Hospital, Kochi, Kerala, India|Choithram Hospital and Research Centre, Indore, Madhya Pradesh, India|Cancer Hospital and Research Institute, Gwalior, Madya Pradesh, India|Seth G S Medical College & K E M Hospital, Parel, Mumbai, India|Christian Medical College, Ludhiana, Punjab, India|P.B.M. Hospital & A.G. of Hospitals, Bikaner, Rajasthan, India|IPGMER, S.S.K.M. Hospital, Kolkata, West Bengal, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|Dr. Ram Manohar Lohia Hospital & PGIMER, New Delhi, India|V M Medical College & Safdarjang Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00694915"
493,"NCT00694798","Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder","STCC","Completed","No Results Available","Bladder Cancer","Biological: Mycobacterium w","Response Rate","Cadila Pharnmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","22","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR-80/8230","October 2008","July 2011","July 2011","June 11, 2008",,"May 3, 2012","Aarogyam Speciality Hospital, Ahmedabad, Gujarat, India|Gandhi Urocare, Ahmedabad, Gujarat, India|Siddhi Vinayak Hospital, Advanced Urology and Orthopedic Centre, Ahmedabad, Gujarat, India|Urocare Hospital, Rajkot, Gujarat, India|Excel Hospital, Advanced Laproscopy and Urology Centre, Surat, Gujarat, India|Desai Urological & Maternity Hospital, Vadodara, Gujarat, India|Muljibhai Patel Urological Hospital, Nadiad, Gujrat, India|Indira Gandhi Medical College, Shimla, Himachal Pradesh, India|Lourdes Hospital, Kochi, Kerala, India|Choithram Hospital and Research Centre, Indore, Madhya Pradesh, India|Cancer Hospital and Research Institute, Gwalior, Madya Pradesh, India|Christian Medical College, Ludhiana, Punjab, India|S.P. Medical College & A. G. of Hospitals, Bikaner, Rajasthan, India|IPGMER, S.S.K.M. Hospital, Kolkata, West Bengal, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|Dr. Ram Manohar Lohia Hospital & PGIMER, New Delhi, India|V. M. Medical College & Safdarjang Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00694798"
494,"NCT04660695","Nasobiliary Drain Assisted EUS-guided Gastroenterostomies in Unresectable Malignant Gastric Outlet Obstruction","PENGUIN","Completed","No Results Available","Gastric Outlet Obstruction|Gastric Cancer|Pancreatic Cancer","Device: EUS-guided gastroenterostomy","Technical Success|Early Clinical Success|Clinical Success|Baseline Gastric outlet obstruction score system (GOOSS)|Early Gastric outlet obstruction score system (GOOSS)|Final Gastric outlet obstruction score system (GOOSS)|Baseline European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30)|Final European Organisation for Research and Treatment of Cancer QoL Questionnaire Core 30 (EORTC-QLQ-C30)|Number of Participants With intraprocedure Treatment-Related Adverse Events as Assessed by the ASGE classification|Number of Participants With Early Treatment-Related Adverse Events as Assessed by the ASGE classification|Number of Participants With Delayed Treatment-Related Adverse Events as Assessed by the ASGE classification|Recurrent GOO|Target bowel loop diameter (mm)|Total volume infused (ml)|Number of patients undergoing balloon dilation|Type of fluid employed","Hospital del Río Hortega|Hospital General Universitario de Alicante|Clinica Universidad de Navarra, Universidad de Navarra|Complejo Hospitalario de Navarra|Christian Medical College, Vellore, India","All","18 Years and older   (Adult, Older Adult)",,"66","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","PI152-19","August 15, 2019","May 12, 2021","May 12, 2021","December 9, 2020",,"May 14, 2021","Christian Medical College, Vellore, India|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital Universitario Río Hortega, Valladolid, Spain","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/95/NCT04660695/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04660695"
495,"NCT00836745","Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent",,"Completed","Has Results","Renal Cell Carcinoma","Other: Non Interventional","Progression Free Survival (PFS)|Percentage of Participants With Objective Response (OR)|Number of Participants Who Required Management of Skin and Subcutaneous Tissue Related Adverse Events|Number of Participants Who Required Management of Other Adverse Events","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)",,"36","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","A6181181","March 2009","July 2012","July 2012","February 4, 2009","December 20, 2013","December 20, 2013","Pfizer Investigational Site, New Delhi, Delhi, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Chandigard, Punjab, India|Pfizer Investigational Site, Kolkata, West Bengal, India|Pfizer Investigational Site, Delhi, India|Pfizer Investigational Site, Jaipur, India",,"https://ClinicalTrials.gov/show/NCT00836745"
496,"NCT00021255","Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer",,"Completed","Has Results","Breast Neoplasms","Drug: Doxorubicin|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Herceptin|Drug: Carboplatin","Percentage of Participants With Disease Free Survival at 5 Years|Percentage of Participants With Disease Free Survival at 10 Years|Overall Survival- Percentage of Participants Who Survived at 10 Years","Sanofi|Cancer International Research Group (CIRG)","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","3222","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAX_GMA_302|BCIRG 006","April 2001","December 2014","December 2014","January 27, 2003","November 15, 2016","November 15, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Sarajevo, Bosnia and Herzegovina|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Vazrjdane Region, Bulgaria|Sanofi-Aventis Administrative Office, Québec, Canada|Sanofi-Aventis Administrative Office, Bogota, Colombia|Sanofi-Aventis Administrative Office, Zagreb, Croatia|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Cairo, Egypt|Sanofi-Aventis Administrative Office, Tallin, Estonia|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Frankfurt, Germany|Sanofi-Aventis Administrative Office, Kallithea, Greece|Sanofi-Aventis Administrative Office, Hong Kong, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Dublin, Ireland|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Beirut, Lebanon|Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico|Sanofi-Aventis Administrative Office, Macquarie Park, New Zealand|Sanofi-Aventis Administrative Office, Warsaw, Poland|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Ljubljana, Slovenia|Sanofi-Aventis Administrative Office, Gauteng, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Genève, Switzerland|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administrative Office, Megrine, Tunisia|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom|Sanofi-Aventis Administrative Office, Montevideo, Uruguay|Sanofi-Aventis Administrative Office, Caracas, Venezuela",,"https://ClinicalTrials.gov/show/NCT00021255"
497,"NCT00283062","Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy",,"Completed","Has Results","Prostatic Neoplasms","Drug: Docetaxel (TAXOTERE®) Chemotherapy|Drug: Leuprolide acetate ( ELIGARD®) Hormonal Therapy","Progression-free Survival (PFS) Assessment - Number of Participants With Disease Progression|Median Overall Survival (OS)|Median Cancer-specific Survival (CSS)|Median Metastasis-free Survival (MFS)|To Evaluate Quality of Life (QoL) as Measured Using a Functional Assessment of Cancer Therapy-Prostate (FACT-P) Questionnaire|Assessment of Safety and Tolerability - Number of Participants With Adverse Events (AE)","Sanofi","Male","18 Years and older   (Adult, Older Adult)","Phase 3","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XRP6976J_3501|EudraCT # : 2004-002203-32","December 2005","December 2010","December 2010","January 27, 2006","January 23, 2012","January 26, 2012","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Macquarie Park, Australia|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Québec, Canada|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Frankfurt, Germany|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Milan, Italy|Sanofi-Aventis Administrative Office, Col. Coyoacan, Mexico|Sanofi-Aventis Administrative Office, PE Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warsaw, Poland|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Gauteng, South Africa|Sanofi-Aventis Administrative Office, Istanbul, Turkey|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00283062"
498,"NCT02303444","An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors","RIFTOS MKI","Completed","No Results Available","Thyroid Neoplasms","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Other Multikinase inhibitors","Time to symptomatic progression (TTSP) from study entry|Overall survival (OS) from time of study entry|Progression free survival (PFS) from time of study entry|OS from time of being diagnosed as radioactive iodine (RAI) refractory|Post-progression survival (PPS) from time of symptomatic progression|OS from initiation of the first Multikinase Inhibitor (MKI)|PFS from initiation of first MKI|OS from initiation of any systemic treatment regimen|PFS from initiation of any systemic treatment regimen|Duration of each systemic treatment regimen|Response assessment to each systemic treatment regimen according to the categories ""Complete Response"", ""Partial Response"", ""Stable Disease"", ""Clinical Progression"", ""Radiological Progression"", and ""Not evaluable at this visit""|OS from initiation of sorafenib|PFS from initiation of sorafenib|Daily dose of sorafenib per patient throughout the treatment period|Number of adverse events during treatment with sorafenib","Bayer","All","18 Years and older   (Adult, Older Adult)",,"667","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17852|NX1401","April 8, 2015","June 10, 2020","July 24, 2020","December 1, 2014",,"June 9, 2021","Birmingham, Alabama, United States|Los Angeles, California, United States|Torrance, California, United States|Aurora, Colorado, United States|Washington, District of Columbia, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Honolulu, Hawaii, United States|Chicago, Illinois, United States|New Orleans, Louisiana, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Bronx, New York, United States|Durham, North Carolina, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|Multiple Locations, Algeria|Multiple Locations, Argentina|Multiple Locations, Brazil|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Germany|Multiple Locations, Greece|Multiple Locations, India|Multiple Locations, Japan|Multiple Locations, Lebanon|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Philippines|Multiple Locations, Russian Federation|Multiple Locations, Saudi Arabia|Multiple Locations, Spain|Multiple Locations, Taiwan|Multiple Locations, Turkey",,"https://ClinicalTrials.gov/show/NCT02303444"
499,"NCT01735175","Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®","PROTECT-1","Completed","Has Results","Neutropenic Complications|Breast Neoplasms|Chemotherapy-induced Neutropenia|Chemotherapeutic Toxicity","Drug: LA-EP2006|Drug: Neulasta®","Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy|Incidence of Febrile Neutropenia (FN)|Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles|Depth of ANC Nadir in Cycle 1|Number of Patients With ANC Nadir Per Day in Cycle 1|Time to ANC Recovery in Days in Cycle 1|Frequency of Infections by Cycle and Across All Cycles|Mortality Due to Infection","Sandoz|Sandoz GmbH","Female","18 Years and older   (Adult, Older Adult)","Phase 3","316","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","LA-EP06-301|2011-004532-58","June 2012","May 2013","February 2014","November 28, 2012","June 15, 2017","August 7, 2017","Sandoz Investigational Site, Ijui, Brazil|Sandoz Investigational Site, Lajeado, Brazil|Sandoz Investigational Site, Santo Andre, Brazil|Sandoz Investigational Site, Andhra Pradesh, India|Sandoz Investigational Site, Delhi, India|Sandoz Investigational Site, Madurai, India|Sandoz Investigational Site, Maharashtra, India|Sandoz Investigational Site, Maharashtra, India|Sandoz Investigational Site, Maharashtra, India|Sandoz Investigational Site, Mumbai, India|Sandoz Investigational Site, Rajasthan, India|Sandoz Investigational Site, Aguascalientes, Mexico|Sandoz Investigational Site, Juchitan, Mexico|Sandoz Investigational Site, Bucharest, Romania|Sandoz Investigational Site, Bucharest, Romania|Sandoz Investigational Site, Iasi, Romania|Sandoz Investigational Site, Suceava, Romania|Sandoz Investigational Site, Barnaul, Russian Federation|Sandoz Investigational Site, Bashkortostan, Russian Federation|Sandoz Investigational Site, Berdsk, Russian Federation|Sandoz Investigational Site, Ivanovo, Russian Federation|Sandoz Investigational Site, Kabardino, Russian Federation|Sandoz Investigational Site, Kazan, Russian Federation|Sandoz Investigational Site, Krasnodar, Russian Federation|Sandoz Investigational Site, Kursk, Russian Federation|Sandoz Investigational Site, Leningrad, Russian Federation|Sandoz Investigational Site, Moscow, Russian Federation|Sandoz Investigational Site, Novgorod, Russian Federation|Sandoz Investigational Site, Oktyabrskaya, Russian Federation|Sandoz Investigational Site, Ryazan, Russian Federation|Sandoz Investigational Site, St. Petersburg, Russian Federation|Sandoz Investigational Site, Tula, Russian Federation|Sandoz Investigational Site, Cherkasy, Ukraine|Sandoz Investigational Site, Chernivtsi, Ukraine|Sandoz Investigational Site, Dnipropetrovsk, Ukraine|Sandoz Investigational Site, Kharkiv, Ukraine|Sandoz Investigational Site, Kriviy Rig, Ukraine|Sandoz Investigational Site, Lugansk, Ukraine|Sandoz Investigational Site, Mariupol, Ukraine|Sandoz Investigational Site, Vinnytsya, Ukraine|Sandoz Investigational Site, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT01735175"
500,"NCT00389441","Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer",,"Completed","Has Results","Thyroid Neoplasms","Drug: AG-013736","Percentage of Participants With Objective Response (OR)|Progression Free Survival (PFS)|Duration of Response (DR)|Overall Survival (OS)|Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Severity Score|Change From Baseline in MD Anderson Symptom Assessment Inventory (MDASI) Symptom Interference Score","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","52","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)","A4061027","December 2006","September 2012","September 2012","October 18, 2006","November 25, 2013","November 25, 2013","Pfizer Investigational Site, Orange, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Wichita, Kansas, United States|Pfizer Investigational Site, Witchita, Kansas, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Vellore, Tamil Nadu, India|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Pisa, Italy|Pfizer Investigational Site, Gliwice, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00389441"
501,"NCT01298323","Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment","88","Active, not recruiting","Has Results","Locally Advanced or Metastatic Medullary Thyroid Cancer|Medullary Thyroid Cancer","Behavioral: Patient outreach|Drug: Vandetanib","Percentage of Time a Patient Experienced at Least 1 AE of CTCAE Grade >=2 in First 12 Months of Receiving Vandetanib in Patients Who Participated in Patient Outreach Program.","Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","205","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D4200C00088|2010-023428-26|LPS14815","February 25, 2011","April 2013","December 31, 2022","February 17, 2011","November 24, 2014","November 1, 2021","Investigational Site Number 301, St Leonards, Australia|Investigational Site Number 401, Wien, Austria|Investigational Site Number 501, Bruxelles, Belgium|Investigational Site Number 701, Porto Alegre, Brazil|Investigational Site Number 702, Ribeirão Preto, Brazil|Investigational Site Number 901, Sofia, Bulgaria|Investigational Site Number 1001, London, Canada|Investigational Site Number 1002, Sherbrooke, Canada|Investigational Site Number 1003, Toronto, Canada|Investigational Site Number 1301, Beijing, China|Investigational Site Number 1302, Shanghai, China|Investigational Site Number 1901, Praha, Czechia|Investigational Site Number 2001, Odense C, Denmark|Investigational Site Number 2201, Helsinki, Finland|Investigational Site Number 2602, Essen, Germany|Investigational Site Number 2603, Halle, Germany|Investigational Site Number 2601, Würzburg, Germany|Investigational Site Number 3001, Athens, Greece|Investigational Site Number 3501, Mumbai, India|Investigational Site Number 3502, Vellore, India|Investigational Site Number 4001, Jerusalem, Israel|Investigational Site Number 4104, Napoli, Italy|Investigational Site Number 4101, Pisa, Italy|Investigational Site Number 4102, Roma, Italy|Investigational Site Number 6001, Seoul, Korea, Republic of|Investigational Site Number 5702, Poznan, Poland|Investigational Site Number 5703, Warsaw, Poland|Investigational Site Number 6201, Moscow, Russian Federation|Investigational Site Number 6204, Moscow, Russian Federation|Investigational Site Number 6202, Obninsk, Russian Federation|Investigational Site Number 6203, St Petersburg, Russian Federation|Investigational Site Number 7201, Uppsala, Sweden|Investigational Site Number 2802, Glasgow, United Kingdom|Investigational Site Number 2801, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01298323"
502,"NCT01554397","Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer",,"Unknown status","No Results Available","Cervical Cancer","Radiation: Intensity Modulated Radiation Therapy (IMRT)|Drug: Cisplatin","Number of Patients with Adverse Events as a Measure of Safety and Tolerability|Number of Patients with Acute and Late Adverse Events as a Measure of Safety and Tolerability|Number of Patients with Locoregional Failure as a Measure of Recurrence","University of California, San Diego|National Cancer Institute (NCI)","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","70","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INTERTECC|R21CA162718-01","October 13, 2011","June 2019","June 2020","March 15, 2012",,"February 5, 2020","Moores UC San Diego Cancer Center, La Jolla, California, United States|University of Miami Miller School of Medicine, Miami, Florida, United States|Xijing Hospital, Xi'an, China|University Hospital Hradec Králové, Hradec Králové, Czechia|Tata Memorial Hospital, Parel, Mumbai, India|Marie Sklodowska Cancer Center, Gliwice, Poland|King Chulalongkorn Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01554397"
503,"NCT00327444","Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites",,"Completed","Has Results","Ovarian Neoplasms|Ascites","Drug: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo","Time to Repeat Paracentesis (TRP)|Area Under the Curve (AUC) for Participant Assessed Ascites Impact Measure (AIM)|60-Day Frequency of Paracentesis (FOP)|Plasma Levels of Free and VEGF-bound Aflibercept","Sanofi|Regeneron Pharmaceuticals","Female","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","58","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EFC6125|EudraCT : 2005-005026-31|AVE0005A /3001","July 2006","October 2009","October 2009","May 18, 2006","January 1, 2013","January 1, 2013","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Vienna, Austria|Sanofi-Aventis Administrative Office, Diegem, Belgium|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Natanya, Israel|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00327444"
504,"NCT03715205","Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)",,"Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung|Melanoma","Drug: Pembrolizumab","Incidence of Adverse Events (AEs)|Incidence of Drug-Related AEs|Incidence of Serious Adverse Events (SAEs)|Incidence of Drug-Related SAEs|Incidence of Treatment Discontinuations|Incidence of Events of Clinical Interest (ECIs)","Merck Sharp & Dohme LLC","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3475-593|MK-3475-593|KEYNOTE 593","January 31, 2019","January 1, 2026","January 1, 2026","October 23, 2018",,"June 14, 2021","Nizam's Institute of Medical Sciences ( Site 0011), Hyderabad, Andhra Pradesh, India|All India Institute of Medical Sciences ( Site 0012), New Delhi, Delhi, India|Indraprastha Apollo Hospitals ( Site 0008), New Delhi, Delhi, India|Artemis Health Institute ( Site 0007), Gurgaon, Haryana, India|Tata Memorial Hospital [M] ( Site 0005), Mumbai, Maharashtra, India|Kokilaben Ben Dhirubhai Ambani Hosp & Med Res Inst. ( Site 0001), Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Center ( Site 0009), Pune, Maharashtra, India|Rajiv Gandhi Cancer Institute and Research Centre ( Site 0003), Delhi, India",,"https://ClinicalTrials.gov/show/NCT03715205"
505,"NCT05082311","Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma","PheoCard","Completed","No Results Available","Pheochromocytoma|Paraganglioma|Cardiovascular Morbidity","Other: Observational study","Change of Systolic function indices measurement by 2D-Echocardiography from Baseline versus after alpha blockade and after surgery|Change of Systolic function indices measurement by 2D-Echocardiography from baseline versus after alpha blockade and after surgery|Change of Systolic function index measurement by 2D-Echocardiography from Baseline at after alpha blockade and at after surgery|Change of Diastolic function index measurement by pulsed wave doppler echocardiography from baseline versus after alpha blockade and after surgery|Change of Diastolic function indices measurement by pulsed wave doppler echocardiography from baseline versus after alpha blockade and after surgery|Change in Speckle tracking echocardiographic parameters at Baseline versus after alpha blockade and at after surgery|Change in Speckle tracking echocardiographic parameters from Baseline in comparison to after alpha blockade and after surgery|Change in Vascular Function indices by doppler Ultrasonography of the brachial artery from baseline at after alpha blockade and at after surgery","Sanjay Gandhi Postgraduate Institute of Medical Sciences","All","7 Years and older   (Child, Adult, Older Adult)",,"55","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2018-185-Mch-EXP-4","January 19, 2019","November 30, 2021","January 31, 2022","October 18, 2021",,"February 10, 2022","Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT05082311"
506,"NCT01479283","Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)","PARITY","Completed","No Results Available","Infection|Bone Neoplasms","Drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen|Drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen","Surgical Site Infections|Functional Outcome and Quality of Life|Antibiotic-Related Complications|Rate of Re-Operation|Oncologic Recurrence and/or Metastases|Mortality","McMaster University|Orthopedic Research and Education Foundation|The Physicians' Services Incorporated Foundation|Canadian Cancer Society (CCS)|Canadian Institutes of Health Research (CIHR)","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","602","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Prevention","GHRT01","January 2013","March 2021","March 2021","November 24, 2011",,"March 11, 2021","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Stanford University Hospital and Clinics, Redwood City, California, United States|UC Davis Comprehensive Cancer Center, Sacramento, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|University of Connecticut Health Center, Farmington, Connecticut, United States|Hartford Hospital, Hartford, Connecticut, United States|University of Florida Health Shands Hospital, Gainesville, Florida, United States|Emory Orthopaedics and Spine Center, Atlanta, Georgia, United States|Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Franklin Square Medical Center, Baltimore, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Albany Medical Center, Albany, New York, United States|Montefiore Medical Center, Bronx, New York, United States|SUNY Upstate University Hospital, East Syracuse, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Long Island Jewish Medical Center   Northwell Health, Queens, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|The Cleveland Clinic - Hillcrest Hospital, Cleveland, Ohio, United States|Wexner Medical Center, Columbus, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|The Rothman Institute at Jefferson, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Medical College of Wisconsin - Froedtert Hospital, Milwaukee, Wisconsin, United States|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, South Australia, Australia|LKH - Universitätsklinikum Graz, Graz, Austria|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto de Ortopedia e Traumatologia, São Paulo, Brazil|Foothills Medical Centre, Calgary, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada|Ottawa Hospital, Ottawa, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Hôtel-Dieu de Québec, Québec City, Quebec, Canada|Children's Cancer Hospital Egypt, Cairo, Egypt|All India Institute of Medical Sciences, New Delhi, Delhi, India|Leiden University Medical Center, Leiden, South Holland, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Singapore General Hospital, Singapore, Singapore|Grey's Hospital, Pietermaritzburg, South Africa|Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01479283"
507,"NCT00229723","IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma",,"Completed","Has Results","Neoplasms, Squamous Cell","Drug: gefitinib (Iressa)|Drug: cisplatin|Radiation: radiotherapy|Drug: Gefitinib (Iressa)","Local Disease Control Rate at 2 Years|Local Disease Control Rate at 1 Year|Complete Response|Tumour Response (Complete Response + Partial Response)|Progression Free Survival|Overall Survival|Safety and Tolerability","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 2","224","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1839IL/0706|EudraCT number 2004-000358-21|D7919C00706","November 2004",,"June 2008","September 30, 2005","August 4, 2009","August 4, 2009","Research Site, Aurora, Colorado, United States|Research Site, Dallas, Texas, United States|Research Site, Brussels, Belgium|Research Site, Gent, Belgium|Research Site, Leuven, Belgium|Research Site, Hradec Kralove, Czech Republic|Research Site, Pardubice, Czech Republic|Research Site, Plzen, Czech Republic|Research Site, Berlin, Germany|Research Site, Essen, Germany|Research Site, Muenster, Germany|Research Site, Saarbrucken, Germany|Research Site, Bangalore, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Thiruvananthapuram, India|Research Site, Gliwice, Poland|Research Site, Kraków, Poland|Research Site, Lodz, Poland|Research Site, Lublin, Poland|Research Site, Warszawa, Poland|Research Site, Belgrade, Serbia|Research Site, Sremska Kamenica, Serbia|Research Site, Taipei, Taiwan|Research Site, Taoynan, Taiwan",,"https://ClinicalTrials.gov/show/NCT00229723"
508,"NCT02500277","Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy","COFFEE","Completed","No Results Available","Pleural Effusion|Pleurisy|Tuberculosis|Metastatic Malignancy","Device: Cryoprobe pleural biopsy first|Device: Flexible forceps biopsy first","Yield of pleural biopsy obtained with the routine flexible thoracoscopic biopsy forceps versus that obtained with a flexible cryoprobe during semirigid thoracoscopy|Biopsy size|Duration of procedure|Ease of biopsy VAS|Artifacts|Tissue depth|Bleeding","Postgraduate Institute of Medical Education and Research","All","12 Years to 79 Years   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NK/1815/Res/2439","January 2015","July 2018","July 2018","July 16, 2015",,"August 31, 2018","PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02500277"
509,"NCT01953913","Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation",,"Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Afatinib","Percentage of Participants With Serious Adverse Events (SAEs)|Time to Symptomatic Progression (TTSP)|Percentage of Participants With Drug-related (Afatinib-related) Adverse Events","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","542","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.66","September 30, 2013","July 6, 2018","July 6, 2018","October 1, 2013","August 12, 2019","August 12, 2019","307 Hospital of PLA, Beijing, China|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Jilin Province Cancer Hospital, Changchun, China|Guangdong Provincial People's Hospital, Guangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|Lin Yi Tumor Hospital, Linyi, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Tianjin Medical University Cancer Institute and Hospital, Tianjin, China|Queen Mary Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Shatin, Hong Kong|Vikram Hospital, Bangalore, India|HCG Hospital, Bengaluru, India|P VS Hospital Pvt Ltd, Calicut, India|V S Hospital, Chennai, India|Max Super Speciality Hospital, Delhi, Delhi, India|Global Hospitals, Hyderabad, India|Basavatarakam Indo - American Cancer Hospital & Research Ins, Hyderabad, India|SEAROC Cancer Centre, Jaipur, India|B. P. Poddar Hospital & Medial Research Ltd, Kolkata,West Bengal, India|Asirvatham Multispeciality Hospital, Madurai, India|Curie Manavata Cancer Centre, Maharashtra, India|Shatabdi Superspeciality Hospital, Maharashtra, India|Prince Aly Khan Hospital, Mumbai, India|Ruby Hall Clinic, Pune, India|National Cancer Centre, Singapore, Singapore|E-Da Hospital, Kaohsiung, Taiwan|NCKUH, Tainan, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang-Gung Memorial Hospital, Linkou, Taoyuan County, Taiwan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01953913/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01953913/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01953913"
510,"NCT04487080","A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer","MARIPOSA","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Amivantamab|Drug: Osimertinib|Drug: Lazertinib|Drug: Placebo","Progression-Free Survival (PFS) According to RECIST v1.1 by Blinded Independent Central Review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-Free Survival After First Subsequent Therapy (PFS2)|Time to Symptomatic Progression (TTSP)|Intracranial PFS|Incidence and Severity of Adverse Events (AEs)|Number of Participants with Clinical Laboratory Abnormalities|Number of Participants with Vital Signs Abnormalities|Number of Participants with Physical Examination Abnormalities|Serum Concentration of Amivantamab|Plasma Concentration of Lazertinib|Number of Participants with Anti-Amivantamab Antibodies|Change from Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)|Change from Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR108856|2020-000743-31|73841937NSC3003","September 30, 2020","April 30, 2024","March 30, 2026","July 27, 2020",,"April 27, 2022","Arizona Oncology Associates, PC - HAL, Goodyear, Arizona, United States|Yuma Regional Medical Center, Yuma, Arizona, United States|Compassionate Cancer Care, Fountain Valley, California, United States|City of Hope Long Beach Elm, Long Beach, California, United States|University of California, Irvine, Orange, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Palo Alto Medical Foundation Research Institute, Sunnyvale, California, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|Illinois Cancer Care, Peoria, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Pontchartrain Cancer Center, Covington, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Maryland Oncology Hematology, PA, Columbia, Maryland, United States|Frederick Health Hospital - James M Stockman Cancer Institute, Frederick, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Minnesota Oncology Hematology, P.A., Edina, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Central Care Cancer Center, Bolivar, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Essex Oncology of North Jersey, Belleville, New Jersey, United States|Astera Cancer Care, East Brunswick, New Jersey, United States|Summit Medical Group, Florham Park, New Jersey, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|TriHealth Network, Cincinnati, Ohio, United States|Ohio Health, Columbus, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Sanford Health, Sioux Falls, South Dakota, United States|Baptist Cancer Center, Bartlett, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology P.A., Austin, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Parkland Health and Hospital System, Dallas, Texas, United States|Oncology Consultants - Texas, Houston, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|NorthWest Medical Specialties, PLLC, Tacoma, Washington, United States|Instituto Alexander Fleming, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, C.a.b.a., Argentina|Centro Oncológico Korben, Ciudad Autónoma de Buenos Aires, Argentina|Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina|Centro Oncologico Riojano Integral (Cori), La Rioja, Argentina|Clínica Viedma, Viedma, Argentina|Flinders Medical Centre, Bedford Park, Australia|Austin Hospital, Heidelberg, Australia|St George Hospital, Kogarah, Australia|Cabrini Medical Centre, Malvern, Australia|St John of God Hospital Murdoch, Murdoch, Australia|St John of God Hospital Murdoch, Murdoch, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|Westmead Hospital, Westmead, Australia|Southern Medical Day Care Centre, Wollongong, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Cliniques Universitaires Saint-Luc, Brussel, Belgium|Grand Hôpital de Charleroi, site Notre Dame, Charleroi, Belgium|UZ Leuven, Leuven, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Algemeen Ziekenhuis Delta, Roeselare, Belgium|Fundacao Pio Xii - Hospital De Cancer De Barretos, Barretos, Brazil|Cetus Oncologia, Belo Horizonte, Brazil|Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Brazil|Ynova Pesquisa Clinica, Florianopolis, Brazil|Hospital de Caridade de Ijui, Ijuí, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Brazil|UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisa em Oncologia - PUCRS, Porto Alegre, Brazil|INCA - Instituto Nacional Do Cancer, Rio de Janeiro, Brazil|Oncoclínicas, Rio de Janeiro, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil|Núcleo de Pesquisa São Camilo, Sao Paulo, Brazil|IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, Brazil|Instituto do Cancer do Estado de Sao Paulo ICESP, São Paulo, Brazil|Fundação Antônio Prudente - A.C. Camargo Cancer Center, São Paulo, Brazil|William Osler Health System, Brampton, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Beijing Friendship Hospital, Capital Medical University, Beijing, China|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Beijing Chest hospital, Capital medical university, Beijing, China|Peking University International Hospital, Beijing, China|Jilin cancer hospital, Changchun, China|Hunan Cancer hospital, Changsha, China|The First People's Hospital Of Changzhou, Changzhou, China|Sichuan Cancer Hospital, Chengdu, China|West China Hospital, Sichuan University, Chengdu, China|Southwest Hospital, ChongQing, China|Third Military Medical University Daping Hospital Cancer Center, Chongqing, China|The First Affiliated Hospital, Sun Yat-sen University, Guang Zhou, China|Sun Yat-Sen Memorial Hospital Sun Yat-sen University, Guangzhou, China|Zhejiang Cancer Hospital, Hang Zhou, China|Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China|Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China|Harbin medical university cancer hospital, Harbin, China|Huizhou Municipal Central Hospital, Huizhou, China|Taizhou Hospital of Zhejiang Province, Linhai, China|Nanjing General Hospital, Nanjing, China|Nantong Tumor Hospital, Nanjing, China|Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China|Shanghai Chest Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai East Hospital, Shanghai, China|Shanghai Zhongshan Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Shengjing Hospital of China Medical University, Shenyang, China|Tianjin Medical University General Hospital, Tianjin, China|Cancer Hospital of Xinjiang Medical University, Urumchi, China|The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China|TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Yantai Yuhuangding Hospital, Yantai, China|Henan Cancer Hospital, Zhengzhou, China|Institut Bergonié, Bordeaux, France|Hospices Civils de Lyon HCL, Bron, France|CHU de Grenoble - Hôpital Albert Michallon, La Tronche, France|CHR Hôpital Calmette, Lille CEDEX, France|CHU de Limoges, Limoges, France|Hopital Nord, Marseille Cedex 20, France|Institut Curie, Paris, France|Hôpital Tenon, Paris, France|CHU Bordeaux, Pessac, France|CHU Nantes, Sain-Herblain, France|HIA Begin, Saint Mande, France|CHU Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif Cedex, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Helios Klinikum Emil von Behring GmbH, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken München-Gauting, Gauting, Germany|LungenClinic Grosshansdorf GmbH, Grosshandorf, Germany|Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle (Saale), Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Onkologische Schwerpunktpraxis, Heilbronn, Germany|Lungenklinik Hemer, Hemer, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Kliniken der Stadt Koeln gGmbH, Koeln, Germany|POIS Leipzig GbR, Leipzig, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Robert-Bosch-Krankenhaus - Klinik Schillerhoehe, Stuttgart, Germany|Orszagos Koranyi Tbc es Pulmonologiai Intezet, Budapest, Hungary|Veszprém Megyei Tudőgyógyintézet, Farkasgyepü, Hungary|Mátrai Gyógyintézet-Bronchológia, Gyöngyös, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktatokorhaz, Szekesfehervar, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Basavatarakam Indo-American Hospital, Hyderabad, India|Tata Medical Center, Kolkata, India|Tata Memorial Hospital, Mumbai, India|HCG Manavta Cancer Centre, Nasik, India|Noble Hospital Pvt Ltd, Pune, India|Soroka Medical Center, Beersheba, Israel|Rambam Health Corporation, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|Ospedale San Giuseppe Moscati di Avellino, Avellino, Italy|Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico, Catania, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|Istituto Europeo di Oncologia, Milano, Italy|San Gerardo Hospital, Monza, Italy|Ospedale Monaldi, Napoli, Italy|Aou San Luigi Gonzaga, Orbassano, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Irccs Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Juntendo University Hospital, Bunkyo-Ku, Japan|National Cancer Center Hospital, Chuo-Ku, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|National Hospital Organization Himeji Medical Center, Himeji, Japan|Kansai Medical University Hospital, Hirakata, Japan|Kanazawa University Hospital, Kanazawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Kurume University Hospital, Kurume, Japan|Matsusaka Municipal Hospital, Matsusaka, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Kindai University Hospital, Osaka-Sayama-shi, Japan|National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|National Hospital Organization Tokyo Medical Center, Tokyo, Japan|Ehime University Hospital, Toon, Japan|National Hospital Organization Osaka Toneyama Medical Center, Toyonaka-shi, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan|National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, Japan|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Hospital Pulau Pinang, George Town, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Beacon Hospital Sdn. Bhd., Petaling Jaya, Malaysia|Mexico Centre for Clinical Research, S.A. de C.V., Ciudad de Mexico, Mexico|Health Pharma Professional Research, Ciudad de Mexico, Mexico|Médica Sur, Ciudad de Mexico, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico|CIMOVA, Morals Vargas Centro de Investigación SC, Leon, Mexico|Instituto Nacional de Cancerologia, Mexico, Mexico|i Can Oncology Center, Monterrey, Mexico|Oncologia Integral Satelite, Naucalpan, Mexico|Rijnstate Ziekenhuis, Arnhem, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|Ziekenhuis St Jansdal, Harderwijk, Netherlands|Maastricht UMC+, Maastricht, Netherlands|UMC Radboud, Nijmegen, Netherlands|Jeroen Bosch Ziekenhuis, s-Hertogenbosch, Netherlands|Centrum Onkologii im. Prof. F. Lukaszczyka, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|Szpitale Pomorskie Sp. z o.o., Gdynia, Poland|Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, Poland|Private Specialist Hospitals - MedPolonia, Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland|Centro Hospitalar Lisboa Norte EPE - Hospital Pulido Valente, Lisboa, Portugal|Centro Hospitalar Universitario do Porto, EPE, Porto, Portugal|Hospital CUF Porto, Porto, Portugal|Instituto Portugues de Oncologia, Porto, Portugal|Centro Hospitalar de São João, EPE, Porto, Portugal|Pan American Center for Oncology Trials LLC, Rio Piedras, Puerto Rico|Irkutsk Regional Oncology Dispensary, Irkutsk, Russian Federation|State Medical Institution 'Republican Clinical Oncological Centre' at Republic of Tatarstan, Kazan, Russian Federation|Moscow City Oncology Hospital № 62, Krasnogorsk, Russian Federation|Krasnoyarsk Regional Oncology Dispensary, Krasnoyarsk, Russian Federation|Leningrad Regional Oncology Dispensary, Kuzmolovsky, Russian Federation|Moscow Oncology Research Center n.a. Blokhin, Moscow, Russian Federation|MCK, Moscow, Russian Federation|Central Clinical Hospital, Moscow, Russian Federation|City Clinical Hospital #1, Nalchik, Russian Federation|Nizhny Novgorod Regional Oncological Dispensary, Nizhniy Novgorod, Russian Federation|Omsk Clinical Oncology Dispensary, Omsk, Russian Federation|Current medical technologies, Saint Petersburg, Russian Federation|N.N. Petrov Research Institute Of Oncology, Saint Petersburg, Russian Federation|Oncology Medical Clinics AV Medical group, St-Petersburg, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Tambov Regional Oncology Clinical Dispansary, Tambov, Russian Federation|Tomsk Cancer Research Institute, Tomsk, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Hosp. Univ. A Coruña, A Coruña, Spain|Inst. Cat. D'Oncologia-Badalona, Badalona, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hosp. Univ. Quiron Dexeus, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Univ. de Burgos, Burgos, Spain|Institut Català D'Oncologia Girona, Girona, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Hosp. Regional Univ. de Malaga, Málaga, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Hosp. Virgen Del Rocio, Seville, Spain|Hosp. Gral. Univ. Valencia, Valencia, Spain|Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-DA Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Phramongkutklao Hospital and Medical College, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Chiangrai Prachanukroh Hospital, Chaing Rai, Thailand|Chiang Mai University, Chiangmai, Thailand|Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand|Adana City Hospital, Adana, Turkey|Başkent University Medical Faculty Adana Application and Research Center, Adana, Turkey|Gazi University Hospital, Ankara, Turkey|Ankara Bilkent City Hospital, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd, Istanbul, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|T.C. Saglik Bakanlıgi Goztepe Prof. Dr. Suleyman Yalcın Sehir Hastanesi, Istanbul, Turkey|Izmir Ekonomi Universitesi Medical Park Hastanesi, Izmir, Turkey|Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey|Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4, Dnipro, Ukraine|Municipal non-profit enterprise 'Regional Center of Oncology', Kharkiv, Ukraine|Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies', Kyiv, Ukraine|National Cancer Institute, Kyiv, Ukraine|Municipal Institution 'Odesa Clinical Oncology Dispensary', Odesa, Ukraine|Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal, Uzhgorod, Ukraine|Edinburgh Cancer Centre Western General, Edinburgh, United Kingdom|UCL Cancer Institute, London, United Kingdom|Chelsea And Westminster Hospital, London, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom|Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|The Royal Marsden NHS Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04487080"
511,"NCT02542293","Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).","NEPTUNE","Active, not recruiting","No Results Available","Non Small Cell Lung Carcinoma NSCLC","Biological: Durvalumab +Tremelimumab|Drug: Paclitaxel + carboplatin|Drug: Gemcitabine + cisplatin|Drug: Gemcitabine + carboplatin|Drug: Pemetrexed + cisplatin|Drug: Pemetrexed + carboplatin","To assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to Standard of Care (SoC) in terms of Overall Survival (OS) in patients with bTMB ≥ 20mut/Mb|To assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of OS|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Progression-free survival (PFS)|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Objective response rate (ORR)|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Duration of response (DoR)|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Proportion of patients alive at 12 months (OS12)|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of OS18|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of OS24|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Proportion of patients alive and progression free at 12 months (APF12)|To further assess the efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of Progression-free survival after subsequent anticancer therapy (PFS2)|To assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of ORR in further PD-L1 defined populations|To assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of PFS in further PD-L1 defined populations|To assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of OS in further PD-L1 defined populations|To further assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of ORR|To further assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of PFS|To further assess efficacy of MEDI4736 + tremelimumab combination therapy compared to SoC in terms of OS|To assess the pharmacokinetics (PK) of MEDI4736 + tremelimumab combination therapy|To investigate the immunogenicity of MEDI4736 and tremelimumab","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","953","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D419AC00003","November 3, 2015","September 21, 2020","October 29, 2021","September 7, 2015",,"July 7, 2021","Research Site, Anaheim, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Louisville, Kentucky, United States|Research Site, Florham Park, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, East Setauket, New York, United States|Research Site, Fresh Meadows, New York, United States|Research Site, Poughkeepsie, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Canton, Ohio, United States|Research Site, Columbus, Ohio, United States|Research Site, Zanesville, Ohio, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Houston, Texas, United States|Research Site, Berazategui, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Córdoba, Argentina|Research Site, La Rioja, Argentina|Research Site, Rosario, Argentina|Research Site, San Salvador de Jujuy, Argentina|Research Site, Santa Rosa, Argentina|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Fortaleza, Brazil|Research Site, Ijui, Brazil|Research Site, Itajai, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Shumen, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Vratza, Bulgaria|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Viña del Mar, Chile|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Chongqing, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Odense C, Denmark|Research Site, Oulu, Finland|Research Site, Tampere, Finland|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Holargos, Athens, Greece|Research Site, Ioannina, Greece|Research Site, Hong Kong, Hong Kong|Research Site, King's Park, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Gurgaon, India|Research Site, Karamsad, India|Research Site, New Delhi, India|Research Site, Beer Sheva, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Nahariya, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Bunkyo-ku, Japan|Research Site, Fukushima-shi, Japan|Research Site, Habikino-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Iizuka-shi, Japan|Research Site, Iwakuni-shi, Japan|Research Site, Kanazawa, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Kobe-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Nagaoka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Sagamihara-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Tokushima-shi, Japan|Research Site, Ube-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Hwasun-gun, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuantan, Malaysia|Research Site, Kuching, Malaysia|Research Site, Acapulco, Mexico|Research Site, Aguascalientes, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Mérida, Mexico|Research Site, México, Mexico|Research Site, Arequipa, Peru|Research Site, Bellavista, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Baguio City, Philippines|Research Site, Cebu, Philippines|Research Site, Las Pinas City, Philippines|Research Site, Manila, Philippines|Research Site, Manila, Philippines|Research Site, Pasay City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Kielce, Poland|Research Site, Kraków, Poland|Research Site, Mrozy, Poland|Research Site, Olsztyn, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Warszawa, Poland|Research Site, Warszawa, Poland|Research Site, Wodzisław Śląski, Poland|Research Site, Łódź, Poland|Research Site, Amadora, Portugal|Research Site, Lisboa, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Doha, Qatar|Research Site, Suceava, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Dammam, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Riyadh, Saudi Arabia|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Eskilstuna, Sweden|Research Site, Linköping, Sweden|Research Site, Stockholm, Sweden|Research Site, Uppsala, Sweden|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Chernivtsі, Ukraine|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kapitanivka Village, Ukraine|Research Site, Kharkiv Region, Ukraine|Research Site, Kirovohrad, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Lyutizh, Ukraine|Research Site, Odesa, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, Guildford, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Wirral, United Kingdom|Research Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02542293"
512,"NCT04988295","A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure","MARIPOSA-2","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Lazertinib|Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin","Progression-Free Survival (PFS) According to RECIST v1.1 Guidelines as Assessed by Blinded Independent Central Review (BICR)|Objective Response as Assessed by BICR|Overall Survival (OS)|Duration of Response (DoR)|Time to Subsequent Therapy (TTST)|Progression-Free Survival After First Subsequent Therapy (PFS2)|Time to Symptomatic Progression (TTSP)|Intracranial PFS|Number of Participants with Adverse Events (AEs)|Number of Participants with Clinical Laboratory Abnormalities|Serum Concentration of Amivantamab|Plasma Concentration of Lazertinib|Number of Participants with Anti-Amivantamab Antibodies|Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NSCLC-SAQ)|European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score|Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR109061|2021-001825-33|61186372NSC3002","November 17, 2021","May 31, 2023","November 17, 2025","August 3, 2021",,"May 11, 2022","Carl T. Hayden Veterans Administration Medical Center, Phoenix, Arizona, United States|City of Hope, Duarte, California, United States|University Of California San Diego, La Jolla, California, United States|Pacific Shores Medical Group in Long Beach, Long Beach, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|Hartford Hospital, Plainville, Connecticut, United States|University of Miami/Sylvester Cancer Center, Aventura, Florida, United States|Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic, Jacksonville, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Pacific Health Research and Education Institute, Honolulu, Hawaii, United States|Sinai Cancer Care, Chicago, Illinois, United States|Cancer Care Specialists of Central Illinois, Decatur, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Louis University, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|VA Sierra Nevada Health Care System, Reno, Nevada, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|North Shore-Long Island Jewish Health System, Lake Success, New York, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|TriHealth Network, Cincinnati, Ohio, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|MUSC-Hollings Cancer Center, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|University of Tennessee Health Sciences Center, Memphis, Tennessee, United States|Baptist Cancer Center, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, United States|Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Oncology Consultants - Texas, Houston, Texas, United States|UT MD Anderson Cancer Center, Houston, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|IADT Instituto Argentino de Diagnostico y Tratamiento, Caba, Argentina|Centro Medico Fleischer, Caba, Argentina|CEMIC (Centro de Educación Médica e Investigaciones Clínicas), Caba, Argentina|CINME - Centro de Investigaciones Metabolicas, Ciudad Autonoma de Buenos Aires, Argentina|Cemaic - Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica, Córdoba, Argentina|Hospital Privado Universitario de Córdoba, Córdoba, Argentina|Hospital Privado de la Comunidad, Mar del Plata, Argentina|Centro de Investigaciones Clinicas-CIC-IESR, Rosario, Argentina|Clínica Viedma, Viedma, Argentina|Grand Hôpital de Charleroi, site Notre Dame, Charleroi, Belgium|UZA, Edegem, Belgium|UZ Gent, Gent, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|UZ Leuven, Leuven, Belgium|CHU Sart-Tilman, Liege, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Cetus Oncologia, Belo Horizonte, Brazil|CIONC - Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil|Ynova Pesquisa Clinica, Florianopolis, Brazil|Fundação São Francisco Xavier, Ipatinga, Brazil|UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Hospital Ernesto Dornelles, Porto Alegre, Brazil|Oncoclínicas, Rio de Janeiro, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil|Instituto COI, Rio de Janeiro, Brazil|Núcleo de Oncologia da Bahia, Salvador, Brazil|Hospital Sao Rafael, Salvador, Brazil|CEPHO - Centro de Estudos e Pesquisa de Hematologia e Oncologia, Santo André, Brazil|IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, Brazil|Hospital Paulistano, São Paulo, Brazil|BP - Beneficencia Portuguesa de São Paulo, São Paulo, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital Nove de Julho, São Paulo, Brazil|Fundação Antônio Prudente - A.C. Camargo Cancer Center, São Paulo, Brazil|Oncoclínicas, Uberlândia, Brazil|Multifunctional Hospital for Active Treatment 'Serdika', Sofia, Bulgaria|Multiprofile Hospital for Active Treatment 'Tokuda Hospital Sofia', Sofia, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria|UMHAT Sofia Med, Sofia, Bulgaria|Multiprofile Hospital for Active Treatment 'Sveta Marina' EAD, Varna, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China|Peking University People's Hospital, Beijing, China|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Beijing Chest hospital, Capital medical university, Beijing, China|Hunan Cancer hospital, Changsha, China|The First People's Hospital Of Changzhou, Changzhou, China|Sichuan Cancer Hospital, Chengdu, China|West China Hospital, Sichuan University, Chengdu, China|Southwest Hospital, ChongQing, China|Chongqing University Cancer Hospital, Chongqing, China|The First Affiliated Hospital, Sun Yat-sen University, Guang Zhou, China|Sun Yat-Sen Memorial Hospital Sun Yat-sen University, Guangzhou, China|Zhejiang Cancer Hospital, Hang Zhou, China|Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China|Harbin medical university cancer hospital, Harbin, China|The First Affiliated hospital of Anliui Medical University, Hefei, China|Huizhou Municipal Central Hospital, Huizhou, China|Taizhou Hospital of Zhejiang Province, Linhai, China|Affiliated Hospital of North Sichuan Medical College, Nanchong, China|Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai East Hospital, Shanghai, China|Shenzhen university General Hospital, Shenzhen, China|Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen, China|Tianjin Medical University General Hospital, Tianjin, China|Weifang People's Hospital, Weifang, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Yantai Yuhuangding Hospital, Yantai, China|Daping Hospital Army Characteristic Medical Center, Yuzhong District, China|Henan Cancer Hospital, Zhengzhou, China|Fakultni nemocnice Olomouc - I.P.Pavlova 6, Olomouc, Czechia|Vitkovicka nemocnice a.s., Ostrava- Vitkovice, Czechia|Fakultni nemocnice Plzen, Plzen, Czechia|Aarhus Universitetshospital, Aarhus, Denmark|Rigshospitalet, Copenhagen, Denmark|Institut Sainte Catherine, Avignon Cedex 9, France|Hospices Civils de Lyon HCL, Bron, France|CHU de Grenoble - Hôpital Albert Michallon, La Tronche, France|Centre Hospitalier Le Mans, le mans Cedex 9, France|CHR Hôpital Calmette, Lille, France|Hopital Nord, Marseille Cedex 20, France|CHU de Montpellier - Arnaud de Villeneuve, Montpellier Cedex 5, France|Institut Curie, Paris, France|CHU Bordeaux, Pessac, France|CHRU Hôpital de Pontchaillou, Rennes, France|CHU Nantes, Sain-Herblain, France|Nouvel Hopital Civil - CHU Strasbourg, Strasbourg cedex, France|CHU Bretonneau, Tours, France|Evangelische Lungenklinik Berlin, Berlin, Germany|Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany|Asklepios Klinikum Harburg, Hamburg, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Onkologische Schwerpunktpraxis, Heilbronn, Germany|ViDia Christliche Kliniken Karlsruhe/St. Vincentius-Kliniken, Karlsruhe, Germany|POIS Sachsen GmbH iG, Leipzig, Germany|Bethanien Krankenhaus, Moers, Germany|Klinikum der Universität München, München, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Oncologianova GmbH, Recklinghausen, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Queen Mary Hospital, Hong Kong, Hong Kong|Health Care Global Enterprises pvt Ltd, Bangalore, India|Artemis Hospital, Gurugram, India|Tata Medical Center, Kolkata, India|Tata Memorial Hospital, Mumbai, India|Kokilaben Dhirubhai Ambani Hosp. & Med. Research Inst, Mumbai, India|Central India Cancer Research Institute, Nagpur, India|HCG Manavta Cancer Centre, Nasik, India|Action Cancer Hospital, New Delhi, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delh, India|Noble Hospital Pvt Ltd, Pune, India|Bhaktivedanta Hospital & Research Institute, Thane, India|Soroka University Medical Center, Beersheba, Israel|Rambam Health Corporation, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Chaim Sheba Medical Center, Ramat Gan, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|CRO, IRCCS, Istituto Nazionale Tumori, Aviano, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliero-Universitaria Di Parma, Parma, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Istituto Nazionale Tumori Regina Elena, Roma, Italy|Policlinico G.B.Rossi, Verona, Italy|National Hospital Organization Shibukawa Medical Center, Gunma, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Hyogo Cancer Center, Hyogo, Japan|Kanagawa Cancer Center, Kanagawa, Japan|Kurume University Hospital, Kurume, Japan|National Hospital Organization Nagoya Medical Center, Nagoya-shi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka International Cancer Institute, Osaka, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Ehime University Hospital, Toon, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan|National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, Japan|National Cancer Center, Gyeonggi-do, Korea, Republic of|GyeongSang National University Hospital, Gyeongsangnam-do, Korea, Republic of|CHA Bundang Medical Center, CHA University, Seongnamsi, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Tengku Ampuan Afzan, Kuantan, Malaysia|Beacon Hospital Sdn. Bhd., Petaling Jaya, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|Mount Miriam Cancer Hospital, Tanjung Bungah, Malaysia|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico|CIMOVA, Morals Vargas Centro de Investigación SC, Leon, Mexico|Health Pharma Professional Research, Mexico, Mexico|Instituto Nacional de Cancerologia, Mexico, Mexico|Oncologia Integral Satelite, Naucalpan, Mexico|NKI-AVL, Amsterdam, Amsterdam, Netherlands|VUMC Amsterdam, Amsterdam, Netherlands|Ziekenhuis St Jansdal, Harderwijk, Netherlands|Erasmus MC, Rotterdam, Netherlands|Centrum Onkologii im. Prof. F. Lukaszczyka, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpitale Pomorskie Sp. z o.o., Gdynia, Poland|Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandow, Poznan, Poland|Private Specialist Hospitals - MedPolonia, Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland|Centro Hospitalar Lisboa Norte EPE - Hospital Pulido Valente, Lisboa, Portugal|Hospital Beatriz Angelo, Loures, Portugal|Centro Hospitalar Universitario do Porto, EPE, Porto, Portugal|Instituto Portugues de Oncologia, Porto, Portugal|Pan American Center for Oncology Trials LLC, Rio Piedras, Puerto Rico|Krasnoyarsk Regional Oncology Dispensary, Krasnoyarsk, Russian Federation|LLC VitaMed, Moscow, Russian Federation|Main Administration for Service to the Diplomatic Corps under the MoFA of the RF, Moscow, Russian Federation|Moscow City Oncology Hospital № 62, Moskovskaya Oblast', Krasnogo, Russian Federation|City Clinical Hospital #1, Nalchik, Russian Federation|Nizhny Novgorod Regional Oncological Dispensary, Nizhniy Novgorod, Russian Federation|Llc, Eurocityclinic, Saint Petersburg, Russian Federation|N.N. Petrov Research Institute Of Oncology, Saint Petersburg, Russian Federation|Oncology Medical Clinics AV Medical group, St-Petersburg, Russian Federation|Tambov Regional Oncology Clinical Dispansary, Tambov, Russian Federation|Tomsk Cancer Research Institute, Tomsk, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Hosp. Univ. A Coruña, A Coruña, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hosp. Univ. Quiron Dexeus, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain|Hosp. Univ. Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Fund. Jimenez Diaz, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. Hm Sanchinarro, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Hosp. Regional Univ. de Malaga, Málaga, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Hosp. Virgen Del Rocio, Seville, Spain|Hosp. Gral. Univ. Valencia, Valencia, Spain|Hosp. Univ. I Politecni La Fe, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Goteborg, Sweden|Linkoping University Hospital, Linkoping, Sweden|Skanes universitetssjukhus, Lund, Sweden|Norrlands Universitetssjukhus, Umea, Sweden|Akademiska Sjukhuset, Uppsala, Sweden|Changhua Christian Hospital, Changhua, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Adana City Hospital, Adana, Turkey|Gazi University Hospital, Ankara, Turkey|Memorial Ankara Hastanesi, Ankara, Turkey|Ankara Bilkent City Hospital, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Bakirkoy Training and Research Hospital, Istanbul, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Acıbadem Maslak Hospital, Istanbul, Turkey|Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Izmir Medical Park Hospital, Izmir, Turkey|Queen Elizabeth Hospital, Birmingham, United Kingdom|Birmingham Heartlands Hospital, Birmingham, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Edinburgh Cancer Centre Western General, Edinburgh, United Kingdom|Royal Surrey County Hospital NHS Trust, Guildford, United Kingdom|Barts Heart Centre, St. Bartholomew's Hospital, London, United Kingdom|UCL Cancer Institute, London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom|The Christie Nhs Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04988295"
513,"NCT04538664","A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","PAPILLON","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Amivantamab|Drug: Pemetrexed|Drug: Carboplatin","Progression-Free Survival (PFS) According to RECIST v1.1 as Assessed by Blinded Independent Central Review (BICR)|Objective Response Rate (ORR)|Duration of Response (DoR)|Overall Survival (OS)|Time to Subsequent Therapy (TST)|Progression-Free Survival After First Subsequent Therapy (PFS2)|Time to Symptomatic Progression (TTSP)|Incidence and Severity of Adverse Events (AEs)|Number of Participants with Clinical Laboratory Abnormalities|Number of Participants with Vital Signs Abnormalities|Number of Participants with Physical Examination Abnormalities|Serum Concentration of Amivantamab|Number of Participants with Anti-Amivantamab Antibodies|European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)|Patient Reported Outcomes Measurement Information System-Physical Function (PROMIS-PF)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108850|2020-000633-40|61186372NSC3001","October 13, 2020","August 31, 2022","January 31, 2025","September 4, 2020",,"April 27, 2022","City of Hope, Duarte, California, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care, Fountain Valley, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|University of California, Irvine, Orange, California, United States|UCLA, Santa Monica, California, United States|University of Colorado, Aurora, Colorado, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Florida, United States|H. Lee Moffitt Cancer & Research Institute, Tampa, Florida, United States|University Cancer & Blood Center, LLC, Athens, Georgia, United States|Hawaii Cancer Care, Honolulu, Hawaii, United States|Illinois Cancer Care, Peoria, Illinois, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Pontchartrain Cancer Center, Covington, Louisiana, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University Medical Center, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Essex Oncology of North Jersey, Belleville, New Jersey, United States|Regional Cancer Care Associates LLC, East Brunswick, New Jersey, United States|Langone Health at NYC University, NYU School of Medicine, New York, New York, United States|Icahn School of Medicine at Mt. Sinai, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Durham VAMC, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio Health, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Sanford Health, Sioux Falls, South Dakota, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|Chris O'Brien Lifehouse, Camperdown, Australia|Austin Hospital, Heidelberg, Australia|St George Hospital, Kogarah, Australia|Cabrini Medical Centre, Malvern, Australia|Sir Charles Gairdner Hospital, Nedlands, Australia|UZ Leuven, Leuven, Belgium|Algemeen Ziekenhuis Delta, Roeselare, Belgium|CHU UCL Namur - Site Godinne, Yvoir, Belgium|Fundacao Pio Xii - Hospital De Cancer De Barretos, Barretos, Brazil|Cetus Oncologia, Belo Horizonte, Brazil|Hospital Evangélico de Cachoeiro de Itapemirim, Cachoeiro de Itapemirim, Brazil|Ynova Pesquisa Clinica, Florianopolis, Brazil|Hospital de Caridade de Ijui, Ijuí, Brazil|Liga Norte Riograndense Contra O Cancer, Natal, Brazil|UPCO Unidade de Pesquisa Clinica em Oncologia, Pelotas, Brazil|Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Centro de Pesquisa em Oncologia - PUCRS, Porto Alegre, Brazil|INCA - Instituto Nacional Do Cancer, Rio de Janeiro, Brazil|Oncoclínicas, Rio de Janeiro, Brazil|Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil|Núcleo de Pesquisa São Camilo, Sao Paulo, Brazil|IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado, Sorocaba, Brazil|Instituto do Cancer do Estado de Sao Paulo ICESP, São Paulo, Brazil|Fundação Antônio Prudente - A.C. Camargo Cancer Center, São Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|Beijing Cancer Hospital, Beijing, China|Chinese PLA General Hospital, Beijing, China|Beijing Chest hospital, Capital medical university, Beijing, China|Peking University International Hospital, Beijing, China|Jilin cancer hospital, Changchun, China|Hunan Cancer hospital, Changsha, China|The First People's Hospital Of Changzhou, Changzhou, China|West China Hospital, Sichuan University, Chengdu, China|Chongqing University Cancer Hospital, Chongqing, China|Fujian Medical University Union Hospital, Fuzhou, China|The First Affiliated Hospital, Sun Yat-sen University, Guang Zhou, China|Zhejiang Cancer Hospital, Hang Zhou, China|The First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, China|The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China|Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China|Harbin medical university cancer hospital, Harbin, China|Taizhou Hospital of Zhejiang Province, Linhai, China|Nanjing Drum Tower Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Zhongshan Hospital, ShangHai, China|Shanghai East Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Shengjing Hospital of China Medical University, Shenyang, China|Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen, China|Tianjin Medical University General Hospital, Tianjin, China|Weifang People's Hospital, Weifang, China|TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology, Wuhan, China|Hospital of Jiangnan University, Wuxi, China|The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Yantai Yuhuangding Hospital, Yantai, China|Henan Cancer Hospital, Zhengzhou, China|Institut Bergonié, Bordeaux, France|Hospices Civils de Lyon HCL, Bron, France|Centre Georges François Leclerc, Dijon, France|Centre Hospitalier Le Mans, le mans Cedex 9, France|CHR Hôpital Calmette, Lille CEDEX, France|CHU Nantes - Hopital Nord Laënnec, NANTES cedex 1, France|Institut Curie, Paris, France|CHU Bordeaux, Pessac, France|HIA Begin, Saint Mande, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Evangelische Lungenklinik Berlin, Berlin, Germany|Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken München-Gauting, Gauting, Germany|Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg, Germany|Onkologische Schwerpunktpraxis, Heilbronn, Germany|Lungenklinik Hemer, Hemer, Germany|Universitaetsklinikum Koeln, Koeln, Germany|Kliniken der Stadt Koeln gGmbH, Koeln, Germany|Bethanien Krankenhaus, Moers, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Oncologianova GmbH, Recklinghausen, Germany|Orszagos Koranyi Tbc es Pulmonologiai Intezet, Budapest, Hungary|Veszprém Megyei Tudőgyógyintézet, Farkasgyepü, Hungary|Mátrai Gyógyintézet-Bronchológia, Gyöngyös, Hungary|Fejer Megyei Szent Gyorgy Egyetemi Oktatokorhaz, Szekesfehervar, Hungary|Markusovszky Egyetemi Oktatokorhaz, Szombathely, Hungary|Tudogyogyintezet Torokbalint, Torokbalint, Hungary|Basavatarakam Indo-American Hospital, Hyderabad, India|Tata Medical Center, Kolkata, India|Tata Memorial Hospital, Mumbai, India|HCG Manavta Cancer Centre, Nasik, India|Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, India|Noble Hospital Pvt Ltd, Pune, India|Soroka Medical Center, Beersheba, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|Rabin Medical Center, Petah Tikva, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|A.O.U Sant'Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico, Catania, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|IRCCS Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|San Gerardo Hospital, Monza, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Irccs Gemelli, Roma, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Juntendo University Hospital, Bunkyo-Ku, Japan|Osaka Habikino Medical Center, Habikino, Japan|Saitama Medical University International Medical Center, Hidaka, Japan|National Hospital Organization Himeji Medical Center, Himeji, Japan|Kansai Medical University Hospital, Hirakata, Japan|Hyogo Cancer Center, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Japan|National Cancer Center Hospital East, Kashiwa, Japan|Kishiwada City Hospital, Kishiwada, Japan|Kobe City Medical Center General Hospital, Kobe, Japan|Kurashiki Central Hospital, Kurashiki, Japan|Kurume University Hospital, Kurume, Japan|Matsusaka Municipal Hospital, Matsusaka, Japan|National Hospital Organization Nagoya Medical Center, Nagoya-shi, Japan|Aichi Cancer Center Hospital, Nagoya-Shi, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Kindai University Hospital, Osaka-Sayama-shi, Japan|Kitasato University Hospital, Sagamihara, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|Iwate Medical University Hospital, Shiwa-gun, Japan|Shizuoka Cancer Center, Shizuoka, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Ehime University Hospital, Toon, Japan|Wakayama Medical University Hospital, Wakayama, Japan|National Hospital Organization Yamaguchi Ube Medical Center, Yamaguchi, Japan|Inje University Haeundae Paik Hospital, Busan, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Jeollanam-do, Korea, Republic of|GyeongSang National University Hospital, Jinju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Kangbuk Samsung Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Hospital Pulau Pinang, George Town, Malaysia|Hospital Sultan Ismail, Johor Bahru, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Centro Oncológico de Chihuahua, Chihuahua, Mexico|Mexico Centre for Clinical Research, S.A. de C.V., Ciudad de Mexico, Mexico|Médica Sur, Ciudad de Mexico, Mexico|Instituto Nacional de Cancerologia, Ciudad de Mexico, Mexico|Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico|Health Pharma Professional Research, Mexico, Mexico|i Can Oncology Center, Monterrey, Mexico|Oncologia Integral Satelite, Naucalpan, Mexico|Centrum Onkologii im. Prof. F. Lukaszczyka, Bydgoszcz, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpitale Pomorskie Sp. z o.o., Gdynia, Poland|Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie, Olsztyn, Poland|Private Specialist Hospitals - MedPolonia, Poznan, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy, Warszawa, Poland|Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|Fundação Champalimaud, Lisboa, Portugal|Hosp. Cuf Descobertas, Lisboa, Portugal|Chlc - Hosp. Sto Antonio Dos Capuchos, Lisboa, Portugal|Centro Hospitalar Universitario do Porto, EPE, Porto, Portugal|Instituto Portugues de Oncologia, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Portugal|Pan American Center for Oncology Trials LLC, Rio Piedras, Puerto Rico|Irkutsk Regional Oncology Dispensary, Irkutsk, Russian Federation|State Medical Institution 'Republican Clinical Oncological Centre' at Republic of Tatarstan, Kazan, Russian Federation|Moscow City Oncology Hospital № 62, Krasnogorsk, Russian Federation|Krasnoyarsk Regional Oncology Dispensary, Krasnoyarsk, Russian Federation|Leningrad Regional Oncology Dispensary, Kuzmolovsky, Russian Federation|Moscow Oncology Research Center n.a. Blokhin, Moscow, Russian Federation|MCK, Moscow, Russian Federation|Central Clinical Hospital, Moscow, Russian Federation|City Clinical Hospital #1, Nalchik, Russian Federation|Nizhny Novgorod Regional Oncological Dispensary, Nizhniy Novgorod, Russian Federation|N.N. Petrov Research Institute Of Oncology, Saint Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, Saint-Petersburg, Russian Federation|Oncology Medical Clinics AV Medical group, St-Petersburg, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Tomsk Cancer Research Institute, Tomsk, Russian Federation|Bashkir State Medical University, Ufa, Russian Federation|Yaroslavl Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Hosp. Univ. A Coruña, A Coruña, Spain|Inst. Cat. D'Oncologia-Badalona, Badalona, Spain|Hosp. de La Santa Creu I Sant Pau, Barcelona, Spain|Hosp. Univ. Quiron Dexeus, Barcelona, Spain|Hosp. Univ. Vall D Hebron, Barcelona, Spain|Hosp. Univ. de Burgos, Burgos, Spain|Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain|Hosp. Univ. Ramon Y Cajal, Madrid, Spain|Hosp. Univ. 12 de Octubre, Madrid, Spain|Hosp. Univ. La Paz, Madrid, Spain|Hosp. Univ. Pta. de Hierro Majadahonda, Majadahonda, Spain|Hosp. Virgen de La Victoria, Málaga, Spain|Clinica Univ. de Navarra, Pamplona, Spain|Hosp. Virgen Del Rocio, Seville, Spain|Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Medical Foundation, Kaohsiung, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Phramongkutklao Hospital and Medical College, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Songklanagarind Hospital, Prince of Songkla University, Songkla, Thailand|Adana City Hospital, Adana, Turkey|Başkent University Medical Faculty Adana Application and Research Center, Adana, Turkey|Gazi University Hospital, Ankara, Turkey|Ankara Bilkent City Hospital, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd, Istanbul, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Izmir Medical Park Hospital, Izmir, Turkey|Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4, Dnipro, Ukraine|Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies', Kyiv, Ukraine|National Cancer Institute, Kyiv, Ukraine|Municipal Institution 'Odesa Clinical Oncology Dispensary', Odesa, Ukraine|Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal, Uzhgorod, Ukraine|Edinburgh Cancer Centre Western General, Edinburgh, United Kingdom|The Royal Marsden NHS Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|The Royal Marsden NHS Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04538664"
514,"NCT00957086","Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer",,"Active, not recruiting","No Results Available","Carcinoma, Squamous Cell of Head and Neck","Drug: Nimotuzumab|Drug: Placebo","To compare the disease-free survival between patients randomized to adjuvant nimotuzumab/cisplatin/RT with the control arm|To compare the overall survival between the two arms|To assess the Toxicity Profile between the 2 arms","National Cancer Centre, Singapore|National Medical Research Council (NMRC), Singapore|Innogene Kalbiotech Pte. Ltd","All","21 Years and older   (Adult, Older Adult)","Phase 3","710","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IHN01","August 13, 2009","January 1, 2024","January 1, 2024","August 12, 2009",,"April 6, 2022","Flinders Medical Centre, Bedford Park, Australia|Peter MacCallum Cancer Centre, Melbourne, Australia|National Institute of Oncology and Radiobiology, Vedado, Cuba|Alexandria University School of Medicine, Alexandria, Egypt|National Cancer Institute, Cairo University, Cairo, Egypt|Apollo Hospital Bangalore, Bangalore, India|Narayana Hrudayalaya Hospital (Mazumdar Shaw Cancer Institute), Bangalore, India|Amrita Institute of Medical Sciences, Kerala, India|Tata Memorial Centre, Mumbai, India|Christian Medical College, Tamil Nadu, India|Regional Cancer Center Trivandrum, India, Trivandrum, India|Cipto Mangunkusumo General Hospital Indonesia, Jakarta, Indonesia|National Cancer Center Korea, Gyeonggi-do, Korea, Republic of|INHA University Hospital, Incheon, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Pantai Medical Centre, Kuala Lumpur, Kuala Lumpur, Malaysia|Mahkota Medical Center, Melaka, Malaysia|University of Santo Tomas Hospital, Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|King Fahad Medical City, Riyadh, Saudi Arabia|National Cancer Centre, Singapore, Singapore|The Oncology Centre, Durban, South Africa|GVI Oncology, Panorama, South Africa|China Medical University Hospital, Taichung, Taiwan|Taipei Med Univ Hosp [TMUH], Taipei, Taiwan|Taipei Veteran General Hospital, Taipei, Taiwan|National Cancer Institute Bangkok (+Chulabhorn for RT), Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Chiang Mai Hospital, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT00957086"
515,"NCT01525550","A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors",,"Completed","Has Results","Well-differentiated Pancreatic Neuroendocrine Tumor","Drug: sunitinib","Progression-Free Survival (PFS): Investigator Assessment|Progression-Free Survival (PFS): Independent Radiological Review (IRR) Assessment|Time to Tumor Progression (TTP): Investigator Assessment|Overall Survival (OS)|Percentage of Participants With Objective Response (OR): Investigator Assessment|Duration of Response (DOR): Investigator Assessment|Time to Tumor Response (TTR): Investigator Assessment|Percentage of Participants With Objective Response (OR): Independent Radiological Review (IRR) Assessment|Duration of Response (DOR): Independent Radiological Review (IRR) Assessment|Time to Tumor Response (TTR): Independent Radiological Review (IRR) Assessment|Percentage of Participants With Chromogranin A (CgA) Response|Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)|Quality of Life Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gastrointestinal Related Neuroendocrine Tumours-21 (EORTC QLQ-GI NET 21)|Plasma Concentration of Soluble Protein Biomarker (sKIT)|Minimum Observed Plasma Concentration (Ctrough) of Sunitinib and Its Metabolite SU012662|Dose-Corrected Trough Plasma Concentration of Sunitinib and Its Metabolite SU012662|Area Under the Curve (AUC24) of Sunitinib and Its Metabolite SU012662|Oral Clearance (CL/F) of Sunitinib and Its Metabolite SU012662|Half Maximal Effective Concentration (EC50) of Sunitinib|Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Adverse Events (AEs) According to Severity|Number of Participants With Clinically Significant Laboratory Abnormalities|Number of Participants With Change From Baseline in Vital Signs Abnormalities|Number of Participants With Increase From Baseline in Corrected QT Interval (QTc)|Number of Participants With Change From Baseline in Physical Examinations Findings|Number of Participants With Change From Baseline in Body Weight|Number of Participants With Eastern Co-operative Oncology Group Performance Status (ECOG-PS)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 4","106","Industry","Interventional","Masking: None (Open Label)|Primary Purpose: Other","A6181202|2011-004363-74","June 6, 2012","March 19, 2016","July 26, 2018","February 3, 2012","May 19, 2017","July 30, 2019","Univeristy of California, Orange, California, United States|Columbia University Medical Center, New York, New York, United States|Barwon Health - University Hospital Geelong, Geelong, Victoria, Australia|Cliniques Universitaires Saint-Luc, Gastroenterologie, Bruxelles, Brussels Gewest, Belgium|China-Japan Friendship Hospital, Beijing, Beijing, China|307 Hospital of PLA, Beijing, Beijing, China|Beijing Cancer Hospital, Beijing, Beijing, China|Nanjing Bayi Hospital, Nanjing, Jiangsu, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Fudan University Shanghai Cancer Center, Shanghai, China|Zhongshan Hospital Fudan University, Shanghai, China|Masarykuv onkologicky ustav, Brno, Czechia|Fakultni poliklinika, Praha 2, Czechia|Vseobecna Fakultni Nemocnice v Praze, Praha 2, Czechia|Hôpital Beaujon, Clichy Cedex, France|Semmelweis Egyetem/II. Sz. Belgyogyaszati Klinika, Budapest, Hungary|Tata Memorial Hospital, Mumbai, Maharashtra, India|IEO Istituto Europeo di Oncologia, IRCCS, Milano, Italy|Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Oslo Universitetssykehus HF, Rikshospitalet, Oslo, Norway|Centrul de Oncologie Sf. Nectarie, Craiova, Dolj, Romania|Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie, Bucuresti, Romania|Narodny Onkologicky ustav, Bratislava, Slovakia|Wits Clinical Research, Johannesburg, Gauteng, South Africa|Hospital Universitario Madrid Sanchinarro - Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01525550"
516,"NCT00190840","A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small Cell Lung","Drug: pemetrexed","Response rate according to RECIST criteria|To assess the following time to event efficacy variables:|o Duration of overall response for responding patients|o Time to progressive disease|o Time to treatment failure|o Survival|To characterize the quantitative and qualitative toxicity of pemetrexed when used at tailored dosing in this patient population","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 2","186","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6685|H3E-AA-S037","September 2003",,"October 2005","September 19, 2005",,"January 26, 2007","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wollongong, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chermside, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ashford, South Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fitzroy, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hong Kong, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Alexandria, Egypt|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cairo, Egypt|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hyderabad, Andhra Pradesh, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ludhiana, Punjab, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chandigarh, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chennai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Gyeonggi-Do, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oradea, Bihor, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Craiova, Dolj, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bucuresti, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iasi, Romania|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Eskisehir, Turkey",,"https://ClinicalTrials.gov/show/NCT00190840"
517,"NCT01459328","Resource-Sparing Curative Treatment for Rectal Cancer",,"Unknown status","No Results Available","Rectal Carcinoma","Radiation: Radiotherapy","Overall Survival|Biological Effect and Tumour Biology|Quality of Life|Health-related Economics","International Atomic Energy Agency|Centre Anti Cancer Hopital Frantz Fanon|Hospital A.C. Camargo|Credit Valley Hospital|Instituto Nacional de Cancerologia, Columbia|University Hospital ""Sestre Milosrdnice""|Minesterio de Cienca, Tecnologia y Medio Ambiente|V.N. Cancer Center GKNM Hospital|Tata Memorial Hospital|Dr Cipto Mangunkusumo General Hospital|National Cancer Center, Bratislava|University of Cape Town|Catholic University of the Sacred Heart","All","18 Years and older   (Adult, Older Adult)","Phase 3","350","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33034","September 2009","September 2013",,"October 25, 2011",,"October 25, 2011","Centre Anti-Cancer, Hopital Franz Fanon, Blida, Algeria|Hospital A.C. Camargo, Fundacao Antonio Prudente, Sao Paulo, Brazil|Credit Valley Hospital, Mississauga, Ontario, Canada|Instituto Nacional de Cancerologia, Minesterio de Salud, Bogota D.C., Colombia|Department of Oncology and Nuclear Medicine, University Hospital Sestre Milosrdnice, Zagreb, Croatia|Ministerio de Cienca, Tecnologia y Medio Ambiente (CITMA), La Habana, Cuba|Department of Radiation Oncology, V.N. Cancer Center, GKNM Hospital, Coimbatore, India|Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India|Department of Radiotherapy, Dr. Cipto Mangunkusuma National General Hospital, University of Indonesia, Jakarta, Indonesia|Instituto di Radiologia, Universita Cattolica del Sacro Cuore, Roma, Italy|National Cancer Institute, Bratislava, Slovakia|University of Cape Town, Cape Town, South Africa",,"https://ClinicalTrials.gov/show/NCT01459328"
518,"NCT00805194","LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer",,"Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: placebo plus docetaxel|Drug: BIBF 1120 plus docetaxel","Progression Free Survival (PFS) as Assessed by Central Independent Review|Overall Survival (Key Secondary Endpoint)|Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review|Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator|Objective Tumour Response|Duration of Confirmed Objective Tumour Response|Time to Confirmed Objective Tumour Response|Disease Control|Duration of Disease Control|Change From Baseline in Tumour Size|Clinical Improvement|Quality of Life (QoL)|Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide|Incidence and Intensity of Adverse Events","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","1314","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1199.13|2007-004803-36","December 3, 2008","November 2, 2010","November 13, 2017","December 9, 2008","December 1, 2014","December 5, 2018","LKH-Univ. Hospital Graz, Graz, Austria|KH St. Vinzenz, Zams, Int. Abtlg., Kufstein, Austria|AKH d. Stadt Linz, Pulmologie, Linz, Austria|Bobruisk Inter-distict, Bobruisk, Belarus|Brest Regional Clinical, Brest Region, Belarus|Gomel Regional Clinical, Gomel, Belarus|Scientific Research Minsk, Minsk Region, Belarus|Public Health Inst. Minsk City Clinical Oncology Dispensary, Minsk, Belarus|Mogilov Regional Oncological Dispensary, Mogilov, Belarus|Vitebsk Regional Clinical Oncology Dispensary, Vitebsk, Belarus|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Liège - HOSP CHR de la Citadelle, Liège, Belgium|Multiprofile Hospital for Active Treatment, Gabrovo, Bulgaria|Univ.Multiprofile Hospital ""Dr. Georgy Stranski"" EAD, Pleven, Pleven, Bulgaria|District Oncology Dispensary Plovdiv, Plovdiv, Bulgaria|Interdistrict Oncology Dispensary, Ruse, Ruse, Bulgaria|District Oncology Dispensary Shumen, Shumen, Bulgaria|Specialized Hospital for Active Treatment in Oncolcogy, Sofia, Bulgaria|307 Hospital of PLA, Beijing, China|Jilin Province Cancer Hospital, Changchun, China|First Hospital of Jilin University, Changchun, China|West China Hospital, Chengdu, China|Southwest Hospital, Chongqing, China|First Affiliated Hospital of Dalian Medical University, Dalian, China|The Second Affiliated Hospital of Dalian Medical University, Dalian, China|Fujian Provincial Tumor Hospital, Fujian, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|Guangdong General Hospital, Guangzhou, China|Sir Run Run Shaw Hospital, Hangzhou, China|Zhejiang Cancer Hospital, Hangzhou, China|The Third Affiliated Hospital of Harbin Medical University, Harbin, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Fudan University Shanghai Cancer Center, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Tongji Hospital, Tongji University, Wuhan, China|Zhongshan Hospital Fudan University, Xuhui Area, Shanghai, China|Clinical Hospital Centar Sestre Milosrdnice, Zagreb, Croatia|UHC Zagreb, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|St. Anna Hospital, 2nd Internal Department, Brno, Czechia|District Hospital Liberec, Liberec, Czechia|Institut onkologie a rehabilitace Na Plesi s.r.o., Nova Ves pod Plesi, Czechia|District Hospital Pribram, Oncology Centrum, Pribram, Czechia|Herlev Hospital, Herlev, Denmark|Odense Universitetshospital, Odense C, Denmark|HOP Croix Rousse, Pneumo, Lyon, Lyon Cedex 4, France|INS Paoli-Calmettes, Marseille Cedex 9, France|HOP Lyon Sud, Pierre Bénite cedex, France|CHU de Rouen - Hôpital de Bois Guillaume, ROUEN cedex, France|HOP Nord Laënnec, Saint Herblain cedex, France|Oncology Institute of the Loire, Saint-Priest en Jarez, France|HOP Civil, Strasbourg cedex, France|Sainte Anne Training hospital for the armies, Toulon Cedex 09, France|Amtel Hospital first Clinical LLC, Tbilisi, Georgia|National Centre of Oncology, Tbilisi, Georgia|Chemotherapy & Immunotherapy Clinic 'Medulla', Tbilisi, Tbilisi, Georgia|Gemeinschaftspraxis Dr. Brudler / Dr. Heinrich, Augsburg, Augsburg, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Evangelische Lungenklinik Berlin, Berlin-Buch, Germany|Universitätsklinikum Benjamin Franklin, Berlin, Berlin, Germany|Helios Klinikum Emil von Behring, Berlin, Germany|Krankenhaus Nordwest, Frankfurt, Frankfurt/Main, Germany|Klinikum Frankfurt Höchst GmbH, Frankfurt/Main, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Germany|Pneumologisches Forschungsinstitut an der LungenClinic Grosshansdorf GmbH, Großhansdorf, Germany|Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle/Saale, Germany|Allgemeines Krankenhaus Harburg, 21075 Hamburg, Hamburg, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum Kassel GmbH, Kassel, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Gemeinschaftspraxis für Hämatologie und Onkologie, Köln, Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|POIS Leipzig GbR, Leipzig, Germany|Klinik, Löwenstein, Löwenstein, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Lübeck, Germany|Katholisches Klinikum St. Hildegardiskrankenhaus, Mainz, Mainz, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinik links der Isar, München, Ziemssenstr. 1, München, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Städt. Krankenhaus, München-Bogenhausen, München, Germany|Pius-Hospital, Oldenburg, Oldenburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany|Evangelisches Krankenhaus, Witten, Witten, Germany|Athens Hospital of Chest Diseasea ""SOTIRIA"", Athens, Greece|University Hospital of Heraklion, University Pulmonology Cl, Heraklio, Greece|Iaso General Hospital, Holargos, Athens, Greece|Papageorgiou Hospital, 1st Cardiological Cl., Thessaloniki, Thessaloniki, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Vedanta Institute of Medical Sciences, Ahmedabad, India|KIDWAI memoraial Institute of oncology, Bangalore, India|Rajalakshmi Multispeciality Hospital, Bangalore, India|Jawaharlal Nehru Cancer Hospital & Research Centre, Bhopal, M.P., India|Apollo Hospital, Chennai, India|SEAROC cancer center,S.K.soni Hospital, Jaipur, Rajasthan, India|Birla Cancer Centre, Jaipur, India|Bhagwan Mahaveer Cancer Hospital & Research Center, Jawahar, Jaipur, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|Kasturba Medical College and Hospital, Mangalore, India|Tata Memorial Centre, Mumbai, India|Shatabdi Superspeciality Hospital, Nashik, India|Sir Gangaram Hospital, New Delhi, India|Indraprastha Apollo Hospitals, New Delhi, India|Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India|Jehangir Hospital Oncology Department, Pune, Maharahtra, India|Regional Cancer Center, Trivandrum, Kerala, India|City Cancer Centre, Cancer Hospital & Research, Vijayawada, India|King George Hospital, Visakhapatnam, India|E. Wolfson Medical Center, Holon 58100, Holon, Israel|Hadassah Medical Center, Ein-Karem, Jerusalem, Israel|Meir Medical Center, Kfar Saba, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Israel|Sourasky Medical Center, Tel-Aviv, Israel|Assaf Harofe Medical Center, Zerifin, Israel|Az. Ospedaliere Umberto I di Ancona, Ancona, Italy|Centro di riferimento Oncologico, Aviano, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|Fond. Poliambulanza Istituto, Brescia, Italy|Azienda Ospedaliera Careggi, Firenze, Italy|Ospedale Civile, Ivrea (TO), Italy|Istituto Scientifico Romagnolo, Meldola, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|Azienda Sanitaria Ospedale S. Luigi Gonzaga, Orbassano, Italy|Fondazione Salvatore Maugeri, Pavia, Italy|Ospedale S.Maria della Misericordia, AO di Perugia, Perugia, Italy|Gachon University Gil Medical Center, Incheon, Korea, Republic of|VHS Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Hospital of Lithuanian Univ.of HealthSciences Kauno Klinikos, Kaunas, Lithuania|Siauliu ligonine, Siauliai, Siauliai, Lithuania|Vilniaus Universiteto, Vilnius, Lithuania|Pulmonology Center in Bydgoszcz, Bydgoszcz, Poland|Regional Complex Hospital, Elblag, Poland|Institute of Tuberculosis & Pulmonology, III. Dept., Olsztyn, Olsztyn, Poland|Mazowieckiego Centrum, Otwock, Poland|Greater PL Cent.Pulmo.&Thor.Surg.Eugenia&Janusz Zeyland, Poznan, Poland|Regional Specialist Hospital, Slupsk, Poland|Independent Public Hospital in Suwalki, Suwalki, Poland|Specialist Hospital, Szczecin-Zdunowo, Szczecin, Poland|Onco.Cent. - Instit. of Maria Sklodowskiej-Curie, Warszawa, Poland|IPO Porto Francisco Gentil, EPE, Coimbra, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|CHS, EPE - Hospital de São Bernardo, Setúbal, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|Baia Mare Emergency County Hospital, Baia Mare, Romania|Spitalul Clinic Judetean de Urgenta Brasov, Brasov, Romania|Institute of Oncology 'Prof. Dr. Alexandru Trestioreanu', Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"", Cluj-Napoca, Romania|County Hospital ""Dr. Alex Simionescu"", Hunedoara, Romania|Centrul de Oncologie Medicala, Iasi, Romania|Emergency Clinical County Hospital ""Sf Spiridon"", Iasi, Iasi, Romania|Onesti County Hospital, Onesti, Romania|Emergency County Hospital ""Sf.loan cel Nou"", Suceava, Romania|Oncomed SRL, Timisoara, Romania|SBIH of Arkhangelsk reg. ""Arkhangelsk Clin. Onc. Dispensary"", Arkhangelsk, Russian Federation|GLPU Cheliabinsky, Chelyabinsk, Russian Federation|GUZ Irkutsk Regional Oncology Dispensary, Irkutsk, Russian Federation|St.Auton.Heal.Inst.""Rep.Clin.Onc.Disp.of MoH of Rep. Tatarstan"", Kazan, Russian Federation|RBIH ""Kursk regional clinical oncology dispensary"", Kursk, Russian Federation|GUZ Regional Oncology Dispensary, Magnitogorsk, Magnitogorsk, Russian Federation|FSBI ""N.N Blokhin Med.Res.Cent.Onc.""MoH of RF, Moscow, Russian Federation|SBIH of Stavropol territory ""Pyatigorsk Oncol. Dispensary"", Pyatigorsk, Russian Federation|GUZ ""Regional Clinical Oncology Dispensary"", Ryazan, Russian Federation|GUZ ""Oncological Dispesary #2"", Sochi, Russian Federation|GUZ Leningradskaya Regional Clin. Hospital, St. Petersburg, St. Petersburg, Russian Federation|1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., St. Petersburg, Russian Federation|SPb SBIH ""City Clinical Oncological Dispensary"", St. Petersburg, Russian Federation|FSBI ""N.N. Petrov National Medical Research Center of Oncology"" of MoH of RF, St. Petersburg, Russian Federation|GUZ Sverdlovsky Regional Oncology Dispensary, Yekaterinburg, Russian Federation|Faculty Hospital Trnava, Trnava, Slovakia|GVI oncology Medi Clinic, Cape Town, South Africa|Parklands Hospital, Durban, South Africa|WCR CMJAH Clinical Trial Site, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Pretoria Academic Hospital, Pretoria, South Africa|Wilgers oncology, Pretoria, South Africa|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario de Elche, Elche, Spain|Hospital Jerez de la Frontera, Jerez De La Frontera-Cádiz, Spain|Hospital La Princesa, Madrid, Spain|Hospital Quirónsalud Madrid, Pozuelo de Alarcon, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, Spain|Servicio de Oncologia Radiotherapica, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain|Kantonsspital Aarau, Aarau, Switzerland|Kantonsspital Baden AG, Baden, Switzerland|Chernigiv Regional Oncology Centre, Chernigiv, Ukraine|Bukovynsk State Medical University, Chernivtsi, Ukraine|Chmelnytskyi Oblasnnyi Oncologichnyi Tsentr, Chmelnytskyi, Ukraine|City Clinical Hospital #4, Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine|Donetsk Regional Antitumor Centre, Donetsk, Ukraine|Kharkiv Medical Acadamy of Postgraduate education, Kharkiv, Ukraine|Kryvorizskyi regional communal clinical oncology centre, Kryvyi Rig, Ukraine|Odesa Regional Oncological Centre, Odesa, Ukraine|Ternopil regional communal clinical oncology centre, Ternopil, Ukraine|Uzhgorod National University, Oncology Centre, Uzhgorod, Ukraine|Vinnytsia Regional Clinical Oncological Dispensary, Vinnytsia, Ukraine|Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom|Bristol Haematology & Onc. Ctr, Bristol, United Kingdom|Broomfield Hospital, Chelmsford, United Kingdom|Wythenshawe Hospital, Manchester, United Kingdom|Poole Hospital, Poole, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00805194"
519,"NCT03141021","Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors",,"Recruiting","No Results Available","Malignant Peripheral Nerve Sheath Tumors",,"Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST)|Immunohistochemical characteristics of malignant peripheral nerve sheath tumor (MPNST)|Molecular characteristics of malignant peripheral nerve sheath tumor (MPNST)|Radiographic characteristics of malignant peripheral nerve sheath tumor (MPNST)|Treatment given to patients with malignant peripheral nerve sheath tumor (MPNST)|Future genomic characterization of malignant peripheral nerve sheath tumor (MPNST)","Washington University School of Medicine|Boston's Children Hospital","All","Child, Adult, Older Adult",,"2000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","201702006","April 28, 2017","April 28, 2027","April 28, 2027","May 4, 2017",,"May 13, 2022","Moffitt Cancer Center, Tampa, Florida, United States|Johns Hopkins, Baltimore, Maryland, United States|National Institutes of Health (NIH), Bethesda, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lifespan, Providence, Rhode Island, United States|Mount Sinai, Toronto, Ontario, Canada|Global Gene Corporation, Mumbai, India|Royal National Orthopedic Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03141021"
520,"NCT00087711","A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",,"Completed","No Results Available","Non Small Cell Lung Carcinoma","Drug: pemetrexed|Drug: gemcitabine|Drug: cisplatin","Overall survival|Progression free survival|Time to progressive disease|Duration of response|Time to treatment failure","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","1713","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2938|H3E-MC-JMDB","July 2004","January 2007","March 2008","July 16, 2004",,"September 12, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sacramento, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Torrance, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Jacksonville, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Macon, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wichita, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Scarborough, Maine, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Duluth, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Billings, Montana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hackensack, New Jersey, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hickory, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Portland, Oregon, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Columbia, South Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arlington, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Richmond, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bahia Blanca, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Buenos Aires, Argentina|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bedford Park, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Camperdown, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chermisdie, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Fitzroy, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hornsby, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Nedlands, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, South Brisbane, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St Leonards, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Grimmenstein, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Leoben, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, St. Poelten, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Vienna, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Wels, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Liege, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Florianopolis, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Porto Alegre, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Salvador, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sao Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, North Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Brampton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sainte-Foy, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tampere, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Grenoble, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Montpellier, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Herblain, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Strasbourg, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Vandoeuvre-les-Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mannheim, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Heraklion, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Patras, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Deszk, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pecs, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bangalore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Cochin, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Hyderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, New Dehli, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Kfar Saba, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tel-Aviv, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tel-Hashomer, Israel|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ancona, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Forli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Genova, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Livorno, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Modena, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Orbassano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Taormina, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ciudad Obregon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Leon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mexicali, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Alkmaar, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Amstelveen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Arnhem, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Den Bosch, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Eindhoven, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Harderwijk, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Heerlen, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Krakow, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lodz, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Szczecin-Zdunowo, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Warszawa, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lisboa, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Porto, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Santa Maria Da Feira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Alicante, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Barcelona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Pamplona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sabadell, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Goteborg, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Stockholm, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Niao Sung Hsiang, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Tao-Yuan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Ankara, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Antalya, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Istanbul, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Izmir, Turkey|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Aberdeen, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Bangor, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Chelmsford, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Fulham, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Plymouth, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00087711"
521,"NCT00254891","Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer",,"Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: PF-3512676 + Paclitaxel + Carboplatin|Drug: Paclitaxel + Carboplatin","Overall Survival|Overall Objective Response|Time to Tumor Progression|Progression Free Survival|Duration of Response|Patient Reported Outcomes|Overall Safety Profile","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","828","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A8501001","November 2005","July 2008","July 2008","November 17, 2005",,"March 30, 2015","Pfizer Investigational Site, Little Rock, Alaska, United States|Pfizer Investigational Site, Hot Springs, Arkansas, United States|Pfizer Investigational Site, Chula Vista, California, United States|Pfizer Investigational Site, La Mesa, California, United States|Pfizer Investigational Site, Oceanside, California, United States|Pfizer Investigational Site, Palm Springs, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Fayetteville, Georgia, United States|Pfizer Investigational Site, Macon, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Tucker, Georgia, United States|Pfizer Investigational Site, Rockford, Illinois, United States|Pfizer Investigational Site, Jefferson, Indiana, United States|Pfizer Investigational Site, New Albany, Indiana, United States|Pfizer Investigational Site, Cedar Rapids, Iowa, United States|Pfizer Investigational Site, Dubuque, Iowa, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Shelbyville, Kentucky, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Gretna, Louisiana, United States|Pfizer Investigational Site, Lafayette, Louisiana, United States|Pfizer Investigational Site, Marrero, Louisiana, United States|Pfizer Investigational Site, Marrero, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Biddeford, Maine, United States|Pfizer Investigational Site, Brunswick, Maine, United States|Pfizer Investigational Site, Scarborough, Maine, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Allegan, Michigan, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Ann Arbor, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, Kalamazoo, Michigan, United States|Pfizer Investigational Site, St. Joseph, Michigan, United States|Pfizer Investigational Site, Columbus, Mississippi, United States|Pfizer Investigational Site, Corinth, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Papillion, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Albuquerque, New Mexico, United States|Pfizer Investigational Site, Ruidoso, New Mexico, United States|Pfizer Investigational Site, Buffalo, New York, United States|Pfizer Investigational Site, Great Neck, New York, United States|Pfizer Investigational Site, Asheville, North Carolina, United States|Pfizer Investigational Site, Brevard, North Carolina, United States|Pfizer Investigational Site, Lexington, North Carolina, United States|Pfizer Investigational Site, Winston-Salem, North Carolina, United States|Pfizer Investigational Site, Canton, Ohio, United States|Pfizer Investigational Site, Dover, Ohio, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Langhorne, Pennsylvania, United States|Pfizer Investigational Site, Chattanooga, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Arlington, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Richardson, Texas, United States|Pfizer Investigational Site, Trophy Club, Texas, United States|Pfizer Investigational Site, Bountiful, Utah, United States|Pfizer Investigational Site, Layton, Utah, United States|Pfizer Investigational Site, Murray, Utah, United States|Pfizer Investigational Site, Provo, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, WVC, Utah, United States|Pfizer Investigational Site, Burlington, Vermont, United States|Pfizer Investigational Site, Everett, Washington, United States|Pfizer Investigational Site, Kennewick, Washington, United States|Pfizer Investigational Site, Richland, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Albury, New South Wales, Australia|Pfizer Investigational Site, Camperdown, New South Wales, Australia|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, Pimlico, Queensland, Australia|Pfizer Investigational Site, Townsville, Queensland, Australia|Pfizer Investigational Site, Woolloongabba, Queensland, Australia|Pfizer Investigational Site, Bedford Park, South Australia, Australia|Pfizer Investigational Site, Toorak Gardens, South Australia, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, East Ringwood, Victoria, Australia|Pfizer Investigational Site, Wodonga, Victoria, Australia|Pfizer Investigational Site, Nedlands, Western Australia, Australia|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Moncton, New Brunswick, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Rimouski, Quebec, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada|Pfizer Investigational Site, Dalian, Xigang District, Liaoning, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Nicosia, Cyprus|Pfizer Investigational Site, Nova Ves Pod Plesi, Czech Republic|Pfizer Investigational Site, Ostrava-Poruba, Czech Republic|Pfizer Investigational Site, Usti nad Labem, Czech Republic|Pfizer Investigational Site, Angers cedex, France|Pfizer Investigational Site, Caen cedex, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Limoges, France|Pfizer Investigational Site, Nantes Cedex 2, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, St Herblain Cedex, France|Pfizer Investigational Site, Strasbourg, France|Pfizer Investigational Site, Toulouse cedex 9, France|Pfizer Investigational Site, Vandoeuvre Les Nancy, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Bielefeld, Germany|Pfizer Investigational Site, Bonn, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Athens, Attica, Greece|Pfizer Investigational Site, Heraklion, Crete, Greece|Pfizer Investigational Site, Thessaloniki, Macedonia, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Rio, Patras, Greece|Pfizer Investigational Site, Pokfulam, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Debrecen, Hungary|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Kochi, Kerala, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Chandigarh, Punjab, India|Pfizer Investigational Site, Jaipur, Rajasthan, India|Pfizer Investigational Site, Zerifin, Israel|Pfizer Investigational Site, Lido di Camaiore (LU), Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, Tiel, GLD, Netherlands|Pfizer Investigational Site, Groningen, GR, Netherlands|Pfizer Investigational Site, Amstelveen, Netherlands|Pfizer Investigational Site, Den Haag, Netherlands|Pfizer Investigational Site, Otwock, Poland|Pfizer Investigational Site, Wodzislaw Sl., Poland|Pfizer Investigational Site, Faro, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Vila Nova de Gaia, Portugal|Pfizer Investigational Site, Parktown, Gauteng, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Johannesburg, South Africa|Pfizer Investigational Site, Badalona, Barcelona, Spain|Pfizer Investigational Site, Alcorcon, Madrid, Spain|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Santa Cruz de Tenerife, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Uppsala, Sweden|Pfizer Investigational Site, Lausanne, Switzerland|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Truro, Cornwall, United Kingdom|Pfizer Investigational Site, Exeter, Devon, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Portsmouth, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Surrey GU2 5XX, United Kingdom|Pfizer Investigational Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00254891"
522,"NCT01085136","LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib",,"Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Investigator´s choice of chemotherapy|Drug: BIBW 2992","Progression Free Survival (Part B)|Progression Free Survival (Part A)|Overall Survival (Part B)|Objective Response (Part A)|Objective Response (Part B)|Intensity and Incidence of Adverse Events (AEs) for Part A & Part B.","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","1154","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.42|2009-014563-39","February 2010","October 2013","January 2016","March 11, 2010","October 3, 2014","April 4, 2017","Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Buenos Aires, Argentina|Boehringer Ingelheim Investigational Site, Kingswood, New South Wales, Australia|Boehringer Ingelheim Investigational Site, South Brisbane, Queensland, Australia|Boehringer Ingelheim Investigational Site, Box Hill, Victoria, Australia|Boehringer Ingelheim Investigational Site, Fitzroy, Victoria, Australia|Boehringer Ingelheim Investigational Site, Wodonga, Victoria, Australia|Boehringer Ingelheim Investigational Site, Salzburg, Austria|Boehringer Ingelheim Investigational Site, Aalst, Belgium|Boehringer Ingelheim Investigational Site, Bruxelles, Belgium|Boehringer Ingelheim Investigational Site, Duffel, Belgium|Boehringer Ingelheim Investigational Site, La Louvière, Belgium|Boehringer Ingelheim Investigational Site, Liège, Belgium|Boehringer Ingelheim Investigational Site, Middelheim, Belgium|Boehringer Ingelheim Investigational Site, Ottignies, Belgium|Boehringer Ingelheim Investigational Site, Porto Alegre, Brazil|Boehringer Ingelheim Investigational Site, Beijing, China|Boehringer Ingelheim Investigational Site, Changchun, China|Boehringer Ingelheim Investigational Site, Chengdu, China|Boehringer Ingelheim Investigational Site, Fuzhou, China|Boehringer Ingelheim Investigational Site, Guangzhou, China|Boehringer Ingelheim Investigational Site, Hangzhou, China|Boehringer Ingelheim Investigational Site, Nanjing, China|Boehringer Ingelheim Investigational Site, Shanghai, China|Boehringer Ingelheim Investigational Site, Helsinki, Finland|Boehringer Ingelheim Investigational Site, Bayonne, France|Boehringer Ingelheim Investigational Site, Caen Cedex 5, France|Boehringer Ingelheim Investigational Site, Dijon, France|Boehringer Ingelheim Investigational Site, La Tronche, France|Boehringer Ingelheim Investigational Site, Lyon Cedex 08, France|Boehringer Ingelheim Investigational Site, Paris cedex 20, France|Boehringer Ingelheim Investigational Site, Paris, France|Boehringer Ingelheim Investigational Site, Saint-Herblain cedex, France|Boehringer Ingelheim Investigational Site, Villejuif Cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Essen, Germany|Boehringer Ingelheim Investigational Site, Esslingen, Germany|Boehringer Ingelheim Investigational Site, Gauting, Germany|Boehringer Ingelheim Investigational Site, Hamburg, Germany|Boehringer Ingelheim Investigational Site, Hannover, Germany|Boehringer Ingelheim Investigational Site, Heidelberg, Germany|Boehringer Ingelheim Investigational Site, Mainz, Germany|Boehringer Ingelheim Investigational Site, Münster, Germany|Boehringer Ingelheim Investigational Site, Budapest, Hungary|Boehringer Ingelheim Investigational Site, Pecs, Hungary|Boehringer Ingelheim Investigational Site, Törökbálint, Hungary|Boehringer Ingelheim Investigational Site, Chennai, India|Boehringer Ingelheim Investigational Site, Jaipur, India|Boehringer Ingelheim Investigational Site, Maharashtra, India|Boehringer Ingelheim Investigational Site, Mumbai, India|Boehringer Ingelheim Investigational Site, Nashik, Maharashtra, India|Boehringer Ingelheim Investigational Site, Kfar Saba, Israel|Boehringer Ingelheim Investigational Site, Petach Tikva, Israel|Boehringer Ingelheim Investigational Site, Tel Hashomer, Israel|Boehringer Ingelheim Investigational Site, Avellino, Italy|Boehringer Ingelheim Investigational Site, Aviano (PN), Italy|Boehringer Ingelheim Investigational Site, Bergamo, Italy|Boehringer Ingelheim Investigational Site, Genova, Italy|Boehringer Ingelheim Investigational Site, Milano, Italy|Boehringer Ingelheim Investigational Site, Monza (mi), Italy|Boehringer Ingelheim Investigational Site, Ravenna, Italy|Boehringer Ingelheim Investigational Site, Roma, Italy|Boehringer Ingelheim Investigational Site, Goyang, Korea, Republic of|Boehringer Ingelheim Investigational Site, Hwasun, Korea, Republic of|Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of|Boehringer Ingelheim Investigational Site, Distrito Federal, Mexico|Boehringer Ingelheim Investigational Site, Maastricht, Netherlands|Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands|Boehringer Ingelheim Investigational Site, Arequipa, Peru|Boehringer Ingelheim Investigational Site, La Victoria, Peru|Boehringer Ingelheim Investigational Site, Gdansk, Poland|Boehringer Ingelheim Investigational Site, Olsztyn, Poland|Boehringer Ingelheim Investigational Site, Otwock, Poland|Boehringer Ingelheim Investigational Site, Warszawa, Poland|Boehringer Ingelheim Investigational Site, Obninsk, Russian Federation|Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation|Boehringer Ingelheim Investigational Site, A Coruña, Spain|Boehringer Ingelheim Investigational Site, Barcelona, Spain|Boehringer Ingelheim Investigational Site, Madrid, Spain|Boehringer Ingelheim Investigational Site, Mataró, Spain|Boehringer Ingelheim Investigational Site, Málaga, Spain|Boehringer Ingelheim Investigational Site, Valencia, Spain|Boehringer Ingelheim Investigational Site, Kaohsiung, Taiwan|Boehringer Ingelheim Investigational Site, Taichung, Taiwan|Boehringer Ingelheim Investigational Site, Tainan, Taiwan|Boehringer Ingelheim Investigational Site, Taipei, Taiwan|Boehringer Ingelheim Investigational Site, Taoyuan, Taiwan|Boehringer Ingelheim Investigational Site, Dnipropetrovks, Ukraine|Boehringer Ingelheim Investigational Site, Donetsk, Ukraine|Boehringer Ingelheim Investigational Site, Kharkiv, Ukraine|Boehringer Ingelheim Investigational Site, Kyiv, Ukraine|Boehringer Ingelheim Investigational Site, Brighton, United Kingdom|Boehringer Ingelheim Investigational Site, Dundee, United Kingdom|Boehringer Ingelheim Investigational Site, Exeter, United Kingdom|Boehringer Ingelheim Investigational Site, London, United Kingdom|Boehringer Ingelheim Investigational Site, Maidstone, United Kingdom|Boehringer Ingelheim Investigational Site, Manchester, United Kingdom|Boehringer Ingelheim Investigational Site, Sutton, Surrey, United Kingdom|Boehringer Ingelheim Investigational Site, Truro, Cornwall, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01085136"
523,"NCT01947608","Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC",,"No longer available","No Results Available","Non-small Cell Lung Cancer (NSCLC)","Drug: LDK378",,"Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"CLDK378A2402",,,,"September 20, 2013",,"November 3, 2020","Ironwood Cancer and Research Centers, Chandler, Arizona, United States|Banner MDACC, Gilbert, Arizona, United States|Western Regional Medical Center, Inc., Goodyear, Arizona, United States|Highlands Oncology Group, Fayetteville, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Moores UCSD Cancer Center, La Jolla, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Stanford University, Stanford, California, United States|Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States|Advanced Medical Specialties, Miami, Florida, United States|Peachtree Hematology/Oncology Consultants, Atlanta, Georgia, United States|Emory University School of Medicine/Winship Cancer Institute, Atlanta, Georgia, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|Indiana University Health Goshen Center for Cancer, Goshen, Indiana, United States|Johns Hopkins Bayview Hospital, Baltimore, Maryland, United States|Maryland Oncology Hematology, P.A., Rockville, Maryland, United States|Massachusetts General Hospital Mass General, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Jackson Oncology Associates, Jackson, Mississippi, United States|Nebraska Cancer Specialist/Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Mercy Clinic Oklahoma Communities Mercy Oncology, Oklahoma City, Oklahoma, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|University of Utah / Huntsman Cancer Institute, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Caba, Argentina|Novartis Investigative Site, Córdoba, Cordoba, Argentina|Novartis Investigative Site, Cali, Valle Del Cauca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Hong Kong, Hong Kong|Novartis Investigative Site, Kowloon, Hong Kong|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Bundang Gu, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Gyeonggi do, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Ciudad De Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico D F, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Taguig City, Metro Manila, Philippines|Novartis Investigative Site, Quezon City, Philippines|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT01947608"
524,"NCT00943553","A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects",,"Withdrawn","No Results Available","Acute Myelogenous Leukemia (AML)","Drug: decitabine Induction Chemotherapy|Drug: Induction Chemotherapy","Primary Endpoint (Core Component): Complete Remission (CR) Rate as defined by International Working Group - 2003 criteria|Secondary Endpoint (Core Component): Methylation of DNA following decitabine therapy.|Secondary Endpoint (Core Component): Time to platelet recovery (≥ 100,000/mm3) and time to neutrophil recovery (absolute neutrophil count [ANC] ≥ 1000/mm3) following induction chemotherapy","Eisai Inc.","All","1 Year to 16 Years   (Child)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7373-G000-201","June 2010","August 2011",,"July 22, 2009",,"April 13, 2015","New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00943553"
525,"NCT01774019","Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer",,"Completed","No Results Available","Pancreatic Carcinoma","Device: WallFlex™ Biliary RX Fully Covered/Uncovered Stent System","Number of serious pre-operative, operative and post-operative adverse events to 120 days post randomization or to 30 days post surgery, whichever comes last|Number of adverse events|Time to surgery|Curative Intent Surgery details pertaining to intraoperative assessment of resectability, surgical resection and reconstruction techniques.|Amount of intraoperative blood loss and number of blood transfusions, duration of surgery|Biliary obstructive symptoms assessment|Improvement of liver function test (LFT) levels as relative to baseline|Stent placement success|Stent removal success|Number, type, reason, and timing of biliary re-interventions|Number of hospital and ICU admissions|Duration of hospital and ICU admissions","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","287","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","90914721|E7059","February 20, 2013","December 13, 2021","December 13, 2021","January 23, 2013",,"February 7, 2022","Standford University Medical Center, Stanford, California, United States|Westmead Hospital, Westmead, New South Wales, Australia|ULB Erasme Hospital, Brussels, Belgium|Beijing Friendship Hospital, Beijing, China|Xijing Hospital of Digestive Diseases Fourth Military Medical University, Xi'an, China|Hopital Edouard Herriot, Lyon, France|Queen Elizabeth Hospital, Kowloon, Hong Kong|Prince of Wales Hospital, the Chinese University of Hong Kong, Sha Tin, Hong Kong|Asian Institute of Gastroenterology, Hyderabad, India|Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy|Tokyo Medical University, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01774019"
526,"NCT05215860","Photographic Evidence of Oral Precancerous Lesions in Current Tobacco and Areca Nut Users Improves Their Quit Rates",,"Completed","No Results Available","Precancerous Conditions","Behavioral: Tobacco and areca nut cessation counselling with standard management for Oral Potentially Malignant Disorders|Other: visual exposure to personal intraoral photographs of oral lesions at baseline and review","Habit quit rates|Size of oral lesions|Oral burning sensation|Colour of oral lesions|Inter incisal mouth opening","All India Institute of Medical Sciences, New Delhi","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Prevention","IEC-616","September 1, 2020","September 30, 2021","September 30, 2021","January 31, 2022",,"February 11, 2022","Oral Medicine and Radiology, CDER, AIIMS, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT05215860"
527,"NCT00102726","SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy",,"Completed","No Results Available","Thrombocytopaenia","Drug: SB497115|Other: Placebo","Change in baseline platelet count from the first day of the second cycle of chemotherapy to the lowest count observed (nadir) during the cycle(21 days)|Safety and tolerability, pharmacodynamics, changes in platelet count during cycle 1(21 days) and beyond cycle 2(21 days), population PK, and deliver intended doses of chemotherapy without thrombocytopenia related AEs|Safety and tolerability as indicated by physical exam, 12-lead ECGs, ophthalmologic examinations, clinical laboratory tests, clinical monitoring/observation, and AE reporting|Pharmacodynamic parameters including platelet count, grade of thrombocytopenia,serum thrombopoietin, and platelet aggregation/activation during the first and second cycles of carboplatin/paclitaxel|Change in platelet count from day 1 (baseline) to nadir during the first cycle and beyond the second cycle of carboplatin/paclitaxel|Population PK of SB-497115, including clearance (CL/F), absorption rate constant(ka), and volume of distribution (V/F) with assessment of demographic covariates influencing SB-497115 PK|The relationship between PK of SB-497115 andrelevant safety and efficacy endpoints will be explored|Dose intensity (percent of intended dose) of carboplatin/paclitaxel|Carboplatin/paclitaxel-associated thrombocytopenia-related AEs, as defined by NCI|Common Terminology Criteria for Adverse Events, CTCAE v3.0, to include the number of platelet transfusions, bleeding events (hematoma), hemorrhage/bleeding,petechiae/purpura), clinical laboratory tests, and clinical observations","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","183","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","497115/003","February 2005","February 2007","February 2007","February 2, 2005",,"March 23, 2017","GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Jonesboro, Arkansas, United States|GSK Investigational Site, Greenbrae, California, United States|GSK Investigational Site, Long Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Newark, Delaware, United States|GSK Investigational Site, Boca Raton, Florida, United States|GSK Investigational Site, Hollywood, Florida, United States|GSK Investigational Site, Tamarac, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Hattiesburg, Mississippi, United States|GSK Investigational Site, Tupelo, Mississippi, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Babylon, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Akron, Ohio, United States|GSK Investigational Site, Mayfield Heights, Ohio, United States|GSK Investigational Site, Toledo, Ohio, United States|GSK Investigational Site, Bryan, Texas, United States|GSK Investigational Site, Ogden, Utah, United States|GSK Investigational Site, Salem, Virginia, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Plovdiv, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Praha 8, Czech Republic|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Regensburg, Bayern, Germany|GSK Investigational Site, Marburg, Hessen, Germany|GSK Investigational Site, Hemer, Nordrhein-Westfalen, Germany|GSK Investigational Site, Trier, Rheinland-Pfalz, Germany|GSK Investigational Site, Grosshansdorf, Schleswig-Holstein, Germany|GSK Investigational Site, Bad Berka, Thueringen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, Andhra Pradesh, India|GSK Investigational Site, Kolkatta, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Benevento, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Campobasso, Molise, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Szczecin, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Moscow Region, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Santa Cruz de Tenerife, Spain|GSK Investigational Site, Santander, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Tau-Yuan County, Taiwan|GSK Investigational Site, Dnepropetrovsk, Ukraine|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lvov, Ukraine|GSK Investigational Site, Truro, Cornwall, United Kingdom|GSK Investigational Site, Chelmsford, Essex, United Kingdom|GSK Investigational Site, Colchester, United Kingdom|GSK Investigational Site, Dundee, United Kingdom|GSK Investigational Site, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00102726"
528,"NCT00683306","Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment",,"Approved for marketing","No Results Available","Non Small Cell Lung Cancer (NSCLC)","Drug: ZD1839 (Iressa)",,"AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"D791AC00008",,,,"May 23, 2008",,"September 13, 2018","Research Site, La Plata, Argentina|Research Site, Concord, Australia|Research Site, Graz, Austria|Research Site, Linz, Austria|Research Site, Wien, Austria|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sorocaba, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Veliko Tarnovo, Bulgaria|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Budapest, Hungary|Research Site, Deszk, Hungary|Research Site, Mosdós, Hungary|Research Site, Pécs, Hungary|Research Site, Zalaegerszeg, Hungary|Research Site, Hyderabad, India|Research Site, Karnataka, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Vellore, India|Research Site, Daugavpils, Latvia|Research Site, Riga, Latvia|Research Site, Kuala Lumpur, Malaysia|Research Site, Nilai, Malaysia|Research Site, Penang, Malaysia|Research Site, Penang, Malaysia|Research Site, Penang, Malaysia|Research Site, Durango, Mexico|Research Site, Mexico Distrito Federal, Mexico|Research Site, Monterrey, Mexico|Research Site, Torreon, Mexico|Research Site, Manila, Philippines|Research Site, Pasig, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Singapore, Singapore|Research Site, Johannesburg, South Africa|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, İstanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00683306"
529,"NCT05063682","The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients","CARTREMENDOUS","Active, not recruiting","No Results Available","Glioblastoma|Glioblastoma Multiforme|Glioma, Malignant","Biological: EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes","Incidence of adverse events|Overall survival|CAR (chimeric antigen receptor) T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Endogenous T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cell phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF)|Cytokine levels (Procartaplex panel) in PB, TCF and CSF|Disease response|Time to progression|CAR T and endogenous cells detected in tumor tissue|EGFRvII (epidermal growth factor receptor) antigen expression levels in tumor tissue.","Chembrain LTD|University of Oulu|Jyväskylä Central Hospital|Apollo Hospital, New Delhi, India","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","6678EGFRvIII","May 15, 2020","October 2023","October 2023","October 1, 2021",,"October 1, 2021","Jyväskylä Central Hospital, Jyväskylä, Finland|University Of Oulu, Oulu, Finland|Apollo Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT05063682"
530,"NCT00532155","A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","VITAL","Completed","Has Results","Carcinoma|Non Small Cell Lung","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Docetaxel (Taxotere®)|Drug: Dexamethasone (pre- and post-medication for docetaxel)","Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response (OR) Rate as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria|Health Related Quality of Life (HRQL) Assessed by the Lung Cancer Symptom Scale (LCSS)|Health Related Quality of Life (HRQL) Assessed by the Average Symptom Burden Index (ASBI)","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","913","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EFC10261|EudraCT 2007-000819-29","September 2007","January 2011","October 2011","September 20, 2007","January 1, 2013","June 7, 2016","Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, New South Wales, Australia|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Sofia, Bulgaria|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Santiago, Chile|Sanofi-Aventis Administrative Office, Shangai, China|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Tallinn, Estonia|Sanofi-Aventis Administrative Office, Helsinki, Finland|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Causeway Bay, Hong Kong|Sanofi-Aventis Administrative Office, Budapest, Hungary|Sanofi-Aventis Administrative Office, Mumbai, India|Sanofi-Aventis Administrative Office, Milano, Italy|Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of|Sanofi-Aventis Administrative Office, Kuala Lumpur, Malaysia|Sanofi-Aventis Administrative Office, Gouda, Netherlands|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Bucuresti, Romania|Sanofi-Aventis Administrative Office, Moscow, Russian Federation|Sanofi-Aventis Administrative Office, Singapore, Singapore|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-Aventis Administrative Office, Taipei, Taiwan|Sanofi-Aventis Administraive Office, Istanbul, Turkey|Sanofi-Aventis Admnistrative Office, Guildford Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00532155"
531,"NCT00355355","A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)",,"Completed","No Results Available","Carcinoma, Hepatocellular|Liver Neoplasms","Drug: Talaporfin sodium|Device: Interstitial Light Emitting Diodes|Procedure: Percutaneous placement of device in the liver|Procedure: Standard Care","Overall survival","Light Sciences Oncology","All","18 Years and older   (Adult, Older Adult)","Phase 3","208","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LSO-OL005","July 2006","September 2012","September 2012","July 21, 2006",,"January 30, 2015","University Hospital Dubrava, Zagreb, Croatia|Tuen Mun Hospital, Tuen Mun, New Territories, Hong Kong|Prince of Wales Hospital, Dept. of Clincal Oncology, New Territories, Hong Kong|Dr. Kamakshi Memorial Hospital, Chennai, India|SMS Medical College, Jaipur, India|Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India|Cancer Clinic, Nagpur, India|Shatabdi Super Specialty Hospital, Nasik, India|Pusan National University Hospital, Busan, Korea, Republic of|Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of|Korea University Medical Center Anam Hospital, Seoul, Korea, Republic of|Kyunghee Univeristy Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Sinchon Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Island Hospital, Penang, Malaysia|Lam Wah Ee Hospital, Penang, Malaysia|Cebu Doctors University Hospital, Cebu City, Philippines|Vicente Sotto Memorial Medical Center, Cebu City, Philippines|Santo Tomas University Hospital, Manila, Philippines|The Medical City, Pasig City, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Szpital Uniwersytecki CMUJ, Krakow, Poland|Centralny Szpital Kliniczny MSWiA, Warsaw, Poland|Clinical Center of Serbia, Institute for Gastroenterology and Hepatology, Belgrade, Serbia|Clinical Center of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore|Karolinska University Hospital, Stockholm, Sweden|Mahidol University, Siriraj Hospital, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand",,"https://ClinicalTrials.gov/show/NCT00355355"
532,"NCT03729453","Intra-operative Pancreatoscopy in Patients With IPMN",,"Recruiting","No Results Available","Intraductal Papillary Mucinous Neoplasm","Device: SpyGlass","Rate of detection of discontinuous (skip) lesions along the main pancreatic duct|Technical success|Adverse Event Evaluation|Recurrence|Comparison of visual and biopsy diagnosis|Inter-observer correspondence of visual impression of IPMN","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)",,"100","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","E7107","March 20, 2019","June 2022","March 2027","November 2, 2018",,"April 15, 2022","University of Colorado Hospital, Denver, Colorado, United States|Indiana University Health, Indianapolis, Indiana, United States|Johns Hopkins Hospital University, Baltimore, Maryland, United States|The First Affiliated Hospital of Nanjing Medical University, Nanjing, China|Asian Institute of Gastroenterology, Hyderabad, India|Kansai Medical University, Hirakata City, Osaka, Japan|Academic Medical Center, Amsterdam, Netherlands|University Hospital of UMEA, Umea, Sweden",,"https://ClinicalTrials.gov/show/NCT03729453"
533,"NCT00558636","A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)",,"Terminated","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Sorafenib + Paclitaxel + Carboplatin|Drug: Placebo + Paclitaxel + Carboplatin","Progression Free Survival|Overall Survival (OS)|Best Tumor Response (Number of Responses Per Category) According to Response Evaluation Criteria in Solid Tumors (RECIST)|Duration of Response|Change From Baseline of Lung Cancer Symptoms (LCS) Score Assessed at Each Treatment Cycle (21 Days Per Cycle) Starting With Cycle 2|Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 3 and Cycle 5|Change From Baseline of Health-Related Quality of Life (HRQoL) Score Assessed at Treatment Cycle 7","Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","91","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","12621","September 2007","May 2008","May 2008","November 15, 2007","October 20, 2010","December 27, 2013","Guangzhou, Guangdong, China|Guangzhou, Guangdong, China|Shatin, Hong Kong, China|Nanjing, Jiangsu, China|Hangzhou, Zhejiang, China|Hangzhou, Zhejiang, China|Beijing, China|Beijing, China|Beijing, China|Chongqing, China|Shanghai, China|Shanghai, China|Mumbai, Maharashtra, India|New- Delhi, India|Gyeonggi-do, Korea, Republic of|Seoul, Korea, Republic of|Singapore, Singapore|Singapore, Singapore|Changhua, Taiwan|Taipei, Taiwan|Bangkok, Thailand|Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT00558636"
534,"NCT02383576","Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223",,"Completed","Has Results","Breast Cancer","Other: No Intervention","Percentage of Participants Who Prematurely Withdrawn From Maintenance Therapy|Percentage of Participants Who Received Further Anti-Cancer Therapies After Discontinuation of Study Treatment|Time From Last Maintenance Study Medication Start to Start of Further Anti-Cancer Therapy|Progression Free Survival (PFS)|Overall Survival","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"185","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","MO29587","April 30, 2015","January 22, 2016","January 22, 2016","March 9, 2015","April 13, 2018","April 13, 2018","Crio - Centro Regional Integrado de Oncologia, Fortaleza, CE, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Faculdade de Medicina do ABC - FMABC; Oncologia e Hematologia, Santo Andre, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital Santa Marcelina;Oncologia, Sao Paulo, SP, Brazil|HOPITAL JEAN MINJOZ; Oncologie, Besancon, France|Chg de Chartres Hopital Louis Pasteur; Pneumologie, Chartres, France|Clinique Sainte Marguerite; Oncologie Medicale, Hyeres, France|Centre Bourgogne, Service de Radiotherapie, Lille, France|Institut Curie; Oncologie Medicale, Paris, France|HOPITAL TENON; Cancerologie Medicale, Paris, France|Clinique Francheville; Radiotherapie, Perigueux, France|Institut D Oncologie Medical, Strasbourg, France|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Università Federico II; Dip. Di Endocrinologia ed Oncologia Molecolare e Clinica, Napoli, Campania, Italy|Uni Degli Studi Di Genova ; Clinica Di Medicina Interna Ad Indirizzo Oncologico, Genova, Liguria, Italy|Ospedale Antonio Perrino; Oncologia Medica, Brindisi, Puglia, Italy|Hospital Virgen de los Lirios; Servicio de Oncologia, Alcoy, Alicante, Spain|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain|Complejo Hospitalario la Mancha Centro;Servicio Oncologia, Alcazar de S. Juan, Ciudad Real, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, Spain|Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia, Jaen, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Complejo Hospitalario de Toledo- H. Virgen de la Salud; Servicio de Oncologia, Toledo, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Akdeniz University Medical Faculty; Medical Oncology Department, Antalya, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, ANKARA, Turkey",,"https://ClinicalTrials.gov/show/NCT02383576"
535,"NCT03052608","A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC",,"Active, not recruiting","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: Lorlatinib|Drug: Crizotinib","Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment|Overall Survival (OS)|Progression-Free Survival (PFS) Based on Investigator's Assessment|Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on BICR Assessment|Objective Response Rate (ORR) - Percentage of Participants With Objective Response (OR) Based on Investigator's Assessment|Intracranial Objective Response Rate (IC-ORR) - Percentage of Participants With Intracranial Objective Response (IC-OR) Based on BICR Assessment|Intracranial Time to Progression (IC-TTP) Based on BICR Assessment|Duration of Response (DR) Based on BICR Assessment|Intracranial Duration of Response (IC-DR) Based on BICR Assessment|Time to Tumor Response (TTR) Based on BICR Assessment|Intracranial Time to Tumor Response (IC-TTR) Based on BICR Assessment|PFS2 Based on Investigator's Assessment|Number of Participants With Treatment-Emergent Adverse Events (AEs; All-Causality and Treatment-Related)|Number of Participants With Changes in Hematology Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4|Number of Participants With Changes in Chemistry Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4|Number of Participants With Changes in Lipid Laboratory Parameters From Baseline Maximum NCI-CTCAE Grade Lower Than 3 to Postbaseline Maximum Grade 3 or Grade 4|Number of Participant With Vital Signs and Body Weight Data Meeting Pre-defined Criteria|Number of Participant With Maximum Increase From Baseline in Electrocardiogram (ECG) Data Meeting Pre-defined Criteria|Number of Participants With Maximum Decrease From Baseline Greater Than or Equal to 20 Points in Left Ventricular Ejection Fraction (LVEF) Percentage|Change From Baseline in Total Scores of Beck Depression Inventory (BDI)-II (Mood Assessment) Across Time|Number of Participants With Suicidal Ideation and Suicidal Behavior Across Time|Change From Baseline in Global Quality of Life (QOL), Functional Scales and Symptoms Scales as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) During Overall Treatment|Change From Baseline in Lung Cancer Symptoms as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) During Overall Treatment|Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Visual Analogue Scale (VAS) Across Time|Change From Baseline in Health Status as Assessed by EuroQol 5 Dimension 5 Level (EQ-5D-5L) - Index Across Time|Time to Deterioration (TTD) in Participant Reported Pain in Chest, Dyspnea, or Cough From QLQ-LC13|Number of Participant With ALK Domain Mutation in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1|Number of Participant With ALK Fusion Variant in Plasma Circulating Nucleic Acid (CNA) Analysis at Screening, Cycle 2 Day 1 and Cycle 7 Day 1","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","296","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B7461006|2016-003315-35","April 27, 2017","March 20, 2020","December 31, 2028","February 14, 2017","April 1, 2021","April 29, 2022","Florida Cancer Specialists, Altamonte Springs, Florida, United States|Florida Cancer Specialists, Brandon, Florida, United States|Florida Cancer Specialists, Clearwater, Florida, United States|Florida Cancer Specialists, Gainesville, Florida, United States|Florida Cancer Specialists, Largo, Florida, United States|Florida Cancer Specialists, Lecanto, Florida, United States|Florida Cancer Specialists, Orange City, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Florida Cancer Specialists, Spring Hill, Florida, United States|Florida Cancer Specialists, Tampa, Florida, United States|Florida Cancer Specialists, Tavares, Florida, United States|Florida Cancer Specialists, The Villages, Florida, United States|Florida Cancer Specialists, Winter Park, Florida, United States|Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States|The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Tennessee Oncology, PLLC, Dickson, Tennessee, United States|Tennessee Oncology, PLLC, Franklin, Tennessee, United States|Tennessee Oncology, PLLC, Gallatin, Tennessee, United States|Tennessee Oncology, PLLC, Hermitage, Tennessee, United States|Tennessee Oncology, PLLC, Lebanon, Tennessee, United States|Tennessee Oncology, PLLC, Murfreesboro, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|The Sarah Cannon Research Institute., Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Tennessee Oncology, PLLC, Shelbyville, Tennessee, United States|Tennessee Oncology, PLLC, Smyrna, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Centro de Investigacion Pergamino SA, Pergamino, Buenos Aires, Argentina|Centro Medico Austral, Caba, Argentina|Bendigo Day Surgery Collection Centre and Laboratory, Bendigo, Victoria, Australia|Bendigo Medical Imaging, Bendigo Hospital, Bendigo, Victoria, Australia|Melbourne Pathology, Bendigo, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Grand Hopital de Charleroi - Site Notre Dame, Charleroi, Belgium|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Centre, Montreal, Quebec, Canada|The Affiliated Hospital of Military Medical Sciences, Beijing, Beijing, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Department of Respiratory,the First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Guangdong General Hospital, Guangzhou, China|Fakultni nemocnice Olomouc, Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Hopital Haut-Léveque-Centre François Magendie, Pessac, Aquitaine, France|Hopital de Chevilly Larue, Chevilly Larue, France|Centre Hospitalier du Mans, Le Mans, France|Institut Paoli-Calmettes, Marseille cedex 09, France|Département d'Imagerie Médicale, Marseille cedex 20, France|Hôpital Nord, Marseille cedex 20, France|Service Ophtalmologie, Marseille cedex 20, France|Groupe Hospitalier Bichat Claude Bernard, AP-HP, Paris, France|CHU de Rennes Hopital Pontchaillou, Rennes cedex 9, France|CHU de Rennes, Hopital Pontchaillou, Rennes cedex 9, France|Hopital Foch, Suresnes, France|Hopital Larrey, Toulouse Cedex 9, France|Hopital Pierre Paul Riquet, Toulouse cedex 9, France|Hôpital Larrey, Toulouse Cedex 9, France|Department d'imagerie medicale, Villejuif, France|Institut Gustave Roussy, Villejuif, France|Uberortliche Radiologische Gemeinschaftspraxis Dr. med. Marc Amler, Dresden, Germany|Technische Universitat Dresden , Medizinische Fakultat Carl Gustav Carus, Dresden, Germany|Thoraxklinik Heidelberg gGmbH, Heidelberg, Germany|Universitatsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum des Saarlandes, Innere Medizin V, Homburg - Saar, Germany|Universitätsklinikum des Saarlandes, Homburg - Saar, Germany|Universitatsklinikum Regensburg, Institut fur Rontgendiagnostik, Regensburg, Germany|Universitatsklinikum Regensburg, Klinik und Poliklinik fur Innere Medizin II, Regensburg, Germany|The University of Hong Kong, Department of Clinical Oncology, Hong Kong, Hong Kong|The University of Hong Kong, Department of Medicine, Hong Kong, Hong Kong|Tuen Mun Hospital, Hong Kong, Hong Kong|Artemis Hospital, Gurugram, Haryana, India|Manipal Hospital, Bangalore, Karnataka, India|Srinivasam Cancer Care Multispeciality Hospitals India Pvt Ltd, Bangalore, Karnataka, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|AOU Policlinico Vittorio Emanuele-P.O.G. Rodolico, Catania, CT, Italy|ASST Monza - A.O. San Gerardo, Monza, MB, Italy|IRCCS Ospedale San Raffaele, Milano, MI, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Istituto Clinico Humanitas, Rozzano, MI, Italy|Azienda Ospedaliera di Perugia - Ospedale S. M. Misericordia, Perugia, PG, Italy|Centro di Riferimento Oncologico-IRCCS, Pordenone, PN, Italy|Azienda Ospedaliero-Universitaria di Parma, Parma, PR, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RM, Italy|Az.Osp.San Camillo-Forlanini, Roma, RM, Italy|Azienda Ospedaliera Dei Colli Ospedale Monaldi, Napoli, Italy|Istituto Nazionale Tumori di Napoli, Napoli, Italy|Ausl della Romagna- Ravenna, Ravenna, Italy|Aichi cancer center central hospital, Nagoya, Aichi, Japan|Nagoya University Hospital, Nagoya, Aichi, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Sendai Kousei Hospital, Sendai, Miyagi, Japan|Osaka International Cancer Institute, Osaka-shi, Osaka, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan|National Hospital Organization, Yamaguchi-Ube Medical Center, Ube, Yamaguchi, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City General Hospital, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Wakayama Medical University Department of Pulmonary Medicine and Oncology, Wakayama, Japan|The Catholic University of Korea, St. Vincents Hospital, Suwon, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Division of Medical Oncology, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Médicos Especialistas en Cancer S.C. / San Peregrino., Aguascalientes, Mexico|Instituto Nacional de Cancerologia, Distrito Federal, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Distrito Federal, Mexico|University Medical Center Groningen, Groningen, Netherlands|Klinika Onkologii i Radioterapii Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Med-Polonia Sp. z o.o., Poznan, Poland|Centrum Medyczne Dom Lekarski S.A., Szczecin, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie-Panstwowy Instytut Badawczy, Warszawa, Poland|RBHI Kursk Regional Clinical Oncology Dispensary, Kislino, Ryshkovsky Rural Council, Kursk Region, Russian Federation|Budgetary Healthcare Institution Omsk Region ""Clinical Oncological Dispensary"", Omsk, OMSK Region, Russian Federation|LEC at SBIH ""Saint-Petersburg Clinical Research Practical Center of specialized types of, Pesochniy Poselok, Saint-petersburg, Russian Federation|Private Medical Institution ""Euromedservice"", Pushkin, Saint-petersburg, Russian Federation|RBHI Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|FSBI ""N.N.Blokhin Medical Research Center of Oncology"", Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Institut Catala d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran Canaria, Canarias, Spain|Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain|Complejo Hospitalario De Navarra, Pamplona, Navarra, Spain|Hospital Teresa Herrera C.H.U.A.C., A Coruna, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Institut Catala d'Oncologia Girona, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario La Fe, Valencia, Spain|National Taiwan University Hospital, Taipei, Taiwan ROC, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Cukurova University Medical Faculty, Adana, Turkey|Istanbul University Oncology Institute, Istanbul, Turkey|Marmara Univ Pendik Training and Research Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|The Ipswich Hospital NHS Trust, Ipswich, Suffolk, United Kingdom|Heart of England NHS Foundation Trust, Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03052608/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/08/NCT03052608/SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03052608"
536,"NCT04111029","Liquid Biopsy in Hepatocellular Carcinoma","HCCGenePanel","Recruiting","No Results Available","Hepatic Carcinoma Malignant Primary Non-Resectable","Diagnostic Test: Cell Free DNA","Comparison of exome sequencing of primary tumor tissue and cell-free DNA from plasma samples|Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment|Time to first recurrence (local or distant) diagnosed on follow up dynamic imaging.|Mortality","Postgraduate Institute of Medical Education and Research","All","18 Years to 70 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","INT/HEP/1078","January 16, 2020","December 2021","December 2021","October 1, 2019",,"September 28, 2021","Postgraduate Institute of Medical Education and Research, Chandigarh, Choose Any State/Province, India",,"https://ClinicalTrials.gov/show/NCT04111029"
537,"NCT00565448","Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents",,"Completed","Has Results","Nasopharyngeal Neoplasms|Carcinoma","Drug: docetaxel|Drug: cisplatin|Drug: 5-fluorouracil","Number of Participants With Complete Response (CR)|Docetaxel Area Under the Plasma Concentration-time Curve (AUC) in the Docetaxel/Cisplatin/5-FU Group|Overall Response (OR)|Overall Survival (OS) Rate","Sanofi","All","1 Month to 21 Years   (Child, Adult)","Phase 2","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EFC10339|2007-001211-33","November 2007","March 2009","January 2012","November 30, 2007","March 25, 2010","July 30, 2015","Investigational Site Number 012001, Alger, Algeria|Investigational Site Number 076002, Rio De Janeiro, Brazil|Investigational Site Number 076001, Sao Paulo, Brazil|Investigational Site Number 156005, Fuzhou, China|Investigational Site Number 250001, Villejuif Cedex, France|Investigational Site Number 356003, Ahmedabad, India|Investigational Site Number 356004, Kolkata, India|Investigational Site Number 356002, Thiruvananthapuram, India|Investigational Site Number 356001, Vellore, India|Investigational Site Number 360001, Jakarta, Indonesia|Investigational Site Number 380001, Milano, Italy|Investigational Site Number 410001, Seoul, Korea, Republic of|Investigational Site Number 410003, Seoul, Korea, Republic of|Investigational Site Number 410002, Seoul, Korea, Republic of|Investigational Site Number 484001, Villahermosa, Mexico|Investigational Site Number 504001, Casablanca, Morocco|Investigational Site Number 504002, Rabat, Morocco|Investigational Site Number 504003, Rabat, Morocco|Investigational Site Number 608002, Quezon City, Philippines|Investigational Site Number 764001, Bangkok, Thailand|Investigational Site Number 764002, Chiang Mai, Thailand|Investigational Site Number 788002, Sousse, Tunisia|Investigational Site Number 788003, Tunis, Tunisia|Investigational Site Number 792003, Abacioglu, Turkey|Investigational Site Number 792001, Ankara, Turkey|Investigational Site Number 792002, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT00565448"
538,"NCT02213263","A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",,"Completed","Has Results","Follicular Lymphoma","Biological: PF-05280586|Biological: MabThera®","Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26|Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Treatment Related Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants With Grade 3 or Higher Treatment-Emergent Adverse Events (AEs) as Graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03|Number of Participants With Grade 3 or Higher Treatment-Related Treatment-Emergent Adverse Events (AEs) as Graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03|Number of Participants With Clinically Significant Laboratory Abnormalities|Time to Treatment Failure (TTF)|Progression-Free Survival (PFS)|Percentage of Participants With Complete Remission (CR) at Week 26|Duration of Response (DOR)|Overall Survival|Maximum Observed Serum Concentration (Cmax) of PF-05280586 and Rituximab-EU|Minimum Observed (Trough) Serum Concentration (Ctrough) of PF-05280586 and Rituximab-EU|Cluster of Differentiation (CD) 19-Positive B-Cell Counts|Number of Participants With Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)|Number of Participants Reporting Immune-Based Adverse Effects","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","394","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","B3281006|2014-000132-41|REFLECTIONS","September 30, 2014","October 23, 2017","April 19, 2018","August 11, 2014","October 30, 2018","June 20, 2019","Pacific Cancer Medical Center, Inc., Anaheim, California, United States|The Oncology Institute of Hope and Innovation, Anaheim, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Corona, California, United States|The Oncology Institute of Hope and Innovation, Downey, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Global Cancer Research Institute (GCRI), Inc, Gilroy, California, United States|Saint Louise Regional Hospital Radiology Department (Radiology Only), Gilroy, California, United States|South Valley Imaging Center (Imaging Only), Gilroy, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|The Oncology Institute of Hope and Innovation, Glendale, California, United States|Los Angeles Hematology Oncology Medical Group, Glendale, California, United States|The Oncology Institute of Hope and Innovation, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|The Oncology Institute of Hope and Innovation, Lynwood, California, United States|The Oncology Institute of Hope and Innovation, Montebello, California, United States|Comprehensive Cancer Center at Desert Regional Medical Center, Palm Springs, California, United States|Torrance Health Association DBA, Torrance Memorial Physician, Network/Cancer Care Associates, Redondo Beach, California, United States|Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc., Riverside, California, United States|Global Cancer Research Institute, Inc., San Jose, California, United States|O'Connor Hospital, San Jose, California, United States|PET Imaging of San Jose (Imaging Only), San Jose, California, United States|The Oncology Institute of Hope and Innovation, Santa Ana, California, United States|Torrance Memorial Medical Center, Torrance, California, United States|The Oncology Institute of Hope and Innovation, Whittier, California, United States|Innovative Clinical Research Institute (ICRI), Whittier, California, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Rocky Mountain Cancer Center-Lakewood (Laboratory), Lakewood, Colorado, United States|Rocky Mountain Cancer Centers (RMCC) - Lakewood - St Anthony, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Center Pueblo, Pueblo, Colorado, United States|John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Lewis Hall Singletary Oncology Center At John D. Archbold Memorial Hospital, Thomasville, Georgia, United States|Northwestern Medicine West Region, DeKalb, Illinois, United States|Cancer Center,Northwestern Medicine, West Region, Geneva, Illinois, United States|Cancer Center of Kansas, Chanute, Kansas, United States|Cancer Center of Kansas, Dodge City, Kansas, United States|Cancer Center of Kansas, El Dorado, Kansas, United States|Cancer Center of Kansas, Independence, Kansas, United States|Cancer Center of Kansas, Kingman, Kansas, United States|Cancer Center of Kansas, Liberal, Kansas, United States|Cancer Center of Kansas, McPherson, Kansas, United States|Cancer Center of Kansas, Newton, Kansas, United States|The University of Kansas Cancer Center, Overland Park, Kansas, United States|Cancer Center of Kansas, Parsons, Kansas, United States|Cancer Center of Kansas, Salina, Kansas, United States|Cancer Center of Kansas, Wellington, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Cancer Center Of Kansas, Winfield, Kansas, United States|PET/CT facility Seton Imaging Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Rcca Md Llc, Bethesda, Maryland, United States|Holy Cross Hospital Resource Center, Silver Spring, Maryland, United States|Holy Cross Hospital Hospital Pharmacy, Silver Spring, Maryland, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Maryland Oncology Hematology, P.A., Wheaton, Maryland, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Kansas City, Missouri, United States|The University of Kansas Cancer Center, Lee's Summit, Missouri, United States|Saint Francis Medical Center, Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Grand Island, Nebraska, United States|Saint Francis Medical Center, Saint Francis Cancer Treatment Center, Hastings, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Henderson, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States|Vidant Medical Center Pharmacy, Greenville, North Carolina, United States|Vidant Medical Center, Greenville, North Carolina, United States|Toledo Clinic Cancer Center - Maumee, Maumee, Ohio, United States|Toledo Clinic Cancer Center - Toledo, Toledo, Ohio, United States|Toledo Clinic, Inc., Toledo, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|University of Tennessee Medical Center, Knoxville, Tennessee, United States|San Antonio Military Medical Center- Department of Pharmacy, Fort Sam Houston, Texas, United States|San Antonio Military Medical Center- Department of Radiology, Fort Sam Houston, Texas, United States|San Antonio Military Medical Center, Fort Sam Houston, Texas, United States|Investigational Products Center (I PC), Fort Worth, Texas, United States|Investigational Products Center (IPC), Fort Worth, Texas, United States|Millennium Oncology, Houston, Texas, United States|US Oncology Investigational Products Center (IPC), Irving, Texas, United States|Millennium Oncology, Kingwood, Texas, United States|Texas Oncology - Longview Cancer Center, Longview, Texas, United States|Millennium Oncology, Shenandoah, Texas, United States|Millennium Oncology, The Woodlands, Texas, United States|Texas Oncology-Tyler, Tyler, Texas, United States|Yakima Valley Memorial Hospital/North Star Lodge Cancer Center, Yakima, Washington, United States|Krankenhaus der Barmherzigen Schwestern Linz, Linz, Austria|Kepler Universitaetsklinikum GmbH, Linz, Austria|Kepler Universitaetsklinikum GmbH, Linz, Austria|SI 'Republican Research and Practice Centre of Oncology and Medical Radiology n.a. N.N. Alexandrov', Lesnoy, Minsk Region, Belarus|SI 'Republican Research and Practice Centre of Oncology and Medical Radiology n.a. N.N. Alexandrov', Lesnoy, Minsk Region, Belarus|Healthcare Institution ""Brest Regional Oncologic Dispensary"", Brest, Belarus|Healthcare Institution 'Minsk City Clinical Oncology Dispensary', Minsk, Belarus|SI Republican Research and Practice Centre of oncology and medical radiology n.a N.N Alexandrov, Republic Of Belarus, Belarus|Hopital Erasme, Brussels, Belgium|Nuclear Medicine Department, Brussels, Belgium|Grand Hopital de Charleroi-Site Notre-Dame, Charleroi, Belgium|PET/CT facility: Grand Hopital de Charleroi (GHdC) - site Notre-Dame, Charleroi, Belgium|Pharmacy Department: Grand Hopital de Charleroi (GHdC) - site Notre-Dame, Charleroi, Belgium|Pharmacy Department, Centre Hospitalier De Jolimont - Lobbes, La Louviere (Haine-Saint Paul), Belgium|Centre Hospitalier de Jolimont - Lobbes, La Louviere (Haine-Saint-Paul), Belgium|Radiology Department, La Louviere (Haine-Saint-Paul), Belgium|C.H.U. Ambroise Pare, Mons, Belgium|Pharmacy Department, CHU Ambroise Pare, Mons, Belgium|Hospital Santa Izabel - Setor de Bioimagem, Salvador, Bahia, Brazil|Hospital Santa Izabel / Santa Casa de Misericordia da Bahia, Salvador, Bahia, Brazil|Clinica Multimagem, Goiania, GO, Brazil|Hospital das Clinicas da Universidade Federal de Goias \ Centro de Pesquisa Clinica, Goiania, GO, Brazil|Centro de Imagens da Faculdade de Medicina - INCT Medicina Nuclear - PET/CT, Belo Horizonte, MG, Brazil|Unidade Funcional Apoio Diagnostico e terapeutica por Imagem do HC/UFMG - CT Scan, Belo Horizonte, MG, Brazil|Hospital das Clinicas Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Central de Misturas Intravenosas do Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre - Centro de Pesquisa Clinica, Porto Alegre, RIO Grande DO SUL, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|Servico de Radiologia do Hospital de Clinicas de Porto Alegre, Porto Alegre, RIO Grande DO SUL, Brazil|CDI - Centro de Diagnostico por Imagem do Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|InsCer - Instituto do Cerebro do Rio Grande do Sul - PUCRS, Porto Alegre, RS, Brazil|Uniao Brasileira de Educacao e Assistencia (UBEA) - Hospital Sao Lucas da PUCRS -, Porto Alegre, RS, Brazil|Fundacao Amaral Carvalho / Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Fundacao Amaral Carvalho / Fundacao Dr. Amaral Carvalho, Jau, SAO Paulo, Brazil|Unidade de Quimioterapia, Jaú, SAO Paulo, Brazil|Casa da Esperanca, Santo Andre, SAO Paulo, Brazil|Tecnolab, Sao Bernardo do Campo, SAO Paulo, Brazil|CEMEDI, Campinas, SP, Brazil|Instituto Radium, Campinas, SP, Brazil|CAEP - Centro Avancado de Estudos e Pesquisas LTDA, Campinas, SP, Brazil|Hospital e Maternidade Madre Theodora LTDA, Campinas, SP, Brazil|CENNI Oncologia, Campinas, SP, Brazil|Fundacao do ABC - FMABC/ Faculdade de Medicina ABC ( CEPHO - Centro de Estudos e Pesquisas de, Santo Andre, SP, Brazil|Hospital Bandeirantes, Sao Paulo, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina da USP / Fundacao Faculdade de Medicina MEC MPAS, Sao Paulo, SP, Brazil|Casa de Saude Santa Marcelina (Centro de Pesquisa Santa Marcelina), Sao Paulo, SP, Brazil|IEP São Lucas (Pharmacy), São Paulo, SP, Brazil|IEP Sao Lucas - Instituto de Ensino e Pesquisa Sao Lucas / HEMOMED - Instituto de Oncologia e, Sao Paulo, Brazil|Fleury, Sao Paulo, Brazil|University Hospital Center Zagreb, Department of Nuclear Medicine and Radiation Protection, Zagreb, Croatia|University Hospital Center Zagreb, Department of Pathology and Cytology, Zagreb, Croatia|University Hospital Center Zagreb, Department of Radiology, Zagreb, Croatia|University Hospital Centre ""Sestre Milosrdnice"", Zagreb, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|CHU Marseille Hopital de La Conception, Marseille, Marseille Cedex 05, France|CH de Mulhouse, Hopital Emile Muller, Mulhouse, Mulhouse Cedex, France|Hopital Duchenne Chu - Boulogne Sur Mer, Boulogne Sur Mer, NAP, France|Hopital Duchenne Chu - Boulogne Sur Mer, Boulogne Sur Mer, France|Centre Hospitalier De Bourg En Bresse, Bourg En Bresse Cedex, France|Hopital Morvan-CHU Brest- Service Hematologie Clinique, Brest, France|Centre Hospitalier Universitaire Cote de Nacre, Caen, France|Centre Hospitalier du Mans, Le Mans, France|Clinique de la Sauvegarde, Lyon, France|""LTD """"M. Zodelava's Hematology Centre"""""", Tbilisi, Georgia|LTD ""Research Institute of Clinical Medicine"", Tbilisi, Georgia|High Technology Medical Center, University Clinic, Tbilisi, Georgia|Charite - Universitaetsmedizin Berlin, Berlin, Germany|Charite - Universitatsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Charite - Universitaetsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany|Charite - Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany|Charite - Universitatsmedizin Berlin, Berlin, Germany|Klinikum Chemnitz gGmbH - Institut fuer Interventionelle Radiologie und Neuroradiologie, Chemnitz, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Chemnitz gGmbH - Klinik fuer Nuklearmedizin, Chemnitz, Germany|Klinikum Chemnitz gGmbH - Zentralapotheke, Chemnitz, Germany|Universitaetsklinikum Essen (AoeR), Essen, Germany|Universitatsklinikum Essen (AoR), Essen, Germany|DokuSan Gesellschaft fuer Medizinische Studien mbH & Co. KG, Herne, Germany|Apotheke des St. Anna Hospital, Herne, Germany|EVK Eickel, Herne, Germany|Praxis im Koeln Triangle, Koeln, Germany|Gemeinschaftspraxis fuer Diagnostische Radiologie und Nuklearmedizin, Mutlangen, Germany|Kliniken Ostalb, Stauferklinikum Schwaebisch Gmuend, Zentrum fuer Innere Medizin, Mutlangen, Germany|Stauferklinikum Schwaebisch Gmuend, Apotheke, Mutlangen, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Klinikum Stuttgart, Klinik fuer Nuklearmedizin, Stuttgart, Germany|Vinzenz von Paul Kliniken gGmbH, Stuttgart, Germany|Radiologie Rhein-Sieg, Troisdorf, Germany|Ueberoertliche Berufsausuebungsgemeinschaft Drs. med. Helmut Forstbauer, Troisdorf, Germany|Zentralapotheke, Troisdorf, Germany|Gen. Hosp. of Athens ""Evangelismos - Eye Hosp.- Polikliniki"", Athens, Greece|Gen. Hosp. of Athens ""Evangelismos-Eye Hosp. - Polikliniki"", Athens, Greece|Gen. Hosp. of Athens ""Evangelismos-Eye Hosp.-Polikliniki"", Athens, Greece|Gen.Hosp.of Athens ""Evangelismos-Eye Hosp.-polikiliniki"", Athens, Greece|General Hospital of Athens ""Evangelismos - Eye Hosp. - Polikliniki"", Athens, Greece|Bioiatriki S.A., Athens, Greece|Bioiatriki, Athens, Greece|General Hospital of Athens 'Laiko', Athens, Greece|""""""ATTIKON"""" Gen. Univ. Hosp"", Athens, Greece|""ATTIKON'' Gen. Univ. Hosp., Chaidari, Athens, Greece|Magnitiki Patron, Patras, Greece|University General Hospital of Patras, Patras, Greece|Super Scan Imaging Centre, Surat, Gujarat, India|Pathology Department, Unique Hospital Multispeciality & Research Institute, Surat, Gujarat, India|Zircon- BIC Imaging Centre, Surat, Gujarat, India|Mangalore Institute of Oncology, Mangalore, Karanataka, India|HealthCare Global Enterprises Limited, Bangalore, Karnataka, India|Kasturba Medical College and Hospital, Manipal, Karnataka, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Department of Radiology, Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Department of Radiology, Pune, Maharashtra, India|Jehangir Clinical Development Centre Pvt. Ltd., Pune, Maharashtra, India|Ruby Hall clinic, Pune, Maharashtra, India|R.K. Birla Cancer Center, Sawai Man Singh Hospital, Jaipur, Rajasthan, India|Apollo Speciality Hospital, Chennai, Tamilnadu, India|Department of Radiology, Chennai, Tamilnadu, India|Global Hospitals, Hyderabad, Telangana, India|Vijaya Diagnostic Centre, Hyderabad, Telangana, India|N.R.S Medical College and Hospital, Kolkata, WEST Bengal, India|Spandan PET-CT Unit, Kolkata, WEST Bengal, India|Rajiv Gandhi Cancer Institute & Research Center (RGCIRC), New Delhi, India|U.O. di Ematologia e CTMO - Istituti Ospedalieri di Cremona, Cremona, CR, Italy|IRST - IRCCS U. O. Oncologia Medica, Meldola, FC, Italy|U.O. Ematologia 1 - IRCCS AOU San Martino-IST, Genova, GE, Italy|Unita di Ricerca Clinica, Monza, MB, Italy|Istituto Europeo di Oncologia, Milano, MI, Italy|Unità semplice di Medicina Nucleare, Latina, NAP, Italy|Clinica Ematologica - A.O.U. Ospedali Riuniti di Ancona, Torrette Ancona, Palermo, Italy|Az Ospedaliera Santa Maria, Terni, PG, Italy|Medicina nucleare, Reggio Emilia, Reggio, Italy|Radiologia, Reggio Emilia, Reggio, Italy|SC Ematologia - SC Ematologia - Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Reggio, Italy|""Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita """"Sapienza"""", Rome, Rome Rm, Italy|IRCSS A.O.U. San Martino - IST - UO Clinica Ematologica, Genova, Italy|SC Ematologia, Fondazione IRCCS Ist Nazionale dei Tumori, Milano, Italy|Padiglione 1, Torre delle medicine, 6 piano, Parma, Italy|Ematologia e Centro Trapianti - AZ Osp. Ospedali Riuniti Marche Nord (AORMN) - Presidio S. Salvatore, Pesaro, Italy|U.O. Ematologia Universitaria - Dip. Di Oncologia dei Trapianti - AOU Pisana, Pisa, Italy|Policlinico Universitario Campus Bio- Medico-U.O.C. di Ematologia Trapianto Cellule Staminali, Roma, Italy|East Nagoya Imaging Diagnosis Center, Nagoya, Aichi, Japan|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|Chiba Cancer Center, Chiba-shi, Chiba, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka-shi, Fukuoka, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Kobe City Medical Center General Hospital, Kobe-City, Hyogo, Japan|National Hospital Organization Kanazawa Medical Center, Kanazawa, Ishikawa, Japan|Kanazawa Advanced Medical Center, Kanazawa, Ishikawa, Japan|Showa University Northern Yokohama Hospital, Yokohama-shi, Kanagawa-ken, Japan|Kochi Medical School Hospital, Okocho, Nankoku, Kochi, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto-shi, Kumamoto-ken, Japan|Uozumi Clinic, Kumamoto-shi, Kumamoto-ken, Japan|Sendai Kousei Hospital, Sendai-shi, Miyagi, Japan|National Hospital Organization Sendai Medical Center, Sendai-shi, Miyagi, Japan|Aizawa Hospital, Matsumoto-shi, Nagano, Japan|Nagano Red Cross Hospital, Nagano-shi, Nagano, Japan|National Hospital Organization Nagasaki Medical Center, Omura, Nagasaki, Japan|National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Osaka, Japan|Hanwa Dai 2 Senboku Hospital, Naka-ku Sakai, Osaka, Japan|Osaka City University Hospital, Osaka-City, Osaka, Japan|Tokushima University Hospital, Tokushima-Shi, Tokushima, Japan|National Hospital Organization Tokyo Medical Center, Meguro-Ku, Tokyo, Japan|Showa University Hospital, Shinagawa-ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center, Tachikawa, Tokyo, Japan|Yamagata University Hospital, Yamagata-Shi, Yamagata, Japan|Fukuoka Wajiro PET Diagnostic Imaging Clinic, Fukuoka, Japan|National Hospital Organization Matsumoto Medical Center, Nagano, Japan|Musashimurayama Hospital, Tokyo, Japan|Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonbuk National University Hospital, Jeonju-si, Jeollabuk-do, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hammoud Hospital, University Medical Center, Saida, Southern Governate, Lebanon|Doctors Center Radiology, Beirut, Lebanon|Mount Lebanon Hospital, Beirut, Lebanon|Middle East Institute Of Health, El Metn, Lebanon|Ain Wazein Hospital, Mount Lebanon, Lebanon|Grupo Medico Camino S.C., Mexico City, Distrito Federal, Mexico|Imagenus, Mexico City, Distrito Federal, Mexico|Isos Pharmacorp, S.A. de C.V., Mexico City, Distrito Federal, Mexico|Vely Grupo Medico Quirurgico, S.A. de C.V., Cuautitlan Izacalli, Estado DE Mexico, Mexico|Phylasis Clinicas Research S. de R.L. de C.V., Cuautitlan Izcalli, Estado DE Mexico, Mexico|Centro Universitario de Imagen Diagnostica, Radiologia e Imagen del Hospital Universitario, Monterrey, Nuevo LEON, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo LEON, Mexico|Cirurgia y Ginecobstetricia de Oaxaca, S.A de C.V., Oaxaca, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|Hospital Angeles Puebla, Puebla, Mexico|Cancerologia de Queretaro S.C., Queretaro, Mexico|Hospital Infantil Teleton de Oncologia, Queretaro, Mexico|Hospital San Jose Norte, Queretaro, Mexico|Instituto Nacional de Enfermedades Neoplasicas, Surquillo, Lima, Peru|Pet Scan Peru, Lima, Peru|Resocentro, Lima, Peru|University of Philippines Manila-Philippine General Hospital, Manila, Metro Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Klinika Nowotworow Ukladu Chlonnego Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|Euromedic Wroclawskie Centrum Medyczne II, Wroclaw, Poland|Euromedic Wroclawskie Centrum Medyczne III, Wroclaw, Poland|Dolnoslaskie Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|Euromedic Wroclawskie Centrum Medyczne I, Wroclaw, Poland|Apteka Dolnoslaskiego Centrum Transplantacji Komorkowych z Krajowym Bankiem Dawcow Szpiku, Wroclaw, Poland|Unidade Local de Saude de Matosinhos E.P.E. - Hospital Pedro Hispano S.A., Matosinhos, Porto, Portugal|Hospital de Braga, Braga, Portugal|Hospital CUF Descobertas, Lisboa, Portugal|CIMC, Porto, Portugal|Dr. Campos Costa Clinic, Porto, Portugal|Centro Hospitalar do Porto-Hospital de Santo Antonio E.P.E., Porto, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil E.P.E, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E., Vila Nova de Gaia, Portugal|Modern Radiology, PSC, Coto Laurel, Puerto Rico|Ad-Vance Medical Research, LLC, Ponce, Puerto Rico|Caribe MRI and CT, Ponce, Puerto Rico|Policlinica de Diagnostic Rapid, Hematologie, Brasov, Romania|Policlinica de Diagnostic Rapid SA, Brasov, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Hiperdia Ritmului, Bucuresti, Romania|Affidea Fundeni, Bucuresti, Romania|Affidea Romania SRL, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Laborator Radiologie si Imagistica Medicala, Cluj-Napoca, Romania|Institutul Oncologic Prof. Dr. Ion Chiricuta, Sectia Oncologie Medicala, Cluj-Napoca, Romania|Clinica de Hematologie-Institutul Oncologic, Prof. Dr. Ion Chiricuta, Cluj-Napoca, Romania|CT Clinic S.R.L., Cluj-Napoca, Romania|A.Tsyb Medical Radiological Research Centre -, Obninsk, Kaluga Region, Russian Federation|State Healthcare Institution Republican Oncology Dispensary, Saransk, Mordovian Republic, Russian Federation|""SBHI of NNR """"Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko"""""", Nizhniy Novgorod, Nizhniy Novgorod Region, Russian Federation|LLC MC ""MRT-Diagnostika"", Nizhniy Novgorod, Nizhniy Novgorod Region, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"" of MoH of RF, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"", Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI 'Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy TOWN, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies n.a. A.M. Granov"" of MoH of RF, Saint-Petersburg, Pesochniy, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies named after academician, Saint-Petersburg, Pesochniy, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies, Saint-Petersburg, Pesochniy, Russian Federation|FSBI 'National Medical Oncology Research Centre n.a. N.N.Petrov', Saint-Petersburg, Pos.pesochny, Russian Federation|Branch office of LLC 'PET-Technology' at Ufa city, Ufa, Republic Bashkortostan, Russian Federation|State Budgetary Healthcare Institution ""Republican Clinical Oncology Dispensary of the Ministry, Ufa, Republic Bashkortostan, Russian Federation|Private medical institution ""Euromedservice"", Pushkin, Saint Petersburg, Russian Federation|FSBI ""Russian Research Centre of Radiology and Surgical Technologies"" of MoH of RF, Pesochniy Town, Saint-petersburg, Russian Federation|Federal State-Financed Institution 'North-Caucasian Research and Clinical Center', Lermontov, Stavropol Region, Russian Federation|SBHI of Stavropol Region ""Pyatigorsk Interdistrict Oncology Dispensary, Pyatigorsk, Stavropol Region, Russian Federation|""State Budget Healthcare Institution """"Chelyabinsk Regional Clinical Center of Oncology, Chelyabinsk, Russian Federation|FSBSI 'N.N.Blokhin Russian Cancer Research Center' of MoH of RF, Moscow, Russian Federation|Russian Cancer Research Centre them N.N. Blokhin, Moscow, Russian Federation|LLC ""VitaMed"", Moscow, Russian Federation|SBHI of Moscow City Clinical Hospital n.a. S.P.Botkin of Healthcare Department of Moscow, Moscow, Russian Federation|Ramsay Diagnostics, Moscow, Russian Federation|State Budgetary Institution of Healthcare ""Leningrad Regional Clinical Hospital"", Saint Petersburg, Russian Federation|Dr. Berezin Medical Institute, Saint-Petersburg, Russian Federation|N.P. Bechtereva Institute of Human Brain of the Russian Academy of Sciences, Saint-Petersburg, Russian Federation|N.P. Bechtereva Institute of the Human Brain of the Russian Academy of Sciences, Saint-Petersburg, Russian Federation|Non-state healthcare institution ""Road Clinical Hospital of Joint Stock Company ""Russian Railways"", Saint-Petersurg, Russian Federation|Yaroslavl State Medical Academy, Yaroslavl, Russian Federation|GBUZ of Yaroslavl Region ""Regional Clinical Hospital"", Yaroslavl, Russian Federation|NIKSCH & PARTNERS t/a CAPITAL RADIOLOGY, Groenkloof, Gauteng, South Africa|The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa|Department of Medical Oncology, University of Pretoria, Steve Biko Academic Hospitals Complex, Pretoria, Gauteng, South Africa|Albert Alberts Stem Cell Transplant Centre, Pretoria, Gauteng, South Africa|Dr JN De Jong and Partners t/a East Rad, Pretoria, Gauteng, South Africa|NIKSCH & PARTNERS t/a CAPITAL RADIOLOGY, Pretoria, Gauteng, South Africa|Drs Sulman & Partners Specialist Radiologists, Rosebank, Gauteng, South Africa|Drs Bloch & Partners Incorporated, Sandton, Gauteng, South Africa|Hospital Parc Tauli, Sabadell, Barcelona, Spain|Onkologikoa, San Sebastian, Guipuzcoa, Spain|Hospital Universitario Sanitas La Zarzuela, Aravaca, Madrid, Spain|Hospital Rey Juan Carlos, Mostoles, Madrid, Spain|Hospital Clinico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital do Meixoeiro Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain|Complejo Hospitalario Universitario A Coruna, A Coruna, Spain|Hospital Modelo, A Coruna, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Quiron de Barcelona, IEC, Barcelona, Spain|CETIR, Centre Medic, Barcelona, Spain|Radiodiagnostic CETIR - Clinica del Pilar, Barcelona, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain|Hospital Universitario Sanitas La Moraleja, Madrid, Spain|Centro CIMES, Malaga, Spain|Hospital universitario Virgen de la Victoria, Malaga, Spain|Centro Mario Gallegos, Malaga, Spain|Complejo Hospitalario de Ourense. Hematología, Ourense, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|H. Quiron Zaragoza, Zaragoza, Spain|Hospital de Dia Quiron Zaragoza, Zaragoza, Spain|Universitatsspital Basel, Basel, Switzerland|Inselspital Bern, Bern, Switzerland|Apotheke, Spital STS AG, Thun, Switzerland|Onkologiezentrum Thun-Berner Oberland Spital Sts Ag, Thun, Switzerland|Kantonsapotheke Zuerich, Zuerich, Switzerland|UniversitaetsSpital Zuerich, Zuerich, Switzerland|Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,, Bangkok, Thailand|Department of Radiology, Ramathibodi Hospital, Bangkok, Thailand|National Cancer Institute, Bangkok, Thailand|Hacettepe Universitesi Tip Fakultesi Onkoloji Hastanesi, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Eg. ve Aras., Ankara, Turkey|Ultramar Tibbi Gorunteleme Merkezi, Ankara, Turkey|Ultramar Tibbi Goruntuleme Merkezi, Ankara, Turkey|Integra Gurses Teshis Tedavi ve Saglik Hizmetleri A.S., Ankara, Turkey|Adnan Menderes University Medical Faculty, Aydin, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama, Gaziantep, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Ic Hastaliklari Anabilim Dali, Izmir, Turkey|EGE-RAD Bilgisayarli Tomografi Ozel Saglik Hizmetleri ve Malzemeleri Tic.Ltd.Sti., Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Nukleer Tip Laboratuvari, Kayseri, Turkey|Erciyes Universitesi Tip Fakultesi Radyoloji Laboratuvari, Kayseri, Turkey|Erciyes Universitesi Tip Fakultesi, Kayseri, Turkey|Inonu Universitesi Tip Fakultesi Turgut Ozal Tip Merkezi, Malatya, Turkey|Celal Bayar University Medical Faculty, Manisa, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|""Mediks-rey International Group"" LLC, Obukhiv District, KYIV Region, Ukraine|""MedX-rey International Group"" LLC, Obukhiv District, KYIV Region, Ukraine|""MedX-Ray International Group"" LLC, Obukhiv, KYIV Region, Ukraine|""Municipal Institution """"Chernivtsi Regional Clinical Oncology Center"""",, Chernivtsi, Ukraine|MI 'City Dnipropetrovsk Multi-field Clin. Hospital #4 of DRC',, Dnipropetrovsk, Ukraine|Municipal Non-Profit Enterprise ""Regional Oncology Centre"", Kharkiv, Ukraine|National Cancer Institute, Kyiv, Ukraine|""Central City Clinical Hospital, City Oncology Center, SHEI """"Uzhhorod National University"""", Chair, Uzhhorod, Ukraine|Podilskyy Regional Oncology Center, Chemotherapy Department, Vinnytsia, Ukraine|Municipal Establishment 'Zaporizhzhia Regional Clinical Oncology Dispensary', Zaporizhzhia, Ukraine|LLC ""Diaservis"", Zaporizhzhia, Ukraine|Southend University Hospital NHS Foundation Trust, Westcliff-On-Sea, Essex, United Kingdom|Cobalt Diagnostic Imaging, Cheltenham, Glos., United Kingdom|Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom|Barts Health NHS Trust, London, United Kingdom|Positron Emission Tomography (PET) Centre, Newcastle upon Tyne, United Kingdom|City Hospitals Sunderland NHS Foundation Trust-Sunderland Royal Hospital, Sunderland, United Kingdom|Diagnostic Imaging, Sunderland, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02213263/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02213263/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02213263"
539,"NCT01147809","Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag",,"Completed","Has Results","Thrombocytopaenia","Drug: Eltrombopag olamine|Other: Placebo","Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Clinical Chemistry Laboratory Parameters, at Anytime Post-Baseline in Phase I|Number of Participants With a Change From Baseline in Creatinine of >=26.5 Micromoles/Liter (UMOL/L) in Phase I|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase I|Number of Participants With Electrocardiogram (ECG) Findings at Anytime Post-Baseline in Phase I|Mean Day 1 Scheduled Pre-chemotherapy Platelet Count Evaluated Across Cycles 1 to 6 in Phase II|Average Pre-chemotherapy Platelet Count at the Indicated Time Points in Phase I|Average Within-subject Central Laboratory Platelet Count Prior to Scheduled Chemotherapy Across Cycles 2 to 6 in Phase I|Platelet Count Nadir for Each Chemotherapy Cycle in Phase I|Central Laboratory Average Daily Area Under the Curve Platelet-time Course Across Cycles 2 to 6 in Phase I|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across All the Chemotherapy Cycles in Phase I, Using Central Laboratory Platelet Count|Maximum Duration of Thrombocytopenia Across Cycles 2 to 6 in Phase I, Estimated Using Central Laboratory Platelet Counts|Central Laboratory Platelet Count for Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase I|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase I, Estimated Using Central Laboratory Platelet Counts|Dose Intensity of Gemcitabine Plus Cisplatin (G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1 to 6 in Phase I|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase I|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE): Pre-therapy, On-therapy + 30 Days and Post-therapy in Phase II|Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale, Across Cycles 1-6 in Phase II|Number of Participants Requiring a Platelet Transfusion in Phase II|Number of Participants With at Least One Delay in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Number of Participants With Any Dose Reduction in Their Scheduled Dose of Chemotherapy in Any Cycle in Phase II|Dose Intensity of Gemcitabine Plus Cisplatin(G+Cis)/Gemcitabine Plus Carboplatin (G+Cb) and Gemcitabine Across Chemotherapy Cycles 1-6 in Phase II|Number of Participants With Indicated Maximum Toxicity Grades for the Indicated Hematology Parameters, at Anytime Post-Baseline in Phase II|Number of Participants With Indicated Worst-case Change From Baseline in Clinical Chemistry Laboratory Parameters Using CTCAE Toxicity Grading, at Anytime Post-Baseline in Phase II|Number of Participants With Change From Baseline in Creatinine of >=26.5 UMOL/L in Phase II|Number of the Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Scores at the Indicated Time Points in Phase II|Number of Participants With Electrocardiogram (ECG) Findings at Cycle 1 Day 4 (2 to 6 Hours Post-dose) in Phase II|Mean Day 8 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Day 15 Scheduled Pre-chemotherapy Platelet Counts Evaluated Across Cycles 1 to 6 in Phase II|Mean Within-subject Platelet Count Prior to Scheduled Chemotherapy Across Cycles 1 to 6 in Phase II|Platelet Count Nadir for Each Chemotherapy Cycle in Phase II|Average Daily Area Under the Platelet-time Course Across Cycles 1 to 6 in Phase II|Number of Participants With Thrombocytopenia of Grade 1, 2, 3 or 4 Across Cycles 1 to 6 in Phase II|Maximum Duration of Thrombocytopenia Across Cycles 1 to 6 in Phase II|Time Taken to Reach Platelet Nadir for Each Chemotherapy Cycle in Phase II|Time to Recovery From Platelet Nadir for Each Chemotherapy Cycle in Phase II","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","112765","June 2010","January 2015","March 2015","June 22, 2010","April 18, 2016","April 18, 2016","GSK Investigational Site, Sedona, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Rancho Cucamonga, California, United States|GSK Investigational Site, Norwich, Connecticut, United States|GSK Investigational Site, Jacksonville, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Rome, Georgia, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Wichita, Kansas, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Rockville, Maryland, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Las Vegas, Nevada, United States|GSK Investigational Site, Cherry Hill, New Jersey, United States|GSK Investigational Site, Albany, New York, United States|GSK Investigational Site, Greensboro, North Carolina, United States|GSK Investigational Site, Bend, Oregon, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Wynnewood, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Arlington, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Bedford, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Tyler, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Edmunds, Washington, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Vancouver, Washington, United States|GSK Investigational Site, Yakima, Washington, United States|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Libramont, Belgium|GSK Investigational Site, Namur, Belgium|GSK Investigational Site, Edmonton, Alberta, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 10, Czech Republic|GSK Investigational Site, Praha 5, Czech Republic|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Freiburg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Augsburg, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Goslar, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Dresden, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Heraklion, Crete, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Törökbálint, Hungary|GSK Investigational Site, Zalaegerszeg, Hungary|GSK Investigational Site, Madurai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Tallaght, Dublin, Ireland|GSK Investigational Site, Ashkelon, Israel|GSK Investigational Site, Haifa, Israel|GSK Investigational Site, Jerusalem, Israel|GSK Investigational Site, Kfar Saba, Israel|GSK Investigational Site, Tel Aviv, Israel|GSK Investigational Site, Zrifin, Israel|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Aviano (PN), Friuli-Venezia-Giulia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Sassari, Sardegna, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Konin, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland",,"https://ClinicalTrials.gov/show/NCT01147809"
540,"NCT03722732","Comparison of Blood Loss in Laparoscopic vs Open Pancreaticoduodenectomy in Patients With Periampullary Carcinoma",,"Recruiting","No Results Available","Periampullary Carcinoma","Procedure: pancreaticoduodenectomy","intraoperative blood loss in ml, quantitative","Govind Ballabh Pant Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","F.1/IEC/MAMC/63/03/18/NO325","September 11, 2018","December 2022","March 2023","October 29, 2018",,"August 2, 2021","G B Pant Hospital, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT03722732"
541,"NCT02492503","Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix",,"Unknown status","No Results Available","Metastatic Carcinoma to the Uterine Cervix|Recurrent Carcinoma Cervix|Cervix Carcinoma Recurrent","Drug: Paclitaxel and carboplatin","Time to progression (length of time from start of chemotherapy to evidence of cancer progression.|Response rate|Overall survival|Quality Of Life Questionnaire","All India Institute of Medical Sciences, New Delhi","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA CX CHEMOTHERAPY","November 2013","August 2015","August 2015","July 8, 2015",,"July 8, 2015","AIIMS, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT02492503"
542,"NCT00899054","Safety and Efficacy Study of P276-00 in Combination With Radiation in Subjects With Advanced Head and Neck Cancer","SPARK","Completed","No Results Available","Squamous Cell Carcinoma of Head and Neck","Drug: P276-00|Radiation: External beam radiotherapy (EBRT)","To determine the maximum tolerated dose (MTD) and dose limiting toxicity (ies) (DLT/s) of P276-00 in combination with radiation in subjects with recurrent and/or locally advanced squamous cell carcinoma of head and neck (SCCHN)|To evaluate safety and tolerability of the combination regimen of P276-00 and radiation in the study population|To analyze pharmacokinetics (PK) of P276-00 in the study population|To evaluate efficacy of the combination regimen of P276-00 and radiation in the study population|To perform exploratory analysis of biomarkers associated with use of P276-00 and radiation in the study population","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","23","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/31/08","August 2009","January 2011","November 2012","May 12, 2009",,"November 22, 2012","Government Medical College, Aurangabad, Maharashtra, India|Curie Manavata Cancer Center, Nashik, Maharashtra, India|Bhagwan Mahawir Cancer Hospital & Research Centre, Jaipur, Rajasthan, India|V. N. Cancer Centre, GKNM Hospital, Coimbatore, Tamil Nadu, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India|Christian Medical College, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00899054"
543,"NCT01593306","Concurrent Chemoradiotherapy With Weekly Cisplatin Versus Concurrent Chemoradiotherapy With Weekly Cisplatin and Paclitaxel in Locally Advanced Carcinoma Cervix",,"Unknown status","No Results Available","Carcinoma Cervix","Drug: Paclitaxel, Cisplatin|Drug: Cisplatin","clinical response of the disease|number of patients with adverse events","Indira Gandhi Medical College, Shimla","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","pragyat1805","July 2011","October 2012","February 2013","May 8, 2012",,"May 8, 2012","Indira Gandhi Medical College, Shimla, Himachal Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01593306"
544,"NCT01117402","Tomotherapy in Postsurgery Recurrent Carcinoma Cervix",,"Unknown status","No Results Available","Postsurgery Recurrent Carcinoma Cervix","Radiation: Radiotherapy","To evaluate the utility of intensity-modulated radiotherapy (IMRT) in delivering dose escalated radiotherapy in postoperative recurrent cases of carcinoma cervix, in terms of local control|To study the late toxicities associated with this treatment","Tata Memorial Hospital","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 588","December 2008","December 2013","December 2014","May 5, 2010",,"May 5, 2010","Tata Memorial Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01117402"
545,"NCT00073385","Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Pivanex|Drug: Docetaxel",,"Titan Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","225","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TTP-200-03-01|NSCLC Clincal Trial","September 2003",,"October 2004","November 21, 2003",,"August 30, 2005","Wilshire Oncology Medical Group, La Verne, California, United States|Hematology and Oncology Specialists, LLC, New Orleans, Louisiana, United States|Montefiore Medical Center, Department of Oncology, Bronx, New York, United States|HemOnCare, Brooklyn, New York, United States|Gaston Hematology & Oncology Associates, Gastonia, North Carolina, United States|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, India|Regional Cancer Centre, Thiruvananthapuram, India|University of Edinburgh, Edinburgh Cancer Centre, Edinburgh, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00073385"
546,"NCT03367702","Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer",,"Recruiting","No Results Available","Stage II Prostate Adenocarcinoma","Radiation: Intensity-Modulated Radiation Therapy (IMRT)|Radiation: Stereotactic Body Radiation Therapy (SBRT)","Incidence of Patients-Reported Gastrointestinal and Genitourinary Toxicity|Disease Free Survival|Biochemical Failure|Distant Metastasis|Health Related Quality of Life|Incidence of adverse events (AEs)|Local Failure|Overall Survival|Presence of Prostate Imaging-Reporting and Data System version (PIRADSv) 2 = 4/5 disease|Prostate Cancer Specific Survival|Regional Failure","NRG Oncology|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)","Phase 3","622","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRG-GU005|NCI-2017-01398|U10CA180868","November 16, 2017","December 2025","December 2030","December 11, 2017",,"January 21, 2022","Mobile Infirmary Medical Center, Mobile, Alabama, United States|Lewis and Faye Manderson Cancer Center, Tuscaloosa, Alabama, United States|Arizona Breast Cancer Specialists-Gilbert, Gilbert, Arizona, United States|Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States|Arizona Breast Cancer Specialists-Scottsdale, Scottsdale, Arizona, United States|Arizona Center for Cancer Care-Surprise, Surprise, Arizona, United States|Arizona Oncology Associates-West Orange Grove, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States|Mercy San Juan Medical Center, Carmichael, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Fresno Cancer Center, Fresno, California, United States|Marin General Hospital, Greenbrae, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|Saint Joseph Hospital - Orange, Orange, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Mercy Cancer Center - Sacramento, Sacramento, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|University of California Davis Comprehensive Cancer Center, Sacramento, California, United States|Salinas Valley Memorial, Salinas, California, United States|Stanford Cancer Center South Bay, San Jose, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UCHealth Memorial Hospital Central, Colorado Springs, Colorado, United States|Memorial Hospital North, Colorado Springs, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Poudre Valley Hospital, Fort Collins, Colorado, United States|Valley View Hospital Cancer Center, Glenwood Springs, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Smilow Cancer Hospital Care Center - Guiford, Guilford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States|Smilow Cancer Hospital Care Center - Waterford, Waterford, Connecticut, United States|Beebe South Coastal Health Campus, Frankford, Delaware, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Broward Health Medical Center, Fort Lauderdale, Florida, United States|GenesisCare USA - Key West, Key West, Florida, United States|GenesisCare USA - Lakewood Ranch, Lakewood Ranch, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|GenesisCare USA - Plantation, Plantation, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory University Hospital Midtown, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States|Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States|Saint Alphonsus Medical Center-Nampa, Nampa, Idaho, United States|Rush - Copley Medical Center, Aurora, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Crossroads Cancer Center, Effingham, Illinois, United States|Edward Hines Jr VA Hospital, Hines, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Carle Cancer Center, Urbana, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Parkview Hospital Randallia, Fort Wayne, Indiana, United States|Parkview Regional Medical Center, Fort Wayne, Indiana, United States|Franciscan Health Indianapolis, Indianapolis, Indiana, United States|Mercy Medical Center - Des Moines, Des Moines, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|Ascension Via Christi Hospitals Wichita, Wichita, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|The James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States|East Jefferson General Hospital, Metairie, Louisiana, United States|LSU Healthcare Network / Metairie Multi-Specialty Clinic, Metairie, Louisiana, United States|Tulane University Health Sciences Center, New Orleans, Louisiana, United States|MaineHealth Coastal Cancer Treatment Center, Bath, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|MaineHealth Cancer Care Center of York County, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Saint Agnes Hospital, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Central Maryland Radiation Oncology in Howard County, Columbia, Maryland, United States|University of Maryland Shore Medical Center at Easton, Easton, Maryland, United States|UM Baltimore Washington Medical Center/Tate Cancer Center, Glen Burnie, Maryland, United States|TidalHealth Richard A Henson Cancer Institute, Ocean Pines, Maryland, United States|TidalHealth Peninsula Regional, Salisbury, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Mass General/North Shore Cancer Center, Danvers, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|McLaren Cancer Institute-Bay City, Bay City, Michigan, United States|GenesisCare USA - Clarkston, Clarkston, Michigan, United States|McLaren Cancer Institute-Clarkston, Clarkston, Michigan, United States|Beaumont Hospital - Dearborn, Dearborn, Michigan, United States|Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States|GenesisCare USA - Farmington Hills, Farmington Hills, Michigan, United States|Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States|Beaumont Hospital - Farmington Hills, Farmington Hills, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|McLaren Cancer Institute-Flint, Flint, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|McLaren-Greater Lansing, Lansing, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|GenesisCare USA - Macomb, Macomb, Michigan, United States|GenesisCare USA - Madison Heights, Madison Heights, Michigan, United States|McLaren Cancer Institute-Macomb, Mount Clemens, Michigan, United States|McLaren Cancer Institute-Northern Michigan, Petoskey, Michigan, United States|McLaren-Port Huron, Port Huron, Michigan, United States|William Beaumont Hospital-Royal Oak, Royal Oak, Michigan, United States|William Beaumont Hospital - Troy, Troy, Michigan, United States|GenesisCare USA - Troy, Troy, Michigan, United States|Metro Health Hospital, Wyoming, Michigan, United States|Sanford Joe Lueken Cancer Center, Bemidji, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Southeast Cancer Center, Cape Girardeau, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Delbert Day Cancer Institute at PCRMC, Rolla, Missouri, United States|SSM Health Saint Louis University Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Mercy Hospital Springfield, Springfield, Missouri, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Community Medical Hospital, Missoula, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Exeter Hospital, Exeter, New Hampshire, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|The Valley Hospital-Luckow Pavilion, Paramus, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Lovelace Radiation Oncology, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Saint Peter's Health Partners, Albany, New York, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Sands Cancer Center, Canandaigua, New York, United States|Mary Imogene Bassett Hospital, Cooperstown, New York, United States|Garnet Health Medical Center, Middletown, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|Highland Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Scotland Memorial Hospital-Laurinburg Cancer Center, Laurinburg, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|NHRMC Radiation Oncology - Supply, Supply, North Carolina, United States|NHRMC Radiation Oncology - 16th Street, Wilmington, North Carolina, United States|Sanford Bismarck Medical Center, Bismarck, North Dakota, United States|Sanford Roger Maris Cancer Center, Fargo, North Dakota, United States|Cleveland Clinic Akron General, Akron, Ohio, United States|UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio, United States|Geauga Hospital, Chardon, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|Cleveland Clinic Cancer Center Independence, Independence, Ohio, United States|Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio, United States|Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|University Hospitals Portage Medical Center, Ravenna, Ohio, United States|North Coast Cancer Care, Sandusky, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital-Cedar Crest, Allentown, Pennsylvania, United States|Bryn Mawr Hospital, Bryn Mawr, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Delaware County Memorial Hospital, Drexel Hill, Pennsylvania, United States|Fox Chase Cancer Center - East Norriton Hospital Outpatient Center, East Norriton, Pennsylvania, United States|Fox Chase Cancer Center Buckingham, Furlong, Pennsylvania, United States|Adams Cancer Center, Gettysburg, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Paoli Memorial Hospital, Paoli, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Jefferson Torresdale Hospital, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Reading Hospital, West Reading, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Asplundh Cancer Pavilion, Willow Grove, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|WellSpan Health-York Cancer Center, York, Pennsylvania, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Self Regional Healthcare, Greenwood, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|The Radiation Oncology Center-Hilton Head/Bluffton, Hilton Head Island, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Texas Cancer Center, Abilene, Texas, United States|Texas Oncology-McKinney, McKinney, Texas, United States|Texas Oncology-Plano West, Plano, Texas, United States|Texas Oncology Cancer Center Sugar Land, Sugar Land, Texas, United States|Deke Slayton Cancer Center, Webster, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Dixie Medical Center Regional Cancer Center, Saint George, Utah, United States|Central Vermont Medical Center/National Life Cancer Treatment, Berlin, Vermont, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Sentara Cancer Institute at Sentara CarePlex Hospital, Hampton, Virginia, United States|Bon Secours DePaul Medical Center, Norfolk, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Bon Secours Cancer Institute at Reynolds Crossing, Richmond, Virginia, United States|Oncology and Hematology Associates of Southwest Virginia, Roanoke, Virginia, United States|Sentara Obici Hospital, Suffolk, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Providence Saint Mary Regional Cancer Center, Walla Walla, Washington, United States|West Virginia University Charleston Division, Charleston, West Virginia, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|Ascension Saint Elizabeth Hospital, Appleton, Wisconsin, United States|Ascension Southeast Wisconsin Hospital - Elmbrook Campus, Brookfield, Wisconsin, United States|Ascension Saint Francis - Reiman Cancer Center, Franklin, Wisconsin, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital Ozaukee, Mequon, Wisconsin, United States|Ascension Columbia Saint Mary's Hospital - Milwaukee, Milwaukee, Wisconsin, United States|Aurora Saint Luke's Medical Center, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Zablocki Veterans Administration Medical Center, Milwaukee, Wisconsin, United States|Drexel Town Square Health Center, Oak Creek, Wisconsin, United States|Ascension Mercy Hospital, Oshkosh, Wisconsin, United States|Vince Lombardi Cancer Clinic - Oshkosh, Oshkosh, Wisconsin, United States|Ascension All Saints Hospital, Racine, Wisconsin, United States|Aurora Medical Center in Summit, Summit, Wisconsin, United States|Froedtert West Bend Hospital/Kraemer Cancer Center, West Bend, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|Ottawa Hospital and Cancer Center-General Campus, Ottawa, Ontario, Canada|Centre De Sante Et De Services Sociaux De Chicoutimi, Chicoutimi, Quebec, Canada|CIUSSSEMTL-Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada|CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke-Fleurimont, Sherbrooke, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Tata Memorial Hospital, Mumbai, India|Beacon Hospital, Dublin, Co Dublin, Ireland|Saint Lukes Hospital, Dublin, Co Dublin, Ireland|Kantonsspital Aarau, Aarau, Switzerland",,"https://ClinicalTrials.gov/show/NCT03367702"
547,"NCT00713427","Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction",,"Completed","Has Results","Biliary Strictures Caused by Malignant Neoplasms","Device: WallFlex™ Biliary Partially-Covered Stent","Number of Participants With Absence of Recurrent Biliary Obstruction|Number of Adverse Events Related to the Device and/or Procedure|Number of Participants With Technical Stent Placement Success|Number of Participants With Occurrence of Re-intervention|Change in Biliary Obstruction Symptoms|Time to Recurrent Biliary Obstruction|Change in Bilirubin","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)","Not Applicable","70","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENDO-WALLFLEX-BIL-PALL-002|E7020","July 2007","May 2008","May 2008","July 11, 2008","June 4, 2021","July 30, 2021","ULB Erasme Hospital, Brussels, Belgium|Hopital Edouard Herriot, Lyon, Cedex 3, France|EVK Krankenhaus der Universitat Dusseldorf, Dusseldorf, Germany|Asian Institute of Gastroenterology, Hyderabaad, India|Università Cattolica del Sacro Cuore, Rome, Italy|Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AZ, Netherlands",,"https://ClinicalTrials.gov/show/NCT00713427"
548,"NCT01615757","Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation","Ara-c","Unknown status","No Results Available","Acute Myeloid Leukemia","Drug: Ara-c","Relapse free survival at 1 yr of follow up|Toxicity- Haematological and Non -Haematological","All India Institute of Medical Sciences, New Delhi","All","Child, Adult, Older Adult","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AML HIDAC, AIIMS","August 2012","September 2014","September 2014","June 11, 2012",,"September 17, 2012","AIIMS, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01615757"
549,"NCT01265849","Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity","IT-MATTERS","Unknown status","No Results Available","Squamous Cell Carcinoma of the Oral Cavity|Squamous Cell Carcinoma of the Soft Palate","Biological: LI|Drug: Cyclophosphamide|Drug: Indomethacin|Dietary Supplement: Zinc|Procedure: Surgery|Drug: Cisplatin|Radiation: Radiotherapy","Overall Survival (OS) in LI + CIZ + SOC vs. SOC|Local regional control (LRC) in LI + CIZ + SOC vs. SOC|Progression Free Survival (PFS) in LI + CIZ + SOC vs.SOC|Quality of Life (QOL) in LI + CIZ + SOC vs. SOC","CEL-SCI Corporation|Teva Branded Pharmaceutical Products R&D, Inc.|Orient Europharma Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","928","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CS001P3|2010-019952-35","December 2010","May 15, 2020","April 15, 2021","December 23, 2010",,"March 19, 2021","Simmons Cancer Institute at Southern Illinois University, Springfield, Illinois, United States|Henry Ford Health System Henry Ford Hospital, Detroit, Michigan, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Medical College Of South Carolina MSC550, Charleston, South Carolina, United States|VA Puget Sound Healthcare System & University of WA, Seattle, Washington, United States|HNO-Klinik der medizinischen Universitat Graz, Graz, Austria|N.N. Alexandrov Research Istitute of Oncology and Medical Radiology, Lesnoy 2, Minsk, Belarus|Vitebsk Regional Oncology Dispensary, Vitebsk, Belarus|University Clinical Centre Tuzla, Trnovac, Tuzla, Bosnia and Herzegovina|Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina|University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Centre University of Sarejevo Clinic for ENT, Sarajevo, Bosnia and Herzegovina|St. Josephs Healthcare Department of Surgery, Hamilton, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|CHU de Quebec - L'Hotel Dieu de Quebec, Quebec, Canada|CHC Osijek, Osijek, Croatia|General Hospital Dr. Josip Bencevic, Slavonski Brod, Croatia|CH Dubrava, Zagreb, Croatia|Clinical Hospital Center Zagreb Kispaticeva 12, Zagreb, Croatia|KBC Sestre Milosrdnice, Zagreb, Croatia|KBC Zagreb, Zagreb, Croatia|ICL 6 avenue Bourgogne CS30519, Vandoeuvre les Nancy, France|University of Debrecen Medical and Health Scioence Centre, Debrecen, Hajdu Bihar, Hungary|National institute of Oncology, Budapest, Rath Gyorgy, Hungary|Semmelweis University, Budapest, Hungary|University of Pecs Institute of Oncotherapy, Pecs, Hungary|University of Szeged Dept of Oral and Maxillofacial Surgery, Szeged, Hungary|Markusovsky Teaching Hospital, Szombathely, Hungary|Bibi General Hospital and Cancer Centre, Malkapet, Andhra Pradesh, India|Amrita Institute of Medical Sciences, Kochi, Kerala, India|Sujan Regional Cancer Hospital & Amravati Cancer Foundation, Amravati, Maharashtra, India|Government Medical College and Hospital, Aurangabad, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Curie Manavata Cancer Center, Mumbai, Naka Nashik, India|Searoc Cancer Center, Jaipur, Rajashlan, India|V.N. Cancer Center G. Kuppuswamy Naidu Memorial Hospital, Coimbatore, Tamil Nadu, India|Meenakshi Mission Hospital and Research Centre, Madurai, Tamil Nadu, India|Regional Cancer Center, Kerola, Thiruvananthapuram, India|Galaxy Cancer Center, Ghaziabad, Uttar Pradesh, India|Rambam Health Care Campus, Sha'ar Ha'Aliya, Saint Haifa, Israel|Rabin Medical Center, Petaẖ Tiqwa, Tikva, Israel|National Tumor Institute of Italy, Naples, Italy|Ospedale S.G. Moscati Santissima Annunziata, Taranto, Italy|Dept of Head and Neck Surgery School of Medical Sciences Univ. Sains, Kuantan, Penang, Malaysia|University Kabangsan Medical Center, Kuala Lumpur, Malaysia|Wojewodzki Szpital Specjalistyczny im Kopernika, Lodz, Ul Paderewskiego 4, Poland|Swietokrzyskie Centrum Onkologii, Kielce, Ul. Artwinskiego 3, Poland|Centrum Onkologii im. Prof. Lukaszcyka, Warsaw, Ul. Roentgena 5, Poland|Centrum Onkologi-Instytut im. Marie Sklodowskiej-Curie, Warszawa, Ul. Roentgena 5, Poland|ul. M. Sklodowskiej-Curie 24A, Bialystok, Poland|Szpital Specialistyczny im. Ludwika Rydgiera, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny Klinika Otolarryngologii I Onkologii Laryngologicznej, Lublin, Poland|Weilkopolskie Centrum Onkologii Klinika Chirurgii Glowy Szye Onkologii Laryngologiczne, Poznan, Poland|Uniwersitecki Szpital Kliniczny Klinika Otolaryngologii Chirugii Glowy i Szxyi, Wroclaw, Poland|Regional Institute of Oncology IASI, Iasi, Romania|Spital Clinic Judetean Mures, Targu Mures, Romania|Sverdlovsk Regional Cancer Center, Sverdlov, Ekaterinberg, Russian Federation|Leningrad Regional Oncology Center, St. Petersburg, Leningradskaya, Russian Federation|Kursk Regional Clinical Oncology Dispensary, Kursk, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|Budget Institution of Healthcare of Omsk Region Clincal Oncology Dispensary, Omsk, Russian Federation|Ryazan Clinical oncology Dispensary, Ryazan, Russian Federation|Serbia Clinic for ENT and Maxillofacial Surgery, Belgrade, Pasterova 14, Serbia|Clincal Center Serbia Clinic for Oral and Maxillofacial Surgery, Belgrade, Serbia|Faculty of Dental Medicine Clinic for Maxillofacial Surgery, Belgrade, Serbia|Military Medical Academy Clinic for Maxillofacial Surgery, Belgrade, Serbia|Clinical Center Nis center for Oncology, Nis, Serbia|Clinic for Stomatology department for maxillofacial Surgery, Nis, Serbia|Clinical center Vojvodina Clinic for ORL, Novi Sad, Serbia|Clinical Centre Vojvodina Clinic for Maxillofacial Surgery, Novi Sad, Serbia|hospiatl Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Princesa, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Complejo Hospitalario Univ. de Santiago, Santiago de Compostela, Spain|Consorsio Hospital General Universitario de valencia, Valencia, Spain|National Cancer Institute Dept of Clinical Oncology & Radiotherapy, Colombo, Sri Lanka|Oncology Unit Teaching Hospital Karapitya, Galle, Sri Lanka|Kaohsiung Branch Chang Gung Memorial Hospital, Niaosong, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Taipei, Tainan, Taiwan|National Taiwan Research Hospital, Chengshan, Taipei, Taiwan|Linkou Branch Chang Gung Memorial Hospital, Guishan, Taoyuan, Taiwan|Changua Christian Hospital, Chang-hua, Taiwan|Buddhist Tzu Chi General Hospital, Hualien Branch, Hualien City, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan|Khon Kaen University Dept of Otolaryngology, Nai- Muang, Thailand|Haceteppe University Dept of Otolaryngology - Head and Neck Surgery, Ankara, Turkey|Acibadem University Maslak Hospital ENT Department, Istanbul, Turkey|Cherkasky Regional Oncological Dyspensary Dept. Head and Neck tumour, Cherkasy, Ukraine|Clinical Diagnostic Laboratory of Dnepropetrovsk Municipal Institution City Multidisciplinary Clinical Hospital No. 4, Dnepropetrovsk, Ukraine|Donetsk Regional Antitumor Center, Donetsk, Ukraine|Grigoriev Institute for Medical Radiology of National Academy of Medical Science of Ukraine Dept. of Remote, Combined Radiation and Complex Therapy, Kharkiv, Ukraine|Kharkiv Regional Clinical Oncology Center Dept. Of Head and Neck Tumour, Kharkiv, Ukraine|Kiev City Clinical Oncology Center of the Main Health Care Dept of Kiev Day Hospital Radiotherapy Dept., Kiev, Ukraine|Kiev City Clinical Oncology Center of the Main Health Care Dept. of the Kiev Day Hospital, Kiev, Ukraine|LVIV State OncologyRegional treatment and Diagnostic Ceneter, Lviv, Ukraine|Sumy Regional Clinical Oncology Dyspensary, Sumy, Ukraine|Zaporiz'ka Regional Clinical Oncology Dispensary, Zaporiz'ka Oblast', Ukraine|Aintree University Hospital, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01265849"
550,"NCT04642469","Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.","MERMAID-2","Recruiting","No Results Available","Carcinoma, Non- Small Cell Lung","Drug: Durvalumab|Other: Placebo","DFS in PD-L1 TC≥1% (using Investigator assessments according to RECIST 1.1)|DFS in FAS (using Investigator assessments according to RECIST 1.1)|PFS (using local standard practice)|Time to first subsequent therapy (TFST)|Time to second subsequent therapy (TSST)|Change from baseline in EORTC QLQ-C30|Change from baseline in EORTC QLQ-LC13|Time to deterioration in EORTC QLQ-C30|Time to deterioration in EORTC QLQ-LC13|IHC analysis of PD-L1 TC expression and spatial distribution within the tumor microenvironment relative to efficacy outcomes (ie, DFS, OS)The Ventana SP263 PD-L1 immunohistochemistry (IHC) assay will be used to determine PDL1 status in all specimens.|DFS (using BICR assessments according to RECIST 1.1) in PD-L1 TC≥1% analysis set|DFS (using BICR assessments according to RECIST 1.1) in FAS|OS in PD-L1 TC≥1% analysis set|OS in FAS","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","284","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D910MC00001","November 30, 2020","November 28, 2025","October 29, 2027","November 24, 2020",,"April 21, 2022","Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Santa Rosa, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Daytona Beach, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Punta Gorda, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Marietta, Georgia, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Cipolletti, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Rosario, Argentina|Research Site, S.C. De Bariloche, Argentina|Research Site, Camperdown, Australia|Research Site, Melbourne, Australia|Research Site, St Leonards, Australia|Research Site, Aalst, Belgium|Research Site, Bruxelles, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Roeselare, Belgium|Research Site, Barretos, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Belo Horizonte, Brazil|Research Site, Cachoeiro De Itapemirim, Brazil|Research Site, Florianopolis, Brazil|Research Site, Florianópolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitoria, Brazil|Research Site, Panagyurishte, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Victoria, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Copenhagen, Denmark|Research Site, Odense C, Denmark|Research Site, Marseille, France|Research Site, Pessac, France|Research Site, St Herblain, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse CEDEX 09, France|Research Site, Villejuif Cedex, France|Research Site, Esslingen, Germany|Research Site, Gauting, Germany|Research Site, Göttingen, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Muenster, Germany|Research Site, Regensburg, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Holargos, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Jordan, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyöngyös - Mátraháza, Hungary|Research Site, Győr, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Törökbálint, Hungary|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Kolkata, India|Research Site, Mohali, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat-Gan, Israel|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Peschiera Del Garda, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Torreón, Mexico|Research Site, Breda, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bellavista, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Lublin, Poland|Research Site, Poznań, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Brasov, Romania|Research Site, Cluj Napoca, Romania|Research Site, Constanta, Romania|Research Site, Floresti, Romania|Research Site, Iasi, Romania|Research Site, Suceava, Romania|Research Site, Timisoara, Romania|Research Site, Krasnoyarsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma, Spain|Research Site, Pamplona, Spain|Research Site, Santiago de Compostela, Spain|Research Site, Stockholm, Sweden|Research Site, Lausanne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Headington, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04642469"
551,"NCT00786838","A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram",,"Completed","Has Results","Solid Tumor","Drug: Trabectedin|Drug: Placebo","The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Fridericia Correction|The Difference in the Change From Baseline (Predose on Day 1) in QTc Intervals Trabectedin Relative to Placebo at 24 Hour Post Dose by Bazett's Correction|Maximum Plasma Concentration of Trabectedin (Cmax)|Time Taken to Acheive Maximum Plasma Concentration (Tmax)|Number of Participants With QTc Interval Increase From Baseline (Predose on Day 1) Greater Than 30 Milli Seconds|Number of Participants With QTc Interval Increase From Baseline (Predose on Day 1) Greater Than 60 Milli Seconds|Number of Participants With QTc Interval Greater Than 450 Milli Seconds|Number of Participants With QTc Interval Greater Than 480 Milli Seconds|Number of Participants With QTc Interval Greater Than 500 Milli Seconds|Number of Participants With PR Interval Greater Than 200 Milli Seconds|Number of Participants With QRS Interval Greater Than 120 Milli Seconds|Mean Heart Rate (Beats Per Minute) Over 24 Hours Postdose","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","76","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CR014917|ET743OVC1001","October 2008","December 2009","December 2009","November 6, 2008","January 23, 2014","April 11, 2014","Miami, Florida, United States|Charlotte, North Carolina, United States|Philadelphia, Pennsylvania, United States|Tacoma, Washington, United States|Brussels, Belgium|Edegem, Belgium|Wilrijk, Belgium|Lyon, France|Marseille, France|Montpellier, France|Villejuif, France|Bangalore N/A, India|Pune, India|Seoul, Korea, Republic of|Moscow N/A, Russian Federation|Moscow, Russian Federation|St Petersburg N/A, Russian Federation|St-Petersburg, Russian Federation|Sanchinarro, Spain",,"https://ClinicalTrials.gov/show/NCT00786838"
552,"NCT01438437","Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis",,"Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: PAI|Procedure: RFA","Local tumor response|Survival rate|Number of patients with complications|Change from baseline in Child status at 1 year","All India Institute of Medical Sciences, New Delhi","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 4","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","23-16/11/2001","March 2001","August 2014","September 2015","September 22, 2011",,"July 13, 2012","AIIMS, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01438437"
553,"NCT04385368","Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)","MERMAID-1","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Durvalumab + SoC chemotherapy|Other: Placebo + SoC chemotherapy","Disease free survival (DFS) in MRD+ analysis set (using Investigator assessments according to RECIST 1.1)|DFS in FAS (using Investigator assessments according to RECIST 1.1)|DFS (using BICR assessments according to RECIST 1.1) in MRD+ analysis set and in FAS|OS in MRD+ analysis set and in FAS|Change from baseline in EORTC QLQ-LC13 score|Time to deterioration in EORTC QLQ-LC13 score|Change from baseline in EORTC QLQ-C30 score|Time to deterioration in EORTC QLQ-C30 score","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","332","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D910LC00001","July 17, 2020","December 31, 2024","September 30, 2026","May 12, 2020",,"May 12, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Fayetteville, Arkansas, United States|Research Site, Long Beach, California, United States|Research Site, Santa Rosa, California, United States|Research Site, West Hollywood, California, United States|Research Site, Norwich, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Fairway, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baltimore, Maryland, United States|Research Site, Silver Spring, Maryland, United States|Research Site, Towson, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Salt Lake City, Utah, United States|Research Site, Fairfax, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Seattle, Washington, United States|Research Site, Bahía Blanca, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Caba, Argentina|Research Site, Cipolletti, Argentina|Research Site, Ciudad Autonoma De Buenos Aire, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Córdoba, Argentina|Research Site, Mar del Plata, Argentina|Research Site, Rosario, Argentina|Research Site, S.C. De Bariloche, Argentina|Research Site, Camperdown, Australia|Research Site, Melbourne, Australia|Research Site, St Leonards, Australia|Research Site, Aalst, Belgium|Research Site, Bruxelles, Belgium|Research Site, Charleroi, Belgium|Research Site, Gent, Belgium|Research Site, Hasselt, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Roeselare, Belgium|Research Site, Belo Horizonte, Brazil|Research Site, Blumenau, Brazil|Research Site, Cachoeira De Itapemirim, Brazil|Research Site, Florianopolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Goiania, Brazil|Research Site, Ibirapuera, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitoria, Brazil|Research Site, Panagyurishte, Bulgaria|Research Site, Pleven, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Victoria, British Columbia, Canada|Research Site, Saint John, New Brunswick, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Copenhagen, Denmark|Research Site, Odense C, Denmark|Research Site, Århus N, Denmark|Research Site, Bordeaux, France|Research Site, Marseille, France|Research Site, Saint Herblain, France|Research Site, Strasbourg Cedex, France|Research Site, Toulouse, France|Research Site, Villejuif Cedex, France|Research Site, Esslingen, Germany|Research Site, Gauting, Germany|Research Site, Göttingen, Germany|Research Site, Halle, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Muenster, Germany|Research Site, München, Germany|Research Site, Regensburg, Germany|Research Site, Würzburg, Germany|Research Site, Athens, Greece|Research Site, Athens, Greece|Research Site, Heraklion, Greece|Research Site, Holargos, Athens, Greece|Research Site, Larissa, Greece|Research Site, Thessaloniki, Greece|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyöngyös - Mátraháza, Hungary|Research Site, Győr, Hungary|Research Site, Szolnok, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Törökbálint, Hungary|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Chandigarh, India|Research Site, Kolkata, India|Research Site, Mohali, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Dehli, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Beer Sheva, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Kfar Saba, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Monza, Italy|Research Site, Napoli, Italy|Research Site, Orbassano, Italy|Research Site, Peschiera Del Garda, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Akashi-shi, Japan|Research Site, Bunkyo-ku, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kashiwa, Japan|Research Site, Koto-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sakai-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Yokohama-shi, Japan|Research Site, Cheongju-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Culiacan, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico City, Mexico|Research Site, Mexico, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Nuevo Leon, Mexico|Research Site, Torreón, Mexico|Research Site, Breda, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Zwolle, Netherlands|Research Site, Bellavista, Peru|Research Site, La Libertad, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Trujillo, Peru|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Lublin, Poland|Research Site, Olsztyn, Poland|Research Site, Poznań, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Constanta, Romania|Research Site, Floresti, Romania|Research Site, Iasi, Romania|Research Site, Timisoara, Romania|Research Site, Kazan, Russian Federation|Research Site, Krasnodar, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Kuzmolovsky, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhny Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Yaroslavl, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Oviedo, Spain|Research Site, Palma, Spain|Research Site, Pamplona, Spain|Research Site, Santiago De Compostela (A Coruña), Spain|Research Site, Stockholm, Sweden|Research Site, Lausanne, Switzerland|Research Site, Zürich, Switzerland|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Tao-Yuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Pathumwan, Thailand|Research Site, Phisanulok, Thailand|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Antalya, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Birmingham, United Kingdom|Research Site, Headington, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Sutton, United Kingdom|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT04385368"
554,"NCT03222895","Distribution of Lymph Node Metastases in Esophageal Carcinoma","TIGER","Recruiting","No Results Available","Esophageal Neoplasms|Lymph Node Metastases",,"Distribution of lymph node metastases|Accuracy of preoperative diagnostics|Prognostic value of different lymph node stations|Distribution pattern of recurrence or metastases|Number of harvested lymph nodes in patients who are treated with and without neo-adjuvant chemoradiotherapy|Skip nodal metastases|Ratio of nodal metastases inside and outside the radiation field|3- and 5-year overall and disease free survival","Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","W17_069","March 1, 2019","December 1, 2021","March 1, 2026","July 19, 2017",,"October 19, 2020","MD Anderson Cancer Center, Houston, Texas, United States|Instituto Nacional de Câncer, Rio De Janeiro, Brazil|University of Toronto, Toronto, Canada|Fudan University Shanghai Cancer Center, Shanghai, Yangpu, China|Hospital District of Helsinki and Uusimaa, Helsinki, Finland|University Medical Center of the Johannes Gutenberg University, Mainz, Germany|University of Athens, School of Medicine, Athens, Greece|University of Hong Kong, Hong Kong, Hong Kong|Tata Memorial Centre, Mumbai, India|IRCCS Policlinico San Donato, Milan, Italy|Ospedale San Raffaele, Milan, Italy|University of Verona, Verona, Italy|Uonuma Institute and Niigata University, Niigata, Japan|Keio University School of Medicine, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Ziekenhuisgroep Twente, Almelo & Hengelo, Almelo, Netherlands|Amsterdam UMC, Amsterdam, Netherlands|Hospital Universitario del Mar, Barcelona, Spain|Karolinska Institutet, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03222895"
555,"NCT00824343","A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer","MONARCH","Completed","No Results Available","Squamous Cell Carcinoma of Head and Neck","Drug: P276-00","Response rate|Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","86","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/21/08","September 2008","April 2011","June 2013","January 16, 2009",,"July 10, 2013","Bharath Hospital & Institute of Oncology, Mysore, Mysore, Karnataka, India|Regional Cancer Centre, Trivandrum, Kerala, India|Kashyap Nursing Home, Mumbai, Maharashtra, India|Jaslok Hospital, Mumbai, Mumbai, Maharashtra, India|Central India Cancer Research Institute,, Nagpur, Maharashtra, India|Deenanath Mangeshkar Hospital & Research Centre, Pune, Maharashtra, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur, Jaipur, Rajasthan, India|V. N. Cancer Centre, GKNM Hospital,, Coimbatore, Tamilnadu, India|Dept. Of Surgical Oncology, CSM Medical University, Lucknow, Lucknow, UttarPradesh, India",,"https://ClinicalTrials.gov/show/NCT00824343"
556,"NCT04427072","Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation","GeoMETry-III","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Capmatinib|Drug: Docetaxel","Progression free survival (PFS) per blinded independent review committee (BIRC) using RECIST v1.1|Overall response (ORR) per RECIST 1.1 by BIRC|Overall response (ORR) per RECIST 1.1 by investigator|Time to response (TTR) per RECIST 1.1 by BIRC|Time to response (TTR) per RECIST 1.1 by investigator|Duration of response (DOR) per RECIST 1.1 by BIRC|Duration of response (DOR) per RECIST 1.1 by investigator|Disease Control Rate (DCR) per RECIST 1.1 by BIRC|Disease Control Rate (DCR) per RECIST 1.1 by investigator|Progression free survival (PFS) per investigator using RECIST v1.1|Overall survival (OS)|Percentage of patients with Adverse Events and Serious Adverse events.|Plasma capmatanib concentration|Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30|Change from baseline in score as per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)|Change from baseline in score as per European Quality of Life 5-Dimension 5-Level (EQ-5D-5L) questionnaire|Overall intracranial response rate (OIRR)|Duration of intracranial response (DOIR)|Time to intracranial response (TTIR)|Intracranial disease control rate (IDCR)|Time to symptom deterioration for chest pain, cough and dyspnea assessed using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Lung Cancer Module (QLQ-LC13)|Time to symptom deterioration for chest pain, cough and dyspnea assessed using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC280A2301","September 25, 2020","July 14, 2023","October 21, 2024","June 11, 2020",,"February 18, 2022","Novartis Investigative Site, Melbourne, Victoria, Australia|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Barretos, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Angers Cedex 9, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Caen Cedex, France|Novartis Investigative Site, Clermont-Ferrand, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pierre Benite Cedex, France|Novartis Investigative Site, Rennes, France|Novartis Investigative Site, Regensburg, Bavaria, Germany|Novartis Investigative Site, Gauting, Bayern, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Gottingen, Germany|Novartis Investigative Site, Grosshansdorf, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Torokbalint, Pest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, New Delhi, Delhi, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Meldola, FC, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Aviano, PN, Italy|Novartis Investigative Site, Parma, PR, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Kuantan, Pahang, Malaysia|Novartis Investigative Site, Kuala Lumpur, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Matosinhos, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Arkhangelsk, Russian Federation|Novartis Investigative Site, Chelyabinsk, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Omsk, Russian Federation|Novartis Investigative Site, Pushkin Saint Petersburg, Russian Federation|Novartis Investigative Site, St- Petersburg, Russian Federation|Novartis Investigative Site, Port Elizabeth, Western Cape, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04427072"
557,"NCT00071188","ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: ZD6474|Drug: Paclitaxel|Drug: Carboplatin",,"Genzyme, a Sanofi Company|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2",,"Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D4200C00007|D4200C00007(run-in)|D4200C0007A (randomization)","February 2004","October 2007","October 2007","October 16, 2003",,"August 25, 2016","Research Site, Concord, California, United States|Research Site, Los Angeles, California, United States|Research Site, Chicago, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, St. Louis, Missouri, United States|Research Site, Providence, Rhode Island, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Helsinki, Finland|Research Site, Turku, Finland|Research Site, Besancon, France|Research Site, Lille, France|Research Site, Strasbourg, France|Research Site, Essen, Germany|Research Site, Frankfurt, Germany|Research Site, Mainz, Germany|Research Site, Ulm, Germany|Research Site, Pune, India|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Cape Town, South Africa|Research Site, Johannesburg, South Africa|Research Site, Panorama, South Africa|Research Site, Parkland, South Africa|Research Site, Pretoria, South Africa|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Malaga, Spain|Research Site, Pamplona, Spain|Research Site, Chiang mai, Thailand",,"https://ClinicalTrials.gov/show/NCT00071188"
558,"NCT03706690","A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients","PACIFIC-5","Active, not recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Durvalumab|Other: Placebo","Progression-Free Survival (PFS) according to RECIST 1.1.|The efficacy of durvalumab treatment compared to placebo in terms of Overall Survival (OS).|The efficacy of durvalumab treatment compared to placebo in terms of proportion of patients alive at 24 months (OS24) from randomisation.|Objective Response Rate (ORR) assessed by BICR according to RECIST 1.1.|Duration of Response (DoR) assessed by BICR according to RECIST 1.1.|Proportion of patients alive and progression free from randomisation to second progression (PFS2) as defined by local standard clinical practice.|Proportion of patients alive and progression free at 12 months from randomisation (PFS12) assessed by BICR according to RECIST 1.1.|Proportion of patients alive and progression free at 18 months from randomisation (PFS18) assessed by BICR according to RECIST 1.1.|Proportion of patients at time to death or distant metastasis (TTDM) assessed by BICR according to RECIST 1.1.|Peak Plasma Concentration (Cmax) in randomised patients|Trough Concentration (Ctrough) in randomised patients|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Detection of ADA neutralising antibodies titres for all randomised patients|IHC analysis of tumoural PD-L1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome OS.|IHC analysis of tumoural PD-L1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome PFS.|IHC analysis of tumoural PD-L1 expression and spatial distribution within the tumour microenvironment relative to efficacy outcome ORR.|Number of participants with abnormal findings with physical examination|vital sign (blood pressure [BP])|vital sign (pulse rate)|vital sign (temperature)|vital sign (respiration rate)|vital sign (12-lead electrocardiogram)|Change in Albumin (g/L)|Change in Alkaline phosphatase (U/L)|Change in Alanine aminotransferase (U/L)|Change in Aspartate aminotransferase (U/L)|Change in Amylase (U/L)|Change in Bicarbonate (mmol/L)|Change in Calcium (mmol/L)|Change in Chloride (mmol/L)|Change in Creatinine (μmol/L)|Change in Gamma glutamyltransferase (U/L)|Change in Glucose (mmol/L)|Change in Lactate dehydrogenase (U/L)|Change in Lipase (U/L)|Change in Magnesium (mmol/L)|Change in Potassium (mmol/L)|Change in Sodium (mmol/L)|Change in Total bilirubin (μmol/L)|Change in total protein (g/L)|Change in TSH (mIU/L)|Change in T3 free (reflex) (mIU/L)|Change in T4 free (reflex) (mIU/L)|Change in Urea or blood urea nitrogen, depending on the local practice (mmol/L)|Change in Uric acid (mmol/L)|Change in absolute neutrophil count (/L)|Change in absolute lymphocyte count (/L)|Change in haemoglobin (g/L)|Change in platelet count (/L)|Change in total white blood cell count (/L)|Change in activated partial thromboplastin time|Change in international normalised ratio|Urinalysis: Change in bilirubin (μmol/L)|Urinalysis: Change in blood|Urinalysis: Change in color and apprearance|Urinalysis: Change in ketones (mmol/L)|Urinalysis: Change in pH|Urinalysis: Change in protein (g/L)|Urinalysis: Change in specific gravity","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","407","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D933YC00001","November 27, 2018","October 14, 2022","November 29, 2024","October 16, 2018",,"April 4, 2022","Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chengdu, China|Research Site, Chongqing, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Linhai, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Ningbo, China|Research Site, Qingdao, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Wenzhou, China|Research Site, Wuhan, China|Research Site, Yangzhou, China|Research Site, Zhengzhou, China|Research Site, Zhengzhou, China|Research Site, Ürümqi, China|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Chennai, India|Research Site, Chennai, India|Research Site, Karamsad, India|Research Site, Kolkata, India|Research Site, Nasik, India|Research Site, Vadodara, India|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Cdmx, Mexico|Research Site, Culiacán, Mexico|Research Site, Mexico City, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Bacolod, Philippines|Research Site, Baguio City, Philippines|Research Site, Cagayan De Oro City, Philippines|Research Site, Cebu, Philippines|Research Site, Davao City, Philippines|Research Site, Quezon City, Philippines|Research Site, Quezon City, Philippines|Research Site, San Juan, Philippines|Research Site, Białystok, Poland|Research Site, Gdańsk, Poland|Research Site, Poznań, Poland|Research Site, Tomaszów Mazowiecki, Poland|Research Site, Warszawa, Poland|Research Site, Kazan, Tatarstan, Russian Federation|Research Site, Kirov, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saransk, Russian Federation|Research Site, Volgograd, Russian Federation|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Konya, Turkey|Research Site, Malatya, Turkey",,"https://ClinicalTrials.gov/show/NCT03706690"
559,"NCT01369433","A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols",,"Terminated","Has Results","Solid Tumors","Drug: Tivozanib + paclitaxel|Drug: Tivozanib + temsirolimus|Drug: Tivozanib|Drug: Tivozanib (AV-951)|Drug: Tivozanib + capecitabine|Drug: Tivo","Number of Subjects With Adverse Events (AEs) and Serious AEs","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","225","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AV-951-09-901","June 2010","June 2015","October 2015","June 9, 2011","September 1, 2020","September 1, 2020","Translational Genomics Research Institute (TGEN), Scottsdale, Arizona, United States|Institute of Urologic Oncology, Los Angeles, California, United States|Stanford University, Stanford, California, United States|Aurora, Colorado, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute Hospital, Inc, Tampa, Florida, United States|Beech Grove, Indiana, United States|Horizon Oncology Research, Inc., Lafayette, Indiana, United States|Wichita, Kansas, United States|Medical Oncology LLC, Baton Rouge, Louisiana, United States|Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC, Metairie, Louisiana, United States|Associates in Oncology/Hematology, Rockville, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Tupelo, Mississippi, United States|Nebraska Methodist Hospital, Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Lebanon, New Hampshire, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|The OU Cancer Institute, Oklahoma City, Oklahoma, United States|Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States|Austin, Texas, United States|Coastal Bend Cancer Center, Corpus Christi, Texas, United States|Dallas, Texas, United States|Tacoma, Washington, United States|Hamilton, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|AVEO Investigational Site, Madurai, India|AVEO Investigational Site, Mumbai, India|Rotterdam, Netherlands|AVEO Investigational Site, Krasnodar, Russian Federation|AVEO Investigational Site - Moscow 1, Moscow, Russian Federation|AVEO Investigational Site - Moscow 2, Moscow, Russian Federation|AVEO Investigational Site - Moscow 3, Moscow, Russian Federation|AVEO Investigational Site - Moscow 4, Moscow, Russian Federation|AVEO Investigational Site - Moscow 5, Moscow, Russian Federation|AVEO Investigational Site, Obninsk, Russian Federation|AVEO Investigational Site, Rostov, Russian Federation|AVEO Investigational Site, Saint Petersburg, Russian Federation|Stavropol', Russian Federation|AVEO Investigational Site, Ufa, Russian Federation|AVEO Investigational Site, Dnipropetrovsk, Ukraine|AVEO Investigational Site, Donetsk, Ukraine|AVEO Investigational Site, Kharkiv, Ukraine|AVEO Investigational Site, Lviv, Ukraine|AVEO Investigational Site, Zaporizhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01369433"
560,"NCT00622193","Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer",,"Completed","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: anamorelin HCl|Drug: placebo","Hand grip strength and body weight|Quality of Life and Biomarker","Helsinn Therapeutics (U.S.), Inc","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","228","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ST-ANAM-207","March 2008","December 2009","December 2009","February 22, 2008",,"April 14, 2017","University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|Osler Medical, Melbourne, Florida, United States|Augusta Oncology Associates, Augusta, Georgia, United States|South Georgia Medical Center, Valdosta, Georgia, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|John Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Center, Boston, Massachusetts, United States|Caritas St. Elizabeth's Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|The West Clinic, Corinth, Mississippi, United States|The West Clinic, Southaven, Mississippi, United States|Washington University School of Medicine, St Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|South Carolina Cancer Specialists, Hilton Head Island, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Baylor College of Medicine/VAMC, Houston, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|North West Medical Specialties, PLLC, Puyallup, Washington, United States|Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India|Cancer Clinic 208, Nagpur, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Kaushalya Medical Foundation Trust Hospital, Thane, Maharashtra, India|SEAROC Cancer Center, Jaipur, Rajasthan, India|Jawaharlal Nehru Cancer Hospital and Research Centre, Bhopal, India|Kamakshi Memorial Hospital, Chennai, India|Dharamshila Cancer Hospital and Research Center, Delhi, India|Bhagwan Mahaveer Cancer Hospital and Resaerch Center, Jaipur, India|Birla Cancer Centre SMS Medical College Hospital, Jaipur, India|Kodlikeri Memorial Hospital, Maharashtra, India|Shatabdi Super Speciality Hospital, Mumbai Naka, Nasik, India|Jaslok Hospital and Research Centre, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT00622193"
561,"NCT01852292","Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy",,"Terminated","Has Results","Head and Neck Squamous Cell Carcinoma","Drug: Buparlisib|Drug: Buparlisib matching Placebo|Drug: Paclitaxel","Progression Free Survival (PFS) Per Investigator Assessment|Overall Survival (OS)|Overall Response Rate (ORR) as Per Local Radiological Assessment|Time to Response (TTR) as Per Local Radiological Assessment|Disease Control Rate (DCR) as Per Local Radiological Assessment|Duration of Response (DoR) as Per Local Investigator|Health-related Quality of Life (HRQoL):Time to 10% Definitive Deterioration in the Global Health Status/Quality of Life Per EORTC-QLQ-C30|Health-related Quality of Life (HRQoL):Time to 10% Definitive Deterioration in the Head and Neck Cancer Symptoms Scales for Pain, Speech Problems, Swallowing and Sense Problems Per EORTC-QLQ-HN35|Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for AUC0-24 and AUClast|Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for Cmax|Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for Tmax|Plasma Concentration-time Profiles of BKM120 Pharmacokinetics (PK) for CL/F","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","157","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBKM120H2201|2013-000744-26","October 1, 2013","March 30, 2017","March 30, 2017","May 13, 2013","June 26, 2018","July 24, 2018","Highlands Oncology Group, Fayetteville, Arkansas, United States|Dana Farber Cancer Institute IRB, Boston, Massachusetts, United States|Washington U School of Medicine Center for Clinical Studies SC - BKM120H2201, Saint Louis, Missouri, United States|The Mount Sinai Hospital Dept of Oncology, New York, New York, United States|University of N.C. at Chapel Hill Lineberger Comp. Cancer Ctr., Chapel Hill, North Carolina, United States|University Hospitals Case Medical Center Univ. Hospitals of Cleveland, Cleveland, Ohio, United States|UPMC Cancer Centers BKM120H2201, Pittsburgh, Pennsylvania, United States|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Saint Herblain cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Nyiregyhaza, Hungary|Novartis Investigative Site, Nashik, Maharashtra, India|Novartis Investigative Site, Dehli, New Delhi, India|Novartis Investigative Site, Jaipur, Rajasthan, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Kerala, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Dublin 4, Ireland|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Salerno, SA, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Venezia, VE, Italy|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Koto-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho-gu, Korea, Republic of|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Leningrad Region, Russia, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Basel, Switzerland|Novartis Investigative Site, Genève, Switzerland|Novartis Investigative Site, Tainan, Taiwan ROC, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Taichung City, Taiwan|Novartis Investigative Site, Songkla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Glasgow, Scotland, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT01852292/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT01852292/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01852292"
562,"NCT04819100","A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)","LIBRETTO-432","Recruiting","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Selpercatinib|Drug: Placebo","Event-Free Survival (EFS)|EFS|Overall Survival (OS)|Time to Distant Disease Recurrence in the Central Nervous System (CNS)|Progression Free Survival on the Next Line of Treatment (PFS2)|Positive Predictive Value (PPV) of Local Lab Tests Compared to Central Lab Test to Detect Rearranged during Transfection (RET) Gene Fusion|Mean Change from Baseline over Time in NSCLC Symptoms|Mean Change from Baseline over Time in Physical Function","Loxo Oncology, Inc.|Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","170","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","18126|J2G-MC-JZJX|2020-005191-35","December 20, 2021","August 31, 2028","November 30, 2032","March 26, 2021",,"April 19, 2022","UCLA Hematology Oncology, Santa Monica, California, United States|Stockton Hematology Oncology Medical Group, Stockton, California, United States|UCLA Medical Center, Torrance, California, United States|GenesisCare, Aventura, Florida, United States|GenesisCare - Boca Raton, Boca Raton, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|New York Oncology Hematology, P.C, Clifton Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|US Oncology, The Woodlands, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Border Medical Oncology, Albury, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|The Townsville Hospital, Douglas, Queensland, Australia|Rockhampton Hospital, Rockhampton, Queensland, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Bendigo Health, Bendigo, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|South West Healthcare, Warrambool, Victoria, Australia|Landeskrankenhaus Feldkirch, Feldkirch, Austria|Klinik Floridsdorf, Wien, Austria|Cliniques Universitaires Saint-Luc, Bruxelles, Brussel, Belgium|Université Catholique de Louvain-Namur - Centre Hospitalier Universitaire Dinant-Godinne - Site Godinne, Yvoir, Namur, Belgium|AZ Delta vzw, Roeselare, West-Vlaanderen, Belgium|Universitair Ziekenhuis Antwerpen, Edegem, Belgium|Clinique Saint Pierre Ottignies, Ottignies, Belgium|Núcleo de Oncologia da Bahia, Salvador, Bahia, Brazil|Oncocentro BH, Belo Horizonte, Minas Gerais, Brazil|COT - Centro Oncológico do Triângulo S.A., Uberlândia, Minas Gerais, Brazil|Multihemo Servicos Medicos S/A, Recife, Pernambuco, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, Rio Grande Do Sul, Brazil|Instituto de Educação, Pesquisa e Gestão em Saúde, Rio de Janeiro, RJ, Brazil|IBCC - Instituto Brasileiro de Controle do Câncer, São Paulo, Brazil|Centro Paulista de Oncologia, São Paulo, Brazil|Princess Margaret Hospital, Toronto, Ontario, Canada|Beijing Friendship Hospital, Beijing, Beijing, China|Beijing Cancer hospital, Haidian District, Beijing, China|The First Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China|Fujian Provincial Hospital, Fuzhou, Fujian, China|Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China|Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China|Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China|Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Hunan Cancer Hospital, Changsha, Hunan, China|Jilin Cancer Hospital, Changchun, Jilin, China|Tangdu Hospital of Fourth Military Medical University of Chinese People's Liberation Army, Xi'an, Shaanxi, China|Jinan Central Hospital, Jinan, Shandong, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, Shanghai, China|the Third People's Hospital of Chengdu, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|First Affiliated Hosp of College of Med, Zhejiang University, Hangzhou, Zhejiang, China|Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China|Beijing Peking Union Medical College Hospital, Beijing, China|Masarykuv onkologicky ustav, Brno, Czech Republic, Czechia|Nemocnice AGEL Ostrava-Vitkovice a.s.-Plicni oddeleni, Ostrava - Vitkovice, Czechia|Fakultni nemocnice Bulovka, Praha 8, Czechia|Odense Universitetshospital, Odense C, Syd, Denmark|HCL-Hôpital Louis Pradel, Lyon (Bron), France|Centre Leon Berard, Lyon Cedex 08, France|Assistance Publique Hôpitaux de Marseille - Hôpital Nord, Marseille Cedex 20, France|Hopital Cochin, Paris, France|CHU Charles Nicolle in Rouen, Rouen cedex, France|Gustave Roussy, Villejuif Cedex, France|Thoraxklinik-Heidelberg gGmbH, Heidelberg, Baden-Württemberg, Germany|Asklepios Fachkliniken München-Gauting, Gauting, Bayern, Germany|Lungenfachklinik Immenhausen, Immenhausen, Hessen, Germany|Franziskus-Hospital Harderberg, Georgsmarienhütte, Lower Saxony, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Schleswig-Holstein, Germany|Charité-Campus Benjamin Franklin-Hematology and Oncology, Berlin, Germany|University Hospital of Patras, Patras, Achaḯa, Greece|Agios Savvas Regional Cancer Hospital, Athens, Attikí, Greece|Sotiria Thoracic Diseases Hospital of Athens, Athens, Attikí, Greece|University General Hospital of Heraklion, Heraklion, Krete, Greece|European Interbalkan Medical Center, Thessaloniki, Thessaloníki, Greece|G. Papanikolaou General Hospital, Thessaloniki, Thessaloníki, Greece|Queen Elizabeth Hospital, Hong Kong, Hong Kong|Hong Kong United Oncology Centre, Kowloon, Hong Kong|Princess Margaret Hospital, Lai Chi Kok, Hong Kong|Regional Cancer Centre, Thiruvananthapuram, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Rashtrasant Tukdoji Regional Cancer Hospital and Research Centre (RSTRCH), Nagpur, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Sheba Medical Center, Ramat Gan, Israel|ASST Grande Ospedale Metropolitano Niguarda, Milan, Milano, Italy|Istituto Clinico Humanitas, Rozzano, Milano, Italy|Azienda Ospedaliera Dei Colli, Naples, Napoli, Italy|Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano, Torino, Italy|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|IRCCS Ospedale Oncologico di Bari, Bari, Italy|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Himeji Medical Center, Himeji, Hyogo, Japan|Kanagawa cancer center, Yokohama, Kanagawa, Japan|Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan|Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan|Japanese Foundation for Cancer Research, Koto, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Hiroshima University Hospital, Hiroshima, Japan|Osaka International Cancer Institute, Osaka, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeollanam Do, Korea, Republic of|Asan Medical Center, Seoul, Korea, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul, Korea, Korea, Republic of|Kyungpook National University Medical Center Chilgok Hospital, Daegu, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Actualidad Basada en la Investigación del Cáncer, Guadalajara, Jalisco, Mexico|ONCARE Viaducto Nápoles, Delegación Benito Juárez, Mexico City, Federal District, Mexico|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Monterrey, Nuevo León, Mexico|Avix Investigación Clinica, S.C., Monterrey, Nuevo León, Mexico|Ziekenhuis St. Jansdal, Harderwijk, Gelderland, Netherlands|Universitair Medisch Centrum St Radboud Nijmegen, Nijmegen, Netherlands|Krakowski Szpital Specjalistyczny im. Jana Pawa II, Krakow, Małopolskie, Poland|Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznan, Wielkopolskie, Poland|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy, Warszawa, Poland|Pan American Center for Oncology Trials, Rio Piedras, Puerto Rico|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Arkhangel'skaya Oblast', Russian Federation|Hadassah Medical LTD, Moscow, Russian Federation|National medical research center of oncology n. a. N. N. Petrov, Saint Petersburg, Russian Federation|EuroCityClinic, Saint-Petersburg, Russian Federation|Parkway Cancer Centre, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore|CHUS - Hospital Clinico Universitario, Santiago de Compostela, A Coruña [La Coruña], Spain|Hospital Universitario Puerta del Mar, Cádiz, Andalucía, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital de Mataró, Mataró, Barcelona [Barcelona], Spain|Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain|Hospital Álvaro Cunqueiro, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias, Santa Cruz de Tenerife, Tenerife, Spain|Hospital General de Albacete, Albacete, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Universitari Dexeusa, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Institut Catala d'Oncologia, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Complejo Asistencial de Leon, Leon, Spain|Hospital Lucus Augusti, Lugo, Spain|MD Anderson, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Regional Universitario, Malaga, Spain|Hospital Santa Maria Nai, Ourense, Spain|Hospital Son Llàtzer-ONCOLOGY, Palma de Mallorca, Spain|Hospital Universitari Sant Joan de Reus, Reus, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Changhua Christian Hospital, Changhua City, Changhua County, Taiwan|Chi Mei Hospital - Liouying Branch, Tainan City, Tainan, Taiwan|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital - Kaohsiung Branch, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Cancer Centre, Taipei City, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital - Linkou, Taoyuan City, Taiwan|Izmir Medical Park Hospital, Izmir, Karşıyaka/İzmir, Turkey|Baskent University Dr. Turgut Noyan Research and Training Center, Adana, Turkey|Adana Sehir Hastanesi, Adana, Turkey|Abdurrahman Yurtaslan Ankara Oncology, education and Research Hospital, Ankara, Turkey|Ankara City Hospital, Ankara, Turkey|Uludag Universitesi, Bursa, Turkey|Dicle University, Diyarbakir, Turkey|Trakya University, Edirne, Turkey|Medipol Mega University Hospital, Istanbul, Turkey|Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi, Istanbul, Turkey|Ege University Medicine of Faculty, Izmir, Turkey|Izmir Katip Celebi University Training and Research Hospital Oncology, Izmir, Turkey|Memorial Antalya Hastanesi, Kepez, Turkey|Inonu University Medical Faculty Oncology, Malatya, Turkey|Maslak Acıbadem Hstanesi, Sarıyer, Turkey|CNPE ""Regional Center of Oncology"", Kharkiv, Kharkivska Oblast, Ukraine|Communal Noncommercial Enterprise ""Podillia Regional Oncology Center Of Vinnytsia Regional Council"", Vinnytsia, Vinnytska Oblast, Ukraine|Medical Center ""Mriya Med-Service"", LLC, Kryvyi Rig, Ukraine|Kyiv City Clinical Oncological Center, Kyiv, Ukraine|Communal Enterprise ""Odesa Regional Clinical Hospital"", Odesa, Ukraine|University clinic of Sumy State University, Sumy, Ukraine|Medical center ""Oncolife"", Zaporizhya, Ukraine|University College Hospital - London, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre, Bebbington, Merseyside, United Kingdom|New Cross Hospital, Wolverhampton, West Midlands, United Kingdom|City Hospital, Nottingham University Hospitals, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04819100"
563,"NCT02765503","Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial","HYPNO","Unknown status","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Radiation: External beam radiotherapy","Primary tumor control in T and N position|Treatment related late Grade 2+ toxicity (CTCAE 4.0)|Overall survival|Disease free survival|Any other treatment related early and late morbidities (CTCAE 4.0)|EORTC QOL-C30/HN-35 (optional)","International Atomic Energy Agency|Centro de Lucha contra el Cáncer, Montevideo, Uruguay|Institute Rotary Cancer Hospital, New Delhi, India|Tata Memorial Centre|Bahawalpur Institute of Nuclear Medicine and Oncology, Bahawalpur, Pakistan|GKNM Hospital, Tamil Nadu, India|Fundacion Escuela de Medicina Nuclear, Mendoza, Argentina|Instituto de Oncología y Radiobiología, Havana, Cuba|University of Indonesia, Jakarta, Indonesia|St Luke's Medical Centre, Quezon City, Manilla, Phillippines|University of Pretoria, Pretoria, South Africa|Mahidol University, Bangkok, Thailand|University of Maryland, College Park|Barretos Cancer Hospital, Barretos, Brazil","All","18 Years and older   (Adult, Older Adult)","Not Applicable","836","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33035","March 2014","November 2020","November 2021","May 6, 2016",,"August 8, 2019","Fundacion Escuela de Medicina Nuclear, Mendoza, Argentina|Instituto Naciolal de Oncologia y Radiobiologia (INOR), Havana, Cuba|Department of Radiation Oncology, V.N. Cancer Center, GKNM Hospital, Coimbatore, India|Tata Memorial Centre (TMC) Department of Atomic Energy (DAE), Mumbai, India|Institute Rotary Cancer Hospital, New Delhi, India|Cipto Magunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia|Bahawalpur Institute of Nuclear Medicine and Oncology (BINO), Bahawalpur, Pakistan|St Luke's Medical Centre, Quezon City, Manila, Philippines|University of Pretoria, Pretoria, South Africa|Mahidol University Faculty of Medicine Siriraj Hospital, Bangkok, Siriraj, Thailand|Centro de Lucha contra el Cáncer, Montevideo, Uruguay",,"https://ClinicalTrials.gov/show/NCT02765503"
564,"NCT01449253","Comparison of Efficacy Different Treatment Regimens in Pulmonary Hypertension Secondary to Lung Disease and or Hypoxia",,"Unknown status","No Results Available","Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia","Drug: Sildenafil|Drug: Bosentan","Echocardiogram|WHO functional classification|6 minute walk test|Pulmonary function test|Visual analog scale for dyspnea|Echocardiography measuring pulmonary artery pressure|Biochemical markers at 3 and 6 months|Monitoring side effects of the drugs","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","pulmonary hypertension","August 2011","July 2013","July 2013","October 10, 2011",,"January 29, 2013","All India Institute Of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01449253"
565,"NCT01523587","LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy",,"Completed","Has Results","Carcinoma, Non-Small-Cell Lung","Drug: afatinib|Drug: erlotinib","Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1|Overall Survival|Number of Participants With Objective Response According to RECIST 1.1|Number of Participants With Disease Control According to RECIST 1.1|Tumour Shrinkage|Number of Participants With Status Change in Cough, Dyspnoea and Pain Related Items Over Time in Health Related Quality of Life Questionnaire|Summary of Time to Deterioration in Coughing, Dyspnoea and Pain.|Change in Score Over Time in Coughing,Dyspnoea and Pain","Boehringer Ingelheim","All","18 Years and older   (Adult, Older Adult)","Phase 3","795","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1200.125|2011-002380-24","March 5, 2012","October 21, 2013","December 27, 2017","February 1, 2012","November 21, 2014","February 15, 2019","Ironwood Cancer and Research Centers, Chandler, Arizona, United States|University of California, La Jolla, California, United States|Sutter Medical Group, Sacramento, California, United States|Boca Raton Reginl Hospital-Lynn Cancer Institute, Boca Raton, Florida, United States|Memorial Healthcare System, Hollywood, Florida, United States|Cancer Care of North Florida, PA, Lake City, Florida, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Orchard Healthcare Research Inc, Skokie, Illinois, United States|University of Louisville, Louisville, Kentucky, United States|West Jefferson General Hospital and Cancer Clinic, Marrero, Louisiana, United States|Lahey Clinic, Burlington, Massachusetts, United States|Commonwealth Hematology-Oncology, PC, Lawrence, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Billings Clinic Cancer Center, Billings, Montana, United States|Montefiore Medical Center, Bronx, New York, United States|Montefiore Medical Center, Bronx, New York, United States|Queens Medical Associates, Fresh Meadows, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology, Inc, Columbus, Ohio, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Oncology Hematology Associates of Norhtern Pennsylvania, PC, DuBois, Pennsylvania, United States|Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Cancer Center, Philadelphia, Pennsylvania, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Cancer Center of Cookeville Regional Medical Center, Cookeville, Tennessee, United States|Paris Cancer Center (PCC), Texas Oncology, Paris, Texas, United States|Cancer Therapy and Research at UTHSCSA, San Antonio, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Ciudad Autonoma de Bs As, Argentina|Instituto Oncologico de Cordoba, Cordoba, Argentina|Clínica Colombo S.A., Cordoba, Argentina|Centro Oncologico de Rosario, Rosario, Argentina|Centro Oncologico CAIPO, San Miguel de Tucuman, Argentina|Medical University of Innsbruck, Innsbruck, Austria|LKH Leoben, Leoben, Austria|AKH d. Stadt Linz, Pulmologie, Linz, Austria|SMZ Baumgartner Hoehe Otto Wagner Spital, Wien, Austria|BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada|Kingston General Hospital, Kingston, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|Centro Oncologico Antofagasta, Antofagasta, Chile|Instituto de Terapias Oncologicas Providencia, Providencia, Santiago, Chile|Centro Internacional de Estudios Clinicos - CIEC, Recoleta, Santiago De Chile, Chile|Orlandi Oncologia, Vitacura, Chile|Beijing Cancer Hospital, Beijing, China|Beijing Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|Xiangya Hospital, Central South University, Changsha, China|Sun Yat-Sen University Cancer Center, Guangzhou, China|the 81th Hospital of PLA, Nanjing, China|Jiangsu Cancer Hospital, Nanjing, China|Shanghai Chest Hospital, Shanghai, China|Shanghai Pulmonary Hospital, Shanghai, China|Herlev Hospital, Herlev, Denmark|Næstved Sygehus, Næstved, Denmark|Odense Universitetshospital, Odense C, Denmark|HOP d'Angers, Angers, France|INS Bergonié, Bordeaux, France|HOP Côte de Nacre, Caen, France|HOP de Chauny, Chauny, France|HOP Gabriel-Montpied, Clermont Ferrand, France|HOP de Creteil, Pneumo, Creteil, Creteil, France|HOP Le Mans, Le Mans, France|CTR Oscar Lambret, Cancéro, Lille, Lille, France|HOP Calmette, Lille, France|HOP Nord, Marseille Cedex 20, France|INS Paoli-Calmettes, Marseille, France|HOP de Mulhouse, Onco, Mulhouse, Mulhouse, France|HOP Cochin, Paris, France|HOP Val de Grâce, Onco, Paris, Paris, France|INS Jean Godinot, Onco, Reims, Reims, France|HOP de Rennes, Pneumo, Rennes, Rennes, France|HOP Saint Quentin, Onco, Saint Quentin, Saint Quentin, France|HOP Civil, Strasbourg, France|HOP Foch, Suresnes, France|INS Gustave Roussy, Villejuif, France|Zentralklinik Bad Berka GmbH, Bad Berka, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Klinikum Esslingen GmbH, Esslingen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Lungenklinik Hemer, Hemer, Germany|Universitätsklinikum Mannheim GmbH, Mannheim, Germany|Universitätsklinikum Münster, Münster, Germany|Mathias-Spital Rheine, Rheine, Germany|""Hippokratio"" Hospital of Athens, 2nd Internal Medicine Clin, Athens, Greece|General Hospital of Chest Diseases Sotiria, Athens, Greece|University General Hospital of Heraklion, Heraklion, Greece|University Hospital of Larisa, Oncology Clinic, Larisa, Greece|General Hospital of Larissa, Larisa, Greece|Metropolitan Hospital, Oncology Clinic, Neo Faliro, Athens, Greece|General Hospital ""G. Papageorgiou"", Thessaloniki, Greece|National Koranyi TBC and Pulm. Internal Med. Clinic, Budapest, Hungary|Semmelweis University, Budapest, Hungary|Institute of Chest Diseases Csongrad County,Dpt. Pulmonology, Deszk, Hungary|Pulmonology Institute of Veszprem County, Farkasgyepu, Farkasgyepü, Hungary|Aladar Petz County Teaching Hospital, Dept. Pulmonology, Györ, Hungary|Lung Hospital of Matra, Dept. Pulmonology, Matrahaza, Hungary|Josa Andras Korhaz, Nyiregyhaza, Nyiregyhaza, Hungary|University of Pecs, 1st internal Med. Dept., Pulmonology, Pecs, Hungary|Pest County Lung Hospital, Department No. 3, Törökbalint, Hungary|Vikram Hospital, Bangalore, India|V S Hospital, Chennai, India|Dr. Kamakshi Memorial Hospital, Chennai, India|Sri Ramachandra Medical College & Research Institute, Chennai, India|M.S. Patel Cancer Hospital, Karamsad, India|B. P .Poddar Hospital & Medical Research Ltd., Kolkata, West Bengal, India|Tata Memorial Hospital, Mumbai, India|Ruby Hall Clinic, Pune, India|St James's Hospital, Dublin 8, Ireland|P.O. Bellaria IRCCS Istituto delle scienze Neurologiche di Bologna, Bologna, Italy|ASST di Cremona, Cremona, Italy|Spedali Riuniti di Livorno, Livorno, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IRCCS, Padova, Italy|Azienda Ospedaliera di Parma, Parma, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Istituto Clinico Humanitas, Rozzano (MI), Italy|Ospedale San Vincenzo, Taormina (ME), Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|A. O. S. Maria della Misericordia, Udine, Italy|Chungbuk National University Hospital, Cheongju, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Gyeongsang National University Hospital, Jinju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|The Catholic University of Korea, St.Vincent's Hospital, Suwon, Korea, Republic of|Ulsan University Hospital, Ulsan, Korea, Republic of|Instituto Nacional de Cancerologia, Mexico, Mexico|Hospital y Clínica OCA S. A. de C. V., Monterrey, Mexico|Centro Hemato-Oncologico Privado de Toluca S.A. de C.V., Toluca, Mexico|Jeroen Bosch Ziekenhuis-Hertogenbosch, 's-HERTOGENBOSCH, Netherlands|Rijnstate Hospital, Arnhem, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|METC Academisch Ziekenhuis Maastricht/Universiteit van Maastricht, Maastricht, Netherlands|St. Antonius ziekenhuis, locatie Nieuwegein, Nieuwegein, Netherlands|Erasmus Medisch Centrum, Rotterdam, Netherlands|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLN, EPE - Hospital de Santa Maria, Lisboa, Portugal|IPO Lisboa Francisco Gentil, EPE, Lisboa, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Vila Nova de Gaia, Vila Nova de Gaia, Portugal|National Cancer Centre, Singapore, Singapore|Johns Hopkins Singapore International Medical Centre, Singapore, Singapore|Hospital A Coruña, A Coruña, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Regional Universitario de Málaga, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain|Chang Gung Memorial Hospital Chiayi, Chiayi, Taiwan|Buddhist Tzu Chi General Hospital, Chiayi, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Koo Foundation Sun Yet-Sen Cancer Center, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Akdeniz Universitesi Tip Fakultesi, Antalya, Turkey|Uludag Universitesi Tip Fakultesi, Bursa, Bursa, Turkey|Dicle Universitesi Tip Fakultesi, Diyarbakir, Turkey|Gaziantep Univ. Tip Fakultesi Tibbi Onkoloji Bilim Dali, Gaziantep, Turkey|Kartal Egitim Ve Arastirma Hastanesi, Istanbul, Turkey|Yedikule Gog. Hst. EAH, Istanbul, Turkey|Ege Universitesi Tip Fakultesi Tibbi Onkoloji Bilim Dali, Izmir, Turkey|Dr.Suat Seren EAH, Izmir, Turkey|Queen Elizabeth Hospital, Birmingham, United Kingdom|Royal Devon and Exeter Hospital, Exeter, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Harrogate District Hospital, Harrogate, United Kingdom|Royal Free Hospital, London, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Maidstone Hospital, Kent Oncology Centre, Maidstone, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Scarborough Hospital, Scarborough, United Kingdom|The Royal Marsden Hospital, Sutton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01523587/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/87/NCT01523587/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01523587"
566,"NCT02788214","Helicobacter Pylori Genome Project (HpGP)",,"Terminated","No Results Available","Gastric Cancer|Non-Atrophic Gastritis|Intestinal Metaplasia",,"Bacterial DNA sequence","National Cancer Institute (NCI)|New England Biolabs, USA|National Institute of Infectious Diseases, Japan|National Institute of Genetics, Japan|Chiba University, Japan|National Institute for Basic Biology, Japan|Instituto Mexicano de Seguro Social, Mexico|Universidade de Lisboa, Portugal|Instituto de Biomedicina de Valencia, Spain|University of Bath, UK|Vanderbilt University Medical Center, USA|Karolinska Institutet|University of Tokyo, Japan|Max von Pettenkofer-Institute of Hygiene and Medical Microbiology, Germany|Universidad de Chile, Chile|HOSEI University, Japan","All","30 Years to 70 Years   (Adult, Older Adult)",,"1000","NIH|Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","NCI-2020-07069|16-C-N120|999916120","July 27, 2016","May 15, 2020","May 15, 2020","June 2, 2016",,"December 19, 2020","White River Medical Center, Batesville, Arkansas, United States|Stanford University, Stanford, California, United States|Georgia Cancer Center Biorepository, Athens, Georgia, United States|Centers for Disease Control and Prevention, Atlanta, Georgia, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Baylor College of Medicine, Houston, Texas, United States|Université Ferhat Abbas, Sétif, Algeria|Hospital Alemán, Buenos Aires, Argentina|Dhaka Medical College and Hospital, Dhaka, Bangladesh|Ghent University, Ghent, Belgium|Universidade Federal de Minas Gerais, Belo Horizonte, Brazil|AC Camargo Cancer Center, Sao Paulo, Brazil|Medical University of Sofia, Sofia, Bulgaria|Tsaritsa Yoanna University Hospital, Sofia, Bulgaria|University of Dschang, Dschang, Cameroon|University of Alberta, Edmonton, Canada|Universidad de Concepción, Concepción, Chile|Hospital Hanga Roa, Easter Island, Chile|Pontificia Universidad Catolica, Santiago, Chile|Instituto Nacional de Cancerología, Bogotá, Colombia|Universidad del Valle, Cali, Colombia|Universidad de Nariño, Pasto, Colombia|University of Kinshasa, Kinshasa, Congo, The Democratic Republic of the|University of Mbuji Mayi, Mbuji-Mayi, Congo, The Democratic Republic of the|Universidad de Costa Rica, San José, Costa Rica|Universidad Autónoma de Santo Domingo, Santo Domingo, Dominican Republic|C.H.U. Pellegrin, Bordeaux, France|Otto-von-Guericke Universitätsklinikum, Magdeburg, Germany|University of Cape Coast, Cape Coast, Ghana|Evangelismos Hospital and Hellenic Pasteur Institute, Athens, Greece|Hellenic Pasteur Institute, Athens, Greece|Universidad San Carlos, Guatemala, Guatemala|Hospital de Occidente, Santa Rosa De Copán, Honduras|National University Hospital, Reykjavík, Iceland|Kasturba Medical College Manipal, Manipal, India|University of Indonesia, Kota Depok, Indonesia|Universitas Airlangga, Kota Surabaya, Indonesia|Digestive Disease Research Institute, Teheran, Iran, Islamic Republic of|Bar Ilan University, Ramat Gan, Israel|Centro di Rferimento Oncologico, Aviano, Italy|Nagoya City University, Nagoya, Japan|HOSEI University, Tokyo, Japan|Kyorin University, Tokyo, Japan|Nippon Medical School, Tokyo, Japan|Oita University, Ōita, Japan|Jordan University of Science and Technology, Ramtha, Jordan|Central Asian Cancer Institute, Almaty, Kazakhstan|Tenwek Hospital, Bomet, Kenya|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|National Cancer Center, Seoul, Korea, Republic of|Kyrgyz State Medical Academy, Bishkek, Kyrgyzstan|University of Latvia, Riga, Latvia|Lithuanian University of Health Sciences, Kaunas, Lithuania|University of Malaya, Kuala Lumpur, Malaysia|Instituto Nacional de Cancerología, Mexico City, Mexico|Defence Services General Hospital, Yangon, Myanmar|Chitwan Medical College, Bharatpur, Nepal|Tribhuvan University Teaching Hospital, Kathmandu, Nepal|University of Calabar Teaching Hospital, Calabar, Nigeria|University of Nigeria Teaching Hospital, Enugu, Nigeria|Babcock Universtiy Teaching Hospital, Ilishan-Remo, Nigeria|University of Jos / University Teaching Hospital, Jos, Nigeria|Federal Medical Center, Lagos, Nigeria|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Universidad Peruana Cayetano Heredia, Lima, Peru|University of Lublin, Publin, Poland|Wroclaw Medical Center, Wroclaw, Poland|Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisbon, Portugal|University of Porto, Porto, Portugal|University of Puerto Rico, San Juan, Puerto Rico|Clinical Research Center of Moscow, Moscow, Russian Federation|National University Hospital, Singapore, Singapore|Chris Hani Baragwanath Academic Hospital, Soweto, South Africa|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital General de Granollers, Barcelona, Spain|Hospital Universitari Parc Tauli, Barcelona, Spain|Institut d'Investigació Biomédica de Bellvitge (Idibell), Barcelona, Spain|L'Hospitalet de Llobregat, Barcelona, Spain|Hospital de Leon, León, Spain|Hospital de la Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario de Asturias, Oviedo, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Donostia, San Sebastian, Spain|Lozano Blesa University Hospital, Zaragoza, Spain|Sudan University of Science and Technology, Khartoum, Sudan|Karolinska Institutet, Stockholm, Sweden|University of Bern, Bern, Switzerland|University of Zurich, Zurich, Switzerland|National Taiwan University Hospital, Taipei, Taiwan|Istanbul University, Istanbul, Turkey|Cho Ray Hospital, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT02788214"
567,"NCT00882063","Study To Evaluate Safety and Efficacy of P276-00 in Subjects With Refractory Multiple Myeloma",,"Completed","No Results Available","Relapsed and/or Refractory Multiple Myeloma","Drug: P276-00","To determine the maximum tolerated dose of P276-00 in subjects with relapsed and/or relapsed/refractory Multiple Myeloma","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","19","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/15/07","January 2008","November 2009","May 2012","April 16, 2009",,"November 21, 2012","Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India|Shatabdi Superspeciality Hospital, Nasik, Maharashtra, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India|Rajiv Gandhi Cancer Institute And Research Centre, Delhi, India|Institute Rotary Cancer Hospital,All India Institute Of Medical Sciences(AIIMS), New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00882063"
568,"NCT00863096","Human Papillomavirus Screening and Vaccine Readiness Program",,"Withdrawn","No Results Available","Human Papilloma Virus-Related Carcinoma","Biological: Gardasil","Acceptability of HPV vaccine","Public Health Research Institute, India|PATH","Female","18 Years to 45 Years   (Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","GAT.1246-04-07527-GRT","June 2009","June 2010","December 2010","March 17, 2009",,"March 3, 2011","Public Health Research Institute, India, Mysore, Karnataka, India",,"https://ClinicalTrials.gov/show/NCT00863096"
569,"NCT03561961","Prostate Radiotherapy Comparing Moderate and Extreme Hypo-fractionation (PRIME Trial)","PRIME","Recruiting","No Results Available","Prostate Adenocarcinoma","Radiation: Moderate Hypo-fractionation|Radiation: Extreme Hypo-fractionation","Biochemical Failure free Survival (BFFS)|Acute toxicity with both treatments.|Late toxicity with both treatments.|Prostate cancer specific survival|Overall Survival|out of pocket expenditure|patient reported quality of life","Tata Memorial Centre|Tata Medical Center","Male","18 Years and older   (Adult, Older Adult)","Not Applicable","464","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRIME","May 24, 2018","March 2030","March 2035","June 19, 2018",,"April 1, 2021","Dr Vedang Murthy, Navi-Mumbai, Maharashtra, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/61/NCT03561961/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT03561961"
570,"NCT00596830","Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology",,"Terminated","Has Results","Carcinoma, Squamous Cell|Carcinoma, Adenosquamous|Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung","Drug: CP-751,871 (Figitumumab)|Drug: Carboplatin|Drug: Paclitaxel","Overall Survival (OS)|Progression-Free Survival (PFS)|Percentage of Participants With Objective Response (OR)|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30)|European Organization for Research and Treatment of Cancer (EORTC), Quality of Life Questionnaire-Lung Cancer 13 (QLQ- LC13) Score|Euro Quality of Life (EQ-5D)- Health State Profile Utility Score|Maximum Observed Plasma Concentration (Cmax) for Figitumumab|Minimum Observed Plasma Trough Concentration (Cmin)for Figitumumab|Number of Participants With Total Anti-drug Antibodies (ADA)|Change From Baseline in Serum Insulin Growth Factor 1 (IGF1) Levels","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","681","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A4021016","April 2008","March 2011","September 2012","January 17, 2008","December 3, 2013","January 13, 2014","Pfizer Investigational Site, Florence, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Muscle Shoals, Alabama, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Hot Springs, Arkansas, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Boulder, Colorado, United States|Pfizer Investigational Site, Colorado Springs, Colorado, United States|Pfizer Investigational Site, Colorado Springs, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Denver, Colorado, United States|Pfizer Investigational Site, Lakewood, Colorado, United States|Pfizer Investigational Site, Littleton, Colorado, United States|Pfizer Investigational Site, Lone Tree, Colorado, United States|Pfizer Investigational Site, Longmont, Colorado, United States|Pfizer Investigational Site, Parker, Colorado, United States|Pfizer Investigational Site, Thornton, Colorado, United States|Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Norwich, Connecticut, United States|Pfizer Investigational Site, Hudson, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Lake City, Florida, United States|Pfizer Investigational Site, Lake City, Florida, United States|Pfizer Investigational Site, Miramar Beach, Florida, United States|Pfizer Investigational Site, New Port Richey, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Pensacola, Florida, United States|Pfizer Investigational Site, Port St. Lucie, Florida, United States|Pfizer Investigational Site, Spring Hill, Florida, United States|Pfizer Investigational Site, Alpharetta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Conyers, Georgia, United States|Pfizer Investigational Site, Cumming, Georgia, United States|Pfizer Investigational Site, Decatur, Georgia, United States|Pfizer Investigational Site, Duluth, Georgia, United States|Pfizer Investigational Site, Lake Spivey, Georgia, United States|Pfizer Investigational Site, Lawrenceville, Georgia, United States|Pfizer Investigational Site, Macon, Georgia, United States|Pfizer Investigational Site, Marietta, Georgia, United States|Pfizer Investigational Site, Snellville, Georgia, United States|Pfizer Investigational Site, Coeur d' Alene, Idaho, United States|Pfizer Investigational Site, Arlington Heights, Illinois, United States|Pfizer Investigational Site, Aurora, Illinois, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Elk Grove Village, Illinois, United States|Pfizer Investigational Site, Galesburg, Illinois, United States|Pfizer Investigational Site, Winfield, Illinois, United States|Pfizer Investigational Site, Yorkville, Illinois, United States|Pfizer Investigational Site, Avon, Indiana, United States|Pfizer Investigational Site, Beech Grove, Indiana, United States|Pfizer Investigational Site, Hobart, Indiana, United States|Pfizer Investigational Site, Hobart, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Mooresville, Indiana, United States|Pfizer Investigational Site, Mooresville, Indiana, United States|Pfizer Investigational Site, Munster, Indiana, United States|Pfizer Investigational Site, Cedar Rapids, Iowa, United States|Pfizer Investigational Site, Kansas City, Kansas, United States|Pfizer Investigational Site, Overland Park, Kansas, United States|Pfizer Investigational Site, Shawnee Mission, Kansas, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Louisville, Kentucky, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Lawrence, Massachusetts, United States|Pfizer Investigational Site, Quincy, Massachusetts, United States|Pfizer Investigational Site, Stoneham, Massachusetts, United States|Pfizer Investigational Site, Weymouth, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Farmington Hills, Michigan, United States|Pfizer Investigational Site, St. Joseph, Michigan, United States|Pfizer Investigational Site, St. Louis Park, Minnesota, United States|Pfizer Investigational Site, Columbus, Mississippi, United States|Pfizer Investigational Site, Corinth, Mississippi, United States|Pfizer Investigational Site, Oxford, Mississippi, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Kansas City, Missouri, United States|Pfizer Investigational Site, Lee's Summit, Missouri, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Lincoln, Nebraska, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Las Vegas, Nevada, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Manchester, New Hampshire, United States|Pfizer Investigational Site, Lake Success, New York, United States|Pfizer Investigational Site, Manhasset, New York, United States|Pfizer Investigational Site, New Hyde Park, New York, United States|Pfizer Investigational Site, Oneida, New York, United States|Pfizer Investigational Site, Oswego, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Syracuse, New York, United States|Pfizer Investigational Site, Burlington, North Carolina, United States|Pfizer Investigational Site, Canton, Ohio, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Dover, Ohio, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Clairton, Pennsylvania, United States|Pfizer Investigational Site, Greensburg, Pennsylvania, United States|Pfizer Investigational Site, Johnstown, Pennsylvania, United States|Pfizer Investigational Site, McKeesport, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Radnor, Pennsylvania, United States|Pfizer Investigational Site, Sayre, Pennsylvania, United States|Pfizer Investigational Site, Wexford, Pennsylvania, United States|Pfizer Investigational Site, Columbia, South Carolina, United States|Pfizer Investigational Site, Sumter, South Carolina, United States|Pfizer Investigational Site, Bartlett, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Knoxville, Tennessee, United States|Pfizer Investigational Site, Maryville, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Austin, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Fort Sam Houston, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Grapevine, Texas, United States|Pfizer Investigational Site, Houston, Texas, United States|Pfizer Investigational Site, Irving, Texas, United States|Pfizer Investigational Site, Longview, Texas, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, Round Rock, Texas, United States|Pfizer Investigational Site, Round Rock, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Marcos, Texas, United States|Pfizer Investigational Site, Tyler, Texas, United States|Pfizer Investigational Site, Bountiful, Utah, United States|Pfizer Investigational Site, Layton, Utah, United States|Pfizer Investigational Site, Murray, Utah, United States|Pfizer Investigational Site, Provo, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, West Valley City, Utah, United States|Pfizer Investigational Site, Arlington, Virginia, United States|Pfizer Investigational Site, Christiansburg, Virginia, United States|Pfizer Investigational Site, Fairfax, Virginia, United States|Pfizer Investigational Site, Gainesville, Virginia, United States|Pfizer Investigational Site, Leesburg, Virginia, United States|Pfizer Investigational Site, Roanoke, Virginia, United States|Pfizer Investigational Site, Salem, Virginia, United States|Pfizer Investigational Site, Winchester, Virginia, United States|Pfizer Investigational Site, Woodbridge, Virginia, United States|Pfizer Investigational Site, Wytheville, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Spokane Valley, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Albury, New South Wales, Australia|Pfizer Investigational Site, Port Macquarie, New South Wales, Australia|Pfizer Investigational Site, Geelong, Victoria, Australia|Pfizer Investigational Site, Wodonga, Victoria, Australia|Pfizer Investigational Site, Linz, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Higienopolis, Sao Paulo/ Brazil, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Varna, Bulgaria|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Levis, Quebec, Canada|Pfizer Investigational Site, Nova Ves pod Plesi, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Pribram I, Czech Republic|Pfizer Investigational Site, Pribram V, Czech Republic|Pfizer Investigational Site, Helsinki, Finland|Pfizer Investigational Site, Pori, Finland|Pfizer Investigational Site, Caen Cedex 05, France|Pfizer Investigational Site, Caen Cedex, France|Pfizer Investigational Site, Clermond-Ferrand Cedex 01, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Lyon Cedex 04, France|Pfizer Investigational Site, Nantes Cedex 2, France|Pfizer Investigational Site, Rennes Cedex 9, France|Pfizer Investigational Site, Saint Herblain Cedex, France|Pfizer Investigational Site, Saint Pierre la Réunion Cedex, France|Pfizer Investigational Site, Grosshansdorf, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Leipzig, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Oldenburg, Germany|Pfizer Investigational Site, Thessaloniki, Pylaia, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Shatin, New Territories, Hong Kong|Pfizer Investigational Site, Tuen Mun, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Deszk, Hungary|Pfizer Investigational Site, Szekesfehervar, Hungary|Pfizer Investigational Site, Szombathely, Hungary|Pfizer Investigational Site, Torokbalint, Hungary|Pfizer Investigational Site, Navrangpura / Ahmedabad, Gujarat, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Mumbai, Maharashtra, India|Pfizer Investigational Site, Nagpur, Maharashtra, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Genova, Italy|Pfizer Investigational Site, Orbassano (TO), Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Kashiwa, Chiba, Japan|Pfizer Investigational Site, Matsuyama-shi, Ehime, Japan|Pfizer Investigational Site, Gifu-shi, Gifu, Japan|Pfizer Investigational Site, Sapporo-shi, Hokkaido, Japan|Pfizer Investigational Site, Akashi, Hyogo, Japan|Pfizer Investigational Site, Yokohama-city, Kanagawa, Japan|Pfizer Investigational Site, Sakai-shi, Osaka-fu, Japan|Pfizer Investigational Site, Osaka-city, Osaka, Japan|Pfizer Investigational Site, Osakasayama-shi, Osaka, Japan|Pfizer Investigational Site, Chuo-Ku, Tokyo, Japan|Pfizer Investigational Site, Tokyo, Japan|Pfizer Investigational Site, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Krakow, Poland|Pfizer Investigational Site, Siedlce, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Ponce, Puerto Rico|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Saint-Petersburg, Russian Federation|Pfizer Investigational Site, Samara, Russian Federation|Pfizer Investigational Site, Sochi, Russian Federation|Pfizer Investigational Site, St-Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Nitra-Zobor, Slovakia|Pfizer Investigational Site, Nove Zamky, Slovakia|Pfizer Investigational Site, Poprad, Slovakia|Pfizer Investigational Site, L'hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Cordoba, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Fribourg, Switzerland|Pfizer Investigational Site, Zuerich, Switzerland|Pfizer Investigational Site, Niao Sung Hsiang, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Adana, Turkey|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Sumy, Ukraine",,"https://ClinicalTrials.gov/show/NCT00596830"
571,"NCT00254904","Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC",,"Terminated","No Results Available","Carcinoma, Non-Small-Cell Lung","Drug: Cisplatin|Drug: Gemcitabine|Drug: PF-3512676|Drug: Gemcitabine + Cisplatin","Overall Survival|Patient Reported Outcomes|Overall Safety Profile|Progression Free Survival|Time to Tumor Progression|Overall Objective Response|Duration of Response","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","839","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A8501002","November 2005","June 2008","June 2008","November 17, 2005",,"March 30, 2015","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Bakersfield, California, United States|Pfizer Investigational Site, St. Joseph, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, St. Louis, Missouri, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Spokane, Washington, United States|Pfizer Investigational Site, Innsbruck, Austria|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Charleroi, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Jette, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Jau, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Greenfield Park, Quebec, Canada|Pfizer Investigational Site, Laval, Quebec, Canada|Pfizer Investigational Site, Levis, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Dalian, Liaoning, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Praha 5, CZ, Czech Republic|Pfizer Investigational Site, Olomouc, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Bielefeld, Germany|Pfizer Investigational Site, Karlsruhe, Germany|Pfizer Investigational Site, Loewenstein, Germany|Pfizer Investigational Site, Mannheim, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Kowloon, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Zalaegerszeg, Külsőkórház-Pózva, Hungary|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, Deszk, Hungary|Pfizer Investigational Site, Gyula, Hungary|Pfizer Investigational Site, Pecs, Hungary|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Kochi, Kerala, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Lucknow, Uttar Pradesh, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Beer-Sheva, Israel|Pfizer Investigational Site, Kfar Saba, Israel|Pfizer Investigational Site, Forli', Italy|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Pisa, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, S.Andrea delle Fratte (PG), Italy|Pfizer Investigational Site, Gyeonggi-do, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Amsterdam, NH, Netherlands|Pfizer Investigational Site, Zaandam, NH, Netherlands|Pfizer Investigational Site, 's-Hertogenbosch, Netherlands|Pfizer Investigational Site, Harderwijk, Netherlands|Pfizer Investigational Site, Nijmegen, Netherlands|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Lodz, Poland|Pfizer Investigational Site, Otwock, Poland|Pfizer Investigational Site, Szczecin-Zdunowo, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wodzislaw Sl., Poland|Pfizer Investigational Site, Coimbra, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Kosice, Slovakia|Pfizer Investigational Site, Kvetnica pri Poprade, Slovakia|Pfizer Investigational Site, Nitra-Zobor, Slovakia|Pfizer Investigational Site, Port Elizabeth, Eastern Cape, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Port Elizabeth, South Africa|Pfizer Investigational Site, Hospitalet de Llobregat, Barcelona, Spain|Pfizer Investigational Site, Santander, Cantabria, Spain|Pfizer Investigational Site, Baracaldo, Vizcaya, Spain|Pfizer Investigational Site, Alicante, Spain|Pfizer Investigational Site, Castellon, Spain|Pfizer Investigational Site, Gerona, Spain|Pfizer Investigational Site, Jaen, Spain|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Ankara, Turkey|Pfizer Investigational Site, Bornova / Izmir, Turkey|Pfizer Investigational Site, Istanbul / Ceraahpasa, Turkey|Pfizer Investigational Site, Bristol, Avon, United Kingdom|Pfizer Investigational Site, Southampton, Hampshire, United Kingdom|Pfizer Investigational Site, Sutton, Surrey, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Dundee, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Leicester, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00254904"
572,"NCT00371566","A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer",,"Completed","Has Results","Squamous Cell Carcinoma of Head and Neck","Drug: Lapatinib oral tablets|Drug: Placebo","Change From Baseline of the Apoptotic Index During Treatment Phase|Change From Baseline of Cell Proliferation Rate of the Ki-67 Proliferative Index in Tumour Biopsy Samples During Treatment Phase|Overall Radiological Response After Treatment Phase in mITT Population|Overall Radiological Response After Follow-up Phase in mITT Population|Overall Radiological Response After Treatment Phase in ITT Population|Overall Radiological Response After Follow-up Phase in ITT Population|Number of Circulating Tumor Cells at Baseline in mITT Population|Number of Participants With Circulating Tumor Cells After Treatment Phase in mITT Population|Number of Participants With Circulating Tumor Cells After Chemoradiotherapy Phase in mITT Population|Number of Biomarkers Including ErbB1, ErbB2, pErbB1, and pErb2 at Baseline and During Treatment Phase|Number of Biomarkers Including Tumor Protein 53 and HPV During Treatment Phase|Summary of Adverse Events by Maximum Toxicity Grade Started During Treatment Phase|Summary of Adverse Events by Maximum Toxicity Grade (Grade 3 or Higher) Started During or After the Chemoradiotherapy Phase|Comparison of Overall Response During Treatment Phase Using CT/MRI and PET Information|Comparison of Overall Response During Follow up Phase Using CT/MRI and PET Information|Summary of Adverse Events Experienced by 15% or More Subjects in Either Treatment Group|Summary of Fatal/Serious Adverse Events During or After Chemoradiotherapy Phase|Summary of Serious Adverse Events During or After Chemoradiotherapy Phase|Adverse Events by Maximum Toxicity Grade 3 During or After Chemoradiotherapy Phase|Adverse Events (AEs) by Maximum Toxicity Grade 4 During or After Chemoradiotherapy Phase|Adverse Events by Maximum Toxicity Grade 5 During or After Chemoradiotherapy Phase|Relative Change From Baseline of Ktrans Median (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Kep Mean (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Kep Perfused (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Kep Whole (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Ktrans Mean (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Ktrans Perfused (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Ktrans Whole (1/Min) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of IAUC Median (90) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of IAUC Mean (90) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Perfused IAUC (90) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Whole IAUC(90) After 2 - 4 Weeks of Treatment|Relative Change From Baseline of Kep Median (1/Min) After 2 - 4 Weeks of Treatment","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","107","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment","EGF104334","March 2006","December 2007","December 2007","September 4, 2006","January 29, 2010","April 6, 2010","GSK Investigational Site, Caen, France|GSK Investigational Site, Montpellier Cedex 5, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Thiruvananthapuram, India|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00371566"
573,"NCT03778229","Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib","SAVANNAH","Active, not recruiting","No Results Available","Carcinoma","Drug: osimertinib|Drug: savolitinib","Objective response rate (ORR) by investigator assessment in accordance with RECIST 1.1|Objective response rate (ORR) by investigator assessment in accordance with RECIST 1.1.|PFS by investigator assessment in accordance with RECIST 1.1.|Overall Survival by investigator assessment in accordance with RECIST 1.1.|Duration of Response by investigator assessment in accordance with RECIST 1.1.|Percentage change in tumour size by investigator assessment in accordance with RECIST 1.1.|Mean change from baseline in the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core quality-of-life questionnaire (QLQ-C30), version 3 (QLQ-C30 v3).|Plasma concentrations of osimertinib, savolitinib and their metabolites.|Prevalence of EGFR mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in EGFR mutation allele frequencies).|AEs, SAEs and discontinuation rate due to AEs, as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5.|Mean change from baseline in the European Organisation for Research and Treatment of Cancer (EORTC) complementary 13-item quality-of-life questionnaire - lung cancer symptoms questionnaire (QLQ-LC13).","AstraZeneca|Hutchison MediPharma","All","18 Years and older   (Adult, Older Adult)","Phase 2","294","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5084C00007|2018-003012-51","January 9, 2019","September 30, 2022","September 30, 2022","December 19, 2018",,"May 4, 2022","Research Site, La Jolla, California, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, Rochester, Minnesota, United States|Research Site, Brooklyn, New York, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Seattle, Washington, United States|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Goiania, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, São Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, North York, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Herlev, Denmark|Research Site, Næstved, Denmark|Research Site, Odense C, Denmark|Research Site, Vejle, Denmark|Research Site, Ålborg, Denmark|Research Site, Dijon, France|Research Site, Marseille Cedex 20, France|Research Site, Nantes, France|Research Site, Paris Cedex 5, France|Research Site, Paris, France|Research Site, Rennes, France|Research Site, Bangalore, India|Research Site, Chennai, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, Avellino, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Orbassano, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Perugia, Italy|Research Site, Peschiera Del Garda, Italy|Research Site, Fukuoka, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kanazawa-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Osakasayama, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Goyang-si, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, San Sebastian, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Kaohsiung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Ha Noi, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03778229"
574,"NCT04078152","Durvalumab Long-Term Safety and Efficacy Study","WAVE","Active, not recruiting","No Results Available","Solid Tumor","Drug: Durvalumab","Number of participants with adverse events as assessed by Common Toxicity Criteria for Adverse Events (CTCAE v5.0)|Efficacy of durvalumab in terms of Overall Response Rate (ORR) in patients who undergo retreatment with durvalumab|Efficacy of durvalumab in terms of Duration of Response (DOR) in patients who undergo retreatment with durvalumab|Overall Survival (OS)","AstraZeneca|Iqvia Pty Ltd|Parexel|Medidata Solutions|CISCRP","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 4","163","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D910FC00001","September 5, 2019","October 31, 2022","October 31, 2022","September 4, 2019",,"April 11, 2022","Research Site, Fullerton, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Augusta, Georgia, United States|Research Site, Baltimore, Maryland, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Mineola, New York, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Huntersville, North Carolina, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Rosario, Argentina|Research Site, Box Hill, Australia|Research Site, Melbourne, Australia|Research Site, Brussels, Belgium|Research Site, Kortrijk, Belgium|Research Site, Leuven, Belgium|Research Site, Florianópolis, Brazil|Research Site, Ijuí, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Sao Jose Do Rio Preto, Brazil|Research Site, Sofia, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Toronto, CA, Canada|Research Site, Newmarket, Ontario, Canada|Research Site, Sudbury, Ontario, Canada|Research Site, Santiago, Chile|Research Site, Olomouc, Czechia|Research Site, Brest Cedex, France|Research Site, Lille, France|Research Site, Lyon Cedex 08, France|Research Site, Dresden, Germany|Research Site, Hannover, Germany|Research Site, Holargos, Athens, Greece|Research Site, Budapest, Hungary|Research Site, Miskolc, Hungary|Research Site, Chennai, India|Research Site, Haifa, Israel|Research Site, Bunkyo-ku, Japan|Research Site, Fukushima-shi, Japan|Research Site, Isehara-shi, Japan|Research Site, Izumi-shi, Japan|Research Site, Kishiwada-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Nagaoka-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Natori-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Saga-shi, Japan|Research Site, Suita-shi, Japan|Research Site, Sunto-gun, Japan|Research Site, Tokushima-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Daegu, Korea, Republic of|Research Site, Gwangju, Korea, Republic of|Research Site, Gyeongsangnam-do, Korea, Republic of|Research Site, Seo-Gu, Korea, Republic of|Research Site, Seongnam-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Kuching, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Olsztyn, Poland|Research Site, Łódź, Poland|Research Site, Łódź, Poland|Research Site, Craiova, Romania|Research Site, Suceava, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, pos.Pesochnyi, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Sremska Kamenica, Serbia|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Girona, Spain|Research Site, Jaén, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella, Spain|Research Site, Málaga, Spain|Research Site, Valencia, Spain|Research Site, Bellinzona, Switzerland|Research Site, Lausanne, Switzerland|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand|Research Site, Songkhla, Thailand|Research Site, Adana, Turkey|Research Site, Istanbul, Turkey|Research Site, Chernivtsі, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kirovohrad, Ukraine|Research Site, Kryvyi Rih, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Sumy, Ukraine|Research Site, Uzhhorod, Ukraine|Research Site, Vinnytsia, Ukraine|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT04078152"
575,"NCT05142982","Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma",,"Not yet recruiting","No Results Available","Seminoma","Radiation: Radiotherapy","Progression free survival(PFS)|Locoregional control (LRC)|Overall survival (OS)|Second-line salvage therapy-free survival|Acute radiation toxicity|Late radiation toxicity|Patient-reported quality of life (QOL)","Tata Memorial Centre","Male","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","74","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PROsem","December 15, 2021","December 15, 2029","December 15, 2029","December 3, 2021",,"December 3, 2021","Tata Memorial Centre, Mumbai, Maharashtra, India|Dr Vedang Murthy, Navi-Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT05142982"
576,"NCT01950611","Proteasome Inhibition in Acute Promyelocytic Leukemia","PIAPL","Unknown status","No Results Available","Relapsed Acute Promyelocytic Leukemia","Drug: Bortezomib","Safety|Efficacy","Christian Medical College, Vellore, India","All","1 Year to 75 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB 8225 27/02/13","May 2013","May 2018","May 2018","September 25, 2013",,"September 25, 2013","Department of Haematology, Christian Medical College, Vellore, TN, India",,"https://ClinicalTrials.gov/show/NCT01950611"
577,"NCT00624143","Antifungal Prophylaxis in Pediatric Acute Leukemia",,"Unknown status","No Results Available","Pediatric Acute Leukemia Induction","Drug: ORAL VORICONAZOLE and IV Amphotericin B","Prevention of possible, probable or proven fungal infection.","All India Institute of Medical Sciences, New Delhi","All","up to 15 Years   (Child)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","antifungal prophylaxis|Dr. SAMEER BAKHSHI","February 2008","December 2009",,"February 26, 2008",,"February 26, 2008","Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00624143"
578,"NCT00527319","Regimen for the Treatment of Cachexia in Subjects With NSCLC","VT-122","Completed","Has Results","Cachexia","Drug: VT-122 low dose|Drug: VT-122 high dose","Proportion of Subjects With a Positive Change From Baseline to Week 4 in Lean Body Mass|Proportion of Subjects With a Positive Change From Baseline to Week 4 in Grip Strength","Vicus Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","37","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","VT-1 CAX-001","January 2007","August 2008","September 2008","September 10, 2007","January 30, 2013","January 30, 2013","First Dynamic Health Care Services, Inc., Waco, Texas, United States|Rajalakshmi Nursing Home, Bangalore, India|Nizam Institute of Medical Sciences, Hyderabaad, India|Orchid Nursing Home, Kolkata, India|Shatabdi Super Specialty Hospital, Nashik, India|All India Institute of Medical Sciences, New Delhi, India|Indraprastha Apollo Hospital, New Delhi, India|Deenanath Mangeshkar Hospital, Pune, India",,"https://ClinicalTrials.gov/show/NCT00527319"
579,"NCT04633564","MYL-1402O Compared With Avastin®, in Patients With Stage IV nsNSCLC",,"Completed","Has Results","NSCLC Stage IV","Biological: Bevacizumab as MYL-1402O|Biological: Bevacizumab as Avastin","Primary Efficacy Analysis of Overall Response Rate ( ORR) of MYL-1402O as Compared to Avastin","Mylan Pharmaceuticals Inc|Viatris Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","671","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MYL-1402O-3001","January 21, 2017","June 5, 2019","November 22, 2019","November 18, 2020","February 1, 2021","March 16, 2022","Grodno Clinical Regional Hospital, Grodno, Hrodzenskaya Voblasts, Belarus|Mogilev Regional Oncology Dispensary, Minsk, Minskaya Voblasts, Belarus|Babruysk Interregional Oncological Dispensary, Babruysk, Belarus|State Institution NN Alexandrov Republican Scientific and Practical Centre of Oncology And Medical R, Minsk, Belarus|Grodno Clinical Regional Hospital, Mogilev, Belarus|Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina|Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina|Javna zdravstvena ustanova bolnica Trebinje, Trebinje, Bosnia and Herzegovina|County Hospital Zenica, Zenica, Bosnia and Herzegovina|Complex Oncology Center-Veliko Tarnovo, Veliko Tarnovo, Bulgaria|Complex Oncology Center - Vratsa EOOD, Vratsa, Bulgaria|Clinical Hospital Centre Osijek, Osijek, Croatia|General Hospital Sibenik, Sibenik, Croatia|Clinical Hospital Center Zagreb - PPDS, Zagreb, Croatia|Research Institute of Clinical Medicine, Tbilisi, Georgia|LTD High Technology Medical Center University Clinic, Tbilisi, Georgia|Orszagos Koranyi Pulmonologiai Intezet, Budapest, Hungary|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Veszprem Megyei Tudogyogyintezet, Farkasgyepü, Hungary|Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|City Cancer Center, Vijayawada, Andhra Pradesh, India|Mahatma Gandhi Medical College and Hospital, Visakhapatnam, Andhra Pradesh, India|Regional Cancer Centre Indira Gandhi Institute of Medical Sciences, Patna, Bihar, India|HCG Cancer Center, Ahmedabad, Gujarat, India|Shree Giriraj Multispeciality Hospital, Rajkot, Gujarat, India|Synexus Affiliate - Apple Hospital, Surat, Gujarat, India|Unique Hospital - Multispeciality & Research Institute, Surat, Gujarat, India|Aadhar Health Institute, Hisar, Haryana, India|BGS Global Hospital, Bangalore, Karnataka, India|Sri Venkateshwara Hospital, Bangalore, Karnataka, India|Shetty's Hospital, Bengaluru, Karnataka, India|Amravati Cancer Foundation Sujan Surgical and Cancer Hospital, Amravati, Maharashtra, India|United CIIGMA Institute of Medical Sciences Pvt.Ltd., Aurangabad, Maharashtra, India|Seth Nandlal Dhoot Hospital, Aurangabad, Maharashtra, India|Government Medical College, Nagpur, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Acharya Tulsi Regional Cancer Institute and Research Centre, Bikaner, Rajasthan, India|Malpani Multispecialty Hospital, Jaipur, Rajasthan, India|Institute of Respiratory Diseases (Chest and TB Hospital), Jaipur, Rajasthan, India|Apex Hospital, Jaipur, Rajasthan, India|Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, Rajasthan, India|Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India|Meenakshi Mission Hospital and Research Center, Madurai, Tamil Nadu, India|Shatabdi Superspeciality Hospital, Lucknow, Uttar Pradesh, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Belagave, India|Prince Aly Khan Hospital Mumbai, Mumbai, India|Jaslok Hospital and Research Centre, Mumbai, India|Sahyadri Speciality Hospital, Pune, India|Kailash Cancer Hospital and Research Centre, Vadodara, India|Ospedale Felice Lotti De Pontedera, Pontedera, Italy|Philippine General Hospital, Manila, National Capital Region, Philippines|Cardinal Santos Medical Center, San Juan City, National Capital Region, Philippines|Med-Polonia Sp. z o.o., Poznań, Poland|Radomskie Centrum Onkologii, Radom, Poland|Medisprof SRL, Cluj-Napoca, Cluj, Romania|Ploiesti Municipal Hospital, Ploiesti, Prahova, Romania|Spitalul Judetean de Urgenta Sf. Pantelimon Focsani, Focsani, Vrancea, Romania|Elias Emergency University Hospital, Bucharest, Romania|Prof. Dr. Alexandru Trestioreanu Oncologic Institute, Bucharest, Romania|Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta, Constanta, Romania|Oncology Center Sfantul Nectarie, Craiova, Romania|Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Chelyabinsk Regional Clinical Oncology Dispensary, Chelyabinsk, Russian Federation|Kaluga Regional Oncology Dispensary, Kaluga, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|Kursk Regional Oncology Centre, Kursk, Russian Federation|Vitamed, Moscow, Russian Federation|City Clinical Hospital #1, Novosibirsk, Russian Federation|Clinical Oncology Dispensary, Omsk, Russian Federation|Stavropol Regional Clinical Oncology Centre Pyatigorsk Affiliate, Pyatigorsk, Russian Federation|Ryazan State Medical University n.a. I.P. Pavlov, Ryazan, Russian Federation|Mordovia State University, Saransk, Russian Federation|Research Institute of Phtisio-pneumology, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|Railway Clinical Hospital JSC RZhD, St. Petersburg, Russian Federation|Clinical Theoretical and Practical Center of Specialized Kinds of Medical Care, St. Petersburg, Russian Federation|Scientific Research Institute of Oncology n.a. N.N. Petrov, St. Petersburg, Russian Federation|City Clinical Oncology Dispensary, St. Petersburg, Russian Federation|Research Oncology Institute of Tomsk Scientific Center, Tomsk, Russian Federation|Volgograd Regional Clinical Oncology Dispensary, Volgograd, Russian Federation|Regional Clinical Oncology Hospital, Yaroslavl, Russian Federation|Hospital Universitario Vall d'Hebrón - PPDS, Barcelona, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Kaohsiung Medical University Hospital, Kaohsiung, Taiwan|E-DA hospital, Kaohsiung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Mackay Memorial Hospital-Taipei branch, Taipei, Taiwan|Gazi University Medical Faculty Gazi Hospital, Ankara, Turkey|Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Turkey|Municipal Institution City Clinical Hospital #4 of Dnipro City Council - PPDS, Dnipropetrovsk, Ukraine|Municipal Institution SubCarpathian ClinicalOncological Centre, Ivano-Frankivsk, Ukraine|MI Kryvyi Rih Oncology Dispensary of Dnipropetrovsk Regional Council, Kryvyi Rih, Ukraine|Municipal non profit enterprise of Sumy Regional Council Sumy Regional Clinical Oncology Dispensary, Sumy, Ukraine|MNPE Central City Clinical Hospital of Uzhhorod City Council, Uzhgorod, Ukraine|MI of Zaporizhzhia Regional Council Zaporizhzhia Regional Clinical Oncology Dispensary, Zaporizhzhia, Ukraine|Bach Mai Hospital, Hanoi, Vietnam|National Cancer Hospital, Hanoi, Vietnam|National Lung Hospital, Hanoi, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04633564/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT04633564/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT04633564"
580,"NCT01917513","Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy",,"Completed","Has Results","Adenoma|Polyps|Colorectal Cancer","Device: G-EYE™ colonoscopy|Device: Standard Colonoscopy","Detection Rate of Adenomas and Serrated Lesions|Number of Polyp and Adenoma Detection, Procedure Times and Safety (Number of Patients With Adverse Events.","Smart Medical Systems Ltd.","All","50 Years and older   (Adult, Older Adult)","Not Applicable","1000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","G-EYE 15505","May 2014","September 2016","September 2016","August 6, 2013","January 23, 2018","January 23, 2018","Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Herlev Hospital, Harlev, Denmark|Universitätsmedizin Johannes Gutenberg University Mainz, Mainz, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Helios Dr. Horst Schmidt Kliniken (HSK), Wiesbaden, Germany|Asian Institute of Gastroenterology, Hyderabad, India|Hadassah Medical Center, Jerusalem, Israel|Laniado Hospital, Netanya, Israel|Assaf Harofeh Medical Center, Tzrifin, Israel|Vita Salute San Raffaele University - Scientific Institute San Raffaele, Milan, Italy|Maastricht University Medical Centre, Maastricht, Netherlands|Radboud UMC, Nijmegen, Netherlands|Birmingham City University, Birmingham, United Kingdom|Russells Hall Hospital, Dudley, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/13/NCT01917513/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT01917513"
581,"NCT00385515","Efficacy of SNX-1012 in the Treatment of Oral Mucositis",,"Completed","Has Results","Stomatitis|Oral Mucositis","Drug: SNX-1012 (meclocycline sulfosalicylate)|Drug: placebo","Duration of Ulcerative Oral Mucositis|Number of Participants With Ulcerative Oral Mucositis","Mucosal Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 2","81","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SNX-1012-CLN2-006","June 2006","May 2008","July 2008","October 9, 2006","March 18, 2009","May 7, 2009","Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Eastern Connecticut Hematology & Oncology Associates, Norwich, Connecticut, United States|Florida Research Cancer Institute, Davie, Florida, United States|Park Nicollet Clinic, St Louis Park, Minnesota, United States|Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Cancer Specialists of South Texas, Corpus Christi, Texas, United States|Cancer Outreach Associates, Abingdon, Virginia, United States|Morgantown Internal Medicine Group, Morgantown, West Virginia, United States|Vedanta Institute of Medical Sciences, Navrangpura, Ahmedabad, Gujarat, India|Jawaharlal Nehru Cancer Hospital and Research Centre, Post Box No. 32, Idgah Hills, Bhopal, Madhya Pradesh, India|Apollo Speciality Hospital, 320, Mount Road, Teynampet, Chennai, Tamil Nadu, India|Dharamshila Cancer Hospital and Research Centre,, Dharamshila Marg, Vasundhara Enclave, Dehli, India|Apollo Hospitals, Jubilee Hills, Hyderabad, Andhra Pradesh, India|Nizams Institute of Medical Sciences, Punjagutta, Hyderabad, Andhra Pradesh, India|Bhagwan Mahavir Cancer Hospital and Research Centre,, Jawaharlal Nehru Marg, Jaipur, Rajasthan, India|S.K Sony Hospital, Vidyadhar Nagar,, Sector-5 Sikar Road, Jaipur, Rajasthan, India|Netaji Subhash Chandra Bose Cancer Hospital & Research Institute, 16A Park Lane, Kolkatta, West Bengal, India|Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Rd., Kolkatta, West Bengal, India|Dayanand Medical College & Hospital, Tagore Nagar, Civil Lines, Ludhiana, Punjab, India|Jaslok Hospital & Research Centre, 15-Dr. G. Deshmukh Marg, Mumbai, Maharashtra, India|Jehangir Hospital,, 32 Sassoon Road, Pune, Maharashtra, India|Ruby Hall Clinic,, 40, Sassoon Road, Pune, Maharashtra, India|Seth Ramdas Shah Memorial Hospital & Research Centre, FP-402, Gokhle Nagar Road, Shivaji Nagar, Pune, Maharashtra, India|North Bengal Oncology Centre,, Pradhan Nagar, Siliguri, Dist- Darjeeling, West Bengal, India|Regional Cancer Centre, Medical College Campus, Post Bag No. 2417, Trivandrum, Kerala, India|Christian Medical College & Hospital, IDA Scuddar Road, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT00385515"
582,"NCT01339260","An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting",,"Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting","Drug: Netupitant and Palonosetron|Drug: Palonosetron|Drug: Dexamethasone","Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1|Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication at Cycle 1","Helsinn Healthcare SA|Parexel","All","18 Years and older   (Adult, Older Adult)","Phase 3","1455","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NETU-08-18","April 2011","November 2012",,"April 20, 2011","November 26, 2014","November 26, 2014","Anniston Oncology/Regional Medical Center, Anniston, Alabama, United States|Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Genesis Cancer Centre, Hot Springs, Arkansas, United States|Compassionate Cancer Care Medical Group Inc, Corona, California, United States|Compassionate Cancer Centre Medical Group, Fountain Valley, California, United States|American Institute of Research, Los Angeles, California, United States|Facey Medical Group, Mission Hills, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|American Institute of Research, Whittier, California, United States|Denver Health and Hospital Authority, Denver, Colorado, United States|Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Deaconess Clinic Downtown, Evansville, Indiana, United States|Floyd Memorial Cancer Center of Indiana, New Albany, Indiana, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|The John R Marsh Cancer Center, Hagerstown, Maryland, United States|Fallon Clinic at Worcester Medical Center, Worcester, Massachusetts, United States|Duke University Medical Center, Durham, North Carolina, United States|Piedmont Hematology Oncology Associates PA, Winston-Salem, North Carolina, United States|Tri-County Hematology and Oncolgy Associates Inc., Massillon, Ohio, United States|Signal Point Clinical Research Center LLC, Middletown, Ohio, United States|Charleston Cancer Center, Charleston, South Carolina, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Wellmont Medical Associates-Oncology and Hematology, Bristol, Tennessee, United States|Cancer Specialists of South Texas, P.A., Corpus Christi, Texas, United States|The University of Texas Health Center, Tyler, Texas, United States|Northern Utah Associates Hematology / Oncology, Ogden, Utah, United States|Northwest Medical Specialties, Tacoma, Washington, United States|Instituto Oncológico de Córdoba - Sanatorio Aconcagua, Cordoba, Argentina|Hospital Italiano de Cordoba, Córdoba, Argentina|Clínica Universitaria Reina Fabiola (Universidad Católica de Córdoba), Córdoba, Argentina|Centro Oncológico Integral (COI), Mar del Plata, Argentina|Centro Oncologico de Integracion Regional (COIR), Mendoza, Argentina|Instituto Médico CER [Oncology], Quilmes, Argentina|Sanatorio Parque, Rosario, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|Bobruisk Interregional Oncological Dispensary, Bobruisk, Belarus|Brest Regional Oncological Dispensary, Brest, Belarus|Gomel Regional Clinical Oncological Dispensary, Brest, Belarus|Minsk city Clinical Oncological Dispensary [Oncology], Minsk, Belarus|State institution N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology, Minsk, Belarus|Mogilev Regional Oncological Dispensary [Oncology], Mogilev, Belarus|OXION-Medicina Oncológica, Belo Horizonte, Brazil|Centro de Pesquisas Clínicas em Oncologia, Cachoeiro de Itapemirim, Brazil|IPCEM - Centro de Ciências da Saúde - Universidade de Caxias, Caxias do Sul, Brazil|Hospital Araújo Jorge, Goiânia, Brazil|Clinica de Neoplasias do Litoral, ItajaÃ, Brazil|Clinica De Oncologia De Porto Alegre S S Ltda, Porto Alegre, Brazil|Hospital Moinhos de Vento, Porto Alegre, Brazil|Instituto Ribeirãopretano de Combate ao Cancer, Ribeirão Preto, Brazil|Oncotrat Oncologia Medica Ltda [Oncology], Rio de Janeiro, Brazil|Nucleo de Oncologia da Bahia, Salvador Bahia, Brazil|Hospital Santa Cruz, São Paulo, Brazil|Casa de Saude Santa Marcelina, São Paulo, Brazil|SHATO ""Sveti Mina"", Blagoevgrad, Bulgaria|MHAT Dr. Tota Venkova [Oncology], Gabrovo, Bulgaria|Specialized Hospital for Active Treatment of Oncology, Haskovo, Bulgaria|UMHAT """"Dr. Georgi Stranski"""" Dept. Medical Oncology, Pleven, Bulgaria|UMHAT ""Sveti Georgi"" [Clinic of Oncology and Hematology], Plovdiv, Bulgaria|District Dispensery with Stationary - Sofia District, Sofia, Bulgaria|UMHAT ""Tsaritsa Yoanna - ISUL"" Ltd.Medical Oncology Clinic, Sofia, Bulgaria|Specialized Hospital for Active Treatment in Oncology, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Onclogy Diseases - Sofia City, Sofia, Bulgaria|Complex Oncology Centre, Stara Zagora, Bulgaria|COC - Veliko Tarnovo Dept. Medical Oncology, Veliko Tarnovo, Bulgaria|Comprehensive Cancer Center - Vratsa Dept. of Palliative Care, Vratsa, Bulgaria|Županijska bolnica Cakovec, Cakovec, Croatia|Klinicki bolnicki centar Osijek [Oncology], Osijek, Croatia|Opca bolnica Pula [Odjel za onklologiju], Pula, Croatia|KBC Rijeka [Gastroenterology], Rijeka, Croatia|Opca bolnica Varazdin [Odjel za hem.onko i klin.imun.], Varazdin, Croatia|Opca Bolnica Zadal Ulica, Zadar, Croatia|Klinički bolnički centar Zagreb [Oncology], Zagreb, Croatia|Klinicka bolnica [Sestre milosrdnice], Zagreb, Croatia|Klinika za tumore [Odjel za kemoter. i internisticku onkolog, Zagreb, Croatia|Klinik und Poliklinik für Onkologie und Hämatologie Universitatsmedizin Charite Mitte, Berlin, Germany|Gynäkologische Arztpraxis, Berlin, Germany|OncoResearch Lerchenfeld UG, Hamburg, Germany|Schwerpktprxs gynäkolog Onkologie Prof. Dr. Diel, Dr. Gebert, Mannheim, Germany|Rotkreuzklinikum [München], München, Germany|Tumorzentrum Munchen Sued - Städtisches Klinikum [Hämato-, Onkologie + Palliativmed], München, Germany|Staedtisches Krankenhaus Muenchen Neuperlach, München, Germany|OncoPRO GbR Dr. R. Dengler, Dr. A. Kröber Gesellschaft für klinische Studien in der ambulanten Hämatologie und Onkologie, Regensburg, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|Praxis Dr. G. Dresemann, Velen, Germany|Onkologische Gemeinschaftspraxis Dr. med M. Perker / PF Dr. med M. Sandherr, Weilheim, Germany|Semmelweis Egyetem Kútvölgyi Klinikai Tömb, Budapest, Hungary|Fővárosi Önkormányzat Uzsoki utcai Kórház, Budapest, Hungary|Petz Aladár Megyei Oktató Kórház [Onkoradiológiai Oszt, Győr, Hungary|Bács-Kiskun Megyei Önkormányzat Kórháza, Szegedi, Kecskemet, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Miskolc, Hungary|Josa Andras Oktato Korhaz [Onkologiai Osztaly], Nyíregyháza, Hungary|Pécsi Tudományegyetem Klinikai Köpont, Pécs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, Hungary|HCG - Multy Speciality Hospital, Ahmedabad, India|Hemato-Oncology Clinic Ahmedabad Pvt Ltd, Ahmedabad, India|Sujan Surgical Cancer Hospital and Amracvati Cancer Foundation, Amravati, India|Sri Venkateshwara Hospital [Medical Oncology], Bangalore, India|Apollo Speciality Hospital, Chennai, India|Dr. Kamahshi Memorial Hospital [Oncology], Chennai, India|BIBI General Hospital & Cancer Centre [Oncology], Hyderabad, India|Yashoda B-Block Hospital, Hyderabad, India|B.P.Poddar Hospital and Medical Research Ltd, Kolkata, India|Apollo Gleneagles Hospitals Kolkata, Kolkata, India|Shatabdhi Superspeciality Hospital, Nashik, India|Grant Medical Foundation - Ruby Hall Clinic, Pune, India|City Cancer Centre [Surgical and Medical Oncology], Vijayawada, India|Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy|Ospedale Vito Fazzi, ASL Lecce, Lecce, Italy|Presidio Ospedaliero ""Alessandro Manzoni"", AO Provincia di Lecco, Lecco, Italy|Ospedale Sacro Cuore e Don Calabria - Negrar, Negrar, Italy|Ospedale S.Carlo di Potenza [U.O. di Oncologia Medica], Potenza, Italy|Centro Oncologico De Chihuahua, Chihuahua, Mexico|Hospital de Jesus, Mexico, Mexico|Centro Medico Quirurgico, Mexico, Mexico|OCA Hospital/Monterrey International Research Center, Monterrey, Mexico|Centro Regiomontano de Investigación Clínica, Monterrey, Mexico|Bialostockie Centrum Onkologii im. M.Sklodowskiej-Curie, Bialystok, Poland|Wojewodzki Szpital Zespolony w Elblagu, Oddzial Onkologiczny, Elblag, Poland|Niepubliczny Specjalist. Onkol. Zaklad Opieki Zdrowotnej, Koscierzyna, Poland|Wojewodzki Szpital Specjalistyczny im. M.Kopernika, Lodz, Poland|Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego, Lomza, Poland|Olsztynski Osrodek Onkologiczny ""KOPERNIK"", Olsztyn, Poland|Szpital Rejonowy im. dr J. Rostka w Raciborzu, Raciborz, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka, Slupsk, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie, Warszawa, Poland|NZOZ Magodent - Centrum Medczyne Ostrobramska, Warszawa, Poland|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"" Baia-Mare [Oncologie Medicala], Baia-Mare, Romania|Spitalul Universitar de Urgenta Elias [Oncologie Medicala], Bucuresti, Romania|Spitalul Clinic CF nr.2 Bucuresti [Oncologie Medicala], Bucuresti, Romania|Spitalul Universitar de Urgenta Bucuresti, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Alex. Trestioreanu"" [Sectia Clinica Radioterapie II], Bucuresti, Romania|Oncolab - Oncology Center Craiova, Craiova, Romania|Institutul Regional de Oncologia, Iasi, Romania|Spitalul Municipal Onesti [Sectia Oncologie Medicala], Onesti, Romania|Spitalul Clinic Judetean Mures, Tg Mures, Romania|Oncomed SRL, Timisoara, Romania|GUZ Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|Ivanovo Regional Oncological Dispensary [Chemotherapy], Ivanovo, Russian Federation|GAUZ Republic Clinical Oncology Dispensary of Ministry of Health of Republic Tatarstan, Kazan, Russian Federation|GOU VPO Krasnoyarsk State Medical University n.a. prof. V.F., Krasnoyarsk, Russian Federation|GUZ Lipetsk Regional Oncology Dispensary [General Oncology], Lipetsk, Russian Federation|GUZ Regional Oncology Dispensary #2, Magnitogorsk, Russian Federation|Russian Cancer Research Center, Moscow, Russian Federation|SBHI of Moscow City Oncology Clinical Hospital #62, Moscow, Russian Federation|MBUZ City Clinical Hospital #1, Novosibirsk, Russian Federation|FGBU Medical Radiology Scientific Center, Obninsk, Russian Federation|GUZ Perm Regional Oncology Dispensary, Perm, Russian Federation|GUZ Pyatigorsk Oncology Dispensary [Outpatient Department], Pyatigorsk, Russian Federation|GOU VPO - Ryazan State Med. Univer. n.a. I.I.Pavlov based Ryazan Regio, Ryazan, Russian Federation|City Oncology Dispensary, Saint Petersburg, Russian Federation|GOU VPO Saint-Petersburg State Medical University n.a. acad., Saint Petersburg, Russian Federation|St. Petersburg Clinical Oncology Dispesary - 3rd Gynecology D, Saint Petersburg, Russian Federation|GUZ ""Leningrad Regional Oncology Dispensary"", Saint-Petersburg, Russian Federation|GUZ Samara Regional Clinical Oncology Dispensary, Samara, Russian Federation|FGU Research Institute of Oncology n.a. N.N.Petrov of Rosmed, St. Petersburg, Russian Federation|Stavropol Regional Clinical Oncology Dispensary, Stavropol, Russian Federation|GBUZ - Clinical Oncology Dispensary of MoH of Republic Bahkortostan, Ufa, Russian Federation|GUZ Republican Clinical Oncological Dispensary of public, Ufa, Russian Federation|Komunalnyi ""Cherkaskyi oblasnyi onkolohichnyi dyspanser"" Cherkaskoi oblasnoi rady, oblasnyi onkokhimioterapevtychnyi tsentr, m. Cherkasy, Cherkasy, Ukraine|Komunalnyi likuvalno-profilaktychnyi zaklad ""Chernigivskyi, Chernigiv, Ukraine|Chmelnytskyi Regional Clinical Oncology Centre [Oncology], Chmelnytskyi, Ukraine|Komunalnyizaklad Miska bahatoprofilna klinichna likarnia #4, Dnipropetrovks, Ukraine|Donetskyi oblasnyi protypukhlynnyi tsentr, Donetsk, Ukraine|Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr, Kharkiv, Ukraine|Kyirskyi Miskyi klinichnyi onkolohichnyi tsentr, Kyiv, Ukraine|KZ KOR Kyivskyi oblasnyi onkologichnyi dyspanser, Kyiv, Ukraine|Lvivskyi derzhavnyi onkologichnyi regionalnyi likuvalno diahnostychyi tsentr, Lviv, Ukraine|Odeska oblasna klinichna likarnia, Odessa, Ukraine|Poltavskyi oblasnyi klinichnyi onkolohichnyi dyspanser Pol, Poltava, Ukraine|Zakarpatskyi oblasnyi klinichnyi onkodyspanser, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01339260"
583,"NCT01363479","An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting",,"Completed","Has Results","Chemotherapy-Induced Nausea and Vomiting","Drug: Oral palonosetron|Drug: I.V. palonosetron|Drug: Dexamethasone","Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication|Percentage of Patients With no Emesis|Percentage of Patients With no Rescue Medication","Helsinn Healthcare SA|Parexel","All","18 Years and older   (Adult, Older Adult)","Phase 3","743","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PALO-10-01","July 2011","November 2012","November 2012","June 1, 2011","November 17, 2014","September 22, 2021","Genesis Cancer Centre, Hot Springs, Arkansas, United States|Compassionate Cancer Center, Corona, California, United States|Compassionate Cancer Centre Medical Group, Fountain Valley, California, United States|Facey Medical Group, Mission Hills, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Wellmont Medical Associates-Oncology and Hematology, Bristol, Rhode Island, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|Northern Utah Associates [Hematology/ Oncology], Ogden, Utah, United States|Centro Oncológico Integral (COI), Mar del Plata, Buenos Aires, Argentina|Instituto Oncológico de Córdoba (IONC), Cordoba, Argentina|Clínica Universitaria Reina Fabiola, Córdoba, Argentina|Instituto Médico CER [Oncology], Quilmes, Argentina|Sanatorio Parque, Rosario, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|MHAT Dr. Tota Venkova, Gabrovo, Bulgaria|Specialized Hospital for Active Treatement of Oncology Diseases - Sofia District Medical Oncology Department, Sofia, Bulgaria|UMHAT ""Tsaritsa Yoanna - ISUL"" Ltd.Medical Oncology Clinic, Sofia, Bulgaria|Specialised Hospital for Active treatment on Oncology, Sofia, Bulgaria|District Dispensery for Oncology Diseases with in-patient, Sofia, Bulgaria|Complex Oncology Centre, Stara Zagora, Bulgaria|Klinicki bolnicki centar [Oncology], Osijek, Croatia|KBC Rijeka, Rijeka, Croatia|Opca bolnica Varazdin, Varazdin, Croatia|KBC Zagreb, Zagreb, Croatia|Klinicka bolnica [Sestre milosrdnice], Zagreb, Croatia|Klinik und Poliklinik für Onkologie und Hämatologie Universitätsmedizin Charité Mitte, Berlin, Germany|OncoResearch Lerchenfeld UG, Hamburg, Germany|Städtisches Klinikum München, München, Germany|Staedtisches Krankenhaus Muenchen Neuperlach, München, Germany|Semmelweis Egyetem Kútvölgyi Klinikai Tömb, Budapest, Hungary|Fővárosi Önkormányzat Uzsoki utcai Kórház, Budapest, Hungary|Petz Aladár Megyei Oktató Kórház, Györ, Hungary|Bács-Kiskun Megyei Önkormányzat Kórháza, Szeged, Kecskemet, Hungary|Pécsi Tudományegyetem [Onkoterápiás Intézet], Pécs, Hungary|Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz, Szolnok, Hungary|Yashoda Super speciality Hospital, Hyderabad, Andhra Pradesh, India|Sujan Surgical Cancer Hospital and Amracvati Cancer Foundation, Pune, Maharashtra, India|Apollo Speciality Hospital, Chennai, Tamil Nadu, India|Sri Venkateshwara Hospital [Medical Oncology], Bangalore, India|Chinmaya Mission Hospital, Bangalore, India|City Cancer Centre [Surgical and Medical Oncology], Vijayawada, India|Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy|Ospedale Vito Fazzi - ASL Lecce, Lecce, Italy|Presidio Ospedaliero ""Alessandro Manzoni"", Lecco, Italy|AO Regionale S.Carlo di Potenza, Potenza, Italy|Szpital Wojewodzki Zespolony, Elblag, Poland|Wojewodzki Szpital Specjalistyczny im. M.Kopernika, Lodz, Poland|Szpital Wojewodzki w Lomzy im. Kardynala S. Wyszynskiego, Lomza, Poland|Wojewodzki Szpital Specjalistyczny im. J. Korczaka, Slupsk, Poland|Centrum Onkologii - Instytut im. Marii Sklodowskiej - Curie, Warszawa, Poland|NZOZ Magodent - Centrum Medczyne Ostrobramska, Warszawa, Poland|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"", Baia-Mare, Romania|Institutul Oncologic ""Prof. Dr. Alex. Trestioreanu"", Bucharest, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"", Cluj-Napoca, Romania|Spitalul Clinic Judetean de Urgenta Cluj (Oncologie Medicala), Cluj-Napoca, Romania|Centrul de Oncologie Euroclinic, Iasi, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Spitalul Clinic Judetean de Urgenta Sibiu [Oncologie], Sibiu, Romania|Oncomed SRL, Timisoara, Romania|GUZ Arkhangelsk Regional Clinical Oncological Dispensary, Arkhangelsk, Russian Federation|GOU VPO Krasnoyarsk State Medical University n.a. prof. V.F., Krasnoyarsk, Russian Federation|GUZ Lipetsk Regional Oncology Dispensary [General Oncology], Lipetsk, Russian Federation|GUZ Regional Oncology Dispensary #2, Magnitogorsk, Russian Federation|RAMN - Russian Cancer Research Center, Moscow, Russian Federation|Russian Oncology Research Center n.a. N.N. Blokhin RAMN, Moscow, Russian Federation|MBUZ City Clinical Hospital #1 [Oncology], Novosibirsk, Russian Federation|FGBU ""Medical Radiology Scientific Center of Minzdravsotsrazvitiya RF, Obninsk, Russian Federation|Ryazan State Med. Univer. n.a. I.I.Pavlov based Ryazan Regio, Ryazan, Russian Federation|GUZ Leningrad Regional Oncological Dispensary, Saint Petersburg, Russian Federation|St. Petersburg Clinical Oncology Dispesary, Saint Petersburg, Russian Federation|Komunalnyi likuvalno-profilaktychnyi zaklad ""Chernigivskyi, Chernihiv, Ukraine|Komunalnyi zaklad Miska bahatoprofilna klinichna likarnia #4, Dnipropetrovsk, Ukraine|Komunalno-klinichnyi likuvalno-profilaktychnyi zaklad, Donetsk, Ukraine|DU IMR AMNU [vd khemter], Kharkiv, Ukraine|Kharkivskyi oblasnyi onkologichnyi klinichnyi tsentr, Kharkiv, Ukraine|Chmelnytskyi Regional Clinical Oncology Centre [Oncology], Khmelnytskyi, Ukraine|Uzhgorod National University, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT01363479"
584,"NCT01459757","Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib",,"Completed","No Results Available","GIST","Other: non-interventional","Mutational status data retrospectively accessed correlated with A6181036 clinical outcomes data in GIST subjects treated with sunitinib","Pfizer","All","18 Years and older   (Adult, Older Adult)",,"322","Industry","Observational","Time Perspective: Retrospective","A6181199","October 2011","April 2013","April 2013","October 26, 2011",,"June 19, 2013","City of Hope, Duarte, California, United States|Washington Hospital Center, Washington, District of Columbia, United States|Davis Cancer Pavilion and Shands Medical Plaza, Gainesville, Florida, United States|Shands Cancer Hospital at the University of Florida, Gainesville, Florida, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Masonic Cancer Center - Clinical Trials Office, Minneapolis, Minnesota, United States|Oregon Health and Science University, Portland, Oregon, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|Prince of Wales Hospital, Oncology Day Center, Randwick, New South Wales, Australia|Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia|Peter MacCallum Cancer Institute, Department of Medical Oncology, East Melbourne, Victoria, Australia|UZ Leuven, Leuven, Belgium|Hopital Notre-dame du Centre Hospitalier Universitaire de Montreal, Montreal, Quebec, Canada|Herlev Hospital, Herlev, Denmark|Helsingin yliopistollinen keskussairaala/Syopatautien klinikka, Helsinki, Finland|Institut Bergonie, Bordeaux Cedex, France|Centre L� B�rd, Lyon Cedex, France|CHU La Timone, Service d'Oncologie Medicale, Marseille, France|HELIOS Klinikum Berlin-Buch, Klinik fuer Interdisziplinaere Onkologie, Berlin, Germany|Schwerpunktpraxis fuer ambulante Tumortherapie, Duesseldorf, Germany|Klinikum der Universitaet zu Koeln, Koeln, Germany|Tata Memorial Centre, Mumbai, Maharashtra, India|Seoul National University Hospital/Department of Internal Medicine, Seoul, Korea, Republic of|Asan Medical Center, Department of Internal Medicine, Seoul, Korea, Republic of|Leids Universitair Medisch Centrum/ Klinische Oncologie, Leiden, Netherlands|Klinika Nowotworow Tkanek Miekkich i Kosci, Warszawa, Poland|Narodny Onkologicky ustav, Bratislava, Slovakia|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Sarcoma Unit, London, United Kingdom|Christie Hospital NHS Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01459757"
585,"NCT01794793","Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies",,"Active, not recruiting","No Results Available","Cushing's Disease|Acromegaly|Neuroendocrine Tumors|Pituitary Tumors|Ectopic ACTH Secreting (EAS) Tumors|Dumping Syndrome|Prostate Cancer|Melanoma Negative for bRAF|Melanoma Negative for nRAS","Drug: Pasireotide|Drug: Cabergoline","Incidence of adverse events to evaluate long term safety data|Percentage of patients with clinical benefit as assessed by the investigator","RECORDATI GROUP","All","18 Years and older   (Adult, Older Adult)","Phase 4","413","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSOM230B2412","June 10, 2013","June 9, 2023","June 9, 2023","February 20, 2013",,"November 3, 2020","Ximed Research SC - SOM230B2412, La Jolla, California, United States|Cedars Sinai Medical Center Cedars Sinai 4, Los Angeles, California, United States|Stanford Universtiy Medical Center Stanford Hospital & Clinics, Stanford, California, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center SC, New York, New York, United States|Virginia Endocrinology Research SC, Chesapeake, Virginia, United States|Swedish Cancer Institute Swedish Cancer Institute (SC), Seattle, Washington, United States|Recordati Investigative Site, Caba, Buenos Aires, Argentina|Recordati Investigative Site, Mar del Plata, Buenos Aires, Argentina|Recordati Investigative Site, Edegem, Antwerpen, Belgium|Recordati Investigative Site, Brugge, Belgium|Recordati Investigative Site, Brussel, Belgium|Recordati Investigative Site, Bruxelles, Belgium|Recordati Investigative Site, Gent, Belgium|Recordati Investigative Site, Leuven, Belgium|Recordati Investigative Site, Liege, Belgium|Recordati Investigative Site, Wilrijk, Belgium|Recordati Investigative Site, Fortaleza, CE, Brazil|Recordati Investigative Site, Curitiba, PR, Brazil|Recordati Investigative Site, Rio de Janeiro, RJ, Brazil|Recordati Investigative Site, Porto Alegre, RS, Brazil|Recordati Investigative Site, Joinville, SC, Brazil|Recordati Investigative Site, Botucatu, SP, Brazil|Recordati Investigative Site, Sao Paulo, SP, Brazil|Recordati Investigative Site, Sofia, Bulgaria|Recordati Investigative Site, Halifax, Nova Scotia, Canada|Recordati Investigative Site, London, Ontario, Canada|Recordati Investigative Site, Montreal, Quebec, Canada|Recordati Investigative Site, Montreal, Quebec, Canada|Recordati Investigative Site, Toulouse, Cedex 9, France|Recordati Investigative Site, Angers cedex 09, France|Recordati Investigative Site, Bron Cedex, France|Recordati Investigative Site, Le Kremlin Bicetre, France|Recordati Investigative Site, Lille Cedex, France|Recordati Investigative Site, Marseille cedex 05, France|Recordati Investigative Site, Pessac Cedex, France|Recordati Investigative Site, Pierre Benite Cedex, France|Recordati Investigative Site, Berlin, Germany|Recordati Investigative Site, Hamburg, Germany|Recordati Investigative Site, Muenchen, Germany|Recordati Investigative Site, Muenchen, Germany|Recordati Investigative Site, Tübingen, Germany|Recordati Investigative Site, Ulm, Germany|Recordati Investigative Site, Wuerzburg, Germany|Recordati Investigative Site, Athens, GR, Greece|Recordati Investigative Site, Budapest, Hungary|Recordati Investigative Site, Bangalore, Karnataka, India|Recordati Investigative Site, Vellore, Tamil Nadu, India|Recordati Investigative Site, Petach Tikva, Israel|Recordati Investigative Site, Ancona, AN, Italy|Recordati Investigative Site, Genova, GE, Italy|Milano Investigative Site, Milano, MI, Italy|Recordati Investigative Site, Padova, PD, Italy|Recordati Investigative Site, Roma, RM, Italy|Recordati Investigative Site, Nagoya, Aichi, Japan|Recordati Investigative Site, Maebashi city, Gunma, Japan|Recordati Investigative Site, Kobe-shi, Hyogo, Japan|Recordati Investigative Site, Nankoku city, Kochi, Japan|Recordati Investigative Site, Kyoto-city, Kyoto, Japan|Recordati Investigative Site, Suita city, Osaka, Japan|Recordati Investigative Site, Seoul, Korea, Republic of|Recordati Investigative Site, Seoul, Korea, Republic of|Recordati Investigative Site, Kuala Lumpur, Malaysia|Recordati Investigative Site, Pulau Pinang, Malaysia|Recordati Investigative Site, México, Distrito Federal, Mexico|Recordati Investigative Site, Guadalajara, Jalisco, Mexico|Recordati Investigative Site, Durango, Mexico|Recordati Investigative Site, Mexico City, Mexico|Recordati Investigative Site, Groningen, Netherlands|Recordati Investigative Site, San Isidro, Lima, Peru|Recordati Investigative Site, Gdansk, Poland|Recordati Investigative Site, Poznan, Poland|Recordati Investigative Site, Warszawa, Poland|Recordati Investigative Site, Wroclaw, Poland|Recordati Investigative Site, Porto, Portugal|Recordati Investigative Site, Bucuresti, Romania|Recordati Investigative Site, Barnaul, Russian Federation|Recordati Investigative Site, Moscow, Russian Federation|Recordati Investigative Site, Saint Petersburg, Russian Federation|Recordati Investigative Site, Tyumen, Russian Federation|Recordati Investigative Site, Alicante, Comunidad Valenciana, Spain|Recordati Investigative Site, Barcelona, Spain|Recordati Investigative Site, Lausanne, Switzerland|Recordati Investigative Site, Zuerich, Switzerland|Recordati Investigative Site, Taichung, Taiwan|Recordati Investigative Site, Bangkok, Thailand|Recordati Investigative Site, Bangkok, Thailand|Recordati Investigative Site, Songkla, Thailand|Recordati Investigative Site, Istanbul, TUR, Turkey|Recordati Investigative Site, Ankara, Turkey|Recordati Investigative Site, Antalya, Turkey|Recordati Investigative Site, Istanbul, Turkey|Recordati Investigative Site, Izmir, Turkey|Recordati Investigative Site, Kocaeli, Turkey",,"https://ClinicalTrials.gov/show/NCT01794793"
586,"NCT03449602","Minirigid Versus Conventional Rigid Thoracoscopy in Undiagnosed Pleural Effusions","MICRO","Recruiting","No Results Available","Pleural Effusion","Device: Mini-thoracoscopy|Device: Conventional rigid thoraoscopy","Diagnostic sensitivity (intention-to-treat)|Diagnostic sensitivity (per protocol)|Sedative and analgesic dose|Pain scores by visual analog scale|Diagnostic specificity|Adverse effects|Scope maneuverability|Ease of obtaining biopsy|Incision size|Procedure duration|Pain scores by Wong Baker FACES pain rating scale","Postgraduate Institute of Medical Education and Research","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","NK/3695/Res","March 1, 2018","September 30, 2022","September 30, 2022","February 28, 2018",,"April 26, 2022","Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03449602"
587,"NCT02773485","Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma",,"Recruiting","No Results Available","Cholangiocarcinoma","Radiation: High Dose Radiation|Drug: Systemic chemotherapy","Overall Survival|loco-regional progression free survival|Toxicity Assessment|Quality of Life Assessment of patients over a period of time|Surgical Resectability Rates|cause specific survival","Tata Memorial Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","155","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TMC IRB 1457","May 2015","June 2022","June 2022","May 16, 2016",,"April 27, 2022","Advanced Centre of Treatment Research and Education In Cancer,Tata Memorial Centre, Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02773485"
588,"NCT01362062","Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy",,"Completed","Has Results","Rheumatoid Arthritis","Drug: Tocilizumab","Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs)|Percentage of Participants Achieving a Clinically Meaningful Improvement in Disease Activity Score 28 (DAS28) (Reduction of At Least 1.2 Units) at Every Visit|Time Required to Achieve Clinically Meaningful Improvement in DAS28 (Reduction of At Least 1.2 Units)|Percentage of Participants Achieving Low Disease Activity (DAS28 Less Than [<] 3.2 Units) at Every Visit|Time Required to Achieve Low Disease Activity (DAS28 <3.2 Units)|Percentage of Participants Achieving Remission (DAS28 <2.6 Units) at Every Visit|Time Taken to Achieve Remission (DAS28 <2.6 Units)|Percentage of Participants Achieving American College of Rheumatology (ACR) 20, ACR50, ACR70 and ACR90 Responses at Every Visit|Change From Baseline (CFB) in ESR Values at Every Visit|Change From Baseline in C-Reactive Protein (CRP) Levels at Every Visit|Participant's Global Assessment of Disease Activity Using VAS: Mean Change From Baseline at Every Visit|Physician's Global Assessment of Disease Activity Using VAS: Mean Change From Baseline at Every Visit|Participant's Assessment of Pain Using VAS: Mean Change From Baseline at Every Visit|Health Assessment Questionnaire Disability Index (HAQ-DI): Mean Change From Baseline at Every Visit","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)",,"110","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ML22835","October 26, 2010","January 1, 2015","January 1, 2015","May 27, 2011","April 4, 2016","August 2, 2017","Sir Gangaram Hospital, New Delhi, Delhi, India|Healing Touch City Clinic, Chandigarh, India|Excel Center, Guwahati, India|Arthritis Superspeciality Centre, Hubli, India|Centre for Rheumatic Diseases - Mumbai, Mumbai, India|Jivdaya Clinic, Mumbai, India|Fortis Hospital, Noida, India",,"https://ClinicalTrials.gov/show/NCT01362062"
589,"NCT02165215","A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors","LAUREL","Completed","Has Results","Colitis, Ulcerative","Drug: Etrolizumab|Drug: Placebo","Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants With a Clinical Response at Week 10, as Determined by the Mayo Clinic Score (MCS)|Maintenance Phase: Percentage of Participants Who Maintained Clinical Remission at Week 62 Among Randomized Participants in Clinical Remission at Week 10, as Determined by the MCS|Maintenance Phase: Percentage of Participants in Clinical Remission at Week 62, as Determined by the MCS|Maintenance Phase: Percentage of Participants in Remission at Week 62 Among Randomized Participants in Remission at Week 10, as Determined by the MCS|Maintenance Phase: Percentage of Participants With Improvement From Baseline in Endoscopic Appearance of the Mucosa at Week 62, as Determined by the MCS Endoscopic Subscore|Maintenance Phase: Percentage of Participants With Endoscopic Remission at Week 62, as Determined by the MCS Endoscopic Subscore|Maintenance Phase: Percentage of Participants With Histologic Remission at Week 62, as Determined by the Nancy Histological Index|Maintenance Phase: Percentage of Participants With Corticosteroid-Free Clinical Remission at Week 62 Among Participants Who Were Receiving Corticosteroids at Baseline, as Determined by the MCS|Maintenance Phase: Percentage of Participants With Corticosteroid-Free Remission at Week 62 Among Participants Who Were Receiving Corticosteroids at Baseline, as Determined by the MCS|Maintenance Phase: Change From Baseline to Week 62 in UC Bowel Movement Signs and Symptoms, as Assessed by the Ulcerative Colitis Patient-Reported Outcome Signs and Symptoms (UC-PRO/SS) Questionnaire|Maintenance Phase: Change From Baseline to Week 62 in UC Functional Symptoms, as Assessed by the UC-PRO/SS Questionnaire|Maintenance Phase: Change From Baseline to Week 62 in Health-Related Quality of Life, as Assessed by the Overall Score of the Inflammatory Bowel Disease Questionnaire (IBDQ)|Number of Participants With at Least One Adverse Event by Severity, According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)|Number of Participants With Adverse Events Leading to Study Drug Discontinuation|Number of Participants With Serious Infection-Related Adverse Events|Number of Participants With Infection-Related Adverse Events by Severity, According to NCI-CTCAE v4.0|Number of Participants With Injection-Site Reactions by Severity, According to NCI-CTCAE v4.0|Number of Participants With Hypersensitivity Reaction Events by Severity, According to NCI-CTCAE v4.0|Number of Participants With Malignancies|Number of Participants With Anti-Therapeutic Antibodies (ATAs) to Etrolizumab|Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Above LLOQ)|Maintenance Phase: Etrolizumab Serum Trough Concentration (for Arms/Timepoints Below LLOQ)","Hoffmann-La Roche","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","359","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GA29102|2013-004280-31","August 12, 2014","April 6, 2020","April 6, 2020","June 17, 2014","June 15, 2021","August 19, 2021","University of California, Irvine Medical Center, Orange, California, United States|Clinical Applications Laboratories, Inc., San Diego, California, United States|University of California at San Francisco, San Francisco, California, United States|Ventura Clinical Trials, Ventura, California, United States|Peak Gastroenterology Associates; Gastroenterology, Colorado Springs, Colorado, United States|Clinical Research of the Rockies, Lafayette, Colorado, United States|West Central Gastroenterology d/b/a Gastro Florida, Clearwater, Florida, United States|IMIC, Inc, Miami Beach, Florida, United States|Regenerate Clinical Trials, Miami, Florida, United States|Advanced Research Institute, Inc., Trinity, Florida, United States|Shafran Gastroenterology Center, Winter Park, Florida, United States|Northwestern University-Feinberg School of Medicine; Division of Gastroenterology and Hepatology, Chicago, Illinois, United States|Southwest Gastroenterology, Oak Lawn, Illinois, United States|Aquiant Research, New Albany, Indiana, United States|Louisiana Research Center, LLC, Shreveport, Louisiana, United States|Commonwealth Clinical Studies, Brockton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Center for Digestive Health, Troy, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Ehrhardt Clinical Research, LLC, Belton, Missouri, United States|Manhattan Clinical Research, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|Asheville Gastroenterology Associates, P.A., Asheville, North Carolina, United States|UNC at Chapel Hill - Dpt of Family Medicine; Center for Functional GI and Motility Disorders, Chapel Hill, North Carolina, United States|Kinston Medical Specialists, Kinston, North Carolina, United States|Texas Digestive Disease Consultants - Dallas, Dallas, Texas, United States|Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States|Digestive Health Specialists of Tyler, Tyler, Texas, United States|Ericksen Research and Development, Clinton, Utah, United States|University of Utah School of Medicine, Salt Lake City, Utah, United States|McGuire Research Institute; Gastroenterology, Richmond, Virginia, United States|Northwest Gastroenterology Associates, Bellevue, Washington, United States|Hospital Universitario Walter Cantidio - UFC, Fortaleza, CE, Brazil|Centro Digestivo de Curitiba, Curitiba, PR, Brazil|Hospital Moinhos de Vento, Porto Alegre, RS, Brazil|CECIP - Centro de Estudos Clínicos do Interior Paulista, Jaú, SP, Brazil|Pesquisare Saúde Sociedade Simples, Santo Andre, SP, Brazil|Hospital Estadual Mario Covas, Santo Andre, SP, Brazil|Hospital Sírio-Libanês, Sao Paulo, SP, Brazil|Hospital do Servidor Público Estadual/HSPE-SP, São Paulo, SP, Brazil|Pacific Gastroenterology Associates, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre; Gastroenterology Research, Halifax, Nova Scotia, Canada|LHSC - University Hospital; Movement Disorders Program, London, Ontario, Canada|London Health Sciences Centre Victoria Hospital; Research Pharmacy, London, Ontario, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Toronto Digestive Disease Associates, Vaughan, Ontario, Canada|Fakultni nemocnice u sv. Anny v Brne; I.Interni kardioangiologicka klinika, Brno, Czechia|Hepato-Gastroenterologie HK, s.r.o., Hradec Kralove, Czechia|Nemocnice Na Bulovce, Prague, Czechia|Alborg Universitets Hospital, Aalborg, Denmark|Herlev og Gentofte Hospital, Herlev, Denmark|Charite Universitaetsmedizin Berlin - Campus Charite Mitte, Berlin, Germany|Berufsgenossenschaftliches Universitaetsklinikum Bergmannsheil GmbH, Bochum, Germany|Ärztezentrum Ellwangen; Gemeinschaftspraxis, Ellwangen, Germany|Klinik Johann Wolfgang von Goethe Uni, Frankfurt, Germany|Medizinische Hochschule Hannover; Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hannover, Germany|Universitaetsklinikum Jena; Apotheke des Uniersitätsklinikums Jena, Jena, Germany|Medizinisches Zentrum Klinikum Lueneburg, Lueneburg, Germany|Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany|DRC Gyogyszervizsgalo Kozpont Kft, Balatonfured, Hungary|Pannónia Klinika Magánorvosi, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pest Megyei Flor Ferenc Korhaz, Kistarcsa, Hungary|Csongrad Megyei Dr. Bugyi Istvan Korhaz, Szentes, Hungary|Osmania General Hospital, Hyderabad, Andhra Pradesh, India|Deccan College of Medical Sciences and Allied Hospitals, Hyderabad, Andhra Pradesh, India|Pushpawati Singhania Research Institute, New Delhi, Delhi, India|Shree Giriraj Multispeciality Hospital, Rajkot, Gujarat, India|Nirmal Hospital, Surat, Gujarat, India|K.L.E. Society's Dr. Prabhakar Kore Hospital and Medical Research Centre, Belgaum, Karnataka, India|M. S. Ramaiah Medical College and Hospital, Bengaluru, Karnataka, India|Midas institute of Gastroenterology, Nagpur, Maharashtra, India|Dayanand Medical College and Hospital, Ludhiana, Punjab, India|S. R. Kalla Memorial General Hospital, Jaipur, India|Kasturba Medical College & Hospital, Mangalore, India|Ruby Hall Clinic, Pune, India|King Edward Memorial Hospital Research Centre, Pune, India|Assaf Harofeh Medical Center, Beer Yaacov, Israel|Bnei Zion Medical Center; Department of Internal Medicine B, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Holy Family Hospital, Nazareth, Israel|Ospedale Sandro Pertini, Roma, Lazio, Italy|Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Lombardia, Italy|Ospedale di Circolo; Neuropsichiatria Infantile, Rho, Lombardia, Italy|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Sicilia, Italy|Centro Regiomontano de Estudios Clínicos Roma S.C., Monterrey, Nuevo LEON, Mexico|Instituto de Investigaciones Aplicadas a la Neurociencia A.C., Durango, Mexico|Phylasis Clinicas Research S de RL de CV, Estado de México, Mexico|Zespó Przychodni Specjalistycznych PRIMA, Warszawa, Poland|LexMedica Osrodek Badan Klinicznych, Wroclaw, Poland|Fakultna nemocnica Nitra, Nitra, Slovakia|Endomed, s.r.o., Vranov nad Topľou, Slovakia|Dr JP Wright Practice, Cape Town, South Africa|Emmed Research, Pretoria, South Africa|CI of SRC Sumy RCH Dept of Rheumatology Sumy SU MI, Sumy, Kharkiv Governorate, Ukraine|CI of Kyiv RC Kyiv Regional Clinical Hospital, Kyiv, KIEV Governorate, Ukraine|Lviv Regional Clinical Hospital, Lviv, KIEV Governorate, Ukraine|A.Novak Transcarpathian Regional Clinical Hospital, Uzhgorod, KIEV Governorate, Ukraine|Odessa regional clinical Hospital, Odessa, Ukraine|M.V. Sklifosovskyi Poltava RCH Dept of Gastroenterology HSEIU UMSA, Poltava, Ukraine|SI Divisional Clinical Hospital of Uzhgorod Station of ST&BA LZ Dep of Therapy SHEI Uzhgorod NU, Uzhgorod, Ukraine|M.I. Pyrogov VRCH Dept of Gastroenterology M.I. Pyrogov VNMU, Vinnytsia, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02165215/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02165215/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02165215"
590,"NCT00431236","A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy",,"Completed","No Results Available","Nausea and Vomiting, Chemotherapy-Induced","Drug: Oral Casopitant (GW679769)|Drug: IV Casopitant (GW679769)|Drug: IV ondansetron hydrochloride|Drug: Oral dexamethasone","Number of participants who achieved complete response|Number of participants who achieved complete response during the acute (0-24 hours) and the delayed (24-120 hours) phase following the first cycle of HEC|Number of participants who achieved a complete response during the overall (0-120 hours) phase following subsequent cycles of HEC|Maximum nausea score (to assess the severity of nausea), as assessed by a visual analogue scale (VAS)|Number of participants who use of anti-emetic rescue medication|Number of participants with first emetic event|Number of participants who received anti-emetic rescue medication|Number of participants who vomited/retched|Number of participants who reported significant nausea (>=25 mm on the VAS)|Number of participants who reported nausea (>=5 mm on the VAS)|Number of participants who achieved complete protection, defined as no vomiting/retching, no significant nausea and no rescue medication|Number of participants who achieved total control, defined as no vomiting/retching, no nausea and no rescue medication|The impact on participants daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the Functional Living Index-Emesis (FLIE) questionnaire-Score|Percentage of participants with impact on daily life activities for the first 120 hours following the first cycle of chemotherapy as assessed by the FLIE questionnaire-interpretation|Participant satisfaction with the prophylactic anti-emetic regimens, as assessed by the participant satisfaction questionnaire|The willingness of participant to use the same treatment during future chemotherapy, as assessed by the participant willingness questionnaire|Number of participants with nausea as assessed by a categorical scale, over the first 120 hours following HEC|Number of participants with adverse events (AE) and serious adverse events (SAE)|Number of participants with abnormalities of Grade 3 and 4 in laboratory parameters (clinical chemistry and hematology)|Summary of abnormal electrocardiogram findings|Summary of mean systolic blood pressure (SBP) and diastolic blood pressure (DBP)|Summary of mean respiratory rate|Summary of mean heart rate","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","810","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Prevention","NKV102551","November 6, 2006","October 9, 2007","October 9, 2007","February 5, 2007",,"August 22, 2017","GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Tucuman, Argentina|GSK Investigational Site, Edegem, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Liège, Belgium|GSK Investigational Site, Sofia, Bulgaria|GSK Investigational Site, Varna, Bulgaria|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Zagreb, Croatia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Jihlava, Czechia|GSK Investigational Site, Ostrava, Czechia|GSK Investigational Site, Praha 5, Czechia|GSK Investigational Site, Tabor, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Kangasala, Finland|GSK Investigational Site, Turku, Finland|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Kavala, Greece|GSK Investigational Site, Papagos, Athens, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Mátraháza, Hungary|GSK Investigational Site, Székesfehérvár, Hungary|GSK Investigational Site, Kochi, India|GSK Investigational Site, Tirupati, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Tallaght, Dublin, Ireland|GSK Investigational Site, Wilton, Cork, Ireland|GSK Investigational Site, Monteforte Irpino, Campania, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Sassari, Sardegna, Italy|GSK Investigational Site, Pisa, Toscana, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Kubang Kerian, Malaysia|GSK Investigational Site, Penang, Malaysia|GSK Investigational Site, Sarawak, Malaysia|GSK Investigational Site, Islamabad, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Baguio City, Benguet, Philippines|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Quezon City, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Bydgoszcz, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Bucuresti, Romania|GSK Investigational Site, Iasi, Romania|GSK Investigational Site, Timisoara, Romania|GSK Investigational Site, Banska Bystrica, Slovakia|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Poprad, Slovakia|GSK Investigational Site, Avila, Spain|GSK Investigational Site, Badalona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, Taichung, Taiwan|GSK Investigational Site, TaoYuan Hsien, Taiwan|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lvov, Ukraine|GSK Investigational Site, Sympheropol, Ukraine|GSK Investigational Site, Uzhgorod, Ukraine",,"https://ClinicalTrials.gov/show/NCT00431236"
591,"NCT03934684","Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma",,"Recruiting","No Results Available","Relapsed Refractory Multiple Myeloma","Drug: Drug: Carfilzomib + Dexamethasone|Drug: Drug: Carfilzomib + Lenalidomide + Dexamethasone","Number of participants with treatment-emergent adverse events as assessed by CTCAE v4.03|Progression Free Survival|Overall Response Rate|Clinical Benefit Rate|Time to Response|Duration of Response","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20160372","September 16, 2019","March 23, 2023","June 26, 2025","May 2, 2019",,"February 25, 2022","Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Apollo Hospital, Hyderabad, Andhra Pradesh, India|M S Ramaiah Memorial Hospital, Bangalore, Karnataka, India|K L E S Dr Prabhakar Kore Hospital and Medical Research Centre, Belagavi, Karnataka, India|Cytecare Cancer Hospitals, Bengaluru, Karnataka, India|Aster Medcity, Kochi, Kerala, India|Government Medical College, Kozhikode, Kerala, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Mumbai Oncocare Center, Mumbai, Maharashtra, India|Navsanjeevani Hospital, Nashik, Maharashtra, India|Heath Care Group Manavata Cancer Centre, Nashik, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, Pondicherry, India|Cancer Institute WIA, Chennai, Tamil Nadu, India|Thangam Cancer Centre, Namakkal, Tamil Nadu, India|Valentis Cancer Hospital, Meerut, Uttar Pradesh, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT03934684"
592,"NCT03768960","A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent",,"Active, not recruiting","No Results Available","Multiple Myeloma","Drug: Daratumumab","Incidence of Treatment Emergent Adverse Events (TEAE)|Overall Response Rate (ORR)|Percentage of Participants with Very Good Partial Response (VGPR) or better|Percentage of Participants with Progression Free Survival (PFS)|Time to Response|Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score|Change from Baseline in EuroQol-5 Dimensions (EQ-5D-5L) Score","Johnson & Johnson Private Limited","All","18 Years and older   (Adult, Older Adult)","Phase 4","150","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR108556|54767414MMY4008","June 10, 2019","July 25, 2022","July 25, 2022","December 7, 2018",,"April 22, 2022","Avron Hospitals Pvt. Ltd, Ahmedabad, India|M S Ramaiah Medical College and Hospital, Bengaluru, India|Sparsh Hospitals & Critical Care (Pvt) Ltd, Bhubaneshwar, India|Apollo Hospitals, Bhubaneswar, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Apollo Hospitals, Hyderabad, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Cytecare Hospitals Pvt. Ltd, Karnataka, India|Tata Medical Center, Kolkata, India|Shatabdi Super Speciality Hospital, Mumbai Naka, India|Kingsway Hospital, Nagpur, India|Apex Wellness Hospital, Nashik, India|All India Institute of Medical Sciences, New Delhi, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, India|Noble Hospital Pvt Ltd, Pune, India",,"https://ClinicalTrials.gov/show/NCT03768960"
593,"NCT01209689","A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy",,"Terminated","Has Results","Spondylitis, Ankylosing","Drug: Tocilizumab|Drug: Placebo","Percentage of ASsessment in Ankylosing Spondylitis 20 (ASAS20) Responders at Week 12","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","113","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA22908|2009-017488-40","October 2010","December 2011","December 2011","September 27, 2010","January 17, 2013","January 17, 2013","Huntington Beach, California, United States|Aventura, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Tampa, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Marietta, Georgia, United States|Idaho Falls, Idaho, United States|Wichita, Kansas, United States|Hagerstown, Maryland, United States|St. Claire Shores, Michigan, United States|Freehold, New Jersey, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Greensboro, North Carolina, United States|Duncansville, Pennsylvania, United States|Austin, Texas, United States|Houston, Texas, United States|Heidelberg, Australia|Hobart, Australia|Sydney, Australia|Woodville, Australia|Bruxelles, Belgium|Gent, Belgium|Kortrijk, Belgium|Liege, Belgium|Yvoir, Belgium|Cuiabá, Brazil|Goiania, Brazil|Sao Paulo, Brazil|Sao Paulo, Brazil|São Paulo, Brazil|Plovdiv, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Sofia, Bulgaria|Calgary, Alberta, Canada|Hamilton, Ontario, Canada|Kitchener, Ontario, Canada|Mississauga, Ontario, Canada|St. Catharines, Ontario, Canada|Toronto, Ontario, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Trois-rivières, Quebec, Canada|St. John's, Canada|Bruntal, Czech Republic|Hlucin, Czech Republic|Olomouc, Czech Republic|Prague, Czech Republic|Uherske Hradiste, Czech Republic|Zlin, Czech Republic|Esbjerg, Denmark|Hellerup, Denmark|Vejle, Denmark|Besancon, France|Bordeaux, France|Boulogne-billancourt, France|Creteil, France|Grenoble, France|Le Kremlin Bicetre, France|Lyon Cedex 3, France|Montpellier, France|Orléans Cedex 2, France|Paris, France|Paris, France|Rouen Cedex, France|Strasbourg, France|Vandoeuvre-les-nancy, France|Berlin, Germany|Berlin, Germany|Erlangen, Germany|Frankfurt, Germany|Gommern, Germany|Hamburg, Germany|Hannover, Germany|Heidelberg, Germany|Herne, Germany|Köln, Germany|München, Germany|Regensburg, Germany|Rostock, Germany|Tuebingen, Germany|Würzburg, Germany|Bangalore, India|Bangalore, India|Jaipur, India|New Delhi, India|Secunderabad, India|Ferrara, Italy|Firenze, Italy|Monserrato, Italy|Padova, Italy|Pisa, Italy|Prato, Italy|Reggio Emilia, Italy|Roma, Italy|Siena, Italy|Kaunas, Lithuania|Klaipeda, Lithuania|Amsterdam, Netherlands|Amsterdam, Netherlands|Amsterdam, Netherlands|Bydgoszcz, Poland|Krakow, Poland|Lublin, Poland|Poznan, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Kosice, Slovakia|Piestany, Slovakia|Cape Town, South Africa|Cape Town, South Africa|Durban, South Africa|Pinelands, South Africa|Pretoria, South Africa|Stellenbosch, South Africa|Alcorcon, Spain|Barcelona, Spain|Córdoba, Spain|La Coruna, Spain|Lugo, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Oviedo, Spain|Oviedo, Spain|Sabadell, Spain|Basingstoke, United Kingdom|Bath, United Kingdom|Greenock, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Salford, United Kingdom|Stoke-on-trent, United Kingdom|Wigan, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01209689"
594,"NCT04046250","Phase 2a Study to Evaluate Suppression of Methotrexate-induced Mucositis by TK112690","TK112690","Completed","Has Results","Mucositis","Drug: TK-112690|Drug: Placebo TK-112690","Mucositis|Incidence Adverse Events That Are Related to Treatment","Tosk, Inc.|Crystal Life Sciences","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","22","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","CLP-2690-0003","May 15, 2019","October 10, 2019","March 31, 2020","August 6, 2019","June 3, 2021","June 3, 2021","Bangalore Cancer, Bangalore, Karnataka, India|Karnatak Cancer Therapy and Research Institute, Navanagar, Karnataka, India|Netaji Subhash Chandra Bose Cancer Hospital, Kolkata, West Bengal, India","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/50/NCT04046250/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04046250"
595,"NCT01646437","The International Polycap Study 3 (TIPS-3)","TIPS-3","Completed","No Results Available","Cardiovascular Disease|Fractures|Cancers","Drug: Polycap|Drug: Aspirin|Drug: Vitamin D|Drug: Matching Placebo","Polycap Primary Objective|Aspirin Primary Objective|Vitamin D Primary Objective|Combined Effects of Polycap and Aspirin on CVD Events|Polycap Secondary Objective|Aspirin Secondary Objective|Vitamin D Secondary Objective|Combined Effects of Polycap and Aspirin on CVD Events Secondary Outcome A|Combined Effects of Polycap and Aspirin on CVD Events Secondary Outcome B","Population Health Research Institute|Cadila Pharnmaceuticals|Wellcome Trust|Canadian Institutes of Health Research (CIHR)|Heart and Stroke Foundation of Ontario","All","50 Years and older   (Adult, Older Adult)","Phase 3","7793","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","TIPS-3","June 2012","June 30, 2020","August 30, 2021","July 20, 2012",,"September 16, 2021","Eminence, Dhaka, Bangladesh|Hamilton Health Sciences, Hamilton, Ontario, Canada|Fundaction Oftamologica De Santander (FOSCAL), Bucaramanga, Colombia|St. John's Medical College Hospital, Bangalore, India|Harapan Kita Hopsital, Jakarta, Indonesia|Universiti Teknologi MARA (UiTM), Shah Alam, Selangor, Malaysia|Adult Medicine & Medical Research Unit, Philippine General Hospital, Manila, Philippines|Pamoja Tunaweza Women's Centre, Moshi, Tanzania|Fattouma Bourguiba University Hospital, Monastir, Tunisia",,"https://ClinicalTrials.gov/show/NCT01646437"
596,"NCT03110562","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma","BOSTON","Active, not recruiting","Has Results","Multiple Myeloma","Drug: Selinexor|Drug: Bortezomib|Drug: Dexamethasone","Progression-free Survival (PFS) as Assessed by IRC|Overall Response Rate (ORR) as Assessed by IRC|Percentage of Participants With Response Rates|Overall Survival (OS)|Duration of Response (DOR) as Assessed by IRC|Time-to-next-treatment (TTNT)|Time-to-response (TTR) as Assessed by IRC|Number of Participants With Grade >= 2 Peripheral Neuropathy Events|Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs|Patient-reported Peripheral Neuropathy Measured by European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-CIPN20 Instrument","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCP-330-023","May 24, 2017","February 18, 2020","September 1, 2023","April 12, 2017","July 8, 2021","November 24, 2021","Boca Raton Clinical Research (BRCR) Medical Center, Plantation, Florida, United States|Emory University, Atlanta, Georgia, United States|Kaiser Permanente Hawaii, Honolulu, Hawaii, United States|McFarland Clinic, Ames, Iowa, United States|Stormont Vail Health Care (Cotton O'Neil Cancer Center ), Topeka, Kansas, United States|Commonwealth Hematology, Danville, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|University of Maryland, Baltimore, Maryland, United States|Central Care Cancer Center, Bolivar, Missouri, United States|The Valley Hospital Luckow Pavilion, Paramus, New Jersey, United States|Mount Sinai, New York, New York, United States|The Cancer Institute at St. Francis Hospital, Roslyn, New York, United States|Novant-Forsyth Memorial Hospital, Winston-Salem, North Carolina, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|Southwest Cancer Center of Oklahoma, Lawton, Oklahoma, United States|Kaiser Permanente Northwest OR, Portland, Oregon, United States|SCOR AnMed Health Cancer Center, Anderson, South Carolina, United States|Prairie Lakes Healthcare, Watertown, South Dakota, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|University of Texas Southwestern, Dallas, Texas, United States|Calvary Mater Newcastle, Waratah, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Misericordiae Limited and Mater Medical Research, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Medical University Innsbruck, Department of Internal Medicine V (Hematology and Oncology), Innsbruck, Austria|University Hospital Krems, Department of Internal Medicine II, Krems, Austria|Medical University of Vienna, Vienna, Austria|General Hospital Hietzing, Vienna, Austria|Wilhelminen Hospital, Department of Internal Medicine I, Center for Oncology & Hematology, Vienna, Austria|Jules Bordet Institute, Brussels, Belgium|UCL Saint-Luc, Brussels, Belgium|University Hospital Ghent, Ghent, Belgium|General Hospital Delta, Roeselare, Belgium|St. Augustinus Hospital, Wilrijk, Belgium|University Multiprofile Hospital for Active Treatment, Sveti Georgi Clinic of Clinical Hematology, Plovdiv, Bulgaria|University Multiprofile Hospital for Active Treatment, Sveti Ivan Rilski Clinic of Hematology, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Hematological Diseases, Clinic of Hematology, Dept. of Clinical Hematology, Sofia, Bulgaria|Tom Baker Cancer Center/ Alberta Health Services, Calgary, Alberta, Canada|Cross Cancer Institute / University of Alberta, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia, Canada|North East Cancer Centre Sudbury, Sudbury, Ontario, Canada|Princess Margaret Cancer Research, Toronto, Ontario, Canada|Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada|Royal Victoria Hospital / McGill University, Montreal, Quebec, Canada|L'Hôtel-Dieu de Québec, Quebec City, Quebec, Canada|Saskatchewan Cancer Agency-Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Saskatoon Cancer Center, Saskatoon, Saskatchewan, Canada|General University Hospital in Prague, Praha 2, Prague, Czechia|University Hopsital Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Olomouc, Olomouc, Czechia|University Hospital Ostrava, Dept. of Hematooncology, Ostrava, Czechia|University Hospital Kralovske Vinohrady, Clinic of Internal Hematology, Prague, Czechia|Necker Children's Hospital, Department of Adult Hematology, Paris, Ile De France, France|Hospital Center Departmental La Roche-Sur-Yon, La Roche-sur-Yon, France|Claude Huriez Hospital, Lille, France|South Lyon Hospital Center, Lyon, France|Brabois Adults Hospital, University Hospital Center of Nancy, Nancy, France|Nantes University Hospital Center, Nantes, France|Saint-Louis Hospital, Paris, France|Miletrie Hospital, University Hospital Center of Poitiers, Poitiers, France|University Hospital Freiburg, Department of Internal Medicine I, Freiburg, Baden-Wuerttemberg, Germany|Klinikum Leverkusen gGmbH Medizinisxhe Klinik 3, Leverkusen, North Rhine Westfalia, Germany|Group Practice for Hematology and Oncology, Dresden, Saxony, Germany|Alexandra General Hospital, Therapeutic Clinic, Athens, Greece|General Hospital of Athens ""Evangelismos"", Department of Hematology and Lymphoma, Athens, Greece|University General Hospital of Patra, Pátra, Greece|Theageneion Cancer Hospital, Hematology Department, Thessaloníki, Greece|Semmelweis University, 1st Department of Internal Medicine, Budapest, Hungary|Integrated Szent Istvan and Szent laszlo Hospital, Department of Hematology and Stem Cell Transplantation, Budapest, Hungary|Semmelweis University, 3rd Department of Internal Medicine, Budapest, Hungary|Kaposi Mor Teaching Hospital, 2nd Department of Internal Medicine, Kaposvar, Hungary|Medical Center of the University of Pecs, Department of Hematology, Pecs, Hungary|Regional Cancer Centre, Patna, Bihar, India|Regional Cancer Centre, Thiruvananthapuram, Kerala, India|Prince Aly Khan Hospital, Mumbai, Maharashta, India|Jaslok Hospital and Research Centre, Mumbai, Maharashta, India|Bhaktivedanta Hospital, Thane, Maharashtra, India|IMS & SUM Hospital, Bhubaneswar, Odisha, India|Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, Punjab, India|Dayanand Medical College & Hospital, Ludhiana, Punjab, India|Cancer Institute, Chennai, Tamil Nadu, India|SRM Institute of Medical Sciences, Chennai, Tamil Nadu, India|Saveetha Medical College Hospital, Chennai, Tamil Nadu, India|G. Kuppuswamy Naidu Hospital, Coimbatore, Tamil Nadu, India|Asviratham Speciality Hospital, Madurai, Tamil Nadu, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, India|Yashoda Hospital, Hyderabad, Telengana, India|King George's Medical University, Lucknow, Uttar Pradesh, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India|Nil Ratan Sircar (NRS) Medical College, Kolkata, West Bengal, India|TATA Memorial Centre, Kolkata, West Bengal, India|Rajiv Gandhi Cancer Hospital, New Delhi, India|Barzilai Medical Center, Ashkelon, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petaẖ Tiqwa, Israel|Hospital Santa Maria of Terni, Terni, Umbria, Italy|Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy|ASST Papa Giovanni XXIII, Bergamo, Italy|Polyclinic S. Orsola-Malpighi, Department of Hematology, Oncology and Laboratory Medicine, Operative Unit of Hematology - Cavo, Bologna, Italy|University Hospital Careggi, Department of Hematology, Florence, Italy|University Hospital San Martino, IRCCA, Dept. of Integrative Cancer Therapies, Operative Unit of Clinical Hematology, Genoa, Italy|Hospital Niguerda Ca Granda, Department of Hematology and Oncology, Hematology Unit, Milan, Italy|Umberto I Polyclinic of Rome, Department of Cellular Biotechnology and Hematology, Hematology Center, Rome, Italy|University Hospital San Giovanni Battista of Turin, Turin, Italy|Jan Biziel University Hospital #2 in Bydgoszcz, Department of Hematology, Bydgoszcz, Poland|Independent Public Healthcare Facility Municipal Hospital Group in Chorzow, Department of Hematology, Chorzow, Poland|University Hospital in Krakow, Teaching Unit of the Hematology Department, Krakow, Poland|Independent Public Teaching Hospital No.1 in Lublin, Department of Hematology-Oncology and Bone Marrow Transplantation, Lublin, Poland|St. John of Dukla Oncology Center of Lublin, Department of Hematology, Lublin, Poland|Military Institute of Medicine, Department of Internal Medicine and Hematology, Warsaw, Poland|Nicolaus Copernicus Memorial Provincial Specialist Hospital in Lodz, Department of Hematology, Łódź, Poland|Hyperclnical MedLife PDR Vulturului Brasov, Hematology Department, Braşov, Romania|Colentina Clinical Hospital, Department of Hematology, Bucharest, Romania|Bucharest University Emergency Hospital, Department of Hematology, Bucharest, Romania|S.P. Botkin City Clinical Hospital, Moscow, Russian Federation|N.A. Semashko Central Clinical Hospital #2 under OJSC Russian Railways, Moscow, Russian Federation|First I.P. Pavlov State Medical University of St. Petersburg, Saint Petersburg, Russian Federation|V.A. Almazov North-West Federal Medical Research Center, Chemotherapy of Oncohematology Diseases and Bone Marrow Transplantation Department #1, Saint Petersburg, Russian Federation|Clinical Center of Serbia, Clinic of Hematology, Belgrade, Serbia|Institute of Oncology and Radiology of Serbia, Clinic of Medical Oncology, Belgrade, Serbia|Clinical Center Kragujevac, Clinic of Hematology, Kragujevac, Serbia|Clinical Center Nis, Clinic of Hematology and Clinical Immunology, Nis, Serbia|Clinical Center of Vojvodina, Clinic of Hematology, Novi Sad, Serbia|University Hospital of the Canary Islands, La Laguna, Santa Cruz De Tenerife, Spain|Catalan Institute of Oncology (ICO) Badalona, Badalona, Spain|University Hospital of Vall d'Hebron, Barcelona, Spain|University Hospital Infanta Leonor, Department of Hematology, Madrid, Spain|University Clinical Hospital of Salamanca, Department of Hematology, Salamanca, Spain|University Hospital Virgen del Rocio (HUVR), Seville, Spain|Cherkasy Regional Oncology Center, Regional Treatment and Diagnostic Hematology Center, Department of Hematology, Cherkasy, Ukraine|City Clinical Hospital No.4 of Dnipro City Council, City hematology center, Dnipropetrovsk, Ukraine|BMT Kiev Center, Kiev, Ukraine|Kiev Cancer Institute, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Department of Hematology with Laboratory Group, Lviv, Ukraine|Vinnytsia M.I. Pyrohov Regional Clinical Hospital, Department of Hematology, Vinnytsia, Ukraine|O.F. Herbachevskyi Regional Clinical Hospital, Hematology Department with Intensive Therapy Wards, Zhytomyr, Ukraine|Belfast Heatlh & Social Care Trust Belfast City Hospital, Belfast, Northern Ireland, United Kingdom|NHS Tayside Ninewells Hospital, Dundee, Scotland, United Kingdom|Cardiff & Vale University Health Board University Hospital of Wales, Cardiff, Wales, United Kingdom|University Hospitals Birmingham NHS Foundation Trust Queen Elizabeth Hospital, Birmingham, United Kingdom|The Leeds Teaching Hospitals NHS Trust St. James University Hospital, Leeds, United Kingdom|University Hospitals of Leicester NHS Trust Royal Leicester Infirmary, Leicester, United Kingdom|Royal Liverpool & Broadgreen University Hospital NHS Trust Royal Liverpool University Hospital, Liverpool, United Kingdom|London North West Healthcare NHS Trust Northwick Park Hospital, London, United Kingdom|University College London, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom|Imperial College Healthcare NHS Trust Hammersmith Hospital, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|The Royal Wolverhampton NHS Trust New Cross Hospital, Wolverhampton, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03110562/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/62/NCT03110562/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03110562"
597,"NCT05317416","Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","MagnetisMM-7","Recruiting","No Results Available","Multiple Myeloma","Drug: Elranatamab|Drug: Lenalidomide","Minimal Residual Disease negativity rate|Progression Free Survival|Overall minimal residual disease negativity rate|Duration of minimal residual disease negativity|Sustained minimal residual disease negativity rate|Complete response rate|Duration of complete response|Overall survival|Frequency of adverse events|Frequency of laboratory abnormalities|Pre-dose concentrations of elranatamab|Post-dose concentrations of elranatamab|Incidence and titers of Anti-Drug Antibody and Neutralizing Antibody against elranatamab|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","366","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C1071007|2021-006052-14","March 25, 2022","June 14, 2027","June 14, 2027","April 7, 2022",,"May 16, 2022","Juravinski Cancer Center, Hamilton, Ontario, Canada|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus), Helsinki, Uusimaa, Finland|Fortis Memorial Research Institute, Gurugram, Haryana, India|Artemis hospital, Gurugram, Haryana, India|Rajiv Gandhi Cancer Institute And Research Centre, Delhi, India|Sheba Medical Center, Ramat Gan, Hamerkaz, Israel|Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [incheon], Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun Gun, Jeonranamdo, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-kwangyǒkshi, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital(Seoul St. Mary's Hospital), Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Kyungpook National University, Daegu, Taegu-kwangyǒkshi, Korea, Republic of|Kyungpook National University Hospital, Jung-gu, Taegu-kwangyǒkshi, Korea, Republic of|Centrum Medyczne Pratia Poznań, Skorzewo, Wielkopolskie, Poland|Pratia Onkologia Katowice, Katowice, Śląskie, Poland|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Medipol Mega Universite Hastanesi, İstanbul, İ̇stanbul, Turkey|Sisli Florence Nightingale Hastanesi, İstanbul, İ̇stanbul, Turkey|Özel Anadolu Sağlık Merkezi, Kocaeli, Turkey",,"https://ClinicalTrials.gov/show/NCT05317416"
598,"NCT00452569","Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","OPTIMUM","Completed","No Results Available","Multiple Myeloma","Drug: Thalidomide|Drug: Dexamethasone","The evaluation of Independent Review Committee-documented time to progression (TTP).|Response rate (CR + PR), according to the EBMT criteria|Response duration|Clinical benefit as measured by ECOG performance status, transfusion requirement and Grade ≥3 infections (assessed by the National Cancer Institute Common Toxicity Criteria)|Progression-free survival (PFS)|Overall survival (OS)|Composite of disease progression and death (recurrent time(s) from randomisation to disease progression and/or death)|Quality of life as determined by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30)|Adverse events (AEs)|Assessment of peripheral neuropathy|Vital signs and physical examination|Clinical laboratory tests","Celgene","All","18 Years and older   (Adult, Older Adult)","Phase 3","499","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","THA PH INT 2005 CL001","February 1, 2006","December 1, 2008","January 1, 2009","March 27, 2007",,"November 18, 2019","Clinic of Haematology, University Multiprofiled Hospital for Active Treatment ""G. Stranski"", Pleven, Bulgaria|Clinic of Haematology, University Multiprofiled Hospital for Active Treatment, Plovdiv, Bulgaria|University of Multiprofiled Hospital for Active Treatment ""Alexandrovska"" - Sofia, Sofia, Bulgaria|Military Medical Academy/Dept Haematology and Oncology, Sofia, Bulgaria|National Center of Haematology & Transfusiology, Sofia, Bulgaria|Clinic of Haematology, Multiprofiled Hospital for Active Treatment ""Sveta Marina"", Varna, Bulgaria|Klinicki Bolnicki Centar Rijeka Interna Klinika, Rijeka, Croatia|Klinika Bolnica SPLIT - Klinika za Unutarnje Bolesti, Split, Croatia|KBC Zagreb - Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica ""Dubrava"" Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica ""Sestre milosrdnice"" Klinika za Unutarnje Bolesti, Zagreb, Croatia|Klinicka Bolnica MERKUR - Klinika za Unutarnje Bolesti, Zagreb, Croatia|Interni Hemato-Onkologicka Klinika, Brno, Czechia|Hematologicka Klinika, Fakultni Nemocnice Hradec Kralove, Hradec Kralove, Czechia|Onkologicke Centrum J.G. Mendela, Novi Jicin, Czechia|Interni Klinika, Oddeleni Hematoonkologie, Olomouc, Czechia|Hematologicka Klinika, Fakultni Nemocnice Kralovske Vinohrady Srobarova, Prague 10, Czechia|Interni Klinika, Oddeleni Hematoonkologie, Prague 2, Czechia|CHRU de Lille - Hopital Claude Huriez, Lille, France|CHU de Nancy - Hopital Brabois, Nancy Cedex, France|Hematologie - CHU Purpan Place du Dr. Baylac, Toulouse, France|Charite, Universitatsmedizin Berlin, Campus Robert-Rossle Klinik, Berlin, Germany|Med. Klinik I/University Bonn, Bonn, Germany|Medizinische Klinik und Poliklinik I/Carl-Gustav-Carus University, Dresden, Germany|Hematology, Oncology & Clinical Immunology/Heinrich-Heine-University, Duesseldorf, Germany|Abt. Haematologie - Onkologie/ Allg. Krankenhaus, Hamburg, Germany|Allgemeinse Krankenhaus St. Georg Hamatologische Abteilung, Hamburg, Germany|Medizinische Klinik Abteilung Innere V/Universitatsklinikum, Heidelberg, Germany|Universitat Schleswig Holstein II Med. Klinik, Kiel, Germany|Universitaetsklinik - Klinik fur innere Medizin, Koeln, Germany|Medizinische Klinik und Poliklinik III/Klinikum der Universitaet Muenchen, Muenchen, Germany|Innere Medizin University Hospital, Muenster, Germany|Abteilung Haematologie - Univeresitaetsklinikum, Saale, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Stuttgart, Germany|Universitaetsklinik - Abteilung Innere Medizin III, Ulm, Germany|Med. Klinik II/Klinikum of the Julius-Maximilians-University, Wuerzburg, Germany|National Medical Centre Dpt Haematology, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, II. Belgyogyaszat, Gyor, Hungary|Pandy Kalman Megyei Korhaz, Megyei Onkologiai Centrum, Gyula, Hungary|Szent-Gyorgyi Albert University II Clinic of Internal Medicine, Szeged, Hungary|Nizam's Institute of Medical Sciences, Department of Medical Oncology, Hyderabaad, India|Department of Medical Oncology, Amrita Institute of Medical Sciences, Kerala, India|Orchid Nursing Home, Kolkata, India|Department of Medical Oncology, Dayanand Medical College DMCH, Ludhiana, India|Department of Medical Oncology/Tata Memorial Hospital, Mumbai, India|Department of Medical Oncology, S.L. Raheja Hospital, Mumbai, India|Department of Medical Oncology, Jaslok Hospital and Research Centre, Mumbai, India|Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, India|Department of Medical Oncology/Regional Cancer Centre, Trivandrum, India|Instituto di Ematologia e Oncologia Medica, Bologna, Italy|Dipartimento Medicina ed Oncologia Sperimentale - Divisione Universitaria di Ematologia Azienda Ospedaliera S. Giovanni Battista, Torino, Italy|Department of Internal Medicine - Baguio General Hospital & Medical Center, Baguio City, Philippines|Chong Hua Hospital, Cebu City, Philippines|Doctors Clinic Makati Medical Center, Makati City, Philippines|University of Sto Tomas Hospital, Manila City, Philippines|Doctors Clinic - National Kidney & Transplant Institute, Quezon City, Philippines|St. Luke's Medical Center, Quezon City, Philippines|SPSK, Klinika Hematologii Akademii Medycznej, Bialystok, Poland|Klinika Hematologii Akademii Medycznej w Gdanskuul, Gdansk, Poland|Katedra i Klinika Hematologii i Transplantacji Szpiku - Slaska Akademia Medyczna, Katowice, Poland|Swietokrzyskie Centrum Onkologii SPZOZ Poradnia Hematologii, Kielce, Poland|Klinika Hematologii Uniwersytetu Medycznego, Lodz, Poland|Klinika Chorob Wewnetrznych i Hemagologii, Warszawa, Poland|Katedra i Klinika Hematologii, Onkologii I Chorob Wewnetrznych, Warszawa, Poland|Instytut Hematologii i Transfuzjologii - Klinika Hematologiczna, Warszawa, Poland|Centrum Onkologii-Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji - Szpiku Akademii Medycznej, Wroclaw, Poland|Hospital da Universidade de Coimbra - Servico de Hematologia Clinica, Coimbra, Portugal|Instituto Portugues de Oncologia, Lisboa, Portugal|Hospital Geral de Santo Antonio - Servico de Hematologia Clinica, Porto, Portugal|Institute of Hematology, Clinical Centre of Serbia, Belgrade, Serbia|Clinic for Hematology, Clinical Centre Nis, Nis, Serbia|Clinic for Hematology, Clinical Centre Novi Sad, Novisad, Serbia|Department of Internal Medicine, National Cancer Institute, Bratilslava, Slovakia|Hematology Department University Hospital, Bratilslava, Slovakia|Hematology Department, University Hospital PJS, Kosice, Slovakia|University of Free State, Faculty of Health Science, Dept of Hematology & Cell Biology, Bloemfontein, South Africa|Tygerberg Hospital, University of Stellenbosch, Department of Haematology, Cape Town, South Africa|Department of Haematology, UCT Medical School, Cape Town, South Africa|Chris Hani Baragwanath Hospital, Clinical Haematology Unit, Johannesburg, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, South Africa|Johannesburg Hospital, Department of Medical Oncology, Parktown, South Africa|Oncology Research Unit Heartlands Hospital, Birmingham, United Kingdom|Clinical Haematology, Guy's Hospital, London, United Kingdom|Haematology Department - King's College Hospital, London, United Kingdom|Department of Haematology-Oncology, The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00452569"
599,"NCT00911859","A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients",,"Completed","Has Results","Multiple Myeloma","Drug: Siltuximab11 mg/kg|Drug: Siltuximab 8.3 mg/kg or 11 mg/kg|Drug: Velcade (bortezomib)|Drug: Melphalan|Drug: Prednisone","Percentage of Participants Who Achieved Complete Response (CR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria|Percentage of Participants Who Achieved Overall Response ie, Complete Response (CR) or Partial Response (PR) - European Group for Blood and Marrow Transplantation (EBMT) Criteria|Percentage of Participants Who Achieved Stringent Complete Response (sCR) - International Myeloma Working Group (IMWG) Criteria|Progression-Free Survival (PFS)|1-year Progression-Free Survival (PFS) Rate|Duration of Response (DOR)|1-year Survival Rate|Overall Survival|Change From Baseline to Cycle 9 in Global Health Status/Quality of Life Subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30)","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR015901|CNTO328MMY2001|2008-007157-12","June 2009","April 2013","April 2013","June 2, 2009","November 18, 2014","November 18, 2014","Boston, Massachusetts, United States|Chapel Hill, North Carolina, United States|Philadelphia, Pennsylvania, United States|Houston, Texas, United States|Adelaide, Australia|Melbourne, Australia|Bordeaux Cedex, France|Montpellier, France|Strasbourg, France|Ahmedabad, India|Calicut, India|Hyderabad N/A, India|Jaipur, India|Mumbai, India|Afula, Israel|Haifa, Israel|Jerusalem, Israel|Petah Tikva, Israel|Ramat-Gan, Israel|Seoul, Korea, Republic of|Bialystok, Poland|Chorzów, Poland|Gdynia, Poland|Lodz, Poland|Wroclaw, Poland|Baia Mare, Romania|Brasov, Romania|Iasi, Romania|Arkhangelsk, Russian Federation|Moscow N/A, Russian Federation|Nizhni Novgorod, Russian Federation|St. Petersburg, Russian Federation|Singapore, Singapore|Barcelona, Spain|Madrid, Spain|Murcia N/A, Spain|Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT00911859"
600,"NCT00776165","Safety and Efficacy Trial of Recombinant Human Granulocyte Colony Stimulating Factor (GCSF)",,"Completed","No Results Available","Chemotherapy-Induced Neutropenia","Biological: Recombinant Human GCSF (Shantha Biotechnics Limited)|Biological: Neupogen","Percentage of patients developing febrile neutropenia (defined as body temperature ≥ 38.2°C or developing a temperature of > 38°C twice in a 12-hour period and absolute neutrophil count < 0.5 x 10e9/L on the same day of the fever or the day after.|Percentage of patients developing adverse events and/ or changes in laboratory values.|Incidence of neutropenia defined as absolute neutrophil count < 0.5 x 10e9/L not associated with fever|Incidence of need for IV anti-infectives and days of admission, as a result of neutropenia","Shantha Biotechnics Limited","All","18 Years and older   (Adult, Older Adult)","Phase 3","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","SBL/GCSF/N/2007/0100","October 2007","July 2009","September 2009","October 21, 2008",,"February 3, 2010","Indo American Cancer Institute and Research Centre, Hyderabad, Andhra Pradesh, India|Nizam's Institute of Medical Sciences, Hyderabad, Andhra Pradesh, India|Vedanta Institute of Medical Sciences, Ahmedabad, Gujrat, India|Lakeshore Hospital and Research Center, Cochin, Kerala, India|Regional Cancer Centre, Trivandrum, Kerala, India|Seth Ramdas Shah Memorial Hospital, Pune, Maharashtra, India|SMS Medical College and Hospital, Jaipur, Rajasthan, India",,"https://ClinicalTrials.gov/show/NCT00776165"
601,"NCT05020236","MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","MAGNETISMM-5","Recruiting","No Results Available","Multiple Myeloma","Drug: Elranatamab|Drug: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone","Part 1 Safety Lead-In: Incidence of dose limiting toxicities|Part 2 Randomized: Progression free survival per International Myeloma Working Group criteria|Part 1 Safety Lead-In: Progression free survival per International Myeloma Working Group criteria|Overall survival|Objective response rate per International Myeloma Working Group criteria|Duration of response per International Myeloma Working Group criteria|Time to response per International Myeloma Working Group criteria|Complete response rate per International Myeloma Working Group criteria|Duration of complete response per International Myeloma Working Group criteria|Minimal residual disease negativity rate per International Myeloma Working Group criteria|Sustained minimal residual disease negativity rate per International Myeloma Working Group criteria|Progression free survival on next-line treatment per International Myeloma Working Group criteria|Frequency of treatment-emergent adverse events|Frequency of abnormal laboratory results|Rate of Grade ≥2 cytokine release syndrome|Elranatamab pharmacokinetics by pre- and post-dose concentrations|Elranatamab immunogenicity by anti-drug antibodies against elranatamab|Daratumumab pharmacokinetics by pre-dose concentrations|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30|Health-related quality of life by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Myeloma 20","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","581","Industry","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","C1071005|2021-000044-22|MAGNETISMM-5","October 4, 2021","November 25, 2024","January 26, 2026","August 25, 2021",,"May 9, 2022","Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus), Helsinki, Finland|Oulun yliopistollinen sairaala, Oulu, Finland|Evangelismos General Hospital of Athens, Athens, Attikí, Greece|Evangelismos Hospital, Athens, Attikí, Greece|Alexandra General Hospital of Athens, Athens, Attikí, Greece|Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, Delhi, India|Rajiv Gandhi Cancer Institute And Research Centre, New Delhi, Delhi, India|Artemis Hospital, Gurugram, Haryana, India|Hamamatsu University Hospital, Hamamatsu, Shizuoka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of|Chonnam National University Hwasun Hospital, Hwasun-gun, Jeonranamdo, Korea, Republic of|Seoul National University Hospital, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Samsung Medical Center, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|The Catholic Univ. of Korea Seoul St. Mary's Hospital, Seoul, Seoul-teukbyeolsi [seoul], Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Pratia Onkologia Katowice, Katowice, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Poland|Instituto Catalan de Oncologia - Hospital Duran i Reynals, L'Hospitalet Del Llobregat, Barcelona [barcelona], Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Girona [gerona], Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Instituto Catalán de Oncología. Hospital Universitario Dr. Josep Trueta, Gerona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario y Politecnico La Fe, Valencia, Spain|Södra Älvsborg Sjukhus, Borås, Sweden|Sahlgrenska Universitetssjukhuset, Göteborg, Sweden|Universitetssjukhuset Örebro, Örebro, Örebro LÄN [se-18], Sweden|National Cheng-Kung Uni. Hosp., Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Sisli Florence Nightingale Hastanesi, İstanbul / Şişli, İ̇stanbul, Turkey|Medipol Mega Universite Hastanesi, İstanbul, İ̇stanbul, Turkey|Acibadem Universitesi Atakent Hastanesi, Istanbul, İ̇stanbul, Turkey|Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi, Ankara, Turkey|Aydın Adnan Menderes Universitesi Hastanesi, Aydin, Turkey|Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi, Gaziantep, Turkey|Özel Anadolu Sağlık Merkezi, Kocaeli, Turkey",,"https://ClinicalTrials.gov/show/NCT05020236"
602,"NCT00315757","Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma",,"Completed","No Results Available","Multiple Myeloma","Biological: Mapatumumab|Drug: Bortezomib","To evaluate disease response to mapatumumab in combination with bortezomib and bortezomib alone|To evaluate the safety, including the frequency and severity of adverse events and laboratory abnormalities, of mapatumumab in combination with bortezomib and bortezomib alone throughout the study period","Human Genome Sciences Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HGS1012-C1055","May 2006","October 2010","October 2010","April 19, 2006",,"August 8, 2013","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Scripps Clinic Medical Group, Inc., La Jolla, California, United States|Cancer and Blood Disorders Center, Lecanto, Florida, United States|University of Chicago, Chicago, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Capitol Comprehensive Cancer Care Clinic, Jefferson City, Missouri, United States|Nebraska Methodist Cancer Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia|Institute of Medical & Veterinary Science, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia|Clinical Haematology & BMT, Alfred Hospital, Melbourne, Victoria, Australia|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Ottawa Health Research Institute - General Campus, Ottawa, Ontario, Canada|Notre Dame Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|Bharath Hospital & Institute of Oncology, Mysore, Karnataka, India|Bangalore Institute of Oncology, Bangalore, India|All India Institute of Medical Sciences, New Delhi, India|Rajiv Gandhi Cancer Institute & Research Center, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00315757"
603,"NCT00101998","Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication",,"Completed","No Results Available","Constipation|Bowel Dysfunction","Drug: alvimopan|Drug: placebo","Change in weekly SCBM frequency. A SCBM is a spontaneous and complete bowel movement, which means a bowel movement that occurs with no laxative use in the prior 24 hours and leaves the subject with the feeling of complete evacuation of the rectum.|Additional measures of Bowel movement (BM) frequency and symptoms, safety profile of the treatment regimens and any changes in pain intensity or opioid use.","Cubist Pharmaceuticals LLC|GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 2","233","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","3753-009|767905/008","October 1, 2003","May 1, 2006","May 1, 2006","January 19, 2005",,"August 30, 2017","GSK Investigational Site, Tucson, Arizona, United States|GSK Investigational Site, Hot Springs, Arkansas, United States|GSK Investigational Site, Duarte, California, United States|GSK Investigational Site, Fountain Valley, California, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, La Verne, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Los Gatos, California, United States|GSK Investigational Site, Modesto, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Santa Monica, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Washington, D.C., District of Columbia, United States|GSK Investigational Site, Gainesville, Florida, United States|GSK Investigational Site, Inverness, Florida, United States|GSK Investigational Site, Lecanto, Florida, United States|GSK Investigational Site, Miami Shores, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, New Port Richey, Florida, United States|GSK Investigational Site, Ocala, Florida, United States|GSK Investigational Site, Palm Harbor, Florida, United States|GSK Investigational Site, Stuart, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, Titusville, Florida, United States|GSK Investigational Site, Decatur, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, West Des Moines, Iowa, United States|GSK Investigational Site, Hutchinson, Kansas, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Worcester, Massachusetts, United States|GSK Investigational Site, Ann Arbor, Michigan, United States|GSK Investigational Site, Flint, Michigan, United States|GSK Investigational Site, Saint Louis Park, Minnesota, United States|GSK Investigational Site, Kansas City, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Reno, Nevada, United States|GSK Investigational Site, Albuquerque, New Mexico, United States|GSK Investigational Site, Bethpage, New York, United States|GSK Investigational Site, Huntington Station, New York, United States|GSK Investigational Site, Jamaica, New York, United States|GSK Investigational Site, Chapel Hill, North Carolina, United States|GSK Investigational Site, Charlotte, North Carolina, United States|GSK Investigational Site, Durham, North Carolina, United States|GSK Investigational Site, Hendersonville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Winston-Salem, North Carolina, United States|GSK Investigational Site, Bismarck, North Dakota, United States|GSK Investigational Site, Bismarck, North Dakota, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Middletown, Ohio, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, Amarillo, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Webster, Texas, United States|GSK Investigational Site, Norfolk, Virginia, United States|GSK Investigational Site, Portsmouth, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Tacoma, Washington, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Redcliffe, Queensland, Australia|GSK Investigational Site, South Brisbane, Queensland, Australia|GSK Investigational Site, Daw Park, South Australia, Australia|GSK Investigational Site, Malvern, Victoria, Australia|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Saint John's, Newfoundland and Labrador, Canada|GSK Investigational Site, Kitchener, Ontario, Canada|GSK Investigational Site, London, Ontario, Canada|GSK Investigational Site, North Bay, Ontario, Canada|GSK Investigational Site, Oshawa, Ontario, Canada|GSK Investigational Site, Sudbury, Ontario, Canada|GSK Investigational Site, Bonaventure, Quebec, Canada|GSK Investigational Site, Chandler, Quebec, Canada|GSK Investigational Site, Levis, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Sherbrooke, Quebec, Canada|GSK Investigational Site, Quebec, Canada|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Brno, Czechia|GSK Investigational Site, Plzen, Czechia|GSK Investigational Site, Praha 10, Czechia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Bordeaux Cedex, France|GSK Investigational Site, Vandoeuvre-Les-Nancy, France|GSK Investigational Site, Villejuif Cedex, France|GSK Investigational Site, Goettingen, Niedersachsen, Germany|GSK Investigational Site, Goslar, Niedersachsen, Germany|GSK Investigational Site, Kwun Tong, Hong Kong|GSK Investigational Site, Pokfulam, Hong Kong|GSK Investigational Site, Shatin, Hong Kong|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Miskolc, Hungary|GSK Investigational Site, Zalaegerszeg-Pozva, Hungary|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Caserta, Campania, Italy|GSK Investigational Site, Napoli, Campania, Italy|GSK Investigational Site, Forlì, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Genova, Liguria, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Pavia, Lombardia, Italy|GSK Investigational Site, Busca (CN), Piemonte, Italy|GSK Investigational Site, Novara, Piemonte, Italy|GSK Investigational Site, Catania, Sicilia, Italy|GSK Investigational Site, Firenze, Toscana, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Leeuwarden, Netherlands|GSK Investigational Site, Dunedin, New Zealand|GSK Investigational Site, Hastings, New Zealand|GSK Investigational Site, Wellington, New Zealand|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Manila, Philippines|GSK Investigational Site, Bialystok, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Otwock, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Lisboa, Portugal|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St'Petersburg, Russian Federation|GSK Investigational Site, Durban, KwaZulu- Natal, South Africa|GSK Investigational Site, Groenkloof, Pretoria, South Africa|GSK Investigational Site, Houghton, Johannesburg, South Africa|GSK Investigational Site, Kenilworth, Cape Town, South Africa|GSK Investigational Site, Alcorcon, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Cordoba, Spain|GSK Investigational Site, Granada, Spain|GSK Investigational Site, Jaén, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Sabadell / Barcelona, Spain|GSK Investigational Site, Serra / Valencia, Spain|GSK Investigational Site, Sevilla, Spain|GSK Investigational Site, Soria, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Chiang Mai, Thailand|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Newcastle-upon-Tyne, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Surrey, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00101998"
604,"NCT00774930","An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome","ELECT","Completed","Has Results","Carcinoid Syndrome","Drug: Lanreotide|Drug: Placebo","Percentage of Days With Subcutaneous Octreotide as Rescue Medication|Average Frequency of Diarrhoea Events (Per Day) Based on Subject Diary Records.|Average Frequency of Flushing Events (Per Day) Based on Subject Diary Records.|Percentage of Days of Use of Other Rescue Medication|Proportion of Subjects Who Rolled Over Into the IOL Phase Before Completing the DB Phase of the Study|Changes From Baseline in ""Global Health Status/Quality of Life (QoL)"" Score (Based on Items 29 and 30 of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ] C30)|Changes From Baseline in ""Gastrointestinal (G.I). Symptoms"" Subscore (Based on Items Q34, Q35, Q36, Q37 and Q38 of EORTC G.I. Neuroendocrine Tumour [NET] 21]|Changes From Baseline in QoL in ""Endocrine Symptoms"" Subscore (Assessed Based on Items Q31, Q32 and Q33 Using EORTC QLQ-G.I.NET-21 Questionnaires)|Absolute Changes From Baseline in Biochemical Markers (Plasma Chromogranin A [CgA])|Absolute Changes From Baseline in Biochemical Markers (Urinary 5-hydroxyindoleacetic Acid [5-HIAA])","Ipsen","All","18 Years and older   (Adult, Older Adult)","Phase 3","115","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2-55-52030-730|TR321|2010-019066-92","May 2009","May 2013","December 2015","October 17, 2008","February 9, 2016","November 5, 2020","VA Greater Los Angeles Health Care System, Los Angeles, California, United States|David Geffen School of Medicine at UCLA, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Cedars Sinai Outpatient Cancer Center, West Hollywood, California, United States|Kentuckiana Cancer Institute, Louisville, Kentucky, United States|Louisiana State University Health Science Center, Kenner, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of New Mexico Cancer Care Center, Albuquerque, New Mexico, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health Science University, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Liver Cancer Center, Pittsburgh, Pennsylvania, United States|Eastern Virginia Medical School, Norfolk, Virginia, United States|Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Biocancer - Centro de Pesquisa e Tratamento do Câncer, Belo Horizonte, Brazil|Hospital LifeCenter, Belo Horizonte, Brazil|Oxion Medicina Oncológica, Belo Horizonte, Brazil|Hospital Universitário de Brasilia, Brasilia, Brazil|Hospital Erasto Gaertner, Curitiba, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Hospital de Base de São José do Rio Preto, São José do Rio Preto, Brazil|VFN Onkologicka klinika, Prague, Czechia|Sir Gangaram Hospital, Delhi, India|Indo-American Cancer Institute & Research Centre, Hyderabad, India|Omega Hospitals, Hyderabad, India|Santokaba Durlabhji Memorial Hospital and Research Institute, Jaipur, India|Bhagwan Mahaveer cancer hospital and research centre, Jaipur, India|Shatabdi Super Speciality hospital, Mumbai, India|Tata Memorial Hospital, Mumbai, India|Paul Stradins Clinical University Hospital, Riga, Latvia|Klinika Endokrynologii, Diabetologii i Leczenia Izotopami, Wrocław, Poland|Non-Federal Institution of Healthcare ""Central Clinical Hospital # 1 of the LLC ""Russian Railways (RZD)"", Moscow, Russian Federation|Russian Academy of Medical Sciences ""Russian Oncological Research Centre named after N.N. Blokhin RAMS"", Moscow, Russian Federation|Federal Institution of Healthcare ""Leningradsky Regional Oncological Dispensary"", Saint-Petersburg, Russian Federation|Clinic of Endocrinology, diabetes and metabolic diseases, Clinical Center of Serbia, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Sremska Kamenica, Serbia|Rondebosch Oncology Unit, Cape Town, South Africa|Groote Schuur Hospital, Cape Town, South Africa|Westridge Medical Centre, Durban, South Africa|GVI Oncology Clinical Trial Unit, Port Elizabeth, South Africa|Erciyes University Medical Faculty, Kayseri, Turkey|Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine|Chernivtsi Regional Oncology Center, Chernivtsi, Ukraine|Oncology and Medical Radiology Chair of Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine|Regional Anticancer Center, Department of oncoproctology, Donetsk, Ukraine|Municipal Clinical Hospital #2, Proctology department, Kharkiv, Ukraine|Kyiv City Oncological Hospital, Thoracic department, Kyiv, Ukraine|Medical Centre ""Mriya"", Kyiv, Ukraine|National Cancer Institute, Kyiv, Ukraine|Odessa Regional Clinical Hospital, Odessa, Ukraine|Uzhgorods'ka Tsentral'na Mis'ka Klinichna Likarnya, Mis'kyy Onkologichnyy Tsentr, Uzhgorod, Ukraine|Vinnytsya Regional Clinical Oncological Center, Vinnytsya State Medical University, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00774930"
605,"NCT00263484","Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma","dtZ","Completed","No Results Available","Multiple Myeloma","Drug: dexamethasone|Drug: thalidomide|Drug: zoledronic acid","1. To determine response rates (RR) and disease progression rates in all MM patients treated with dtZ regimen.|To assess overall survival (OS) in all patients treated with dtZ regimen.|Assessment of incidence of skeletal related events (SREs).|Assessment of percent change in renal function in all patients.","Gleneagles Hospital|Singapore General Hospital|National Cancer Centre, Singapore|Tan Tock Seng Hospital|Seoul National University Hospital|Asan Medical Center|Samsung Medical Center|Chonnam National University Hospital|Christian Medical College, Vellore, India|Tata Memorial Hospital","All","21 Years and older   (Adult, Older Adult)","Phase 2","56","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SQMM01(dtZ)","December 2005","October 2008","October 2010","December 8, 2005",,"July 21, 2011","Christian Medical College, Vellore, Tamil Nadu, India|Tata Memorial Hospital, Mumbai, India|Chonnam National University Hwasun Hospital, Kwangju, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, South Korea, Seoul, Korea, Republic of|ASAN Medical Center, University of Ulsan, South Korea, Seoul, Korea, Republic of|Singapore General Hospital, Singapore, Singapore|National Cancer Centre, Singapore, Singapore, Singapore|Gleneagles Hospital, Singapore, Singapore, Singapore|Tan Tock Seng Hospital, Singapore, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00263484"
606,"NCT00110110","Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma",,"Active, not recruiting","No Results Available","Retinoblastoma","Biological: filgrastim|Drug: Carboplatin|Drug: Cyclosporine|Drug: Etoposide|Drug: vincristine sulfate|Procedure: cryosurgery|Procedure: laser therapy","Comparing efficacy of study treatment with historic world data, in terms of increasing the proportion of eyes that remains relapse-free while avoiding external beam radiation and/or enucleation|Toxicity during treatment","The Hospital for Sick Children|Terry Fox Foundation","All","Child, Adult, Older Adult","Phase 2","71","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1000005587|HFSC-OCRN-RB-2003|CDR0000422340","June 2004","April 20, 2016","December 31, 2022","May 4, 2005",,"May 4, 2022","Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada|Hospital for Sick Children, Toronto, Ontario, Canada|Montreal Children's Hospital at McGill University Health Center, Montreal, Quebec, Canada|Hospital San Juan de Dios, Santiago, Chile|Sankara Nethralaya Super Specialty Clinic, Chennai, India|Kandang Kerbau Women's and Children's Hospital, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT00110110"
607,"NCT00652613","Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)",,"Unknown status","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Radiation: 3 Dimensional Radiation Therapy|Radiation: Intensity Modulated Radiation Therapy","Major salivary gland sparing by 3-D CRT vis-à-vis IMRT. Assess adequacy of target volume coverage|Determine the pattern of local and loco-regional recurrence|Disease Free Survival (DFS) and Overall Survival (OAS)|Quality of life 3. Dose to OAR|Assess the reduction in dose with IMRT to the normal larynx and normal pharyngeal constrictors in oropharyngeal cancers, uninvolved oral mucosa and auditory apparatus","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","H&N_3DCRT_IMRT07","August 2005","March 2008","August 2009","April 4, 2008",,"April 11, 2008","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00652613"
608,"NCT00691236","Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma","ZOL","Unknown status","No Results Available","Osteosarcoma","Drug: Zoledronic acid|Drug: Standard chemotherapy","histological response disease free interval","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","382","May 2008","May 2013","August 2013","June 5, 2008",,"June 23, 2011","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00691236"
609,"NCT00689195","Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma","OSCAT","Unknown status","No Results Available","Osteosarcoma","Dietary Supplement: Curcumin powder|Dietary Supplement: Ashwagandha extract","response, toxicity, disease progression|quality of life","Tata Memorial Hospital|Pharmanza Herbals Pvt Limited (PHPL)","All","8 Years to 65 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","381","May 2008","June 2013","June 2013","June 3, 2008",,"June 23, 2011","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00689195"
610,"NCT02830230","""Performance of HPV DNA Test in Presence of Co-infection With Common RTIs""",,"Unknown status","No Results Available","Cervical Inflammation and Human Papilloma Virus Performance","Drug: Tab cefixime,Tab Azithromycin","Difference in the number of participants diagnosed with HPV infections before and after treating clinical cervicitis","Tata Memorial Hospital","Female","30 Years to 50 Years   (Adult)","Not Applicable","508","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Screening","1671 RTIs And HPVDNA Test","July 2016","December 2017","July 2018","July 12, 2016",,"July 12, 2016","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02830230"
611,"NCT03237637","Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas",,"Unknown status","No Results Available","Infantile Hemangioma","Drug: oral propranolol|Drug: oral atenolol","Mean difference in number of patients achieving complete clinical clearance of lesion (PGA Score of 5) in the two groups|Mean difference in number of days required to achieve complete clinical clearance of lesion (PGA Score of 5) in the two groups|Mean difference in Hemangioma Activity Score in the two groups|Frequency of adverse effects (minor and serious) in the two groups|Mean difference in HIF-1α levels before and after treatment in Group A and Group B","Postgraduate Institute of Medical Education and Research","All","up to 12 Months   (Child)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","INT/IEC/2017/322","March 24, 2017","December 2018","December 2018","August 2, 2017",,"August 28, 2018","PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT03237637"
612,"NCT02281019","SpyGlass AMEA Registry",,"Completed","No Results Available","Biliary Stricture|Biliary Obstruction Due to Common Bile Duct Stone|Periampullary Tumor|Hemobilia","Procedure: ERCP (Endoscopic Retrograde Cholangiopancreatography)|Device: SpyGlass DVS and SpyGlass Digital Simple (DS)","Procedural success for indeterminate strictures or undefined filling defects|Procedural success for biliary stone cases|Procedural success for other indications|Evaluation of serious adverse events (SAEs) related to the SpyGlass devices and/or the SpyGlass procedure|Impact of SpyGlass procedure on suspected diagnosis based on prior ERCP|Evaluation of impact of use of antibiotics on incidence of SAEs related to the device and/or procedure.|For patients undergoing SpyBite biopsy: correlation between number of biopsies and conclusive histopathology of SpyBite biopsies.|For patients undergoing stone management: number of SpyGlass procedures needed to reach stone clearance.|For patients undergoing stone management: correlation between stone size and ability to reach stone clearance in one SpyGlass session.|For patients undergoing stone management: incidence of visualization of stones not suspected during previous ERCP.","Boston Scientific Corporation","All","18 Years and older   (Adult, Older Adult)",,"526","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","90947376","November 15, 2014","September 2016","October 18, 2016","November 2, 2014",,"July 10, 2019","Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, Australia|Royal Prince Alfred Hospital, Newtown, Australia|Prince of Wales Hospital, Shatin, Hong Kong|Apollo Gleneagles Hospitals Kolkata, Kolkata, West Bengal, India|Postgraduate Institute of Medical Education & Research, Chandigarh, India|Medanta -The Medicity Institute of Digestive & Hepatobiliary Sciences, Gurgaon, India|Asian Institute of Gastroenterology, Hyderabad, India|Baldota Institute of Digestive Sciences, Parel, India|Teikyo University Mizonokuchi Hospital, Kawasaki, Japan|Kinki University School of Medicine, Osaka-sayama, Japan|Tokyo Medical University, Tokyo, Japan|Soon Chun Hyang University Bucheon Hospital, Bucheon, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Civil Hospital- Karachi, Karachi, Pakistan|King Khalid University Hospital, Riyadh, Saudi Arabia|Changi General Hospital Pte Ltd., Singapore, Singapore|Netcare Unitas Hospital, Centurion, South Africa|King Chulalongkorn Memorial Hospital, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT02281019"
613,"NCT02239120","Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)",,"Completed","Has Results","Stroke|Secondary Prevention","Drug: optional ASA as comedication|Drug: placebo to ASA|Drug: placebo to optional ASA as comedication|Drug: placebo to dabigatran etexilate|Drug: ASA 100 mg|Drug: dabigatran etexilate","Adjudicated Recurrent Stroke|First Major Bleed (Adjudicated)|Adjudicated Ischaemic Stroke|Adjudicated Composite of Non-fatal Stroke, Non-fatal Myocardial Infarction, or Cardiovascular Death|Disabling Stroke|All-cause Death|Adjudicated Intracranial Hemorrhage|Adjudicated Fatal Bleed|Adjudicated Life-threatening Bleed|Any Bleed (Investigator-reported)","Boehringer Ingelheim","All","18 Years to 150 Years   (Adult, Older Adult)","Phase 3","5390","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","1160.189|2013-003444-24","November 27, 2014","August 14, 2018","August 14, 2018","September 12, 2014","September 6, 2019","September 6, 2019","Bronislava Shafran, MD PC, Phoenix, Arizona, United States|Westside Medical Associates of Los Angeles, Beverly Hills, California, United States|TriWest Research Associates, LLC, El Cajon, California, United States|University of California, Fresno, California, United States|Glendale Adventist Medical Center, Glendale, California, United States|Collaborative Neuroscience Network, LLC (CNS), Long Beach, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|University of California Los Angeles, Los Angeles, California, United States|Huntington Hospital, Pasadena, California, United States|University of California, San Diego, California, United States|University of California, San Francisco, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Colorado Neurological Institute, Englewood, Colorado, United States|University of Colorado Denver, Fort Collins, Colorado, United States|St. Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States|Hartford Hospital, Hartford, Connecticut, United States|JEM Research Institute, Atlantis, Florida, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Tenet Florida Physician Services, Boynton Beach, Florida, United States|Nova Clinical Research, LLC, Bradenton, Florida, United States|Broward Health North, Deerfield Beach, Florida, United States|Center for Advanced Research Excellence, Hialeah, Florida, United States|Bruce W. Carter, Miami VA Healthcare System, Miami, Florida, United States|University of Miami, Miami, Florida, United States|Bay Neurological Institute, Panama City, Florida, United States|Carol L Pappas, MD PhD PA, Saint Petersburg, Florida, United States|University of South Florida, Tampa, Florida, United States|Vero Beach Neurology and Research Institute, Vero Beach, Florida, United States|Palm Beach Neuroscience Institute, West Palm Beach, Florida, United States|Augusta University, Augusta, Georgia, United States|WellStar Medical Group - Neurosurgery, Marietta, Georgia, United States|The Queen's Medical Center, Honolulu, Hawaii, United States|Saint Alphonsus Medical Center-Neurology, Boise, Idaho, United States|Northwest Heart Clinical Research, LLC, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Medicoricium, LLC, Fairview Heights, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Quincy Physicians and Surgeons Clinic, S.C., Quincy, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|Ruan Neurology Clinic and Research Center, Des Moines, Iowa, United States|Associates in Neurology, PSC, Lexington, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Alexandria Cardiology Clinic, Alexandria, Louisiana, United States|Culicchia Neurological Clinic, Marrero, Louisiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins Hospital, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Flint, Flint, Michigan, United States|Mercy Health Saint Mary's, Grand Rapids, Michigan, United States|Spectrum Health Medical Center, Grand Rapids, Michigan, United States|Sparrow Clinical Research Institute, Lansing, Michigan, United States|St. Joseph Mercy Oakland, Pontiac, Michigan, United States|The Duluth Clinic dba Essentia Health Duluth Clinic, Duluth, Minnesota, United States|Abbott Northwestern Hospital, Radiology Department, Minneapolis, Minnesota, United States|HealthPartners Neuroscience Center, Saint Paul, Minnesota, United States|Jackson Heart Clinic, P.A., Jackson, Mississippi, United States|Boone Hospital Center, Columbia, Missouri, United States|University of Missouri Health System, Columbia, Missouri, United States|SSM Health St. Clare Hospital, Fenton, Missouri, United States|Saint Luke's Hospital of Kansas City, Kansas City, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|St. Louis Heart and Vascular, P.C., Saint Louis, Missouri, United States|The Nebraska Medical Center, Omaha, Nebraska, United States|Renown Institute for Neurosciences, Reno, Nevada, United States|NYC Health + Hospitals/Coney Island, Brooklyn, New York, United States|New York Presbyterian Hudson Valley Hospital, Cortlandt Manor, New York, United States|UHS Wilson Medical Center,Office of Clin Trials, Johnson City, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Mount Sinai Beth Israel, New York, New York, United States|Novant Health Neurology Specialists, Charlotte, North Carolina, United States|Duke Clinic 1L, Durham, North Carolina, United States|Cone Health System, Greensboro, North Carolina, United States|Novant Health Neurology Hickory, Hickory, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Altru Health System, Grand Forks, North Dakota, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Holzer Clinic LLC, Gallipolis, Ohio, United States|Advanced Neurology Associates, Youngstown, Ohio, United States|Oregon Health and Sciences University, Portland, Oregon, United States|Veterans Affairs Portland Health Care System, Portland, Oregon, United States|Sacred Heart Medical Center at RiverBend, Springfield, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Abington Neurological Associates, Willow Grove, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Greenville Memorial Hospital, Greenville, South Carolina, United States|Methodist University Hospital, Memphis, Tennessee, United States|Centennial Heart Cardiovascular Consultants, LLC, Nashville, Tennessee, United States|Saint Thomas Health, Nashville, Tennessee, United States|Seton Medical Center Austin, Austin, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Bhupesh Dihenia, M.D.,P.A., Lubbock, Texas, United States|University of Vermont, Burlington, Vermont, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Carilion Riverside, Roanoke, Virginia, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Marshall University, Huntington, West Virginia, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|STAT Research, Caba, Argentina|Fundación Favaloro, Caba, Argentina|Hospital Italiano de Buenos Aires, Caba, Argentina|Instituto Médico DAMIC S.R.L., Cordoba, Argentina|Clinica Coronel Suarez SA, Coronel Suarez, Argentina|Hospital Privado de Comunidad, Mar del Plata, Argentina|Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Kanwal Medical Complex, Kanwal, New South Wales, Australia|John Hunter Hospital, New Lambton, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Calvary North Adelaide Hospital, Adelaide, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Alfred Health, Victoria, Australia|LKH-Univ. Hospital Graz, Graz, Austria|Medical University of Innsbruck, Innsbruck, Austria|Kepler Univ. Klinikum Linz, Linz, Austria|Kepler Univ. Klinikum Linz, Linz, Austria|KH d. Barmherzigen Brüder Linz, Neurologie, Linz, Austria|Universitätsklinikum Tulln, Abteilung für Neurologie, Tulln, Austria|Hosp.Hietzing with Neuro.Centr Rosenhuegel,II Neuro.dep,Wien, Vienna, Austria|Wilhelminenspital, Wien, Austria|Aalst - HOSP Onze-Lieve-Vrouw, Aalst, Belgium|Arlon - HOSP Sud Luxembourg - Vivalia, Arlon, Belgium|AZ Sint-Jan Brugge, Brugge, Belgium|Brussels-UNIV Brugmann -Horta, Brussel, Belgium|Brussels - HOSP Europe (Ste-Elisabeth), Brussel, Belgium|Brussels - UNIV Saint-Luc, Bruxelles, Belgium|UNIV UZ Gent, Gent, Belgium|Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium|UZ Leuven, Leuven, Belgium|Liège - HOSP St-Joseph, Liège, Belgium|Roeselare - HOSP AZ Delta, Roeselare, Belgium|Rumst - HOSP AZ Heilige Familie, Rumst, Belgium|Sint-Truiden - HOSP St-Trudo (St-Jozef), Sint-Truiden, Belgium|Wilrijk - HOSP GZA (St-Augustinus), Wilrijk, Belgium|Yvoir - UNIV UCL de Mont-Godinne, Yvoir, Belgium|Hospital Clinicas de Botucatu, Botucatu, Brazil|Instituto de Medicina Flumignano, Curitiba, Brazil|Clinica Neurologica e Neurocirurgica de Joinvile, Joinvile, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|H.C.da Fac. de Medicina de Ribeirao Preto, Ribeirao Preto, Brazil|Hospital Quinta D¿Or, Rio de Janeiro, Brazil|Foothills Medical Centre, Calgary, Alberta, Canada|University of Alberta Hospital (University of Alberta), Edmonton, Alberta, Canada|Grey Nuns Hospital, Edmonton, Alberta, Canada|Prairie Mountain Health, Brandon, Manitoba, Canada|Hopital Notre-Dame du CHUM, Montreal, Migration Data, Canada|Jewish General Hospital, Montreal, Migration Data, Canada|Saint John Regional Hospital, Saint John, New Brunswick, Canada|Eastern Health (MUN), St. John's, Newfoundland and Labrador, Canada|Victoria Hospital (LHSC), London, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto Western Hospital, Toronto, Ontario, Canada|CSSS de Chicoutimi, Chicoutimi, Quebec, Canada|Hopital Charles - LeMoyne, Greenfield Park, Quebec, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|CHUS Fleurimont, Sherbrooke, Quebec, Canada|St Jerome Medical Research Inc., St-Jerome, Quebec, Canada|CHU de Quebec-Universite Laval Research Centre, Quebec, Canada|Clínica Alemana de Santiago S.A., Santiago, Chile|Clínica Dávila, Santiago, Chile|Clinica Alemana de Temuco, Temuco, Chile|Beijing Tiantan Hospital affiliated to Cap Med University, Beijing, China|Peking University Third Hospital, Beijing, China|First Hospital of Jilin University, Changchun, China|First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, China|The First Affiliated Hospital of Jinan University, Guangzhou, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, China|2nd Affiliated Hosp Zhejiang University College of Medical, Hangzhou, China|Zhejiang Hospital, Hangzhou, China|The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China|Zhejiang University School of Medicine SIR RUN RUN SHAW Hospital, Hangzhou, China|Jinlin Central Hospital, Jilin, China|The Second Affiliated Hospital to Nanchang University, Nanchang, China|Nanjing Drum Tower Hospital, Nanjing, China|Zhongda Hospital Southeast University, Nanjing, China|QingDao Municipal Hospital, Qingdao, China|The affiliated hospital of medicalcollege qingdao university, Qingdao, China|Huashan Hospital, Fudan University, Shanghai, China|Tongji Hospital, Tongji University, Shanghai, China|General Hospital of Shenyang Military Region, Shenyang, China|First Affiliated Hospital of Xiamen University, Xiamen, China|Affiliated Hospital, Xuzhou Medical college, Xuzhou, China|Servicios Médicos Muñoz Solano, Bogotá, Colombia|Sociedad de Cirugia de Bogota Hospital de San José, Bogotá, Colombia|Fundación Valle del Lili, Cali, Colombia|Fundación Cardiovascular de Colombia, Floridablanca, Colombia|General Hospital Varazdin, Varazdin, Croatia|Clin.Hosp.Centre Zagreb,Cerebrovascul.disease w/ intens.care, Zagreb, Croatia|University hospital center Zagreb, Zagreb, Croatia|Univ. Hosp. Sisters of Mercy, Neurology Clinic, Zagreb, Zagreb, Croatia|Cerebrovascular site, private prac., Brno, Brno, Czechia|Hospital Jihlava, Jihlava, Czechia|University Hospital Olomouc, Olomouc, Czechia|Cerebrovascular site, Ostrava, Ostrava, Czechia|Cerebrovascular site, Ostrava, Ostrava, Czechia|Hospital Homolka, Prague, Prague 5, Czechia|University Hospital Motol, Praha 5, Czechia|East Estonia Central Hospital, Neurology Dept, Ahtme, Ahtme, Estonia|West Tallinn Central Hospital, Neurology Dept., Tallinn, Estonia|North Estonia Medical Centre Foundation, Tallin, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|HOP Pays d'Aix, Aix en Provence, France|HOP de Bayonne, Bayonne, France|HOP Jean Minjoz, Besançon, France|HOP Pellegrin, Bordeaux, France|HOP de la Cavale Blanche, Brest, France|HOP Pierre Wertheimer, Bron, France|HOP Côte de Nacre, Caen, France|HOP Grenoble, Neuro, Grenoble, Grenoble, France|HOP Roger Salengro, Lille, France|HOP Mercy, Metz, France|HOP Paris Saint-Joseph, Paris, France|GHU Paris Psychiatrie et Neurosciences, Paris, France|HOP Purpan, Toulouse, France|Klinikum Altenburger Land GmbH, Altenburg, Germany|Neurologische Klinik GmbH, Bad Neustadt, Bad Neustadt, Germany|Vivantes Netzwerk für Gesundheit GmbH, Berlin, Germany|Evangelisches Klinikum Bethel gGmbH, Bielefeld, Germany|Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil gGmbH, Bochum, Germany|St. Josef- und St. Elisabeth-Hospital gGmbH, Bochum, Germany|Gesundheit Nord gGmbH   Klinikverbund Bremen, Bremen, Germany|Klinikum Bremerhaven, Bremen, Germany|Krankenhäuser Buchholz und Winsen gGmbH, Buchholz, Germany|Allgemeines Krankenhaus, Celle, Celle, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Coburg gGmbH, Coburg, Germany|Klinikzentrum Mitte, Dortmund, Dortmund, Germany|Städtisches Klinikum Dresden, Dresden, Germany|Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Marien-Hospital, Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Alfried Krupp Krankenhaus Essen, Essen, Germany|Universitätsklinikum Essen AöR, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt am Main, Germany|Klinikum Frankfurt Höchst GmbH, Frankfurt, Germany|Klinikum Friedrichshafen, Friedrichshafen, Germany|Klinikum Fulda gAG, Fulda, Germany|Evangelische Klinik Gelsenkirchen, Gelsenkirchen, Germany|SRH Wald-Klinikum Gera GmbH, Gera, Germany|Universitätsklinikum Gießen und Marburg GmbH, Gießen, Germany|Universitätsmedizin Greifswald, Greifswald, Germany|Bezirkskrankenhaus, Günzburg, Günzburg, Germany|Asklepios Klinik St. Georg, Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Asklepios Klinik Harburg, Hamburg, Germany|Asklepios Klinik Wandsbek, Hamburg, Germany|Asklepios Klinik Barmbek, Hamburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Klinikum Hanau GmbH, Hanau, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Idar-Oberstein, Idar-Oberstein, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsklinikum Köln (AöR), Köln, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Klinikum der Stadt Ludwigshafen am Rhein gGmbH, Ludwigshafen, Germany|Universitätsklinikum Magdeburg AöR, Magdeburg, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Elblandklinikum Meißen, Meißen, Germany|Johannes Wesling Klinikum, Minden, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Germany|Ökumenisches Hainich Klinikum gGmbH, Mühlhausen, Germany|Klinikum der Universität München - Campus Großhadern, München, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany|Klinikum Nürnberg, Nürnberg, Germany|Sana Klinikum Offenbach GmbH, Offenbach, Germany|Klinikum Osnabrück GmbH, Osnabrück, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Nordwest-Krankenhaus Sanderbusch gGmbH, Sande, Germany|Kreisklinikum Siegen GmbH, Siegen, Germany|Bürgerhospital, Stuttgart, Stuttgart, Germany|Nervenklinik Teupitz, Teupitz, Teupitz, Germany|Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|RKU - Universitäts- und Rehabilitationskliniken Ulm gGmbH, Ulm, Germany|Sophien- und Hufeland-Klinikum gGmbH, Weimar, Germany|Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Univ.Hosp. of Alexandroupolis, Alexandroupolis, Greece|Gen.Hosp.of Ath.Evangelismos, Athens, Greece|Attikon University Hospital, Athens, Greece|Gen.Univ. Hosp. of Herakleion, Herakleion, Greece|General University Hospital of Larissa, Larissa, Greece|Univ. Gen. Hosp. of Patras, Patras, Greece|Univ.Gen.Hosp. of Thessaloniki, Thessaloniki, Greece|Prince of Wales Hospital, Hong Kong, Hong Kong|Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Semmelweis University, Budapest, Hungary|National Instit.of Neurosciences,Neurology Dept,Budapest, Budapest, Hungary|Univ. Debrecen Medical Health Science Center, Neurology Dept, Debrecen, Hungary|Pest Megyei Flor Ferenc Hospital, Kistarcsa, Hungary|CRU Hungary Ltd, Private Practice, Miskolc, Miskolc, Hungary|Univ. of Pecs Clinic for Neurology, Pecs, Hungary|St. Johns medical College and Hospital, Bangalore, India|Post Graduate Institute of Medical Education and Research, Chandigarh, India|Lalitha Super Specialities Hospital, Guntur, India|Nizam's Institute of Medical Sciences, Hyderabad, India|Shree Krishna Hospital and Research Centre, Karamsad, India|Caritas Hospital, Kottayam, India|Mangala Hospital and Mangala Kidney Foundation, Mangalore, India|LTMMC & GH Medical College,, Mumbai, India|Magnum Heart Institute, Nashik, India|All India Institute of Medical Sciences, New Delhi, India|Sahyadri Speciality Hospital, Pune, India|Hillel Yaffe Medical Center, Hadera, Hadera, Israel|Wolfson Medical Center, Holon, Israel|The Chaim Sheba Medical Center Tel Hashomer, Tel Hashomer, Ramat Gan, Israel|Sourasky Medical Center, Telaviv, Israel|Osp. SS Filippo Nicola, Avezzano, Italy|Policlinico S. Orsola Malpighi, Bologna, Italy|A.O. Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliero Universitaria di Ferrara, Cona (FE), Italy|Policlinico San Martino, Genova, Italy|A.O.U.Policlinico G.Martino, Messina, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Istituto Auxologico Italiano, Milano, Italy|Nuovo Ospedale Civile S. Agostino-Estense, Modena, Italy|Azienda Ospedaliera Universitaria di Padova, Padova, Italy|Ospedale S.Maria della Misericordia, AO di Perugia, Perugia, Italy|Osp. Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|Ospedale Santa Corona Azienda Sanitaria Locale n.2 Savonese, Pietra Ligure, Italy|Università degli Studi Campus Bio-Medico, Roma, Italy|A.O. San Camillo Forlanini, Roma, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy|Ospedale Molinette, AO Città della Salute e della, Torino, Italy|Ospedale Maria Vittoria, Torino, Italy|Ospedale S. Maria di Ca' Foncello Azienda ULSS9 TREVISO, Treviso, Italy|A. O. Ospedale Circolo Fond. Macchi, Varese, Italy|Ospedale Policlinico G.B. Rossi (Borgo Roma) di Verona, Verona, Italy|Chubu Rosai Hospital, Aichi, Nagoya, Japan|National Hospital Organization Toyohashi Medical Center, Aichi, Toyohashi, Japan|Toyota Memorial Hospital, Aichi, Toyota, Japan|Reserch Institute for Brain and Blood Vessels Akita, Akita, Akita, Japan|Juntendo University Urayasu Hospital, Chiba, Urayasu, Japan|Go Neurosurgical Clinic, Fukuoka, Chikushi-gun, Japan|Fukuoka University Chikushi Hospital, Fukuoka, Chikushino, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Fukuoka, Japan|Fukuoka Wajiro Hospital, Fukuoka, Fukuoka, Japan|Fukuoka University Hospital, Fukuoka, Fukuoka, Japan|Fukuoka Tokushukai Medical Center, Fukuoka, Kasuga, Japan|Steel Memorial Yawata Hospital, Fukuoka, Kitakyushu, Japan|Japan Community Health Care Organization Kyushu Hospital, Fukuoka, Kitakyushu, Japan|St. Mary's Hospital, Fukuoka, Kurume, Japan|Shin Koga Hospital, Fukuoka, Kurume, Japan|Fukuoka Shin Mizumaki Hospital, Fukuoka, Onga, Japan|Social Insurance Tagawa Hospital, Fukuoka, Tagawa, Japan|Shin Yukuhashi Hospital, Fukuoka, Yukuhashi, Japan|Fujita General Hospital, Fukushima, Date-Gun, Japan|Shinseikai Masu Memorial Hospital, Fukushima, Nihonmatsu, Japan|Asahi University Hospital, Gifu, Gifu, Japan|Japanese Red Cross Takayama Hospital, Gifu, Takayama, Japan|Mihara Memorial Hospital, Gunma, Isesaki, Japan|Maebashi Red Cross Hospital, Gunma, Maebashi, Japan|Medical corporation Suiseikai Suiseikai Kajikawa Hospital, Hiroshima, Hiroshima, Japan|Araki Neurosurgical Hospital, Hiroshima, Hiroshima, Japan|Hiroshima Prefectural Hospital, Hiroshima, Hiroshima, Japan|Sapporo Shiroishi Memorial Hospital, Hokkaido, Sapporo, Japan|Nakamura Memorial Hospital, Hokkaido, Sapporo, Japan|Kobe City Medical Center General Hospital, Hyogo, Kobe, Japan|JA Toride Medical Center, Ibaraki, Toride, Japan|Tsukuba Medical Center Hospital, Ibaraki, Tsukuba, Japan|Iwate Medical University Hospital, Iwate, Morioka, Japan|Kagoshima City Hospital, Kagoshima, Kagoshima, Japan|National Hospital Organization Kagoshima Medical Center, Kagoshima, Kagoshima, Japan|Shonan Kamakura General Hospital, Kanagawa, Kamakura, Japan|Saiseikai Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Kumamoto, Japan|Kumamoto City Hospital, Kumamoto, Kumamoto, Japan|Uji-Tokushukai Medical Center, Kyoto, Uji, Japan|National Hospital Organization Sendai Medical Center, Miyagi, Sendai, Japan|South Miyagi Medical Center, Miyagi, Shibata-gun, Japan|Ina Central Hospital, Nagano, Ina, Japan|Nagano Municipal Hospital, Nagano, Naganoi, Japan|Nagasaki University Hospital, Nagasaki, Nagasaki, Japan|Nozaki Tokushukai Hospital, Osaka, Daito, Japan|Higashiosaka City Medical Center, Osaka, Higashiosaka, Japan|Wakakusa Daiichi Hospital, Osaka, Higashiosaka, Japan|Rinku General Medical Center, Osaka, Izumisano, Japan|Kishiwada Tokushukai Hospital, Osaka, Kishiwada, Japan|Yagi Neurosurgical Hospital, Osaka, Osaka, Japan|Tominaga Hospital, Osaka, Osaka, Japan|Osaka University Hospital, Osaka, Suita, Japan|TMG Asaka Medical Center, Saitama, Asaka, Japan|Saitama Medical University International Medical Center, Saitama, Hidaka, Japan|Sainokuni Higashiomiya Medical Center, Saitama, Saitama, Japan|Saitama Municipal Hospital, Saitama, Saitama, Japan|Nippon Medical School Hospital, Tokyo, Bunkyo-ku, Japan|Tokyo Metropolitan Geriatric Hospital, Tokyo, Itabashi-ku, Japan|Kyorin University Hospital, Tokyo, Mitaka, Japan|Tokyo Women's Medical University Hospital, Tokyo, Shinjuku-ku, Japan|Saiseikai Wakayama Hospital, Wakayama, Wakayama, Japan|Yamagata City Hospital SAISEIKAN, Yamagata, Yamagata, Japan|Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of|Dong-A University Hospital, Busan, Korea, Republic of|Kyungpook National Univ. Hosp, Daegu, Korea, Republic of|Chungnam National University Hospital, Daejoen, Korea, Republic of|Inje University Ilsan Paik Hospital, Goyang, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Chosun University Hospital, Gwangju, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Chung-Ang University Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of|Ajou University Hospital, Suwon, Korea, Republic of|Sarawak General Hospital, Kuching, Malaysia|Hospital Seberang Jaya, Pulau Pinang, Malaysia|Hospital Sultanah Nur Zahirah, Terengganu, Malaysia|Hospital General de Culiacán ""Dr. Bernardo J. Gastellum"", Culiacán, Mexico|Hospital General ""Dr. Miguel Silva"", Morelia, Mexico|Hospital Angeles del Pedregal, México, D.F., Mexico|Hospital Universitario Dr Jose Eleuterio Gonzalez, Nuevo Leon, Mexico|H. Central Dr Ignacio M. P., San Luis Potosi, Mexico|Auckland City Hospital, Grafton / Auckland, New Zealand|North Shore Hospital, Takapuna, Takpuna Auckland, New Zealand|Wellington Hospital, Wellington, New Zealand|Instituto Nacional de Ciencias Neurológicas, Barrios Altos, Peru|Hospital Nacional Guillermo Almenara Irigoyen, La Victoria, Peru|PI HOUSE Sp. z o.o., Gdansk, Gdansk, Poland|Spec.Hosp.of Dr. Wladyslaw Bieganski in Grudziadz, Grudziadz, Poland|Univ.Clin.Centr Gibinski of Silesian Med,Neurol.dep,Katowice, Katowice, Poland|University Hospital in Krakow, Krakow, Poland|Center of Clinical Neurology, private prac, Krakow, Krakow, Poland|Clin.Research Center,Leszek Szczepanski,Private Prac.,Lublin, Lublin, Poland|Medicome Sp. z o.o., Oswiecim, Poland|Specialist Holy Spirit Hospital, Neurology Dept,Sandomierz, Sandomierz, Poland|Public Central Clinical Hosp,Neurology Clinic,Warsaw, Warsaw, Poland|Military Institute of Medicine Neurology Clinic, Warsaw, Warsaw, Poland|Hospital Garcia de Orta, EPE, Almada, Portugal|Hospital Fernando Fonseca, EPE, Amadora, Portugal|Hospital de Braga - Centro Clínico Académico (2CA), Braga, Portugal|CHUC - Centro Hospitalar e Universitário de Coimbra, EPE, Coimbra, Portugal|CHLC, EPE - Hospital de São José, Lisboa, Portugal|CHLO, EPE - Hospital Egas Moniz, Lisboa, Portugal|CHULN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Hospital Beatriz Ângelo, Loures, Portugal|USLM, EPE - Hospital Pedro Hispano, Matosinhos, Portugal|H. Santo António - Centro Hospitalar do Porto, Porto, Portugal|Centro Hospitalar São João,EPE, Porto, Portugal|Centro Hospitalar de Entre o Douro e Vouga, E.P.E. - Hospital de São Sebastião, Santa Maria da Feira, Portugal|Interreg. Clinical & Diagnostic Center, Neurol. Dept., Kazan, Kazan, Russian Federation|Reg.Clin.Hosp#1 na S.V.Ochapovskiy,Neurology#1 Dep,Krasnodar, Krasnodar, Russian Federation|City Clin.Emergency Hosp of Kursk, Neurology Department No.2, Kursk, Russian Federation|Clin.Hosp#2,na.Semashko,Russ.Railways,Restorative Med&Rehab., Moscow, Russian Federation|CityClin.Hosp na I.V.Davydovsky of Dept of Healthcare Moscow, Moscow, Russian Federation|Research&Clini Cent Neuropsychiatry Dep. Healthcare,Moscow, Moscow, Russian Federation|City Clin.Hosp#1na N.I.Pirogov,Dept of Healthcare of Moscow, Moscow, Russian Federation|Ltd liabilityCom.CityNeurologic Cntr Sibneiromed,Novosibirsk, Novosibirsk, Russian Federation|Saratov State Med.Univ na V.I.Razumovsky,FacultyTherapy Clin, Saratov, Russian Federation|Reg.State Instit.of Healthc.Smolensk Reg.Clin.Hosp,Neurology, Smolensk, Russian Federation|Research Inst. of Emerg. Med., Vascul. Center,St. Petersburg, St. Petersburg, Russian Federation|Military Medical Academy n.a. C. M. Kirov, St. Petersburg, St. Petersburg, Russian Federation|Sverdlovsk Reg.Clin.Hosp.No.1, Yekaterinburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Special Hosp.for Cerebrovascul.Disease,'Sveti Sava,Belgrade, Belgrade, Serbia|Clinical Centre Nis, Nis, Serbia|Clinical Center of Vojvodina, Novi Sad, Serbia|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Neuroscience Institute, Singapore, Singapore|Faculty Hospital L. Pasteura, Kosice, Kosice, Slovakia|Faculty Hospital Nitra, Nitra, Slovakia|Instit.f.applicative Research in med.rehab.Dobrna, Dobrna, Slovenia|Cardial d.o.o., Specialist out-patient unit, Ljubljana, Ljubljana, Slovenia|Univ. Medical Center Maribor, Maribor, Slovenia|University of Pretoria, Pretoria, South Africa|Dr. Moodley and Dr. Sarvan, Tongaat, South Africa|Hospital General Universitario de Albacete, Albacete, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Hospital La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Son Espases, Palma de Mallorca, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Donostia, San Sebastian, Spain|Hospital Clínico de Santiago, Santiago de Compostela, Spain|Hospital Virgen del Rocío, Sevilla, Spain|Hospital Universitari Joan XXIII, Tarragona, Spain|Hospital Mútua Terrassa, Tarrasa (Barcelona), Spain|Hospital Clínico de Valencia, Valencia, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain|Sahlgrenska US, Göteborg, Göteborg, Sweden|Sahlgrenska Universitetssjukhuset, Östra, Göteborg, Sweden|Skaraborgs Sjukhus, Skövde, Sweden|Karolinska Univ. sjukhuset, Stockholm, Sweden|Karolinska Univ. sjukhuset, Stockholm, Sweden|Danderyds Sjukhus, Stockholm, Sweden|Canton Hospital Aarau, Neurology Dept., Stroke Center, Aarau, Switzerland|University Hospital Basel, Basel, Switzerland|Univ. Hospital Bern, Neurology Dept, Stroke Center, Bern, Switzerland|CHUV - Centre hospitalier universitaire vaudois, Lausanne, Switzerland|Regional Hospital Lugano,Neurocenter of Southern Switzerland, Lugano, Switzerland|Kantonsspital St.Gallen, St. Gallen, Switzerland|University Hosp. Zürich, Dept. of Neurology, Stroke Center, Zürich, Switzerland|Chang-Hua Christian Hospital, Changhua, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan,, Taiwan|NCKUH, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan|Cheng Hsin General Hospital, Taipei, Taiwan|Taipe Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital(TaoYuan), Taoyuan, Taiwan|Chulalongkorn University, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Siriraj Hospital, Bangkok, Thailand|Lampang Hospital, Lampang, Thailand|Ankara Universitesi Tip Fakultesi, Ankara, Turkey|Hacettepe Universitesi Tip Fakultesi Noroloji A.B.D., Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Eskisehir Osmangazi Universitesi Tip Fakultesi, Eskisehir, Turkey|Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi, Istanbul, Turkey|Istanbul Universitesi Istanbul Tip Fakultesi Noroloji A.B.D., Istanbul, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Bakırkoy Dr. Sadi Konuk Egitim Ve Arastirma Hastanesi, Istanbul, Turkey|Bakirkoy Prof. Dr. Mazhar Osman Ruh Sagligi ve Sinir Hastaliklari, Istanbul, Turkey|Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi, Istanbul, Turkey|Dokuz Eylul Universitesi Tip Fakultesi Noroloji A.B.D., Izmir, Turkey|Ondokuz Mayis Universitesi Tip Fakultesi, Samsun, Turkey|Namik Kemal Universitesi Tip Fakultesi, Tekirdag, Turkey|Bukovinian Med.Univ.Chernivtsi Reg.Psychiatric Hosp,Neurolog, Chernivtsi, Ukraine|City Clinical Hospital No. 7, Kharkov, Kharkiv, Ukraine|Instit.of Neurol,Psychiatry&Narcol,Vascul. Malformations Dep, Kharkiv, Ukraine|Instit.of Gerontology na D.F.Chebotarev,Brain Vascular Path., Kyiv, Ukraine|Lviv Regional Clinical Hospital, Lviv, Lviv, Ukraine|Ternopil State Med.Univ.na Gorbachevskiy,Neurology Dept N3, Ternopil, Ukraine|Vinnitsia Reg.Psychoneurol.Hosp.na Yushchenko,Dept.N3,Neurol, Vinnitsia, Ukraine|Zhytomyr Reg.ClinHosp na Gerbachevskiy RegCouncil,Neurol.Dep, Zhytomyr, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02239120/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/20/NCT02239120/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT02239120"
614,"NCT03975205","To Study the Concentration Level of, Doxil, and Doxorubicin at Various Time Frames","Doxil","Unknown status","No Results Available","Lymphoma Leukemia","Drug: Doxorubicin","Bioavailability of Doxil versus Doxorubicin","Sutphin Drugs|Bharath Charitable Cancer Hospital and Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","500","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Global CRO Doxil","July 1, 2019","October 31, 2019","December 31, 2019","June 5, 2019",,"June 5, 2019","Bharat Cancer Hospital, Surat, Gujarat, India",,"https://ClinicalTrials.gov/show/NCT03975205"
615,"NCT01191138","Gastric Emptying After Infracolic or Supracolic Gastrojejunostomy Following Pancreaticoduodenectomy",,"Completed","No Results Available","Postprocedural Gastric Stasis","Procedure: Infracolic gastrojejunal anastamosis|Procedure: Supracolic gastrojejunal anastamosis","Gastric Emptying assessed clinically and correlated objectively with liquid and solid emptying of radionucleotide|Correlation of pancreatic duct leak with gastric emptying","Asian Institute of Gastroenterology, India|KK Nuclear Scan","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AIG-GIS-20090","January 2009","February 2012","March 2012","August 30, 2010",,"June 20, 2012","Asian Institute Of Gastroenterology India, Hyderabad, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01191138"
616,"NCT00631371","Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","INTORACT","Completed","Has Results","Renal Cell Carcinoma","Drug: Bevacizumab|Drug: Temsirolimus|Drug: Interferon-Alfa 9MU","Progression-Free Survival (PFS): Independent-Assessment|Progression-Free Survival (PFS): Investigator-Assessment|Percentage of Participants With Objective Response (Complete Response/Partial Response): Independent-Assessment|Overall Survival (OS)","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","791","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3066K1-3311|B1771006|2007-003793-26","April 2008","April 2012","April 2015","March 7, 2008","June 4, 2013","April 27, 2016","Hematology Oncology Services of Arkansas, Little Rock, Arkansas, United States|South County Hematology/Oncology, Chula Vista, California, United States|Cancer Center Oncology Medical Group, La Mesa, California, United States|UCLA Medical Center, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|UCLA, Los Angeles, California, United States|North County Oncology Medical Clinic, Oceanside, California, United States|Medical Oncology Associates - SD, San Diego, California, United States|Sharp Memorial Hospital Investigational Pharmacy, San Diego, California, United States|Sharp Rees-Stealy, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|Pacific Hematology/Oncology Associates, San Francisco, California, United States|San Francisco Oncology Associates, San francisco, California, United States|Cohen & Hufford MD's INC, San Francisco, California, United States|The Jones Clinic, PC, New Albany, Mississippi, United States|The Cleveland Clinic, Cleveland, Ohio, United States|Edmond Oncology Center, Edmond, Oklahoma, United States|OU Medical Center, Oklahoma City, Oklahoma, United States|OU Physician's Building, Oklahoma City, Oklahoma, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|The Jones Clinic, PC, Germantown, Tennessee, United States|The Vanderbilt Clinic, Nashville, Tennessee, United States|University of Washington Medical Center, Seattle, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Centro Oncológico Rosario, Rosario, Santa Fé, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|ISIS Clinica Especializado, Santa Fe, Argentina|Mater Adult Hospital, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ashford Cancer Center Research, Kurralta Park, South Australia, Australia|Cancer Care SA, Kurralta Park, Australia|Mater Private Hospital, South Brisbane, Australia|ZNA Middelheim, Antwerpen, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Jessa Ziekenhuis - campus Virga Jessa, Hasselt, Belgium|Cliniques Universitaires de Mont-Godinne UCL, Mont-Godinne, Belgium|Centro Goiano de Oncologia, Goiania, GO, Brazil|Centro Goiano de Oncologia - CGO, Goiania, GO, Brazil|ProCura - Centro Goiano de Pesquisa Clínica Ltda, Goiania, GO, Brazil|Clínica de Oncologia de Porto Alegre Sociedade Simples Ltda, Porto Alegre, Rio Grande do Sul, Brazil|Instituto Nacional de Cancer - INCA, Rio de Janeiro, RJ, Brazil|Associaçao Hospital de Caridade Ijui, Ijui, RS, Brazil|Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil|Clinica de Oncologia de Porto Alegre - Sociedade Simples Ltda., Porto Alegre, RS, Brazil|Fundação Pio XII - Hospital de Câncer de Barretos, Barretos, Sao Paulo, Brazil|Instituto de Oncologia de Piracicaba S/S Ltda, Piracicaba, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo Octavio Frias de Oliveira - ICESP, Sao Paulo, SP, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Instituto Nacional do Cancer - INCA, Rio de Janeiro, Brazil|Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre de Sante et de Services Sociaux de Rimouski - Neigette, Rimouski, Quebec, Canada|Instituto Nacional del Cancer, Santiago, Region Metropolitana / Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Instituto Clinico Oncologico del Sur, Santiago, Chile|Oncologos del Occidente S.A, Pereira, Risaralda, Colombia|Oblastni nemocnice Jicin a s, Jicin, Ceska republika, Czech Republic|Masarykuv onkologicky ustav, Brno, Czech Republic|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Krajska zdravotni, a.s., Usti nad Labem, Czech Republic|Centre Jean Perrin, Clermont-Ferrand, France|Clinique Sainte Marguerite, Hyères, France|Hopital Andre Mignot, Le Chesnay, France|Centre médical Oncogard, Nimes, France|CHU de Poitiers, Poitiers Cedex, France|CHU de Rouen, Rouen Cedex, France|Centre rené Gauducheau, Saint-Herblain-Nantes, France|Hopital Foch, Suresnes, France|Institut Gustave Roussy, Villejuif Cedex, France|Vivantes Klinikum am Urban, Neztwerk fuer Gesundheit GmbH, Berlin, Germany|Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany|Klinikum Region Hannover, Krankenhaus Siloah, Hannover, Germany|TU Muenchen, rechts der Isar, Muenchen, Germany|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Orszagos Onkologiai Intezet, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Josa Andras Oktato Korhaz Nonprofit Kft., Nyiregyhaza, Hungary|Szegedi Tudomanyegyetem, Urologiai Klinika, Szeged, Hungary|Veszprem Megyei Csolnoky Ferenc, Veszprem, Hungary|Vedanta Institute of Medical Sciences, Ahmedabad, Gujarat, India|Healthcare Global Enterprises Limited, Bangalore, Karnataka, India|Lakeshore Hospital & Research Center Limited, Kochi, Kerala, India|Jawaharlal Nehru Cancer Hospital, Department of Medical Oncology, Bhopal, Madhya Pradesh, India|Tata Memorial Center, Mumbai, Maharashtra, India|Tata Memorial Centre, Navi Mumbai, Maharashtra, India|Jehangir Hospital, Pune, Maharashtra, India|Searoc Cancer Centre, Jaipur, Rajasthan, India|Apollo Hospital, Chennai, Tamil Nadu, India|Regional Cancer Centre, Kerela, Trivandrum, India|Divisione di Urologia, Azienda Ospedaliera Policlinico Consorziale di Bari, Bari, Italy|Sezione di Oncologia Medica Centro di Ricerca Clinica, Chieti, Italy|Unità Operativa di Oncologia, Azienda Ospedaliera Policlinico di Modena, Modena, Italy|Farmacia del Comitato Etico Provinciale di Modena, Modena, Italy|Struttura Complessa di Oncologia Medica Ospedale Santa Maria della Misericordia, Perugia, Italy|IFO- Istituti Fisioterapici Ospitalieri, Roma, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Samsung Medical Center, Seoul, Korea, Korea, Republic of|Yonsei University Health System-Severance Hospital, Seoul, Korea, Republic of|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Hospital Aranda de la Parra, Leon, Guanajuato, Mexico|Spaarne Ziekenhuis, Hoofddorp, Netherlands|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Szpital Specjalistyczny im. L. Rydygiera Sp. z o.o., Krakow, Poland|Centrum Onkologii Ziemi Lubelskiej im. sw Jana z Dukli, Lublin, Poland|Szpital Kliniczny Przemienienia Panskiego UM im. Karola Marcinkowskiego w Poznaniu, Poznan, Poland|Centrum Onkologii, Instytut im. M. Sklodowskiej-Curie, Warszawa, Poland|Centrum Medyczne Ostrobramska NZOZ ""Magodent"", Warszawa, Poland|Wojskowy Instytut Medyczny, Pracownia Badan Cynnosciowych Ukladu Oddechowego, Klinika Chorob Wewnetr, Warszawa, Poland|Wojskowy Intsytut Medyczny, Zaklad Diagnostyki Laboratoryjnej CSK MON, Warszawa, Poland|Wojskowy Intsytut Medyczny, Zaklad Medycyny Nuklearnej CSK MON, Warszawa, Poland|Hospital de San Joao, Porto, Portugal|Hospital de São João, Porto, Portugal|Medical Radiology Research Center of the Minzdravsotsrazvitiya of Russia, Obninsk, Kaluga region, Russian Federation|Leningrad Regional Oncology Dispensary, Saint-Petersburg, Leningradskaya oblast, Russian Federation|Republican Clinical Oncology Dispensary of Minzdrav of Tatarstan Republic, Kazan, Russian Federation|Chair of Radiology and Radiotherapy, Moscow, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Department of Clinical Pharmacology and Chemotherapy, Moscow, Russian Federation|N.N. Blokhin Russian Cancer Research Center, Department of Urology, Moscow, Russian Federation|Moscow Scientific Research Oncology Institute P.A. Herzen, Moscow, Russian Federation|Privolzhskiy District Medical Center of Federal Biomedical Agency, Nizhni Novgorod, Russian Federation|Scientific research Institute of Oncology N.N. Petrov, Pesochny, Saint-Petersburg, Russian Federation|City Hospital No.26, Saint-Petersburg, Russian Federation|City Pokrovskaya Hospital, Saint-Petersburg, Russian Federation|Clinical Center of Serbia, Belgrade, Serbia|Institute for Oncology and Radiology of Serbia, Belgrade, Serbia|Military Medical Academy, Belgrade, Serbia|National Cancer Centre Singapore, Singapore, Singapore|Fakultna Nemocnica s poliklinikou F D Roosevelta, Banska Bystrica, Slovakia|Oddelenie funkcnej diagnostiky, Banska Bystrica, Slovakia|Klinika pneumologie a ftiziologie FNsP LFUK, Bratislava, Slovakia|Fakultna Nemocnica s poliklinikou akad L Derera, Bratislava, Slovakia|Klinica nuklcarncj mediciny, Martin, Slovakia|Klinika nuklearnej mediciny JLF UK a Martinskej fakultnej nemocnice, Martin, Slovakia|Klinika tuberkulozy a plucnych chorob UK JLF a Martinskej fakultnej nemocince, Martin, Slovakia|Nemocnica s poliklinikou Skalica, Skalica, Slovakia|KK MED, s.r.o., Zilina, Slovakia|MEDIVASA s.r.o., Zilina, Slovakia|Nemocnica s poliklinikou Zilina, Zilina, Slovakia|GVI Oncology Trial Unit, Kraaifontein, Cape Town, South Africa|Westridge Medical Centre, Mayville, Durban, South Africa|Pretoria Urology Hospital, Hatfield, Pretoria, South Africa|Panorama Medical Centre, Panorama, Cape Town, Western Cape, South Africa|University of the Witwatersrand Oncology, Parktown, South Africa|Langenhoven Drive Oncology Centre, Port Elizabeth, South Africa|Dr. Fourie & Voges, Pretoria, South Africa|Institut Catala Doncologia, L'hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Sant Creu I Sant Pau, Barcelona, Spain|Hospital del mar de Barcelona, Barcelona, Spain|Hospital de Madrid Norte-Sanchinarro, Madrid, Spain|Instituto Valenciano de Oncología, Valencia, Spain|Veterans General Hospital-Taipei, Taipei, ROC, Taiwan|Tri-Service General Hospital, Neihu, Tapei, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei TOC, Taiwan|Division of Oncology, Tao Yuan, Taiwan|Universitet, kafedra onkologyy, Chenivtsi, Ukraine|A.P Romodanov Itstitut nejrohirurhii, Chernovtsi, Ukraine|Uchbobo-naukovyi likuvalnyi kompleks DDMU im. M.Gor'kogo, Donetsk, Ukraine|Donetskyy Oblasyy protypukhlynnyy Tsenter, Donetsk, Ukraine|Donetske Obl. clinico-teritorial'ne medichne ob'yednannya, Donetsk, Ukraine|""State Institution """"Institute for Occupational Health of the, Kiev, Ukraine|R.E.Kavetsky Institute of experimental pathology, oncology and radiobiology NAS of Ukraine,Laborator, Kiev, Ukraine|A.P Romodanov Itstitut nejrohirurhii, Kiyv, Ukraine|Oblasnyy onkologychnyy dispanser, onkourologichne viddilennya, Ivano-Frankivskiy Derzhavniy Medichni, Medychna vul., Ivano-Frankivsk, Ukraine|Southampton General Hospital, Southampton, Hampshire, United Kingdom|Christie Hospital, Withington, Manchester, United Kingdom|University of Leeds, Leeds, North Yorkshire, United Kingdom|Guy's Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00631371"
617,"NCT01304849","Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes",,"Completed","No Results Available","Hodgkin's Lymphoma","Drug: Escalated BEACOPP","Efficacy of interim PET guided therapy strategy interms of EFS in advanced HL|Toxicity of escalated BEACOPP","Cancer Institute WIA","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CIA-HL-1","January 2011","September 2013","September 2013","February 28, 2011",,"February 4, 2015","Department of Medical Oncology, Cancer Institute (WIA), Adyar, Chennai, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT01304849"
618,"NCT04538547","Randomized Trial to Evaluate Accelerated Radiotherapy in Locally Advanced Carcinoma of Nasopharynx","EARN","Recruiting","No Results Available","Carcinoma, Nasopharyngeal","Radiation: Accelerated Radiotherapy|Radiation: Non Accelerated Radiotherapy","To compare acute treatment related toxicity between the two study groups|To compare overall response rates between the two study group","Postgraduate Institute of Medical Education and Research|Indian Council of Medical Research","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IEC-02/2019-1122","September 16, 2019","September 2022","September 2022","September 4, 2020",,"September 4, 2020","Post Graduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT04538547"
619,"NCT05068076","Role of Perfluorobutane in Lesion Detection, Targeting and Response Assessment for Ablation of HCC",,"Completed","No Results Available","Hepatocellular Carcinoma|Microwave Ablation","Drug: Perfluorobutane","Comparison of treatment response two hours post procedure with Perfluorobutane with routine CECT/CEMRI done at 1 month post procedure using modified RECIST criteria for HCC.|Targeting of lesions (fulfilling CEUS LIRADS 4/5 criteria) in the Kupffer phase for ablation","Institute of Liver and Biliary Sciences, India","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","ILBS-HCC-04","October 1, 2021","December 16, 2021","December 16, 2021","October 5, 2021",,"December 21, 2021","Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT05068076"
620,"NCT04443049","To Study the Effects of Addition of Mebendazole to Lenvatinib in Cirrhotics With Advanced Hepatocellular Carcinoma.",,"Recruiting","No Results Available","Hepatocellular Carcinoma|Liver Cirrhosis","Drug: Lenvatinib|Drug: Mebendazole|Other: Placebo","Overall survival in both groups|Death|Progressive disease requiring change of therapy in both groups|Progressive disease requiring quitting therapy in both groups|Therapy related adverse effects in both groups|Worsening of performance status in both groups|Decompensation of underlying cirrhosis in both groups","Institute of Liver and Biliary Sciences, India","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ILBS-Cirrhosis-32","July 10, 2020","June 19, 2022","June 19, 2022","June 23, 2020",,"October 5, 2021","Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04443049"
621,"NCT03338647","SBRT or TACE for Advanced HCC",,"Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: DEB|Radiation: SBRT","Progression (total of local, intra- and extrahepatic)|Response|Local control of treated tumor|Intrahepatic failure|Extrahepatic failure|Overall survival|Treatment related toxicity|Cost-benefit","University of Aarhus|International Atomic Energy Agency","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UAarhus HCC","October 26, 2017","December 31, 2023","December 31, 2023","November 9, 2017",,"December 2, 2021","Medanta, Delhi, NCT, India",,"https://ClinicalTrials.gov/show/NCT03338647"
622,"NCT04250064","A Study of Low Dose Bevacizumab With Conventional Radiotherapy Alone in Diffuse Intrinsic Pontine Glioma","LoBULarDIPG","Recruiting","No Results Available","DIPG","Drug: Bevacizumab Injection|Radiation: Ultra-low-dose RT","Overall Survival|Progression-free survival|Adverse events|Steroid Use|Pattern of relapse|Overall survival|Compliance|Inconvenience rates|Quality of Life scores","Tata Memorial Centre","All","3 Years to 18 Years   (Child, Adult)","Phase 2","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3201","February 4, 2020","February 2023","February 2023","January 31, 2020",,"May 4, 2022","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04250064"
623,"NCT04474964","Focal Radiotherapy Plus Low Dose Craniospinal Irradiation Followed by Adjuvant Chemotherapy in WNT Medulloblastoma.","FOR-WNT2","Recruiting","No Results Available","Medulloblastoma, WNT-activated","Radiation: Low dose Craniospinal Irradiation plus Focal Radiotherapy","Relapse-free survival will be analysed using using the product-limit method of Kaplan-Meier and compared using the log-rank test.|Overall Survival of Participants will be analysed using the product-limit method of Kaplan-Meier and compared using the log-rank test.|Neuro-cognitive function of Participants will be analysed longitudinally over time using linear regression model with time-test for trend|Growth Hormone levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend.|Thyroid function levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend.|Cortisol levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend.|Sex Hormone levels of Participants will be analysed longitudinally over time using linear regression model with time-test for trend.|Pure tone Audiometry of Participants will be analysed longitudinally over time using linear regression model with time-test for trend.","Tata Memorial Centre","All","3 Years to 16 Years   (Child)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3468","August 13, 2020","July 2030","July 2030","July 17, 2020",,"October 6, 2021","Tata Memorial Hospital, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT04474964"
624,"NCT02041793","Laparoscopic Cystogastrostomy Versus Endoscopic Cystogastrostomy",,"Completed","No Results Available","Pancreatic Pseudocyst","Procedure: Laparoscopic cystogastrostomy|Procedure: Endoscopic cystogastrostomy","Resolution of Pseudocyst|Adverse Events|Cost per patient|Recurrence rate of pseudocyst","All India Institute of Medical Sciences, New Delhi|Indian Council of Medical Research","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICMR-PP 5/10","May 2010","April 2015","November 2015","January 22, 2014",,"July 2, 2017","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02041793"
625,"NCT04712929","Candida Associated Cytokines in Oral Leukoplakia",,"Completed","No Results Available","Oral Leukoplakia","Other: Fluconazole","Oral burning sensation|Clinical size of lesion|Pro- inflammatory cytokines|Erythema of oral lesion|Thickness of oral lesion|candida positivity|Phospholipase Activity of Candida in Oral leukoplakia|Secreted aspartyl proteinase activity of Candidain Oral leukoplakia|Biofilm formation|Antifungal sensitivity|Histopathology|Malignant transformation","All India Institute of Medical Sciences, New Delhi","All","18 Years to 100 Years   (Adult, Older Adult)",,"90","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","A-634","November 1, 2018","February 15, 2020","March 30, 2020","January 19, 2021",,"January 20, 2021","All india Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT04712929"
626,"NCT02160600","Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial",,"Completed","No Results Available","Renal Cell Carcinoma|Renal Cysts|Transitional Cell Carcinoma|AML","Other: Standard multiphase CT|Other: split bolus Dual energy CT","Appropriateness of the treatment recieved","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic","IESC/T-457/29.11.2013","April 2014","December 2016","December 2016","June 10, 2014",,"April 27, 2017","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02160600"
627,"NCT04251845","Evaluation of Effect of Topical Melatonin in Treatment of Oral Leukoplakia",,"Unknown status","No Results Available","Oral Leukoplakia","Dietary Supplement: topical melatonin|Other: PLACEBO","Change in the size of the lesion.|Degree of dysplasia|Expression of immunopositivity of ki67 cells in the lesion.","Postgraduate Institute of Dental Sciences Rohtak","All","18 Years and older   (Adult, Older Adult)","Not Applicable","66","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Shubhangi OMR","February 1, 2020","August 30, 2020","September 30, 2020","February 5, 2020",,"February 5, 2020","Post graduate institute of dental sciences, Rohtak, Haryana, India",,"https://ClinicalTrials.gov/show/NCT04251845"
628,"NCT02259647","Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma",,"Completed","No Results Available","Hepatocellular Carcinoma","Drug: Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Drug: Sorafenib 400 mg twice daily + Intravenousinfusion of placebo","Overall Survival|Objective response rate (ORR) of tumour based on mRECIST (Response Evaluation Criteria In Solid Tumors ) criteria|Disease control rate (DCR) of tumour based on mRECIST (Response Evaluation Criteria In Solid Tumors ) criteria|Biochemical response - improvement in tumor biomarker level|Safety","Institute of Liver and Biliary Sciences, India","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ILBS-HCC-02","October 1, 2014","October 31, 2015","October 31, 2015","October 8, 2014",,"October 28, 2019","Institute of Liver & Biliary Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02259647"
629,"NCT02240771","Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma",,"Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: Transarterial chemotherapy|Drug: Oral chemotherapy","Survival rate-|Tumor response","All India Institute of Medical Sciences, New Delhi|Indian Council of Medical Research","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","124","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TAC-HCC","January 2006","December 2014","March 2015","September 16, 2014",,"September 16, 2014","AII India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT02240771"
630,"NCT02155452","Fluorescence and Glioma Heterogeneity","ALAglioma","Completed","No Results Available","Malignant Gliomas","Procedure: ALA","Degree of fluorescence|High throughput proteomic screening of tissue samples","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Case-Control|Time Perspective: Other","TMC- ACTREC IRB project no 139","May 2014","July 2019","July 2019","June 4, 2014",,"May 6, 2022","Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Navi Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02155452"
631,"NCT01438450","Oral Chemotherapy Versus Supportive Therapy In The Treatment Of Unresectable Hepatocellular Carcinoma","OTCHCC","Unknown status","No Results Available","Hepatocellular Carcinoma","Drug: Oral|Other: Supportive","Survival|Tumour response|Number of patients with side effects|Quality of life|Change from baseline in Child status at 1 year","All India Institute of Medical Sciences, New Delhi","All","12 Years to 70 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICMR- D.O No.5/8/7/26/99-ECD-1","October 2007","August 2013","September 2014","September 22, 2011",,"July 13, 2012","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01438450"
632,"NCT00889018","Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma",,"Unknown status","No Results Available","Intraocular Retinoblastoma","Drug: carboplatin","Ocular salvage rates in two randomly divided groups of group C and D retinoblastomas, treated with primary chemotherapy protocol using 560mg/m2 carboplatin and 750mg/m2 carboplatin respectively|To evaluate the response of subtenon carboplatin injections in cases of group C and D retinoblastomas that fail to respond to primary chemotherapy and local treatment","All India Institute of Medical Sciences, New Delhi|Council of Scientific and Industrial Research, India","All","Child, Adult, Older Adult","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","RACHNAMEEL","April 2009","April 2012","April 2012","April 28, 2009",,"February 9, 2012","Dr RPC AIIMS, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00889018"
633,"NCT02583282","A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion",,"Active, not recruiting","No Results Available","Malignant Pleural Effusion","Other: Doxycycline|Other: Iodopovidine","Complete success|Partial success|Failed pleurodesis|Time to pleurodesis","Postgraduate Institute of Medical Education and Research","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","INT/IEC/2015/232","August 1, 2015","December 31, 2020","August 31, 2021","October 22, 2015",,"March 23, 2021","Bronchoscopy suite, PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT02583282"
634,"NCT00522405","Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma",,"Unknown status","No Results Available","Hepatocellular Carcinoma","Procedure: TACE","Survival rate- calculated from the start of TACE|a) Tumor response on dual phase CECT b) Patient tolerance c) Childs' status of cirrhosis- will be ascertained at one and two years of follow up depending upon the Childs' scoreScore <6- Childs'A, 7-9 Childs'B and >10 Childs'C","All India Institute of Medical Sciences, New Delhi|Indian Council of Medical Research","All","12 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3",,"Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","A-39/29.1.2007|ICMR No-5/8/7/26/99-ECD-I","October 2007","August 2014","October 2014","August 29, 2007",,"July 16, 2012","All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00522405"
635,"NCT01143584","Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.",,"Unknown status","No Results Available","Macroprolactinoma","Drug: Cabergoline|Drug: cabergoline","Normoprolactinemia|Duration for resolution of Hypogonadism","Postgraduate Institute of Medical Education and Research","All","Child, Adult, Older Adult","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","prlcab2020","May 2010","December 2011","March 2012","June 14, 2010",,"June 14, 2010","Postgraduate Institute of Medical Education and Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01143584"
636,"NCT01630954","A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole",,"Unknown status","No Results Available","Hydatidiform Mole","Procedure: Suction and evacuation","Proportion of patents diagnosed as GTN following treatment in each group|Maternal complications,|Time interval of normalization of HCG|Duration of hospital stay","Nilratan Sircar Medical College","Female","15 Years to 45 Years   (Child, Adult)","Phase 4","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","4-Chaudhuri","June 2012","December 2018","June 2019","June 28, 2012",,"March 23, 2016","Dr Snehamay Chaudhuri, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT01630954"
637,"NCT00430664","A Comparative Study of the Safety and Efficacy of Face Talc Slurry and Iodopovidone for Pleurodesis",,"Unknown status","No Results Available","Malignant Pleural Effusions|Recurrent Pleural Effusions|Primary Spontaneous Pneumothorax|Secondary Spontaneous Pneumothorax","Procedure: Pleurodesis with either talc or iodopovidone","Success|Failure|Death|Pain by VAS|Time to Pleurodesis|Others","Postgraduate Institute of Medical Education and Research","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","7134-PG-1Tg-05/5469-71","January 2006",,"December 2007","February 2, 2007",,"February 2, 2007","PGIMER, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT00430664"
638,"NCT01142869","An Observational Study to Evaluate the Safety and Efficacy of Cetuximab in Combination With Platinum-based Chemotherapy in the First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck",,"Terminated","No Results Available","Carcinoma, Squamous Cell","Drug: Cetuximab","To obtain further safety information on the use of Cetuximab in combination with platinum-based chemotherapy in patients with recurrent/metastatic SCCHN.|To obtain clinical effectiveness information of Cetuximab in combination with platinum based chemotherapy in patients with recurrent/ metastatic SCCHN.","Merck KGaA, Darmstadt, Germany|Merck Ltd., India","All","Child, Adult, Older Adult",,"133","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR 062202-514","December 31, 2009","July 31, 2013","August 5, 2014","June 11, 2010",,"May 8, 2017","Ambaa Hospitals, Hyderabad, Andhra Pradesh, India|Indo- American Cancer Institute & Research Centre, Hyderabad, Andhra Pradesh, India|NVS Ramakrishna's Clinic, Hyderabad, Andhra Pradesh, India|Dr. Nikhil's Clinic, Secunderabad, Andhra Pradesh, India|Swarna Sai Hospital, Secunderabad, Andhra Pradesh, India|Sparsh Hospital, Orissa, Bhubaneswar, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Wellness Consultants Clinic, Surat, Gujarat, India|Global Health Pvt Ltd, Gurgaon, Haryana, India|The Cancer Clinic, Kochin, Kerala, India|Dr. T. P. Sahoo's Clinic, Bhopal, Madhya Pradesh, India|BND Onco Centre, Mumbai, Maharashtra, India|S.L.Raheja Hospital, Mumbai, Maharashtra, India|S M Karandikar's Clinic, Pune, Maharashtra, India|Ruby Hall Clinic, Pune, Maharashtra, India|Galaxy Care Laproscopic Institute, Pune, Maharashtra, India|Neigrihms, Shillong, Meghalaya, India|Grace Nursing Home, Aizwal, Mizoram, India|Cancer Clinic, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Bhagwan Mahaveer Cancer Hospital, Jaipur, Rajasthan, India|J.K.Cancer Institute, Kanpur, Uttar Pradesh, India|Annapurna Medical and Cancer Relief Society, Lucknow, Uttar Pradesh, India|Dr. Vineet's Clinic, New Delhi, Uttar Pradesh, India|SMH-Curie Cancer Centre, Shanti Mukand Hospital, New Delhi, Uttar Pradesh, India|Apollo Gleneagles Cancer Hospital, Kolkata, West Bengal, India|B.R. Singh Hospital, Kolkatta, West Bengal, India|Sunil Gupta's Clinic, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01142869"
639,"NCT05193006","Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma",,"Recruiting","No Results Available","Peritoneal Malignant Mesothelioma","Other: No intervention","Assessment of pronostic impact of nuclear grade in comparison with combined grade in peritoneal malignant mesothelioma","Hospices Civils de Lyon","All","18 Years to 80 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","69HCL21_1120","December 28, 2021","July 15, 2022","January 1, 2023","January 14, 2022",,"January 14, 2022","UZ Gent, Gent, Belgium|University Hospital of Lyon, Pierre-Bénite, France|Institut f. Pathologie und Neuropathologie, Tübingen, Germany|Zydus Hospitals, Ahmedabad, India|The Norwegian Radium Hospital, Oslo, Norway|Fundação Champalimaud, Lisboa, Portugal",,"https://ClinicalTrials.gov/show/NCT05193006"
640,"NCT02625389","Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.","In-Live","Unknown status","No Results Available","Congenital Hemangioma|Hemangioendothelioma|Angiosarcoma|Arteriovenous Malformation","Drug: Lipiodol® Ultra Fluid with surgical glues","Adverse drug reactions during any session of embolization|Adverse drug reactions up to one month follow-up|Adverse events up to one month follow-up|Obliteration rate","Guerbet","All","18 Years and older   (Adult, Older Adult)","Phase 4","125","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LUF-44-001|CTRI/2017/05/008607|EUPAS15045","November 29, 2017","September 2020","October 2020","December 9, 2015",,"February 19, 2020","Division of Peripheral Vascular & Endovascular sciences, Medanta-The Medicity Hospital, Gurgaon, Haryana, India|Christian Medical College Hospital, Vellore, Tamil Nadu, India",,"https://ClinicalTrials.gov/show/NCT02625389"
641,"NCT03974893","Dietary Intake, Sarcopenic Obesity, and Other Treatment-Related Outcomes in Indian Children With Acute Lymphoblastic Leukemia","TATA","Unknown status","No Results Available","Sarcopenic Obesity","Other: Vegetarian Diet","Incidence of Sarcopenic Obesity|Association of a Vegetarian Diet and Sarcopenic Obesity","Columbia University|Tata Memorial Hospital","All","5 Years to 15 Years   (Child)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","AAAR8814","April 18, 2019","November 2021","December 2021","June 5, 2019",,"June 6, 2019","Tata Memorial Hospital, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT03974893"
642,"NCT02964858","Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","DOBL","Recruiting","No Results Available","NonHodgkin Lymphoma","Radiation: Standard Arm|Radiation: Experimental Arm","Event Free Survival|Local Control Rate|Overall Survival|Overall response rate|Late toxicity|Acute toxicity|Quality of Life scores","Tata Memorial Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","840","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Project No-1627","November 2016","November 2022","June 2023","November 16, 2016",,"February 23, 2017","Tata Memorial Center, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02964858"
643,"NCT03847428","Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment","EMERALD-2","Active, not recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Durvalumab|Drug: Bevacizumab|Other: Placebo","Recurrence-free survival (RFS) for Arm A vs Arm C|Recurrence-free survival (RFS) Arm B vs Arm C|Overall Survival (OS) for Arm A vs Arm C and Arm B vs Arm C|Recurrence-free survival at 24 months (RFS24) and 36 months (RFS36) for Arm A vs Arm C and Arm B vs Arm C|Time to recurrence (TTR) for Arm A vs Arm C and Arm B vs Arm C|Time from randomization to recurrence/progression on next therapy (RFS2/PFS2) for Arm A vs Arm C and Arm B vs Arm C","AstraZeneca","All","18 Years to 150 Years   (Adult, Older Adult)","Phase 3","877","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D910DC00001|2018-004105-85","April 29, 2019","June 5, 2023","May 31, 2024","February 20, 2019",,"May 5, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Orange, California, United States|Research Site, Sacramento, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Miami, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Westwood, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Detroit, Michigan, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Omaha, Nebraska, United States|Research Site, New Brunswick, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Spartanburg, South Carolina, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Madison, Wisconsin, United States|Research Site, Kogarah, Australia|Research Site, Melbourne, Australia|Research Site, Nedlands, Australia|Research Site, Westmead, Australia|Research Site, Innsbruck, Austria|Research Site, Linz, Austria|Research Site, St. Pölten, Austria|Research Site, Florianópolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Santo Andre, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Vitória, Brazil|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Bengbu, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Hohhot, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Ningbo, China|Research Site, Shanghai, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Alexandria, Egypt|Research Site, Assiut, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Cairo, Egypt|Research Site, Dakahlia, Egypt|Research Site, New Cairo, Egypt|Research Site, Shebeen El Kom, Egypt|Research Site, Amiens Cedex 1, France|Research Site, ANGERS Cedex 9, France|Research Site, Besançon, France|Research Site, Clichy, France|Research Site, Dijon Cedex, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, PARIS Cedex 12, France|Research Site, Pessac, France|Research Site, Toulouse Cedex 9, France|Research Site, TOURS Cedex 9, France|Research Site, Berlin, Germany|Research Site, Bonn, Germany|Research Site, Chemnitz, Germany|Research Site, Freiburg, Germany|Research Site, Heidelberg, Germany|Research Site, Köln, Germany|Research Site, Leipzig, Germany|Research Site, Lübeck, Germany|Research Site, München, Germany|Research Site, Tuebingen, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Hong Kong, Hong Kong|Research Site, HongKong, Hong Kong|Research Site, Kwai Chung, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Bologna, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Tricase, Lecce, Italy|Research Site, Verona, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Gifu-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Kyoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Mitaka-shi, Japan|Research Site, Musashino-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Shiwa-gun, Japan|Research Site, Takasaki-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Wakayama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, Lima, Peru|Research Site, San Isidro, Peru|Research Site, Manila, Philippines|Research Site, Muntinlupa City, Philippines|Research Site, Pasig City, Philippines|Research Site, Bydgoszcz, Poland|Research Site, Gdańsk, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Ponce, Puerto Rico|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Singapore, Singapore|Research Site, Changhua, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Yunlin, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Pathumthani, Thailand|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Malatya, Turkey|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh city, Vietnam|Research Site, Ho Chi Minh, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03847428"
644,"NCT01901666","Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission",,"Unknown status","No Results Available","Chronic Myelogenous Leukemia|Short Stature","Drug: Growth Hormone","To know whether patients of CML who are faltering on growth after imatinib therapy are GH deficient or having GH resistance by performing GH provocation tests and IGF-1 generation test.|To administer growth hormone therapy to children with CML on Imatinib in remission having GH deficiency and to measure IGF-1 levels, gain in height and height velocity on GH therapy.","Postgraduate Institute of Medical Education and Research","All","Child, Adult, Older Adult","Phase 4","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","GH-IGF-1 AXIS AND CML","January 2013","June 2014","December 2014","July 17, 2013",,"July 17, 2013","Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT01901666"
645,"NCT01266811","A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",,"Withdrawn","No Results Available","Multiple Myeloma","Drug: Placebo, Velcade and dexamethasone|Biological: Siltuximab, Velcade and dexamethasone","Progression-free survival (PFS)|Overall survival|Overall response rate|Siltuximab pharmacokinetic evaluations (Cmin, Cmax) to provide information on the pharmacokinetic profile of siltuximab|Dexamethasone pharmacokinetic evaluations (Cmin, AUC[t1-t2]) from approx. 30 patients from each treatment arm to provide information on the pharmacokinetic profile of dexamethasone|Number of adverse events as a measure of safety and tolerability","Centocor, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR017743|CNTO328MMY3001","July 2011","April 2014","December 2014","December 24, 2010",,"January 28, 2013","Iowa City, Iowa, United States|Boston, Massachusetts, United States|Toledo, Ohio, United States|Willow Grove, Pennsylvania, United States|Milwaukee, Wisconsin, United States|Adelaide, Australia|Camperdown, Australia|Heidelberg, Australia|Parkville, Australia|Prahran, Australia|Edegem, Belgium|Liège, Belgium|Turnhout, Belgium|Yvoir, Belgium|Plovdiv N/A, Bulgaria|Sofia, Bulgaria|Varna, Bulgaria|Toronto, Canada|Hradec Kralove, Czech Republic|Liberec, Czech Republic|Praha 2, Czech Republic|Praha, Czech Republic|Gandhinagar Guiarat, India|Hwasun Gun, Korea, Republic of|Seoul, Korea, Republic of|Apeldoorn, Netherlands|Deventer, Netherlands|Zwolle, Netherlands|Christchurch, New Zealand|Grafton, New Zealand|Nz 9 Takapuna Auckland, New Zealand|Palmerston North, New Zealand|Brzozow, Poland|Gdansk, Poland|Lodz, Poland|Opole, Poland|Wroclaw, Poland|Ankara, Turkey|Bursa, Turkey|Edirne, Turkey|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Kharkov, Ukraine|Khmelnitskiy, Ukraine|Kiev, Ukraine|Odessa, Ukraine|Simferopol, Ukraine|Vinnitsa, Ukraine|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01266811"
646,"NCT00810680","Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL)",,"Unknown status","No Results Available","Chronic Lymphocytic Leukemia","Drug: Valproic acid","Best clinical response as defined by NCIWG criteria for CLL|Hematological toxicity (graded according to NCIWG criteria for CLL)|Non- hematological toxicity (graded according to NCI common toxicity criteria)","All India Institute of Medical Sciences, New Delhi","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCH-VAL-01","September 2008","March 2009","March 2009","December 18, 2008",,"December 18, 2008","Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, Delhi, India",,"https://ClinicalTrials.gov/show/NCT00810680"
647,"NCT01721876","Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)",,"Completed","Has Results","Leukemia, Myeloid, Acute","Drug: Placebo|Drug: Volasertib|Drug: Cytarabine","Objective Response (OR)|Overall Survival (OS)|Event-free Survival (EFS)|Relapse-free Survival (RFS)","Boehringer Ingelheim","All","65 Years and older   (Older Adult)","Phase 3","666","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","1230.14|2012-002487-27","January 29, 2013","August 12, 2014","May 28, 2021","November 6, 2012","November 19, 2021","November 19, 2021","University of California, Los Angeles, California, United States|St. Luke's Hospital Association of Duluth, Inc., Duluth, Minnesota, United States|Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Fundacion COIR, Mendoza, Argentina|Hospital Central de Salud Zenón Santillan, San Miguel de Tucumán, Argentina|LKH-Univ. Hospital Graz, Graz, Austria|LKH Leoben, Leoben, Austria|Hospital Hietzing, Wien, Austria|AZ Sint-Jan Brugge, Brugge, Belgium|Brussels - UNIV Saint-Luc, Bruxelles, Belgium|Haine-St-Paul - HOSP Jolimont, Haine-Saint-Paul, Belgium|Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Belgium|UZ Leuven, Leuven, Belgium|Centre Hospitalier Universitaire de Liège, Liège, Belgium|Roeselare - HOSP AZ Delta, Roeselare, Belgium|Yvoir - UNIV UCL de Mont-Godinne, Yvoir, Belgium|Hospital Doutor Amaral Carvalho, Jau, Brazil|Hospital Mãe de Deus, Porto Alegre, Brazil|H.C.da Fac. de Medicina de Ribeirao Preto, Ribeirao Preto, Brazil|University of Alberta Hospital (University of Alberta), Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Maisonneuve-Rosemont Hospital, Montreal, Migration Data, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Montreal General Hospital - McGill University Health Centre, Montreal, Quebec, Canada|Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Plzen, Plzen-Lochotin, Plzen - Lochotin, Czechia|Univ. Hospital Kralovske Vinohrady, Praha 10, Czechia|Meilahden sairaala, Helsinki, Finland|TYKS, Sisätautien klinikka, Turku, Finland|HOP Amiens-Picardie Sud, Amiens, France|HOP Côte de Nacre, Caen, France|HOP Michallon, La Tronche, France|HOP André Mignot, Le Chesnay, France|HOP Dupuytren 1, Limoges Cedex 1, France|INS Paoli-Calmettes, Marseille, France|HOP Nantes, Hémato, Nantes, Nantes, France|HOP Saint-Antoine, Paris Cedex 12, France|HOP Haut-Lévêque, Pessac, France|HOP Lyon Sud, Pierre Bénite, France|HOP Pontchaillou, Rennes Cedex 9, France|INS Universitaire du Cancer, Toulouse, France|Universitätsklinikum Augsburg, Augsburg, Germany|Med. Klinik m.S. Hämatologie und Onkologie, Berlin, Germany|Städtisches Klinikum Braunschweig gGmbH, Braunschweig, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen, Germany|Universitätsklinikum Frankfurt, Frankfurt/Main, Germany|Universitätsmedizin Göttingen, Georg-August-Universität, Göttingen, Germany|Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Germany|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany|Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz, Germany|Universitätsklinikum Gießen und Marburg GmbH, Marburg, Germany|Klinikum rechts der Isar der Technischen Universität München, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universitätsklinikum Regensburg, Regensburg, Germany|Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany|Universitätsklinikum Ulm, Ulm, Germany|Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany|General Hospital of Athens ""G. Gennimatas"", Athens, Greece|General Hospital of Athens ""Laiko"", Athens, Greece|Univ. Gen. Hosp. of Ioannina, Ioannina, Greece|University of Patras Medical School, Patras, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Semmelweis University, Budapest, Hungary|Petz Aldar Hospital, 2nd Dept. of Internal Med., Haematology, Gyor, Hungary|Univ. of Szeged, 2nd Dept. of Internal Med., Haematology, Szeged, Hungary|St. John Medical College and hospital, Bangalore, India|Tata Memorial Hospital, Mumbai, India|A.O. Spedali Civili di Brescia, Brescia, Italy|ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy|AO Città della Salute e della, Torino, Italy|National Hospital Organization Nagoya Medical Center, Aichi, Nagoya, Japan|Japanese Red Cross Nagoya Daini Hospital, Aichi, Nagoya, Japan|Akita University Hospital, Akita, Akita, Japan|University of Fukui Hospital, Fukui, Yoshida-gun, Japan|Kyushu University Hospital, Fukuoka, Fukuoka, Japan|Kobe University Hospital, Hyogo, Kobe, Japan|Tokai University Hospital, Kanagawa, Isehara, Japan|Yokohama City University Medical Center, Kanagawa, Yokohama, Japan|Tohoku University Hospital, Miyagi, Sendai, Japan|Nagasaki University Hospital, Nagasaki, Nagasaki, Japan|Kurashiki Central Hospital, Okayama, Kurashiki, Japan|Okayama University Hospital, Okayama, Okayama, Japan|Osaka City University Hospital, Osaka, Osaka, Japan|National Cancer Center Hospital, Tokyo, Chuo-ku, Japan|NTT Medical Center Tokyo, Tokyo, Sinagawa-ku, Japan|Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of|The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico|Amsterdam UMC Locatie VUMC, Amsterdam, Netherlands|Haukeland Universitetssykehus, Bergen, Norway|Sykehuset Østfold Kalnes, Grålum, Norway|Reg. Specialist Hospital of M. Kopernik, Dept. Haematology, Lodz, Poland|City Hospital Torun, Department of Hematology, Torun, Poland|CHULN, EPE - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António, Porto, Portugal|IPO Porto Francisco Gentil, EPE, Porto, Portugal|Centro Hospitalar Universitário São João,EPE, Porto, Portugal|Regional Clinical Hospital 'The Badge of Honor Order', Irkutsk, Russian Federation|FSBI ""N.N Blokhin Med.Res.Cent.Onc.""MoH of RF, Moscow, Russian Federation|Nizhniy Novgorod Reg. Clinical Hospital, Dept. Haematology, Nizhniy Novgorod, Russian Federation|Leningrad Reg. Clin. Hosp., Oncohematology Department No. 2, St. Petersburg, Russian Federation|Netcare Pretoria East Hospital, Moreleta Park, Pretoria, South Africa|Hospital Germans Trias i Pujol, Badalona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Clínic de Barcelona, Barcelona, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Politècnic La Fe, Valencia, Spain|Chang-Hua Christian Hospital, ChangHua, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Mackay Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01721876"
648,"NCT03062436","To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission",,"Unknown status","No Results Available","Chronic Myeloid Leukemia|Treatment Free Remission","Other: Stopping the standard drug therpy|Diagnostic Test: Quantitative bcrabl recording every month for first 6 months","Disease Recurrence","Command Hospital, India","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFMRC 4714/2016","August 1, 2017","December 31, 2019","December 2020","February 23, 2017",,"July 23, 2019","Command Hospital, Pune, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT03062436"
649,"NCT01394861","Endoscopic Submucosal Dissection (ESD)- Master Slave Robotic System - Human Study","ESD","Completed","No Results Available","Endoscopic Submucosal Dissection","Device: ESD using Master Slave Robotic System","Ease of the procedure|Completeness of the Procedure|Immediate Procedure Related Complications|Delayed Procedure Related Complications","Asian Institute of Gastroenterology, India|Nanyang Technological University","All","25 Years to 60 Years   (Adult)","Early Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AIG-GI2011-04","June 2011","July 2011","October 2011","July 15, 2011",,"March 6, 2012","Asian Institute Of Gastroenterology India, Hyderabad, Andhra Pradesh, India",,"https://ClinicalTrials.gov/show/NCT01394861"
650,"NCT04411641","Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)","HERCULES","Recruiting","No Results Available","Secondary Progressive Multiple Sclerosis","Drug: Tolebrutinib|Drug: Placebo to match Tolebrutinib","6-month confirmed disability progression (CDP)|3-months change in T25-FW and 9-HPT|3-month CDP|New and enlarging T2 hyperintense lesions by MRI|Time to onset of confirmed disability improvement (CDI)|Brain volume loss (BVL)|Change in cognitive function|Change in Multiple Sclerosis Quality of Life-54 (MSQoL-54)|Safety and Tolerability|Population pharmacokinetics|Change in plasma neurofilament light chain (NfL)|Changes in serum Immunoglobulin level|Change in lymphocyte phenotype subsets|Change in serum chitinase-3 like protein 1 (Chi3L1)","Sanofi","All","18 Years to 60 Years   (Adult)","Phase 3","1290","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16645|U1111-1246-7768","September 24, 2020","August 2024","August 2024","June 2, 2020",,"May 12, 2022","Investigational Site Number :8400013, Birmingham, Alabama, United States|Investigational Site Number :8400089, Phoenix, Arizona, United States|Investigational Site Number :8400070, Arcadia, California, United States|Investigational Site Number :8400101, La Jolla, California, United States|Investigational Site Number :8400045, Long Beach, California, United States|Investigational Site Number :8400143, Los Angeles, California, United States|Investigational Site Number :8400137, San Francisco, California, United States|Investigational Site Number :8400088, Torrance, California, United States|Investigational Site Number :8400059, West Hollywood, California, United States|Investigational Site Number :8400128, Basalt, Colorado, United States|Investigational Site Number :8400012, Denver, Colorado, United States|Investigational Site Number :8400025, Fort Collins, Colorado, United States|Investigational Site Number :8400029, Boca Raton, Florida, United States|Investigational Site Number :8400004, Maitland, Florida, United States|Investigational Site Number :8400027, Naples, Florida, United States|Investigational Site Number :8400001, Tampa, Florida, United States|Investigational Site Number :8400006, Tampa, Florida, United States|Investigational Site Number :8400003, Savannah, Georgia, United States|Investigational Site Number :8400011, Northbrook, Illinois, United States|Investigational Site Number :8400023, Kansas City, Kansas, United States|Investigational Site Number :8400110, Lexington, Kentucky, United States|Investigational Site Number :8400072, Boston, Massachusetts, United States|Investigational Site Number :8400014, Worcester, Massachusetts, United States|Investigational Site Number :8400046, Detroit, Michigan, United States|Investigational Site Number :8400033, Owosso, Michigan, United States|Investigational Site Number :8400051, Minneapolis, Minnesota, United States|Investigational Site Number :8400111, Rochester, Minnesota, United States|Investigational Site Number :8400019, Saint Louis, Missouri, United States|Investigational Site Number :8400117, Las Vegas, Nevada, United States|Investigational Site Number :8400104, Teaneck, New Jersey, United States|Investigational Site Number :8400032, Albuquerque, New Mexico, United States|Investigational Site Number :8400038, New York, New York, United States|Investigational Site Number :8400042, Stony Brook, New York, United States|Investigational Site Number :8400005, Raleigh, North Carolina, United States|Investigational Site Number :8400126, Fargo, North Dakota, United States|Investigational Site Number :8400083, Cleveland, Ohio, United States|Investigational Site Number :8400125, Cleveland, Ohio, United States|Investigational Site Number :8400147, Columbus, Ohio, United States|Investigational Site Number :8400002, Dayton, Ohio, United States|Investigational Site Number :8400010, Westerville, Ohio, United States|Investigational Site Number :8400020, Portland, Oregon, United States|Investigational Site Number :8400142, Philadelphia, Pennsylvania, United States|Investigational Site Number :8400016, Philadelphia, Pennsylvania, United States|Investigational Site Number :8400069, Greer, South Carolina, United States|Investigational Site Number :8400024, Greer, South Carolina, United States|Investigational Site Number :8400087, Cordova, Tennessee, United States|Investigational Site Number :8400035, Franklin, Tennessee, United States|Investigational Site Number :8400136, Houston, Texas, United States|Investigational Site Number :8400036, San Antonio, Texas, United States|Investigational Site Number :8400130, Burlington, Vermont, United States|Investigational Site Number :8400028, Milwaukee, Wisconsin, United States|Investigational Site Number :0320002, Capital Federal, Buenos Aires, Argentina|Investigational Site Number :0320001, Caba, Ciudad De Buenos Aires, Argentina|Investigational Site Number :0320005, San Miguel de Tucuman, Tucumán, Argentina|Investigational Site Number :0320007, Buenos Aires, Argentina|Investigational Site Number :0320006, Córdoba, Argentina|Investigational Site Number :0360003, Woolloongabba, Queensland, Australia|Investigational Site Number :0360002, Kent Town, South Australia, Australia|Investigational Site Number :0360004, Hobart, Tasmania, Australia|Investigational Site Number :0360001, Fitzroy, Victoria, Australia|Investigational Site Number :0360006, Heidelberg West, Victoria, Australia|Investigational Site Number :0400003, Innsbruck, Austria|Investigational Site Number :0400001, Linz, Austria|Investigational Site Number :0400004, Linz, Austria|Investigational Site Number :0400002, Wien, Austria|Investigational Site Number :1120004, Vitebsk, Belarus|Investigational Site Number :1120005, Vitebsk, Belarus|Investigational Site Number :0560007, Bruxelles, Belgium|Investigational Site Number :0560003, Edegem, Belgium|Investigational Site Number :0560006, Leuven, Belgium|Investigational Site Number :0560008, Liège, Belgium|Investigational Site Number :0560002, Mons, Belgium|Investigational Site Number :0560001, Pelt, Belgium|Investigational Site Number :1000002, Pleven, Bulgaria|Investigational Site Number :1000005, Plovdiv, Bulgaria|Investigational Site Number :1000004, Sofia, Bulgaria|Investigational Site Number :1000008, Sofia, Bulgaria|Investigational Site Number :1000001, Sofia, Bulgaria|Investigational Site Number :1000006, Sofia, Bulgaria|Investigational Site Number :1000009, Sofia, Bulgaria|Investigational Site Number :1240017, Burnaby, British Columbia, Canada|Investigational Site Number :1240011, Halifax, Nova Scotia, Canada|Investigational Site Number :1240003, Ottawa, Ontario, Canada|Investigational Site Number :1240008, Toronto, Ontario, Canada|Investigational Site Number :1240006, Gatineau, Quebec, Canada|Investigational Site Number :1240005, Greenfield Park, Quebec, Canada|Investigational Site Number :1240004, Montreal, Quebec, Canada|Investigational Site Number :1240015, Montreal, Quebec, Canada|Investigational Site Number :1240007, Sherbrooke, Quebec, Canada|Investigational Site Number :1240021, Quebec, Canada|Investigational Site Number :1560006, Beijing, China|Investigational Site Number :1560012, Beijing, China|Investigational Site Number :1560021, Beijing, China|Investigational Site Number :1560003, Beijing, China|Investigational Site Number :1560009, Beijing, China|Investigational Site Number :1560004, Changchun, China|Investigational Site Number :1560015, Changsha, China|Investigational Site Number :1560005, Chengdu, China|Investigational Site Number :1560019, Chongqing, China|Investigational Site Number :1560035, Fuzhou, China|Investigational Site Number :1560001, Guangzhou, China|Investigational Site Number :1560007, Hangzhou, China|Investigational Site Number :1560014, Shijiazhuang, China|Investigational Site Number :1560008, Taiyuan, China|Investigational Site Number :1560017, Xi'an, China|Investigational Site Number :2030002, Brno, Czechia|Investigational Site Number :2030004, Hradec Kralove, Czechia|Investigational Site Number :2030001, Jihlava, Czechia|Investigational Site Number :2030010, Ostrava - Poruba, Czechia|Investigational Site Number :2030005, Praha 2, Czechia|Investigational Site Number :2030003, Teplice, Czechia|Investigational Site Number :2080001, Esbjerg, Denmark|Investigational Site Number :2080005, Holstebro, Denmark|Investigational Site Number :2080004, Odense, Denmark|Investigational Site Number :2460003, Helsinki, Finland|Investigational Site Number :2460001, Tampere, Finland|Investigational Site Number :2460002, Turku, Finland|Investigational Site Number :2500011, Bron, France|Investigational Site Number :2500005, Clermont Ferrand, France|Investigational Site Number :2500015, Gonesse, France|Investigational Site Number :2500009, Lille, France|Investigational Site Number :2500006, Montpellier, France|Investigational Site Number :2500008, Nancy, France|Investigational Site Number :2500010, Nantes, France|Investigational Site Number :2500017, Nimes, France|Investigational Site Number :2500016, Paris, France|Investigational Site Number :2500014, Paris, France|Investigational Site Number :2500007, Paris, France|Investigational Site Number :2500003, Rennes, France|Investigational Site Number :2500001, Strasbourg, France|Investigational Site Number :2500012, Toulouse, France|Investigational Site Number :2760005, Bayreuth, Germany|Investigational Site Number :2760009, Berlin, Germany|Investigational Site Number :2760001, Dresden, Germany|Investigational Site Number :2760012, Essen, Germany|Investigational Site Number :2760002, Gießen, Germany|Investigational Site Number :2760010, Halle (Saale), Germany|Investigational Site Number :2760006, Hannover, Germany|Investigational Site Number :2760008, Münster, Germany|Investigational Site Number :2760004, Rostock, Germany|Investigational Site Number :2760011, Ulm, Germany|Investigational Site Number :3000001, Athens, Greece|Investigational Site Number :3000006, Athens, Greece|Investigational Site Number :3000002, Athens, Greece|Investigational Site Number :3000007, Athens, Greece|Investigational Site Number :3000004, Larissa, Greece|Investigational Site Number :3000003, Thessaloniki, Greece|Investigational Site Number :3000005, Thessaloniki, Greece|Investigational Site Number :3480008, Budapest, Hungary|Investigational Site Number :3480004, Budapest, Hungary|Investigational Site Number :3480007, Budapest, Hungary|Investigational Site Number :3480002, Pécs, Hungary|Investigational Site Number :3480001, Szeged, Hungary|Investigational Site Number :3480006, Tatabánya, Hungary|Investigational Site Number :3560007, Gurgaon, India|Investigational Site Number :3560003, Gurgaon, India|Investigational Site Number :3560005, India, India|Investigational Site Number :3560004, Mangaluru, India|Investigational Site Number :3560006, New Delhi, India|Investigational Site Number :3560002, New Delhi, India|Investigational Site Number :3760002, Ashkelon, Israel|Investigational Site Number :3760003, Haifa, Israel|Investigational Site Number :3760008, Jerusalem, Israel|Investigational Site Number :3760001, Tel HaShomer, Israel|Investigational Site Number :3760004, Zefat, Israel|Investigational Site Number :3800011, Bergamo, Italy|Investigational Site Number :3800007, Cagliari, Italy|Investigational Site Number :3800012, Firenze, Italy|Investigational Site Number :3800016, Firenze, Italy|Investigational Site Number :3800014, Genova, Italy|Investigational Site Number :3800013, L'Aquila, Italy|Investigational Site Number :3800004, Milano, Italy|Investigational Site Number :3800001, Milano, Italy|Investigational Site Number :3800010, Milano, Italy|Investigational Site Number :3800008, Pavia, Italy|Investigational Site Number :3800005, Roma, Italy|Investigational Site Number :3800009, Roma, Italy|Investigational Site Number :3920016, Chiba-shi, Chiba, Japan|Investigational Site Number :3920022, Morioka-shi, Iwate, Japan|Investigational Site Number :3920011, Kyoto-shi, Kyoto, Japan|Investigational Site Number :3920020, Sendai-shi, Miyagi, Japan|Investigational Site Number :3920005, Niigata-shi, Niigata, Japan|Investigational Site Number :3920004, Moriguchi-shi, Osaka, Japan|Investigational Site Number :3920001, Osaka-shi, Osaka, Japan|Investigational Site Number :3920018, Kawagoe-shi, Saitama, Japan|Investigational Site Number :3920003, Kodaira-shi, Tokyo, Japan|Investigational Site Number :3920010, Ota-ku, Tokyo, Japan|Investigational Site Number :3920023, Sagamihara-shi, Japan|Investigational Site Number :4400003, Kaunas, Lithuania|Investigational Site Number :4400002, Klaipeda, Lithuania|Investigational Site Number :4400001, Vilnius, Lithuania|Investigational Site Number :5280001, Amsterdam, Netherlands|Investigational Site Number :5280003, Breda, Netherlands|Investigational Site Number :5280006, Groningen, Netherlands|Investigational Site Number :5280002, Sittard-Geleen, Netherlands|Investigational Site Number :5780003, Bergen, Norway|Investigational Site Number :5780002, Namsos, Norway|Investigational Site Number :5780001, Oslo, Norway|Investigational Site Number :6160003, Bydgoszcz, Kujawsko-pomorskie, Poland|Investigational Site Number :6160001, Lodz, Lódzkie, Poland|Investigational Site Number :6160005, Warszawa, Mazowieckie, Poland|Investigational Site Number :6160006, Warszawa, Mazowieckie, Poland|Investigational Site Number :6160002, Katowice, Slaskie, Poland|Investigational Site Number :6160007, Katowice, Slaskie, Poland|Investigational Site Number :6160004, Katowice, Slaskie, Poland|Investigational Site Number :6160008, Plewiska, Wielkopolskie, Poland|Investigational Site Number :6160012, Lublin, Poland|Investigational Site Number :6160011, Zabrze, Poland|Investigational Site Number :6200001, Braga, Portugal|Investigational Site Number :6200011, Lisboa, Portugal|Investigational Site Number :6200007, Lisboa, Portugal|Investigational Site Number :6200006, Lisboa, Portugal|Investigational Site Number :6200002, Matosinhos, Portugal|Investigational Site Number :6200010, Porto, Portugal|Investigational Site Number :6420008, Bucuresti, Romania|Investigational Site Number :6420004, Campulung, Romania|Investigational Site Number :6420006, Cluj-Napoca, Romania|Investigational Site Number :6420003, Constanta, Romania|Investigational Site Number :6420013, Oradea, Romania|Investigational Site Number :6420005, Sibiu, Romania|Investigational Site Number :6420001, Targu Mures, Romania|Investigational Site Number :6420002, Timisoara, Romania|Investigational Site Number :6430018, Barnaul, Russian Federation|Investigational Site Number :6430023, Ekaterinburg, Russian Federation|Investigational Site Number :6430025, Kaliningrad, Russian Federation|Investigational Site Number :6430003, Kazan, Russian Federation|Investigational Site Number :6430022, Kemerovo, Russian Federation|Investigational Site Number :6430017, Kirov, Russian Federation|Investigational Site Number :6430024, Krasnoyarsk, Russian Federation|Investigational Site Number :6430020, Moscow, Russian Federation|Investigational Site Number :6430002, Moscow, Russian Federation|Investigational Site Number :6430013, Moscow, Russian Federation|Investigational Site Number :6430001, Moscow, Russian Federation|Investigational Site Number :6430008, Moscow, Russian Federation|Investigational Site Number :6430021, Nizhny Novgorod, Russian Federation|Investigational Site Number :6430006, Nizhny Novgorod, Russian Federation|Investigational Site Number :6430005, Novosibirsk, Russian Federation|Investigational Site Number :6430026, Perm, Russian Federation|Investigational Site Number :6430007, Pyatigorsk, Russian Federation|Investigational Site Number :6430016, Rostov-on-Don, Russian Federation|Investigational Site Number :6430004, Saint-Petersburg, Russian Federation|Investigational Site Number :6430009, Samara, Russian Federation|Investigational Site Number :6430019, Saransk, Russian Federation|Investigational Site Number :6430014, Smolensk, Russian Federation|Investigational Site Number :6430011, St-Petersburg, Russian Federation|Investigational Site Number :6430012, Tyumen, Russian Federation|Investigational Site Number :6430010, Ufa, Russian Federation|Investigational Site Number :7240007, Sevilla, Andalucia, Spain|Investigational Site Number :7240013, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240016, Barcelona, Barcelona [Barcelona], Spain|Investigational Site Number :7240015, Lleida / Lleida, Catalunya [Cataluña], Spain|Investigational Site Number :7240014, Salt, Girona [Gerona], Spain|Investigational Site Number :7240004, Majadahonda, Madrid, Spain|Investigational Site Number :7240001, Pozuelo De Alarcón, Madrid, Spain|Investigational Site Number :7240012, Donostia, Pais Vasco, Spain|Investigational Site Number :7240008, Córdoba, Spain|Investigational Site Number :7240005, Madrid, Spain|Investigational Site Number :7240002, Madrid, Spain|Investigational Site Number :7240003, Madrid, Spain|Investigational Site Number :7240010, Murcia, Spain|Investigational Site Number :7240009, Málaga, Spain|Investigational Site Number :7240011, Valencia, Spain|Investigational Site Number :7920005, Eskisehir, Turkey|Investigational Site Number :7920010, Hatay, Turkey|Investigational Site Number :7920002, Istanbul, Turkey|Investigational Site Number :7920009, Istanbul, Turkey|Investigational Site Number :7920007, Istanbul, Turkey|Investigational Site Number :7920006, Istanbul, Turkey|Investigational Site Number :7920003, Istanbul, Turkey|Investigational Site Number :7920013, Izmir, Turkey|Investigational Site Number :7920001, Izmit, Turkey|Investigational Site Number :7920011, Kuttahta, Turkey|Investigational Site Number :7920012, Mersin, Turkey|Investigational Site Number :7920008, Trabzon, Turkey|Investigational Site Number :8040008, Chernivtsi, Ukraine|Investigational Site Number :8040016, Chernivtsi, Ukraine|Investigational Site Number :8040003, Dnipro, Ukraine|Investigational Site Number :8040010, Ivano-Frankivsk, Ukraine|Investigational Site Number :8040007, Kharkiv, Ukraine|Investigational Site Number :8040011, Kharkiv, Ukraine|Investigational Site Number :8040012, Kharkiv, Ukraine|Investigational Site Number :8040013, Kyiv, Ukraine|Investigational Site Number :8040005, Lutsk, Ukraine|Investigational Site Number :8040009, Lviv, Ukraine|Investigational Site Number :8040004, Lviv, Ukraine|Investigational Site Number :8040002, Odesa, Ukraine|Investigational Site Number :8040006, Vinnytsia, Ukraine|Investigational Site Number :8040014, Zhytormyr, Ukraine|Investigational Site Number :8260003, Exeter, Devon, United Kingdom|Investigational Site Number :8260008, Plymouth, Devon, United Kingdom|Investigational Site Number :8260018, London, London, City Of, United Kingdom|Investigational Site Number :8260010, Swansea, Neath Port Talbot, United Kingdom|Investigational Site Number :8260012, Nottingham, Nottinghamshire, United Kingdom|Investigational Site Number :8260013, Oxford, Oxfordshire, United Kingdom|Investigational Site Number :8260009, Bristol, United Kingdom|Investigational Site Number :8260001, Cardiff, United Kingdom|Investigational Site Number :8260014, Newcastle Upon Tyne, United Kingdom|Investigational Site Number :8260019, Salford, United Kingdom|Investigational Site Number :8260005, Tooting, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04411641"
651,"NCT01514188","Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma",,"Unknown status","No Results Available","Metastatic Soft Tissue Sarcoma|Locally Advanced Soft Tissue Sarcoma|Unresectable Soft Tissue Sarcoma","Drug: INNO-206|Drug: Doxorubicin","Progression-free survival|Overall Survival|Progression-free survival at 4 and 6 months|Objective overall response rate (ORR)|Safety measures.","CytRx","All","15 Years to 80 Years   (Child, Adult, Older Adult)","Phase 2","105","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","INNO-206-P2-STS-01","December 2011","December 2013","April 2014","January 23, 2012",,"September 13, 2013","Sarcoma Oncology Center, Santa Monica, California, United States|Stanford University, Stanford, California, United States|University of Iowa, Iowa City, Iowa, United States|Pennsylvania Hematology Oncology Associates, Philadelphia, Pennsylvania, United States|CTRC Institute for Drug Development, University of Texas, San Antonio, Texas, United States|Royal North Shore, St. Leonards, New South Wales, Australia|Epworth HealthCare Clinical Trials and Research Centre, Richmond, Victoria, Australia|Border Medical Oncology, Wodonga, Victoria, Australia|Royal Hobart Hospital, Hobart, Australia|Royal Perth Hospital, Perth, Australia|Mount Medical Centre, Perth, Australia|The Crown Princess Mary Cancer Centre Westmead, Sydney, Australia|State Health Centre Oncology Department, Budapest, Hungary|Hemato Oncology Clinic, Vedanta Institute of Medical Science, Navrangpura, Ahmedaba, India|Delhi State Cancer Institute, Dilshad Garden, Delhi, India|Hemato Oncology Clinic, Vedanta Institute of Medical Science, Navrangpura Ahmedabad, Gujarat, India|M.S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Delhi State Cancer Institute, Pune, Maharashtra, India|Jehangir Clinical Development Centre Pvt Ltd, Pune, Maharashtra, India|Noble Hospital Clinical Research Department 1st Floor, Hadapsar, Pune Maharashtra, India|Christian Medical College, Vellore, Tami Nadu, India|Tata Memorial Hospital, Department of Medical Oncology, Mumbai, India|Oncological Institute ""Prof. Dr. I. Chiricuta"", Cluj-Napoca, Cluj-Napoca, County Cluj, Romania|Clinical County Hospital Mures, Medical Oncology Department, Targu-Mures, County Mures, Romania|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"" Baia-Mare, Sectia Oncologie, Baia-Mare, Judet Maramures, Romania|Medisprof SRL, Cluj-Napoca, Romania|State Healthcare Institution ""Republican Clinical Oncological Center of the Ministry of Health of Republic of Tatarstan"", Kazan, Republic of Tatarstan, Russian Federation|Blokhin Cancer Research Center, Moscow, Russian Federation|Municipal institution ""Chernivtsi Regional Clinical Oncologic Dispensary"",, Chernivtsi, Ukraine|Municipal Institution ""Dnipropetrovsk City Multi-Field Clinical Hospital #4"" of Dnipropetrovsk Regional Councel, Dnipropetrovsk, Ukraine|State Institution ""Institute of Medical Radiology named after S.P.Grygoryev of National Academy of Medical Sciences of Ukraine"",, Kharliv, Ukraine|Lviv State Oncological Regional Treatment - Diagnostics Center, Chemotherapy Department, Lviv, Ukraine|Vinnytsya Regional Clinical Oncologic Dispensary, Surgical Department, Vinnytsya, Ukraine",,"https://ClinicalTrials.gov/show/NCT01514188"
652,"NCT01168791","Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma","PICASSO III","Completed","No Results Available","Soft Tissue Sarcoma","Drug: doxorubicin in combination with palifosfamide-tris|Drug: doxorubicin in combination with placebo","Progression Free Survival followed by Overall Survival|Quality of Life, as assessed by EORTC QLQ-C30 and EQ-5D questionnaires|Safety and Tolerability as evaluated using CTCAE v 4.0","Alaunos Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","IPM3001","July 2010","March 2013","March 2013","July 23, 2010",,"July 18, 2013","Birmingham, Alabama, United States|Arizona Oncology Associates, Phoenix, Arizona, United States|Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|University of California, Los Angeles, Los Angeles, California, United States|Los Angeles, California, United States|University of California, Irvine, Orange, California, United States|Pomona, California, United States|Sarcoma Oncology Center, Santa Monica, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Medical Oncology Hematology Consultants, Newark, Delaware, United States|MedStar Research Institute, Washington, District of Columbia, United States|Washington, District of Columbia, United States|Jacksonville, Florida, United States|Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory, Atlanta, Georgia, United States|Medical College of Georgia, Augusta, Georgia, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Indiana University Simon Cancer Center, Indiannapolis, Indiana, United States|University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|Kansas City Cancer Center, Overland Park, Kansas, United States|New Orleans, Louisiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Baltimore, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|St.Louis University, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Las Vegas, Nevada, United States|Hackensack, New Jersey, United States|Morristown, New Jersey, United States|Saint Barnabas, West Orange, New Jersey, United States|Albuquerque, New Mexico, United States|Bronx, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Durham, North Carolina, United States|Raleigh, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|Summa Health System, Akron, Ohio, United States|UC Cancer Institute, Cinncinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Cancer Care Associates, Tulsa, Oklahoma, United States|Oregon Health and Science University, Portland, Oregon, United States|Bethelehem, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Pennsylvania Oncology/Hematology Associates, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburg, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Memphis, Tennessee, United States|Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology - Medical City Dallas, Dallas, Texas, United States|Cancer Therapy and Research Center, San Antonio, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Burlington, Vermont, United States|Virginia Cancer Specialists, Fairfax, Virginia, United States|University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, United States|Bellin Cancer Center, Green Bay, Wisconsin, United States|University of Wisconsin, Madison, Wisconsin, United States|Milwaukee, Wisconsin, United States|Ciudad de Buenos Aires, Argentina|Cordoba, Argentina|Ramos Mejia, Argentina|Instituto CAICI, Rosario, Argentina|Sante Fe, Argentina|North Adelaide Oncology, Adelaide, Australia|Royal Adelaide Hospital, Adelaide, Australia|Camperdown, Australia|East Melbourne, Australia|The Canberra Hospital, Garran, Australia|Garran, Australia|Kurralta Park, Australia|Nedlands, Australia|Prince of Wales Hospital, Randwick, Australia|Princess Alexandra Hospital, Woolloongabba, Australia|Antwerp, Belgium|Bruxelles, Belgium|Leuven, Belgium|Liege, Belgium|Institution name: Hospital de Câncer de Barretos - Fundação PIOXII, Barretos, Brazil|Belo Horizonte, Brazil|Santa Casa da Misericórdia de Curitiba, Curitiba, Brazil|Florianopolis, Brazil|Jau, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, Brazil|Hospital das Clínicas de Porto Alegre, Porto Alegre, Brazil|Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil|Centro de Oncologia da Bahia, Salvador, Brazil|Sao Paulo, Brazil|Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Mount Sinai Hospital, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|McGill University, Montreal, Quebec, Canada|Santiago, Chile|Instituto Clínico Oncológico del Sur, Temuco, Chile|Vina del Mar, Chile|Bogota, Colombia|Medellin, Colombia|Monteria, Colombia|Angers, France|Bordeaux, France|Institut Paoli Calmettes, Marseilles, France|Marseille, France|Montpellier, France|Nice, France|Paris, France|Toulouse, France|Villejuif, France|HELIOS Klinikum Berlin Buch, Bad Sarrow, Germany|Hannover, Germany|Universitätsklinikum Köln, Koln, Germany|Mannheim, Germany|Tuebingen University Hospital, Tuebingen, Germany|Guatemala, Guatemala|Jaipur, India|Mumbai, India|Nasik, India|Pune, India|Secunderabad, India|Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Jerusalem, Israel|Petach Tikva, Israel|Ramat Gan, Israel|Ramat-Gan, Israel|Tel Aviv, Israel|Candiolo, Italy|Humanitas Cancer Center, Rozzana, Italy|Ospedale Gradenigo Oncology, Torino, Italy|Centro Hemato Oncologico Paitilla, Panama, Panama|Medical and Research Center, Panama, Panama|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Gilwice, Poland|Centrum Onkologii Instytut, Warszawa, Poland|Bucharest, Romania|Cluj Napoca, Romania|Craiova, Romania|Moscow, Russian Federation|Obninsk, Russian Federation|St. Petersburg, Russian Federation|Yaroslavl, Russian Federation|Singapore, Singapore|Badalona, Spain|Madrid, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Spain|Valencia, Spain|The Royal Marsden NHS Foundation Trust Sarcoma, London, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01168791"
653,"NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)",,"Completed","Has Results","Macular Edema Secondary to Central Retinal Vein Occlusion","Biological: VEGF Trap-Eye 2.0mg|Drug: Sham","Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score|Change From Baseline in BCVA as Measured by ETDRS Letter Score at Week 24 - Last Observation Carried Forward (LOCF)|Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF|Percentage of Participants Progressing to Any of the Following: Anterior Segment Neovascularization, New Vessels of the Disc (NVD) or New Vessels Elsewhere (NVE) During the First 24 Weeks|Change From Baseline in the NEI VFQ-25 in Total Score at Week 24 (LOCF)","Regeneron Pharmaceuticals|Bayer","All","18 Years and older   (Adult, Older Adult)","Phase 3","189","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VGFT-OD-0819","July 2009","October 2010","April 2012","July 21, 2009","May 27, 2013","May 27, 2013","Phoenix, Arizona, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Arcadia, California, United States|Beverly Hills, California, United States|La Jolla, California, United States|Mountain View, California, United States|Oakland, California, United States|Sacramento, California, United States|Torrance, California, United States|New London, Connecticut, United States|Altamonte Springs, Florida, United States|Fort Lauderdale, Florida, United States|Fort Myers, Florida, United States|Fort Myers, Florida, United States|Miami, Florida, United States|Palm Beach Gardens, Florida, United States|Winter Haven, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Wichita, Kansas, United States|Baltimore, Maryland, United States|Hagerstown, Maryland, United States|Towson, Maryland, United States|Boston, Massachusetts, United States|Grand Rapids, Michigan, United States|Jackson, Michigan, United States|Lincoln, Nebraska, United States|Las Vegas, Nevada, United States|Northfield, New Jersey, United States|Toms River, New Jersey, United States|Rochester, New York, United States|Winston-Salem, North Carolina, United States|Cleveland, Ohio, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Salem, Oregon, United States|Kingston, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|West Columbia, South Carolina, United States|Rapid City, South Dakota, United States|Nashville, Tennessee, United States|Abilene, Texas, United States|Ft Worth, Texas, United States|Houston, Texas, United States|San Antonio, Texas, United States|Vancouver, British Columbia, Canada|Victoria, British Columbia, Canada|Halifax, Nova Scotia, Canada|London, Ontario, Canada|Mississauga, Ontario, Canada|Toronto, Ontario, Canada|Medellin, Antioquia, Colombia|Bogota, Colombia|Hyderabad, A.p., India|Bangalore, Karnataka, India|Kolkata, West Bengal, India|Kfar-Saba, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel",,"https://ClinicalTrials.gov/show/NCT00943072"
654,"NCT00610272","Optimization of Radiotherapy in Treatment of Painful Bone Metastasis","bone mets","Completed","No Results Available","Pain|Bone Metastasis","Radiation: Radiotherapy","Pain Relief (response rate) at 4 weeks|Onset and Duration of Pain Relief in Responders|Toxicity|Quality of Life|Rates of Pathological Fractures and Spinal Cord Compression","International Atomic Energy Agency","All","18 Years and older   (Adult, Older Adult)","Phase 3","650","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33028","January 2008","April 2012","August 2012","February 7, 2008",,"August 7, 2013","Centre Pierre et Marie Curie, Centre hospitalier universitaire Mustapha (CHU), Alger, Algeria|Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Misr Oncology Center (MOC), Cairo, Egypt|Tata Memorial Hospital, Mumbai, India|Institute of Oncology, University of Vilinius, Vilnius, Lithuania|Institute of Radiotherapy and Oncology, Skopje, Macedonia, The Former Yugoslav Republic of|Instituto Nacional de Cancerología (INCAN), Ciudad de Mexico, Mexico|Institute of Oncology and Radiology, Belgrade, Serbia|Hospital Clinic Universidad de Barcelona, Barcelona, Spain|Hospital Son Dureta, Palma de Mallorca, Spain|Institut national de cancer Salah Azaiz, Tunis, Tunisia|Mount Vernon Cancer Centre, Northwood, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00610272"
655,"NCT02703064","Furocyst - Poly Cystic Ovary Syndrome Study",,"Completed","No Results Available","PCOS","Dietary Supplement: Furocyst","Reduction in Overian volume & Number of overian Cysts|Restoration of normal menstrual cycle","Chemical Resources","Female","18 Years to 45 Years   (Adult)","Not Applicable","107","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Protocol No. CR-PCOS/1-15","March 26, 2015","July 2017","July 2017","March 9, 2016",,"September 15, 2017","Dept of Obs & Gynae, King George's Medical University, Lucknow, UP, India, Lucknow, Uttar Pradesh, India",,"https://ClinicalTrials.gov/show/NCT02703064"
656,"NCT00699517","A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies",,"Completed","No Results Available","Sarcoma","Drug: OMBRABULIN (AVE8062)|Drug: Placebo","Progression free survival|Overall survival|Response rate|Safety profile","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","355","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC10145|EudraCT 2007-003592-39","June 2008","April 2013","April 2013","June 18, 2008",,"December 21, 2015","Investigational Site Number 840004, Santa Monica, California, United States|Investigational Site Number 840003, Orlando, Florida, United States|Investigational Site Number 840005, Maywood, Illinois, United States|Investigational Site Number 840002, Newark, New Jersey, United States|Investigational Site Number 840007, Philadelphia, Pennsylvania, United States|Investigational Site Number 840001, San Antonio, Texas, United States|Investigational Site Number 056001, Bruxelles, Belgium|Investigational Site Number 056004, Haine-Saint-Paul, Belgium|Investigational Site Number 056005, Liège, Belgium|Investigational Site Number 076007, Belo Horizonte, Brazil|Investigational Site Number 076008, Goiania, Brazil|Investigational Site Number 076003, Ijui, Brazil|Investigational Site Number 076004, Jau, Brazil|Investigational Site Number 076006, Novo Hamburgo, Brazil|Investigational Site Number 076002, Porto Alegre, Brazil|Investigational Site Number 076005, Porto Alegre, Brazil|Investigational Site Number 076009, Rio De Janeiro, Brazil|Investigational Site Number 250008, Bordeaux, France|Investigational Site Number 250002, Dijon, France|Investigational Site Number 250004, Lille, France|Investigational Site Number 250001, Lyon Cedex 03, France|Investigational Site Number 250010, Marseille, France|Investigational Site Number 250006, Montpellier Cedex, France|Investigational Site Number 250007, Nice Cedex 02, France|Investigational Site Number 250005, Rennes, France|Investigational Site Number 250003, Saint Cloud, France|Investigational Site Number 250012, Saint Priest En Jarez, France|Investigational Site Number 250009, Saint-Herblain, France|Investigational Site Number 348001, Budapest, Hungary|Investigational Site Number 348002, Debrecen, Hungary|Investigational Site Number 356005, Bangalore, India|Investigational Site Number 356003, Hyderabad, India|Investigational Site Number 356004, New Delhi, India|Investigational Site Number 380001, Aviano, Italy|Investigational Site Number 380003, Milano, Italy|Investigational Site Number 380004, Milano, Italy|Investigational Site Number 380002, Rozzano, Italy|Investigational Site Number 891001, Belgrade, Serbia|Investigational Site Number 891002, Sremska Kamenica, Serbia|Investigational Site Number 724004, Barcelona, Spain|Investigational Site Number 724001, Madrid, Spain|Investigational Site Number 724003, Pamplona, Spain|Investigational Site Number 826001, Bebington, United Kingdom|Investigational Site Number 826003, Bristol, United Kingdom|Investigational Site Number 826002, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00699517"
657,"NCT03778957","A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","EMERALD-1","Active, not recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Durvalumab|Drug: Bevacizumab|Other: Placebo|Procedure: Transarterial Chemoembolization (TACE)","Progression Free Survival (PFS) for Arm B vs Arm C|Progression Free Survival (PFS) for Arm A vs Arm C|Overall Survival (OS)|Health status/quality of life measured by European Organization for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30)|Disease-related symptoms measured by European Organization for Research and Treatment of Cancer (EORTC) 18-item hepatocellular cancer health-related quality of life questionnaire (QLQ-HCC18)","AstraZeneca","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 3","724","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D933GC00001|2018-002134-20","November 30, 2018","September 19, 2022","August 19, 2024","December 19, 2018",,"April 14, 2022","Research Site, Mobile, Alabama, United States|Research Site, Phoenix, Arizona, United States|Research Site, Tucson, Arizona, United States|Research Site, Costa Mesa, California, United States|Research Site, La Jolla, California, United States|Research Site, Orange, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Honolulu, Hawaii, United States|Research Site, Chicago, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Westwood, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Stony Brook, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Durham, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Cleveland, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Sioux Falls, South Dakota, United States|Research Site, Knoxville, Tennessee, United States|Research Site, Memphis, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Morgantown, West Virginia, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Benowa, Australia|Research Site, Box Hill, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Herston, Australia|Research Site, Liverpool, Australia|Research Site, Melbourne, Australia|Research Site, Barretos, Brazil|Research Site, Florianópolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santa Maria, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São José do Rio Preto, Brazil|Research Site, Vitória, Brazil|Research Site, Hamilton, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Shanghai, China|Research Site, Shenyang, China|Research Site, Shenzhen, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Bobigny, France|Research Site, Clichy, France|Research Site, Grenoble cedex 9, France|Research Site, Montpellier CEDEX 5, France|Research Site, Nice Cedex 3, France|Research Site, Paris Cedex 13, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Toulouse Cedex 9, France|Research Site, Vandoeuvre Les Nancy, France|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Hyderabad, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Madurai, India|Research Site, Mumbai, India|Research Site, Nasik, India|Research Site, Pune, India|Research Site, Surat, India|Research Site, Vijayawada, India|Research Site, Vishakhapatnam, India|Research Site, Arezzo, Italy|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Pisa, Italy|Research Site, Bunkyo-ku, Japan|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Hiroshima-shi, Japan|Research Site, Kurume-shi, Japan|Research Site, Musashino-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Okayama, Japan|Research Site, Osaka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shiwa-gun, Japan|Research Site, Tsu-shi, Japan|Research Site, Yokohama-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Alc. Cuauhtémoc, Mexico|Research Site, Culiacan, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mexico, Distrito Federal+52 55, Mexico|Research Site, Mexico, Mexico|Research Site, Monterrey, Mexico|Research Site, Monterrey, Mexico|Research Site, Mérida, Mexico|Research Site, Tuxtla Gutierrez, Mexico|Research Site, Barnaul, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Sankt-Peterburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Bukit Merah, Singapore|Research Site, Córdoba, Spain|Research Site, Madrid, Spain|Research Site, Pamplona, Spain|Research Site, San Sebastián(Guipuzcoa), Spain|Research Site, Kaohsiung, Taiwan|Research Site, Liou Ying Township, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Yunlin, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phisanulok, Thailand|Research Site, Hanoi, Vietnam|Research Site, Hanoi, Vietnam|Research Site, Ho Chi Minh City, Vietnam|Research Site, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03778957"
658,"NCT03225586","Prospective Urban Rural Epidemiology Study","PURE","Recruiting","No Results Available","Cardiovascular Diseases|Risk Factor, Cardiovascular|Health Behavior|Environmental Exposure|Lung Diseases|Cancer|Injuries|Renal Disease|Communicable Disease",,"incident cardiovascular disease|incident cancer|Incident COPD|Incident Asthma|Pneumonia|Respiratory outcomes|All Cause Hospitalizations|Kidney disease|All cause and cause specific mortality|incident diabetes|obesity|hypertension|incident injuries","Population Health Research Institute|Canadian Institutes of Health Research (CIHR)|Heart and Stroke Foundation of Ontario","All","35 Years to 70 Years   (Adult, Older Adult)",,"200000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PURE","January 1, 2002","December 31, 2030","December 31, 2030","July 21, 2017",,"June 19, 2020","Estudios Clinicos Latinoamerica ECLA, Rosario, Santa Fe, Argentina|Independent University, Bangladesh, Dhaka, Bangladesh|Dante Pazzanese Institute of Cardiology, São Paulo, Brazil|Simon Fraser University, Vancouver, British Columbia, Canada|Population Health Research Institute, Hamilton, Ontario, Canada|University of Ottawa, Ottawa, Ontario, Canada|Université Laval Institut universitaire de cardiologie et de pneumologie de Québec, Quebec City, Quebec, Canada|Universidad de La Frontera, Temuco, Chile|State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Beijing, China|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Santander, Colombia|St John's Research Institute, Bangalore, Karnataka, India|Health Action by People, Thiruvananthapuram, Kerala, India|Eternal Heart Care Centre and Research Institute, Jaipur, Rajasthan, India|Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India|Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of|Research Institute of Cardiology & Internal Diseases, Almaty, Kazakhstan|Kyrgyz Society of Cardiology, National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan|Universiti Teknologi MARA, UCSI Universiti, Kuala Lumpur, Malaysia|University Kebangsaan Malaysia, Kuala Lumpur, Malaysia|Aga Khan University, Karachi, Pakistan|Birzeit University, Birzeit, Ramallah, Palestinian Territory, occupied|Universidad Peruana Cayetano Heredia, Lima, Peru|University of Philippines, Section of Adult Medicine & Medical Research Unit, Manila, Philippines|Wroclaw Medical University & Department of Internal Medicine, Wrocław, Poland|Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation|King Saud University, Riyadh, Saudi Arabia|School of Public Health, University of the Western Cape, Bellville, South Africa|North-West University, Potchefstroom, South Africa|Sahlgrenska University Hospital/Östra Hospital, Göteborg, Sweden|Pamoja Tunaweza Women Center, Moshi, Tanzania|Istanbul Medeniyet University, İstanbul, Turkey|Dubai Medical University, Dubai, United Arab Emirates|University of Zimbabwe College of Health Sciences, Harare, Zimbabwe",,"https://ClinicalTrials.gov/show/NCT03225586"
659,"NCT04142398","Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men",,"Not yet recruiting","No Results Available","HIV Infection|Human Papillomavirus Infection|Human Papillomavirus-Related Carcinoma","Other: Cytology Specimen Collection Procedure|Procedure: High Resolution Anoscopy with Biopsy|Other: Laboratory Biomarker Analysis|Procedure: Medical Examination|Procedure: Physical Examination|Other: Questionnaire Administration","Prevalence of HPV-associated high-grade anal intraepithelial neoplasia (HGAIN)|Prevalence of premalignant lesions of the penis|Prevalence and incidence of human papillomavirus (HPV)|The proportion of men with HGAIN at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18).|The proportion of men with premalignant lesions of the penis at baseline according to reported number of sex partners in the last 6 months|The proportion of men with HGAIN at baseline according to reported number of sex partners in the last 6 months|The proportion of men with premalignant lesions of the penis at baseline according CD4+ level.|The proportion of men with HGAIN at baseline according CD4+ level.|The proportion of men with premalignant lesions of the penis at baseline according to presence and absence of HPV infection (types 6, 11, 16, and/or 18).","AIDS Malignancy Consortium|National Cancer Institute (NCI)","Male","18 Years and older   (Adult, Older Adult)",,"246","Other|NIH","Observational","Observational Model: Cohort|Time Perspective: Prospective","AMC-094|NCI-2016-01347|R21CA167653|UM1CA121947","April 30, 2022","December 31, 2024","December 31, 2024","October 29, 2019",,"February 17, 2022","UCSF Medical Center-Parnassus, San Francisco, California, United States|Tata Memorial Hospital, Mumbai, India|Udaan Trust, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT04142398"
660,"NCT03299244","Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)",,"Completed","Has Results","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Etelcalcetide|Drug: Cinacalcet","Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis Intact Parathyroid Hormone During the Efficacy Assessment Phase - Non-inferiority Analysis|Percentage of Participants With > 50% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase|Percentage of Participants With > 30% Reduction From Baseline in Mean Predialysis iPTH During the Efficacy Assessment Phase - Superiority Analysis|Percent Change From Baseline in Mean Predialysis Corrected Calcium During the Efficacy Assessment Phase|Percentage of Participants With Mean Predialysis Serum Phosphorus ≤ 4.5 mg/dL During the Efficacy Assessment Phase","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","637","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20150238","May 15, 2018","April 8, 2020","April 8, 2020","October 3, 2017","April 30, 2021","April 30, 2021","Research Site, Beijing, Beijing, China|Research Site, Lanzhou, Gansu, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Guangzhou, Guangdong, China|Research Site, Shenzhen, Guangdong, China|Research Site, Zhanjiang, Guangdong, China|Research Site, Nanning, Guangxi, China|Research Site, Nanning, Guangxi, China|Research Site, Zhengzhou, Henan, China|Research Site, Zhengzhou, Henan, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Wuhan, Hubei, China|Research Site, Changsha, Hunan, China|Research Site, Changsha, Hunan, China|Research Site, Changzhou, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Nanjing, Jiangsu, China|Research Site, Wuxi, Jiangsu, China|Research Site, Changchun, Jilin, China|Research Site, Changchun, Jilin, China|Research Site, Dalian, Liaoning, China|Research Site, Dalian, Liaoning, China|Research Site, Dalian, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Shenyang, Liaoning, China|Research Site, Xian, Shaanxi, China|Research Site, Qingdao, Shandong, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Shanghai, Shanghai, China|Research Site, Taiyuan, Shanxi, China|Research Site, Chengdu, Sichuan, China|Research Site, Chengdu, Sichuan, China|Research Site, Tianjin, Tianjin, China|Research Site, Tianjin, Tianjin, China|Research Site, Urumqi, Xinjiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hangzhou, Zhejiang, China|Research Site, Hong Kong, Hong Kong|Research Site, Kowloon, Hong Kong|Research Site, New Territories, Hong Kong|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, New Delhi, Delhi, India|Research Site, Ahmedabad, Gujarat, India|Research Site, Nadiad, Gujarat, India|Research Site, Belagavi, Karnataka, India|Research Site, Mysuru, Karnataka, India|Research Site, Kozhikode, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Chandigarh, Punjab, India|Research Site, Chennai, Tamil Nadu, India|Research Site, Lucknow, Uttar Pradesh, India|Research Site, Dehradun, Uttaranchal, India|Research Site, Wardha, India|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Gumi-si, Gyeongsangbuk-do, Korea, Republic of|Research Site, Guri-si, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ipoh, Perak, Malaysia|Research Site, George Town, Pinang, Malaysia|Research Site, Kuching, Sarawak, Malaysia|Research Site, Batu Caves, Selangor (incl. Putrajaya), Malaysia|Research Site, Changhua, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Keelung, Taiwan|Research Site, New Taipei, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03299244/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/44/NCT03299244/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03299244"
661,"NCT03633708","A Study of Etelcalcetide in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis",,"Recruiting","No Results Available","Secondary Hyperparathyroidism|Chronic Kidney Disease","Drug: Etelcalcetide","Proportion of participants with ≥ 30% reduction from baseline in intact parathyroid hormone (iPTH) level during the efficacy assessment phase (EAP)|Maximum serum concentration (Cmax) of etelcalcetide|Minimum serum concentration (Cmin) of etelcalcetide|Incidence of adverse events|Frequency of hypocalcemia|Number of participants with corrected serum calcium levels at any time during the study|Number of participants with serum phosphorous levels below normal for age|Number of participants with predialysis iPTH levels below normal|Change from baseline in systolic blood pressure|Change from baseline in diastolic blood pressure|Change from baseline in heart rate|Change in Tanner Stage|Change in height|Change in weight|Achievement of ≥ 30% reduction in iPTH from baseline on two consecutive visits|Mean change from baseline in predialysis iPTH|Percentage change from baseline in predialysis iPTH|Percentage change from baseline in corrected total serum calcium|Percentage change from baseline in corrected total serum phosphorous","Amgen","All","up to 18 Years   (Child, Adult)","Phase 3","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20140315|2017-002411-34","April 29, 2019","January 31, 2023","January 31, 2023","August 16, 2018",,"March 31, 2022","Childrens Hospital of Los Angeles, Los Angeles, California, United States|Childrens Hospital Colorado, Aurora, Colorado, United States|Childrens Mercy Hospital, Kansas City, Missouri, United States|Mount Sinai Kidney Center - B1 Renal Treatment, New York, New York, United States|Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Childrens Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Childrens Medical Center Dallas, Dallas, Texas, United States|Primary Childrens Hospital Outpatient Services, Salt Lake City, Utah, United States|Hospital Italiano, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Fresenius Escobar, Escobar, Buenos Aires, Argentina|Centro Infantil Del Rinon, San Miguel de Tucuman, Tucuman, Argentina|Fortis Flt Lt Rajan Dhall Hospital, New Delhi, Delhi, India|All India Institute of Medical Sciences, New Delhi, Delhi, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Manipal Hospital, Bangalore, Karnataka, India|KLES Dr Prabhakar Kore Hospital and Medical Research Centre, Belagavi, Karnataka, India|NRS Medical College and Hospital, Kolkata, West Bengal, India|Seoul National University Hospital, Seoul, Korea, Republic of|Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do, Korea, Republic of|Hospital Raja Perempuan Zainab II, Kota Bharu, Kelantan, Malaysia|Hospital TuanKu Jaafar, Seremban, Negri Sembilan, Malaysia|Hospital Wanita Dan Kanak-Kanak Kuala Lumpur, Kuala Lumpur, Wilayah Persekutuan, Malaysia|SBHI Pediatrics city clinical hospital of Saint Vladimir, Moscow, Russian Federation|Municipal Children Hospital 1, Saint Petersburg, Russian Federation|State Budgetary Healthcare Institution Samara Regional Clinical Hospital na V D Seredavin, Samara, Russian Federation|National University Hospital, Singapore, Singapore|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan|Hacettepe Universitesi Tip Fakultesi Ihsan Dogramaci Cocuk Hastanesi, Ankara, Turkey|Baskent Universitesi Ankara Hastanesi, Ankara, Turkey|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Mustafa Eraslan ve Fevzi Mercan Cocuk Hastanesi, Kayseri, Turkey|National Childrens Specializated Hospital OKHMATDIT, Kyiv, Ukraine",,"https://ClinicalTrials.gov/show/NCT03633708"
662,"NCT01480479","Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma","ACT IV","Completed","No Results Available","Glioblastoma|Small Cell Glioblastoma|Giant Cell Glioblastoma|Gliosarcoma|Glioblastoma With Oligodendroglial Component","Drug: Rindopepimut (CDX-110) with GM-CSF|Drug: Temozolomide|Drug: KLH","Overall Survival|Progression-free survival|Safety and Tolerability","Celldex Therapeutics","All","18 Years and older   (Adult, Older Adult)","Phase 3","745","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CDX110-04","November 2011","November 2016","November 2016","November 29, 2011",,"January 16, 2018","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States|Barrow Neurological Institute at St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|University of Arizona Health Network, Tucson, Arizona, United States|University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope Cancer Center, Duarte, California, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Kaiser Permanente, Redwood City Medical Center, Redwood City, California, United States|University of California, Davis, Sacramento, California, United States|University of California, San Francisco, San Francisco, California, United States|Stanford Cancer Institute, Stanford University, Stanford, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University Medical Center, New Haven, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|University of Florida, Gainesville, Florida, United States|Mount Sinai Medical Center, Comprehensive Cancer Center, Miami Beach, Florida, United States|MD Anderson Cancer Center Orlando, Orlando, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Atlanta Cancer Care, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States|Northwestern University Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|North Shore University Health System, Evanston, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Covenant Clinic / Iowa Spine and Brain Institute, Waterloo, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport, Louisiana, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Center for Cancer and Blood Disorders, PC, Bethesda, Maryland, United States|Dana-Farber Cancer Institute and Mass General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Edward W. Sparrow Hospital Association - Sparrow Regional Cancer Center, Lansing, Michigan, United States|St. Mary's of Michigan Medical Center/Field Neurosciences Institute, Saginaw, Michigan, United States|Allina Health, Abbott Northwestern Hospital, John Nasseff Neuroscience Institute, Minneapolis, Minnesota, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|New Jersey Neuroscience Institute, JFK Medical Center, Edison, New Jersey, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Monmouth Medical Center, Long Branch, New Jersey, United States|Dent Neurosciences Research Institute, Amherst, New York, United States|Montefiore Medical Center, Bronx, New York, United States|New York Methodist Hospital, Brooklyn, New York, United States|The Long Island Brain Tumor Center at Neurology Surgery, P.C., Great Neck, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Columbia University Medical Center - The Neurologic Institute of New York, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Brain and Spine Surgeons of New York, White Plains, New York, United States|The Preston Robert Tisch Brain Tumor Center at Duke University Medical Center, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|University Hospitals, Case Medical Center (Cleveland), Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Oncology & Hematology Care, Portland, Oregon, United States|Pacific Neurosurgical, Portland, Oregon, United States|Lehigh Valley Physician Group-Hematology-Oncology Associates, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|West Penn. Allegheny Health System, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina - Department of Neuroscience, Charleston, South Carolina, United States|University of Tennessee Medical Center - Knoxville, Knoxville, Tennessee, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology Midtwon, Austin, Texas, United States|Baylor Research Institute, Dallas, Texas, United States|The Methodist Neurological Institute, Houston, Texas, United States|University of Utah Department of Neurosurgery, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|University of Virginia Healthcare System, Charlottesville, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|University of Wisconsin Paul P Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Royal North Shore Hospital, St Leonards, New South Wales, Australia|The Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Mater Adult Hospital, Mater Misericordiae Health Services Brisbane Limited, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Calvary North Adelaide Hospital, North Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Launceston General Hospital, Launceston, Tasmania, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Liverpool Hospital, Liverpool, Australia|Medical University Innsbruck, Dept of Neurology, Anichstrabe 35, Innsbruck, Austria|Medizinische Universität Wien, Innere Medizin I, Onkologie, Vienna, Austria|Universitair Ziekenhuis Antwerpen, Edegem, Antwerp, Belgium|ZNA Middelheim, Antwerpen, Belgium|Ghent University Hospital, Ghent, Belgium|Hospital Mae de Deus-Centro de Pesquisa em Oncologia Clinica, Porto Alegre, Rio Grande Do Sul, Brazil|Centro de Pesquisas Clinicas da Fundação Dr Amaral Carvalho, Jaú, São Paulo, Brazil|Fundação Faculdade Regional de Medicina de de São José do Rio Preto - Hospital de Base, São José do Rio Preto, São Paulo, Brazil|Instituto Nacional do Cancer (INCA), Rio de Janeiro, Brazil|Hospital Albert Einstein, Sao Paulo, Brazil|Instituto do Câncer do Estado de São Paulo - ICESP, São Paulo, Brazil|Real e Benemerita Associação Portuguesa de Beneficiência/ Hospital São José, São Paulo, Brazil|Hospital A C Camargo, São Paulo, Brazil|Foothills Hospital Medical Centre, Calgary, Alberta, Canada|British Columbia Cancer Agency, Vancouver Clinic, Vancouver, British Columbia, Canada|BC Cancer Agency - Vancouver Island Centre, Victoria, British Columbia, Canada|University of Manitoba-Cancer Care Manitoba, Winnipeg, Manitoba, Canada|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Ottawa Hospital, Regional Cancer Centre, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame, Montreal, Quebec, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHUS Hôpital Fleurimont, Shenbrooke, Quebec, Canada|CHUQ L'Hotel Dieu de Qujebec, Quebec, Canada|Fundacion Santa Fe, Bogota, Bogota D.C, Colombia|Hospital Ceske Budejovice, Ceske Budejovice, Czechia|Umiversity Hospital (Fakultni Nemocnice), Prague, Czechia|Hospital Na Homolce, Prague, Czechia|Multiscan s.r.o., Praha 5, Czechia|Masaryk´s Hospital Usti nad Labem, Usti nad Labem, Czechia|Institut de Cancerologie de I'Quest-Paul Papin, Angers, France|Institute Bergonie, Bordeaux, France|Centre Leon Berard de Lyon, Lyon, France|ICM Val d'Aurel Montpellier, Montpellier, France|Institut de Cancerologie de L'Quest-Center Rane Gauducheau, Nantes, France|Service de Neurologie-GH, Paris, France|Centre Eugene Marquis, Rennes, France|Institut de Cancerologie de l'ouest-Center Rene Gauducheau, St Herblain, France|Institut Gustave Roussy, Villejuif, France|Klinik und Poliklinik fur Neurologie der Universitat Regensburg, Regensburg, Bavaria, Germany|Strahlenklinik Universitatsklinikum Erlangen, Erlangen, Germany|Dr. Senchkenbergisches Institut fur Neuroonkologie, Frankfurt, Germany|University Hospital Hamburg Kopf und Neurozentrum, Hamburg, Germany|Universitaetsklinikum Heidelberg, Neurologische Klinik, IM Neuenheimer Feld 672, Heidelberg, Germany|University Medical Centre, Kiel, Germany|Universitaetsklinikum Muenster, Muenster, Germany|LMU Munich, Munich, Germany|NNA, Athens, Attiki, Greece|""HYGEIA"" Hospital, Marousi, District Of Attica, Greece|Országos Onkológiai Intézet Sugárterápiás Osztály, Budapest, Hungary|Debreceni Egyetem Orvos- és Egészségtudományi Centrum Onkológiai Intézet, Debrecen, Hungary|Borsod-Abaúj-Zemplén Megyei Kórház és Egyetemi Oktató Kórház, Sugárterápiás Osztály, Miskolc, Hungary|Pécsi Tudományegyetem Általános Orvostudományi Kar, Pécs, Hungary|Szegedi Tudományegyetem Onkoterápiás Klinika, Szeged, Hungary|Vas Megyei Markusovszky Lajos Általános Rehabilitációs és Gyógyfürdő Kórház, Egyetemi Oktatókórház Nonprofit Zrt, Szombathely, Hungary|City Cancer Centre, Vijayawada, Vijayawada, Andhra Pradesh, India|HCG - Bangalore Institute of Oncology, Bangalore, Bengaluru, Karnataka, India|Amrita Institute of Medical Sciences and Research Centre, Kochi, Kochi, Kerala, India|Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, Thiruvananthapuram, Kerala, India|Marathwada Regional Cancer Centre and Research Institute - Government, Aurangabad, Maharashtra, India|Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Andheri-West, Mumbai, India|Tata Memorial Hospital , Mumbai, Parel, Mumbai, India|Indraprastha Apollo Hospital, New Delhi, Jasola Viha, New Delhi, India|Sahyadri Hospitals Limited, Erandauame, Pune, India|Dr. Rai Memorial Medical Centre, Chennai, Chennai, Tamil Nadu, India|HCG Shanti Mukand Hospital - Curie Cancer Centre, Delhi, Delhi, India|Soroka University M.C., Beer-Sheva, Israel|Rambam Health Care Campus, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|SHEBA Medical Center, Tel Hashomer, Israel|Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel|UO Oncologie Medica Dipartimento Oncologico, Bologna, Italy|Fondazione IRCCS Instituto Neurologico Carlo Besta, Milano, Italy|Sacred Heart Catholic University, Rome, Italy|Universita e AO Citta delia Scienza, Universita Di Torino, Torino, Italy|Grupo Médico Camino S.C., Mexico, D.F, Mexico|Hospital Civil de Guadalajara ""Fray Antonio Alcalde"", Guadalajara, Jalisco, Mexico|Ensayos Clínicos y Medicina de Alta Especialidad, S.C., Culiacán, Sinaloa, Mexico|Servicios Medicos de Investigacion Clinica Sc, Durango, Mexico|Hospital Central ""Ignacio Morones Prieto"", San Luis Potosí, Mexico|Medisch Centrum Haaglanden, The Hague, Zuid Holland, Netherlands|VUMC, Amsterdam, Netherlands|Radboud University Nijmegen Medical Center, Nijmegen, Netherlands|Christchurch Hospital, Christchurch Central, Christchurch, New Zealand|Palmerston North Hospital, Roslyn, Palmerston North, New Zealand|Waikato Hospital, Regional Cancer Centre, Hamilton, Waikato District, New Zealand|Waikato Hospital, Regional Cancer Center, Hamilton, Waikato Distric, New Zealand|Hospital Almanzor Aguinaga Asenjo, Chiclayo, Peru|Instituto Oncologico Miraflores, Lima, Peru|Clinica Anglo Americana, Lima, Peru|Clinica Ricardo Palma, Lima, Peru|Oncosalud, Lima, Peru|Institut Catala d Oncologia, LaHospitalet De Lubregat, Catalonia, Spain|Dra. Sonia Del Barco Berron, ICO Girona Avda,, Franca, Girona, Spain|Hospital Clinic, Barcelona, Spain|ICO Badalona-Hospital Germans Trias i Pujol, Barcelonia, Spain|Hospital 12 de Octubre, Madrid, Spain|Kantonsspital Aarau Medizinische Onkologie Tellstrasse, Aarau, AG, Switzerland|CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, VD, Switzerland|Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland|Inselspital, Universitatsspital Bern, Universitatsklinik fur Medizinische Onkologie, Freiburgstrasse, Bern, Switzerland|Hopitaux Universitaires de Geneve-HUG-Centre d'Oncologie, Geneva, Switzerland|Brain Tumor Center, University Hospital Zurich, Zurich, Switzerland|National Cheng Kung University Hospital, Tainan City, Bei District, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan|Chang Gung Memorial Hospital Linkou Branch, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Chi Mei Medical Center, Tainan City - Yongkang District, Taiwan|Tri-Service General Hospital, Taipei city - Neihu District, Taiwan|Siriraj Hospital, Bangkoknoi, Bangkok, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, Bankok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Amphoe Muang, Chiang Mai, Thailand|Songkhlanagarind Hospital, Hat Yai, Songkla, Thailand|Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom|The Bristol Haematology and Oncology Centre, Bristol, United Kingdom|Edinburgh Cancer Centre Western General Hospital, Edinburgh, United Kingdom|Beatson West of Scotland Cancer Centrel, Glasgow, United Kingdom|Guy's and St Thomas' NHS, Westminister Bridge Road, London, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01480479"
663,"NCT02744131","OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women","OCP","Unknown status","No Results Available","Polycystic Ovary Syndrome","Drug: Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|Drug: Metformin 1500mgs per day","Improvements in Menstrual cycle in women with polycystic ovary syndrome.|Improvement in hirsutism|Improvement in acne score|Weight loss following treatment|Reduction in total testosterones|Reduction in serum fasting insulin|Improvements in lipid profile|Improvement in glucose tolerance","Kar Clinic & Hospital Pvt. Ltd.|All India Institute of Medical Sciences, New Delhi|Nova IVI Fertility, New Delhi|Dr Patil's Fertility & Endoscopy Clinic, Bangalore|Shreyas Hospital & Sushrut Assisted Conception Clinic, Kolhapur|University of Messina","Female","16 Years to 40 Years   (Child, Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OCP-MET-2016","May 2016","September 2018","December 2019","April 20, 2016",,"February 5, 2018","KAR clinic and hospital pvt ltd, Bhubaneswar, Odisha, India",,"https://ClinicalTrials.gov/show/NCT02744131"
664,"NCT05113030","Impact of PCOS on Periodontal Status of Adolescent and Adult Age Group Women",,"Not yet recruiting","No Results Available","Polycystic Ovary Syndrome|Gingival Inflammation","Other: PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADOLESCENT AGE GROUP WILL BE ASSESSED|Other: PERIODONTAL STATUS OF FEMALE PATIENTS WITH PCOS (NEWLY DIAGNOSED) OF ADULT AGE GROUP WILL BE ASSESSED","Bleeding on probing(BOP),|Probing pocket depth(PPD), in both the groups.|Serum hsCRP levels( high sensitivity C reactive proteins)","Postgraduate Institute of Dental Sciences Rohtak","Female","11 Years to 40 Years   (Child, Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Cross-Sectional","swati PCOS perio","November 2021","March 2022","June 2022","November 9, 2021",,"November 9, 2021","Post Graduate Institute of Dental Sciences, Rohtak, Haryana, India",,"https://ClinicalTrials.gov/show/NCT05113030"
665,"NCT03579303","Homoeopathy and Yoga in the Treatment of Menstrual Disorders in Females With Polycystic Ovarian Syndrome",,"Unknown status","No Results Available","Menstrual Disorders|Polycystic Ovary Syndrome","Other: Homoeopathic Remedies","To assess if the interventions can facilitate regular menstrual cycle.|To assess reduction in hyperandrogenism","Fr Muller Homoeopathic Medical College","Female","18 Years to 36 Years   (Adult)","Not Applicable","84","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AJP123","October 2018","April 15, 2021","October 15, 2021","July 6, 2018",,"July 9, 2018","Fr Muller Homoeopathic Medical College, Mangalore, Karnataka, India","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT03579303/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT03579303"
666,"NCT05021861","Evaluation of Periodontal Status and hsCRP Levels in Females With PCOS on CPA/EE Combination Drug Regimen",,"Not yet recruiting","No Results Available","Periodontitis|Polycystic Ovary Syndrome|Gingivitis","Drug: Cyproterone Acetate, Ethinyl Estradiol Drug Combination|Diagnostic Test: FEMALE PATIENTS WITH PCOS|Diagnostic Test: Control group","Bleeding on probing|Pocket depth|HsCRP levels","Postgraduate Institute of Dental Sciences Rohtak","Female","15 Years to 40 Years   (Child, Adult)",,"150","Other","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","RidhimaPerio","November 2021","July 31, 2022","September 30, 2022","August 26, 2021",,"November 15, 2021","Post Graduate Institute of Dental Science, Rohtak, Haryana, India",,"https://ClinicalTrials.gov/show/NCT05021861"
667,"NCT00761280","Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma","SAPPHIRE","Terminated","Has Results","Anaplastic Astrocytoma|Glioblastoma","Drug: trabedersen|Drug: temozolomide|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System|Drug: carmustine|Drug: lomustine","Survival Rate at 24 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 24 Months in the Intent-to-treat Population - Number of Participants|Survival Rate at 12, 18, and 21 Months in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Survival at 12, 18, and 21 Months in the Intent-to-treat Population - Number of Participants|Median Overall Survival (Days) From Randomization in the Intent-to-treat Population (Descriptive Analysis, Only)|Response Category by Independent Review in the Intent-to-treat Population - Number of Participants|Overall Response Rate (CR+PR) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Tumor Control Rate (CR+PR+SD) by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Duration of Response (Days) by Independent Review (Descriptive Analysis, Only)|Disease Progression at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Number of Participants|Disease Progression Rate at 10, 12, 14, 16, 18, 21, and 24 Months by Independent Review in the Intent-to-treat Population - Percentage of Participants (Descriptive Analysis, Only)|Median Time to Progression (Days) by Independent Review for the Intent-to-treat Population (Descriptive Analysis, Only)","Isarna Therapeutics GmbH","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP 12009-G005","December 2008","February 2012","June 2012","September 29, 2008","August 22, 2014","November 14, 2014","NJ Neuroscience Institute; JFK Medical Center, Edison, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Hospital Británico, Ciudad Autónoma de Buenos Aires, Argentina|FLENI, Ciudad Autónoma de Buenos Aires, Argentina|Sanatorio Allende, Córdoba, Argentina|Universitätsklinik Innsbruck, Abteilung für Neurologie, Innsbruck, Austria|AKH Wien, Klinik für Neurochirurgie, Wien, Austria|Hospital de Câncer de Barretos, Barretos / SP, Brazil|Centro Goiano de Oncologia (CGO), Goiania, Brazil|Hospital Sao Vicente de Paulo, Passo Fundo, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, Brazil|Hospital do Servidor Público Estadual, Sao Paulo, Brazil|ECOGENE-21 Centre d'études cliniques, Chicoutimi, Quebec, Canada|Foothills Medical Centre, Calgary, Canada|Montreal Neurological Institute and Hospital, Montreal, Canada|La Timone University Hospital, Marseille, France|Klinik und Poliklinik für Neurochirurgie, Frankfurt/M., Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Neurochirurgische Klinik an der Universität Ulm am Bezirkskrankenhaus Günzburg, Günzburg, Germany|Universitätklinikum Hamburg-Eppendorf, Klinik für Neurochirurgie, Hamburg, Germany|Medizinische Hochschule Hannover Neurochirurgische Klinik, Hannover, Germany|Universitätsklinik Heidelberg Neurologische Klinik, Heidelberg, Germany|Universitätsklinikum Leipzig, Neurochirurgische Klinik, Leipzig, Germany|Otto-von-Guericke-Universität, Klinik für Neurochirurgie, Magdeburg, Germany|Klinik und Poliklinik für Neurochirurgie, Münster, Germany|Klinik und Poliklinik für Neurologie, Regensburg, Germany|Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ, Szeged, Hungary|Manipal Hospital & Manipal Institute for Neurological Disorders, Bangalore, India|NIMHANS, Bangalore, India|BGS Global Hospital, Bangalore, India|Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Apollo Speciality Hospitals, Chennai, India|Amrita Institute of Medical Sciences Research Center, Cochin, India|Care Hospitals, Hyderabaad, India|AMRI Hospitals, Kolkata, India|SGPGI of Medical Sciences, Lucknow, India|Advanced Centre for Treatment Research and Education in Cancer (ACTREC), Mumbai, India|All India Institute of Medical Sciences (AIIMS), New Delhi, India|SCTIMST, Dept. of Neurosurgery, Thiruvananthapuram, India|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Kangnam St. Mary's Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Hospital San Javier, Guadalajara, Mexico|Hospital General de Mexico, Mexico City, Mexico|Medica Sur, Mexico City, Mexico|Wojskowy Szpital Kliniczny, Klinika Neurochirurgii, Bydgoszcz, Poland|Akademickie Centrum Kliniczne, Gdańsk, Poland|Samodzielny Publiczny Szpital Kliniczny nr 4, Klinika Neurochirurgii i Neurochirurgii Dziecięcej, Lublin, Poland|Kliniczny Oddzial Neurochirurgii SUM w Sosnowcu Wojewódzki Szpital Specjalistyczny nr 5, Sosnowiec, Poland|Centrum Onkologii - Instytut Im. Marii Sklodowskiej-Curie, Warszawa, Poland|SP ZOZ Uniwersytecki Szpital Kliniczny nr 1, Klinika Neurochirurgii, Łódź, Poland|Chelyabinsk City Hospital #3; Department of Neurosurgery, Chelyabinsk, Russian Federation|State Institution Russian Oncology Research Center N.N. Blokhin, Moscow, Russian Federation|Samara Region Clinical Hospital M.I. Kalinin, Samara, Russian Federation|Russian Scientific Research Neurosurgical Institute A.L. Polenov, St. Petersburg, Russian Federation|Military Medical Academy, Neurosurgery Dept, St. Petersburg, Russian Federation|Hospital de Cruces, Baracaldo, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|China Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-Service General Hospital, Taipei City, Taiwan|Edinburgh Centre for Neuro-Oncology, Western General Hospital, Edinburgh, United Kingdom|The National Hospital for Neurology and Neurosurgery, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00761280"
668,"NCT02866786","The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS",,"Completed","No Results Available","Polycystic Ovary Syndrome","Drug: Metformin|Drug: ethinyl estradiol and cyproterone acetate","Improvement in menstrual cycle pattern|Change in Abdominal Fat as measured by Waist Circumference in centimeter|Change in weight as measured in kg|Improvement in hirsutism measured by Modified Ferriman and Gallwey scores|Improvement in glucose tolerance (measured by of fasting plasma glucose and 2-hour post prandial plasma glucose)|Change in waist-to-hip ratio|Change in Body mass index (kg/m2)|Lipid profile (Cholesterol, LDL, HDL and Triglyceride) improvement|Change in blood level of luteinizing hormone [LH] (mIU/ml)|Change in blood level of follicle stimulating hormone [FSH] (mIU/ml)|Change in blood level of Testosterone (nmol/L)|Change in blood level of Sex hormone binding globulin (SHBG) (ng/ml)|Change in Free androgen Index (FAI)|Change in Dehydroepiandrosterone sulfate (DHEAS) level (microgram/dl)|Changes in fasting serum insulin levels (mIU/L)|Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)|Ovarian Stromal artery Pulsatility index|Ovarian Stromal artery Resistivity index|Chang in ovarian Follicle number by Ultrasonography (USG)|Change in ovarian Follicle diameter (in mm) by USG|Change in Ovarian volume (in cc) by USG|Change in Endometrial thickness (in mm)|Change in ovarian stromal/total area ratio (S/A)","S.C.B. Medical College and Hospital","Female","18 Years to 35 Years   (Adult)","Phase 4","101","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","OG/2016/13","August 15, 2016","April 20, 2017","August 1, 2017","August 15, 2016",,"April 20, 2018","Department of Obstetrics & Gynecology, Cuttack, Odisha, India",,"https://ClinicalTrials.gov/show/NCT02866786"
669,"NCT00431561","Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma",,"Completed","No Results Available","Glioblastoma|Anaplastic Astrocytoma","Drug: AP 12009 10 µM|Drug: AP 12009 80 µM|Drug: temozolomide or PCV|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System","Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans|Overall survival|Response rates|Progression-free survival|Time to progression|Time to response|Best of all response rates assessed by survival status and variation of tumor size on brain MRI|Change of quality of life and Karnofsky Performance Status (KPS)|Best of all response rates|Safety and tolerability","Isarna Therapeutics GmbH","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","141","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AP 12009-G004","April 2003","March 2009","March 2009","February 6, 2007",,"December 3, 2013","Universitätsklinik Innsbruck; Abteilung für Neurochirurgie, Innsbruck, Austria|Landes-Nervenklinik Wagner-Jauregg, Linz, Austria|Kaiser Franz Josef Spital, Abteilung für Neurologie, Wien, Austria|Sarajishvili Institute of Clinical Neurology and Neurosurgery, Tbilisi, Georgia|Medizinische Klinik und Poliklinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin, Germany|Klinik und Poliklinik für Neurologie, Cottbus, Germany|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany|Universitätsklinikum Gießen, Neurochirurgische Universitätsklinik, Gießen, Germany|Universitätsklinikum Kiel, Klinik für Neurochirurgie, Kiel, Germany|Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurochirurgie, Leipzig, Germany|Universitätsklinik Magdeburg, Klinik für Neurochirurgie, Magdeburg, Germany|Universitätskliniken Mainz, Neurochirurgische Klinik und Poliklinik, Mainz, Germany|Universitätsklinikum Münster, Klinik und Poliklinik für Neurochirurgie, Münster, Germany|Klinikum und Poliklinik für Neurologie, Universität Regensburg, Regensburg, Germany|Klinikum Saarbrücken, Neurochirurgie, Saarbrücken, Germany|Neurologische Universitätsklinik Tübingen, Tübingen, Germany|Department of Neurosurgery, Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, India|Sree Chitra Tirunal Institute for Medical Sciences & Technology, Department of Neurosurgery, Trivandrum, Kerala, India|Manipal Hospital; Manipal Institute for Neurological Disorders, Bangalore, India|Department of Neurosurgery, National Institute of Mental Health and Neurosciences, Bangalore, India|Department of Medical Oncology, Nizam's Institute of Medical Sciences, Hyderabad, India|Department of Neurosurgery, LTMG Hospital & LTM Medical College, Mumbai, India|Department of Neurosurgery, Neurosciences Center, New Dehli, India|Department of Neurological Sciences, Christian Medical College & Hospital, Vellore, India|Soroka Medical Center, Neurosurgery Department, Beer Sheva, Israel|Rambam Medical Center, Neurosurgery Department, Haifa, Israel|Rabin Medical Center, Neurosurgery Department, Petach Tikva, Israel|Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation|Republican Clinical Hospital of Ministry of Health of Tatarstan Republic, Kazan, Russian Federation|Burdenko Neurosurgery Research Institute, Moscow, Russian Federation|Omsk State Medical Academy; State Educational Institution of Higher Professional Education, Omsk, Russian Federation|State Institution of Healthcare, Samara Regional Clinical Hospital in the name of M.I. Kalinin, Samara, Russian Federation|Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation|Military Medical Academy named after I.S.M. Kirov, Neurosurgery Department, St. Petersburg, Russian Federation|Medical Center ""XXI century"", St. Petersburg, Russian Federation|Tcheliabinsk Regional Clinical Hospital; State Medical Institution for Prophylaxis and Treatment, Tcheliabinsk, Russian Federation",,"https://ClinicalTrials.gov/show/NCT00431561"
670,"NCT01838122","Prevalence of HbA1C in Women With PCOS","WHI","Unknown status","No Results Available","Polycystic Ovarian Syndrome|Pelvic Endometriosis|Insulin Resistance|Non-insulin Dependent Diabetes Mellitus|Tubal Obstruction",,"Prevalence of HbA1C in both arms of the cohort of subjects","Southern Cross Fertility Centre","Female","15 Years to 40 Years   (Child, Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","HbA1C-PCOS|PCOS-IR","April 2013","September 2013","November 2013","April 23, 2013",,"April 23, 2013","Southern Cross Fertility Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01838122"
671,"NCT03196115","Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)","BioHFS","Active, not recruiting","No Results Available","Hyalinosis|Hyaline Membrane Disease|Juvenile Hyaline Fibromatosis|Fibromatosis Hyalinica Multiplex Juvenilis|Skin and Connective Tissue Diseases",,"Sequencing of the Hyaline Fibromatosis Syndrome related gene|The Hyaline Fibromatosis Syndrome specific biomarker candidates finding","CENTOGENE GmbH Rostock","All","2 Months and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BHFS 06-2018","August 20, 2018","June 2021","June 2021","June 22, 2017",,"May 13, 2021","Centogene AG, Rostock, Germany|NIRMAN Navi Mumbai Institute of Research In Mental And Neurological Handicap/Pediatric Geneticist, Mumbai, India|Lady Ridgeway Hospital for Children, Colombo 8, Sri Lanka",,"https://ClinicalTrials.gov/show/NCT03196115"
672,"NCT04335227","Yoga Therapy and Aerobic Exercise on Anti-Mullerian Hormone in Young Women With Polycystic Ovary Syndrome",,"Not yet recruiting","No Results Available","Polycystic Ovary Syndrome|Anti-Mullerian Hormone Deficiency|Female Infertility Endocrine","Other: Structured yoga therapy program|Other: Aerobic exercise training program|Other: Combined yoga and aerobic training program|Other: Nutritional management","Serum Anti-Mullerian hormone Concentration|Antral follicle count|Serum Follicle-stimulating hormone Concentration|Serum Luteinizing hormone Concentration|Serum Testosterone Concentration|Serum Prolactin Concentration|Serum Thyroid-stimulating hormone Concentration|Serum Dehydroepiandrosterone sulfate Concentration|Serum Insulin fasting Concentration|Serum Glucose fasting Concentration|Homeostatic Model Assessment for Insulin Resistance|Concentration of Lipid profiles in serum","Maharishi Markendeswar University (Deemed to be University)","Female","18 Years to 30 Years   (Adult)","Not Applicable","128","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MMDU/IEC/141E","November 14, 2021","March 12, 2023","April 14, 2023","April 6, 2020",,"August 24, 2021","Maharishi Markandeshwar Hospital, Mullana, Ambala, Haryana, India|Maharishi Markandeshwar Medical College & Hospital, Kumarhatti, Solan, Himachal Pradesh, India",,"https://ClinicalTrials.gov/show/NCT04335227"
673,"NCT00517712","Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia","IAPLSG04","Unknown status","No Results Available","Acute Promyelocytic Leukemia","Drug: Single agent arsenic trioxide","Measure complete hematological remission rate|Measure complete molecular remission rate|Measure duration of response|Document early and late toxicities|Measure relapse rates|Measure treatment related mortality","Christian Medical College, Vellore, India|Ministry of Science and Technology, India","All","Child, Adult, Older Adult","Phase 2|Phase 3","400","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IAPLSG2004|BT/PR4460/Med/14/531/2003","June 2004",,"July 2009","August 17, 2007",,"August 17, 2007","Kidwai Memorial Institute of Oncology, Bangalore, Karnataka, India|St. Johns Hospital, Bangalore, Karnataka, India|Regional Cancer Center, Trivandrum, Kerala, India|Prince Aly Khan Hospital, Mumbai, Maharastra, India|KEM Hospital, Mumbai, Maharastra, India|Tata Memorial Hospital, Mumbai, Maharastra, India|Sahyadri Speciality Hospital, Pune, Maharastra, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India|Institute Rotary Cancer Hospital, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00517712"
674,"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma","ORCHARRD","Completed","Has Results","Lymphoma, Large-Cell, Diffuse","Drug: OFATUMUMAB + DHAP|Drug: RITUXIMAB + DHAP","Progression-free Survival as Assessed by Independent Reviewers|Number of Participants With Overall Response (OR) and Complete Response (CR) After Salvage Chemoimmunotherapy|Number of Participants With Overall Response (OR) and Complete Response (CR) Three Months After Autologous Stem Cell Transplant|Event-free Survival|Overall Survival (OS)|Number of Participants With the Ability to Mobilize at Least 2 Million Cluster of Differentiation (CD)34+ Cells Per Kilogram From Peripheral Blood|Number of Participants Completing Autologous Stem Cell Transplant (ASCT)|Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G) During Treatment|Change From Baseline in the Functional Assessment of Cancer Therapy Lymphoma Trial Outcome Index (FACT-Lym TOI) Total Score During Treatment|Time to Neutrophil and Platelet Recovery After Each Cycle of Salvage Chemotherapy|Time to Engraftment After High-dose Therapy (HDT)/ASCT","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110928","March 2010","February 2014","November 2014","November 16, 2009","October 16, 2014","August 7, 2015","GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Westwood, Kansas, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Syracuse, New York, United States|GSK Investigational Site, Chaple Hill, North Carolina, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Providence, Rhode Island, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Greenville, South Carolina, United States|GSK Investigational Site, Nashville, Tennessee, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Seattle, Washington, United States|GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, La Plata, Buenos Aires, Argentina|GSK Investigational Site, Graz, Austria|GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Linz, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Wien, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Hasselt, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Yvoir, Belgium|GSK Investigational Site, Fuzhou, Fujian, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Guangzhou, Guangdong, China|GSK Investigational Site, Nanjing, Jiangsu, China|GSK Investigational Site, Jianan, Shandong, China|GSK Investigational Site, Hangzhou, Zhejiang, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Chengdu, China|GSK Investigational Site, Jiang Su Province, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Shanghai, China|GSK Investigational Site, Tianjin, China|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Aarhus, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Helsinki, Finland|GSK Investigational Site, Oulu, Finland|GSK Investigational Site, Tampere, Finland|GSK Investigational Site, Ulm, Baden-Wuerttemberg, Germany|GSK Investigational Site, Aachen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Muenster, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Budapest, Hungary|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Kaposvár, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Szombathely, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, James Street, Ireland|GSK Investigational Site, Petach-Tikva, Israel|GSK Investigational Site, Ramat Gan, Israel|GSK Investigational Site, Aichi, Japan|GSK Investigational Site, Akita, Japan|GSK Investigational Site, Fukuoka, Japan|GSK Investigational Site, Hokkaido, Japan|GSK Investigational Site, Hyogo, Japan|GSK Investigational Site, Ibaraki, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kanagawa, Japan|GSK Investigational Site, Kyoto, Japan|GSK Investigational Site, Miyagi, Japan|GSK Investigational Site, Nagano, Japan|GSK Investigational Site, Nagasaki, Japan|GSK Investigational Site, Okayama, Japan|GSK Investigational Site, Osaka, Japan|GSK Investigational Site, Tochigi, Japan|GSK Investigational Site, Tokushima, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Tokyo, Japan|GSK Investigational Site, Jellanamdo, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Amersfoort, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Amsterdam, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Enschede, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Hoofddorp, Netherlands|GSK Investigational Site, Leiden, Netherlands|GSK Investigational Site, Maastricht, Netherlands|GSK Investigational Site, Nieuwegein, Netherlands|GSK Investigational Site, Nijmegen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Sittard-geleen, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Zwolle, Netherlands|GSK Investigational Site, Oslo, Norway|GSK Investigational Site, Chorzow, Poland|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Wroclaw, Poland|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St-Petersburg, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Singapore, Singapore|GSK Investigational Site, Barcelona, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Majadahonda (Madrid), Spain|GSK Investigational Site, Murcia, Spain|GSK Investigational Site, Pamplona, Spain|GSK Investigational Site, Pozuelo de Alarcón/Madrid, Spain|GSK Investigational Site, Salamanca, Spain|GSK Investigational Site, Göteborg, Sweden|GSK Investigational Site, Lund, Sweden|GSK Investigational Site, Stockholm, Sweden|GSK Investigational Site, Uppsala, Sweden|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Blackpool, United Kingdom|GSK Investigational Site, Bristol, United Kingdom|GSK Investigational Site, Cambridge, United Kingdom|GSK Investigational Site, Cheltenham, United Kingdom|GSK Investigational Site, Edinburgh, United Kingdom|GSK Investigational Site, Glasgow, United Kingdom|GSK Investigational Site, Headington, Oxford, United Kingdom|GSK Investigational Site, Leeds, United Kingdom|GSK Investigational Site, Liverpool, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Manchester, United Kingdom|GSK Investigational Site, Newcastle upon Tyne, United Kingdom|GSK Investigational Site, Northwood, United Kingdom|GSK Investigational Site, Nottingham, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom|GSK Investigational Site, Southampton, United Kingdom|GSK Investigational Site, Whitchurch, Cardiff, United Kingdom|GSK Investigational Site, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01014208"
675,"NCT05301842","Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","EMERALD-3","Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Tremelimumab|Drug: Durvalumab|Procedure: Transarterial Chemoembolization (TACE)|Drug: Lenvatinib","Progression Free Survival (PFS) for Arm A vs Arm C|Progression Free Survival (PFS) for Arm B vs Arm C|Overall Survival (OS) for Arm A vs Arm C|Overall Survival (OS) for Arm B vs Arm C","AstraZeneca","All","18 Years to 120 Years   (Adult, Older Adult)","Phase 3","525","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","D910VC00001|2021-003822-54","March 28, 2022","October 30, 2025","January 29, 2027","March 31, 2022",,"May 11, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Commack, New York, United States|Research Site, Memphis, Tennessee, United States|Research Site, Barretos, Brazil|Research Site, Brasilia, Brazil|Research Site, Niterói, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Santa Maria, Brazil|Research Site, Santo Andre, Brazil|Research Site, São Paulo, Brazil|Research Site, Vitória, Brazil|Research Site, Toronto, CA, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, Kingston, Ontario, Canada|Research Site, Ottawa, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Fuzhou, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Guangzhou, China|Research Site, Haikou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Lanzhou, China|Research Site, Lishui, China|Research Site, Nanjing, China|Research Site, Nantong, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Urumqi, China|Research Site, Wuhan, China|Research Site, Xi'an, China|Research Site, Zhengzhou, China|Research Site, Zhuhai, China|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Heidelberg, Germany|Research Site, Kiel, Germany|Research Site, Ahmedabad, India|Research Site, Ahmedabad, India|Research Site, Anand, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Gurugram, India|Research Site, JAipur, India|Research Site, Kolkata, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Arezzo, Italy|Research Site, Firenze, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Rozzano, Italy|Research Site, Tricase (Lecce), Italy|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Kashihara-shi, Japan|Research Site, Morioka-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Osakasayama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, George Town, Malaysia|Research Site, Kuala Lumpur, Malaysia|Research Site, Kuching, Malaysia|Research Site, Selangor, Malaysia|Research Site, Makati, Philippines|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, San Sebastian, Spain|Research Site, Taichung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan City, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Hat Yai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phisanulok, Thailand",,"https://ClinicalTrials.gov/show/NCT05301842"
676,"NCT02778295","Biomarker for Patients With Fabry Disease (BioFabry)","BioFabry","Active, not recruiting","No Results Available","Angiokeratomas|Chronic Kidney Disease|Ocular Abnormalities|Hearing Loss",,"Sequencing of the Fabry disease related gene|The Fabry disease specific biomarker candidates finding","CENTOGENE GmbH Rostock","All","2 Months and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","BFA 06-2018","August 20, 2018","June 2021","June 2021","May 19, 2016",,"May 13, 2021","Centogene GmbH, Rostock, Germany|NIRMAN-University of Mumbai-Institute of Research in Mental and Neurological handicap, Mumbai, India|Lady Ridgeway Hospital for Children, Colombo 8, Sri Lanka",,"https://ClinicalTrials.gov/show/NCT02778295"
677,"NCT00677716","Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse",,"Completed","No Results Available","Glioblastoma Multiforme","Drug: 131I-chTNT-1/B MAb (Cotara)","To confirm the safety and tolerability of the maximum tolerated dose|To estimate overall survival, progression free survival and proportion of patients alive at six months after treatment.","Peregrine Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","41","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PPHM 0503","July 2007","September 2011","November 2011","May 14, 2008",,"April 24, 2014","Barrow Neurological Institute, Phoenix, Arizona, United States|University of Pennsylvania, Department of Neurosurgery, Philadelphia, Pennsylvania, United States|Medical University of South Carolina, Charleston,, South Carolina, United States|Amrita Institute of Medical Sciences and Research Center,, Cochin, Kerala, India|Manipal Institute for Neurological Disorders,, Bangalore, India|Department of Neurosurgery Jaslok Hospital and Research Centre, Mumbai, India|All India Instutite of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00677716"
678,"NCT01922102","Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","Brilliance","Completed","Has Results","Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)","Drug: Ranibizumab 0.5mg|Drug: Ranibizumab 0.5 mg|Drug: Verteporfin PDT","Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 3|Change From Baseline BCVA to the Average Level of BCVA Over All Monthly Assessments From Month 1 to Month 6|The Average Change in BCVA Score From Baseline to Month 1 Through Month 12|Mean Change From Baseline in Visual Acuity Over Time|Categorized BCVA Changes at Months 3, 6 and 12 Compared With Baseline for the Study Eye|Mean Change From Baseline Over Time in Central Sub-field Thickness (CSFT)|Number of Patients With CNV Leakage (Center Involvement) in the Study Eye at Baseline and Month 12|NEI-VFQ-25 - Change From Baseline to Month 3, 6 and 12|Number of Ranibizumab Injections Received in the Study Eye for the Ranibizumab Groups","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","457","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRFB002F2302","September 11, 2013","September 14, 2016","September 14, 2016","August 14, 2013","June 24, 2019","June 24, 2019","Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chongqing, Chongqing, China|Novartis Investigative Site, Shantou, Guangdong, China|Novartis Investigative Site, Harbin, Heilongjiang, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Changsha, Hunan, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Wu XI, Jiangsu, China|Novartis Investigative Site, Nanchang, Jiangxi, China|Novartis Investigative Site, Qingdao, Shandong, China|Novartis Investigative Site, Xi'an, Shanxi, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Wenzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chongqing, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Hongkong, Hong Kong|Novartis Investigative Site, Chandigarh, Haryana, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vanchiyoor, Kerala, India|Novartis Investigative Site, Bhubaneswar, Orissa, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Chennai, Tamil Nadu, India|Novartis Investigative Site, Coimbatore, Tamil Nadu, India|Novartis Investigative Site, Hyderabad, Telangana, India|Novartis Investigative Site, Angamaly, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pusan, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Manila, Metro Manila, Philippines|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Nakornphathom, Thailand",,"https://ClinicalTrials.gov/show/NCT01922102"
679,"NCT03994627","Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma",,"Available","No Results Available","Soft Tissue Sarcoma","Drug: Olaratumab",,"Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"17468|I5B-MC-Y001",,,,"June 21, 2019",,"May 5, 2022","Ironwood Cancer & Research Centers, Glendale, Arizona, United States|Marin Specialty Care, Inc, Greenbrae, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente West Los Angeles, Los Angeles, California, United States|Kaiser Permanente Moreno Valley, Moreno Valley, California, United States|University of Colorado Health Hospital, Aurora, Colorado, United States|UCHealth Cancer Center, Fort Collins, Colorado, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Ocala Oncology, P.A., Ocala, Florida, United States|Florida Cancer Specialists, Orlando, Florida, United States|Orlando Health UF Health Cancer Center, Orlando, Florida, United States|Florida Cancer Specialists, Sarasota, Florida, United States|Oncology-Hematology Associates of West Broward, Tamarac, Florida, United States|Northside Hospital, Athens, Georgia, United States|Tift Regional Health System Anita Stewart Oncology Center, Tifton, Georgia, United States|Beacon Cancer Care, Coeur d'Alene, Idaho, United States|Rush University Medical Center, Chicago, Illinois, United States|Illinois CancerCare, Peoria, Illinois, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Hematology Oncology Clinic, Baton Rouge, Louisiana, United States|Alton Ochsner Medical Center, New Orleans, Louisiana, United States|University of Maryland, Baltimore, Baltimore, Maryland, United States|SKCCC at Johns Hopkins, Baltimore, Maryland, United States|Baltimore Washington Health Services, Glen Burnie, Maryland, United States|University of Massachusetts Medical Center, Worcester, Massachusetts, United States|Henry Ford Macomb Hospital, Clinton Township, Michigan, United States|Cancer & Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States|St. Luke's Hospital of Duluth, Duluth, Minnesota, United States|Masonic Cancer Center, University, Minneapolis, Minnesota, United States|Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|County Oncologist, Inc., Saint Louis, Missouri, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Regional Cancer Care Associates, LLC, East Brunswick, New Jersey, United States|Hudson Valley Cancer Center, Fishkill, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|East Carolina School of Medicine, Greenville, North Carolina, United States|Aultman Medical Group Hematology & Oncology, Canton, Ohio, United States|University of Cincinnati Cancer Institute, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|The James Cancer Hospital, Columbus, Ohio, United States|UPMC Hillman Cancer Center, Greenville, Pennsylvania, United States|Steward Sharon Regional Cancer Center, Hermitage, Pennsylvania, United States|UPMC Hillman Cancer Center, New Castle, Pennsylvania, United States|Abramson Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|The West Clinic, Germantown, Tennessee, United States|Tennessee Oncology PLLC, Hixson, Tennessee, United States|UVAHS Emily Couric Clin Cancer Ctr, Charlottesville, Virginia, United States|Kaiser Permanente of WA, Olympia, Washington, United States|Harrison HealthPartners Hematology, Poulsbo, Washington, United States|Seattle Integrative Cancer Center, Renton, Washington, United States|Mon Health Medical Center, Morgantown, West Virginia, United States|SSM Health Cancer Care Center, Madison, Wisconsin, United States|West Allis Memorial Hospital, West Allis, Wisconsin, United States|Ordensklinikum Linz GmbH Elisabethinen, Linz, Oberösterreich, Austria|Kepler Universitätsklinikum GmbH, Med Campus III, Linz, Oberösterreich, Austria|CLION - Clínica de Oncologia, Salvador, Bahia, Brazil|Instituto Londrina de Radioterapia, Londrina, Paraná, Brazil|CHUM, Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Szabolcs-Szatmar-Bereg M-i Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary|National Institute of Oncology, Budapest, Hungary|Healthcare Global Enterprises Limited (HCG), Bangalore, Karnataka, India|Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|IRCCS - AOU di Bologna, Bologna, Italy|Ospedale Santa Chiara di Trento, Trento, Italy|Inha University Hospital, Incheon, Incheon-gwangyeoksi [Incheon], Korea, Republic of|Gachon University Gil Hospital, Namdong-gu, Incheon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, Kyǒnggi-do, Korea, Republic of|Pusan National University Hospital, Busan, Pusan-Kwangyǒkshi, Korea, Republic of|Wonkwang University Hospital, Iksan-si, Jeonlabuk-do, Korea, Republic of|Hospital Universitario de Canarias, Tenerife, La Laguna, Spain|Hospital De Navarra, Pamplona, Navarra, Spain|Clínica Mompia, Cantabria, Santa Cruz De Bezana, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Cl. Universitaria Navarra, Madrid, Spain|Centro Oncológico MD Anderson, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Gerencia de Asistencia Sanitaria de Segovia_Hospital General de Segovia, Segovia, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Fundación Instituto Valenciano de Oncología, Valencia, Spain|Hospital Universitario La Fe de Valencia, Valencia, Spain|China Medical University Hospital, Taichung, Taiwan|The Christie, Manchester, Greater Manchester, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Queen Elizabeth Hospital, NHS Foundation Trust, Birmingham, United Kingdom|Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03994627"
680,"NCT00824265","Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia",,"Completed","Has Results","Leukaemia, Lymphocytic, Chronic","Drug: OFC Infusion|Drug: FC infusion","Progression-free Survival (PFS), as Assessed by the Independent Review Committee (IRC)|Overall Survival (OS)|Time to Response, as Assessed by the IRC|Duration of Response (DOR), as Assessed by the IRC|Time to Progression, as Assessed by the IRC|Time to Next Therapy|Number of Participants With Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status|Number of Participants With no B-Symptoms or at Least One B-symptoms Over the Time|Percentage of Participants With the Best Overall Response (OR), as Assessed by the IRC|Percentage of Participants With the Best OR, as Assessed by the Investigator|Number of Participants Who Were Negative for Minimal Residual Disease (MRD) Assessed by IRC|Number of Participants Who Were Negative for MRD Assessed by Investigator|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result at Indicated Time Points|Number of Participants With Autoimmune Hemolytic Anaemia (AIHA)|Number of Participants With Drug Related Infections Reported as AEs and SAEs of Maximum Severity of Grade 3 or Higher|Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression Adverse Events|Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study|Mean Level of Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM|Change From Baseline in Cluster of Differentiation (CD) Cell Counts, CD5+ and CD19+|Change From Baseline in Cell Counts, CD5- CD19+|Prognostic and Biological Markers Correlating With Clinical Response|Changes in Patient Reported Outcome (PRO) Measures and Scores for European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)|Change From Baseline in Patient Reported Outcome (PRO) as Assessed by EuroQoL Five-Dimension (EQ-5D) Score at Indicated Visit|Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score|Mean of Health Change Questionnaire (HCQ)|Mean Area Under the Time-concentration Curve (AUC) Curve Over the Dosing Interval (AUC[0-tau]) of Ofatumumab|Maximum Concentration (Cmax) and Observed Drug Concentration Prior to the Next Dose (Ctrough) of Ofatumumab|Time of Occurrence of Cmax (Tmax) of Ofatumumab","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","365","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","110913","March 12, 2009","December 17, 2014","October 25, 2017","January 16, 2009","July 25, 2016","June 18, 2020","Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Clinton, Maryland, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Brasilia, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigational Site, Porto Alegre, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigation Site, Rio de Janeiro, Brazil|Novartis Investigative Site, Rio de Janeiro, Brazil|Novartis Investigational Site, Sao Paulo, Brazil|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigational Site, Sofia, Bulgaria|Novartis Investigational Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Varna, Bulgaria|Novartis Investigative Site, New Westminster, British Columbia, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Newmarket, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Villingen-Schwenningen, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Lehrte, Niedersachsen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach-Rheydt, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigational Site, Hamburg, Germany|Novartis Investigational Site, Lubeck, Germany|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Vadodara, India|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Pavia, Lombardia, Italy|Novartis Investigative Site, Ascoli Piceno, Marche, Italy|Novartis Investigative Site, Alessandria, Piemonte, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Catania, Sicilia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mexico City, Mexico|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Krakow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Opole, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Bucharest, Romania|Novartis Investigative Site, Bucharest, Romania|Iasi, Romania|Novartis Investigative Site, Iasi, Romania|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei city, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigational Site, Taipei, Taiwan|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigational Site, Simferopil, Ukraine|Novartis Investigative Site, Vinnitsa, Ukraine|Novartis Investigational Site, Zhytomyr, Ukraine|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Burton on Trent, United Kingdom|Novartis Investigative Site, Cottingham, United Kingdom|Novartis Investigative Site, Dudley, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leicester, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Sutton, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Truro, United Kingdom|Novartis Investigative Site, Uxbridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00824265"
681,"NCT04529772","A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)","ESCALADE","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: acalabrutinib|Drug: placebo|Drug: Prednisone|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Doxorubicin","Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B|Investigator-assessed event-free survival (EFS) for NHL in Arm A compared to Arm B|Overall survival in Arm A compared to Arm B|Percentage of Participants Who Achieved a Complete Response (CR) per 2014 Lugano Classification at the end of study treatment","Acerta Pharma BV|AstraZeneca","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","D8227C00001","October 8, 2020","August 31, 2026","August 31, 2026","August 28, 2020",,"May 11, 2022","Research Site, Tucson, Arizona, United States|Research Site, Orange, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Denver, Colorado, United States|Research Site, Norwich, Connecticut, United States|Research Site, Fort Myers, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Saint Petersburg, Florida, United States|Research Site, Tallahassee, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Fort Wayne, Indiana, United States|Research Site, Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Louisville, Kentucky, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Grand Rapids, Michigan, United States|Research Site, Duluth, Minnesota, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Albany, New York, United States|Research Site, New York, New York, United States|Research Site, New York, New York, United States|Research Site, Stony Brook, New York, United States|Research Site, Eugene, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Chattanooga, Tennessee, United States|Research Site, Nashville, Tennessee, United States|Research Site, Fort Sam Houston, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Lubbock, Texas, United States|Research Site, Salem, Virginia, United States|Research Site, Adelaide, Australia|Research Site, Camperdown, Australia|Research Site, Clayton, Australia|Research Site, Darlinghurst, Australia|Research Site, Heidelberg, Australia|Research Site, Hobart, Australia|Research Site, Kogarah, Australia|Research Site, Liverpool, Australia|Research Site, Murdoch, Australia|Research Site, Nedlands, Australia|Research Site, South Brisbane, Australia|Research Site, Westmead, Australia|Research Site, Graz, Austria|Research Site, Krems, Austria|Research Site, Linz, Austria|Research Site, Salzburg, Austria|Research Site, Wels, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Brugge, Belgium|Research Site, Gent, Belgium|Research Site, Curitiba, Brazil|Research Site, Florianopolis, Brazil|Research Site, Goiania, Brazil|Research Site, Passo Fundo, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Paulo, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Toronto, CA, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Lévis, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Ottawa, Canada|Research Site, Quebec, Canada|Research Site, Changchun, China|Research Site, Chengdu, China|Research Site, Guangzhou, China|Research Site, Haidian District, China|Research Site, Hangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Luoyang, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Shanghai, China|Research Site, Shijiazhuang, China|Research Site, Suzhou, China|Research Site, Tianjin, China|Research Site, Wuhan, China|Research Site, Xiamen, China|Research Site, Xuhui District, China|Research Site, Zhengzhou, China|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Ostrava - Poruba, Czechia|Research Site, Plzen, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 2, Czechia|Research Site, Bordeaux, France|Research Site, Brest, France|Research Site, Caen Cedex 9, France|Research Site, Dijon, France|Research Site, Limoges, France|Research Site, Lyon, France|Research Site, Marseille cedex 5, France|Research Site, Montpellier, France|Research Site, Nantes, France|Research Site, Paris, France|Research Site, Pessac, France|Research Site, Pierre Benite, France|Research Site, Rennes Cedex 9, France|Research Site, Toulouse, France|Research Site, Bamberg, Germany|Research Site, Berlin, Germany|Research Site, Bremen, Germany|Research Site, Dresden, Germany|Research Site, Hamburg, Germany|Research Site, Homburg, Germany|Research Site, Mutlangen, Germany|Research Site, Münster, Germany|Research Site, Neumünster, Germany|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Kochi, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, Nashik, India|Research Site, Pune, India|Research Site, Afula, Israel|Research Site, Beer Sheba, Israel|Research Site, Haifa, Israel|Research Site, Haifa, Israel|Research Site, Holon, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Tel Aviv, Israel|Research Site, Zerifin, Israel|Research Site, Bari, Italy|Research Site, Bergamo, Italy|Research Site, Bologna, Italy|Research Site, Firenze, Italy|Research Site, Genova, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Novara, Italy|Research Site, Palermo, Italy|Research Site, Pavia, Italy|Research Site, Pisa, Italy|Research Site, Ravenna, Italy|Research Site, Reggio Emilia, Italy|Research Site, Roma, Italy|Research Site, Roma, Italy|Research Site, Rozzano, Italy|Research Site, Siena, Italy|Research Site, Torino, Italy|Research Site, Tricase (Lecce), Italy|Research Site, Venezia, Italy|Research Site, Chiba-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Itabashi-ku, Japan|Research Site, Kahoku-gun, Japan|Research Site, Kashiwa, Japan|Research Site, Kobe-shi, Japan|Research Site, Koto-ku, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Matsuyama-shi, Japan|Research Site, Nagasaki-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Nagoya-shi, Japan|Research Site, Niigata-shi, Japan|Research Site, Okayama-shi, Japan|Research Site, Osaka-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Shimotsuke-shi, Japan|Research Site, Tsu-shi, Japan|Research Site, Busan, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Jeonjusi Deokjingu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Suwon-si, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Chihuahua, Mexico|Research Site, Hermosillo, Mexico|Research Site, Monterrey, Mexico|Research Site, Kraków, Poland|Research Site, Poznan, Poland|Research Site, Warszawa, Poland|Research Site, Wrocław, Poland|Research Site, Łódź, Poland|Research Site, Braga, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisboa, Portugal|Research Site, Lisbon, Portugal|Research Site, Matosinhos, Portugal|Research Site, Porto, Portugal|Research Site, Porto, Portugal|Research Site, Vila Nova de Gaia, Portugal|Research Site, Chelyabinsk, Russian Federation|Research Site, Kazan, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Petrozavodsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Alcalá De Henares, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Gijón, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Palma, Spain|Research Site, Pamplona, Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Salamanca, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei 112, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan City, Taiwan|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Balcova, Turkey|Research Site, Edirne, Turkey|Research Site, Izmir, Turkey|Research Site, Kayseri, Turkey|Research Site, Mersin, Turkey|Research Site, Samsun, Turkey|Research Site, Trabzon, Turkey|Research Site, Cherkasy, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Khmelnytskyi, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Mykolayiv, Ukraine|Research Site, Zaporizhzhia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04529772"
682,"NCT01915303","Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease",,"Terminated","Has Results","Cushings Disease","Drug: Pasireotide with or without cabergoline","Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN Collected or Imputed at Week 35|Mean Urinary Free Cortisol (mUFC) at Scheduled Visits|Percentage of Responders With Mean Urinary Free Cortisol (mUFC) ≤ 1.0xULN|Percentage of Participants Who Attain mUFC ≤ 1.0 x ULN or Have at Least 50% Reduction From Baseline in mUFC|Duration (Weeks) of Controlled or Partially Controlled Response|Plasma Adrenocorticotropic Hormone (ACTH)|Serum Cortisol Levels|Sitting Systolic Blood Pressure at Week 35|Sitting Diastolic Blood Pressure at Week 35|Body Weight at Week 35|Body Mass Index at Week 35|Waist Circumference at Week 35|LDL, HDL and Total Cholesterol at Week 35|Mean Scores of Cushing QoL Standardized Score at Week 17 and 35|Mean Scores of SF-12v2 Domain Scores at Week 17 and 35|Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Facial Rubor|Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Hirsutism|Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Striae|Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Supraclavicular Fat Pad|Number of Participants With Improvement in Clinical Symptom of Hypercortisolism From Baseline - Dorsal Fat Pad|Number of Participants With Shift From Mild to Severe in Clinical Signs of Hypercortisolism|Number of Patients With Shift From Standing Easily to Not Being Able to Stand","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 2","68","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSOM230B2411","March 6, 2014","September 5, 2016","September 4, 2019","August 2, 2013","September 18, 2020","September 18, 2020","University of Alabama at Birmingham The Kirklin Clinic, Birmingham, Alabama, United States|Oregon Health and Science University SOM230B2411, Portland, Oregon, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Vandoeuvre Cedex, France|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Chandigarh, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Wilayah Persekutuan, Malaysia|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Durango, Mexico|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Pendik / Istanbul, Turkey","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01915303/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT01915303/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01915303"
683,"NCT00748189","Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia","COMPLEMENT 1","Terminated","Has Results","Leukaemia, Lymphocytic, Chronic","Drug: chlorambucil, tablets|Drug: ofatumumab (GSK1841157) infusion","Progression-Free Survival (PFS), as Assessed by the Independent Review Committee (IRC)|Number of Participants With the Best Overall Response (OR), as Assessed by the IRC|Number of Participants Who Were Negative for Minimal Residual Disease (MRD)|Overall Survival|Time to Response, as Assessed by the IRC|Duration of Response (DOR), as Assessed by the IRC|Time to Progression, as Assessed by the IRC|Time to Next Therapy|Number of Participants With Improvement in ECOG Performance Status of 0 or 1|Number of Participants With Improvement in Constitutional Symptoms (CS)|Number of Participants With a Human Anti-human Antibody (HAHA) Positive Result|Cmax and Ctrough of Ofatumumab|Total Plasma Clearance (CL) of Ofatumumab|AUC(0-tau) of Ofatumumab|Volume of Distribution at Steady State (Vss) of Ofatumumab|Plasma Half Life (t1/2) of Ofatumumab|Dose-normalized Cmax of Chlorambucil and Phenylacetic Acid Mustard (PAAM)|Dose-normalized AUC(0-6) and AUC(0-inf) of Chlorambucil and Dose-normalized AUC(0-6) of Phenylacetic Acid Mustard (PAAM)|Change From Baseline in Health Related Quality of Life (HRQOL)|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With AEs and SAEs of Maximum Severity of Grade 3 or Higher|Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia)|Number of Participants With Autoimmune Hemolytic Anaemia (AIHA) Disease|Number of Participants Who Received no Transfusion or at Least One Transfusion During the Study|Mean Change From Baseline in the Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","447","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","OMB110911","December 22, 2008","March 20, 2013","May 17, 2018","September 8, 2008","March 26, 2014","June 25, 2019","Novartis Investigative Site, Sedona, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Murrieta, California, United States|Novartis Investigative Site, Aurora, Colorado, United States|Novartis Investigative Site, Denver, Colorado, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, New Port Richey, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Ocoee, Florida, United States|Novartis Investigative Site, Marietta, Georgia, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Lee's Summit, Missouri, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Abilene, Texas, United States|Novartis Investigative Site, Arlington, Texas, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Fort Worth, Texas, United States|Novartis Investigative Site, Midland, Texas, United States|Novartis Investigative Site, Odessa, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Tyler, Texas, United States|Novartis Investigative Site, Waco, Texas, United States|Novartis Investigative Site, Webster, Texas, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Vancouver, Washington, United States|Novartis Investigative Site, Yakima, Washington, United States|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Haine-Saint-Paul, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Porto Alegre, Rio De Janeiro, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Creteil, France|Novartis Investigative Site, Pierre Benite, France|Novartis Investigative Site, Karlsruhe, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Stuttgart, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Ulm, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Erlangen, Bayern, Germany|Novartis Investigative Site, Muenchen, Bayern, Germany|Novartis Investigative Site, Regensburg, Bayern, Germany|Novartis Investigative Site, Wuerzburg, Bayern, Germany|Novartis Investigative Site, Frankfurt, Hessen, Germany|Novartis Investigative Site, Kassel, Hessen, Germany|Novartis Investigative Site, Hannover, Niedersachsen, Germany|Novartis Investigative Site, Lehrte, Niedersachsen, Germany|Novartis Investigative Site, Essen, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Koeln, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Moenchengladbach-Rheydt, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Muenster, Nordrhein-Westfalen, Germany|Novartis Investigative Site, Saarbruecken, Saarland, Germany|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Bangalore, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Cork, Ireland|Novartis Investigative Site, Dublin, Ireland|Novartis Investigative Site, Galway, Ireland|Novartis Investigative Site, James Street, Ireland|Novartis Investigative Site, Limerick, Ireland|Novartis Investigative Site, Tullamore, Ireland|Novartis Investigative Site, Waterford, Ireland|Novartis Investigative Site, Potenza, Basilicata, Italy|Novartis Investigative Site, Napoli, Campania, Italy|Novartis Investigative Site, Albano Laziale (Roma), Lazio, Italy|Novartis Investigative Site, Genova, Liguria, Italy|Novartis Investigative Site, Brescia, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Milano, Lombardia, Italy|Novartis Investigative Site, Ascoli Piceno, Marche, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Bari, Puglia, Italy|Novartis Investigative Site, Palermo, Sicilia, Italy|Novartis Investigative Site, Venezia - Mestre, Veneto, Italy|Novartis Investigative Site, Vicenza, Veneto, Italy|Novartis Investigative Site, Udine, Italy|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Nijmegen, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Lodz, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Valencia, Spain|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Plymouth, Devon, United Kingdom|Novartis Investigative Site, Taunton, Somerset, United Kingdom|Novartis Investigative Site, Sunderland, Tyne, United Kingdom|Novartis Investigative Site, Bath, United Kingdom|Novartis Investigative Site, Belfast, United Kingdom|Novartis Investigative Site, Birmingham, United Kingdom|Novartis Investigative Site, Bournemouth, United Kingdom|Novartis Investigative Site, Bradford, United Kingdom|Novartis Investigative Site, Cambridge, United Kingdom|Novartis Investigative Site, Canterbury, Kent, United Kingdom|Novartis Investigative Site, Carshalton, United Kingdom|Novartis Investigative Site, Cornwall, United Kingdom|Novartis Investigative Site, Dudley, United Kingdom|Novartis Investigative Site, Exeter, United Kingdom|Novartis Investigative Site, Glasgow, United Kingdom|Novartis Investigative Site, Leeds, United Kingdom|Novartis Investigative Site, Liverpool, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, London, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Milton Keynes, United Kingdom|Novartis Investigative Site, Newcastle-upon-Tyne, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Oxford, United Kingdom|Novartis Investigative Site, Peterborough, United Kingdom|Novartis Investigative Site, Rhyl, Denbighshire, United Kingdom|Novartis Investigative Site, Salford, United Kingdom|Novartis Investigative Site, Stoke on Trent, United Kingdom|Novartis Investigative Site, Swindon, United Kingdom|Novartis Investigative Site, Uxbridge, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00748189"
684,"NCT00018954","Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Leukemia|Lymphoma","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: ifosfamide|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: conventional surgery|Radiation: radiation therapy",,"National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","Child, Adult, Older Adult","Phase 2",,"NIH","Interventional","Primary Purpose: Treatment","CDR0000077227|NCI-92-C-0030|NCI-T91-0259N|OH92-C-0030","October 1992",,"October 2002","June 12, 2003",,"February 20, 2012","Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States|National Cancer Institute of Egypt, Cairo, Egypt|Kidwai Memorial Institute of Oncology, Bangalore, India|Cancer Institute (W.I.A.), Madras, India|Tata Memorial Centre, Mumbai, India",,"https://ClinicalTrials.gov/show/NCT00018954"
685,"NCT02629692","Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant CML Failing ≥3 Prior CML Therapies",,"Recruiting","No Results Available","Healthy (For Part A)|Chronic Myeloid Leukemia (for Part B and C)","Drug: Vodobatinib (K0706) capsules","To determine the Maximum Tolerated Dose (MTD) as determined by frequency of Dose Limiting Toxicities|Incidence and severity of treatment emergent AEs as assessed by CTCAE v4.03|For CML subjects in CP at study entry|For CML subjects in AP at study entry|For CML subjects in BP at study entry|Pharmacokinetic profile of K0706 - Cmax [The maximum (peak) observed drug concentration after dose administration]|Pharmacokinetic profile of Vodobatinib (K0706) - Tmax [The time to reach maximum (peak) drug concentration after dose administration]|Pharmacokinetic profile of Vodobatinib (K0706) - Cmin [ Minimum observed drug concentration after dose administration]|In subjects with CML- CP:Proportion of subjects achieving Complete Hematological Response as assessed by complete blood count of peripheral blood sample|In subjects with CML- CP:Proportion of subjects achieving Complete Cytogenetic Response as assessed by conventional Karyotyping of Bone marrow aspirate|In subjects with CML- CP:Proportion of subjects achieving Major Molecular Response as assessed by BCR-ABL transcript levels (BCR-ABL1 ratio of ≤ 0.1%) in peripheral blood using PCR (Polymerase Chain Reaction)|In subjects with CML-AP & BP: Proportion of subjects achieving Complete cytogenetic response as assessed by conventional Karyotyping of Bone marrow aspirate|In subjects with CML-AP & BP: Proportion of subjects achieving Partial Cytogenetic Response (PCyR) as assessed by conventional Karyotyping of Bone marrow aspirate|In subjects with CML-AP & BP: Proportion of subjects achieving Major Molecular Response as assessed by BCR-ABL transcript levels (BCR-ABL1 ratio of ≤ 0.1%) in peripheral blood using PCR (Polymerase Chain Reaction)|Time to Major Cytogenetic Response (MCyR): Time to MCyR is the time from first dose to first MCyR (0-35% Ph+ metaphases) ; computed only for subjects who achieved MCyR|Time to Major Molecular Response : Time to MMR is the time from first dose to first MMR (BCR-ABL1 ratio of ≤ 0.1%) computed only for subjects who achieved MMR|In all subjects Progression free survival (PFS)|In all subjects Overall survival (OS)|Incidence and severity of treatment emergent AEs as assessed by CTCAE v5.0","Sun Pharma Advanced Research Company Limited","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","303","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CLR_15_03 V 12 Amendment 12","April 25, 2017","August 2022","August 2026","December 14, 2015",,"April 28, 2022","The Oncology Institute of Hope and Innovation, Innovative Clinical Research Institute, Downey, California, United States|UCLA Hematologic Malignancy Program, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|Mayo Clinic, Jacksonville, Florida, United States|Board of Regents of the University System of Georgia, Augusta, Georgia, United States|IU Simon Cancer Center, Indianapolis, Indiana, United States|Indiana Blood Marro Transplant, Indianapolis, Indiana, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center - MAIN, New York, New York, United States|New York Medical College, Valhalla, New York, United States|East Carolina University, Greenville, North Carolina, United States|Baylor University Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, United States|ZNA Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|UZ Leuven, Leuven, Belgium|Institut Paoli Calmettes, Marseille Cedex 9, Bouches-du-Rhône, France|Institut Bergonié, Bordeaux cedex, Gironde, France|CHU de Limoges - Hôpital Dupuytren, Limoges cedex, Haute Vienne, France|CHU Rennes - Hopital Pontchaillou, Rennes cedex 9, Ille Et Vilaine, France|CHU de Nantes - Hotel Dieu, Nantes cedex 1, Loire Atlantique, France|CHU Angers - Hôpital Hôtel Dieu, Angers, Maine Et Loire, France|CHU de Nancy - Hôpital de Brabois Adultes, Vandœuvre-lès-Nancy, Meurthe Et Moselle, France|Hopital Claude Huriez - CHRU Lille, Lille cedex, Nord, France|Hôpital Saint-Louis, Paris cedex 10, Paris, France|Centre Léon Bérard, Lyon Cedex 08, Rhone, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, Rhone, France|Hôpital Avicenne, Bobigny cedex, Seine Saint Denis, France|CHU Amiens - Hopital Sud, Salouel, Somme, France|CHU Poitiers - Hôpital la Milétrie, Poitiers, Vienne, France|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem, Debrecen, Hungary|SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz, Nyiregyhaza, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Prince Aly Khan Hospital, Mumbai, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Sahyadri Specialty Hospital, Pune, Maharashtra, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamilnadu, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India|Tata Medical Centre, Kolkata, West Bengal, India|Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Forli - Cesena, Italy|Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Milano, Italy|Azienda Ospedaliera Universitaria ""Policlinico - Vittorio Emanuele"" (Presidio Ferrarotto Alessi), Catania, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda), Milano, Italy|Ospedale Sant'Eugenio, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza, Roma, Italy|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Gyeonggi-do, Korea, Republic of|Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi-do, Korea, Republic of|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Institutul Oncologic ""Prof. Dr. Ion Chiricuta"" Cluj-Napoca, Cluj-Napoca, Romania|Spitalul Clinic Municipal Filantropia Craiova, Craiova, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Târgu Mureș, Romania|Singapore General Hospital, Singapore, Singapore|ICO Badalona - Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|ICO Girona - Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02629692"
686,"NCT02944682","Household Air Pollution and Health: A Multi-country LPG Intervention Trial","HAPIN","Active, not recruiting","No Results Available","Infant, Low Birth Weight","Other: Liquefied petroleum gas (LPG) cookstove","Birth weight|Incidence of HAPIN Severe Pneumonia|Length-for-age z-score|Blood pressure|Maternal blood pressure|Change in fetal growth|Preterm birth|Gestational age at birth|Change in child development|Brachial artery reactivity testing (BART)|Carotid intima-media thickness (CIMT)|Adult respiratory health and well-being|Short Form 36 survey|Severe pneumonia","Emory University|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI)|Bill and Melinda Gates Foundation|Berkeley Air Monitoring Group|Colorado State University|Global Alliance for Clean Cookstoves|Global LPG Partnership|Harvard University|Johns Hopkins University|London School of Hygiene and Tropical Medicine|Asociacion Benefica Prisma|Sri Ramachandra University|Universidad del Valle, Guatemala|Universidad Peruana Cayetano Heredia|University of Georgia|Washington University School of Medicine|University of Rwanda|Eagle Research Center|University of Oxford","All","18 Years to 79 Years   (Adult, Older Adult)","Not Applicable","3640","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","IRB00089799|1UM1HL134590-01","April 16, 2018","October 1, 2021","June 30, 2022","October 26, 2016",,"April 8, 2022","Universidad del Valle de Guatemala, Guatemala, Guatemala|Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India|Puno Global Non-Communicable Disease Research Site, School of Medicine, Johns Hopkins University, Puno, Peru|Rwanda Research Site, London School of Hygiene and Tropical Medicine, Kigali, Rwanda","""Statistical Analysis Plan: Birthweight (Intention-to-treat and Exposure-Response)"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02944682/SAP_000.pdf|""Statistical Analysis Plan: Stunting (Intention-to-treat)"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02944682/SAP_002.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/82/NCT02944682/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT02944682"
687,"NCT00777036","A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib",,"Active, not recruiting","Has Results","Leukemia","Drug: Dasatinib","Major Cytogenetic Response (MCyR) Rate|Complete Hematologic Response (CHR) Rate|Complete Cytogenetic Response (CCyR) Rate|Major Cytogenetic Response (MCyR) Rate in Cohort 2|Complete Hematologic Response (CHR) Rate in Cohorts 1 and 3|Rate of Best Cytogenetic Response|Time to Major Cytogenetic Response (MCyR)|Duration of Major Cytogenetic Response (MCyR)|Time to Complete Cytogenetic Response (CCyR)|Duration of Complete Cytogenetic Response (CCyR)|Progression-Free Survival (PFS) Rate at 2 Years|Time to Complete Hematologic Response (CHR)|Duration of Complete Hemotologic Response (CHR)|Disease-Free Survival Rate at 2 Years|Overall Survival (OS) Rate at 2 Years|Major Molecular Response (MMR) Rate|Complete Molecular Response (CMR) Rate|Major Cytogenetic Response (MCyR) Rate up to 2 Years|Complete Cytogenetic Response (CCyR) Rate up to 2 Years|Major Molecular Response (MMR) Rate up to 2 Years|Complete Molecular Response (CMR) Rate up to 2 Years","Bristol-Myers Squibb","All","up to 18 Years   (Child, Adult)","Phase 2","145","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA180-226|2008-002260-33","March 20, 2009","September 1, 2016","December 16, 2022","October 22, 2008","January 5, 2018","May 5, 2022","Local Institution, Birmingham, Alabama, United States|Phoenix Children'S Hospital, Phoenix, Arizona, United States|Jonathan Jaques Children'S Cancer Center, Long Beach, California, United States|Jonathan Jaques Children'S Cancer Center, Long Beach, California, United States|Children'S Hospital Of Orange County, Orange, California, United States|Children'S Hospital, Aurora, Colorado, United States|Children's Healthcare Of Atlanta - Egleston, Atlanta, Georgia, United States|Children's Hospital of Chicago, Chicago, Illinois, United States|Local Institution - 0072, Chicago, Illinois, United States|Local Institution, Chicago, Illinois, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Stephen D. Hassenfeld Children'S Center, New York, New York, United States|Local Institution - 0061, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, New York, New York, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Oregon Health & Sci Univ, Portland, Oregon, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Children'S Hospital Of Pittsburgh, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Texas Children'S Cancer Center, Houston, Texas, United States|Seattle Children'S, Seattle, Washington, United States|Local Institution, Bunos Aires, Buenos Aires, Argentina|Hospital Nacional Profesor Alejandro Posadas, El Palomar, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, North Adelaide, South Australia, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Campinas, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Alberta Children'S Hospital, Calgary, Alberta, Canada|Stollery Children'S Hospital, Edmonton, Alberta, Canada|Bc Children'S Hospital, Vancouver, British Columbia, Canada|Iwk Health Centre, Halifax, Nova Scotia, Canada|Children'S Hospital Of Eastern Ontario, Ottawa, Ontario, Canada|The Hospital For Sick Children, Toronto, Ontario, Canada|Chu Ste-Justine, Montreal, Quebec, Canada|Local Institution, Lyon, France|Local Institution, Nantes, France|Local Institution, Paris Cedex 12, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Frankfurt, Germany|Local Institution, Hannover, Germany|Local Institution - 0089, Navrangpura, Ahmedabad, Gujarat, India|Local Institution, Navrangpura, Ahmedabad, Gujarat, India|Local Institution, Bangalore, Karnataka, India|Local Institution, Mumbai, Maharashtra, India|Local Institution, Pune, Maharashtra, India|Local Institution, Madurai, Tamil Nadu, India|Local Institution, Vellore, Tamilnadu, India|Local Institution, Kolkatta, India|Local Institution, Mumbai, India|Local Institution, Trivandrum, India|Local Institution, Bologna, Italy|Local Institution, Monza (mb), Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Torino, Italy|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Mexico, D. F., Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Hospital Civil De Guadalajara - Nuevo Dr. Juan I. Menchaca, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, N.l., Nuevo Leon, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Rotterdam, Netherlands|Local Institution - 0099, Utrecht, Netherlands|Local Institution, Bucharest, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Bloemfontein, FREE State, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Tygerberg, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Glasgow, Central, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00777036"
688,"NCT00802841","Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib","LASOR","Completed","Has Results","Chronic Myelogenous Leukemia","Drug: nilotinib|Drug: imatinib","Percentage of Participants With Complete Cytogenetic Response (CCyR)|Percentage of Participants With Major Molecular Response (MMR)|Percentage of Participants With CCyr|Time to CCyR|Duration of CCyR|Progression-Free Survival (PFS)|Event-Free Survival (EFS)|Overall Survival (OS)","Novartis Pharmaceuticals|Novartis","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","191","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMN107A2404|2008-007054-35","May 2009","July 2014","July 2014","December 5, 2008","November 16, 2015","November 16, 2015","Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Rio Negro, Viedma, Argentina|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Cuiaba, MG, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Florianopolis, SC, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Jaú, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Nanjing, Jiangsu, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Fuzhou, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Monteria, Colombia|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Guatemala City, Guatemala|Novartis Investigative Site, Hyderabad, Andhra Pradesh, India|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Mumbai 400 020, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, México, Distrito Federal, Mexico|Novartis Investigative Site, Zapopan, Jalisco, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Panama City, Panamá, Panama|Novartis Investigative Site, Kraków, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Krasnoyarsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, Saint-Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Caracas, Distrito Capital, Venezuela|Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela",,"https://ClinicalTrials.gov/show/NCT00802841"
689,"NCT01254188","Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients","ENESTxtnd","Completed","Has Results","Chronic Myeloid Leukemia","Drug: Nilotinib","The Percentage of Patients Achieving MMR by 12 Months|Time to Molecular Response at 24 Months|Duration of Major Molecular Response|Complete Cytogenetic Response|Percentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.|Overall Survival|Kaplan-Meier Estimates of Progression-free Survival|Kaplan-Meier Estimates of Failure-free Survival","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","421","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAMN107E2401","April 2011","November 2014","November 2014","December 6, 2010","March 3, 2016","March 3, 2016","Novartis Investigative Site, Alger, Bouzareah, Algeria|Novartis Investigative Site, Oran, Algeria|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Paraná, Entre Rios, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Concord NSW, New South Wales, Australia|Novartis Investigative Site, Gosford, New South Wales, Australia|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Kogarah, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, St. Leonards, New South Wales, Australia|Novartis Investigative Site, Westmead, New South Wales, Australia|Novartis Investigative Site, Douglas, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Adelaide, South Australia, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Hobart, Tasmania, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Fitzroy, Victoria, Australia|Novartis Investigative Site, Heidelberg, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Wodonga, Victoria, Australia|Novartis Investigative Site, Nedlands, Western Australia, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Curitiba, PR, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Vancouver, British Columbia, Canada|Novartis Investigative Site, Moncton, New Brunswick, Canada|Novartis Investigative Site, Saint John, New Brunswick, Canada|Novartis Investigative Site, St. John's, Newfoundland and Labrador, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Barrie, Ontario, Canada|Novartis Investigative Site, Brampton, Ontario, Canada|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, London, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Weston, Ontario, Canada|Novartis Investigative Site, Windsor, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Québec, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Tamil Nadu, Chennai, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Saida, Lebanon|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Hermosillo, Sonora, Mexico|Novartis Investigative Site, San Luis Potosi, Mexico|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Arkhangelsk, Russia, Russian Federation|Novartis Investigative Site, Novosibirsk, Russia, Russian Federation|Novartis Investigative Site, Perm, Russia, Russian Federation|Novartis Investigative Site, Ryazan, Russia, Russian Federation|Novartis Investigative Site, St Petersburg, Russia, Russian Federation|Novartis Investigative Site, Tumen, Russia, Russian Federation|Novartis Investigative Site, Ekaterinburg, Russian Federation|Novartis Investigative Site, Irkutsk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Nizhnii Novgorod, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, Rostov-on-Don, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, St-Petersburg, Russian Federation|Novartis Investigative Site, Tula, Russian Federation|Novartis Investigative Site, Dammam, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Jeddah, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Bloemfontein, South Africa|Novartis Investigative Site, Observatory, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Taipei, Taiwan, ROC, Taiwan|Novartis Investigative Site, Lin-Kou, Taiwan|Novartis Investigative Site, Niaosong Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Muang, Thailand|Novartis Investigative Site, Sousse, Tunisie, Tunisia|Novartis Investigative Site, Tunis, Tunisia|Novartis Investigative Site, Dubai, United Arab Emirates",,"https://ClinicalTrials.gov/show/NCT01254188"
690,"NCT01303237","A Post Marketing Surveillance Study to Assess the Safety and Efficacy of Cetuximab Plus Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck","PMS LAD SCCHN","Terminated","No Results Available","Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|LA SCCHN","Drug: Cetuximab + RT","Number of Patients with Serious Adverse Reactions|Response Rate|Progression Free Survival|Duration of Locoregional Disease Control|Overall Survival|Management of skin conditions due to treatment protocol","Merck KGaA, Darmstadt, Germany|Merck Ltd., India","All","Child, Adult, Older Adult",,"88","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","EMR062202-539","February 28, 2011","June 30, 2013","August 5, 2014","February 24, 2011",,"June 9, 2017","Omega Hospital, Hyderabad, Andhra Pradesh, India|Shanti Chandra Family Clinic, Hyderabad, Andhra Pradesh, India|Swarna Sai Hospital, Hyderabad, Andhra Pradesh, India|Dr. Nikhil's Clinic, Secunderabad, Andhra Pradesh, India|Arogya Multispeciality Clinic, Mangalore, Bangalore, India|Aastha Oncology Associates, Ahmedabad, Gujarat, India|Navneet Memorial Centre, Ahmedabad, Gujarat, India|Meharbai TATA Memorial Hospital, Bistupur, Jamshedpur, India|Dr. T. P. Sahoo's Clinic, Bhopal, Madhya Pradesh, India|Ruby Hall Clinic, Pune, Maharashtra, India|Dr S M Karandikar Hospital, Pune, Maharashtra, India|Dwidal Nursing Home, Pune, Maharashtra, India|Regional cancer center, Sheikpura, Patna, India|Grecian Superspeciality Hospital, Mohali, Punjab, India|Harmony Health Care, Mohali, Punjab, India|Bhagwan Mahaveer Cancer Hospital & Research Center, Jaipur, Rajasthan, India|SMS Hospital, Jaipur, Rajasthan, India|Cancer Care Centre, Jaipur, Rajasthan, India|Balaji Clinic & General Hospital, Jaipur, Rajasthan, India|Royal Cancer Institute and Research Centre, Kanpur, Uttar Pradesh, India|SMH Curie Cancer Centre, New Delhi, Uttar Pradesh, India|Bengal Oncology, Kolkata, West Bengal, India|Apollo Gleneagles Cancer Hospital, Kolkata, West Bengal, India|Oncologist & Palliative Care Specialist Clinic, Kolkata, West Bengal, India|Dr. Meenu's Clinic, Delhi, India",,"https://ClinicalTrials.gov/show/NCT01303237"
691,"NCT00019409","Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia",,"Withdrawn","No Results Available","Leukemia","Drug: asparaginase|Drug: cyclophosphamide|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: mercaptopurine|Drug: methotrexate|Drug: prednisone|Drug: therapeutic hydrocortisone|Drug: vincristine sulfate|Radiation: radiation therapy",,"National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)","All","1 Year to 20 Years   (Child, Adult)","Phase 3","0","NIH","Interventional","Allocation: Randomized|Primary Purpose: Treatment","999998007|98-C-N007|MCP943|NCI-0H98-C-N007|CDR0000066120","October 1999",,"July 2001","February 27, 2004",,"March 23, 2012","Pediatric Oncology Branch, Bethesda, Maryland, United States|Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, United States|Kidwai Memorial Institute of Oncology, Bangalore, India|Cancer Institute (W.I.A.), Madras, India|Tata Memorial Centre, Mumbai, India|All-India Institute of Medical Sciences, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT00019409"
692,"NCT00206219","Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX)",,"Completed","No Results Available","Squamous Cell Carcinoma of the Head and Neck","Drug: Gefitinib|Drug: methotrexate","Compare ZD1839 versus methotrexate in overall survival|Compare ZD1839 versus methotrexate in symptom improvement, tumor response, safety and tolerability and quality of life - assessed throughout the study.","AstraZeneca","All","18 Years and older   (Adult, Older Adult)","Phase 3","477","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1839IL/0704|EudraCT no.2004-002662-38","November 2003","September 2007","September 2007","September 21, 2005",,"January 27, 2011","Research Site, Birmingham, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Palm Springs, California, United States|Research Site, Aurora, Colorado, United States|Research Site, New Haven, Connecticut, United States|Research Site, Norwalk, Connecticut, United States|Research Site, Miami, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Ormand Beach, Florida, United States|Research Site, Savannah, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Des Moines, Iowa, United States|Research Site, Louisville, Kentucky, United States|Research Site, Baton Rouge, Louisiana, United States|Research Site, Waterville, Maine, United States|Research Site, Bethesda, Maryland, United States|Research Site, Detroit, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Brooklyn, New York, United States|Research Site, New York, New York, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Norfolk, Virginia, United States|Research Site, Olympia, Washington, United States|Research Site, Milwaukee, Wisconsin, United States|Research Site, Capital Federal, Buenos Aires, Argentina|Research Site, El Palomar, Buenos Aires, Argentina|Research Site, Salta, Argentina|Research Site, Santa Fe, Argentina|Research Site, Westmead, New South Wales, Australia|Research Site, Brussels (Woluwé-St-Lambert), Belgium|Research Site, Brussels, Belgium|Research Site, Edegem, Belgium|Research Site, Gent, Belgium|Research Site, Haine-Saint-Paul, Belgium|Research Site, Goiânia, GO, Brazil|Research Site, Rio de Janeiro, RJ, Brazil|Research Site, São Paulo, SP, Brazil|Research Site, Vancouver, British Columbia, Canada|Research Site, Winnipeg, Manitoba, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Windsor, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Zagreb, Croatia|Research Site, Brno, Czech Republic|Research Site, Ostrava - Poruba, Czech Republic|Research Site, Ostrava, Czech Republic|Research Site, Praha 2, Czech Republic|Research Site, Praha 5, Czech Republic|Research Site, Praha 8, Czech Republic|Research Site, Tallinn, Estonia|Research Site, Tartu, Estonia|Research Site, Thessaloniki, Greece|Research Site, Kochi, Kerala, India|Research Site, Thiruvananthapuram, Kerala, India|Research Site, Bhopal, Madhya Pradesh, India|Research Site, Pune, Maharashtra, India|Research Site, Ansari Nagar, New Dehli, India|Research Site, Jaipur, Rajasthan, India|Research Site, Kolkatta, West Bengal, India|Research Site, New Dehli, India|Research Site, Petach Tikva, Israel|Research Site, Tel-Hashomer, Israel|Research Site, Bologna, Italy|Research Site, Cuneo, Italy|Research Site, Forli', Italy|Research Site, Genova, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy|Research Site, Torino, Italy|Research Site, Riga, Latvia|Research Site, Klaipeda, Lithuania|Research Site, Vilnius, Lithuania|Research Site, Nilai, Malaysia|Research Site, Petaling Jaya, Malaysia|Research Site, Amsterdam, Netherlands|Research Site, Maastricht, Netherlands|Research Site, Nijmegen, Netherlands|Research Site, Utrecht, Netherlands|Research Site, Oslo, Norway|Research Site, Krasnogorsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, St.Petersburg, Russian Federation|Research Site, Zaloska, Ljubljana, Slovenia|Research Site, Ljubljana, Slovenia|Research Site, Bloemfontein, South Africa|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Johannesburg, South Africa|Research Site, Pretoria, South Africa|Research Site, Tygerberg, South Africa|Research Site, Santiago de Compostela, A Coruña, Spain|Research Site, Leganés, Madrid, Spain|Research Site, Baracaldo, Vizcaya, Spain|Research Site, Granada, Spain|Research Site, Madrid, Spain|Research Site, Pontevedra, Spain|Research Site, Santander, Spain|Research Site, Valencia, Spain|Research Site, Vitoria, Álava, Spain|Research Site, Göteborg, Sweden|Research Site, Malmö, Sweden|Research Site, Stockholm, Sweden|Research Site, Bangkok, Thailand|Research Site, Chiang Mai, Thailand|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00206219"
693,"NCT00375219","Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation",,"Completed","Has Results","Chronic Myeloid Leukemia","Drug: Omacetaxine mepesuccinate","Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population|Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total|Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)|Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS|Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL|Percentage of Participants in Each Hematologic Response Category|Percentage of Participants With Extramedullary Disease (EMD) at Baseline Achieving a Clinical Response|Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL|Number of Treatment Cycles Needed to Achieve Best Hematologic Response|Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response|Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response|Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response|Kaplan-Meier Estimates for Duration of Best Hematologic Response|Kaplan-Meier Estimates for Duration of Best Cytogenetic Response|Kaplan-Meier Estimates for Time to Disease Progression|Kaplan-Meier Estimates for Overall Survival","Teva Branded Pharmaceutical Products R&D, Inc.|Cephalon|ChemGenex Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","103","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CGX-635-CML-202|2006-000176-32","September 20, 2006","March 23, 2010","June 28, 2013","September 12, 2006","June 3, 2014","November 15, 2021","Teva Investigational Site 003, Los Angeles, California, United States|Teva Investigational Site 007, Jacksonville, Florida, United States|Teva Investigational Site 006, Atlanta, Georgia, United States|Teva Investigational Site 008, Beech Grove, Indiana, United States|Teva Investigational Site 011, Baltimore, Maryland, United States|Teva Investigational Site 004, Boston, Massachusetts, United States|Teva Investigational Site 002, Bronx, New York, United States|Teva Investigational Site 005, Buffalo, New York, United States|Teva Investigational Site 010, Philadelphia, Pennsylvania, United States|Teva Investigational Site 001, Houston, Texas, United States|Teva Investigational Site 013, Montreal, Canada|Teva Investigational Site 009, Toronto, Canada|Teva Investigational Site 029, Bordeaux, France|Teva Investigational Site 021, Le Chesnay Cedex, France|Teva Investigational Site 022, Lille, France|Teva Investigational Site 020, Lyon Cedex 03, France|Teva Investigational Site 024, Nice, France|Teva Investigational Site 028, Paris, France|Teva Investigational Site 023, Poitiers Cedex, France|Teva Investigational Site 027, Strasbourg, France|Teva Investigational Site 025, Toulouse, France|Teva Investigational Site 026, Vandoeuvre-Les-Nancy CEDEX, France|Teva Investigational Site 031, Berlin, Germany|Teva Investigational Site 030, Mannheim, Germany|Teva Investigational Site 050, Budapest, Hungary|Teva Investigational Site 071, Hyderabad, India|Teva Investigational Site 070, Mumbai, India|Teva Investigational Site 090, Bologna, Italy|Teva Investigational Site 060, Gdansk, Poland|Teva Investigational Site 061, Warszawa, Poland|Teva Investigational Site 080, Singapore, Singapore|Teva Investigational Site 040, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00375219"
694,"NCT00755755","PGL4001 Versus Placebo in Uterine Myomas","PEARLI","Completed","Has Results","Uterine Myomas","Drug: PGL4001 (ulipristal) and iron|Drug: PGL4001 matching placebo and iron","Co-primary Endpoint: Percentage of Subjects With Reduction in Uterine Bleeding Defined as a Pictorial Blood-loss Assessment Chart (PBAC) Score <75 at End-of-treatment Visit (Week 13)|Co-primary Endpoint: Percent Change in Total Myoma Volume Assessed by Magnetic Resonance Imaging (MRI) From Screening to End of Treatment Visit (Week 13 Visit)","PregLem SA","Female","18 Years to 50 Years   (Adult)","Phase 3","241","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","PGL07-021","October 2008","March 2010","August 2010","September 19, 2008","November 16, 2012","December 13, 2012","Gynekologicko-porodnicka klinika FN Brno, Brno, Czech Republic|Mediva, Praha, Czech Republic|Gynekologicko-porodnicka klinika 1.LF UK a VFN, Praha, Czech Republic|Gynekologicko-porodnicka klinika UK 2.LF a FN, Praha, Czech Republic|Rethy-Pal Hospital-Clinic Bekescsaba, Department of Obstetrics and Gynecology, Bekescsaba, Hungary|Saint Stephen Hospital of Budapest,Department of Obstetrics, Gynecology and Gynecological Oncology, Budapest, Hungary|Fovarosi Bajcsy-Zsilinszky Hospital, Department of Obstetrics and Gynecology, Budapest, Hungary|Saint George Hospital of Fejer County, Department of Obstetrics and Gynecology, Szekesfehervar, Hungary|Dr. Bugyi Istvan Hospital, Department of Obstetrics and Gynecology, Szentes, Hungary|Saint Borbala Hospital of Komarom-Esztergom County, Department of Obstetrics and Gynecology, Tatabanya, Hungary|Dr. Jilla Hospital, Aurangabad, India|M. S. Ramaiah Medical College and Memorial Hospital, Bangalore, India|Divakars Speciality Hospital, Bangalore, India|Sri Ramachandra Medical College and Research Institute, Chennai, India|Om Women's Hospital, Nagpur, India|Nagpur Test Tube Baby Centre, Nagpur, India|Central Medical Sanador, Bucharest, Romania|Departamentul de Obstretica Ginecologie si Nou Nascuti, Bucharest, Romania|Sectia Obstretica-Ginecologie Spitalul Clinic Dr. Ioan Cantacuzino, Bucharest, Romania|Centrul Medical Euromed, departementul de Obstetrica/Ginecologie, Bucuresti, Romania|Spitalul Clinic de Obstetrica Ginecologie Oradea, Oradea, Romania|Spitalul Clinic Judetean de urgenta, sectia de obstetrica Ginecologie I, Targu Mures, Romania|Northern State Medical University, Arkhangelsk, Russian Federation|Kursk State Medical University, Kursk, Russian Federation|OAO ""Medical company IDK"", Samara, Russian Federation|American Medical Clinic, St. Petersburg, Russian Federation|Saint-Petersburg City Alexandrovsky Hospital, St.Petersburg, Russian Federation|Military Medical Academy n.a.S.M Kirov, chair of Obstetrics and Gynecology, St.Petersburg, Russian Federation|Medical Research Institute (MRI), St.Petersburg, Russian Federation|Russian Scientific Research Center of Radiology and Surgical Technologies, St.Petersburg, Russian Federation|Scientific Research Institute of Obstetrics and Gynecology n.a. D.O.Ott of RAMS, St.Petersburg, Russian Federation|Donetsk National Medical University, Department of Obstetrics, Gynecology and Perinatology FPE, Donetsk, Ukraine|City Clinical Hospital N9, Kiev, Ukraine|Institute of Pediatrics, Obstetrics and Gynecology, Department of Endocrine Gynecology, Kiev, Ukraine|Kiev Maternity Hospital No.2, Kiev, Ukraine|State Enterprise ""Institute of Pediatrics, Obstetrics and Gynecology of AMS of Ukraine, Kyiv, Ukraine|Lviv National Medical University named after Danylo Halytskyy, Lviv, Ukraine|Medical Sanitory Centre VAT ""Motor Sich"" Gynecology department, Zaporizhzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00755755"
695,"NCT04576156","A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment",,"Recruiting","No Results Available","Myelofibrosis","Drug: Imetelstat|Drug: Best Available Therapy (BAT)","Overall survival|Symptom response rate|Progression-free survival|Spleen response rate|Complete remission (CR), partial remission (PR), clinical improvement (CI), spleen response, symptoms response, and anemia response per modified 2013 IWG-MRT criteria|Reduction in the degree of bone marrow fibrosis|Number of Participants with Adverse Events|Assessment of Cmax|European Organization for Research and Treatment of Cancer Quality-of-Life-Questionnaire-Core-30 (EORTC QLQ-C30) scores|EuroQol-EQ-5D (EQ-5D-5L) questionnaire scores|Assessment of AUC","Geron Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 3","320","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MYF3001|2020-003288-24","April 12, 2021","May 1, 2024","May 1, 2024","October 6, 2020",,"April 19, 2022","University of California-San Diego/Moores UCSD Cancer Center, La Jolla, California, United States|UCLA david geffen school of medicine, Los Angeles, California, United States|BRCR Medical Center Inc, Plantation, Florida, United States|University of South Florida, Tampa, Florida, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Duke, Durham, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Prairie Lakes Health Care System, Inc., Watertown, South Dakota, United States|The University of Texas MD, Houston, Texas, United States|Northwest Medical Specialties PLLC, Tacoma, Washington, United States|Hospital Aleman, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Sanatorio de la Mujer, Rosario, Santa Fe, Argentina|Fundaleu, Buenos Aires, Argentina|Sanatorio Allende, Córdoba, Argentina|Royal North Shore Hospital, St Leonards, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Epworth Healthcare, Richmond, Victoria, Australia|Krankenhaus der Elisabethinen, Linz, Oberösterreich, Austria|UZ Antwerpen, Edegem, Antwerpen, Belgium|Centre Hospitalier de Jolimont, Haine-Saint-Paul, Hainaut, Belgium|Zna - Campus Middelheim, Antwerpen, Belgium|ZNA Stuyvenberg Antwerpen, Antwerpen, Belgium|AZ Klina, Antwerpen, Belgium|Universitair Ziekenhuis Brussel - Myeloom Centrum Brussel (MCB), Jette, Belgium|Centro de oncologia Leonardo da Vinci, Fortaleza, Ceará, Brazil|Hospital das Clínicas UFG, Goiânia, Goiás, Brazil|Hospital Erasto Gaertner, Curitiba, Paraná, Brazil|Hospital de Clinicas de Porto Alegre - UFRGS, Porto Alegre, Rio Grande Do Sul, Brazil|Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa LTDA, Porto Alegre, Rio Grande Do Sul, Brazil|CEPON Centro de Pesquisas Oncologicas SC, Florianópolis, Brazil|Instituto de Educação, Pesquisa e Gestão em Saúde, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital A.C.Camargo Cancer Center - Clinical Oncology, São Paulo, Brazil|UMHAT ""Dr. Georgi Stranski"", Pleven, Bulgaria|UMBAL Sveti Georgi, Plovdiv, Bulgaria|Specialized Hospital for Active Therapy of Hematological dis, Sofia, Bulgaria|Oncologos del Occidente S.A, Pereira, Risaralda, Colombia|Hospital Pablo Tobon Uribe, Antioquia, Colombia|Centro Medico Imbanaco de Cali S.A., Cali, Colombia|FOSCAL, Floridablanca-Santander, Colombia|Aarhus University Hospital - Hematology, Aarhus, Denmark|Odense University Hospital - Hematology, Odense, Denmark|Institut de cancérologie du Gard - Hematologie clinique, Nimes Cedex 09, Gard, France|CHU Bretonneau, Tours, Indre-et-Loire, France|CHU De Nantes - HÃ©matologie C, Nantes, Loire-Atlantique, France|Centre Hospitalier Lyon, Pierre-benite, Rhône-Alpes, France|Centre Hospitalier Du Mans - Cancérologie Médicale, Le Mans, Sarthe, France|Hopital Avicenne - HÃ©matologie Clinique, Bobigny, Seine-Saint-Denis, France|CHRU Brest - Hôpital Morvan, Brest cedex, France|CHU - HÃ´pital Saint Louis - Centre D'Investigations Cliniq, Paris, France|Hopital Cochin - Aphp Hôpitaux Universitaires Paris Centre, Paris, Île-de-France, France|CHRU Brest - Hôpital Morvan, Georgia, Georgia|Multi Profile Clinic Consilium, Georgia, Georgia|LTD Israeli-Georgian Medical R, Tbilisi, Georgia|M.Zodelava Hematology Center L, Tbilisi, Georgia|J.S.C.""K.Eristavi National Cen, Tbilisi, Georgia|Ltd ""Medinvest"" Institute of H, Tbilisi, Georgia|Universitätsk+B4:O4linikum Tüb, Tübingen, Baden-Württemberg, Germany|Universitätsklinikum Carl Gust, Dresden, Hamburg, Germany|University Hospital RWTH Aache, Aachen, Nordrhein-Westfalen, Germany|Universitaetsklinik und Polikl, Halle (Saale), Sachsen-Anhalt, Germany|Universitätsklinikum Leipzig AöR, Leipzig, Sachsen, Germany|Universitätsklinikum Schleswig, Kiel, Schleswig-Holstein, Germany|Klinikum Kempten-Oberallgaeu G, Kempten, Germany|Semmelweis Egyetem - III. sz., Budapest, Hungary|Dél-pesti Centrumkórház Ország, Budapest, Hungary|Szabolcs-Szatmár-Bereg Megyei Önkormányzat Jósa András, Nyíregyháza, Hungary|Fejer Megyei Szent Gyorgy Egye, Székesfehérvár, Hungary|All India Institute of Medical Sciences, Dept. of Hematology, New Delhi (All India Institute Of Medical Sciences), New Delhi, Delhi, India|Sir Ganga Ram Hospital, New Delhi, Delhi, India|Nirmal Hospital - Hematology, Surat, Gujarat, India|St. John's Medical College Hospital, Bangalore, Karnataka, India|Fortis Hospital 154/9, Bengaluru, Karnataka, India|Fortis Memorial Research Institute, Gurgaon, New Delhi, India|All India Institute of Medical Sciences, Bhubaneswar, Orissa, India|Nilratan Sircar Medical College, Kolkata, West Bengal, India|Deenanath Mangeshkar Hospital & Research Center, Pune, India|Sahyadri Specialty Hospital, Pune, India|Assuta Ashdod University Hospi, Ashdod, HaDarom, Israel|Barzilai Medical Center, Ashkelon, HaDarom, Israel|Kaplan Medical Center, Rehovot, HaMerkaz, Israel|Shamir Medical Center (Assaf Harofeh), Zerifin, HaMerkaz, Israel|Western Galilee Hospital - Nahariya, Nahariya, HaZafon, Israel|Tel Aviv Sourasky Medical Cent, Tel Aviv, Tel-Aviv, Israel|Hadassah Medical Organization, Jerusalem, Yerushalayim, Israel|Bnai Zion Medical Center, Haifa, Israel|Carmel MC, Haifa, Israel|Arcispedale S.Anna - Ematologi, Cona, Ferrara, Italy|Istituto Clinico Humanitas Roz, Rozzano, Milano, Italy|AOU San Luigi Gonzaga, Orbassano, Torino, Italy|PO Civile SS.Antonio e Biagio, Alessandria, Italy|A.O.di Bologna Policl.S.Orsola, Bologna, Italy|Presidio Ospedaliero Garibaldi, Catania, Italy|AOU Careggi, Firenze, Italy|Clinica Ematologica, Univ. Deg, Genova, Italy|Irccs Irst, Meldola, Italy|Ospedale San Raffaele, Milano, Italy|ASST Grande Ospedale Metropoli, Milano, Italy|Azienda Ospedaliera San Gerard, Monza, Italy|AOU Federico II, Napoli, Italy|Ospedale Civile S.Maria delle, Ravenna, Italy|Azienda Ospedaliera Bianchi-Me, Reggio Calabria, Italy|AUSL di Rimini Ospedale Inferm, Rimini, Italy|ASL Roma 2 - PO ""S. Eugenio"", Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Ospedale S.Bortolo, AULSS n.6, Vicenza, Italy|Kyungpook National University, Daegu, Daegu Gwang'yeogsi [Taegu-Kwan], Korea, Republic of|Seoul National University Hospital - Department of Internal, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, Korea, Republic of|Pusan National University Hospital - Hematology and Oncology, Busan, Korea, Republic of|The Catholic University of Korea, Seongdong, Korea, Republic of|Severance Hospital, Yonsei Uni, Seoul, Korea, Republic of|Hospital Pulau Pinang, Georgetown, Pulau Pinang, Malaysia|Sarawak General Hospital, Kuching, Sarawak, Malaysia|Hospital Ampang, Ampang, Selangor, Malaysia|Hospital Raja Perempuan Zainab II, Kelantan, Malaysia|Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Sl, Slupsk, Pomorskie, Poland|Ars Medical Sp. z o.o., Piła, Wielkopolskie, Poland|Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie, Poland|Pratia Onkologia Katowice, Katowice, Śląskie, Poland|CCA-Braga. Centro Clínico Académico - Hospital Braga, Braga, Portugal|CHUC - Centro Hospitalar e Uni, Coimbra, Portugal|Instituto Português de Oncologia de Lisboa, Lisboa, Portugal|Centro Clinico Fundacao Champalimaud, Lisboa, Portugal|H. São Francisco Xavier-Centro, Lisboa, Portugal|H. Santa Maria. Centro Hospita, Lisboa, Portugal|Moscow City Hospital n.a. Botkin, Moscow, Moska, Russian Federation|MONIKI - Oncology, Moscow, Moskovskaya Oblast', Russian Federation|Moscow City Hospital n.a. Botkin, Moscow, Moskva, Russian Federation|Novosibirsk State Medical Univ, Novosibirsk, Novosibirskaya Oblast', Russian Federation|GOU VPO Saratov State Medical University n.a. V.I. Razumovsk, Saratov, Saratovskaya Oblast', Russian Federation|LLC ""Interleykin"", Pyatigorsk, Stavropol'skiy Kray, Russian Federation|Tula Regional Clinical Hospital, Tula, Tul'skaya Oblast', Russian Federation|Clinical oncological dispensar, Omsk, Russian Federation|FGU ""Russian Research Institute, Saint Petersburg, Russian Federation|Saint-Petersburg State Medical, Saint Petersburg, Russian Federation|V.A. Almazov National Medical, Saint-Petersburg, Russian Federation|National University Cancer Institute (NCIS), Singapore, Central Singapore, Singapore|Singapore General Hospital, Singapore, Central Singapore, Singapore|Institut Català d'Oncologia-Ho, Badalona, Barcelona, Spain|C.S. Parc Tauli, Sabadell, Barcelona, Spain|Hospital Universitario de Gran, Las Palmas de Gran Canaria, Canarias, Spain|H.U. Ribera de Alzira, Alzira, Valencia, Spain|H.G.U. Alicante, Alicante, Spain|H. San Pedro de Alcántara, Cáceres, Spain|ICO-Hospital Universitari de G, Girona, Spain|Hospital Universitario Virgen, Granada, Spain|Hospital Universitario Fundaci, Madrid, Spain|Hospital U. 12 Octubre, Madrid, Spain|H.U. La Paz, Madrid, Spain|H.U.V. de la Victoria, Málaga, Spain|Complejo Asistencial Universit, Salamanca, Spain|Hospital Universitario Doctor, Valencia, Spain|H. Quirón Zaragoza, Zaragoza, Spain|Universitaetsspital Zuerich, Zurich, Switzerland|Chang Gung Medical Foundation, Chiayi City, Chiayi, Taiwan|China Medical University Hospital, Taichung City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Ankara University Medical Facu, Ankara, Turkey|Istanbul Üniversitesi Cerrahpaşa, Istanbul, Turkey|Marmara university pendik training and research hospital, Istanbul, Turkey|Ege Universitesi Tip Fakultesi, Izmir, Turkey|Maidstone Hospital, Maidstone, Kent, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Guys and St Thomas' Hospital, London, United Kingdom|Oxford University Hospitals, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04576156"
696,"NCT04297254","A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC",,"Recruiting","No Results Available","Carcinoma, Hepatocellular","Drug: Lenvatinib","Percentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events (TEAEs)|Number of Participants with Serious Adverse Events (SAEs)|Number of Participants with Grades 1 and 2 Treatment-emergent Adverse Events (TEAEs)|Objective Response Rate (ORR)|Progression-free Survival (PFS)|Percentage of Participants Requiring Dose Modifications (Dose Interruptions or Dose Reductions)|Time to First Dose Reduction","Eisai Pharmaceuticals India Pvt. Ltd|Eisai Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 4","50","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E7080-M091-511","February 4, 2021","August 27, 2022","August 27, 2022","March 5, 2020",,"February 23, 2022","Sri Venkateshwara Hospital, Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|HCG Manavata Cancer Centre, Nashik, Maharashtra, India|Shatabdi Hospital, Nashik, Maharashtra, India|LMMF's Deenanath Mangeshkar Hospital & Research Center, Pune, Maharashtra, India|Noble Hospital, Pune, Maharashtra, India|Somani Hospital, Jaipur, Rajasthan, India|Meenakshi Mission Hospital, Madurai, Tamil Nadu, India|Apollo Gleneagles Hospital Limited, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT04297254"
697,"NCT03677596","A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",,"Active, not recruiting","No Results Available","Leukemia|Precursor b-Cell Lymphoblastic Leukemia-Lymphoma|ACUTE LYMPHOBLASTIC LEUKEMIA","Drug: inotuzumab ozogamicin-dose level 2|Drug: Inotuzumab ozogamicin-dose level 1","Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi])|Rate of veno-occlusive disease (VOD)|Frequency of adverse events|Minimal residual disease (MRD) negativity|Duration of remission (DoR) for Participants Who Achieved CR/CRi|Progression free survival (PFS)|Overall survival (OS)|Rate of hematopoietic stem cell transplantation (HSCT)|Post HSCT relapse|Post HSCT mortality|Post HSCT non relapse mortality|Post HSCT relapse related mortality|Pharmacokinetics, Cmax|Percentage of patients with positive anti-drug antibody response|Percentage of patients with laboratory abnormalities (NCI CTCAE grade)|Pharmacokinetics, Ctrough|Pharmacokinetics, Clearance|Pharmacokinetics, Area under the curve (AUC)","Pfizer","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","103","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1931030|2018-001557-27","July 1, 2019","September 14, 2022","September 22, 2023","September 19, 2018",,"March 11, 2022","Keck Hospital of USC-Norris Comprehensive Cancer Center (HC3), Los Angeles, California, United States|Keck Hospital of USC, Los Angeles, California, United States|LAC+USC Medical Center, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Maryland- Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States|Debreceni Egyetem Klinikai Központ, Orvosi Kepalkotó Klinika, Radiológia, Debrecen, Hungary|Debreceni Egyetem Klinikai Központ, Pathológiai lntézet, Debrecen, Hungary|Szabolcs-Szatmar Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Korhaz, Hematologia, Nyiregyhaza, Hungary|Artemis hospital, Gurugram, Haryana, India|Sahyadri Clinical Research and Development Centre, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital Nagar Road, Pune, Maharashtra, India|Sahyadri Super Speciality Hospital, Pune, Maharashtra, India|Christian Medical College, Vellore, Tamil Nadu, India|Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Instytut Hematologii i Transfuzjologii, Warsaw, Poland|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza - Radeckiego we Wroclawiu, Wroclaw, Poland|Apteka Centralna, Wroclaw, Poland|National University Hospital, Singapore, Singapore|Pharmacy @ NCIS, National University Hospital, Singapore, Singapore|Raffles Hospital, Singapore, Singapore|Raffles Radiology, Singapore, Singapore|Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Clinico Universitario de Valencia, Valencia, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Changhua Christian Hospital, Changhua, Taiwan|Clinical Research Pharmacy, Changhua Christian Hospital, Changhua, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Anadolu Health Center Hospital, Gebze, Istanbul, Turkey|Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Clinical Research Center, Ankara, Turkey|Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Hematology Department, Ankara, Turkey|Ankara University Faculty of Medicine Cebeci Hospital Hematology Department, Ankara, Turkey|Private Medstar Antalya Hosp. Hematology and Stem Cell Transplantation Center, Antalya, Turkey|Marmara University Pendik Training and Research Hospital Hematology Unit, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Medical Faculty, Izmir, Turkey|Medicalpark Izmir Hospital, Izmir, Turkey|Erciyes Universitesi Tip Fakultesi Hastaneleri, Kayseri, Turkey|Ondokuz Mayis University Faculty Of Medicine Hospital, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT03677596"
698,"NCT03452137","A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck",,"Active, not recruiting","No Results Available","Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)","Drug: Atezolizumab|Drug: Placebo","Investigator-assessed Event Free Survival (EFS)|Overall Survival (OS) after Randomization|Independent Review Facility-assessed Event Free Survival (IRF-assessed EFS)|Change from baseline in physical function and Quality of Life Global Health Status/Quality of Life Scales of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire|Percentage of Participants with Adverse Events|Serum Concentration of Atezolizumab|Incidence of ADA Response to Atezolizumab","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","406","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WO40242|2017-003302-40","April 3, 2018","September 3, 2023","July 3, 2026","March 2, 2018",,"March 2, 2022","City of Hope National Medical Center, Duarte, California, United States|University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States|UCLA Hematology/Oncology, Santa Monica, California, United States|Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States|Woodlands Medical Specialists, P.A., Pensacola, Florida, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital, Marietta, Georgia, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Billings Clinic Research Center, Billings, Montana, United States|Cleveland Clinic; Taussig Cancer Institute, Cleveland, Ohio, United States|Blue Ridge Cancer Care, Roanoke, Virginia, United States|St George Hospital, Kogarah, New South Wales, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Clinique Ste-Elisabeth, Namur, Belgium|Santa Casa de Misericordia de Salvador, Salvador, BA, Brazil|Hospital do Cancer de Pernambuco - HCP, Recife, PE, Brazil|Instituto Nacional de Cancer - INCa; Oncologia, Rio de Janeiro, RJ, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre, RS, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Cancer Care Manitoba, Winnipeg, Manitoba, Canada|London Health Sciences Centre, London, Ontario, Canada|Beijing Cancer Hospital, Beijing, China|West China Hospital, Sichuan University, Chengdu, China|Fujian Cancer Hospital, Fuzhou, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou City, China|Fudan University Shanghai Cancer Center, Shanghai City, China|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China|Shanghai East Hospital, Shanghai, China|Tianjin Medical University General Hospital, Tianjin, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|Zhejiang Cancer Hospital, Zhejiang, China|Institut Sainte Catherine, Avignon, France|Centre Georges Francois Leclerc, Dijon, France|CENTRE LEON BERARD; Département d'Hématologie et d'Oncologie, Lyon, France|Hopital Timone Adultes; Oncologie Medicale Et Usp, Marseille, France|ICM; Radiotherapie, Montpellier Cedex 5, France|Hopital Tenon; Oncologie Radiotherapie, Paris, France|CHU Bordeaux, Pessac, France|Hôpitaux D'Instruction Des Armees Begin, St Mande, France|Gustave Roussy Cancer Campus; Radiotherapie, VILLEJUIF Cedex, France|Universitätsklinikum Bonn; Med. Klinik und Poliklinik III; Hämatologie, Onkologie und Rheumatologie, Bonn, Germany|Universitätsklinikum Freiburg, Klinik für Strahlenheilkunde, Freiburg, Germany|Klinikum d. Uni. München; Campus Großhadern; Klinik und Poliklinik f. Strahlenthera. und Radioonko, München, Germany|Universitätsmedizin Rostock, Klinik und Poliklinik für Strahlentherapie; Zentrum für Radiologie, Rostock, Germany|Orszagos Onkologial Intezet; Onkologiai Osztaly X, Budapest, Hungary|Uzsoki Utcai Korhaz, Budapest, Hungary|Pécsi Tudományegyetem; Klinikai Központ Onkoterápiás Intézet, Pécs, Hungary|Medanta-The Medicity, Gurgaon, Haryana, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Istituto Nazionale Tumori Fondazione G. Pascale; S.C. Oncol. Medica Testa-Collo e Sarcoma, Napoli, Campania, Italy|Ospedale Umberto I ASL di Ravenna Presidio Ospedaliero di Lugo, Lugo, Emilia-Romagna, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche, Roma, Lazio, Italy|Ospedale Civile; Servizio Oncologia, Savona, Liguria, Italy|Spedali Civili di Brescia, Brescia, Lombardia, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori;S.S. Trattamento MedicoTumori dellaTesta e delCollo, Milano, Lombardia, Italy|Asst Santi Paolo E Carlo; Unita Operativa Di Oncologia Medica, Milano, Lombardia, Italy|Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia, Rozzano, Lombardia, Italy|Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia, Firenze, Toscana, Italy|IOV - Istituto Oncologico Veneto IRCCS, Padova, Veneto, Italy|Aichi Cancer Center Hospital, Aichi, Japan|National Cancer Center Hospital East, Chiba, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe University Hospital, Hyogo, Japan|Miyagi Cancer Center, Miyagi, Japan|Okayama University Hospital, Okayama, Japan|Osaka International Cancer Institute, Osaka, Japan|Shizuoka Cancer Center, Shizuoka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Jikei University Hospital, Tokyo, Japan|Tokyo Medical and Dental University Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Tokyo Medical University Hospital, Tokyo, Japan|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdańsk, Poland|Narodowy Inst.Onkol.im.Sklodowskiej-Curie Panstw.Inst.Bad Gliwice; III Klin. Radioter. i Chemioter., Gliwice, Poland|Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowotworów Głowy i Szyi, Warszawa, Poland|IPO de Coimbra; Servico de Oncologia Medica, Coimbra, Portugal|Hospital de Santa Maria; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Moscow City Oncology Hospital #62, Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation|Main Military Clinical Hospital named after N.N. Burdenko, Moscow, Moskovskaja Oblast, Russian Federation|First MSMU n.a. Sechenov Univercity Hospital 1; Plastic surgery, Moskva, Moskovskaja Oblast, Russian Federation|FSAI Treatment and rehabilitation Centre Ministry of Health; Clinical research and chemotherapy., Moskva, Moskovskaja Oblast, Russian Federation|Sverdlovsk Regional Oncology Dispensary; Chemotherapy, Ekaterinburg, Russian Federation|Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky; Chemotherapy, Krasnoyarsk, Russian Federation|P.A. Herzen Oncological Inst. ; Oncology, Moscow, Russian Federation|Novosibirsk Regional Oncological Dispancer, Novosibirsk, Russian Federation|BHI of Omsk region Clinical Oncology Dispensary, Omsk, Russian Federation|S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint-Petersburg, Russian Federation|Tomsk scientific research institute of oncology SO RAMN, PAD; Pathological, Tomsk, Russian Federation|Tygerberg Hospital; Oncology Dept, Cape Town, South Africa|GVI Oncology Outeniqua Unit; GVI Oncology Outeniqua Unit, George, South Africa|The Oncology Centre; Haematology - Radiation Oncology, Mayville, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Badalona, Barcelona, Spain|Insititut Catala D'Oncologia, Hospitalet de Llobregat, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Univ. Nuestra Señora de Valme; Servicio de Oncologia, Sevilla, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, Spain|China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H, Taichung, Taiwan|Taichung Veterans General Hospital; Radiation Oncology, Taichung, Taiwan|National Cheng Kung University Hospital; Oncology, Tainan, Taiwan|Division of Hematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan|National Taiwan University Hospital; Oncology, Zhongzheng Dist., Taiwan|Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc, Bangkok, Thailand|Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok, Thailand|Songklanagarind Hospital; Department of Oncology, Songkhla, Thailand|Hacettepe Universitesi Tip Fakultesi Hastanesi; Ic Hastaliklari Anabiim Dali, Ankara, Turkey|Dr. Abdurrahman Yurtarslan Oncology Hospital; 2nd Oncology Clinic, Ankara, Turkey|Gazi University Medical Faculty, Oncology Hospital, Ankara, Turkey|Medikal Park Izmir Hospital, Karşıyaka, Turkey|Municipal Noncommercial Institution Regional Center of Oncology, Kharkiv, Kharkiv Governorate, Ukraine|Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsya, Podolia Governorate, Ukraine|Ivano-Frankivsk Regional Oncology Center, Ivano-Frankivsk, Ukraine|Kyiv City Clinical Oncological Center, Day Hospital Department for Oncological patients, Kiev, Ukraine|ME Kryviy Rih Oncology Dispensary of Dnipropetrovs'k Regional Council; Chemotherapy Department, Kryvyi Rih, Ukraine|Lviv State Oncology Regional Treatment and Diagnostic Centre; Department of hemotherapy, Lviv, Ukraine|RCI Sumy Regional Clinical Oncological Dispensary, Sumy, Ukraine|Aberdeen Royal Infirmary; Medical Oncology Dept, Aberdeen, United Kingdom|Velindre Cancer Centre, Cardiff, United Kingdom|The Royal Marsden Hospital, Fulham, London, United Kingdom|Derriford Hospital, Plymouth, United Kingdom|Royal Marsden NHS Foundation Trust, Sutton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03452137"
699,"NCT02747043","Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","JASMINE","Completed","Has Results","Lymphoma, Non-Hodgkin","Biological: ABP 798|Biological: Rituximab","Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease|Percentage of Participants Who Responded (Overall Response Rate - ORR) at Week 12 Based on Independent Central Assessment of Disease|Pharmacokinetic Serum Concentrations by Visit|Percentage of Participants With Complete Depletion of Clusters of Differentiation 19-Positive (CD19+) Cell Count From Baseline to Day 8|Total Immunoglobulin G (IgG) Results by Visit|Total Immunoglobulin M (IgM) Results by Visit|Participants With Treatment-Emergent Adverse Events|Percentage of Participants With Treatment-emergent Adverse Events of Interest (AEOIs)|Number of Participants Who Developed Anti-drug Antibodies|Participants' Progression-Free Survival (PFS) Status Based on the Independent Central Assessment of Disease|Percentage of Participants Who Survived -- Overall Survival (OS)","Amgen","All","18 Years and older   (Adult, Older Adult)","Phase 3","256","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20130109|2013-005542-11","May 25, 2016","June 28, 2019","June 28, 2019","April 21, 2016","August 18, 2020","August 18, 2020","Research Site, Encinitas, California, United States|Research Site, Mount Sterling, Kentucky, United States|Research Site, Billings, Montana, United States|Research Site, Zanesville, Ohio, United States|Research Site, Roanoke, Virginia, United States|Research Site, Gosford, New South Wales, Australia|Research Site, Frankston, Victoria, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Plovdiv, Bulgaria|Research Site, Stara Zagora, Bulgaria|Research Site, Windsor, Ontario, Canada|Research Site, Medellin, Antioquia, Colombia|Research Site, Bogota, Cundinamarca, Colombia|Research Site, Praha 5, Praha, Czechia|Research Site, Ostrava - Poruba, Severomoravsky KRAJ, Czechia|Research Site, Bordeaux Cedex, Aquitaine, France|Research Site, Clermont Ferrand, Auvergne, France|Research Site, Cesson-Sevigne, Bretagne, France|Research Site, Boulogne sur Mer, NORD Pas-de-calais, France|Research Site, La Rochelle, Poitou-charentes, France|Research Site, Poitiers Cedex, Poitou-charentes, France|Research Site, Batumi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Tbilisi, Georgia|Research Site, Freiburg, Baden-wuerttemberg, Germany|Research Site, Augsburg, Bayern, Germany|Research Site, Würzburg, Bayern, Germany|Research Site, Kassel, Hessen, Germany|Research Site, Münster, Nordrhein-westfalen, Germany|Research Site, Leipzig, Sachsen, Germany|Research Site, Flensburg, Schleswig-holstein, Germany|Research Site, Athens, Attica, Greece|Research Site, Athens, Attica, Greece|Research Site, Patra, Peloponnese, Greece|Research Site, Surat, Gujarat, India|Research Site, Vadodara, Gujarat, India|Research Site, Bangalore, Karnataka, India|Research Site, Mangalore, Karnataka, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Bikaner, Rajasthan, India|Research Site, Be'er Ya'akov, Rehoboth, Israel|Research Site, San Giovanni Rotondo, Foggia, Italy|Research Site, Bergamo, Lombardia, Italy|Research Site, Pesaro, Pesaro E Urbino, Italy|Research Site, Aviano, Pordenone, Italy|Research Site, Candiolo, Torino, Italy|Research Site, Brescia, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Padova, Italy|Research Site, Parma, Italy|Research Site, Ravenna, Italy|Research Site, Rimini, Italy|Research Site, Terni, Italy|Research Site, Chiba-city, Chiba, Japan|Research Site, Fukuoka-shi, Fukuoka, Japan|Research Site, Maebashi-city, Gunma, Japan|Research Site, Kobe-city, Hyogo, Japan|Research Site, Tsu, MIE, Japan|Research Site, Utsunomiya City, Tochigi, Japan|Research Site, Tachikawa-city, Tokyo, Japan|Research Site, Tokyo, Japan|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Seoul, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Gyeongsangnam-do, Korea, Republic of|Research Site, Jinju-si, Gyeongsangnam-do, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Ulsan, Korea, Republic of|Research Site, Mexico City, Distrito Federal, Mexico|Research Site, Chihuahua, Mexico|Research Site, Legnica, Dolnoslaskie, Poland|Research Site, Toruń, Kujawsko-pomorskie, Poland|Research Site, Kraków, Malopolskie, Poland|Research Site, Gdańsk, Pomorskie, Poland|Research Site, Targu-Mures, Mures, Romania|Research Site, Targu-Mures, Mures, Romania|Research Site, Timisoara, Timis, Romania|Research Site, Bucuresti, Romania|Research Site, Sabadell, Barcelona, Spain|Research Site, Córdoba, Cordoba, Spain|Research Site, Majadahonda, Madrid, Spain|Research Site, La Laguna Tenerife, Santa CRUZ DE Tenerife, Spain|Research Site, Barcelona, Spain|Research Site, Caceres, Spain|Research Site, Cadiz, Spain|Research Site, Madrid, Spain|Research Site, Salamanca, Spain|Research Site, Kyiv, Kiev, Ukraine|Research Site, Kyiv, Kiev, Ukraine|Research Site, Uzhgorod, Transcarpathia, Ukraine|Research Site, Chernivtsi, Ukraine|Research Site, Dnipropetrovsk, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02747043/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/43/NCT02747043/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02747043"
700,"NCT05239507","OREIOS International Study","OREIOS","Recruiting","No Results Available","Hepatocellular Carcinoma",,"To describe the OS rate in patients with unresectable HCC including estimates of survival rates at 6, 12, and 18 months and at 2 years|To describe the management patterns in patients with unresectable HCC|To describe the demographic and clinical characteristics of patients with unresectable HCC","AstraZeneca","All","Child, Adult, Older Adult",,"1440","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","D419CR00025","February 1, 2022","August 31, 2022","August 31, 2022","February 15, 2022",,"May 10, 2022","Research Site, Alexandira, Egypt|Research Site, Cairo, Egypt|Research Site, Menufia, Egypt|Research Site, Faridabad, India|Research Site, Howrah, India|Research Site, Kolkata, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India|Research Site, New Delhi, India|Research Site, Chelyabinsk, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Makkah, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT05239507"
701,"NCT01031069","Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females",,"Completed","Has Results","Infections, Papillomavirus|Papillomavirus Vaccines","Biological: GSK Biologicals' HPV vaccine 580299|Biological: Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)","Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms|Number of HIV+ Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of HIV+ Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)|Number of HIV+ Subjects With Serious Adverse Events (SAEs)|Number of HIV+ Subjects With Medically Significant Conditions (MSCs)|Number of HIV+ Subjects With Potential Immune-mediated Diseases (pIMDs)|Number of HIV+ Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies|Number of HIV+ Subjects With Haematological and Biochemical Parameter Abnormalities|Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Month 7|HIV Viral Load (VL) in HIV+ Subjects at Month 7|Number of HIV+ Subjects by World Health Organization (WHO) HIV Clinical Staging|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Adapted According-to-protocol (ATP) Cohort for Immunogenicity|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV+ Subjects, Based on Total Vaccinated Cohort (TVC)|Number of HIV- Subjects With Any and Grade 3 Solicited Local Symptoms|Number of HIV- Subjects With Any, Grade 3 and Related Solicited General Symptoms|Number of HIV- Subjects With Unsolicited Adverse Events (AEs)|Number of HIV- Subjects With Serious Adverse Events (SAEs)|Number of HIV- Subjects With Medically Significant Conditions (MSCs)|Number of HIV- Subjects With Potential Immune-mediated Disease (pIMDs)|Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies|Number of Subjects With Relevant Abnormalities in Alanine Aminotransferase, Basophils, Creatinine and Eosinophils Parameters|Number of Subjects With Relevant Abnormalities in Haematocrit, Haemoglobin, Lymphocytes and Monocytes Parameters|Number of Subjects With Relevant Abnormalities in Neutrophils, Platelets, Red Blood Cells and White Blood Cells Parameters|Number of Subjects With SAEs|Number of Subjects With Medically Significant Conditions (MSCs)|Number of Subjects With Potential Immune-mediated Diseases (pIMDs)|Cluster of Differentiation 4 (CD4+) Cell Count in HIV+ Subjects at Months 12, 18 and 24|HIV Viral Load (VL) in HIV+ Subjects at Months 12, 18 and 24|Number of HIV+ Subjects by WHO HIV Clinical Staging|Pseudovirion-Based Neutralization Assay (PBNA) Titers of Anti-HPV-16/18 Antibodies in HIV- Subjects, Based on TVC|Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by Enzyme-linked Immunosorbent Assay (ELISA) in Serum|Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations by ELISA in Cervicovaginal Secretion (CVS)|Frequency of Specific B-cells for HPV-16/18 Antigens|Frequency of Cluster of Differentiation 4/8 [CD4+/CD8+] T-cell Response","GlaxoSmithKline","Female","15 Years to 25 Years   (Child, Adult)","Phase 4","873","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","109823|2013-003429-28","October 26, 2010","January 13, 2016","April 19, 2017","December 14, 2009","July 24, 2019","July 21, 2020","GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Ribeirão Preto, São Paulo, Brazil|GSK Investigational Site, Campinas, Brazil|GSK Investigational Site, Rio de Janeiro, Brazil|GSK Investigational Site, São Paulo, Brazil|GSK Investigational Site, Kohtla-Järve, Estonia|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Chennai, India|GSK Investigational Site, Kolkata, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Bangkok, Thailand|GSK Investigational Site, Chiangmai, Thailand|GSK Investigational Site, Khon Kaen, Thailand",,"https://ClinicalTrials.gov/show/NCT01031069"
702,"NCT00502307","A Study of Tivozanib (AV-951), an Oral VEGF Receptor Tyrosine Kinase Inhibitor, in the Treatment of Renal Cell Carcinoma",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Tivozanib (AV-951)|Drug: Placebo comparator","Number of Subjects With Adverse Events (AEs)/Serious AEs (SAEs)|Objective Response [Complete Response (CR) + Partial Response (PR)] Rate at 16 Week Open-Label Period (All Treated Population)|Percentage of Randomly Assigned Subjects Remaining Progression Free at 12 Weeks Following Random Assignment to Tivozanib (AV-951) or Placebo|Number of Subjects With Progression Free-survival (PFS) After Random Assignment (Randomized Sub-set Only) (at 12 Weeks Post Randomization )|Overall Progression-free Survival (From Start of Treatment)|Time to Peak Plasma Concentration (Tmax) of Tivozanib in a Subset of Subjects|Maximum Observed Serum Concentration During a Dosing Interval at Steady State (Cmax)|Area Under the Serum Concentration Versus Time Curve From Zero to the Last Quantifiable Sampling Point [AUC(0→24)]","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","272","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AV-951-07-201","October 2007","August 2010","August 2010","July 17, 2007","September 1, 2020","September 1, 2020","Vellore, Tamil Nadu, India|Kolkata, India|Mumbai, India|New Delhi, India|Pune, India|Astrakhan, Russian Federation|Ioshkar-Ola, Russian Federation|Kazan, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Moscow, Russian Federation|Novgorod, Russian Federation|Obninsk, Russian Federation|Pyatigorsk, Russian Federation|Rostove-on-Don, Russian Federation|Sochi, Russian Federation|St. Petersburg, Russian Federation|Tomsk, Russian Federation|Ufa, Russian Federation|Cherkassy, Ukraine|Dnepropetrovsk, Ukraine|Donetsk, Ukraine|Kharkov, Ukraine|Lviv, Ukraine|Uzhgorod, Ukraine|Zaporizzhya, Ukraine",,"https://ClinicalTrials.gov/show/NCT00502307"
703,"NCT05043090","Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC","SAMETA","Recruiting","No Results Available","Papillary Renal Cell Carcinoma","Drug: savolitinib|Drug: durvalumab|Drug: sunitinib","Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to sunitinib|Overall Survival (OS) /savolitinib plus durvalumab relative to sunitinib|Objective Response Rate (ORR) / savolitinib plus durvalumab relative to sunitinib|Duration of Response (DoR) / savolitinib plus durvalumab relative to sunitinib|Disease Control Rate (DCR) at 24 and 48 weeks /savolitinib plus durvalumab relative to sunitinib|Time from randomisation to second progression or death (PFS2) /savolitinib plus durvalumab relative to sunitinib|Assessment of patient-reported symptoms, functioning, and HRQoL /savolitinib plus durvalumab relative to sunitinib|Objective Response Rate (ORR) / savolitinib plus durvalumab relative to durvalumab monotherapy|Duration of Response (DoR) / savolitinib plus durvalumab relative to durvalumab monotherapy|Progression-Free Survival (PFS) /savolitinib plus durvalumab relative to durvalumab monotherapy|Evaluation of the PK of savolitinib pre-dose|Evaluation of the PK of savolitinib post-dose|Evaluation of the PK of durvalumab pre-dose|Evaluation of the PK of durvalumab / Cmax (maximum plasma concentration)","AstraZeneca","All","18 Years to 130 Years   (Adult, Older Adult)","Phase 3","220","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D5086C00001|2021-000336-55","October 28, 2021","March 28, 2024","June 9, 2025","September 13, 2021",,"April 20, 2022","Research Site, Whittier, California, United States|Research Site, Gurnee, Illinois, United States|Research Site, Boston, Massachusetts, United States|Research Site, New York, New York, United States|Research Site, Syracuse, New York, United States|Research Site, Bahía Blanca, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Caba, Argentina|Research Site, Cordoba, Argentina|Research Site, La Plata, Argentina|Research Site, Rosario, Argentina|Research Site, San Miguel de Tucuman, Argentina|Research Site, Box Hill, Australia|Research Site, Macquarie University, Australia|Research Site, Malvern, Australia|Research Site, St Leonards, Australia|Research Site, Belo Horizonte, Brazil|Research Site, Brasilia, Brazil|Research Site, Cachoeiro De Itapemirim, Brazil|Research Site, Criciuma, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianopolis, Brazil|Research Site, Fortaleza, Brazil|Research Site, Natal, Brazil|Research Site, Pelotas, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Salvador, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, São Jose do Rio Preto, Brazil|Research Site, Săo Paulo, Brazil|Research Site, Vitoria, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Providencia, Chile|Research Site, Santiago, Chile|Research Site, Santiago, Chile|Research Site, Temuco, Chile|Research Site, Brno, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Olomouc, Czechia|Research Site, Praha 10, Czechia|Research Site, Praha 5, Czechia|Research Site, Praha 8, Czechia|Research Site, Praha, Czechia|Research Site, Bordeaux, France|Research Site, Nice, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, München, Germany|Research Site, Tübingen, Germany|Research Site, Ulm, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Shatin, Hong Kong|Research Site, Bangalore, India|Research Site, Belagavi, India|Research Site, Jaipur, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, Mysore, India|Research Site, Nashik, India|Research Site, Ashdod, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Jerusalem, Israel|Research Site, Petah Tikva, Israel|Research Site, Rehovot, Israel|Research Site, Safed, Israel|Research Site, Tel-Aviv, Israel|Research Site, Arezzo, Italy|Research Site, Avellino, Italy|Research Site, Bari, Italy|Research Site, Firenze, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Milan, Italy|Research Site, Padova, Italy|Research Site, Reggio Emilia, Italy|Research Site, Tricase (Lecce), Italy|Research Site, Verona, Italy|Research Site, Daejeon, Korea, Republic of|Research Site, Goyang-si, Korea, Republic of|Research Site, Incheon, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Aguascalientes, Mexico|Research Site, Cancún, Mexico|Research Site, Monterrey, Mexico|Research Site, México, Mexico|Research Site, Queretaro, Mexico|Research Site, Toluca De Lerdo, Mexico|Research Site, Amsterdam, Netherlands|Research Site, Arnhem, Netherlands|Research Site, Rotterdam, Netherlands|Research Site, Gdansk, Poland|Research Site, Gdynia, Poland|Research Site, Kraków, Poland|Research Site, Otwock, Poland|Research Site, Poznan, Poland|Research Site, Warsaw, Poland|Research Site, Baia Mare, Romania|Research Site, Cluj Napoca, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Constanta, Romania|Research Site, Craiova, Romania|Research Site, Craiova, Romania|Research Site, Iasi, Romania|Research Site, Arkhangelsk, Russian Federation|Research Site, Ekaterinburg, Russian Federation|Research Site, Krasnoyarsk, Russian Federation|Research Site, Kursk, Russian Federation|Research Site, Kuzmolovskiy, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, St-Petersburg, Russian Federation|Research Site, Singapore, Singapore|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Barcelona, Spain|Research Site, Cordoba, Spain|Research Site, Coruña, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Majadahonda, Spain|Research Site, Málaga, Spain|Research Site, Pamplona, Spain|Research Site, Sabadell, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Kaohsiung City, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Ankara, Turkey|Research Site, Edirne, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Istanbul, Turkey|Research Site, Izmir, Turkey|Research Site, Karsiyaka, Turkey|Research Site, Kazımkarabekir, Turkey|Research Site, Chernivtsі, Ukraine|Research Site, Dnipropetrovsk, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Poltava, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Zaporizhzhia, Ukraine|Research Site, Leicester, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05043090"
704,"NCT00312845","Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",,"Completed","Has Results","Non-Hodgkin's Lymphoma","Drug: Bortezomib + Rituximab|Drug: Rituximab","Progression Free Survival|Overall Response Rate","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","All","18 Years and older   (Adult, Older Adult)","Phase 3","676","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26866138-LYM-3001","March 2006","June 2010","July 2010","April 11, 2006","July 26, 2011","June 25, 2012","East Alabama Medical Center, Opelika,, Alabama, United States|Central Hematology Oncology Medical Group, Inc, Alhambra, California, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Providence Saint Joseph Medical Center, Burbank, California, United States|St. Jude Heritage Medical Group, Fullerton, California, United States|Wilshire Oncology Medical Group, Inc., La Verne, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles, Los Angeles, California, United States|North Valley Hematology Oncology, Mission Hills, California, United States|University of California, Irvine Medical Center, Orange, California, United States|Ventura County Hematology-Oncology Specialists, Oxnard, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Norwalk Medical Group, Norwalk, Connecticut, United States|Hematology Oncology PC, Stamford, Connecticut, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|Innovative Clinical Research of South Florida, Miami, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory Univeersity ,Winship Cancer Institute, Atlanta, Georgia, United States|Suburban Hematology-Oncology Associates, Lawrenceville, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|North Idaho Cancer Center, Coeur D Alene, Idaho, United States|Investigative Clinical Research of Indiana, Indianapolis, Indiana, United States|Siouxland Hematolgoy-Oncology Associates, Sioux City, Iowa, United States|Kansas City Cancer Center, LLC, Kansas City, Kansas, United States|Louisville Oncology, Louisville, Kentucky, United States|Hematology & Oncology Specialists, Metairie, Louisiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Hattiesburg Clinic, Hattesburg, Missouri, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Lancaster Cancer Center, Ltd., Lancaster, Pennsylvania, United States|The Western Pennsylvania Hospital, Pittsburg, Pennsylvania, United States|South Carolina Oncology Associates, PA, Columbia, South Carolina, United States|South Carolina Oncology Associates, Columbia, South Carolina, United States|Vanderbilt University, Nashville, Tennessee, United States|The Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Oncology Consultants, Houston, Texas, United States|South Texas Oncology and Hematology, San Antonio, Texas, United States|Medical College of Wisconsin Milwaukee, Milwaukee, Wisconsin, United States|Higa San Martin, La Plata - Buenos Aires, Argentina|Hospital Professor Rodolfo Rossi, La Plata - Buenos Aires, Argentina|Centro Oncologico Integracion Regional, Mendoza, Argentina|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Institute, East Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Fremantle Hospital, Fremantle, Western Australia, Australia|ULB Erasme, Anderlecht, Belgium|AZ Stuivenberg, Antwerpen, Belgium|AZ Sint Jan, Brugge, Belgium|Institute J. Bordet, Bruxelles, Belgium|Clinique Notre Dame, Charleroi, Belgium|UZ Antwerpen - Universitair Ziekenhuis Antwerpen, Edegem, Belgium|UZ Gent - Universitair Ziekenhuis Gent, Gent, Belgium|Virga Jesse Ziekenhuis, Dienst Hematologie, Hasselt, Belgium|CHR La Citadelle, Liege, Belgium|CHU Sart Tilman, Liege, Belgium|Heilig Hart Roeselare, Roeselare, Belgium|Servico de Oncologia do Hospital Sao Lucas da PUC do rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil|Instituto Nacional de Cancer, Rio de Janeiro, Brazil|Hospital Brigadeiro, Sao Paulo, Brazil|Faculdade de Medicina do ABC, Sao Paulo, Brazil|Toronto Sunnybrook Regional Cancer Centre, Toronto, Ontario, Canada|University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada|Juravinski Cancer Centre, Hamilton, Canada|West China Hospital of Sichuan, Chengdu, Sichuan, China|Cancer Hospital (Institute), CAMS&PUMC, Beijing, China|Beijing Cancer Hospital, Beijing, China|Peking University People's Hospital, Beijing, China|Affiliated Hospital of the Academy of Military Medical Sciences, Beijing, China|Cancer Center, Sun Yat-Sen University, Guangzhou, China|Peking University Third Hospital, Haidian District Beijing, China|RuiJin Hospital, Shanghai, China|Cancer Hospital - FuDan University, Shanghai, China|Bank of Cyprus Oncology Centre, Nikosia, Cyprus|Fakultni nemocnice Brno, Brno, Czech Republic|Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czech Republic|Fakultni nemocnice Olomouc, Olomouc, Czech Republic|Vseobecna Fakultni Nemocnice, Praha, Czech Republic|Paijat - Hameen Keskussairaala, Lahti, Finland|Satakunnan Keskussairaala, Pori, Finland|Institut Bergonie, Bordeaux, France|Clinique Victor Hugo, Le Mans, France|Hopital Claude Huriez, Lille, France|Centre Léon Bérard, Lyon, France|Hopital Hotel Dieu, Nantes, France|Service des Maladies due sang - Hopital haut Leveque, Pessac, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Onkologische Schwerpunktpraxis, Herrsching, Germany|Universitatsklinikum Munster - Klinik fur Innere Medizin, Munster, Germany|Praxis für Hämetologie und Oncologie, Würzburg, Germany|Laiko General Hospital of Athens - 1st Internist Clinic - Hematology Department, Athens, Greece|University General Hospital Attikon - 2nd Department of Internal Medicine - Propedeutic & Research Institute, Athens, Greece|University Hospital of Patras - Department of Internal Medicine - Hematology Division, Rio Patras, Greece|Debreceni Egyetem, Orvos- es Egeszsegtudomanyl Centrum, iii. Belgyogyaszati Klinika, Debrecen, Hungary|Petz Aladar County Hospital, Gyor, Hungary|SZEgedi Tudomanyegyetem, II Belgyaszati Klinika, Szeged, Hungary|Institution Manipal Hospital, Bangalore, India|Postgraduate Institute of Medical Education and Research, Chandigarh, India|Apollo Speciality Hospital, Chennai, India|Nizam's Institute of Medical Sciences, Hyderabaad, India|SMS Medical College Hospital, Jaipur, India|Apollo Hospitals, Hyderabad Apollo Hospital Complex, Jubilee Hills, India|Shirdi Saibaba Cancer Hospital, Karnataka, India|Department of Medical Oncology - Regional Cancer Centre, Kerala, India|Regional Cancer Centre, Kerala, India|Tata Memorial Centre, Mumbai, India|Soroka Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Sorraski Tel Aviv Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel HaShomer, Israel|Azienda Ospedaliero Universitaria di Bologna, Bologna, Italy|Universita degli Studi di Perugia, Perugia, Italy|Azienda Ospedallera Universitaria Policlinico Tor Vergata, Roma, Italy|Azienda Sanitaria Ospedaliera Molinette S. Giovanni Battista, Torino, Italy|Lung Cancer Center - National Cancer Center, Gyeonggi-Do, Korea, Republic of|Samsung Medical Center - Division of Hematology-Oncology, Department of Medicine, Ilmon-Dong, Kangnam-Ku, Seoul, Korea, Republic of|Hematology-Oncology Clinic, Center for Specific Organs Cancer - National Cancer Center, Ilsandong-Gu, Goyang-Si, and Gyeonggi-Do, Korea, Republic of|Samsung Medical Center - Department of Internal Medicine, Ilwon dong, Kangnam-Ku, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Instituto Nacional De Ciencias Medicas Y Nutricion Salvador Zubiran, Delagacion Tlalpan, Mexico|Instituto Nacional De Cancerologia Incan, Delagacion Tlalpan, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez UANL, Monterrey, Nuevo leon, Mexico|Canterbury Health Laboratories, Christchurch, New Zealand|Klinika Hematologii Instytut Chorob Wewnetrznych, Gdansk, Poland|Klinika Hematologii CMUJ, Krakow, Poland|Klinika Hematologii - Uniwersytetu Medycznego, Lodz, Poland|Klinika Hematologii i Transplantologii Szpiku AM, Lublin, Poland|Wojskowy Instytut Medyczny - Klinika Hematologii, Warsawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Klinika Hematologii AM, Warszawa, Poland|Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Katedra i Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku, Wroclaw, Poland|Servico de Hematologia - Hospital de Dia - Hospital Da Universidade de Coimbra, Coimbra, Portugal|Instituto Portugues de Oncologia de Lisboa Francisco Gentil, E.P.E. - Departmento de Hematologia, Lisboa, Portugal|Hospital de Dia de Hematologia - Hospital de Santa Maria E.P.E., Lisboa, Portugal|Serviço de Onco-hematologia, Instituto Português de Oncologia do Porto Franscisco Gentil, EPE, Porto, Portugal|San Juan VA Medical Center, San Juan, Puerto Rico|Spitalul clinic de urgenta, Brasov, Romania|Institutul Clinic Fundeni Clinica de Hematologie, Bucuresti, Romania|Spitalul Universitar de Urgenta Hematologie, Bucuresti, Romania|Spitalul Clinic judetean de urgenta ""Sf. Spiridon, Clinica Hematologie, Iasi, Romania|Spitalul Clinic judetean de urgenta Mures, Targu Mures, Romania|Arkhangelsk Region Clinical Hospital, Arghangelsk, Russian Federation|Altay Regional Oncology Dispensary, Barnaul, Russian Federation|Belgorod Regional Oncology Center, Belgorod, Russian Federation|Cheliabinsk Regional Oncology Dispensary, Cheliabinsk, Russian Federation|Ekaterinburg City Clinical Hospital #7, Ekaterinburg, Russian Federation|1st Republican Clinical Hospital of Udmurtia, Izhevsk, Russian Federation|Cancer Research Center, Moscow, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|Moscow Region Clinical Research Institute, Moscow, Russian Federation|Semashko Central Clinical Hospital #2, Moscow, Russian Federation|City Oncology Hospital #62, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation|Novosibirsk State Regional Clinical Hospital, Novosibirsk, Russian Federation|Novosibirsk State Medical University, Novosibirsk, Russian Federation|Medical Scientifical Radiology Center, Obninsk, Russian Federation|Republikan Hospital named after V.A. Baranov, Petrozavodsk, Russian Federation|Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|St. Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|St. Petersburg City Hospital #31, St. Petersburg, Russian Federation|Tomsk Research Oncology Institute, Tomsk, Russian Federation|Republican Clinical Hospital of Bashkorkostan, Ufa, Russian Federation|FN F.D. Roosevelt - Oddelenie hematologie, Banska Bysterica, Slovakia|Fakultna nemocnica L. Pasteura - Klinika hematologie a onkohematologie, Kosice, Slovakia|Vychodoslovensky Onkologicky Ustave, a.s., Kosice, Slovakia|Martinska FN, Klinika hematologie a transfuziologie, Martin, Slovakia|GVI Oncology Clinical Trial Unit, Panorama, Cape Town, South Africa|Mary Potter Oncology Centre - Little Company of Mary Hospital, Groenkloof, Pretoria, South Africa|Chris Hani Baragwanath Hospital, Johannesburg, South Africa|East Cape Oncology Centre - St. Georges Hospital, Port Elizabeth, South Africa|Hospital Durans I Reynals - Institut Catala d'Oncologia, Barcelona, Spain|Hospital Germans Trias i Pujol Institut Catala d'Oncologia, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Onkologiska kliniken Universitetssjukhuset, Lund, Sweden|Centrum for Hematologi Karolinska University Hospital, Stockholm, Sweden|Hematologiska kliniken M54 Karolinska University Hospital, Stockholm, Sweden|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Siriraj Hospital, Mahidol University, Bangkok, Thailand|Maharaj Nakorn Chiang Mai Hospital, Chiang Mai University, Chiang Mai, Thailand|Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine|Dnepropetrovsk Regional Clinical Oncology Dispensary, Dnepropetrovsk, Ukraine|Institute for Emergency and Urgent Medical Assistance named after V.K. Gusak of AMS of Ukraine, Donetsk, Ukraine|Khmelnitskiy Regional Hopsital, Khmelnitsky, Ukraine|Kiev Center of Marrow Transplantaion, Kiev, Ukraine|Krivoy Rog Oncology Dispensary, Krivoy Rog, Ukraine|Institute of Blood Pathology and Transfusional Medicine of AMS of Ukraine, Lviv Clinical Hospital #5, Lviv, Ukraine|Ukrainian Medical Stomatological Academy, Poltava Regional Dispensary, Poltava, Ukraine|Crimean Republic Clinical Oncology Dispensary, Simferopol, Ukraine|Zhitomir Gerbachevsky Regional Clinical Hospital, Zhitomir, Ukraine|Aberdeen Royal Infirmary - Department of Haematology, Aberdeen, United Kingdom|Addenbrooke's Hospital - Department of Haematology, Cambridge, United Kingdom|University Hospital of Wales, Cardiff, United Kingdom|Guy's & St. Thomas Hospital, London, United Kingdom|Derriford Hospital - Department of Haematology, Plymouth, United Kingdom|Taunton & Somerset Hospital, Taunton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00312845"
705,"NCT00088530","BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)",,"Completed","Has Results","Lymphoma, Non-Hodgkin","Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Drug: Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab","Complete Response (CR) and Complete Response Unconfirmed (CRu)|Progression-Free Survival (PFS)|Overall Survival|Overall Response Rate (ORR) Lasting at Least 4 Months","CTI BioPharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PIX301","July 2004","February 2010","July 2010","July 29, 2004","June 1, 2017","February 5, 2020","Robert A. Moss, M.D., FACP, Inc., Fountain Valley, California, United States|UCLA Medical Center, Los Angeles, California, United States|Watson Clinic for Cancer Care and Research, Lakeland, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|New Mexico Oncology/Hematology, Albuquerque, New Mexico, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Northwest Kaiser Permanente, Portland, Oregon, United States|Northern Utah Hematology Oncology, P.C., Ogden, Utah, United States|Clinica Modelo S.A., Parana, Entre Rios, Argentina|Instituto de Investigaciones Clinicas, Rosario, Santa Fe, Argentina|Centro Oncologico Rosario, Rosario, Santa Fe, Argentina|FUNDALEU - fundacion para combatir le Leucernia, Buenos Aires, Argentina|Hospital Universitario Austral, Buenos Aires, Argentina|Academia Nacional de Medicina, Caba, Argentina|Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|University Gernal Hospital for Active Treatment ""Alexandrovska"" - Clinic of Hematology, Sofia, Bulgaria|National Centre for Hemotransfusion, Sofia, Bulgaria|University General Hospital for Active Treatment ""St. Marina"" Clinic of Hematology, Varna, Bulgaria|Hospital CIMA San Jose, Escazu, Costa Rica|Hospital Oncologico de Solca, Capilla Mauta, Guayaquil, Ecuador|Hospital Carlos Andrade Marin Oncologia, Quito,, Pinchincha, Ecuador|Hospital Solca Quito, Quito, Ecuador|Tartu University Clinics, Hematology Oncology Clinic, Tartu, Estonia|Institute Bergonie, Bordeaux, France|Centre Hospitalier Lyo Sud, Service d'Hematologie et d'Oncologie, Pierre-Benite, France|Hopitaux Universitaires de Strabourg - Hopital de Hautepierre, Strasbourg, France|Staedtische Kliniken Hoechst, Frankfurt, HE, Germany|Charite, Campus Benjamin Franklin, Berlin, Germany|Universitatklinik des Saarlandes, Innere Medzin I, Hamburg, Germany|Westpfalzklinikum Kaiserslautern, Kaiserslautern, Germany|Klinikum der Universitaet zu Koeln, Koeln, Germany|Kliniken Maria Hilf GmbH, Moenchengladbach, Germany|Mutterhaus der Borromaeerinne, Trier, Germany|Szent Laszlo Korhaz, Budapest, Hungary|Petz Aladar Megyei Okato Korhaz, Gyor, Hungary|Bekes Megyei Pandy Kalman Korhaz, Gyula, Hungary|Kaposi Mor Megyei Korhaz, Kaposvar, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Orvos-es Gyogy II, Szeged, Hungary|Indo-American Cancer Institute & Research Center, Hyderabaad, AndhPrad, India|Nizam's Institute of Medical Sciences, Panjagutta, Hyderabad, India|Manipal Hospital, Bangalore, Karnataka, India|Shirdi Sai Baba Cancer Hospital, K.M.C. Manipal, Manipala, Karna, India|Regional Cancer Center, Thiruvananthapuram, Kerla, India|Bhagwan Mahaveer Cancer Hospital & Research Center, Jaipur, Rajasthan, India|M.S. Ramaiah Medical College, Bangalore, India|Tata Memorial Hospital, Mumbai, India|Policlinico S. Orsola, Instituto di Ematologia, Bologna, Italy|Ospedale Oncologico ""A. Businco"", Cagliari, Italy|Ospedale S. Martino, Genova, Italy|Universita degli Studi Perugia Policlinico Monteluce, Perugia, Italy|Azienda ospedaliera Pisana ""Santa Chiara"", Pisa, Italy|Azienda Ospedaliera Pisanan ""Santana Chiara"", Pisa, Italy|Ospedale Oncolgoico Regionale della Basilicata, Rionero in Vulture, Italy|Ospedale S. Eugenio, Roma, Italy|Universita La Sapienza, Roma, Italy|Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy|Policlinico S. Maria alle Scotte, Siena, Italy|Presidio San Giuseppe Moscati, Taranto, Italy|Ospedale Civile, Udine, Italy|Fundacion Centro De Investigacion, Medellin, Columbia, Mexico|Medical Solutions, Guatimala, Guatemala, Mexico|Complejo Hospitalario ""Arnulfo Arias Madrid, Panama, Panama|Hospital Edgardo Rebagliati Martins, Lima, Peru|Onococenter, San Borja, Peru|Klinika Hematologii, Onkologii i Chorob Wewnetrznych, Gdansk, Poland|Brasov Counthy Hospital, Brasov, Romania|Colentina Clinical Hospital Hem Dept, Bucharest, Romania|Fundei Clinical Institute, Bucharest, Romania|Prof. Dr. Ian Chiricuta, Institute of Oncology, Radiotheraphy, Cluj Napoca, Romania|Institutul Oncologic ""Ion Chiricuta"" Oncologie Medicala, Cluj-Napoca, Romania|Mures County Clinical Hospital, Targu Mures, Romania|State Medical Institution Altai Territorial Oncological Center, Barnaul, Russian Federation|State Medical Institution Replubican Oncological Center, Bashkortostan, Russian Federation|State Therapeutical & Prophlatic Institution: Cheylabinsk Regional Oncological Center, Chelyabinsk, Russian Federation|State Medical Institution, Irkutsk, Russian Federation|State Medical Institution: Clinical Oncological Center, Krasnodar, Russian Federation|Russian Oncological Research Center n.a. N.N. Blokhin, Moscow, Russian Federation|State Institution: Hematological Research Center under the Russian Academy of Medical Sciences, Moscow, Russian Federation|State Institution: Moscow Regional Research Clinical institute n.a. M.F., Moscow, Russian Federation|Semashko Central Clinical Hospital, Moscow, Russian Federation|Medical Radiological Research Center under the Russian academey of Medical Sciences, Obninsk, Russian Federation|Research Insitute of Hematology and Blood Transfusion, St. Petersburg, Russian Federation|St. Petersburg Pavlov State Medical Clinic of Intensive Care & Bone Marrow Transplantation, St. Petersburg, Russian Federation|St. Petersburg State Medical univ. n.a. I.P. Pavlov, St. Petersburg, Russian Federation|St. Petersburg State Medical Institution: Municipal Hospital #31, St. Petersburg, Russian Federation|Central Research Rontgenological and Radiological Institute, St. Petersburg, Russian Federation|State Research Institution: Research Institute of Oncology, St. Petersburg, Russian Federation|Institute of Clinical Radiology of the Research Center for Radiation Medicine under the UAMS, Kyiv, Ukraine|Kyiv Bone Marrow Transplantation, Kyiv, Ukraine|Institute of Blood Pathology & Transfusion Medicine under the UAMS, Lviv, Ukraine|Zhtomyr O.F. Gerbachevsky Regional Hospital, Zhytomyr, Ukraine|Beatson Oncology Centre, Western Infirmary, Glasgow, United Kingdom|St. Georges Hospital, London, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Hospital Maciel, Montevideo, Uruguay|Hospital Policial de Montevideo, Poblado Montevideo Chico, Uruguay",,"https://ClinicalTrials.gov/show/NCT00088530"
706,"NCT03298451","Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma","HIMALAYA","Recruiting","No Results Available","Hepatocellular Carcinoma","Drug: Durvalumab|Drug: Tremelimumab (Regimen 1)|Drug: Tremelimumab (Regimen 2)|Drug: Sorafenib|Drug: Durvalumab (Regimen 1)|Drug: Durvalumab (Regimen 2)","Overall Survival (OS)|Time to Progression (TTP)|Progression-free survival (PFS)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)","AstraZeneca","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 3","1504","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D419CC00002","October 11, 2017","August 27, 2021","August 27, 2024","October 2, 2017",,"April 29, 2022","Research Site, Los Angeles, California, United States|Research Site, Orange, California, United States|Research Site, San Francisco, California, United States|Research Site, Washington, District of Columbia, United States|Research Site, Fort Myers, Florida, United States|Research Site, Jacksonville, Florida, United States|Research Site, Westwood, Kansas, United States|Research Site, Baltimore, Maryland, United States|Research Site, Ann Arbor, Michigan, United States|Research Site, Rochester, Minnesota, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Portland, Oregon, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Murray, Utah, United States|Research Site, Barretos, Brazil|Research Site, Curitiba, Brazil|Research Site, Florianopolis, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Kingston, Ontario, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Sherbrooke, Quebec, Canada|Research Site, Beijing, China|Research Site, Beijing, China|Research Site, Changchun, China|Research Site, Changsha, China|Research Site, Chengdu, China|Research Site, Dalian, China|Research Site, Fuzhou, China|Research Site, Guangzhou, China|Research Site, Hangzhou, China|Research Site, Harbin, China|Research Site, Hefei, China|Research Site, Nanchang, China|Research Site, Nanjing, China|Research Site, Nanning, China|Research Site, Neijiang, China|Research Site, Shanghai, China|Research Site, Suzhou, China|Research Site, Wuhan, China|Research Site, Xian, China|Research Site, Yibin, China|Research Site, Zhengzhou, China|Research Site, Clichy, France|Research Site, Lile, France|Research Site, Lyon, France|Research Site, Marseille, France|Research Site, Montpellier, France|Research Site, Nancy, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Pessac, France|Research Site, Poitiers, France|Research Site, Reims, France|Research Site, Rouen, France|Research Site, Saint-Etienne, France|Research Site, Toulouse, France|Research Site, Villejuif, France|Research Site, Aachen, Germany|Research Site, Essen, Germany|Research Site, Hannover, Germany|Research Site, Heidelberg, Germany|Research Site, Koeln, Germany|Research Site, Leipzig, Germany|Research Site, Mainz, Germany|Research Site, Muenchen, Germany|Research Site, Tuebingen, Germany|Research Site, Ulm, Germany|Research Site, Hong Kong, Hong Kong|Research Site, Bangalore, India|Research Site, Bhubneshwar, India|Research Site, Chennai, India|Research Site, Chennai, India|Research Site, Hubli, India|Research Site, Hyderabad, India|Research Site, Kanpur, India|Research Site, Karmsad, India|Research Site, Ludhiana, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Benevento, Italy|Research Site, Meldola, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Rozzano (MI), Italy|Research Site, Bunkyoku, Japan|Research Site, Chiba, Japan|Research Site, Fukuoka, Japan|Research Site, Hiroshima, Japan|Research Site, Iizuka, Japan|Research Site, Kanazawa, Japan|Research Site, Kotoku, Japan|Research Site, Kumamoto, Japan|Research Site, Kurume, Japan|Research Site, Matsuyama, Japan|Research Site, Mitakashi, Japan|Research Site, Musashino, Japan|Research Site, Nagoya, Japan|Research Site, Ogaki, Japan|Research Site, Okayama, Japan|Research Site, Osaka Sayama, Japan|Research Site, Osaka, Japan|Research Site, Osaka, Japan|Research Site, Saga, Japan|Research Site, Sapporo, Japan|Research Site, Shiwa, Japan|Research Site, Suntogun, Japan|Research Site, Tsu, Japan|Research Site, Yokohama, Japan|Research Site, Ilsan, Gyeonggi-do, Korea, Republic of|Research Site, Seongnam-si, Gyeonggi-do, Korea, Republic of|Research Site, Busan, Korea, Republic of|Research Site, Daegu, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Seoul, Korea, Republic of|Research Site, Moscow, Russian Federation|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Novosibirsk, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Omsk, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Ufa, Russian Federation|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Oviedo, Spain|Research Site, Pamplona Madrid, Spain|Research Site, Santander, Spain|Research Site, Chiayi, Taiwan|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, Taiwan|Research Site, Tainan, Taiwan|Research Site, Tainan, Taiwan|Research Site, Taipei, Taiwan|Research Site, Taoyuan, Taiwan|Research Site, Bangkok, Thailand|Research Site, Bangkok, Thailand|Research Site, Chang Mai, Thailand|Research Site, Khon Kaen, Thailand|Research Site, Phitsanulok, Thailand|Research Site, Songkhla, Thailand|Research Site, Dnipro, Ukraine|Research Site, IvanoFrankivsk, Ukraine|Research Site, Kharkiv, Ukraine|Research Site, Kropyvnitskyi, Ukraine|Research Site, Kyiv, Ukraine|Research Site, Lviv, Ukraine|Research Site, Odesa, Ukraine|Research Site, Uzhgorod, Ukraine|Research Site, Hanoi, Vietnam|Research Site, Hochiminh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03298451"
707,"NCT00332202","PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin",,"Completed","Has Results","Non Hodgkin Lymphoma","Drug: enzastaurin|Drug: placebo","Overall Disease-Free Survival|Disease Free Survival at 2 Years|Event-Free Survival|Event-Free Survival at 2 Years|Overall Survival|Number of Participants With Treatment-Emergent Adverse Events|Quality of Life: Change From Baseline in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Score|Change From Baseline in EuroQol-5D (EQ-5D) Score|Translational Research: DFS Participants With Diffuse Large B-cell Lymphoma (DLBCL) Germinal-center B-cells (GCB) Versus Non-germinal-center B-cells|Translational Research: DFS of Participants With Diffuse Large B-cell Lymphoma (DLBCL) Protein Kinase C-β2 (PKC-β2) Expression|Pharmacokinetics: Average Steady-State Concentration (Cavg,ss) for Total Analyte","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","758","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","9823|H6Q-MC-JCBJ|PRELUDE","June 2006","April 2013","July 2013","June 1, 2006","September 10, 2018","September 10, 2018","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Anchorage, Alaska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Orlando, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bloomington, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lexington, Kentucky, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Robbinsdale, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Durham, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tulsa, Oklahoma, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., The Woodlands, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Everett, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Garran, Australian Capital Territory, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gosford, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Casuarina, Northern Territory, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Woolloongabba, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prahran, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brugge, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gent, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roeselare, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Belo Horizonte, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Campinas, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goiania, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rio De Janeiro, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., São Paulo, Brazil|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edmonton, Alberta, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamilton, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Regina, Saskatchewan, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Beijing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chengdu, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guang Zhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hangzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nanjing, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shanghai, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Suzhou, China|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brno, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olomouc, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Prague, Czechia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Herlev, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Odense, Denmark|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Helsinki, Finland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Avignon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bayonne, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., La Roche Sur Yon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Le Mans, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nantes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nice, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nimes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pessac, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vandoeuvre Les Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berlin, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chemnitz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Erlangen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Frankfurt, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Giessen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hamburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Homburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kassel, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mainz, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Muenchen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Haidari/Athens, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Thessaloniki, Greece|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Budapest, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miskolc, Hungary|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pune, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Secunderabad, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Trivandrum, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aviano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bergamo, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pisa, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Reggio Emilia, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rome, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vicenza, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aichi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gunma, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kanagawa, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kyoto, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mie, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Miyagi, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nagasaki, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Okayama, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Shiga, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daegu, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Goyang-Si, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hwasun-Gun, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seoul, Korea, Republic of|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Col. Florida, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Luis Potosi, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Olsztyn, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poznan, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wroclaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Coimbra, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lisbon, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Maria Da Feira, Portugal|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Juan, Puerto Rico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salamanca, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santander, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toledo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Zaragoza, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lund, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Umea, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Changhua, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiayi City, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kaohsiung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liouying/Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neihu Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taichung, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tainan, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Taipei, Taiwan|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brighton, East Sussex, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maidstone, Kent, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aberdeen, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00332202"
708,"NCT00532259","CT-011 MAb in DLBCL Patients Following ASCT",,"Completed","Has Results","Lymphoma, Large Cell, Diffuse|Lymphoma, Mixed Cell, Diffuse|Primary Mediastinal Large B-Cell Lymphoma","Drug: CT-011","Progression-free Survival|Overall Survival","CureTech Ltd","All","18 Years and older   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CT-2007-01","October 2007","August 2011","August 2011","September 20, 2007","September 12, 2014","September 12, 2014","Moores UCSD Cancer Center, La Jolla,, California, United States|Scripps Cancer Center, San Diego, California, United States|Northside Hospital, Atlanta,, Georgia, United States|Emory University-Winship Cancer Institute, Atlanta, Georgia, United States|Northwestestern Memorial Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|The University of Chicago, Chicago, Illinois, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Ohio State University, Colombus, Ohio, United States|Temple University, Philadelphia, Pennsylvania, United States|The University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Cancer Center of the Carolinas, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Sammons Cancer Center, Dallas,, Texas, United States|M.D. Anderson Cancer Center, Houston, Texas, United States|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharashtra, India|Gujarat Cancer and Research Institute, Ahmedabad, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Rambam Medical Center, Haifa, Israel|Hadassah Medical Organization, Jerusalem, Israel|Chaim Sheba Medical Center, Tel Hashomaer, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT00532259"
709,"NCT01030783","A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","TIVO-1","Completed","Has Results","Advanced Renal Cell Carcinoma","Drug: tivozanib (AV-951)|Drug: Sorafenib","Progression-free Survival (PFS) of Subjects With Advanced Renal Cell Cancer (RCC) Randomized to Treatment With Tivozanib or Sorafenib|Overall Survival (OS) of Subjects Randomized to Treatment With Tivozanib or Sorafenib|Objective Response Rate (ORR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib|Duration of Response (DR) of Subjects Randomized to Treatment With Tivozanib or Sorafenib|Safety and Tolerability of Tivozanib and Sorafenib|To Compare Kidney-specific Symptoms and Health Outcome Measurements in Subjects Randomized to Treatment With Tivozanib or Sorafenib|Pharmacokinetics (Serum Concentrations) of Tivozanib","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","517","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AV-951-09-301","December 2009","July 2012","June 2013","December 11, 2009","October 28, 2019","October 28, 2019","Site 185, Los Angeles, California, United States|Site 180, Gainesville, Florida, United States|Site 184, Orlando, Florida, United States|Site 182, Minneapolis, Minnesota, United States|Site 186, New York, New York, United States|Site 187, Dallas, Texas, United States|Site 102, Sante Fe, Argentina|Site 403, Plovdiv, Bulgaria|Site 404, Sofia, Bulgaria|Site 400, Sofia, Bulgaria|Site 401, Varna, Bulgaria|Site 402, Veliko Tarnovo, Bulgaria|Site 110, Montréal, Quebec, Canada|Site 121, La Reina, Santiago De Chile, Chile|Site 122, Santiago, Chile|Site 123, Temuco, Chile|Site 411, Prague 8, Czechia|Site 130, Marseille, France|Site 133, Saint Herblain Cedex, France|Site 423, Budapest, Hungary|Site 421, Kaposvár, Hungary|Site 422, Pécs, Hungary|Site 424, Szombathely, Hungary|Site 157, Hyderabad, Andhra Pradesh, India|Site 190, Patna, Bihar, India|Site 156, Ahmedabad, Gujarat, India|Site 151, Nashik, Maharashtra, India|Site 153, Pune, Maharashtra, India|Site 159, Pune, Maharashtra, India|Site 191, Jaipur, Rajasthan, India|Site 155, Jaipur, Rajasthan, India|Site 152, Vellore, Tamil Nadu, India|Site 158, Lucknow, Uttar Pradesh, India|Site 150, Kolkata, West Bengal, India|Site 154, Delhi, India|Site 160, Arezzo, Italy|Site 161, Pavia, Italy|Site 162, Roma, Italy|Site 432, Bialystok, Poland|Site 434, Bydgoszcz, Poland|Site 431, Gdansk, Poland|Site 435, Olsztyn, Poland|Site 433, Poznan, Poland|Site 430, Warsaw, Poland|Site 436, Warsaw, Poland|Site 444, Brasov, Romania|Site 441, Bucharest, Romania|Site 440, Bucharest, Romania|Site 443, Bucharest, Romania|Site 442, Timisoara, Romania|Site 459, Ufa, Republic Of Bashkortostan, Russian Federation|Site 451, Chelyabinsk, Russian Federation|Site 455, Ekaterinburg, Russian Federation|Site 468, Ioshkar Ola, Russian Federation|Site 452, Kazan, Russian Federation|Site 454, Moscow, Russian Federation|Site 453, Moscow, Russian Federation|Site 458, Moscow, Russian Federation|Site 460, Moscow, Russian Federation|Site 461, Moscow, Russian Federation|Site 462, Moscow, Russian Federation|Site 450, Nizhny Novgorod, Russian Federation|Site 456, Obninsk, Russian Federation|Site 467, Omsk, Russian Federation|Site 463, Pyatigorsk, Russian Federation|Site 457, Rostov-on-Don, Russian Federation|Site 466, St. Petersburg, Russian Federation|Site 465, St. Petersburg, Russian Federation|Site 464, Yaroslavi, Russian Federation|Site 480, Belgrade, Serbia|Site 481, Belgrade, Serbia|Site 482, Belgrade, Serbia|Site 483, Nis, Serbia|Site 484, Sremska Kamenica, Serbia|Site 491, Chernihiv, Ukraine|Site 492, Dniproperovsk, Ukraine|Site 498, Dnipropetrovsk, Ukraine|Site 493, Donetsk, Ukraine|Site 496, Donetsk, Ukraine|Site 490, Ivano-Frankivsk, Ukraine|Site 494, Kharkiv, Ukraine|Site 497, Uzhhorod, Ukraine|Site 495, Zaporizhia, Ukraine|Site 170, Cambridge, United Kingdom|Site 173, Ipswich, United Kingdom|Site 172, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01030783"
710,"NCT01076010","An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).",,"Completed","Has Results","Advanced Renal Cell Carcinoma","Drug: Tivozanib|Drug: Sorafenib","Number of Days Subjects Received Treatment in Each Treatment Arm|Number of Cycles Subjects Received Treatment in Each Treatment Arm|Total Dose Administered to Subjects in Each Treatment Arm (mg)|Average Daily Dose Administered to Subjects in Each Treatment Arm|Relative Dose Intensity (RDI) of Treatment Administered to Subjects in Each Treatment Arm|Number of Subjects With Adverse Events|Number of Subjects With Objective Response Rate (ORR) Who Continued Treatment With Tivozanib or Sorafenib and Who Received Tivozanib After Failure of Sorafenib|Duration of Response (DR)|Progression-free Survival (PFS)|Overall Survival (OS)","AVEO Pharmaceuticals, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","277","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AV-951-09-902|2009-015987-32","March 2010","July 2014","July 2014","February 25, 2010","October 5, 2020","October 5, 2020","Site 185, Los Angeles, California, United States|Site 184, Orlando, Florida, United States|Site 182, Minneapolis, Minnesota, United States|Site 186, New York, New York, United States|Site 187, Dallas, Texas, United States|Site 403, Plovdiv, Bulgaria|Site 404, Sofia, Bulgaria|Site 400, Sofia, Bulgaria|Site 401, Varna, Bulgaria|Site 402, Veliko Tarnovo, Bulgaria|Site 110, Montréal, Quebec, Canada|Site 122, Santiago, Chile|Site 123, Temuco, Chile|Site 411, Prague 8, Czechia|Site 133, Saint Herblain Cedex, France|Site 423, Budapest, Hungary|Site 421, Kaposvár, Hungary|Site 422, Pécs, Hungary|Site 156, Ahmedabad, Gujarat, India|Site 151, Nashik, Maharashtra, India|Site 153, Pune, Maharashtra, India|Site 191, Jaipur, Rajasthan, India|Site 152, Vellore, Tamil Nadu, India|Site 158, Lucknow, Uttar Pradesh, India|Site 150, Kolkata, West Bengal, India|Site 154, Delhi, India|Site 160, Arezzo, Italy|Site 161, Pavia, Italy|Site 162, Roma, Italy|Site 432, Bialystok, Poland|Site 434, Bydgoszcz, Poland|Site 431, Gdansk, Poland|Site 435, Olsztyn, Poland|Site 433, Poznan, Poland|Site 430, Warsaw, Poland|Site 436, Warsaw, Poland|Site 444, Brasov, Romania|Site 441, Bucharest, Romania|Site 440, Bucharest, Romania|Site 443, Bucharest, Romania|Site 442, Timisoara, Romania|Site 459, Ufa, Republic Of Bashkortostan, Russian Federation|Site 451, Chelyabinsk, Russian Federation|Site 455, Ekaterinburg, Russian Federation|Site 452, Kazan, Russian Federation|Site 454, Moscow, Russian Federation|Site 453, Moscow, Russian Federation|Site 458, Moscow, Russian Federation|Site 460, Moscow, Russian Federation|Site 461, Moscow, Russian Federation|Site 462, Moscow, Russian Federation|Site 450, Nizhny Novgorod, Russian Federation|Site 456, Obninsk, Russian Federation|Site 467, Omsk, Russian Federation|Site 463, Pyatigorsk, Russian Federation|Site 457, Rostov-on Don, Russian Federation|Site 466, St. Petersburg, Russian Federation|Site 465, St. Petersburg, Russian Federation|Site 464, Yaroslavl, Russian Federation|Site 480, Belgrade, Serbia|Site 481, Belgrade, Serbia|Site 482, Belgrade, Serbia|Site 483, Nis, Serbia|Site 484, Sremska Kamenica, Serbia|Site 491, Chernihiv, Ukraine|Site 498, Dniproperovsk, Ukraine|Site 492, Dniproperovsk, Ukraine|Site 493, Donetsk, Ukraine|Site 496, Donetsk, Ukraine|Site 490, Ivano-Frankivsk, Ukraine|Site 494, Kharkiv, Ukraine|Site 497, Uzhhorod, Ukraine|Site 495, Zaporizhia, Ukraine|Site 170, Cambridge, United Kingdom|Site 172, Leicester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01076010"
711,"NCT01307397","A Study of Vemurafenib in Participants With Metastatic Melanoma",,"Completed","Has Results","Malignant Melanoma","Drug: Vemurafenib","Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.0|Percentage of Participants With at Least 1 AE Leading to Study Drug Interruption or Drug Discontinuation|Percentage of Participants With AEs of Special Interest|Mean Cumulative Dose of Vemurafenib|Duration of Vemurafenib Treatment|Mean Total Vemurafenib Dose Per Day|Dose Intensity of Vemurafenib|Percentage of Participants With Improvement in Eastern Cooperative Group (ECOG) Performance Status|Percentage of Participants Who Received Any Concomitant Medications|Percentage of Participants With Best Overall Response (BOR) of Confirmed Complete Response (CR) or Partial Response (PR), as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)|Duration of Response|Time to Response|Percentage of Participants With PD Assessed According to RECIST v1.1 or Death|Progression Free Survival (PFS)|Percentage of Participants Who Died|Overall Survival (OS)","Hoffmann-La Roche","All","16 Years and older   (Child, Adult, Older Adult)","Phase 3","3219","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO25515|2010-023526-21","March 1, 2011","February 24, 2016","February 24, 2016","March 2, 2011","December 18, 2017","December 18, 2017","University ""Mother Theresa"" Hospital Center; Oncology Department, Tirana, Albania|Hospital Britanico; Oncologia, Buenos Aires, Argentina|Fundación CIDEA, Buenos Aires, Argentina|Inst. Alexander Fleming; Oncologia, Buenos Aires, Argentina|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Newcastle Mater Misericordiae Hospital; Oncology, Waratah, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Border Medical Oncology, Wodonga, New South Wales, Australia|Greenslopes Private Hospital; Gallipoli Research Centre, Greenslopes, Queensland, Australia|The Townsville Hospital; Townsville Cancer Centre, Townsville, Queensland, Australia|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital; Oncology, Adelaide, South Australia, Australia|Geelong Hospital; Geelong Cardiology Practice, Geelong, Victoria, Australia|Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia|Alfred Hospital, Melbourne, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Landeskrankenhaus Feldkirch; Abteilung für Innere Medizin, Feldkirch, Austria|LKH Graz; Abteilung für allgemeine Dermatologie, Graz, Austria|LKH Innsbruck; Universitätsklinik für Dermatologie, Innsbruck, Austria|Krankenhaus der Elisabethinen Linz; Abteilung für Dermatologie, Linz, Austria|Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria|LKH Salzburg; Universitätsklinik für Dermatologie, Salzburg, Austria|Landesklinikum St. Pölten, St. Pölten, Austria|Medizinische Universität Wien; Univ.Klinik für Dermatologie, Wien, Austria|UZ Brussel, Brussel, Belgium|Cliniques Universitaires St-Luc, Bruxelles, Belgium|Sint Augustinus Wilrijk, Wilrijk, Belgium|University Clinical Center of the Republic of Srpska, Banja Luka, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina|Instituto Nacional de Cancer - INCa; Pesquisa Clinica, Rio de Janeiro, RJ, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, SP, Brazil|Hospital A. C. Camargo; Oncologia, Sao Paulo, SP, Brazil|Hospital Sao Jose, São Paulo, SP, Brazil|District Oncology Dispensary; Department for Oncology and Dermatology, Plovdiv, Bulgaria|National Specialized Hospital for Active Oncology Treatment; Dermatology Clinic, Sofia, Bulgaria|Cross Cancer Institute ; Dept of Medical Oncology, Edmonton, Alberta, Canada|Lion'S Gate Hospital, North Vancouver, British Columbia, Canada|British Columbia Cancer Agency (Bcca) - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|St. Boniface General Hospital; Medicine, Winnipeg, Manitoba, Canada|QEII HSC; Oncology, Halifax, Nova Scotia, Canada|Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada|London Regional Cancer Centre, London, Ontario, Canada|The Ottawa Hospital; Division of Infectious Diseases, Ottawa, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada|McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal, Quebec, Canada|Chuq - Hopital Hotel Dieu de Quebec; Oncology, Quebec City, Quebec, Canada|Centro Javeriano de Oncología, Bogota, Colombia|Fundacion Santa Fe de Bogotá, Bogota, Colombia|Clínica Imbanaco; Oncology, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin-Antioquia, Colombia|Clinical Hospital Sisters of Mercy, Zagreb, Croatia|Masarykův onkologický ústav; Klinika komplexní onkologické péče, Brno, Czechia|University Hospital; Oncology and Radiotherapy, Hradec Kralove, Czechia|Fakultni nemocnice Olomouc; Onkologicka klinika, Olomouc, Czechia|Faculty Hospital; Dialysis Unit, Ostrava, Czechia|1 Lekarska Fakulta Uni Karlovy; 3 Interni Klinika, Labor. Pro Endokrinologii A Metabolismus, Praha, Czechia|Faculty Hospital Kralovske Vinohrady; Oncology, Praha, Czechia|Aarhus Universitetshospital; Kræftafdelingen, Aarhus C, Denmark|Herlev Hospital; Onkologisk afdeling, Herlev, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense, Denmark|Hospital Regional Vicente Corral Moscoso, Servicio de Oncología, Cuenca, Ecuador|Hospital Abel Gilbert Ponton; Oncology, Guayaquil, Ecuador|Hospital Solca Portoviejo; Oncologia, Portoviejo, Ecuador|East Tallinn Central Hospital; Clinic of Internal Medicine, Tallinn, Estonia|North Estonia Medical Centre Foundation; Oncology Center, Tallinn, Estonia|Tartu University Hospital; Clinic of Hematology and Oncology, Tartu, Estonia|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Turku Uni Central Hospital; Oncology Clinics, Turku, Finland|Uniklinik RWTH Aachen; Klinik für Dermatologie und Allergologie - Hautklinik, Aachen, Germany|Klinikum Augsburg Süd; Klinik für Dermatologie und Allergologie, Augsburg, Germany|CAMPUS BENJAMIN FRANKLIN CharitéCentrum 14 Med.Klinik f.Hämatologie u.Onkologie, Berlin, Germany|St. Josef-Hospital Klinik f. Dermatologie u. Allergologie, Bochum, Germany|Elbekliniken Buxtehude; Klinik für Dermatologie, Buxtehude, Germany|DRK-Krankenhaus; Hautklinik, Chemnitz, Germany|Universitätsklinikum ""Carl Gustav Carus""; Medizinische Klinik und Poliklinik I, Dresden, Germany|Universitätsklinikum Düsseldorf; Hautklinik, Düsseldorf, Germany|HELIOS Klinikum Erfurt, Klinik für Hautkrankheiten und Allergologie, Erfurt, Germany|Universitätsklinikum Erlangen; Hautklinik, Erlangen, Germany|Universitätsklinikum Essen, Essen, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik fuer Allgemein- und Viszeralchirurgie, Frankfurt, Germany|Uniklinikum Freiburg Dermatol, Freiburg, Germany|SRH Wald-Klinikum Gera; Klinik für Hautkrankheiten und Allergologie, Gera, Germany|Universitätsmedizin Göttingen Georg-August-Universität Zentrum Dermatologie, Göttingen, Germany|Universitätsklinikum Hamburg-Eppendorf Zentrum f.Innere Medizin Klinik f.Dermatologie, Hamburg, Germany|Medizinische Hochschule; Hautklinik Linden, Hannover, Germany|Uni-Hautklinik, Heidelberg, Germany|Klinikum am Gesundbrunnen; Tumorzentrum, Heilbronn, Germany|Universitätsklinikum Jena; Klinik für Hautkrankheiten, Jena, Germany|Klinikum Kassel; Hautklinik, Kassel, Germany|UNI-Klinikum Campus Kiel Klinik f.Dermatologie Tagesklinik f.Dermatologie, Kiel, Germany|Klinik der Uni zu Köln; Klinik & Poliklinik fuer Dermatologie & Venerologie, Köln, Germany|Universitätsklinikum Leipzig Klinik f.Dermatologie Venerologie u.Allergologie, Leipzig, Germany|Klinikum d.Stadt Ludwigshafen Hautklinik, Ludwigshafen, Germany|Universitätsklinikum Schleswig-Holstein; Campus Lübeck, Lübeck, Germany|Universitätsklinikum Magdeburg; Hautklinik; Klinik für Dermatologie und Venerologie, Magdeburg, Germany|Johannes Gutenberg Unis-Klinik; Dept For Dermatology, Mainz, Germany|Klinikum Mannheim Klinik fuer Dermatologie, Venerologie und Allergologie, Mannheim, Germany|Universitätsklinikum Marburg Klinik f. Dermatologie, Marburg, Germany|Johannes-Wesling-Klinikum Minden; Onkologische Ambulanz / Tagesklinik, Minden, Germany|Klinikum der LMU München; Klinik und Poliklinik für Dermatologie und Allergologie, München, Germany|Staedtisches Krankenhaus Muenchen-Schwabing, Haematologie & Onkolgie, München, Germany|Universitätsklinikum Münster, Münster, Germany|Fachklinik Hornheide; Internistische Onkologie, Münster, Germany|Klinikum Nürnberg Nord; Hautklinik; Klinik für Dermatologie, Nürnberg, Germany|Klinikum Dorothea Ch.Erxleben; Klinik für Dermatologie und Allergologie, Quedlinburg, Germany|KLINIKUM VEST GmbH Knappschaftskrankenhaus Abt.Haut- Allergie- Venen- und Umwelterkrankungen, Recklinghausen, Germany|Universitätsklinikum Regensburg; Klinik und Poliklinik für Dermatologie, Regensburg, Germany|Universitaets-Hautklinik Tuebingen, Tübingen, Germany|Wilhelm Fresenius Klinik; Klinik f. Dermatologie u. Allergologie, Wiesbaden, Germany|HELIOS Klinikum Barmen Zentrum Dermatologie Allergologie und Umweltmedizin, Wuppertal, Germany|Universitätsklinikum Würzburg; Klinik und Poliklinik für Dermatologie Venerologie u. Allergologie, Würzburg, Germany|Laiko General Hospital; 1St Pathological Clinic, Athens, Greece|Hospital Hygeia; 1St Oncology Dept., Athens, Greece|Univ General Hosp Heraklion; Medical Oncology, Heraklion, Greece|Metropolitan Hospital; Dept. of Oncology, Piraeus, Greece|Semmelweis Egyetem; Bor-, Nemikortani es Boronkologiai Klinika, Budapest, Hungary|Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly, Budapest, Hungary|Debreceni Egyetem OEC; Borgyogyaszati Klinika, Debrecen, Hungary|Pecsi Tudomanyegyetem AOK; Borgyogyaszati Klinika, Pecs, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin.Kozp., Szeged, Hungary|Rajiv Gandhi Cancer Inst.&Research Center; Medical Oncology, New Delhi, Delhi, India|Tata Memorial Hospital; Dept of Medical Oncology, Mumbai, Maharashtra, India|Curie Manavata Cancer Centre, Nashik, Maharashtra, India|Basavatarakam Indo-American Cancer Hospital & Research Institute, Hyderabad, India|Chhatrapati Shahuji Maharaj Medical University; Department of Oncology, Lucknow, India|Regional Cancer Centre; Dept of Oncology, Trivandrum, India|Christian Med Clg & Hspt, Vellore, India|Cork Uni Hospital; Oncology Dept, Cork, Ireland|St Vincent'S Uni Hospital; Medical Oncology, Dublin, Ireland|Mater Misericordiae Uni Hospital; Oncology, Dublin, Ireland|Mater Private Hospital, Dublin, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Galway Uni Hospital; Oncology Dept, Galway, Ireland|University Hospital Limerick - Oncology, Limerick, Ireland|Waterford Regional Hospital; Department Of Medical Oncology, Waterford, Ireland|Soroka Medical Center; Oncology Dept, Beer Sheva, Israel|Ranbam Health Care Campus; Oncology - Hafia, Hafia, Israel|Hadassah Ein Karem Hospital; Oncology Dept, Jerusalem, Israel|Chaim Sheba Medical Center; Oncology Dept, Ramat Gan, Israel|Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Campania, Italy|IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy|A.O. Universitaria Policlinico Di Modena; Oncologia, Modena, Emilia-Romagna, Italy|AO Santa Maria Nuova; U.O. Day Hospital di Oncologi, Reggio Emilia, Emilia-Romagna, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, Italy|Istituto Dermopatico dell'Immacolata (IDI)-IRCCS; IV Divisione Oncologica e Dermatologia Oncologica, Roma, Lazio, Italy|IFO - Istituto Regina Elena; Oncologia Medica, Roma, Lazio, Italy|IRCCS Istituto Nazionale Per La Ricerca Sul Cancro (IST); Oncologia Medica A, Genova, Liguria, Italy|Asst Papa Giovanni XXIII; Oncologia Medica, Bergamo, Lombardia, Italy|Az. Osp. Spedali Civili; Divisione Di Oncologia - Iii Medicina, Brescia, Lombardia, Italy|Irccs Ospedale San Raffaele;Oncologia Medica, Milano, Lombardia, Italy|Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2, Milano, Lombardia, Italy|Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica, Milano, Lombardia, Italy|Policlinico Le Molinette; Clinica Dermatologica, Torino, Piemonte, Italy|Istituto Tumori Giovanni Paolo II IRCSS; Ospedale Oncologico Bari, Bari, Puglia, Italy|Policlinico P. Giaccone; Istituto Di Oncologia, Clinica Medica 1, Palermo, Sicilia, Italy|Azienda Ospedaliero-Universitaria Careggi;S.C. Oncologia Medica 1, Firenze, Toscana, Italy|Azienda Ospedaliera S. Chiara; Dip di Onc,Trapianti e delle Nuove Tecnologie in Medicina, Pisa, Toscana, Italy|A.O.U. Senese Policlinico Santa Maria Alle Scotte, Siena, Toscana, Italy|Azienda Ospedaliera S. Maria - Terni; Oncologia, Terni, Umbria, Italy|IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda, Padova, Veneto, Italy|Samsung Medical Center, Seoul, Korea, Republic of|Seoul St Mary's Hospital, Seoul, Korea, Republic of|Seoul National University Hosp; Dept Internal Med Hem Onc, Seoul, Korea, Republic of|Yonsei University Severance Hospital; Medical Oncology, Seoul, Korea, Republic of|Asan Medical Center., Seoul, Korea, Republic of|Daugavpils Regional Hospital, Daugavpils, Latvia|Rigas Austrumu Kliniska Universitates slimnica, Latvijas Onkologijas centrs, Riga, Latvia|Klaipeda University Hospital, Klaipeda, Lithuania|Vilnius University Hospital Santariskiu Clinic, Hematology, Oncology and Tranfusion Medicine Center, Vilnius, Lithuania|University Clinic for Radiotherapy and Oncology Skopje; Department of skin malignancies, Skopje, Macedonia, The Former Yugoslav Republic of|Fundación Rodolfo Padilla Padilla, A.C.; Oncology, Leon, Mexico|Inst. Nacional de Cancerologia; Investigacion Clinica, Mexico City, Mexico|Hospital General de México; Unidad de Oncologia, Mexico DF, Mexico|Antoni Van Leeuwenhoek Ziekenhuis; Inwendige Geneeskunde, Amsterdam, Netherlands|VU MEDISCH CENTRUM; Dept. of Medical Oncology, Amsterdam, Netherlands|Tergooiziekenhuizen, Blaricum, Netherlands|Amphia Ziekenhuis, Breda, Netherlands|Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands|Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands|Academish Ziekenhuis Maastricht (Azm); Inwendige Geneeskunde, Maastricht, Netherlands|UMC St Radboud; Interne Oncologie; Medical Oncology Department, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, Netherlands|Haukeland Universitetshospital; Onkologisk Avd., Bergen, Norway|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, Norway|Hospital Nacional Carlos Alberto Seguin Escobedo-Essalud; Oncology & Haemathology, Arequipa, Peru|Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru|Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii, Krakow, Poland|ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii;Wojska Polskiego 37, Olsztyn, Poland|NZOZ Med.-Polonia sp. z o.o., Poznań, Poland|Centrum Onkologii- Instytut; im. M.Skłodowskiej-Curie, Warszawa, Poland|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, Portugal|Institut of Oncology Al. Trestioreanu Bucharest; Oncology, Bucuresti, Romania|Medisprof SRL, Cluj-Napoca, Romania|S.C. Life Search S.R.L; Medical Oncology Clinic, Timisoara, Romania|FSBI ""Scientific Research Institute of Oncology named after N.N.Petrov"" Ministry of Health of RF, St Petersburg, Leningrad, Russian Federation|Regional Clinical Oncology Dispensary, Krasnodar, Russian Federation|Russian Cancer Research Center, Moscow, Russian Federation|Moscow city oncology hospital #62 of Moscow Healthcare Department, Moscow, Russian Federation|St. Petersburg Oncology & Gynecology; City Clinical Oncology Dispensary, Saint-Petersburg, Russian Federation|Stavropol Clinical Oncology Dispansary, Stavropol, Russian Federation|Bashkirian Republican Clinical Oncology Dispensary, UFA, Russian Federation|Institute for Oncology and Radiology of Serbia; Medical Oncology, Belgrade, Serbia|Clinical Center Bezanijska Kosa; Oncology, Belgrade, Serbia|Onkologicky ustav sv. Alzbety; Oddelenie ambulantnej chemoterapie, Bratislava, Slovakia|Narodny Onkologicky Ustav; Oddelenie klinickej onkologie E, Bratislava, Slovakia|POKO Poprad; Department of Oncology, Poprad, Slovakia|Institute of Oncology Ljubljana, Ljubljana, Slovenia|Universitas Annex, University of the Free State; Clinical Oncology, Bloemfontein, South Africa|Cape Town Oncology Trials, Cape Town, South Africa|Cancercare, Cape Town, South Africa|Medical Oncology Centre of Rosebank; Oncology, Johannesburg, South Africa|Steve Biko Academic Hospital; Oncology, Pretoria, South Africa|Sandton Oncology Centre, Sandton, South Africa|Hospital Univ. Central de Asturias; Servicio de Oncologia, Oviedo, Asturias, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, Spain|Hospital Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain|Hospital Universitario Materno Infantil de Gran Canaria; Servicio de Oncologia, Las Palmas de Gran Canaria, Las Palmas, Spain|Hospital Universitario de Santa Lucía; Servicio de Oncología Médica, Cartagena (Murcia), Murcia, Spain|Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain|Hospital Xeral Cíes; Servicio de Oncologia, Vigo, Pontevedra, Spain|Hospital Universitario de Canarias (HUC), La Laguna (Tenerife), Tenerife, Spain|Hospital de Cruces; Servicio de Oncologia, Barakaldo, Vizcaya, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain|Hospital Clínic i Provincial; Servicio de Hematología y Oncología, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia, Barcelona, Spain|Hospital Reina Sofia, Cordoba, Spain|Hospital Universitario Virgen de las Nieves; Servicio de Oncologia, Granada, Spain|Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología, La Coruña, Spain|Complejo Asistencial Universitario de Leon; Servicio de Oncologia, Leon, Spain|Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain|Hospital Universitario Clínico San Carlos; Servicio de Oncologia, Madrid, Spain|Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid, Spain|Hospital Universitario La Paz; Servicio de Oncologia, Madrid, Spain|Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia, Malaga, Spain|Hospital Regional Universitario Carlos Haya; Servicio de Oncologia, Malaga, Spain|Hospital Clinico Universitario de Salamanca; Servicio de Oncologia, Salamanca, Spain|Hospital Universitario Virgen Macarena; Servicio de Oncologia, Sevilla, Spain|Hospital General Universitario de Valencia; Servicio de oncologia, Valencia, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Spain|Sahlgrenska Universitetssjukhuset; Onkology, Gothenburg, Sweden|Skånes Onkologiska Klinik, Universitetssjukhuset, Lund, Sweden|Karolinska Universitetssjukhuset, Solna, Stockholm, Sweden|Norrlands universitetssjukhus; Onkologkliniken, Umeå, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Universitaetsspital Basel; Onkologie, Basel, Switzerland|Inselspital Bern; Medizinische Onkologie, Bern, Switzerland|Kantonsspital Graubünden;Onkologie und Hämatologie, Chur, Switzerland|CHUV; Departement d'Oncologie, Lausanne, Switzerland|Kantonsspital St. Gallen; Onkologie/Hämatologie, St. Gallen, Switzerland|Universitätsspital Zürich; Dermatologische Klinik, Zürich, Switzerland|Adana Baskent University Hospital; Medical Oncology, Adana, Turkey|Cukurova Uni Faculty of Medicine; Medical Oncology, Adana, Turkey|Ankara Uni , Ibn-I Sina Hospital; Oncology Dept, Ankara, Turkey|Gazi Uni Medical Faculty Hospital; Oncology Dept, Ankara, Turkey|Akdeniz University School of Medicine; General Surgery, Antalya, Turkey|Ege University Medical Faculty; Medical Oncology Department, Bornova, İZMİR, Turkey|Gaziantep University Medical Faculty, Medical Oncology Department, Gaziantep, Turkey|Kartal Training and Research Hospital;Medical Oncology Department, Istanbul, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, Turkey|American Hospital, Medical Oncology Department, Istanbul, Turkey|Dokuz Eylul Uni ; Medical Oncology, Izmir, Turkey|Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sıhhiye, ANKARA, Turkey|Addenbrookes Nhs Trust; Oncology Clinical Trials Unit, Cambridge, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Surrey County Hospital; St. Lukes Cancer Centre, Guildford, United Kingdom|St James University Hospital, Leeds, United Kingdom|Royal Marsden Hospital, London, United Kingdom|Christie Hospital; Breast Cancer Research Office, Manchester, United Kingdom|Northern Centre for Cancer Care Freeman Hospital; Sir Bobby Robson Cancer Trials Research Centre, Newcastle upon Tyne, United Kingdom|Mount Vernon Hospital; Centre For Cancer Treatment, Northwood, United Kingdom|Nottingham University Hospitals City Campus, Nottingham, United Kingdom|Churchill Hospital; Oxford Cancer and Haematology Centre, Oxford, United Kingdom|Southampton General Hospital; Medical Oncology, Southampton, United Kingdom|Singleton Hospital; Oncology, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01307397"
712,"NCT00858871","First Line Hepato Cellular Carcinoma (HCC)","BRISK FL","Completed","No Results Available","Hepato Cellular Carcinoma (HCC)","Drug: Brivanib|Drug: Placebo|Drug: Sorafenib","To compare the overall survival of brivanib versus sorafenib in subjects with advanced HCC who have not received prior systemic treatment|To compare the time to progression (TTP) (investigator assessed using modified RECIST criteria for HCC|To compare the investigator assessed objective response rate (ORR) and disease control rate (DCR) using modified RECIST criteria for HCC|To determine duration of response, duration of disease control, and time to response (TTR)|To assess the safety profile of brivanib and sorafenib|To explore PK and exposure-response in the study population|To compare time to symptomatic progression|To compare health-related quality of life","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","1714","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CA182-033|EUDRACT # 2008-003533-24","May 2009","June 2012","September 2013","March 10, 2009",,"October 17, 2016","Mayo Clinic Arizona, Scottsdale, Arizona, United States|Univ Of Ark For Med Sci, Little Rock, Arkansas, United States|Agajanian Institute Of Hematology And Oncology, Downey, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Va Ct Healthcare System, West Haven, Connecticut, United States|Medical Specialists Of Palm Beaches, Lake Worth, Florida, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|3912 Taubman Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Thomas Jefferson Univ., Philadelphia, Pennsylvania, United States|Mcguire Dvamc, Richmond, Virginia, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Concord, New South Wales, Australia|Local Institution, Westmead Nsw, New South Wales, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Prahan, Victoria, Australia|Local Institution, Liege, Belgium|Local Institution, Salvador - Ba, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Goiania, Goias, Brazil|Local Institution, Divinopolis, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, Rio Grande do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Barretos, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, London, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Nanning, Guangxi, China|Local Institution, Wuhan, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Suzhou, Jiangsu, China|Local Institution, Dalian, Liaoning, China|Local Institution, Xi An, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Brno, Czech Republic|Local Institution, Prague 5, Czech Republic|Local Institution, Praha 2, Czech Republic|Local Institution, Bordeaux, France|Local Institution, Clichy Cedex, France|Local Institution, Creteil Cedex, France|Local Institution, Grenoble Cedex 09, France|Local Institution, Lille, France|Local Institution, Lyon Cedex 04, France|Local Institution, Marseille Cedex 05, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Vandoeuvre Cedex, France|Local Institution, Berlin, Germany|Local Institution, Halle, Germany|Local Institution, Hamburg, Germany|Local Institution, Magdeburg, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Shatin, Hong Kong|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Kochi, Kerala, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Pune, Maharashtra, India|Local Institution, Ahmedabad, India|Local Institution, Chennai, India|Local Institution, Coimbatore, India|Local Institution, Hyderabad, India|Local Institution, Kolkata, India|Local Institution, Kolkata, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, New Delhi, India|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Torrette -Ancona, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kanazawa-Shi, Ishikawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Tsu-shi, MIE, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Higashinari-ku, Osaka, Japan|Local Institution, Osaka-Sayama City, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-Ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Musashino-shi, Tokyo, Japan|Local Institution, Shimonoseki-shi, Yamaguchi, Japan|Local Institution, Nishinomiya-shi, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Kyunggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, D.f., Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Distrito Federal, Mexico|Local Institution, Gdansk, Poland|Local Institution, Gliwice, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Durban, Kwa Zulu Natal, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Observatory, Cape Town, Western Cape, South Africa|Local Institution, Rondebosch, Western Cape, South Africa|Local Institution, Santiago De Compostela, A Coruna, Spain|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan R.O.C., Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00858871"
713,"NCT00334282","Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma",,"Completed","Has Results","Carcinoma, Renal Cell","Drug: Pazopanib|Drug: placebo","Progression-free Survival|Overall Survival|Overall Response|Participants With Complete Response, Partial Response, or 6 Months of Stable Disease|Duration of Response|Time to Response as Assessed by an Independent Review Committee (IRC) and the Investigator|Adjusted Mean Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ C-30) Score at Weeks 6, 12, 18, 24, and 48|Adjusted Mean Change From Baseline in the Index Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48|Adjusted Mean Change From Baseline in the Visual Analog Scale (VAS) Score of the EQ-5D (EuroQoL [Quality of Life]-5D) Questionnaire at Weeks 6, 12, 18, 24, and 48|Plasma Pazopanib Concentrations Before Dosing and at 2, 4, and 8 Hours After Dosing on Day 1 and Week 3|Baseline Expression Levels of the Indicated Target Proteins in Pazopanib- and Placebo-treated Participants","GlaxoSmithKline","All","18 Years and older   (Adult, Older Adult)","Phase 3","435","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VEG105192","April 2006","May 2008","December 2014","June 7, 2006","August 2, 2010","February 5, 2016","GSK Investigational Site, Capital Federal, Buenos Aires, Argentina|GSK Investigational Site, Cordoba, Córdova, Argentina|GSK Investigational Site, Córdoba, Córdova, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Quilmes, Argentina|GSK Investigational Site, Tucuman, Argentina|GSK Investigational Site, St Leonards, New South Wales, Australia|GSK Investigational Site, Waratah, New South Wales, Australia|GSK Investigational Site, Hobart, Tasmania, Australia|GSK Investigational Site, Heidelberg, Victoria, Australia|GSK Investigational Site, Wodonga, Victoria, Australia|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Belo Horizonte, Minas Gerais, Brazil|GSK Investigational Site, Porto Alegre, Rio Grande Do Sul, Brazil|GSK Investigational Site, Jaú, São Paulo, Brazil|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Viña del Mar, Valparaíso, Chile|GSK Investigational Site, Beijing, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Brno, Czech Republic|GSK Investigational Site, Chomutov, Czech Republic|GSK Investigational Site, Ostrava - Poruba, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Tallinn, Estonia|GSK Investigational Site, Tartu, Estonia|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Athens, Greece|GSK Investigational Site, Patra, Greece|GSK Investigational Site, Thessaloniki, Greece|GSK Investigational Site, Hong Kong, Hong Kong|GSK Investigational Site, Kowloon, Hong Kong|GSK Investigational Site, Tuen Mun, New Territories, Hong Kong|GSK Investigational Site, Bangalore, India|GSK Investigational Site, Hyderabad, India|GSK Investigational Site, Mumbai, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Trivandrum, India|GSK Investigational Site, Galway, Ireland|GSK Investigational Site, Tallaght, Dublin, Ireland|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Casalpusterlengo (LO), Lombardia, Italy|GSK Investigational Site, Crema, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Rozzano (MI), Lombardia, Italy|GSK Investigational Site, Orbassano (TO), Piemonte, Italy|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, songpa-gu, Seoul, Korea, Republic of|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Kaunas, Lithuania|GSK Investigational Site, Klaipeda, Lithuania|GSK Investigational Site, Vilnius, Lithuania|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, Merida, Yucatán, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Christchurch, New Zealand|GSK Investigational Site, Newtown, Wellington, New Zealand|GSK Investigational Site, Palmerston North, New Zealand|GSK Investigational Site, Islamabad, Pakistan|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Gdansk, Poland|GSK Investigational Site, Krakow, Poland|GSK Investigational Site, Kraków, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Olsztyn, Poland|GSK Investigational Site, Poznan, Poland|GSK Investigational Site, Warszawa, Poland|GSK Investigational Site, Chelyabinsk, Russian Federation|GSK Investigational Site, Kazan, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Omsk, Russian Federation|GSK Investigational Site, Samara, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Voronezh, Russian Federation|GSK Investigational Site, Yaroslavl, Russian Federation|GSK Investigational Site, Bratislava, Slovakia|GSK Investigational Site, Sfax, Tunisia|GSK Investigational Site, Sousse, Tunisia|GSK Investigational Site, Tunis, Tunisia|GSK Investigational Site, Tunis, Tunisia|GSK Investigational Site, Donetsk, Ukraine|GSK Investigational Site, Kharkiv, Ukraine|GSK Investigational Site, Kyiv, Ukraine|GSK Investigational Site, Lviv, Ukraine|GSK Investigational Site, Zaporizhzhya, Ukraine|GSK Investigational Site, Exeter, Devon, United Kingdom|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Bebington, Wirral, United Kingdom|GSK Investigational Site, Belfast, United Kingdom|GSK Investigational Site, Swansea, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00334282"
714,"NCT00130897","Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma",,"Approved for marketing","No Results Available","Carcinoma, Renal Cell","Drug: Sutent",,"Pfizer","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"A6181037","July 2005","November 2011","November 2011","August 16, 2005",,"March 9, 2012","Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, San Francisco, California, United States|Pfizer Investigational Site, Aurora, Colorado, United States|Pfizer Investigational Site, Norwalk, Connecticut, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Maywood, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Council Bluffs, Iowa, United States|Pfizer Investigational Site, Covington, Louisiana, United States|Pfizer Investigational Site, Gretna, Louisiana, United States|Pfizer Investigational Site, Marrero, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, Metairie, Louisiana, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Baltimore, Maryland, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Detroit, Michigan, United States|Pfizer Investigational Site, Minneapolis, Minnesota, United States|Pfizer Investigational Site, Southaven, Mississippi, United States|Pfizer Investigational Site, Tupelo, Mississippi, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Columbia, Missouri, United States|Pfizer Investigational Site, Omaha, Nebraska, United States|Pfizer Investigational Site, Bronx, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Durham, North Carolina, United States|Pfizer Investigational Site, Cleveland, Ohio, United States|Pfizer Investigational Site, Norman, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Oklahoma City, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Portland, Oregon, United States|Pfizer Investigational Site, Hershey, Pennsylvania, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Memphis, Tennessee, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Salt Lake City, Utah, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Madison, Wisconsin, United States|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Buenos Aires, Argentina|Pfizer Investigational Site, Randwick, New South Wales, Australia|Pfizer Investigational Site, St Leonards, New South Wales, Australia|Pfizer Investigational Site, Westmead, New South Wales, Australia|Pfizer Investigational Site, South Brisbane, Queensland, Australia|Pfizer Investigational Site, Elizabeth Vale, South Australia, Australia|Pfizer Investigational Site, Woodville South, South Australia, Australia|Pfizer Investigational Site, East Melbourne, Victoria, Australia|Pfizer Investigational Site, Heidelburg, Victoria, Australia|Pfizer Investigational Site, Perth, Western Australia, Australia|Pfizer Investigational Site, Innsbruck, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Sarajevo, Bosnia and Herzegovina|Pfizer Investigational Site, Salvador, BA, Brazil|Pfizer Investigational Site, Belo Horizonte, MG, Brazil|Pfizer Investigational Site, Porto Alegre, Rio Grande do Sul, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Jau, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, Jaú, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Sofia, Bulgaria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Edmonton, Alberta, Canada|Pfizer Investigational Site, Kelowna, British Columbia, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Victoria, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Winnnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, London, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Quebec, Canada|Pfizer Investigational Site, Santiago, RM, Chile|Pfizer Investigational Site, Bogotá, Cundinamarca, Colombia|Pfizer Investigational Site, Cali, Colombia|Pfizer Investigational Site, Rijeka, Croatia|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Brno, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Praha 8, Czech Republic|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Cairo, Egypt|Pfizer Investigational Site, Giza, Egypt|Pfizer Investigational Site, Turku, Finland|Pfizer Investigational Site, Lyon, Cedex 08, France|Pfizer Investigational Site, Saint Herblain, Cedex, France|Pfizer Investigational Site, Strasbourg, Cedex, France|Pfizer Investigational Site, Bordeaux, France|Pfizer Investigational Site, Clermont Ferand, France|Pfizer Investigational Site, Marseille Cedex 9, France|Pfizer Investigational Site, Marseille, France|Pfizer Investigational Site, Montpellier, France|Pfizer Investigational Site, Paris Cedex 13, France|Pfizer Investigational Site, Paris, France|Pfizer Investigational Site, Reims, France|Pfizer Investigational Site, Rennes, France|Pfizer Investigational Site, Tours, France|Pfizer Investigational Site, Vandoeuvre les Nancy, France|Pfizer Investigational Site, Aachen, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Essen, Germany|Pfizer Investigational Site, Frankfurt, Germany|Pfizer Investigational Site, Freiburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hannover, Germany|Pfizer Investigational Site, Homburg/Saar, Germany|Pfizer Investigational Site, Jena, Germany|Pfizer Investigational Site, Kassel, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Rostock, Germany|Pfizer Investigational Site, Ulm, Germany|Pfizer Investigational Site, Athens, Attiki, Greece|Pfizer Investigational Site, Athens, Greece|Pfizer Investigational Site, Patras, Greece|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Hong Hong, Hong Kong|Pfizer Investigational Site, Budapest, Hungary|Pfizer Investigational Site, New Delhi, Delhi, India|Pfizer Investigational Site, Pune, Maharashtra, India|Pfizer Investigational Site, Parel, Mumbai, India|Pfizer Investigational Site, Jaipur, Rajasthan, India|Pfizer Investigational Site, New Delhi, India|Pfizer Investigational Site, Dublin 24, Ireland|Pfizer Investigational Site, Dublin, Ireland|Pfizer Investigational Site, Jerusalem, Israel|Pfizer Investigational Site, Tel Hashomer, Israel|Pfizer Investigational Site, Bergamo, Italy|Pfizer Investigational Site, Brescia, Italy|Pfizer Investigational Site, Cattolica (RN), Italy|Pfizer Investigational Site, Cuneo, Italy|Pfizer Investigational Site, Legnago, VR, Italy|Pfizer Investigational Site, Modena, Italy|Pfizer Investigational Site, Napoli, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Parma, Italy|Pfizer Investigational Site, Pavia, Italy|Pfizer Investigational Site, Perugia, Italy|Pfizer Investigational Site, Pordenone, Italy|Pfizer Investigational Site, Rimini, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Roma, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Beirut, Lebanon|Pfizer Investigational Site, Petaling Jaya, Selangor, Malaysia|Pfizer Investigational Site, Kuala Lumpur, Malaysia|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Mexico, DF, Mexico|Pfizer Investigational Site, Toluca, Estado de Mexico, Mexico|Pfizer Investigational Site, Guadalajara, Jalisco, Mexico|Pfizer Investigational Site, Merida, Yucatan, Mexico|Pfizer Investigational Site, Chihuahua, Mexico|Pfizer Investigational Site, Puebla, Mexico|Pfizer Investigational Site, Groningen, GR, Netherlands|Pfizer Investigational Site, Amsterdam, NH, Netherlands|Pfizer Investigational Site, Amsterdam, Netherlands|Pfizer Investigational Site, Rotterdam, Netherlands|Pfizer Investigational Site, Oslo, Norway|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Panama, Panama|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Quezon City, Philippines|Pfizer Investigational Site, Gdansk, Poland|Pfizer Investigational Site, Lodz, Poland|Pfizer Investigational Site, Poznan, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Wroclaw, Poland|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Porto, Portugal|Pfizer Investigational Site, Bucuresti, Romania|Pfizer Investigational Site, Cluj-Napoca, Romania|Pfizer Investigational Site, Obninsk, Kaluga region, Russian Federation|Pfizer Investigational Site, Chelyabinsk, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bratislava, Slovakia|Pfizer Investigational Site, Zilina, Slovakia|Pfizer Investigational Site, Ljubljana, Slovenia|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, L'hospitalet Del Llobregat, Barcelona, Spain|Pfizer Investigational Site, Pamplona, Navarra, Spain|Pfizer Investigational Site, Baracaldo, Vizcaya, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, La Coruña, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Salamanca, Spain|Pfizer Investigational Site, Sevilla, Spain|Pfizer Investigational Site, Valencia, Spain|Pfizer Investigational Site, Göteborg, Sweden|Pfizer Investigational Site, Lund, Sweden|Pfizer Investigational Site, Stockholm, Sweden|Pfizer Investigational Site, Umeå, Sweden|Pfizer Investigational Site, Basel, Switzerland|Pfizer Investigational Site, Bellinzona, Switzerland|Pfizer Investigational Site, Bern, Switzerland|Pfizer Investigational Site, Biel, Switzerland|Pfizer Investigational Site, CH-4058 Basel, Switzerland|Pfizer Investigational Site, CH-4101 Bruderholz, Switzerland|Pfizer Investigational Site, CH-4410 Liesthal, Switzerland|Pfizer Investigational Site, Chur, Switzerland|Pfizer Investigational Site, Genève 14, Switzerland|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Taoyun, Taiwan|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Bangkok, Thailand|Pfizer Investigational Site, Istanbul, Capa, Turkey|Pfizer Investigational Site, Istanbul, Cerrahpasa, Turkey|Pfizer Investigational Site, Whitchurch, Cardiff, United Kingdom|Pfizer Investigational Site, London, Se1 9rt, United Kingdom|Pfizer Investigational Site, Sutton, Surrey, United Kingdom|Pfizer Investigational Site, Leeds, West Yorkshire, United Kingdom|Pfizer Investigational Site, Belfast, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Birmingham, United Kingdom|Pfizer Investigational Site, Bristol, United Kingdom|Pfizer Investigational Site, Cottingham, United Kingdom|Pfizer Investigational Site, Edinburgh, United Kingdom|Pfizer Investigational Site, Guildford, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, Manchester, United Kingdom|Pfizer Investigational Site, Northwood, United Kingdom|Pfizer Investigational Site, Nottingham, United Kingdom|Pfizer Investigational Site, Sheffield, United Kingdom|Pfizer Investigational Site, Southampton, United Kingdom|Pfizer Investigational Site, Swansea, United Kingdom|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela|Pfizer Investigational Site, Caracas, Estado Miranda, Venezuela",,"https://ClinicalTrials.gov/show/NCT00130897"
715,"NCT00562965","Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)",,"Terminated","Has Results","Lymphoma, Follicular","Drug: inotuzumab ozogamicin|Drug: rituximab|Drug: cyclophosphamide|Drug: vincristine|Drug: prednisone/prednisolone|Drug: mitoxantrone|Drug: fludarabine|Drug: dexamethasone","Progression-Free Survival (PFS)|Percentage of Participants With Objective Response (OR)|Overall Survival Probability at Months 6, 12 and 24|Pharmacokinetics of Inotuzumab Ozogamicin in Combination With Rituximab","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","29","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","3129K4-3301|B1931006|2007-000219-27","November 2007","April 2011","April 2011","November 26, 2007","January 9, 2018","January 9, 2018","Facey Medical Group, Mission Hills, California, United States|Deaconess Clinic, Evansville, Indiana, United States|The Harry & Jeanette Weinberg Cancer Inst at Franklin Square, Baltimore, Maryland, United States|Newland Medical Associates, Novi, Michigan, United States|Newland Medical Associates, PC, Southfield, Michigan, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Hematology and Oncology Associates, Columbus, Mississippi, United States|Hematology and Oncology Associates, Corinth, Mississippi, United States|Hematology and Oncology Associates at Bridgepoint, Tupelo, Mississippi, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology Oncology Associates of Northern New Jersy, Morristown, New Jersey, United States|Advanced Oncology Associates, Armonk, New York, United States|Avi Einzing, MD, Bronx, New York, United States|Advanced Oncology Associates, New Rochelle, New York, United States|Marc Zimmerman, MD, Pomona, New York, United States|Wenatchee Valley Medical Center, Wenatchee, Washington, United States|Centro de Transplantes de medula Osea de Rosario, CETRAMOR, Rosario, Santa FE, Argentina|Universitair Ziekenhuis Gent, Gent, Belgium|Oncologisch Centrum GZA - Location St. Augustinus, Wilrijk, Belgium|Hopital Charles LeMoyne, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CHUS-Hopital Fleurimont, Sherbrooke, Quebec, Canada|C.H.A. Enfant-Jesus, Quebec, Canada|Prince of Wales Hospital, Shatin, NEW Territories, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Jehangir Clinical Development Centre, Pune, Maharashtra, India|MMF Joshi Hospital and Ratna Memorial Hospital, Pune, Maharashtra, India|B. P. Poddar Hospital and Medical Research Ltd., Kolkata, WEST Bengal, India|Divisione di Ematologia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Yonsei University Health System-Severance Hospital, Seoul, Korea, Republic of|Hospital Universitario de Nuevo Leon, Monterrey, Nuevo LEON, Mexico|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Hospitais Da Universidade De Coimbra, Coimbra, Portugal|Moscow Regional Research Clinical Institute named after Vladimirsky, Moscow, Russian Federation|Wits Donald Gordon Clinical Trial Site, Johannesburg, Gauteng, South Africa|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital de La Princesa, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00562965"
716,"NCT01587144","Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)",,"Terminated","No Results Available","Glioblastoma Multiforme","Drug: Lucanthone|Drug: Temozolomide (TMZ)|Radiation: Radiation|Drug: Placebo","Progression Free Survival|Objective response rate (ORR)|Overall Survival|Safety Profile of Lucanthone","Spectrum Pharmaceuticals, Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","SPI-LUC-11-01","June 19, 2012","April 15, 2013","April 15, 2013","April 30, 2012",,"October 19, 2021","UCSD Moores Cancer Center, La Jolla, California, United States|UCI Medical Center, Orange, California, United States|Dent Neurologic Institute, Amherst, New York, United States|Fairview Hospital Moll Cancer Center/Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Hillcrest Hospital Hirsh Cancer Center/Cleveland Clinic, Mayfield, Ohio, United States|Gujarat Cancer Research Institute, Ahmedabad, Gujarat, India|Jaslok Hospital & Research Centre, Mumbai, Maharashtra, India|Bhagwan Mahaveer Cancer Hospital & Reseach Centre, Jaipur, Rajasthan, India|Chittaranjan National Cancer Institute, Kolkata, West Bengal, India",,"https://ClinicalTrials.gov/show/NCT01587144"
717,"NCT02180217","Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease",,"Completed","Has Results","Cushings Disease","Drug: osilodrostat|Drug: LCI699 matching placebo","Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and Strata|Percentage of Secondary Efficacy Responder at Week 24 (Key Secondary Endpoint)|Time-to-loss of Control of Mean Urinary Free Cortisol (mUFC) by Randomized Treatment Group|Complete Response Rate (CRR)|Actual Change From Baseline in mUFC|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Fasting Glucose|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Hemoglobin A1C (HbA1C)|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Cholesterol, LDL Cholesterol, HDL Cholesterol & Triglyceride|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Sitting Systolic Blood Pressure (SBP) & Sitting Diastolic Blood Pressure (DBP)|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Weight|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Body Mass Index (BMI)|Actual Change From Baseline in Cardiovascular-related Parameter Associated With Cushing's Disease: Waist Circumference|Actual Change From Baseline in Patient-Reported Outcomes (Cushing's Health-Related Quality of Life (QoL)) - Total Score|Actual Change From Baseline in Patient-Reported Outcomes: Beck Depression Inventory-II (BDI-II)|Actual Change in Patient-Reported Outcomes: EQ-5D-5L Utility Index|Actual Change in Patient-Reported Outcomes: EQ-5D-5L Vascular Analog Scale (VAS)|Change From Baseline in the Physical Features of Cushing's Disease by Photography|Change From Baseline in Bone Mineral Density - All Participants|Time-to-escape|LCI699 Exposures|Percentage of Participants With Complete Response Rate (CRR)|Percentage of Participants With Partial Response Rate (PRR)|Percentage of Participants With Overall Response Rate (ORR)","Novartis Pharmaceuticals|Novartis","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","137","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLCI699C2301|2013-004766-34","October 6, 2014","February 21, 2018","December 4, 2019","July 2, 2014","June 16, 2020","January 6, 2021","University of Colorado Hospital SC - LCI699C2301, Aurora, Colorado, United States|Emory University School of Medicine G2304 - C2301, Atlanta, Georgia, United States|Northwestern University SC - LCI699C2301, Chicago, Illinois, United States|The Johns Hopkins University School of Medicine Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital Neuroendocrine Unit, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine SC - LCI699C2301, New York, New York, United States|Columbia University Medical Center New York Presbyterian SC - LCI699C2301, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health and Science University SC LCI699C2301, Portland, Oregon, United States|University of Pennsylvania Clinical Studies Unit Unniv SC, Philadelphia, Pennsylvania, United States|Medical College of Wisconsin MCW 2, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Edmonton, Alberta, Canada|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Cali, Colombia|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Muenchen, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Chandigarh, Punjab, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Pisa, PI, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Kobe-shi, Hyogo, Japan|Novartis Investigative Site, Nishinomiya, Hyogo, Japan|Novartis Investigative Site, Yokohama, Kanagawa, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02180217/SAP_002.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/17/NCT02180217/Prot_003.pdf","https://ClinicalTrials.gov/show/NCT02180217"
718,"NCT04524273","Myasthenia Gravis Inebilizumab Trial","MINT","Recruiting","No Results Available","Myasthenia Gravis","Drug: inebilizumab|Drug: IV Placebo","Change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) Profile score.|Change in Quantitative Myasthenia Gravis (QMG) scores.|Proportion of subjects with both (1) ≥ 3-point improvement in MG-ADL and (2) no use of rescue therapy.|Change in MG-ADL at Week 26 in the AChR-Ab+ population. (AChR-Ab+ Only)|Time to first exacerbation.|Change in Myasthenia Gravis Composite (MGC) score.|Change in Myasthenia Gravis Quality of Life-15, revised (MGQOL-15r) score.|Change in Patient Global Impression of Change (PGIC) score.|Number of participants with treatment-emergent adverse events (TEAEs), adverse events of special interest (AESIs), and treatment-emergent serious adverse events (TESAEs) during the randomized controlled period and open-label period.","Viela Bio (acquired by Horizon Therapeutics)","All","18 Years and older   (Adult, Older Adult)","Phase 3","270","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VIB0551.P3.S1","August 30, 2020","June 30, 2023","December 28, 2024","August 24, 2020",,"April 11, 2022","Viela Bio Investigative Site - 1010, Scottsdale, Arizona, United States|Viela Bio Investigative Site - 1015, Orange, California, United States|Viela Bio Investigative Site - 1013, Aurora, Colorado, United States|Viela Bio Investigative Site - 1002, New Haven, Connecticut, United States|Viela Bio Investigative Site - 1005, Tampa, Florida, United States|Viela Bio Investigative Site - 1016, Augusta, Georgia, United States|Viela Bio Investigative Site - 1012, Kansas City, Kansas, United States|Viela Bio Investigative Site - 1011, Minneapolis, Minnesota, United States|Viela Bio Investigative Site - 1020, Great Neck, New York, United States|Viela Bio Investigative Site - 1007, New York, New York, United States|Viela Bio Investigative Site - 1018, Charlotte, North Carolina, United States|Viela Bio Investigative Site - 1001, Cincinnati, Ohio, United States|Viela Bio Investigative Site - 1009, Columbus, Ohio, United States|Viela Bio Investigative Site - 1008, Pittsburgh, Pennsylvania, United States|Viela Bio Investigative Site - 1019, Austin, Texas, United States|Viela Bio Investigative Site - 1003, Houston, Texas, United States|Viela Bio Investigative Site - 1014, San Antonio, Texas, United States|Viela Bio Investigative Site - 1017, Salt Lake City, Utah, United States|Viela Bio Investigative Site - 1004, Burlington, Vermont, United States|Viela Bio Investigative Site - 1006, Richmond, Virginia, United States|VielaBio Investigative Site - 2002, Buenos Aires, Argentina|Viela Bio Investigative Site - 2001, Buenos Aires, Argentina|Viela Bio Investigative Site - 5203, Grodno, Belarus|Viela Bio Investigative Site - 5202, Minsk, Belarus|Viela Bio Investigative Site - 5204, Minsk, Belarus|Viela Bio Investigative Site - 5201, Vitebsk, Belarus|VielaBio Investigative Site - 2201, Porto Alegre, Brazil|VielaBio Investigative Site - 2203, Porto Alegre, Brazil|VielaBio Investigative Site - 2207, Ribeirão Preto, Brazil|VielaBio Investigative Site - 2206, San Paolo, Brazil|Viela Bio Investigative Site - 1102, Toronto, Ontario, Canada|Viela Bio Investigative Site - 1101, Montréal, Quebec, Canada|Viela Bio Investigative Site - 1103, Montréal, Quebec, Canada|Viela Bio Investigative Site - 1104, West Vancouver, Canada|Viela Bio Investigative Site - 4007, Beijing, China|Viela Bio Investigative Site - 4005, Guiyang, China|Viela Bio Investigative Site - 4006, Shanghai, China|Viela Bio Investigative Site - 4008, Suzhou, China|Viela Bio Investigative Site - 4004, Tianjin, China|Viela Bio Investigative Site - 5602, Aarhus, Denmark|Viela Bio Investigative Site - 5601, Copenhagen, Denmark|Viela Bio Investigative Site - 3003, Lille Cedex, France|Viela Bio Investigative Site - 3001, Nice Cedex 01, France|Viela Bio Investigative Site - 3002, Strasbourg, France|VielaBio Investigative Site - 3101, Essen, Germany|Viela Bio Investigative Site - 4113, Nagpur, Maharashtra, India|Viela Bio Investigative Site - 4111, Vellore, Tamil Nadu, India|Viela Bio Investigative Site - 4112, Hyderabad, Telangana, India|Viela Bio Investigative Site - 4104, Bangalore, India|Viela Bio investigative Site - 4105, Lucknow, India|Viela Bio Investigative Site - 4103, Manipala, India|Viela Bio Investigative Site - 4107, Nagpur, India|Viela Bio Investigative Site - 4102, Nashik, India|Viela Bio Investigative Site - 4108, Pune, India|Viela Bio Investigative Site - 4109, Pune, India|Viela Bio Investigative Site - 4101, Surat, India|Viela Bio Investigative Site - 5701, Jerusalem, Israel|Viela Bio Investigative Site - 5702, Tel Aviv, Israel|Viela Bio Investigative Site - 3204, Milano, Italy|Viela Bio Investigative Site - 3203, Milano, Italy|Viela Bio Investigative Site - 3201, Pavia, Italy|Viela Bio Investigative Site - 3202, Rome, Italy|Viela Bio Investigative Site - 4402, Chiba, Japan|Viela Bio Investigative Site - 4401, Hanamaki, Japan|VielaBio Investigative Site - 4408, Hokkaido, Japan|VielaBio Investigative Site - 4407, Morioka-shi, Japan|Viela Bio Investigative Site - 4404, Saitama, Japan|Viela Bio Investigative Site - 4202, Seoul, Korea, Republic of|Viela Bio Investigative Site - 4203, Seoul, Korea, Republic of|Viela Bio Investigative Site - 4201, Seoul, Korea, Republic of|Viela Bio Investigative Site - 3301, Kraków, Poland|Viela Bio Investigative Site - 5303, Barnaul, Russian Federation|Viela Bio Investigative Site - 5302, Nizhny Novgorod, Russian Federation|Viela Bio Investigative Site - 5304, Novosibirsk, Russian Federation|Viela Bio Investigative Site - 5311, Rostov-on-Don, Russian Federation|Viela Bio Investigative Site - 5309, Rostov-on-Don, Russian Federation|Viela Bio Investigative Site - 5308, Saint Petersburg, Russian Federation|Viela Bio Investigative Site - 5305, Samara, Russian Federation|Viela Bio Investigative Site - 5306, Smolensk, Russian Federation|Viela Bio Investigative Site - 5301, Tomsk, Russian Federation|Viela Bio Investigative Site - 5312, Ufa, Russian Federation|Viela Bio Investigative Site - 3403, Badalona, Spain|Viela Bio Investigative Site - 3402, Barcelona, Spain|Viela Bio Investigative Site - 3404, Córdoba, Spain|Viela Bio Investigative Site - 3401, Madrid, Spain|Viela Bio Investigative Site - 4601, Changhua, Taiwan|Viela Bio investigative Site - 4605, Kaohsiung City, Taiwan|Viela Bio Investigative Site - 4606, Tainan, Taiwan|Viela Bio Investigative Site - 4604, Taipei, Taiwan|Viela Bio Investigative Site - 4603, Taipei, Taiwan|Viela Bio Investigative Site - 4602, Taoyuan City, Taiwan|Viela Bio Investigative Site - 5103, Dnipro, Ukraine|Viela Bio Investigative Site - 5105, Ivano-Frankivs'k, Ukraine|Viela Bio Investigative Site - 5104, Lutsk, Ukraine|Viela Bio Investigative Site - 5101, Lviv, Ukraine|Viela Bio Investigative Site - 5106, Vinnytsia, Ukraine",,"https://ClinicalTrials.gov/show/NCT04524273"
719,"NCT01374906","Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease",,"Completed","Has Results","Cushing's Disease","Drug: pasireotide LAR|Drug: SOM230 LAR 30 mg|Drug: SOM230 LAR 10 mg","Percentage Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 Regardless of Dose Titration|Percentage of Participants That Attained a mUFC ≤ 1.0 x ULN at Month 7 and Had Not Had a Dose Increase at Month 4|Actual Change in Mean Urinary Free Cortisol (mUFC) From Baseline|Percentage Change in Mean Urinary Free Cortisol (mUFC) From Baseline|Percentage of Patients Who Attain mUFC ≤ 1.0 x ULN|Percentage of Patients Who Attain mUFC ≤1.0 x ULN or Have at Least 50 % Reduction From Baseline in mUFC|Percentage of Patients Who Are Controlled Responders (mUFC ≤ 1.0 xULN) on at Least 4 of the 7 mUFC Assessments by Month 7 & on at Least 7 of the 12 mUFC Assessments by Month 12.|Percentage of Patients With Uncontrolled Response at Month 7 & Month 12 Within the Subset of Patients Who Had Uncontrolled Response at a) Months 1 and 2; b) Months 1, 2, and 3|Percent of Participants Attaining a mUFC ≤ 1.0 x ULN or at Least a 50% Reduction in mUFC From Baseline at Indicated Time Points|Percent of Participants Attaining a Duration of Controlled or Partially Controlled Response at Indicated Time Points|Percentage Change From Baseline on Plasma Adrenocorticotropic Hormone (ACTH) Over Time|Percentage Change From Baseline on Serum Cortisol Over Time|Actual Change From Baseline in Clinical Signs Over Time: Blood Pressure|Actual Change From Baseline in Clinical Signs Over Time: Body Mass Index (BMI)|Actual Change From Baseline in Clinical Signs Over Time: Weight|Actual Change From Baseline in Clinical Signs Over Time: Body Composition: Region|Actual Change From Baseline in Clinical Signs Over Time: Waist Circumference|Actual Change From Baseline in Clinical Signs Over Time: Cholesterol & Triglycerides|Percentage Change From Baseline in Clinical Signs Over Time|Percentage of Participants Having a Favorable Shift From Baseline in Clinical Signs|Percentage of Participants That Attained a Mean Urinary Free Cortisol (mUFC) <= 1.0 x Upper Limit of Normal (ULN) at Month 7 Regardless of Dose Up-titration at Month 4.|Percentage of Patients That Attain a Reduction of at Least 50% in mUFC From Baseline|Percent of Participants Attaining a Time to First Achievement of at Least a 50% Reduction in mUFC From Baseline at Indicated Time Points|Percent of Participants With a Duration of at Least 50% Reduction in mUFC From Baseline at Indicated Time Points|Pharmacokinetic (PK) Parameter: Ctrough|Pharmacokinetic (PK) Parameter: Cmax|Actual Change in Standardized Score of Cushing's Disease HRQoL (CushingQOL) Score From Baseline|Actual Change in SF-12v2 Score From Baseline - Mental Component Summary|Actual Change in SF-12v2 Score From Baseline - Physical Component Summary","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CSOM230G2304|2009-011128-70","November 4, 2011","December 21, 2016","December 21, 2016","June 16, 2011","April 11, 2018","May 22, 2018","ClinTriCo, Phoenix, Arizona, United States|University of California at Los Angeles UCLA Tiverton, Los Angeles, California, United States|Harbor-UCLA Medical Center LA Biomed, Torrance, California, United States|Emory University School of Medicine/Winship Cancer Institute G2304 - C2301, Atlanta, Georgia, United States|Pituitary Center, Division of Endocrinology SC, Baltimore, Maryland, United States|University of Michigan Comprehensive Cancer Center SC-2, Ann Arbor, Michigan, United States|Mount Sinai School of Medicine Mt. Sinai Medical Center, New York, New York, United States|Oregon Health & Sciences University DeptofOregonHealth&Sciences(2), Portland, Oregon, United States|University of Pennsylvania - Clinical Studies Unit Unniv SC, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center CSOM230G2304, Nashville, Tennessee, United States|Swedish Medical Center Swedish, Seattle, Washington, United States|Medical College of Wisconsin MCW 2, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Edegem, Antwerpen, Belgium|Novartis Investigative Site, Jette, Brussel, Belgium|Novartis Investigative Site, Bruxelles, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Ribeirao Preto, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Halifax, Nova Scotia, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Besancon cedex, France|Novartis Investigative Site, Caen Cedex9, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Marseille Cédex 5, France|Novartis Investigative Site, Pessac Cedex, France|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Germering, Germany|Novartis Investigative Site, Wurzburg, Germany|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, New Delhi, India|Novartis Investigative Site, Petach Tikva, Israel|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Padova, PD, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Maebashi city, Gunma, Japan|Novartis Investigative Site, Sapporo-city, Hokkaido, Japan|Novartis Investigative Site, Kobe-city, Hyogo, Japan|Novartis Investigative Site, Nankoku-city, Kochi, Japan|Novartis Investigative Site, Kyoto-city, Kyoto, Japan|Novartis Investigative Site, Suita-city, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Minato-ku, Tokyo, Japan|Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Jesus Maria, Lima, Peru|Novartis Investigative Site, Miraflores, Lima, Peru|Novartis Investigative Site, Gdansk, Poland|Novartis Investigative Site, Poznan, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, St.- Petersburg, Russian Federation|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Alzira, Comunidad Valenciana, Spain|Novartis Investigative Site, Barcelona, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Diskapi / Ankara, Ankara, Turkey|Novartis Investigative Site, Istanbul, TUR, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Salford, Manchester, United Kingdom|Novartis Investigative Site, Norwich, United Kingdom|Novartis Investigative Site, Sheffield, United Kingdom|Novartis Investigative Site, Southampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01374906"
720,"NCT04930536","Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma",,"Recruiting","No Results Available","Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma","Drug: Acalabrutinib capsule","To assess the safety of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma|To assess the efficacy of Acalabrutinib capsules in Indian adult patients with chronic lymphocytic leukaemia and relapsed and refractory mantle cell lymphoma|Patient reported outcome","AstraZeneca","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 4","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D8220C00022","July 14, 2021","October 3, 2022","October 3, 2022","June 18, 2021",,"May 10, 2022","Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Bangalore, India|Research Site, Bengaluru, India|Research Site, Chandigarh, India|Research Site, Gurugram, India|Research Site, Guwahati, India|Research Site, Hyderabad, India|Research Site, Hyderabad, India|Research Site, Kochi, India|Research Site, Kolkata, India|Research Site, Ludhiana, India|Research Site, Mumbai, India|Research Site, Mumbai, India|Research Site, New Delhi, India",,"https://ClinicalTrials.gov/show/NCT04930536"
721,"NCT00295815","Enzastaurin Versus Lomustine in Glioblastoma",,"Completed","No Results Available","Glioblastoma","Drug: enzastaurin|Drug: lomustine","The primary objective is to compare Enzastaurin versus Lomustine in patients who for the second time have brain cancer (specifically intracranial glioblastoma) to see what effect the drugs have on keeping the disease from progressing (worsening).|To measure survival to see how the tumor responded to the therapy and how long the response lasted using MRI (a scanning technique).|To measure changes in patient's ability to care for themselves (this will be determined through a standard survey).|To measure changes from baseline and a neurologic exam.|To review all bad reactions reported by the patient and detected in blood tests.|To review the effect of the cancer on the patient's ability to care for themselves and on their general health status.|To determine through blood tests how long the medication is in the patient's body.|To review through testing of tumor and blood samples to see if there are reasons why some patients responded to the drugs better than other patients.","Eli Lilly and Company","All","18 Years and older   (Adult, Older Adult)","Phase 3","397","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","9817|H6Q-MC-JCBF","January 2006","August 2007","May 2014","February 24, 2006",,"September 12, 2019","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Phoenix, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tucson, Arizona, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Berkeley, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Los Angeles, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Francisco, California, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Aurora, Colorado, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Newark, Delaware, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tampa, Florida, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Atlanta, Georgia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Honolulu, Hawaii, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chicago, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Peoria, Illinois, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Iowa City, Iowa, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kansas City, Kansas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Baltimore, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bethesda, Maryland, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Boston, Massachusetts, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Detroit, Michigan, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Minneapolis, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rochester, Minnesota, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbia, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saint Louis, Missouri, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Omaha, Nebraska, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Las Vegas, Nevada, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lebanon, New Hampshire, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Albuquerque, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Santa Fe, New Mexico, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Buffalo, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New York, New York, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Winston-Salem, North Carolina, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Columbus, Ohio, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pittsburgh, Pennsylvania, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Memphis, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nashville, Tennessee, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lubbock, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Antonio, Texas, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Salt Lake City, Utah, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Charlottesville, Virginia, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Seattle, Washington, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madison, Wisconsin, United States|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St Leonards, New South Wales, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Auchenflower, Queensland, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Victoria, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nedlands, Western Australia, Australia|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Graz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Innsbruck, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Linz, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wien, Austria|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Brussels, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leuven, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liège, Belgium|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ottawa, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toronto, Ontario, Canada|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lyon, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Marseille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Nancy, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Paris, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Poitiers, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bonn, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dresden, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Freiburg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Heidelberg, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., München, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tübingen, Germany|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mumbai, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., New Delhi, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vellore, India|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bologna, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Milano, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Napoli, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Roma, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Torino, Italy|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Ciudad Obregon, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Guadalajara, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Monterrey, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tijuana, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tlalpan, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toluca, Mexico|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Amsterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Den Haag, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Maastricht, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rotterdam, Netherlands|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lublin, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Warsaw, Poland|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Badalona, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Hospitalet Llobregat, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Madrid, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oviedo, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Valencia, Spain|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bristol, Avon, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cambridge, Cambridgeshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Edinburgh, Scotland, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Glasgow, Scotland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00295815"
722,"NCT03476655","Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India",,"Completed","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Mantle-Cell","Drug: Ibrutinib","Overall Response Rate (ORR)|Time to Progression (TTP)|Percentage of Participants with Complete Response (CR)|Percentage of Participants with Partial Response (PR)|Percentage of Participants with Stable Disease (SD)|Percentage of Participants with Progressive Disease (PD)|Median time to Response with Ibrutinib|Change from Baseline in Hemoglobin Levels|Change from Baseline in Platelet Counts|Number of Participants with Response to Ibrutinib by Prior Lines of Therapy|Number of Participants with Hematological and Non-hematological Adverse Drug Reactions (ADR)","Johnson & Johnson Private Limited","All","18 Years and older   (Adult, Older Adult)",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CR108441|54179060LYM4007","April 28, 2018","May 14, 2019","May 31, 2019","March 26, 2018",,"August 7, 2020","Apollo Hospitals International Limited, Ahmedabad, India|Healthcare Global (HCG) Hospital, Bangalore, India|Fortis Memorial Research Institute, Gurgaon, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Bhagwan Mahaveer Hospital & Research Centre, Jaipur, India|Tata Medical Center, Kolkata, India|All India Institute of Medical Sciences, New Delhi, India|Yashoda Hematology Clinic, Pune, India",,"https://ClinicalTrials.gov/show/NCT03476655"
723,"NCT03190330","A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion",,"Active, not recruiting","No Results Available","Leukemia, Lymphocytic, Chronic, B-Cell|Lymphoma, Mantle-Cell","Drug: Ibrutinib 420 mg|Drug: Ibrutinib 560 mg","Number of Participants With Adverse Events as a Measure of Safety and Tolerability","Johnson & Johnson Private Limited","All","18 Years and older   (Adult, Older Adult)","Phase 4","75","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","CR108316|54179060LYM4005","June 26, 2019","April 9, 2022","April 21, 2023","June 16, 2017",,"May 5, 2022","Avron Hospitals Pvt. Ltd, Ahmedabad, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India|Cytecare Hospitals Pvt. Ltd, Karnataka, India|Apollo Multispeciality Hospital Ltd, Kolkata, India|Tata Medical Center, Kolkata, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, India|Noble Hospital Pvt Ltd, Pune, India|Regional Cancer Centre, Thiruvananthapuram, India|Christian Medical College, Vellore, India",,"https://ClinicalTrials.gov/show/NCT03190330"
724,"NCT04964908","Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia","CREEK","Recruiting","No Results Available","Chronic Lymphocytic Leukemia",,"To describe the clinical characteristics for with chronic lymphocytic leukemia (CLL) patients|Calculation of Epidemiological Measure(s) of Interest|To describe disease Characteristics|Recording the treatment patterns|Subsequent lines of therapies","AstraZeneca","All","Child, Adult, Older Adult",,"1333","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","D8220R00031","November 7, 2021","September 30, 2022","September 30, 2022","July 16, 2021",,"April 20, 2022","Research Site, Argentina, Argentina|Research Site, Cairo, Egypt|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Faridabad, India|Research Site, Hitech, India|Research Site, New Delhi, India|Research Site, Shibpur, India|Research Site, Kuwait, Kuwait|Research Site, Riyadh, Saudi Arabia|Research Site, Adana, Turkey|Research Site, Ankara, Turkey|Research Site, Izmir, Turkey|Research Site, Samsun, Turkey",,"https://ClinicalTrials.gov/show/NCT04964908"
725,"NCT02085408","Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",,"Active, not recruiting","No Results Available","Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia","Drug: clofarabine|Drug: daunorubicin hydrochloride|Other: clinical observation|Drug: cytarabine|Drug: decitabine|Other: laboratory biomarker analysis|Procedure: quality-of-life assessment|Other: questionnaire administration","Overall survival|Mortality rate|Induction complete response rates|Disease-free survival (DFS)|Epidemiological factors, measured using the Acute Leukemia Epidemiology and Survival in ECOG (ALESE) questionnaire|Change in the Functional Assessment of Cancer Therapy (FACT)-Leukemia-specific (Leu) Trial Outcome Index (TOI) score|Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)","All","60 Years and older   (Adult, Older Adult)","Phase 3","727","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E2906|NCI-2011-01992|CDR0000659585|ECOG-E2906|U10CA021115","December 28, 2010","March 15, 2021","October 2024","March 12, 2014",,"February 25, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Arizona Cancer Center at University Medical Center North, Tucson, Arizona, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|The Medical Center of Aurora, Aurora, Colorado, United States|Boulder Community Hospital, Boulder, Colorado, United States|Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States|Saint Anthony Central Hospital, Denver, Colorado, United States|Porter Adventist Hospital, Denver, Colorado, United States|Exempla Saint Joseph Hospital, Denver, Colorado, United States|Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States|Rose Medical Center, Denver, Colorado, United States|Colorado Cancer Research Program CCOP, Denver, Colorado, United States|Swedish Medical Center, Englewood, Colorado, United States|North Colorado Medical Center, Greeley, Colorado, United States|Littleton Adventist Hospital, Littleton, Colorado, United States|Sky Ridge Medical Center, Lone Tree, Colorado, United States|Longmont United Hospital, Longmont, Colorado, United States|McKee Medical Center, Loveland, Colorado, United States|Parker Adventist Hospital, Parker, Colorado, United States|Saint Mary Corwin Medical Center, Pueblo, Colorado, United States|North Suburban Medical Center, Thornton, Colorado, United States|Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States|Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States|The Hospital of Central Connecticut, New Britain, Connecticut, United States|Beebe Medical Center, Lewes, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|University of Florida, Gainesville, Florida, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Florida Hospital, Orlando, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Atlanta Regional CCOP, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Well Star Cobb Hospital, Austell, Georgia, United States|John B Amos Cancer Center, Columbus, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Gwinnett Medical Center, Lawrenceville, Georgia, United States|Wellstar Kennestone Hospital, Marietta, Georgia, United States|Southern Regional Medical Center, Riverdale, Georgia, United States|Harbin Clinic Medical Oncology and Clinical Research, Rome, Georgia, United States|Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Oncare Hawaii Inc - Kapiolani Medical Center at Pali Momi, 'Aiea, Hawaii, United States|Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States|Queen's Medical Center, Honolulu, Hawaii, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|University of Hawaii, Honolulu, Hawaii, United States|OnCare Hawaii-Liliha, Honolulu, Hawaii, United States|Kuakini Medical Center, Honolulu, Hawaii, United States|Oncare Hawaii Inc-Kuakini, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Castle Medical Center, Kailua, Hawaii, United States|Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States|Saint Alphonsus Regional Medical Center, Boise, Idaho, United States|Saint Anthony's Health, Alton, Illinois, United States|Illinois CancerCare-Bloomington, Bloomington, Illinois, United States|Saint Joseph Medical Center, Bloomington, Illinois, United States|Graham Hospital Association, Canton, Illinois, United States|Illinois CancerCare-Canton, Canton, Illinois, United States|Illinois CancerCare-Carthage, Carthage, Illinois, United States|Memorial Hospital, Carthage, Illinois, United States|Mount Sinai Hospital Medical Center, Chicago, Illinois, United States|Hematology and Oncology Associates, Chicago, Illinois, United States|Northwestern University, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Eureka Hospital, Eureka, Illinois, United States|Illinois CancerCare-Eureka, Eureka, Illinois, United States|Illinois CancerCare Galesburg, Galesburg, Illinois, United States|Western Illinois Cancer Treatment Center, Galesburg, Illinois, United States|Illinois CancerCare-Havana, Havana, Illinois, United States|Mason District Hospital, Havana, Illinois, United States|Hematology Oncology Associates of Illinois-Highland Park, Highland Park, Illinois, United States|Hinsdale Hematology Oncology Associates Incorporated, Hinsdale, Illinois, United States|Presence Saint Mary's Hospital, Kankakee, Illinois, United States|Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States|North Shore Hematology Oncology, Libertyville, Illinois, United States|Illinois CancerCare-Macomb, Macomb, Illinois, United States|Mcdonough District Hospital, Macomb, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Holy Family Medical Center, Monmouth, Illinois, United States|Illinois CancerCare-Monmouth, Monmouth, Illinois, United States|Illinois Cancer Specialists-Niles, Niles, Illinois, United States|Bromenn Regional Medical Center, Normal, Illinois, United States|Community Cancer Center Foundation, Normal, Illinois, United States|Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States|Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States|Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States|Pekin Cancer Treatment Center, Pekin, Illinois, United States|Illinois CancerCare-Pekin, Pekin, Illinois, United States|Methodist Medical Center of Illinois, Peoria, Illinois, United States|Proctor Hospital, Peoria, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Illinois Oncology Research Association CCOP, Peoria, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Illinois CancerCare-Peru, Peru, Illinois, United States|Illinois Valley Hospital, Peru, Illinois, United States|Illinois CancerCare-Princeton, Princeton, Illinois, United States|Perry Memorial Hospital, Princeton, Illinois, United States|Swedish American Hospital, Rockford, Illinois, United States|Hematology Oncology Associates of Illinois - Skokie, Skokie, Illinois, United States|Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|Saint Francis Hospital and Health Centers, Beech Grove, Indiana, United States|Fort Wayne Medical Oncology and Hematology Inc - State Boulevard, Fort Wayne, Indiana, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|Reid Hospital and Health Care Services, Richmond, Indiana, United States|McFarland Clinic, Ames, Iowa, United States|Siouxland Hematology Oncology Associates, Sioux City, Iowa, United States|Mercy Medical Center-Sioux City, Sioux City, Iowa, United States|Saint Luke's Regional Medical Center, Sioux City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Norton Health Care Pavilion - Downtown, Louisville, Kentucky, United States|Ochsner Clinic Foundation-Baton Rouge, Baton Rouge, Louisiana, United States|Ochsner Baptist Medical Center, New Orleans, Louisiana, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Harold Alfond Center for Cancer Care, Augusta, Maine, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Walter Reed National Military Medical Center, Bethesda, Maryland, United States|Union Hospital of Cecil County, Elkton, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Caritas Saint Elizabeth's Medical Center, Brighton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|Michigan Cancer Research Consortium Community Clinical Oncology Program, Ann Arbor, Michigan, United States|Bronson Battle Creek, Battle Creek, Michigan, United States|Mecosta County Medical Center, Big Rapids, Michigan, United States|Oakwood Hospital, Dearborn, Michigan, United States|Wayne State University, Detroit, Michigan, United States|Saint John Hospital and Medical Center, Detroit, Michigan, United States|Hurley Medical Center, Flint, Michigan, United States|Genesys Hurley Cancer Institute, Flint, Michigan, United States|Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States|Genesys Regional Medical Center, Grand Blanc, Michigan, United States|Grand Rapids Clinical Oncology Program, Grand Rapids, Michigan, United States|Saint Mary's Health Care, Grand Rapids, Michigan, United States|Spectrum Health at Butterworth Campus, Grand Rapids, Michigan, United States|Allegiance Health, Jackson, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|West Michigan Cancer Center, Kalamazoo, Michigan, United States|Sparrow Hospital, Lansing, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Mercy Health Partners-Mercy Campus, Muskegon, Michigan, United States|Saint Joseph Mercy Oakland, Pontiac, Michigan, United States|Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States|Spectrum Health Reed City Hospital, Reed City, Michigan, United States|Saint Mary's of Michigan, Saginaw, Michigan, United States|Providence Hospital, Southfield, Michigan, United States|Munson Medical Center, Traverse City, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Sanford Clinic North-Bemidgi, Bemidji, Minnesota, United States|Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota, United States|Essentia Health Duluth Clinic CCOP, Duluth, Minnesota, United States|Essentia Health Saint Mary's Medical Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Lake Region Healthcare Corporation-Cancer Care, Fergus Falls, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Saint Francis Medical Center, Cape Girardeau, Missouri, United States|Saint Louis Cancer and Breast Institute-South City, Saint Louis, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Saint Louis-Cape Girardeau CCOP, Saint Louis, Missouri, United States|Montana Cancer Consortium CCOP, Billings, Montana, United States|Saint Vincent Healthcare, Billings, Montana, United States|Hematology-Oncology Centers of the Northern Rockies PC, Billings, Montana, United States|Billings Clinic, Billings, Montana, United States|Bozeman Deaconess Cancer Center, Bozeman, Montana, United States|Bozeman Deaconess Hospital, Bozeman, Montana, United States|Saint James Community Hospital and Cancer Treatment Center, Butte, Montana, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|Northern Montana Hospital, Havre, Montana, United States|Saint Peter's Community Hospital, Helena, Montana, United States|Glacier Oncology PLLC, Kalispell, Montana, United States|Kalispell Medical Oncology, Kalispell, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|Montana Cancer Specialists, Missoula, Montana, United States|Saint Patrick Hospital - Community Hospital, Missoula, Montana, United States|Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Park Ridge Hospital Breast Health Center, Hendersonville, North Carolina, United States|Kinston Medical Specialists PA, Kinston, North Carolina, United States|Roger Maris Cancer Center, Fargo, North Dakota, United States|Sanford Clinic North-Fargo, Fargo, North Dakota, United States|Sanford Medical Center-Fargo, Fargo, North Dakota, United States|Summa Akron City Hospital, Akron, Ohio, United States|Akron General Medical Center, Akron, Ohio, United States|Summa Barberton Hospital, Barberton, Ohio, United States|Aultman Health Foundation, Canton, Ohio, United States|The Jewish Hospital, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|Grandview Hospital, Dayton, Ohio, United States|Good Samaritan Hospital - Dayton, Dayton, Ohio, United States|Miami Valley Hospital, Dayton, Ohio, United States|Samaritan North Health Center, Dayton, Ohio, United States|Dayton CCOP, Dayton, Ohio, United States|Blanchard Valley Hospital, Findlay, Ohio, United States|Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio, United States|Wayne Hospital, Greenville, Ohio, United States|Kettering Medical Center, Kettering, Ohio, United States|Saint Rita's Medical Center, Lima, Ohio, United States|Upper Valley Medical Center, Troy, Ohio, United States|Clinton Memorial Hospital, Wilmington, Ohio, United States|Greene Memorial Hospital, Xenia, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Clackamas Radiation Oncology Center, Clackamas, Oregon, United States|Providence Milwaukie Hospital, Milwaukie, Oregon, United States|Providence Newberg Medical Center, Newberg, Oregon, United States|Providence Willamette Falls Medical Center, Oregon City, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Columbia River Oncology Program, Portland, Oregon, United States|Providence Saint Vincent Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Center-Cancer Center Hazelton, Hazleton, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Geisinger Medical Group, State College, Pennsylvania, United States|Mount Nittany Medical Center, State College, Pennsylvania, United States|Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States|York Hospital, York, Pennsylvania, United States|AnMed Health Cancer Center, Anderson, South Carolina, United States|Saint Francis Hospital, Greenville, South Carolina, United States|Carolina Blood and Cancer Care Associates PA-Lancaster, Lancaster, South Carolina, United States|Carolina Blood and Cancer Care Associates PA, Rock Hill, South Carolina, United States|Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States|Upstate Carolina CCOP, Spartanburg, South Carolina, United States|Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States|Medical X-Ray Center, Sioux Falls, South Dakota, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|Erlanger Medical Center, Chattanooga, Tennessee, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|PeaceHealth Southwest Medical Center, Vancouver, Washington, United States|Northwest Cancer Specialists, Vancouver, Washington, United States|West Virginia University Charleston, Charleston, West Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Green Bay Oncology at Saint Vincent Hospital, Green Bay, Wisconsin, United States|Saint Vincent Hospital, Green Bay, Wisconsin, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States|Saint Mary's Hospital, Green Bay, Wisconsin, United States|Gundersen Lutheran, La Crosse, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Holy Family Memorial Hospital, Manitowoc, Wisconsin, United States|Bay Area Medical Center, Marinette, Wisconsin, United States|Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|D N Greenwald Center, Mukwonago, Wisconsin, United States|Oconomowoc Memorial Hospital-ProHealth Care Inc, Oconomowoc, Wisconsin, United States|Saint Nicholas Hospital, Sheboygan, Wisconsin, United States|Waukesha Memorial Hospital - ProHealth Care, Waukesha, Wisconsin, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States|Rocky Mountain Oncology, Casper, Wyoming, United States|Welch Cancer Center, Sheridan, Wyoming, United States|Mayo Clinic Methodist Hospital, Nagpur, India|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02085408"
726,"NCT01903733","Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008",,"Completed","Has Results","Chronic Myeloid Leukemia","Drug: bosutinib","Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)|Number of Participants With Grade 3 or 4 Treatment-Emergent Adverse Events (AEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)|Number of Participants With Treatment-Emergent Treatment Related Adverse Events (AEs) Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 3.0)|Number of Participants With Laboratory Test Abnormalities Based on National Cancer Institute Common Terminology Criteria for AEs (NCI CTCAE) (Version 4.03)|Number of Participants With Adverse Events as Reason for Treatment Discontinuation|Number of Participants With Diarrhea After Switch From Bosutinib Clinical Formulation to Bosutinib Commercial Formulation|Number of Participants With Breakpoint Cluster Region Abelson Protooncogene (BCR-ABL) Mutations Present at Time of Bosutinib Treatment Discontinuation|Overall Survival (OS) Rate at Year 10|Plasma Steady-State Trough Concentrations (Ctrough) of Bosutinib|Kaplan-Meier Estimate of Probability of Maintaining Major Cytogenetic Response (MCyR) at Year 10: B1871006 Participants|Kaplan-Meier Estimate of Probability of Maintaining Complete Cytogenetic Response (CCyR) at Year 10: B1871006 Participants|Kaplan-Meier Estimate of Probability of Maintaining Complete Hematologic Response (CHR) at Year 10: B1871006 Participants|Cumulative Incidence of Progression/Death Events at Year 10: B1871006 Participants|Cumulative Incidence of Rate of Transformation to Accelerated Phase (AP) or Blast Phase (BP) at Year 10: B1871006 Participants","Pfizer","All","18 Years and older   (Adult, Older Adult)","Not Applicable","281","Industry","Interventional","Masking: None (Open Label)","B1871040|2013-000691-15","August 28, 2013","June 5, 2020","June 5, 2020","July 19, 2013","August 17, 2021","August 17, 2021","Orlando Health, Inc, Orlando, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|The Emory Clinic, Atlanta, Georgia, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Northside Hospital Inc., - GCS/Northside, Atlanta, Georgia, United States|Northside Hospital, Inc. - Central Research Department, Atlanta, Georgia, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Rcca Md,Llc, Bethesda, Maryland, United States|Hudson Valley Hematology and Oncology Associates, Hawthorne, New York, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States|Instituto Medico Especializado Alexander Fleming, Cd. Autonoma De Buenos Aires, Buenos Aires, Argentina|Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina|Hospital Dr. Jose Ramon Vidal, Corrientes, Argentina|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|GHDC (Grand Hopital de Charleroi), Charleroi, Belgium|Universidade Estadual de Campinas / Centro de Hematologia e Hemoterapia, Campinas, SP, Brazil|Faculdade de Medicina do ABC - Centro de Estudos e Pesquisa em Hematologia e Oncologia (CEPHO), Santo Andre, SP, Brazil|Alberta Health Services - Department of Medical Oncology - Cross Cancer Institute, Edmonton, Alberta, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada|Instituto Oncologico, Clinica Renaca, Renaca, V Region, Chile|Instituto Oncologico, Renaca, V Region, Chile|Peking Union Medical College Hospital, Beijing, Beijing, China|The First affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Chinese People's Liberation Army General Hospital, Beijing, China|Ruijin Hospital- Shanghai Jiaotong University School of Medicine, Shanghai, China|Blood Disease Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Helsingin Yliopistollinen Keskussairaala, Hematologian poliklinikka, Helsinki, Finland|CHU de CAEN, Caen Cedex 9, France|CHU Hotel Dieu - Service Hematologie, Nantes cedex 1, France|CHU de Poitiers, Poitiers Cedex, France|CHU Poitiers, Poitiers, France|Strasbourg Oncologie Liberale -Centre de Radiotherapie, Clinique Ste Anne, Strasbourg, France|Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong|Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Somogy Megyei Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly, Kaposvar, Hungary|Christian Medical College. Vellore, Vellore, Tamil NADU, India|A.O.U. Policlinico S.Orsola Malpighi, Bologna, BO, Italy|ASST Monza - Ospedale san Gerardo, Monza, Monza AND Brianza, Italy|A.O.U. San Luigi Gonzaga di Orbassano, Orbassano, TO, Italy|Ospedale S. Eugenio - UOC Ematologia, Roma, Italy|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa-shi, Ishikawa, Japan|Kindai University Hospital, Osakasayama-city, Osaka, Japan|Osaka University Hospital, Suita-city, Osaka, Japan|Hamamatsu University School of Medicine University Hospital, Hamamatsu-shi, Shizuoka, Japan|Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of|Riga East Clinical University Hospital, Riga, Latvia|VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Department of Hematology, Groningen, Netherlands|Unidad de Investigacion de Hematologia - Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|State Budgetary Institution of Healthcare of Sverdlovsk Region, Ekaterinburg, Sverdlovsk Region, Russian Federation|Federal State-Funded Institution National Research Center of Hematology of the Ministry of, Moscow, Russian Federation|State Budgetary Institution of Rostov Region - Rostov Regional Clinical Hospital, Rostov-on-Don, Russian Federation|State Budgetary Educational Institution of Higher Professional Education, Rostov-on-Don, Russian Federation|State Budgetary Institution of Healthcare - Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|Clinic ""Institute of Pediatric Oncology, Hematology and Transplantation n.a. R.M. Gorbachova"", Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""Federal Almazov Medical Research Centre"", Saint Petersburg, Russian Federation|State Budgetary Institution of Healthcare Samara Regional Clinical Hospital n.a. V.D. Seredavin, Samara, Russian Federation|Singapore General Hospital, Singapore, Singapore|Wits Clinical Research-Chris Hani Baragwanath Hospital, Soweto, Gauteng, South Africa|Hospital Clinic Barcelona, Barcelona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Madrid Sanchinarro, Centro Integral Oncologico Clara Campal, Madrid, Spain|Hospital Virgen de la Salud, Toledo, Spain|Hospital Clinico Universitario De Valencia (CHUV), Valencia, Spain|Division of Hematology, Department of Medicine, Faculty of Medicine, Siriraj Hospital,, Bangkok, Thailand|Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi, Gaziantep, Sehit Kamil, Turkey|Hacettepe Universitesi Tip Fakultesi, Ankara, Turkey|Municipal Institution ""Cherkasy Regional Oncology Dispensary"", Cherkasy, Ukraine|MI ""Dnipropetrovsk City Multi-field Clinical Hospital #4"" of DRC Hematology Center, Dnipropetrovsk, Ukraine|State Institution ""National Research Center for Radiation Medicine of the National Academy of, Kyiv, Ukraine|Kyiv City Clinical Hospital #9, SI ""Institute of Hematology and Transfusiology of NAMS of Ukraine"", Kyiv, Ukraine|State Institution ""Institute of Blood Pathology and Transfusion Medicine of, Lviv, Ukraine|Freeman Hospital, Newcastle Upon Tyne, United Kingdom|Nottingham University Hospitals NHS Trust, Nottinhgam, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01903733/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/33/NCT01903733/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01903733"
727,"NCT00462943","Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML",,"Completed","Has Results","Chronic Myeloid Leukemia","Drug: Omacetaxine mepesuccinate","Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population|Percentage of Participants Achieving a Major Cytogenetic Response by Subpopulation and Total Population|Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Subpopulation and Total|Percentage of Participants in Each Cytogenetic Response Category Representing the Degree of Suppression of the Philadelphia Chromosome (Ph+)|Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene GUS|Percentage of Participants With Major Molecular Response (MMR) Representing the Degree of Suppression of BCR-ABL Transcript Levels Using the Housekeeping Gene ABL|Percentage of Participants in Each Hematologic Response Category|Percentage of Participants With Extramedullary Disease (EMD) at Baseline Achieving a Clinical Response|Percentage of Participants With the Largest Percentage Reduction From Baseline of T315I Mutated BCR-ABL|Number of Treatment Cycles Needed to Achieve Best Hematologic Response|Number of Treatment Cycles Needed to Achieve Best Cytogenetic Response|Kaplan-Meier Estimates for Time to Onset of Best Hematologic Response|Kaplan-Meier Estimates for Time to Onset of Best Cytogenetic Response|Kaplan-Meier Estimates for Duration of Best Hematologic Response|Kaplan-Meier Estimates for Duration of Best Cytogenetic Response|Kaplan-Meier Estimates for Time to Disease Progression|Kaplan-Meier Estimates for Overall Survival","Teva Branded Pharmaceutical Products R&D, Inc.|Cephalon|ChemGenex Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CGX-635-CML-203|2007-001286-15","March 7, 2007","August 4, 2009","June 27, 2013","April 19, 2007","June 30, 2014","December 28, 2021","Teva Investigational Site 303, Los Angeles, California, United States|Teva Investigational Site 308, Beech Grove, Indiana, United States|Teva Investigational Site 311, Baltimore, Maryland, United States|Teva Investigational Site 302, Bronx, New York, United States|Teva Investigational Site 305, Buffalo, New York, United States|Teva Investigational Site 310, Philadelphia, Pennsylvania, United States|Teva Investigational Site 301, Houston, Texas, United States|Teva Investigational Site 314, Seattle, Washington, United States|Teva Investigational Site 313, Montreal, Canada|Teva Investigational Site 309, Toronto, Canada|Teva Investigational Site 329, Bordeaux, France|Teva Investigational Site 321, Le Chesnay Cedex, France|Teva Investigational Site 322, Lille, France|Teva Investigational Site 320, Lyon Cedex 03, France|Teva Investigational Site 324, Nice, France|Teva Investigational Site 328, Paris, France|Teva Investigational Site 323, Poitiers Cedex, France|Teva Investigational Site 327, Strasbourg, France|Teva Investigational Site 325, Toulouse, France|Teva Investigational Site 331, Berlin, Germany|Teva Investigational Site 330, Mannheim, Germany|Teva Investigational Site 350, Budapest, Hungary|Teva Investigational Site 371, Hyderabad, India|Teva Investigational Site 370, Mumbai, India|Teva Investigational Site 390, Bologna, Italy|Teva Investigational Site 360, Gdansk, Poland|Teva Investigational Site 361, Warszawa, Poland|Teva Investigational Site 380, Singapore, Singapore|Teva Investigational Site 340, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00462943"
728,"NCT01701232","Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma",,"Completed","No Results Available","Follicular Non-Hodgkin's Lymphoma|Nodal Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma","Biological: rituximab","Overall response rate|CD20-positive cells count|Cmax|AUC(0-168)|Complete response rate|Frequency of AEs/sAEs grade 3-4 (CTCAE v.4.03)|Levels of binding and neutralizing antibodies to rituximab|AUC(0-1176), AUC(0-inf)","Biocad","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 3","174","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BIORIX (BCD-020-3)","September 2011","January 2017","January 2017","October 5, 2012",,"November 6, 2017","Instituto Nacional de Cancerología, Bogotá, Colombia|Fundación Reina Isabel, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellín, Colombia|HCG Multi Specialty Hospitals, Ahmedabad, India|Department of Medical Oncology, Navneet Memorial Hospital, ""Sushrusha"", Ahmedabad, India|Sujan Surgicals, Amaravati, India|HCG Bangalore Institute of Oncology, Bangalore, India|Department of Medicine (Haemotology), St.John's Medical College Hospital, Bangalore, India|Narayana Hrudayalaya Hospitals, Bangalore, India|Srinivasam Cancer Care Hospital, Bangalore, India|All India Institute of medical Sciences (AIIMS), Bhubaneswar, India|Acharya Tulasi Regional Cancer Treatment and Research Centre, Bikaner, India|G.Kuppuswamy Naidu Memorial Hospital, Coimbatore, India|Medical Oncology Department, The Karnatak Cancer Therapy and Research Institute, Hubli, India|BIBI General hospital & cancer center, Hyderabad, India|Department of Medical Oncology, Basavatarakam Indo-American Cancer Hospital and Research Institute, Hyderabad, India|Omega Hospitals, Hyderabad, India|Nilratan Siracar Medical College & Hospital, Kolkata, India|King George Medical University, Lucknow, India|Department of Radiation Oncology, Meenakshi Mission Hospital & Research Centre, Madurai, India|Manas Super Speciality Hospital, Nashik, India|City Cancer Center, Vijayawada, India|Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|City Hospital N8, Barnaul, Russian Federation|Municipal Institution ""Central City Hospital № 7"", Ekaterinburg, Russian Federation|Public health facility ""Irkutsk Regional Oncology Center"", Irkutsk, Russian Federation|Ivanovo Regional Oncology Center, Ivanovo, Russian Federation|State Health Care Institution ""Republican Clinical Cancer Center,"" the Ministry of Health of the Udmurt Republic, Izhevsk, Russian Federation|Public health facility ""Kemerovo Regional Hospital"", Kemerovo, Russian Federation|Clinical Oncology Dispensary N1, Krasnodar, Russian Federation|Public health facility ""Kursk Regional Cancer Center,"" Health Committee of Kursk region, Kursk, Russian Federation|Public health facility ""Lipetsk Regional Oncology Center"", Lipetsk, Russian Federation|N.N. Burdenko General Military Clinical Hospital, Moscow, Russian Federation|Russian Medical Academy of Post-Graduate Education, Ministry of Health and Social Development of the Russian Federation, Moscow, Russian Federation|Research Center for Hematology MHSD RF, Moscow, Russian Federation|Official body of the health of the city of Moscow ""Moscow City Clinical Hospital named after S. P. Botkin"", Moscow, Russian Federation|Medical Radiological Research Center, Ministry of Health and Social Development of the Russian Federation, Obninsk, Russian Federation|Regional government health care ""Oryol Regional Hospital"", Oryol, Russian Federation|Perm Region Oncology Dispensary, Perm, Russian Federation|V.A. Baranov Republican Hospital of Ministry of Health republic Karelia, Petrozavodsk, Russian Federation|Pyatigorsk Oncology Center, Pyatigorsk, Russian Federation|Russian Research Institute of Hematology and Transfusiology Federal State Institution of Federal Medical and Biological Agency, Saint Petersburg, Russian Federation|St. Petersburg State Health Care Institution ""Alexander City Hospital"", Saint Petersburg, Russian Federation|Saint Petersburg City Clinical Oncology Center, Saint Petersburg, Russian Federation|Saint Petersburg Pavlov State Medical University, Saint Petersburg, Russian Federation|V.A. Almazov Federal Center for Heart, Blood and Endocrinology, Ministry of Health and Social Development of the Russian Federation, Saint Petersburg, Russian Federation|The federal government military educational institution of higher education, ""Military Medical Academy named after SM Kirov's' Ministry of Defense"", Saint Petersurg, Russian Federation|Provincial health official body ""Smolensk Regional Clinical Oncological Dispensary"", Smolensk, Russian Federation|Oncology Dispensary 2, Sochi, Russian Federation|N.N.Petrov Oncology Research Center, St.Petersburg, Russian Federation|Russian scientific center of radiology and surgery technologies, St.Petersburg, Russian Federation|Tambov Regional Oncology Center, Tambov, Russian Federation|Municipal Health ""Clinical Hospital № 5"" Togliatti, Togliatti, Russian Federation|Tula Regional Hospital, Tula, Russian Federation|Public health care setting of the Tyumen region ""Regional Oncology Center"", Tyumen, Russian Federation|State Health Care Institution Republican Clinical Hospital named after G. G. Kuvatova, Ufa, Russian Federation|Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan, Ufa, Russian Federation|Volgograd District Oncology Dispensary №1, Volgograd, Russian Federation|Medi-Clinic Vereeniging, Vereeniging, South Africa|Khmel'nyts'kyy Regional Hospital, Hematology Department, Khmel'nyts'kyy, Ukraine|National Cancer Institute of Ukraine, Oncohematology Department, Kiev, Ukraine|State Institution ""Institute of Blood Pathology and Transfusion Medicine AMS of Ukraine"", Hematology Department, L'viv, Ukraine",,"https://ClinicalTrials.gov/show/NCT01701232"
729,"NCT02268045","Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma",,"Completed","Has Results","Diffuse Large B-cell Lymphoma","Biological: RTXM83|Biological: Mabthera","Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL|AUC 0-∞ (h μg/mL) at Cycle 1 of RTXM83 and Mabthera®|AUC 0-∞ (h μg/mL) at Cycle 6 of RTXM83 and Mabthera®|Cmax (μg/mL) at Cycle 1 of RTXM83 and Mabthera®|Cmax (μg/mL) at Cycle 6 of RTXM83 and Mabthera®|Percentage Change From Baseline in Pharmacodynamic (PD) Markers (CD19+ and CD20+ Cells) Blood Counts of RTXM83 and Mabthera®|Comparable Safety Profile in Both Treatment Arms|Comparable Immunogenicity Profile Between RTXM83 and Mabthera®|Event Free Survival (EFS) in RTXM83 Arm and Mabthera® Arm","mAbxience S.A|Pisa® Farmacéutica|Laboratorios de Productos Éticos C.E.I.S.A.|Laboratorio Elea Phoenix S.A.|Tecnoquimicas S.A|Innogene Kalbiotech Pte. Ltd|Libbs Farmacêutica LTDA|Key Oncologics (Pty) Ltd|Nanolek LLC|Actoverco","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","272","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","RTXM83-AC-01-11","May 2013","May 2016","July 2017","October 20, 2014","September 26, 2019","September 26, 2019","Hosp. Interzonal ""R"" Carrillo, Ciudadela, Bariloche, Argentina|Clinica Radiologica del Sur, Cipolletti, Río Negro, Argentina|Clinica Viedma, Viedma, Río Negro, Argentina|Hospital Britanico, Buenos Aires, Argentina|Hospital Gral. de Agudos Donación Francisco Santojanni, Buenos Aires, Argentina|Instituto Roffo, Buenos Aires, Argentina|Centro Oncologico Riojano Integral (CORI), Cordoba, Argentina|Hospital Nacional de Clinicas, Cordoba, Argentina|Hospital Privado de Cordoba, Cordoba, Argentina|Sanatorio Allende, Cordoba, Argentina|Ctr. Oncologico de Rosario, Rosario, Argentina|Inst. Cardiovascular Rosario, Rosario, Argentina|Instituto de Hematología y Medicina Clínica Dr. Rubén Dávoli, Rosario, Argentina|Sanatorio Parque, Rosario, Argentina|Fundación ARS Médica, San Salvador de Jujuy, Argentina|Hospital J. B. Iturraspe, Santa Fe, Argentina|Hospital Angel Padilla, Tucumán, Argentina|Hospital Clinicas Porto Alegre, Pôrto Alegre, Rio Grande Do Sul, Brazil|Hospital de Caridade de Ijuí, Ijuí, RS, Brazil|Hospital da Cidade de Passo Fundo, Passo Fundo, RS, Brazil|Hospital São Lucas da PUCRS, Porto Alegre, RS, Brazil|Hospital Santa Marcelina, Itaquera, Sao Paulo, Brazil|Hospital Amaral Carvalho Jaú, Jaú, SP, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo-HCFMRP, Ribeirão Preto, SP, Brazil|CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia / Faculdade de Medicina do ABC, Santo André, SP, Brazil|Fundação Antônio Prudente - AC Camargo Câncer Center, Sao Paulo, SP, Brazil|Hospital das Clinicas-UFMG, Belo Horizonte, Brazil|UNICAMP-Univ Zeferino Vaz, Campinas, Brazil|Hospital Uniao Oeste Paranaense de Estudos e Comabte ao Cancer (UOPECCAN), Cascavel, Brazil|Hospital Erasto Gaertner CEPEP, Curitiba, Brazil|Hospital das Clínicas da Universidade Federal de Goiás, Goiânia, Brazil|Santa Casa de Porto Alegre, Porto Alegre, Brazil|Hospital Universitário Clemente Fraga Filho - UFRJ, Rio de Janeiro, Brazil|Instituto COI de Educação e Pesquisa, Rio de Janeiro, Brazil|Instituto Est. de Hematologia Arthur de Siqueira Cavalcanti, Rio de Janeiro, Brazil|Monte Tabor - Hospital São Rafael, Salvador, Brazil|Centro de Pesquisa do Instituto Brasileiro de Controle do Câncer - IBCC, Sao Paulo, Brazil|Hospital Clinica Faculdade Medicina USP, Sao Paulo, Brazil|Hospital de Base de São José, São José do Rio Prêto, Brazil|Inst. Nacional de Cancerologia, Bogotá, Colombia|Fundación Valle de Lili, Cali, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Srinivasam Cancer Care Hospital, Bangalore, India|Cancer Institute, Chennai, India|Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India|Bibi General Hospital&Canc Ct, Hyderabad, India|Birla Cancer Center - SMS Hospital, Jaipur, India|Health Point Multi-specialty Hospital, Kolkata, India|Institute of Hematology and Transfusion Medicine, Kolkata, India|Netaji Subhash Chandra Bose Cancer Research Institute, Kolkata, India|Acharya Tulsi Regional Cancer Treatment and Research Institute, Madurai, India|Guru Hospital, Madurai, India|Meenakshi Mission Hospital, Madurai, India|Kailash Cancer Hospital and Research Centre, Vadodara, India|Dr. Hasan Sadikin Hospital, Bandung, Indonesia|Dharmais N. C. Center, Jakarta, Indonesia|Imam Khomeini Complex Hospital - Cancer Institute, Tehrān, Iran, Islamic Republic of|Hospital Sultanah Aminah, Johor Bahru, Malaysia|University Malaya Medical Centre - UMMC, Kuala Lumpur, Malaysia|Mount Miriam Cancer Hospital, Pulau Pinang, Malaysia|Hospital Pulau Pinang, Pulau Pinang, Malaysia|Insituto Nacional de Cancerología, Mexico City, Mexico|Instituto Privado de Hematologia e Investigaciona Clinica, Asunción, Paraguay|Cebu Doctors University Hospital, Cebu, Philippines|Perpetual Succour Hospital, Cebu, Philippines|Davao Doctors Hospital, Davao, Philippines|National Kidney and Transplant Institute, Quezon City, Philippines|Veterans Memorial Medical Center, Quezon City, Philippines|Arkhangelsk Clinical Oncology Dispensary, Arkhangelsk, Russian Federation|Kursk regional clinical oncology dispensary, Kursk, Russian Federation|N.N. Blokhin Russian Cancer Research Cente, Moscow, Russian Federation|National Medical Surgical Center n.a. N.I. Pirogov, Moscow, Russian Federation|Murmansk regional oncology dispensary, Murmansk, Russian Federation|State Budgetary Healthcare Institution of Stavropol region ""Pyatigorsk oncology center"", Pyatigorsk, Russian Federation|Rostov Scientific Research Oncology Institute, Rostov-na-Donu, Russian Federation|Russian Research Center for Radiology and Surgical Technologies, Saint-Petersburg, Russian Federation|Saint-Petersburg State Budgetary Institution ""City Clinical Oncology Dispensary"", Saint-Petersburg, Russian Federation|Scientific Research Institute of Oncology n.a. N.N. Petrov, Saint-Petersburg, Russian Federation|Oncology Center # 2, Sochi, Russian Federation|Komi Republican Oncology Dispensary, Syktyvkar, Russian Federation|State Healthcare Institution of Tula region ""Tula regional clinical hospital"", Tula, Russian Federation|Republican Clinical Oncology Dispensary, Ufa, Russian Federation|Volgograd Regional Clinical Oncology Center, Volgograd, Russian Federation|Rainbow Oncology Centre, Amanzimtoti, South Africa|Tygerberg Academic Hosp, Cape Town, South Africa|GVI Oncology, Port Elizabeth, South Africa|Chris Hani Baragwanath Hospital, Soweto, South Africa",,"https://ClinicalTrials.gov/show/NCT02268045"
730,"NCT02227251","Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",,"Recruiting","No Results Available","Diffuse Large B-cell Lymphoma","Drug: Selinexor","Part 1: Overall Response Rate (ORR)|Part 2: Overall Response Rate (ORR) Based on Lugano Criteria|Part 1: Duration of Response (DOR)|Part 1: Disease Control Rate (DCR)|Part 1: Number of Participants with Treatment-emergent Adverse Events (TEAEs)|Part 1: Number of Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status|Part 2: Duration of response (DOR)|Part 2: Disease control rate (DCR)|Part 2: Overall Response Rate (ORR) Based on Modified Lugano Criteria|Part 2: Number of Participants with Treatment-emergent Adverse Events|Part 2: Number of Participants with Eastern Cooperative Oncology Group (ECOG) Performance Status","Karyopharm Therapeutics Inc","All","18 Years and older   (Adult, Older Adult)","Phase 2","244","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KCP-330-009|2014-001977-15","November 2014","August 2022","December 2024","August 28, 2014",,"May 9, 2022","UACC Arizona, Tucson, Arizona, United States|University of California San Francisco, San Francisco, California, United States|University of California Los Angeles (UCLA), Santa Monica, California, United States|Boca Raton Cancer Research Medical Center, Plantation, Florida, United States|University of Chicago, Chicago, Illinois, United States|Robert H. Lurie Comprehensive Cancer Center/Northwestern University, Chicago, Illinois, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Tufts Medical Center, Boston, Massachusetts, United States|Lahey Clinic, Burlington, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|New York Presbyterian Hospital/ Cornell Medical College, New York, New York, United States|Stony Brook University Hospital, Stony Brook, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Greenville Hospital System, Greenville, South Carolina, United States|MD Anderson, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Virginia Mason Hospital & Medical Center, Seattle, Washington, United States|St. Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia|Liverpool Hospital, Ingham Institute of Medical Research, Liverpool, New South Wales, Australia|Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia|Icon Cancer Care, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ashford Cancer Centre, Kurralta Park, South Australia, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Epworth Hospital, East Melbourne, Victoria, Australia|St. Vincent's Melbourne, Fitzroy, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Medical University of Graz, Graz, Austria|Medizinische Universität Innsbruck für Innere Medizin, Innsbruck, Austria|LKH Leoben Department for Haemato-Oncology, Leoben, Austria|Akh Linz Innere Med III - Zentrum für Hämatologie und med. Onkologie, Linz, Austria|Krankenhaus Barmherzigen Schwestern Linz, Linz, Austria|Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria|Uni. Klinik für Innere Medizin III Universitätsklinikum der PMU LKH Salzburg, Salzburg, Austria|Medical University of Vienna (MUW) Department of Medicine I, Vienna, Austria|Univ. General Hospital Hietzing, Vienna, Austria|Ziekenhuis Netwerk Antwerpen, Antwerpen, Belgium|AZ Sint-Jan, Bruges, Belgium|Institut Jules Bordet, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|UZ Gent, Gent, Belgium|CH Jolimont, La Louviere, Belgium|AZ Delta, Roeselare, Belgium|H-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|University Hospital for Active Treatment Dr. Georgi Stranski, Pleven, Bulgaria|University Multiprofile Hospital for Active Treatment Sveti Ivan Rilski EAD, Sofia, Bulgaria|Specialized Hospital for Active Treatment of Haematological Diseases EAD, Sofia, Bulgaria|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Sir Mortimer B Davis Jewish General Hospital/McGill University, Montreal, Quebec, Canada|CHU Lyon Sud, Pierre-Bénite, Lyon, France|University Hospital Brest, Brest, France|Centre Hospitalier Universitaire Henri Mondor, Créteil, France|Unite Hemopathies Lymphoides Chu Henri Mondor, Créteil, France|Chu Dijon-Bourgogne - Hematologie Clinique, Dijon, France|Hospitalier de la Rochelle-Ré-Aunis, La Rochelle, France|CHRU de Lille - Hopital Claude-Huriez, Lille, France|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes, Marseille, France|CHU Montpellier, Montpellier, France|Hostpial Saint Louis - CIRCO (Centre d'Investigations et de Recherche Clinique en Oncologie), Paris, France|Hôpital Necker Service d'Hématologie Adult, Paris, France|Pitié-Salpêtrière Hospital, Paris, France|Centre Henri Becquerel, Rouen, France|Uniklinik Aachen Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation, Aachen, Germany|HELIOS Klinikum Bad Saarow, Bad Saarow, Germany|Charite Universitatsmedizin Berlin (Benjamin Franklin Campus), Berlin, Germany|Charite Universitatsmedizin Berlin (Virchow Campus), Berlin, Germany|Ev. Diakonie-Krankenhaus gGmbH, Bremen, Germany|Gemeinschaftspraxis Haematologie and Onkologie-Dresden, Dresden, Germany|Martin-Luther-University Halle-Wittenberg Department of Oncology, Halle, Germany|Medizinische Hochschule, Hannover, Germany|Universität Heidelberg Medizinische Klinik V Hämatologie, Onkologie und Rheumatologie, Heidelberg, Germany|Klinikum Kempten Klinik für Innere Medizin III - Hämatologie, Onkologie und Palliativmedizin, Koln, Germany|Klinikum Leverkusen, Leverkusen, Germany|Klinikum Ludwigshafen, Ludwigshafen, Germany|Rotkreuzklinikum München, Muenchen, Germany|Klinikum Nürnberg Nord, Nuernberg, Germany|Haematology Department and HCT Unit G.Papanicolaou Hospital, Exochi, Thessaloniki, Greece|Hematology Clinic,General Hospital of Athens,G. Gennimatos, Athens, Greece|National & Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece|Hematology Department Laiko General Hospital, Athens, Greece|Second Depth of Internal Medicine, Attiko University Hospital, Athens, Greece|National & Kapodistrian University of Athens, Attiko University Hospital, Chaidari, Greece|Department of clinical hematology ,university hospital Ioannina, Ioánnina, Greece|University of Patras Medical School, Patras, Greece|Semmelweis Egyetem Általános Orvosi Kar, Budapest, Hungary|Országos Onkológiai Intézet ""A"" Belgyógyászati Onkológiai Osztály, Budapest, Hungary|Semmelweis University Department of Medicine and Oncology, Budapest, Hungary|DEKK Belgyogyaszati Klinika Hematologia, Debrecen, Hungary|Somogy Megyei Kaposi Mór Oktató Kórház, Kaposvár, Hungary|Pécsi Tudományegyetem, ÁOK, I. számú Belgyógyászati Klinika, Pécs, Hungary|Veszprém Megyei Csolnoky Ferenc Kórház, Veszprém, Hungary|CSolnoky ferenc Hospital, Veszprém, Hungary|Regional Cancer Centre, IGIMS, Patna, Bihar, India|SRM Institutes for Medical Science, Vadapalani, Chennai, India|Rajiv Gandhi Cancer Hospital, New Delhi, Delhi, India|Regional Cancer Centre, Thiruvananthapuram, Kerala, India|Prince Aly Khan Hospital, Mumbai, Maharashtra, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Deenanath Mangeshkar Hospital, Pune, Maharashtra, India|Institute of Medical Sciences & SUM Hospital, Bhubaneswar, Odisha, India|Dayanand Medical College and Hospital, Ludhiāna, Punjab, India|Cancer Institute (WIA), Chennai, Tamil Nadu, India|Saveetha Medical College Hospital, Chennai, Tamil Nadu, India|G. Kuppu Swamy Naidu Hospital, Coimbatore, Tamil Nadu, India|Meenakshi Mission Hospital & Research Centre, Madurai, Tamil Nadu, India|King George's Medical University (KGMU), Lucknow, Uttar Pradesh, India|Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India|Netaji Subhas Chandra Bose Cancer Research Hospital, Kolkata, West Bengal, India|TATA Memorial Centre, Kolkata, West Bengal, India|Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, West Bengal, India|IRCH, All India Institute of Medical Sciences, Delhi, India|Dr. B.R.A. Institute Rotary Cancer Hospital All India Institute of Medical Sciences, New Delhi, India|Hematology-Soroka, Beer Sheva, Israel|Rambam Healthcare Campus, Haifa, Israel|Wolfson MC, Holon, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Assuta Medical Center, Tel Aviv, Israel|TLV Sorasky Medical Center, Tel Aviv, Israel|Sheba Medical Center, Tel Hashomer, Israel|Instituto di Ematologia Seragnoli Pad 8 Universita di Bologna, Bologna, Italy|SODc Ematologica ,AOU Careggi, Florence, Italy|AOU Maggiore della Carità SCDU Ematologia, Florence, Italy|Hematology-Oncology & Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy|SCDU Ematologia, Division of Hematology, Dept. of Translational Medicine, Universita del Piemonte Orientale, Novara, Italy|Fondazione Policlinico Universitario A. Gemelli, Rome, Italy|Azienda Ospedaliero-Universitaria Senese, Siena, Italy|Città della Salute e della Scienza di Torino, Torino, Italy|VUMc (Vrije Universiteit Amsterdam), Amsterdam, Netherlands|LUMC (leidse universitair medisch centrum), Leiden, Netherlands|North Shore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza, Wrocław, Radeckiego, Poland|Szpitale Wojewódzkie w Gdyni, Gdyńskie Centrum onkologii, Gdynia, Poland|MCM (Małopolskie Centrum Medyczne), Krakow, Poland|Wojewodzki Szpital Specjalistyczny w Legnicy, Legnica, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|Hematology Department St John's Cancer Centre, Lublin, Poland|Samodzielny Publiczny Zakład Opieki Zdrowotnej Ministerstwa, Olsztyn, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii- Insytut Im. Marii Skłodowskiej-Curie Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Maria Sklodowska Curie National Research Institute, Warszawa, Poland|Memorial Provincial Specialist Hospital in Lodz, Łódź, Poland|Institut za onkologiju i radiologiju Srbije, Belgrade, Serbia|Klinicko Bolnick Centar Zemun Odeljenje hematologije, Belgrade, Serbia|Klinički centar Srbije Klinika za hematologiju, Belgrade, Serbia|Kliničko bolnički centar Zvezdara, Belgrade, Serbia|Klinički centar Niš Klinika za hematologiju, Nis, Serbia|Institut za onkologiju Vojvodine, Sremska Kamenica, Serbia|Hospitla Universitari Germans Trias i Pujol - ICO, Badalona, Spain|Hospital University Vall d'Hebron, Barcelona, Spain|Hospital Clinic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Son Llàtzer, Palma de Mallorca, Spain|Clínica Universidad De Navarra, Pamplona, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Gloucestershire Royal Hospital, Gloucester, Gloucestershire, United Kingdom|Southampton University Hospital, Southampton, Hampshire, United Kingdom|Royal Marsden Hospital, Sutton, London, United Kingdom|Northwick Park Hospital, Harrow, Middlesex, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, Yorkshire, United Kingdom|Addenbrooke's Hospital Cambridge, Cambridge, United Kingdom|Royal Liverpool University Hospital, Liverpool, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom|King's College Hospital, London, United Kingdom|Princess Royal University Hospital (PRUH), London, United Kingdom|Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Oxford University Hospitals NHS Trust Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom|Derriford Hospital, Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02227251"
731,"NCT01206764","A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.",,"Completed","Has Results","Renal Cell Carcinoma","Drug: RAD001","PFS (Progression-Free Survival)|Disease Control Rate (Stable Disease [SD] + Partial Response [PR] + Complete Response [CR]);|Objective Response Rate (ORR; Where ORR = CR + PR)|Duration of Response (DOR)|Overall Survival","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","143","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRAD001LIC01","November 11, 2009","June 6, 2017","July 1, 2017","September 22, 2010","June 24, 2019","June 24, 2019","Novartis Investigative Site, Alger, Algeria|Novartis Investigative Site, Oran, Algeria|Novartis Investigative Site, Alexandria, Egypt|Novartis Investigative Site, Cairo, Egypt|Novartis Investigative Site, Mansoura, Egypt|Novartis Investigative Site, Indore, Madhya Pradesh, India|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Amman, Jordan|Novartis Investigative Site, Ashrafieh, Lebanon|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Samara, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Cape Town, South Africa|Novartis Investigative Site, Durban, South Africa|Novartis Investigative Site, Parktown, South Africa|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Tunis, Tunisie, Tunisia|Novartis Investigative Site, Ariana, Tunisia|Novartis Investigative Site, Sousse, Tunisia","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01206764/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/64/NCT01206764/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT01206764"
732,"NCT00683969","A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis",,"Completed","No Results Available","Myasthenia Gravis, Generalized","Drug: mycophenolate mofetil (CellCept)|Drug: placebo","Proportion of subjects reaching responder status|Time to start of response|Mean and median prednisone dose and cholinesterase inhibitor dose|Adverse events, lab parameters, vital signs","Hoffmann-La Roche|Aspreva Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","136","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WX17798","August 2004",,"May 2007","May 26, 2008",,"May 26, 2008","Sun City, Arizona, United States|Sacramento, California, United States|Miami, Florida, United States|Kansas City, Kansas, United States|Rochester, New York, United States|Chapel Hill, North Carolina, United States|Columbus, Ohio, United States|Upland, Pennsylvania, United States|Dallas, Texas, United States|Galveston, Texas, United States|Edmonton, Alberta, Canada|London, Ontario, Canada|Belgrade, Former Serbia and Montenegro|Bordeaux Cedex, France|Nice, France|Düsseldorf, Germany|München, Germany|Regensburg, Germany|Tübingen, Germany|Hyderabad, India|Mumbai, India|New Delhi, India|Jerusalem, Israel|Milano, Italy|Roma, Italy|San Donato Milanese, Italy|Mexico City, Mexico|Mexico City, Mexico|Mexico City, Mexico|Leiden, Netherlands|Maastricht, Netherlands|Rotterdam, Netherlands|Kazan, Russian Federation|Moscow, Russian Federation|Nizhniy Novgorad, Russian Federation|Barcelona, Spain|Madrid, Spain|Kharkov, Ukraine|Kiev, Ukraine|Zaporozhye, Ukraine|Liverpool, United Kingdom|Oxford, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00683969"
733,"NCT01419665","GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)","ASSIST_FL","Completed","Has Results","Follicular Lymphoma","Biological: GP2013|Biological: rituximab","Overall Response Rate (ORR)|To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period|To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period|To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization|To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths|To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)|To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)|To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)|To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy","Sandoz|Novartis Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","629","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","GP13-301|2010-019522-13","December 1, 2011","July 10, 2015","January 22, 2018","August 18, 2011","May 14, 2021","May 14, 2021","Investigative site, La Plata, Argentina|Investigative site, Rosario, Argentina|Investigative site, San Miguel de Tucuman, Argentina|Investigative site, Adelaide, Australia|Investigative site, Ballarat, Australia|Investigative site, Epping, Australia|Investigative site, Footscray, Australia|Investigative site, Wodonga, Australia|Investigative site, Graz, Austria|Investigative site, Wien, Austria|Investigative site, Barretos, Brazil|Investigator site, Barretos, Brazil|Investigative site, Botucatu, Brazil|Investigative site, Campinas, Brazil|Investigative site, Curitiba, Brazil|Investigative site, Florianopolis, Brazil|Investigative site, Fortaleza, Brazil|Investigative site, Goiania, Brazil|Investigative site, Jau, Brazil|Investigative site, Passo Fundo, Brazil|Investigative site, Porto Alegre, Brazil|Investigative Site, Rio de Janeiro, Brazil|Investigative site, Santo Andre, Brazil|Investigative site, Sao Paulo, Brazil|Investigative site, Sorocaba, Brazil|Investigative site, Pleven, Bulgaria|Investigative site, Plovdiv, Bulgaria|Investigative site, Ruse, Bulgaria|Investigative site, Sofia, Bulgaria|Investigative site, Varna, Bulgaria|Investigative site, Medellin, Colombia|Investigative site, Monteria, Colombia|Investigative site, Colmar, France|Investigative site, Nimes, France|Investigative site, Strasbourg, France|Investigative site, Bad Saarow, Germany|Investigative site, Koblenz, Germany|Investigative site, Athens, Greece|Investigative site, Ioannina, Greece|Investigative site, Larissa, Greece|Investigative site, Patras, Greece|Investigative site, Györ, Hungary|Investigative site, Kaposvar, Hungary|Investigative site, Ahmedabad, India|India, Amritsar, India|Investigative site, Aurangabad, India|Investigative site, Bangalore, India|Investigative site, Chennai, India|Investigative site, Hyderabad, India|Investigative site, Kolkata, India|Investigtive site, Kolkata, India|Investigative site, Madurai, India|Investigative site, Mumbai, India|Investigative site, Nashik, India|Investigative site, New Delhi, India|Investigative site, Pune, India|Investigative site, Surat, India|Investigative site, Trivandrum, India|Investigative site, Vellore, India|Investigative site, Dublin, Ireland|Investigative site, Limerick, Ireland|Investigative site, Waterford, Ireland|Investigative site, Ashkelon, Israel|Investigative site, Nahariya, Israel|Investigative site, Bari, Italy|Investigative site, Firenze, Italy|Investigative site, Meldola, Italy|Investigative site, Milano, Italy|Investigative site, Palermo, Italy|Investigative site, Pavia, Italy|Investigative site, Pescara, Italy|Investigative site, Piacenza, Italy|Investigative site, Ravenna, Italy|Investigative site, Reggio Calabria, Italy|Investigative site, Varese, Italy|Investigative site, Aomori, Japan|Investigative site, Fukuoka, Japan|Investigative site, Gifu, Japan|Investigative site, Kagoshima, Japan|Investigative site, Kitakyushu, Japan|Investigative site, Kobe, Japan|Investigative site, Komaki, Japan|Investigative site, Matsuyama, Japan|Investigative site, Ogaki, Japan|Investigative site, Okayama, Japan|Invstigative site, Omura, Japan|Investigative site, Saga, Japan|Investigative site, Tachikawa, Japan|Investigative site, Ōtake, Japan|Investigative site, Alor Setar, Malaysia|Investigative site, Ampang, Malaysia|Investigative site, George Town, Malaysia|Investigative site, Ipoh, Malaysia|Investigative site, Johor Bahru, Malaysia|Investigative site, Klang, Malaysia|Investigative site, Kuala Lumpur, Malaysia|Investigative site, Kuching, Malaysia|Investigative site, Melaka, Malaysia|Investigative site, Pulau Pinang, Malaysia|Investigative site, Subang Jaya, Malaysia|Investigative site, Amsterdam, Netherlands|Investigative site, Delft, Netherlands|Investigative site, Gouda, Netherlands|Investigative site, Heerlen, Netherlands|Investigative site, Rotterdam, Netherlands|Investigative site, Schiedam, Netherlands|Investigative site, Sittard, Netherlands|Investigative site, Zwolle, Netherlands|Investigative site, Lima, Peru|Investigative site, Brzozow, Poland|Investigative site, Bydgoszcz, Poland|Investigative site, Chorzow, Poland|Investigative site, Krakow, Poland|Investigative site, Lublin, Poland|Investigative site, Warszawa, Poland|Investigative site, Braga, Portugal|Investigative site, Coimbra, Portugal|Investigative site, Lisboa, Portugal|Investigative site, Porto, Portugal|Investigative site, Brasov, Romania|Investigative site, Bucharest, Romania|Investigative site, Cluj-Napoca, Romania|Investigative site, Iasi, Romania|Investigative site, Timisoara, Romania|Investigative site, Arkhangelsk, Russian Federation|Investigative site, Chelyabinsk, Russian Federation|Investigative site, Krasnodar, Russian Federation|Investigative site, Kursk, Russian Federation|Investigative site, Moscow, Russian Federation|Investigative site, Nizhniy Novgorod, Russian Federation|Investigative site, Rostov-on -Don, Russian Federation|Investigative site, St. Petersburg, Russian Federation|Investigative site, Cape Town, South Africa|Investigative site, George, South Africa|Investigative site, Johannesburg, South Africa|Investigative site, Port Elizabeth, South Africa|Investigative site, Pretoria, South Africa|Investigative site, Barcelona, Spain|Investigative site, Madrid, Spain|Investigative site, Oviedo, Spain|Investigative site, San Sebastian, Spain|Investigative site, Sevilla, Spain|Investigative site, Zaragoza, Spain|Investigative site, Cherkasy, Ukraine|Investigative site, Dnipropetrovsk, Ukraine|Investigative site, Donetsk, Ukraine|Investigative site, Ivano-Frankivsk, Ukraine|Investigative site, Kharkiv, Ukraine|Investigative site, Kyiv, Ukraine|Investigative site, Lviv, Ukraine|Investigative site, Eastbourne, United Kingdom|Investigative site, London, United Kingdom|Investigative site, Worthing, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01419665"
734,"NCT00835419","Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression","ENVER","Completed","No Results Available","Melanoma","Drug: P276-00","Progression Free Survival rate at Day 168|Overall survival rate at 1 year, objective response rate,duration of response","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/27/08","May 2009","April 2011","November 2012","February 3, 2009",,"December 4, 2012","University of Newcastle, School of Medicine and Public Health, Newcastle, New South Wales, Australia|Mater Adult Hospital Raymond Tce South Brisbane, QLD 4101, Brisbane, Australia|Peninsula Oncology Centre, Frankston, Australia|John Fawkner Cancer Trial Centre, Victoria, Australia|Curie Manavata Cancer Center, Nasik, Maharashtra, India|Chhatrapati Shahuji Maharaj Medical University, Lucknow, Uttar Pradesh, India|Christchurch Oncology Research Unit, Oncology Service, Christchurch Hospital, Riccarton Avenue, Private Bag 4710, Christchurch,, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT00835419"
735,"NCT04266301","Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)","STIMULUS-MDS2","Active, not recruiting","No Results Available","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic","Drug: MBG453|Drug: Azacitidine|Drug: Placebo","Overall Survival|Key secondary endpoint 1: Time to definitive deterioration of fatigue using Functional Assessment of Cancer Therapy (FACIT)-Fatigue score|Key secondary endpoint 2: Red Blood Cell transfusion-free intervals|Key secondary endpoint: Percent of subjects with at least 3 point confirmed improvement from baseline in FACIT-fatigue scoresscore|Key secondary endpoint 4: Percent of subjects with at least 10 point confirmed improvement from baseline in physical functioning using European Or ganization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)|Key secondary endpoint 5: Percent of subjects with at least 10 point confirmed improvement from baseline in emotional functioning using EORTC-QLQ-C30|Percentage of subjects with either CR, or mCR, or PR, or HI in each treatment arm according to International Working Group for MDS (IWG-MDS) as per investigator assessment|Percentage of subjects with SD in each treatment arm according to International Working Group for MDS (IWG-MDS) as per investigator assessment|Progression Free Survival (PFS)|Leukemia-free survival|Number of transfusion dependent subjects at baseline who become Red Blood Cells/platelets transfusion independent after randomization|Percentage of transfusion dependent subjects at baseline who become Red Blood Cells/platelets transfusion independent after randomization|Pharmacokinetics of MBG453 (parameter Cmax)|Pharmacokinetics of MBG453 (parameter AUC)|Anti-drug Antibody (ADA) prevalence at baseline and ADA incidence on-treatment|Change from baseline in the European Quality of Life (EuroQol) - 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) score over time|Change from baseline in the European Quality of Life (EuroQoL) - 5 Dimensions, 5 Level Questionnaire (EQ-5D-5L) Visual Analogue Scale over time|Change from baseline to C12D1 of Global Health Status/Quality of Life scores using European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC-QLQ-C30)","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","530","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CMBG453B12301|2019-002089-11","June 8, 2020","January 15, 2027","January 15, 2027","February 12, 2020",,"April 26, 2022","Yuma Regional Cancer Center, Yuma, Arizona, United States|University of California at Los Angeles, Los Angeles, California, United States|Yale University School of Medicine Smilow Cancer Hospital, New Haven, Connecticut, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|University of Miami, Miami, Florida, United States|Northwestern University Div of Hematology/Oncology, Chicago, Illinois, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Hackensack University Medical Center SC, Hackensack, New Jersey, United States|Weill Cornell Medicine NewYork Presbyterian Hospital, New York, New York, United States|University of Rochester Medical Center Dept.ofUniv.Rochester/JPWilmot, Rochester, New York, United States|University of Virginia University of Virginia, Charlottesville, Virginia, United States|Novartis Investigative Site, Pilar, Buenos Aires, Argentina|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Graz, Austria|Novartis Investigative Site, Innsbruck, Austria|Novartis Investigative Site, Linz, Austria|Novartis Investigative Site, Brasschaat, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Florianopolis, SC, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shenzhen, Guangdong, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Suzhou, Jiangsu, China|Novartis Investigative Site, Chang Chun, Jilin, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Chengdu, China|Novartis Investigative Site, Jinan, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Shanghai, China|Novartis Investigative Site, Tianjin, China|Novartis Investigative Site, Rionegro, Antioquia, Colombia|Novartis Investigative Site, Bogota, Colombia|Novartis Investigative Site, Praha 2, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Brno - Bohunice, Czechia|Novartis Investigative Site, Praha, Czechia|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Kuopio, Finland|Novartis Investigative Site, Grenoble, France|Novartis Investigative Site, Lille Cedex, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tours, France|Novartis Investigative Site, Vandoeuvre Les Nancy, France|Novartis Investigative Site, Velbert, North Rhine-westphalia, Germany|Novartis Investigative Site, Dresden, Sachsen, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Greifswald, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Kiel, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Alexandroupolis, Evros, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Ahmedabad, Gujrat, India|Novartis Investigative Site, Faridabad, Haryana, India|Novartis Investigative Site, Madurai, Tamil NADU, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Kolkata, West Bengal, India|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Kashiwa, Chiba, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Sapporo, Hokkaido, Japan|Novartis Investigative Site, Isehara, Kanagawa, Japan|Novartis Investigative Site, Sendai city, Miyagi, Japan|Novartis Investigative Site, Nagasaki-city, Nagasaki, Japan|Novartis Investigative Site, Osaka Sayama, Osaka, Japan|Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Yamagata, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Vilnius, Lithuania|Novartis Investigative Site, Kuching, Sarawak, Malaysia|Novartis Investigative Site, Kuala Lumpur, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Satelite, Edo Mexico, Mexico|Novartis Investigative Site, Morelia, Michoacan, Mexico|Novartis Investigative Site, Estado de Mexico, Mexico|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Muscat, Oman|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Porto, Portugal|Novartis Investigative Site, Sain Petersburg, Russian Federation|Novartis Investigative Site, St Petersburg, Russian Federation|Novartis Investigative Site, Riyadh, Saudi Arabia|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Sevilla, Andalucia, Spain|Novartis Investigative Site, Oviedo, Asturias, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Badalona, Catalunya, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bern, Switzerland|Novartis Investigative Site, Zürich, Switzerland|Novartis Investigative Site, Hualien City, Hualien, Taiwan|Novartis Investigative Site, Kaohsiung City, Taiwan|Novartis Investigative Site, Liouying Township, Taiwan|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, Taipei, Taiwan|Novartis Investigative Site, Taoyuan, Taiwan|Novartis Investigative Site, Songkhla, Hat Yai, Thailand|Novartis Investigative Site, Khon Kaen, THA, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Chiang Mai, Thailand|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Edirne, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Samsun, Turkey|Novartis Investigative Site, Portsmouth, Hants, United Kingdom|Novartis Investigative Site, Edinburgh, United Kingdom|Novartis Investigative Site, Manchester, United Kingdom|Novartis Investigative Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04266301"
736,"NCT00843050","A Phase II Study to Evaluate Efficacy and Safety of P276-00 in Relapsed and/or Refractory Mantle Cell Lymphoma",,"Terminated","Has Results","Mantle Cell Lymphoma","Drug: P276-00","Best Overall Objective Response Rate|Duration of Response|Time to Progression","Piramal Enterprises Limited","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P276-00/23/08","November 2009","February 2011","August 2012","February 13, 2009","July 27, 2012","July 27, 2012","Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Phoenix, Arizona, Phoenix, Arizona, United States|Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic, Arizona, Scottsdale, Arizona, United States|College of Medicine, Mayo Clinic, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Gabrail Cancer Center Research, Dover, Ohio, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cancer Care Centers of South Texas, New Braunfels, Texas, United States|Cancer Care Centers of South Texas, San Antonio, Texas, United States|Huntsman Cancer Institute, 2000 Circle of Hope, Room 2145, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Department of Medicine, University of Washington, Seattle, Washington, United States|Dept of Hematology/Oncology, University of Wisconsin- Madison, Madison, Wisconsin, United States|Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, Delhi, India|St. Johns Medical College & Hospital, Bangalore, Karnataka, India|Malabar Institute of Medical Sciences, Calicut, Kerala, India|Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Cancer Care Clinic and Hospital, Nagpur, Maharashtra, India|Meenakshi mission hospital and research centre, Madurai, Tamil nadu, India",,"https://ClinicalTrials.gov/show/NCT00843050"
737,"NCT04057040","Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)",,"Active, not recruiting","No Results Available","Polycythemia Vera","Drug: PTG-300|Drug: Placebo","Proportion of responders during the blinded randomized withdrawal period (Week 29 to Week 41).|Change in rate of phlebotomy events between Week 17 through Week 29 (inclusive; 12 weeks) compared to each subject's historical rate.|Change in rate of phlebotomy events between Week 1 through Week 29 (inclusive; 28 weeks) compared to each subject's historical rate.|Proportion of subjects achieving a response at Week 29, with response defined as having achieved the absence of ""phlebotomy eligibility"" during the efficacy evaluation phase beginning at Week 17 and continuing to Week 29.|Proportion of subjects with reduction in the rate of phlebotomy events beginning at the Week 17 visit and continuing to Week 29 (12 weeks) compared to each subject's historical rate.","Protagonist Therapeutics, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PTG-300-04","October 1, 2019","October 15, 2025","January 1, 2026","August 14, 2019",,"April 14, 2022","Mayo Clinic - Mayo Clinic Hospital, Phoenix, Arizona, United States|Marin Cancer Care, Greenbrae, California, United States|Stanford University, Palo Alto, California, United States|Moffitt Cancer Center, Tampa, Florida, United States|University of Kansas, Westwood, Kansas, United States|Pontchartrain Cancer Care, Covington, Louisiana, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Mount Sinai, New York, New York, United States|New York Presbyterian Hospital - Weill Cornell Medical Center, New York, New York, United States|Cleveland Clinic - Taussig Cancer Center, Cleveland, Ohio, United States|Mary Crowley Cancer Research Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Sahyadri Super Specialty Hospital, Pune, Maharashtra, India|All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India",,"https://ClinicalTrials.gov/show/NCT04057040"
738,"NCT00722137","Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma",,"Completed","Has Results","Mantle Cell Lymphoma","Drug: Rituximab 375 mg/m^2|Drug: Cyclophosphamide 750 mg/m^2|Drug: Doxorubicin 50 mg/m^2|Drug: VELCADE 1.3 mg/m^2|Drug: Prednisone 100 mg/m^2|Drug: Vincristine 1.4 mg/m^2","Progression Free Survival (PFS)|Time to Progression (TTP)|Duration of Response|Time to Next Anti-lymphoma Treatment (TTNT)|Treatment-free Interval (TFI)|Overall Response Rate (ORR)|Overall Complete Response (CR + CRu)|Overall Survival (OS)|18-Month Survival|Overall Survival (OS) in Long Term Follow-up Period|Number of Participants Experiencing an Adverse Event (AE)","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Takeda","All","18 Years and older   (Adult, Older Adult)","Phase 3","487","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","26866138-LYM-3002|26866138-LYM-3002CTIL|2007-005669-37|0970313683|U1111-1195-3827","May 1, 2008","January 1, 2014","June 17, 2017","July 25, 2008","November 17, 2014","July 12, 2018","St. Francis Hosptial and Medical Center, Hartford, Connecticut, United States|Center for Cancer Care at Goshen Hospital, Goshen, Indiana, United States|Sinai Hospital, Baltimore, Maryland, United States|Capitol Comp. Cancer Center, Jefferson City, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Hematology-Oncology Associates of Northern NJ, Morristown, New Jersey, United States|Legacy Pharma Research, Bismarck, North Dakota, United States|Division of Hematology and Oncology Vanderbilt University, Nashville, Tennessee, United States|Cancer Outreach Associates, PC, Abingdon, Virginia, United States|St.Johanns Spital/Landeskrankenhaus Salzburg, Salzburg, Austria|Allgemeines Krankenhaus der Stadt Wien, Wien, Austria|AZ Stuivenberg Oncologie/ Hematologie, Antwerpen, Belgium|AZ St Jan AV, Brugge, Belgium|UZ Brussel Department Medical Oncology, Brussels, Belgium|UZA Hematologie, 1e verdiep, Edegem, Belgium|Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie, Gent, Belgium|UZ Leuven Gasthuisberg Hematologie, Leuven, Belgium|C.H.R. Citadelle, Liege, Belgium|Centre Hospitalier Universitaire, Liege, Belgium|Ucl de Mont-Godinne, Yvoir, Belgium|Centro de Hematologia E Hemoterapia - Unicamp, Campinas, Brazil|Fundacao Hospital Amaral Carvalho, Jau, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, Brazil|Hospital Sao Lucas Puc-Rs, Porto Alegre, Brazil|Inca - Instituto Nacional Do Cancêr, Rio de Janeiro, Brazil|Centro de Estudos de Hematologia E Oncologia Da Fmabc, Sao Paulo, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Sao Paulo, Brazil|Hospital Ac Camargo, Sao Paulo, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina da USP, Sao Paulo, Brazil|Santa Casa de Misericórida de São Paulo, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Hospital Clinico Universidad Catolica de Chile, Santiago, Chile|Hospital Del Salvador, Santiago, Chile|Instituto Nacional Del Cancer, Santiago, Chile|Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China|West China Hospital, Sichuan University, Chengdu, Sichuan, China|Zhejiang University First Hospital, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Beijing, China|Cancer Institute & Cancer Hospital, CAMS&PUMC, Beijing, China|Peking University Third Hospital, Beijing, China|Cancer hospital, Fudan University, Shanghai, China|Ruijin Hospital, Shanghai, China|Tianjin Medical University Cancer Hospital and Institute, Tianjin, China|Clinica Reina Sofia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Hospital Universitario San Vicente de Paul, Medellin, Colombia|Interni hematoonkoligicka klinika, Brno, Czechia|Interni klinika - Oddeleni klin. hematologie Fakultni nemocnice Hradec Kralove, Hradec Kralove, Czechia|Oddeleni klinicke hematologie, Fakultni nemocnice Kralovske Vinohrady, Praha, Czechia|Vivantes Klinikum Neukölln Klinik für Innere Medizin Hämatologie und Onkologie, Berlin, Germany|Vivantes Klinikum Spandau Klinik für Innere Medizin - Hämatologie, Onkologie und Gastroenterologie, Berlin, Germany|Städt. Kliniken Frankfurt-Hoechst Med. Klinik II - Hämatologie und Onkologie, Frankfurt, Germany|Tumorklinik SANAFONTIS Alpine GmbH, Freiburg, Germany|Wilhelm-Anton-Hospital Goch gGmbH Klinik für Hämatologie und internistische Onkologie, Goch, Germany|Klinikum Lippe-Lemgo Med. Klinik II - Hämatologie und Onkologie, Lemgo, Germany|Johannes-Gutenberg-Universität Mainz III. Med. Klinik, Mainz, Germany|Mutterhaus der Borromäerinnen Med. Klinik I, Trier, Germany|Schwarzwald-Baar-Kliniken Innere Med. II, Villingen, Germany|Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika, Debrecen, Hungary|Petz Aladár Kórház, II. Belgyógyászat, Győr, Hungary|Kaposi Mor Megyei Korhaz, Belgyogyaszat, Kaposvar, Hungary|Apollo Hospital and Research Foundation, Apollo Hospitals, Hyderabad 500033, Andhra Pradesh, India|Sir Ganga Ram Hospital, New Delhi- 110060, Delhi, India|Kidwai Memorial Institute of Oncology, Bangalore 560 029, Karnataka, India|Regional Cancer Centre, Medical Oncology, Thiruvananthapuram, Kerala-695011, India|Jehangir Hospital, Pune-411002, Maharashtra, India|Apollo Speciality Hospital, Chennai, Chennai-600035, Tamil Nadu, India|Netaji Subash Chanda Bose Cancer Research Institute, Kolkata- 700016, West Bengal, India|Rambam Medical Center-Hematology department, Haifa, Israel|Hadassah Medical Center - Hematology department, Jerusalem, Israel|Rabin Medical Center, Beilinson Campus, Petach Tiqva, Israel|Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center - Hematology Institute, Rechovot, Israel|Azienda Ospedaliera Universitaria di Bologna Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche ""L. e A. Seragnoli"", Bologna, Italy|Spedali Civili di Brescia, Brescia, Italy|Dipartimento di Oncologia ed Ematologia Università di Modena e Reggio Emilia, Modena, Italy|AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO TOR VERGATA DIPARTIMENTO DI MEDICINA U.O.C. Ematologia, Roma, Italy|Azienda Ospedaliera San Giovanni Battista ""Molinette"" Struttura Complessa Ematologia 2, Torino, Italy|University Malaya Medical Centre, Kuala Lumpur, Malaysia|Gleneagles Medical Centre, Pulau Pinang, Malaysia|Hopital Du 20 Aout 1953, Casablanca, Morocco|Centre D'oncologie Al Azhar, Rabat, Morocco|Institut National D'oncologie, Rabat, Morocco|National Kidney and Transplant Institute, Quezon City, Philippines|St Lukes Medical Center, Quezon City, Philippines|Szpital Morski im. PCK w Gdyni Gdynskie Centrum Onkologii Oddzial Chemioterapii, Gdynia, Poland|Klinika Hematologii Uniwersytetu Medycznego w Lodzi, Lodz, Poland|""Katedra i Klinika Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego, Poznan, Poland|Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku Akademii Medycznej we Wroclawiu, Wroclaw, Poland|Hospital Sao Marcos, Braga, Portugal|Hospitais da Universidade de Coimbra, Coimbra, Portugal|Hospital de Santa Maria, Lisboa, Portugal|Instituto Portugues de Oncologia, Porto, Portugal|Spitalul Judetean de Urgenta ""Dr. Constantin Opris"", Hematologie, Baia Mare, Romania|Institutul Clinic Fundeni, Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica Hematologie, Bucuresti, Romania|Spitalul Clinic Universitar de Urgenta Bucuresti, Hematologie, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta ""Sf. Spiridon"" Iasi, Oncologie Medicala, Iasi, Romania|Arkhangelsk Regional Clinical Hospital, Arkhangelsk, Russian Federation|Belgorod Regional Oncology Center, Belgorod, Russian Federation|Chelyabinsk Regional Oncology Center, Chelyabinsk, Russian Federation|Sverdlovsk Regional Oncology Dispensary, Ekaterinburg, Russian Federation|1st Republican Clinical Hospital of Udmurtia, Izhevsk, Russian Federation|Cancer Research Center RAMS - N.N. Blokhin - Academy of Medical Science, Moscow, Russian Federation|Hematology Scientific Center, Moscow, Russian Federation|Moscow Regional Clinical Research Institute, Moscow, Russian Federation|S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation|Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russian Federation|Medical Scientific Radiology - Center, Obninsk, Russian Federation|Omsk Regional Oncology Dispensary, Omsk, Russian Federation|Medical Sanitary Unit # 1, Perm, Russian Federation|Republikan Hospital named after V.A/ Baranov, Petrozavodsk, Russian Federation|Rostov Research Institute of Oncology, Rostov-on-Don, Russian Federation|City Clinical Oncology Dispensary, St Petersburg, Russian Federation|Central Res. Inst. of Roentgen-Radiology, St-Petersburg, Russian Federation|Pavlov State Medical Univercity, St-Petersburg, Russian Federation|Leningrad Region Clinical Hospital, St. Petersburg, Russian Federation|St.-Petersburg Clinical Research Institute of Hematology and Transfusiology, St. Petersburg, Russian Federation|National Cancer Centre, Singapore, Singapore|Singapore General Hospital - Hematology, Singapore, Singapore|Chris Hani Baragwanath Hospital, Johannesburg, Gauteng, South Africa|Medical Oncology Center of Rosebank, Johannesburg, Gauteng, South Africa|University of the Witwatersrand Oncology, Johannesburg, Gauteng, South Africa|Pretoria Academic Hospital-Dr. Savage Road, 3rd Floor Radiotherapy Building, Prinshof, Pretoria, Gauteng, South Africa|Dr AI Pirjol & Dr WM Szpak Inc., Durban, Kwazulu Natal, South Africa|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Clinic I Provincial de Barcelona, Barcelona, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Clinico Universitario Salamanca, Salamanca, Spain|Chang Gung Memorial Hospital, Linkou, Tao-Yuan, Taiwan|King Chulalongkorn Memorial Hospital, Bangkok, Thailand|Ramathibodi Hospital, Bangkok, Thailand|Siriraj Hospital-Hematology Unit, Bangkok, Thailand|Maharaj Nakorn Chiang Mai hospital - Faculty of Medicine, Chiang Mai, Thailand|Hôpital Farhat Hached, Sousse, Tunisia|Centre National de Greffe de Moelle osseuse, Tunis, Tunisia|Hôpital Aziza Othmana, Tunis, Tunisia|Institut Salah Azaiz, Tunis, Tunisia|Hacettepe University Medical Faculty, Ankara, Turkey|Dokuz Eylul University Med. Fac., Izmir, Turkey|Cherkassy Regional Oncology Center, Dept. of Hematology, Cherkassy, Ukraine|Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center, Dnepropetrovsk, Ukraine|Institute of Urgent and Recovery Surgery named after V.K.Gusaka of AMS of Ukraine, Haematology Dept., Donetsk, Ukraine|Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitsky, Ukraine|National Cancer Institute, Department of chemotherapy of hemoblastosis, Kiev, Ukraine|Institute of Blood Pathology and Transfusion Medicine, Lviv Clinical Hospital #5, Hematology Dept., Lviv, Ukraine|Crimean Republic Clinical Oncology Dispensary, Haematology Department, Simferopol, Ukraine","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT00722137/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT00722137/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT00722137"
739,"NCT00481247","A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia","DASISION","Completed","Has Results","Myeloid Leukemia, Chronic","Drug: Dasatinib|Drug: Imatinib","Number of Participants With Best Confirmed Complete Cytogenetic Response (cCCyR) Within 12 Months|Percentage of Participants Remaining in Confirmed Complete Cytogenetic Response (cCCyR)|Percentage of Participants With Major Molecular Response (MMR) at Any Time|Time to Confirmed Complete Cytogenic Response (cCCyR) Overall|Time to Major Molecular Response (MMR) Overall|Percentage of Participants With Progression-free Survival (PFS)|Percentage of Participants With Overall Survival (OS)","Bristol-Myers Squibb","All","18 Years and older   (Adult, Older Adult)","Phase 3","547","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CA180-056|2006-005712-27","September 2007","December 2009","December 2015","June 1, 2007","March 15, 2011","February 15, 2017","Molecular Md, Portland, Oregon, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Waratah, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Innsbruck, Austria|Local Institution, Wien, Austria|Local Institution, Brugge, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Curitiba, Parana, Brazil|Local Institution, Campinas, Sao Paulo, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Colombia, Bogota, Colombia|Local Institution, Bogota, Colombia|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Olomouc, Czech Republic|Local Institution, Prague 2, Czech Republic|Local Institution, Aarhus, Denmark|Local Institution, Nantes, Cedex 1, France|Local Institution, Brest Cedex 02, France|Local Institution, Lille Cedex, France|Local Institution, Limoges, France|Local Institution, Montpellier Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Paris, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Poitiers Cedex, France|Local Institution, Rennes, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Berlin, Germany|Local Institution, Rostock, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Vellore, Tamilnadu, India|Local Institution, Ahmedabad, India|Local Institution, Cochin, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, Mumbai, India|Local Institution, Trivandrum, India|Local Institution, Bologna, Italy|Local Institution, Catania, Italy|Local Institution, Monza (mb), Italy|Local Institution, Orbassano (to), Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kamogawa-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinagawa-ku, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Mexico, D. F., Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo Leon, Mexico|Local Institution, Culiacan, Sinaloa, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Chorzow, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Warsaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Rostov-on-don, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Oviedo, Spain|Local Institution, Salamanca, Spain|Local Institution, Valencia, Spain|Local Institution, Ankara, Turkey|Local Institution, Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT00481247"
740,"NCT00391066","Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)","LUCID","Terminated","No Results Available","Chronic Lymphocytic Leukemia","Drug: FCR + Lumiliximab|Drug: FCR","Complete Response (CR) rate|Time to event variables (progression free survival, duration of response, time to next therapy, time to progression and overall survival)|Response variables","Biogen","All","18 Years and older   (Adult, Older Adult)","Phase 2","627","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","152CL201","November 2006","July 2010","December 2010","October 23, 2006",,"October 2, 2015","Research Site, Scottsdale, Arizona, United States|Research Site, Alhambra, California, United States|Research Site, Burbank, California, United States|Research Site, Fullerton, California, United States|Research Site, La Jolla, California, United States|Research Site, Long Beach, California, United States|Research Site, Los Angeles, California, United States|Research Site, Northridge, California, United States|Research Site, Oxnard, California, United States|Research Site, Pomona, California, United States|Research Site, Redondo Beach, California, United States|Research Site, Sacramento, California, United States|Research Site, Santa Maria, California, United States|Research Site, Fort Myers, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Maywood, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Overland Park, Kansas, United States|Research Site, Shreveport, Louisiana, United States|Research Site, Boston, Massachusetts, United States|Research Site, Detroit, Michigan, United States|Research Site, St. Joseph, Michigan, United States|Research Site, Ypsilant,, Michigan, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Columbia, Missouri, United States|Research Site, St. Louis, Missouri, United States|Research Site, Billings, Montana, United States|Research Site, Omaha, Nebraska, United States|Research Site, Hackensack, New Jersey, United States|Research Site, Morristown, New Jersey, United States|Research Site, Chapel Hill, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Kettering, Ohio, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Pittsburgh, Pennsylvania, United States|Research Site, Greenville, South Carolina, United States|Research Site, Nashville, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Bedford, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Fort Worth, Texas, United States|Research Site, Fredericksburg, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Norfolk, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Kennewick, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, St. Louis, Washington, United States|Research Site, Yakima, Washington, United States|Research Site, Cordoba, Argentina|Research Site, Mendoza, Argentina|Research Site, Darlinghurst, New South Wales, Australia|Research Site, Gosford, New South Wales, Australia|Research Site, St. Leonards, New South Wales, Australia|Research Site, Waratah, New South Wales, Australia|Research Site, Westmead, New South Wales, Australia|Research Site, Greenslopes, Queensland, Australia|Research Site, Herston, Queensland, Australia|Research Site, South Brisbane, Queensland, Australia|Research Site, Woolloongabba, Queensland, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Adelaide, South Australia, Australia|Research Site, Ashford, South Australia, Australia|Research Site, Woodville, South Australia, Australia|Research Site, Box Hill, Victoria, Australia|Research Site, Clayton, Victoria, Australia|Research Site, Clayton, Victoria, Australia|Research Site, East Melbourne, Victoria, Australia|Research Site, Fitzroy, Victoria, Australia|Research Site, Freemantle, Western Australia, Australia|Research Site, Nedlands, Western Australia, Australia|Research Site, Perth, Western Australia, Australia|Research Site, Melbourne, Australia|Research Site, Graz, Austria|Research Site, Innsbruck, Austria|Research Site, Salzburg, Austria|Research Site, Wien, Austria|Research Site, Antwerpen, Belgium|Research Site, Brugge, Belgium|Research Site, Bruxelles, Belgium|Research Site, Edegem, Belgium|Research Site, Ghent, Belgium|Research Site, Herestraat, Belgium|Research Site, Yvoir, Belgium|Research Site, Goiania - GO, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Rio de Janeiro, Brazil|Research Site, Santo Andre, Brazil|Research Site, Sao Paulo, Brazil|Research Site, Calgary, Alberta, Canada|Research Site, Edmonton, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Hamilton, Canada|Research Site, Quebec City, Canada|Research Site, Brno, Czech Republic|Research Site, Hradec Kralove, Czech Republic|Research Site, Prague, Czech Republic|Research Site, Angers, France|Research Site, Bordeaux, France|Research Site, Le Mans, France|Research Site, Lille, France|Research Site, Limoges, France|Research Site, Nantes, France|Research Site, Nice, France|Research Site, Pessac, France|Research Site, Rennes, France|Research Site, Rouen, France|Research Site, Tours, France|Research Site, Augsburg, Germany|Research Site, Dessau, Germany|Research Site, Frankfurt, Germany|Research Site, Greifswald, Germany|Research Site, Kiel, Germany|Research Site, Wurzburg, Germany|Research Site, Athens, Greece|Research Site, Herakleion, Greece|Research Site, Ahmedabad, India|Research Site, Bangalore, India|Research Site, Delhi, India|Research Site, Mumbai, India|Research Site, Nashik, India|Research Site, New Delhi, India|Research Site, Pune, India|Research Site, Trivandrum, India|Research Site, Ashkelon, Israel|Research Site, Haifa, Israel|Research Site, Jerusalem, Israel|Research Site, Petach Tikva, Israel|Research Site, Ramat Gan, Israel|Research Site, Rehovo, Israel|Research Site, Milano, Italy|Research Site, Novara, Italy|Research Site, Roma, Italy|Research Site, Rome, Italy|Research Site, Rozzano, Italy|Research Site, Verona, Italy|Research Site, Klaipeda, Lithuania|Research Site, Auckland, New Zealand|Research Site, Christchurch, New Zealand|Research Site, Hamilton, New Zealand|Research Site, Palmerston North, New Zealand|Research Site, Wellington, New Zealand|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Katowice, Poland|Research Site, Krakow, Poland|Research Site, Lodz, Poland|Research Site, Szczecin, Poland|Research Site, Warszawa, Poland|Research Site, Almada, Portugal|Research Site, Braga, Portugal|Research Site, Coimbra, Portugal|Research Site, Lisbon, Portugal|Research Site, Porto, Portugal|Research Site, Viseu, Portugal|Research Site, Brasov, Romania|Research Site, Bucharest, Romania|Research Site, Iasi, Romania|Research Site, Ekaterinburg, Russian Federation|Research Site, Nizhniy Novgorod, Russian Federation|Research Site, Obninsk, Russian Federation|Research Site, Ryazan, Russian Federation|Research Site, Samara, Russian Federation|Research Site, Saratov, Russian Federation|Research Site, St. Peterburg, Russian Federation|Research Site, St. Petersburg, Russian Federation|Research Site, Banska Bystrica, Slovakia|Research Site, Bratislava, Slovakia|Research Site, Martin, Slovakia|Research Site, Madrid, Spain|Research Site, Murcia, Spain|Research Site, Palma de Mallorca, Spain|Research Site, Salamanca, Spain|Research Site, Toledo, Spain|Research Site, Zaragoza, Spain|Research Site, Bath, United Kingdom|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Bournemouth, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Surrey, United Kingdom|Research Site, Taunton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00391066"
741,"NCT02060383","Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly",,"Completed","Has Results","Cushing's Disease|Acromegaly","Drug: Pasireotide s.c.|Drug: Sitagliptin|Drug: Liraglutide|Drug: Insulin|Drug: Pasireotide LAR|Drug: Metformin","Change in HbA1c From Randomization to Approximately 16 Weeks|Change in HbA1c From Randomization (R) Over Time Per Randomized Arm|Change in FPG (Fasting Plasma Glucose) From Randomization Until End of Core Phase|Percentage of Participants in the Incretin-based Arm Who Required Anti-diabetic Rescue Therapy With Insulin|Absolute Change in HbA1c From Baseline to End of Core Phase|Absolute Change in FPG From Baseline to End of Core Phase|Percentage of Participants With ≤ 0.3% HbA1c Increase to End of Core Phase","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 4","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","CSOM230B2219|2012-002916-16","May 23, 2014","February 5, 2018","March 26, 2018","February 12, 2014","May 29, 2019","May 29, 2019","Diabetes and Endocrine Associates La Mesa Location, Multiple Locations, California, United States|LA Biomedical Research at Harbor UCLA Medical Center SC - SOM230B2219, Torrance, California, United States|Coastal Metabolic Research Centre SC, Ventura, California, United States|East Coast Institute for Research East Coast Inst. for Res(ECIR), Jacksonville, Florida, United States|Washington University SC - SOM230B2411, Saint Louis, Missouri, United States|Great Falls Clinic, Great Falls, Montana, United States|Robert Wood Johnson Medical School - Rutgers SC, New Brunswick, New Jersey, United States|The Mount Sinai Hospital SC, New York, New York, United States|Columbia University Medical Center New York Presbyterian Neuroendocrine Unit, New York, New York, United States|Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital SC, New York, New York, United States|Allegheny Endocrinology Associates SC, Pittsburgh, Pennsylvania, United States|Vanderbilt Clinical Trials Center SOM230B2219, Nashville, Tennessee, United States|Baylor College of Medicine Ben Taub General Hosp., Houston, Texas, United States|Virginia Endocrinology Research SC-2, Chesapeake, Virginia, United States|Swedish Medical Center Dept.ofSeattle Neuroscience(2), Seattle, Washington, United States|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Porto Alegre, RS, Brazil|Novartis Investigative Site, Joinville, SC, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Aalborg, Denmark|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Odense C, Denmark|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Freiburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Bangalore, Karnataka, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, San Isidro, Lima, Peru|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Songkla, Thailand|Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Antalya, Turkey","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02060383/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/83/NCT02060383/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02060383"
742,"NCT00574873","Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML",,"Completed","Has Results","Chronic Myeloid Leukemia","Drug: Bosutinib|Drug: imatinib","Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1|Percentage of Participants With Major Molecular Response (MMR) at Year 1|Kaplan-Meier Estimate of Probability of Retaining CCyR at 192 Weeks|Kaplan-Meier Estimate of Probability of Retaining Complete Hematologic Response (CHR) at 192 Weeks|Kaplan-Meier Estimate of Probability of Retaining Derived MMR at 144 Weeks|Cumulative Incidence of On-Treatment Transformation to Accelerated Phase (AP) or Blast Phase (BP) at 192 Weeks","Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","502","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3160A4-3000|B1871008|2007-003780-50","February 5, 2008","August 31, 2010","May 27, 2015","December 17, 2007","November 4, 2012","January 8, 2019","Pacific Cancer Medical Center Inc, Anaheim, California, United States|Tower Cancer Research Foundation (TCRF), Beverly Hills, California, United States|Robert A Moss, MD, FACP, Inc, Fountain Valley, California, United States|UCSD Medical Center-Thornton, La Jolla, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|UCSD Medical Center-Hillcrest, San Diego, California, United States|Stanford Hospital and Clinics Investigational Drug Services, Stanford, California, United States|Stanford Hospitals and Clinics, Stanford, California, United States|Stanford University Medical Center, Stanford, California, United States|Cancer Care Centers of Florida, Hudson, Florida, United States|Cancer Care Centers of Florida, New Port Richey, Florida, United States|Pasco Pinellas Cancer Center, New Port Richey, Florida, United States|Orlando Health, Inc., Orlando, Florida, United States|Pasco Pinellas Cancer Center, Tarpon Springs, Florida, United States|Northside Hospital, Inc. - GCS/Annex, Atlanta, Georgia, United States|Indiana Blood and Marrow Transplantation Research Franciscan St. Francis Health Center Inc., Indianapolis, Indiana, United States|Indiana Blood and Marrow Transplantation Research, Indianapolis, Indiana, United States|Siouxland Hematology-Oncology Associates, LLP, Sioux City, Iowa, United States|Cancer Center of Kansas, Salinas, Kansas, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Josephine Ford Cancer - Downriver, Brownstown, Michigan, United States|Henry Ford Medical Center- Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Hospital - West Bloomfield, Detroit, Michigan, United States|Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Study Supplies: Regional Cancer Care Associates, Cherry Hill, New Jersey, United States|Somerset Hematology Oncology Associates, Somerville, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Associates In Oncology and Hematology, Chattanooga, Tennessee, United States|The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States|Hospital Italiano de la Plata, La Plata, Buenos Aires, Argentina|Hospital Privado de Cordoba, Cordoba, Prov. DE Cordoba, Argentina|Centro de Investigaciones Oncologicas, Bahia Blanca, Provincia Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Cliniques Universitaires Saint Luc, Brussels, Belgium|C.H.R.ST. - R. Fabiola (N-D), Charleroi, Belgium|University Hospital Gent - Department of Hematology, Gent, Belgium|Centre Hospitalier de Jolimont - Lobbes, La Louviere, Belgium|CHU de Charleroi - Hopital civil Marie Curie, Lodelinsart, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|Centro De Hematologia E Hemoterapia Da Unicamp, Campinas/ SP, Brazil|Vancouver General Hospital, Vancouver, British Columbia, Canada|University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada|Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada|Instituto Oncologico del Sur, Temuco, Chile|Instituto Oncologico, Vina del Mar, Chile|Ruiging Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, China|The Chinese PLA General Hospital, Beijing, China|The Hematology Hospital of Chinese Academy of Medical Science, Tianjin, China|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|CIOSAD Centro de Investigaciones Oncologicas, Bogota, Colombia|Institut Bergonie, Bordeaux, France|CHU Caen - Cote de Nacre, Caen, France|Centre Hospitalier de Versailles Hopital Andre Mignot, Le Chesnay Cedex, France|Hopital EDOUARD HERRIOT, Lyon, France|Hopital HOTEL DIEU, Nantes, France|Hospital Archet 1, Nice Cedex 3, France|Centre d'Investigation Clinique- CIC INSERM802, Poitiers, France|CHU de Poitiers, Poitiers, France|Clinique Sainte Anne, Strasbourg, France|Hopitaux Universitaires de Strasbourg - Hopital Civil, Strasbourg, France|Charite University Medical Center - Campus Virchow Klinikum, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Univeristatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Leipzig Zentrum fur Innere Medizin, Leipzig, Germany|III. Medizinische Klinik, Universitaetsklinikum Mannheim gGmbH, Mannheim, Germany|III. Medizinischen Klinik und Poliklinik des Klinikums Rechts der Isar der TU-MUNCHEN, Muenchen, Germany|Prince Of Wales Hospital, Shatin N.T., Hong Kong|Egyesitett Szent Istvan es Szent Laszlo Korhaz-Rendelointezet, Budapest, Hungary|Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary|Kaposi Mor Oktato Korhaz, Belgyogyaszati Osztaly, Kaposvar, Hungary|Josa Andras Hospital, Nyiregyhaza, Hungary|Tata Memorial Center, Tata Memorial Hospital, Mumbai, Maharashtra, India|Advanced Centre for Treatment, Research and Education in Cancer, Mumbai, Maharashtra, India|Jehangir Clinical Development Centre,, Pune, Maharashtra, India|Birla Cancer Centre, Jaipur, Rajasthan, India|SEAROC Cancer Center, Soni Manipal Hospital, Jaipur, Rajasthan, India|Azienda Ospedaliera San Gerardo, Monza, Lombardia, Italy|Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|Ospedale Ferrarotto - Divisione di Ematologia, Catania, Italy|Dipartimento Di Ematologia Ospedale Santo Eugenio, Roma, Italy|Toyohashi Municipal Hospital, Toyohashi, Aichi, Japan|Akita University Hospital, Akita City, Akita, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-Shi, Fukuoka, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Tohoku Univesity Hospital, Sendai, Miyagi, Japan|Kinki University School Of Medicine, Osakasayama, Osaka, Japan|Jikei University Hospital Daisan, Komae-shi, Tokyo, Japan|Japanese Red Cross Nagoya First Hospital, Aichi, Japan|Aichi Cancer Center Hospital, Aichi, Japan|Chiba University Hospital, Chiba, Japan|Tokai University Hospital, Kanagawa, Japan|Nagasaki University Hospital, Nagasaki, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Osaka University Hospital, Osaka, Japan|Hamamatsu Medical University Hospital Faculty of Medicine, Shizuoka, Japan|Tokyo Metropolitan Cancer & Infectious Disease Centre Komagome Hp, Tokyo, Japan|The Catholic University of Korea, Seoul St. Mary's Hospital/Division of Hematology, Seoul, Korea, Republic of|Riga Centre Of Haematology, Riga, Latvia|Hematology, Oncology & Transfusion Medicine Center, Vilnius, Lithuania|Centro Medico de las Americas, Merida, Mexico|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Samodzielny Publiczny Szpital Kliniczny Im. A. Mieleckiego Slaskiego Uniwersytetu Medycznego, Katowice, Poland|SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland|Wojewodzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland|Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie, Lublin, Poland|GUZ Komi Republican Oncology Center, Syktyvkar, KOMI Republic, Russian Federation|Regional State Budgetary Healthcare Institution ""Barnaul City Hospital #8"", Barnaul, Russian Federation|Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Central City Hospital #7, Ekaterinburg, Russian Federation|Kirov Research Institute of Hematology and Blood Transfusion of, Kirov, Russian Federation|Federal State Budget Institution Hematology Scientific Center of Minzdravsotsrazvitiya of Russia, Moscow, Russian Federation|State Novosibirsk Regional Clinical Hospital, Novosibirsk, Russian Federation|Perm Territory State Budgetary Healthcare Inst, Perm, Russian Federation|Republican Hospital na Baranov, Petrozavodsk, Russian Federation|Rostov Regional Clinical Hospital, Rostov-on-Don, Russian Federation|Rostov State Medical University of the Minzdravsotsrazvitiya of Russia, Rostov-On-Don, Russian Federation|Leningrad Regional Clinical Hospital, Saint Petersburg, Russian Federation|St-Petersburg Pavlov's State Medical University, Saint Petersburg, Russian Federation|St-Petersburg State Medical University, Saint Petersburg, Russian Federation|Samara Regional Clinical Hospital M.I. Kalinin, Samara, Russian Federation|St-Petersburg Pavlov's State Medical University, St. Petersburg, Russian Federation|Yaroslavl Region State Budgetary Healthcare Institution Regional Clinical Hospital, Yaroslavl, Russian Federation|Singapore General Hospital, Singapore, Singapore|University Witwatersrand and Oncology, Johannesburg, South Africa|Johannesburg Hospital, Department of Medical Oncology, Parktown, South Africa|Clinical Haematology Unit - Department of Medicine, Soweto, South Africa|Department of Cardiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Department of Radiology, Chris Hani Baragwanath Hospital, Soweto, South Africa|Hospital Universitari Clinic de Barcelona, Barcelona, Spain|Hospital De La Princesa, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital de Madrid Norte-Sanchinarro Centro Integral Oncologico, Madrid, Spain|Complejo Hospitalario de Toledo- Servicio de Hematologia., Toledo, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, Spain|Changhua Christian Hospital, Changhua City, Taiwan|National Taiwan University Hospital, Taipei TOC, Taiwan|Division of Hematology, Department of Medicine, Bangkoknoi, Bangkok, Thailand|Hacettepe Universitesi Tip Fakultesi, Ankara, Sihhiye, Turkey|Ankara Universitesi Tip Fakultesi Cebeci Hastanesi, Ankara, Turkey|Gaziantep Universitesi Tip Fakultesi, Gaziantep, Turkey|Cherkaskiy oblasniy onkologichniy dispanser, Cherkassy, Ukraine|Clinical Assocation of Emergency Care, Dnipropetrovsk, Ukraine|Clinical Diagnostic Laboratory of Komunalnyj Zaklad, Dnipropetrovsk, Ukraine|Komunalnyj Zaklad ""Dnipropetrovska Miska Bagatoprofilna Klinichna Likarnja #4"", Dnipropetrovsk, Ukraine|Instytut Nevidkladnoi ta Vidnovnoi Hirurgii im. P.K. Husaka NAMN Ukrainy, Viddilennja Hematologii, Donetsk, Ukraine|Oleksandrovska clinical hospital cardiological rehabilitation department, Kiev, Ukraine|Miska klinichna likarnja # 9, Kyev, Ukraine|Institut Klinichnoi Radiologii DU ""Natsionalnyj Naukovyj Centr Radiacijnoi Medicini NAMN Ukraini"", Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo Centru Radiacijnoi Medicini NAMN Ukraini, Kyiv, Ukraine|Institut Klinichnoi Radiologii Naukovogo, Kyiv, Ukraine|Ultrasaund Educational and Diagnostic Center, Lviv, Ukraine|Instutut Patologii Krovi to Transfuziynoi Medicinu AMN Ukraini, Lviv, Ukraine|Polyclinic of 5th Municipal Hospital, Lviv, Ukraine|3rd Floor Centre for Clinical Haematology, Nottingham, EAST Midlands, United Kingdom|The Park Hospital, Nottingham, EAST Midlands, United Kingdom|Hammersmith Hospital Clinical Trial Units, Hammersmith, London, United Kingdom|Good Hope Hospital, Birmingham, WEST Midlands, United Kingdom|Birmingham Heartlands Hospital, Birmingham, WEST Midlands, United Kingdom|Department of Haematology - Level 3, Bexley Wing, Leeds, WEST Yorkshire, United Kingdom|Department of Haematology, London, United Kingdom|Hammersmith Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00574873"
743,"NCT02038036","Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.","RESPONSE-2","Completed","Has Results","Polycythemia Vera","Drug: Best Available Therapy|Drug: Ruxolitinib","Number of Participants Achieving Hematocrit (Hct) Control at Week 28|Number of Participants Achieving a Complete Hematological Remission at Week 28|Number of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80|Number of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80|Number of Participants With Phlebotomies Over Time|Change From Baseline in Hematocrit (Hct) at Each Visit|Change From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib|Spleen Length by Visit|Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28|Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28|Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80|Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.|Number of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260|Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.|Number of Participants With Transformation Free Survival Events|Number of Participants With Overall Survival (OS) Events|Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)|Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover|Change From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire|Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover|Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire|Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover|Patient Global Impression of Change (PGIC)|Summary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover|Number of Participants Developing Thrombosis","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","149","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424B2401","March 25, 2014","September 29, 2015","April 7, 2020","January 16, 2014","July 20, 2021","July 20, 2021","Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Bayonne, Bayonne Cedex, France|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Nice Cedex, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Augsburg, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Minden, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Mumbai, Maharashtra, India|Novartis Investigative Site, Vellore, Tamil Nadu, India|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Netanya, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Malaga, Andalucia, Spain|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Alicante, Comunidad Valenciana, Spain|Novartis Investigative Site, La Coruna, Galicia, Spain|Novartis Investigative Site, Las Palmas de Gran Canaria, Las Palmas De G.C, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT02038036"
744,"NCT01232556","A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy",,"Terminated","Has Results","Lymphoma, Non-Hodgkin","Drug: Inotuzumab ozogamicin|Drug: Rituximab|Drug: rituximab + gemcitabine|Drug: rituximab +bendamustine","Overall Survival|Percentage of Participants With a Treatment Emergent Adverse Event (TEAE) (Safety Population)|Progression-Free Survival (PFS)|Percentage of Participants With A Best Overall Response of CR or Partial Response (PR) Per NCI International Response Criteria for NHL|Percentage of Participants With A Best Overall Response of CR, Unconfirmed CR (unCR), PR, or Unconfirmed PR (unPR) Per NCI International Response Criteria for NHL|Duration of Response|Health Status as Assessed by the European Quality of Life 5 Dimension (EQ-5D) Questionnaire|Health Related Quality of Life as Assessed by the Functional Assessment of Cancer Therapy for Lymphoma (FACT-Lym) Questionnaire","Pfizer|UCB Pharma","All","18 Years and older   (Adult, Older Adult)","Phase 3","338","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","B1931008|3129K5-3303|2010-020147-12","April 4, 2011","March 28, 2014","March 28, 2014","November 2, 2010","August 21, 2018","January 8, 2019","Disney Family Cancer Center at Providence St Joseph Medical Center, Burbank, California, United States|Providence St Joseph Medical Center, Burbank, California, United States|Hematology-Oncology Medical Group of Fresno Inc, Fresno, California, United States|Ronald Reagan UCLA Medical Center Drug Information Center Department of Pharmaceutical Services, Los Angeles, California, United States|Clinical Research Unit, Los Angeles, California, United States|Peter Morton Medical Plaza, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Sansum Clinic, Santa Barbara, California, United States|UCLA Santa Monica Hematology Oncology, Santa Monica, California, United States|Sansum Clinic, Solvang, California, United States|Howard University Hospital, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|University Cancer Institute, Boynton Beach, Florida, United States|21st Century Oncology of Jacksonville, LLC, Fernandina Beach, Florida, United States|Davis Cancer Pavilion and Shands Medical Plaza, Gainesville, Florida, United States|Shands Cancer Hospital at the University of Florida, Gainesville, Florida, United States|UF Health Davis Cancer Pavillion and Shands Med Plaza, Gainesville, Florida, United States|UF Health Shands Cancer Hospital, Gainesville, Florida, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|UF Health Shands Hospital, Gainesville, Florida, United States|21st Century Oncology of Jacksonville, LLC, Jacksonville, Florida, United States|21st Century Oncology of Jacksonville, LLC, Jacksonville, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Baptist Medical Center, Jacksonville, Florida, United States|21st Century Oncology of Jacksonville, LLC, Jacksonville, Florida, United States|21st Century Oncology of Jacksonville, Inc., Jacksonville, Florida, United States|Medical Specialists Of The Palm Beaches, Lake Worth, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Advanced Medical Specialties, Miami, Florida, United States|Mercy Hospital, Miami, Florida, United States|Mercy Research Institute, Miami, Florida, United States|21st Century Oncology of Jacksonville, LLC, Orange Park, Florida, United States|Georgia Regents Medical Cancer Pharmacy, Augusta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Kootenai Cancer Center, Coeur d'Alene, Idaho, United States|Kootenai Cancer Center, Post Falls, Idaho, United States|Decatur Memorial Hospital (DMH), Decatur, Illinois, United States|Floyd Memorial Cancer Center of Indiana, New Albany, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|University of Kentucky A.B. Chandler Medical Center, Lexington, Kentucky, United States|University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Barbara Ann Karmanos Cancer Institute at farmington Hills, Farmington Hills, Michigan, United States|Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States|Barnes-Jewish Hospital, Saint Louis, Missouri, United States|Washington University in St Louis, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States|Barnes-Jewish St. Peters, Saint Peters, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C. d/b/a Southeast Nebraska Cancer Center, Lincoln, Nebraska, United States|Beth Israel Medical Center;, New York, New York, United States|Beth Israel Comprehensive Cancer Center, New York, New York, United States|St Luke's- Roosevelt Hospital Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Stony Brook University Medical Center, The Cancer Center, Stony Brook, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|University Hospital, Cincinnati, Ohio, United States|West Chester Hospital Medical Building, West Chester, Ohio, United States|OU Medical Center Presbyterian Professional Building, Oklahoma City, Oklahoma, United States|OU Medical Center Presbyterian Tower, Oklahoma City, Oklahoma, United States|Peggy and Charles Stephenson Cancer Center (chemo & infusion), Oklahoma City, Oklahoma, United States|Peggy and Charles Stephenson Cancer Center (clinic location), Oklahoma City, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Good Samaritan Hospital, Corvallis, Corvallis, Oregon, United States|Samaritan Ambulatory Infusion Services, Corvallis, Oregon, United States|Samaritan Pacific Coast Hospital, Newport, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Guthrie Clinic, Ltd., Sayre, Pennsylvania, United States|Robert Packer Hospital, Sayre, Pennsylvania, United States|Thompson Oncology Group, Knoxville, Tennessee, United States|Thompson Oncology Group, Knoxville, Tennessee, United States|Thompson Oncology Group, Maryville, Tennessee, United States|Thompson Oncology Group, Sevierville, Tennessee, United States|University Hospital - St. Paul, Dallas, Texas, United States|University Hospital - Zale Lipshy, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|Baylor: Charles A. Sammons Cancer Center, Dallas, Texas, United States|Simmons Comprehensive Cancer Center, Dallas, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Universitaire Ziekenhuizen Leuven, Leuven, Vlaams Brabant, Belgium|Institut Jules Bordet, Bruxelles, Belgium|Grand Hopital de Charleroi, Charleroi, Belgium|H.-Hartziekenhuis Roeselare-Menen, Roeselare, Belgium|St Augustinus Ziekenhuis, Wilrijk, Belgium|Cliniques universitaires UCL de Mont-Godinne,, Yvoir, Belgium|UMBAL Sveti Georgi, Klinika po hematologia, Plovdiv, Bulgaria|SBAL na Hematologichnichni Zabolyavania,CTH Sofia, Sofia, Bulgaria|Spetsializirana Bolnitsa za Aktivno Lechenie na Hematologichni Zabolyavania, CTH Sofia, Sofia, Bulgaria|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Sherbrooke (CHUS), Hopital Fleurimont, Sherbrooke, Quebec, Canada|University Hospital Zagreb, Zagreb, Croatia|University Hospital Dubrava Department of Internal Medicine Division of Hematology, Zagreb, Croatia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czech Republic, Czechia|Fakultni nemocnice Brno, Brno, Czechia|Département Pharmacie, Marseille, Bouches-du-rhône, France|Institut Paoli Calmettes, Marseille, Cedex 09, France|Hospital Universitaire Andre Mignot, Le Chesnay Cedex, Yvelines, France|Hopital Andre Mignot, Le Chesnay, Yvelines, France|Centre Leon Berard, Lyon, France|CHU Saint Eloi, Montpellier, France|Hopital du haut Leveque, Pessac, France|Centre Henri Becquerel, Rouen, France|Universitaetsklinikum Aachen, Aachen, Germany|Sozialstiftung Bamberg, Bamberg, Germany|Charite Campus Benjamin Franklin, Berlin, Germany|Charite Campus Virchow-Klinikum, Berlin, Germany|Universitaetsklinikum Mainz, Mainz, Germany|TU Muenchen III. Medizinische Klinik, Muenchen, Germany|Universitaetsklinik Ulm, Ulm, Germany|Egyesitett Szent Istvan es Szent Laszlo Korhaz /, Budapest, Hungary|DEOEC, Belgyogyaszati Intezet, Debrechen, Hungary|Somongy Megyei Kaposi Mor Okato Korhaz/ Belgyogyaszati osztaly, Kaposvar, Hungary|Kodlikeri Memorial Hospital, Aurangabad, Maharashtra, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|OEC Record Management Company Pvt. Ltd.,, Pune, Maharashtra, India|Sahyadri Speciality Hospital, Pune, Maharashtra, India|Bon Secours Hospital, Cork, Ireland|Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Ehime University Hospital, Toon-shi, Ehime, Japan|Gunma University Hospital, Maebashi-city, Gunma, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Matsushita Memorial Hospital, Moriguchi, Osaka, Japan|Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Cancer Institute Hospital, Japanese Foundation For Cancer Research, Koto-Ku, Tokyo, Japan|Akita University Hospital, Akita, Japan|National Kyushu Cancer Center, Fukuoka, Japan|Tokai University Hospital, Kanagawa, Japan|University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan|Klaipeda Seamen's Hospital, Public Institution, department of Oncology, Klaipeda, Lithuania|Instituto Biomédico de Investigación A.C., Aguascalientes, Aguascalientes. Mexico, Mexico|Niepubliczny Zaklad Opieki Zdrowotnej AVI Diagnostyka Obrazowa, Warszawa, Poland|Klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Advanced Infusion Services, Catano, Puerto Rico|Hospital Espanol Auxilio Mutuo de Puerto Rico Inc, San Juan, Puerto Rico|Federal State Budgetary Institution Hematology Scientific Centre of Ministry of, Moscow, Russian Federation|Moscow State Healthcare Institution City clinical hospital S.P. Botkin, Moscow, Russian Federation|Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva, Saint-Petersburg, Russian Federation|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|Narodny onkologicky ustav, Bratislava, Slovakia|Hospital Virgen Del Rocio, Sevilla, Andalucia, Spain|Hospital Universitario De Salamanca, Salamanca, Castille AND LION, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Clinic Universitari de Barcelona, Barcelona, Spain|Institut Catala d'Oncologia-L'Hospitalet, L'Hospitalet De Llobregat (bcn), Spain|Hospital Universitario de Canarias, La Laguna (Tenerife), Spain|Hospital de la Princesa, Madrid, Spain|Universitetssjukhuset, Linkoping, Sweden|Skanes Universitetssjukhus i Lund, Lund, Sweden|Chang Gung Medical Foundation - Linkou Branch, Kuei-Shan Hsiang, Taoyuan County, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Hematology Division Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University, Bangkoknoi, Bangkok, Thailand|Chiang Mai University, Chiang Mai, Thailand|Regional Treatment and Diagnostic Hematology Center Communal Establishment, Cherkasy, Ukraine|Department of Oncology and Medical Radiology of State Institution, Dnipropetrovsk, Ukraine|SI""Research Center for Radiation Medicine of NAMS of Ukraine"", Kyiv, Ukraine|Barts Cancer Centre Dept Haemato-oncology St. Bartholomew's Hospital Barts Health NHS Trust, London, United Kingdom|Chemotherapy Preparative Unit St. Bartholomew's Hospital, London, United Kingdom|Department of Medical Oncology St. Bartholomew's Hospital, London, United Kingdom|The Christie NHS Foundation Trust - Christie Hospital, Manchester, United Kingdom|Department of Clinical Pathology Newcastle upon Tyne Hospitals NHS Foundation Trust Royal Victoria I, Newcastle upon Tyne, United Kingdom|Department of Clinical Biochemistry Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom|Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom|Nottingham University Hospital, Nottingham, United Kingdom|Pathology Department Nottingham University Hospital - City Hospital Campus, Nottingham, United Kingdom|Pharmacy Nottingham University Hospital - City Hospital Campus, Nottingham, United Kingdom|Local Laboratory Nottingham University Hospital - City Hospital Campus, Nottingham, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01232556"
745,"NCT01039376","Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy","PROLONG","Terminated","Has Results","Leukaemia, Lymphocytic, Chronic","Biological: Ofatumumab|Other: Observation","Progression-free Survival, as Assessed by the Investigator|Progression-free Survival, as Assessed by the Independent Review Committee (IRC)|Overall Survival|Number of Participants With Improvement in Response From Baseline|Time to Next Therapy|Progression-free Survival After Next-line Therapy|Time to Progression After Next-line Therapy|Change From Baseline (BL) in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Chronic Lymphocytic Leukaemia 16 Item Module (EORTC QLQ-CLL 16)|Change From Baseline in the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Score|Change From Baseline in the Quality of Life Status as Assessed by the EuroQol-5D (EQ-5D) Scale|Number of Participants With an Improvement in Eastern Cooperative Oncology Group (ECOG) Performance Status at the Indicated Time Points|Number of Participants With the Indicated Constitutional or B-symptoms at the Indicated Time Points|Number of Participants With Grade 3 and Above Adverse Event of Infection|Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)|Number of Participants With a Grade 3 or Grade 4 Myelosuppression (Anemia, Neutropenia, or Thrombocytopenia) at Indicated Time Points|Number of Participants Who Received at Least One Transfusion During the Study|Number of Participants Diagnosed With Autoimmune Hemolytic Anemia (AIHA)|Number of Participants With a Positive Anti-ofatumumab Antibody (Human Anti-human Antibody; HAHA) Result|Mean Change From Baseline in the Immunoglobulin (Ig) Antibodies IgA, IgG, and IgM at Indicated Time Points|Number of Participants Who Were Positive and Negative for Minimal Residual Disease (MRD) at Any Visit|Change From Baseline in Cluster of Differentiation (CD) CD5+CD19+ and CD5-CD19+ Cell Counts at the Indicated Time Points|Summary of Covariates to Compute Cox Proportional Hazards Regression Model for Relationship Between Investigator Assessed Progression-free Survival and the Indicated Prognostic Markers|Cmax and Ctrough of Ofatumumab|Total Plasma Clearance (CL) of Ofatumumab|AUC(0-tau) of Ofatumumab|Vss of Ofatumumab|Plasma Half-life (t1/2) of Ofatumumab","Novartis Pharmaceuticals|Novartis","All","Child, Adult, Older Adult","Phase 3","480","Industry","Interventional","Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment","112517|COMB157C2301","May 6, 2010","February 20, 2017","June 26, 2018","December 25, 2009","April 21, 2015","July 30, 2019","Novartis Investigative Site, Gilbert, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Jonesboro, Arkansas, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, La Verne, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, San Pablo, California, United States|Novartis Investigative Site, Hartford, Connecticut, United States|Novartis Investigative Site, Gainesville, Florida, United States|Novartis Investigative Site, Lake Worth, Florida, United States|Novartis Investigative Site, Orlando, Florida, United States|Novartis Investigative Site, Pembroke Pines, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Macon, Georgia, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Post Falls, Idaho, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Iowa City, Iowa, United States|Novartis Investigative Site, Westwood, Kansas, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Cumberland, Maryland, United States|Novartis Investigative Site, Hagerstown, Maryland, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Springfield, Missouri, United States|Novartis Investigative Site, Henderson, Nevada, United States|Novartis Investigative Site, New Brunswick, New Jersey, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Albuquerque, New Mexico, United States|Novartis Investigative Site, Mineola, New York, United States|Novartis Investigative Site, Rochester, New York, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Durham, North Carolina, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Greenville, South Carolina, United States|Novartis Investigative Site, Chattanooga, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Orem, Utah, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Capital Federal, Buenos Aires, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Novartis Investigative Site, Derqui, Pilar, Buenos Aires, Argentina|Novartis Investigative Site, La Plata, Buenos Aires, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Ciudad Autonoma de Buenos Aires, Argentina|Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, Randwick, New South Wales, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, East Melbourne, Victoria, Australia|Novartis Investigative Site, Parkville, Victoria, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Brussels, Belgium|Novartis Investigative Site, Gent, Belgium|Novartis Investigative Site, Hasselt, Belgium|Novartis Investigative Site, Roeselare, Belgium|Novartis Investigative Site, Wilrijk, Belgium|Novartis Investigative Site, Salvador, Bahía, Brazil|Novartis Investigative Site, Goiania - GO, Goiás, Brazil|Novartis Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Novartis Investigative Site, Barretos, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Sao Paulo, São Paulo, Brazil|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Kitchener, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Sherbrooke, Quebec, Canada|Novartis Investigative Site, Saskatoon, Saskatchewan, Canada|Novartis Investigative Site, Brno, Czechia|Novartis Investigative Site, Hradec Kralove, Czechia|Novartis Investigative Site, Olomouc, Czechia|Novartis Investigative Site, Pelhrimov, Czechia|Novartis Investigative Site, Praha 10, Czechia|Novartis Investigative Site, Herlev, Denmark|Novartis Investigative Site, Kobenhavn, Denmark|Novartis Investigative Site, Roskilde, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Jyvaskyla, Finland|Novartis Investigative Site, Pori, Finland|Novartis Investigative Site, Tampere, Finland|Novartis Investigative Site, Turku, Finland|Novartis Investigative Site, Blois cedex, France|Novartis Investigative Site, Caen cedex 5, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Lille cedex, France|Novartis Investigative Site, Marseille Cedex 9, France|Novartis Investigative Site, Mulhouse, France|Novartis Investigative Site, Pessac cedex, France|Novartis Investigative Site, Saint Pierre cedex, France|Novartis Investigative Site, Strasbourg cedex, France|Novartis Investigative Site, Toulouse cedex 9, France|Novartis Investigative Site, Vandoeuvre-Les-Nancy, France|Novartis Investigative Site, Athens,, Greece|Novartis Investigative Site, Athens, Greece|Novartis Investigative Site, Piraeus, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Thessaloniki, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Ahmedabad, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Mumbai, India|Novartis Investigative Site, Pune, India|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Haifa, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Kfar Saba, Israel|Novartis Investigative Site, Nahariya, Israel|Novartis Investigative Site, Petach-Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Rehovot, Israel|Novartis Investigative Site, Tel-Aviv, Israel|Novartis Investigative Site, Zrifin, Israel|Novartis Investigative Site, Modena, Emilia-Romagna, Italy|Novartis Investigative Site, Piacenza, Emilia-Romagna, Italy|Novartis Investigative Site, Roma, Lazio, Italy|Novartis Investigative Site, Novara, Piemonte, Italy|Novartis Investigative Site, Torino, Piemonte, Italy|Novartis Investigative Site, Pisa, Toscana, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Amersfoort, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Amsterdam, Netherlands|Novartis Investigative Site, Blaricum, Netherlands|Novartis Investigative Site, Breda, Netherlands|Novartis Investigative Site, Den Bosch, Netherlands|Novartis Investigative Site, Den Haag, Netherlands|Novartis Investigative Site, Deventer, Netherlands|Novartis Investigative Site, Dordrecht, Netherlands|Novartis Investigative Site, Enschede, Netherlands|Novartis Investigative Site, Groningen, Netherlands|Novartis Investigative Site, Hoofddorp, Netherlands|Novartis Investigative Site, Leiden, Netherlands|Novartis Investigative Site, Maastricht, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Sittard-geleen, Netherlands|Novartis Investigative Site, Tilburg, Netherlands|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Bialystok, Poland|Novartis Investigative Site, Chorzow, Poland|Novartis Investigative Site, Slupsk, Poland|Novartis Investigative Site, Szczecin, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Warszawa, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, San Juan, Puerto Rico|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Penza, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St'Petersburg, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Volgograd, Russian Federation|Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Salamanca, Spain|Novartis Investigative Site, Sevilla, Spain|Novartis Investigative Site, Toledo, Spain|Novartis Investigative Site, Zaragoza, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Orebro, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Uppsala, Sweden|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Cherkasy, Ukraine|Novartis Investigative Site, Dnipropetrovsk, Ukraine|Novartis Investigative Site, Kharkiv, Ukraine|Novartis Investigative Site, Khmelnytskyi, Ukraine|Novartis Investigative Site, Kyiv, Ukraine|Novartis Investigative Site, Lviv, Ukraine|Novartis Investigative Site, Makiivka, Ukraine|Novartis Investigative Site, Vinnitsa, Ukraine|Novartis Investigative Site, Zhytomyr, Ukraine","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01039376/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/76/NCT01039376/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT01039376"
746,"NCT01602952","Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI",,"Completed","No Results Available","Leukemia|Leukemia, Myeloid|Leukemia, Myelogenous, Chronic, BCR-ABL Positive|Philadelphia Chromosome|Hematologic Diseases","Drug: Radotinib","To investigate the Maximum Tolerated Dose(Phase 1)|Rate of Complete hematologic response(CHR)(Phase 2)|To investigate the Dose Limiting Toxicity(Phase 1)|Rate of complete Cytogenetic Response(CCyR)(Phase 2)|Adverse events(Phase 1& Phase 2)|Progression-free survival or PFS","Il-Yang Pharm. Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","85","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IY5511A1201","July 2008","October 2012","July 13, 2018","May 21, 2012",,"August 29, 2018","Local institution, Mumbai, Maharashtra, India|Local institution, Mumbai, Mazagaon, India|Local institution, Daegu, Buk-gu, Korea, Republic of|Local institution, Jeonju, Deokjin-gu, Korea, Republic of|Local institution, Ulsan, Dong-gu, Korea, Republic of|Local institution, Anyang-si, Dongan-gu, Korea, Republic of|Local institution, Hwasun, Hwasun-eup, Korea, Republic of|Local institution, Seoul, Jongro-ku, Korea, Republic of|Local institution, Busan, Seo-gu, Korea, Republic of|Seoul St. Mary's hospital, Seoul, Seocho-gu, Korea, Republic of|Local institution, Suwon, Yeongtong-gu, Korea, Republic of|Local institution, Bangkok, Phyathai, Thailand",,"https://ClinicalTrials.gov/show/NCT01602952"
747,"NCT02829775","A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies",,"Completed","Has Results","Chronic Myelogenous Leukemia|Malignant Melanoma|Renal Cell Carcinoma","Drug: Pegylated Interferon Alfa-2a|Drug: Recombinant Interferon Alfa 2a","Number of Participants With Serious Adverse Events (SAEs)|Number of Participants With Overall Tumor Response","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NO17754|2004-002093-30","January 2004","January 2008","January 2008","July 12, 2016","November 17, 2016","January 9, 2017","Sofia, Bulgaria|Halifax, Nova Scotia, Canada|Lucknow, India|Moscow, Russian Federation|Moscow, Russian Federation|Kosice, Slovakia|Durban, South Africa|Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT02829775"
748,"NCT03180268","Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery",,"Recruiting","No Results Available","Grade II Meningioma|Intracranial Meningioma","Other: Clinical Observation|Radiation: Radiation Therapy","Progression-Free Survival (PFS)|Overall Survival (OS)|5 Year Overall Survival (OS)|Disease-Specific Survival (DSS)|3 Year Disease-Specific Survival (DSS)|5 Year Disease-Specific Survival (DSS)|3 Year Progression-Free Survival (PFS)|5 Year Progression-Free Survival (PFS)|Neurocognitive Function (NCF)|Patient Reported Outcomes (PRO) as assessed by MDASI-BT|Assessment of pHH3 mitotic index|Incidence of adverse events as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4 (exclusive of alopecia)","NRG Oncology|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","148","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NRG-BN003|NCI-2016-01619|U10CA180868","June 14, 2017","June 15, 2027","August 31, 2027","June 8, 2017",,"January 18, 2022","University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States|Saint Joseph's Hospital and Medical Center, Phoenix, Arizona, United States|Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States|Mayo Clinic in Arizona, Scottsdale, Arizona, United States|University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States|Kaiser Permanente-Anaheim, Anaheim, California, United States|Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States|Kaiser Permanente Dublin, Dublin, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Los Angeles County-USC Medical Center, Los Angeles, California, United States|USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States|Memorial Medical Center, Modesto, California, United States|Kaiser Permanente Oakland-Broadway, Oakland, California, United States|UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States|Stanford Cancer Institute Palo Alto, Palo Alto, California, United States|Kaiser Permanente-Rancho Cordova Cancer Center, Rancho Cordova, California, United States|Rohnert Park Cancer Center, Rohnert Park, California, United States|Sutter Cancer Centers Radiation Oncology Services-Roseville, Roseville, California, United States|The Permanente Medical Group-Roseville Radiation Oncology, Roseville, California, United States|Sutter Medical Center Sacramento, Sacramento, California, United States|South Sacramento Cancer Center, Sacramento, California, United States|Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, United States|Kaiser Permanente Cancer Treatment Center, South San Francisco, California, United States|Sutter Solano Medical Center/Cancer Center, Vallejo, California, United States|Hartford Hospital, Hartford, Connecticut, United States|Yale University, New Haven, Connecticut, United States|Helen F Graham Cancer Center, Newark, Delaware, United States|Christiana Care Health System-Christiana Hospital, Newark, Delaware, United States|Beebe Health Campus, Rehoboth Beach, Delaware, United States|TidalHealth Nanticoke / Allen Cancer Center, Seaford, Delaware, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States|UM Sylvester Comprehensive Cancer Center at Deerfield Beach, Deerfield Beach, Florida, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Miami Cancer Institute, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|AdventHealth East Orlando, Orlando, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Grady Health System, Atlanta, Georgia, United States|Emory Proton Therapy Center, Atlanta, Georgia, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States|Northside Hospital, Atlanta, Georgia, United States|Northside Hospital-Forsyth, Cumming, Georgia, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Piedmont Newnan Hospital, Newnan, Georgia, United States|Piedmont Henry Hospital, Stockbridge, Georgia, United States|Queen's Medical Center, Honolulu, Hawaii, United States|The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Northwestern Medicine Cancer Center Delnor, Geneva, Illinois, United States|NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States|NorthShore University HealthSystem-Highland Park Hospital, Highland Park, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Methodist Hospital, Indianapolis, Indiana, United States|Iowa Methodist Medical Center, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|University of Kansas Cancer Center, Kansas City, Kansas, United States|University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States|University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States|MaineHealth Coastal Cancer Treatment Center, Bath, Maine, United States|Maine Medical Center-Bramhall Campus, Portland, Maine, United States|MaineHealth Cancer Care Center of York County, Sanford, Maine, United States|Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States|Maryland Proton Treatment Center, Baltimore, Maryland, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Saint Joseph Mercy Chelsea, Chelsea, Michigan, United States|Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Ascension Saint John Hospital, Detroit, Michigan, United States|Saint Mary Mercy Hospital, Livonia, Michigan, United States|Ascension Saint Mary's Hospital, Saginaw, Michigan, United States|Saint John Macomb-Oakland Hospital, Warren, Michigan, United States|Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States|Essentia Health Cancer Center, Duluth, Minnesota, United States|Miller-Dwan Hospital, Duluth, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Park Nicollet Clinic - Saint Louis Park, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|University of Missouri - Ellis Fischel, Columbia, Missouri, United States|Siteman Cancer Center at West County Hospital, Creve Coeur, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Siteman Cancer Center-South County, Saint Louis, Missouri, United States|Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States|Benefis Healthcare- Sletten Cancer Institute, Great Falls, Montana, United States|Kalispell Regional Medical Center, Kalispell, Montana, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Rutgers New Jersey Medical School, Newark, New Jersey, United States|Capital Health Medical Center-Hopewell, Pennington, New Jersey, United States|ProCure Proton Therapy Center-Somerset, Somerset, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Somerville, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York-Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|The New York Hospital Medical Center of Queens, Flushing, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States|Case Western Reserve University, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Mercy Cancer Center-Elyria, Elyria, Ohio, United States|UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio, United States|ProMedica Flower Hospital, Sylvania, Ohio, United States|UHHS-Westlake Medical Center, Westlake, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Mount Hood Medical Center, Gresham, Oregon, United States|Legacy Good Samaritan Hospital and Medical Center, Portland, Oregon, United States|Saint Luke's University Hospital-Bethlehem Campus, Bethlehem, Pennsylvania, United States|Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania, United States|Lewistown Hospital, Lewistown, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Geisinger Cancer Services-Pottsville, Pottsville, Pennsylvania, United States|Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania, United States|Lankenau Medical Center, Wynnewood, Pennsylvania, United States|Prisma Health Cancer Institute - Spartanburg, Boiling Springs, South Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Prisma Health Cancer Institute - Faris, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Eastside, Greenville, South Carolina, United States|Prisma Health Cancer Institute - Greer, Greer, South Carolina, United States|Prisma Health Cancer Institute - Seneca, Seneca, South Carolina, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|American Fork Hospital / Huntsman Intermountain Cancer Center, American Fork, Utah, United States|Intermountain Medical Center, Murray, Utah, United States|Utah Valley Regional Medical Center, Provo, Utah, United States|Riverton Hospital, Riverton, Utah, United States|LDS Hospital, Salt Lake City, Utah, United States|Norris Cotton Cancer Center-North, Saint Johnsbury, Vermont, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|University of Washington Medical Center - Montlake, Seattle, Washington, United States|Legacy Salmon Creek Hospital, Vancouver, Washington, United States|Marshfield Medical Center-EC Cancer Center, Eau Claire, Wisconsin, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Marshfield Medical Center-Marshfield, Marshfield, Wisconsin, United States|Froedtert Menomonee Falls Hospital, Menomonee Falls, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin, United States|Marshfield Clinic Stevens Point Center, Stevens Point, Wisconsin, United States|Diagnostic and Treatment Center, Weston, Wisconsin, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada|The Research Institute of the McGill University Health Centre (MUHC), Montreal, Quebec, Canada|Allan Blair Cancer Centre, Regina, Saskatchewan, Canada|Tata Memorial Hospital, Mumbai, India|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, Japan|Keio University, Shinjuku-ku, Tokyo, Japan|Hiroshima University Hospital, Hiroshima City, Japan|Saitama Medical University International Medical Center, Saitama, Japan|National Cancer Center Hospital, Tokyo, Japan|King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia",,"https://ClinicalTrials.gov/show/NCT03180268"
749,"NCT02654340","Biomarkers for Tuberous Sclerosis Complex (BioTuScCom)","TuScCom","Active, not recruiting","No Results Available","Hypomelanotic Macules|Facial Angiofibroma|Shagreen Patches|Ungual Fibromas|Cortical Dysplasia|Cardiac Rhabdomyoma|Lymphangioleiomyomatosis|Renal Angiomyolipoma|Subependymal Giant Cell Astrocytoma",,"Identification of TSC biomarker/s|Exploring the clinical robustness, specificity, and longterm variability of TSC biomarker/s","CENTOGENE GmbH Rostock","All","2 Years to 50 Years   (Child, Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","TSC 08-2018","August 1, 2018","December 30, 2023","December 30, 2023","January 13, 2016",,"March 24, 2022","University Hospital Center Mother Teresa, Tirana, Albania|Department of Pediatrics, Alexandria University Children's Hospital, Alexandria, Egypt|Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi, Georgia|Department of Pediatric Genetics, Amrita Institute of Medical Sciences & Research Centre, Cochin, Kerala, India|Rare diseases coordinating centre, Vilnius University Hospital Santaros klinikos, Vilnius, Lithuania|Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health, Lahore, Pakistan|Emergency Hospital for Children ""Louis Turcanu"", Timişoara, Romania|Lady Ridgeway Hospital for Children, Colombo, Sri Lanka",,"https://ClinicalTrials.gov/show/NCT02654340"
750,"NCT01933945","Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib","OPTIMIS","Completed","No Results Available","Carcinoma, Hepatocellular","Procedure: TACE (transarterial chemoembolization)|Drug: Sorafenib (Nexavar, BAY43-9006)","Overall survival (OS)|Overall survival from initial TACE|Progression-free survival (PFS) from initial TACE|Time to progression (TTP) from initial TACE|Tumor response according to mRECIST criteria|Duration of TACE treatment|Number of patients with TEAEs (treatment emergent adverse events)|TACE unsuitability|Time to TACE non-eligibility|Deterioration of liver dysfunction|OS from initiation of sorafenib|PFS from initiation of sorafenib|Tumor status at different visits response according to mRECIST|Duration of sorafenib treatment|TTP from initiation of sorafenib","Bayer","All","Child, Adult, Older Adult",,"1676","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","16560|NX1301","October 28, 2013","July 22, 2017","November 10, 2017","September 2, 2013",,"November 6, 2018","Multiple Locations, Austria|Multiple Locations, Brazil|Multiple Locations, Canada|Multiple Locations, China|Multiple Locations, Czechia|Multiple Locations, Denmark|Multiple Locations, Egypt|Multiple Locations, France|Multiple Locations, Greece|Multiple Locations, Hong Kong|Multiple Locations, Hungary|Multiple Locations, India|Multiple Locations, Indonesia|Multiple Locations, Israel|Multiple Locations, Japan|Multiple Locations, Kazakhstan|Multiple Locations, Korea, Republic of|Multiple Locations, Mexico|Multiple Locations, Netherlands|Multiple Locations, Pakistan|Multiple Locations, Poland|Multiple Locations, Russian Federation|Multiple Locations, Singapore|Multiple Locations, Slovakia|Multiple Locations, Spain|Multiple Locations, Sweden|Multiple Locations, Switzerland|Multiple Locations, Taiwan|Multiple Locations, Thailand|Multiple Locations, Turkey|Multiple Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT01933945"
751,"NCT00812175","Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib","GIDEON","Completed","No Results Available","Carcinoma, Hepatocellular","Drug: Sorafenib (Nexavar, BAY43-9006)","The safety of Nexavar in all patients with unresectable HCC who are candidates for systemic therapy and in whom a decision to treat with Nexavar has been made under real-life practice conditions|Efficacy [overall survival (OS), progression-free survival (PFS), time to progression (TTP), response rate (RR), stable disease(SD) rate] by the Response Evaluation Criteria in Solid Tumor (RECIST) Criteria of Nexavar|The duration of therapy with Nexavar in a variety of settings according to patient characteristics and other variables|To evaluate the methods of patient evaluation, diagnosis and follow up|To evaluate the co-morbidities in patients with unresectable HCC and their influence on treatment and outcome|To evaluate the practice patterns of the physicians involved in the care of patients with HCC under real-life conditions|Reports of adverse events","Bayer","All","18 Years and older   (Adult, Older Adult)",,"3371","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","13414|NX0802","January 2009","April 2012","April 2012","December 22, 2008",,"October 17, 2016","Many Locations, Alabama, United States|Many Locations, Arizona, United States|Many Locations, Arkansas, United States|Many Locations, California, United States|Many Locations, Colorado, United States|Many Locations, Connecticut, United States|Many Locations, Florida, United States|Many Locations, Georgia, United States|Many Locations, Hawaii, United States|Many Locations, Illinois, United States|Many Locations, Indiana, United States|Many Locations, Iowa, United States|Many Locations, Kansas, United States|Many Locations, Kentucky, United States|Many Locations, Louisiana, United States|Many Locations, Maryland, United States|Many Locations, Massachusetts, United States|Many Locations, Michigan, United States|Many Locations, Minnesota, United States|Many Locations, Missouri, United States|Many Locations, Nebraska, United States|Many Locations, Nevada, United States|Many Locations, New Hampshire, United States|Many Locations, New Jersey, United States|Many Locations, New York, United States|Many Locations, North Carolina, United States|Many Locations, Ohio, United States|Many Locations, Oklahoma, United States|Many Locations, Oregon, United States|Many Locations, Pennsylvania, United States|Many Locations, South Carolina, United States|Many Locations, Tennessee, United States|Many Locations, Texas, United States|Many Locations, Utah, United States|Many Locations, Virginia, United States|Many Locations, Washington, United States|Many Locations, Wisconsin, United States|Many Locations, Canada|Many Locations, China|Many Locations, Colombia|Many Locations, Croatia|Many Locations, Czech Republic|Many Locations, Finland|Many Locations, France|Many Locations, Greece|Many Locations, Hong Kong|Many Locations, Hungary|Many Locations, India|Many Locations, Indonesia|Many Locations, Israel|Many Locations, Italy|Many Locations, Japan|Many Locations, Kazakhstan|Many Locations, Korea, Republic of|Many Locations, Libyan Arab Jamahiriya|Many Locations, Malaysia|Many Locations, Mexico|Many Locations, Norway|Many Locations, Pakistan|Many Locations, Philippines|Many Locations, Portugal|Many Locations, Qatar|Many Locations, Romania|Many Locations, Russian Federation|Many Locations, Singapore|Many Locations, Slovakia|Many Locations, Spain|Many Locations, Sweden|Many Locations, Syrian Arab Republic|Many Locations, Thailand|Many Locations, Ukraine|Many Locations, United Arab Emirates|Many Locations, Uruguay|Many Locations, Venezuela|Many Locations, Vietnam",,"https://ClinicalTrials.gov/show/NCT00812175"
752,"NCT00335738","Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma",,"Completed","Has Results","Intraocular Retinoblastoma","Drug: liposomal vincristine sulfate|Drug: carboplatin|Drug: etoposide","Event-free Survival (EFS)|Overall Survival (OS)|Toxicity As Assessed By the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0|Pathological Features Present At Diagnosis - Posterior Uveal Invasion (PVI)|Pathological Features Present At Diagnosis - Tumor Involving the Optic Nerve Posterior to the Lamina Cribrosa (LC) as an Independent Finding|Pathological Features Present at Diagnosis - Scleral Invasion (SI)|Pathological Features Present At Diagnosis - Anterior Chamber Seeding (ACS)|Pathological Features Present At Diagnosis - Iris Infiltration (II)|Pathological Features Present At Diagnosis - Ciliary Body Infiltration (CBI)","Children's Oncology Group|National Cancer Institute (NCI)","All","up to 6 Years   (Child)","Phase 3","331","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARET0332|NCI-2009-00423|CDR0000483043|U10CA098543|COG-ARET0332","December 2005","September 2011","September 30, 2020","June 12, 2006","April 17, 2018","February 18, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of Arizona Health Sciences Center, Tucson, Arizona, United States|Children's Oncology Group, Arcadia, California, United States|Southern California Permanente Medical Group, Downey, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|University of California San Francisco Medical Center-Parnassus, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|University of Illinois, Chicago, Illinois, United States|Childrens Memorial Hospital, Chicago, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|University of Kentucky, Lexington, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|The Childrens Mercy Hospital, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Brooklyn Hospital Center, Brooklyn, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Rainbow Babies and Childrens Hospital, Cleveland, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|The Children's Medical Center of Dayton, Dayton, Ohio, United States|Lehigh Valley Hospital - Muhlenberg, Bethlehem, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Covenant Children's Hospital, Lubbock, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Medical Center, Salt Lake City, Utah, United States|Childrens Hospital-King's Daughters, Norfolk, Virginia, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Midwest Children's Cancer Center, Milwaukee, Wisconsin, United States|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Royal Children's Hospital, Parkville, Victoria, Australia|Princess Margaret Hospital for Children, Perth, Western Australia, Australia|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Hospital Sainte-Justine, Montreal, Quebec, Canada|L V Prasad Eye Institute, Hyderabad, India|Starship Children's Hospital, Grafton, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand",,"https://ClinicalTrials.gov/show/NCT00335738"
753,"NCT01450449","Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme",,"Completed","No Results Available","Glioblastoma Multiforme","Radiation: Radiotherapy","Overall Survival|Progression-free survival|Quality of Life","International Atomic Energy Agency|Fundación Escuela de Medicina Nuclear|N.N. Alexandrov National Cancer Centre of Belarus|Hospital A.C. Camargo|Irmandade Santa Casa de Misericórdia de Porto Alegre|Instituto de Radiomedicina (IRAM)|Postgraduate Institute of Medical Education and Research|Dr Cipto Mangunkusumo General Hospital|Maria Sklodowska-Curie National Research Institute of Oncology|Chiang Mai University|Salah Azaïz Cancer Institute|Wilson Roa Professional Corporation|Cancer Trials Ireland|Ege University|High Technology Medical Center","All","50 Years and older   (Adult, Older Adult)","Phase 3","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E33033","February 2009","December 2013","November 2014","October 12, 2011",,"March 24, 2015","Fundacion Escuela de Medicina Nuclear, Mendoza, Argentina|N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus|Irmandade de Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Brazil|Hospital ""A.C. Camargo"", Fundacao ""Antonio Prudente"", Sao Paulo, Brazil|Wilson Roa Professional Corporation, Edmonton, Canada|Instituto de Radiomedicina (IRAM), Santiago, Chile|Regionaalhailga, Tallinn, Estonia|High Technology Medical Center, University Clinic, Tbilisi, Georgia|Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India|Cipto Magunkusumo General Hospital, University of Indonesia, Jakarta, Indonesia|ICORG The All Ireland Cooperative Oncology, Dublin, Ireland|Marie Curie- Sklodowska Institute of Oncology, Warsaw, Poland|Division of Therapeutic Radiology and Oncology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand|Institut National de Cancer Salah Aziz, Ministere de la Sante Publique, Tunis, Tunisia|Ege University Hospital, Izmir, Turkey",,"https://ClinicalTrials.gov/show/NCT01450449"
754,"NCT02386800","CINC424A2X01B Rollover Protocol",,"Recruiting","No Results Available","Primary Myelofibrosis|Chronic Idiopathic Myelofibrosis|Post Polycythemia Vera Myelofibrosis|Post Essential Thrombocythaemia Myelofibrosis|Steroid Refractory Graft Versus Host Disease","Drug: ruxolitinib tablets or oral pediatric formulation, panobinostat capsules|Drug: ruxolitinib tablets or oral pediatric formulation","Number of Participants with Adverse Events as a Measure of Safety and Tolerability|To evaluate clinical benefit as assessed by the investigator","Novartis Pharmaceuticals|Novartis","All","1 Month and older   (Child, Adult, Older Adult)","Phase 4","356","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CINC424A2X01B|2014-003527-22","March 5, 2015","September 16, 2027","September 16, 2027","March 12, 2015",,"March 31, 2022","Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Santiago, RM, Chile|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Pune, Maharashtra, India|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Brescia, BS, Italy|Novartis Investigative Site, San Giovanni Rotondo, FG, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Rozzano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Fukuoka city, Fukuoka, Japan|Novartis Investigative Site, Isehara, Kanagawa, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Bunkyo ku, Tokyo, Japan|Novartis Investigative Site, Osaka, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Gliwice, Slaskie, Poland|Novartis Investigative Site, Wroclaw, Poland|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Sain Petersburg, Russian Federation|Novartis Investigative Site, Bratislava, Slovakia|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Cape Town, Western Province, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Bangkok, Bangkoknoi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",,"https://ClinicalTrials.gov/show/NCT02386800"
755,"NCT00068952","Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme",,"Completed","No Results Available","Glioblastoma","Drug: Edotecarin|Drug: Temozolomide|Drug: Carmustine (BCNU)|Drug: Lomustine (CCNU)","To compare the overall survival associated with edotecarin versus that associated with temozolomide or BCNU or CCNU for the treatment of patients with GBM at first relapse previously treated with alkylator-based (neo)adjuvant therapy|To assess measures of tumor control To evaluate measures of clinical benefit To assess the safety profile of edotecarin To assess the PK profile of edotecarin and the potential for drug interactions between anticonvulsants and edotecarin","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 3","118","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDOAGL-8725-001|A5921009","August 2003",,"March 2006","September 16, 2003",,"April 1, 2008","Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Little Rock, Arkansas, United States|Pfizer Investigational Site, New Haven, Connecticut, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Evanston, Illinois, United States|Pfizer Investigational Site, Edgewood, Kentucky, United States|Pfizer Investigational Site, Edgweood, Kentucky, United States|Pfizer Investigational Site, Lexington, Kentucky, United States|Pfizer Investigational Site, Boston, Massachusetts, United States|Pfizer Investigational Site, Lebanon, New Hampshire, United States|Pfizer Investigational Site, Edison, New Jersey, United States|Pfizer Investigational Site, Summit, New Jersey, United States|Pfizer Investigational Site, Cincinnati, Ohio, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Pittsburgh, Pennsylvania, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Charlottesville, Virginia, United States|Pfizer Investigational Site, St. Leonards, New South Wales, Australia|Pfizer Investigational Site, East Bentleigh, Victoria, Australia|Pfizer Investigational Site, Clayton, Australia|Pfizer Investigational Site, Graz, Austria|Pfizer Investigational Site, Wien, Austria|Pfizer Investigational Site, Calgary, Alberta, Canada|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Moncton, New Brunswick, Canada|Pfizer Investigational Site, Halifax, Nova Scotia, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Ottawa, Ontario, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Split, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Praha 5, Czech Republic|Pfizer Investigational Site, Lyon, France|Pfizer Investigational Site, Nantes St. Herblain, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Mainz, Germany|Pfizer Investigational Site, Regensburg, Germany|Pfizer Investigational Site, Tuebingen, Germany|Pfizer Investigational Site, Bangalore, India|Pfizer Investigational Site, Bologna, Italy|Pfizer Investigational Site, Padova, Italy|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Badalona, Spain|Pfizer Investigational Site, Hospitalet de Llobregat, Spain|Pfizer Investigational Site, Oviedo, Spain|Pfizer Investigational Site",,"https://ClinicalTrials.gov/show/NCT00068952"
756,"NCT02562443","Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA","INSPIRE","Active, not recruiting","No Results Available","Myelodysplastic Syndrome|MDS|Refractory Anemia With Excess Blasts|RAEB","Drug: rigosertib|Drug: Any approved or standard-of-care therapy|Drug: best supportive care (BSC)","Overall survival of all randomized patients and overall survival of patients scored as IPSS-R very high risk.|Overall survival of patients with monosomy 7 chromosomal aberrations.|Overall survival of patients with trisomy 8 chromosomal aberrations.|Percent of patients with response according to 2006 IWG criteria.|Scores of Quality of Life Questionnaire.|Percent of patients with bone marrow blast response rate according to 2006 IWG criteria.|Percent of patients with hematologic improvement (HI) (erythroid, platelet and neutrophil responses) according to 2006 IWG criteria.","Onconova Therapeutics, Inc.","All","18 Years to 81 Years   (Adult, Older Adult)","Phase 3","360","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Onconova 04-30|2015-001476-22","December 2, 2015","October 17, 2020","December 31, 2021","September 29, 2015",,"June 14, 2021","UC San Diego Moores Cancer Center, La Jolla, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|UCLA Medical Center, Los Angeles, California, United States|Cancer Specialists of North Florida, Fleming Island, Florida, United States|UF Health Shands Cancer Hospital, Gainesville, Florida, United States|Mid Florida Hematology and Oncology Centers, Orange City, Florida, United States|Advanced Research Institute, Inc, Saint Petersburg, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Loyola University Chicago at Loyola University Medical Center, Maywood, Illinois, United States|Indiana University Health Hospital, Indianapolis, Indiana, United States|The University of Kansas Cancer Center, Westwood, Kansas, United States|Tulane Medical Center, New Orleans, Louisiana, United States|University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Minnesota Physicians Bone Marrow Transplant Clinic, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Mount Sinai School of Medicine, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Albert Einstein Medical Center, Cancer Center, Philadelphia, Pennsylvania, United States|Greenville Health System (GHS) Cancer Institute, Greenville, South Carolina, United States|UT Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Emily Couric Clinical Cancer Center, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance (SCCA), Seattle, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States|Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States|Icon Cancer Care Icon South Brisbane, South Brisbane, Queensland, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Monash Health, Monash Medical Centre, Melbourne, Victoria, Australia|Hospital of the Elisabethinen Linz GmbH, Linz, Austria|Salzburg University Hospital, Salzburg, Austria|Hanusch Hospital, Vienna, Austria|Antwerp Hospital Network Stuivenberg, Antwerp, Belgium|University Hospital Ghent, Ghent, Belgium|University Hospital Leuven, Campus Gasthuisberg, Leuven, Belgium|CHU UCL Namur - Site Godinne, Yvoir, Belgium|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Sunnybrook Research Institute, Toronto, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Klinički bolnički centar Osijek, Osijek, Croatia|Clinical Hospital Merkur, Zagreb, Croatia|Klinički bolnicki centar Sestre milosrdnice, Zagreb, Croatia|Klinički bolnički centar Zagreb, Zagreb, Croatia|University Hospital Brno, Brno, Czechia|University Hospital Hradec Kralove, Hradec Kralove, Czechia|University Hospital Ostrava, Department of Hematooncology, Ostrava Poruba, Czechia|General University Hospital, Prague 2, Czechia|Institute of Hematology and Blood Transfusion, Prague 2, Czechia|North Estonia Medical Centre, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|CHD Vendée, La Roche Sur Yon Cedex 9, France|Hôpital Claude Huriez, CHRU Lille, Lille Cedex, France|Institut Paoli-Calmettes, Marseille, France|Hôpital l'Archet 1, Nice Cedex 3, France|Institut de Cancérologie du Gard, Nimes Cedex 9, France|Hôpital Saint Louis, Paris Cedex 10, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, France|Hôpital civil, Strasbourg, Strasbourg Cedex, France|CHRU Tours Hôspital Bretonneau, Tours, France|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Marien Hospital Düsseldorf, Düsseldorf, Germany|Universitätsklinikum Frankfurt am Main, Frankfurt, Germany|Semmelweis University Medical School, Budapest, Hungary|Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary|Jósa András Teaching Hospital, Nyíregyháza, Hungary|University of Pécs 1st Department of Internal Medicine, Pécs, Hungary|Hemato Oncology Clinic Pvt. Ltd, Ahmedabad, Gujarat, India|St. John's Medical College Hospital, Bangalore, Karnataka, India|Tata Memorial Hospital, Mumbai, Maharashtra, India|Jaslok Hospital and Research Center, Mumbai, Maharashtra, India|Sahyadri Clinical Research and Development Center, Pune, Maharashtra, India|Christian Medical College, Vellore, Tamil Nadu, India|Institute Of Hematology And Transfusion Medicine, Kolkata, West Bengal, India|Cork University Hospital, Cork, Ireland|Adelaide and Meath Hospital, Incorporating the National Children's Hospital, Dublin, Ireland|University Hospital Waterford, Waterford, Ireland|Ha'Emek Medical Center, 'Afula, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah Medical Center, Jerusalem, Israel|Kaplan Medical Center, Rehovot, Israel|Sourasky Medical Center, Tel Aviv, Israel|The Chaim Sheba Medical Center, Tel Hashomer, Israel|Polyclinic S. Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliera Spedali Civili, Brescia, Italy|Azienda Ospedaliero Universitaria Careggi, Firenze, Italy|Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy|A.O.U. Pisana, Divisione di Ematologia - University Hospital of Pisa, Pisa, Italy|Policlinico Universitario Tor Vergata, Roma, Italy|Ospedale S. Eugenio - S. Eugenio Hospital, Roma, Italy|Azienda Ospedaliera Santa Maria di Terni, Terni, Italy|Cittá della Salute e della Scienza di Torino, Torino, Italy|Kokura Memorial Hospital, Kitakyushu, Fukuoka, Japan|Chugoku Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuyama, Hiroshima, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Yokohama City University Hospital, Yokohama-shi, Kanagawa, Japan|Shimane University Hospital, Izumo, Shimane, Japan|Japanese Red Cross Medical Center, Shibuya, Tokyo, Japan|Akita University Hospital, Akita, Japan|Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka-shi, Japan|Kagoshima University Hospital, Kagoshima, Japan|Tokai Central Hospital of the Mutual Aid Association of Public School Teachers, Kakamigahara, Japan|Saitama Medical Center, Kawagoe, Japan|Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan|Nagasaki University Hospital, Nagasaki, Japan|Japanese Red Cross Nagoya Daini Hospital, Nagoya-shi, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Oita Prefectural Hospital, Oita, Japan|National Hospital Organization Okayama Medical Center, Okayama, Japan|Kindai University Hospital, Osakasayama-shi, Japan|Hokkaido University Hospital, Sapporo-shi, Japan|Tohoku University Hospital, Sendai-shi, Japan|NTT Medical Center Tokyo, Shinagawa-ku, Japan|Tokyo Medical University Hospital, Shinjuku-ku, Japan|Dokkyo Medical University Hospital, Tochigi, Japan|Tokushima University Hospital, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan|Saiseikai Yokohamashi Nanbu Hospital, Yokohama-shi, Japan|University of Fukui Hospital, Yoshida, Japan|Independent Public Healthcare Facility University Hospital in Cracow, Clinical Department of Hematology, Kraków, Poland|Independent Public Health Care Facility of the Ministry of Internal Affairs with Warmia and Mazury Oncology Centre in Olsztyn, Olsztyn, Poland|Ludwik Rydygier Provinicial Hospital in Suwalki, Department of Clinical Oncology and Hematology, Suwalki, Poland|MTZ Clinical Research Sp. z o.o., Warsaw, Poland|Independent Public University Hospital No. 1 in Wroclaw, Department of Hematology, Blood Cancers and Bone Marrow, Wroclaw, Poland|State Autonomous Healthcare Institution of Kemerovo region ""Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev"",, Kemerovo, Russian Federation|State Budgetary Healthcare Institution of Moscow City, Moscow, Russian Federation|FSBI ""Russian Scientific Research Hematology and Tranfusiology Institute of the Federal Biomedical Agency"", Saint Petersburg, Russian Federation|Hospital Son Llàtzer, Palma de Mallorca, Balearic Islands, Spain|Hospital Duran i Reynals - Instituto Catalán de Oncología, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Vall d'Hebron, Barcelona, Spain|Hospital Universitari Germans Trias i Pujol, Barcelona, Spain|Hospital Universitario Gregorio Marañón, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Salamanca, Salamanca, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Spain|Karolinska University Hospital, Stockholm, Huddinge, Sweden|Skåne University Hospital, Department of Hematology, Lund, Sweden|Uppsala University Hospital, Uppsala, Sweden|Linköping University Hospital, Linköping, Östergötland, Sweden|University Hospital and University of Bern; Inselspital Bern, Bern, Switzerland|University Hospital Zurich, Zurich, Switzerland|Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom|Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom|The Royal Liverpool University Hospital, Liverpool, United Kingdom|St Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom|King's College Hospital NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02562443"
757,"NCT01024036","A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease",,"Completed","Has Results","Multicentric Castleman's Disease","Drug: Siltuximab|Drug: Placebo|Drug: Best Supportive Care (BSC)","Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review|Median Duration of Tumor and Symptomatic Response - by Independent Radiology Review|Percentage of Participants Who Achieved Complete Response (CR) + Partial Response (PR) (Tumor Response Rate) - by Independent Radiology Review|Median Duration of Tumor Response - by Independent Radiology Review|Time to Treatment Failure|Percentage of Participants Who Achieved Greater Than or Equal to (>=) 15 Gram Per Liter (g/L) Hemoglobin at Week 13 (Hemoglobin Response Rate)|Percentage of Participants Who Achieved >= 20 g/L Hemoglobin at Week 13 (Hemoglobin Response Rate)|Percentage of Participants Who Discontinued Corticosteroids|6-year Survival Rate|Median Time Required to Achieve >=1 Point Decrease in the Multicentric Castleman's Disease Symptom Scale (MCD-SS) Score From Baseline|Median Time Required to Achieve >=3-point Increase in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores From Baseline|Median Time Required to Achieve >=5-point Increase in the Short-Form-36 (SF-36) Physical Component Summary (PCS) Scores From Baseline","Janssen Research & Development, LLC","All","18 Years and older   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CR016705|CNTO328MCD2001|2009-012380-34","March 18, 2010","March 25, 2013","February 24, 2017","December 2, 2009","August 20, 2014","March 21, 2018","Little Rock, Arkansas, United States|Los Angeles, California, United States|Tampa, Florida, United States|Boston, Massachusetts, United States|Lansing, Michigan, United States|Rochester, Minnesota, United States|Chapel Hill, North Carolina, United States|Greenville, South Carolina, United States|Houston, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|East Melbourne, Australia|Brussels, Belgium|Leuven, Belgium|Brasilia, Brazil|Porto Alegre, Brazil|Rio De Janeiro, Brazil|Sao Paulo, Brazil|Toronto, Canada|Beijing, China|Chengdu, China|Guangzhou, China|Hangzhou, China|Shanghai, China|Cairo, Egypt|Clermont Ferrand, France|Grenoble Cedex 1, France|Lille Cedex, France|Montpellier, France|Paris, France|Rennes, France|Tours Cedex 9, France|Vandoeuvre Les Nancy, France|Berlin, Germany|Mainz, Germany|München, Germany|Sha Tin, Hong Kong|Budapest, Hungary|Hyderabad N/A, India|Pune, India|Petach Tikva, Israel|Ramat Gan, Israel|Seoul, Korea, Republic of|Pandan, Malaysia|Rotterdam, Netherlands|Auckland, New Zealand|Oslo, Norway|Kazan, Russian Federation|Moscow, Russian Federation|Saint-Petersburg, Russian Federation|St.-Petersburg, Russian Federation|Singapore, Singapore|Barcelona, Spain|Madrid, Spain|Taipei, Taiwan|London, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01024036"
758,"NCT04971226","A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP",,"Recruiting","No Results Available","Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","Drug: Imatinib|Drug: Nilotinib|Drug: Bosutinib|Drug: Dasatinib|Drug: Asciminib","Major Molecular Response (MMR) at week 48|Major Molecular response at week 96|Time to discontinuation of study treatment due to Adverse Events (TTDAE)|Major Molecular response at scheduled data collection time points|Major Molecular response by scheduled data collection time points|MR4.0 at scheduled data collection time points|MR4.5 at all scheduled data collection time points|MR4.0 by scheduled data collection time points|MR4.5 by all scheduled data collection time points|Complete Hematological response (CHR) at all scheduled data collection time points|Complete Hematological response (CHR) by all scheduled data collection time points|Complete Cytogenic response (CCyR) at Week 48 & Week 96|Complete Cytogenic response (CCyR) by Week 48 & Week 96|Duration of MMR|Duration of MR4.0|Duration of MR4.5|Time to first MMR|Time to first MR4.0|Time to first MR4.5|Time to treatment failure (TTF)|Failure Free Survival (FFS)|Event Free Survival (EFS)|Progression Free Survival (PFS)|Overall Survival (OS)|Trough plasma concentrations.|Pharmacokinetics (PK) of Asciminib: Cmax|PK of Asciminib: Tmax|PK of Asciminib: AUCtau and AUClast|PK of Asciminib: CL/F|Change from baseline in overall scores and individual scales of the EORTC QLQ-C30|Change from baseline in overall scores and individual scales of the EORTC QLQ-CML24","Novartis Pharmaceuticals|Novartis","All","18 Years and older   (Adult, Older Adult)","Phase 3","402","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CABL001J12301|2021-000678-27","October 6, 2021","September 27, 2024","November 24, 2028","July 21, 2021",,"May 11, 2022","Rocky Mountain Cancer Centers, Denver, Colorado, United States|Florida Cancer Specialists Dept of Oncology (2), Fort Myers, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Florida Cancer Specialists Panhandle, Tallahassee, Florida, United States|Florida Cancer Specialists, West Palm Beach, Florida, United States|Illinois Cancer Care P.C. IL Cancer Specialists, Peoria, Illinois, United States|University of Kentucky, Lexington, Kentucky, United States|Oncology Hematology Care Inc, Cincinnati, Ohio, United States|Williamette Cancer Center, Eugene, Oregon, United States|Avera Cancer Avera Cancer Institute, Sioux Falls, South Dakota, United States|Chattanooga Oncology and Hematology Associates PC Tennessee Oncology Chattanooga, Chattanooga, Tennessee, United States|Texas Oncology Texas Onc - Amarillo, Dallas, Texas, United States|Texas Oncology-Baylor USO, Dallas, Texas, United States|Texas Oncology P A Austin, Dallas, Texas, United States|US Oncology P A, Tyler, Texas, United States|Virginia Cancer Specialists, Gainesville, Virginia, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Novartis Investigative Site, Kingswood, New South Wales, Australia|Novartis Investigative Site, Port Macquarie, New South Wales, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Linz, Upper Austria, Austria|Novartis Investigative Site, Wien, Austria|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Hamilton, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Toronto, Ontario, Canada|Novartis Investigative Site, Guangzhou, Guangdong, China|Novartis Investigative Site, Shenzhen, Guangdong, China|Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Nantong, Jiangsu, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Tianjin, Tianjin, China|Novartis Investigative Site, Brno Bohunice, Czech Republic, Czechia|Novartis Investigative Site, Ostrava Poruba, Czech Republic, Czechia|Novartis Investigative Site, Hradec Kralove, CZE, Czechia|Novartis Investigative Site, Aarhus, Denmark|Novartis Investigative Site, Helsinki, Finland|Novartis Investigative Site, Bordeaux, France|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Nantes Cedex 1, France|Novartis Investigative Site, Paris Cedex 10, France|Novartis Investigative Site, Mannheim, Baden-Wuerttemberg, Germany|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Frankfurt, Germany|Novartis Investigative Site, Jena, Germany|Novartis Investigative Site, Luebeck, Germany|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Delhi, India|Novartis Investigative Site, Petah Tikva, Israel|Novartis Investigative Site, Ramat Gan, Israel|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Bologna, BO, Italy|Novartis Investigative Site, Verona, VR, Italy|Novartis Investigative Site, Toyoake city, Aichi, Japan|Novartis Investigative Site, Fukushima city, Fukushima, Japan|Novartis Investigative Site, Suita city, Osaka, Japan|Novartis Investigative Site, Sunto Gun, Shizuoka, Japan|Novartis Investigative Site, Shimotsuke, Tochigi, Japan|Novartis Investigative Site, Akita, Japan|Novartis Investigative Site, Yamagata, Japan|Novartis Investigative Site, Uijeongbu si, Gyeonggi Do, Korea, Republic of|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Kuantan, Pahang, Malaysia|Novartis Investigative Site, Subang Jaya, Selangor, Malaysia|Novartis Investigative Site, Pulau Pinang, Malaysia|Novartis Investigative Site, Selangor, Malaysia|Novartis Investigative Site, Bergen, Norway|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Trondheim, Norway|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Saint Petersburg, Russian Federation|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Singapore, Singapore|Novartis Investigative Site, Bratislava, Slovak Republic, Slovakia|Novartis Investigative Site, Kosice, Slovak Republic, Slovakia|Novartis Investigative Site, Granada, Andalucia, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, El Palmar, Murcia, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Goteborg, Sweden|Novartis Investigative Site, Stockholm, Sweden|Novartis Investigative Site, Bellinzona, Switzerland|Novartis Investigative Site, Taichung, Taiwan|Novartis Investigative Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04971226"
759,"NCT04182204","A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","POLARGO","Recruiting","No Results Available","Diffuse Large B-Cell Lymphoma","Drug: Polatuzumab Vedotin|Drug: Rituximab|Drug: Gemcitabine|Drug: Oxaliplatin","Stage 1: Percentage of Participants with Adverse Events (AEs)|Stage 2: Overall Survival (OS)|Stage 1: Percentage of Participants with Peripheral Neuropathy|Stage 1: Percentage of Participants with Polatuzumab Vedotin Dose Interruptions and Dose Reductions|Stage 1: Polatuzumab Vedotin Dose Intensity|Stage 1: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin at Baseline|Stage 1: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin Post-Baseline|Stage 1: Percentage of Participants with Complete Response (CR)|Stage 1: Percentage of Participants with Objective Response (OR)|Stage 1: Best Overall Response (BOR)|Stage 1: Progression Free Survival (PFS)|Stage 1: Overall Survival (OS)|Stage 1: Event Free Survival (EFS)|Stage 2: Percentage of Participants with Objective Response (OR)|Stage 2: Percentage of Participants with Complete Response (CR)|Stage 2: Best Overall Response (BOR)|Stage 2: Progression Free Survival (PFS)|Stage 2: Duration of Response (DOR)|Stage 2: Event Free Survival (EFS)|Stage 2: Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire Core 30 (QLQ-C30) Score|Stage 2: Time to Deterioration in Physical Functioning and Fatigue|Stage 2: Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Total Score|Stage 2: Time to Progression in Lymphoma Symptoms According to FACT-Lym Subscale|Stage 2: Change from Baseline in Peripheral Neuropathy According to FACT/GOG-NTX-12 Subscale Score|Stage 2: Percentage of Participants with Adverse Events (AEs)|Stage 2: Percentage of Participants with Polatuzumab Vedotin Dose Interruptions and Dose Reductions|Stage 2: Polatuzumab Vedotin Dose Intensity|Stage 2: Percentage of Participants with Peripheral Neuropathy|Stage 2: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin at Baseline|Stage 2: Percentage of Participants with Anti-drug Antibodies (ADAs) to Polatuzumab Vedotin Post-Baseline","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","216","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MO40598|2018-003727-10","February 7, 2020","July 18, 2023","July 18, 2023","December 2, 2019",,"May 9, 2022","Memorial Regional Hospital, Hollywood, Florida, United States|Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States|Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States|Oncology Hematology Associates - Springfield, Springfield, Missouri, United States|Nebraska Cancer Specialists; Oncology Hematology West, PC, Omaha, Nebraska, United States|MSKCC at Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering - Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Cancer Center at Bergen, Montvale, New Jersey, United States|MSKCC @ Commack, Commack, New York, United States|The Cancer Institute at St Francis Hospital, East Hills, New York, United States|Memorial Sloan Kettering Cancer Center at Westchester, Harrison, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Millennium Research & Clinical Development, Houston, Texas, United States|Hospital Sao Rafael - HSR, Salvador, BA, Brazil|Liga Norte Riograndense Contra O Câncer, Natal, RN, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil|London Health Sciences Centre, London, Ontario, Canada|Niagara Health Systems - St. Catherines General Site; Niagara Health System-St. Catharines Site, St. Catharines, Ontario, Canada|McGill University Health Centre - Glen Site, Montreal, Quebec, Canada|Centre hospitalier regional de Trois-Rivieres, Trois-Rivieres, Quebec, Canada|Hu Nan Provincial Cancer Hospital, Changsha, China|West China Hospital - Sichuan University, Chengdu City, China|Cancer Center, Sun Yat-sen University of Medical Sciences; Department of Medical Oncology, Guangzhou, China|Zhujiang Hospital, Southern Medical University, Guangzhou, China|The 1st Affiliated Hospital of Nanchang Unversity, Nanchang, China|Guangxi Cancer Hospital of Guangxi Medical University, Nanning, China|Institute of Hematology and Hospital of Blood Disease, Tianjin City, China|Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China|First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xi'an, China|Helsinki University Central Hospital; Dept of Oncology, Helsinki, Finland|Kuopio Uni Hospital; Oncology Dept, Kuopio, Finland|Oulu University Hospital; Oncology, Oulu, Finland|Tampere University Hospital; Dept of Oncology, Tampere, Finland|Hopital Henri Mondor; 51 Av Mal Lattre De Tassigny, Creteil, France|CHU de Nîmes - Hôpital Carémeau, Nimes, France|Centre Henri Becquerel; Service Hématologie, Rouen, France|ICANS, Strasbourg, France|Hopital Bretonneau; Hematologie Therapie Cellulaire, TOURS Cedex, France|Universitätsklinikum Ulm; Medizinische Uni-Klinik III Abt. Innere Medizin III Hämatologie u. Onkolo., Ulm, Germany|Laiko General Hospital; Hematology Clinic, Athens, Greece|Attiko Hospital; Haematology Clinic, Athens, Greece|All India Institute of Medical Sciences ,Institute Rotary Cancer Hospital; Department of Oncology, New Delhi, India|Cork University Hospital, Cork, Ireland|St James' Hospital; Cancer Clinical Trials Office, Dublin, Ireland|Azienda Ospedaliero-Universitaria Policlinico di Modena Ematologia, Modena, Emilia-Romagna, Italy|Az. Osp. Uni Ria Policlinico Tor Vergata; Unita Di Ematologia, Roma, Lazio, Italy|Osp. San Raffaele; Dip. Di Oncoematologia, Milano, Lombardia, Italy|ARNAS Garibaldi; Ematologia, Catania, Sicilia, Italy|USL 4 di Prato - Nuovo Ospeale di Prato, Prato, Toscana, Italy|Ematologia/immunologia Clinica Azienda Ospedaliera Policlinico di Padova, Padova, Veneto, Italy|Pusan National University Hospital, Busan, Korea, Republic of|Chungnam National University Hospital, Daejeon, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Health Pharma Professional Research, Cdmx, Mexico CITY (federal District), Mexico|Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico|Hospital de Especialidades Centro Medico Nacional La Raza; Haematology, Mexico City, Mexico|Hospital Universitari Germans Trias i Pujol; Servicio de Hematologia, Badalona, Barcelona, Spain|Hospital Universitario de Canarias;servicio de Hematologia, La Laguna, Tenerife, Spain|Hospital Univ. 12 de Octubre; Servicio de Hematologia, Madrid, Spain|Hospital Clinico Universitario de Salamanca;Servicio de Hematologia, Salamanca, Spain|Hospital Universitario Dr. Peset; Servicio de Hematologia, Valencia, Spain|Akademiska sjukhuset, Onkologkliniken, Uppsala, Sweden|Sakarya Universitesi Egitim ve Arastirma Hastanesi, Adapazari/Sakarya, Turkey|Abdurrahman Yurtarslan Onkoloji Training and Research Hospital, Ankara, Turkey|Akdeniz Uni School of Medicine; Hematology, Antalya, Turkey|Istanbul Uni Istanbul Medical Faculty, Istanbul, Turkey|Istanbul University Cerrahpasa Medical Faculty; Hematology Department, Istanbul, Turkey|Kocaeli Universitesi Tip Fakultesi, Kocaeli, Turkey|Amerikan HAstanesi Onkoloji Birimi Teşvikiye, Nişantaşı, Turkey|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Kings College Hospital, London, United Kingdom|Nottingham City Hospital; Dept of Haematology, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04182204"
760,"NCT00261846","Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias",,"Completed","Has Results","Chronic Myeloid Leukemia","Drug: Bosutinib","Number of Participants With Dose Limiting Toxicity (DLT)|Maximum Tolerated Dose (MTD)|Maximum Observed Plasma Concentration (Cmax) - Part 1|Time to Reach Maximum Observed Plasma Concentration (Tmax) - Part 1|Plasma Decay Half-Life (t1/2) - Part 1|Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC(0-48)] - Part 1|Area Under the Concentration-Time Curve (AUC) - Part 1|Apparent Oral Clearance (CL/F) - Part 1|Apparent Volume of Distribution (Vz/F) - Part 1|Maximum Observed Plasma Concentration at Steady State (Cmax,ss) - Part 1|Time to Reach Maximum Observed Plasma Concentration at Steady State (Tmax,ss) - Part 1|Plasma Decay Half-Life at Steady State (t1/2,ss) - Part 1|Area Under the Concentration-Time Curve at Steady State (AUCss) - Part 1|Apparent Oral Clearance at Steady State (CL/F,ss) - Part 1|Accumulation Ratio (R)|Percentage of Participants With MCyR at Week 24 in Chronic Phase Second-line Imatinib Resistant CML Population - Part 2|Percentage of Participants With Major Cytogenetic Response (MCyR) - Part 1|Phosphorylation Inhibition of Breakpoint Cluster Region-Abelson Kinase (Bcr-Abl) - Part 1|Phosphorylation Inhibition of Crk Like (CrkL) Protein at Baseline - Part 1|Percent Change From Baseline in Phosphorylation Inhibition of Crk Like Protein (CrkL) at Day 1, 8 and 15 - Part 1|Percentage of Participants With Major Cytogenetic Response (MCyR) in Chronic Phase Second-line and Chronic Phase Third-line CML Population - Part 2|Kaplan-Meier Estimate of Retaining an Attained/Maintained Major Cytogenetic Response (MCyR) at Year 5 in Chronic Phase Second-line CML - Part 2|Time to Achieve Major Cytogenetic Response (MCyR) in Chronic Phase Second-line CML for Responders Only - Part 2|Kaplan-Meier Estimate of Maintaining Complete Hematologic Response (CHR) at Year 4 (CP3L and ADV) or Year 5 (CP2L) - Part 2|Duration of Complete Hematologic Response (CHR) - Part 2|Time to Achieve Complete Hematologic Response (CHR) for Responders Only - Part 2|Cumulative Incidence of Progression/Death - Part 2|Progression Free Survival (PFS) - Part 2|Kaplan-Meier Estimate of Overall Survival (OS) - Part 2|Overall Survival (OS) - Part 2|Percentage of Participants With Confirmed Complete Hematologic Response (CHR) - Part 2|Percentage of Participants With Overall Hematologic Response (OHR) by Week 48 in Advanced Leukemia Population - Part 2|Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)|Duration of Potentially Clinically Important (PCI) Adverse Events (AEs)|Percentage of Participants With Change From Baseline in Laboratory Tests Results|Percentage of Participants With On-treatment PCI Change From Baseline in Electrocardiogram (ECG) Findings|Number of Participants With Change From Baseline in Findings of Chest X-ray|Number of Participants Who Received Concomitant Medications for Management of Adverse Events (AEs)|Number of Participants With Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG-PS)|Percentage of Participants With Change From Baseline in Physical Examinations and Vital Signs|Percentage of Participants With Change From Baseline in Physical Examinations and Vital Signs and Number of Participants With PCI Values","Pfizer","All","18 Years and older   (Adult, Older Adult)","Phase 2","571","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3160A4-200|B1871006, 3160A4-200-WW|2005-004230-40|B1871006","January 18, 2006","September 25, 2009","August 6, 2015","December 5, 2005","March 12, 2013","July 27, 2017","City of Hope National Medical Center, Duarte, California, United States|HealthONE Presbyterian, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Georgetown University Hospital, Washington, D.C., District of Columbia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Oncology Specialists, S.C., Niles, Illinois, United States|Indiana Blood and Marrow Transplantation, Indianapolis, Indiana, United States|LSU Health Sciences Center, Shreveport, Louisiana, United States|University Of Maryland Medical Center, Baltimore, Maryland, United States|University Of Maryland, Baltimore, Maryland, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Hudson Valley Hematology and Oncology Associates, Hawthorne, New York, United States|Westchester Oncology Hematology Group, P.C., Hawthorne, New York, United States|Westchester Oncology Hematology, Group, P.C., Hawthorne, New York, United States|New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital, New York, New York, United States|University of Rochester Cancer Center Pharmacy, Rochester, New York, United States|University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of Rochester-James P. Wilmot Cancer Center, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|The University of Texas, Houston, Texas, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Hospital Italiano de la Plata, La Plata, Provincia de Buenos Aires, Argentina|Hospital Britanico, Buenos Aires, Argentina|Academia Nacional de Medicina-Instituto de Investigaciones Hematologicas, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Clinica del Sol, Ciudad Autonoma de Buenos Aires, Argentina|Centro Medico S.A., Corrientes, Argentina|Hospital Jose Ramon Vidal, Corrientes, Argentina|Hospital universitario austral, Pcia de Buenos Aires, Argentina|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Institute of Medical and Veterinary Science, Adelaide, Australia|Department of Clinical Haematology and Bone Marrow Transplantation, Melbourne, Australia|Royal Brisbane and Women's Hospital, Queensland, Australia|Haematology and Oncology Clinics of Australia, Queensland, Australia|Klinikum Kreuzschwestern Wels, Wels, Austria|Hospital Brigadeiro da Secretaria de Estado da Saude de Sao Paulo, Jardim Paulista, Sao Paulo/sp - Brazil, Brazil|Centro de Estudos da Disciplina dr Hematologia da Faculdade de Medicine do ABC, Santo Andre, Sp - Brazil, Brazil|Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sp Brazil, Brazil|Hospital de Clinicas - Universidade Federal do Parana, Curitiba, PR, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|University Health Network Princess Margaret Hospital, Toronto, Ontario, Canada|Sir Mortimer B. Davis, Jewish General Hospital, Montreal, Quebec, Canada|Instituto Clinico Oncologico del Sur, Temuco, Chile|The First Hospital affiliated to the Medical School of Zhejiang University, Zhejiang, P.r China, China|Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, P.r. China, China|The Department of Hematology, The Chinese PLA General Hospital, Beijing, P.r. China, China|The Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, P.r. China, China|The Department of Hematology, Ruijin Hospital Affiliated to School of Medicine of Shanghai Jiaotong, Shanghai, China|Hospital Pablo Tobon Uribe, Medellin, Antioquia, Colombia|Fundacion Santa Fe de Bogota, Bogota, Cundinamarca, Colombia|Biomedicum Helsinki, Helsinki, Finland|Universitaet Mainz, Mainz, RP, Germany|University Hospital Carl Gustav Carus, Dresden, Germany|Universitaetsklinikum Hamburg - Eppendorf, Hamburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitaetsklinikum Magdeburg A. oe. R., Magdeburg, Germany|III Medizinische Klinik und Poliklinik, Mainz, Germany|Klinikum der Johann Gutenberg Universitaet Mainz, Mainz, Germany|Universitaet Mainz Iii. Medizinische Klinik Abteilung Fuer Haematologie, Mainz, Germany|Universitaetsklinikum Mainz, Mainz, Germany|III. Medizinische Klinik, Mannheim, Germany|Pamela Youde Nethersole Eastern Hosp., Chai Wan, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Fovarosi Onkormanyzat Egyesitett Szent Istvan es Szent Laszlo, Budapest, Hungary|Christian Medical College, Vellore, Tamil Nadu, India|University of Bologna, Bologna, Province of Bologna, Italy|Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano, Torino, Italy|AOU-S.Orsola-Malpighi - Universita degli Studi di Bologna, Bologna, Italy|Azienda Ospedaliera San Gerardo, Monza, Italy|The Catholic University of Korea, Seoul St. Mary Hospital, Seoul, Korea, Republic of|Dept. of Hematology, Seoul, Korea, Republic of|Hospital Universitario ""Dr. Jose Eleuterio Gonzalez"", Nuevo Leon, Mexico|Centro Oncologico Estatal ISSEMYM, Toluca Estado de Mexico, Mexico|VU University Medical Center, Amsterdam, Netherlands|University Medical Center Groningen, Groningen, Netherlands|UMCG - Pharmacy, Groningen, Netherlands|Universitair Medisch Centrum Groningen, Groningen, Netherlands|VUMC, The Netherlands, Netherlands|Avd. for blodsykdommer, Trondheim, Norge, Norway|Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru|State Healthcare Institution, Sverdlovsk Regional Clinical Hospital, Ekaterinburg, Russian Federation|Kirov Research Institute of Hematology and Blood transfusion of Roszdrav Hematology clinic, Kirov, Russian Federation|Hematological Research Centre of RAMS, Moscow, Russian Federation|Moscow regional Clinical Research Institute named after M.F Vladimirsky, Moscow, Russian Federation|Rostov State Medical University of Roszdrav, Rostov-on Don, Russian Federation|Saint Petersburg State Medical University Hematology Department, Saint Petersburg, Russian Federation|Singapore General Hospital, Singapore, Singapore|University of the Free State, Bloemfontein, South Africa|University of Cape Town, Cape Town, South Africa|Johannesburg Hospital, Parktown, South Africa|Clinical Haematology Unit, Soweto, South Africa|Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Catalonia, Spain|Hospital Universitari Clinic de Barcelona, Barcelona, Catalonia, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital Clinico Universitario de Valencia (CHUV), Valencia, Spain|Akademiska University Hospital, Uppsala, Sweden|National Taiwan University Hospital - Section of Hematology-Oncology, Taipei 100, Taiwan|Northern Centre for Cancer Care - The Newcastle Upon Tyne Hospitals - NHS Foundation Trust, Newcastle Upon Tyne, North East England, United Kingdom|School of Clinical and Laboratory Sciences, University upon Tyne, North East England, United Kingdom|Hammersmith Hospital, London, United Kingdom|Clinical Research Facility, Newcastle Upon Tyne, North East England, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00261846"
